1	1	heart failure	[heart failure]	478.9124087591241	2	482	423	137
2	2	patient with heart failure	[patient with heart failure]	143.09239576823188	4	92	55	32
3	3	ejection fraction	[ejection fraction]	105.21212121212122	2	108	92	33
4	4	heart failure HF	[heart failure HF]	93.584831292581	3	61	43	22
5	5	heart	[heart]	65.28620689655172	1	656	273	87
6	6	patient	[patient]	55.46540880503145	1	557	373	159
7	7	ventricular ejection fraction	[ventricular ejection fraction]	52.91336348561399	3	36	34	13
8	8	hazard ratio	[hazard ratio]	52.714285714285715	2	54	45	35
9	9	left ventricular ejection fraction	[left ventricular ejection fraction]	49.020625915161474	4	32	15	14
10	10	chronic heart failure	[chronic heart failure]	47.8885098432178	3	32	25	14
11	11	left ejection fraction	[left ejection fraction]	47.73534119819012	3	32	32	17
12	12	patient with HF	[patients with HF]	37.51077918373404	3	25	20	15
13	13	heart failure patient	[heart failure patients]	35.84453655477077	3	24	18	13
14	14	quality of life	[quality of life]	34.86917501586544	3	23	4	4
15	15	congestive heart failure	[congestive heart failure]	34.076693765504864	3	23	12	8
16	16	HF	[HF]	33.06666666666667	1	333	182	78
17	17	heart failure with ejection fraction	[heart failure with ejection fraction]	30.0	5	31	5	5
18	18	systolic heart failure	[systolic heart failure]	26.54812188707937	3	18	15	12
19	19	acute heart failure	[acute heart failure]	24.72541501125004	3	17	14	10
20	20	myocardial infarction	[myocardial infarction]	23.666666666666668	2	26	14	6
21	21	ventricular assist device	[ventricular assist device]	23.61594126074523	3	16	11	10
22	22	p	[P]	22.76	1	229	49	35
23	23	heart rate	[heart rate]	21.846153846153847	2	23	15	13
24	24	ventricular ejection	[ventricular ejection]	20.5	2	28	15	2
25	25	heart disease	[heart disease]	20.1	2	22	19	10
26	26	HF hospitalization	[HF hospitalization]	18.77777777777778	2	20	11	9
27	27	exercise training	[exercise training]	17.555555555555557	2	19	13	9
28	28	patient with hfpef	[patients with HFpEF]	17.43458750793272	3	12	10	10
29	29	atrial fibrillation	[atrial fibrillation]	16.666666666666668	2	18	8	6
30	30	functional capacity	[functional capacity]	15.857142857142858	2	17	8	7
31	31	glomerular filtration rate	[glomerular filtration rate]	15.585464590424705	3	11	7	6
32	32	assist device	[assist device]	15.3	2	17	17	10
33	33	cardiac resynchronization therapy	[cardiac resynchronization therapy]	15.057143756850985	3	11	9	6
34	34	renal function	[renal function]	15.0	2	16	6	6
35	35	heart failure CHF	[heart failure CHF]	14.792983340064124	3	14	14	3
36	36	study	[study]	14.675925925925927	1	148	67	54
37	37	risk of heart failure	[risk of heart failure]	14.264662506490406	4	10	4	4
38	38	patient with heart failure HF	[patients with heart failure HF]	14.0	5	15	6	6
39	39	heart Failure	[Heart Failure]	13.666666666666666	2	15	12	9
40	40	outcome	[outcome]	13.436666666666667	1	136	98	60
41	41	result	[result]	13.25	1	134	24	16
42	42	acute myocardial infarction	[acute myocardial infarction]	13.20802083934297	3	10	5	3
43	43	resynchronization therapy	[resynchronization therapy]	13.125	2	15	15	8
44	44	blood pressure	[blood pressure]	12.777777777777779	2	14	11	9
45	45	hazard ratio hr	[hazard ratio HR]	12.67970000576925	3	9	7	7
46	45	body mass index	[body mass index]	12.67970000576925	3	9	3	3
47	46	primary outcome	[primary outcome]	12.333333333333334	2	14	5	3
48	47	follow-up visit	[follow-up visits]	12.166666666666666	2	14	11	6
49	48	renal dysfunction	[renal dysfunction]	12.0	2	13	2	2
50	48	consecutive patient	[consecutive patients]	12.0	2	13	11	11
51	48	all-cause mortality	[all-cause mortality]	12.0	2	13	6	6
52	49	odd ratio	[odds ratio]	11.9	2	13	11	10
53	50	risk factor	[risk factor]	11.875	2	13	9	8
54	51	risk	[risk]	11.865000000000002	1	121	94	40
55	52	ventricular assist	[ventricular assist]	11.666666666666666	2	13	4	3
56	53	ejection fraction hfpef	[ejection fraction HFpEF]	11.623058338621812	3	9	5	3
57	54	chronic heart failure CHF	[chronic heart failure CHF]	11.094737505048094	4	7	0	0
58	54	treatment of heart failure	[treatment of heart failure]	11.094737505048094	4	8	2	2
59	54	right heart failure	[right heart failure]	11.094737505048094	3	8	4	4
60	55	mortality	[mortality]	11.037500000000001	1	112	65	40
61	56	New York	[New York]	11.0	2	16	5	1
62	56	ejection	[ejection]	11.0	1	117	70	10
63	56	HF patient	[HF patients]	11.0	2	12	7	7
64	56	clinical trial	[clinical trial]	11.0	2	12	6	6
65	56	cardiovascular event	[cardiovascular event]	11.0	2	12	5	5
66	57	LV ejection fraction	[LV ejection fraction]	10.868314290659358	3	8	8	7
67	58	treatment	[treatment]	10.736170212765957	1	109	77	47
68	59	body mass	[body mass]	10.6	2	13	12	5
69	60	rhythm control therapy	[rhythm control therapy]	10.566416671474375	3	8	4	3
70	60	York heart Association class	[York Heart Association class]	10.566416671474375	4	8	8	6
71	61	advanced heart failure	[advanced heart failure]	10.46075250475963	3	8	7	5
72	62	conclusion	[CONCLUSION]	10.3	1	103	0	0
73	63	peak vo2	[peak VO2]	10.0	2	11	7	7
74	63	6 month	[6 months]	10.0	2	11	4	4
75	64	exercise	[exercise]	9.651515151515152	1	98	49	33
76	65	predictor of mortality	[predictor of mortality]	9.509775004326938	3	7	7	7
77	66	high risk	[higher risk]	9.333333333333334	2	11	10	6
78	67	systolic HF	[systolic HF]	9.0	2	10	4	4
79	67	body composition	[body composition]	9.0	2	10	7	7
80	67	clinical outcome	[clinical outcome]	9.0	2	10	6	6
81	67	adverse event	[adverse event]	9.0	2	10	5	5
82	67	functional ms	[functional MS]	9.0	2	10	1	1
83	67	control group	[control group]	9.0	2	10	5	5
84	68	7-day follow-up visit	[7-day follow-up visits]	8.981454170753219	3	7	4	3
85	68	risk of death	[risk of death]	8.981454170753219	3	7	4	3
86	69	end point	[end point]	8.875	2	10	9	8
87	70	patient with chronic heart failure	[patient with chronic heart failure]	8.8	5	10	6	5
88	71	1.73 m 2	[1.73 m 2]	8.71729375396636	3	7	3	2
89	72	acute infarction	[acute infarction]	8.714285714285714	2	10	9	7
90	73	1.73 m	[1.73 m]	8.666666666666666	2	12	10	3
91	74	hr	[HR]	8.570588235294117	1	87	44	34
92	75	New York heart Association	[New York Heart Association]	8.453133337179501	4	8	8	3
93	76	year	[year]	8.384057971014492	1	85	80	69
94	77	mm hg	[mm Hg]	8.333333333333334	2	10	10	6
95	78	Cox hazard model	[Cox hazards models]	8.32105312878607	3	7	7	4
96	79	filtration rate	[filtration rate]	8.25	2	11	11	4
97	80	ventricular dysfunction	[ventricular dysfunction]	8.0	2	9	3	3
98	80	cardiovascular death	[cardiovascular death]	8.0	2	9	1	1
99	80	diabete mellitus	[diabetes mellitus]	8.0	2	9	1	1
100	81	congestive heart failure CHF	[congestive heart failure CHF]	7.924812503605781	4	6	2	2
101	81	millileter per m	[mL per m]	7.924812503605781	3	6	6	6
102	81	patient with CHF	[patients with CHF]	7.924812503605781	3	6	6	6
103	81	length of stay	[length of stay]	7.924812503605781	3	6	3	3
104	81	angiotensin receptor blocker	[angiotensin receptor blockers]	7.924812503605781	3	6	2	2
105	81	30-day readmission rate	[30-day readmission rate]	7.924812503605781	3	6	4	4
106	81	diagnosis of heart failure	[diagnosis of heart failure]	7.924812503605781	4	6	3	3
107	81	coronary artery disease	[coronary artery disease]	7.924812503605781	3	6	5	5
108	81	Cox proportional hazard model	[Cox proportional hazards models]	7.924812503605781	4	6	2	2
109	81	objective of this study	[objective of this study]	7.924812503605781	4	6	1	1
110	81	millileter per 1.73 m	[mL per 1.73 m]	7.924812503605781	4	6	5	5
111	81	outcome in patient	[outcome in patients]	7.924812503605781	3	6	5	5
112	82	risk stratification	[risk stratification]	7.857142857142858	2	9	8	7
113	83	HeartMate ii	[HeartMate II]	7.75	2	9	5	4
114	84	artery disease	[artery disease]	7.714285714285714	2	9	9	7
115	84	event rate	[event rate]	7.714285714285714	2	9	9	7
116	85	patient with heart disease	[patients with heart disease]	7.528571878425493	4	6	5	4
117	86	natriuretic peptide	[natriuretic peptide]	7.4	2	9	8	5
118	87	exercise capacity	[exercise capacity]	7.333333333333333	2	9	5	3
119	88	methov	[METHODS]	7.300000000000001	1	73	0	0
120	89	rhythm control	[rhythm control]	7.2	2	9	9	5
121	90	LV	[LV]	7.167857142857144	1	73	37	28
122	91	end-stage heart failure	[end-stage heart failure]	7.132331253245203	3	6	6	4
123	91	peak oxygen uptake	[peak oxygen uptake]	7.132331253245203	3	6	3	2
124	91	York heart Association	[York Heart Association]	7.132331253245203	3	6	6	4
125	92	effect	[effect]	7.026315789473684	1	72	66	38
126	93	CV event	[CV events]	7.0	2	8	5	5
127	93	cardiovascular disease	[cardiovascular disease]	7.0	2	8	4	4
128	93	heart Association	[Heart Association]	7.0	2	9	8	4
129	93	cardiac function	[cardiac function]	7.0	2	9	6	3
130	94	death	[death]	6.95	1	71	36	24
131	95	pulmonary hypertension	[pulmonary hypertension]	6.857142857142858	2	8	8	7
132	95	ventricular function	[ventricular function]	6.857142857142858	2	8	8	7
133	96	readmission rate	[readmission rate]	6.833333333333333	2	8	7	6
134	97	function	[function]	6.803225806451613	1	70	61	31
135	98	hazard	[hazard]	6.791304347826088	1	70	48	23
136	99	left ventricle	[left ventricle]	6.75	2	8	5	4
137	99	New York heart Association class	[New York Heart Association class]	6.75	5	8	5	4
138	100	background	[BACKGROUND]	6.7	1	68	2	2
139	101	cohort study	[cohort study]	6.666666666666667	2	8	8	6
140	101	old patient	[older patients]	6.666666666666667	2	8	4	3
141	102	systematic review	[systematic review]	6.5	2	8	3	2
142	103	significant improvement	[significant improvement]	6.4	2	8	8	5
143	104	adult with heart failure	[adults with heart failure]	6.339850002884625	4	5	5	5
144	104	development of heart failure	[development of heart failure]	6.339850002884625	4	5	2	2
145	104	Health Buddy Program	[Health Buddy Program]	6.339850002884625	3	4	0	0
146	104	aim of this study	[aim of this study]	6.339850002884625	4	5	1	1
147	104	cohort of patient	[cohort of patients]	6.339850002884625	3	5	4	4
148	104	chronic obstructive pulmonary disease	[chronic obstructive pulmonary disease]	6.339850002884625	4	5	1	1
149	104	N-terminal pro-brain natriuretic peptide	[N-terminal pro-brain natriuretic peptide]	6.339850002884625	4	4	0	0
150	104	acute myocardial infarction AMI	[acute myocardial infarction AMI]	6.339850002884625	4	5	2	2
151	104	b-type natriuretic peptide	[B-type natriuretic peptide]	6.339850002884625	3	4	0	0
152	104	ang ii infusion	[ANG II infusion]	6.339850002884625	3	4	0	0
153	104	purpose of this study	[purpose of this study]	6.339850002884625	4	4	0	0
154	104	cardiac resynchronization therapy CRT	[cardiac resynchronization therapy CRT]	6.339850002884625	4	4	0	0
155	104	angiotensin-converting enzyme inhibitor	[angiotensin-converting enzyme inhibitors]	6.339850002884625	3	5	3	3
156	104	ejection fraction ef	[ejection fraction EF]	6.339850002884625	3	4	0	0
157	104	mortality in patient	[mortality in patients]	6.339850002884625	3	5	5	5
158	104	acute kidney injury	[acute kidney injury]	6.339850002884625	3	5	1	1
159	104	coronary heart disease	[coronary heart disease]	6.339850002884625	3	5	2	2
160	104	systolic blood pressure	[systolic blood pressure]	6.339850002884625	3	5	4	4
161	105	ventricular-arterial coupling	[ventricular-arterial coupling]	6.0	2	7	1	1
162	105	functional class	[functional class]	6.0	2	7	5	5
163	105	long mortality	[long-term mortality]	6.0	2	7	1	1
164	105	diastolic dysfunction	[diastolic dysfunction]	6.0	2	7	5	5
165	105	LV dysfunction	[LV dysfunction]	6.0	2	7	6	6
166	106	follow-up of year	[follow-up of years]	5.943609377704336	3	5	5	4
167	106	acute infarction AMI	[acute infarction AMI]	5.943609377704336	3	5	5	4
168	106	patient with hypertension	[patients with hypertension]	5.943609377704336	3	5	5	4
169	107	disease	[disease]	5.8500000000000005	1	60	42	28
170	108	management of patient	[management of patients]	5.811529169310907	3	5	4	3
171	108	severe heart failure	[severe heart failure]	5.811529169310907	3	5	4	3
172	109	hr variability	[HR variability]	5.8	2	7	6	5
173	109	outcome measure	[outcome measures]	5.8	2	7	6	5
174	110	CHF	[CHF]	5.7625	1	59	22	16
175	111	change	[change]	5.703846153846154	1	59	51	26
176	112	clinical practice	[clinical practice]	5.666666666666667	2	7	4	3
177	112	all-cause hospitalization	[all-cause hospitalization]	5.666666666666667	2	7	4	3
178	112	old adult	[older adults]	5.666666666666667	2	7	4	3
179	113	independent predictor	[independent predictor]	5.6	2	7	7	5
180	113	chronic disease	[chronic disease]	5.6	2	7	7	5
181	114	follow-up	[follow-up]	5.572727272727273	1	57	28	22
182	115	angiotensin receptor	[angiotensin receptor]	5.5	2	7	6	4
183	116	medical treatment	[medical treatment]	5.333333333333333	2	7	5	3
184	117	chronic pulmonary disease	[chronic pulmonary disease]	5.2832083357371875	3	5	5	3
185	117	ventricular LV ejection fraction	[ventricular LV ejection fraction]	5.2832083357371875	4	5	5	3
186	118	trial	[trial]	5.148	1	53	38	25
187	119	baseline	[baseline]	5.04	1	52	16	10
188	120	reverse remodeling	[reverse remodeling]	5.0	2	6	2	2
189	120	New York heart Association NYHA	[New York Heart Association NYHA]	5.0	5	6	1	1
190	120	mitral regurgitation	[mitral regurgitation]	5.0	2	6	6	6
191	120	dysfunction	[dysfunction]	5.0	1	52	48	24
192	120	cardiac resynchronization	[cardiac resynchronization]	5.0	2	6	2	2
193	120	respectively p	[respectively p]	5.0	2	6	3	3
194	120	sympathetic activity	[sympathetic activity]	5.0	2	6	3	3
195	120	patient with systolic heart failure	[patients with systolic heart failure]	5.0	5	6	2	2
196	120	gastrointestinal bleed	[gastrointestinal bleeding]	5.0	2	6	2	2
197	120	biological phenotype	[biological phenotype]	5.0	2	5	0	0
198	120	catheter ablation	[catheter ablation]	5.0	2	6	4	4
199	120	deficit index	[deficit index]	5.0	2	6	1	1
200	120	systolic function	[systolic function]	5.0	2	6	5	5
201	120	gene expression	[gene expression]	5.0	2	6	6	6
202	120	1 year	[1 year]	5.0	2	6	3	3
203	120	3 month	[3 months]	5.0	2	6	2	2
204	120	sympathetic tone	[sympathetic tone]	5.0	2	6	2	2
205	120	prospective study	[prospective study]	5.0	2	6	5	5
206	120	interquartile range	[interquartile range]	5.0	2	6	2	2
207	120	insulin resistance	[insulin resistance]	5.0	2	6	3	3
208	120	major complication	[major complications]	5.0	2	6	3	3
209	120	biomedical treatment	[biomedical treatment]	5.0	2	6	3	3
210	120	mechanical support	[mechanical support]	5.0	2	6	6	6
211	121	event	[event]	4.934615384615385	1	51	43	26
212	122	millileter	[mL]	4.881481481481482	1	50	32	27
213	123	age	[age]	4.764705882352941	1	49	23	17
214	124	adverse CV event	[adverse CV events]	4.754887502163469	3	4	3	3
215	124	pro-b-type natriuretic peptide	[pro-B-type natriuretic peptide]	4.754887502163469	3	4	4	4
216	124	Retrospective cohort study	[Retrospective cohort study]	4.754887502163469	3	3	0	0
217	124	period versus 1	[period versus 1]	4.754887502163469	3	4	2	2
218	124	sudden cardiac death	[sudden cardiac death]	4.754887502163469	3	3	0	0
219	124	risk for heart failure	[risk for heart failure]	4.754887502163469	4	4	2	2
220	124	heart failure HF patient	[heart failure HF patients]	4.754887502163469	4	4	2	2
221	124	acute coronary syndrome	[acute coronary syndrome]	4.754887502163469	3	3	0	0
222	124	bundle branch block	[bundle branch block]	4.754887502163469	3	4	3	3
223	124	HF risk factor	[HF risk factors]	4.754887502163469	3	4	3	3
224	124	time of admission	[time of admission]	4.754887502163469	3	3	0	0
225	124	patient with systolic HF	[patients with systolic HF]	4.754887502163469	4	4	1	1
226	124	Kansas City Cardiomyopathy Questionnaire	[Kansas City Cardiomyopathy Questionnaire]	4.754887502163469	4	4	3	3
227	124	peak oxygen consumption	[peak oxygen consumption]	4.754887502163469	3	4	3	3
228	124	right ventricular reserve	[right ventricular reserve]	4.754887502163469	3	4	3	3
229	124	chronic obstructive disease	[chronic obstructive disease]	4.754887502163469	3	5	4	2
230	124	low-volume ed case	[low-volume ED cases]	4.754887502163469	3	3	0	0
231	124	Mediterranean diet score	[Mediterranean diet score]	4.754887502163469	3	4	2	2
232	124	mechanical cardiac support	[mechanical cardiac support]	4.754887502163469	3	4	3	3
233	124	patient with atrial fibrillation	[patients with atrial fibrillation]	4.754887502163469	4	4	3	3
234	124	patient with ejection fraction	[patients with ejection fraction]	4.754887502163469	4	4	4	4
235	124	right ventricular contractile reserve	[right ventricular contractile reserve]	4.754887502163469	4	4	2	2
236	124	heart failure hospitalization	[heart failure hospitalization]	4.754887502163469	3	4	1	1
237	124	cardiopulmonary exercise testing	[cardiopulmonary exercise testing]	4.754887502163469	3	4	1	1
238	124	outcome of death	[outcome of death]	4.754887502163469	3	4	4	4
239	124	peripheral vascular disease	[peripheral vascular disease]	4.754887502163469	3	3	0	0
240	124	implantable cardioverter defibrillator-CRT	[implantable cardioverter defibrillator-CRT]	4.754887502163469	3	4	3	3
241	124	right contractile reserve	[right contractile reserve]	4.754887502163469	3	4	4	4
242	124	cause of death	[cause of death]	4.754887502163469	3	4	3	3
243	124	chronic myocardial ischemia	[chronic myocardial ischemia]	4.754887502163469	3	3	0	0
244	124	ejection fraction HFrEF	[ejection fraction HFrEF]	4.754887502163469	3	3	0	0
245	124	ejection fraction HFPEF	[ejection fraction HFPEF]	4.754887502163469	3	4	1	1
246	124	risk of event	[risk of events]	4.754887502163469	3	4	3	3
247	124	LV end-diastolic pressure	[LV end-diastolic pressure]	4.754887502163469	3	4	3	3
248	125	prediction rule	[prediction rule]	4.75	2	6	5	4
249	126	sinus rhythm	[sinus rhythm]	4.666666666666667	2	6	4	3
250	126	RV failure	[RV failure]	4.666666666666667	2	6	4	3
251	127	CI	[CI]	4.6000000000000005	1	47	12	12
252	128	sudden death	[sudden death]	4.5	2	6	3	2
253	128	beneficial effect	[beneficial effect]	4.5	2	7	5	2
254	128	m 2	[m 2]	4.5	2	8	7	2
255	128	endothelial function	[endothelial function]	4.5	2	6	3	2
256	128	valve plasty	[valve plasty]	4.5	2	6	6	4
257	129	group	[group]	4.4750000000000005	1	46	25	20
258	130	hospital	[hospital]	4.3	1	44	24	24
259	130	minute	[min]	4.3	1	44	13	13
260	131	York heart Association NYHA	[York Heart Association NYHA]	4.226566668589751	4	4	4	3
261	131	patient with pulmonary hypertension	[patients with pulmonary hypertension]	4.226566668589751	4	4	4	3
262	131	type 2 diabete	[type 2 diabetes]	4.226566668589751	3	4	4	3
263	131	annular size reduction	[annular size reduction]	4.226566668589751	3	4	4	3
264	131	patient with fibrillation	[patients with fibrillation]	4.226566668589751	3	4	4	3
265	131	treatment for HF	[treatment for HF]	4.226566668589751	3	4	4	3
266	131	Cardiac resynchronization therapy	[Cardiac Resynchronization Therapy]	4.226566668589751	3	4	4	3
267	132	n	[n]	4.2	1	43	1	1
268	132	confidence	[confidence]	4.2	1	43	5	5
269	133	high mortality	[high mortality]	4.0	2	5	3	3
270	133	medical management	[medical management]	4.0	2	5	4	4
271	133	end stage	[end stage]	4.0	2	5	5	5
272	133	2 week	[2 weeks]	4.0	2	5	2	2
273	133	long outcome	[long-term outcomes]	4.0	2	5	1	1
274	133	systolic dysfunction	[systolic dysfunction]	4.0	2	5	3	3
275	133	transcription factor	[transcription factor]	4.0	2	5	3	3
276	133	adverse outcome	[adverse outcome]	4.0	2	5	3	3
277	133	degenerative mr	[degenerative MR]	4.0	2	5	1	1
278	133	chronic HF	[chronic HF]	4.0	2	4	0	0
279	133	mortality rate	[mortality rate]	4.0	2	5	3	3
280	133	receptor antagonist	[receptor antagonist]	4.0	2	6	6	3
281	133	fail heart	[failing heart]	4.0	2	5	4	4
282	133	4 year	[4 years]	4.0	2	5	2	2
283	133	low-dose dopamine	[low-dose dopamine]	4.0	2	5	1	1
284	133	idiopathic cardiomyopathy	[idiopathic cardiomyopathy]	4.0	2	5	4	4
285	133	low-dose nesiritide	[low-dose nesiritide]	4.0	2	5	1	1
286	133	salt loading	[salt loading]	4.0	2	5	4	4
287	133	usual care	[usual care]	4.0	2	5	1	1
288	133	severe cad	[severe CAD]	4.0	2	5	1	1
289	133	health outcome	[health outcomes]	4.0	2	5	3	3
290	133	baseline characteristic	[baseline characteristics]	4.0	2	5	3	3
291	133	physician volume	[Physician volume]	4.0	2	5	1	1
292	133	familiar physician	[familiar physician]	4.0	2	5	1	1
293	133	clinical status	[clinical status]	4.0	2	4	0	0
294	133	membrane oxygenation	[membrane oxygenation]	4.0	2	5	5	5
295	133	Exercise training	[Exercise Training]	4.0	2	5	5	5
296	133	systolic pressure	[systolic pressure]	4.0	2	5	5	5
297	133	breast cancer	[breast cancer]	4.0	2	5	3	3
298	133	inappropriate therapy	[inappropriate therapy]	4.0	2	5	1	1
299	133	pulmonary embolism	[pulmonary embolism]	4.0	2	5	1	1
300	133	medical record	[medical records]	4.0	2	4	0	0
301	133	15 millileter	[15 mL]	4.0	2	5	3	3
302	133	further study	[further study]	4.0	2	5	2	2
303	133	type 2	[type 2]	4.0	2	5	3	3
304	133	concurrent HF	[Concurrent HF]	4.0	2	4	0	0
305	133	social support	[social support]	4.0	2	5	2	2
306	133	patient population	[patient population]	4.0	2	4	0	0
307	133	exercise rehabilitation	[exercise rehabilitation]	4.0	2	5	4	4
308	133	Multivariate analysis	[Multivariate analysis]	4.0	2	4	0	0
309	133	cardiac hypertrophy	[cardiac hypertrophy]	4.0	2	5	3	3
310	133	mitral valve	[mitral valve]	4.0	2	5	3	3
311	133	mean age	[mean age]	4.0	2	7	3	1
312	133	similar result	[Similar results]	4.0	2	4	0	0
313	133	hr reduction	[HR reduction]	4.0	2	5	5	5
314	133	dialysis patient	[dialysis patients]	4.0	2	5	1	1
315	133	RV dysfunction	[RV dysfunction]	4.0	2	6	4	2
316	133	cardiac transplant	[cardiac transplant]	4.0	2	5	4	4
317	133	Nordic walking	[Nordic walking]	4.0	2	5	1	1
318	133	nyha class	[NYHA class]	4.0	2	5	4	4
319	133	diet score	[diet score]	4.0	2	5	5	5
320	133	MAIN outcome	[MAIN OUTCOME]	4.0	2	5	1	1
321	133	present study	[present study]	4.0	2	5	1	1
322	133	follow-up period	[follow-up period]	4.0	2	5	5	5
323	133	contextual reason	[contextual reasons]	4.0	2	5	3	3
324	133	CHF patient	[CHF patients]	4.0	2	5	5	5
325	134	implantable cardioverter-defibrillator deactivation discussion	[implantable cardioverter-defibrillator deactivation discussions]	3.9624062518028906	4	4	3	2
326	134	successful valve plasty	[successful valve plasty]	3.9624062518028906	3	4	3	2
327	134	myocardial infarction AMI	[myocardial infarction AMI]	3.9624062518028906	3	5	5	2
328	134	obstructive pulmonary disease	[obstructive pulmonary disease]	3.9624062518028906	3	5	5	2
329	134	effect of exercise training	[effect of exercise training]	3.9624062518028906	4	4	3	2
330	134	resynchronization therapy CRT	[resynchronization therapy CRT]	3.9624062518028906	3	5	5	2
331	135	hospitalization	[hospitalization]	3.873684210526316	1	40	24	19
332	136	care	[care]	3.8619047619047624	1	40	29	21
333	137	improvement	[improvement]	3.8520000000000003	1	40	37	25
334	138	month	[month]	3.8100000000000005	1	40	38	20
335	139	patient with heart failure CHF	[patient with heart failure CHF]	3.75	5	5	5	4
336	139	LV ejection	[LV ejection]	3.75	2	5	5	4
337	139	beta-blocker therapy	[beta-blocker therapy]	3.75	2	5	5	4
338	140	control	[control]	3.6944444444444446	1	38	19	18
339	141	prognostic factor	[prognostic factor]	3.666666666666667	2	5	4	3
340	141	ed visit	[ED visits]	3.666666666666667	2	5	4	3
341	141	TNF antagonist	[TNF antagonist]	3.666666666666667	2	5	4	3
342	142	hfpef	[HFpEF]	3.6500000000000004	1	38	21	14
343	143	physician	[physician]	3.521428571428572	1	37	25	14
344	144	significant difference	[significant difference]	3.5	2	6	5	2
345	144	ECMO group	[ECMO group]	3.5	2	5	3	2
346	144	severe hypertension	[severe hypertension]	3.5	2	5	3	2
347	145	datum	[data]	3.3882352941176475	1	35	19	17
348	146	m	[m]	3.3375000000000004	1	35	26	16
349	147	myocardial ischemia	[myocardial ischemia]	3.333333333333333	2	5	5	3
350	147	enzyme inhibitor	[enzyme inhibitor]	3.333333333333333	2	5	5	3
351	147	cardioverter-defibrillator deactivation	[cardioverter-defibrillator deactivation]	3.333333333333333	2	5	5	3
352	147	disease management	[disease management]	3.333333333333333	2	5	5	3
353	147	albumin level	[albumin level]	3.333333333333333	2	5	5	3
354	147	peak oxygen	[peak oxygen]	3.333333333333333	2	5	5	3
355	148	quality	[quality]	3.325	1	36	33	12
356	149	analysis	[analysis]	3.279166666666667	1	34	29	24
357	150	hypertension	[hypertension]	3.2785714285714285	1	34	17	14
358	151	health	[health]	3.2625	1	34	22	16
359	152	therapy	[therapy]	3.25	1	34	24	16
360	153	day	[day]	3.188	1	33	28	25
361	154	survival	[survival]	3.1833333333333336	1	33	21	18
362	155	advanced heart failure HF	[advanced heart failure HF]	3.1699250014423126	4	2	0	0
363	155	human heart failure	[Human heart failure]	3.1699250014423126	3	3	2	2
364	155	functional enrichment analysis	[functional enrichment analysis]	3.1699250014423126	3	2	0	0
365	155	LV end-diastolic volume	[LV end-diastolic volume]	3.1699250014423126	3	3	3	3
366	155	N-terminal pro-b-type natriuretic peptide	[N-terminal pro-B-type natriuretic peptide]	3.1699250014423126	4	3	2	2
367	155	end of life	[end of life]	3.1699250014423126	3	2	0	0
368	155	treatment for heart failure	[treatment for heart failure]	3.1699250014423126	4	3	3	3
369	155	ventricular assist device lvas	[ventricular assist devices LVADs]	3.1699250014423126	4	3	2	2
370	155	right atrial myxoma	[Right atrial myxoma]	3.1699250014423126	3	2	0	0
371	155	biomedical reason for nonprescribing	[biomedical reasons for nonprescribing]	3.1699250014423126	4	2	0	0
372	155	creatine kinase activity	[creatine kinase activity]	3.1699250014423126	3	2	0	0
373	155	effect on cardiac function	[effects on cardiac function]	3.1699250014423126	4	3	3	3
374	155	event in patient	[events in patients]	3.1699250014423126	3	3	3	3
375	155	renal function in child	[renal function in children]	3.1699250014423126	4	2	0	0
376	155	left assist device	[left assist device]	3.1699250014423126	3	3	3	3
377	155	HF hospital admission	[HF hospital admissions]	3.1699250014423126	3	2	0	0
378	155	HF with ef	[HF with EF]	3.1699250014423126	3	3	2	2
379	155	aortic blood flow	[aortic blood flow]	3.1699250014423126	3	2	0	0
380	155	8 month of treatment	[8 months of treatment]	3.1699250014423126	4	2	0	0
381	155	relationship between sex	[Relationship between sex]	3.1699250014423126	3	2	0	0
382	155	heart failure after CABG	[heart failure after CABG]	3.1699250014423126	4	2	0	0
383	155	stable heart failure	[stable heart failure]	3.1699250014423126	3	3	3	3
384	155	diastolic mitral valve tethering	[diastolic mitral valve tethering]	3.1699250014423126	4	2	0	0
385	155	ventricular contractile reserve	[ventricular contractile reserve]	3.1699250014423126	3	4	4	2
386	155	prevention of HF	[prevention of HF]	3.1699250014423126	3	3	2	2
387	155	refractory heart failure	[refractory heart failure]	3.1699250014423126	3	3	3	3
388	155	worsen of heart failure	[worsening of heart failure]	3.1699250014423126	4	2	0	0
389	155	high risk for hyperkalemia	[high risk for hyperkalemia]	3.1699250014423126	4	2	0	0
390	155	medical treatment for HF	[medical treatment for HF]	3.1699250014423126	4	3	2	2
391	155	ambulatory patient with HF	[ambulatory patients with HF]	3.1699250014423126	4	2	0	0
392	155	nyha functional class	[NYHA functional class]	3.1699250014423126	3	3	2	2
393	155	pathophysiology of HF	[pathophysiology of HF]	3.1699250014423126	3	3	1	1
394	155	mortality hazard ratio	[mortality hazard ratio]	3.1699250014423126	3	3	2	2
395	155	systolic heart failure HF	[systolic heart failure HF]	3.1699250014423126	4	2	0	0
396	155	high furosemide dose	[higher furosemide dose]	3.1699250014423126	3	2	0	0
397	155	left ventricular assist device	[left ventricular assist device]	3.1699250014423126	4	3	3	3
398	155	Cox regression analysis	[Cox regression analysis]	3.1699250014423126	3	3	2	2
399	155	predict CV event	[predicting CV events]	3.1699250014423126	3	3	3	3
400	155	patient with precapillary ph	[patients with precapillary PH]	3.1699250014423126	4	2	0	0
401	155	severe pulmonary hypertension	[severe pulmonary hypertension]	3.1699250014423126	3	2	0	0
402	155	early rhythm control therapy	[early rhythm control therapy]	3.1699250014423126	4	3	1	1
403	155	implantable cardioverter-defibrillator deactivation	[implantable cardioverter-defibrillator deactivation]	3.1699250014423126	3	3	2	2
404	155	low testosterone status	[low testosterone status]	3.1699250014423126	3	3	1	1
405	155	proportion of patient	[proportion of patients]	3.1699250014423126	3	3	2	2
406	155	heart Failure Survey	[Heart Failure Survey]	3.1699250014423126	3	2	0	0
407	155	less than 130 msec	[less than 130 msec]	3.1699250014423126	4	2	0	0
408	155	risk of mortality	[risk of mortality]	3.1699250014423126	3	3	2	2
409	155	end stage heart failure	[end stage heart failure]	3.1699250014423126	4	3	2	2
410	155	chronic heart failure HF	[chronic heart failure HF]	3.1699250014423126	4	3	1	1
411	155	median rate ratio	[median rate ratio]	3.1699250014423126	3	2	0	0
412	155	mva of 1.2 cm2	[MVA of 1.2 cm2]	3.1699250014423126	4	2	0	0
413	155	mitral annulus velocity	[mitral annulus velocity]	3.1699250014423126	3	3	3	3
414	155	predictive cutoff value	[predictive cutoff value]	3.1699250014423126	3	3	2	2
415	155	goal of this study	[goal of this study]	3.1699250014423126	4	2	0	0
416	155	predictor of outcome	[predictor of outcomes]	3.1699250014423126	3	3	3	3
417	155	cardiovascular risk factor	[cardiovascular risk factors]	3.1699250014423126	3	3	3	3
418	155	acute heart failure HF	[acute heart failure HF]	3.1699250014423126	4	2	0	0
419	155	risk of inappropriate therapy	[risk of inappropriate therapy]	3.1699250014423126	4	2	0	0
420	155	cardiac autonomic balance	[cardiac autonomic balance]	3.1699250014423126	3	2	0	0
421	155	heart failure in patient	[heart failure in patients]	3.1699250014423126	4	3	1	1
422	155	left assist device implantation	[left assist device implantation]	3.1699250014423126	4	3	3	3
423	155	management of heart failure	[management of heart failure]	3.1699250014423126	4	3	2	2
424	155	treatment with carvedilol	[treatment with carvedilol]	3.1699250014423126	3	2	0	0
425	155	mean follow-up of year	[mean follow-up of years]	3.1699250014423126	4	3	3	3
426	155	skeletal muscle mass	[skeletal muscle mass]	3.1699250014423126	3	3	2	2
427	155	mitral valve opening	[mitral valve opening]	3.1699250014423126	3	3	3	3
428	155	72-hour cumulative urine volume	[72-hour cumulative urine volume]	3.1699250014423126	4	3	1	1
429	155	primary end point	[primary end point]	3.1699250014423126	3	3	1	1
430	155	therapy with ivabradine	[Therapy with ivabradine]	3.1699250014423126	3	2	0	0
431	155	narrow qrs complex	[narrow QRS complex]	3.1699250014423126	3	2	0	0
432	155	post-acute care transfer policy	[post-acute care transfer policy]	3.1699250014423126	4	2	0	0
433	155	adverse event rate	[adverse event rates]	3.1699250014423126	3	3	2	2
434	155	HeartMate ii lvad	[HeartMate II LVAD]	3.1699250014423126	3	3	1	1
435	155	multicenter automatic defibrillator	[Multicenter Automatic Defibrillator]	3.1699250014423126	3	2	0	0
436	155	outpatient with heart failure	[outpatients with heart failure]	3.1699250014423126	4	3	1	1
437	155	mild reduction in lvef	[mild reduction in LVEF]	3.1699250014423126	4	3	2	2
438	155	history of myocardial infarction	[history of myocardial infarction]	3.1699250014423126	4	2	0	0
439	155	primary outcome of death	[primary outcome of death]	3.1699250014423126	4	3	2	2
440	155	percentage of myocardial collagen	[percentage of myocardial collagen]	3.1699250014423126	4	2	0	0
441	155	N-terminal pro-b-type peptide	[N-terminal pro-B-type peptide]	3.1699250014423126	3	3	3	3
442	155	heart rate reduction	[heart rate reduction]	3.1699250014423126	3	3	2	2
443	155	treat patient with DCM	[treating patients with DCM]	3.1699250014423126	4	2	0	0
444	155	study end point	[study end point]	3.1699250014423126	3	3	3	3
445	155	mineralocorticoid receptor antagonist	[mineralocorticoid receptor antagonists]	3.1699250014423126	3	4	2	1
446	155	adenine nucleotide content	[adenine nucleotides contents]	3.1699250014423126	3	2	0	0
447	155	patient with pad	[patients with PAD]	3.1699250014423126	3	3	2	2
448	155	coronary artery disease cad	[coronary artery disease CAD]	3.1699250014423126	4	2	0	0
449	155	atrial fibrillation af	[atrial fibrillation AF]	3.1699250014423126	3	3	1	1
450	155	effect on function	[effects on function]	3.1699250014423126	3	3	3	3
451	155	mean ejection fraction	[mean ejection fraction]	3.1699250014423126	3	3	1	1
452	155	normalization of albumin level	[normalization of albumin levels]	3.1699250014423126	4	3	2	2
453	155	kg body mass	[kg body mass]	3.1699250014423126	3	2	0	0
454	155	6-month risk of death	[6-month risk of death]	3.1699250014423126	4	2	0	0
455	155	transverse aortic constriction tac	[transverse aortic constriction TAC]	3.1699250014423126	4	2	0	0
456	155	other outcome measure	[other outcome measures]	3.1699250014423126	3	2	0	0
457	155	non-ischemic heart failure	[non-ischemic heart failure]	3.1699250014423126	3	2	0	0
458	155	patient with ph	[patients with PH]	3.1699250014423126	3	3	3	3
459	155	exercise group p	[exercise group P]	3.1699250014423126	3	2	0	0
460	155	survival of patient	[survival of patients]	3.1699250014423126	3	3	2	2
461	155	cause of systolic HF	[cause of systolic HF]	3.1699250014423126	4	2	0	0
462	155	association between frailty	[association between frailty]	3.1699250014423126	3	2	0	0
463	155	hospitalization for HF	[hospitalization for HF]	3.1699250014423126	3	3	3	3
464	155	history of valve plasty	[history of valve plasty]	3.1699250014423126	4	3	1	1
465	155	Chronic heart failure	[Chronic heart failure]	3.1699250014423126	3	3	1	1
466	155	maintenance of sinus rhythm	[maintenance of sinus rhythm]	3.1699250014423126	4	2	0	0
467	155	acute RV failure	[acute RV failure]	3.1699250014423126	3	3	2	2
468	155	transverse aortic constriction	[transverse aortic constriction]	3.1699250014423126	3	3	1	1
469	155	quality improvement initiative	[quality improvement initiative]	3.1699250014423126	3	2	0	0
470	155	preoperative renal dysfunction	[preoperative renal dysfunction]	3.1699250014423126	3	2	0	0
471	155	treatment with crt-d	[Treatment with CRT-D]	3.1699250014423126	3	2	0	0
472	155	breast cancer patient	[breast cancer patients]	3.1699250014423126	3	3	2	2
473	155	heart failure cost-effectiveness Model	[Heart Failure Cost-Effectiveness Model]	3.1699250014423126	4	2	0	0
474	155	p for trend	[P for trend]	3.1699250014423126	3	3	3	3
475	155	use of medication	[use of medications]	3.1699250014423126	3	3	3	3
476	155	patient aged year	[patients aged years]	3.1699250014423126	3	3	3	3
477	155	prevalence of HF	[prevalence of HF]	3.1699250014423126	3	3	2	2
478	155	patient receive carvedilol	[patients receiving carvedilol]	3.1699250014423126	3	2	0	0
479	155	pulmonary arterial pressure	[pulmonary arterial pressure]	3.1699250014423126	3	3	2	2
480	155	patient with disease	[patients with disease]	3.1699250014423126	3	3	3	3
481	155	left ventricular diastolic function	[left ventricular diastolic function]	3.1699250014423126	4	2	0	0
482	155	need of diuretic	[need of diuretics]	3.1699250014423126	3	2	0	0
483	155	mitral valve plasty	[mitral valve plasty]	3.1699250014423126	3	3	1	1
484	155	ability of BNP	[ability of BNP]	3.1699250014423126	3	2	0	0
485	155	heart rate hr	[heart rate HR]	3.1699250014423126	3	3	2	2
486	155	LV assist device implantation	[LV assist device implantation]	3.1699250014423126	4	2	0	0
487	155	Cox proportional hazard analysis	[Cox proportional hazards analyses]	3.1699250014423126	4	2	0	0
488	155	millileter per m 2	[mL per m 2]	3.1699250014423126	4	3	3	3
489	155	patient with cardiomyopathy	[patients with cardiomyopathy]	3.1699250014423126	3	3	3	3
490	155	patient with diabete	[patients with diabetes]	3.1699250014423126	3	2	0	0
491	155	patient with low sst2	[Patients with low sST2]	3.1699250014423126	4	2	0	0
492	155	number of patient	[number of patients]	3.1699250014423126	3	3	2	2
493	155	evidence from trial	[evidence from trials]	3.1699250014423126	3	3	3	3
494	156	kg	[kg]	3.0941176470588236	1	32	18	17
495	157	body	[body]	3.0700000000000003	1	33	23	10
496	158	role	[role]	3.0500000000000003	1	32	30	20
497	158	difference	[difference]	3.0500000000000003	1	32	21	14
498	159	rate	[rate]	3.0375	1	32	26	16
499	160	peak	[peak]	3.033333333333333	1	32	15	9
500	161	LV volume	[LV volume]	3.0	2	4	4	4
501	161	LCX model	[LCX model]	3.0	2	4	2	2
502	161	survival rate	[survival rates]	3.0	2	4	4	4
503	161	general population	[general population]	3.0	2	4	1	1
504	161	cardiac remodeling	[cardiac remodeling]	3.0	2	4	2	2
505	161	acute care	[acute care]	3.0	2	3	0	0
506	161	hfvt(+) group	[HFVT(+) group]	3.0	2	3	0	0
507	161	treatment strategy	[treatment strategies]	3.0	2	4	3	3
508	161	dyssynchronous HF	[dyssynchronous HF]	3.0	2	4	1	1
509	161	rs synchrony	[RS synchrony]	3.0	2	4	2	2
510	161	health care	[health care]	3.0	2	4	2	2
511	161	LV pressure	[LV pressure]	3.0	2	4	4	4
512	161	preoperative hypoalbuminemia	[preoperative hypoalbuminemia]	3.0	2	3	0	0
513	161	guideline-recommended medication	[guideline-recommended medications]	3.0	2	4	2	2
514	161	cardiac output	[cardiac output]	3.0	2	4	1	1
515	161	2 group	[2 groups]	3.0	2	3	0	0
516	161	HF mortality	[HF mortality]	3.0	2	4	4	4
517	161	spironolactone use	[spironolactone use]	3.0	2	4	3	3
518	161	left ventricular LV ejection fraction	[left ventricular LV ejection fraction]	3.0	5	4	1	1
519	161	medical therapy	[medical therapy]	3.0	2	4	2	2
520	161	severe HF	[severe HF]	3.0	2	4	2	2
521	161	ambulatory patient	[ambulatory patients]	3.0	2	4	2	2
522	161	primary endpoint	[primary endpoint]	3.0	2	4	2	2
523	161	cardiovascular mortality	[cardiovascular mortality]	3.0	2	4	1	1
524	161	ventricular fill	[ventricular filling]	3.0	2	4	1	1
525	161	cardiac index	[cardiac index]	3.0	2	4	3	3
526	161	longitudinal strain	[longitudinal strain]	3.0	2	4	4	4
527	161	other condition	[other conditions]	3.0	2	4	2	2
528	161	age group	[age group]	3.0	2	4	4	4
529	161	high sst2	[high sST2]	3.0	2	4	1	1
530	161	mitral stenosis	[mitral stenosis]	3.0	2	4	3	3
531	161	health status	[health status]	3.0	2	4	2	2
532	161	bnp level	[BNP level]	3.0	2	4	4	4
533	161	muscle mass	[muscle mass]	3.0	2	4	4	4
534	161	HF symptom	[HF symptom]	3.0	2	3	0	0
535	161	lvad implantation	[LVAD implantation]	3.0	2	4	2	2
536	161	beta blocker	[beta blockers]	3.0	2	4	1	1
537	161	Fontan failure	[Fontan failure]	3.0	2	3	0	0
538	161	4 wk	[4 wk]	3.0	2	4	1	1
539	161	significant ms	[significant MS]	3.0	2	3	0	0
540	161	arterial pressure	[arterial pressure]	3.0	2	4	3	3
541	161	12 month	[12 months]	3.0	2	4	2	2
542	161	physician continuity	[physician continuity]	3.0	2	4	1	1
543	161	first month	[first month]	3.0	2	4	1	1
544	161	young adult	[young adults]	3.0	2	4	3	3
545	161	heart transplantation	[heart transplantation]	3.0	2	4	3	3
546	161	inhospital mortality	[inhospital mortality]	3.0	2	4	1	1
547	161	cardiac death	[cardiac death]	3.0	2	5	4	2
548	161	bottleneck stent	[bottleneck stent]	3.0	2	4	2	2
549	161	new target	[new targets]	3.0	2	4	3	3
550	161	care management	[care management]	3.0	2	4	2	2
551	161	pro-b-type peptide	[pro-B-type peptide]	3.0	2	4	4	4
552	161	adult patient	[adult patients]	3.0	2	4	4	4
553	161	LV dilatation	[LV dilatation]	3.0	2	4	4	4
554	161	shock therapy	[shock therapy]	3.0	2	4	1	1
555	161	human resistin	[human resistin]	3.0	2	4	2	2
556	161	implantable cardioverter-defibrillator	[implantable cardioverter-defibrillator]	3.0	2	3	0	0
557	161	one patient	[One patient]	3.0	2	3	0	0
558	161	emergency department	[emergency department]	3.0	2	4	3	3
559	161	cardiac nurse	[cardiac nurse]	3.0	2	3	0	0
560	161	12 week	[12 weeks]	3.0	2	3	0	0
561	161	unclear etiology	[unclear etiology]	3.0	2	3	0	0
562	161	mild mr	[mild MR]	3.0	2	3	0	0
563	161	30 day	[30 days]	3.0	2	4	2	2
564	161	fill pressure	[filling pressure]	3.0	2	4	3	3
565	161	black race	[black race]	3.0	2	3	0	0
566	161	dash diet	[DASH diet]	3.0	2	4	4	4
567	161	office hour	[office hours]	3.0	2	3	0	0
568	161	hospital discharge	[hospital discharge]	3.0	2	4	2	2
569	161	observational study	[observational study]	3.0	2	4	3	3
570	161	cardiac patient	[cardiac patients]	3.0	2	3	0	0
571	161	cardiac rehabilitation	[cardiac rehabilitation]	3.0	2	4	1	1
572	161	myocardial collagen	[myocardial collagen]	3.0	2	3	0	0
573	161	ANS mouse	[ANS mice]	3.0	2	4	2	2
574	161	pulmonary artery	[pulmonary artery]	3.0	2	4	2	2
575	161	cardiac event	[cardiac event]	3.0	2	3	0	0
576	161	all-cause readmission	[all-cause readmission]	3.0	2	4	3	3
577	161	long survival	[long-term survival]	3.0	2	4	3	3
578	161	three group	[three groups]	3.0	2	3	0	0
579	161	study design	[STUDY DESIGN]	3.0	2	4	2	2
580	161	human HF	[human HF]	3.0	2	4	1	1
581	161	air pollution	[air pollution]	3.0	2	4	3	3
582	161	patient with acute heart failure	[patients with acute heart failure]	3.0	5	4	2	2
583	161	low-dose bb	[low-dose BB]	3.0	2	3	0	0
584	161	vascular resistance	[vascular resistance]	3.0	2	4	4	4
585	161	signal pathway	[signaling pathway]	3.0	2	4	2	2
586	161	unfit man	[unfit men]	3.0	2	3	0	0
587	161	acute HF	[acute HF]	3.0	2	4	1	1
588	161	lung weight	[lung weight]	3.0	2	4	2	2
589	161	Hum-Retn mouse	[Hum-Retn mice]	3.0	2	4	2	2
590	161	arterial elastance	[arterial elastance]	3.0	2	4	2	2
591	161	20 week	[20 weeks]	3.0	2	4	1	1
592	161	high-dose bb	[high-dose BB]	3.0	2	3	0	0
593	161	diagnostic procedure	[diagnostic procedure]	3.0	2	3	0	0
594	161	cardiac cachexia	[cardiac cachexia]	3.0	2	3	0	0
595	161	body weight	[body weight]	3.0	2	4	1	1
596	161	echocardiographic score	[echocardiographic score]	3.0	2	4	4	4
597	161	biventricular support	[biventricular support]	3.0	2	4	1	1
598	161	aldosterone antagonist	[aldosterone antagonist]	3.0	2	4	3	3
599	161	recent year	[recent years]	3.0	2	3	0	0
600	161	30 millileter	[30 mL]	3.0	2	4	3	3
601	161	cardiac dysfunction	[cardiac dysfunction]	3.0	2	4	2	2
602	161	standard criterion	[standard criteria]	3.0	2	3	0	0
603	161	ECMO+VAD group	[ECMO+VAD group]	3.0	2	4	1	1
604	161	right reserve	[right reserve]	3.0	2	4	3	3
605	161	early diastolic mitral annular velocity	[early diastolic mitral annular velocity]	3.0	5	3	0	0
606	162	participant	[participant]	2.9923076923076923	1	31	14	13
607	163	model	[model]	2.980952380952381	1	31	25	21
608	164	receptor	[receptor]	2.975	1	31	20	16
609	165	diabete	[diabetes]	2.9000000000000004	1	31	14	7
610	166	cohort	[cohort]	2.877777777777778	1	30	22	18
611	167	benefit	[benefit]	2.875	1	31	27	12
612	168	life	[life]	2.8200000000000003	1	33	24	5
613	169	use	[use]	2.754545454545455	1	30	27	11
614	170	development	[development]	2.7333333333333334	1	30	24	9
615	170	increase	[increase]	2.7333333333333334	1	29	25	15
616	171	management	[management]	2.7	1	29	22	11
617	172	readmission	[readmission]	2.688888888888889	1	28	10	9
618	173	aortic constriction	[aortic constriction]	2.666666666666667	2	4	4	3
619	173	gene program	[gene program]	2.666666666666667	2	4	4	3
620	173	exercise testing	[exercise testing]	2.666666666666667	2	4	4	3
621	173	resource use	[resource use]	2.666666666666667	2	4	4	3
622	173	type diabete	[type diabetes]	2.666666666666667	2	4	4	3
623	173	size reduction	[size reduction]	2.666666666666667	2	4	4	3
624	173	mrna level	[mRNA level]	2.666666666666667	2	4	4	3
625	174	association	[association]	2.6500000000000004	1	29	25	10
626	175	adult	[adult]	2.6307692307692307	1	28	22	13
627	176	cell	[cell]	2.6	1	27	13	13
628	176	include	[including]	2.6	1	27	16	16
629	177	evidence	[evidence]	2.5850000000000004	1	27	23	20
630	178	intervention	[intervention]	2.581818181818182	1	27	13	11
631	179	symptom	[symptom]	2.575	1	27	15	12
632	180	time	[time]	2.5583333333333336	1	27	17	12
633	181	blood	[blood]	2.5571428571428574	1	27	20	14
634	182	exercise group	[exercise group]	2.5	2	4	3	2
635	182	obstructive disease	[obstructive disease]	2.5	2	5	5	2
636	182	qrs duration	[QRS duration]	2.5	2	4	3	2
637	182	Minnesota live	[Minnesota Living]	2.5	2	4	3	2
638	182	kidney injury	[kidney injury]	2.5	2	5	5	2
639	182	male patient	[male patients]	2.5	2	4	3	2
640	182	study patient	[study patients]	2.5	2	4	3	2
641	182	pulmonary disease	[pulmonary disease]	2.5	2	5	5	2
642	182	autonomic balance	[autonomic balance]	2.5	2	4	3	2
643	182	UM cohort	[UM cohort]	2.5	2	4	3	2
644	182	blood flow	[blood flow]	2.5	2	4	3	2
645	182	p value	[p value]	2.5	2	4	3	2
646	183	index	[index]	2.4800000000000004	1	26	18	15
647	184	week	[week]	2.442857142857143	1	26	22	14
648	185	support	[support]	2.4214285714285717	1	26	25	14
649	186	gene	[gene]	2.3947368421052633	1	25	20	19
650	187	device	[device]	2.3833333333333333	1	25	14	12
651	188	measure	[measure]	2.3785714285714286	1	25	17	14
652	189	cumulative urine volume	[cumulative urine volume]	2.3774437510817346	3	3	3	2
653	189	treatment in patient	[Treatment in patients]	2.3774437510817346	3	3	3	2
654	189	ventricular assist device implantation	[ventricular assist device implantation]	2.3774437510817346	4	3	3	2
655	189	Trial investigate outcome	[Trial Investigating Outcomes]	2.3774437510817346	3	3	3	2
656	189	72-hour urine volume	[72-hour urine volume]	2.3774437510817346	3	3	3	2
657	189	early annular velocity	[early annular velocity]	2.3774437510817346	3	3	3	2
658	189	early diastolic mitral velocity	[early diastolic mitral velocity]	2.3774437510817346	4	3	3	2
659	189	patient with sst2	[Patients with sST2]	2.3774437510817346	3	3	3	2
660	189	mitral annular velocity	[mitral annular velocity]	2.3774437510817346	3	3	3	2
661	189	diastolic mitral velocity	[diastolic mitral velocity]	2.3774437510817346	3	3	3	2
662	189	assist device implantation	[assist device implantation]	2.3774437510817346	3	3	3	2
663	189	early mitral annular velocity	[early mitral annular velocity]	2.3774437510817346	4	3	3	2
664	189	diastolic mitral annular velocity	[diastolic mitral annular velocity]	2.3774437510817346	4	3	3	2
665	189	early mitral velocity	[early mitral velocity]	2.3774437510817346	3	3	3	2
666	189	patient with ras	[patients with RAS]	2.3774437510817346	3	3	3	2
667	189	early diastolic annular velocity	[early diastolic annular velocity]	2.3774437510817346	4	3	3	2
668	189	treatment of anemia	[Treatment of anemia]	2.3774437510817346	3	3	3	2
669	189	reduction in lvef	[reduction in LVEF]	2.3774437510817346	3	3	3	2
670	189	early diastolic velocity	[early diastolic velocity]	2.3774437510817346	3	3	3	2
671	189	LV reverse remodeling	[LV reverse remodeling]	2.3774437510817346	3	3	3	2
672	189	diastolic annular velocity	[diastolic annular velocity]	2.3774437510817346	3	3	3	2
673	189	reason for nonprescribing	[reasons for nonprescribing]	2.3774437510817346	3	3	3	2
674	189	risk stratification of patient	[risk stratification of patients]	2.3774437510817346	4	3	3	2
675	189	filtration rate of millileter	[filtration rate of ml]	2.3774437510817346	4	3	3	2
676	189	outcome in heart failure	[outcomes in heart failure]	2.3774437510817346	4	3	3	2
677	189	left ventricular function	[left ventricular function]	2.3774437510817346	3	3	3	2
678	189	artery disease cad	[artery disease CAD]	2.3774437510817346	3	3	3	2
679	189	patient at risk	[patients at risk]	2.3774437510817346	3	3	3	2
680	189	eplerenone in patient	[eplerenone in patients]	2.3774437510817346	3	3	3	2
681	190	predictor	[predictor]	2.35	1	25	21	14
682	191	CRT	[CRT]	2.3000000000000003	1	25	12	6
683	191	objective	[objective]	2.3000000000000003	1	27	8	2
684	191	reduction	[reduction]	2.3000000000000003	1	25	22	11
685	192	artery	[artery]	2.2636363636363637	1	24	15	11
686	193	protein	[protein]	2.1818181818181817	1	23	13	11
687	194	nt-probnp	[NT-proBNP]	2.18	1	23	12	10
688	195	pressure	[pressure]	2.1785714285714284	1	23	17	14
689	196	end	[end]	2.1750000000000003	1	23	15	12
690	197	impact	[impact]	2.1333333333333333	1	24	24	9
691	198	diagnosis	[diagnosis]	2.1222222222222222	1	23	16	9
692	199	review	[review]	2.1	1	23	14	7
693	200	setting	[SETTING]	2.088888888888889	1	22	10	9
694	201	factor	[factor]	2.088235294117647	1	22	19	17
695	202	mechanism	[mechanism]	2.0785714285714287	1	22	17	14
696	203	Cox	[Cox]	2.075	1	22	15	12
697	204	valve	[valve]	2.07	1	22	13	10
698	205	RV	[RV]	2.066666666666667	1	22	8	6
699	206	infarction	[infarction]	2.0666666666666664	1	29	25	3
700	207	ef	[EF]	2.025	1	22	7	4
701	208	study cohort	[study cohort]	2.0	2	2	0	0
702	208	20 year	[20 years]	2.0	2	2	0	0
703	208	linear model	[linear models]	2.0	2	3	2	2
704	208	common condition	[common condition]	2.0	2	3	3	3
705	208	low rate	[lower rate]	2.0	2	4	4	2
706	208	systolic HF of unclear etiology	[systolic HF of unclear etiology]	2.0	5	2	0	0
707	208	pulmonary pressure	[pulmonary pressure]	2.0	2	3	3	3
708	208	1.8 cm2	[1.8 cm2]	2.0	2	2	0	0
709	208	2 receptor	[2 receptors]	2.0	2	3	1	1
710	208	millileter per 1.73 m 2	[mL per 1.73 m 2]	2.0	5	3	3	3
711	208	patient with ventricular assist device	[patients with ventricular assist devices]	2.0	5	2	0	0
712	208	extracellular matrix	[extracellular matrix]	2.0	2	3	2	2
713	208	poor prognosis	[poor prognosis]	2.0	2	3	1	1
714	208	restrict the anterior leaflet opening	[restricting the anterior leaflet opening]	2.0	5	2	0	0
715	208	prediction of LV reverse remodeling	[prediction of LV reverse remodeling]	2.0	5	2	0	0
716	208	grip strength	[grip strength]	2.0	2	3	3	3
717	208	ventricular pressure	[ventricular pressure]	2.0	2	3	2	2
718	208	outcome in heart failure HF	[outcomes in heart failure HF]	2.0	5	2	0	0
719	208	dialysis-dependent patient	[dialysis-dependent patients]	2.0	2	4	2	1
720	208	total expenditure	[total expenditure]	2.0	2	3	2	2
721	208	Exercise intolerance	[Exercise intolerance]	2.0	2	3	1	1
722	208	unfamiliar physician	[unfamiliar physician]	2.0	2	3	1	1
723	208	physician adherence	[physician adherence]	2.0	2	3	2	2
724	208	coronary artery	[coronary artery]	2.0	2	3	2	2
725	208	RV function	[RV function]	2.0	2	3	3	3
726	208	cardiovascular hospitalization	[cardiovascular hospitalization]	2.0	2	2	0	0
727	208	titin modification	[titin modification]	2.0	2	2	0	0
728	208	DNA fragmentation	[DNA fragmentation]	2.0	2	3	1	1
729	208	progenitor cell	[progenitor cells]	2.0	2	3	2	2
730	208	stable HF	[stable HF]	2.0	2	3	2	2
731	208	significant interaction	[significant interaction]	2.0	2	3	3	3
732	208	Minnesota live with heart Failure Questionnaire	[Minnesota Living with Heart Failure Questionnaire]	2.0	6	2	0	0
733	208	cardiovascular complication	[cardiovascular complications]	2.0	2	3	1	1
734	208	heart failure disease management program	[Heart failure disease management programs]	2.0	5	2	0	0
735	208	major role	[major role]	2.0	2	2	0	0
736	208	b treatment	[B treatment]	2.0	2	2	0	0
737	208	potential benefit	[potential benefit]	2.0	2	3	1	1
738	208	laboratory report	[laboratory report]	2.0	2	3	2	2
739	208	clinical care	[clinical care]	2.0	2	2	0	0
740	208	similar distribution	[similar distribution]	2.0	2	2	0	0
741	208	heart team	[heart team]	2.0	2	2	0	0
742	208	coronary angiography	[coronary angiography]	2.0	2	2	0	0
743	208	8296 millileter	[8296 mL]	2.0	2	2	0	0
744	208	chart review	[chart review]	2.0	2	3	1	1
745	208	age year	[age years]	2.0	2	3	2	2
746	208	Ninth revision	[Ninth Revision]	2.0	2	2	0	0
747	208	total mortality	[total mortality]	2.0	2	2	0	0
748	208	two reviewer	[Two reviewers]	2.0	2	2	0	0
749	208	1-year survival	[1-year survival]	2.0	2	3	1	1
750	208	ras uptitration	[RAS uptitration]	2.0	2	3	2	2
751	208	electrical activation	[electrical activation]	2.0	2	2	0	0
752	208	clinical benefit	[clinical benefit]	2.0	2	3	3	3
753	208	metoprolol	[metoprolol]	2.0	1	21	10	10
754	208	1.2 cm2	[1.2 cm2]	2.0	2	2	0	0
755	208	HF epidemiology	[HF epidemiology]	2.0	2	2	0	0
756	208	HF risk	[HF risk]	2.0	2	3	2	2
757	208	eplerenone in patient at risk	[eplerenone in patients at risk]	2.0	5	2	0	0
758	208	dobutamine requirement	[Dobutamine requirement]	2.0	2	2	0	0
759	208	hm ii	[HM II]	2.0	2	3	2	2
760	208	70 bpm	[70 bpm]	2.0	2	3	3	3
761	208	outcome in heart failure patient	[outcome in heart failure patients]	2.0	5	2	0	0
762	208	3.5 mmol	[3.5 mmol]	2.0	2	2	0	0
763	208	2.5 year	[2.5 years]	2.0	2	2	0	0
764	208	beneficial effect of exercise training	[beneficial effect of exercise training]	2.0	5	2	0	0
765	208	primary end	[primary end]	2.0	2	2	0	0
766	208	diastolic function	[diastolic function]	2.0	2	5	3	1
767	208	7 day	[7 days]	2.0	2	3	3	3
768	208	placebo group	[placebo group]	2.0	2	3	1	1
769	208	fractional shortening	[fractional shortening]	2.0	2	2	0	0
770	208	cardiac angiogenesis	[cardiac angiogenesis]	2.0	2	3	2	2
771	208	lvef hr	[LVEF HR]	2.0	2	2	0	0
772	208	diet group	[diet group]	2.0	2	2	0	0
773	208	exercise tolerance	[exercise tolerance]	2.0	2	3	2	2
774	208	patient undergo assist device implantation	[patients undergoing assist device implantation]	2.0	5	2	0	0
775	208	cardiac support	[cardiac support]	2.0	2	4	4	2
776	208	five patient	[five patients]	2.0	2	3	2	2
777	208	muscular strength	[muscular strength]	2.0	2	2	0	0
778	208	30-day readmission	[30-day readmission]	2.0	2	2	0	0
779	208	β-adrenoceptor blockade	[β-adrenoceptor blockade]	2.0	2	3	2	2
780	208	nursing-sensitive outcome	[Nursing-sensitive outcome]	2.0	2	2	0	0
781	208	high-volume physician	[high-volume physicians]	2.0	2	3	1	1
782	208	ivc occlusion	[IVC occlusion]	2.0	2	2	0	0
783	208	therapeutic implication	[therapeutic implications]	2.0	2	3	3	3
784	208	Kansas City Cardiomyopathy Questionnaire KCCQ	[Kansas City Cardiomyopathy Questionnaire KCCQ]	2.0	5	2	0	0
785	208	total adiponectin	[total adiponectin]	2.0	2	2	0	0
786	208	total sample	[total sample]	2.0	2	3	1	1
787	208	resistin level	[resistin levels]	2.0	2	3	3	3
788	208	left ventricular assist device implantation	[left ventricular assist device implantation]	2.0	5	3	2	2
789	208	inflammatory marker	[inflammatory markers]	2.0	2	2	0	0
790	208	bundle branch	[bundle branch]	2.0	2	4	4	2
791	208	volume index	[volume index]	2.0	2	3	3	3
792	208	Cochrane Library	[Cochrane Library]	2.0	2	2	0	0
793	208	1.7 cm2	[1.7 cm2]	2.0	2	2	0	0
794	208	CHF-INV rabbit	[CHF-INV rabbits]	2.0	2	2	0	0
795	208	long time	[long time]	2.0	2	2	0	0
796	208	erythropoiesis-stimulating agent	[erythropoiesis-stimulating agents]	2.0	2	2	0	0
797	208	skeletal muscle	[skeletal muscle]	2.0	2	3	2	2
798	208	6-month survival	[6-month survival]	2.0	2	2	0	0
799	208	discrimination improvement	[discrimination improvement]	2.0	2	2	0	0
800	208	exercise performance	[exercise performance]	2.0	2	3	1	1
801	208	high-volume ed	[high-volume EDs]	2.0	2	2	0	0
802	208	protein expression	[protein expression]	2.0	2	2	0	0
803	208	low mortality	[lower mortality]	2.0	2	3	2	2
804	208	ultrastructural change	[ultrastructural changes]	2.0	2	3	1	1
805	208	patient with severe heart failure	[patients with severe heart failure]	2.0	5	3	1	1
806	208	nt-probnp level	[NT-proBNP levels]	2.0	2	3	2	2
807	208	620 foot	[620 feet]	2.0	2	2	0	0
808	208	exercise time	[exercise time]	2.0	2	3	3	3
809	208	clinical variable	[clinical variables]	2.0	2	3	2	2
810	208	several cancer	[several cancers]	2.0	2	2	0	0
811	208	patient with left ejection fraction	[patients with left ejection fraction]	2.0	5	3	3	3
812	208	myocardial function	[myocardial function]	2.0	2	2	0	0
813	208	adipose tissue	[adipose tissue]	2.0	2	2	0	0
814	208	Fontan circulation	[Fontan circulation]	2.0	2	3	3	3
815	208	quality-of-life score	[quality-of-life score]	2.0	2	3	1	1
816	208	elderly patient	[elderly patients]	2.0	2	2	0	0
817	208	cognitive impairment	[cognitive impairment]	2.0	2	3	2	2
818	208	flow-mediated dilatation	[flow-mediated dilatation]	2.0	2	3	2	2
819	208	adult population	[adult population]	2.0	2	2	0	0
820	208	baseline Hgb	[baseline Hgb]	2.0	2	2	0	0
821	208	physical activity	[physical activity]	2.0	2	3	2	2
822	208	network meta-analysis	[network meta-analysis]	2.0	2	2	0	0
823	208	contractile reserve	[contractile reserve]	2.0	2	4	4	2
824	208	qrs prolongation	[QRS prolongation]	2.0	2	2	0	0
825	208	vad group	[VAD group]	2.0	2	4	2	1
826	208	surgical indication	[surgical indication]	2.0	2	3	2	2
827	208	Functional ms	[Functional MS]	2.0	2	2	0	0
828	208	124 patient	[124 patients]	2.0	2	2	0	0
829	208	6 minute	[6 min]	2.0	2	3	3	3
830	208	physical examination	[physical examination]	2.0	2	2	0	0
831	208	271 patient	[271 patients]	2.0	2	2	0	0
832	208	child with end-stage heart failure	[children with end-stage heart failure]	2.0	5	2	0	0
833	208	add ctnt	[Adding cTnT]	2.0	2	2	0	0
834	208	qrs duration of 130 msec	[QRS duration of 130 msec]	2.0	5	2	0	0
835	208	relative risk	[relative risk]	2.0	2	3	2	2
836	208	fat mass	[fat mass]	2.0	2	3	3	3
837	208	clinical datum	[clinical data]	2.0	2	3	1	1
838	208	late-onset HF	[late-onset HF]	2.0	2	2	0	0
839	208	male mouse	[male mice]	2.0	2	2	0	0
840	208	two group	[two groups]	2.0	2	3	1	1
841	208	weight loss	[weight loss]	2.0	2	3	3	3
842	208	acute syndrome	[acute syndrome]	2.0	2	3	2	2
843	208	disease progression	[disease progression]	2.0	2	2	0	0
844	208	caloric restriction	[caloric restriction]	2.0	2	3	2	2
845	208	frequency of 7-day follow-up visit	[frequency of 7-day follow-up visits]	2.0	5	2	0	0
846	208	low sst2	[low sST2]	2.0	2	4	2	1
847	208	iron deficiency	[iron deficiency]	2.0	2	3	1	1
848	208	new approach	[new approach]	2.0	2	3	1	1
849	208	4-year survival	[4-year survival]	2.0	2	3	2	2
850	208	rheumatic fever	[rheumatic fever]	2.0	2	2	0	0
851	208	mean difference	[mean difference]	2.0	2	3	2	2
852	208	test-retest reliability	[test-retest reliability]	2.0	2	3	2	2
853	208	patient with severe pulmonary hypertension	[patients with severe pulmonary hypertension]	2.0	5	2	0	0
854	208	functional status	[functional status]	2.0	2	3	1	1
855	208	young patient	[younger patients]	2.0	2	4	2	1
856	208	data extraction	[Data Extraction]	2.0	2	2	0	0
857	208	apical rotation	[apical rotation]	2.0	2	2	0	0
858	208	atherosclerotic cad	[atherosclerotic CAD]	2.0	2	2	0	0
859	208	favorable outcome	[favorable outcome]	2.0	2	3	1	1
860	208	high BNP	[high BNP]	2.0	2	2	0	0
861	208	risk stratification of cardiac patient	[risk stratification of cardiac patients]	2.0	5	2	0	0
862	208	chronic ischemia	[chronic ischemia]	2.0	2	3	3	3
863	208	trastuzumab user	[trastuzumab users]	2.0	2	2	0	0
864	208	protein kinase	[protein kinase]	2.0	2	3	2	2
865	208	rate control	[rate control]	2.0	2	3	1	1
866	208	avd variation	[AVD variation]	2.0	2	2	0	0
867	208	intensive transition of care program	[intensive transitions of care program]	2.0	5	2	0	0
868	208	myocardial perfusion	[myocardial perfusion]	2.0	2	2	0	0
869	208	clinical characteristic	[clinical characteristics]	2.0	2	3	2	2
870	208	High eo-cfus	[Higher EO-CFUs]	2.0	2	2	0	0
871	208	adjunctive treatment	[adjunctive treatment]	2.0	2	3	3	3
872	208	Univariate analysis	[Univariate analysis]	2.0	2	2	0	0
873	208	lean mass	[lean mass]	2.0	2	3	2	2
874	208	molecular mechanism	[molecular mechanism]	2.0	2	2	0	0
875	208	regression analysis	[regression analysis]	2.0	2	4	2	1
876	208	β coefficient	[β coefficient]	2.0	2	2	0	0
877	208	prior HF	[prior HF]	2.0	2	2	0	0
878	208	intravenous iron	[intravenous iron]	2.0	2	2	0	0
879	208	mitochondrial function	[mitochondrial function]	2.0	2	2	0	0
880	208	use model	[using models]	2.0	2	3	3	3
881	208	contractile function	[contractile function]	2.0	2	3	1	1
882	208	New York heart association class	[New York Heart Association class]	2.0	5	3	1	1
883	208	therapeutic strategy	[therapeutic strategy]	2.0	2	3	1	1
884	208	progressive disease	[progressive disease]	2.0	2	2	0	0
885	208	parasympathetic tone	[parasympathetic tone]	2.0	2	2	0	0
886	208	t1 time	[T1 time]	2.0	2	3	2	2
887	208	HDL healthy	[HDL healthy]	2.0	2	2	0	0
888	208	Gill index	[Gill index]	2.0	2	2	0	0
889	208	poor outcome	[poor outcome]	2.0	2	3	1	1
890	208	small study	[Small studies]	2.0	2	2	0	0
891	208	transverse constriction	[transverse constriction]	2.0	2	3	3	3
892	208	diagnostic performance	[diagnostic performance]	2.0	2	3	3	3
893	208	extreme decile	[extreme decile]	2.0	2	2	0	0
894	208	LV strain	[LV strain]	2.0	2	3	1	1
895	208	ed case	[ED cases]	2.0	2	4	4	2
896	208	mitral annulus	[mitral annulus]	2.0	2	3	3	3
897	208	6 patient	[6 patients]	2.0	2	2	0	0
898	208	pulmonary resistance	[pulmonary resistance]	2.0	2	3	2	2
899	208	regression model	[regression models]	2.0	2	3	3	3
900	208	lead cause	[leading cause]	2.0	2	4	4	2
901	208	early physician follow-up after discharge	[Early physician follow-up after discharge]	2.0	5	2	0	0
902	208	precapillary ph with heart failure	[precapillary PH with heart failure]	2.0	5	2	0	0
903	208	ischemic event	[ischemic events]	2.0	2	3	3	3
904	208	Inappropriate therapy	[Inappropriate therapy]	2.0	2	2	0	0
905	208	heart transplant	[heart transplant]	2.0	2	3	2	2
906	208	incident HF	[incident HF]	2.0	2	3	1	1
907	208	mitochondrial dysfunction	[mitochondrial dysfunction]	2.0	2	3	1	1
908	208	ang infusion	[ANG infusion]	2.0	2	4	4	2
909	208	data source	[DATA SOURCES]	2.0	2	3	1	1
910	208	myofiber shortening	[myofiber shortening]	2.0	2	3	2	2
911	208	inotropic effect	[inotropic effect]	2.0	2	3	3	3
912	208	Cox regression	[Cox regression]	2.0	2	3	3	3
913	208	healthy control	[healthy control]	2.0	2	3	2	2
914	208	237 millisecond	[237 milliseconds]	2.0	2	2	0	0
915	208	use datum	[using data]	2.0	2	3	2	2
916	208	0.11 mg	[0.11 mg]	2.0	2	2	0	0
917	208	patient with atrial fibrillation af	[Patients with atrial fibrillation AF]	2.0	5	2	0	0
918	208	precapillary ph	[precapillary PH]	2.0	2	2	0	0
919	208	exclusion criterion	[exclusion criteria]	2.0	2	2	0	0
920	208	atrial area	[atrial area]	2.0	2	3	3	3
921	208	cardioverter defibrillator-CRT	[cardioverter defibrillator-CRT]	2.0	2	4	4	2
922	208	treatment group	[Treatment group]	2.0	2	3	3	3
923	208	60 year	[60 years]	2.0	2	3	1	1
924	208	rest hr	[resting HR]	2.0	2	3	2	2
925	208	derivation cohort	[derivation cohort]	2.0	2	2	0	0
926	208	Mediterranean diet	[Mediterranean diet]	2.0	2	2	0	0
927	208	old age	[older age]	2.0	2	2	0	0
928	208	collateral growth	[collateral growth]	2.0	2	3	2	2
929	208	first HF hospitalization hazard ratio	[first HF hospitalization hazard ratio]	2.0	5	2	0	0
930	208	≥160 m	[≥160 ms]	2.0	2	2	0	0
931	208	20 mm	[20 mm]	2.0	2	2	0	0
932	208	chromatin-associated protein	[Chromatin-associated proteins]	2.0	2	2	0	0
933	208	ventricular reserve	[ventricular reserve]	2.0	2	4	4	2
934	208	acs consultation	[ACS consultation]	2.0	2	2	0	0
935	208	magnetic resonance	[magnetic resonance]	2.0	2	3	1	1
936	208	6-minute walk	[6-minute walk]	2.0	2	2	0	0
937	208	patient with advanced heart failure	[patients with advanced heart failure]	2.0	5	3	1	1
938	208	3 week	[3 weeks]	2.0	2	3	2	2
939	208	5 day	[5 day]	2.0	2	2	0	0
940	208	further investigation	[further investigation]	2.0	2	3	1	1
941	208	HDL function	[HDL function]	2.0	2	3	1	1
942	208	angiotensin-receptor blocker	[angiotensin-receptor blocker]	2.0	2	2	0	0
943	208	ankle-brachial index	[ankle-brachial index]	2.0	2	2	0	0
944	208	Time-dependent analysis	[Time-dependent analysis]	2.0	2	2	0	0
945	208	large cohort	[large cohort]	2.0	2	2	0	0
946	208	annular size reduction by surgery	[annular size reduction by surgery]	2.0	5	2	0	0
947	208	evidence-based treatment	[Evidence-based treatment]	2.0	2	2	0	0
948	208	Secondary outcome	[Secondary outcomes]	2.0	2	2	0	0
949	208	target dose	[target dose]	2.0	2	3	2	2
950	208	healthy individual	[healthy individuals]	2.0	2	2	0	0
951	208	thromboembolic event	[thromboembolic events]	2.0	2	3	3	3
952	208	LV hypertrophy	[LV hypertrophy]	2.0	2	3	3	3
953	208	sarcomeric microstructure	[sarcomeric microstructure]	2.0	2	3	1	1
954	208	edge-to-edge anastomosis	[edge-to-edge anastomosis]	2.0	2	2	0	0
955	208	2 patient	[2 patients]	2.0	2	2	0	0
956	208	vascular disease	[vascular disease]	2.0	2	4	4	2
957	208	few study	[Few studies]	2.0	2	2	0	0
958	208	follow variable	[following variables]	2.0	2	2	0	0
959	208	important role	[important role]	2.0	2	3	1	1
960	208	patient preference	[patient preferences]	2.0	2	2	0	0
961	208	high pasp	[higher PASP]	2.0	2	2	0	0
962	208	Rad Q66P	[Rad Q66P]	2.0	2	2	0	0
963	208	patient with ventricular ejection fraction	[patients with ventricular ejection fraction]	2.0	5	3	3	3
964	208	advanced HF	[advanced HF]	2.0	2	3	2	2
965	208	male sex	[male sex]	2.0	2	2	0	0
966	208	peripheral disease	[peripheral disease]	2.0	2	4	4	2
967	208	pilot study	[pilot study]	2.0	2	3	2	2
968	208	wall stress	[wall stress]	2.0	2	3	1	1
969	208	select patient	[selecting patients]	2.0	2	2	0	0
970	208	contrast agent	[contrast agent]	2.0	2	3	2	2
971	208	chromatin structure	[chromatin structure]	2.0	2	3	1	1
972	208	adaptive remodelling	[adaptive remodelling]	2.0	2	3	2	2
973	208	remodeling aspect	[remodeling aspects]	2.0	2	3	3	3
974	208	response	[response]	2.0	1	21	15	15
975	209	remodeling	[remodeling]	1.9692307692307693	1	21	17	13
976	210	safety	[safety]	1.9666666666666668	1	21	8	6
977	211	cause	[cause]	1.925	1	21	21	12
978	212	assist	[assist]	1.9000000000000001	1	23	16	4
979	212	mouse	[mouse]	1.9000000000000001	1	20	7	7
980	213	target	[target]	1.8923076923076925	1	20	14	13
981	214	stroke	[stroke]	1.888888888888889	1	20	10	9
982	215	cad	[CAD]	1.8142857142857143	1	20	13	7
983	216	ms	[MS]	1.788888888888889	1	20	19	9
984	217	HFpEF	[HFpEF]	1.75	1	19	6	4
985	218	β-blocker	[β-blocker]	1.7000000000000002	1	18	7	7
986	218	placebo	[placebo]	1.7000000000000002	1	18	1	1
987	219	biomarker	[biomarker]	1.6923076923076925	1	18	14	13
988	220	hypertrophy	[hypertrophy]	1.6909090909090911	1	18	12	11
989	221	diet	[diet]	1.688888888888889	1	18	10	9
990	222	rat	[rat]	1.685714285714286	1	18	8	7
991	223	case	[case]	1.6833333333333333	1	18	7	6
992	224	prognosis	[prognosis]	1.6800000000000002	1	19	11	5
993	225	range	[range]	1.6785714285714286	1	18	17	14
994	226	finding	[finding]	1.675	1	18	10	8
995	227	ratio	[ratio]	1.6714285714285717	1	18	9	7
996	228	man	[man]	1.666666666666667	1	18	12	9
997	228	population	[population]	1.666666666666667	1	18	12	9
998	229	pasp	[PASP]	1.6500000000000001	1	18	9	6
999	230	AMI	[AMI]	1.6333333333333333	1	18	5	3
1000	231	admission	[admission]	1.6	1	17	5	5
1001	231	surgery	[surgery]	1.6	1	17	6	6
1002	232	lvad	[LVAD]	1.5875000000000001	1	17	9	8
1003	233	cause of hospitalization	[cause of hospitalization]	1.5849625007211563	3	2	2	2
1004	233	low-dose nesiritide 0.005 μg	[low-dose nesiritide 0.005 μg]	1.5849625007211563	4	1	0	0
1005	233	vary atrioventricular delay avd	[varying atrioventricular delay AVD]	1.5849625007211563	4	1	0	0
1006	233	novel treatment strategy	[novel treatment strategies]	1.5849625007211563	3	1	0	0
1007	233	ejection fraction outcome trial	[ejection fraction outcomes trial]	1.5849625007211563	4	1	0	0
1008	233	obese diabetic zsf1 rat	[obese diabetic ZSF1 rats]	1.5849625007211563	4	1	0	0
1009	233	new-onset post-lvad ai	[new-onset post-LVAD AI]	1.5849625007211563	3	1	0	0
1010	233	cardiac β-ar responsiveness	[cardiac β-AR responsiveness]	1.5849625007211563	3	1	0	0
1011	233	potentially high risk	[potentially higher risks]	1.5849625007211563	3	1	0	0
1012	233	maximal spironolactone dose	[maximal spironolactone dose]	1.5849625007211563	3	1	0	0
1013	233	hr per kg	[HR per kg]	1.5849625007211563	3	1	0	0
1014	233	American College of Cardiology	[American College of Cardiology]	1.5849625007211563	4	2	1	1
1015	233	hyperkalemia of study medication	[hyperkalemia of study medication]	1.5849625007211563	4	1	0	0
1016	233	long 4 wk effect	[long-term 4 wk effects]	1.5849625007211563	4	1	0	0
1017	233	safety of spironolactone	[safety of spironolactone]	1.5849625007211563	3	1	0	0
1018	233	most adverse event	[Most adverse events]	1.5849625007211563	3	1	0	0
1019	233	young normal reference mean	[young normal reference mean]	1.5849625007211563	4	1	0	0
1020	233	cohort of ambulatory patient	[cohort of ambulatory patients]	1.5849625007211563	4	2	1	1
1021	233	CRT off p=0.06	[CRT OFF P=0.06]	1.5849625007211563	3	1	0	0
1022	233	patient with HFpEF	[patients with HFpEF]	1.5849625007211563	3	2	1	1
1023	233	index of QTV	[index of QTV]	1.5849625007211563	3	1	0	0
1024	233	routine bnp measurement	[routine BNP measurements]	1.5849625007211563	3	1	0	0
1025	233	patient with cardiomyopathy DCM	[patients with cardiomyopathy DCM]	1.5849625007211563	4	1	0	0
1026	233	angiotensin receptor blocker median	[angiotensin receptor blockers median]	1.5849625007211563	4	1	0	0
1027	233	reversibility of heart failure	[reversibility of heart failure]	1.5849625007211563	4	1	0	0
1028	233	cardiac Mena deletion	[cardiac Mena deletion]	1.5849625007211563	3	1	0	0
1029	233	reason for nontreatment	[Reasons for nontreatment]	1.5849625007211563	3	1	0	0
1030	233	ejection fraction treatment option	[ejection fraction treatment options]	1.5849625007211563	4	1	0	0
1031	233	blood cell transfusion	[blood cell transfusion]	1.5849625007211563	3	1	0	0
1032	233	idiopathic cardiomyopathy in Tuscany	[idiopathic cardiomyopathy in Tuscany]	1.5849625007211563	4	1	0	0
1033	233	Aerobic Exercise training	[Aerobic Exercise Training]	1.5849625007211563	3	1	0	0
1034	233	bioprosthetic aortic valve replacement	[bioprosthetic aortic valve replacement]	1.5849625007211563	4	1	0	0
1035	233	implantable cardioverter-defibrillator device	[implantable cardioverter-defibrillator device]	1.5849625007211563	3	1	0	0
1036	233	ventricular systolic strain	[ventricular systolic strain]	1.5849625007211563	3	2	2	2
1037	233	aas with HF	[AAs with HF]	1.5849625007211563	3	1	0	0
1038	233	measurement of peptide	[Measurement of peptides]	1.5849625007211563	3	2	2	2
1039	233	eccentric hypertrophy eh	[eccentric hypertrophy EH]	1.5849625007211563	3	1	0	0
1040	233	overall financial burden	[overall financial burden]	1.5849625007211563	3	1	0	0
1041	233	rise in camp level	[rise in cAMP levels]	1.5849625007211563	4	1	0	0
1042	233	specific diagnostic strategy	[specific diagnostic strategies]	1.5849625007211563	3	1	0	0
1043	233	increase in incidence	[increase in incidence]	1.5849625007211563	3	2	2	2
1044	233	loss of full-length scn5a	[loss of full-length SCN5A]	1.5849625007211563	4	1	0	0
1045	233	all-cause death hazard ratio	[all-cause death hazard ratio]	1.5849625007211563	4	1	0	0
1046	233	abnormal body composition	[abnormal body composition]	1.5849625007211563	3	1	0	0
1047	233	exercise training on KCCQ	[exercise training on KCCQ]	1.5849625007211563	4	1	0	0
1048	233	few HF study	[few HF studies]	1.5849625007211563	3	1	0	0
1049	233	HF in non-aa	[HF in non-AAs]	1.5849625007211563	3	1	0	0
1050	233	left end diameter	[left end diameter]	1.5849625007211563	3	2	2	2
1051	233	patient with hfpef p	[patients with HFpEF P]	1.5849625007211563	4	1	0	0
1052	233	myocardial t1 in swine	[myocardial T1 in swine]	1.5849625007211563	4	1	0	0
1053	233	chemical instability of nitrite	[chemical instability of nitrite]	1.5849625007211563	4	1	0	0
1054	233	pluripotency marker nanog	[pluripotency marker Nanog]	1.5849625007211563	3	1	0	0
1055	233	process of care delivery	[processes of care delivery]	1.5849625007211563	4	1	0	0
1056	233	activation of vegf pathway	[activation of VEGF pathway]	1.5849625007211563	4	1	0	0
1057	233	Study on biomedical treatment	[Studies on biomedical treatment]	1.5849625007211563	4	1	0	0
1058	233	left ventricular systolic strain	[left ventricular systolic strain]	1.5849625007211563	4	2	2	2
1059	233	bmi-matched apparently healthy volunteer	[BMI-matched apparently healthy volunteers]	1.5849625007211563	4	1	0	0
1060	233	diastolic fill formalism	[diastolic filling formalism]	1.5849625007211563	3	1	0	0
1061	233	number of explant c-kit	[number of explant c-Kit]	1.5849625007211563	4	1	0	0
1062	233	dyssynchronous fail heart	[dyssynchronous failing heart]	1.5849625007211563	3	1	0	0
1063	233	symptom of heart failure	[symptoms of heart failure]	1.5849625007211563	4	2	2	2
1064	233	three training per week	[three trainings per week]	1.5849625007211563	4	1	0	0
1065	233	western blot analysis	[Western blot analysis]	1.5849625007211563	3	1	0	0
1066	233	aspect of remodeling	[aspects of remodeling]	1.5849625007211563	3	2	2	2
1067	233	approximately 2900 hm ii	[approximately 2900 HM II]	1.5849625007211563	4	1	0	0
1068	233	therapy refractory cardiogenic shock	[therapy refractory cardiogenic shock]	1.5849625007211563	4	1	0	0
1069	233	patient with non-lbbb	[patients with non-LBBB]	1.5849625007211563	3	2	2	2
1070	233	two 6-wk period	[two 6-wk periods]	1.5849625007211563	3	1	0	0
1071	233	right heart circulatory failure	[right heart circulatory failure]	1.5849625007211563	4	1	0	0
1072	233	expression of type	[expression of type]	1.5849625007211563	3	1	0	0
1073	233	3 month p=0·035	[3 months p=0·035]	1.5849625007211563	3	1	0	0
1074	233	hazard ratio for mortality	[hazard ratio for mortality]	1.5849625007211563	4	2	2	2
1075	233	recent hospital discharge	[recent hospital discharge]	1.5849625007211563	3	2	1	1
1076	233	improve HF prediction	[improving HF prediction]	1.5849625007211563	3	1	0	0
1077	233	Centre for review	[Centre for Reviews]	1.5849625007211563	3	1	0	0
1078	233	LV end-diastolic dimension p	[LV end-diastolic dimension P]	1.5849625007211563	4	1	0	0
1079	233	longitudinal strain of ventricle	[longitudinal strain of ventricle]	1.5849625007211563	4	2	2	2
1080	233	left diastolic end diameter	[left diastolic end diameter]	1.5849625007211563	4	2	2	2
1081	233	Concomitant treatment with SS31	[Concomitant treatment with SS31]	1.5849625007211563	4	1	0	0
1082	233	similar cardiovascular mortality	[similar cardiovascular mortality]	1.5849625007211563	3	1	0	0
1083	233	advanced human HF	[advanced human HF]	1.5849625007211563	3	1	0	0
1084	233	future prospective experimental research	[future prospective experimental research]	1.5849625007211563	4	1	0	0
1085	233	aggressive treatment for HF	[aggressive treatment for HF]	1.5849625007211563	4	2	2	2
1086	233	cohort of elderly patient	[cohort of elderly patients]	1.5849625007211563	4	1	0	0
1087	233	aortic pressure curve	[aortic pressure curve]	1.5849625007211563	3	1	0	0
1088	233	HF patient plasma	[HF patient plasma]	1.5849625007211563	3	1	0	0
1089	233	surface ecg at baseline	[surface ECGs at baseline]	1.5849625007211563	4	1	0	0
1090	233	lesson for nurse leader	[lessons for nurse leaders]	1.5849625007211563	4	1	0	0
1091	233	p .001 relative decrease	[P .001 relative decrease]	1.5849625007211563	4	1	0	0
1092	233	other outcome in patient	[other outcomes in patients]	1.5849625007211563	4	2	2	2
1093	233	homogeneous sandwich alphalisa® immunoassay	[homogeneous sandwich AlphaLISA® immunoassays]	1.5849625007211563	4	1	0	0
1094	233	incident cardiovascular event	[incident cardiovascular events]	1.5849625007211563	3	1	0	0
1095	233	free-breathing pulse sequence	[free-breathing pulse sequence]	1.5849625007211563	3	1	0	0
1096	233	risk of CHF	[risk of CHF]	1.5849625007211563	3	1	0	0
1097	233	speckle tracking echocardiography STE	[speckle tracking echocardiography STE]	1.5849625007211563	4	1	0	0
1098	233	absence of fluid overload	[absence of fluid overload]	1.5849625007211563	4	1	0	0
1099	233	five patient with HF	[five patients with HF]	1.5849625007211563	4	1	0	0
1100	233	systolic dysfunction treatment paradigm	[systolic dysfunction treatment paradigm]	1.5849625007211563	4	1	0	0
1101	233	new onset heart failure	[new onset heart failure]	1.5849625007211563	4	1	0	0
1102	233	t1 of 2 minute	[t1 of 2 minutes]	1.5849625007211563	4	1	0	0
1103	233	high baseline sdqt-to-sdrr ratio	[higher baseline SDQT-to-SDRR ratio]	1.5849625007211563	4	1	0	0
1104	233	group of patient	[group of patients]	1.5849625007211563	3	2	1	1
1105	233	only in patient	[only in patients]	1.5849625007211563	3	2	2	2
1106	233	poc measurement of nps	[POC measurement of NPs]	1.5849625007211563	4	1	0	0
1107	233	traditional myocardial enhancement imaging	[traditional myocardial enhancement imaging]	1.5849625007211563	4	1	0	0
1108	233	aas hazard ratio	[AAs hazard ratio]	1.5849625007211563	3	1	0	0
1109	233	incessant ventricular tachycardia storm	[incessant ventricular tachycardia storm]	1.5849625007211563	4	1	0	0
1110	233	outcome in HF	[outcomes in HF]	1.5849625007211563	3	1	0	0
1111	233	multicenter automatic defibrillator implantation	[Multicenter Automatic Defibrillator Implantation]	1.5849625007211563	4	2	2	2
1112	233	surgical ring implantation	[surgical ring implantation]	1.5849625007211563	3	1	0	0
1113	233	heart Failure Trial	[Heart Failure Trial]	1.5849625007211563	3	2	2	2
1114	233	support with the lvass	[Support with the LVAS]	1.5849625007211563	4	1	0	0
1115	233	relationship among ST2	[relationship among ST2]	1.5849625007211563	3	1	0	0
1116	233	High-cost Medicare fee-for-service beneficiary	[High-cost Medicare fee-for-service beneficiaries]	1.5849625007211563	4	1	0	0
1117	233	natriuretic peptide system	[natriuretic peptide system]	1.5849625007211563	3	1	0	0
1118	233	prevent the breakdown	[preventing the breakdown]	1.5849625007211563	3	1	0	0
1119	233	dyssynchronous heart failure HF	[dyssynchronous heart failure HF]	1.5849625007211563	4	1	0	0
1120	233	heart failure treatment era	[heart failure treatment eras]	1.5849625007211563	4	1	0	0
1121	233	rs synchrony p	[RS synchrony P]	1.5849625007211563	3	1	0	0
1122	233	convert enzyme inhibitor intolerance	[converting enzyme inhibitors intolerance]	1.5849625007211563	4	1	0	0
1123	233	chronic pulmonary hypertension	[chronic pulmonary hypertension]	1.5849625007211563	3	2	2	2
1124	233	stress doppler echocardiography	[stress Doppler echocardiography]	1.5849625007211563	3	2	1	1
1125	233	risk for all outcome	[risk for all outcomes]	1.5849625007211563	4	1	0	0
1126	233	catabolic isoenzyme paf-acetylhydrolase	[catabolic isoenzymes PAF-acetylhydrolase]	1.5849625007211563	3	1	0	0
1127	233	animal with heart failure	[animals with heart failure]	1.5849625007211563	4	1	0	0
1128	233	sampling frame select control	[sampling frame selecting controls]	1.5849625007211563	4	1	0	0
1129	233	30-day risk-adjusted mortality	[30-day risk-adjusted mortality]	1.5849625007211563	3	1	0	0
1130	233	pathological gene induction	[pathological gene induction]	1.5849625007211563	3	1	0	0
1131	233	pulmonary arterial hypertension	[pulmonary arterial hypertension]	1.5849625007211563	3	2	2	2
1132	233	endpoint of cardioverter-defibrillator therapy	[endpoint of cardioverter-defibrillator therapy]	1.5849625007211563	4	1	0	0
1133	233	mean score of 44·3	[mean score of 44·3]	1.5849625007211563	4	1	0	0
1134	233	such as anemia	[such as anemia]	1.5849625007211563	3	1	0	0
1135	233	direct effect on macrophage	[direct effects on macrophages]	1.5849625007211563	4	1	0	0
1136	233	HFrEF 30 day	[HFrEF 30 days]	1.5849625007211563	3	1	0	0
1137	233	suggest myocardial angiogenesis	[suggesting myocardial angiogenesis]	1.5849625007211563	3	1	0	0
1138	233	exercise with testosterone group	[exercise with testosterone group]	1.5849625007211563	4	1	0	0
1139	233	2005 2008 performance	[2005 2008 performance]	1.5849625007211563	3	1	0	0
1140	233	median 388.3 m	[median 388.3 ms]	1.5849625007211563	3	1	0	0
1141	233	woman versus man	[women vs men]	1.5849625007211563	3	1	0	0
1142	233	use angiotensin-converting enzyme inhibitor	[using angiotensin-converting enzyme inhibitors]	1.5849625007211563	4	1	0	0
1143	233	ivabradine 7.5 mg	[ivabradine 7.5 mg]	1.5849625007211563	3	1	0	0
1144	233	patient with degenerative mr	[patients with degenerative MR]	1.5849625007211563	4	1	0	0
1145	233	different gastrointestinal region	[different gastrointestinal regions]	1.5849625007211563	3	1	0	0
1146	233	human myocardial tissue	[human myocardial tissue]	1.5849625007211563	3	1	0	0
1147	233	benefit of crt-d	[benefit of CRT-D]	1.5849625007211563	3	1	0	0
1148	233	prior myocardial infarction-both n	[prior myocardial infarction-both n]	1.5849625007211563	4	1	0	0
1149	233	high risk for hHF	[higher risk for hHF]	1.5849625007211563	4	1	0	0
1150	233	Global longitudinal strain	[Global longitudinal strain]	1.5849625007211563	3	2	2	2
1151	233	ventricular end diameter	[ventricular end diameter]	1.5849625007211563	3	2	2	2
1152	233	regional circumferential strain cs	[regional circumferential strain CS]	1.5849625007211563	4	1	0	0
1153	233	xanthine oxidase xo	[Xanthine oxidase XO]	1.5849625007211563	3	1	0	0
1154	233	endothelial no synthase activation	[endothelial NO synthase activation]	1.5849625007211563	4	1	0	0
1155	233	end-systolic elastance ees	[end-systolic elastance Ees]	1.5849625007211563	3	1	0	0
1156	233	change in clinical status	[change in clinical status]	1.5849625007211563	4	1	0	0
1157	233	ventricular assist device lvad	[ventricular assist device LVAD]	1.5849625007211563	4	2	2	2
1158	233	CHF include fat	[CHF including fat]	1.5849625007211563	3	1	0	0
1159	233	antihypertensive medication use	[antihypertensive medication use]	1.5849625007211563	3	1	0	0
1160	233	limitation in economic model	[limitations in economic models]	1.5849625007211563	4	1	0	0
1161	233	mortality in western society	[mortality in Western society]	1.5849625007211563	4	1	0	0
1162	233	Peripheral artery disease pad	[Peripheral artery disease PAD]	1.5849625007211563	4	1	0	0
1163	233	3 experienced electrocardiographer	[3 experienced electrocardiographers]	1.5849625007211563	3	1	0	0
1164	233	present consensus report	[present consensus report]	1.5849625007211563	3	1	0	0
1165	233	different hospital ranking	[different hospital rankings]	1.5849625007211563	3	1	0	0
1166	233	composite of cardiovascular death	[composite of cardiovascular death]	1.5849625007211563	4	1	0	0
1167	233	different Raf-MEK1 scaffold protein	[different Raf-MEK1 scaffold proteins]	1.5849625007211563	4	1	0	0
1168	233	four treatment group	[Four treatment groups]	1.5849625007211563	3	1	0	0
1169	233	biomarker of neurohormonal stimulation	[Biomarkers of neurohormonal stimulation]	1.5849625007211563	4	1	0	0
1170	233	assist device lvad	[assist device LVAD]	1.5849625007211563	3	2	2	2
1171	233	remodeling in heart failure	[remodeling in heart failure]	1.5849625007211563	4	2	1	1
1172	233	strict statistical standard	[strict statistical standards]	1.5849625007211563	3	1	0	0
1173	233	compete risk hr	[competing risk HR]	1.5849625007211563	3	1	0	0
1174	233	mean ejection fraction EF	[mean ejection fraction EF]	1.5849625007211563	4	1	0	0
1175	233	end of the trial	[end of the trial]	1.5849625007211563	4	1	0	0
1176	233	Clinical artery tonometry variable	[Clinical artery tonometry variables]	1.5849625007211563	4	1	0	0
1177	233	change in thigh muscle	[change in thigh muscle]	1.5849625007211563	4	1	0	0
1178	233	mitochondrial oxidative metabolism	[mitochondrial oxidative metabolism]	1.5849625007211563	3	1	0	0
1179	233	risk of hospital admission	[risk of hospital admission]	1.5849625007211563	4	1	0	0
1180	233	goal-directed lipid-lowering therapy	[goal-directed lipid-lowering therapy]	1.5849625007211563	3	1	0	0
1181	233	cardiac-resynchronization therapy CRT	[Cardiac-resynchronization therapy CRT]	1.5849625007211563	3	1	0	0
1182	233	mitral fill flow	[mitral filling flow]	1.5849625007211563	3	2	1	1
1183	233	high confidence in estimate	[High confidence in estimates]	1.5849625007211563	4	1	0	0
1184	233	increase in follow-up visit	[increase in follow-up visits]	1.5849625007211563	4	1	0	0
1185	233	quality of life qol	[quality of life QOL]	1.5849625007211563	4	1	0	0
1186	233	chronic heart failure patient	[chronic heart failure patients]	1.5849625007211563	4	2	2	2
1187	233	strata of hospital volume	[strata of hospital volume]	1.5849625007211563	4	1	0	0
1188	233	presence of EH	[presence of EH]	1.5849625007211563	3	1	0	0
1189	233	203 HeartMate ii device	[203 HeartMate II devices]	1.5849625007211563	4	1	0	0
1190	233	s'lateral of cm	[s'lateral of cm]	1.5849625007211563	3	2	2	2
1191	233	major health problem	[major health problem]	1.5849625007211563	3	2	2	2
1192	233	improvement in functional capacity	[improvement in functional capacity]	1.5849625007211563	4	2	1	1
1193	233	interaction with exercise training	[interaction with exercise training]	1.5849625007211563	4	2	1	1
1194	233	cytotoxic effect of doxorubicin	[cytotoxic effect of doxorubicin]	1.5849625007211563	4	1	0	0
1195	233	postoperative mortality in patient	[postoperative mortality in patients]	1.5849625007211563	4	1	0	0
1196	233	whole grain intake	[whole grain intake]	1.5849625007211563	3	1	0	0
1197	233	odd ratio aor	[odds ratio aOR]	1.5849625007211563	3	1	0	0
1198	233	pace non-dnx chf-inv	[pace non-DNx CHF-INV]	1.5849625007211563	3	1	0	0
1199	233	≥70 year respectively p	[≥70 years respectively p]	1.5849625007211563	4	1	0	0
1200	233	stable chronic heart failure	[stable chronic heart failure]	1.5849625007211563	4	1	0	0
1201	233	select appropriate end point	[selecting appropriate end points]	1.5849625007211563	4	1	0	0
1202	233	4 Fontan subject	[4 Fontan subjects]	1.5849625007211563	3	1	0	0
1203	233	role in CC	[role in CC]	1.5849625007211563	3	1	0	0
1204	233	surgery 3 month	[surgery 3 months]	1.5849625007211563	3	1	0	0
1205	233	impact of normalization	[impact of normalization]	1.5849625007211563	3	1	0	0
1206	233	renal atherosclerotic Lesion CORAL	[Renal Atherosclerotic Lesions CORAL]	1.5849625007211563	4	1	0	0
1207	233	high activity of paf-ah	[higher activities of PAF-AH]	1.5849625007211563	4	1	0	0
1208	233	196 persistent af patient	[196 persistent AF patients]	1.5849625007211563	4	1	0	0
1209	233	shape the future	[shaping the future]	1.5849625007211563	3	1	0	0
1210	233	long clinical outcome	[long-term clinical outcomes]	1.5849625007211563	3	1	0	0
1211	233	composite quality measure	[composite quality measure]	1.5849625007211563	3	2	1	1
1212	233	Chinese herbal medicine	[Chinese herbal medicine]	1.5849625007211563	3	2	1	1
1213	233	role of irs1	[role of IRS1]	1.5849625007211563	3	1	0	0
1214	233	various transcatheter approach	[Various transcatheter approaches]	1.5849625007211563	3	1	0	0
1215	233	receiver curve auc	[receiver curve AUC]	1.5849625007211563	3	2	2	2
1216	233	clear organic lesion	[clear organic lesion]	1.5849625007211563	3	2	1	1
1217	233	significant interaction by EF	[significant interaction by EF]	1.5849625007211563	4	1	0	0
1218	233	ventricular ejection fraction hfpef	[ventricular ejection fraction HFpEF]	1.5849625007211563	4	2	2	2
1219	233	myocardial extracellular matrix accumulation	[myocardial extracellular matrix accumulation]	1.5849625007211563	4	1	0	0
1220	233	use of this device	[use of these devices]	1.5849625007211563	4	1	0	0
1221	233	decline in renal function	[decline in renal function]	1.5849625007211563	4	1	0	0
1222	233	blocker at final evaluation	[blockers at final evaluation]	1.5849625007211563	4	1	0	0
1223	233	Gene Expression Omnibus	[Gene Expression Omnibus]	1.5849625007211563	3	1	0	0
1224	233	Systolic blood pressure	[Systolic blood pressure]	1.5849625007211563	3	1	0	0
1225	233	health-related quality of life	[health-related quality of life]	1.5849625007211563	4	2	2	2
1226	233	tool for analysis	[Tools for Analysis]	1.5849625007211563	3	2	2	2
1227	233	effectiveness of spironolactone	[Effectiveness of spironolactone]	1.5849625007211563	3	2	1	1
1228	233	wide qrs complex	[wide QRS complex]	1.5849625007211563	3	1	0	0
1229	233	of stenting in RAS	[of stenting in RAS]	1.5849625007211563	4	1	0	0
1230	233	HF heart failure	[HF heart failure]	1.5849625007211563	3	1	0	0
1231	233	257 millisecond 237 millisecond	[257 milliseconds 237 milliseconds]	1.5849625007211563	4	1	0	0
1232	233	monitoring of the patient	[monitoring of the patient]	1.5849625007211563	4	1	0	0
1233	233	implantable cardioverter-defibrillator deactivation preference	[implantable cardioverter-defibrillator deactivation preferences]	1.5849625007211563	4	1	0	0
1234	233	hypertensive LV dysfunction	[hypertensive LV dysfunction]	1.5849625007211563	3	1	0	0
1235	233	independent predictor of mortality	[independent predictor of mortality]	1.5849625007211563	4	2	1	1
1236	233	two patient undergo mt	[two patients undergoing MT]	1.5849625007211563	4	1	0	0
1237	233	normal ventricular ejection fraction	[normal ventricular ejection fraction]	1.5849625007211563	4	1	0	0
1238	233	symptomatic systolic heart failure	[symptomatic systolic heart failure]	1.5849625007211563	4	1	0	0
1239	233	careful clinical evaluation	[careful clinical evaluation]	1.5849625007211563	3	1	0	0
1240	233	implantable cardioverter defibrillator icd	[implantable cardioverter defibrillators ICDs]	1.5849625007211563	4	1	0	0
1241	233	three patient undergo vad	[three patients undergoing VAD]	1.5849625007211563	4	1	0	0
1242	233	finding from this study	[Findings from this study]	1.5849625007211563	4	1	0	0
1243	233	case of a patient	[case of a patient]	1.5849625007211563	4	1	0	0
1244	233	experience with CRT	[experience with CRT]	1.5849625007211563	3	1	0	0
1245	233	rate constant k	[rate constant k]	1.5849625007211563	3	1	0	0
1246	233	symptom of hfpef	[symptom of HFPEF]	1.5849625007211563	3	2	1	1
1247	233	large outcome trial	[large outcomes trial]	1.5849625007211563	3	1	0	0
1248	233	assessment of barrier	[assessment of barriers]	1.5849625007211563	3	1	0	0
1249	233	use each metric	[Using each metric]	1.5849625007211563	3	1	0	0
1250	233	myocardial infarction MI	[myocardial infarction MI]	1.5849625007211563	3	1	0	0
1251	233	people with heart failure	[people with heart failure]	1.5849625007211563	4	1	0	0
1252	233	possible contribution of nursing	[possible contribution of nursing]	1.5849625007211563	4	1	0	0
1253	233	guideline-recommended target dose	[guideline-recommended target dose]	1.5849625007211563	3	2	2	2
1254	233	first 2 trial	[first 2 trials]	1.5849625007211563	3	1	0	0
1255	233	single tertiary referral centre	[Single tertiary referral centre]	1.5849625007211563	4	1	0	0
1256	233	inappropriate implantable cardioverter-defibrillator therapy	[inappropriate implantable cardioverter-defibrillator therapy]	1.5849625007211563	4	2	2	2
1257	233	propensity score decile	[propensity score decile]	1.5849625007211563	3	1	0	0
1258	233	use of ERC	[use of ERC]	1.5849625007211563	3	1	0	0
1259	233	CHF atrial explant	[CHF atrial explants]	1.5849625007211563	3	1	0	0
1260	233	other antihyperglycemic agent	[other antihyperglycemic agents]	1.5849625007211563	3	1	0	0
1261	233	aldosterone antagonist spironolactone	[aldosterone antagonist spironolactone]	1.5849625007211563	3	1	0	0
1262	233	30-day all-cause readmission	[30-day all-cause readmissions]	1.5849625007211563	3	1	0	0
1263	233	low killip class	[lower Killip class]	1.5849625007211563	3	1	0	0
1264	233	risk for Ie	[risk for IE]	1.5849625007211563	3	1	0	0
1265	233	surprisingly Kv4.3 channel rrna	[surprisingly Kv4.3 channel mRNAs]	1.5849625007211563	4	1	0	0
1266	233	function in vitro	[function in vitro]	1.5849625007211563	3	1	0	0
1267	233	Observational cohort study	[Observational cohort study]	1.5849625007211563	3	1	0	0
1268	233	completion of the study	[completion of the study]	1.5849625007211563	4	1	0	0
1269	233	62 primary care clinician	[62 primary care clinicians]	1.5849625007211563	4	1	0	0
1270	233	Multivariable hierarchical regression model	[Multivariable hierarchical regression models]	1.5849625007211563	4	1	0	0
1271	233	percentage of ed visit	[percentage of ED visits]	1.5849625007211563	4	1	0	0
1272	233	very few pdrelated complication	[very few PDrelated complications]	1.5849625007211563	4	1	0	0
1273	233	plasma membrane translocation	[plasma membrane translocation]	1.5849625007211563	3	1	0	0
1274	233	outcome for patient	[outcomes for patients]	1.5849625007211563	3	2	2	2
1275	233	systemic ultra-violet treatment	[systemic UV treatment]	1.5849625007211563	3	1	0	0
1276	233	19 CV death	[19 CV deaths]	1.5849625007211563	3	1	0	0
1277	233	side effect of intervention	[side effects of interventions]	1.5849625007211563	4	1	0	0
1278	233	Seattle heart failure Model	[Seattle Heart Failure Model]	1.5849625007211563	4	1	0	0
1279	233	5 exercise patient	[5 exercise patients]	1.5849625007211563	3	1	0	0
1280	233	total of 293 deg	[total of 293 DEGs]	1.5849625007211563	4	1	0	0
1281	233	Community ARIC study	[Communities ARIC study]	1.5849625007211563	3	1	0	0
1282	233	MADIT-CRT trial defibrillator implantation	[MADIT-CRT trial Defibrillator Implantation]	1.5849625007211563	4	1	0	0
1283	233	refill compliance strata	[refill compliance strata]	1.5849625007211563	3	1	0	0
1284	233	Ambulatory heart Failure Trial	[Ambulatory Heart Failure Trial]	1.5849625007211563	4	2	1	1
1285	233	expression of pluripotency marker	[expression of pluripotency markers]	1.5849625007211563	4	1	0	0
1286	233	LV internal diameter	[LV internal diameter]	1.5849625007211563	3	1	0	0
1287	233	cardiac index score p	[cardiac index score P]	1.5849625007211563	4	1	0	0
1288	233	6-min walk test	[6-min walk test]	1.5849625007211563	3	1	0	0
1289	233	cardiac transplant survival	[cardiac transplant survival]	1.5849625007211563	3	1	0	0
1290	233	solid Ehrlich carcinoma	[solid Ehrlich carcinoma]	1.5849625007211563	3	1	0	0
1291	233	physician in public health	[Physicians in public health]	1.5849625007211563	4	1	0	0
1292	233	commoner among woman	[commoner among women]	1.5849625007211563	3	1	0	0
1293	233	interleukin receptor family member	[interleukin receptor family member]	1.5849625007211563	4	1	0	0
1294	233	rr interval SDRR	[RR intervals SDRR]	1.5849625007211563	3	1	0	0
1295	233	relative value of mdc	[relative value of MDC]	1.5849625007211563	4	1	0	0
1296	233	dialysis-dependent patient with HF	[dialysis-dependent patients with HF]	1.5849625007211563	4	1	0	0
1297	233	ratio good disclose prognosis	[ratio better disclosing prognosis]	1.5849625007211563	4	1	0	0
1298	233	human-to-machine interface hm	[human-to-machine interface HM]	1.5849625007211563	3	1	0	0
1299	233	event at follow-up visit	[events at follow-up visits]	1.5849625007211563	4	1	0	0
1300	233	non-dilated left ventricle	[non-dilated left ventricle]	1.5849625007211563	3	1	0	0
1301	233	brief hypothermic circulatory arrest	[brief hypothermic circulatory arrest]	1.5849625007211563	4	1	0	0
1302	233	myocardial phosphodiesterase-2 pde2	[myocardial phosphodiesterase-2 PDE2]	1.5849625007211563	3	1	0	0
1303	233	AUCs of E	[AUCs of E]	1.5849625007211563	3	1	0	0
1304	233	presence of diastolic dysfunction	[presence of diastolic dysfunction]	1.5849625007211563	4	2	2	2
1305	233	aortic valve oversewing	[aortic valve oversewing]	1.5849625007211563	3	1	0	0
1306	233	clinical sign of HF	[clinical signs of HF]	1.5849625007211563	4	1	0	0
1307	233	ms before the surgery	[MS before the surgery]	1.5849625007211563	4	1	0	0
1308	233	dash diet score	[DASH diet score]	1.5849625007211563	3	2	1	1
1309	233	central venous pressure 18	[central venous pressure 18]	1.5849625007211563	4	1	0	0
1310	233	2,462 cardiovascular event	[2,462 cardiovascular events]	1.5849625007211563	3	1	0	0
1311	233	total ed visit	[total ED visits]	1.5849625007211563	3	1	0	0
1312	233	other ethnic group	[other ethnic groups]	1.5849625007211563	3	1	0	0
1313	233	transcription factor gata4	[transcription factor GATA4]	1.5849625007211563	3	1	0	0
1314	233	need for angiography	[need for angiography]	1.5849625007211563	3	1	0	0
1315	233	peak quadricep force	[peak quadriceps force]	1.5849625007211563	3	2	2	2
1316	233	self-care management scale	[Self-Care Management Scale]	1.5849625007211563	3	1	0	0
1317	233	mortality in nondiabetic patient	[mortality in nondiabetic patients]	1.5849625007211563	4	1	0	0
1318	233	hospital on the basis	[hospitals on the basis]	1.5849625007211563	4	1	0	0
1319	233	International classification of Disease	[International Classification of Diseases]	1.5849625007211563	4	1	0	0
1320	233	high cumulative hazard	[highest cumulative hazard]	1.5849625007211563	3	1	0	0
1321	233	amino-terminal pro-b-type natriuretic peptide	[amino-terminal pro-B-type natriuretic peptide]	1.5849625007211563	4	1	0	0
1322	233	convert enzyme inhibitor	[converting enzyme inhibitors]	1.5849625007211563	3	2	1	1
1323	233	521 patient spironolactone	[521 patients spironolactone]	1.5849625007211563	3	1	0	0
1324	233	principal discharge diagnosis	[principal discharge diagnosis]	1.5849625007211563	3	1	0	0
1325	233	recent study include RELAX-AHF	[recent studies including RELAX-AHF]	1.5849625007211563	4	1	0	0
1326	233	high-cost Medicare beneficiary	[high-cost Medicare beneficiaries]	1.5849625007211563	3	1	0	0
1327	233	benefit of af ablation	[benefit of AF ablation]	1.5849625007211563	4	1	0	0
1328	233	sign of heart failure	[signs of heart failure]	1.5849625007211563	4	1	0	0
1329	233	heart failure in pig	[heart failure in pigs]	1.5849625007211563	4	1	0	0
1330	233	high risk for HF	[higher risk for HF]	1.5849625007211563	4	1	0	0
1331	233	more than 14 day	[more than 14 days]	1.5849625007211563	4	1	0	0
1332	233	patient with thalassaemia major	[patients with thalassaemia major]	1.5849625007211563	4	1	0	0
1333	233	CPET guide exercise rehabilitation	[CPET guiding exercise rehabilitation]	1.5849625007211563	4	1	0	0
1334	233	small subgroup of child	[small subgroup of children]	1.5849625007211563	4	1	0	0
1335	233	(31)p magnetic resonance spectroscopy	[(31)P magnetic resonance spectroscopy]	1.5849625007211563	4	1	0	0
1336	233	point of care poc	[point of care POC]	1.5849625007211563	4	1	0	0
1337	233	pathological gene expression	[pathological gene expression]	1.5849625007211563	3	1	0	0
1338	233	left bundle branch block	[left bundle branch block]	1.5849625007211563	4	2	1	1
1339	233	RVPO with BiVP	[RVPO with BiVP]	1.5849625007211563	3	1	0	0
1340	233	serial measurement of CPC	[serial measurements of CPCs]	1.5849625007211563	4	1	0	0
1341	233	purpose of this article	[purpose of this article]	1.5849625007211563	4	1	0	0
1342	233	completion of training protocol	[completion of training protocol]	1.5849625007211563	4	1	0	0
1343	233	rate of patient	[Rates of patients]	1.5849625007211563	3	1	0	0
1344	233	patient with DCM	[patients with DCM]	1.5849625007211563	3	2	1	1
1345	233	American heart Association AHA	[American Heart Association AHA]	1.5849625007211563	4	1	0	0
1346	233	co-activate transcription factor network	[co-activating transcription factor networks]	1.5849625007211563	4	1	0	0
1347	233	increase in parasympathetic tone	[increase in parasympathetic tone]	1.5849625007211563	4	1	0	0
1348	233	myocardial oxygen consumption	[myocardial oxygen consumption]	1.5849625007211563	3	1	0	0
1349	233	target of bet	[targets of BETs]	1.5849625007211563	3	1	0	0
1350	233	steady decline in eGFR	[steady decline in eGFR]	1.5849625007211563	4	1	0	0
1351	233	lvas CF device	[LVADs CF devices]	1.5849625007211563	3	1	0	0
1352	233	rhythm-control vs. rate-control strategy	[rhythm-control vs. rate-control strategies]	1.5849625007211563	4	1	0	0
1353	233	tapse vs. pasp relationship	[TAPSE vs. PASP relationship]	1.5849625007211563	4	1	0	0
1354	233	peak o2 per kilogram	[peak o2 per kilogram]	1.5849625007211563	4	1	0	0
1355	233	quality of life score	[quality of life score]	1.5849625007211563	4	1	0	0
1356	233	considerable number of patient	[considerable number of patients]	1.5849625007211563	4	1	0	0
1357	233	Survival after lvad surgery	[Survival after LVAD surgery]	1.5849625007211563	4	1	0	0
1358	233	cardiac function in b-treated	[cardiac function in B-treated]	1.5849625007211563	4	1	0	0
1359	233	large randomized control study	[larger randomized control studies]	1.5849625007211563	4	1	0	0
1360	233	level of plasma catecholamine	[levels of plasma catecholamines]	1.5849625007211563	4	1	0	0
1361	233	relation of hemoglobin hgb	[relation of hemoglobin Hgb]	1.5849625007211563	4	1	0	0
1362	233	mortality use random-effect model	[mortality using random-effects models]	1.5849625007211563	4	1	0	0
1363	233	left main 3-vessel cad	[left main 3-vessel CAD]	1.5849625007211563	4	1	0	0
1364	233	heart failure nurse practitioner	[heart failure nurse practitioner]	1.5849625007211563	4	1	0	0
1365	233	exertional shortness of breath	[Exertional Shortness of Breath]	1.5849625007211563	4	1	0	0
1366	233	38 control non-cachectic CHF	[38 controls non-cachectic CHF]	1.5849625007211563	4	1	0	0
1367	233	benefit in exercise capacity	[benefits in exercise capacity]	1.5849625007211563	4	1	0	0
1368	233	heart failure Health Initiative	[heart failure Health Initiative]	1.5849625007211563	4	1	0	0
1369	233	patient require biventricular support	[patients requiring biventricular support]	1.5849625007211563	4	1	0	0
1370	233	resting hr 70 bpm	[resting HR 70 bpm]	1.5849625007211563	4	1	0	0
1371	233	nonpace dnx sham-dnx	[nonpace DNx sham-DNx]	1.5849625007211563	3	1	0	0
1372	233	Anecdotal evidence of benefit	[Anecdotal evidence of benefit]	1.5849625007211563	4	1	0	0
1373	233	dysfunction in molecular pathway	[dysfunction in molecular pathways]	1.5849625007211563	4	1	0	0
1374	233	parameter between the group	[parameters between the groups]	1.5849625007211563	4	1	0	0
1375	233	mitochondrial phosphorylation capacity	[mitochondrial phosphorylation capacity]	1.5849625007211563	3	2	2	2
1376	233	band of caspase	[band of Caspase]	1.5849625007211563	3	1	0	0
1377	233	proportion of deficit present	[proportion of deficits present]	1.5849625007211563	4	1	0	0
1378	233	other tonometric index	[other tonometric indices]	1.5849625007211563	3	1	0	0
1379	233	p for trend 0.01	[P for trend 0.01]	1.5849625007211563	4	1	0	0
1380	233	lead cause of death	[leading causes of death]	1.5849625007211563	4	1	0	0
1381	233	Clinical symptom in HFpEF	[Clinical symptoms in HFpEF]	1.5849625007211563	4	1	0	0
1382	233	patient without diabete	[patients without diabetes]	1.5849625007211563	3	1	0	0
1383	233	ventricular ejection time	[ventricular ejection time]	1.5849625007211563	3	2	2	2
1384	233	right ventricular contractile function	[right ventricular contractile function]	1.5849625007211563	4	1	0	0
1385	233	vivo coronary perfusion	[vivo coronary perfusion]	1.5849625007211563	3	1	0	0
1386	233	Raf-MEK1 signalling pathway	[Raf-MEK1 signalling pathway]	1.5849625007211563	3	1	0	0
1387	233	p for heterogeneity	[P for heterogeneity]	1.5849625007211563	3	1	0	0
1388	233	Medicare demonstration participate clinic	[Medicare demonstration participating clinics]	1.5849625007211563	4	1	0	0
1389	233	measure hospital longitudinal change	[measuring hospital longitudinal change]	1.5849625007211563	4	1	0	0
1390	233	Comparison of baseline characteristic	[Comparison of baseline characteristics]	1.5849625007211563	4	1	0	0
1391	233	comanagement with other clinician	[comanagement with other clinicians]	1.5849625007211563	4	1	0	0
1392	233	acute pulmonary embolism	[acute pulmonary embolism]	1.5849625007211563	3	1	0	0
1393	233	high pde2 activity	[higher PDE2 activity]	1.5849625007211563	3	1	0	0
1394	233	enhancement of evidence-based care	[Enhancement of Evidence-based care]	1.5849625007211563	4	1	0	0
1395	233	grade 2 systolic	[grade 2 systolic]	1.5849625007211563	3	1	0	0
1396	233	efficacy in vivo	[efficacy in vivo]	1.5849625007211563	3	1	0	0
1397	233	benefit of involvement	[benefits of involvement]	1.5849625007211563	3	1	0	0
1398	233	patient require HeartMate ii	[patients requiring HeartMate II]	1.5849625007211563	4	1	0	0
1399	233	cardiac troponin T cTnT	[cardiac troponin T cTnT]	1.5849625007211563	4	1	0	0
1400	233	underlying clinical trial	[underlying clinical trials]	1.5849625007211563	3	1	0	0
1401	233	0.81 percentage point	[0.81 percentage points]	1.5849625007211563	3	1	0	0
1402	233	Recent clinical study	[Recent clinical studies]	1.5849625007211563	3	1	0	0
1403	233	association between psoriasis	[association between psoriasis]	1.5849625007211563	3	1	0	0
1404	233	stimulation of cgmp synthesis	[stimulation of cGMP synthesis]	1.5849625007211563	4	1	0	0
1405	233	LV diastolic dysfunction	[LV diastolic dysfunction]	1.5849625007211563	3	2	1	1
1406	233	risk of GLS	[risk of GLS]	1.5849625007211563	3	1	0	0
1407	233	primary efficacy end point	[primary efficacy end points]	1.5849625007211563	4	1	0	0
1408	233	clinical variable contribute	[clinical variables contributing]	1.5849625007211563	3	1	0	0
1409	233	icd shock during follow-up	[ICD shocks during follow-up]	1.5849625007211563	4	1	0	0
1410	233	different type of beta-blocker	[different types of beta-blockers]	1.5849625007211563	4	1	0	0
1411	233	120 mm hg	[120 mm Hg]	1.5849625007211563	3	1	0	0
1412	233	unfavourable clinical outcome	[unfavourable clinical outcome]	1.5849625007211563	3	1	0	0
1413	233	patient undergo mt	[Patients undergoing MT]	1.5849625007211563	3	2	1	1
1414	233	HF hospitalization hr 1.46	[HF hospitalization HR 1.46]	1.5849625007211563	4	1	0	0
1415	233	new pharmacologic target	[new pharmacologic targets]	1.5849625007211563	3	1	0	0
1416	233	worsen GLS hr	[worsening GLS HR]	1.5849625007211563	3	1	0	0
1417	233	measure of reserve	[measure of reserve]	1.5849625007211563	3	2	2	2
1418	233	Biventricular pacing bivp	[Biventricular pacing BiVP]	1.5849625007211563	3	1	0	0
1419	233	end point include death	[end point including death]	1.5849625007211563	4	1	0	0
1420	233	various physiologic process	[various physiologic processes]	1.5849625007211563	3	1	0	0
1421	233	Texas Cancer Registry–Medicare database	[Texas Cancer Registry–Medicare databases]	1.5849625007211563	4	1	0	0
1422	233	urgent all-cause readmission	[urgent all-cause readmission]	1.5849625007211563	3	1	0	0
1423	233	use a taxonomy	[using a taxonomy]	1.5849625007211563	3	1	0	0
1424	233	estimate of resource use	[estimates of resource use]	1.5849625007211563	4	1	0	0
1425	233	use of trastuzumab	[use of trastuzumab]	1.5849625007211563	3	1	0	0
1426	233	standard clinical practice	[standard clinical practice]	1.5849625007211563	3	1	0	0
1427	233	adherence with exercise training	[adherence with exercise training]	1.5849625007211563	4	1	0	0
1428	233	hazard ratio of 0.86	[hazard ratios of 0.86]	1.5849625007211563	4	1	0	0
1429	233	term of recruitment	[terms of recruitment]	1.5849625007211563	3	1	0	0
1430	233	vasopressin receptor antagonist tolvaptan	[vasopressin receptor antagonist tolvaptan]	1.5849625007211563	4	1	0	0
1431	233	heart failure index version	[Heart Failure Index Version]	1.5849625007211563	4	2	1	1
1432	233	fat free mass FFM	[fat free mass FFM]	1.5849625007211563	4	1	0	0
1433	233	acute HF 4 year	[acute HF 4 years]	1.5849625007211563	4	1	0	0
1434	233	efficiency of c-kit	[efficiency of c-Kit]	1.5849625007211563	3	1	0	0
1435	233	control for patient	[controlling for patient]	1.5849625007211563	3	1	0	0
1436	233	right reserve in patient	[right reserve in patients]	1.5849625007211563	4	2	2	2
1437	233	aortic valve replacement	[aortic valve replacement]	1.5849625007211563	3	2	2	2
1438	233	healthy volunteers--a pilot study	[healthy volunteers--a pilot study]	1.5849625007211563	4	1	0	0
1439	233	exclusion of one trial	[Exclusion of one trial]	1.5849625007211563	4	1	0	0
1440	233	effectiveness of Chinese medicine	[Effectiveness of Chinese medicine]	1.5849625007211563	4	2	2	2
1441	233	monomeric g protein	[monomeric G proteins]	1.5849625007211563	3	1	0	0
1442	233	Ontario Case Costing Initiative	[Ontario Case Costing Initiative]	1.5849625007211563	4	1	0	0
1443	233	spontaneous cardiac dysfunction	[spontaneous cardiac dysfunction]	1.5849625007211563	3	1	0	0
1444	233	cardiac output CO	[cardiac output CO]	1.5849625007211563	3	1	0	0
1445	233	obese zsf1 group	[obese ZSF1 groups]	1.5849625007211563	3	1	0	0
1446	233	CF lvad patient	[CF LVAD patients]	1.5849625007211563	3	2	2	2
1447	233	use of cardioverter defibrillator	[use of cardioverter defibrillators]	1.5849625007211563	4	1	0	0
1448	233	patient in this study	[patients in this study]	1.5849625007211563	4	1	0	0
1449	233	heart failure of therapy	[heart failure of therapies]	1.5849625007211563	4	1	0	0
1450	233	exploratory factor analysis	[exploratory factor analysis]	1.5849625007211563	3	1	0	0
1451	233	simple experimental procedure	[simple experimental procedures]	1.5849625007211563	3	1	0	0
1452	233	large increase in incidence	[largest increases in incidence]	1.5849625007211563	4	1	0	0
1453	233	etiology of the MR	[etiology of the MR]	1.5849625007211563	4	1	0	0
1454	233	Evidence Practice Centre	[Evidence Practice Centres]	1.5849625007211563	3	1	0	0
1455	233	low-sodium dash diet	[Low-sodium DASH diet]	1.5849625007211563	3	1	0	0
1456	233	140 80 mm	[140 80 mm]	1.5849625007211563	3	1	0	0
1457	233	approximately 4.5 second	[approximately 4.5 seconds]	1.5849625007211563	3	1	0	0
1458	233	cohort of old patient	[cohort of older patients]	1.5849625007211563	4	1	0	0
1459	233	abdominal aortic constriction AAC	[abdominal aortic constriction AAC]	1.5849625007211563	4	1	0	0
1460	233	impact on medical resource	[impact on medical resources]	1.5849625007211563	4	1	0	0
1461	233	chromatin-dependent signal transduction	[chromatin-dependent signal transduction]	1.5849625007211563	3	1	0	0
1462	233	1 bioprosthetic valve replacement	[1 bioprosthetic valve replacement]	1.5849625007211563	4	1	0	0
1463	233	300 m respectively	[300 ms respectively]	1.5849625007211563	3	1	0	0
1464	233	left ventricular dilatation	[left ventricular dilatation]	1.5849625007211563	3	1	0	0
1465	233	exercise training in patient	[exercise training in patients]	1.5849625007211563	4	2	1	1
1466	233	HF risk prediction	[HF risk prediction]	1.5849625007211563	3	2	2	2
1467	233	state of PKA subunit	[state of PKA subunits]	1.5849625007211563	4	1	0	0
1468	233	impaired systolic function	[impaired systolic function]	1.5849625007211563	3	1	0	0
1469	233	patient rest hr	[Patients resting HR]	1.5849625007211563	3	1	0	0
1470	233	metabolic enzyme in patient	[metabolic enzymes in patients]	1.5849625007211563	4	1	0	0
1471	233	end of diastole	[end of diastole]	1.5849625007211563	3	1	0	0
1472	233	number of study	[number of studies]	1.5849625007211563	3	2	1	1
1473	233	human embryonic kidney	[human embryonic kidney]	1.5849625007211563	3	1	0	0
1474	233	nontraumatic death during sport	[nontraumatic death during sport]	1.5849625007211563	4	1	0	0
1475	233	ischemic event ies	[ischemic events IEs]	1.5849625007211563	3	1	0	0
1476	233	disappearance of mr	[disappearance of MR]	1.5849625007211563	3	1	0	0
1477	233	change circulate progenitor cell	[Changes circulating progenitor cells]	1.5849625007211563	4	1	0	0
1478	233	aortic valve surgery	[aortic valve surgery]	1.5849625007211563	3	1	0	0
1479	233	finding from the get	[findings from the Get]	1.5849625007211563	4	1	0	0
1480	233	exercise with placebo group	[exercise with placebo group]	1.5849625007211563	4	1	0	0
1481	233	same community HF cohort	[same community HF cohort]	1.5849625007211563	4	1	0	0
1482	233	low peak vo2	[lower peak VO2]	1.5849625007211563	3	1	0	0
1483	233	ability of cardiomyocyte	[ability of cardiomyocytes]	1.5849625007211563	3	1	0	0
1484	233	possibly worsen of disease	[possibly worsening of disease]	1.5849625007211563	4	1	0	0
1485	233	baseline glomerular filtration rate	[baseline glomerular filtration rate]	1.5849625007211563	4	1	0	0
1486	233	injection in patient	[injections in patients]	1.5849625007211563	3	1	0	0
1487	233	Obese zsf1 rat	[Obese ZSF1 rats]	1.5849625007211563	3	1	0	0
1488	233	N-terminal pro-b-type np	[N-terminal pro-B-type NP]	1.5849625007211563	3	1	0	0
1489	233	small pilot study	[small pilot study]	1.5849625007211563	3	1	0	0
1490	233	parallel-group study design	[parallel-group study designs]	1.5849625007211563	3	1	0	0
1491	233	patient with cad	[patients with CAD]	1.5849625007211563	3	2	1	1
1492	233	renal artery stenosis	[Renal artery stenosis]	1.5849625007211563	3	2	1	1
1493	233	ratio of the sdqt	[ratio of the SDQT]	1.5849625007211563	4	1	0	0
1494	233	long ventricular assist device	[long-term ventricular assist device]	1.5849625007211563	4	1	0	0
1495	233	assessment of volume status	[assessment of volume status]	1.5849625007211563	4	1	0	0
1496	233	marker for coagulability	[markers for coagulability]	1.5849625007211563	3	1	0	0
1497	233	transverse constriction tac	[transverse constriction TAC]	1.5849625007211563	3	2	2	2
1498	233	l-type channel inhibition	[L-type channel inhibition]	1.5849625007211563	3	1	0	0
1499	233	mortality in icd-hf patient	[mortality in ICD-HF patients]	1.5849625007211563	4	1	0	0
1500	233	efficacy of CHM	[efficacy of CHM]	1.5849625007211563	3	1	0	0
1501	233	confirmation on other population	[confirmation on other populations]	1.5849625007211563	4	1	0	0
1502	233	mild mitral regurgitation	[mild mitral regurgitation]	1.5849625007211563	3	1	0	0
1503	233	rheumatoid arthritis RA	[rheumatoid arthritis RA]	1.5849625007211563	3	1	0	0
1504	233	conventional clinical systolic parameter	[conventional clinical systolic parameters]	1.5849625007211563	4	1	0	0
1505	233	hospitalisation for heart failure	[hospitalisation for heart failure]	1.5849625007211563	4	2	1	1
1506	233	public health problem	[public health problem]	1.5849625007211563	3	2	2	2
1507	233	14 consecutive patient	[14 consecutive patients]	1.5849625007211563	3	1	0	0
1508	233	initial diagnosis of af	[initial diagnosis of AF]	1.5849625007211563	4	1	0	0
1509	233	trial involve 115 center	[trial involving 115 centers]	1.5849625007211563	4	1	0	0
1510	233	minimal physical exertion	[minimal physical exertion]	1.5849625007211563	3	1	0	0
1511	233	PAF dtt]-insensitive cdp choline	[PAF DTT]-insensitive CDP choline]	1.5849625007211563	4	1	0	0
1512	233	visit with a physician	[visits with a physician]	1.5849625007211563	4	1	0	0
1513	233	uncontrolled hypertension p=0.049	[uncontrolled hypertension P=0.049]	1.5849625007211563	3	1	0	0
1514	233	risk for stroke	[risk for stroke]	1.5849625007211563	3	2	1	1
1515	233	rate of death	[rate of death]	1.5849625007211563	3	2	1	1
1516	233	patient with LBBB	[patients with LBBB]	1.5849625007211563	3	1	0	0
1517	233	enrollment of old patient	[enrollment of older patients]	1.5849625007211563	4	1	0	0
1518	233	contemporary heart failure HF	[Contemporary heart failure HF]	1.5849625007211563	4	1	0	0
1519	233	mva velocity time integral	[MVA velocity time integral]	1.5849625007211563	4	1	0	0
1520	233	LV diastolic stiffness	[LV diastolic stiffness]	1.5849625007211563	3	1	0	0
1521	233	guideline for the recognition	[guidelines for the recognition]	1.5849625007211563	4	1	0	0
1522	233	g-protein-coupled receptor kinase-2	[G-protein-coupled receptor kinase-2]	1.5849625007211563	3	2	1	1
1523	233	cardiac explant c-kit	[cardiac explant c-Kit]	1.5849625007211563	3	1	0	0
1524	233	uptitration after a hospitalization	[uptitration after a hospitalization]	1.5849625007211563	4	1	0	0
1525	233	clinical CHF predictive model	[clinical CHF predictive model]	1.5849625007211563	4	1	0	0
1526	233	use this process	[Using this process]	1.5849625007211563	3	1	0	0
1527	233	weekly trastuzumab administration	[weekly trastuzumab administration]	1.5849625007211563	3	1	0	0
1528	233	inflammatory biomarker hscrp	[inflammatory biomarkers hsCRP]	1.5849625007211563	3	1	0	0
1529	233	15 millileter per m	[15 mL per m]	1.5849625007211563	4	2	2	2
1530	233	equivalent adverse outcome	[equivalent adverse outcomes]	1.5849625007211563	3	1	0	0
1531	233	Medicare fee-for-service beneficiary	[Medicare fee-for-service beneficiaries]	1.5849625007211563	3	2	1	1
1532	233	least 66 year	[least 66 years]	1.5849625007211563	3	1	0	0
1533	233	Cardiac cachexia CC	[Cardiac cachexia CC]	1.5849625007211563	3	1	0	0
1534	233	macrophage from Hum-Retn mouse	[Macrophages from Hum-Retn mice]	1.5849625007211563	4	1	0	0
1535	233	use of biomarker	[use of biomarkers]	1.5849625007211563	3	1	0	0
1536	233	multivariable-adjusted hazard ratio	[Multivariable-adjusted hazard ratios]	1.5849625007211563	3	1	0	0
1537	233	first HF hospitalization	[first HF hospitalization]	1.5849625007211563	3	3	2	1
1538	233	male patient with CHF	[Male patients with CHF]	1.5849625007211563	4	2	2	2
1539	233	HF with ef r=-0.55	[HF with EF r=-0.55]	1.5849625007211563	4	1	0	0
1540	233	hospitalization for wrf	[hospitalization for WRF]	1.5849625007211563	3	1	0	0
1541	233	presence of JQ1	[presence of JQ1]	1.5849625007211563	3	1	0	0
1542	233	Seattle heart Failure survival	[Seattle Heart Failure survival]	1.5849625007211563	4	1	0	0
1543	233	echocardiographic score for prediction	[echocardiographic score for prediction]	1.5849625007211563	4	1	0	0
1544	233	new imaging technique	[Newer imaging techniques]	1.5849625007211563	3	1	0	0
1545	233	structure of the SCHFI	[structure of the SCHFI]	1.5849625007211563	4	1	0	0
1546	233	weak grip strength	[weak grip strength]	1.5849625007211563	3	1	0	0
1547	233	subject with advanced HF	[Subjects with advanced HF]	1.5849625007211563	4	1	0	0
1548	233	patient with AHF	[patients with AHF]	1.5849625007211563	3	1	0	0
1549	233	r-like er kinase perk	[R-like ER kinase PERK]	1.5849625007211563	4	1	0	0
1550	233	significant economic consideration	[significant economic considerations]	1.5849625007211563	3	1	0	0
1551	233	capillary wedge pressure	[capillary wedge pressure]	1.5849625007211563	3	2	2	2
1552	233	seven ischemic abdominal problem	[seven ischemic abdominal problems]	1.5849625007211563	4	1	0	0
1553	233	right ventricular assist device	[right ventricular assist devices]	1.5849625007211563	4	1	0	0
1554	233	contextual reason prescribe angiotensin	[Contextual reasons prescribing angiotensin]	1.5849625007211563	4	1	0	0
1555	233	tac-induced proteomic alteration	[TAC-induced proteomic alterations]	1.5849625007211563	3	1	0	0
1556	233	right ventricular RV function	[right ventricular RV function]	1.5849625007211563	4	1	0	0
1557	233	voltage-gated cardiac na	[voltage-gated cardiac Na]	1.5849625007211563	3	1	0	0
1558	233	such as septal defect	[such as septal defects]	1.5849625007211563	4	1	0	0
1559	233	proximal lad model	[proximal LAD model]	1.5849625007211563	3	1	0	0
1560	233	measure of ventricular reserve	[measure of ventricular reserve]	1.5849625007211563	4	2	2	2
1561	233	non-ischemic heart failure sample	[non-ischemic heart failure samples]	1.5849625007211563	4	2	2	2
1562	233	postmenopausal woman with HF	[postmenopausal women with HF]	1.5849625007211563	4	1	0	0
1563	233	implication of biomarker	[implications of biomarkers]	1.5849625007211563	3	2	2	2
1564	233	poorly contract ventricle	[poorly contracting ventricles]	1.5849625007211563	3	1	0	0
1565	233	In-trial resource utilization	[In-trial resource utilization]	1.5849625007211563	3	1	0	0
1566	233	3.5-fold risk of hyperkalemia	[3.5-fold risk of hyperkalemia]	1.5849625007211563	4	1	0	0
1567	233	normal mouse heart	[normal mouse heart]	1.5849625007211563	3	1	0	0
1568	233	secondary study end point	[secondary study end point]	1.5849625007211563	4	1	0	0
1569	233	decline in ejection fraction	[decline in ejection fraction]	1.5849625007211563	4	1	0	0
1570	233	body composition study	[body composition study]	1.5849625007211563	3	1	0	0
1571	233	tumor necrosis factor tnf)α	[tumor necrosis factor TNF)α]	1.5849625007211563	4	1	0	0
1572	233	percent lean body mass	[percent lean body mass]	1.5849625007211563	4	1	0	0
1573	233	cardiopulmonary exercise test	[cardiopulmonary exercise test]	1.5849625007211563	3	2	2	2
1574	233	surgical indication for ms	[surgical indication for MS]	1.5849625007211563	4	1	0	0
1575	233	onset heart failure	[onset heart failure]	1.5849625007211563	3	2	2	2
1576	233	emergency setting current status	[emergency setting current status]	1.5849625007211563	4	1	0	0
1577	233	other Antihyperglycemic drug	[Other Antihyperglycemic Drugs]	1.5849625007211563	3	1	0	0
1578	233	hospitalization for acute HF	[hospitalization for acute HF]	1.5849625007211563	4	1	0	0
1579	233	pulmonary arterial systolic pressure	[pulmonary arterial systolic pressure]	1.5849625007211563	4	2	1	1
1580	233	role treat heart failure	[role treating heart failure]	1.5849625007211563	4	1	0	0
1581	233	hence of critical importance	[Hence of critical importance]	1.5849625007211563	4	1	0	0
1582	233	patient with hr variability	[patients with HR variability]	1.5849625007211563	4	1	0	0
1583	233	particularly high mortality	[particularly high mortality]	1.5849625007211563	3	1	0	0
1584	233	circulatory assist device	[circulatory assist device]	1.5849625007211563	3	1	0	0
1585	233	ventricular assist device vad	[ventricular assist device VAD]	1.5849625007211563	4	1	0	0
1586	233	adverse neurohormonal activation	[adverse neurohormonal activation]	1.5849625007211563	3	1	0	0
1587	233	Functional electrical stimulation fes	[Functional electrical stimulation FES]	1.5849625007211563	4	1	0	0
1588	233	independent predictor of outcome	[independent predictor of outcomes]	1.5849625007211563	4	2	2	2
1589	233	above comparison statistically significant	[above comparisons statistically significant]	1.5849625007211563	4	1	0	0
1590	233	transition from compensatory hypertrophy	[transition from compensatory hypertrophy]	1.5849625007211563	4	1	0	0
1591	233	serum of participant	[serum of participants]	1.5849625007211563	3	1	0	0
1592	233	change in peak vo2	[change in peak VO2]	1.5849625007211563	4	1	0	0
1593	233	discussion in this review	[Discussion In this review]	1.5849625007211563	4	1	0	0
1594	233	eGFR group iii p	[eGFR group III P]	1.5849625007211563	4	1	0	0
1595	233	use of immunoprecipitation	[use of immunoprecipitation]	1.5849625007211563	3	1	0	0
1596	233	result of patient	[results of patients]	1.5849625007211563	3	1	0	0
1597	233	development of trastuzumab-related CHF	[development of trastuzumab-related CHF]	1.5849625007211563	4	1	0	0
1598	233	diastolic end diameter	[diastolic end diameter]	1.5849625007211563	3	2	2	2
1599	233	examination of DNA fragmentation	[examination of DNA fragmentation]	1.5849625007211563	4	1	0	0
1600	233	multivariable Cox modeling	[multivariable Cox modeling]	1.5849625007211563	3	1	0	0
1601	233	characteristic of young adult	[characteristics of young adults]	1.5849625007211563	4	2	1	1
1602	233	use in clinical practice	[use in clinical practice]	1.5849625007211563	4	1	0	0
1603	233	video edge detection	[video edge detection]	1.5849625007211563	3	1	0	0
1604	233	recent onset heart failure	[recent onset heart failure]	1.5849625007211563	4	1	0	0
1605	233	CI 9.4 millileter	[CI 9.4 ml]	1.5849625007211563	3	1	0	0
1606	233	measure of right reserve	[measure of right reserve]	1.5849625007211563	4	2	2	2
1607	233	subject with HF	[subjects with HF]	1.5849625007211563	3	2	2	2
1608	233	randomized factorial trial	[Randomized factorial trial]	1.5849625007211563	3	1	0	0
1609	233	patient with hf-ref	[patients with HF-REF]	1.5849625007211563	3	2	2	2
1610	233	one hundred forty-six patient	[One hundred forty-six patients]	1.5849625007211563	4	1	0	0
1611	233	patient a Trial	[patients A Trial]	1.5849625007211563	3	2	2	2
1612	233	1 year after discharge	[1 year after discharge]	1.5849625007211563	4	1	0	0
1613	233	CRF after 2 trial	[CRF after 2 trials]	1.5849625007211563	4	1	0	0
1614	233	low cost related	[lower costs related]	1.5849625007211563	3	1	0	0
1615	233	moderate heart failure	[moderate heart failure]	1.5849625007211563	3	1	0	0
1616	233	right-sided cardiac catheterization	[right-sided cardiac catheterization]	1.5849625007211563	3	1	0	0
1617	233	Functional electrical stimulation	[Functional electrical stimulation]	1.5849625007211563	3	2	2	2
1618	233	subgroup of patient	[subgroups of patients]	1.5849625007211563	3	2	2	2
1619	233	drive this gene program	[driving these gene programs]	1.5849625007211563	4	1	0	0
1620	233	systolic pressure pasp	[systolic pressure PASP]	1.5849625007211563	3	2	2	2
1621	233	intervention post study	[intervention post study]	1.5849625007211563	3	1	0	0
1622	233	safety proof-of-principle cohort study	[safety proof-of-principle cohort study]	1.5849625007211563	4	1	0	0
1623	233	failure detect at	[failure detecting AT]	1.5849625007211563	3	1	0	0
1624	233	single-center retrospective chart review	[single-center retrospective chart review]	1.5849625007211563	4	1	0	0
1625	233	bundle branch morphology	[bundle branch morphology]	1.5849625007211563	3	1	0	0
1626	233	very common condition	[very common condition]	1.5849625007211563	3	1	0	0
1627	233	data on study design	[Data on study design]	1.5849625007211563	4	1	0	0
1628	233	social support score psss	[social support score PSSS]	1.5849625007211563	4	1	0	0
1629	233	unadjusted practice-level prescription rate	[unadjusted practice-level prescription rates]	1.5849625007211563	4	1	0	0
1630	233	evidence of reverse remodeling	[evidence of reverse remodeling]	1.5849625007211563	4	1	0	0
1631	233	low mortality for HF	[lower mortality for HF]	1.5849625007211563	4	1	0	0
1632	233	association between the development	[association between the development]	1.5849625007211563	4	1	0	0
1633	233	left heart twist	[left heart twist]	1.5849625007211563	3	1	0	0
1634	233	other cardiovascular condition	[other cardiovascular conditions]	1.5849625007211563	3	1	0	0
1635	233	interaction term analysis	[Interaction term analysis]	1.5849625007211563	3	1	0	0
1636	233	young adult with HF	[young adults with HF]	1.5849625007211563	4	1	0	0
1637	233	urban academic medical center	[urban academic medical center]	1.5849625007211563	4	1	0	0
1638	233	main effect analysis	[main effects analysis]	1.5849625007211563	3	1	0	0
1639	233	contrast group validity	[Contrasting groups validity]	1.5849625007211563	3	1	0	0
1640	233	atherosclerosis the Rotterdam Study	[atherosclerosis the Rotterdam Study]	1.5849625007211563	4	1	0	0
1641	233	maximal cardiopulmonary exercise test	[maximal cardiopulmonary exercise test]	1.5849625007211563	4	1	0	0
1642	233	simple laboratory report model	[simpler laboratory report model]	1.5849625007211563	4	1	0	0
1643	233	long mortality in patient	[long-term mortality in patients]	1.5849625007211563	4	1	0	0
1644	233	basis of the assumption	[basis of the assumption]	1.5849625007211563	4	1	0	0
1645	233	10-cell decrease in cd34+vegfr2	[10-cell decrease in CD34+VEGFR2]	1.5849625007211563	4	1	0	0
1646	233	regulation of feeding	[regulation of feeding]	1.5849625007211563	3	1	0	0
1647	233	subgroup at risk	[subgroups at risk]	1.5849625007211563	3	2	2	2
1648	233	absence of change	[absence of changes]	1.5849625007211563	3	1	0	0
1649	233	dual x-ray absorptiometry DXA	[dual x-ray absorptiometry DXA]	1.5849625007211563	4	1	0	0
1650	233	mitochondrial ultrastructural change	[mitochondrial ultrastructural changes]	1.5849625007211563	3	1	0	0
1651	233	High transfusion threshold	[Higher transfusion thresholds]	1.5849625007211563	3	1	0	0
1652	233	specific research question	[specific research questions]	1.5849625007211563	3	1	0	0
1653	233	age 60 year p=0.016	[age 60 years P=0.016]	1.5849625007211563	4	1	0	0
1654	233	sitagliptin versus pioglitazone CI	[sitagliptin versus pioglitazone CI]	1.5849625007211563	4	1	0	0
1655	233	fat-free mass index	[fat-free mass index]	1.5849625007211563	3	1	0	0
1656	233	score range 0	[score range 0]	1.5849625007211563	3	1	0	0
1657	233	body mass index level	[body mass index levels]	1.5849625007211563	4	1	0	0
1658	233	myocardial insulin resistance	[myocardial insulin resistance]	1.5849625007211563	3	1	0	0
1659	233	cardiac fill pressure	[cardiac filling pressures]	1.5849625007211563	3	1	0	0
1660	233	throughput of at-risk patient	[throughput of at-risk patients]	1.5849625007211563	4	1	0	0
1661	233	salt loading ans	[salt loading ANS]	1.5849625007211563	3	1	0	0
1662	233	heart failure AHF	[heart failure AHF]	1.5849625007211563	3	2	2	2
1663	233	Inhibitor Ivabradine Trial	[Inhibitor Ivabradine Trial]	1.5849625007211563	3	1	0	0
1664	233	new therapeutic approach	[new therapeutic approach]	1.5849625007211563	3	2	1	1
1665	233	pressure-overload-induced heart failure	[pressure-overload-induced heart failure]	1.5849625007211563	3	2	1	1
1666	233	certain dialysis patient	[Certain dialysis patients]	1.5849625007211563	3	1	0	0
1667	233	regard appropriate referral	[regarding appropriate referrals]	1.5849625007211563	3	1	0	0
1668	233	lean ZSF1 group	[lean ZSF1 group]	1.5849625007211563	3	1	0	0
1669	233	permanent periodic breathing pb	[permanent periodic breathing PB]	1.5849625007211563	4	1	0	0
1670	233	posterior wall infarction	[posterior wall infarction]	1.5849625007211563	3	1	0	0
1671	233	participant satisfaction response	[participant satisfaction responses]	1.5849625007211563	3	1	0	0
1672	233	similar cardiac index	[similar cardiac index]	1.5849625007211563	3	1	0	0
1673	233	low egfr 60 year	[low eGFR 60 years]	1.5849625007211563	4	1	0	0
1674	233	symptom of anxiety	[symptoms of anxiety]	1.5849625007211563	3	1	0	0
1675	233	concentric remodeling cr	[concentric remodeling CR]	1.5849625007211563	3	1	0	0
1676	233	month of follow-up	[months of follow-up]	1.5849625007211563	3	2	2	2
1677	233	34 16-month follow-up period	[34 16-month follow-up period]	1.5849625007211563	4	1	0	0
1678	233	ras β-blocker dose change	[RAS β-blocker dose changes]	1.5849625007211563	4	1	0	0
1679	233	more hypokalemia with spironolactone	[more hypokalemia with spironolactone]	1.5849625007211563	4	1	0	0
1680	233	human fail heart	[human failing hearts]	1.5849625007211563	3	1	0	0
1681	233	distressing implantable cardioverter-defibrillator shock	[distressing implantable cardioverter-defibrillator shocks]	1.5849625007211563	4	1	0	0
1682	233	protein response upr	[protein response UPR]	1.5849625007211563	3	1	0	0
1683	233	brain natriuretic peptide	[brain natriuretic peptide]	1.5849625007211563	3	2	2	2
1684	233	history of HF	[history of HF]	1.5849625007211563	3	1	0	0
1685	233	2 week post-aac	[2 weeks post-AAC]	1.5849625007211563	3	1	0	0
1686	233	Cardiac resynchronization therapy CRT	[Cardiac resynchronization therapy CRT]	1.5849625007211563	4	1	0	0
1687	233	available outpatient model	[available outpatient models]	1.5849625007211563	3	1	0	0
1688	233	low rate in patient	[lower rate in patients]	1.5849625007211563	4	1	0	0
1689	233	time of discharge	[time of discharge]	1.5849625007211563	3	1	0	0
1690	233	national patient safety initiative	[national patient safety initiatives]	1.5849625007211563	4	1	0	0
1691	233	mechanical support device	[mechanical support devices]	1.5849625007211563	3	1	0	0
1692	233	frailty for heart failure	[Frailty for heart failure]	1.5849625007211563	4	2	2	2
1693	233	rat metabolic risk model	[rat metabolic risk model]	1.5849625007211563	4	1	0	0
1694	233	biomarker in the treatment	[biomarkers in the treatment]	1.5849625007211563	4	1	0	0
1695	233	prognosis in HFPEF	[prognosis in HFPEF]	1.5849625007211563	3	1	0	0
1696	233	two final multivariate model	[Two final multivariate models]	1.5849625007211563	4	1	0	0
1697	233	debilitating chronic disease	[debilitating chronic disease]	1.5849625007211563	3	1	0	0
1698	233	patient-operated electrocardiographic device	[patient-operated electrocardiographic device]	1.5849625007211563	3	1	0	0
1699	233	left ventricular LV dilatation	[left ventricular LV dilatation]	1.5849625007211563	4	1	0	0
1700	233	exercise training on outcome	[exercise training on outcomes]	1.5849625007211563	4	1	0	0
1701	233	Ser83 mutant riα protein	[Ser83 mutant RIα proteins]	1.5849625007211563	4	1	0	0
1702	233	attenuation in LV dilatation	[attenuation in LV dilatation]	1.5849625007211563	4	1	0	0
1703	233	diuretic resistant volume overload	[diuretic resistant volume overload]	1.5849625007211563	4	1	0	0
1704	233	age of legal majority	[age of legal majority]	1.5849625007211563	4	1	0	0
1705	233	HeartMate ii insertion	[HeartMate II insertion]	1.5849625007211563	3	1	0	0
1706	233	abnormal cardiac t2 value	[Abnormal cardiac T2 values]	1.5849625007211563	4	1	0	0
1707	233	cost of the intervention	[cost of the intervention]	1.5849625007211563	4	1	0	0
1708	233	web of complicity	[web of complicity]	1.5849625007211563	3	1	0	0
1709	233	set of transcription factor	[set of transcription factors]	1.5849625007211563	4	1	0	0
1710	233	impact of rm	[impact of RM]	1.5849625007211563	3	1	0	0
1711	233	HFPEF animal model	[HFPEF animal models]	1.5849625007211563	3	1	0	0
1712	233	risk develop heart failure	[risk developing heart failure]	1.5849625007211563	4	2	1	1
1713	233	other device therapy	[other device therapies]	1.5849625007211563	3	1	0	0
1714	233	user of alendronate	[users of alendronate]	1.5849625007211563	3	1	0	0
1715	233	multivariable logistic analysis	[multivariable logistic analysis]	1.5849625007211563	3	1	0	0
1716	233	clinical prediction rule	[clinical prediction rule]	1.5849625007211563	3	2	1	1
1717	233	disease risk score	[disease risk score]	1.5849625007211563	3	1	0	0
1718	233	self-care confidence scale	[Self-Care Confidence scale]	1.5849625007211563	3	1	0	0
1719	233	five ACS procedure	[five ACS procedures]	1.5849625007211563	3	1	0	0
1720	233	abnormal hr variability	[Abnormal HR variability]	1.5849625007211563	3	1	0	0
1721	233	acute RV decompensation	[acute RV decompensation]	1.5849625007211563	3	1	0	0
1722	233	performance in patient	[performance in patients]	1.5849625007211563	3	2	2	2
1723	233	adjust for confounder	[adjusting for confounders]	1.5849625007211563	3	1	0	0
1724	233	value of mdc	[value of MDC]	1.5849625007211563	3	2	2	2
1725	233	high-volume ed case	[high-volume ED cases]	1.5849625007211563	3	1	0	0
1726	233	patient with diagnosis	[patient with diagnosis]	1.5849625007211563	3	1	0	0
1727	233	ambulatory icd patient	[ambulatory ICD patients]	1.5849625007211563	3	1	0	0
1728	233	trial of exercise training	[trial of exercise training]	1.5849625007211563	4	1	0	0
1729	233	Beck Depression inventory	[Beck Depression Inventory]	1.5849625007211563	3	2	1	1
1730	233	left systolic strain	[left systolic strain]	1.5849625007211563	3	2	2	2
1731	233	express human resistin Retn	[expressing human resistin Retn]	1.5849625007211563	4	1	0	0
1732	233	strain rate at systole	[strain rate at systole]	1.5849625007211563	4	1	0	0
1733	233	duration of support	[duration of support]	1.5849625007211563	3	2	2	2
1734	233	early myocardial fibrosis	[early myocardial fibrosis]	1.5849625007211563	3	1	0	0
1735	233	increase in 30-day rehospitalization	[increase in 30-day rehospitalization]	1.5849625007211563	4	2	1	1
1736	233	respiratory gas analysis	[respiratory gas analysis]	1.5849625007211563	3	1	0	0
1737	233	favorable adverse event profile	[favorable adverse event profile]	1.5849625007211563	4	1	0	0
1738	233	nationwide retrospective cohort study	[nationwide retrospective cohort study]	1.5849625007211563	4	1	0	0
1739	233	adult with heart disease	[adults with heart disease]	1.5849625007211563	4	1	0	0
1740	233	American heart Association	[American Heart Association]	1.5849625007211563	3	2	2	2
1741	233	chronic end-stage heart failure	[chronic end-stage heart failure]	1.5849625007211563	4	1	0	0
1742	233	measurement of natriuretic peptide	[Measurement of natriuretic peptides]	1.5849625007211563	4	2	2	2
1743	233	16 healthy control HDL	[16 healthy controls HDL]	1.5849625007211563	4	1	0	0
1744	233	similar efficacy outcome	[similar efficacy outcomes]	1.5849625007211563	3	1	0	0
1745	233	cerebral blood flow	[cerebral blood flow]	1.5849625007211563	3	1	0	0
1746	233	trial of monitoring device	[trial of monitoring devices]	1.5849625007211563	4	1	0	0
1747	233	Medicare inpatient datum	[Medicare inpatient data]	1.5849625007211563	3	1	0	0
1748	233	extensive change on exercise	[extensive changes on exercise]	1.5849625007211563	4	1	0	0
1749	233	nuclear factor-κB nf-κb	[nuclear factor-κB NF-κB]	1.5849625007211563	3	1	0	0
1750	233	ratio of phosphocreatine	[ratio of phosphocreatine]	1.5849625007211563	3	1	0	0
1751	233	chronic stable hfpef	[chronic stable HFPEF]	1.5849625007211563	3	1	0	0
1752	233	excellent fit index	[excellent fit indices]	1.5849625007211563	3	1	0	0
1753	233	12 556 patient	[12 556 patients]	1.5849625007211563	3	1	0	0
1754	233	cystatin c level nesiritide	[cystatin C level nesiritide]	1.5849625007211563	4	1	0	0
1755	233	open 1:1 allocation ratio	[open 1:1 allocation ratio]	1.5849625007211563	4	1	0	0
1756	233	ch LV end-diastolic volume	[CH LV end-diastolic volume]	1.5849625007211563	4	1	0	0
1757	233	report in cell	[reporting in Cell]	1.5849625007211563	3	1	0	0
1758	233	concept of a disorder	[concept of a disorder]	1.5849625007211563	4	1	0	0
1759	233	considerable national attention	[considerable national attention]	1.5849625007211563	3	1	0	0
1760	233	effectiveness of implementation strategy	[Effectiveness of implementation strategies]	1.5849625007211563	4	1	0	0
1761	233	uptitration in patient	[Uptitration in patients]	1.5849625007211563	3	1	0	0
1762	233	non-linear hr variability measure	[non-linear HR variability measures]	1.5849625007211563	4	1	0	0
1763	233	Novel noninvasive tool	[Novel noninvasive tools]	1.5849625007211563	3	1	0	0
1764	233	N-terminal fragment nt-probnp	[N-terminal fragment NT-proBNP]	1.5849625007211563	3	1	0	0
1765	233	myocardial t1 change	[myocardial T1 changes]	1.5849625007211563	3	1	0	0
1766	233	predictor after resynchronization therapy	[predictors after resynchronization therapy]	1.5849625007211563	4	2	2	2
1767	233	ventricular action potential	[ventricular action potential]	1.5849625007211563	3	2	1	1
1768	233	circulation of HF patient	[circulation of HF patients]	1.5849625007211563	4	1	0	0
1769	233	development of event	[development of events]	1.5849625007211563	3	2	2	2
1770	233	xanthine oxidase inhibition	[Xanthine oxidase inhibition]	1.5849625007211563	3	1	0	0
1771	233	Cox regression model	[Cox regression models]	1.5849625007211563	3	1	0	0
1772	233	high risk develop hyperkalemia	[high risk developing hyperkalemia]	1.5849625007211563	4	1	0	0
1773	233	569 individual aged 55	[569 individuals aged 55]	1.5849625007211563	4	1	0	0
1774	233	heart failure scan	[heart failure scans]	1.5849625007211563	3	1	0	0
1775	233	intermediate outcome 0.92 event	[intermediate outcomes 0.92 events]	1.5849625007211563	4	1	0	0
1776	233	future AMI mortality rate	[future AMI mortality rates]	1.5849625007211563	4	1	0	0
1777	233	predict future high performer	[predicting future high performers]	1.5849625007211563	4	1	0	0
1778	233	primary safety end point	[primary safety end point]	1.5849625007211563	4	1	0	0
1779	233	use of antibody	[use of antibodies]	1.5849625007211563	3	1	0	0
1780	233	guideline-heart failure registry	[Guideline-Heart Failure Registry]	1.5849625007211563	3	1	0	0
1781	233	global proteomics change	[global proteomics changes]	1.5849625007211563	3	2	2	2
1782	233	randomized Aldactone evaluation Study	[Randomized Aldactone Evaluation Study]	1.5849625007211563	4	1	0	0
1783	233	impact of PD	[impact of PD]	1.5849625007211563	3	1	0	0
1784	233	Caspase-3 gene expression	[Caspase-3 gene expression]	1.5849625007211563	3	1	0	0
1785	233	coronary artery bypass grafting	[coronary artery bypass grafting]	1.5849625007211563	4	2	1	1
1786	233	RV dysfunction hazard ratio	[RV dysfunction hazard ratio]	1.5849625007211563	4	1	0	0
1787	233	diagnosis of hfpef	[Diagnosis of HFpEF]	1.5849625007211563	3	1	0	0
1788	233	change in patient presentation	[Changes in patient presentation]	1.5849625007211563	4	1	0	0
1789	233	athlete under 35	[athletes under 35]	1.5849625007211563	3	1	0	0
1790	233	left-to-right interatrial shunting	[left-to-right interatrial shunting]	1.5849625007211563	3	2	2	2
1791	233	heart failure admission	[heart failure admission]	1.5849625007211563	3	2	1	1
1792	233	optimal treatment measure	[optimal treatment measure]	1.5849625007211563	3	1	0	0
1793	233	ventricular diastolic function	[ventricular diastolic function]	1.5849625007211563	3	3	2	1
1794	233	indication for lvass support	[indications for LVAS support]	1.5849625007211563	4	1	0	0
1795	233	fixed-rate atrial pacing	[fixed-rate atrial pacing]	1.5849625007211563	3	1	0	0
1796	233	obese old patient	[obese older patients]	1.5849625007211563	3	2	2	2
1797	233	International Classification of Disease	[International Classification of Diseases]	1.5849625007211563	4	2	1	1
1798	233	LV assist device	[LV assist device]	1.5849625007211563	3	1	0	0
1799	233	percentage of CHF patient	[percentage of CHF patients]	1.5849625007211563	4	1	0	0
1800	233	Witness with severe anemia	[Witness with severe anemia]	1.5849625007211563	4	1	0	0
1801	233	renal function end point	[renal function end point]	1.5849625007211563	4	1	0	0
1802	233	effect on HDL function	[effect on HDL function]	1.5849625007211563	4	1	0	0
1803	233	congenital heart lesion	[congenital heart lesions]	1.5849625007211563	3	1	0	0
1804	233	pathophysiology of HFpEF	[pathophysiology of HFpEF]	1.5849625007211563	3	1	0	0
1805	233	postischemic heart failure	[postischemic heart failure]	1.5849625007211563	3	1	0	0
1806	233	TAPSE vs. PASP relationship	[TAPSE vs. PASP relationship]	1.5849625007211563	4	1	0	0
1807	233	99 patient with dyspnea	[99 patients with dyspnea]	1.5849625007211563	4	1	0	0
1808	233	impact of the intervention	[impact of the intervention]	1.5849625007211563	4	1	0	0
1809	233	presence of peripheral oedema	[presence of peripheral oedema]	1.5849625007211563	4	1	0	0
1810	233	diabete odd ratio	[diabetes odds ratio]	1.5849625007211563	3	1	0	0
1811	233	link between inflammation	[link between inflammation]	1.5849625007211563	3	1	0	0
1812	233	treatment of HFpEF	[treatment of HFpEF]	1.5849625007211563	3	1	0	0
1813	233	2-fold camp hydrolytic activity	[2-fold cAMP hydrolytic activity]	1.5849625007211563	4	1	0	0
1814	233	1.5-t MRI scanner	[1.5-T MRI scanner]	1.5849625007211563	3	1	0	0
1815	233	range of health outcome	[range of health outcomes]	1.5849625007211563	4	1	0	0
1816	233	hospital length of stay	[hospital length of stay]	1.5849625007211563	4	1	0	0
1817	233	American College of physician	[American College of Physicians]	1.5849625007211563	4	2	1	1
1818	233	coronary microembolization-induced HF	[coronary microembolization-induced HF]	1.5849625007211563	3	1	0	0
1819	233	consequence of the increase	[consequence of the increase]	1.5849625007211563	4	1	0	0
1820	233	trend for improvement	[trend for improvement]	1.5849625007211563	3	1	0	0
1821	233	article by Dodson	[article by Dodson]	1.5849625007211563	3	1	0	0
1822	233	A peptide nps	[A peptides NPs]	1.5849625007211563	3	1	0	0
1823	233	Clinical Modification code 402.x1	[Clinical Modification codes 402.x1]	1.5849625007211563	4	1	0	0
1824	233	HF hospitalization hazard ratio	[HF hospitalization hazard ratio]	1.5849625007211563	4	3	2	1
1825	233	incidence of esrd	[incidence of ESRD]	1.5849625007211563	3	1	0	0
1826	233	Bcl-2 mrna expression	[Bcl-2 mRNA expression]	1.5849625007211563	3	1	0	0
1827	233	learning from recent trial	[Learning from recent trials]	1.5849625007211563	4	1	0	0
1828	233	tobacco use odd ratio	[tobacco use odds ratio]	1.5849625007211563	4	1	0	0
1829	233	reverse cardiac remodeling	[reverse cardiac remodeling]	1.5849625007211563	3	1	0	0
1830	233	heart rate response	[heart rate response]	1.5849625007211563	3	1	0	0
1831	233	onset of heart failure	[onset of heart failure]	1.5849625007211563	4	1	0	0
1832	233	low bte all p	[lower BTES All P]	1.5849625007211563	4	1	0	0
1833	233	acute setting for management	[acute settings for management]	1.5849625007211563	4	1	0	0
1834	233	Exercise time at 3	[Exercise time at 3]	1.5849625007211563	4	1	0	0
1835	233	patient with assist device	[patients with assist devices]	1.5849625007211563	4	2	2	2
1836	233	doxorubicin 25mg kg ip	[doxorubicin 25mg kg ip]	1.5849625007211563	4	1	0	0
1837	233	6-minute walk test 6mwt	[6-minute walk test 6MWT]	1.5849625007211563	4	1	0	0
1838	233	Implantable cardioverter-defibrillators icd	[Implantable cardioverter-defibrillators ICDs]	1.5849625007211563	3	1	0	0
1839	233	improvement in eGFR	[improvement in eGFR]	1.5849625007211563	3	2	1	1
1840	233	one centre in Canada	[one centre in Canada]	1.5849625007211563	4	1	0	0
1841	233	cardiac magnetic resonance	[cardiac magnetic resonance]	1.5849625007211563	3	1	0	0
1842	233	further large-scale randomised study	[Further large-scale randomised studies]	1.5849625007211563	4	1	0	0
1843	233	conduct long cost-effectiveness analysis	[conducting long-term cost-effectiveness analyses]	1.5849625007211563	4	1	0	0
1844	233	albeit with limited ability	[albeit with limited ability]	1.5849625007211563	4	1	0	0
1845	233	cardiac specialty hospital	[cardiac specialty hospital]	1.5849625007211563	3	1	0	0
1846	233	use national medicare datum	[Using national Medicare data]	1.5849625007211563	4	1	0	0
1847	233	Extracorporeal life support	[Extracorporeal life support]	1.5849625007211563	3	1	0	0
1848	233	patient with cardiovascular disease	[patients with cardiovascular disease]	1.5849625007211563	4	2	1	1
1849	233	observational study of transfusion	[observational studies of transfusion]	1.5849625007211563	4	1	0	0
1850	233	American HF guideline	[American HF guidelines]	1.5849625007211563	3	1	0	0
1851	233	salt loading as	[salt loading AS]	1.5849625007211563	3	1	0	0
1852	233	target of signal transduction	[targeting of signal transduction]	1.5849625007211563	4	1	0	0
1853	233	biomarker-guided clinical trial	[biomarker-guided clinical trials]	1.5849625007211563	3	1	0	0
1854	233	examination of PKA subunit	[Examination of PKA subunits]	1.5849625007211563	4	1	0	0
1855	233	pulmonary systolic pressure	[pulmonary systolic pressure]	1.5849625007211563	3	2	2	2
1856	233	mean of mm hg	[mean of mm Hg]	1.5849625007211563	4	1	0	0
1857	233	tool conduct cost-effectiveness analysis	[tool conducting cost-effectiveness analyses]	1.5849625007211563	4	1	0	0
1858	233	aspect of nursing care	[aspects of nursing care]	1.5849625007211563	4	1	0	0
1859	233	myofiber shortening onset	[myofiber shortening onset]	1.5849625007211563	3	1	0	0
1860	233	clinical datum among group	[clinical data among groups]	1.5849625007211563	4	1	0	0
1861	233	low fat mass index	[lower fat mass index]	1.5849625007211563	4	1	0	0
1862	233	year of the study	[year of the study]	1.5849625007211563	4	1	0	0
1863	233	right atrial mass removal	[right atrial mass removal]	1.5849625007211563	4	1	0	0
1864	233	left pulmonary artery	[left pulmonary artery]	1.5849625007211563	3	1	0	0
1865	233	myocardial glycolysis rate	[myocardial glycolysis rates]	1.5849625007211563	3	1	0	0
1866	233	age-dependent increase in incidence	[age-dependent increase in incidence]	1.5849625007211563	4	1	0	0
1867	233	projection of resource use	[Projections of resource use]	1.5849625007211563	4	1	0	0
1868	233	nutrition in heart failure	[Nutrition in heart failure]	1.5849625007211563	4	1	0	0
1869	233	early transmitral flow	[early transmitral flow]	1.5849625007211563	3	1	0	0
1870	233	Latin America LA	[Latin America LA]	1.5849625007211563	3	1	0	0
1871	233	first time feasible	[first time feasible]	1.5849625007211563	3	1	0	0
1872	233	stable pulmonary hypertension medication	[stable pulmonary hypertension medication]	1.5849625007211563	4	1	0	0
1873	233	angiotensin convert enzyme inhibitor	[angiotensin converting enzyme inhibitor]	1.5849625007211563	4	1	0	0
1874	233	rate of trastuzumb-related CHF	[rates of trastuzumb-related CHF]	1.5849625007211563	4	1	0	0
1875	233	small gtpase rac1 activity	[small GTPase Rac1 activity]	1.5849625007211563	4	1	0	0
1876	233	effective practice within domain	[effective practice within domain]	1.5849625007211563	4	1	0	0
1877	233	Student t test	[Student t test]	1.5849625007211563	3	1	0	0
1878	233	good long value	[good long-term value]	1.5849625007211563	3	1	0	0
1879	233	leg strength p	[leg strength P]	1.5849625007211563	3	1	0	0
1880	233	adjustment for covariate	[adjustment for covariates]	1.5849625007211563	3	1	0	0
1881	233	date of HF hospitalization	[date of HF hospitalization]	1.5849625007211563	4	1	0	0
1882	233	patient with systolic dysfunction	[patients with systolic dysfunction]	1.5849625007211563	4	2	1	1
1883	233	septal wall cs	[septal wall CS]	1.5849625007211563	3	1	0	0
1884	233	treatment for this complication	[treatments for this complication]	1.5849625007211563	4	1	0	0
1885	233	low SVR index	[lower SVR index]	1.5849625007211563	3	1	0	0
1886	233	index beat method	[index beat method]	1.5849625007211563	3	1	0	0
1887	233	ED visit for CHF	[ED visits for CHF]	1.5849625007211563	4	1	0	0
1888	233	ivabradine on exercise capacity	[ivabradine on exercise capacity]	1.5849625007211563	4	1	0	0
1889	233	more comorbid condition	[more comorbid conditions]	1.5849625007211563	3	1	0	0
1890	233	lesion such as defect	[lesions such as defects]	1.5849625007211563	4	1	0	0
1891	233	adjustment for age	[adjustment for age]	1.5849625007211563	3	1	0	0
1892	233	hfref hazard ratio hr	[HFrEF hazard ratio HR]	1.5849625007211563	4	1	0	0
1893	233	association between social support	[association between social support]	1.5849625007211563	4	1	0	0
1894	233	Hazard ratio for variable	[Hazard ratios for variables]	1.5849625007211563	4	1	0	0
1895	233	content-driven telehealth technology	[content-driven telehealth technology]	1.5849625007211563	3	1	0	0
1896	233	outpatient with HF	[outpatients with HF]	1.5849625007211563	3	2	1	1
1897	233	quality of care	[quality of care]	1.5849625007211563	3	2	1	1
1898	233	sign of HF	[signs of HF]	1.5849625007211563	3	2	2	2
1899	233	population-based new-user cohort study	[Population-based new-user cohort study]	1.5849625007211563	4	1	0	0
1900	233	study-related serious adverse event	[study-related serious adverse events]	1.5849625007211563	4	1	0	0
1901	233	health care system	[health care system]	1.5849625007211563	3	1	0	0
1902	233	post hoc analysis	[post hoc analysis]	1.5849625007211563	3	1	0	0
1903	233	expression of target gene	[expression of target genes]	1.5849625007211563	4	1	0	0
1904	233	proof-of-principle cohort study	[proof-of-principle cohort study]	1.5849625007211563	3	1	0	0
1905	233	median of 4.6 year	[median of 4.6 years]	1.5849625007211563	4	1	0	0
1906	233	radial strain rs	[radial strain RS]	1.5849625007211563	3	1	0	0
1907	233	survive left ventricle	[surviving left ventricle]	1.5849625007211563	3	1	0	0
1908	233	history of cardiovascular disease	[history of cardiovascular disease]	1.5849625007211563	4	1	0	0
1909	233	more remarkable role	[more remarkable role]	1.5849625007211563	3	1	0	0
1910	233	total symptom domain	[Total Symptom domains]	1.5849625007211563	3	1	0	0
1911	233	with similar value	[with similar values]	1.5849625007211563	3	1	0	0
1912	233	left ventricular strain	[left ventricular strain]	1.5849625007211563	3	2	2	2
1913	233	variability in qt interval	[Variability in QT intervals]	1.5849625007211563	4	1	0	0
1914	233	rapid right ventricular pacing	[rapid right ventricular pacing]	1.5849625007211563	4	1	0	0
1915	233	low systolic blood pressure	[lower systolic blood pressure]	1.5849625007211563	4	1	0	0
1916	233	risk of thromboembolic event	[risk of thromboembolic events]	1.5849625007211563	4	2	2	2
1917	233	consequence of pathological remodelling	[consequence of pathological remodelling]	1.5849625007211563	4	1	0	0
1918	233	transcatheter aortic valve procedure	[transcatheter aortic valve procedure]	1.5849625007211563	4	1	0	0
1919	233	Functional mitral stenosis MS	[Functional mitral stenosis MS]	1.5849625007211563	4	1	0	0
1920	233	venous thromboembolic event	[venous thromboembolic events]	1.5849625007211563	3	1	0	0
1921	233	Preoperative clinical characteristic	[Preoperative clinical characteristics]	1.5849625007211563	3	1	0	0
1922	233	control adenovirus ad-c	[control adenovirus Ad-C]	1.5849625007211563	3	1	0	0
1923	233	HeartMate ii exchange	[HeartMate II exchange]	1.5849625007211563	3	1	0	0
1924	233	within-day test-retest reliability	[Within-day test-retest reliability]	1.5849625007211563	3	2	1	1
1925	233	mitochondrial oxidative stress	[mitochondrial oxidative stress]	1.5849625007211563	3	1	0	0
1926	233	immunodetection of NT-proBNP	[Immunodetection of NT-proBNP]	1.5849625007211563	3	1	0	0
1927	233	frequency of administration	[frequency of administration]	1.5849625007211563	3	1	0	0
1928	233	ET of CHF-NYHA-IIIb	[ET of CHF-NYHA-IIIb]	1.5849625007211563	3	1	0	0
1929	233	Danish heart Failure database	[Danish Heart Failure database]	1.5849625007211563	4	1	0	0
1930	233	normal coronary artery	[normal coronary arteries]	1.5849625007211563	3	1	0	0
1931	233	activation of the pathway	[activation of the pathway]	1.5849625007211563	4	1	0	0
1932	233	simple clinical prediction rule	[simple clinical prediction rule]	1.5849625007211563	4	1	0	0
1933	233	indicate a change	[indicating a change]	1.5849625007211563	3	1	0	0
1934	233	B-type natriuretic peptide BNP	[B-type natriuretic peptide BNP]	1.5849625007211563	4	1	0	0
1935	233	heart failure discharge	[heart failure discharges]	1.5849625007211563	3	1	0	0
1936	233	risk of long mortality	[risk of long-term mortality]	1.5849625007211563	4	2	1	1
1937	233	outcome of Exercise training	[Outcomes of Exercise Training]	1.5849625007211563	4	2	2	2
1938	233	development of therapeutic approach	[development of therapeutic approaches]	1.5849625007211563	4	2	2	2
1939	233	nitroxyl HNO donor salt	[nitroxyl HNO donor salt]	1.5849625007211563	4	1	0	0
1940	233	haematopoietic cell transplantation HCT	[Haematopoietic cell transplantation HCT]	1.5849625007211563	4	1	0	0
1941	233	18 health insurance	[18 health insurance]	1.5849625007211563	3	1	0	0
1942	233	hypertensive heart disease	[hypertensive heart disease]	1.5849625007211563	3	1	0	0
1943	233	elevate atrial pressure	[elevated atrial pressure]	1.5849625007211563	3	1	0	0
1944	233	isoelectric focus of RIα	[Isoelectric focusing of RIα]	1.5849625007211563	4	1	0	0
1945	233	improve patient outcome	[improving patient outcomes]	1.5849625007211563	3	1	0	0
1946	233	appropriate icd shock	[appropriate ICD shocks]	1.5849625007211563	3	1	0	0
1947	233	cause a stenotic physiology	[causing a stenotic physiology]	1.5849625007211563	4	1	0	0
1948	233	refractory congestive heart failure	[refractory congestive heart failure]	1.5849625007211563	4	2	2	2
1949	233	risk for esrd	[risk for ESRD]	1.5849625007211563	3	1	0	0
1950	233	93 heart failure admission	[93 heart failure admissions]	1.5849625007211563	4	1	0	0
1951	233	large idiopathic cardiomyopathy cohort	[large idiopathic cardiomyopathy cohort]	1.5849625007211563	4	1	0	0
1952	233	short-term mortality rate	[short-term mortality rates]	1.5849625007211563	3	1	0	0
1953	233	estimation of caspase-3 activity	[estimation of caspase-3 activity]	1.5849625007211563	4	1	0	0
1954	233	case of angiotensin	[case of angiotensin]	1.5849625007211563	3	1	0	0
1955	233	obese patient with hfpef	[obese patients with HFPEF]	1.5849625007211563	4	2	2	2
1956	233	myocyte hypertrophy antecedent	[Myocyte hypertrophy antecedent]	1.5849625007211563	3	1	0	0
1957	233	increase in glycolysis rate	[increase in glycolysis rates]	1.5849625007211563	4	1	0	0
1958	233	further review of preference	[further review of preferences]	1.5849625007211563	4	1	0	0
1959	233	pg bnp group	[pg BNP group]	1.5849625007211563	3	2	2	2
1960	233	additional model vary combination	[additional models varying combinations]	1.5849625007211563	4	1	0	0
1961	233	systolic blood pressure hr	[systolic blood pressure HR]	1.5849625007211563	4	1	0	0
1962	233	749 self-identified black patient	[749 self-identified black patients]	1.5849625007211563	4	1	0	0
1963	233	treatment of hfref	[treatment of HFrEF]	1.5849625007211563	3	1	0	0
1964	233	net reclassification improvement nri	[net reclassification improvement NRI]	1.5849625007211563	4	1	0	0
1965	233	developmental chromatin remodeling event	[developmental chromatin remodeling events]	1.5849625007211563	4	1	0	0
1966	233	pace dnx chf-dnx	[pace DNx CHF-DNx]	1.5849625007211563	3	1	0	0
1967	233	symptomatic severe ai	[symptomatic severe AI]	1.5849625007211563	3	1	0	0
1968	233	patient with fibrillation af	[Patients with fibrillation AF]	1.5849625007211563	4	2	2	2
1969	233	patient in many region	[patients in many regions]	1.5849625007211563	4	1	0	0
1970	233	prognosis of idiopathic cardiomyopathy	[prognosis of idiopathic cardiomyopathy]	1.5849625007211563	4	1	0	0
1971	233	nanomolar dose of JQ1	[nanomolar doses of JQ1]	1.5849625007211563	4	1	0	0
1972	233	heart failure hHF	[heart failure hHF]	1.5849625007211563	3	1	0	0
1973	233	effect of a decade	[effects of a decade]	1.5849625007211563	4	1	0	0
1974	233	other subspecialty group	[other subspecialty groups]	1.5849625007211563	3	1	0	0
1975	233	metoprolol hazard ratio hr	[metoprolol hazard ratio HR]	1.5849625007211563	4	1	0	0
1976	233	Cardiovascular Disease Registry Innovation	[Cardiovascular Disease Registry Innovation]	1.5849625007211563	4	1	0	0
1977	233	label-free shotgun proteomics approach	[label-free shotgun proteomics approach]	1.5849625007211563	4	1	0	0
1978	233	dash target sodium	[DASH target sodium]	1.5849625007211563	3	1	0	0
1979	233	subject with RV dysfunction	[Subjects with RV dysfunction]	1.5849625007211563	4	2	1	1
1980	233	such as early detection	[such as early detection]	1.5849625007211563	4	1	0	0
1981	233	positron emission tomography imaging	[positron emission tomography imaging]	1.5849625007211563	4	1	0	0
1982	233	process of endothelial repair	[process of endothelial repair]	1.5849625007211563	4	1	0	0
1983	233	exercise group hazard ratio	[exercise group hazard ratio]	1.5849625007211563	4	1	0	0
1984	233	≥5 mg hr 1.54	[≥5 mg HR 1.54]	1.5849625007211563	4	1	0	0
1985	233	stem cell source allogeneic	[stem cell source allogeneic]	1.5849625007211563	4	1	0	0
1986	233	characteristic of adult	[characteristics of adults]	1.5849625007211563	3	2	2	2
1987	233	level of plasma norepinephrine	[levels of plasma norepinephrine]	1.5849625007211563	4	1	0	0
1988	233	control case cohort analysis	[control case cohort analysis]	1.5849625007211563	4	1	0	0
1989	233	myofilament can 2 sensitivity	[myofilament Ca 2 sensitivity]	1.5849625007211563	4	1	0	0
1990	233	4 enrollment period	[4 enrollment periods]	1.5849625007211563	3	1	0	0
1991	233	Multivariate logistic regression analysis	[Multivariate logistic regression analysis]	1.5849625007211563	4	1	0	0
1992	233	small high-risk group	[small high-risk group]	1.5849625007211563	3	1	0	0
1993	233	benefit of trial	[benefits of trials]	1.5849625007211563	3	1	0	0
1994	233	health system datum partner	[health system data partners]	1.5849625007211563	4	1	0	0
1995	233	cardiovascular event stroke	[cardiovascular events stroke]	1.5849625007211563	3	1	0	0
1996	233	pcwp of mm hg	[PCWP of mm Hg]	1.5849625007211563	4	1	0	0
1997	233	iii HF ejection fraction	[III HF ejection fractions]	1.5849625007211563	4	1	0	0
1998	233	pressure volume relation	[pressure volume relation]	1.5849625007211563	3	1	0	0
1999	233	top 10 NOC outcome	[top 10 NOC outcomes]	1.5849625007211563	4	1	0	0
2000	233	assumption a measure	[assumption a measure]	1.5849625007211563	3	1	0	0
2001	233	especially 160 m	[especially 160 ms]	1.5849625007211563	3	1	0	0
2002	233	progress in anticoagulation	[progress in anticoagulation]	1.5849625007211563	3	1	0	0
2003	233	separate Cox regression	[separate Cox regression]	1.5849625007211563	3	1	0	0
2004	233	hemodynamically stable situation	[hemodynamically stable situation]	1.5849625007211563	3	1	0	0
2005	233	right atrium mass	[right atrium mass]	1.5849625007211563	3	1	0	0
2006	233	shuttle walk test	[shuttle walk test]	1.5849625007211563	3	2	2	2
2007	233	wasting of fat	[Wasting of fat]	1.5849625007211563	3	1	0	0
2008	233	1-year mortality rate	[1-year mortality rate]	1.5849625007211563	3	1	0	0
2009	233	currently under investigation	[currently under investigation]	1.5849625007211563	3	1	0	0
2010	233	Japanese heart failure patient	[Japanese heart failure patients]	1.5849625007211563	4	1	0	0
2011	233	cystatin c level	[cystatin C level]	1.5849625007211563	3	2	2	2
2012	233	development of cardiac hypertrophy	[development of cardiac hypertrophy]	1.5849625007211563	4	2	1	1
2013	233	peak oxygen consumption range	[Peak oxygen consumption range]	1.5849625007211563	4	1	0	0
2014	233	skeletal muscle mass t-score	[skeletal muscle mass T-score]	1.5849625007211563	4	1	0	0
2015	233	impact of RV function	[impact of RV function]	1.5849625007211563	4	1	0	0
2016	233	Paradigm-hf a paradigm shift	[PARADIGM-HF a paradigm shift]	1.5849625007211563	4	1	0	0
2017	233	validity of individual scale	[validity of individual scales]	1.5849625007211563	4	1	0	0
2018	233	RGK Rem family	[RGK Rem family]	1.5849625007211563	3	1	0	0
2019	233	addition of salt loading	[addition of salt loading]	1.5849625007211563	4	1	0	0
2020	233	interesting therapeutic concept	[interesting therapeutic concepts]	1.5849625007211563	3	1	0	0
2021	233	incident HF case	[incident HF cases]	1.5849625007211563	3	1	0	0
2022	233	variant of gene code	[variants of genes coding]	1.5849625007211563	4	1	0	0
2023	233	structure of the RV	[structure of the RV]	1.5849625007211563	4	1	0	0
2024	233	26 observational study	[26 observational studies]	1.5849625007211563	3	1	0	0
2025	233	sphingosine-1-phosphate receptor 1 s1pr1	[sphingosine-1-phosphate receptor 1 S1PR1]	1.5849625007211563	4	1	0	0
2026	233	effect on CRT	[effect on CRT]	1.5849625007211563	3	1	0	0
2027	233	LV diastolic dysfunction alone	[LV diastolic dysfunction alone]	1.5849625007211563	4	1	0	0
2028	233	sitagliptin for sitagliptin	[sitagliptin for sitagliptin]	1.5849625007211563	3	2	2	2
2029	233	quality of LV dysfunction	[quality of LV dysfunction]	1.5849625007211563	4	1	0	0
2030	233	interventricular delay VVD	[interventricular delay VVD]	1.5849625007211563	3	1	0	0
2031	233	use Cox regression	[Using Cox regression]	1.5849625007211563	3	1	0	0
2032	233	HF of etiology	[HF of etiology]	1.5849625007211563	3	2	2	2
2033	233	sarcomeric microstructure at baseline	[sarcomeric microstructure at baseline]	1.5849625007211563	4	1	0	0
2034	233	interactor of the DEGs	[Interactors of the DEGs]	1.5849625007211563	4	1	0	0
2035	233	year after 2011	[year after 2011]	1.5849625007211563	3	1	0	0
2036	233	pathological change in cardiomyocyte	[pathological changes in cardiomyocytes]	1.5849625007211563	4	1	0	0
2037	233	nurse in all setting	[Nurses in all settings]	1.5849625007211563	4	1	0	0
2038	233	adjust for important covariate	[adjusting for important covariates]	1.5849625007211563	4	1	0	0
2039	233	lack of benefit	[lack of benefit]	1.5849625007211563	3	1	0	0
2040	233	liberal transfusion protocol	[liberal transfusion protocols]	1.5849625007211563	3	1	0	0
2041	233	development of lifesaving drug	[development of lifesaving drugs]	1.5849625007211563	4	1	0	0
2042	233	brain natriuretic peptide bnp	[brain natriuretic peptide BNP]	1.5849625007211563	4	1	0	0
2043	233	dipeptidyl peptidase-4 dpp-4 inhibitor	[dipeptidyl peptidase-4 DPP-4 inhibitors]	1.5849625007211563	4	1	0	0
2044	233	High dash diet score	[Higher DASH diet scores]	1.5849625007211563	4	1	0	0
2045	233	specific pde2 inhibition	[specific PDE2 inhibition]	1.5849625007211563	3	1	0	0
2046	233	old adult with HF	[older adults with HF]	1.5849625007211563	4	1	0	0
2047	233	death confidence interval 0.60	[death confidence interval 0.60]	1.5849625007211563	4	1	0	0
2048	233	2 chordal rupture	[2 chordal ruptures]	1.5849625007211563	3	1	0	0
2049	233	such as defect	[such as defects]	1.5849625007211563	3	1	0	0
2050	233	use Doppler echocardiography	[using Doppler echocardiography]	1.5849625007211563	3	1	0	0
2051	233	category of actin cytoskeleton	[categories of actin cytoskeleton]	1.5849625007211563	4	1	0	0
2052	233	dyssynchronous heart failure	[dyssynchronous heart failure]	1.5849625007211563	3	2	2	2
2053	233	LV contractile function	[LV contractile function]	1.5849625007211563	3	1	0	0
2054	233	extent of RV dysfunction	[extent of RV dysfunction]	1.5849625007211563	4	1	0	0
2055	233	cornerstone in the assessment	[cornerstone in the assessment]	1.5849625007211563	4	1	0	0
2056	233	Systolic heart failure treatment	[Systolic Heart Failure Treatment]	1.5849625007211563	4	1	0	0
2057	233	mechanism underlie this defect	[mechanisms underlying these defects]	1.5849625007211563	4	1	0	0
2058	233	mitochondrial oxidation of glucose	[mitochondrial oxidation of glucose]	1.5849625007211563	4	1	0	0
2059	233	left ventricular longitudinal strain	[left ventricular longitudinal strain]	1.5849625007211563	4	2	2	2
2060	233	have ≥3 co-morbidity	[having ≥3 co-morbidities]	1.5849625007211563	3	1	0	0
2061	233	management of heart lesion	[management of heart lesions]	1.5849625007211563	4	1	0	0
2062	233	change association with DNA	[changing association with DNA]	1.5849625007211563	4	1	0	0
2063	233	high glomerular filtration rate	[higher glomerular filtration rate]	1.5849625007211563	4	1	0	0
2064	233	correlation of remain index	[correlation of remaining indices]	1.5849625007211563	4	1	0	0
2065	233	many risk factor	[many risk factors]	1.5849625007211563	3	1	0	0
2066	233	ka chloride channel gene	[Ka chloride channel gene]	1.5849625007211563	4	1	0	0
2067	233	result of a constriction	[result of an constriction]	1.5849625007211563	4	1	0	0
2068	233	.001 all comparison	[.001 all comparisons]	1.5849625007211563	3	1	0	0
2069	233	transplantation eligibility status	[transplantation eligibility status]	1.5849625007211563	3	2	2	2
2070	233	systemic adverse event evaluation	[systemic adverse events evaluation]	1.5849625007211563	4	1	0	0
2071	233	young patient with HF	[youngest patients with HF]	1.5849625007211563	4	1	0	0
2072	233	decline in early-onset	[Declines in early-onset]	1.5849625007211563	3	1	0	0
2073	233	conditional gene-targeted Hand2 mouse	[conditional gene-targeted Hand2 mice]	1.5849625007211563	4	1	0	0
2074	233	association of Mediterranean Approaches	[associations of Mediterranean Approaches]	1.5849625007211563	4	1	0	0
2075	233	transmitral flow velocity e	[transmitral flow velocities E]	1.5849625007211563	4	1	0	0
2076	233	tachycardia-induced heart failure	[tachycardia-induced heart failure]	1.5849625007211563	3	1	0	0
2077	233	total of 139 patient	[total of 139 patients]	1.5849625007211563	4	1	0	0
2078	233	p-value for difference 0.001	[P-value for difference 0.001]	1.5849625007211563	4	1	0	0
2079	233	confirmatory factor analysis CFA	[confirmatory factor analysis CFA]	1.5849625007211563	4	1	0	0
2080	233	systolic mitral leaflet motion	[systolic mitral leaflet motions]	1.5849625007211563	4	1	0	0
2081	233	human-to-human contact HH	[human-to-human contact HH]	1.5849625007211563	3	1	0	0
2082	233	role in cardiac pathogenesis	[role in cardiac pathogenesis]	1.5849625007211563	4	1	0	0
2083	233	high amount of malondialdehyde	[higher amount of malondialdehyde]	1.5849625007211563	4	1	0	0
2084	233	care for this patient	[caring for these patients]	1.5849625007211563	4	1	0	0
2085	233	peak respiratory quotient	[peak respiratory quotient]	1.5849625007211563	3	1	0	0
2086	233	cost across volume group	[costs across volume groups]	1.5849625007211563	4	1	0	0
2087	233	Rad a member	[Rad a member]	1.5849625007211563	3	1	0	0
2088	233	anemia in HF	[Anemia in HF]	1.5849625007211563	3	1	0	0
2089	233	angiotensin ii infusion	[angiotensin II infusion]	1.5849625007211563	3	1	0	0
2090	233	management of gastrointestinal bleed	[management of gastrointestinal bleeding]	1.5849625007211563	4	1	0	0
2091	233	peak vo2 p	[peak VO2 P]	1.5849625007211563	3	2	1	1
2092	233	similar distribution in HFrEF	[similar distribution in HFrEF]	1.5849625007211563	4	1	0	0
2093	233	biomarker of anthracycline-induced cardiotoxicity	[biomarker of anthracycline-induced cardiotoxicity]	1.5849625007211563	4	1	0	0
2094	233	mean of 244 m	[mean of 244 m]	1.5849625007211563	4	1	0	0
2095	233	patient with a history	[patient with a history]	1.5849625007211563	4	2	2	2
2096	233	progenitor cell CPC	[progenitor cells CPCs]	1.5849625007211563	3	1	0	0
2097	233	overall significant improvement	[Overall significant improvements]	1.5849625007211563	3	1	0	0
2098	233	57±22 month of follow-up	[57±22 months of follow-up]	1.5849625007211563	4	1	0	0
2099	233	approximately 200 HeartWare patient	[approximately 200 HeartWare patients]	1.5849625007211563	4	1	0	0
2100	233	development of cardiac insulin-resistance	[development of cardiac insulin-resistance]	1.5849625007211563	4	1	0	0
2101	233	hdl-mediated vascular effect	[HDL-mediated vascular effects]	1.5849625007211563	3	1	0	0
2102	233	patient with severe HF	[patients with severe HF]	1.5849625007211563	4	1	0	0
2103	233	30 millileter per m	[30 mL per m]	1.5849625007211563	4	2	2	2
2104	233	1-year mortality in survivor	[1-year mortality in survivors]	1.5849625007211563	4	2	2	2
2105	233	eGFR group IV p	[eGFR group IV P]	1.5849625007211563	4	1	0	0
2106	233	spontaneous ventricular tachycardia hfvt(+)	[spontaneous ventricular tachycardia HFVT(+)]	1.5849625007211563	4	1	0	0
2107	233	0.1 unit increase	[0.1 unit increase]	1.5849625007211563	3	1	0	0
2108	233	trend toward few day	[trend toward fewer days]	1.5849625007211563	4	1	0	0
2109	233	pressure-volume conductance catheter system	[pressure-volume conductance catheter system]	1.5849625007211563	4	1	0	0
2110	233	emergency department volume	[emergency department volume]	1.5849625007211563	3	1	0	0
2111	233	ventricular LV dysfunction	[ventricular LV dysfunction]	1.5849625007211563	3	1	0	0
2112	233	cardiovascular event for psoriasis	[cardiovascular events for psoriasis]	1.5849625007211563	4	1	0	0
2113	233	administration of contrast agent	[administration of contrast agent]	1.5849625007211563	4	1	0	0
2114	233	optimal treatment median	[optimal treatment median]	1.5849625007211563	3	1	0	0
2115	233	lean mass quantification	[lean mass quantification]	1.5849625007211563	3	1	0	0
2116	233	mortality hazard ratio hr	[mortality hazard ratio HR]	1.5849625007211563	4	1	0	0
2117	233	use of Exercise	[Use of Exercise]	1.5849625007211563	3	1	0	0
2118	233	temporary CentriMag rvad	[temporary CentriMag RVAD]	1.5849625007211563	3	1	0	0
2119	233	subject with mild HF	[subjects with mild HF]	1.5849625007211563	4	1	0	0
2120	233	coronary artery disease hr	[coronary artery disease HR]	1.5849625007211563	4	1	0	0
2121	233	unique post-translational state	[unique post-translational states]	1.5849625007211563	3	1	0	0
2122	233	majority of patient	[majority of patients]	1.5849625007211563	3	2	1	1
2123	233	adult male wistar rat	[adult male Wistar rats]	1.5849625007211563	4	1	0	0
2124	233	mean SD of 0.25	[mean SD of 0.25]	1.5849625007211563	4	1	0	0
2125	233	occurrence of heart failure	[occurrence of heart failure]	1.5849625007211563	4	1	0	0
2126	233	same exercise time test	[same exercise time tests]	1.5849625007211563	4	1	0	0
2127	233	64.26 year versus 72.83	[64.26 years vs 72.83]	1.5849625007211563	4	1	0	0
2128	233	aortocaval fistula ACF	[aortocaval fistula ACF]	1.5849625007211563	3	1	0	0
2129	233	manage the device	[managing the device]	1.5849625007211563	3	1	0	0
2130	233	mean LV ejection fraction	[mean LV ejection fraction]	1.5849625007211563	4	1	0	0
2131	233	impact of self-management counseling	[impact of self-management counseling]	1.5849625007211563	4	1	0	0
2132	233	ef ef≤ 40	[EF EF≤ 40]	1.5849625007211563	3	1	0	0
2133	233	significant improvement in 6-minute	[significant improvement in 6-minute]	1.5849625007211563	4	1	0	0
2134	233	patient with concurrent HF	[patients with concurrent HF]	1.5849625007211563	4	1	0	0
2135	233	454 patient ecct	[454 patients ECCT]	1.5849625007211563	3	1	0	0
2136	233	average of 7 month	[average of 7 months]	1.5849625007211563	4	1	0	0
2137	233	Duke activity status index	[Duke Activity Status Index]	1.5849625007211563	4	1	0	0
2138	233	improvement in contractile function	[improvement in contractile function]	1.5849625007211563	4	1	0	0
2139	233	blood urea nitrogen	[blood urea nitrogen]	1.5849625007211563	3	1	0	0
2140	233	special therapeutic intervention	[special therapeutic interventions]	1.5849625007211563	3	1	0	0
2141	233	stable severe systolic HF	[stable severe systolic HF]	1.5849625007211563	4	1	0	0
2142	233	acute HF diagnosis	[acute HF diagnosis]	1.5849625007211563	3	1	0	0
2143	233	setting of pulmonary embolism	[setting of pulmonary embolism]	1.5849625007211563	4	1	0	0
2144	233	quick safe pump-exchange technique	[quick safe pump-exchange technique]	1.5849625007211563	4	1	0	0
2145	233	nad(p) h-oxidase subunit rac2	[NAD(P) H-oxidase subunit RAC2]	1.5849625007211563	4	1	0	0
2146	233	purely hemodynamic disorder	[purely hemodynamic disorder]	1.5849625007211563	3	1	0	0
2147	233	high bnp level	[higher BNP levels]	1.5849625007211563	3	2	2	2
2148	233	plasma nps at baseline	[plasma NPs at baseline]	1.5849625007211563	4	1	0	0
2149	233	significant cardioprotection via inhibition	[significant cardioprotection via inhibition]	1.5849625007211563	4	1	0	0
2150	233	passive k constant	[passive k constants]	1.5849625007211563	3	1	0	0
2151	233	Connecticut heart Failure Center	[Connecticut Heart Failure Center]	1.5849625007211563	4	1	0	0
2152	233	differential effect of lvef	[differential effect of LVEF]	1.5849625007211563	4	1	0	0
2153	233	180 day of inclusion	[180 days of inclusion]	1.5849625007211563	4	1	0	0
2154	233	use small-molecule inhibitor c-kit	[using small-molecule inhibitors c-Kit]	1.5849625007211563	4	1	0	0
2155	233	past 30 year	[past 30 years]	1.5849625007211563	3	1	0	0
2156	233	25.6 kg 2	[25.6 kg 2]	1.5849625007211563	3	1	0	0
2157	233	tool for economic analysis	[Tools for Economic Analysis]	1.5849625007211563	4	2	1	1
2158	233	goal achieve a level	[goal achieving a level]	1.5849625007211563	4	1	0	0
2159	233	Beneficial effect of ARNI	[Beneficial effect of ARNI]	1.5849625007211563	4	1	0	0
2160	233	old patient with hfpef	[older patients with HFPEF]	1.5849625007211563	4	2	2	2
2161	233	reoperation for bleed	[reoperation for bleeding]	1.5849625007211563	3	1	0	0
2162	233	HABC battery score	[HABC Battery score]	1.5849625007211563	3	2	1	1
2163	233	degenerative mitral valve	[degenerative mitral valve]	1.5849625007211563	3	1	0	0
2164	233	use the ppr	[using the PPR]	1.5849625007211563	3	1	0	0
2165	233	seven ischemic problem	[seven ischemic problems]	1.5849625007211563	3	1	0	0
2166	233	treatment with ejection fraction	[treatment with ejection fraction]	1.5849625007211563	4	2	2	2
2167	233	mechanism of disease unique	[mechanisms of disease unique]	1.5849625007211563	4	1	0	0
2168	233	first diagnosis of af	[first diagnosis of AF]	1.5849625007211563	4	1	0	0
2169	233	left ventricular function assessment	[left ventricular function assessment]	1.5849625007211563	4	1	0	0
2170	233	effect of Ie	[effect of IE]	1.5849625007211563	3	1	0	0
2171	233	1,045 patient with ic	[1,045 patients with IC]	1.5849625007211563	4	1	0	0
2172	233	heart Failure Cost-Effectiveness Model	[Heart Failure Cost-Effectiveness Model]	1.5849625007211563	4	1	0	0
2173	233	Pulmonary capillary wedge pressure	[Pulmonary capillary wedge pressure]	1.5849625007211563	4	1	0	0
2174	233	only ANS mouse	[only ANS mice]	1.5849625007211563	3	1	0	0
2175	233	soluble guanylate cyclase	[soluble guanylate cyclase]	1.5849625007211563	3	1	0	0
2176	233	relationship between tapse force	[relationship between TAPSE force]	1.5849625007211563	4	1	0	0
2177	233	cardiac transplant recipient	[cardiac transplant recipients]	1.5849625007211563	3	1	0	0
2178	233	use linear model	[using linear models]	1.5849625007211563	3	2	1	1
2179	233	swine with heart failure	[swine with heart failure]	1.5849625007211563	4	1	0	0
2180	233	treatment of a patient	[treatment of a patient]	1.5849625007211563	4	1	0	0
2181	233	major cardiovascular complication stroke	[major cardiovascular complications stroke]	1.5849625007211563	4	1	0	0
2182	233	right ventricular function	[right ventricular function]	1.5849625007211563	3	2	1	1
2183	233	heart failure with dysfunction	[heart failure with dysfunction]	1.5849625007211563	4	2	2	2
2184	233	2374428 ED visit 32036	[2,374,428 ED visits 32,036]	1.5849625007211563	4	1	0	0
2185	233	atheromatous coronary disease	[atheromatous coronary disease]	1.5849625007211563	3	1	0	0
2186	233	onset of myofiber shortening	[onset of myofiber shortening]	1.5849625007211563	4	1	0	0
2187	233	quality of care programme	[quality of care programme]	1.5849625007211563	4	1	0	0
2188	233	t1 time r=0.98	[T1 time R=0.98]	1.5849625007211563	3	1	0	0
2189	233	major clinical trial	[Major clinical trials]	1.5849625007211563	3	1	0	0
2190	233	inferior vena cava IVC	[inferior vena cava IVC]	1.5849625007211563	4	1	0	0
2191	233	Multicenter automatic Defibrillator	[Multicenter Automatic Defibrillator]	1.5849625007211563	3	1	0	0
2192	233	β1-adrenergic receptor β1ar	[β1-adrenergic receptor β1AR]	1.5849625007211563	3	1	0	0
2193	233	datum regard risk factor	[data regarding risk factors]	1.5849625007211563	4	1	0	0
2194	233	mva of 1.8 cm2	[MVA of 1.8 cm2]	1.5849625007211563	4	1	0	0
2195	233	City of Hope	[City of Hope]	1.5849625007211563	3	1	0	0
2196	233	laboratory report model	[laboratory report model]	1.5849625007211563	3	2	1	1
2197	233	benefit of bb therapy	[benefit of BB therapy]	1.5849625007211563	4	1	0	0
2198	233	functional class ii	[functional class II]	1.5849625007211563	3	1	0	0
2199	233	pulseless ventricular fibrillation pvf	[pulseless ventricular fibrillation PVF]	1.5849625007211563	4	1	0	0
2200	233	adaptive cardiac remodelling	[adaptive cardiac remodelling]	1.5849625007211563	3	2	2	2
2201	233	increase in the percentage	[increases in the percentage]	1.5849625007211563	4	1	0	0
2202	233	ventricular action potential duration	[ventricular action potential duration]	1.5849625007211563	4	1	0	0
2203	233	ratio ees ea	[ratio Ees Ea]	1.5849625007211563	3	1	0	0
2204	233	adverse outcome related	[adverse outcomes related]	1.5849625007211563	3	1	0	0
2205	233	arterial tonometry study	[arterial tonometry study]	1.5849625007211563	3	1	0	0
2206	233	flow-mediated dilatation diameter	[flow-mediated dilatation diameter]	1.5849625007211563	3	1	0	0
2207	233	aortic valve procedure	[aortic valve procedure]	1.5849625007211563	3	2	2	2
2208	233	ventricular LV hypertrophy	[ventricular LV hypertrophy]	1.5849625007211563	3	1	0	0
2209	233	interval from consultation	[interval from consultation]	1.5849625007211563	3	1	0	0
2210	233	role of vasopressin	[role of vasopressin]	1.5849625007211563	3	1	0	0
2211	233	mouse HF model	[mouse HF model]	1.5849625007211563	3	2	2	2
2212	233	harm include hypertension	[harms including hypertension]	1.5849625007211563	3	1	0	0
2213	233	wide blood-flow path	[wide blood-flow paths]	1.5849625007211563	3	1	0	0
2214	233	heart failure pathophysiology	[Heart Failure Pathophysiology]	1.5849625007211563	3	1	0	0
2215	233	effect of low-dose dopamine	[effect of low-dose dopamine]	1.5849625007211563	4	1	0	0
2216	233	high-density lipoprotein HDL	[High-density lipoprotein HDL]	1.5849625007211563	3	1	0	0
2217	233	caspase 3 expression	[caspase 3 expression]	1.5849625007211563	3	1	0	0
2218	233	patient with baseline ef	[patients with baseline EF]	1.5849625007211563	4	1	0	0
2219	233	electrocardiographic q wave	[electrocardiographic Q waves]	1.5849625007211563	3	1	0	0
2220	233	Zung depression score	[Zung depression scores]	1.5849625007211563	3	1	0	0
2221	233	interventricular septum biopsy	[interventricular septum biopsies]	1.5849625007211563	3	1	0	0
2222	233	repeat procedure in patient	[repeat procedures in patients]	1.5849625007211563	4	1	0	0
2223	233	myocardial loss of irs1	[Myocardial loss of IRS1]	1.5849625007211563	4	1	0	0
2224	233	congestive heart failure exacerbation	[congestive heart failure exacerbation]	1.5849625007211563	4	1	0	0
2225	233	limited mitral valve opening	[limited mitral valve opening]	1.5849625007211563	4	1	0	0
2226	233	guideline-recommended medication for patient	[guideline-recommended medications for patients]	1.5849625007211563	4	1	0	0
2227	233	renin-angiotensin-aldosterone nervous system	[renin-angiotensin-aldosterone nervous systems]	1.5849625007211563	3	1	0	0
2228	233	final datum analysis	[final data analysis]	1.5849625007211563	3	1	0	0
2229	233	treatment of HF	[treatment of HF]	1.5849625007211563	3	3	2	1
2230	233	lifesaving drug for HF	[lifesaving drugs for HF]	1.5849625007211563	4	1	0	0
2231	233	development of RV dysfunction	[development of RV dysfunction]	1.5849625007211563	4	1	0	0
2232	233	HeartMate ii implantation	[HeartMate II implantation]	1.5849625007211563	3	1	0	0
2233	233	structure of medical record	[structure of medical records]	1.5849625007211563	4	1	0	0
2234	233	outcome in HF patient	[outcomes in HF patients]	1.5849625007211563	4	1	0	0
2235	233	improve process of care	[improving processes of care]	1.5849625007211563	4	1	0	0
2236	233	heart of ANS mouse	[hearts of ANS mice]	1.5849625007211563	4	1	0	0
2237	233	systolic dysfunction LV ef	[systolic dysfunction LV EF]	1.5849625007211563	4	1	0	0
2238	233	test for interaction	[test for interaction]	1.5849625007211563	3	1	0	0
2239	233	even after adjustment	[even after adjustment]	1.5849625007211563	3	2	2	2
2240	233	composite of repeat procedure	[composite of repeat procedures]	1.5849625007211563	4	1	0	0
2241	233	randomization group p=0.035	[randomization group P=0.035]	1.5849625007211563	3	1	0	0
2242	233	lipoprotein-associated phospholipase a2 lp-pla2	[lipoprotein-associated phospholipase A2 Lp-PLA2]	1.5849625007211563	4	1	0	0
2243	233	predict death hospitalization	[predicting death hospitalization]	1.5849625007211563	3	1	0	0
2244	233	left longitudinal strain	[left longitudinal strain]	1.5849625007211563	3	2	2	2
2245	233	myofiber shorten velocity	[myofiber shortening velocity]	1.5849625007211563	3	1	0	0
2246	233	differential g-protein coupling	[differential G-protein coupling]	1.5849625007211563	3	1	0	0
2247	233	cardiomyopathy in patient	[cardiomyopathy in patients]	1.5849625007211563	3	1	0	0
2248	233	systemic hypertension sh	[systemic hypertension SH]	1.5849625007211563	3	1	0	0
2249	233	patient with ambulatory HF	[patients with ambulatory HF]	1.5849625007211563	4	1	0	0
2250	233	gene expression of Bax	[gene expressions of Bax]	1.5849625007211563	4	1	0	0
2251	233	remote monitoring rm strategy	[Remote monitoring RM strategies]	1.5849625007211563	4	1	0	0
2252	233	90 day of follow-up	[90 days of follow-up]	1.5849625007211563	4	1	0	0
2253	233	Kaiser Permanente Northern California	[Kaiser Permanente Northern California]	1.5849625007211563	4	1	0	0
2254	233	rehospitalization for stroke	[rehospitalization for stroke]	1.5849625007211563	3	1	0	0
2255	233	human rad q66p	[human Rad Q66P]	1.5849625007211563	3	1	0	0
2256	233	catheter ablation relate	[catheter ablation relating]	1.5849625007211563	3	1	0	0
2257	233	emergency department ED	[emergency department ED]	1.5849625007211563	3	1	0	0
2258	233	development in diagnostic procedure	[developments in diagnostic procedure]	1.5849625007211563	4	1	0	0
2259	233	298 124 sitagliptin user	[298 124 sitagliptin users]	1.5849625007211563	4	1	0	0
2260	233	mt group 50 day	[MT group 50 days]	1.5849625007211563	4	1	0	0
2261	233	mitochondrial oxidative phosphorylation capacity	[mitochondrial oxidative phosphorylation capacity]	1.5849625007211563	4	2	1	1
2262	233	therapeutic strategy capable	[therapeutic strategies capable]	1.5849625007211563	3	1	0	0
2263	233	patient in sinus rhythm	[Patients in sinus rhythm]	1.5849625007211563	4	1	0	0
2264	233	difference in HF hospitalization	[difference in HF hospitalizations]	1.5849625007211563	4	1	0	0
2265	233	12 non-fatal stroke	[12 non-fatal stroke]	1.5849625007211563	3	1	0	0
2266	233	adherence in this study	[adherence in this study]	1.5849625007211563	4	1	0	0
2267	233	sphingosine-1-phosphate a s1pr1 agonist	[sphingosine-1-phosphate an S1PR1 agonist]	1.5849625007211563	4	1	0	0
2268	233	age 65 year	[age 65 years]	1.5849625007211563	3	1	0	0
2269	233	other guideline-recommended medication	[other guideline-recommended medications]	1.5849625007211563	3	1	0	0
2270	233	patient with dysfunction	[patients with dysfunction]	1.5849625007211563	3	2	2	2
2271	233	Statewide Health Planning	[Statewide Health Planning]	1.5849625007211563	3	1	0	0
2272	233	present study population	[present study population]	1.5849625007211563	3	1	0	0
2273	233	SCHFI v.6.2 scale	[SCHFI v.6.2 scales]	1.5849625007211563	3	1	0	0
2274	233	terminal heart failure	[terminal heart failure]	1.5849625007211563	3	1	0	0
2275	233	dual-energy x-ray absorptiometry	[dual-energy X-ray absorptiometry]	1.5849625007211563	3	1	0	0
2276	233	moderate LV dilatation	[moderate LV dilatation]	1.5849625007211563	3	1	0	0
2277	233	orthotopic heart transplantation OHT	[Orthotopic heart transplantation OHT]	1.5849625007211563	4	1	0	0
2278	233	low event rate hr	[lower event rate HR]	1.5849625007211563	4	1	0	0
2279	233	low exercise performance	[lower exercise performance]	1.5849625007211563	3	1	0	0
2280	233	decrease in cd34+vegfr2	[decrease in CD34+VEGFR2]	1.5849625007211563	3	2	1	1
2281	233	diffuse myocardial change	[diffuse myocardial changes]	1.5849625007211563	3	1	0	0
2282	233	unfamiliar physician s	[unfamiliar physician s]	1.5849625007211563	3	1	0	0
2283	233	patient from Québec	[patients from Québec]	1.5849625007211563	3	1	0	0
2284	233	death for heart failure	[death for heart failure]	1.5849625007211563	4	2	1	1
2285	233	three-year HF hospitalization rate	[Three-year HF hospitalization rates]	1.5849625007211563	4	1	0	0
2286	233	contemporaneous control group	[contemporaneous control group]	1.5849625007211563	3	1	0	0
2287	233	endothelial function flow-mediated dilatation	[endothelial function flow-mediated dilatation]	1.5849625007211563	4	1	0	0
2288	233	left ventricular midpapillary level	[left ventricular midpapillary level]	1.5849625007211563	4	1	0	0
2289	233	heart failure therapy	[heart failure therapy]	1.5849625007211563	3	2	2	2
2290	233	impact of hr reduction	[impact of HR reduction]	1.5849625007211563	4	1	0	0
2291	233	scientific literature January	[scientific literature January]	1.5849625007211563	3	1	0	0
2292	233	many reason for nonprescribing	[many reasons for nonprescribing]	1.5849625007211563	4	1	0	0
2293	233	last participant contact	[last participant contact]	1.5849625007211563	3	1	0	0
2294	233	QT variability QTV	[QT variability QTV]	1.5849625007211563	3	1	0	0
2295	233	6 fragment of nt-probnp	[6 fragments of NT-proBNP]	1.5849625007211563	4	1	0	0
2296	233	contain chronic heart failure	[containing chronic heart failure]	1.5849625007211563	4	1	0	0
2297	233	small retrospective study	[small retrospective studies]	1.5849625007211563	3	1	0	0
2298	233	exercise-induced pasp increase	[exercise-induced PASP increase]	1.5849625007211563	3	2	1	1
2299	233	mortality in modern society	[mortality in modern society]	1.5849625007211563	4	1	0	0
2300	233	measure of health status	[measure of health status]	1.5849625007211563	4	2	2	2
2301	233	Wilcoxon matched-pair signed-rank test	[Wilcoxon matched-pairs signed-rank tests]	1.5849625007211563	4	1	0	0
2302	233	diagnosis of therapy	[diagnosis of therapy]	1.5849625007211563	3	1	0	0
2303	233	MAIN outcome measure	[MAIN OUTCOME MEASURES]	1.5849625007211563	3	1	0	0
2304	233	filtration rate millileter	[filtration rate ml]	1.5849625007211563	3	2	2	2
2305	233	failure of xo inhibition	[failure of XO inhibition]	1.5849625007211563	4	1	0	0
2306	233	KCCQ summary score	[KCCQ Summary scores]	1.5849625007211563	3	2	1	1
2307	233	mechanism of regulation	[mechanisms of regulation]	1.5849625007211563	3	1	0	0
2308	233	health service planning	[health service planning]	1.5849625007211563	3	1	0	0
2309	233	less renal impairment	[less renal impairment]	1.5849625007211563	3	1	0	0
2310	233	purpose of review	[PURPOSE OF REVIEW]	1.5849625007211563	3	1	0	0
2311	233	iii heart failure HF	[III heart failure HF]	1.5849625007211563	4	1	0	0
2312	233	neprilysin inhibitor prodrug	[neprilysin inhibitor prodrug]	1.5849625007211563	3	1	0	0
2313	233	risk of hyperkalemia	[risk of hyperkalemia]	1.5849625007211563	3	2	2	2
2314	233	professional from multiple discipline	[professionals from multiple disciplines]	1.5849625007211563	4	1	0	0
2315	233	average weight loss	[average weight loss]	1.5849625007211563	3	1	0	0
2316	233	reduction in oxidation	[reduction in oxidation]	1.5849625007211563	3	1	0	0
2317	233	temporary right ventricular support	[temporary right ventricular support]	1.5849625007211563	4	1	0	0
2318	233	communication among cardiologist	[communication among cardiologists]	1.5849625007211563	3	1	0	0
2319	233	left-hand grip strength	[left-hand grip strength]	1.5849625007211563	3	1	0	0
2320	233	confidence in estimate	[confidence in estimates]	1.5849625007211563	3	2	1	1
2321	233	once at baseline	[once at baseline]	1.5849625007211563	3	1	0	0
2322	233	incidence of hyperkalemia	[incidence of hyperkalemia]	1.5849625007211563	3	1	0	0
2323	233	2.8 0.7 L 2	[2.8 0.7 L 2]	1.5849625007211563	4	1	0	0
2324	233	g'mt-treated nyha functional class	[GDMT-treated NYHA functional class]	1.5849625007211563	4	1	0	0
2325	233	classic signal paradigm	[classic signaling paradigms]	1.5849625007211563	3	1	0	0
2326	233	extracorporeal membrane oxygenation	[extracorporeal membrane oxygenation]	1.5849625007211563	3	2	2	2
2327	233	congenital accessory pathway	[congenital accessory pathways]	1.5849625007211563	3	1	0	0
2328	233	prolonged electromechanical delay	[prolonged electromechanical delay]	1.5849625007211563	3	1	0	0
2329	233	heart disease in patient	[heart disease in patients]	1.5849625007211563	4	1	0	0
2330	233	efficacy of catheter ablation	[efficacy of catheter ablation]	1.5849625007211563	4	1	0	0
2331	233	apparent circulate nt-probnp concentration	[apparent circulating NT-proBNP concentration]	1.5849625007211563	4	1	0	0
2332	233	membrane oxygenation on function	[membrane oxygenation on function]	1.5849625007211563	4	2	2	2
2333	233	heartmate ii lvad	[HeartMate II LVAD]	1.5849625007211563	3	1	0	0
2334	233	patient with preoperative hypoalbuminemia	[patients with preoperative hypoalbuminemia]	1.5849625007211563	4	2	1	1
2335	233	ischemic HF pathogenesis	[ischemic HF pathogenesis]	1.5849625007211563	3	1	0	0
2336	233	analysis of HF-ACTION	[analysis of HF-ACTION]	1.5849625007211563	3	1	0	0
2337	233	lack of hypertension	[lack of hypertension]	1.5849625007211563	3	1	0	0
2338	233	novel pure HNO donor	[novel pure HNO donor]	1.5849625007211563	4	1	0	0
2339	233	heart Association class ii	[Heart Association class II]	1.5849625007211563	4	1	0	0
2340	233	849 patient 200	[849 patients 200]	1.5849625007211563	3	1	0	0
2341	233	general linear model	[general linear models]	1.5849625007211563	3	1	0	0
2342	233	affect antitumor activity	[affecting antitumor activity]	1.5849625007211563	3	1	0	0
2343	233	clinically stable hfpef	[clinically stable HFPEF]	1.5849625007211563	3	1	0	0
2344	233	E all p value	[E all p values]	1.5849625007211563	4	1	0	0
2345	233	ventricular longitudinal systolic strain	[ventricular longitudinal systolic strain]	1.5849625007211563	4	2	2	2
2346	233	low cumulative hazard	[lowest cumulative hazard]	1.5849625007211563	3	1	0	0
2347	233	test a cardioverter-defibrillator device	[testing a cardioverter-defibrillator device]	1.5849625007211563	4	1	0	0
2348	233	effect on the efficacy	[effect on the efficacy]	1.5849625007211563	4	1	0	0
2349	233	effectiveness of resynchronization therapy	[effectiveness of resynchronization therapy]	1.5849625007211563	4	1	0	0
2350	233	biomedical treatment alone	[biomedical treatment alone]	1.5849625007211563	3	2	1	1
2351	233	versus without diabete	[vs without diabetes]	1.5849625007211563	3	1	0	0
2352	233	long survival rate	[long-term survival rates]	1.5849625007211563	3	1	0	0
2353	233	proximal left descend artery	[proximal left descending artery]	1.5849625007211563	4	1	0	0
2354	233	cardiac index 2.2	[cardiac index 2.2]	1.5849625007211563	3	1	0	0
2355	233	follow a unplanned admission	[following an unplanned admission]	1.5849625007211563	4	1	0	0
2356	233	systematic review protocol	[systematic review protocol]	1.5849625007211563	3	1	0	0
2357	233	predict adverse CV event	[predicting adverse CV events]	1.5849625007211563	4	2	1	1
2358	233	new-onset aortic insufficiency ai	[New-onset aortic insufficiency AI]	1.5849625007211563	4	1	0	0
2359	233	ejection fraction development	[ejection fraction development]	1.5849625007211563	3	1	0	0
2360	233	decrease in ejection fraction	[decreases in ejection fraction]	1.5849625007211563	4	1	0	0
2361	233	measurement of hr variability	[measurement of HR variability]	1.5849625007211563	4	2	2	2
2362	233	only among patient	[only among patients]	1.5849625007211563	3	1	0	0
2363	233	modest reduction in mva	[modest reduction in MVA]	1.5849625007211563	4	1	0	0
2364	233	β-adrenergic receptor activation	[β-adrenergic receptor activation]	1.5849625007211563	3	1	0	0
2365	233	user of saxagliptin	[users of saxagliptin]	1.5849625007211563	3	1	0	0
2366	233	0.53 event p=0.001	[0.53 events P=0.001]	1.5849625007211563	3	1	0	0
2367	233	quality of life assessment	[quality of life assessment]	1.5849625007211563	4	1	0	0
2368	233	LV end-systolic volume	[LV end-systolic volume]	1.5849625007211563	3	1	0	0
2369	233	target patient population	[target patient population]	1.5849625007211563	3	1	0	0
2370	233	t2d type 2 diabete	[T2D Type 2 diabetes]	1.5849625007211563	4	1	0	0
2371	233	significant liver disease	[significant liver disease]	1.5849625007211563	3	1	0	0
2372	233	acute heart failure AHF	[Acute heart failure AHF]	1.5849625007211563	4	1	0	0
2373	233	highlight diastolic dysfunction	[highlighting diastolic dysfunction]	1.5849625007211563	3	1	0	0
2374	233	14 HF unit	[14 HF units]	1.5849625007211563	3	1	0	0
2375	233	different mechanism of action	[different mechanism of action]	1.5849625007211563	4	1	0	0
2376	233	ventricular structure geometry	[ventricular structure geometry]	1.5849625007211563	3	1	0	0
2377	233	role of appropriate timing	[role of appropriate timing]	1.5849625007211563	4	1	0	0
2378	233	β-adrenergic receptor blocker therapy	[β-adrenergic receptor blocker therapy]	1.5849625007211563	4	1	0	0
2379	233	cause of morbidity	[cause of morbidity]	1.5849625007211563	3	2	2	2
2380	233	ED outpatient setting	[ED outpatient settings]	1.5849625007211563	3	1	0	0
2381	233	4.6 mm hg Fig	[4.6 mm Hg Fig]	1.5849625007211563	4	1	0	0
2382	233	after percutaneous coronary revascularization	[After percutaneous coronary revascularization]	1.5849625007211563	4	1	0	0
2383	233	heart magnetic resonance imaging	[heart magnetic resonance imaging]	1.5849625007211563	4	2	1	1
2384	233	individual quality measure	[individual quality measures]	1.5849625007211563	3	1	0	0
2385	233	development of pacing-induced cardiomyopathy	[development of pacing-induced cardiomyopathy]	1.5849625007211563	4	1	0	0
2386	233	effectiveness of medicine	[Effectiveness of medicine]	1.5849625007211563	3	2	2	2
2387	233	LVET at icu admission	[LVET at ICU admission]	1.5849625007211563	4	1	0	0
2388	233	simple clinical tool	[simple clinical tool]	1.5849625007211563	3	1	0	0
2389	233	myocardial pde2 expression	[Myocardial PDE2 expression]	1.5849625007211563	3	1	0	0
2390	233	total arterial compliance tac	[total arterial compliance TAC]	1.5849625007211563	4	1	0	0
2391	233	majority of potential candidate	[majority of potential candidates]	1.5849625007211563	4	1	0	0
2392	233	overview of this rirnas	[overview of these miRNAs]	1.5849625007211563	4	1	0	0
2393	233	multiparametric echocardiographic score	[multiparametric echocardiographic score]	1.5849625007211563	3	2	1	1
2394	233	reduction of sympathetic tone	[reduction of sympathetic tone]	1.5849625007211563	4	1	0	0
2395	233	bet bromodomain-containing protein brd4	[BET bromodomain-containing protein BRD4]	1.5849625007211563	4	1	0	0
2396	233	good quintile of hospital	[best quintile of hospitals]	1.5849625007211563	4	1	0	0
2397	233	KCCQ overall summary	[KCCQ Overall Summary]	1.5849625007211563	3	1	0	0
2398	233	datum examine long outcome	[data examining long-term outcomes]	1.5849625007211563	4	1	0	0
2399	233	first AMI between 1996	[first AMI between 1996]	1.5849625007211563	4	1	0	0
2400	233	woman undergo anthracycline-containing chemotherapy	[women undergoing anthracycline-containing chemotherapy]	1.5849625007211563	4	1	0	0
2401	233	α-myosin heavy chain	[α-myosin heavy chain]	1.5849625007211563	3	1	0	0
2402	233	small noncoding rna	[small noncoding RNAs]	1.5849625007211563	3	1	0	0
2403	233	expression during cardiac hypertrophy	[expression during cardiac hypertrophy]	1.5849625007211563	4	1	0	0
2404	233	interpretation of exercise testing	[interpretation of exercise testing]	1.5849625007211563	4	1	0	0
2405	233	implantable cardiac arrhythmia device	[implantable cardiac arrhythmia devices]	1.5849625007211563	4	1	0	0
2406	233	provision of life-sustaining treatment	[provision of life-sustaining treatment]	1.5849625007211563	4	1	0	0
2407	233	peak aerobic capacity	[peak aerobic capacity]	1.5849625007211563	3	1	0	0
2408	233	medical therapy mt	[medical therapy MT]	1.5849625007211563	3	1	0	0
2409	233	use a stent	[using a stent]	1.5849625007211563	3	1	0	0
2410	233	new chromatin subproteome	[new chromatin subproteome]	1.5849625007211563	3	1	0	0
2411	233	primary composite endpoint	[primary composite endpoint]	1.5849625007211563	3	1	0	0
2412	233	device-related adverse event	[device-related adverse events]	1.5849625007211563	3	1	0	0
2413	233	mean of 11 year	[mean of 11 years]	1.5849625007211563	4	1	0	0
2414	233	KCCQ overall summary score	[KCCQ Overall Summary scores]	1.5849625007211563	4	1	0	0
2415	233	adult aged 20 year	[adults aged 20 years]	1.5849625007211563	4	1	0	0
2416	233	VVD variation p	[VVD variation P]	1.5849625007211563	3	1	0	0
2417	233	excellent prognostic ability	[excellent prognostic ability]	1.5849625007211563	3	1	0	0
2418	233	expression of Bax protein	[expression of Bax proteins]	1.5849625007211563	4	1	0	0
2419	233	renal artery stenosis RAS	[Renal artery stenosis RAS]	1.5849625007211563	4	1	0	0
2420	233	treatment of several cancer	[treatment of several cancers]	1.5849625007211563	4	1	0	0
2421	233	Magnet(®) research requirement	[Magnet(®) research requirements]	1.5849625007211563	3	1	0	0
2422	233	confirmatory diagnostic test	[Confirmatory diagnostic tests]	1.5849625007211563	3	1	0	0
2423	233	key adverse event	[Key adverse events]	1.5849625007211563	3	1	0	0
2424	233	serum potassium 5.0 mmol	[serum potassium 5.0 mmol]	1.5849625007211563	4	1	0	0
2425	233	5 age group 20	[5 age groups 20]	1.5849625007211563	4	1	0	0
2426	233	fifty-one percent of patient	[Fifty-one percent of patients]	1.5849625007211563	4	1	0	0
2427	233	baseline kccq scale	[baseline KCCQ scales]	1.5849625007211563	3	1	0	0
2428	233	development of hypertrophy	[development of hypertrophy]	1.5849625007211563	3	2	2	2
2429	233	net economic savings	[net economic savings]	1.5849625007211563	3	1	0	0
2430	233	5.0 42.4 gram p=0.04	[5.0 42.4 g P=0.04]	1.5849625007211563	4	1	0	0
2431	233	cardioprotective effect of nicorandil	[cardioprotective effect of nicorandil]	1.5849625007211563	4	1	0	0
2432	233	compliance with treatment	[compliance with treatment]	1.5849625007211563	3	2	1	1
2433	233	diagnosis of af	[diagnosis of AF]	1.5849625007211563	3	2	2	2
2434	233	Coronary artery disease cad	[Coronary artery disease CAD]	1.5849625007211563	4	1	0	0
2435	233	expression of exogenous variant	[expression of exogenous variants]	1.5849625007211563	4	1	0	0
2436	233	association between race	[association between race]	1.5849625007211563	3	1	0	0
2437	233	over 12 month	[over 12 months]	1.5849625007211563	3	1	0	0
2438	233	Framingham heart study criterion	[Framingham Heart Study criteria]	1.5849625007211563	4	1	0	0
2439	233	end stage kidney failure	[end stage kidney failure]	1.5849625007211563	4	1	0	0
2440	233	hospital quality improvement initiative	[hospital quality improvement initiative]	1.5849625007211563	4	1	0	0
2441	233	renin-angiotensin system RAS	[renin-angiotensin system RAS]	1.5849625007211563	3	1	0	0
2442	233	target nonterminal epitope	[targeting nonterminal epitopes]	1.5849625007211563	3	1	0	0
2443	233	pediatric mechanical cardiac support	[pediatric mechanical cardiac support]	1.5849625007211563	4	1	0	0
2444	233	heart failure hr 1.07	[heart failure HR 1.07]	1.5849625007211563	4	1	0	0
2445	233	novel bottleneck stent	[novel bottleneck stent]	1.5849625007211563	3	1	0	0
2446	233	have ≥1 independent predictor	[having ≥1 independent predictor]	1.5849625007211563	4	1	0	0
2447	233	influx via L-type can	[influx via L-type Ca]	1.5849625007211563	4	1	0	0
2448	233	increase ejection fraction	[increasing ejection fraction]	1.5849625007211563	3	1	0	0
2449	233	1.73 m 2 age	[1.73 m 2 age]	1.5849625007211563	4	1	0	0
2450	233	decrease in eo-cfus	[decrease in EO-CFUs]	1.5849625007211563	3	1	0	0
2451	233	least 55 year	[least 55 years]	1.5849625007211563	3	1	0	0
2452	233	include intravenous inotrope	[including intravenous inotropes]	1.5849625007211563	3	1	0	0
2453	233	predictor of primary outcome	[predictors of primary outcome]	1.5849625007211563	4	1	0	0
2454	233	difference in the risk	[difference in the risk]	1.5849625007211563	4	1	0	0
2455	233	echocardiography at 8 wk	[Echocardiography at 8 wk]	1.5849625007211563	4	1	0	0
2456	233	6 CF lvad patient	[6 CF LVAD patients]	1.5849625007211563	4	1	0	0
2457	233	patient require isolated lvad	[patients requiring isolated LVAD]	1.5849625007211563	4	1	0	0
2458	233	maximum o2 consumption rate	[maximum O2 consumption rate]	1.5849625007211563	4	1	0	0
2459	233	combination with anticoagulant	[combination with anticoagulants]	1.5849625007211563	3	1	0	0
2460	233	log rank p	[log rank P]	1.5849625007211563	3	1	0	0
2461	233	long-standing persistent af	[long-standing persistent AF]	1.5849625007211563	3	1	0	0
2462	233	conscious HF rat	[conscious HF rats]	1.5849625007211563	3	1	0	0
2463	233	clinical characteristic of eh	[clinical characteristics of EH]	1.5849625007211563	4	1	0	0
2464	233	vasopressin receptor antagonist therapy	[vasopressin receptor antagonist therapy]	1.5849625007211563	4	1	0	0
2465	233	chronic renal failure CRF	[chronic renal failure CRF]	1.5849625007211563	4	1	0	0
2466	233	late-activated lateral wall	[late-activated lateral wall]	1.5849625007211563	3	1	0	0
2467	233	focus of research investigation	[focus of research investigations]	1.5849625007211563	4	1	0	0
2468	233	World Health Organization website	[World Health Organization website]	1.5849625007211563	4	1	0	0
2469	233	LV reverse remodeling n=161	[LV reverse remodeling n=161]	1.5849625007211563	4	1	0	0
2470	233	advance in treatment	[Advances in treatment]	1.5849625007211563	3	2	1	1
2471	233	intervention with tgf-β signal	[intervention with TGF-β signaling]	1.5849625007211563	4	1	0	0
2472	233	Eplerenone Post myocardial infarction	[Eplerenone Post myocardial infarction]	1.5849625007211563	4	1	0	0
2473	233	two L-type channel isoform	[two L-type channel isoforms]	1.5849625007211563	4	1	0	0
2474	233	elastic N2Bus segment	[elastic N2Bus segment]	1.5849625007211563	3	1	0	0
2475	233	cause of heart failure	[cause of heart failure]	1.5849625007211563	4	2	2	2
2476	233	aerobic exercise training	[aerobic exercise training]	1.5849625007211563	3	2	1	1
2477	233	257692 ICD patient	[257,692 ICD patients]	1.5849625007211563	3	1	0	0
2478	233	Gene expression of Bax	[Gene expression of Bax]	1.5849625007211563	4	1	0	0
2479	233	esrd 1.3 patient-year	[ESRD 1.3 patient-years]	1.5849625007211563	3	1	0	0
2480	233	use a cost-minimization approach	[using a cost-minimization approach]	1.5849625007211563	4	1	0	0
2481	233	association between any predictor	[association between any predictor]	1.5849625007211563	4	1	0	0
2482	233	thromboembolic event in patient	[thromboembolic events in patients]	1.5849625007211563	4	1	0	0
2483	233	attenuation by mitochondrial-targeted peptide	[attenuation by mitochondrial-targeted peptides]	1.5849625007211563	4	1	0	0
2484	233	ejection fraction rEF	[ejection fraction rEF]	1.5849625007211563	3	1	0	0
2485	233	p value for interaction=0.032	[P value for interaction=0.032]	1.5849625007211563	4	1	0	0
2486	233	predominantly rural South Dakota	[predominantly rural South Dakota]	1.5849625007211563	4	1	0	0
2487	233	accumulation of deficit	[accumulation of deficits]	1.5849625007211563	3	1	0	0
2488	233	clcnka gg genotype	[CLCNKA GG genotype]	1.5849625007211563	3	1	0	0
2489	233	drs-stratified hazard ratio	[DRS-stratified hazard ratios]	1.5849625007211563	3	1	0	0
2490	233	stroke volume sv	[stroke volume SV]	1.5849625007211563	3	1	0	0
2491	233	adverse health outcome	[adverse health outcomes]	1.5849625007211563	3	1	0	0
2492	233	sodium-restricted dietary approach	[sodium-restricted dietary approaches]	1.5849625007211563	3	1	0	0
2493	233	additive adverse impact	[additive adverse impact]	1.5849625007211563	3	1	0	0
2494	233	adult with HF	[adults with HF]	1.5849625007211563	3	2	2	2
2495	233	atrial fibrillation AF	[Atrial fibrillation AF]	1.5849625007211563	3	1	0	0
2496	233	additional prospective study	[additional prospective studies]	1.5849625007211563	3	1	0	0
2497	233	far elevation in resistin	[Further elevation in resistin]	1.5849625007211563	4	1	0	0
2498	233	free wall rs p	[free wall RS P]	1.5849625007211563	4	1	0	0
2499	233	point of care	[point of care]	1.5849625007211563	3	2	2	2
2500	233	functional etiology of MR	[functional etiology of MR]	1.5849625007211563	4	1	0	0
2501	233	increase cardiac volume index	[increasing cardiac volume index]	1.5849625007211563	4	1	0	0
2502	233	finding through briefing report	[findings through briefing reports]	1.5849625007211563	4	1	0	0
2503	233	idiopathic-dilated cardiomyopathy all p	[idiopathic-dilated cardiomyopathy all p]	1.5849625007211563	4	1	0	0
2504	233	moderate-severe right ventricular dysfunction	[moderate-severe right ventricular dysfunction]	1.5849625007211563	4	1	0	0
2505	233	patient with lvef	[patients with LVEF]	1.5849625007211563	3	1	0	0
2506	233	change in energy metabolism	[changes in energy metabolism]	1.5849625007211563	4	1	0	0
2507	233	pathway alteration in TAC	[pathway alterations in TAC]	1.5849625007211563	4	1	0	0
2508	233	3.01 1.39 year	[3.01 1.39 years]	1.5849625007211563	3	1	0	0
2509	233	dual ras inhibition	[Dual RAS inhibition]	1.5849625007211563	3	1	0	0
2510	233	beta receptor blocker	[beta receptor blockers]	1.5849625007211563	3	1	0	0
2511	233	2 month post-procedure	[2 months post-procedure]	1.5849625007211563	3	1	0	0
2512	233	incremental shuttle walk test	[incremental shuttle walk test]	1.5849625007211563	4	1	0	0
2513	233	Kansas City cardiomyopathy questionnaire	[Kansas City Cardiomyopathy Questionnaire]	1.5849625007211563	4	1	0	0
2514	233	nyha class iii	[NYHA class III]	1.5849625007211563	3	1	0	0
2515	233	negative inotropic effect	[negative inotropic effect]	1.5849625007211563	3	1	0	0
2516	233	calcineurin nfat signalling	[calcineurin Nfat signalling]	1.5849625007211563	3	1	0	0
2517	233	old breast cancer patient	[older breast cancer patients]	1.5849625007211563	4	1	0	0
2518	233	right coronary artery	[right coronary artery]	1.5849625007211563	3	1	0	0
2519	233	most ethically complex situation	[most ethically complex situations]	1.5849625007211563	4	1	0	0
2520	233	extent of cad	[extent of CAD]	1.5849625007211563	3	1	0	0
2521	233	ventricular diastolic end diameter	[ventricular diastolic end diameter]	1.5849625007211563	4	2	2	2
2522	233	change in atrial pressure	[changes in atrial pressure]	1.5849625007211563	4	1	0	0
2523	233	Gene expression profile GSE9128	[Gene expression profile GSE9128]	1.5849625007211563	4	1	0	0
2524	233	therefore afterload burden	[therefore afterload burden]	1.5849625007211563	3	1	0	0
2525	233	subgroup at high risk	[subgroups at high risk]	1.5849625007211563	4	2	2	2
2526	233	adjunctive treatment for cardiomyopathy	[adjunctive treatment for cardiomyopathy]	1.5849625007211563	4	1	0	0
2527	233	exercise rehabilitation in patient	[exercise rehabilitation in patients]	1.5849625007211563	4	2	1	1
2528	233	left ventricular mechanic	[left ventricular mechanics]	1.5849625007211563	3	1	0	0
2529	233	readily available datum	[readily available data]	1.5849625007211563	3	1	0	0
2530	233	use 2005 2008 composite	[using 2005 2008 composite]	1.5849625007211563	4	1	0	0
2531	233	bone 4 expression	[bone 4 expression]	1.5849625007211563	3	1	0	0
2532	233	Beck Depression Inventory	[Beck Depression Inventory]	1.5849625007211563	3	1	0	0
2533	233	renin angiotensin-aldosterone pathway	[renin angiotensin-aldosterone pathway]	1.5849625007211563	3	1	0	0
2534	233	consecutive case series	[consecutive case series]	1.5849625007211563	3	2	2	2
2535	233	univariate model p	[univariate models p]	1.5849625007211563	3	1	0	0
2536	233	patient without uptitration	[patients without uptitration]	1.5849625007211563	3	1	0	0
2537	233	tricuspid annular plane excursion	[Tricuspid annular plane excursion]	1.5849625007211563	4	2	2	2
2538	233	use ingenuity pathway analysis	[using ingenuity pathway analysis]	1.5849625007211563	4	1	0	0
2539	233	successful reperfusion therapy	[successful reperfusion therapy]	1.5849625007211563	3	1	0	0
2540	233	cystatin c level dopamine	[cystatin C level dopamine]	1.5849625007211563	4	1	0	0
2541	233	cardiac surgery patient	[cardiac surgery patients]	1.5849625007211563	3	1	0	0
2542	233	adequate blood pressure control	[Adequate blood pressure control]	1.5849625007211563	4	1	0	0
2543	233	prognosis in heart failure	[prognosis in heart failure]	1.5849625007211563	4	2	1	1
2544	233	prevalence of heart failure	[prevalence of heart failure]	1.5849625007211563	4	2	1	1
2545	233	Multivariate Cox regression analysis	[Multivariate Cox regression analyses]	1.5849625007211563	4	1	0	0
2546	233	peak oxygen uptake p	[peak oxygen uptake P]	1.5849625007211563	4	1	0	0
2547	233	cardiac transplant n=36	[cardiac transplant n=36]	1.5849625007211563	3	1	0	0
2548	233	systolic blood pressure median	[systolic blood pressure median]	1.5849625007211563	4	1	0	0
2549	233	key secondary outcome	[Key secondary outcomes]	1.5849625007211563	3	1	0	0
2550	233	mouse via phenylephrine	[mice via phenylephrine]	1.5849625007211563	3	1	0	0
2551	233	high readmission rate p	[higher readmission rates P]	1.5849625007211563	4	1	0	0
2552	233	longitudinal systolic strain	[longitudinal systolic strain]	1.5849625007211563	3	2	2	2
2553	233	sympathetic parasympathetic activity	[sympathetic parasympathetic activity]	1.5849625007211563	3	1	0	0
2554	233	cardiac vagal tone	[cardiac vagal tone]	1.5849625007211563	3	1	0	0
2555	233	high rate of rehospitalization	[higher rate of rehospitalization]	1.5849625007211563	4	1	0	0
2556	233	evidence for this drug	[evidence for these drugs]	1.5849625007211563	4	1	0	0
2557	233	rate of CHF	[rate of CHF]	1.5849625007211563	3	2	1	1
2558	233	atrial natriuretic peptide	[atrial natriuretic peptide]	1.5849625007211563	3	1	0	0
2559	233	cardiac gene expression	[cardiac gene expression]	1.5849625007211563	3	2	2	2
2560	233	cyclic adenosine monophosphate camp	[cyclic adenosine monophosphate cAMP]	1.5849625007211563	4	1	0	0
2561	233	stroke prevention Trial	[Stroke prevention Trial]	1.5849625007211563	3	2	1	1
2562	233	Exercise Training HF-ACTION	[Exercise Training HF-ACTION]	1.5849625007211563	3	2	2	2
2563	233	1 year of oht	[1 year of OHT]	1.5849625007211563	4	1	0	0
2564	233	case post-hct CHF	[Cases post-HCT CHF]	1.5849625007211563	3	1	0	0
2565	233	ies in this population	[IEs in this population]	1.5849625007211563	4	1	0	0
2566	233	free wall cs	[free wall CS]	1.5849625007211563	3	1	0	0
2567	233	6 minute walking	[6 minutes walking]	1.5849625007211563	3	1	0	0
2568	233	action of receptor kinase-2	[actions of receptor kinase-2]	1.5849625007211563	4	1	0	0
2569	233	other dietary measure	[other dietary measures]	1.5849625007211563	3	1	0	0
2570	233	prior 1 month	[prior 1 months]	1.5849625007211563	3	1	0	0
2571	233	median body mass index	[median body mass index]	1.5849625007211563	4	1	0	0
2572	233	predictor use multivariable regression	[predictor using multivariable regression]	1.5849625007211563	4	1	0	0
2573	233	acute anthracycline-induced cardiotoxicity	[acute anthracycline-induced cardiotoxicity]	1.5849625007211563	3	1	0	0
2574	233	invasive haemodynamic assessment	[invasive haemodynamic assessment]	1.5849625007211563	3	1	0	0
2575	233	defibrillator-only therapy hr 0.87	[defibrillator-only therapy HR 0.87]	1.5849625007211563	4	1	0	0
2576	233	genomic reprogramming event	[genomic reprogramming events]	1.5849625007211563	3	1	0	0
2577	233	full length nt-probnp molecule	[full length NT-proBNP molecule]	1.5849625007211563	4	1	0	0
2578	233	emphasis-hf study subgroup Eplerenone	[EMPHASIS-HF study subgroups Eplerenone]	1.5849625007211563	4	1	0	0
2579	233	16 candidate gene	[16 candidate genes]	1.5849625007211563	3	1	0	0
2580	233	low body mass index	[lower body mass index]	1.5849625007211563	4	1	0	0
2581	233	chronic insulin exposure	[chronic insulin exposure]	1.5849625007211563	3	1	0	0
2582	233	basal resistin level similar	[basal resistin levels similar]	1.5849625007211563	4	1	0	0
2583	233	bhlh transcription factor Hand2	[bHLH transcription factor Hand2]	1.5849625007211563	4	1	0	0
2584	233	net reclassification improvement	[net reclassification improvement]	1.5849625007211563	3	2	1	1
2585	233	number of case	[number of cases]	1.5849625007211563	3	1	0	0
2586	233	negative binomial regression model	[negative binomial regression models]	1.5849625007211563	4	1	0	0
2587	233	significant mitral stenosis	[significant mitral stenosis]	1.5849625007211563	3	1	0	0
2588	233	otherwise effective rate control	[otherwise effective rate control]	1.5849625007211563	4	1	0	0
2589	233	activate myocardial pde2	[activating myocardial PDE2]	1.5849625007211563	3	1	0	0
2590	233	rapid onset of	[rapid onset of]	1.5849625007211563	3	1	0	0
2591	233	typical adverse event	[typical adverse event]	1.5849625007211563	3	1	0	0
2592	233	bioprosthetic valve replacement	[bioprosthetic valve replacement]	1.5849625007211563	3	2	2	2
2593	233	high stroke volume	[higher stroke volume]	1.5849625007211563	3	1	0	0
2594	233	correction for age	[correction for age]	1.5849625007211563	3	1	0	0
2595	233	3 week after AAC	[3 weeks after AAC]	1.5849625007211563	4	1	0	0
2596	233	chronic systolic heart failure	[chronic systolic heart failure]	1.5849625007211563	4	1	0	0
2597	233	range 51 year	[range 51 years]	1.5849625007211563	3	1	0	0
2598	233	increase of 0.2 millileter	[increase of 0.2 mL]	1.5849625007211563	4	1	0	0
2599	233	dietary sodium restriction	[dietary sodium restriction]	1.5849625007211563	3	1	0	0
2600	233	measure of contractile reserve	[measure of contractile reserve]	1.5849625007211563	4	2	2	2
2601	233	factor of sh	[factors of SH]	1.5849625007211563	3	1	0	0
2602	233	total of patient	[total of patients]	1.5849625007211563	3	2	2	2
2603	233	cumulative anthracycline exposure	[cumulative anthracycline exposure]	1.5849625007211563	3	1	0	0
2604	233	advanced structural heart disease	[advanced structural heart disease]	1.5849625007211563	4	1	0	0
2605	233	initial functional class	[initial functional class]	1.5849625007211563	3	1	0	0
2606	233	coprimary end point	[Coprimary end points]	1.5849625007211563	3	1	0	0
2607	233	sixty-one patient with HFPEF	[Sixty-one patients with HFPEF]	1.5849625007211563	4	1	0	0
2608	233	combination of exercise	[combination of exercise]	1.5849625007211563	3	1	0	0
2609	233	heart Failure Adherence Trial	[Heart Failure Adherence Trial]	1.5849625007211563	4	1	0	0
2610	233	anaerobic threshold at	[anaerobic threshold AT]	1.5849625007211563	3	1	0	0
2611	233	aggressive dose uptitration	[aggressive dose uptitration]	1.5849625007211563	3	1	0	0
2612	233	mean follow-up time	[mean follow-up times]	1.5849625007211563	3	1	0	0
2613	233	further remodeling aspect	[further remodeling aspects]	1.5849625007211563	3	1	0	0
2614	233	manage this disease	[managing this disease]	1.5849625007211563	3	1	0	0
2615	233	good outcome among patient	[better outcomes among patients]	1.5849625007211563	4	1	0	0
2616	233	disappointment in large phase	[disappointments in large phase]	1.5849625007211563	4	1	0	0
2617	233	activation of p38	[activation of p38]	1.5849625007211563	3	1	0	0
2618	233	similar baseline covariate	[similar baseline covariates]	1.5849625007211563	3	1	0	0
2619	233	0.5 kg p	[0.5 kg p]	1.5849625007211563	3	1	0	0
2620	233	average age of patient	[average age of patients]	1.5849625007211563	4	1	0	0
2621	233	maladaptive molecular process	[maladaptive molecular processes]	1.5849625007211563	3	1	0	0
2622	233	perspective on the timing	[perspective on the timing]	1.5849625007211563	4	1	0	0
2623	233	early-outgrowth colony-forming unit eo-cfus	[early-outgrowth colony-forming units EO-CFUs]	1.5849625007211563	4	1	0	0
2624	233	role of Nucleolin	[role of Nucleolin]	1.5849625007211563	3	1	0	0
2625	233	possibility of MS	[possibility of MS]	1.5849625007211563	3	1	0	0
2626	233	SkM mitochondrial structure	[SkM mitochondrial structure]	1.5849625007211563	3	1	0	0
2627	233	development of Ie	[development of IE]	1.5849625007211563	3	2	1	1
2628	233	excellent HF prediction model	[excellent HF prediction model]	1.5849625007211563	4	1	0	0
2629	233	essential role support patient	[essential role supporting patients]	1.5849625007211563	4	1	0	0
2630	233	first-in-class inhibitor JQ1	[first-in-class inhibitor JQ1]	1.5849625007211563	3	1	0	0
2631	233	odd ratio of 0.50	[odds ratio of 0.50]	1.5849625007211563	4	1	0	0
2632	233	postnatal mammalian myocardium	[postnatal mammalian myocardium]	1.5849625007211563	3	1	0	0
2633	233	hospitalization for hyperkalemia	[hospitalization for hyperkalemia]	1.5849625007211563	3	1	0	0
2634	233	potassium 5.0 mmol	[potassium 5.0 mmol]	1.5849625007211563	3	1	0	0
2635	233	resistin in heart failure	[resistin in heart failure]	1.5849625007211563	4	2	2	2
2636	233	endothelial function in HFpEF	[endothelial function in HFpEF]	1.5849625007211563	4	1	0	0
2637	233	development of CHF	[development of CHF]	1.5849625007211563	3	2	2	2
2638	233	logistic regression analysis	[logistic regression analysis]	1.5849625007211563	3	2	2	2
2639	233	18 heart transplantation	[18 heart transplantations]	1.5849625007211563	3	1	0	0
2640	233	possible biomarker for HFPEF	[possible biomarker for HFPEF]	1.5849625007211563	4	1	0	0
2641	233	cardiac l-type channel activity	[cardiac L-type channel activity]	1.5849625007211563	4	1	0	0
2642	233	concordance c statistic	[concordance c statistics]	1.5849625007211563	3	1	0	0
2643	233	peak work rate	[peak work rate]	1.5849625007211563	3	1	0	0
2644	233	inappropriate cardioverter-defibrillator therapy	[inappropriate cardioverter-defibrillator therapy]	1.5849625007211563	3	2	2	2
2645	233	stand-alone diagnostic device	[stand-alone diagnostic devices]	1.5849625007211563	3	1	0	0
2646	233	similar rate of hypertension	[similar rates of hypertension]	1.5849625007211563	4	1	0	0
2647	233	severe LV fibrosis	[Severe LV fibrosis]	1.5849625007211563	3	1	0	0
2648	233	correlation with baseline hgb	[correlation with baseline Hgb]	1.5849625007211563	4	1	0	0
2649	233	hypertension diet dash	[hypertension diet DASH]	1.5849625007211563	3	1	0	0
2650	233	25 heart failure patient	[25 heart failure patients]	1.5849625007211563	4	1	0	0
2651	233	global longitudinal strain	[global longitudinal strain]	1.5849625007211563	3	2	2	2
2652	233	4-year follow-up period	[4-year follow-up period]	1.5849625007211563	3	1	0	0
2653	233	median high pasp	[median high PASP]	1.5849625007211563	3	1	0	0
2654	233	Exercise training in patient	[Exercise training in patients]	1.5849625007211563	4	1	0	0
2655	233	vivo inhibition of mir-25	[vivo inhibition of miR-25]	1.5849625007211563	4	1	0	0
2656	233	phenylephrine-mediated hypertrophy of cardiomyocyte	[phenylephrine-mediated hypertrophy of cardiomyocytes]	1.5849625007211563	4	1	0	0
2657	233	SkM growth consistent	[SkM growth consistent]	1.5849625007211563	3	1	0	0
2658	233	patient with af	[patients with AF]	1.5849625007211563	3	1	0	0
2659	233	area under the curve	[area under the curve]	1.5849625007211563	4	2	1	1
2660	233	consultation for abdominal problem	[consultation for abdominal problems]	1.5849625007211563	4	1	0	0
2661	233	LV contractility low lvef	[LV contractility lower LVEF]	1.5849625007211563	4	1	0	0
2662	233	intervention atrial pacing	[interventions atrial pacing]	1.5849625007211563	3	1	0	0
2663	233	insulin-stimulated rate of glycolysis	[insulin-stimulated rates of glycolysis]	1.5849625007211563	4	1	0	0
2664	233	distinct subset of hfpef	[distinct subset of HFpEF]	1.5849625007211563	4	1	0	0
2665	233	difference among ef	[difference among EF]	1.5849625007211563	3	2	2	2
2666	233	patient with mild anemia	[patients with mild anemia]	1.5849625007211563	4	1	0	0
2667	233	collaborative research initiative	[collaborative research initiatives]	1.5849625007211563	3	1	0	0
2668	233	normal albumin level	[normal albumin levels]	1.5849625007211563	3	1	0	0
2669	233	target the right patient	[targeting the right patients]	1.5849625007211563	4	1	0	0
2670	233	β-adrenergic receptor agonist treatment	[β-adrenergic receptor agonist treatment]	1.5849625007211563	4	1	0	0
2671	233	predictor of esrd	[predictors of ESRD]	1.5849625007211563	3	1	0	0
2672	233	Trial investigate outcome hf-action	[Trial Investigating Outcomes HF-ACTION]	1.5849625007211563	4	1	0	0
2673	233	have heart failure	[having heart failure]	1.5849625007211563	3	2	2	2
2674	233	Carvedilol a nonselective β-blocker	[Carvedilol a nonselective β-blocker]	1.5849625007211563	4	1	0	0
2675	233	similar clinical benefit	[similar clinical benefit]	1.5849625007211563	3	1	0	0
2676	233	relative risk among trial	[relative risk among trials]	1.5849625007211563	4	1	0	0
2677	233	membrane oxygenation ecmo	[membrane oxygenation ECMO]	1.5849625007211563	3	2	2	2
2678	233	low von willebrand factor	[lower von Willebrand factor]	1.5849625007211563	4	1	0	0
2679	233	heart failure population	[heart failure population]	1.5849625007211563	3	2	1	1
2680	233	prevalent coronary heart disease	[prevalent coronary heart disease]	1.5849625007211563	4	1	0	0
2681	233	inappropriate shock therapy hr	[inappropriate shock therapy HR]	1.5849625007211563	4	1	0	0
2682	233	grade recommendation evidence	[Grade recommendation evidence]	1.5849625007211563	3	2	2	2
2683	233	prognostic indicator in patient	[prognostic indicator in patients]	1.5849625007211563	4	1	0	0
2684	233	diuretic use in HF	[diuretic use in HF]	1.5849625007211563	4	1	0	0
2685	233	use medicare datum	[using medicare data]	1.5849625007211563	3	2	1	1
2686	233	pulmonary vascular resistance	[pulmonary vascular resistance]	1.5849625007211563	3	2	2	2
2687	233	reality of heart failure	[reality of heart failure]	1.5849625007211563	4	1	0	0
2688	233	control group p	[control group P]	1.5849625007211563	3	2	1	1
2689	233	category of fit	[categories of fit]	1.5849625007211563	3	1	0	0
2690	233	Medicare hospital claim	[Medicare hospital claims]	1.5849625007211563	3	1	0	0
2691	233	preliminary descriptive study	[preliminary descriptive study]	1.5849625007211563	3	1	0	0
2692	233	percent of hospital	[percent of hospitals]	1.5849625007211563	3	2	2	2
2693	233	Cardiac overexpression of Mammalian	[Cardiac overexpression of Mammalian]	1.5849625007211563	4	1	0	0
2694	233	Beck Depression inventory p	[Beck Depression Inventory P]	1.5849625007211563	4	1	0	0
2695	233	603 consecutive patient age	[603 consecutive patients age]	1.5849625007211563	4	1	0	0
2696	233	experience heart failure	[experiencing heart failure]	1.5849625007211563	3	1	0	0
2697	233	type ii regulatory riiα	[type II regulatory RIIα]	1.5849625007211563	4	1	0	0
2698	233	diagnostic procedure for	[diagnostic procedures for]	1.5849625007211563	3	1	0	0
2699	233	change in abundance	[changes in abundance]	1.5849625007211563	3	1	0	0
2700	233	presence of sign	[presence of signs]	1.5849625007211563	3	1	0	0
2701	233	institutional experience between 2008	[institutional experience between 2008]	1.5849625007211563	4	1	0	0
2702	233	continuous flow cf	[continuous flow CF]	1.5849625007211563	3	1	0	0
2703	233	effectiveness of herbal medicine	[Effectiveness of herbal medicine]	1.5849625007211563	4	2	2	2
2704	233	web-based simulation tool	[Web-based simulation tool]	1.5849625007211563	3	1	0	0
2705	233	outcome except mortality	[outcomes except mortality]	1.5849625007211563	3	1	0	0
2706	233	systolic human heart failure	[systolic human heart failure]	1.5849625007211563	4	1	0	0
2707	233	shift heart failure treatment	[SHIFT Heart Failure Treatment]	1.5849625007211563	4	1	0	0
2708	233	implantable cardioverter-defibrillator therapy	[implantable cardioverter-defibrillator therapy]	1.5849625007211563	3	2	2	2
2709	233	good renal function	[better renal function]	1.5849625007211563	3	1	0	0
2710	233	thirteen patient with hypertension	[Thirteen patients with hypertension]	1.5849625007211563	4	1	0	0
2711	233	repeat metabolic evaluation	[repeat metabolic evaluations]	1.5849625007211563	3	1	0	0
2712	233	left ventricular end diameter	[left ventricular end diameter]	1.5849625007211563	4	2	2	2
2713	233	risk of new HF	[risk of new HF]	1.5849625007211563	4	1	0	0
2714	233	include quality of life	[including quality of life]	1.5849625007211563	4	1	0	0
2715	233	growth of Ehrlich carcinoma	[growth of Ehrlich carcinoma]	1.5849625007211563	4	1	0	0
2716	233	metoprolol 50 mg	[metoprolol 50 mg]	1.5849625007211563	3	1	0	0
2717	233	basal heart rate	[basal heart rate]	1.5849625007211563	3	1	0	0
2718	233	evidence in HFpEF	[evidence in HFpEF]	1.5849625007211563	3	1	0	0
2719	233	acute hospital facility	[acute hospital facilities]	1.5849625007211563	3	1	0	0
2720	233	duration of the symptom	[duration of the symptoms]	1.5849625007211563	4	1	0	0
2721	233	peak oxygen consumption vo2	[peak oxygen consumption VO2]	1.5849625007211563	4	1	0	0
2722	233	23 mm hg SD	[23 mm Hg SD]	1.5849625007211563	4	1	0	0
2723	233	hrqol change in HRQoL	[HRQoL changes in HRQoL]	1.5849625007211563	4	1	0	0
2724	233	English language on anemia	[English language on anemia]	1.5849625007211563	4	1	0	0
2725	233	dapc dystrophin-associated protein complex	[DAPC dystrophin-associated protein complex]	1.5849625007211563	4	1	0	0
2726	233	site specific riiα Ser96	[site specific RIIα Ser96]	1.5849625007211563	4	1	0	0
2727	233	condition require surgery	[conditions requiring surgery]	1.5849625007211563	3	1	0	0
2728	233	simple sex-specific model	[simple sex-specific model]	1.5849625007211563	3	1	0	0
2729	233	fluorescence resonance energy assay	[fluorescence resonance energy assays]	1.5849625007211563	4	1	0	0
2730	233	few CHF patient present	[fewer CHF patients presenting]	1.5849625007211563	4	1	0	0
2731	233	clinical circumstance common	[clinical circumstances common]	1.5849625007211563	3	1	0	0
2732	233	severe developmental impairment	[severe developmental impairment]	1.5849625007211563	3	1	0	0
2733	233	cyclic guanosine monophosphate cgmp	[cyclic guanosine monophosphate cGMP]	1.5849625007211563	4	1	0	0
2734	233	adjust decrease in score	[adjusting decrease in score]	1.5849625007211563	4	1	0	0
2735	233	patient with ic	[patients with IC]	1.5849625007211563	3	2	2	2
2736	233	70 year q	[70 years Q]	1.5849625007211563	3	1	0	0
2737	233	level of nps	[levels of NPs]	1.5849625007211563	3	1	0	0
2738	233	ischemic mitral regurgitation	[ischemic mitral regurgitation]	1.5849625007211563	3	2	1	1
2739	233	patient with eh	[patients with EH]	1.5849625007211563	3	1	0	0
2740	233	nonidentification of at	[Nonidentification of AT]	1.5849625007211563	3	1	0	0
2741	233	regulation of cell death	[regulation of cell death]	1.5849625007211563	4	1	0	0
2742	233	early beneficial clinical outcome	[early beneficial clinical outcomes]	1.5849625007211563	4	1	0	0
2743	233	absence of atrial fibrillation	[absence of atrial fibrillation]	1.5849625007211563	4	1	0	0
2744	233	datum from non-hf population	[data from non-HF populations]	1.5849625007211563	4	1	0	0
2745	233	phosphorylation of eNOS-Ser	[phosphorylation of eNOS-Ser]	1.5849625007211563	3	1	0	0
2746	233	patient at high risk	[patients at higher risk]	1.5849625007211563	4	3	2	1
2747	233	promising field of investigation	[promising field of investigation]	1.5849625007211563	4	1	0	0
2748	233	median of 1080 day	[median of 1,080 days]	1.5849625007211563	4	1	0	0
2749	233	key health outcome	[key health outcomes]	1.5849625007211563	3	2	2	2
2750	233	significantly low HF mortality	[significantly lower HF mortality]	1.5849625007211563	4	1	0	0
2751	233	use hr 1.30	[use HR 1.30]	1.5849625007211563	3	1	0	0
2752	233	further rigorous investigation	[further rigorous investigation]	1.5849625007211563	3	1	0	0
2753	233	mean age of participant	[Mean age of participants]	1.5849625007211563	4	1	0	0
2754	233	10-week treatment period	[10-week treatment period]	1.5849625007211563	3	1	0	0
2755	233	double-blind 2:1 ratio	[double-blind 2:1 ratio]	1.5849625007211563	3	1	0	0
2756	233	such as HF	[such as HF]	1.5849625007211563	3	1	0	0
2757	233	respective age category	[respective age categories]	1.5849625007211563	3	1	0	0
2758	233	cardiac function via echocardiography	[cardiac function via echocardiography]	1.5849625007211563	4	1	0	0
2759	233	cardiomyocyte in the presence	[cardiomyocytes in the presence]	1.5849625007211563	4	1	0	0
2760	233	physiological proteolysis between pro2-leu3	[physiological proteolysis between Pro2-Leu3]	1.5849625007211563	4	1	0	0
2761	233	irs2 double-knockout l-dko mouse	[IRS2 double-knockout L-DKO mice]	1.5849625007211563	4	1	0	0
2762	233	increase in parasympathetic function	[increase in parasympathetic function]	1.5849625007211563	4	1	0	0
2763	233	percentage of fibrosis	[percentage of fibrosis]	1.5849625007211563	3	1	0	0
2764	233	angiotensin receptor antagonist valsartan	[angiotensin receptor antagonist valsartan]	1.5849625007211563	4	1	0	0
2765	233	1 large trial	[1 large trial]	1.5849625007211563	3	1	0	0
2766	233	use Cox model	[using Cox models]	1.5849625007211563	3	1	0	0
2767	233	less ischemic etiology	[less ischemic etiology]	1.5849625007211563	3	1	0	0
2768	233	outcome of nursing care	[outcomes of nursing care]	1.5849625007211563	4	1	0	0
2769	233	CRT on assignment	[CRT ON assignment]	1.5849625007211563	3	1	0	0
2770	233	however a single-arm analysis	[However a single-arm analysis]	1.5849625007211563	4	1	0	0
2771	233	novel therapeutic approach	[novel therapeutic approaches]	1.5849625007211563	3	1	0	0
2772	233	(tac)-induced heart failure	[(TAC)-induced heart failure]	1.5849625007211563	3	1	0	0
2773	233	centrifugal flow pump	[centrifugal flow pump]	1.5849625007211563	3	1	0	0
2774	233	eight-week-old c57bl 6	[Eight-week-old C57BL 6]	1.5849625007211563	3	1	0	0
2775	233	potentially significant cost savings	[potentially significant cost savings]	1.5849625007211563	4	1	0	0
2776	233	increase population of anthracycline	[increasing population of anthracycline]	1.5849625007211563	4	1	0	0
2777	233	bhlh transcription factor	[bHLH transcription factor]	1.5849625007211563	3	2	2	2
2778	233	high diastolic blood pressure	[higher diastolic blood pressure]	1.5849625007211563	4	1	0	0
2779	233	underlying myocardial DD	[underlying myocardial DD]	1.5849625007211563	3	1	0	0
2780	233	effect of air pollution	[effects of air pollution]	1.5849625007211563	4	1	0	0
2781	233	cause among the elderly	[cause among the elderly]	1.5849625007211563	4	2	2	2
2782	233	heart failure a study	[heart failure a study]	1.5849625007211563	4	2	2	2
2783	233	minute of exercise	[minutes of exercise]	1.5849625007211563	3	2	2	2
2784	233	composite of death	[composite of death]	1.5849625007211563	3	2	2	2
2785	233	major public health problem	[major public health problem]	1.5849625007211563	4	2	1	1
2786	233	so-called end stage	[so-called end stage]	1.5849625007211563	3	1	0	0
2787	233	maximal systolic elastance	[maximal systolic elastance]	1.5849625007211563	3	1	0	0
2788	233	all-cause mortality in patient	[all-cause mortality in patients]	1.5849625007211563	4	1	0	0
2789	233	s1pr1 cardiac gene therapy	[S1PR1 cardiac gene therapy]	1.5849625007211563	4	1	0	0
2790	233	cardiac arrest in human	[cardiac arrest in humans]	1.5849625007211563	4	1	0	0
2791	233	unloading of the heart	[unloading of the heart]	1.5849625007211563	4	1	0	0
2792	233	trend from 1996	[Trends from 1996]	1.5849625007211563	3	1	0	0
2793	233	Prospective two-center pilot project	[Prospective two-center pilot project]	1.5849625007211563	4	1	0	0
2794	233	vasopressin receptor antagonist	[vasopressin receptor antagonist]	1.5849625007211563	3	2	2	2
2795	233	most urban area	[most urban areas]	1.5849625007211563	3	1	0	0
2796	233	Pediatric heart failure HF	[Pediatric heart failure HF]	1.5849625007211563	4	1	0	0
2797	233	receptor 1 s1pr1	[receptor 1 S1PR1]	1.5849625007211563	3	1	0	0
2798	233	suppression of downstream signalling	[suppression of downstream signalling]	1.5849625007211563	4	1	0	0
2799	233	follow-up visit 16	[follow-up visits 16]	1.5849625007211563	3	1	0	0
2800	233	diagnosis of ischemic-hypertensive cardiomyiopathy	[diagnosis of ischemic-hypertensive cardiomyiopathy]	1.5849625007211563	4	1	0	0
2801	233	2 aortic valve repair	[2 aortic valve repairs]	1.5849625007211563	4	1	0	0
2802	233	score with death	[score with death]	1.5849625007211563	3	1	0	0
2803	233	human HF tissue	[human HF tissues]	1.5849625007211563	3	1	0	0
2804	233	study drug dose	[study drug dose]	1.5849625007211563	3	1	0	0
2805	233	patient with comorbidity	[patient with comorbidities]	1.5849625007211563	3	1	0	0
2806	233	strike difference in presentation	[striking differences in presentation]	1.5849625007211563	4	1	0	0
2807	233	chf-developed infarcted animal	[CHF-developed infarcted animals]	1.5849625007211563	3	1	0	0
2808	233	high oxygen flow	[higher oxygen flow]	1.5849625007211563	3	1	0	0
2809	233	small trial of patient	[small trial of patients]	1.5849625007211563	4	1	0	0
2810	233	other study drug	[other study drugs]	1.5849625007211563	3	1	0	0
2811	233	sixty-one patient with HFpEF	[Sixty-one patients with HFpEF]	1.5849625007211563	4	1	0	0
2812	233	reduction in Ea p	[reduction in Ea p]	1.5849625007211563	4	1	0	0
2813	233	use of erythropoiesis-stimulating agent	[use of erythropoiesis-stimulating agents]	1.5849625007211563	4	1	0	0
2814	233	Medical treatment Guideline	[Medical Treatment Guidelines]	1.5849625007211563	3	1	0	0
2815	233	carotid intima-media thickness	[carotid intima-media thickness]	1.5849625007211563	3	1	0	0
2816	233	great self-reported physical activity	[greater self-reported physical activity]	1.5849625007211563	4	1	0	0
2817	233	congestive heart failure visit	[Congestive heart failure visits]	1.5849625007211563	4	1	0	0
2818	233	baseline serum creatinine level	[baseline serum creatinine level]	1.5849625007211563	4	1	0	0
2819	233	use strong acid	[using strong acid]	1.5849625007211563	3	1	0	0
2820	233	high fat mass	[higher fat mass]	1.5849625007211563	3	1	0	0
2821	233	allopurinol 100 mg·kg(-1)·day(-1)	[allopurinol 100 mg·kg(-1)·day(-1)]	1.5849625007211563	3	1	0	0
2822	233	patient aged 18 year	[Patients aged 18 years]	1.5849625007211563	4	1	0	0
2823	233	sodium-restricted dash diet	[sodium-restricted DASH diet]	1.5849625007211563	3	1	0	0
2824	233	difference in longitudinal performance	[differences in longitudinal performance]	1.5849625007211563	4	1	0	0
2825	233	transient receptor potential	[transient receptor potential]	1.5849625007211563	3	1	0	0
2826	233	mean of 19.4 month	[mean of 19.4 months]	1.5849625007211563	4	1	0	0
2827	233	Systolic ventricular dysfunction reverse	[Systolic vEntricular dysfunction REVERSE]	1.5849625007211563	4	1	0	0
2828	233	left longitudinal systolic strain	[left longitudinal systolic strain]	1.5849625007211563	4	2	2	2
2829	233	penalty for higher-than-expected rate	[penalties for higher-than-expected rates]	1.5849625007211563	4	1	0	0
2830	233	cox-proportional hazard model	[Cox-proportional hazard models]	1.5849625007211563	3	1	0	0
2831	233	principle of pharmacologic treatment	[principles of pharmacologic treatment]	1.5849625007211563	4	1	0	0
2832	233	renin-angiotensin-aldosterone system RAAS	[renin-angiotensin-aldosterone system RAAS]	1.5849625007211563	3	1	0	0
2833	233	role of human resistin	[role of human resistin]	1.5849625007211563	4	1	0	0
2834	233	complex set of variable	[complex set of variables]	1.5849625007211563	4	1	0	0
2835	233	heart failure home	[heart failure home]	1.5849625007211563	3	1	0	0
2836	233	LV end-diastolic pressure p	[LV end-diastolic pressure P]	1.5849625007211563	4	1	0	0
2837	233	ec coupling gain	[EC coupling gain]	1.5849625007211563	3	1	0	0
2838	233	channel α-subunit scn5a	[channel α-subunit SCN5A]	1.5849625007211563	3	1	0	0
2839	233	address practice-level difference	[Addressing practice-level differences]	1.5849625007211563	3	1	0	0
2840	233	functional mitral stenosis	[functional mitral stenosis]	1.5849625007211563	3	1	0	0
2841	233	erythropoiesis-stimulating agent therapy	[erythropoiesis-stimulating agent therapy]	1.5849625007211563	3	1	0	0
2842	233	only at high dose	[only at higher doses]	1.5849625007211563	4	1	0	0
2843	233	Preventable readmission ppr	[Preventable Readmission PPR]	1.5849625007211563	3	1	0	0
2844	233	cardiac index score value	[cardiac index score value]	1.5849625007211563	4	1	0	0
2845	233	HF with ejection fraction	[HF with ejection fraction]	1.5849625007211563	4	2	2	2
2846	233	6-minute hall walk distance	[6-minute hall walk distance]	1.5849625007211563	4	1	0	0
2847	233	reserve in patient	[reserve in patients]	1.5849625007211563	3	2	2	2
2848	233	CLCNKA polymorphism rs10927887 p	[CLCNKA polymorphism rs10927887 p]	1.5849625007211563	4	1	0	0
2849	233	even mild dysfunction	[even mild dysfunction]	1.5849625007211563	3	1	0	0
2850	233	high-volume physician a difference	[high-volume physicians a difference]	1.5849625007211563	4	1	0	0
2851	233	right grip strength	[right grip strength]	1.5849625007211563	3	1	0	0
2852	233	other vascular disease	[other vascular diseases]	1.5849625007211563	3	1	0	0
2853	233	profound change in Paco2	[profound change in Paco2]	1.5849625007211563	4	1	0	0
2854	233	clinical composite response	[clinical composite response]	1.5849625007211563	3	2	2	2
2855	233	exercise programme for patient	[exercise programme for patients]	1.5849625007211563	4	1	0	0
2856	233	bundle-branch block LBBB	[bundle-branch block LBBB]	1.5849625007211563	3	1	0	0
2857	233	namely direct renin inhibitor	[namely direct renin inhibitors]	1.5849625007211563	4	1	0	0
2858	233	program of exercise rehabilitation	[program of exercise rehabilitation]	1.5849625007211563	4	1	0	0
2859	233	adjustment for difference	[adjustment for differences]	1.5849625007211563	3	1	0	0
2860	233	clinically significant gastrointestinal bleed	[clinically significant gastrointestinal bleeding]	1.5849625007211563	4	1	0	0
2861	233	similar long mortality	[similar long-term mortality]	1.5849625007211563	3	1	0	0
2862	233	functional capacity peak vo2	[functional capacity peak VO2]	1.5849625007211563	4	1	0	0
2863	233	prognostic significance of BNP	[prognostic significance of BNP]	1.5849625007211563	4	1	0	0
2864	233	CHF patient 778	[CHF patients 778]	1.5849625007211563	3	1	0	0
2865	233	age-matched reference value z-score	[age-matched reference values Z-score]	1.5849625007211563	4	1	0	0
2866	233	low rate of hypokalemia	[lower rates of hypokalemia]	1.5849625007211563	4	1	0	0
2867	233	majority of study	[majority of studies]	1.5849625007211563	3	1	0	0
2868	233	nitric oxide donor	[nitric oxide donors]	1.5849625007211563	3	1	0	0
2869	233	1.61 vs. 1.39 time	[1.61 vs. 1.39 times]	1.5849625007211563	4	1	0	0
2870	233	subset of 910 patient	[subset of 910 patients]	1.5849625007211563	4	1	0	0
2871	233	patient with rheumatoid arthritis	[patients with rheumatoid arthritis]	1.5849625007211563	4	1	0	0
2872	233	epigenetic eraser histone deacetylase	[epigenetic erasers histone deacetylases]	1.5849625007211563	4	1	0	0
2873	233	Chronic heart failure CHF	[Chronic heart failure CHF]	1.5849625007211563	4	1	0	0
2874	233	dietary pattern with outcome	[dietary patterns with outcomes]	1.5849625007211563	4	1	0	0
2875	233	acute β-ar stimulation	[acute β-AR stimulation]	1.5849625007211563	3	1	0	0
2876	233	hr reduction by ivabradine	[HR reduction by ivabradine]	1.5849625007211563	4	1	0	0
2877	233	urgent cardiac transplant	[urgent cardiac transplant]	1.5849625007211563	3	1	0	0
2878	233	database of MEDLINE	[databases of MEDLINE]	1.5849625007211563	3	1	0	0
2879	233	new antiarrhythmic drug	[new antiarrhythmic drugs]	1.5849625007211563	3	1	0	0
2880	233	adjustment for clinical variable	[adjustment for clinical variables]	1.5849625007211563	4	1	0	0
2881	233	contemporary therapeutic option	[Contemporary therapeutic options]	1.5849625007211563	3	1	0	0
2882	233	rate of ed visit	[Rates of ED visits]	1.5849625007211563	4	2	1	1
2883	233	improvement in long prognosis	[improvement in long-term prognosis]	1.5849625007211563	4	1	0	0
2884	233	Chinese herbal medicine CHM	[Chinese herbal medicine CHM]	1.5849625007211563	4	1	0	0
2885	233	50 μmol L	[50 μmol L]	1.5849625007211563	3	1	0	0
2886	233	2 simple ecg parameter	[2 simple ECG parameters]	1.5849625007211563	4	1	0	0
2887	233	1.35 kg p	[1.35 kg p]	1.5849625007211563	3	1	0	0
2888	233	mandatory 7-day follow-up visit	[mandatory 7-day follow-up visits]	1.5849625007211563	4	1	0	0
2889	233	153 HF death	[153 HF deaths]	1.5849625007211563	3	1	0	0
2890	233	specifically on idiopathic cardiomyopathy	[specifically on idiopathic cardiomyopathy]	1.5849625007211563	4	1	0	0
2891	233	connection between experienced center	[connection between experienced centers]	1.5849625007211563	4	1	0	0
2892	233	lp-pla2 than control	[Lp-PLA2 than controls]	1.5849625007211563	3	1	0	0
2893	233	SAF versus PF mean	[SAF versus PF mean]	1.5849625007211563	4	1	0	0
2894	233	control group patient	[control group patients]	1.5849625007211563	3	1	0	0
2895	233	LVEF on long mortality	[LVEF on long-term mortality]	1.5849625007211563	4	1	0	0
2896	233	rheumatic cause of ms	[rheumatic causes of MS]	1.5849625007211563	4	1	0	0
2897	233	beat-to-beat QT interval	[beat-to-beat QT interval]	1.5849625007211563	3	1	0	0
2898	233	other major database	[other major databases]	1.5849625007211563	3	1	0	0
2899	233	cell expansion protocol	[cell expansion protocols]	1.5849625007211563	3	1	0	0
2900	233	regulation of rad q66p	[regulation of Rad Q66P]	1.5849625007211563	4	1	0	0
2901	233	44 674 man	[44 674 men]	1.5849625007211563	3	1	0	0
2902	233	superior reverse remodeling	[superior reverse remodeling]	1.5849625007211563	3	1	0	0
2903	233	risk stratification for death	[Risk stratification for death]	1.5849625007211563	4	1	0	0
2904	233	appropriate risk stratification	[appropriate risk stratification]	1.5849625007211563	3	1	0	0
2905	233	cause of cardiovascular hospitalization	[cause of cardiovascular hospitalization]	1.5849625007211563	4	2	2	2
2906	233	0.4 mm hg	[0.4 mm Hg]	1.5849625007211563	3	1	0	0
2907	233	contribution of titin	[contributions of titin]	1.5849625007211563	3	1	0	0
2908	233	randomised-controlled trial RCT	[randomised-controlled trials RCTs]	1.5849625007211563	3	1	0	0
2909	233	risk of incident CVD	[risk of incident CVD]	1.5849625007211563	4	1	0	0
2910	233	gating movement of channel	[gating movement of channels]	1.5849625007211563	4	1	0	0
2911	233	mitochondrial energy production	[mitochondrial energy production]	1.5849625007211563	3	1	0	0
2912	233	mass spectrometric analysis	[mass spectrometric analysis]	1.5849625007211563	3	1	0	0
2913	233	peak can 2	[peak Ca 2]	1.5849625007211563	3	1	0	0
2914	233	change in sr can	[changes in SR Ca]	1.5849625007211563	4	1	0	0
2915	233	short 6-minute walk distance	[shorter 6-minute walk distance]	1.5849625007211563	4	1	0	0
2916	233	acs problem in patient	[ACS problems in patients]	1.5849625007211563	4	1	0	0
2917	233	discharge follow-up medication list	[discharge follow-up medication lists]	1.5849625007211563	4	1	0	0
2918	233	cardiac vegf expression	[cardiac VEGF expression]	1.5849625007211563	3	1	0	0
2919	233	doxorubicin efflux transporter abcc2	[doxorubicin efflux transporter ABCC2]	1.5849625007211563	4	1	0	0
2920	233	prospective observational study	[prospective observational study]	1.5849625007211563	3	1	0	0
2921	233	major right ventricle overload	[Major right ventricle overload]	1.5849625007211563	4	1	0	0
2922	233	patient with t1 time	[Patients with T1 times]	1.5849625007211563	4	1	0	0
2923	233	ischemic heart failure stent	[ischemic heart failure stent]	1.5849625007211563	4	1	0	0
2924	233	100 pg bnp group	[100 pg BNP group]	1.5849625007211563	4	2	2	2
2925	233	new prevention strategy	[new prevention strategies]	1.5849625007211563	3	1	0	0
2926	233	STE analysis of twist	[STE analysis of twist]	1.5849625007211563	4	1	0	0
2927	233	duration of antiplatelet medication	[duration of antiplatelet medication]	1.5849625007211563	4	1	0	0
2928	233	common inpatient medical condition	[common inpatient medical conditions]	1.5849625007211563	4	1	0	0
2929	233	intravenous bolus of metoprolol	[intravenous bolus of metoprolol]	1.5849625007211563	4	1	0	0
2930	233	poorer vo2 max	[poorer VO2 max]	1.5849625007211563	3	1	0	0
2931	233	mean score of 13	[mean score of 13]	1.5849625007211563	4	1	0	0
2932	233	combination with other factor	[combination with other factors]	1.5849625007211563	4	1	0	0
2933	233	cardiovascular event rate	[cardiovascular event rate]	1.5849625007211563	3	2	2	2
2934	233	improve functional capacity	[improving functional capacity]	1.5849625007211563	3	1	0	0
2935	233	long administration of pyridostigmine	[long-term administration of pyridostigmine]	1.5849625007211563	4	1	0	0
2936	233	large cohort study	[large cohort study]	1.5849625007211563	3	1	0	0
2937	233	use of loop diuretic	[use of loop diuretics]	1.5849625007211563	4	1	0	0
2938	233	single drug-free success rate	[single drug-free success rates]	1.5849625007211563	4	1	0	0
2939	233	adopt evidence-based practice	[adopting evidence-based practices]	1.5849625007211563	3	1	0	0
2940	233	health care provider	[health care providers]	1.5849625007211563	3	1	0	0
2941	233	signal transduction cascade	[signal transduction cascade]	1.5849625007211563	3	1	0	0
2942	233	subsequent heart failure	[subsequent heart failure]	1.5849625007211563	3	2	2	2
2943	233	success in future trial	[success in future trials]	1.5849625007211563	4	1	0	0
2944	233	prediction of CV event	[prediction of CV events]	1.5849625007211563	4	1	0	0
2945	233	risk of hospitalization	[risk of hospitalization]	1.5849625007211563	3	2	1	1
2946	233	creatinine hazard ratio	[creatinine hazard ratio]	1.5849625007211563	3	1	0	0
2947	233	severe frailty hr	[severe frailty HR]	1.5849625007211563	3	1	0	0
2948	233	left LV ejection fraction	[left LV ejection fraction]	1.5849625007211563	4	2	2	2
2949	233	individual with heart failure	[individuals with heart failure]	1.5849625007211563	4	2	2	2
2950	233	mitochondrial complex V activity	[mitochondrial complex V activity]	1.5849625007211563	4	1	0	0
2951	233	artery bypass grafting	[artery bypass grafting]	1.5849625007211563	3	2	2	2
2952	233	cardiac transplant ECCT program	[cardiac transplant ECCT programs]	1.5849625007211563	4	1	0	0
2953	233	old age group	[older age group]	1.5849625007211563	3	1	0	0
2954	233	signal pathway change	[signaling pathway changes]	1.5849625007211563	3	1	0	0
2955	233	uti with major complication	[UTI with major complications]	1.5849625007211563	4	1	0	0
2956	233	reach statitistical significance	[reaching statitistical significance]	1.5849625007211563	3	1	0	0
2957	233	standing blood pressure	[standing blood pressure]	1.5849625007211563	3	1	0	0
2958	233	enhance medical management	[enhancing medical management]	1.5849625007211563	3	1	0	0
2959	233	follow myocardial infarction	[following myocardial infarction]	1.5849625007211563	3	1	0	0
2960	233	increase circulate plasma NE	[increase circulating plasma NE]	1.5849625007211563	4	1	0	0
2961	233	2 distinct g-protein-coupled receptor	[2 distinct G-protein-coupled receptors]	1.5849625007211563	4	1	0	0
2962	233	stable clinical condition	[stable clinical conditions]	1.5849625007211563	3	1	0	0
2963	233	ingenuity pathway analysis	[ingenuity pathway analysis]	1.5849625007211563	3	2	2	2
2964	233	fit versus unfit man	[fit versus unfit men]	1.5849625007211563	4	1	0	0
2965	233	Nicorandil 3 mg	[Nicorandil 3 mg]	1.5849625007211563	3	1	0	0
2966	233	arterial systolic pressure	[arterial systolic pressure]	1.5849625007211563	3	2	2	2
2967	233	quarterly inpatient admission	[quarterly inpatient admissions]	1.5849625007211563	3	1	0	0
2968	233	terminal stage of CHF	[terminal stage of CHF]	1.5849625007211563	4	1	0	0
2969	233	cardiac sympathetic activity	[cardiac sympathetic activity]	1.5849625007211563	3	2	2	2
2970	233	1.05 per 0.1 mg	[1.05 per 0.1 mg]	1.5849625007211563	4	1	0	0
2971	233	MS at that time	[MS at that time]	1.5849625007211563	4	1	0	0
2972	233	treatment of severe hyponatremia	[treatment of severe hyponatremia]	1.5849625007211563	4	1	0	0
2973	233	antitachycardia pacing atp	[antitachycardia pacing ATP]	1.5849625007211563	3	1	0	0
2974	233	transition from LV hypertrophy	[transition from LV hypertrophy]	1.5849625007211563	4	1	0	0
2975	233	high metabolic exercise	[higher metabolic exercise]	1.5849625007211563	3	1	0	0
2976	233	association with functional capacity	[Association with functional capacity]	1.5849625007211563	4	1	0	0
2977	233	heart failure t1-mapping value	[heart failure T1-mapping values]	1.5849625007211563	4	1	0	0
2978	233	kv4.3 mrna level result	[Kv4.3 mRNA levels resulting]	1.5849625007211563	4	1	0	0
2979	233	6-month observation period	[6-month observation period]	1.5849625007211563	3	1	0	0
2980	233	peripheral muscle pump	[peripheral muscle pump]	1.5849625007211563	3	1	0	0
2981	233	contrast agent administration	[contrast agent administration]	1.5849625007211563	3	1	0	0
2982	233	reclassification of risk	[reclassification of risk]	1.5849625007211563	3	1	0	0
2983	233	absolute value of mdc	[absolute value of MDC]	1.5849625007211563	4	1	0	0
2984	233	relationship between pathobiology	[relationship between pathobiology]	1.5849625007211563	3	1	0	0
2985	233	HF risk factor present	[HF risk factors present]	1.5849625007211563	4	1	0	0
2986	233	patient receive this agent	[patients receiving these agents]	1.5849625007211563	4	1	0	0
2987	233	presence of dysfunction	[presence of dysfunction]	1.5849625007211563	3	2	2	2
2988	233	inducible myocardial ischemia	[inducible myocardial ischemia]	1.5849625007211563	3	1	0	0
2989	233	reduction in mortality	[Reduction in Mortality]	1.5849625007211563	3	2	1	1
2990	233	total of 151 subject	[total of 151 subjects]	1.5849625007211563	4	1	0	0
2991	233	change in lvet	[change in LVET]	1.5849625007211563	3	1	0	0
2992	233	thereby re-activate transcription	[thereby re-activating transcription]	1.5849625007211563	3	1	0	0
2993	233	more recent enrollment period	[more recent enrollment period]	1.5849625007211563	4	1	0	0
2994	233	maximal treadmill exercise testing	[maximal treadmill exercise testing]	1.5849625007211563	4	1	0	0
2995	233	death in crt-d recipient	[death in CRT-D recipients]	1.5849625007211563	4	1	0	0
2996	233	patient with functional ms	[patients with functional MS]	1.5849625007211563	4	1	0	0
2997	233	hazard ratio 0.73	[hazard ratio 0.73]	1.5849625007211563	3	1	0	0
2998	233	less severe systolic dysfunction	[less severe systolic dysfunction]	1.5849625007211563	4	1	0	0
2999	233	General use of beta-blocker	[General use of beta-blockers]	1.5849625007211563	4	1	0	0
3000	233	use sex-specific model	[Using sex-specific models]	1.5849625007211563	3	1	0	0
3001	233	hazard ratio 0.93	[hazard ratio 0.93]	1.5849625007211563	3	1	0	0
3002	233	prior cardiovascular disease	[prior cardiovascular disease]	1.5849625007211563	3	1	0	0
3003	233	particularly in low-volume institution	[particularly in low-volume institutions]	1.5849625007211563	4	1	0	0
3004	233	LV fill pressure	[LV filling pressure]	1.5849625007211563	3	2	2	2
3005	233	important metabolic risk factor	[important metabolic risk factors]	1.5849625007211563	4	1	0	0
3006	233	readmission metric choice	[readmission metric choice]	1.5849625007211563	3	1	0	0
3007	233	therapeutic implication of biomarker	[Therapeutic implications of biomarkers]	1.5849625007211563	4	2	2	2
3008	233	cardiac explant-derived cell	[cardiac explant-derived cells]	1.5849625007211563	3	1	0	0
3009	233	progression of heart failure	[progression of heart failure]	1.5849625007211563	4	1	0	0
3010	233	development of ies	[development of IEs]	1.5849625007211563	3	2	1	1
3011	233	Unilateral renal denervation	[Unilateral renal denervation]	1.5849625007211563	3	1	0	0
3012	233	24 hour of admission	[24 hours of admission]	1.5849625007211563	4	1	0	0
3013	233	fat mass fm	[fat mass FM]	1.5849625007211563	3	1	0	0
3014	233	future prospective research	[future prospective research]	1.5849625007211563	3	1	0	0
3015	233	magnetic resonance angiography	[magnetic resonance angiography]	1.5849625007211563	3	1	0	0
3016	233	SVR index 1680	[SVR index 1,680]	1.5849625007211563	3	1	0	0
3017	233	degree of functional ms	[degree of functional MS]	1.5849625007211563	4	1	0	0
3018	233	early risk of stroke	[early risk of stroke]	1.5849625007211563	4	1	0	0
3019	233	acetylcholinesterase inhibitor pyridostigmine	[acetylcholinesterase inhibitor pyridostigmine]	1.5849625007211563	3	1	0	0
3020	233	most common contextual reason	[most common contextual reasons]	1.5849625007211563	4	1	0	0
3021	233	half of this patient	[Half of these patients]	1.5849625007211563	4	1	0	0
3022	233	small muscle strip	[small muscle strips]	1.5849625007211563	3	1	0	0
3023	233	β-blocker enzyme inhibitor	[β-blocker enzyme inhibitor]	1.5849625007211563	3	1	0	0
3024	233	province of Québec Canada	[province of Québec Canada]	1.5849625007211563	4	1	0	0
3025	233	surgery by echocardiography	[surgery by echocardiography]	1.5849625007211563	3	1	0	0
3026	233	thorough medical history	[thorough medical history]	1.5849625007211563	3	1	0	0
3027	233	thus reduce Ea	[thus reducing Ea]	1.5849625007211563	3	1	0	0
3028	233	primary efficacy outcome	[primary efficacy outcome]	1.5849625007211563	3	1	0	0
3029	233	mitral fill flow volume	[mitral filling flow volume]	1.5849625007211563	4	1	0	0
3030	233	oxidative stress marker	[oxidative stress markers]	1.5849625007211563	3	1	0	0
3031	233	self-care maintenance scale	[Self-Care Maintenance Scale]	1.5849625007211563	3	1	0	0
3032	233	poor social support	[Poor social support]	1.5849625007211563	3	1	0	0
3033	233	Szeto-Schiller ss 31	[Szeto-Schiller SS 31]	1.5849625007211563	3	1	0	0
3034	233	failure of cardiovascular reserve	[failure of cardiovascular reserve]	1.5849625007211563	4	1	0	0
3035	233	use datum from HF-ACTION	[Using data from HF-ACTION]	1.5849625007211563	4	1	0	0
3036	233	include few st-segment-elevation MIs	[including fewer ST-segment-elevation MIs]	1.5849625007211563	4	1	0	0
3037	233	correlation among metric	[Correlations among metrics]	1.5849625007211563	3	1	0	0
3038	233	worsen renal function	[worsening renal function]	1.5849625007211563	3	2	1	1
3039	233	exercise training therapy	[exercise training therapy]	1.5849625007211563	3	1	0	0
3040	233	Dynamic collateral growth pattern	[Dynamic collateral growth patterns]	1.5849625007211563	4	1	0	0
3041	233	benefit of participation	[benefits of participation]	1.5849625007211563	3	1	0	0
3042	233	low event rate	[lowest event rate]	1.5849625007211563	3	2	2	2
3043	233	left-to-right interatrial shunt	[left-to-right interatrial shunt]	1.5849625007211563	3	1	0	0
3044	233	1 valve replacement	[1 valve replacement]	1.5849625007211563	3	1	0	0
3045	233	catecholamine infusion in rat	[catecholamine infusions in rats]	1.5849625007211563	4	1	0	0
3046	233	contractile reserve in patient	[contractile reserve in patients]	1.5849625007211563	4	2	2	2
3047	233	low risk-adjusted all-cause mortality	[lower risk-adjusted all-cause mortality]	1.5849625007211563	4	1	0	0
3048	233	5-year follow-up period	[5-year follow-up period]	1.5849625007211563	3	1	0	0
3049	233	traditional cost-effectiveness limit	[traditional cost-effectiveness limits]	1.5849625007211563	3	1	0	0
3050	233	s'lateral of 4.5 cm	[s'lateral of 4.5 cm]	1.5849625007211563	4	1	0	0
3051	233	present preliminary study	[present preliminary study]	1.5849625007211563	3	1	0	0
3052	233	change in myofiber dynamic	[changes in myofiber dynamics]	1.5849625007211563	4	1	0	0
3053	233	complication after implantation	[complications after implantation]	1.5849625007211563	3	1	0	0
3054	233	than in littermate control	[than in littermate controls]	1.5849625007211563	4	1	0	0
3055	233	clinical evaluation at baseline	[clinical evaluations at baseline]	1.5849625007211563	4	1	0	0
3056	233	low exercise time	[lower exercise time]	1.5849625007211563	3	1	0	0
3057	233	caloric restriction diet	[caloric restriction diet]	1.5849625007211563	3	1	0	0
3058	233	total cost per patient	[total cost per patient]	1.5849625007211563	4	1	0	0
3059	233	abnormal chamber patterning	[abnormal chamber patterning]	1.5849625007211563	3	1	0	0
3060	233	annually up year	[annually up years]	1.5849625007211563	3	1	0	0
3061	233	s'lateral of ≤4.5 cm	[s'lateral of ≤4.5 cm]	1.5849625007211563	4	1	0	0
3062	233	practical recommendation for application	[practical Recommendations for application]	1.5849625007211563	4	1	0	0
3063	233	marker of hemostasis	[markers of hemostasis]	1.5849625007211563	3	1	0	0
3064	233	heart failure-related mortality	[heart failure-related mortality]	1.5849625007211563	3	1	0	0
3065	233	heart failure rat	[heart failure rats]	1.5849625007211563	3	1	0	0
3066	233	medical resource use	[medical resource use]	1.5849625007211563	3	1	0	0
3067	233	safety of this agent	[safety of these agents]	1.5849625007211563	4	1	0	0
3068	233	beneficial effect on mortality	[beneficial effect on mortality]	1.5849625007211563	4	1	0	0
3069	233	risk for hHF	[risk for hHF]	1.5849625007211563	3	2	1	1
3070	233	approximately 1.6 second	[approximately 1.6 seconds]	1.5849625007211563	3	1	0	0
3071	233	5.1 million American aged	[5.1 million Americans aged]	1.5849625007211563	4	1	0	0
3072	233	true change in measure	[true change in measures]	1.5849625007211563	4	1	0	0
3073	233	provide guideline-recommended care	[providing guideline-recommended care]	1.5849625007211563	3	1	0	0
3074	233	risk of HF	[risk of HF]	1.5849625007211563	3	2	1	1
3075	233	descriptive research design	[descriptive research design]	1.5849625007211563	3	1	0	0
3076	233	fractional flow reserve measurement	[Fractional flow reserve measurements]	1.5849625007211563	4	1	0	0
3077	233	implantable cardioverter defibrillator	[implantable cardioverter defibrillators]	1.5849625007211563	3	2	1	1
3078	233	death hazard ratio	[death hazard ratio]	1.5849625007211563	3	2	1	1
3079	233	effective arterial elastance Ea	[effective arterial elastance Ea]	1.5849625007211563	4	1	0	0
3080	233	setting of atp demand	[setting of ATP demand]	1.5849625007211563	4	1	0	0
3081	233	implantable cardiac defibrillator	[implantable cardiac defibrillator]	1.5849625007211563	3	1	0	0
3082	233	Health ABC HF Model	[Health ABC HF Model]	1.5849625007211563	4	1	0	0
3083	233	cardiomyocyte-like cell in vitro	[cardiomyocyte-like cells in vitro]	1.5849625007211563	4	1	0	0
3084	233	change in FM	[changes in FM]	1.5849625007211563	3	1	0	0
3085	233	clinical diastolic dysfunction	[clinical diastolic dysfunction]	1.5849625007211563	3	2	2	2
3086	233	inclusion of the parameter	[inclusion of the parameters]	1.5849625007211563	4	1	0	0
3087	233	ability of GLS	[ability of GLS]	1.5849625007211563	3	1	0	0
3088	233	right heart circulation	[right heart circulation]	1.5849625007211563	3	1	0	0
3089	233	atrial area 26 cm	[atrial area 26 cm]	1.5849625007211563	4	1	0	0
3090	233	biomarker in heart failure	[biomarker in heart failure]	1.5849625007211563	4	2	2	2
3091	233	attention correct nutrition function	[Attention correcting nutrition function]	1.5849625007211563	4	1	0	0
3092	233	reduction of sympathetic outflow	[reduction of sympathetic outflow]	1.5849625007211563	4	1	0	0
3093	233	advanced chronic organ failure	[advanced chronic organ failure]	1.5849625007211563	4	1	0	0
3094	233	gadolinium-chelate contrast agent	[gadolinium-chelate contrast agent]	1.5849625007211563	3	1	0	0
3095	233	aldosterone receptor antagonist	[Aldosterone receptor antagonists]	1.5849625007211563	3	1	0	0
3096	233	heart disease HHD	[heart disease HHD]	1.5849625007211563	3	1	0	0
3097	233	tissue from control animal	[tissue from control animals]	1.5849625007211563	4	2	2	2
3098	233	hr reduction in patient	[HR reduction in patients]	1.5849625007211563	4	1	0	0
3099	233	patient with low bte	[patients with lower BTES]	1.5849625007211563	4	1	0	0
3100	233	ivabradine group p	[ivabradine group p]	1.5849625007211563	3	1	0	0
3101	233	association of the score	[association of the score]	1.5849625007211563	4	1	0	0
3102	233	standard error of measurement	[standard error of measurement]	1.5849625007211563	4	2	1	1
3103	233	effect of Nordic walking	[effects of Nordic walking]	1.5849625007211563	4	1	0	0
3104	233	diuretic refractory severe-end-stage HF	[diuretic refractory severe-end-stage HF]	1.5849625007211563	4	1	0	0
3105	233	Public reporting on quality	[Public reporting on quality]	1.5849625007211563	4	1	0	0
3106	233	less aggressive protocol	[less aggressive protocols]	1.5849625007211563	3	1	0	0
3107	233	good diagnostic performance	[good diagnostic performance]	1.5849625007211563	3	2	2	2
3108	233	over 2 week	[over 2 weeks]	1.5849625007211563	3	1	0	0
3109	233	most study in HF	[most studies in HF]	1.5849625007211563	4	1	0	0
3110	233	early follow-up visit	[early follow-up visits]	1.5849625007211563	3	1	0	0
3111	233	total of 1483 patient	[total of 1483 patients]	1.5849625007211563	4	1	0	0
3112	233	total of 8204 patient	[total of 8204 patients]	1.5849625007211563	4	1	0	0
3113	233	left heart fill pressure	[left heart filling pressures]	1.5849625007211563	4	1	0	0
3114	233	decision about life-sustaining treatment	[decisions about life-sustaining treatment]	1.5849625007211563	4	1	0	0
3115	233	strong predictor of mortality	[strong predictor of mortality]	1.5849625007211563	4	2	1	1
3116	233	left ejection fraction hfpef	[left ejection fraction HFpEF]	1.5849625007211563	4	2	2	2
3117	233	left ventricular end-diastolic pressure	[left ventricular end-diastolic pressure]	1.5849625007211563	4	1	0	0
3118	233	shortcoming in research study	[shortcomings in research studies]	1.5849625007211563	4	1	0	0
3119	233	control for demographic characteristic	[controlling for demographic characteristics]	1.5849625007211563	4	1	0	0
3120	233	30 day than medium	[30 days than medium]	1.5849625007211563	4	1	0	0
3121	233	multivariate Cox model analysis	[multivariate Cox model analysis]	1.5849625007211563	4	1	0	0
3122	233	have systolic heart failure	[having systolic heart failure]	1.5849625007211563	4	1	0	0
3123	233	model use historical datum	[models using historical data]	1.5849625007211563	4	1	0	0
3124	233	78 553 saxagliptin user	[78 553 saxagliptin users]	1.5849625007211563	4	1	0	0
3125	233	primary study end point	[Primary study end point]	1.5849625007211563	4	2	1	1
3126	233	regulatory subunit RI	[regulatory subunit RI]	1.5849625007211563	3	1	0	0
3127	233	power spectral analysis	[Power spectral analysis]	1.5849625007211563	3	1	0	0
3128	233	mild heart failure	[mild heart failure]	1.5849625007211563	3	2	1	1
3129	233	use of spironolactone	[use of spironolactone]	1.5849625007211563	3	1	0	0
3130	233	logistic regression model	[Logistic regression models]	1.5849625007211563	3	1	0	0
3131	233	8009 reference subject	[8,009 reference subjects]	1.5849625007211563	3	1	0	0
3132	233	low-volume physician p	[low-volume physicians P]	1.5849625007211563	3	1	0	0
3133	233	three group of sample	[three groups of samples]	1.5849625007211563	4	1	0	0
3134	233	heart failure myocardial tissue	[heart failure myocardial tissue]	1.5849625007211563	4	1	0	0
3135	233	efficacy of the device	[efficacy of the device]	1.5849625007211563	4	1	0	0
3136	233	99930 HF patient	[99,930 HF patients]	1.5849625007211563	3	1	0	0
3137	233	datum from clinical trial	[data from clinical trials]	1.5849625007211563	4	1	0	0
3138	233	rest of the group	[rest of the group]	1.5849625007211563	4	1	0	0
3139	233	relationship with mortality	[relationships with mortality]	1.5849625007211563	3	1	0	0
3140	233	outcome among patient	[outcomes among patients]	1.5849625007211563	3	2	2	2
3141	233	24 373 patient	[24 373 patients]	1.5849625007211563	3	1	0	0
3142	233	ventricular reserve in patient	[ventricular reserve in patients]	1.5849625007211563	4	2	2	2
3143	233	two group patient p	[two groups patients P]	1.5849625007211563	4	1	0	0
3144	233	reduction in the ratio	[reduction in the ratio]	1.5849625007211563	4	1	0	0
3145	233	20-week time span	[20-week time span]	1.5849625007211563	3	1	0	0
3146	233	reliability in stable HF	[reliability in stable HF]	1.5849625007211563	4	1	0	0
3147	233	myofibrillar can atpase activity	[myofibrillar Ca ATPase activity]	1.5849625007211563	4	1	0	0
3148	233	central end-systolic pressure	[central end-systolic pressure]	1.5849625007211563	3	1	0	0
3149	233	ring annuloplasty for regurgitation	[ring annuloplasty for regurgitation]	1.5849625007211563	4	2	2	2
3150	233	adjunctive treatment for patient	[adjunctive treatment for patients]	1.5849625007211563	4	1	0	0
3151	233	composite vs. Hospital Compare	[composite vs. Hospital Compare]	1.5849625007211563	4	1	0	0
3152	233	community of 150000 population	[community of 150,000 population]	1.5849625007211563	4	1	0	0
3153	233	10 patient with CHF	[10 patients with CHF]	1.5849625007211563	4	1	0	0
3154	233	prescribing of guideline-recommended medication	[prescribing of guideline-recommended medications]	1.5849625007211563	4	1	0	0
3155	233	require biventricular support	[requiring biventricular support]	1.5849625007211563	3	2	1	1
3156	233	improvement from baseline	[improvements from baseline]	1.5849625007211563	3	1	0	0
3157	233	subject without psoriasis	[subjects without psoriasis]	1.5849625007211563	3	1	0	0
3158	233	case-control study design	[case-control study design]	1.5849625007211563	3	1	0	0
3159	233	CHF inhibition of avp	[CHF Inhibition of AVP]	1.5849625007211563	4	1	0	0
3160	233	maximal ventricular power index	[maximal ventricular power index]	1.5849625007211563	4	1	0	0
3161	233	QT interval sdqt	[QT intervals SDQT]	1.5849625007211563	3	1	0	0
3162	233	odd ratio hazard ratio	[odds ratio hazard ratio]	1.5849625007211563	4	1	0	0
3163	233	long continuity of care	[long-term continuity of care]	1.5849625007211563	4	1	0	0
3164	233	feature of heart failure	[features of heart failure]	1.5849625007211563	4	1	0	0
3165	233	typical amyloidotic pattern	[typical amyloidotic pattern]	1.5849625007211563	3	1	0	0
3166	233	cardiac benign tumor	[cardiac benign tumors]	1.5849625007211563	3	1	0	0
3167	233	use of guideline-recommended medication	[use of guideline-recommended medications]	1.5849625007211563	4	1	0	0
3168	233	select control without CHF	[selecting controls without CHF]	1.5849625007211563	4	1	0	0
3169	233	significant interaction with LVEF	[significant interaction with LVEF]	1.5849625007211563	4	1	0	0
3170	233	timing of myocardial infarction	[timing of myocardial infarction]	1.5849625007211563	4	1	0	0
3171	233	patient with hypoalbuminemia	[patients with hypoalbuminemia]	1.5849625007211563	3	2	2	2
3172	233	human heart failure HF	[Human heart failure HF]	1.5849625007211563	4	1	0	0
3173	233	ms in this patient	[MS in this patient]	1.5849625007211563	4	1	0	0
3174	233	July 2005 performance	[July 2005 performance]	1.5849625007211563	3	1	0	0
3175	233	factor predict survival	[factors predicting survival]	1.5849625007211563	3	1	0	0
3176	233	same signalling protein	[same signalling proteins]	1.5849625007211563	3	1	0	0
3177	233	mouse tac model	[mouse TAC model]	1.5849625007211563	3	1	0	0
3178	233	vivo experiment of HF	[vivo experiments of HF]	1.5849625007211563	4	1	0	0
3179	233	risk for adverse event	[risk for adverse events]	1.5849625007211563	4	1	0	0
3180	233	NYHA Class ii	[NYHA Class II]	1.5849625007211563	3	1	0	0
3181	233	less invasive alternative	[less invasive alternatives]	1.5849625007211563	3	1	0	0
3182	233	median follow-up duration	[median follow-up duration]	1.5849625007211563	3	1	0	0
3183	233	use nursing terminology	[Using nursing terminologies]	1.5849625007211563	3	1	0	0
3184	233	right pulmonary artery	[right pulmonary artery]	1.5849625007211563	3	1	0	0
3185	233	secondary end point	[secondary end point]	1.5849625007211563	3	2	1	1
3186	233	high phosphorylation at eNOS-Thr	[higher phosphorylation at eNOS-Thr]	1.5849625007211563	4	1	0	0
3187	233	spironolactone in clinical practice	[spironolactone in clinical practice]	1.5849625007211563	4	1	0	0
3188	233	clinical practice guideline	[clinical practice guideline]	1.5849625007211563	3	2	2	2
3189	233	similar dose uptitration	[similar dose uptitration]	1.5849625007211563	3	1	0	0
3190	233	relative wall thickness	[relative wall thickness]	1.5849625007211563	3	1	0	0
3191	233	year of age	[years of age]	1.5849625007211563	3	2	2	2
3192	233	aerobic exercise training exercise	[aerobic exercise training exercise]	1.5849625007211563	4	1	0	0
3193	233	worsen heart failure	[worsening heart failure]	1.5849625007211563	3	2	1	1
3194	233	subject with a history	[subjects with a history]	1.5849625007211563	4	1	0	0
3195	233	basis of systematic review	[basis of systematic review]	1.5849625007211563	4	1	0	0
3196	233	College of Cardiology	[College of Cardiology]	1.5849625007211563	3	2	2	2
3197	233	onset of symptom	[onset of symptoms]	1.5849625007211563	3	1	0	0
3198	233	diagnosis of CHF dysfunction	[diagnosis of CHF dysfunction]	1.5849625007211563	4	1	0	0
3199	233	Health Initiative participant	[Health Initiative participants]	1.5849625007211563	3	1	0	0
3200	233	disease such as HF	[diseases such as HF]	1.5849625007211563	4	1	0	0
3201	233	correlation coefficient R	[correlation coefficient R]	1.5849625007211563	3	1	0	0
3202	233	other preventive measure	[other preventive measures]	1.5849625007211563	3	1	0	0
3203	233	refractory cardiogenic shock	[refractory cardiogenic shock]	1.5849625007211563	3	1	0	0
3204	233	iv heart failure	[IV heart failure]	1.5849625007211563	3	1	0	0
3205	233	6-mwt of 620 foot	[6-MWT of 620 feet]	1.5849625007211563	4	1	0	0
3206	233	magnetic resonance postcontrast	[magnetic resonance postcontrast]	1.5849625007211563	3	2	2	2
3207	233	soluble concentration ST2	[Soluble concentrations ST2]	1.5849625007211563	3	1	0	0
3208	233	2-fold risk of death	[2-fold risk of death]	1.5849625007211563	4	1	0	0
3209	233	determination of therapeutic option	[determination of therapeutic options]	1.5849625007211563	4	1	0	0
3210	233	grade 4 holosystolic murmur	[grade 4 holosystolic murmur]	1.5849625007211563	4	1	0	0
3211	233	new severe ai	[new severe AI]	1.5849625007211563	3	1	0	0
3212	233	6 wk of treatment	[6 wk of treatment]	1.5849625007211563	4	1	0	0
3213	233	79.9 year in 2011	[79.9 years in 2011]	1.5849625007211563	4	1	0	0
3214	233	invasive hemodynamic assessment	[invasive hemodynamic assessments]	1.5849625007211563	3	1	0	0
3215	233	ventricular longitudinal strain	[ventricular longitudinal strain]	1.5849625007211563	3	2	2	2
3216	233	2 high drs decile	[2 highest DRS deciles]	1.5849625007211563	4	1	0	0
3217	233	200 minute of exercise	[200 minutes of exercise]	1.5849625007211563	4	1	0	0
3218	233	such functional ms	[such functional MS]	1.5849625007211563	3	1	0	0
3219	233	change in body composition	[changes in body composition]	1.5849625007211563	4	1	0	0
3220	233	heart failure HF therapy	[heart failure HF therapy]	1.5849625007211563	4	1	0	0
3221	233	CRT hazard ratio	[CRT hazard ratio]	1.5849625007211563	3	1	0	0
3222	233	particularly poor prognosis	[particularly poor prognosis]	1.5849625007211563	3	1	0	0
3223	233	treatment of CHF	[treatment of CHF]	1.5849625007211563	3	1	0	0
3224	233	effect of CRT	[effect of CRT]	1.5849625007211563	3	2	1	1
3225	233	patient with high sst2	[Patients with high sST2]	1.5849625007211563	4	1	0	0
3226	233	recent onset hfref	[recent onset HFrEF]	1.5849625007211563	3	2	1	1
3227	233	3 clinical trial	[3 clinical trials]	1.5849625007211563	3	1	0	0
3228	233	Australian reference datum	[Australian reference data]	1.5849625007211563	3	1	0	0
3229	233	pathophysiology of chronic HF	[pathophysiology of chronic HF]	1.5849625007211563	4	1	0	0
3230	233	patient with hypertensive hfpef	[patients with hypertensive HFPEF]	1.5849625007211563	4	1	0	0
3231	233	incidence of pump dysfunction	[incidence of pump dysfunction]	1.5849625007211563	4	1	0	0
3232	233	include 3 normal sample	[including 3 normal samples]	1.5849625007211563	4	1	0	0
3233	233	index ed visit	[index ED visit]	1.5849625007211563	3	1	0	0
3234	233	≤75 year hr	[≤75 years HR]	1.5849625007211563	3	1	0	0
3235	233	overall atp production rate	[Overall ATP production rates]	1.5849625007211563	4	1	0	0
3236	233	endothelial-protective effect via stimulation	[endothelial-protective effects via stimulation]	1.5849625007211563	4	1	0	0
3237	233	Organisation of Care Taxonomy	[Organisation of Care Taxonomy]	1.5849625007211563	4	1	0	0
3238	233	hand-search relevant article	[hand-searching relevant articles]	1.5849625007211563	3	1	0	0
3239	233	Danish Registry on Dialysis	[Danish Registry on Dialysis]	1.5849625007211563	4	1	0	0
3240	233	nonmitochondrial protein change	[nonmitochondrial protein changes]	1.5849625007211563	3	1	0	0
3241	233	atrial area cm	[atrial area cm]	1.5849625007211563	3	2	2	2
3242	233	choice of chelation regimen	[choice of chelation regimens]	1.5849625007211563	4	1	0	0
3243	233	relationship between physician volume	[relationship between physician volume]	1.5849625007211563	4	1	0	0
3244	233	idiopathic dilated cardiomyopathy	[idiopathic dilated cardiomyopathy]	1.5849625007211563	3	1	0	0
3245	233	cardiovascular disease CVD	[cardiovascular disease CVD]	1.5849625007211563	3	1	0	0
3246	233	unilateral renal dnx	[unilateral renal DNx]	1.5849625007211563	3	1	0	0
3247	233	documentation of contextual reason	[documentation of contextual reasons]	1.5849625007211563	4	1	0	0
3248	233	further heart failure research	[further heart failure research]	1.5849625007211563	4	1	0	0
3249	233	develop heart failure	[developing heart failure]	1.5849625007211563	3	2	2	2
3250	233	low 50 mg	[low 50 mg]	1.5849625007211563	3	1	0	0
3251	233	incidence of attributable	[incidence of attributable]	1.5849625007211563	3	1	0	0
3252	233	pathogenesis of heart failure	[pathogenesis of heart failure]	1.5849625007211563	4	1	0	0
3253	233	measure of functional capacity	[measures of functional capacity]	1.5849625007211563	4	1	0	0
3254	233	percutaneous coronary intervention hr	[percutaneous coronary intervention HR]	1.5849625007211563	4	1	0	0
3255	233	increase in rehospitalization	[increase in rehospitalization]	1.5849625007211563	3	2	2	2
3256	233	continuous wave doppler echocardiography	[continuous wave Doppler echocardiography]	1.5849625007211563	4	1	0	0
3257	233	lack of Canadian datum	[lack of Canadian data]	1.5849625007211563	4	1	0	0
3258	233	diet score component	[Diet score components]	1.5849625007211563	3	1	0	0
3259	233	improvement in capacity	[improvement in capacity]	1.5849625007211563	3	2	2	2
3260	233	single-arm prospective multicenter study	[single-arm prospective multicenter study]	1.5849625007211563	4	1	0	0
3261	233	normalize Mena level	[normalizing Mena levels]	1.5849625007211563	3	1	0	0
3262	233	primary oscillation originate	[primary oscillations originating]	1.5849625007211563	3	1	0	0
3263	233	Swedish National Inpatient Registry	[Swedish National Inpatient Registry]	1.5849625007211563	4	1	0	0
3264	233	patient with hfpef n=100	[Patients with HFPEF n=100]	1.5849625007211563	4	1	0	0
3265	233	stage i-iii breast cancer	[stage I-III breast cancer]	1.5849625007211563	4	1	0	0
3266	233	heart failure clinic outpatient	[heart failure clinic outpatients]	1.5849625007211563	4	1	0	0
3267	233	reduction in blood pressure	[reduction in blood pressure]	1.5849625007211563	4	1	0	0
3268	233	understanding of this topic	[understanding of this topic]	1.5849625007211563	4	1	0	0
3269	233	ejection fraction hfref	[ejection fraction HFrEF]	1.5849625007211563	3	1	0	0
3270	233	velocity of circumferential shortening	[velocity of circumferential shortening]	1.5849625007211563	4	1	0	0
3271	233	result from the Resynchronization-Defibrillation	[Results from the Resynchronization-Defibrillation]	1.5849625007211563	4	1	0	0
3272	233	thirty-day all-cause readmission	[Thirty-day all-cause readmissions]	1.5849625007211563	3	1	0	0
3273	233	limited number of patient	[limited number of patients]	1.5849625007211563	4	1	0	0
3274	233	402 patient 48	[402 patients 48]	1.5849625007211563	3	1	0	0
3275	233	next generation nt-probnp assay	[next generation NT-proBNP assay]	1.5849625007211563	4	1	0	0
3276	233	argument for beta-blocker hypo-response	[arguments for beta-blocker hypo-response]	1.5849625007211563	4	1	0	0
3277	233	outcome for adult	[outcomes for adults]	1.5849625007211563	3	1	0	0
3278	233	emergency cardiac catheterization	[emergency cardiac catheterization]	1.5849625007211563	3	1	0	0
3279	233	exercise training on HRQoL	[exercise training on HRQoL]	1.5849625007211563	4	1	0	0
3280	233	treatment heart failure	[treatment heart failure]	1.5849625007211563	3	1	0	0
3281	233	2331 patient with HF	[2331 patients with HF]	1.5849625007211563	4	1	0	0
3282	233	actin cytoskeleton pathway	[actin cytoskeleton pathways]	1.5849625007211563	3	1	0	0
3283	233	minute without bolus	[min without bolus]	1.5849625007211563	3	1	0	0
3284	233	coronary artery calcium score	[coronary artery calcium scores]	1.5849625007211563	4	1	0	0
3285	233	patient with artery disease	[patients with artery disease]	1.5849625007211563	4	2	2	2
3286	233	proportion of eligible patient	[proportion of eligible patients]	1.5849625007211563	4	1	0	0
3287	233	phenotype of pathological hypertrophy	[phenotype of pathological hypertrophy]	1.5849625007211563	4	1	0	0
3288	233	attenuate cardiac remodeling	[attenuating cardiac remodeling]	1.5849625007211563	3	1	0	0
3289	233	Secondary outcome measure related	[Secondary outcome measures related]	1.5849625007211563	4	1	0	0
3290	233	great antecedent weight loss	[greater antecedent weight loss]	1.5849625007211563	4	1	0	0
3291	233	such as venous thromboembolism	[such as venous thromboembolism]	1.5849625007211563	4	1	0	0
3292	233	ambient air pollution	[Ambient air pollution]	1.5849625007211563	3	1	0	0
3293	233	l-type channel-dependent process	[L-type channel-dependent processes]	1.5849625007211563	3	1	0	0
3294	233	once at heart failure	[once at heart failure]	1.5849625007211563	4	1	0	0
3295	233	impact of implementation strategy	[impact of implementation strategies]	1.5849625007211563	4	1	0	0
3296	233	risk for adverse outcome	[risk for adverse outcomes]	1.5849625007211563	4	1	0	0
3297	233	ANG ii infusion at	[ANG II infusion AT]	1.5849625007211563	4	1	0	0
3298	233	further molecular analysis	[Further molecular analysis]	1.5849625007211563	3	1	0	0
3299	233	ischemic cerebrovascular event	[ischemic cerebrovascular events]	1.5849625007211563	3	1	0	0
3300	233	intraclass correlation coefficient icc	[intraclass correlation coefficient ICC]	1.5849625007211563	4	1	0	0
3301	233	great difference among ef	[greatest difference among EF]	1.5849625007211563	4	1	0	0
3302	233	hazard ratio hr 1.41	[hazard ratio HR 1.41]	1.5849625007211563	4	1	0	0
3303	233	serum resistin level	[serum resistin levels]	1.5849625007211563	3	2	1	1
3304	233	transcription factor Hand2	[transcription factor Hand2]	1.5849625007211563	3	1	0	0
3305	233	data support iron use	[Data supporting iron use]	1.5849625007211563	4	1	0	0
3306	233	aldosterone a neurohormone	[Aldosterone a neurohormone]	1.5849625007211563	3	1	0	0
3307	233	β-Adrenergic receptor blockade	[β-Adrenergic receptor blockade]	1.5849625007211563	3	1	0	0
3308	233	hg β coefficient	[Hg β coefficient]	1.5849625007211563	3	1	0	0
3309	233	glomerular filtration rate millileter	[glomerular filtration rate ml]	1.5849625007211563	4	2	2	2
3310	233	concomitant downregulation of na	[concomitant downregulation of Na]	1.5849625007211563	4	1	0	0
3311	233	complete coronary occlusion	[Complete coronary occlusion]	1.5849625007211563	3	1	0	0
3312	233	novel mouse HF model	[novel mouse HF model]	1.5849625007211563	4	2	2	2
3313	233	population-based Rotterdam Study	[population-based Rotterdam Study]	1.5849625007211563	3	1	0	0
3314	233	performance of this lvass	[performance of this LVAS]	1.5849625007211563	4	1	0	0
3315	233	congestive heart failure phenotype	[congestive heart failure phenotypes]	1.5849625007211563	4	1	0	0
3316	233	lvef hazard ratio hr	[LVEF hazard ratio HR]	1.5849625007211563	4	1	0	0
3317	233	unintentional weight loss	[unintentional weight loss]	1.5849625007211563	3	1	0	0
3318	233	odd of CHF	[odds of CHF]	1.5849625007211563	3	1	0	0
3319	233	few tunel-positive cell	[few TUNEL-positive cells]	1.5849625007211563	3	1	0	0
3320	233	therefore of significant value	[therefore of significant value]	1.5849625007211563	4	1	0	0
3321	233	mortality in woman	[mortality in women]	1.5849625007211563	3	2	1	1
3322	233	right atrial pressure	[right atrial pressure]	1.5849625007211563	3	1	0	0
3323	233	change in distribution	[change in distribution]	1.5849625007211563	3	1	0	0
3324	233	peak oxygen consumption vo2max	[Peak oxygen consumption VO2max]	1.5849625007211563	4	1	0	0
3325	233	institute mechanical circulatory support	[instituting mechanical circulatory support]	1.5849625007211563	4	1	0	0
3326	233	proteome of HDL particle	[proteome of HDL particles]	1.5849625007211563	4	1	0	0
3327	233	past 3 decade	[past 3 decades]	1.5849625007211563	3	1	0	0
3328	233	congestive heart failure patient	[congestive heart failure patients]	1.5849625007211563	4	1	0	0
3329	233	accounting for hospital clustering	[accounting for hospital clustering]	1.5849625007211563	4	1	0	0
3330	233	peripheral arterial disease	[peripheral arterial disease]	1.5849625007211563	3	1	0	0
3331	233	benefit of exercise	[benefits of exercise]	1.5849625007211563	3	1	0	0
3332	233	right ventricle RV	[right ventricle RV]	1.5849625007211563	3	1	0	0
3333	233	optimal medical management	[optimal medical management]	1.5849625007211563	3	1	0	0
3334	233	datum safety monitoring board	[data safety monitoring board]	1.5849625007211563	4	1	0	0
3335	233	kappa coefficient from .49	[kappa coefficients from .49]	1.5849625007211563	4	1	0	0
3336	233	regular physical activity control	[Regular physical activity controls]	1.5849625007211563	4	1	0	0
3337	233	left ventricular pressure	[left ventricular pressure]	1.5849625007211563	3	2	2	2
3338	233	catheter ablation for AF	[Catheter ablation for AF]	1.5849625007211563	4	1	0	0
3339	233	abnormal liver texture change	[abnormal liver texture changes]	1.5849625007211563	4	1	0	0
3340	233	heart failure. rirnas	[heart failure. miRNAs]	1.5849625007211563	3	1	0	0
3341	233	4 ischemic sample	[4 ischemic samples]	1.5849625007211563	3	1	0	0
3342	233	many acute HF trial	[many acute HF trials]	1.5849625007211563	4	1	0	0
3343	233	January 2000 2009	[January 2000 2009]	1.5849625007211563	3	1	0	0
3344	233	post-TAC cardiac functional deterioration	[post-TAC cardiac functional deterioration]	1.5849625007211563	4	1	0	0
3345	233	urinary tract infection uti	[urinary tract infection UTI]	1.5849625007211563	4	1	0	0
3346	233	30-day risk-standardized mortality	[30-day risk-standardized mortality]	1.5849625007211563	3	1	0	0
3347	233	morpholino-based knockdown of nucleolin	[Morpholino-based knockdown of nucleolin]	1.5849625007211563	4	1	0	0
3348	233	review of this drug	[review of this drug]	1.5849625007211563	4	1	0	0
3349	233	appropriate out-patient follow-up	[appropriate out-patient follow-up]	1.5849625007211563	3	1	0	0
3350	233	future high performer	[future high performers]	1.5849625007211563	3	2	1	1
3351	233	College of physician	[College of Physicians]	1.5849625007211563	3	2	2	2
3352	233	adult mouse ventricular myocyte	[adult mouse ventricular myocytes]	1.5849625007211563	4	1	0	0
3353	233	acute care surgery	[Acute care surgery]	1.5849625007211563	3	2	2	2
3354	233	especially in elderly people	[especially in elderly people]	1.5849625007211563	4	1	0	0
3355	233	ventricular ejection time LVET	[ventricular ejection time LVET]	1.5849625007211563	4	1	0	0
3356	233	Fontan adult versus control	[Fontan adults versus controls]	1.5849625007211563	4	1	0	0
3357	233	vivo RV length-force relationship	[vivo RV length-force relationship]	1.5849625007211563	4	1	0	0
3358	233	Canadian special access programme	[Canadian special access programme]	1.5849625007211563	4	1	0	0
3359	233	identify superior hospital	[identifying superior hospitals]	1.5849625007211563	3	1	0	0
3360	233	High baseline CRF	[Higher baseline CRF]	1.5849625007211563	3	1	0	0
3361	233	project long cost	[projecting long-term costs]	1.5849625007211563	3	1	0	0
3362	233	benefit of ras uptitration	[benefit of RAS uptitration]	1.5849625007211563	4	1	0	0
3363	233	involve young adult	[involving young adults]	1.5849625007211563	3	1	0	0
3364	233	muscle aerobic capacity	[Muscle aerobic capacity]	1.5849625007211563	3	1	0	0
3365	233	mutant mouse overexpress Hand2	[mutant mice overexpressing Hand2]	1.5849625007211563	4	1	0	0
3366	233	high hemoglobin level	[higher hemoglobin levels]	1.5849625007211563	3	1	0	0
3367	233	improvement in the distance	[improvements in the distance]	1.5849625007211563	4	1	0	0
3368	233	large-scale clinical trial	[large-scale clinical trial]	1.5849625007211563	3	1	0	0
3369	233	MADIT-CRT with study	[MADIT-CRT With study]	1.5849625007211563	3	1	0	0
3370	233	embryonic gene program	[embryonic gene programs]	1.5849625007211563	3	2	2	2
3371	233	lvet between admission measurement	[LVET between admission measurement]	1.5849625007211563	4	1	0	0
3372	233	Recent postmarketing trial	[Recent postmarketing trials]	1.5849625007211563	3	1	0	0
3373	233	patient in atrial fibrillation	[patients in atrial fibrillation]	1.5849625007211563	4	1	0	0
3374	233	late-onset 8 day	[late-onset 8 days]	1.5849625007211563	3	1	0	0
3375	233	proximal circumflex artery LCX	[proximal circumflex artery LCX]	1.5849625007211563	4	1	0	0
3376	233	morbidity in HFpEF	[Morbidity in HFpEF]	1.5849625007211563	3	1	0	0
3377	233	depressive symptom Beck	[depressive symptoms Beck]	1.5849625007211563	3	1	0	0
3378	233	various cardiovascular disease	[various cardiovascular diseases]	1.5849625007211563	3	1	0	0
3379	233	high bb dose	[higher BB doses]	1.5849625007211563	3	1	0	0
3380	233	heart failure development	[heart failure development]	1.5849625007211563	3	1	0	0
3381	233	Skeletal muscle mass	[Skeletal muscle mass]	1.5849625007211563	3	1	0	0
3382	233	length of follow-up	[length of follow-up]	1.5849625007211563	3	1	0	0
3383	233	twenty week of diet	[Twenty weeks of diet]	1.5849625007211563	4	1	0	0
3384	233	acute heart failure trial	[acute heart failure trials]	1.5849625007211563	4	1	0	0
3385	233	base of treatment	[base of treatment]	1.5849625007211563	3	1	0	0
3386	233	prevalence of systolic HF	[prevalence of systolic HF]	1.5849625007211563	4	1	0	0
3387	233	intramuscular testosterone supplementation	[intramuscular testosterone supplementation]	1.5849625007211563	3	1	0	0
3388	233	hr 1.58 CI 1.27	[HR 1.58 CI 1.27]	1.5849625007211563	4	1	0	0
3389	233	Clinical sign of HF	[Clinical signs of HF]	1.5849625007211563	4	1	0	0
3390	233	Depression scale score	[Depression Scale score]	1.5849625007211563	3	1	0	0
3391	233	relationship between the intervention	[relationship between the intervention]	1.5849625007211563	4	1	0	0
3392	233	improvement of hemodynamic perturbation	[improvement of hemodynamic perturbations]	1.5849625007211563	4	1	0	0
3393	233	function in heart failure	[function in heart failure]	1.5849625007211563	4	2	2	2
3394	233	ventricular wall stress	[ventricular wall stress]	1.5849625007211563	3	1	0	0
3395	233	interval from transplantation	[interval from transplantation]	1.5849625007211563	3	1	0	0
3396	233	improvement in one domain	[improvement in one domains]	1.5849625007211563	4	1	0	0
3397	233	patient with reduction	[patients with reduction]	1.5849625007211563	3	2	2	2
3398	233	basis of this datum	[basis of these data]	1.5849625007211563	4	1	0	0
3399	233	subsequent heart failure HF	[subsequent heart failure HF]	1.5849625007211563	4	1	0	0
3400	233	mortality in survivor	[mortality in survivors]	1.5849625007211563	3	2	2	2
3401	233	difference in baseline characteristic	[differences in baseline characteristics]	1.5849625007211563	4	1	0	0
3402	233	impact of evidence-based management	[impact of evidence-based management]	1.5849625007211563	4	1	0	0
3403	233	1 dacron patch closure	[1 Dacron patch closure]	1.5849625007211563	4	1	0	0
3404	233	such opposing response	[such opposing responses]	1.5849625007211563	3	1	0	0
3405	233	prospective open-label crossover study	[prospective open-label crossover study]	1.5849625007211563	4	1	0	0
3406	233	systemic vascular resistance	[systemic vascular resistance]	1.5849625007211563	3	1	0	0
3407	233	Exercise training hf-action	[Exercise TraiNing HF-ACTION]	1.5849625007211563	3	2	2	2
3408	233	HF hospitalization hr	[HF hospitalization HR]	1.5849625007211563	3	2	2	2
3409	233	concentric hypertrophy ch	[concentric hypertrophy CH]	1.5849625007211563	3	1	0	0
3410	233	cardiac sympathetic activity (123)i-meta-iodobenzylguanidine	[cardiac sympathetic activity (123)I-meta-iodobenzylguanidine]	1.5849625007211563	4	1	0	0
3411	233	nyha functional class rank	[NYHA functional class ranking]	1.5849625007211563	4	1	0	0
3412	233	SkM skeletal muscle structure	[SkM skeletal muscle structure]	1.5849625007211563	4	1	0	0
3413	233	history of atrial fibrillation	[history of atrial fibrillation]	1.5849625007211563	4	1	0	0
3414	233	6-minute walk test	[6-minute walk test]	1.5849625007211563	3	2	2	2
3415	233	eight healthy age-matched control	[eight healthy age-matched controls]	1.5849625007211563	4	1	0	0
3416	233	acute right heart failure	[Acute right heart failure]	1.5849625007211563	4	2	2	2
3417	233	clinical model alone	[clinical models alone]	1.5849625007211563	3	1	0	0
3418	233	substantial proportion of patient	[substantial proportion of patients]	1.5849625007211563	4	1	0	0
3419	233	heart failure atherosclerosis risk	[heart failure atherosclerosis risk]	1.5849625007211563	4	1	0	0
3420	233	effect of fes	[effects of FES]	1.5849625007211563	3	1	0	0
3421	233	significantly more hypertension	[significantly more hypertension]	1.5849625007211563	3	1	0	0
3422	233	centrifugal-flow chronic lvass	[centrifugal-flow chronic LVAS]	1.5849625007211563	3	1	0	0
3423	233	ejection fraction HFpEF	[ejection fraction HFpEF]	1.5849625007211563	3	2	1	1
3424	233	more careful management	[more careful management]	1.5849625007211563	3	1	0	0
3425	233	age-specific low CRF category	[age-specific low CRF categories]	1.5849625007211563	4	1	0	0
3426	233	less clinical benefit	[less clinical benefit]	1.5849625007211563	3	1	0	0
3427	233	median baseline ST2 level	[median baseline ST2 level]	1.5849625007211563	4	1	0	0
3428	233	basis for this difference	[basis for these differences]	1.5849625007211563	4	1	0	0
3429	233	dog with HF	[dogs with HF]	1.5849625007211563	3	2	2	2
3430	233	important therapeutic implication	[important therapeutic implications]	1.5849625007211563	3	1	0	0
3431	233	renal chloride channel	[renal chloride channel]	1.5849625007211563	3	1	0	0
3432	233	neutral endopeptidase inhibitor	[neutral endopeptidase inhibitors]	1.5849625007211563	3	1	0	0
3433	233	use of bisoprolol	[use of bisoprolol]	1.5849625007211563	3	1	0	0
3434	233	21 beagle dog	[21 beagle dogs]	1.5849625007211563	3	1	0	0
3435	233	sr can 2+)-pump function	[SR Ca 2+)-pump function]	1.5849625007211563	4	1	0	0
3436	233	use a different metric	[using a different metric]	1.5849625007211563	4	1	0	0
3437	233	great number of study	[great number of studies]	1.5849625007211563	4	1	0	0
3438	233	diabete mellitus at baseline	[diabetes mellitus at baseline]	1.5849625007211563	4	1	0	0
3439	233	middle-aged recreational athlete	[middle-aged recreational athletes]	1.5849625007211563	3	1	0	0
3440	233	reduction in risk	[reduction in risk]	1.5849625007211563	3	1	0	0
3441	233	myocardial titin hypophosphorylation	[Myocardial titin hypophosphorylation]	1.5849625007211563	3	1	0	0
3442	233	ischemic mitral regurgitation mr	[ischemic mitral regurgitation MR]	1.5849625007211563	4	1	0	0
3443	233	development of ischemic event	[development of ischemic events]	1.5849625007211563	4	2	2	2
3444	233	twice a day	[twice a day]	1.5849625007211563	3	1	0	0
3445	233	degenerative mitral regurgitation	[degenerative mitral regurgitation]	1.5849625007211563	3	1	0	0
3446	233	eligibility for heart transplantation	[eligibility for heart transplantation]	1.5849625007211563	4	1	0	0
3447	233	10.7 nmol 309 ng	[10.7 nmol 309 ng]	1.5849625007211563	4	1	0	0
3448	233	intrinsic ventricular dysfunction	[intrinsic ventricular dysfunction]	1.5849625007211563	3	1	0	0
3449	233	investigation for the development	[investigation for the development]	1.5849625007211563	4	1	0	0
3450	233	cognitive impairment at hospitalization	[cognitive impairment at hospitalization]	1.5849625007211563	4	1	0	0
3451	233	malfunction HeartMate ii lvas	[malfunctioning HeartMate II LVADs]	1.5849625007211563	4	1	0	0
3452	233	care transfer policy	[care transfer policy]	1.5849625007211563	3	2	2	2
3453	233	increase in all	[increases in all]	1.5849625007211563	3	1	0	0
3454	233	clinical deterioration of HFPEF	[clinical deterioration of HFPEF]	1.5849625007211563	4	1	0	0
3455	233	cardiac sympathovagal balance	[cardiac sympathovagal balance]	1.5849625007211563	3	1	0	0
3456	233	several key gene related	[several key genes related]	1.5849625007211563	4	1	0	0
3457	233	22 hvad device	[22 HVAD devices]	1.5849625007211563	3	1	0	0
3458	233	ventilatory efficiency slope	[ventilatory efficiency slope]	1.5849625007211563	3	1	0	0
3459	233	affect basal contractility	[affecting basal contractility]	1.5849625007211563	3	1	0	0
3460	233	haematopoietic cell transplantation	[haematopoietic cell transplantation]	1.5849625007211563	3	2	1	1
3461	233	4-year survival rate	[4-year survival rates]	1.5849625007211563	3	1	0	0
3462	233	biomarker-guided clinical trial design	[biomarker-guided clinical trial design]	1.5849625007211563	4	1	0	0
3463	233	objective of the measure	[objective of the measure]	1.5849625007211563	4	1	0	0
3464	233	Cardiac symptom in child	[Cardiac symptoms in children]	1.5849625007211563	4	1	0	0
3465	233	increase body of evidence	[increasing body of evidence]	1.5849625007211563	4	1	0	0
3466	233	testing of cardiac biomarker	[testing of cardiac biomarkers]	1.5849625007211563	4	1	0	0
3467	234	mm	[mm]	1.576923076923077	1	17	16	13
3468	235	Exercise	[Exercise]	1.5750000000000002	1	17	15	12
3469	236	addition	[addition]	1.5666666666666667	1	17	4	3
3470	236	regression	[regression]	1.5666666666666667	1	17	16	12
3471	237	practice	[practice]	1.5636363636363637	1	17	15	11
3472	238	efficacy	[efficacy]	1.56	1	17	7	5
3473	239	fibrillation	[fibrillation]	1.5571428571428572	1	18	17	7
3474	240	subject	[subject]	1.5555555555555556	1	17	13	9
3475	241	resynchronization	[resynchronization]	1.54	1	18	13	5
3476	242	peptide	[peptide]	1.5375	1	17	13	8
3477	243	race	[race]	1.5333333333333334	1	17	5	3
3478	244	energy metabolism	[energy metabolism]	1.5	2	3	3	2
3479	244	valve opening	[valve opening]	1.5	2	3	3	2
3480	244	relationship	[relationship]	1.5	1	18	15	5
3481	244	diastolic velocity	[diastolic velocity]	1.5	2	3	3	2
3482	244	coronary syndrome	[coronary syndrome]	1.5	2	3	3	2
3483	244	ring annuloplasty	[ring annuloplasty]	1.5	2	3	3	2
3484	244	mild reduction	[mild reduction]	1.5	2	3	3	2
3485	244	early velocity	[early velocity]	1.5	2	3	3	2
3486	244	study end	[study end]	1.5	2	3	3	2
3487	244	cutoff value	[cutoff value]	1.5	2	3	3	2
3488	244	signal	[signaling]	1.5	1	16	9	9
3489	244	protective effect	[protective effects]	1.5	2	3	3	2
3490	244	qrs	[QRS]	1.5	1	16	5	5
3491	244	pasp increase	[PASP increase]	1.5	2	3	3	2
3492	244	common form	[common form]	1.5	2	3	3	2
3493	244	strategy	[strategy]	1.5	1	16	10	10
3494	244	left function	[left function]	1.5	2	3	3	2
3495	244	annular velocity	[annular velocity]	1.5	2	3	3	2
3496	244	optimal treatment	[optimal treatment]	1.5	2	3	3	2
3497	244	therapeutic approach	[therapeutic approach]	1.5	2	3	3	2
3498	244	testosterone status	[testosterone status]	1.5	2	3	3	2
3499	244	SR can	[SR Ca]	1.5	2	3	3	2
3500	244	valve replacement	[valve replacement]	1.5	2	3	3	2
3501	244	urine volume	[urine volume]	1.5	2	3	3	2
3502	244	HeartMate lvad	[HeartMate LVAD]	1.5	2	3	3	2
3503	244	design	[DESIGN]	1.5	1	15	0	0
3504	244	standard error	[standard error]	1.5	2	3	3	2
3505	244	qrs complex	[QRS complex]	1.5	2	3	3	2
3506	244	mitral velocity	[mitral velocity]	1.5	2	3	3	2
3507	245	cardiomyopathy	[cardiomyopathy]	1.4916666666666667	1	16	13	12
3508	246	type	[type]	1.4909090909090912	1	16	12	11
3509	247	volume	[volume]	1.4900000000000002	1	16	11	10
3510	248	trend	[trend]	1.4833333333333334	1	16	14	12
3511	249	lvef	[LVEF]	1.4800000000000002	1	16	6	5
3512	250	failure	[failure]	1.4666666666666668	1	16	12	9
3513	251	odd	[odds]	1.4571428571428573	1	16	10	7
3514	252	activity	[activity]	1.4555555555555557	1	16	13	9
3515	253	SD	[SD]	1.4000000000000001	1	15	2	2
3516	253	af	[AF]	1.4000000000000001	1	15	4	4
3517	253	York	[York]	1.4000000000000001	1	19	15	3
3518	253	cost	[cost]	1.4000000000000001	1	15	9	9
3519	253	spironolactone	[spironolactone]	1.4000000000000001	1	15	7	7
3520	254	medication	[medication]	1.3900000000000001	1	15	11	10
3521	255	E	[E]	1.375	1	15	5	4
3522	256	cardiomyocyte	[cardiomyocyte]	1.3625	1	15	11	8
3523	257	reason	[reason]	1.36	1	15	14	10
3524	258	complication	[complication]	1.3444444444444446	1	15	14	9
3525	259	ventricle	[ventricle]	1.3375000000000001	1	15	13	8
3526	260	mg	[mg]	1.2916666666666667	1	14	13	12
3527	260	assessment	[assessment]	1.2916666666666667	1	14	13	12
3528	261	t1	[T1]	1.29	1	14	11	10
3529	262	channel	[channel]	1.288888888888889	1	14	10	9
3530	263	period	[period]	1.2875	1	14	9	8
3531	264	woman	[woman]	1.2857142857142858	1	14	8	7
3532	265	hyperkalemia	[hyperkalemia]	1.2833333333333334	1	14	7	6
3533	265	Health	[Health]	1.2833333333333334	1	14	7	6
3534	266	score	[score]	1.2800000000000002	1	14	12	10
3535	267	muscle	[muscle]	1.2750000000000001	1	14	10	8
3536	267	individual	[individuals]	1.2750000000000001	1	14	10	8
3537	267	capacity	[capacity]	1.2750000000000001	1	17	17	4
3538	268	HDL	[HDL]	1.2714285714285714	1	14	9	7
3539	269	data	[Data]	1.2625000000000002	1	14	11	8
3540	270	number	[number]	1.2555555555555555	1	14	13	9
3541	271	ed	[ED]	1.25	1	14	9	6
3542	272	frailty	[frailty]	1.2000000000000002	1	13	6	6
3543	272	echocardiography	[echocardiography]	1.2000000000000002	1	13	5	5
3544	272	guideline	[guideline]	1.2000000000000002	1	13	4	4
3545	272	research	[research]	1.2000000000000002	1	13	8	8
3546	272	performance	[performance]	1.2000000000000002	1	13	9	9
3547	272	ras	[RAS]	1.2000000000000002	1	13	6	6
3548	272	resistin	[resistin]	1.2000000000000002	1	13	9	9
3549	272	plasma	[plasma]	1.2000000000000002	1	13	5	5
3550	272	ST2	[ST2]	1.2000000000000002	1	13	4	4
3551	272	recommendation	[recommendation]	1.2000000000000002	1	13	5	5
3552	273	value	[value]	1.1909090909090911	1	13	12	11
3553	274	drug	[drug]	1.1888888888888889	1	13	10	9
3554	275	transplant	[transplant]	1.1857142857142857	1	13	8	7
3555	276	BNP	[BNP]	1.1833333333333333	1	13	7	6
3556	277	class	[class]	1.1777777777777778	1	13	11	9
3557	278	interaction	[interaction]	1.175	1	13	10	8
3558	279	status	[status]	1.17	1	13	13	10
3559	280	level	[level]	1.1625	1	13	11	8
3560	281	kidney	[kidney]	1.1400000000000001	1	13	8	5
3561	282	mr	[MR]	1.125	1	14	11	4
3562	282	cardioverter-defibrillator	[cardioverter-defibrillator]	1.125	1	13	7	4
3563	283	measurement	[measurement]	1.1199999999999999	1	13	9	5
3564	284	anemia	[anemia]	1.1	1	12	3	3
3565	284	subgroup	[subgroup]	1.1	1	12	7	7
3566	284	emergency	[emergency]	1.1	1	12	3	3
3567	284	evaluation	[evaluation]	1.1	1	12	11	11
3568	284	approach	[approach]	1.1	1	12	9	9
3569	284	morbidity	[morbidity]	1.1	1	12	6	6
3570	285	stress	[stress]	1.088888888888889	1	12	10	9
3571	286	insulin	[insulin]	1.0875000000000001	1	12	9	8
3572	287	bnp	[BNP]	1.0833333333333335	1	12	7	6
3573	288	angiotensin	[angiotensin]	1.08	1	13	11	5
3574	289	condition	[condition]	1.077777777777778	1	12	11	9
3575	290	discharge	[discharge]	1.075	1	12	5	4
3576	291	incidence	[incidence]	1.05	1	12	9	6
3577	291	fill	[filling]	1.05	1	12	9	6
3578	292	decrease	[decrease]	1.042857142857143	1	12	11	7
3579	293	expression	[expression]	1.0333333333333334	1	12	10	6
3580	294	enzyme	[enzyme]	1.0166666666666666	1	12	11	6
3581	295	encourage decline in the incidence	[encouraging declines in the incidence]	1.0	5	1	0	0
3582	295	potential candidate	[potential candidates]	1.0	2	1	0	0
3583	295	hgb level	[Hgb level]	1.0	2	1	0	0
3584	295	diagnostic testing	[diagnostic testing]	1.0	2	1	0	0
3585	295	clinical tool	[clinical tool]	1.0	2	2	2	2
3586	295	two distinct population of patient	[two distinct populations of patients]	1.0	5	1	0	0
3587	295	less comorbidity	[less comorbidities]	1.0	2	1	0	0
3588	295	Patient Safety Monitoring System MPSMS	[Patient Safety Monitoring System MPSMS]	1.0	5	1	0	0
3589	295	post-lvad ai with valve oversewing	[post-LVAD AI with valve oversewing]	1.0	5	1	0	0
3590	295	etiologic cause of RV failure	[etiologic causes of RV failure]	1.0	5	1	0	0
3591	295	patient with peripheral artery disease	[patients with peripheral artery disease]	1.0	5	1	0	0
3592	295	hazard ratio for the outcome	[hazard ratio for the outcome]	1.0	5	1	0	0
3593	295	composite quality	[Composite quality]	1.0	2	2	1	1
3594	295	continuous relationship between broad qrs	[continuous relationship between broader QRS]	1.0	5	1	0	0
3595	295	high risk of hyperkalemia patient	[high risk of hyperkalemia patients]	1.0	5	1	0	0
3596	295	HDL NYHA-IIIb	[HDL NYHA-IIIb]	1.0	2	2	2	2
3597	295	renin-angiotensin system blocker beta-blocker therapy	[renin-angiotensin system blocker beta-blocker therapy]	1.0	5	1	0	0
3598	295	five patient IL 0.5 mg	[five patients IL 0.5 mg]	1.0	5	1	0	0
3599	295	transthoracic echocardiography	[transthoracic echocardiography]	1.0	2	1	0	0
3600	295	Rankin score	[Rankin Score]	1.0	2	1	0	0
3601	295	predictor of mortality in patient	[predictor of mortality in patients]	1.0	5	2	2	2
3602	295	maladaptive remodelling	[maladaptive remodelling]	1.0	2	1	0	0
3603	295	fit man	[fit men]	1.0	2	1	0	0
3604	295	separate cohort	[separate cohort]	1.0	2	1	0	0
3605	295	most patient	[Most patients]	1.0	2	1	0	0
3606	295	ratio form	[ratio form]	1.0	2	1	0	0
3607	295	beta-adrenergic response	[beta-adrenergic responses]	1.0	2	1	0	0
3608	295	even after multivariable adjustment hazard ratio	[even after multivariable adjustment hazard ratio]	1.0	6	1	0	0
3609	295	next generation	[next generation]	1.0	2	1	0	0
3610	295	predictor after cardiac resynchronization therapy	[predictors after cardiac resynchronization therapy]	1.0	5	2	2	2
3611	295	determination of risk treatment strategy	[Determination of risk treatment strategies]	1.0	5	1	0	0
3612	295	area under the curve auc	[area under the curve AUC]	1.0	5	1	0	0
3613	295	self-care education	[self-care education]	1.0	2	1	0	0
3614	295	undergo left ventricular assist device implantation	[undergoing left ventricular assist device implantation]	1.0	6	2	1	1
3615	295	exogenous variant	[exogenous variants]	1.0	2	1	0	0
3616	295	glomerular filtration	[glomerular filtration]	1.0	2	1	0	0
3617	295	single diagnostic test for HFpEF	[single diagnostic test for HFpEF]	1.0	5	1	0	0
3618	295	low skeletal muscle mass r=0.67	[Low skeletal muscle mass r=0.67]	1.0	5	1	0	0
3619	295	recent trial	[recent trials]	1.0	2	2	2	2
3620	295	24 h	[24 h]	1.0	2	1	0	0
3621	295	use exercise testing guide exercise rehabilitation	[using exercise testing guide exercise rehabilitation]	1.0	6	1	0	0
3622	295	mild anemia	[mild anemia]	1.0	2	1	0	0
3623	295	patient with normal albumin level	[patients with normal albumin levels]	1.0	5	1	0	0
3624	295	flow-mediated dilatation improvement by ET	[flow-mediated dilatation improvement by ET]	1.0	5	1	0	0
3625	295	rationale of the early treatment	[rationale of the Early treatment]	1.0	5	1	0	0
3626	295	good understanding of the mechanism	[better understanding of the mechanism]	1.0	5	1	0	0
3627	295	t1 change	[T1 changes]	1.0	2	2	1	1
3628	295	heart failure in this model	[heart failure in this model]	1.0	5	1	0	0
3629	295	vivo assessment of cardiac function	[vivo assessment of cardiac function]	1.0	5	1	0	0
3630	295	awful paradox	[awful paradox]	1.0	2	1	0	0
3631	295	large fluctuation in beat-to-beat qt interval	[larger fluctuations in beat-to-beat QT intervals]	1.0	6	1	0	0
3632	295	15 millileter per 1.73 m 2	[15 mL per 1.73 m 2]	1.0	6	1	0	0
3633	295	HNorm group	[HNorm group]	1.0	2	1	0	0
3634	295	baseline ECGs	[baseline ECGs]	1.0	2	1	0	0
3635	295	interview datum	[interview data]	1.0	2	1	0	0
3636	295	simultaneous reduction in exercise-induced increase	[simultaneous reduction in exercise-induced increase]	1.0	5	1	0	0
3637	295	ivabradine group	[ivabradine group]	1.0	2	2	1	1
3638	295	practitioner in office-based emergency room practice	[practitioners in office-based emergency room practice]	1.0	6	1	0	0
3639	295	atropine infusion	[atropine infusion]	1.0	2	1	0	0
3640	295	244 m	[244 m]	1.0	2	1	0	0
3641	295	3.4 year	[3.4 years]	1.0	2	1	0	0
3642	295	target audience for this guideline	[target audience for this guideline]	1.0	5	1	0	0
3643	295	sonographic abnormality	[sonographic abnormalities]	1.0	2	1	0	0
3644	295	crude rate of severe hyperkalemia	[Crude rates of severe hyperkalemia]	1.0	5	1	0	0
3645	295	insulin action	[insulin action]	1.0	2	1	0	0
3646	295	VEGF inhibition	[VEGF inhibition]	1.0	2	1	0	0
3647	295	Neurohormonal abnormality	[Neurohormonal abnormalities]	1.0	2	1	0	0
3648	295	2-vessel model	[2-vessel model]	1.0	2	1	0	0
3649	295	come decade	[coming decades]	1.0	2	1	0	0
3650	295	cumulative dose of 18 mg	[cumulative dose of 18 mg]	1.0	5	1	0	0
3651	295	severe anemia	[severe anemia]	1.0	2	1	0	0
3652	295	subscale relative	[subscales relative]	1.0	2	1	0	0
3653	295	advanced copd	[advanced COPD]	1.0	2	2	1	1
3654	295	first-ever MI	[first-ever MI]	1.0	2	1	0	0
3655	295	English language	[English language]	1.0	2	1	0	0
3656	295	SNP rs10927887	[SNP rs10927887]	1.0	2	1	0	0
3657	295	significant difference in outcome rating	[significant difference in outcome ratings]	1.0	5	1	0	0
3658	295	update on exercise parameter for diagnosis	[update on exercise parameters for diagnosis]	1.0	6	1	0	0
3659	295	final diagnosis of multiple myeloma	[final diagnosis of multiple myeloma]	1.0	5	1	0	0
3660	295	antiplatelet agent	[antiplatelet agents]	1.0	2	2	1	1
3661	295	bpm p	[bpm P]	1.0	2	2	2	2
3662	295	hemodynamic phenotype of the fail Fontan	[Hemodynamic phenotype of the failing Fontan]	1.0	6	1	0	0
3663	295	2100 kcal	[2100 kcal]	1.0	2	1	0	0
3664	295	transplant process	[transplant process]	1.0	2	1	0	0
3665	295	b-type np	[B-type NP]	1.0	2	1	0	0
3666	295	ECCT patient	[ECCT patients]	1.0	2	1	0	0
3667	295	cardiac comorbidity	[cardiac comorbidities]	1.0	2	1	0	0
3668	295	real-time hfpsi use va-rt cohort	[real-time HFPSI use VA-RT cohort]	1.0	5	1	0	0
3669	295	β-ar responsiveness	[β-AR responsiveness]	1.0	2	2	1	1
3670	295	implementation issue	[implementation issues]	1.0	2	1	0	0
3671	295	duration of treadmill exercise testing	[duration of treadmill exercise testing]	1.0	5	1	0	0
3672	295	user of bisphophonate crude rr	[users of bisphophonates crude RR]	1.0	5	1	0	0
3673	295	study closure	[study closure]	1.0	2	1	0	0
3674	295	case report of a patient	[case report of a patient]	1.0	5	1	0	0
3675	295	patient with HFrEF versus HFpEF	[patients with HFrEF versus HFpEF]	1.0	5	1	0	0
3676	295	advanced phase	[advanced phase]	1.0	2	2	1	1
3677	295	few depressive symptom Hospital anxiety	[fewer depressive symptoms Hospital Anxiety]	1.0	5	1	0	0
3678	295	139 patient	[139 patients]	1.0	2	1	0	0
3679	295	30 mm	[30 mm]	1.0	2	1	0	0
3680	295	sst2	[sST2]	1.0	1	12	12	6
3681	295	resistin level with the development	[resistin levels with the development]	1.0	5	1	0	0
3682	295	rest hemodynamics	[resting hemodynamics]	1.0	2	1	0	0
3683	295	Chronic HF	[Chronic HF]	1.0	2	1	0	0
3684	295	treat patient with advanced heart failure	[treating patients with advanced heart failure]	1.0	6	1	0	0
3685	295	6-month echocardiogram	[6-month echocardiograms]	1.0	2	1	0	0
3686	295	incubation of EC with HDL NYHA-IIIb	[Incubation of EC with HDL NYHA-IIIb]	1.0	6	1	0	0
3687	295	relevant health service provision related	[relevant health service provision related]	1.0	5	1	0	0
3688	295	fat loss	[fat loss]	1.0	2	1	0	0
3689	295	combine parameter	[combining parameters]	1.0	2	1	0	0
3690	295	smoking cessation	[smoking cessation]	1.0	2	1	0	0
3691	295	old person	[older persons]	1.0	2	1	0	0
3692	295	patient irrespective of disease phase	[patients irrespective of disease phase]	1.0	5	1	0	0
3693	295	mortality risk	[mortality risk]	1.0	2	1	0	0
3694	295	patient receive membrane oxygenation membrane support	[patients receiving membrane oxygenation membrane support]	1.0	6	1	0	0
3695	295	less hyperkalemia	[less hyperkalemia]	1.0	2	1	0	0
3696	295	therapeutic alternative	[therapeutic alternative]	1.0	2	1	0	0
3697	295	dog with coronary microembolization-induced HF	[dogs with coronary microembolization-induced HF]	1.0	5	1	0	0
3698	295	September 2010	[September 2010]	1.0	2	1	0	0
3699	295	salt intake	[salt intake]	1.0	2	1	0	0
3700	295	akt→forkhead box class o-1 signal	[Akt→forkhead box class O-1 signaling]	1.0	5	1	0	0
3701	295	liver disease in the adult	[Liver disease in the adults]	1.0	5	1	0	0
3702	295	CHF visit rate as a percentage	[CHF visit rates as a percentage]	1.0	6	1	0	0
3703	295	virtual cohort	[virtual cohorts]	1.0	2	1	0	0
3704	295	physician continuity on death readmission	[physician continuity on death readmission]	1.0	5	1	0	0
3705	295	ten-year experience with criterion cardiac transplantation	[Ten-year experience with criteria cardiac transplantation]	1.0	6	1	0	0
3706	295	overall icu mortality median stay	[Overall ICU mortality median stay]	1.0	5	1	0	0
3707	295	left ventricular longitudinal systolic strain	[left ventricular longitudinal systolic strain]	1.0	5	2	2	2
3708	295	Internal reliability	[Internal reliability]	1.0	2	1	0	0
3709	295	sympathovagal balance	[sympathovagal balance]	1.0	2	2	1	1
3710	295	collagen cross-linking	[collagen cross-linking]	1.0	2	1	0	0
3711	295	explain variation in future mortality	[explaining variation in future mortality]	1.0	5	1	0	0
3712	295	food-frequency questionnaire	[food-frequency questionnaires]	1.0	2	1	0	0
3713	295	7 kg	[7 kg]	1.0	2	2	1	1
3714	295	right ventricular ejection fraction r=0.28 p=0.01	[right ventricular ejection fraction R=0.28 P=0.01]	1.0	6	1	0	0
3715	295	ANG ii	[ANG II]	1.0	2	2	1	1
3716	295	pathological remodelling	[pathological remodelling]	1.0	2	1	0	0
3717	295	mean duration of biventricular support	[mean duration of biventricular support]	1.0	5	1	0	0
3718	295	21 day	[21 days]	1.0	2	1	0	0
3719	295	glucose oxidation	[glucose oxidation]	1.0	2	1	0	0
3720	295	29 subject	[29 subjects]	1.0	2	1	0	0
3721	295	tachypacing-induced HF	[tachypacing-induced HF]	1.0	2	1	0	0
3722	295	5 minute	[5 minutes]	1.0	2	1	0	0
3723	295	stable phenotype	[stable phenotypes]	1.0	2	1	0	0
3724	295	promise in a pilot trial	[promise in a pilot trial]	1.0	5	1	0	0
3725	295	reversible myocardial ischemia open stent	[reversible myocardial ischemia open stent]	1.0	5	1	0	0
3726	295	direct comparison	[direct comparison]	1.0	2	1	0	0
3727	295	ED patient	[ED patients]	1.0	2	2	2	2
3728	295	patient outcome	[patient outcomes]	1.0	2	2	1	1
3729	295	heart failure a disease complex	[Heart failure a disease complex]	1.0	5	1	0	0
3730	295	normal heart	[normal hearts]	1.0	2	2	2	2
3731	295	pharmacologic treatment	[pharmacologic treatment]	1.0	2	1	0	0
3732	295	9,535 patient	[9,535 patients]	1.0	2	1	0	0
3733	295	diagnostic approach	[diagnostic approaches]	1.0	2	1	0	0
3734	295	ventricular cardiomyocyte	[ventricular cardiomyocytes]	1.0	2	1	0	0
3735	295	exercise test	[exercise test]	1.0	2	2	2	2
3736	295	infarct size	[infarct size]	1.0	2	1	0	0
3737	295	preoperative albumin	[preoperative albumin]	1.0	2	1	0	0
3738	295	4372 hospital	[4372 hospitals]	1.0	2	1	0	0
3739	295	heart of tta tgtetmena mouse	[hearts of TTA TgTetMena mice]	1.0	5	1	0	0
3740	295	herbal medicine	[herbal medicine]	1.0	2	2	2	2
3741	295	left pressure	[left pressure]	1.0	2	2	2	2
3742	295	KCl-KI treatment	[KCl-KI treatment]	1.0	2	1	0	0
3743	295	ultimately lead	[ultimately leading]	1.0	2	1	0	0
3744	295	chronic pulmonary arterial hypertension pah	[chronic pulmonary arterial hypertension PAH]	1.0	5	1	0	0
3745	295	renal disease	[renal disease]	1.0	2	2	2	2
3746	295	old adult with heart failure	[older adults with heart failure]	1.0	5	2	1	1
3747	295	self-care management	[Self-Care Management]	1.0	2	1	0	0
3748	295	SkM biopsy	[SkM biopsies]	1.0	2	1	0	0
3749	295	congestive heart failure in human	[congestive heart failure in humans]	1.0	5	1	0	0
3750	295	hemolysis event	[hemolysis events]	1.0	2	1	0	0
3751	295	304 patient	[304 patients]	1.0	2	1	0	0
3752	295	bisphosphonate user	[Bisphosphonate users]	1.0	2	1	0	0
3753	295	3-month survival	[3-month survival]	1.0	2	1	0	0
3754	295	90-day survivor	[90-day survivors]	1.0	2	1	0	0
3755	295	clinical prognostic diastolic dysfunction lead	[clinical prognostic diastolic dysfunction leading]	1.0	5	1	0	0
3756	295	study selection	[Study Selection]	1.0	2	2	1	1
3757	295	paediatric cardiac transplant in child	[paediatric cardiac transplants in children]	1.0	5	1	0	0
3758	295	120 consecutive patient with pad	[120 consecutive patients with PAD]	1.0	5	1	0	0
3759	295	improvement in the composite response	[improvement in the composite response]	1.0	5	1	0	0
3760	295	periprocedural death	[periprocedural deaths]	1.0	2	1	0	0
3761	295	HF-ACTION trial	[HF-ACTION trial]	1.0	2	1	0	0
3762	295	left ventricular assist device lvad implantation	[left ventricular assist device LVAD implantation]	1.0	6	1	0	0
3763	295	diagnostic purpose	[diagnostic purposes]	1.0	2	1	0	0
3764	295	adult with the Fontan circulation exhibit	[adults with the Fontan circulation exhibit]	1.0	6	1	0	0
3765	295	patient with pulmonary arterial hypertension	[patients with pulmonary arterial hypertension]	1.0	5	1	0	0
3766	295	pre-crt LV end-diastolic dimension index	[pre-CRT LV end-diastolic dimension index]	1.0	5	1	0	0
3767	295	peak vo2 of 0.28 millileter	[peak VO2 of 0.28 mL]	1.0	5	1	0	0
3768	295	baseline Ea	[baseline Ea]	1.0	2	1	0	0
3769	295	Impact of heart magnetic resonance imaging	[Impact of heart magnetic resonance imaging]	1.0	6	1	0	0
3770	295	low socioeconomic status versus white	[lower socioeconomic status versus whites]	1.0	5	1	0	0
3771	295	early treatment of atrial fibrillation	[Early treatment of Atrial fibrillation]	1.0	5	1	0	0
3772	295	conscious dog with tachypacing-induced HF	[conscious dogs with tachypacing-induced HF]	1.0	5	1	0	0
3773	295	modern society	[modern society]	1.0	2	1	0	0
3774	295	Intermediate frailty	[Intermediate frailty]	1.0	2	1	0	0
3775	295	molecular dysfunction	[molecular dysfunction]	1.0	2	1	0	0
3776	295	composite response	[composite response]	1.0	2	2	2	2
3777	295	30-day readmission rate for patient	[30-day readmission rate for patients]	1.0	5	1	0	0
3778	295	1:1 allocation	[1:1 allocation]	1.0	2	1	0	0
3779	295	electronic database	[electronic databases]	1.0	2	2	1	1
3780	295	recent datum	[recent data]	1.0	2	1	0	0
3781	295	systolic tethering	[systolic tethering]	1.0	2	1	0	0
3782	295	clinical usefulness	[clinical usefulness]	1.0	2	1	0	0
3783	295	150000 population	[150,000 population]	1.0	2	1	0	0
3784	295	understanding of the role of resistin	[understanding of the role of resistin]	1.0	6	1	0	0
3785	295	ED	[ED]	1.0	1	11	3	3
3786	295	median age	[median age]	1.0	2	1	0	0
3787	295	2950 patient	[2950 patients]	1.0	2	1	0	0
3788	295	resistive afterload of the heart	[resistive afterload of the heart]	1.0	5	1	0	0
3789	295	electron microscopy	[electron microscopy]	1.0	2	1	0	0
3790	295	STS intervention	[STS interventions]	1.0	2	1	0	0
3791	295	pro-b-type natriuretic peptide a biomarker approach	[pro-B-type natriuretic peptide a biomarker approach]	1.0	6	1	0	0
3792	295	569 individual	[569 individuals]	1.0	2	1	0	0
3793	295	cardiac fibrosis	[cardiac fibrosis]	1.0	2	1	0	0
3794	295	financial cost	[financial costs]	1.0	2	1	0	0
3795	295	psychosocial factor	[Psychosocial Factors]	1.0	2	2	1	1
3796	295	range from 1 in 50000	[ranging from 1 in 50,000]	1.0	5	1	0	0
3797	295	remain patient	[remaining patients]	1.0	2	1	0	0
3798	295	New York heart Association class I	[New York Heart Association class I]	1.0	6	1	0	0
3799	295	change in co. during rvpo	[changes in CO. During RVPO]	1.0	5	1	0	0
3800	295	prognosis of C 'D HF	[prognosis of C 'D HF]	1.0	5	1	0	0
3801	295	serious harm	[serious harms]	1.0	2	1	0	0
3802	295	echocardiographic measure	[echocardiographic measures]	1.0	2	2	1	1
3803	295	diastole with early transmitral flow	[diastole with early transmitral flow]	1.0	5	1	0	0
3804	295	Bioinformatic analysis of microarray datum	[Bioinformatic analysis of microarray data]	1.0	5	1	0	0
3805	295	harm such as venous thromboembolism	[harms such as venous thromboembolism]	1.0	5	1	0	0
3806	295	patient with a egfr millileter	[patients with an eGFR mL]	1.0	5	1	0	0
3807	295	level of epithelial transition marker	[level of epithelial transition markers]	1.0	5	1	0	0
3808	295	healthcare staff	[healthcare staff]	1.0	2	1	0	0
3809	295	28 consultation	[28 consultations]	1.0	2	1	0	0
3810	295	walk test	[walk test]	1.0	2	2	2	2
3811	295	control animal	[control animals]	1.0	2	2	2	2
3812	295	t1 time below the median	[T1 times below the median]	1.0	5	1	0	0
3813	295	patient with glomerular filtration rate	[patients with glomerular filtration rate]	1.0	5	1	0	0
3814	295	200 beat	[200 beats]	1.0	2	1	0	0
3815	295	trastuzumb-related CHF	[trastuzumb-related CHF]	1.0	2	1	0	0
3816	295	change in prognosis of a cohort	[changes in prognosis of a cohort]	1.0	6	1	0	0
3817	295	xo-mediated ros	[XO-mediated ROS]	1.0	2	2	1	1
3818	295	na channel mrna splice variant	[Na channel mRNA splice variants]	1.0	5	1	0	0
3819	295	secondary outcome	[secondary outcome]	1.0	2	2	2	2
3820	295	receive guideline-recommended drug for heart failure	[receiving guideline-recommended drugs for heart failure]	1.0	6	1	0	0
3821	295	adjust for over 20 clinical variable	[adjusting for over 20 clinical variables]	1.0	6	1	0	0
3822	295	heart failure Assessment of reduction	[Heart Failure Assessment of Reduction]	1.0	5	1	0	0
3823	295	Eplerenone in mild patient hospitalization	[Eplerenone in Mild Patients Hospitalization]	1.0	5	1	0	0
3824	295	total cholesterol	[total cholesterol]	1.0	2	1	0	0
3825	295	grade evidence	[Grade evidence]	1.0	2	2	2	2
3826	295	average age	[average age]	1.0	2	2	2	2
3827	295	health system	[health system]	1.0	2	2	2	2
3828	295	patient-level regression	[patient-level regression]	1.0	2	1	0	0
3829	295	risk avoidance	[risk avoidance]	1.0	2	1	0	0
3830	295	human monocyte	[human monocytes]	1.0	2	1	0	0
3831	295	Canadian datum	[Canadian data]	1.0	2	1	0	0
3832	295	annual ed	[annual ED]	1.0	2	1	0	0
3833	295	67 year	[67 years]	1.0	2	1	0	0
3834	295	chf-derived c-kit	[CHF-derived c-Kit]	1.0	2	1	0	0
3835	295	systolic volume	[systolic volume]	1.0	2	1	0	0
3836	295	proteomic remodeling	[proteomic remodeling]	1.0	2	1	0	0
3837	295	trigger for excitation-contraction ec coupling	[trigger for excitation-contraction EC coupling]	1.0	5	1	0	0
3838	295	implementation strategy improve physician adherence	[implementation strategies improving physician adherence]	1.0	5	1	0	0
3839	295	stent respectively	[stenting respectively]	1.0	2	1	0	0
3840	295	implantation with Cardiac resynchronization therapy	[Implantation With Cardiac Resynchronization Therapy]	1.0	5	1	0	0
3841	295	group with particularly high mortality	[group with particularly high mortality]	1.0	5	1	0	0
3842	295	61.6 millileter	[61.6 mL]	1.0	2	1	0	0
3843	295	CHF n=68	[CHF n=68]	1.0	2	1	0	0
3844	295	energy expenditure	[energy expenditure]	1.0	2	1	0	0
3845	295	hemoglobin hgb with hrqol change	[hemoglobin Hgb with HRQoL changes]	1.0	5	1	0	0
3846	295	common deg	[common DEGs]	1.0	2	1	0	0
3847	295	HF care	[HF care]	1.0	2	1	0	0
3848	295	same number	[same number]	1.0	2	1	0	0
3849	295	impact on embryonic gene program	[impact on embryonic gene programs]	1.0	5	1	0	0
3850	295	additional benefit in the prediction	[additional benefit in the prediction]	1.0	5	1	0	0
3851	295	ED use	[ED use]	1.0	2	1	0	0
3852	295	annulus velocity	[annulus velocity]	1.0	2	2	2	2
3853	295	current measurement	[current measurements]	1.0	2	1	0	0
3854	295	family of acetyl-lysine reader protein	[family of acetyl-lysine reader proteins]	1.0	5	1	0	0
3855	295	inflammatory biomarker	[inflammatory biomarkers]	1.0	2	2	2	2
3856	295	epigenetic change in chromatin structure	[epigenetic changes in chromatin structure]	1.0	5	1	0	0
3857	295	67.2 year	[67.2 years]	1.0	2	1	0	0
3858	295	LV fill	[LV filling]	1.0	2	2	2	2
3859	295	predict survival	[predicting survival]	1.0	2	2	2	2
3860	295	evaluation of the muscular strength	[evaluation of the muscular strength]	1.0	5	1	0	0
3861	295	74 year	[74 years]	1.0	2	1	0	0
3862	295	disease-specific cost	[disease-specific costs]	1.0	2	1	0	0
3863	295	patient with end stage heart failure	[Patients with end stage heart failure]	1.0	6	1	0	0
3864	295	sex-specific model	[sex-specific model]	1.0	2	2	2	2
3865	295	clinical deterioration	[clinical deterioration]	1.0	2	2	1	1
3866	295	large trial	[large trial]	1.0	2	2	1	1
3867	295	previous spironolactone use from 2006	[previous spironolactone use from 2006]	1.0	5	1	0	0
3868	295	inflammation intervention	[inflammation interventions]	1.0	2	1	0	0
3869	295	preliminary datum for key health outcome	[preliminary data for key health outcomes]	1.0	6	1	0	0
3870	295	cα thr197	[Cα Thr197]	1.0	2	1	0	0
3871	295	evidence-based medication	[evidence-based medications]	1.0	2	1	0	0
3872	295	particularly between a large low-risk group	[particularly between a large low-risk group]	1.0	6	1	0	0
3873	295	major branch	[major branches]	1.0	2	1	0	0
3874	295	objective of this clinical trial	[objective of this clinical trial]	1.0	5	1	0	0
3875	295	tissue doppler	[tissue Doppler]	1.0	2	2	1	1
3876	295	PD on clinical status hospitalization	[PD on clinical status hospitalizations]	1.0	5	1	0	0
3877	295	risk for subsequent heart failure	[risk for subsequent heart failure]	1.0	5	1	0	0
3878	295	kappa coefficient	[kappa coefficient]	1.0	2	2	1	1
3879	295	use time-dependent Cox regression analysis	[Using time-dependent Cox regression analysis]	1.0	5	1	0	0
3880	295	p respectively	[P respectively]	1.0	2	1	0	0
3881	295	anaerobic threshold	[anaerobic threshold]	1.0	2	2	2	2
3882	295	cardiac tone	[cardiac tone]	1.0	2	2	2	2
3883	295	present report	[present report]	1.0	2	1	0	0
3884	295	intravenous metoprolol	[intravenous metoprolol]	1.0	2	1	0	0
3885	295	pediatric cohort	[pediatric cohort]	1.0	2	1	0	0
3886	295	protein content for SR can 2+)-pump	[protein content for SR Ca 2+)-pump]	1.0	6	1	0	0
3887	295	significant alteration in energy metabolism	[significant alterations in energy metabolism]	1.0	5	1	0	0
3888	295	patient with a filtration rate	[patients with an filtration rate]	1.0	5	1	0	0
3889	295	Baroreflex sensitivity	[Baroreflex sensitivity]	1.0	2	1	0	0
3890	295	natural vasodilatory	[natural vasodilatory]	1.0	2	1	0	0
3891	295	cardiovascular health	[cardiovascular health]	1.0	2	2	1	1
3892	295	patient with congestive heart failure	[patients with congestive heart failure]	1.0	5	2	1	1
3893	295	pathological change	[pathological changes]	1.0	2	2	2	2
3894	295	rhythm	[rhythm]	1.0	1	12	8	4
3895	295	irs1 protein	[IRS1 proteins]	1.0	2	1	0	0
3896	295	most country	[most countries]	1.0	2	1	0	0
3897	295	118.5 minute	[118.5 minutes]	1.0	2	1	0	0
3898	295	pathophysiological origin	[pathophysiological origin]	1.0	2	1	0	0
3899	295	notable example	[notable example]	1.0	2	1	0	0
3900	295	impaired function	[impaired function]	1.0	2	1	0	0
3901	295	change in platelet-activating factor paf	[changes in platelet-activating factor PAF]	1.0	5	1	0	0
3902	295	abnormal can	[abnormal Ca]	1.0	2	1	0	0
3903	295	kidney infection	[kidney infection]	1.0	2	2	1	1
3904	295	5 year	[5 years]	1.0	2	1	0	0
3905	295	recent study	[recent studies]	1.0	2	2	1	1
3906	295	encode a decoy vegf receptor ad-flk	[encoding a decoy VEGF receptor Ad-Flk]	1.0	6	1	0	0
3907	295	use a quality improvement database	[Using a quality improvement database]	1.0	5	1	0	0
3908	295	pro-adrenomedullin mr-proadm	[pro-adrenomedullin MR-proADM]	1.0	2	1	0	0
3909	295	subsequent meta-analy	[subsequent meta-analyses]	1.0	2	1	0	0
3910	295	short-term outcome	[short-term outcomes]	1.0	2	1	0	0
3911	295	rate of treatment for outpatient	[rates of treatment for outpatients]	1.0	5	1	0	0
3912	295	outpatient setting	[outpatient setting]	1.0	2	1	0	0
3913	295	patient in the ECMO group	[patients in the ECMO group]	1.0	5	2	1	1
3914	295	early research	[early research]	1.0	2	1	0	0
3915	295	principal finding	[PRINCIPAL FINDINGS]	1.0	2	1	0	0
3916	295	50 day	[50 days]	1.0	2	1	0	0
3917	295	various measure	[Various measures]	1.0	2	2	1	1
3918	295	mitochondrial-targeted antioxidant	[mitochondrial-targeted antioxidant]	1.0	2	1	0	0
3919	295	well-treated cohort	[well-treated cohort]	1.0	2	1	0	0
3920	295	40 year	[40 years]	1.0	2	1	0	0
3921	295	muscle-wasting syndrome	[muscle-wasting syndrome]	1.0	2	1	0	0
3922	295	ED physician	[ED physicians]	1.0	2	1	0	0
3923	295	human model	[human models]	1.0	2	1	0	0
3924	295	cardiovascular reason	[cardiovascular reason]	1.0	2	1	0	0
3925	295	patient receive angiotensin-converting enzyme inhibitor	[patients receiving angiotensin-converting enzyme inhibitors]	1.0	5	1	0	0
3926	295	two type of heart failure	[two types of heart failure]	1.0	5	1	0	0
3927	295	many advance	[Many advances]	1.0	2	1	0	0
3928	295	pathological remodelling of the heart	[pathological remodelling of the heart]	1.0	5	1	0	0
3929	295	Kansas City Cardiomyopathy questionnaire summary	[Kansas City Cardiomyopathy Questionnaire summary]	1.0	5	1	0	0
3930	295	64.26 year versus 72.83 year	[64.26 years vs 72.83 years]	1.0	5	1	0	0
3931	295	result from the 1:1 propensity analysis	[Results from the 1:1 propensity analyses]	1.0	6	1	0	0
3932	295	coronary disease	[coronary disease]	1.0	2	2	1	1
3933	295	90 day of the index	[90 days of the index]	1.0	5	1	0	0
3934	295	VAD group	[VAD group]	1.0	2	2	1	1
3935	295	sequence-specific binding	[sequence-specific binding]	1.0	2	1	0	0
3936	295	intubation for congestive heart failure	[intubations for congestive heart failure]	1.0	5	1	0	0
3937	295	cardiac apoptosis	[cardiac apoptosis]	1.0	2	1	0	0
3938	295	repolarization lability	[repolarization lability]	1.0	2	1	0	0
3939	295	large phase	[large phase]	1.0	2	1	0	0
3940	295	use International Classification of Disease	[using International Classification of Diseases]	1.0	5	1	0	0
3941	295	most country include the State	[most countries including the States]	1.0	5	1	0	0
3942	295	current study	[current study]	1.0	2	1	0	0
3943	295	cardiopulmonary exercise testing guide exercise rehabilitation	[cardiopulmonary exercise testing guide exercise rehabilitation]	1.0	6	1	0	0
3944	295	ED patient with heart failure	[ED patients with heart failure]	1.0	5	1	0	0
3945	295	clear lesion	[clear lesion]	1.0	2	2	2	2
3946	295	stable hfpef	[stable HFPEF]	1.0	2	2	2	2
3947	295	4.5 cm	[4.5 cm]	1.0	2	1	0	0
3948	295	EMPHASIS-HF Study	[EMPHASIS-HF Study]	1.0	2	1	0	0
3949	295	saxagliptin versus pioglitazone for saxagliptin	[saxagliptin versus pioglitazone for saxagliptin]	1.0	5	1	0	0
3950	295	wild-type Rad	[wild-type Rad]	1.0	2	1	0	0
3951	295	use neonatal rat ventricular cardiomyocyte	[Using neonatal rat ventricular cardiomyocytes]	1.0	5	1	0	0
3952	295	low-volume hospital	[low-volume hospitals]	1.0	2	1	0	0
3953	295	gender-matched control	[gender-matched control]	1.0	2	1	0	0
3954	295	describe trend in HF after MI	[describing trends in HF after MI]	1.0	6	1	0	0
3955	295	peak quotient	[peak quotient]	1.0	2	1	0	0
3956	295	originally part of this study	[originally part of this study]	1.0	5	1	0	0
3957	295	patient with HF with ejection fraction	[patients with HF with ejection fraction]	1.0	6	1	0	0
3958	295	receive chemotherapy	[receiving chemotherapy]	1.0	2	1	0	0
3959	295	examine long outcome with this strategy	[examining long-term outcomes with this strategy]	1.0	6	1	0	0
3960	295	same period	[same period]	1.0	2	1	0	0
3961	295	obese old patient with hfpef	[obese older patients with HFPEF]	1.0	5	2	1	1
3962	295	outcome assessment	[outcome assessments]	1.0	2	1	0	0
3963	295	ultimately target specific effector molecule	[ultimately targeting specific effector molecules]	1.0	5	1	0	0
3964	295	liver texture	[liver texture]	1.0	2	1	0	0
3965	295	noncardiologist physician	[noncardiologist physicians]	1.0	2	1	0	0
3966	295	single parameter	[single parameters]	1.0	2	1	0	0
3967	295	high expenditure	[higher expenditures]	1.0	2	1	0	0
3968	295	follow	[follow]	1.0	1	11	3	3
3969	295	individualized assessment	[individualized assessment]	1.0	2	1	0	0
3970	295	TUG test	[TUG test]	1.0	2	1	0	0
3971	295	previous study investigate hf-related cachexia	[Previous studies investigating HF-related cachexia]	1.0	5	1	0	0
3972	295	538 protein	[538 proteins]	1.0	2	1	0	0
3973	295	4.6 mm	[4.6 mm]	1.0	2	1	0	0
3974	295	new understanding of the structure	[new understanding of the structure]	1.0	5	1	0	0
3975	295	open stent	[open stent]	1.0	2	1	0	0
3976	295	2 year	[2 years]	1.0	2	1	0	0
3977	295	use CardioPulmonary Exercise test CPET guide	[using CardioPulmonary Exercise Testing CPET guide]	1.0	6	1	0	0
3978	295	end-systolic elastance	[end-systolic elastance]	1.0	2	2	1	1
3979	295	7.1 year	[7.1 years]	1.0	2	1	0	0
3980	295	left-to-right interatrial	[left-to-right interatrial]	1.0	2	1	0	0
3981	295	transplant pool	[transplant pool]	1.0	2	1	0	0
3982	295	compare b-treated with drug-untreated fail heart	[comparing B-treated with drug-untreated failing hearts]	1.0	6	1	0	0
3983	295	different mechanism	[different mechanism]	1.0	2	2	1	1
3984	295	variation in AMI mortality rate	[variation in AMI mortality rates]	1.0	5	1	0	0
3985	295	cardiac-resynchronization therapy	[Cardiac-resynchronization therapy]	1.0	2	2	2	2
3986	295	vad support	[VAD support]	1.0	2	1	0	0
3987	295	association between preoperative renal dysfunction	[association between preoperative renal dysfunction]	1.0	5	1	0	0
3988	295	beyond meeting	[beyond meeting]	1.0	2	1	0	0
3989	295	murine myocardium	[murine myocardium]	1.0	2	1	0	0
3990	295	system proteomics of cardiac chromatin	[Systems proteomics of cardiac chromatin]	1.0	5	1	0	0
3991	295	noncardiovascular drug in the rate-control group	[noncardiovascular drugs in the rate-control group]	1.0	6	1	0	0
3992	295	beneficial adaptation	[beneficial adaptation]	1.0	2	1	0	0
3993	295	ischemic regurgitation	[ischemic regurgitation]	1.0	2	2	2	2
3994	295	TUNEL method from autopsy sample	[TUNEL method from autopsy samples]	1.0	5	1	0	0
3995	295	life expectancy	[life expectancy]	1.0	2	2	1	1
3996	295	catheter-based revascularization	[catheter-based revascularization]	1.0	2	1	0	0
3997	295	advantage of the period of fibrillation	[advantage of the period of fibrillation]	1.0	6	1	0	0
3998	295	prevention of HF in LA	[prevention of HF in LA]	1.0	5	1	0	0
3999	295	presence of diastolic dysfunction in patient	[Presence of diastolic dysfunction in patients]	1.0	6	1	0	0
4000	295	relationship between right ventricular function	[Relationships between right ventricular function]	1.0	5	1	0	0
4001	295	hypotension however without a need	[hypotension however without a need]	1.0	5	1	0	0
4002	295	low gross national income per capita	[lower gross national income per capita]	1.0	6	1	0	0
4003	295	hfpef ef≥50	[HFpEF EF≥50]	1.0	2	1	0	0
4004	295	target individual with congestive heart failure	[targeting individuals with congestive heart failure]	1.0	6	1	0	0
4005	295	emotional status	[emotional status]	1.0	2	1	0	0
4006	295	quality-adjusted survival	[quality-adjusted survival]	1.0	2	1	0	0
4007	295	high-risk patient	[high-risk patient]	1.0	2	2	2	2
4008	295	noninvasive assessment include stress echocardiography	[noninvasive assessments including stress echocardiography]	1.0	5	1	0	0
4009	295	3 electrocardiographer	[3 electrocardiographers]	1.0	2	1	0	0
4010	295	mt group	[MT group]	1.0	2	2	1	1
4011	295	patient with coronary heart disease	[patients with coronary heart disease]	1.0	5	1	0	0
4012	295	significant progress	[Significant progress]	1.0	2	1	0	0
4013	295	residual confounding	[Residual confounding]	1.0	2	1	0	0
4014	295	similar incidence in vad group	[similar incidence in VAD groups]	1.0	5	1	0	0
4015	295	investigate Outcome of Exercise Training HF-ACTION	[Investigating Outcomes of Exercise Training HF-ACTION]	1.0	6	2	1	1
4016	295	study short-form	[Study Short-Form]	1.0	2	1	0	0
4017	295	guideline-recommended target dose for beta-blocker therapy	[guideline-recommended target doses for beta-blocker therapy]	1.0	6	1	0	0
4018	295	blood transfusion	[blood transfusions]	1.0	2	2	1	1
4019	295	diastolic end	[diastolic end]	1.0	2	2	1	1
4020	295	third trial	[third trial]	1.0	2	1	0	0
4021	295	case-fatality rate	[case-fatality rate]	1.0	2	1	0	0
4022	295	few cardiac procedure 146 vs. 238	[fewer cardiac procedures 146 vs. 238]	1.0	6	1	0	0
4023	295	low BP	[low BP]	1.0	2	1	0	0
4024	295	multicenter defibrillator	[Multicenter Defibrillator]	1.0	2	2	1	1
4025	295	therapeutic function	[therapeutic functions]	1.0	2	1	0	0
4026	295	Cardiovascular event	[Cardiovascular events]	1.0	2	1	0	0
4027	295	exercise rehabilitation in male patient	[exercise rehabilitation in male patients]	1.0	5	1	0	0
4028	295	Transoesophageal echocardiography at 1 month	[Transoesophageal echocardiography at 1 month]	1.0	5	1	0	0
4029	295	use multivariate logistic regression analysis	[Using multivariate logistic regression analysis]	1.0	5	1	0	0
4030	295	endothelial repair	[endothelial repair]	1.0	2	1	0	0
4031	295	left ventricular ejection fraction 0.35	[left ventricular ejection fraction 0.35]	1.0	5	1	0	0
4032	295	compete priority	[competing priorities]	1.0	2	1	0	0
4033	295	Czech Republic	[Czech Republic]	1.0	2	1	0	0
4034	295	cardiac biomarker	[cardiac biomarkers]	1.0	2	2	2	2
4035	295	2 practice	[2 practices]	1.0	2	1	0	0
4036	295	risk factor for poor outcome	[risk factor for poor outcomes]	1.0	5	1	0	0
4037	295	3-min record of surface ecg	[3-min records of surface ECGs]	1.0	5	1	0	0
4038	295	unplanned readmission	[unplanned readmission]	1.0	2	1	0	0
4039	295	2 diabete	[2 diabetes]	1.0	2	2	1	1
4040	295	30 percent	[30 percent]	1.0	2	1	0	0
4041	295	Exercise attendance	[Exercise attendance]	1.0	2	1	0	0
4042	295	expression mistarget	[expression mistargeting]	1.0	2	1	0	0
4043	295	inactive cxl-1051	[inactive CXL-1051]	1.0	2	1	0	0
4044	295	odd of future July 30-day	[odds of future July 30-day]	1.0	5	1	0	0
4045	295	6 wk	[6 wk]	1.0	2	2	2	2
4046	295	right myxoma	[Right myxoma]	1.0	2	2	1	1
4047	295	tendency toward e wave ratio	[tendency toward E wave ratio]	1.0	5	1	0	0
4048	295	upr effector	[UPR effectors]	1.0	2	1	0	0
4049	295	rest hr 70 versus ≥70	[resting HR 70 versus ≥70]	1.0	5	1	0	0
4050	295	driveline infection	[driveline infection]	1.0	2	1	0	0
4051	295	Recent evidence	[Recent evidence]	1.0	2	1	0	0
4052	295	8 week	[8 weeks]	1.0	2	1	0	0
4053	295	measurable benefit	[measurable benefits]	1.0	2	1	0	0
4054	295	early-onset HF for late-onset HF	[early-onset HF for late-onset HF]	1.0	5	1	0	0
4055	295	receive extracorporeal membrane oxygenation membrane support	[receiving extracorporeal membrane oxygenation membrane support]	1.0	6	1	0	0
4056	295	Preliminary report	[Preliminary report]	1.0	2	1	0	0
4057	295	2-way ANOVA	[2-way ANOVA]	1.0	2	1	0	0
4058	295	pulmonary congestion	[pulmonary congestion]	1.0	2	1	0	0
4059	295	treatment group effect on HRQoL	[Treatment group effects on HRQoL]	1.0	5	1	0	0
4060	295	16 mm	[16 mm]	1.0	2	1	0	0
4061	295	undergo left assist device implantation	[undergoing left assist device implantation]	1.0	5	2	2	2
4062	295	have the HF risk factor	[having the HF risk factors]	1.0	5	1	0	0
4063	295	intestinal barrier	[intestinal barrier]	1.0	2	1	0	0
4064	295	advanced phase of the disease	[advanced phase of the disease]	1.0	5	1	0	0
4065	295	mitochondrial respiration	[mitochondrial respiration]	1.0	2	1	0	0
4066	295	pb cycle	[PB cycle]	1.0	2	1	0	0
4067	295	first research	[first research]	1.0	2	1	0	0
4068	295	use the extracellular flux analyzer	[using the extracellular flux analyzer]	1.0	5	1	0	0
4069	295	angiotensin ii receptor blocker use	[angiotensin II receptor blocker use]	1.0	5	1	0	0
4070	295	determination of a predictive cutoff value	[Determination of a predictive cutoff value]	1.0	6	1	0	0
4071	295	10-eo-cfu increase	[10-EO-CFU increase]	1.0	2	1	0	0
4072	295	receive metoprolol	[receiving metoprolol]	1.0	2	1	0	0
4073	295	hemoglobin level	[hemoglobin levels]	1.0	2	2	1	1
4074	295	liver-specific irs1	[liver-specific IRS1]	1.0	2	1	0	0
4075	295	composite end-point	[composite end-point]	1.0	2	1	0	0
4076	295	therapy of underlying heart disease	[therapy of underlying heart disease]	1.0	5	1	0	0
4077	295	ventricular-arterial coupling in hypertensive hfpef	[ventricular-arterial coupling in hypertensive HFPEF]	1.0	5	1	0	0
4078	295	eighty-one percent of 7-day visit	[Eighty-one percent of 7-day visits]	1.0	5	1	0	0
4079	295	115 center	[115 centers]	1.0	2	1	0	0
4080	295	uncontrolled hypertension	[uncontrolled hypertension]	1.0	2	2	1	1
4081	295	change in nyha functional class	[changes in NYHA functional class]	1.0	5	1	0	0
4082	295	undergo ventricular assist device implantation	[undergoing ventricular assist device implantation]	1.0	5	2	2	2
4083	295	current smoking	[current smoking]	1.0	2	1	0	0
4084	295	peak oxygen Consumption in patient	[Peak Oxygen Consumption in Patients]	1.0	5	1	0	0
4085	295	2825 participant aged 70 year	[2825 participants aged 70 years]	1.0	5	1	0	0
4086	295	30 day of acs consultation	[30 days of ACS consultation]	1.0	5	1	0	0
4087	295	severe hyperkalemia	[severe hyperkalemia]	1.0	2	2	1	1
4088	295	chronic hfpef	[chronic HFPEF]	1.0	2	2	1	1
4089	295	SkM growth consistent with regeneration	[SkM growth consistent with regeneration]	1.0	5	1	0	0
4090	295	80 participation	[80 participation]	1.0	2	1	0	0
4091	295	three day	[three days]	1.0	2	1	0	0
4092	295	vasopeptidase inhibitor	[vasopeptidase inhibitors]	1.0	2	1	0	0
4093	295	metabolic exercise	[metabolic exercise]	1.0	2	2	1	1
4094	295	two network	[Two networks]	1.0	2	1	0	0
4095	295	LV end-diastolic volume LV end-systolic volume	[LV end-diastolic volume LV end-systolic volume]	1.0	6	1	0	0
4096	295	aggressive medical treatment for HF	[aggressive medical treatment for HF]	1.0	5	2	1	1
4097	295	severe mr	[severe MR]	1.0	2	1	0	0
4098	295	cardiac washout	[cardiac washout]	1.0	2	1	0	0
4099	295	electromechanical delay	[electromechanical delay]	1.0	2	2	2	2
4100	295	MLHF Questionnaire	[MLHF Questionnaire]	1.0	2	1	0	0
4101	295	coronary artery bypass grafting CABG	[coronary artery bypass grafting CABG]	1.0	5	1	0	0
4102	295	cost-effectiveness of disease management program	[cost-effectiveness of disease management programs]	1.0	5	1	0	0
4103	295	multiple cardiac gene in HF	[multiple cardiac genes in HF]	1.0	5	1	0	0
4104	295	general anaesthesia	[general anaesthesia]	1.0	2	1	0	0
4105	295	remain in extreme decile of agreement	[remaining in extreme deciles of agreement]	1.0	6	1	0	0
4106	295	global longitudinal strain of left ventricle	[global longitudinal strain of left ventricle]	1.0	6	1	0	0
4107	295	perk activation	[PERK activation]	1.0	2	1	0	0
4108	295	further validation in large study	[further validation in larger studies]	1.0	5	1	0	0
4109	295	4.6 year	[4.6 years]	1.0	2	1	0	0
4110	295	HF risk prediction atherosclerosis risk	[HF risk prediction Atherosclerosis Risk]	1.0	5	1	0	0
4111	295	post-translational modification of pka subunit	[post-translational modification of PKA subunits]	1.0	5	1	0	0
4112	295	sex difference in BNP value	[sex differences in BNP values]	1.0	5	1	0	0
4113	295	diuretic HF	[diuretic HF]	1.0	2	1	0	0
4114	295	absolute risk of heart failure	[absolute risk of heart failure]	1.0	5	1	0	0
4115	295	little impact on gross morphological development	[little impact on gross morphological development]	1.0	6	1	0	0
4116	295	Joanna Briggs Institute Evidence Practice	[Joanna Briggs Institute Evidence Practice]	1.0	5	1	0	0
4117	295	First-in-class angiotensin receptor neprilysin inhibitor	[First-in-class angiotensin receptor neprilysin inhibitor]	1.0	5	1	0	0
4118	295	temporal incidence	[temporal incidence]	1.0	2	1	0	0
4119	295	long prognosis	[long-term prognosis]	1.0	2	1	0	0
4120	295	additional risk	[additional risk]	1.0	2	1	0	0
4121	295	beta-blocker therapy in chronic heart failure	[beta-blocker therapy in chronic heart failure]	1.0	6	1	0	0
4122	295	haemodynamic abnormality	[haemodynamic abnormalities]	1.0	2	1	0	0
4123	295	technical advisor	[technical advisors]	1.0	2	1	0	0
4124	295	restoration of high-density lipoprotein functional property	[restoration of high-density lipoprotein functional properties]	1.0	6	1	0	0
4125	295	inhibition of apoptotic signal pathway	[inhibition of apoptotic signaling pathway]	1.0	5	1	0	0
4126	295	Catheter-based percutaneous revascularization with angioplasty	[Catheter-based percutaneous revascularization with angioplasty]	1.0	5	1	0	0
4127	295	mir-25 by a specific antagomir	[miR-25 by a specific antagomir]	1.0	5	1	0	0
4128	295	1.2 millileter	[1.2 mL]	1.0	2	1	0	0
4129	295	impaired cardiac metabolic gene expression	[impaired cardiac metabolic gene expression]	1.0	5	1	0	0
4130	295	renin-angiotensin system	[renin-angiotensin system]	1.0	2	2	2	2
4131	295	induction of scn5a variant with angii	[Induction of SCN5A variants with AngII]	1.0	6	1	0	0
4132	295	severe ai	[severe AI]	1.0	2	2	2	2
4133	295	value of standard error of measurement	[Values of standard error of measurement]	1.0	6	1	0	0
4134	295	novel heart failure mouse model	[novel heart failure mice model]	1.0	5	1	0	0
4135	295	rate-control patient	[Rate-control patients]	1.0	2	1	0	0
4136	295	magnetic resonance postcontrast t1 time	[magnetic resonance postcontrast T1 time]	1.0	5	2	2	2
4137	295	rheumatoid arthritis	[rheumatoid arthritis]	1.0	2	2	1	1
4138	295	15-mL decrease	[15-mL decrease]	1.0	2	1	0	0
4139	295	uptake of Practice Guideline recommendation	[uptake of Practice Guideline recommendations]	1.0	5	1	0	0
4140	295	patient with type 2 diabete	[patients with type 2 diabetes]	1.0	5	1	0	0
4141	295	100 pg low bnp group	[100 pg low BNP group]	1.0	5	1	0	0
4142	295	cardiovascular morbidity	[cardiovascular morbidity]	1.0	2	1	0	0
4143	295	study site	[study sites]	1.0	2	1	0	0
4144	295	mouse heart failure HF model	[mouse heart failure HF model]	1.0	5	1	0	0
4145	295	standard practice	[standard practice]	1.0	2	2	2	2
4146	295	other outcome	[other outcomes]	1.0	2	2	2	2
4147	295	71.1 year	[71.1 years]	1.0	2	1	0	0
4148	295	parasympathetic function	[parasympathetic function]	1.0	2	1	0	0
4149	295	37 patient in the ECMO group	[37 patients in the ECMO group]	1.0	6	1	0	0
4150	295	comprehensive echocardiography	[comprehensive echocardiography]	1.0	2	1	0	0
4151	295	emotional stress	[emotional stress]	1.0	2	1	0	0
4152	295	psoriasis patient with predominantly mild disease	[Psoriasis patients with predominantly mild disease]	1.0	6	1	0	0
4153	295	p .001	[P .001]	1.0	2	2	1	1
4154	295	cardiac fill	[cardiac filling]	1.0	2	2	1	1
4155	295	effect on heart rate hr	[effect on heart rate HR]	1.0	5	1	0	0
4156	295	similar improvement in shuttle walk test	[Similar improvements in shuttle walk test]	1.0	6	1	0	0
4157	295	effectiveness of bisoprolol reduce mortality	[effectiveness of bisoprolol reducing mortality]	1.0	5	1	0	0
4158	295	clinical outcome in patient with HFrEF	[clinical outcome in patients with HFrEF]	1.0	6	1	0	0
4159	295	scaffold protein	[scaffold protein]	1.0	2	1	0	0
4160	295	grow population within cardiac rehabilitation	[growing population within cardiac rehabilitation]	1.0	5	1	0	0
4161	295	patient participate	[patients participating]	1.0	2	1	0	0
4162	295	lvad surgery	[LVAD surgery]	1.0	2	2	1	1
4163	295	59.4 m	[59.4 m]	1.0	2	1	0	0
4164	295	cardiac insulin-resistance	[cardiac insulin-resistance]	1.0	2	2	1	1
4165	295	mild reduction in lvef respectively	[mild reductions in LVEF respectively]	1.0	5	1	0	0
4166	295	patient with right heart failure	[patients with right heart failure]	1.0	5	1	0	0
4167	295	particularly in patient with systolic dysfunction	[particularly in patients with systolic dysfunction]	1.0	6	1	0	0
4168	295	left remodeling in heart failure	[left remodeling in heart failure]	1.0	5	1	0	0
4169	295	intervention compliance	[intervention compliance]	1.0	2	1	0	0
4170	295	inverse association	[inverse association]	1.0	2	1	0	0
4171	295	Ethics Round	[Ethics Rounds]	1.0	2	1	0	0
4172	295	hdl-induced no production by EC	[HDL-induced NO production by EC]	1.0	5	1	0	0
4173	295	Southeastern Minnesota resident with HF	[Southeastern Minnesota residents with HF]	1.0	5	1	0	0
4174	295	National Inpatient	[National Inpatient]	1.0	2	1	0	0
4175	295	CRF category	[CRF categories]	1.0	2	2	2	2
4176	295	evidence gap	[evidence gaps]	1.0	2	1	0	0
4177	295	hfvt(-) group	[HFVT(-) groups]	1.0	2	1	0	0
4178	295	732 pg	[732 pg]	1.0	2	1	0	0
4179	295	hfpef α=0.96	[HFpEF α=0.96]	1.0	2	1	0	0
4180	295	Ischemic cardiomyopathy	[Ischemic cardiomyopathy]	1.0	2	1	0	0
4181	295	spontaneous VT	[spontaneous VT]	1.0	2	2	1	1
4182	295	mitochondrial structure	[mitochondrial structure]	1.0	2	1	0	0
4183	295	conjoint education	[conjoint education]	1.0	2	1	0	0
4184	295	literature search in the database	[literature search in the databases]	1.0	5	1	0	0
4185	295	cardiac irs1	[cardiac IRS1]	1.0	2	1	0	0
4186	295	first week	[first week]	1.0	2	1	0	0
4187	295	hypertrophic response	[hypertrophic response]	1.0	2	2	2	2
4188	295	General hospital	[General hospital]	1.0	2	1	0	0
4189	295	non-fatal stroke	[non-fatal stroke]	1.0	2	2	1	1
4190	295	contractility of the left ventricle	[contractility of the left ventricle]	1.0	5	1	0	0
4191	295	66 millileter	[66 mL]	1.0	2	1	0	0
4192	295	oral glucocorticoid	[Oral glucocorticoids]	1.0	2	1	0	0
4193	295	pump replacement	[pump replacement]	1.0	2	2	1	1
4194	295	perk inhibition	[PERK inhibition]	1.0	2	1	0	0
4195	295	induction of a fetal gene program	[induction of a fetal gene program]	1.0	6	1	0	0
4196	295	three variant consistent with report	[three variants consistent with reports]	1.0	5	1	0	0
4197	295	fes group	[FES group]	1.0	2	1	0	0
4198	295	three year	[three years]	1.0	2	1	0	0
4199	295	sex difference	[sex differences]	1.0	2	2	1	1
4200	295	additional study	[additional studies]	1.0	2	2	1	1
4201	295	means of stress doppler echocardiography	[means of stress Doppler echocardiography]	1.0	5	1	0	0
4202	295	male patient with heart failure	[male patients with heart failure]	1.0	5	2	2	2
4203	295	American heart Association guideline on evaluation	[American Heart Association guidelines on evaluation]	1.0	6	1	0	0
4204	295	haemodynamic stress	[haemodynamic stress]	1.0	2	1	0	0
4205	295	outcome in a well-treated cohort	[outcomes in a well-treated cohort]	1.0	5	1	0	0
4206	295	further examination	[further examination]	1.0	2	1	0	0
4207	295	such as short-term fractal scaling exponent	[such as short-term fractal scaling exponent]	1.0	6	1	0	0
4208	295	normal body mass index category	[normal body mass index categories]	1.0	5	1	0	0
4209	295	heart muscle	[heart muscle]	1.0	2	1	0	0
4210	295	right ventricular fractional area change	[right ventricular fractional area change]	1.0	5	1	0	0
4211	295	important tool in the diagnosis	[important tool in the diagnosis]	1.0	5	1	0	0
4212	295	71 year	[71 years]	1.0	2	1	0	0
4213	295	usually the result of congenital lesion	[usually the result of congenital lesions]	1.0	6	1	0	0
4214	295	population characteristic	[population characteristics]	1.0	2	1	0	0
4215	295	continuous nris	[continuous NRIs]	1.0	2	1	0	0
4216	295	23.7 ng interquartile range 18.6	[23.7 ng interquartile range 18.6]	1.0	5	1	0	0
4217	295	aldosterone blockade	[aldosterone blockade]	1.0	2	1	0	0
4218	295	clinician expertise	[clinician expertise]	1.0	2	1	0	0
4219	295	molecular pathway	[molecular pathways]	1.0	2	2	1	1
4220	295	change in the case mix	[change in the case mix]	1.0	5	1	0	0
4221	295	prognostic assessment	[prognostic assessment]	1.0	2	1	0	0
4222	295	care outcome	[care outcomes]	1.0	2	1	0	0
4223	295	broad panel of noninvasive assessment	[broad panel of noninvasive assessments]	1.0	5	1	0	0
4224	295	use a arbitrary start date	[using an arbitrary start date]	1.0	5	1	0	0
4225	295	results—retrospective cohort of all adult	[Results—Retrospective cohort of all adults]	1.0	5	1	0	0
4226	295	inappropriate atp	[inappropriate ATP]	1.0	2	2	1	1
4227	295	heart failure with inhospital outcome	[heart failure with inhospital outcomes]	1.0	5	1	0	0
4228	295	renin-angiotensin-aldosterone system	[renin-angiotensin-aldosterone system]	1.0	2	2	2	2
4229	295	independent prognostic role in HF	[independent prognostic role in HF]	1.0	5	1	0	0
4230	295	increase rate	[increase rate]	1.0	2	1	0	0
4231	295	Campbell Collaboration	[Campbell Collaboration]	1.0	2	1	0	0
4232	295	patient HDL	[patients HDL]	1.0	2	2	2	2
4233	295	disease complex with challenging therapeutics	[disease complex with challenging therapeutics]	1.0	5	1	0	0
4234	295	6-week follow-up	[6-week follow-up]	1.0	2	1	0	0
4235	295	study period	[study period]	1.0	2	2	1	1
4236	295	accurate recognition of advanced disease	[accurate recognition of advanced disease]	1.0	5	1	0	0
4237	295	chronic hypertension	[chronic hypertension]	1.0	2	2	2	2
4238	295	nontrastuzumab user hazard ratio hr	[nontrastuzumab users hazard ratio HR]	1.0	5	1	0	0
4239	295	catabolic imbalance	[catabolic imbalance]	1.0	2	1	0	0
4240	295	limited evidence	[limited evidence]	1.0	2	1	0	0
4241	295	primary symptom of chronic hfpef	[primary symptom of chronic HFPEF]	1.0	5	1	0	0
4242	295	factor analysis	[factor analysis]	1.0	2	2	2	2
4243	295	event such as pressure ulcer	[events such as pressure ulcers]	1.0	5	1	0	0
4244	295	effective way	[effective way]	1.0	2	1	0	0
4245	295	change in 30-day readmission rate	[change in 30-day readmission rate]	1.0	5	1	0	0
4246	295	number of Raf-MEK1 scaffold protein	[number of Raf-MEK1 scaffold proteins]	1.0	5	1	0	0
4247	295	financial incentive	[financial incentives]	1.0	2	1	0	0
4248	295	I recommendation	[I recommendations]	1.0	2	1	0	0
4249	295	541 day	[541 days]	1.0	2	1	0	0
4250	295	ABCD classification	[ABCD classification]	1.0	2	1	0	0
4251	295	sST2 concentration	[sST2 concentrations]	1.0	2	1	0	0
4252	295	t1-mapping technique	[T1-mapping technique]	1.0	2	1	0	0
4253	295	63 predictor on 257692 ICD patient	[63 predictors on 257,692 ICD patients]	1.0	6	1	0	0
4254	295	current dietary recommendation for patient	[Current dietary recommendations for patients]	1.0	5	1	0	0
4255	295	symptomatic improvement	[symptomatic improvement]	1.0	2	1	0	0
4256	295	pde2-overexpressing cardiomyocyte	[PDE2-overexpressing cardiomyocytes]	1.0	2	1	0	0
4257	295	QT interval	[QT interval]	1.0	2	2	2	2
4258	295	11 patient	[11 patients]	1.0	2	1	0	0
4259	295	patient in the MADIT-CRT study	[patients in the MADIT-CRT study]	1.0	5	1	0	0
4260	295	50 year	[50 years]	1.0	2	1	0	0
4261	295	several marker indicative of autonomic balance	[several markers indicative of autonomic balance]	1.0	6	1	0	0
4262	295	above comparison	[above comparisons]	1.0	2	1	0	0
4263	295	target epitope	[targeting epitopes]	1.0	2	2	2	2
4264	295	new therapeutic target for HHD	[new therapeutic targets for HHD]	1.0	5	1	0	0
4265	295	quality measure	[quality measures]	1.0	2	2	2	2
4266	295	guideline-recommended treatment	[guideline-recommended treatment]	1.0	2	1	0	0
4267	295	saxagliptin versus sitagliptin for saxagliptin	[saxagliptin versus sitagliptin for saxagliptin]	1.0	5	1	0	0
4268	295	5 mg	[5 mg]	1.0	2	1	0	0
4269	295	inhibition of protein kinase a	[inhibition of protein kinase A]	1.0	5	1	0	0
4270	295	45 practice	[45 practices]	1.0	2	1	0	0
4271	295	oxygen consumption	[oxygen consumption]	1.0	2	2	2	2
4272	295	parasympathetic activity	[parasympathetic activity]	1.0	2	2	1	1
4273	295	BiVP setting for STE analysis	[BiVP setting for STE analysis]	1.0	5	1	0	0
4274	295	dose-related benefit across all study participant	[dose-related benefits across all study participants]	1.0	6	1	0	0
4275	295	coprimary outcome	[coprimary outcome]	1.0	2	1	0	0
4276	295	thigh muscle intermuscular fat ratio	[thigh muscle intermuscular fat ratio]	1.0	5	1	0	0
4277	295	histological analysis	[histological analysis]	1.0	2	1	0	0
4278	295	clinical finding	[CLINICAL FINDINGS]	1.0	2	1	0	0
4279	295	literature in the English language	[literature in the English language]	1.0	5	1	0	0
4280	295	high-risk patient with heart failure	[high-risk patient with heart failure]	1.0	5	1	0	0
4281	295	prognostic meaning	[prognostic meaning]	1.0	2	1	0	0
4282	295	pump dysfunction require pump replacement	[pump dysfunction requiring pump replacement]	1.0	5	1	0	0
4283	295	subsequent event	[subsequent events]	1.0	2	1	0	0
4284	295	appropriate timing of patient enrollment	[appropriate timing of patient enrollment]	1.0	5	1	0	0
4285	295	lack of achievement of metabolism	[lack of achievement of metabolism]	1.0	5	1	0	0
4286	295	intestinal dysfunction	[intestinal dysfunction]	1.0	2	1	0	0
4287	295	application in the clinical setting	[application in the clinical setting]	1.0	5	1	0	0
4288	295	three stage	[three stages]	1.0	2	1	0	0
4289	295	good quintile	[best quintile]	1.0	2	2	1	1
4290	295	decrease albumin level during lvad support	[decreasing albumin levels during LVAD support]	1.0	6	1	0	0
4291	295	match donor	[matching donors]	1.0	2	1	0	0
4292	295	evaluate the change in platelet-activating factor	[evaluating the changes in platelet-activating factor]	1.0	6	1	0	0
4293	295	progressive improvement	[progressive improvement]	1.0	2	1	0	0
4294	295	immunoreactive nt-probnp	[immunoreactive NT-proBNP]	1.0	2	1	0	0
4295	295	myxomas in the right atrium	[Myxomas in the right atrium]	1.0	5	1	0	0
4296	295	ivabradine patient	[ivabradine patients]	1.0	2	1	0	0
4297	295	presentation Canadian Cardiovascular Society guideline	[Presentation Canadian Cardiovascular Society guidelines]	1.0	5	1	0	0
4298	295	100 participant	[100 participants]	1.0	2	2	1	1
4299	295	high sensitivity	[high sensitivity]	1.0	2	1	0	0
4300	295	0.1 unit	[0.1 unit]	1.0	2	1	0	0
4301	295	nonstandardized N-terminal pro-b-type natriuretic peptide	[nonstandardized N-terminal pro-B-type natriuretic peptide]	1.0	5	1	0	0
4302	295	use Cytoscape	[using Cytoscape]	1.0	2	1	0	0
4303	295	implantation of a bottleneck stent	[implantation of a bottleneck stent]	1.0	5	1	0	0
4304	295	accumulate evidence	[Accumulating evidence]	1.0	2	1	0	0
4305	295	leaflet motion	[leaflet motion]	1.0	2	2	2	2
4306	295	Hand2-dependent manner	[Hand2-dependent manner]	1.0	2	1	0	0
4307	295	good survival	[better survival]	1.0	2	1	0	0
4308	295	identify cad as a cause	[Identifying CAD as a cause]	1.0	5	1	0	0
4309	295	concentric hypertrophy	[concentric hypertrophy]	1.0	2	2	2	2
4310	295	albumin level during lvad support	[albumin levels during LVAD support]	1.0	5	1	0	0
4311	295	Cardiac failure	[Cardiac failure]	1.0	2	1	0	0
4312	295	ongoing gdmt	[ongoing GDMT]	1.0	2	2	2	2
4313	295	central region of this molecule	[central region of this molecule]	1.0	5	1	0	0
4314	295	hemoglobin threshold of 7 gram	[hemoglobin threshold of 7 g]	1.0	5	1	0	0
4315	295	stretch rate	[stretch rate]	1.0	2	1	0	0
4316	295	HF in patient with pad	[HF in patients with PAD]	1.0	5	1	0	0
4317	295	HF readmission	[HF readmissions]	1.0	2	1	0	0
4318	295	case of a 57-year-old man	[case of a 57-year-old man]	1.0	5	1	0	0
4319	295	baseline electrocardiogram	[baseline electrocardiogram]	1.0	2	1	0	0
4320	295	obese zsf1 with high-fat diet n=11	[obese ZSF1 with high-fat diet n=11]	1.0	6	1	0	0
4321	295	potential candidate for cell therapy	[potential candidates for cell therapy]	1.0	5	1	0	0
4322	295	hemodynamic alteration	[hemodynamic alterations]	1.0	2	1	0	0
4323	295	143 patient	[143 patients]	1.0	2	1	0	0
4324	295	new strategy	[new strategies]	1.0	2	1	0	0
4325	295	pulsatile device	[pulsatile devices]	1.0	2	1	0	0
4326	295	redo sternotomy	[redo sternotomy]	1.0	2	2	1	1
4327	295	peak oxygen uptake with simultaneous reduction	[peak oxygen uptake with simultaneous reduction]	1.0	6	1	0	0
4328	295	921 patient	[921 patients]	1.0	2	1	0	0
4329	295	15 millileter per 1.73 m	[15 mL per 1.73 m]	1.0	5	2	1	1
4330	295	ejection fraction a Clinical Trial	[Ejection Fraction A Clinical Trial]	1.0	5	1	0	0
4331	295	porcine model	[porcine model]	1.0	2	2	1	1
4332	295	617 death	[617 deaths]	1.0	2	1	0	0
4333	295	psoriasis as a time-dependent variable	[psoriasis as a time-dependent variable]	1.0	5	1	0	0
4334	295	individual with pre-hct chest radiation	[individuals with pre-HCT chest radiation]	1.0	5	1	0	0
4335	295	trastuzumab in the adjuvant setting	[trastuzumab in the adjuvant setting]	1.0	5	1	0	0
4336	295	62.4 year	[62.4 years]	1.0	2	1	0	0
4337	295	Preoperative demographic	[Preoperative demographics]	1.0	2	1	0	0
4338	295	utilize voluntary testimony with participate nurse	[Utilizing voluntary testimonies with participating nurses]	1.0	6	1	0	0
4339	295	sham-operated animal	[Sham-operated animals]	1.0	2	1	0	0
4340	295	cardiovascular system	[cardiovascular system]	1.0	2	1	0	0
4341	295	operative outcome	[operative outcomes]	1.0	2	1	0	0
4342	295	even in the presence of mr	[even in the presence of MR]	1.0	6	1	0	0
4343	295	contextual factor	[contextual factors]	1.0	2	2	2	2
4344	295	patient with ischemic cardiomyopathy ic	[patients with ischemic cardiomyopathy IC]	1.0	5	1	0	0
4345	295	old athlete	[older athletes]	1.0	2	1	0	0
4346	295	0.5 mg	[0.5 mg]	1.0	2	1	0	0
4347	295	feasibility of a 12-week program	[feasibility of a 12-week program]	1.0	5	1	0	0
4348	295	reduction in the primary outcome	[reduction in the primary outcome]	1.0	5	1	0	0
4349	295	venous pressure	[venous pressure]	1.0	2	2	2	2
4350	295	thirty-day rehospitalization	[Thirty-day rehospitalization]	1.0	2	1	0	0
4351	295	circulate nt-probnp	[circulating NT-proBNP]	1.0	2	2	2	2
4352	295	protection from norepinephrine-induced hypertrophic response	[protection from norepinephrine-induced hypertrophic responses]	1.0	5	1	0	0
4353	295	echocardiographic substudy	[echocardiographic substudy]	1.0	2	1	0	0
4354	295	Minnesota live with heart failure questionnaire	[Minnesota Living with Heart Failure Questionnaire]	1.0	6	1	0	0
4355	295	8.8±6.3 year	[8.8±6.3 years]	1.0	2	1	0	0
4356	295	change in hdl-induced no production	[changes in HDL-induced NO production]	1.0	5	1	0	0
4357	295	use MEDLINE	[using MEDLINE]	1.0	2	1	0	0
4358	295	current knowledge	[current knowledge]	1.0	2	2	2	2
4359	295	relaxation c	[relaxation c]	1.0	2	1	0	0
4360	295	heart failure-related hospitalization in patient	[heart failure-related hospitalization in patients]	1.0	5	1	0	0
4361	295	prognostic value	[prognostic value]	1.0	2	1	0	0
4362	295	cardiac insulin-resistance by 2 week post-aac	[cardiac insulin-resistance by 2 weeks post-AAC]	1.0	6	1	0	0
4363	295	prevalence of chronic heart failure	[prevalence of chronic heart failure]	1.0	5	1	0	0
4364	295	treatment in patient with heart disease	[Treatment in patients with heart disease]	1.0	6	2	2	2
4365	295	echocardiographic assessment of myocardial function	[echocardiographic assessment of myocardial function]	1.0	5	1	0	0
4366	295	baseline hrqol	[baseline HRQoL]	1.0	2	1	0	0
4367	295	279 millileter	[279 mL]	1.0	2	1	0	0
4368	295	patient with heart failure prone	[patients with heart failure prone]	1.0	5	1	0	0
4369	295	RV function on body composition	[RV function on body composition]	1.0	5	1	0	0
4370	295	implantable cardioverter-defibrillator deactivation at implant	[implantable cardioverter-defibrillator deactivation at implant]	1.0	5	1	0	0
4371	295	covariate adjustment	[Covariate adjustment]	1.0	2	1	0	0
4372	295	volume overload	[volume overload]	1.0	2	2	2	2
4373	295	diagnosis of myocarditis versus cardiomyopathy	[diagnosis of myocarditis versus cardiomyopathy]	1.0	5	1	0	0
4374	295	recent trial in acute HF	[recent trials in acute HF]	1.0	5	1	0	0
4375	295	high rate of hyperkalemia potassium	[higher rates of hyperkalemia potassium]	1.0	5	1	0	0
4376	295	improve uptake of class cpg recommendation	[improving uptake of class CPG recommendations]	1.0	6	1	0	0
4377	295	major development	[major development]	1.0	2	1	0	0
4378	295	self-care maintenance with limited success	[Self-Care Maintenance with limited success]	1.0	5	1	0	0
4379	295	therapeutic interruption of neurohormonal system	[therapeutic interruption of neurohormonal systems]	1.0	5	1	0	0
4380	295	temporal trend	[temporal trends]	1.0	2	1	0	0
4381	295	thirty-day mortality	[Thirty-day mortality]	1.0	2	1	0	0
4382	295	TUNEL assay	[TUNEL assay]	1.0	2	1	0	0
4383	295	Hereditary abnormality of the heart	[Hereditary abnormalities of the heart]	1.0	5	1	0	0
4384	295	1080 day	[1,080 days]	1.0	2	1	0	0
4385	295	use a cutoff of 8	[Using a cutoff of 8]	1.0	5	1	0	0
4386	295	Echocardiographic measure	[Echocardiographic measures]	1.0	2	1	0	0
4387	295	analysis use 2005 2008 performance	[analysis using 2005 2008 performance]	1.0	5	1	0	0
4388	295	important determinant of long survival	[important determinants of long-term survival]	1.0	5	1	0	0
4389	295	CI for early HF respectively	[CI for early HF respectively]	1.0	5	1	0	0
4390	295	recommendation for implantable cardioverter-defibrillator deactivation discussion	[recommendation for implantable cardioverter-defibrillator deactivation discussions]	1.0	6	1	0	0
4391	295	8204 patient	[8204 patients]	1.0	2	1	0	0
4392	295	clinical recommendation	[clinical recommendations]	1.0	2	1	0	0
4393	295	Clinical Practice Guideline CPG recommendation	[Clinical Practice Guideline CPG recommendations]	1.0	5	1	0	0
4394	295	relation with commissioning on completion	[relation with commissioning on completion]	1.0	5	1	0	0
4395	295	develop certain malignancy include cancer	[developing certain malignancies including cancer]	1.0	5	1	0	0
4396	295	trastuzumab-treated patient	[trastuzumab-treated patients]	1.0	2	1	0	0
4397	295	atrial mass	[atrial mass]	1.0	2	1	0	0
4398	295	main cause of cardiovascular hospitalization	[main cause of cardiovascular hospitalization]	1.0	5	1	0	0
4399	295	STS hm	[STS HM]	1.0	2	1	0	0
4400	295	investigate outcome	[Investigating Outcomes]	1.0	2	3	2	1
4401	295	of remodeling	[of remodeling]	1.0	2	1	0	0
4402	295	vitro model	[vitro model]	1.0	2	1	0	0
4403	295	health behavior	[health behaviors]	1.0	2	1	0	0
4404	295	early diastolic mitral annulus velocity E	[early diastolic mitral annulus velocity E]	1.0	6	1	0	0
4405	295	rat possible mechanism of cardioprotection	[rats possible mechanism of cardioprotection]	1.0	5	1	0	0
4406	295	significant reduction	[significant reduction]	1.0	2	4	3	1
4407	295	western society	[Western society]	1.0	2	1	0	0
4408	295	modest conservation	[modest conservation]	1.0	2	1	0	0
4409	295	1 study	[1 study]	1.0	2	1	0	0
4410	295	ef≤ 40	[EF≤ 40]	1.0	2	1	0	0
4411	295	left ventricular ejection fraction LVEF	[left ventricular ejection fraction LVEF]	1.0	5	1	0	0
4412	295	high-sensitivity assay	[high-sensitivity assay]	1.0	2	1	0	0
4413	295	clinical evaluation	[clinical evaluation]	1.0	2	2	2	2
4414	295	Subgroup analysis of patient with hypoalbuminemia	[Subgroup analysis of patients with hypoalbuminemia]	1.0	6	1	0	0
4415	295	artery bypass	[artery bypass]	1.0	2	1	0	0
4416	295	physiological significance	[physiological significance]	1.0	2	1	0	0
4417	295	massive embolism	[massive embolism]	1.0	2	1	0	0
4418	295	role of reader bromodomain protein	[role of readers bromodomain proteins]	1.0	5	1	0	0
4419	295	much work	[much work]	1.0	2	1	0	0
4420	295	consistent approach extrapolate short-term outcome	[consistent approach extrapolating short-term outcomes]	1.0	5	1	0	0
4421	295	subsequent HF	[subsequent HF]	1.0	2	1	0	0
4422	295	renal denervation DNx in CHF patient	[Renal denervation DNx in CHF patients]	1.0	6	1	0	0
4423	295	recent finding	[RECENT FINDINGS]	1.0	2	1	0	0
4424	295	past decade	[past decades]	1.0	2	2	1	1
4425	295	year 2008	[year 2008]	1.0	2	1	0	0
4426	295	hr reduction with beta blocker	[HR reduction with beta blockers]	1.0	5	1	0	0
4427	295	heart failure hospitalization in patient	[heart failure hospitalizations in patients]	1.0	5	1	0	0
4428	295	at-risk patient	[at-risk patients]	1.0	2	1	0	0
4429	295	insurance status	[insurance status]	1.0	2	1	0	0
4430	295	serious complication	[serious complications]	1.0	2	1	0	0
4431	295	post-acute care	[post-acute care]	1.0	2	2	1	1
4432	295	low-dose BB	[low-dose BB]	1.0	2	1	0	0
4433	295	kd for the double mutant	[Kd for the double mutant]	1.0	5	1	0	0
4434	295	future performer	[future performers]	1.0	2	2	2	2
4435	295	independent predictor of severe cad	[independent predictors of severe CAD]	1.0	5	1	0	0
4436	295	patient in the terminal phase	[patients in the terminal phase]	1.0	5	1	0	0
4437	295	MI animal	[MI animals]	1.0	2	2	1	1
4438	295	CC patient	[CC patients]	1.0	2	1	0	0
4439	295	CHF-INV animal	[CHF-INV animals]	1.0	2	1	0	0
4440	295	blood work	[blood work]	1.0	2	1	0	0
4441	295	sst2 measurement	[sST2 measurement]	1.0	2	1	0	0
4442	295	blood loss	[blood loss]	1.0	2	1	0	0
4443	295	patient above the median bnp level	[patients above the median BNP level]	1.0	6	1	0	0
4444	295	level of various serum factor	[levels of various serum factors]	1.0	5	1	0	0
4445	295	cardiac arrest	[cardiac arrest]	1.0	2	2	1	1
4446	295	young adult with heart failure	[young adults with heart failure]	1.0	5	2	1	1
4447	295	contractile response	[contractile response]	1.0	2	1	0	0
4448	295	hemodynamic status	[hemodynamic status]	1.0	2	1	0	0
4449	295	patient with end-stage heart failure	[Patients with end-stage heart failure]	1.0	5	1	0	0
4450	295	2 handling	[2 handling]	1.0	2	1	0	0
4451	295	similar mortality	[similar mortality]	1.0	2	2	2	2
4452	295	grow need	[growing needs]	1.0	2	1	0	0
4453	295	150 event	[150 events]	1.0	2	1	0	0
4454	295	system major adverse neurological event	[system major adverse neurological events]	1.0	5	1	0	0
4455	295	acr metric	[ACR metrics]	1.0	2	2	1	1
4456	295	regardless of serum sodium level	[regardless of serum sodium levels]	1.0	5	1	0	0
4457	295	underlying hypertension	[underlying hypertension]	1.0	2	1	0	0
4458	295	DNA accessibility	[DNA accessibility]	1.0	2	1	0	0
4459	295	use relationship	[using relationships]	1.0	2	1	0	0
4460	295	myofibre regeneration	[myofibre regeneration]	1.0	2	1	0	0
4461	295	thromboembolic event in heart failure	[thromboembolic events in heart failure]	1.0	5	1	0	0
4462	295	biomarker in chronic heart failure	[biomarkers in chronic heart failure]	1.0	5	1	0	0
4463	295	legal majority	[legal majority]	1.0	2	1	0	0
4464	295	heart rate reduction with ivabradine	[heart rate reduction with ivabradine]	1.0	5	2	2	2
4465	295	non-aa participant	[non-AA participants]	1.0	2	1	0	0
4466	295	across-the-board improvement	[across-the-board improvements]	1.0	2	1	0	0
4467	295	309 ng	[309 ng]	1.0	2	1	0	0
4468	295	administrative database for all adult	[administrative databases for all adults]	1.0	5	1	0	0
4469	295	HFPEF	[HFPEF]	1.0	1	11	3	3
4470	295	8.4 mm	[8.4 mm]	1.0	2	1	0	0
4471	295	capillary perfusion in b-treated rat	[capillary perfusion in B-treated rats]	1.0	5	1	0	0
4472	295	even with normal systolic ventricular function	[even with normal systolic ventricular function]	1.0	6	1	0	0
4473	295	lvad implantation hazard ratio 0.521	[LVAD implantation hazard ratio 0.521]	1.0	5	1	0	0
4474	295	breathing control	[breathing control]	1.0	2	1	0	0
4475	295	reference subject	[reference subjects]	1.0	2	2	2	2
4476	295	1483 patient	[1483 patients]	1.0	2	1	0	0
4477	295	association with outcome for disease	[association with outcomes for diseases]	1.0	5	1	0	0
4478	295	other setting	[other settings]	1.0	2	1	0	0
4479	295	medication change	[medication changes]	1.0	2	1	0	0
4480	295	2 trial	[2 trials]	1.0	2	2	2	2
4481	295	one mechanism	[one mechanism]	1.0	2	1	0	0
4482	295	2 complexity	[2 complexities]	1.0	2	1	0	0
4483	295	3.5 kg	[3.5 kg]	1.0	2	1	0	0
4484	295	cross talk	[cross talk]	1.0	2	2	2	2
4485	295	25th-75th percentile	[25th-75th percentiles]	1.0	2	1	0	0
4486	295	3 trial of intravenous iron	[3 trials of intravenous iron]	1.0	5	1	0	0
4487	295	xo inhibition	[XO inhibition]	1.0	2	2	1	1
4488	295	two Cox proportional hazard model	[Two Cox proportional hazards models]	1.0	5	1	0	0
4489	295	investigate outcome of Exercise training	[Investigating Outcomes of Exercise Training]	1.0	5	2	1	1
4490	295	multivariable regression	[multivariable regression]	1.0	2	1	0	0
4491	295	10420 study	[10,420 studies]	1.0	2	1	0	0
4492	295	destination therapy	[destination therapy]	1.0	2	2	1	1
4493	295	patient with versus without diabete	[patients with vs without diabetes]	1.0	5	1	0	0
4494	295	10 transplant	[10 transplant]	1.0	2	1	0	0
4495	295	Skeletal muscle abnormality in adult	[Skeletal muscle abnormalities in adults]	1.0	5	1	0	0
4496	295	30±2 year	[30±2 years]	1.0	2	1	0	0
4497	295	hazard ratio across high CRF category	[hazard ratios across high CRF categories]	1.0	6	1	0	0
4498	295	difference among the three group	[difference among the three groups]	1.0	5	1	0	0
4499	295	left bundle branch block pattern	[left bundle branch block pattern]	1.0	5	1	0	0
4500	295	possible cause of the array	[possible causes of the array]	1.0	5	1	0	0
4501	295	therapeutic option	[therapeutic options]	1.0	2	2	1	1
4502	295	cms metric	[CMS metric]	1.0	2	1	0	0
4503	295	8-fluo-cAMP binding by wild type	[8-fluo-cAMP binding by wild type]	1.0	5	1	0	0
4504	295	HFrEF patient	[HFrEF patients]	1.0	2	1	0	0
4505	295	baseline egfr group ii p	[Baseline eGFR group II P]	1.0	5	1	0	0
4506	295	July 2008	[July 2008]	1.0	2	1	0	0
4507	295	aforementioned parameter	[aforementioned parameters]	1.0	2	1	0	0
4508	295	cardiac diameter	[cardiac diameters]	1.0	2	1	0	0
4509	295	fluid retention	[fluid retention]	1.0	2	1	0	0
4510	295	4 kg	[4 kg]	1.0	2	1	0	0
4511	295	high-quality work	[high-quality work]	1.0	2	1	0	0
4512	295	15 minute	[15 minutes]	1.0	2	1	0	0
4513	295	mouse heart	[mouse heart]	1.0	2	2	2	2
4514	295	LV structure	[LV structure]	1.0	2	1	0	0
4515	295	partly a result of shortcoming	[partly a result of shortcomings]	1.0	5	1	0	0
4516	295	0.2 millileter	[0.2 mL]	1.0	2	1	0	0
4517	295	correlation between the acr metric	[Correlations between the ACR metrics]	1.0	5	1	0	0
4518	295	Median age of the entire cohort	[Median age of the entire cohort]	1.0	6	1	0	0
4519	295	lead cause of heart failure	[leading cause of heart failure]	1.0	5	1	0	0
4520	295	requirement for assist device use	[requirement for assist device use]	1.0	5	1	0	0
4521	295	activation of p38α protein kinase p38	[activation of p38α protein kinase p38]	1.0	6	1	0	0
4522	295	vagal tone	[vagal tone]	1.0	2	2	1	1
4523	295	ventricular DD	[ventricular DD]	1.0	2	1	0	0
4524	295	cellular dysfunction	[cellular dysfunction]	1.0	2	1	0	0
4525	295	Impact of qrs morphology on outcome	[Impact of QRS morphology on outcomes]	1.0	6	1	0	0
4526	295	left ventricular ejection fraction mean difference	[left ventricular ejection fraction mean difference]	1.0	6	1	0	0
4527	295	dietary recommendation	[dietary recommendations]	1.0	2	2	1	1
4528	295	first wk	[first wk]	1.0	2	1	0	0
4529	295	health problem	[health problem]	1.0	2	2	2	2
4530	295	28 hospitalisation for heart failure	[28 hospitalisations for heart failure]	1.0	5	1	0	0
4531	295	perhaps the single most important component	[perhaps the single most important component]	1.0	6	1	0	0
4532	295	STE analysis	[STE analysis]	1.0	2	2	2	2
4533	295	pressure-overload hypertrophy	[pressure-overload hypertrophy]	1.0	2	1	0	0
4534	295	state of mitochondrial oxidative stress	[state of mitochondrial oxidative stress]	1.0	5	1	0	0
4535	295	extend EMD	[extending EMD]	1.0	2	2	2	2
4536	295	even mild clinical diastolic dysfunction	[even mild clinical diastolic dysfunction]	1.0	5	1	0	0
4537	295	development of systolic heart failure	[development of systolic heart failure]	1.0	5	1	0	0
4538	295	treat heart failure in the absence	[treating heart failure in the absence]	1.0	6	1	0	0
4539	295	left ventricular ejection fraction p	[left ventricular ejection fraction P]	1.0	5	1	0	0
4540	295	970 participant	[970 participants]	1.0	2	1	0	0
4541	295	molecular level	[molecular level]	1.0	2	1	0	0
4542	295	maximal exercise	[maximal exercise]	1.0	2	1	0	0
4543	295	frailty for heart failure HF	[frailty for heart failure HF]	1.0	5	1	0	0
4544	295	30 mm hg low pasp	[30 mm Hg low PASP]	1.0	5	1	0	0
4545	295	predictive value for heart failure	[predictive value for heart failure]	1.0	5	1	0	0
4546	295	seven day	[Seven days]	1.0	2	1	0	0
4547	295	case-control analysis match for age	[case-control analysis matching for age]	1.0	5	1	0	0
4548	295	cardiac murmur	[cardiac murmurs]	1.0	2	1	0	0
4549	295	healthy cardiomyocyte	[healthy cardiomyocytes]	1.0	2	2	1	1
4550	295	relationship between length of stay	[relationship between length of stay]	1.0	5	1	0	0
4551	295	overview of the sonographic abnormality	[overview of the sonographic abnormalities]	1.0	5	1	0	0
4552	295	first hospitalization worsen heart failure	[first hospitalization worsening heart failure]	1.0	5	1	0	0
4553	295	Healthcare common Procedure Coding System code	[Healthcare Common Procedure Coding System codes]	1.0	6	1	0	0
4554	295	subpulmonary ventricle the Fontan circulation	[subpulmonary ventricle the Fontan circulation]	1.0	5	1	0	0
4555	295	141 outcome	[141 outcomes]	1.0	2	1	0	0
4556	295	kg 2	[kg 2]	1.0	2	2	1	1
4557	295	540 pg	[540 pg]	1.0	2	1	0	0
4558	295	risk for stroke cha₂ds₂vasc score	[risk for stroke CHA₂DS₂VASc score]	1.0	5	1	0	0
4559	295	successful intervention	[successful interventions]	1.0	2	1	0	0
4560	295	rate of energy substrate metabolism	[rates of energy substrate metabolism]	1.0	5	1	0	0
4561	295	have hfpef	[having HFpEF]	1.0	2	2	1	1
4562	295	several Medical outcome study short-form quality	[several Medical Outcomes Study Short-Form quality]	1.0	6	1	0	0
4563	295	distance Kansas City Cardiomyopathy Questionnaire	[distance Kansas City Cardiomyopathy Questionnaire]	1.0	5	1	0	0
4564	295	low pasp	[low PASP]	1.0	2	2	1	1
4565	295	follow-up with local cardiology service	[follow-up with local cardiology services]	1.0	5	1	0	0
4566	295	investigate the role of bet	[Investigating the role of BETs]	1.0	5	1	0	0
4567	295	Survival projection	[Survival projections]	1.0	2	1	0	0
4568	295	perturbation in skeletal muscle sarcomere structure	[Perturbations in skeletal muscle sarcomere structure]	1.0	6	1	0	0
4569	295	kg p	[kg p]	1.0	2	2	2	2
4570	295	trastuzumab-related CHF	[trastuzumab-related CHF]	1.0	2	2	1	1
4571	295	center for Medicare 30-day readmission cms	[Centers for Medicare 30-day readmission CMS]	1.0	6	1	0	0
4572	295	post-lvad AI	[post-LVAD AI]	1.0	2	1	0	0
4573	295	core laboratory	[core laboratory]	1.0	2	1	0	0
4574	295	antirheumatic drug	[antirheumatic drug]	1.0	2	1	0	0
4575	295	Bradycardia indicative of cardiac sympathetic tone	[Bradycardia indicative of cardiac sympathetic tone]	1.0	6	1	0	0
4576	295	fragment of N-terminal pro-b-type natriuretic peptide	[fragments of N-terminal pro-B-type natriuretic peptides]	1.0	6	1	0	0
4577	295	possibly diminish the xo-mediated ros effect	[possibly diminishing the XO-mediated ROS effects]	1.0	6	1	0	0
4578	295	inpatient use	[inpatient use]	1.0	2	1	0	0
4579	295	South Dakota	[South Dakota]	1.0	2	2	2	2
4580	295	patient with pulmonary hypertension ph	[patients with pulmonary hypertension PH]	1.0	5	1	0	0
4581	295	of nursing	[of nursing]	1.0	2	1	0	0
4582	295	ventricular stiffness	[ventricular stiffness]	1.0	2	1	0	0
4583	295	follow ring annuloplasty for ischemic mr	[following ring annuloplasty for ischemic MR]	1.0	6	1	0	0
4584	295	L-DKO mouse	[L-DKO mice]	1.0	2	1	0	0
4585	295	right ventricle in heart failure	[right ventricle in heart failure]	1.0	5	1	0	0
4586	295	patient with York heart Association class	[Patients with York Heart Association class]	1.0	6	2	2	2
4587	295	research design	[research design]	1.0	2	2	1	1
4588	295	risk of fatal arrhythmia event	[risk of fatal arrhythmia events]	1.0	5	1	0	0
4589	295	exist quality indicator include mortality	[existing quality indicators including mortality]	1.0	5	1	0	0
4590	295	3.0 year	[3.0 years]	1.0	2	1	0	0
4591	295	transfusion requirement	[transfusion requirements]	1.0	2	1	0	0
4592	295	prognostic factor in cardiovascular disease	[prognostic factor in cardiovascular diseases]	1.0	5	1	0	0
4593	295	right atrium	[right atrium]	1.0	2	2	1	1
4594	295	implantation of a assist device	[implantation of a assist device]	1.0	5	1	0	0
4595	295	renal optimization strategy evaluation rose	[Renal Optimization Strategies Evaluation ROSE]	1.0	5	1	0	0
4596	295	reversible cause	[reversible causes]	1.0	2	1	0	0
4597	295	symptom of heart failure HF	[symptoms of heart failure HF]	1.0	5	1	0	0
4598	295	quarterly admission	[quarterly admissions]	1.0	2	1	0	0
4599	295	twenty-one RCT	[Twenty-one RCTs]	1.0	2	1	0	0
4600	295	16 procedure	[16 procedures]	1.0	2	1	0	0
4601	295	beta-blocker dose after 12 month	[Beta-blocker dose after 12 months]	1.0	5	1	0	0
4602	295	Renal DNx	[Renal DNx]	1.0	2	1	0	0
4603	295	53 consecutive patient with ph	[53 consecutive patients with PH]	1.0	5	1	0	0
4604	295	adequacy of health service provision	[adequacy of health service provision]	1.0	5	1	0	0
4605	295	develop hyperkalemia	[developing hyperkalemia]	1.0	2	1	0	0
4606	295	enhance neoangiogenesis in the fail heart	[enhancing neoangiogenesis in the failing heart]	1.0	6	1	0	0
4607	295	pharmacologic therapy	[pharmacologic therapies]	1.0	2	1	0	0
4608	295	cost analysis	[cost analysis]	1.0	2	1	0	0
4609	295	patient categorization in the emergency department	[patient categorization in the emergency department]	1.0	6	1	0	0
4610	295	measurement of natriuretic peptide NPs	[measurement of natriuretic peptides NPs]	1.0	5	1	0	0
4611	295	death during the observation period	[death during the observation period]	1.0	5	1	0	0
4612	295	low activity	[low activity]	1.0	2	2	1	1
4613	295	equitable access	[equitable access]	1.0	2	1	0	0
4614	295	left ventricular ejection fraction lvef	[left ventricular ejection fraction LVEF]	1.0	5	1	0	0
4615	295	AF-free probability	[AF-free probability]	1.0	2	1	0	0
4616	295	beneficial result	[beneficial results]	1.0	2	1	0	0
4617	295	overall summary in all subdomain	[overall summary in all subdomains]	1.0	5	1	0	0
4618	295	resonance imaging	[resonance imaging]	1.0	2	2	2	2
4619	295	cardiac tissue	[cardiac tissue]	1.0	2	2	1	1
4620	295	murine equivalent of rad q66p	[murine equivalent of Rad Q66P]	1.0	5	1	0	0
4621	295	widespread use	[widespread use]	1.0	2	1	0	0
4622	295	activation of VEGF signal pathway	[activation of VEGF signaling pathway]	1.0	5	1	0	0
4623	295	high bnp level in patient	[high BNP levels in patients]	1.0	5	1	0	0
4624	295	same assessor	[same assessors]	1.0	2	1	0	0
4625	295	compelling improvement after device implantation	[compelling improvement after device implantation]	1.0	5	1	0	0
4626	295	myocardial tissue	[myocardial tissue]	1.0	2	2	1	1
4627	295	mixed-method study	[mixed-methods study]	1.0	2	2	1	1
4628	295	HeartWare Intl	[HeartWare Intl]	1.0	2	1	0	0
4629	295	hyperkalemia lead	[hyperkalemia leading]	1.0	2	1	0	0
4630	295	generate variant encode nonfunctional channel	[generating variants encoding nonfunctional channels]	1.0	5	1	0	0
4631	295	metric choice for common application	[metric choice for common applications]	1.0	5	1	0	0
4632	295	functional decline atrial explant-derived c-kit	[functional decline atrial explant-derived c-Kit]	1.0	5	1	0	0
4633	295	cornerstone of heart failure therapy	[cornerstone of heart failure therapy]	1.0	5	1	0	0
4634	295	concentrate on the pathophysiologic mechanism	[concentrating on the pathophysiologic mechanisms]	1.0	5	1	0	0
4635	295	end-diastolic pressure	[end-diastolic pressure]	1.0	2	2	2	2
4636	295	t1-mapping value	[T1-mapping values]	1.0	2	1	0	0
4637	295	β-blocker therapy for optimal treatment	[β-blockers therapy for optimal treatment]	1.0	5	1	0	0
4638	295	Functional electrical stimulation of peripheral muscle	[Functional electrical stimulation of peripheral muscles]	1.0	6	1	0	0
4639	295	group 95.2	[groups 95.2]	1.0	2	1	0	0
4640	295	mediate a negative cross talk	[mediating a negative cross talk]	1.0	5	1	0	0
4641	295	artery stenosis	[artery stenosis]	1.0	2	2	2	2
4642	295	central pressure	[central pressure]	1.0	2	2	2	2
4643	295	calf muscle	[calf muscle]	1.0	2	1	0	0
4644	295	good outcome	[better outcomes]	1.0	2	2	2	2
4645	295	take advantage of the period	[taking advantage of the period]	1.0	5	1	0	0
4646	295	post-lvad ai	[post-LVAD AI]	1.0	2	2	2	2
4647	295	efficacy outcome	[efficacy outcome]	1.0	2	2	2	2
4648	295	model use simple experimental procedure	[model using simple experimental procedures]	1.0	5	1	0	0
4649	295	715 patient	[715 patients]	1.0	2	1	0	0
4650	295	ang ii	[ANG II]	1.0	2	4	3	1
4651	295	New Jersey	[New Jersey]	1.0	2	1	0	0
4652	295	long mortality in this population	[long-term mortality in this population]	1.0	5	1	0	0
4653	295	pump malfunction	[pump malfunctions]	1.0	2	1	0	0
4654	295	data synthesis	[Data Synthesis]	1.0	2	1	0	0
4655	295	concentration of soluble s ST2	[Concentrations of soluble s ST2]	1.0	5	1	0	0
4656	295	significant MS	[significant MS]	1.0	2	1	0	0
4657	295	myocardial event	[myocardial events]	1.0	2	1	0	0
4658	295	thus lead	[thus leading]	1.0	2	1	0	0
4659	295	atrial pacing	[atrial pacing]	1.0	2	2	1	1
4660	295	cardiac disease include heart failure	[cardiac disease including heart failure]	1.0	5	1	0	0
4661	295	advanced disease	[advanced disease]	1.0	2	2	2	2
4662	295	bet inhibition	[BET inhibition]	1.0	2	1	0	0
4663	295	diagnostic test	[diagnostic test]	1.0	2	2	2	2
4664	295	cumulative hazard	[cumulative hazard]	1.0	2	2	2	2
4665	295	normal albumin concentration ≥3.5 gram	[normal albumin concentration ≥3.5 g]	1.0	5	1	0	0
4666	295	ejection fraction in this woman	[ejection fraction in these women]	1.0	5	1	0	0
4667	295	usual care by antiarrhythmic drug	[usual care by antiarrhythmic drugs]	1.0	5	1	0	0
4668	295	can handling	[Ca handling]	1.0	2	2	1	1
4669	295	clinic note	[clinic notes]	1.0	2	1	0	0
4670	295	descriptive assessment of this patient	[descriptive assessment of these patients]	1.0	5	1	0	0
4671	295	vascular effect	[vascular effects]	1.0	2	2	1	1
4672	295	limited value	[limited value]	1.0	2	1	0	0
4673	295	use Spearman correlation with difference	[using Spearman correlations with differences]	1.0	5	1	0	0
4674	295	tidal respiration	[tidal respiration]	1.0	2	2	1	1
4675	295	class iii	[class III]	1.0	2	1	0	0
4676	295	circulatory support	[circulatory support]	1.0	2	2	1	1
4677	295	serial evaluation	[serial evaluation]	1.0	2	1	0	0
4678	295	2005 2008 composite vs. Hospital compare	[2005 2008 composite vs. Hospital Compare]	1.0	6	1	0	0
4679	295	HF resource within health system	[HF resources within health systems]	1.0	5	1	0	0
4680	295	anthracycline-containing chemotherapy	[anthracycline-containing chemotherapy]	1.0	2	1	0	0
4681	295	common problem with high mortality	[common problem with high mortality]	1.0	5	1	0	0
4682	295	risk for acute RV failure	[risk for acute RV failure]	1.0	5	1	0	0
4683	295	significant improvement in functional capacity	[significant improvement in functional capacity]	1.0	5	1	0	0
4684	295	systolic dysfunction by 3 week	[systolic dysfunction by 3 weeks]	1.0	5	1	0	0
4685	295	cost-effective participatory population-specific health intervention	[cost-effective participatory population-specific health interventions]	1.0	5	1	0	0
4686	295	vascular endothelial growth factor blockade	[Vascular endothelial growth factor blockade]	1.0	5	1	0	0
4687	295	hypoxia activator of scn5a mrna splicing	[hypoxia activators of SCN5A mRNA splicing]	1.0	6	1	0	0
4688	295	11 study	[11 studies]	1.0	2	1	0	0
4689	295	dose-dependent reduction	[dose-dependent reduction]	1.0	2	1	0	0
4690	295	broad qrs	[broader QRS]	1.0	2	1	0	0
4691	295	several trial of TNF antagonist	[several trials of TNF antagonists]	1.0	5	1	0	0
4692	295	current strategy for the treatment	[current strategies for the treatment]	1.0	5	1	0	0
4693	295	BB therapy	[BB therapy]	1.0	2	1	0	0
4694	295	hyperkalemia in African American AAs	[hyperkalemia in African Americans AAs]	1.0	5	1	0	0
4695	295	Yorkshire swine	[Yorkshire swine]	1.0	2	1	0	0
4696	295	echocardiographic evidence of left ventricular dyssynchrony	[echocardiographic evidence of left ventricular dyssynchrony]	1.0	6	1	0	0
4697	295	diastole email	[diastole e]	1.0	2	1	0	0
4698	295	all-cause hospitalization with no difference	[all-cause hospitalizations with no difference]	1.0	5	1	0	0
4699	295	wall stiffness	[wall stiffness]	1.0	2	1	0	0
4700	295	mitochondrial dysfunction in doxorubicin-induced heart failure	[mitochondrial dysfunction in doxorubicin-induced heart failure]	1.0	6	1	0	0
4701	295	significant effect on Ie risk	[significant effect on IE risk]	1.0	5	1	0	0
4702	295	serum resistin level in woman	[serum resistin levels in women]	1.0	5	1	0	0
4703	295	baseline exercise capacity 4.2 METs	[baseline exercise capacity 4.2 METs]	1.0	5	1	0	0
4704	295	significant deterioration	[significant deterioration]	1.0	2	1	0	0
4705	295	multivariable adjustment	[multivariable adjustment]	1.0	2	2	1	1
4706	295	glomerular filtration rate of 15 millileter	[glomerular filtration rate of 15 mL]	1.0	6	1	0	0
4707	295	hfpef α=0.96 for overall summary	[HFpEF α=0.96 for overall summary]	1.0	5	1	0	0
4708	295	careful evaluation	[careful evaluation]	1.0	2	2	2	2
4709	295	incorporate a rotor with blood-flow path	[incorporating a rotor with blood-flow paths]	1.0	6	1	0	0
4710	295	management of end stage heart failure	[Management of end stage heart failure]	1.0	6	1	0	0
4711	295	practice guideline	[practice guideline]	1.0	2	2	2	2
4712	295	Medicaid Service	[Medicaid Services]	1.0	2	1	0	0
4713	295	longitudinal study	[longitudinal study]	1.0	2	1	0	0
4714	295	subject of this brief review	[subject of this brief review]	1.0	5	1	0	0
4715	295	Cardiac insulin-resistance	[Cardiac insulin-resistance]	1.0	2	1	0	0
4716	295	contemporary trend in heart failure	[Contemporary trends in heart failure]	1.0	5	1	0	0
4717	295	PB in patient with HF	[PB in patients with HF]	1.0	5	1	0	0
4718	295	insight from heart failure a Trial	[Insights From Heart Failure A Trial]	1.0	6	1	0	0
4719	295	relative appendicular lean mass index	[relative appendicular lean mass index]	1.0	5	1	0	0
4720	295	Kaplan-Meier curve for death hospitalization	[Kaplan-Meier curves for death hospitalization]	1.0	5	1	0	0
4721	295	76 patient	[76 patients]	1.0	2	1	0	0
4722	295	scn5a variant	[SCN5A variants]	1.0	2	2	1	1
4723	295	19.8±10.4 year	[19.8±10.4 years]	1.0	2	1	0	0
4724	295	physical exhaustion	[physical exhaustion]	1.0	2	1	0	0
4725	295	cardioverter-defibrillator therapy	[cardioverter-defibrillator therapy]	1.0	2	2	2	2
4726	295	new HF	[new HF]	1.0	2	1	0	0
4727	295	Median age	[Median age]	1.0	2	2	1	1
4728	295	lvad use	[LVAD use]	1.0	2	2	1	1
4729	295	mitochondrial damage	[mitochondrial damage]	1.0	2	1	0	0
4730	295	multivariate Cox proportional hazard regression modeling	[multivariate Cox proportional hazards regression modeling]	1.0	6	1	0	0
4731	295	57-year-old man	[57-year-old man]	1.0	2	1	0	0
4732	295	epifluorescence microscopy	[epifluorescence microscopy]	1.0	2	1	0	0
4733	295	statistical model	[statistical model]	1.0	2	1	0	0
4734	295	extracorporeal membrane oxygenation on function	[extracorporeal membrane oxygenation on function]	1.0	5	2	2	2
4735	295	rehospitalization of medicare fee-for-service beneficiary	[rehospitalization of medicare fee-for-service beneficiaries]	1.0	5	1	0	0
4736	295	unfavorable outcome	[unfavorable outcome]	1.0	2	2	1	1
4737	295	surgical ring	[surgical ring]	1.0	2	1	0	0
4738	295	myocardial DD	[myocardial DD]	1.0	2	2	1	1
4739	295	mouse model lack murine resistin	[mouse model lacking murine resistin]	1.0	5	1	0	0
4740	295	occlusion time	[occlusion time]	1.0	2	1	0	0
4741	295	uninephrectomy a	[uninephrectomy AN]	1.0	2	1	0	0
4742	295	pathological hypertrophy	[pathological hypertrophy]	1.0	2	1	0	0
4743	295	pde2 overexpression in healthy cardiomyocyte	[PDE2 overexpression in healthy cardiomyocytes]	1.0	5	1	0	0
4744	295	congestive symptom	[congestive symptoms]	1.0	2	1	0	0
4745	295	heart failure patient with device	[heart failure patients with devices]	1.0	5	1	0	0
4746	295	proximal lad	[proximal LAD]	1.0	2	1	0	0
4747	295	chronic hf-ref	[chronic HF-REF]	1.0	2	1	0	0
4748	295	low tapse	[lower TAPSE]	1.0	2	1	0	0
4749	295	prognosis of patient with CHF	[prognosis of patients with CHF]	1.0	5	1	0	0
4750	295	aerobic exercise	[aerobic exercise]	1.0	2	2	2	2
4751	295	cognitive impairment with 6-month mortality	[cognitive impairment with 6-month mortality]	1.0	5	1	0	0
4752	295	5.5 mmol	[5.5 mmol]	1.0	2	2	1	1
4753	295	reference list	[reference lists]	1.0	2	1	0	0
4754	295	statistical parameter	[statistical parameters]	1.0	2	1	0	0
4755	295	interaction with exercise training in patient	[interactions with exercise training in patients]	1.0	6	1	0	0
4756	295	young athlete	[young athletes]	1.0	2	2	2	2
4757	295	mitral regurgitation as well as	[Mitral regurgitation as well as]	1.0	5	1	0	0
4758	295	hr 1.30	[HR 1.30]	1.0	2	1	0	0
4759	295	hr 1.36	[HR 1.36]	1.0	2	1	0	0
4760	295	tapse longitudinal RV fiber shortening	[TAPSE longitudinal RV fiber shortening]	1.0	5	1	0	0
4761	295	ischemic right	[ischemic right]	1.0	2	1	0	0
4762	295	11 year	[11 years]	1.0	2	1	0	0
4763	295	initial result	[initial results]	1.0	2	1	0	0
4764	295	heart rate variability in risk stratification	[Heart rate variability in risk stratification]	1.0	6	1	0	0
4765	295	myocardial infarction a community study	[myocardial infarction a community study]	1.0	5	1	0	0
4766	295	bisoprolol b	[bisoprolol B]	1.0	2	1	0	0
4767	295	cell yield	[cell yield]	1.0	2	1	0	0
4768	295	sinus rhythm hazard ratio hr	[sinus rhythm hazard ratio HR]	1.0	5	1	0	0
4769	295	home environment	[home environment]	1.0	2	1	0	0
4770	295	hr 1.07	[HR 1.07]	1.0	2	1	0	0
4771	295	duration of mechanical cardiac support	[duration of mechanical cardiac support]	1.0	5	1	0	0
4772	295	intact heart in experimental model	[intact hearts in experimental models]	1.0	5	1	0	0
4773	295	patient with ejection fraction hfpef	[patients with ejection fraction HFpEF]	1.0	5	1	0	0
4774	295	examine the major safety measure	[examining the major safety measures]	1.0	5	1	0	0
4775	295	contractile efficiency	[contractile efficiency]	1.0	2	1	0	0
4776	295	however a important disease accounting	[however an important disease accounting]	1.0	5	1	0	0
4777	295	left bundle branch block odd ratio	[left bundle branch block odds ratio]	1.0	6	1	0	0
4778	295	gene expression profiling of cardiomyocyte	[Gene expression profiling of cardiomyocytes]	1.0	5	1	0	0
4779	295	eplerenone in patient with hf-ref	[eplerenone in patients with HF-REF]	1.0	5	1	0	0
4780	295	gly16 haplotype of the β2-receptor	[Gly16 haplotype of the β2-receptor]	1.0	5	1	0	0
4781	295	end-diastolic volume	[end-diastolic volume]	1.0	2	1	0	0
4782	295	many patient	[many patients]	1.0	2	1	0	0
4783	295	aberrant reactivation of embryonic gene program	[aberrant reactivation of embryonic gene programs]	1.0	6	1	0	0
4784	295	serum	[serum]	1.0	1	11	6	6
4785	295	understand of chronic heart failure HF	[Understanding of chronic heart failure HF]	1.0	6	1	0	0
4786	295	anthracycline metabolism	[anthracycline metabolism]	1.0	2	1	0	0
4787	295	new drug	[newer drugs]	1.0	2	2	1	1
4788	295	ser83 phosphorylation	[Ser83 phosphorylation]	1.0	2	1	0	0
4789	295	6-month period	[6-month period]	1.0	2	1	0	0
4790	295	bradycardic response	[bradycardic response]	1.0	2	1	0	0
4791	295	activator of abnormal scn5a mrna splicing	[activators of abnormal SCN5A mRNA splicing]	1.0	6	1	0	0
4792	295	need for strict statistical standard	[need for strict statistical standards]	1.0	5	1	0	0
4793	295	cs p	[CS P]	1.0	2	1	0	0
4794	295	Median follow-up	[Median follow-up]	1.0	2	1	0	0
4795	295	ventricular strain	[ventricular strain]	1.0	2	2	2	2
4796	295	valve procedure	[valve procedure]	1.0	2	2	2	2
4797	295	Resynchronization-Defibrillation for heart Failure Trial	[Resynchronization-Defibrillation for Heart Failure Trial]	1.0	5	1	0	0
4798	295	echocardiographic outcome	[echocardiographic outcomes]	1.0	2	1	0	0
4799	295	Medical outcome	[Medical Outcomes]	1.0	2	2	1	1
4800	295	statistical improvement	[statistical improvement]	1.0	2	1	0	0
4801	295	different approach	[Different approaches]	1.0	2	1	0	0
4802	295	acute kidney injury during spironolactone use	[acute kidney injury during spironolactone use]	1.0	6	1	0	0
4803	295	current cardiology	[current cardiology]	1.0	2	1	0	0
4804	295	biventricular dysfunction	[biventricular dysfunction]	1.0	2	1	0	0
4805	295	annular size	[annular size]	1.0	2	2	1	1
4806	295	metoprolol hr	[metoprolol HR]	1.0	2	1	0	0
4807	295	CRT implantation	[CRT implantation]	1.0	2	1	0	0
4808	295	Exercise adherence	[Exercise Adherence]	1.0	2	1	0	0
4809	295	enhancement of dapc protein level	[enhancement of DAPC protein levels]	1.0	5	1	0	0
4810	295	individual measure	[individual measures]	1.0	2	1	0	0
4811	295	evaluation of patient with RAS	[evaluation of patients with RAS]	1.0	5	1	0	0
4812	295	mitochondrial pathway	[mitochondrial pathways]	1.0	2	1	0	0
4813	295	HF tissue	[HF tissue]	1.0	2	2	2	2
4814	295	m respectively	[ms respectively]	1.0	2	2	1	1
4815	295	30-day death	[30-day death]	1.0	2	1	0	0
4816	295	heart failure a common disorder	[heart failure a common disorder]	1.0	5	1	0	0
4817	295	protein kinase a subunit expression	[protein kinase A subunit expression]	1.0	5	1	0	0
4818	295	75 year	[75 years]	1.0	2	2	1	1
4819	295	current status	[current status]	1.0	2	2	2	2
4820	295	follow-up 1385	[follow-up 1385]	1.0	2	1	0	0
4821	295	previous pacemaker	[previous pacemaker]	1.0	2	1	0	0
4822	295	LV end-diastolic pressure in 20 week	[LV end-diastolic pressure in 20 weeks]	1.0	6	1	0	0
4823	295	diabete status	[diabetes status]	1.0	2	1	0	0
4824	295	baseline HRQoL	[baseline HRQoL]	1.0	2	1	0	0
4825	295	2.0±3.2 millileter increase in vo2max	[2.0±3.2 mL increase in VO2max]	1.0	5	1	0	0
4826	295	versus kg	[vs kg]	1.0	2	1	0	0
4827	295	promising biomarker	[promising biomarker]	1.0	2	2	1	1
4828	295	6-month mortality	[6-month mortality]	1.0	2	1	0	0
4829	295	lvad support on postoperative survival	[LVAD support on postoperative survival]	1.0	5	1	0	0
4830	295	≥70 year	[≥70 years]	1.0	2	2	1	1
4831	295	50 mg	[50 mg]	1.0	2	2	2	2
4832	295	report in vivo phosphorylation site	[reports in vivo phosphorylation sites]	1.0	5	1	0	0
4833	295	SCHFI v.6.2	[SCHFI v.6.2]	1.0	2	1	0	0
4834	295	poc technology	[POC technology]	1.0	2	1	0	0
4835	295	low mitral e wave ratio	[lower mitral E wave ratio]	1.0	5	1	0	0
4836	295	cardiac surgery	[cardiac surgery]	1.0	2	1	0	0
4837	295	many multisite study in practice setting	[Many multisite studies in practice settings]	1.0	6	1	0	0
4838	295	implantation strategy	[implantation strategies]	1.0	2	1	0	0
4839	295	adjustment for age sex fraction	[adjustment for age sex fraction]	1.0	5	1	0	0
4840	295	tug test	[TUG test]	1.0	2	1	0	0
4841	295	pulse-wave velocity	[pulse-wave velocity]	1.0	2	1	0	0
4842	295	adenoviral vector	[adenoviral vector]	1.0	2	1	0	0
4843	295	certain stimulus	[certain stimuli]	1.0	2	1	0	0
4844	295	1.5 m	[1.5 m]	1.0	2	1	0	0
4845	295	Witness with sickle cell disease	[Witness with sickle cell disease]	1.0	5	1	0	0
4846	295	275 patient	[275 patients]	1.0	2	1	0	0
4847	295	grade weak recommendation low-quality evidence	[Grade weak recommendation low-quality evidence]	1.0	5	1	0	0
4848	295	average hospital rate for HF patient	[Average hospital rates for HF patients]	1.0	6	1	0	0
4849	295	waist circumference	[waist circumference]	1.0	2	1	0	0
4850	295	Cox regression with time-varying covariate	[Cox regression with time-varying covariates]	1.0	5	1	0	0
4851	295	measure heart failure care by readmission	[Measuring heart failure care by readmission]	1.0	6	1	0	0
4852	295	wild-type rad	[wild-type Rad]	1.0	2	1	0	0
4853	295	6317 patient	[6317 patients]	1.0	2	1	0	0
4854	295	change in the c statistic	[changes in the C statistic]	1.0	5	1	0	0
4855	295	second HF	[second HF]	1.0	2	1	0	0
4856	295	additive for peak vo2 joint effect	[additive for peak VO2 joint effect]	1.0	6	1	0	0
4857	295	Main etiology of HF in LA	[Main etiologies of HF in LA]	1.0	6	1	0	0
4858	295	anterior descend	[anterior descending]	1.0	2	1	0	0
4859	295	experimental procedure	[experimental procedures]	1.0	2	2	1	1
4860	295	specific antagomir	[specific antagomir]	1.0	2	1	0	0
4861	295	subcellular alteration	[subcellular alterations]	1.0	2	1	0	0
4862	295	adult patient with heart disease	[adult patients with heart disease]	1.0	5	2	1	1
4863	295	promising alternative for this population	[promising alternative for this population]	1.0	5	1	0	0
4864	295	echo-doppler cardiography	[echo-Doppler cardiography]	1.0	2	1	0	0
4865	295	bottleneck shape	[bottleneck shape]	1.0	2	1	0	0
4866	295	3 trial	[3 trials]	1.0	2	2	1	1
4867	295	30-day readmission rate use three metric	[30-day readmission rates using three metrics]	1.0	6	1	0	0
4868	295	diseased cardiomyocyte	[diseased cardiomyocytes]	1.0	2	1	0	0
4869	295	plateau phase of action potential	[plateau phase of action potentials]	1.0	5	1	0	0
4870	295	sitagliptin for saxagliptin versus pioglitazone	[sitagliptin for saxagliptin versus pioglitazone]	1.0	5	1	0	0
4871	295	rate-control group	[rate-control groups]	1.0	2	2	1	1
4872	295	10000 pair of virtual cohort	[10,000 pairs of virtual cohorts]	1.0	5	1	0	0
4873	295	prognostic implication	[prognostic implications]	1.0	2	1	0	0
4874	295	left atrium	[left atrium]	1.0	2	1	0	0
4875	295	ischemic mr with LV dilatation	[ischemic MR with LV dilatation]	1.0	5	1	0	0
4876	295	primary mechanism	[primary mechanism]	1.0	2	1	0	0
4877	295	receptor kinase-2	[receptor kinase-2]	1.0	2	2	2	2
4878	295	present with a most responsible diagnosis	[presenting with a most responsible diagnosis]	1.0	6	1	0	0
4879	295	safe means improve muscle function	[safe means improving muscle function]	1.0	5	1	0	0
4880	295	have nyha class iiib symptom	[having NYHA class IIIB symptoms]	1.0	5	1	0	0
4881	295	International Classification	[International Classification]	1.0	2	2	2	2
4882	295	statistical significance	[statistical significance]	1.0	2	1	0	0
4883	295	plasma of heart failure patient	[plasma of heart failure patients]	1.0	5	1	0	0
4884	295	body composition a prospective study	[body composition a prospective study]	1.0	5	1	0	0
4885	295	significant morbidity	[significant morbidity]	1.0	2	1	0	0
4886	295	arterial hypertension	[arterial hypertension]	1.0	2	2	2	2
4887	295	right ventricle	[right ventricle]	1.0	2	2	2	2
4888	295	62 year	[62 years]	1.0	2	1	0	0
4889	295	100 old obese participant mean	[100 older obese participants mean]	1.0	5	1	0	0
4890	295	cardiac vagal	[cardiac vagal]	1.0	2	1	0	0
4891	295	≥1 year	[≥1 year]	1.0	2	1	0	0
4892	295	sham group	[sham group]	1.0	2	1	0	0
4893	295	statistically significant improvement in outcome rating	[statistically significant improvement in outcome ratings]	1.0	6	1	0	0
4894	295	peritoneal dialysis PD for long management	[Peritoneal dialysis PD for long-term management]	1.0	6	1	0	0
4895	295	low no production of ec	[lower NO production of EC]	1.0	5	1	0	0
4896	295	terminal region	[terminal regions]	1.0	2	1	0	0
4897	295	pathophysiologic mechanism	[pathophysiologic mechanism]	1.0	2	2	1	1
4898	295	driveline injury	[driveline injury]	1.0	2	1	0	0
4899	295	sham explant	[sham explants]	1.0	2	1	0	0
4900	295	coronary intervention	[coronary intervention]	1.0	2	2	2	2
4901	295	metabolic abnormality	[metabolic abnormalities]	1.0	2	1	0	0
4902	295	setting other than hospital discharge	[settings other than hospital discharge]	1.0	5	1	0	0
4903	295	Cardiac c-kit	[Cardiac c-Kit]	1.0	2	1	0	0
4904	295	4.2 METs vs. 5.7 METs	[4.2 METs vs. 5.7 METs]	1.0	5	1	0	0
4905	295	vasopressin type 2 receptor antagonist	[vasopressin type 2 receptor antagonist]	1.0	5	1	0	0
4906	295	prognostic information	[prognostic information]	1.0	2	2	2	2
4907	295	Chronic Kidney	[Chronic Kidney]	1.0	2	1	0	0
4908	295	2.1 kg versus 2.5 kg	[2.1 kg vs 2.5 kg]	1.0	5	1	0	0
4909	295	prescribe guideline-recommended medication with heart failure	[prescribing guideline-recommended medications with heart failure]	1.0	6	1	0	0
4910	295	participate in a multihospital study	[Participating in a multihospital study]	1.0	5	1	0	0
4911	295	AlphaLISA immunoassay	[AlphaLISA immunoassays]	1.0	2	1	0	0
4912	295	apoptotic cell	[apoptotic cells]	1.0	2	1	0	0
4913	295	receiver curve	[receiver curve]	1.0	2	2	2	2
4914	295	behavioural-change intervention in chronic disease	[behavioural-change interventions in chronic disease]	1.0	5	1	0	0
4915	295	4.4 mm	[4.4 mm]	1.0	2	1	0	0
4916	295	time-dependent covariate	[time-dependent covariates]	1.0	2	1	0	0
4917	295	limited datum	[limited data]	1.0	2	1	0	0
4918	295	intubation rate	[Intubation rates]	1.0	2	1	0	0
4919	295	aim of the present study	[aim of the present study]	1.0	5	1	0	0
4920	295	by imaging	[By imaging]	1.0	2	1	0	0
4921	295	patient a Trial investigate Outcome	[patients A Trial Investigating Outcomes]	1.0	5	1	0	0
4922	295	long 4-year survival of patient	[long-term 4-year survival of patients]	1.0	5	1	0	0
4923	295	atrial pressure	[atrial pressure]	1.0	2	2	2	2
4924	295	21 patient	[21 patients]	1.0	2	1	0	0
4925	295	Renin-angiotensin-aldosterone system inhibitor in heart failure	[Renin-angiotensin-aldosterone system inhibitors in heart failure]	1.0	6	1	0	0
4926	295	basic helix-loop-helix bhlh transcription factor	[basic helix-loop-helix bHLH transcription factor]	1.0	5	1	0	0
4927	295	inverse correlation	[inverse correlation]	1.0	2	1	0	0
4928	295	exercise protocol with gas analysis	[exercise protocol with gas analysis]	1.0	5	1	0	0
4929	295	long axis	[long axis]	1.0	2	1	0	0
4930	295	interaction term	[Interaction term]	1.0	2	2	1	1
4931	295	antibody target nonglycosylated epitope p	[antibodies targeting nonglycosylated epitopes P]	1.0	5	1	0	0
4932	295	treatment of MI animal with metoprolol	[Treatment of MI animals with metoprolol]	1.0	6	1	0	0
4933	295	point-of-care system	[Point-of-care systems]	1.0	2	1	0	0
4934	295	require support	[requiring support]	1.0	2	2	2	2
4935	295	membrane oxygenation on renal function	[membrane oxygenation on renal function]	1.0	5	2	2	2
4936	295	novel finding	[novel finding]	1.0	2	1	0	0
4937	295	heart failure index version schfi	[Heart Failure Index Version SCHFI]	1.0	5	1	0	0
4938	295	leaflet resection	[leaflet resection]	1.0	2	1	0	0
4939	295	important comorbidity	[important comorbidities]	1.0	2	1	0	0
4940	295	hdl-bound malondialdehyde	[HDL-bound malondialdehyde]	1.0	2	1	0	0
4941	295	crucial problem of current cardiology	[crucial problem of current cardiology]	1.0	5	1	0	0
4942	295	right function	[right function]	1.0	2	2	2	2
4943	295	fourteen electronic database include MEDLINE	[Fourteen electronic databases including MEDLINE]	1.0	5	1	0	0
4944	295	Depression Inventory	[Depression Inventory]	1.0	2	1	0	0
4945	295	HF concurrent with AMI admission	[HF concurrent with AMI admission]	1.0	5	1	0	0
4946	295	careful evaluation of the surgical indication	[careful evaluation of the surgical indications]	1.0	6	1	0	0
4947	295	liver disease	[liver disease]	1.0	2	2	2	2
4948	295	nine pig	[nine pigs]	1.0	2	1	0	0
4949	295	multicenter study of exercise training	[multicenter study of exercise training]	1.0	5	1	0	0
4950	295	individualized approach	[individualized approaches]	1.0	2	1	0	0
4951	295	uneventful recovery	[uneventful recovery]	1.0	2	1	0	0
4952	295	life-threatening anemia	[life-threatening anemia]	1.0	2	1	0	0
4953	295	only modest effect on heart failure	[only modest effects on heart failure]	1.0	6	1	0	0
4954	295	transform growth factor beta-dependent yield	[transforming growth factor beta-dependent yield]	1.0	5	1	0	0
4955	295	policy recommendation	[policy recommendations]	1.0	2	1	0	0
4956	295	combination into a echocardiographic score	[Combination into an echocardiographic score]	1.0	5	1	0	0
4957	295	cav1.2 channel	[CaV1.2 channels]	1.0	2	1	0	0
4958	295	cardiac activity	[cardiac activity]	1.0	2	2	2	2
4959	295	precede mechanism	[preceding mechanisms]	1.0	2	1	0	0
4960	295	common application of readmission metric	[common applications of readmission metrics]	1.0	5	1	0	0
4961	295	myocardial washout	[myocardial washout]	1.0	2	1	0	0
4962	295	time death	[time death]	1.0	2	1	0	0
4963	295	LV ejection fraction of 0.40	[LV ejection fraction of 0.40]	1.0	5	1	0	0
4964	295	bet family bromodomain protein bet	[BET family bromodomain proteins BETs]	1.0	5	1	0	0
4965	295	high psss	[higher PSSS]	1.0	2	1	0	0
4966	295	thirty hfpef patient aged 69 year	[Thirty HFpEF patients aged 69 years]	1.0	6	1	0	0
4967	295	online material	[online material]	1.0	2	1	0	0
4968	295	high level of social support	[higher levels of social support]	1.0	5	1	0	0
4969	295	regional strain	[regional strain]	1.0	2	2	2	2
4970	295	major change	[Major changes]	1.0	2	1	0	0
4971	295	atrial tachyarrhythmias	[atrial tachyarrhythmias]	1.0	2	1	0	0
4972	295	cgmp synthesis via oxide donor	[cGMP synthesis via oxide donors]	1.0	5	1	0	0
4973	295	11 kg in the exercise	[11 kg in the exercise]	1.0	5	1	0	0
4974	295	readmission quality	[readmission quality]	1.0	2	1	0	0
4975	295	otherwise healthy heart muscle cell	[otherwise healthy heart muscle cells]	1.0	5	1	0	0
4976	295	follow-up echocardiogram	[follow-up echocardiograms]	1.0	2	1	0	0
4977	295	use trichrome blue histologic analysis	[using trichrome blue histologic analysis]	1.0	5	1	0	0
4978	295	second evaluation	[second evaluation]	1.0	2	1	0	0
4979	295	four year	[Four years]	1.0	2	1	0	0
4980	295	genomic scale	[genomic scale]	1.0	2	1	0	0
4981	295	Secondary endpoint	[Secondary endpoints]	1.0	2	1	0	0
4982	295	measurement value of 1.6 second	[measurement value of 1.6 seconds]	1.0	5	1	0	0
4983	295	diuretic effect of natriuretic peptide	[diuretic effect of natriuretic peptides]	1.0	5	1	0	0
4984	295	end-stage renal disease in outpatient	[end-stage renal disease in outpatients]	1.0	5	1	0	0
4985	295	pre-participation screen of young athlete	[pre-participation screening of young athletes]	1.0	5	1	0	0
4986	295	CI 0.018	[CI 0.018]	1.0	2	1	0	0
4987	295	exercise variable	[exercise variables]	1.0	2	2	1	1
4988	295	two hundred ninety-three HF patient hfref	[Two hundred ninety-three HF patients HFrEF]	1.0	6	1	0	0
4989	295	mass spectrometry	[Mass spectrometry]	1.0	2	1	0	0
4990	295	cellular metabolism	[cellular metabolism]	1.0	2	1	0	0
4991	295	February 2009	[February 2009]	1.0	2	1	0	0
4992	295	2137 patient	[2137 patients]	1.0	2	1	0	0
4993	295	independent association between spironolactone use	[independent association between spironolactone use]	1.0	5	1	0	0
4994	295	pharmacological treatment	[Pharmacological treatment]	1.0	2	2	1	1
4995	295	809 patient	[809 patients]	1.0	2	1	0	0
4996	295	eventual resort	[eventual resort]	1.0	2	1	0	0
4997	295	muscle strength	[muscle strength]	1.0	2	1	0	0
4998	295	nt-pro bnp	[NT-pro BNP]	1.0	2	1	0	0
4999	295	percentage point	[percentage points]	1.0	2	2	2	2
5000	295	regard the circulate form of nt-probnp	[regarding the circulating forms of NT-proBNP]	1.0	6	1	0	0
5001	295	transgenic mouse	[transgenic mice]	1.0	2	1	0	0
5002	295	x-ray absorptiometry	[X-ray absorptiometry]	1.0	2	2	2	2
5003	295	second-generation sulfonylurea	[second-generation sulfonylureas]	1.0	2	1	0	0
5004	295	composite measure of quality for HF	[Composite measures of quality for HF]	1.0	6	1	0	0
5005	295	other group	[other groups]	1.0	2	2	2	2
5006	295	physical therapy	[physical therapy]	1.0	2	1	0	0
5007	295	mouse HF	[mouse HF]	1.0	2	2	2	2
5008	295	TissueFAXS technology	[TissueFAXS technology]	1.0	2	1	0	0
5009	295	less c-kit	[less c-Kit]	1.0	2	1	0	0
5010	295	user of bisphosphonate between 1996	[users of bisphosphonates between 1996]	1.0	5	1	0	0
5011	295	diagnostic evaluation	[diagnostic evaluations]	1.0	2	1	0	0
5012	295	current status of np measurement	[current status of NP measurement]	1.0	5	1	0	0
5013	295	protective peptide	[protective peptides]	1.0	2	1	0	0
5014	295	health service	[health service]	1.0	2	2	1	1
5015	295	left ventricular diastolic end diameter	[left ventricular diastolic end diameter]	1.0	5	2	1	1
5016	295	hr 0.90	[HR 0.90]	1.0	2	1	0	0
5017	295	hr 0.91	[HR 0.91]	1.0	2	1	0	0
5018	295	sarcomere shortening	[sarcomere shortening]	1.0	2	1	0	0
5019	295	90-day mortality	[90-day mortality]	1.0	2	1	0	0
5020	295	paucity of datum examine outcome	[paucity of data examining outcomes]	1.0	5	1	0	0
5021	295	hr 0.87	[HR 0.87]	1.0	2	1	0	0
5022	295	use the process redesign contextual framework	[using the Process Redesign contextual framework]	1.0	6	1	0	0
5023	295	Age dysfunction	[Age dysfunction]	1.0	2	1	0	0
5024	295	cardiac progenitor	[cardiac progenitor]	1.0	2	1	0	0
5025	295	beneficial effect of beta-blocker therapy	[beneficial effects of beta-blocker therapy]	1.0	5	1	0	0
5026	295	hospital characteristic	[hospital characteristics]	1.0	2	1	0	0
5027	295	thereby alter the gene expression profile	[thereby altering the gene expression profile]	1.0	6	1	0	0
5028	295	difference in plasma b-type peptide level	[differences in plasma B-type peptide levels]	1.0	6	1	0	0
5029	295	bromodomain inhibition	[Bromodomain inhibition]	1.0	2	1	0	0
5030	295	56 year	[56 years]	1.0	2	1	0	0
5031	295	hr 0.51	[HR 0.51]	1.0	2	1	0	0
5032	295	clinical symptom	[clinical symptoms]	1.0	2	1	0	0
5033	295	cardiac gene	[cardiac gene]	1.0	2	2	1	1
5034	295	STS HH	[STS HH]	1.0	2	2	2	2
5035	295	ongoing rhythm	[ongoing rhythm]	1.0	2	1	0	0
5036	295	Health ABC short performance Battery	[Health ABC Short Performance Battery]	1.0	5	1	0	0
5037	295	addition of low-dose dopamine 2 μg	[addition of low-dose dopamine 2 μg]	1.0	6	1	0	0
5038	295	Ambulatory heart Failure Trial RAFT	[Ambulatory Heart Failure Trial RAFT]	1.0	5	1	0	0
5039	295	use Nursing Outcome Classification NOC	[using Nursing Outcomes Classification NOC]	1.0	5	1	0	0
5040	295	severe ischemia	[severe ischemia]	1.0	2	1	0	0
5041	295	careful consideration	[Careful consideration]	1.0	2	1	0	0
5042	295	HNorm subject	[HNorm subjects]	1.0	2	1	0	0
5043	295	clinical implication	[clinical implications]	1.0	2	1	0	0
5044	295	longitudinal analysis use medicare datum	[longitudinal analysis using medicare data]	1.0	5	1	0	0
5045	295	Mechanical dyssynchrony	[Mechanical dyssynchrony]	1.0	2	1	0	0
5046	295	absolute change	[absolute change]	1.0	2	2	2	2
5047	295	indeterminable threshold in heart failure	[indeterminable threshold in heart failure]	1.0	5	1	0	0
5048	295	Comparison of predictor of hospitalization	[Comparison of predictors of hospitalization]	1.0	5	1	0	0
5049	295	inclusion criterion	[inclusion criteria]	1.0	2	2	1	1
5050	295	sst2 concentration	[sST2 concentrations]	1.0	2	1	0	0
5051	295	antibody target the extreme N termini	[antibodies targeting the extreme N termini]	1.0	6	1	0	0
5052	295	effective target in the treatment	[effective target in the treatment]	1.0	5	1	0	0
5053	295	heterogenous improvement in ejection fraction	[Heterogenous improvement in ejection fraction]	1.0	5	1	0	0
5054	295	rat model	[rat model]	1.0	2	1	0	0
5055	295	cardiorespiratory fitness	[Cardiorespiratory fitness]	1.0	2	2	2	2
5056	295	improvement in the vad group	[improvement in the VAD group]	1.0	5	2	2	2
5057	295	peritoneal dialysis	[peritoneal dialysis]	1.0	2	2	1	1
5058	295	polytetrafluoroethylene tube	[polytetrafluoroethylene tube]	1.0	2	1	0	0
5059	295	renal dnx	[renal DNx]	1.0	2	2	1	1
5060	295	four group	[four groups]	1.0	2	2	1	1
5061	295	underlying pathophysiology of heart failure	[underlying pathophysiology of heart failure]	1.0	5	1	0	0
5062	295	multivariable analysis	[multivariable analysis]	1.0	2	2	1	1
5063	295	Connecticut Health Center 398 patient	[Connecticut Health Center 398 patients]	1.0	5	1	0	0
5064	295	postoperative survival	[postoperative survival]	1.0	2	1	0	0
5065	295	left atrial area hazard ratio	[left atrial area hazard ratio]	1.0	5	1	0	0
5066	295	high risk of 30-day death	[higher risk of 30-day death]	1.0	5	1	0	0
5067	295	congestive HF	[congestive HF]	1.0	2	1	0	0
5068	295	41-year-old man with cardiac arrest	[41-year-old man with cardiac arrest]	1.0	5	1	0	0
5069	295	better-than-usual support	[better-than-usual support]	1.0	2	1	0	0
5070	295	major parameter	[major parameter]	1.0	2	1	0	0
5071	295	median bnp in woman versus man	[median BNP in women vs men]	1.0	6	1	0	0
5072	295	cardiac hypertrophy in tta animal	[cardiac hypertrophy in TTA animals]	1.0	5	1	0	0
5073	295	224 man mean 65±12 year	[224 men mean 65±12 years]	1.0	5	1	0	0
5074	295	antiarrhythmic medication	[antiarrhythmic medication]	1.0	2	1	0	0
5075	295	5 patient as control without exercise	[5 patients as control without exercise]	1.0	6	1	0	0
5076	295	toxicity on systemic blood pressure	[toxicity on systemic blood pressure]	1.0	5	1	0	0
5077	295	30-day mortality	[30-day mortality]	1.0	2	2	2	2
5078	295	high mortality than several cancer	[higher mortality than several cancers]	1.0	5	1	0	0
5079	295	originate from the central pattern generator	[originating from the central pattern generator]	1.0	6	1	0	0
5080	295	active individual	[active individuals]	1.0	2	1	0	0
5081	295	baseline follow-up level of paf	[Baseline follow-up levels of PAF]	1.0	5	1	0	0
5082	295	mi-induced decrease in septum systolic thickness	[MI-induced decreases in septum systolic thickness]	1.0	6	1	0	0
5083	295	use cardiac magnetic resonance t1 mapping	[using cardiac magnetic resonance T1 mapping]	1.0	6	1	0	0
5084	295	survivor of childhood malignant disease	[survivors of childhood malignant disease]	1.0	5	1	0	0
5085	295	time-dependent variable	[time-dependent variable]	1.0	2	1	0	0
5086	295	performance measurement	[performance measurement]	1.0	2	1	0	0
5087	295	internal consistency	[internal consistency]	1.0	2	2	1	1
5088	295	right artery	[right artery]	1.0	2	2	1	1
5089	295	pathological cardiac gene expression programme	[pathological cardiac gene expression programme]	1.0	5	1	0	0
5090	295	resynchronization therapy with a defibrillator	[resynchronization therapy with a defibrillator]	1.0	5	2	2	2
5091	295	average length of stay 37	[average length of stay 37]	1.0	5	1	0	0
5092	295	fundamental definition of the distinctive component	[fundamental definitions of the distinctive components]	1.0	6	1	0	0
5093	295	old counterpart	[older counterparts]	1.0	2	1	0	0
5094	295	Candesartan in heart failure Assessment	[Candesartan in Heart Failure Assessment]	1.0	5	1	0	0
5095	295	outcome among patient with HF	[outcomes among patients with HF]	1.0	5	1	0	0
5096	295	antiplatelet drug	[antiplatelet drugs]	1.0	2	1	0	0
5097	295	most datum	[Most data]	1.0	2	1	0	0
5098	295	log-rank testing	[log-rank testing]	1.0	2	1	0	0
5099	295	self-care confidence	[Self-Care Confidence]	1.0	2	1	0	0
5100	295	nursing action	[nursing actions]	1.0	2	1	0	0
5101	295	pulmonary embolectomy	[pulmonary embolectomy]	1.0	2	1	0	0
5102	295	50 mmol	[50 mmol]	1.0	2	1	0	0
5103	295	LV systolic index LV ejection fraction	[LV systolic indices LV ejection fraction]	1.0	6	1	0	0
5104	295	besides target	[Besides targets]	1.0	2	1	0	0
5105	295	primary outcome hospitalization for HF	[primary outcome hospitalization for HF]	1.0	5	1	0	0
5106	295	regression line	[regression line]	1.0	2	2	1	1
5107	295	need of cardiopulmonary resuscitation cpr	[need of cardiopulmonary resuscitation CPR]	1.0	5	1	0	0
5108	295	only after 4 week of pacing	[only after 4 weeks of pacing]	1.0	6	1	0	0
5109	295	relative importance for myocardial DD	[relative importance for myocardial DD]	1.0	5	1	0	0
5110	295	clinical study	[clinical studies]	1.0	2	2	2	2
5111	295	9868 participant without prevalent HF	[9868 participants without prevalent HF]	1.0	5	1	0	0
5112	295	1-year period	[1-year period]	1.0	2	1	0	0
5113	295	aldosterone antagonism in heart failure	[Aldosterone antagonism in heart failure]	1.0	5	1	0	0
5114	295	obese man	[obese men]	1.0	2	1	0	0
5115	295	transform growth factor-β tgf-β signal level	[transforming growth factor-β TGF-β signaling level]	1.0	6	1	0	0
5116	295	further study with long follow-up	[further studies with long-term follow-up]	1.0	5	1	0	0
5117	295	patient have HFrEF on diuretic	[patients having HFrEF on diuretics]	1.0	5	1	0	0
5118	295	7 day of hospital discharge	[7 days of hospital discharge]	1.0	5	1	0	0
5119	295	S12884 site	[S12884 site]	1.0	2	1	0	0
5120	295	antiarrhythmic drug	[antiarrhythmic drugs]	1.0	2	2	1	1
5121	295	cardiac inflammatory IL6 hscrp biomarker	[cardiac inflammatory IL6 hsCRP biomarkers]	1.0	5	1	0	0
5122	295	even accounting for the cost	[even accounting for the cost]	1.0	5	1	0	0
5123	295	appropriate timing	[appropriate timing]	1.0	2	1	0	0
5124	295	0.2 mg	[0.2 mg]	1.0	2	1	0	0
5125	295	pharmacologic management for acute HF	[pharmacologic management for acute HF]	1.0	5	1	0	0
5126	295	chronic heart failure in Hungary	[chronic heart failure in Hungary]	1.0	5	1	0	0
5127	295	overall improvement	[overall improvements]	1.0	2	2	2	2
5128	295	cardiomyocyte bioenergetics	[cardiomyocyte bioenergetics]	1.0	2	1	0	0
5129	295	4 month	[4 months]	1.0	2	1	0	0
5130	295	autonomic imbalance	[autonomic imbalance]	1.0	2	1	0	0
5131	295	serum potassium level of maq	[serum potassium level of mEq]	1.0	5	1	0	0
5132	295	initial approach	[initial approach]	1.0	2	1	0	0
5133	295	heart with level of Mena	[hearts with levels of Mena]	1.0	5	1	0	0
5134	295	implantable defibrillator	[implantable defibrillator]	1.0	2	1	0	0
5135	295	participant with acute heart failure	[participants with acute heart failure]	1.0	5	1	0	0
5136	295	multiple domain	[multiple domains]	1.0	2	1	0	0
5137	295	36 patient	[36 patients]	1.0	2	1	0	0
5138	295	treatment algorithm	[Treatment algorithms]	1.0	2	1	0	0
5139	295	improve outcome in patient with fibrillation	[Improving outcomes in patients with fibrillation]	1.0	6	1	0	0
5140	295	S3991 site	[S3991 site]	1.0	2	1	0	0
5141	295	health benefit	[health benefits]	1.0	2	1	0	0
5142	295	twenty-seven study with 1887 patient	[Twenty-seven studies with 1887 patients]	1.0	5	1	0	0
5143	295	hfpef patient	[HFpEF patients]	1.0	2	2	2	2
5144	295	CRT group	[CRT group]	1.0	2	2	2	2
5145	295	selectively potentiate the adaptive response	[selectively potentiating the adaptive response]	1.0	5	1	0	0
5146	295	1.2±7.7 millileter	[1.2±7.7 mL]	1.0	2	1	0	0
5147	295	Fontan subject	[Fontan subjects]	1.0	2	2	1	1
5148	295	high barrier	[high barriers]	1.0	2	1	0	0
5149	295	proximal LCX late 2-vessel model	[proximal LCX later 2-vessel model]	1.0	5	1	0	0
5150	295	ascend phase	[ascending phase]	1.0	2	1	0	0
5151	295	association in the care group	[association in the care group]	1.0	5	1	0	0
5152	295	β-blocker median	[β-blockers median]	1.0	2	1	0	0
5153	295	renal DNx	[renal DNx]	1.0	2	2	1	1
5154	295	qualitative study	[qualitative study]	1.0	2	1	0	0
5155	295	nutritional abnormality	[nutritional abnormalities]	1.0	2	1	0	0
5156	295	few treatment	[Few treatments]	1.0	2	1	0	0
5157	295	nurse assessment of cognitive impairment	[nurse assessment of cognitive impairment]	1.0	5	1	0	0
5158	295	post-transplant morbidity	[post-transplant morbidity]	1.0	2	1	0	0
5159	295	patient in small retrospective study	[patients in small retrospective studies]	1.0	5	1	0	0
5160	295	ivabradine	[ivabradine]	1.0	1	12	8	4
5161	295	chf-inv group	[CHF-INV group]	1.0	2	1	0	0
5162	295	change in	[changes in]	1.0	2	1	0	0
5163	295	patient receive ventricular assist device support	[patients receiving ventricular assist device support]	1.0	6	1	0	0
5164	295	four group of rat Wistar-Kyoto	[Four groups of rats Wistar-Kyoto]	1.0	5	1	0	0
5165	295	HF progression	[HF progression]	1.0	2	1	0	0
5166	295	baseline echocardiography	[baseline echocardiography]	1.0	2	1	0	0
5167	295	effective rate	[effective rate]	1.0	2	2	1	1
5168	295	cardiac looping	[cardiac looping]	1.0	2	1	0	0
5169	295	novel approach	[novel approach]	1.0	2	2	1	1
5170	295	resident of Olmsted County Minnesota	[residents of Olmsted County Minnesota]	1.0	5	1	0	0
5171	295	hospital-to-home a hospital readmission reduction program	[Hospital-to-Home a hospital readmission reduction program]	1.0	6	1	0	0
5172	295	55 year	[55 years]	1.0	2	2	1	1
5173	295	special treatment	[special treatment]	1.0	2	1	0	0
5174	295	potential for success in trial	[potential for success in trials]	1.0	5	1	0	0
5175	295	interleukin receptor	[interleukin receptor]	1.0	2	1	0	0
5176	295	7 week	[7 weeks]	1.0	2	1	0	0
5177	295	change dose of β-blocker bb	[changing doses of β-blocker BB]	1.0	5	1	0	0
5178	295	functional deficit	[functional deficits]	1.0	2	1	0	0
5179	295	area under the receiver curve	[area under the receiver curve]	1.0	5	2	2	2
5180	295	overlapping part of the network	[overlapping part of the network]	1.0	5	1	0	0
5181	295	fibrosis of heart failure tissue	[fibrosis of heart failure tissue]	1.0	5	1	0	0
5182	295	economic Analysis	[Economic Analysis]	1.0	2	1	0	0
5183	295	low-strength evidence from 6 trial	[Low-strength evidence from 6 trials]	1.0	5	1	0	0
5184	295	1.02±0.16 mm	[1.02±0.16 mm]	1.0	2	1	0	0
5185	295	urgent readmission	[urgent readmission]	1.0	2	1	0	0
5186	295	Mediterranean diet score with heart failure	[Mediterranean diet scores with heart failure]	1.0	6	1	0	0
5187	295	mean age of the patient	[mean age of the patients]	1.0	5	1	0	0
5188	295	restore mitochondrial oxidative phosphorylation capacity	[restoring mitochondrial oxidative phosphorylation capacity]	1.0	5	1	0	0
5189	295	outcome in chronic heart failure	[outcomes in chronic heart failure]	1.0	5	1	0	0
5190	295	novel useful mouse HF model	[novel useful mouse HF model]	1.0	5	1	0	0
5191	295	medicare datum	[medicare data]	1.0	2	2	1	1
5192	295	good result	[good results]	1.0	2	1	0	0
5193	295	prediction rule for severe cad	[prediction rule for severe CAD]	1.0	5	1	0	0
5194	295	simulation result	[simulation results]	1.0	2	1	0	0
5195	295	potential usefulness	[potential usefulness]	1.0	2	2	2	2
5196	295	mir-25 expression	[miR-25 expression]	1.0	2	1	0	0
5197	295	ring annuloplasty for ischemic regurgitation	[ring annuloplasty for ischemic regurgitation]	1.0	5	2	2	2
5198	295	19.4 month	[19.4 months]	1.0	2	1	0	0
5199	295	reduce the risk of thromboembolic event	[reducing the risk of thromboembolic events]	1.0	6	1	0	0
5200	295	dearth of biomarker-guided clinical trial	[dearth of biomarker-guided clinical trials]	1.0	5	1	0	0
5201	295	bb dose	[BB dose]	1.0	2	2	2	2
5202	295	lad model	[LAD model]	1.0	2	2	1	1
5203	295	single-arm study	[single-arm study]	1.0	2	1	0	0
5204	295	major concern	[major concerns]	1.0	2	1	0	0
5205	295	many region	[many regions]	1.0	2	1	0	0
5206	295	hr for the TNF antagonist	[HR for the TNF antagonists]	1.0	5	1	0	0
5207	295	patient with qrs 160 m	[patients with QRS 160 ms]	1.0	5	1	0	0
5208	295	low-volume site	[low-volume sites]	1.0	2	1	0	0
5209	295	leaflet repair	[leaflet repair]	1.0	2	1	0	0
5210	295	early measurement of hr variability	[early measurement of HR variability]	1.0	5	1	0	0
5211	295	ventricular pump	[ventricular pump]	1.0	2	1	0	0
5212	295	PDE superfamily	[PDE superfamily]	1.0	2	1	0	0
5213	295	co. lack of correlation of index	[CO. Lack of correlation of indices]	1.0	6	1	0	0
5214	295	160 m	[160 ms]	1.0	2	2	1	1
5215	295	interval 0.290	[interval 0.290]	1.0	2	1	0	0
5216	295	metoprolol irrespective of β2-adrenergic receptor haplotype	[metoprolol irrespective of β2-adrenergic receptor haplotype]	1.0	6	1	0	0
5217	295	Centers for Medicare Service CMS	[Centers for Medicare Services CMS]	1.0	5	1	0	0
5218	295	reduction in LV end-diastolic volume	[reduction in LV end-diastolic volume]	1.0	5	1	0	0
5219	295	patient with stable heart failure	[patients with stable heart failure]	1.0	5	2	1	1
5220	295	heart failure patient a study	[heart failure patients a study]	1.0	5	1	0	0
5221	295	30 millileter per 1.73 m 2	[30 mL per 1.73 m 2]	1.0	6	1	0	0
5222	295	titin isoform	[titin isoforms]	1.0	2	1	0	0
5223	295	chronic acf in the rat	[chronic ACF in the rat]	1.0	5	1	0	0
5224	295	stable cad	[stable CAD]	1.0	2	1	0	0
5225	295	92 participant	[92 participants]	1.0	2	1	0	0
5226	295	divergent etiology	[divergent etiology]	1.0	2	1	0	0
5227	295	increase bte in the exercise group	[increasing BTES in the exercise group]	1.0	6	1	0	0
5228	295	sst2 value	[sST2 values]	1.0	2	1	0	0
5229	295	with icc value range from .85	[with ICC values ranging from .85]	1.0	6	1	0	0
5230	295	ventricular action	[ventricular action]	1.0	2	2	1	1
5231	295	standard therapy with beta blockade	[standard therapy with beta blockade]	1.0	5	1	0	0
5232	295	heart failure among old person	[heart failure among older persons]	1.0	5	1	0	0
5233	295	frequent comorbidity in heart failure	[frequent comorbidities in heart failure]	1.0	5	1	0	0
5234	295	respective molecular pathway in patient	[respective molecular pathways in patients]	1.0	5	1	0	0
5235	295	action potential	[action potential]	1.0	2	2	2	2
5236	295	2.4 year	[2.4 years]	1.0	2	1	0	0
5237	295	surgical condition	[surgical conditions]	1.0	2	1	0	0
5238	295	significant difference in that parameter	[significant differences in those parameters]	1.0	5	1	0	0
5239	295	prevalence of HF in patient	[prevalence of HF in patients]	1.0	5	1	0	0
5240	295	Diastolic function	[Diastolic function]	1.0	2	1	0	0
5241	295	majority of patient with ras	[majority of patients with RAS]	1.0	5	1	0	0
5242	295	910 patient	[910 patients]	1.0	2	1	0	0
5243	295	1-year mortality in 28-day survivor	[1-year mortality in 28-day survivors]	1.0	5	1	0	0
5244	295	Global proteomics	[Global proteomics]	1.0	2	1	0	0
5245	295	median left ventricular ejection fraction	[median left ventricular ejection fraction]	1.0	5	1	0	0
5246	295	beta-blocker on the primary endpoint	[beta-blockers on the primary endpoint]	1.0	5	1	0	0
5247	295	heart failure mortality in man	[heart failure mortality in men]	1.0	5	1	0	0
5248	295	low expenditure	[lower expenditure]	1.0	2	2	1	1
5249	295	western blot	[Western blot]	1.0	2	2	1	1
5250	295	functional capacity for CF lvad patient	[functional capacity for CF LVAD patients]	1.0	6	1	0	0
5251	295	survival study in heart failure	[SurvIval Study in Heart Failure]	1.0	5	1	0	0
5252	295	young woman	[young woman]	1.0	2	1	0	0
5253	295	decrease in heart failure-related mortality period	[decreases in heart failure-related mortality period]	1.0	6	1	0	0
5254	295	myocardial DD of collagen deposition	[myocardial DD of collagen deposition]	1.0	5	1	0	0
5255	295	carotid baroreflex activation therapy bat	[carotid baroreflex activation therapy BAT]	1.0	5	1	0	0
5256	295	compliance with treatment of heart disease	[compliance with treatment of heart disease]	1.0	6	1	0	0
5257	295	cardiopulmonary exercise test a quality	[cardiopulmonary exercise test a quality]	1.0	5	1	0	0
5258	295	vascular endothelial growth factor VEGF	[vascular endothelial growth factor VEGF]	1.0	5	1	0	0
5259	295	emphasize the importance of follow-up	[emphasizing the importance of follow-up]	1.0	5	1	0	0
5260	295	great benefit from implantable cardioverter defibrillator-CRT	[greater benefit from implantable cardioverter defibrillator-CRT]	1.0	6	1	0	0
5261	295	ratio Bcl-2	[ratio Bcl-2]	1.0	2	1	0	0
5262	295	8 minute	[8 min]	1.0	2	1	0	0
5263	295	western Australia	[Western Australia]	1.0	2	1	0	0
5264	295	IV HF	[IV HF]	1.0	2	1	0	0
5265	295	testosterone supplementation	[testosterone supplementation]	1.0	2	2	2	2
5266	295	23 mm	[23 mm]	1.0	2	1	0	0
5267	295	hallmark of type 2 diabete	[hallmark of type 2 diabetes]	1.0	5	1	0	0
5268	295	increase in low-frequency lf ratio	[increase in low-frequency LF ratio]	1.0	5	1	0	0
5269	295	8.4 mm hg Fig 1B	[8.4 mm Hg Fig 1B]	1.0	5	1	0	0
5270	295	April 2013	[April 2013]	1.0	2	1	0	0
5271	295	single-institution cohort	[single-institution cohort]	1.0	2	1	0	0
5272	295	fail myocardium	[failing myocardium]	1.0	2	1	0	0
5273	295	physician specialty	[physician specialty]	1.0	2	1	0	0
5274	295	guidelines-heart failure	[Guidelines-Heart Failure]	1.0	2	1	0	0
5275	295	pulmonary vascular resistance hazard ratio	[pulmonary vascular resistance hazard ratio]	1.0	5	1	0	0
5276	295	heart failure in the young	[Heart failure in the young]	1.0	5	1	0	0
5277	295	conduct study in this area	[conducting studies in this area]	1.0	5	1	0	0
5278	295	effect on pb characteristic period	[effect on PB characteristics period]	1.0	5	1	0	0
5279	295	hospital in a extreme decile	[hospitals in an extreme decile]	1.0	5	1	0	0
5280	295	hospital quality	[hospital quality]	1.0	2	2	1	1
5281	295	multicenter trial	[Multicenter trial]	1.0	2	2	2	2
5282	295	extracorporeal membrane oxygenation on renal function	[extracorporeal membrane oxygenation on renal function]	1.0	6	2	1	1
5283	295	few day	[fewer days]	1.0	2	1	0	0
5284	295	experienced center	[experienced centers]	1.0	2	1	0	0
5285	295	total of 44 674 man	[total of 44 674 men]	1.0	5	1	0	0
5286	295	upcoming year	[upcoming years]	1.0	2	1	0	0
5287	295	sympathetic outflow	[sympathetic outflow]	1.0	2	1	0	0
5288	295	profile of paf biosynthetic enzyme	[profile of PAF biosynthetic enzymes]	1.0	5	1	0	0
5289	295	three trial	[Three trials]	1.0	2	1	0	0
5290	295	voltage-gated na	[voltage-gated Na]	1.0	2	1	0	0
5291	295	high-risk subgroup	[high-risk subgroups]	1.0	2	1	0	0
5292	295	ejection fraction after myocardial infarction	[ejection fraction after myocardial infarction]	1.0	5	1	0	0
5293	295	insulin-stimulated rate	[insulin-stimulated rates]	1.0	2	1	0	0
5294	295	early modern rhythm control therapy	[early modern rhythm control therapy]	1.0	5	1	0	0
5295	295	cardiac centre	[cardiac centre]	1.0	2	1	0	0
5296	295	advanced chronic obstructive pulmonary disease	[advanced chronic obstructive pulmonary disease]	1.0	5	1	0	0
5297	295	Sham-Innervated Sham-INV	[Sham-Innervated Sham-INV]	1.0	2	1	0	0
5298	295	≥65 year	[≥65 years]	1.0	2	1	0	0
5299	295	odd ratio of 6.77 p	[odds ratio of 6.77 P]	1.0	5	1	0	0
5300	295	program infrastructure	[program infrastructure]	1.0	2	1	0	0
5301	295	β-blocker hr	[β-blockers HR]	1.0	2	1	0	0
5302	295	can 2	[Ca 2]	1.0	2	2	2	2
5303	295	treadmill testing vo2max maximum oxygen consumption	[treadmill testing VO2max maximum oxygen consumption]	1.0	6	1	0	0
5304	295	endothelial growth	[endothelial growth]	1.0	2	3	2	1
5305	295	CRF n=72	[CRF n=72]	1.0	2	1	0	0
5306	295	study objective	[study objectives]	1.0	2	1	0	0
5307	295	worldwide epidemic	[worldwide epidemic]	1.0	2	1	0	0
5308	295	good model	[good model]	1.0	2	1	0	0
5309	295	multivariate assessment with the inclusion	[multivariate assessment with the inclusion]	1.0	5	1	0	0
5310	295	include death heart failure related	[including death heart failure related]	1.0	5	1	0	0
5311	295	separate sub-sample	[separate sub-sample]	1.0	2	1	0	0
5312	295	collaboration of professional from discipline	[collaboration of professionals from disciplines]	1.0	5	1	0	0
5313	295	risk of potassium 5.5 mmol	[risk of potassium 5.5 mmol]	1.0	5	1	0	0
5314	295	3 decade	[3 decades]	1.0	2	2	2	2
5315	295	oppose action on adenylyl cyclase	[opposing actions on adenylyl cyclase]	1.0	5	1	0	0
5316	295	s1pr1 downregulation	[S1PR1 downregulation]	1.0	2	1	0	0
5317	295	periprocedural complication	[periprocedural complications]	1.0	2	1	0	0
5318	295	cellular plasticity	[cellular plasticity]	1.0	2	1	0	0
5319	295	Coronary angiography	[Coronary angiography]	1.0	2	1	0	0
5320	295	time domain heart rate variability HRV	[time domain heart rate variability HRV]	1.0	6	1	0	0
5321	295	patient compliance	[patient compliance]	1.0	2	1	0	0
5322	295	visit with a familiar physician	[visits with a familiar physician]	1.0	5	1	0	0
5323	295	camp hydrolysis	[cAMP hydrolysis]	1.0	2	1	0	0
5324	295	significant trend in the risk	[significant trends in the risk]	1.0	5	1	0	0
5325	295	health-related quality-of-life	[health-related quality-of-life]	1.0	2	1	0	0
5326	295	AMI patient	[AMI patient]	1.0	2	1	0	0
5327	295	multicenter study	[multicenter study]	1.0	2	2	2	2
5328	295	downstream signal	[downstream signaling]	1.0	2	1	0	0
5329	295	possibly transplantation	[possibly transplantation]	1.0	2	1	0	0
5330	295	mrna level for β-myosin heavy chain	[mRNA level for β-myosin heavy chain]	1.0	6	1	0	0
5331	295	5 m	[5 m]	1.0	2	1	0	0
5332	295	53±12 year	[53±12 years]	1.0	2	1	0	0
5333	295	open without any clear organic lesion	[opening without any clear organic lesion]	1.0	6	1	0	0
5334	295	30-day rehospitalization	[30-day rehospitalization]	1.0	2	2	1	1
5335	295	estimate LV fill pressure in HF	[estimating LV filling pressure in HF]	1.0	6	1	0	0
5336	295	exercise tolerance in heart failure	[exercise tolerance in heart failure]	1.0	5	1	0	0
5337	295	0.07 mg	[0.07 mg]	1.0	2	1	0	0
5338	295	confidence interval	[confidence interval]	1.0	2	2	1	1
5339	295	two group with heart failure	[two groups with heart failure]	1.0	5	1	0	0
5340	295	effectiveness of Chinese herbal medicine	[Effectiveness of Chinese herbal medicine]	1.0	5	2	2	2
5341	295	reciprocal regulation in mouse heart	[reciprocal regulation in mouse hearts]	1.0	5	1	0	0
5342	295	26 participant	[26 participants]	1.0	2	1	0	0
5343	295	vehicle-treated rat	[vehicle-treated rats]	1.0	2	1	0	0
5344	295	management of patient with hypertension	[management of patients with hypertension]	1.0	5	1	0	0
5345	295	mitral fill	[mitral filling]	1.0	2	2	1	1
5346	295	1 kg	[1 kg]	1.0	2	1	0	0
5347	295	role of PDE2 in HF	[role of PDE2 in HF]	1.0	5	1	0	0
5348	295	60 millileter	[60 ml]	1.0	2	2	1	1
5349	295	multiple procedure	[Multiple procedures]	1.0	2	1	0	0
5350	295	indicator of functional status 6-mwt	[indicators of functional status 6-MWT]	1.0	5	1	0	0
5351	295	mild HF	[mild HF]	1.0	2	1	0	0
5352	295	sheet orientation	[sheet orientation]	1.0	2	1	0	0
5353	295	autonomic dysbalance	[autonomic dysbalance]	1.0	2	1	0	0
5354	295	cardioverter defibrillator	[cardioverter defibrillators]	1.0	2	2	2	2
5355	295	refractory end-stage congestive heart failure	[refractory end-stage congestive heart failure]	1.0	5	1	0	0
5356	295	additional benefit	[additional benefit]	1.0	2	2	2	2
5357	295	insulin receptor substrate 1 irs1	[insulin receptor substrates 1 IRS1]	1.0	5	1	0	0
5358	295	practice site	[practice site]	1.0	2	1	0	0
5359	295	American College of physician ACP	[American College of Physicians ACP]	1.0	5	1	0	0
5360	295	circulate cd34	[circulating CD34]	1.0	2	1	0	0
5361	295	fill flow	[filling flow]	1.0	2	2	2	2
5362	295	surgical tactic	[Surgical tactics]	1.0	2	1	0	0
5363	295	patient receive implantable cardioverter defibrillator-CRT	[patients receiving implantable cardioverter defibrillator-CRT]	1.0	5	1	0	0
5364	295	such as poor patient compliance	[such as poor patient compliance]	1.0	5	1	0	0
5365	295	disease unique	[disease unique]	1.0	2	1	0	0
5366	295	air pollution on heart failure	[air pollution on heart failure]	1.0	5	1	0	0
5367	295	erythropoiesis-sis-sis-sisg agent	[Erythropoiesis-stimulating agents]	1.0	2	1	0	0
5368	295	substantial subset	[substantial subset]	1.0	2	1	0	0
5369	295	survivor of haematopoietic cell transplantation	[survivors of haematopoietic cell transplantation]	1.0	5	1	0	0
5370	295	predict CV event in af	[predicting CV events in AF]	1.0	5	1	0	0
5371	295	continuous-flow lvas	[continuous-flow LVADs]	1.0	2	1	0	0
5372	295	mrna level for SR can 2+)-pump	[mRNA levels for SR Ca 2+)-pump]	1.0	6	1	0	0
5373	295	left ventricular assist device use	[left ventricular assist device use]	1.0	5	1	0	0
5374	295	outcome after cardiac resynchronization therapy	[outcomes after cardiac resynchronization therapy]	1.0	5	1	0	0
5375	295	1 wk	[1 wk]	1.0	2	1	0	0
5376	295	other factor	[other factors]	1.0	2	2	1	1
5377	295	fundamental mechanism of cardiac dysfunction	[fundamental mechanism of cardiac dysfunction]	1.0	5	1	0	0
5378	295	66.6 year versus 53.2 year	[66.6 years versus 53.2 years]	1.0	5	1	0	0
5379	295	ras-blocker uptitration	[RAS-blocker uptitration]	1.0	2	1	0	0
5380	295	measure frailty in heart failure	[Measuring frailty in heart failure]	1.0	5	1	0	0
5381	295	multivariate regression	[multivariate regression]	1.0	2	1	0	0
5382	295	16 patient	[16 patients]	1.0	2	2	2	2
5383	295	period versus 1 hazard ratio	[period versus 1 hazard ratio]	1.0	5	1	0	0
5384	295	moderate-intensity aerobic exercise per week	[moderate-intensity aerobic exercise per week]	1.0	5	1	0	0
5385	295	peak quadricep	[peak quadriceps]	1.0	2	2	2	2
5386	295	ring size	[ring size]	1.0	2	1	0	0
5387	295	suggest a surrogate of catabolism	[suggesting a surrogate of catabolism]	1.0	5	1	0	0
5388	295	rrna transcription	[rRNA transcription]	1.0	2	1	0	0
5389	295	reflect rapid R-R interval oscillation	[reflecting rapid R-R interval oscillations]	1.0	5	1	0	0
5390	295	321 protein	[321 proteins]	1.0	2	1	0	0
5391	295	20.8 mo	[20.8 mo]	1.0	2	1	0	0
5392	295	outcome in patient with atrial fibrillation	[outcomes in patients with atrial fibrillation]	1.0	6	1	0	0
5393	295	45 center in the State	[45 centers in the States]	1.0	5	1	0	0
5394	295	health-related quality of life Minnesota live	[health-related quality of life Minnesota Living]	1.0	6	1	0	0
5395	295	effect of a hno donor	[effects of a HNO donor]	1.0	5	1	0	0
5396	295	ambulatory patient with heart failure	[ambulatory patients with heart failure]	1.0	5	2	1	1
5397	295	47025 patient	[47,025 patients]	1.0	2	1	0	0
5398	295	β-ar stimulation	[β-AR stimulation]	1.0	2	2	2	2
5399	295	use Cox proportional hazard model	[using Cox proportional hazards models]	1.0	5	1	0	0
5400	295	CRT on versus CRT off	[CRT ON versus CRT OFF]	1.0	5	1	0	0
5401	295	treatment for heart failure HF	[treatment for heart failure HF]	1.0	5	1	0	0
5402	295	High PSSS	[Higher PSSS]	1.0	2	1	0	0
5403	295	use the Health ABC performance Battery	[using the Health ABC Performance Battery]	1.0	6	1	0	0
5404	295	chronic pah	[chronic PAH]	1.0	2	1	0	0
5405	295	management of acute heart failure	[management of acute heart failure]	1.0	5	1	0	0
5406	295	patient with a qrs complex	[patients with a QRS complex]	1.0	5	1	0	0
5407	295	refill compliance	[refill compliance]	1.0	2	2	2	2
5408	295	inhospital mortality among this subgroup	[inhospital mortality among these subgroups]	1.0	5	1	0	0
5409	295	global attenuation	[global attenuation]	1.0	2	2	2	2
5410	295	5 would	[5 d]	1.0	2	1	0	0
5411	295	western Australian administrative health datum	[Western Australian administrative health data]	1.0	5	1	0	0
5412	295	discharge 5336	[discharge 5336]	1.0	2	1	0	0
5413	295	enrollment period	[enrollment period]	1.0	2	2	2	2
5414	295	common element of successful intervention	[common elements of successful interventions]	1.0	5	1	0	0
5415	295	study population	[study population]	1.0	2	2	1	1
5416	295	afterload of patient with heart failure	[afterload of patients with heart failure]	1.0	6	1	0	0
5417	295	change in global gene expression	[changes in global gene expression]	1.0	5	1	0	0
5418	295	heart of fish lack Nucleolin	[hearts of fish lacking Nucleolin]	1.0	5	1	0	0
5419	295	improvement of the mitral valve opening	[improvement of the mitral valve opening]	1.0	6	1	0	0
5420	295	health care expenditure of patient	[health care expenditures of patients]	1.0	5	1	0	0
5421	295	cardiovascular risk factor such as obesity	[cardiovascular risk factors such as obesity]	1.0	6	1	0	0
5422	295	postoperative echocardiography	[postoperative echocardiography]	1.0	2	1	0	0
5423	295	myocardial ischaemia	[myocardial ischaemia]	1.0	2	1	0	0
5424	295	number of hospital day for participant	[number of hospital days for participants]	1.0	6	1	0	0
5425	295	community perspective	[community perspective]	1.0	2	1	0	0
5426	295	dual energy x-ray absorptiometry DXA	[dual energy X-ray absorptiometry DXA]	1.0	5	1	0	0
5427	295	patient circulation	[patient circulation]	1.0	2	1	0	0
5428	295	month 1	[month 1]	1.0	2	1	0	0
5429	295	Recent study	[Recent studies]	1.0	2	2	1	1
5430	295	life-sustaining treatment	[life-sustaining treatment]	1.0	2	2	1	1
5431	295	bad heart failure-related qol co-primary outcome	[worse heart failure-related QOL co-primary outcome]	1.0	6	1	0	0
5432	295	ischemic cardiomyopathy	[ischemic cardiomyopathy]	1.0	2	2	1	1
5433	295	phenylephrine-induced gene	[phenylephrine-induced genes]	1.0	2	1	0	0
5434	295	non-aa 4.29±0.5-4.55±0.49	[non-AAs 4.29±0.5-4.55±0.49]	1.0	2	1	0	0
5435	295	q65p substitution	[Q65P substitution]	1.0	2	1	0	0
5436	295	prevalent HF	[prevalent HF]	1.0	2	1	0	0
5437	295	42 percent	[42 percent]	1.0	2	1	0	0
5438	295	good way	[better ways]	1.0	2	1	0	0
5439	295	future perspective	[future perspectives]	1.0	2	1	0	0
5440	295	laboratory variable	[laboratory variables]	1.0	2	1	0	0
5441	295	blockade of the neuro-hormonal system	[blockade of the neuro-hormonal system]	1.0	5	1	0	0
5442	295	7 month of follow-up datum	[7 months of follow-up data]	1.0	5	1	0	0
5443	295	incremental cost-effectiveness ratio from user input	[incremental cost-effectiveness ratios from user inputs]	1.0	6	1	0	0
5444	295	hospital admission	[hospital admission]	1.0	2	2	1	1
5445	295	8 patient with CHF-NYHA-II HDL	[8 patients with CHF-NYHA-II HDL]	1.0	5	1	0	0
5446	295	old patient with breast cancer	[older patients with breast cancer]	1.0	5	1	0	0
5447	295	multiple discipline	[multiple disciplines]	1.0	2	1	0	0
5448	295	466 participant	[466 participants]	1.0	2	1	0	0
5449	295	endothelial dysfunction	[endothelial dysfunction]	1.0	2	1	0	0
5450	295	tissue from healthy control animal	[tissue from healthy control animals]	1.0	5	1	0	0
5451	295	pde2 expression	[PDE2 expression]	1.0	2	2	1	1
5452	295	more barrier	[more barriers]	1.0	2	1	0	0
5453	295	interval between local myocyte depolarization	[interval between local myocyte depolarization]	1.0	5	1	0	0
5454	295	angiotensin ii	[angiotensin II]	1.0	2	2	1	1
5455	295	grade strong recommendation moderate-quality evidence	[Grade strong recommendation moderate-quality evidence]	1.0	5	1	0	0
5456	295	have CHF	[having CHF]	1.0	2	1	0	0
5457	295	14.4±3.3 millileter	[14.4±3.3 mL]	1.0	2	1	0	0
5458	295	surgical palliation	[surgical palliation]	1.0	2	1	0	0
5459	295	228 millisecond	[228 milliseconds]	1.0	2	1	0	0
5460	295	maintain sinus rhythm at follow-up	[maintaining sinus rhythm at follow-up]	1.0	5	1	0	0
5461	295	24 telephone support STS programme	[24 telephone support STS programmes]	1.0	5	1	0	0
5462	295	several poc system measure np level	[Several POC systems measuring NP levels]	1.0	6	1	0	0
5463	295	current assay	[current assays]	1.0	2	1	0	0
5464	295	STS HH with medical support	[STS HH with medical support]	1.0	5	1	0	0
5465	295	Discharge data	[Discharge Data]	1.0	2	1	0	0
5466	295	pathophysiologic state	[pathophysiologic state]	1.0	2	1	0	0
5467	295	68 year	[68 years]	1.0	2	1	0	0
5468	295	detrimental alteration in sarcomeric microstructure	[detrimental alterations in sarcomeric microstructure]	1.0	5	1	0	0
5469	295	bad quintile	[worst quintile]	1.0	2	1	0	0
5470	295	circulate mediator of insulin resistance	[circulating mediator of insulin resistance]	1.0	5	1	0	0
5471	295	90 day	[90 days]	1.0	2	2	2	2
5472	295	12-week program	[12-week program]	1.0	2	1	0	0
5473	295	endoplasmic reticulum	[endoplasmic reticulum]	1.0	2	1	0	0
5474	295	Fontan	[Fontan]	1.0	1	11	6	6
5475	295	134 death	[134 deaths]	1.0	2	1	0	0
5476	295	1 month	[1 month]	1.0	2	2	2	2
5477	295	arrhythmia substrate	[arrhythmia substrate]	1.0	2	1	0	0
5478	295	≥7 rat	[≥7 rats]	1.0	2	1	0	0
5479	295	few cardioversion	[fewer cardioversions]	1.0	2	1	0	0
5480	295	HF pathogenesis	[HF pathogenesis]	1.0	2	2	2	2
5481	295	178 control	[178 controls]	1.0	2	1	0	0
5482	295	RGK protein	[RGK proteins]	1.0	2	1	0	0
5483	295	LV ejection fraction velocity of shortening	[LV ejection fraction velocity of shortening]	1.0	6	1	0	0
5484	295	4.9 year for alendronate- patient respectively	[4.9 years for alendronate- patients respectively]	1.0	6	1	0	0
5485	295	patient safety	[patient safety]	1.0	2	2	1	1
5486	295	risk-adjusted mortality	[risk-adjusted mortality]	1.0	2	2	2	2
5487	295	improve outcome	[improving outcomes]	1.0	2	2	2	2
5488	295	criterion standard	[criterion standard]	1.0	2	1	0	0
5489	295	H-DKO mouse	[H-DKO mice]	1.0	2	1	0	0
5490	295	exercise-induced increase in the ratio	[exercise-induced increase in the ratio]	1.0	5	1	0	0
5491	295	beta-blocker therapy on cardiac function	[beta-blocker therapy on cardiac function]	1.0	5	1	0	0
5492	295	recent hospital discharge in patient	[recent hospital discharge in patients]	1.0	5	1	0	0
5493	295	stroke volume	[stroke volume]	1.0	2	2	2	2
5494	295	104 mm	[104 mm]	1.0	2	1	0	0
5495	295	thus give rise in dyssynchronous HF	[thus giving rise in dyssynchronous HF]	1.0	6	1	0	0
5496	295	serum potassium	[serum potassium]	1.0	2	2	2	2
5497	295	myocyte differentiation	[myocyte differentiation]	1.0	2	1	0	0
5498	295	care package	[Care packages]	1.0	2	1	0	0
5499	295	gross income	[gross income]	1.0	2	2	1	1
5500	295	2.0±3.2 millileter	[2.0±3.2 mL]	1.0	2	1	0	0
5501	295	anaerobic metabolism peak respiratory quotient	[anaerobic metabolism peak respiratory quotient]	1.0	5	1	0	0
5502	295	baseline sst2 status low ≤35	[baseline sST2 status low ≤35]	1.0	5	1	0	0
5503	295	577 participant	[577 participants]	1.0	2	1	0	0
5504	295	ventricular dilatation	[ventricular dilatation]	1.0	2	2	2	2
5505	295	ARNI lcz696	[ARNI LCZ696]	1.0	2	1	0	0
5506	295	151 subject	[151 subjects]	1.0	2	1	0	0
5507	295	Clinician interview	[Clinician interviews]	1.0	2	1	0	0
5508	295	predict 4-year survival at the time	[predicting 4-year survival at the time]	1.0	6	1	0	0
5509	295	2005 2008 performance on quality indicator	[2005 2008 performance on quality indicators]	1.0	6	1	0	0
5510	295	right atrial area 20 cm 2	[right atrial area 20 cm 2]	1.0	6	1	0	0
5511	295	Robot-assisted training for heart failure patient	[Robot-assisted training for heart failure patients]	1.0	6	1	0	0
5512	295	breakdown of peptide b-type peptide	[breakdown of peptide B-type peptide]	1.0	5	1	0	0
5513	295	naturally occur	[naturally occurring]	1.0	2	1	0	0
5514	295	alternative treatment	[alternative treatments]	1.0	2	1	0	0
5515	295	prevalence of modifiable risk factor	[prevalence of modifiable risk factors]	1.0	5	1	0	0
5516	295	experimental evidence	[Experimental evidence]	1.0	2	1	0	0
5517	295	one way	[one way]	1.0	2	1	0	0
5518	295	shunt implant	[Shunt implants]	1.0	2	1	0	0
5519	295	median rate	[median rate]	1.0	2	1	0	0
5520	295	success rate	[success rate]	1.0	2	2	1	1
5521	295	nonadherence in young vs. old	[nonadherence in youngest vs. oldest]	1.0	5	1	0	0
5522	295	molecular biomarker	[molecular biomarkers]	1.0	2	1	0	0
5523	295	investigate outcome in Exercise training hf-action	[Investigating Outcomes in Exercise TraiNing HF-ACTION]	1.0	6	1	0	0
5524	295	cardiac dysfunction with conduction abnormality	[cardiac dysfunction with conduction abnormalities]	1.0	5	1	0	0
5525	295	pre-post comparison	[pre-post comparisons]	1.0	2	1	0	0
5526	295	isolated lvad	[isolated LVAD]	1.0	2	1	0	0
5527	295	haemodynamic stressor	[haemodynamic stressors]	1.0	2	1	0	0
5528	295	case report	[case report]	1.0	2	2	1	1
5529	295	multiacquisition t1-mapping MRI during tidal respiration	[Multiacquisition T1-mapping MRI during tidal respiration]	1.0	6	1	0	0
5530	295	optimal therapy	[optimal therapy]	1.0	2	2	1	1
5531	295	working heart	[working hearts]	1.0	2	1	0	0
5532	295	testosterone therapy during exercise rehabilitation	[Testosterone therapy during exercise rehabilitation]	1.0	5	1	0	0
5533	295	Rotterdam Study	[Rotterdam Study]	1.0	2	2	2	2
5534	295	hazard ratio for log2 ng	[hazard ratios for log2 ng]	1.0	5	1	0	0
5535	295	association of hHF with saxagliptin	[associations of hHF with saxagliptin]	1.0	5	1	0	0
5536	295	positive inotropic effect in vivo	[positive inotropic effects in vivo]	1.0	5	1	0	0
5537	295	background—heart failure	[Background—Heart failure]	1.0	2	1	0	0
5538	295	Thoratec Corp	[Thoratec Corp]	1.0	2	1	0	0
5539	295	assess the link between air pollution	[Assessing the link between air pollution]	1.0	6	1	0	0
5540	295	composite end point of esrd	[composite end point of ESRD]	1.0	5	1	0	0
5541	295	stage 3 chronic kidney disease CKD	[Stage 3 chronic kidney disease CKD]	1.0	6	1	0	0
5542	295	6 minute walk test distance	[6 min walk test distance]	1.0	5	1	0	0
5543	295	increase evidence	[increasing evidence]	1.0	2	1	0	0
5544	295	treatment course	[TREATMENT COURSE]	1.0	2	1	0	0
5545	295	elderly male patient with CHF	[elderly male patients with CHF]	1.0	5	1	0	0
5546	295	clinician belief	[clinician belief]	1.0	2	1	0	0
5547	295	exertional increase	[exertional increase]	1.0	2	1	0	0
5548	295	low left ventricular ejection fraction	[low left ventricular ejection fraction]	1.0	5	1	0	0
5549	295	subsequent cardiotoxicity	[subsequent cardiotoxicity]	1.0	2	1	0	0
5550	295	case series	[case series]	1.0	2	2	2	2
5551	295	2300 pg	[2300 pg]	1.0	2	1	0	0
5552	295	partial pressure of end-tidal co2 petco2	[partial pressure of end-tidal CO2 PETCO2]	1.0	6	1	0	0
5553	295	Δ50%W intensity	[Δ50%W intensity]	1.0	2	1	0	0
5554	295	beneficial trend	[beneficial trends]	1.0	2	1	0	0
5555	295	safety of eplerenone in patient	[safety of eplerenone in patients]	1.0	5	1	0	0
5556	295	pure epicatechin	[pure epicatechin]	1.0	2	1	0	0
5557	295	fatal outcome	[Fatal outcomes]	1.0	2	1	0	0
5558	295	resting hr	[resting HR]	1.0	2	2	2	2
5559	295	3 hour	[3 hours]	1.0	2	1	0	0
5560	295	echo-doppler study	[echo-Doppler studies]	1.0	2	1	0	0
5561	295	improvement range	[improvement range]	1.0	2	1	0	0
5562	295	several N form circulate nt-probnp	[several N forms circulating NT-proBNP]	1.0	5	1	0	0
5563	295	quantitative proteomics	[quantitative proteomics]	1.0	2	1	0	0
5564	295	RM strategy	[RM strategies]	1.0	2	1	0	0
5565	295	nt-probnp testing	[NT-proBNP testing]	1.0	2	1	0	0
5566	295	16 patient in the ECMO+VAD group	[16 patients in the ECMO+VAD group]	1.0	6	1	0	0
5567	295	composite measure	[composite measure]	1.0	2	2	1	1
5568	295	vascular endothelial growth factor protein	[vascular endothelial growth factor protein]	1.0	5	1	0	0
5569	295	b-type natriuretic peptide level in patient	[B-type natriuretic peptide levels in patients]	1.0	6	1	0	0
5570	295	religious belief	[religious beliefs]	1.0	2	1	0	0
5571	295	heart t2	[Heart T2]	1.0	2	1	0	0
5572	295	71.3 m	[71.3 m]	1.0	2	1	0	0
5573	295	Chinese medicine	[Chinese medicine]	1.0	2	2	2	2
5574	295	sixteen New York heart Association Class	[Sixteen New York Heart Association Class]	1.0	6	1	0	0
5575	295	2 institution	[2 institutions]	1.0	2	1	0	0
5576	295	step forward	[step forward]	1.0	2	1	0	0
5577	295	downstream signalling	[downstream signalling]	1.0	2	1	0	0
5578	295	clinical dysfunction	[clinical dysfunction]	1.0	2	2	2	2
5579	295	restorative effect of (-)-epicatechin-rich cocoa	[restorative effects of (-)-epicatechin-rich cocoa]	1.0	5	1	0	0
5580	295	i phosphorylation	[I phosphorylation]	1.0	2	1	0	0
5581	295	clinical outcome use a aldosterone antagonist	[clinical outcomes using an aldosterone antagonist]	1.0	6	1	0	0
5582	295	cardiac pathology	[cardiac pathology]	1.0	2	1	0	0
5583	295	benefit of spironolactone in practice	[benefits of spironolactone in practice]	1.0	5	1	0	0
5584	295	shunt implantation	[shunt implantation]	1.0	2	1	0	0
5585	295	heart failure risk among patient	[Heart failure risk among patients]	1.0	5	1	0	0
5586	295	U.S. food	[U.S. Food]	1.0	2	1	0	0
5587	295	left ventricular assist device lvas	[left ventricular assist devices LVADs]	1.0	5	1	0	0
5588	295	median follow-up	[median follow-up]	1.0	2	3	2	1
5589	295	adverse event rate between 2005	[adverse event rates between 2005]	1.0	5	1	0	0
5590	295	prognostic indicator	[prognostic indicator]	1.0	2	2	2	2
5591	295	pump exchange	[pump exchanges]	1.0	2	1	0	0
5592	295	citrate cycle	[citrate cycle]	1.0	2	1	0	0
5593	295	hallmark feature of heart failure	[hallmark feature of heart failure]	1.0	5	1	0	0
5594	295	fail	[failing]	1.0	1	11	5	5
5595	295	9 study	[9 studies]	1.0	2	1	0	0
5596	295	exercise modality	[exercise modality]	1.0	2	1	0	0
5597	295	medical literature	[medical literature]	1.0	2	1	0	0
5598	295	outpatient with systolic heart failure	[outpatients with systolic heart failure]	1.0	5	1	0	0
5599	295	interaction between this ecg parameter	[interaction between these ECG parameters]	1.0	5	1	0	0
5600	295	longitudinal strain of left ventricle	[longitudinal strain of left ventricle]	1.0	5	2	2	2
5601	295	28-day survivor	[28-day survivors]	1.0	2	1	0	0
5602	295	heart association	[Heart Association]	1.0	2	2	2	2
5603	295	if-channel inhibition on hemodynamic status	[If-channel inhibition on hemodynamic status]	1.0	5	1	0	0
5604	295	LA country	[LA countries]	1.0	2	1	0	0
5605	295	chromatin subproteome	[chromatin subproteome]	1.0	2	2	1	1
5606	295	preoperative dysfunction	[preoperative dysfunction]	1.0	2	2	2	2
5607	295	epigenetic writer protein histone acetyltransferase	[epigenetic writer proteins histone acetyltransferases]	1.0	5	1	0	0
5608	295	significant challenge	[significant challenges]	1.0	2	1	0	0
5609	295	level 100 pg high bnp group	[levels 100 pg high BNP group]	1.0	6	1	0	0
5610	295	morphogenetic protein	[morphogenetic protein]	1.0	2	1	0	0
5611	295	life-threatening situation	[life-threatening situation]	1.0	2	1	0	0
5612	295	3 scenario	[3 scenarios]	1.0	2	1	0	0
5613	295	Trial investigate Outcome multicenter study	[Trial Investigating Outcomes multicenter study]	1.0	5	1	0	0
5614	295	presence of separate scale dimension	[presence of separate scale dimensions]	1.0	5	1	0	0
5615	295	212 millisecond	[212 milliseconds]	1.0	2	1	0	0
5616	295	mortality effect of a intervention	[mortality effects of an intervention]	1.0	5	1	0	0
5617	295	protective mechanism	[protective mechanisms]	1.0	2	1	0	0
5618	295	end diameter	[end diameter]	1.0	2	2	2	2
5619	295	other reason	[other reasons]	1.0	2	1	0	0
5620	295	cardiogenic shock	[cardiogenic shock]	1.0	2	2	1	1
5621	295	iron-deficient adult patient with heart disease	[iron-deficient adult patients with heart disease]	1.0	6	1	0	0
5622	295	conclusions—low-volume ed	[Conclusions—Low-volume EDs]	1.0	2	1	0	0
5623	295	Functional stimulation	[Functional stimulation]	1.0	2	2	2	2
5624	295	prognosis in patient with heart failure	[prognosis in patients with heart failure]	1.0	6	1	0	0
5625	295	cellular response	[cellular responses]	1.0	2	1	0	0
5626	295	treatment aim	[treatment aims]	1.0	2	1	0	0
5627	295	lack of improvement in prognosis	[lack of improvement in prognosis]	1.0	5	1	0	0
5628	295	surgical patient	[surgical patients]	1.0	2	1	0	0
5629	295	multiple non-diastolic abnormality in cardiovascular function	[multiple non-diastolic abnormalities in cardiovascular function]	1.0	6	1	0	0
5630	295	community study	[communities study]	1.0	2	2	1	1
5631	295	recent discharge	[recent discharge]	1.0	2	1	0	0
5632	295	treatment for anemia in adult	[treatments for anemia in adults]	1.0	5	1	0	0
5633	295	marker of SkM growth consistent	[markers of SkM growth consistent]	1.0	5	1	0	0
5634	295	young group	[youngest group]	1.0	2	1	0	0
5635	295	stable body weight in CC	[stable body weight in CC]	1.0	5	1	0	0
5636	295	score of Minnesota quality of life	[score of Minnesota quality of life]	1.0	6	1	0	0
5637	295	genuine effect	[genuine effect]	1.0	2	1	0	0
5638	295	Gly16 individual	[Gly16 individuals]	1.0	2	1	0	0
5639	295	same day	[same day]	1.0	2	1	0	0
5640	295	over 80 year of age	[over 80 years of age]	1.0	5	1	0	0
5641	295	more severe LV systolic dysfunction	[more severe LV systolic dysfunction]	1.0	5	1	0	0
5642	295	intrinsic dysfunction	[intrinsic dysfunction]	1.0	2	1	0	0
5643	295	Exercise intolerance in heart failure	[Exercise intolerance in heart failure]	1.0	5	1	0	0
5644	295	Safety of eplerenone in patient analysis	[Safety of eplerenone in patients analyses]	1.0	6	1	0	0
5645	295	principal mechanism	[principal mechanisms]	1.0	2	1	0	0
5646	295	alcohol related	[alcohol related]	1.0	2	1	0	0
5647	295	positive effect	[positive effects]	1.0	2	2	2	2
5648	295	outcome such as heart failure HF	[outcomes such as heart failure HF]	1.0	6	1	0	0
5649	295	Cardiac hypertrophy	[Cardiac hypertrophy]	1.0	2	1	0	0
5650	295	28 day	[28 days]	1.0	2	1	0	0
5651	295	feasible alternative	[feasible alternative]	1.0	2	1	0	0
5652	295	seventy-seven case with pre-hct germline DNA	[Seventy-seven cases with pre-HCT germline DNA]	1.0	6	1	0	0
5653	295	antihyperglycemic agent	[antihyperglycemic agents]	1.0	2	2	1	1
5654	295	pacing-induced cardiomyopathy	[pacing-induced cardiomyopathy]	1.0	2	1	0	0
5655	295	arrhythmia-related cost	[Arrhythmia-related costs]	1.0	2	1	0	0
5656	295	great risk of heart failure	[greater risk of heart failure]	1.0	5	1	0	0
5657	295	52-year-old man	[52-year-old man]	1.0	2	1	0	0
5658	295	preliminary study	[preliminary study]	1.0	2	2	1	1
5659	295	e email	[E e]	1.0	2	1	0	0
5660	295	isoprenaline infusion	[isoprenaline infusion]	1.0	2	1	0	0
5661	295	limited mortality	[limited mortality]	1.0	2	1	0	0
5662	295	8574 millileter	[8574 mL]	1.0	2	1	0	0
5663	295	participate in the pilot program	[participating in the pilot program]	1.0	5	1	0	0
5664	295	Michigan HF clinic UM cohort	[Michigan HF clinic UM cohort]	1.0	5	1	0	0
5665	295	mild restriction of leaflet motion	[mild restriction of leaflet motion]	1.0	5	1	0	0
5666	295	transplantation eligibility	[transplantation eligibility]	1.0	2	2	2	2
5667	295	common application	[common applications]	1.0	2	1	0	0
5668	295	evidence on association of dietary pattern	[evidence on associations of dietary patterns]	1.0	6	1	0	0
5669	295	computational study	[computational study]	1.0	2	1	0	0
5670	295	ion channelopathy	[ion channelopathies]	1.0	2	1	0	0
5671	295	further adjustment for patient characteristic	[Further adjustment for patient characteristics]	1.0	5	1	0	0
5672	295	oppose action on camp production	[opposing action on cAMP production]	1.0	5	1	0	0
5673	295	compensatory hypertrophy	[compensatory hypertrophy]	1.0	2	1	0	0
5674	295	≤90 day	[≤90 days]	1.0	2	1	0	0
5675	295	Mena expression	[Mena expression]	1.0	2	1	0	0
5676	295	contextual factor on physician adherence	[contextual factors on physician adherence]	1.0	5	1	0	0
5677	295	28-day mortality	[28-day mortality]	1.0	2	1	0	0
5678	295	abdominal problem	[abdominal problems]	1.0	2	2	2	2
5679	295	demographic characteristic	[demographic characteristics]	1.0	2	2	2	2
5680	295	exercise adherence	[exercise adherence]	1.0	2	1	0	0
5681	295	long effect	[long-term effects]	1.0	2	1	0	0
5682	295	anthracycline-induced cardiotoxicity	[anthracycline-induced cardiotoxicity]	1.0	2	2	1	1
5683	295	CRF distribution	[CRF distribution]	1.0	2	1	0	0
5684	295	LV ejection fraction of a ventricle	[LV ejection fraction of a ventricle]	1.0	6	1	0	0
5685	295	prognostic composite	[prognostic composite]	1.0	2	1	0	0
5686	295	health-related quality	[health-related quality]	1.0	2	2	2	2
5687	295	subject with RA receive methotrexate	[Subjects with RA receiving methotrexate]	1.0	5	1	0	0
5688	295	high serum level of creatinine	[higher serum levels of creatinine]	1.0	5	1	0	0
5689	295	further research	[Further research]	1.0	2	1	0	0
5690	295	case-control analysis	[case-control analysis]	1.0	2	2	1	1
5691	295	adult with heart failure HF	[adults with heart failure HF]	1.0	5	2	2	2
5692	295	length-force relationship	[length-force relationship]	1.0	2	1	0	0
5693	295	1≤5 mg	[1≤5 mg]	1.0	2	1	0	0
5694	295	package of R. cluster analysis	[packages of R. Cluster analysis]	1.0	5	1	0	0
5695	295	cardiac resynchronization therapy with a defibrillator	[cardiac resynchronization therapy with a defibrillator]	1.0	6	2	1	1
5696	295	human resistin in heart failure	[Human resistin in heart failure]	1.0	5	2	1	1
5697	295	little information	[little information]	1.0	2	1	0	0
5698	295	uniform nomenclature	[uniform nomenclature]	1.0	2	1	0	0
5699	295	local depolarization	[local depolarization]	1.0	2	1	0	0
5700	295	even on optimal therapy include anticoagulation	[Even on optimal therapy including anticoagulation]	1.0	6	1	0	0
5701	295	total myosin binding protein-C phosphorylation	[total myosin binding protein-C phosphorylation]	1.0	5	1	0	0
5702	295	Québec Health Insurance Board database	[Québec Health Insurance Board databases]	1.0	5	1	0	0
5703	295	quartile of the diet score	[quartiles of the diet score]	1.0	5	1	0	0
5704	295	indicate possible suboptimal care of patient	[indicating possible suboptimal care of patients]	1.0	6	1	0	0
5705	295	long support	[long-term support]	1.0	2	1	0	0
5706	295	14.0 millileter vs. 17.0 millileter	[14.0 ml vs. 17.0 ml]	1.0	5	1	0	0
5707	295	4.4 mm hg fig 1a	[4.4 mm Hg Fig 1A]	1.0	5	1	0	0
5708	295	protein response	[protein response]	1.0	2	2	1	1
5709	295	Kaplan-Meier analysis	[Kaplan-Meier analyses]	1.0	2	1	0	0
5710	295	clear evidence	[clear evidence]	1.0	2	1	0	0
5711	295	beta1-adrenergic receptor	[beta1-adrenergic receptor]	1.0	2	1	0	0
5712	295	neuro-hormonal system	[neuro-hormonal system]	1.0	2	1	0	0
5713	295	HF with ejection fraction hfpef	[HF with ejection fraction HFpEF]	1.0	5	1	0	0
5714	295	good hospital	[better hospitals]	1.0	2	1	0	0
5715	295	cardiac β-ar	[cardiac β-AR]	1.0	2	1	0	0
5716	295	identify death in the icu	[identifying death in the ICU]	1.0	5	1	0	0
5717	295	aerobic training intervention with feedback	[aerobic training intervention with feedback]	1.0	5	1	0	0
5718	295	protocol-driven poc testing of np	[protocol-driven POC testing of NP]	1.0	5	1	0	0
5719	295	Nitroxyl HNO	[Nitroxyl HNO]	1.0	2	1	0	0
5720	295	cardiovascular outcome	[cardiovascular outcomes]	1.0	2	1	0	0
5721	295	increase in peak oxygen uptake	[increase in peak oxygen uptake]	1.0	5	1	0	0
5722	295	sarcoplasmic reticular SR can 2+)-uptake	[sarcoplasmic reticular SR Ca 2+)-uptake]	1.0	5	1	0	0
5723	295	patient require temporary RV support	[Patients requiring temporary RV support]	1.0	5	1	0	0
5724	295	depressive symptom	[depressive symptoms]	1.0	2	2	2	2
5725	295	postcontrast t1	[postcontrast T1]	1.0	2	1	0	0
5726	295	394 m	[394 m]	1.0	2	1	0	0
5727	295	predictive value	[predictive value]	1.0	2	2	2	2
5728	295	8656 new user of a nbdmard	[8656 new users of a nbDMARD]	1.0	6	1	0	0
5729	295	estimate the jugular venous pressure	[Estimating the jugular venous pressure]	1.0	5	1	0	0
5730	295	nonsurvivor with a similar distribution	[nonsurvivors with a similar distribution]	1.0	5	1	0	0
5731	295	right failure	[right failure]	1.0	2	1	0	0
5732	295	baseline in peak oxygen uptake	[baseline in peak oxygen uptake]	1.0	5	1	0	0
5733	295	epidemiology of chronic heart failure	[Epidemiology of chronic heart failure]	1.0	5	1	0	0
5734	295	post-translational state	[post-translational state]	1.0	2	2	1	1
5735	295	different region	[different regions]	1.0	2	1	0	0
5736	295	swine model	[swine model]	1.0	2	1	0	0
5737	295	original construct	[original construct]	1.0	2	1	0	0
5738	295	differential response	[differential response]	1.0	2	2	1	1
5739	295	care surgery	[care surgery]	1.0	2	2	2	2
5740	295	diastolic murmur	[diastolic murmurs]	1.0	2	1	0	0
5741	295	ongoing gdmt alone control group	[ongoing GDMT alone control group]	1.0	5	1	0	0
5742	295	baseline examination	[baseline examination]	1.0	2	1	0	0
5743	295	energy deficit	[energy deficit]	1.0	2	1	0	0
5744	295	catheterization finding	[catheterization findings]	1.0	2	1	0	0
5745	295	treatment plan	[treatment plans]	1.0	2	1	0	0
5746	295	p trend=0.01	[P trend=0.01]	1.0	2	1	0	0
5747	295	model fit	[model fit]	1.0	2	1	0	0
5748	295	all-cause hospitalisation for tm intervention	[all-cause hospitalisations for TM interventions]	1.0	5	1	0	0
5749	295	end-diastolic area	[end-diastolic area]	1.0	2	1	0	0
5750	295	patient with prior cardiovascular disease	[patients with prior cardiovascular disease]	1.0	5	1	0	0
5751	295	N-terminal proBNP NT-proBNP midregional proanp MR-proANP	[N-terminal proBNP NT-proBNP midregional proANP MR-proANP]	1.0	6	1	0	0
5752	295	63 patient	[63 patients]	1.0	2	1	0	0
5753	295	hazard ratio for 10-year increase	[hazard ratio for 10-year increase]	1.0	5	1	0	0
5754	295	natriuretic peptide level like other biomarker	[Natriuretic peptide levels like other biomarkers]	1.0	6	1	0	0
5755	295	upstream signal	[upstream signal]	1.0	2	1	0	0
5756	295	troponin T	[Troponin T]	1.0	2	2	1	1
5757	295	class recommendation	[class recommendation]	1.0	2	1	0	0
5758	295	trastuzumab-related CHF among old patient	[trastuzumab-related CHF among older patients]	1.0	5	1	0	0
5759	295	healthcare utilization	[healthcare utilization]	1.0	2	1	0	0
5760	295	intervention exercise	[interventions exercise]	1.0	2	1	0	0
5761	295	association between treatment variation independent	[association between treatment variation independent]	1.0	5	1	0	0
5762	295	ED volume	[ED volume]	1.0	2	1	0	0
5763	295	high BTES	[higher BTES]	1.0	2	1	0	0
5764	295	survival estimate	[survival estimates]	1.0	2	1	0	0
5765	295	therapeutic target	[therapeutic targets]	1.0	2	2	2	2
5766	295	4.6 year of follow-up 1385	[4.6 years of follow-up 1385]	1.0	5	1	0	0
5767	295	attention control	[attention control]	1.0	2	1	0	0
5768	295	76 year	[76 years]	1.0	2	1	0	0
5769	295	l-type ca2	[L-type Ca2]	1.0	2	2	1	1
5770	295	Multivariate model	[Multivariate models]	1.0	2	1	0	0
5771	295	cardiovascular surgeon	[cardiovascular surgeons]	1.0	2	1	0	0
5772	295	interagency registry for Circulatory performance goal	[Interagency Registry for Circulatory performance goal]	1.0	6	1	0	0
5773	295	chronic heart failure with ejection fraction	[chronic heart failure with ejection fraction]	1.0	6	1	0	0
5774	295	p3 prolapse	[P3 prolapse]	1.0	2	1	0	0
5775	295	even after adjustment for all confounder	[even after adjustment for all confounders]	1.0	6	1	0	0
5776	295	LCZ696 a receptor neprilysin inhibitor	[LCZ696 an receptor neprilysin inhibitor]	1.0	5	1	0	0
5777	295	1-year mortality	[1-year mortality]	1.0	2	2	2	2
5778	295	conscious rabbit	[conscious rabbits]	1.0	2	1	0	0
5779	295	two bisphosphonate	[two bisphosphonates]	1.0	2	1	0	0
5780	295	diastolic failure from cardiomyopathic restriction	[diastolic failure from cardiomyopathic restriction]	1.0	5	1	0	0
5781	295	advancement of the pathophysiologic state	[advancement of the pathophysiologic state]	1.0	5	1	0	0
5782	295	Baseline Hgb	[Baseline Hgb]	1.0	2	1	0	0
5783	295	clinical application	[clinical application]	1.0	2	2	2	2
5784	295	clinical composite	[clinical composite]	1.0	2	1	0	0
5785	295	exercise-induced increase	[exercise-induced increase]	1.0	2	1	0	0
5786	295	heart iron	[heart iron]	1.0	2	1	0	0
5787	295	forty-one patient	[Forty-one patients]	1.0	2	1	0	0
5788	295	4 non-ischemic heart failure sample	[4 non-ischemic heart failure samples]	1.0	5	1	0	0
5789	295	respiratory gas	[respiratory gas]	1.0	2	1	0	0
5790	295	degenerative regurgitation	[degenerative regurgitation]	1.0	2	1	0	0
5791	295	challenging therapeutics	[challenging therapeutics]	1.0	2	1	0	0
5792	295	Chronic β-ar stimulation via catecholamine infusion	[Chronic β-AR stimulation via catecholamine infusions]	1.0	6	1	0	0
5793	295	rose acute heart failure trial	[ROSE acute heart failure trial]	1.0	5	1	0	0
5794	295	early-onset 0 day after MI	[early-onset 0 days after MI]	1.0	5	1	0	0
5795	295	defibrillator implantation	[Defibrillator Implantation]	1.0	2	2	2	2
5796	295	lean zsf1	[lean ZSF1]	1.0	2	1	0	0
5797	295	brief review	[brief review]	1.0	2	1	0	0
5798	295	70 year	[70 years]	1.0	2	2	1	1
5799	295	6.0 mmol	[6.0 mmol]	1.0	2	1	0	0
5800	295	up test	[Up test]	1.0	2	2	2	2
5801	295	HF rat	[HF rats]	1.0	2	2	1	1
5802	295	cardiovascular function with echocardiographic measure	[cardiovascular function with echocardiographic measures]	1.0	5	1	0	0
5803	295	outcome in the resynchronization reverse remodeling	[outcomes in the REsynchronization reVErses Remodeling]	1.0	6	1	0	0
5804	295	University Health Network Toronto Canada	[University Health Network Toronto Canada]	1.0	5	1	0	0
5805	295	100 pg	[100 pg]	1.0	2	2	2	2
5806	295	8524 millileter	[8524 mL]	1.0	2	1	0	0
5807	295	ischemic cause	[ischemic cause]	1.0	2	1	0	0
5808	295	venoarterial dilation	[venoarterial dilation]	1.0	2	1	0	0
5809	295	long-acting insulin product from 2006	[long-acting insulin products from 2006]	1.0	5	1	0	0
5810	295	diastolic property	[diastolic properties]	1.0	2	1	0	0
5811	295	E ratio for pcwp estimation	[E ratios for PCWP estimation]	1.0	5	1	0	0
5812	295	future study	[Future studies]	1.0	2	1	0	0
5813	295	multivariate model	[multivariate model]	1.0	2	2	1	1
5814	295	monomeric g	[monomeric G]	1.0	2	1	0	0
5815	295	unfavourable outcome	[unfavourable outcome]	1.0	2	1	0	0
5816	295	clinical setting	[clinical setting]	1.0	2	1	0	0
5817	295	acute dyspnea	[acute dyspnea]	1.0	2	1	0	0
5818	295	low-volume ed	[low-volume EDs]	1.0	2	1	0	0
5819	295	use the implementation as a quasi-experiment	[using the implementation as a quasi-experiment]	1.0	6	1	0	0
5820	295	24-hour brachial systolic pressure 155 35	[24-hour brachial systolic pressure 155 35]	1.0	6	1	0	0
5821	295	quality improvement	[quality improvement]	1.0	2	2	1	1
5822	295	major public health problem worldwide	[major public health problem worldwide]	1.0	5	1	0	0
5823	295	absorption function in patient with CHF	[absorption function in patients with CHF]	1.0	6	1	0	0
5824	295	right after coronary artery ligation	[right after coronary artery ligation]	1.0	5	1	0	0
5825	295	debilitating stroke	[debilitating stroke]	1.0	2	1	0	0
5826	295	follow hospital stay for heart failure	[following hospital stay for heart failure]	1.0	6	1	0	0
5827	295	carvedilol	[carvedilol]	1.0	1	12	2	1
5828	295	fatty acid	[fatty acids]	1.0	2	1	0	0
5829	295	several study	[several studies]	1.0	2	1	0	0
5830	295	cardiorespiratory fitness Cooper Center longitudinal Study	[Cardiorespiratory fitness Cooper Center Longitudinal Study]	1.0	6	1	0	0
5831	295	insignificant ms	[insignificant MS]	1.0	2	1	0	0
5832	295	death visit in the subsequent	[death visit in the subsequent]	1.0	5	1	0	0
5833	295	United State	[United States]	1.0	2	1	0	0
5834	295	1790 patient	[1,790 patients]	1.0	2	1	0	0
5835	295	SVR index	[SVR index]	1.0	2	2	2	2
5836	295	protein level of this gene	[protein levels of these genes]	1.0	5	1	0	0
5837	295	cardiac angiogenesis in heart failure	[cardiac angiogenesis in heart failure]	1.0	5	1	0	0
5838	295	≥18 year	[≥18 years]	1.0	2	1	0	0
5839	295	prognosis in advanced heart failure	[prognosis in advanced heart failure]	1.0	5	1	0	0
5840	295	initiative frequency	[initiative frequency]	1.0	2	1	0	0
5841	295	4.2 METs	[4.2 METs]	1.0	2	1	0	0
5842	295	mortality hospitalization	[mortality hospitalization]	1.0	2	1	0	0
5843	295	Mena overexpression in tta mouse	[Mena overexpression in TTA mice]	1.0	5	1	0	0
5844	295	combine salt loading with ang infusion	[combining salt loading with ANG infusion]	1.0	6	1	0	0
5845	295	future trial	[future trials]	1.0	2	2	1	1
5846	295	heart failure with ejection fraction HFPEF	[Heart failure with ejection fraction HFPEF]	1.0	6	1	0	0
5847	295	initial safety	[initial safety]	1.0	2	1	0	0
5848	295	mechanical stimulus	[mechanical stimuli]	1.0	2	1	0	0
5849	295	possible HF	[possible HF]	1.0	2	1	0	0
5850	295	validation study in the model system	[Validation studies in the model system]	1.0	6	1	0	0
5851	295	key biosynthetic enzyme lyso-paf acetyltransferase	[key biosynthetic enzymes lyso-PAF acetyltransferase]	1.0	5	1	0	0
5852	295	modification of diet in renal disease	[modification of diet in renal disease]	1.0	6	1	0	0
5853	295	full length	[full length]	1.0	2	1	0	0
5854	295	information regard condition in Turkey	[information regarding conditions in Turkey]	1.0	5	1	0	0
5855	295	downward regression	[downward regression]	1.0	2	1	0	0
5856	295	shuttle walk	[shuttle walk]	1.0	2	2	2	2
5857	295	cardiopulmonary bypass	[cardiopulmonary bypass]	1.0	2	1	0	0
5858	295	patient with a ras dose increase	[Patients with a RAS dose increase]	1.0	6	1	0	0
5859	295	10 month	[10 months]	1.0	2	1	0	0
5860	295	Postoperative normalization of albumin level	[Postoperative normalization of albumin level]	1.0	5	1	0	0
5861	295	postsystolic function	[postsystolic function]	1.0	2	1	0	0
5862	295	affect the level of epinephrine	[affecting the levels of epinephrine]	1.0	5	1	0	0
5863	295	Cox hazard model for time	[Cox hazard models for time]	1.0	5	1	0	0
5864	295	acf rat	[ACF rats]	1.0	2	1	0	0
5865	295	full-length scn5a	[full-length SCN5A]	1.0	2	1	0	0
5866	295	aerobic training	[aerobic training]	1.0	2	1	0	0
5867	295	acute treatment	[acute treatment]	1.0	2	1	0	0
5868	295	linear pathway	[linear pathway]	1.0	2	1	0	0
5869	295	295 patient	[295 patients]	1.0	2	1	0	0
5870	295	Northwest State	[Northwest States]	1.0	2	1	0	0
5871	295	hemodynamic perturbation	[hemodynamic perturbations]	1.0	2	1	0	0
5872	295	Anoop Shah	[Anoop Shah]	1.0	2	1	0	0
5873	295	surgical treatment of post-lvad ai	[Surgical treatment of post-LVAD AI]	1.0	5	1	0	0
5874	295	good agreement	[Good agreement]	1.0	2	1	0	0
5875	295	blood testing	[blood testing]	1.0	2	1	0	0
5876	295	even in patient with a history	[even in patients with a history]	1.0	6	1	0	0
5877	295	Retrospective cohort	[Retrospective cohort]	1.0	2	1	0	0
5878	295	bottleneck stent model for ischemia	[bottleneck stent model for ischemia]	1.0	5	1	0	0
5879	295	295 veteran aged 50 year	[295 veterans aged 50 years]	1.0	5	1	0	0
5880	295	patient with without ejection fraction	[patients with without ejection fraction]	1.0	5	1	0	0
5881	295	sequential phosphorylation	[sequential phosphorylation]	1.0	2	1	0	0
5882	295	Clinical Trial	[Clinical Trial]	1.0	2	1	0	0
5883	295	wall cs	[wall CS]	1.0	2	2	2	2
5884	295	clinical trials-Enriching patient identification by Collins	[clinical trials-Enriching patient identification by Collins]	1.0	6	1	0	0
5885	295	take into account all follow-up visit	[Taking into account all follow-up visits]	1.0	6	1	0	0
5886	295	remodeling parameter	[remodeling parameters]	1.0	2	1	0	0
5887	295	cardiomyopathy origin	[cardiomyopathy origin]	1.0	2	1	0	0
5888	295	coronary intervention during the trial	[coronary interventions during the trial]	1.0	5	1	0	0
5889	295	testosterone supplementation during a program	[testosterone supplementation during a program]	1.0	5	1	0	0
5890	295	few year	[few years]	1.0	2	1	0	0
5891	295	major adverse neurological event-free rate	[major adverse neurological event-free rate]	1.0	5	1	0	0
5892	295	p value for age-by-LVEF interaction	[p value for age-by-LVEF interaction]	1.0	5	1	0	0
5893	295	analysis of the emphasis-hf study subgroup	[analyses of the EMPHASIS-HF study subgroups]	1.0	6	1	0	0
5894	295	significant difference in the ability	[significant difference in the ability]	1.0	5	1	0	0
5895	295	Psychometric testing of the self-care	[Psychometric testing of the Self-Care]	1.0	5	1	0	0
5896	295	placebo-treated group	[placebo-treated group]	1.0	2	1	0	0
5897	295	use clinical practice guideline grading system	[using clinical practice guidelines grading system]	1.0	6	1	0	0
5898	295	main objective of this study	[main objective of this study]	1.0	5	1	0	0
5899	295	effect of treatment with ivabradine	[effects of treatment with ivabradine]	1.0	5	1	0	0
5900	295	scar size	[scar size]	1.0	2	1	0	0
5901	295	low median activity of lyso-paf-at p	[lower median activities of lyso-PAF-AT P]	1.0	6	1	0	0
5902	295	use the Grading Assessment GRADE methodology	[using the Grading Assessment GRADE methodology]	1.0	6	1	0	0
5903	295	inconsistent result	[inconsistent results]	1.0	2	1	0	0
5904	295	four different US healthcare programme	[four different US healthcare programmes]	1.0	5	1	0	0
5905	295	nontrastuzumab user	[nontrastuzumab users]	1.0	2	2	1	1
5906	295	turn off Mena overexpression immediately	[turning off Mena overexpression immediately]	1.0	5	1	0	0
5907	295	congestion-like symptom	[congestion-like symptoms]	1.0	2	1	0	0
5908	295	express na channel mrna splice variant	[expressing Na channel mRNA splice variants]	1.0	6	1	0	0
5909	295	Excessive secretion of arginine vasopressin avp	[Excessive secretion of arginine vasopressin AVP]	1.0	6	1	0	0
5910	295	LV compliance	[LV compliance]	1.0	2	1	0	0
5911	295	include the establishment of responsiveness	[including the establishment of responsiveness]	1.0	5	1	0	0
5912	295	involvement in a multisite study	[involvement in a multisite study]	1.0	5	1	0	0
5913	295	example antagonize excessive β-ar drive	[example antagonizing excessive β-AR drive]	1.0	5	1	0	0
5914	295	health-related quality of life HRQoL	[health-related quality of life HRQoL]	1.0	5	1	0	0
5915	295	group iii	[group III]	1.0	2	1	0	0
5916	295	event-free rate	[event-free rate]	1.0	2	2	2	2
5917	295	differential analysis	[differential analysis]	1.0	2	1	0	0
5918	295	Mini-Sentinel program	[Mini-Sentinel program]	1.0	2	1	0	0
5919	295	LV size	[LV size]	1.0	2	1	0	0
5920	295	anti-oxidant defence	[anti-oxidant defence]	1.0	2	1	0	0
5921	295	hfref therapy	[HFrEF therapy]	1.0	2	1	0	0
5922	295	overwhelming contribution of atherosclerotic cad	[overwhelming contribution of atherosclerotic CAD]	1.0	5	1	0	0
5923	295	metabolic gene	[metabolic gene]	1.0	2	1	0	0
5924	295	prevalence of high bnp level	[prevalence of high BNP levels]	1.0	5	1	0	0
5925	295	regard effective treatment of old adult	[regarding effective treatment of older adults]	1.0	6	1	0	0
5926	295	good well-being in all participant	[better well-being in all participants]	1.0	5	1	0	0
5927	295	current guideline	[Current guidelines]	1.0	2	1	0	0
5928	295	annular size reduction for degenerative mr	[annular size reduction for degenerative MR]	1.0	6	1	0	0
5929	295	cell senescence	[cell senescence]	1.0	2	1	0	0
5930	295	zsf1 rat	[ZSF1 rats]	1.0	2	2	2	2
5931	295	current knowledge of nutritional abnormality	[current knowledge of nutritional abnormalities]	1.0	5	1	0	0
5932	295	4 VA health care system	[4 VA health care systems]	1.0	5	1	0	0
5933	295	CI 1.34	[CI 1.34]	1.0	2	1	0	0
5934	295	doppler mitral inflow velocity contour	[Doppler mitral inflow velocity contours]	1.0	5	1	0	0
5935	295	TTA mouse	[TTA mice]	1.0	2	1	0	0
5936	295	only in patient maintain sinus rhythm	[only in patients maintaining sinus rhythm]	1.0	6	1	0	0
5937	295	59.6 m vs. 1.5 m	[59.6 m vs. 1.5 m]	1.0	5	1	0	0
5938	295	valvular disease	[valvular disease]	1.0	2	1	0	0
5939	295	patient consultation	[patient consultation]	1.0	2	1	0	0
5940	295	CI 1.59	[CI 1.59]	1.0	2	1	0	0
5941	295	most common cause of ras	[most common cause of RAS]	1.0	5	1	0	0
5942	295	co-primary outcome	[co-primary outcome]	1.0	2	2	1	1
5943	295	support for the concept also appropriate	[support for the concept also appropriate]	1.0	6	1	0	0
5944	295	recent onset HFrEF 30 day	[recent onset HFrEF 30 days]	1.0	5	1	0	0
5945	295	patient with heart association class	[patients with Heart Association class]	1.0	5	1	0	0
5946	295	myocardial ischemic event in patient	[myocardial ischemic events in patients]	1.0	5	1	0	0
5947	295	long survival in ED patient	[long-term survival in ED patients]	1.0	5	1	0	0
5948	295	detrimental alteration	[detrimental alterations]	1.0	2	2	2	2
5949	295	renal denervation	[renal denervation]	1.0	2	2	2	2
5950	295	CI 1.02	[CI 1.02]	1.0	2	1	0	0
5951	295	ambulatory HF	[ambulatory HF]	1.0	2	1	0	0
5952	295	CI 1.00	[CI 1.00]	1.0	2	1	0	0
5953	295	left ventricular ejection fraction hfpef	[left ventricular ejection fraction HFpEF]	1.0	5	2	1	1
5954	295	x12 with	[x12 w]	1.0	2	1	0	0
5955	295	subgroup of patient with disease	[subgroups of patients with disease]	1.0	5	1	0	0
5956	295	median egfr	[median eGFR]	1.0	2	1	0	0
5957	295	change in treatment in most subject	[changes in treatment in most subjects]	1.0	6	1	0	0
5958	295	just size	[just size]	1.0	2	1	0	0
5959	295	improve quality of care for patient	[improving quality of care for patients]	1.0	6	1	0	0
5960	295	also evaluate the effect of intervention	[also evaluating the effect of interventions]	1.0	6	1	0	0
5961	295	elevation in tumor necrosis factor	[elevations in tumor necrosis factor]	1.0	5	1	0	0
5962	295	measurable overall improvement for patient	[measurable overall improvements for patients]	1.0	5	1	0	0
5963	295	vasopressin in congestive heart failure	[vasopressin in congestive heart failure]	1.0	5	1	0	0
5964	295	adult patient with fail Fontan circulation	[adult patients with failing Fontan circulation]	1.0	6	1	0	0
5965	295	sustain the workload during stress	[sustaining the workload during stress]	1.0	5	1	0	0
5966	295	np level	[NP levels]	1.0	2	2	1	1
5967	295	elevation in BNP nt-probnp level	[elevations in BNP NT-proBNP levels]	1.0	5	1	0	0
5968	295	Titin hypophosphorylation	[Titin hypophosphorylation]	1.0	2	1	0	0
5969	295	HFPSI model	[HFPSI model]	1.0	2	1	0	0
5970	295	tricuspid annular plane systolic excursion	[Tricuspid annular plane systolic excursion]	1.0	5	2	1	1
5971	295	cell phenotype	[cell phenotype]	1.0	2	1	0	0
5972	295	T1-mapping sequence	[T1-mapping sequence]	1.0	2	1	0	0
5973	295	blood cell	[blood cell]	1.0	2	1	0	0
5974	295	peripheral edema	[peripheral edema]	1.0	2	1	0	0
5975	295	PEVK segment	[PEVK segment]	1.0	2	1	0	0
5976	295	telephone call	[telephone calls]	1.0	2	1	0	0
5977	295	create uncertainty about the safety	[creating uncertainty about the safety]	1.0	5	1	0	0
5978	295	high incidence	[high incidence]	1.0	2	1	0	0
5979	295	historical datum	[historical data]	1.0	2	1	0	0
5980	295	control model	[control model]	1.0	2	1	0	0
5981	295	aim of the consensus report	[aims of the consensus report]	1.0	5	1	0	0
5982	295	future expansion	[future expansion]	1.0	2	1	0	0
5983	295	rethink the quality of outcome measure	[Rethinking the quality of outcome measures]	1.0	6	1	0	0
5984	295	real world	[real world]	1.0	2	1	0	0
5985	295	implementation strategy	[implementation strategies]	1.0	2	3	2	1
5986	295	rotor with wide blood-flow path	[rotor with wide blood-flow paths]	1.0	5	1	0	0
5987	295	three kinase	[three kinases]	1.0	2	1	0	0
5988	295	CHM versus biomedical treatment alone	[CHM versus biomedical treatment alone]	1.0	5	1	0	0
5989	295	overexpress Hand2 in heart muscle cell	[overexpressing Hand2 in heart muscle cells]	1.0	6	1	0	0
5990	295	desensitization process	[desensitization processes]	1.0	2	1	0	0
5991	295	triangular resection	[triangular resection]	1.0	2	1	0	0
5992	295	increase in LV posterior wall thickness	[increase in LV posterior wall thickness]	1.0	6	1	0	0
5993	295	twenty-seven symptomatic adult Fontan SAF patient	[Twenty-seven symptomatic adult Fontan SAF patients]	1.0	6	1	0	0
5994	295	descriptive statistic	[descriptive statistics]	1.0	2	1	0	0
5995	295	systolic mitral annulus velocity Sa	[systolic mitral annulus velocity Sa]	1.0	5	1	0	0
5996	295	receive the last dose of doxorubicin	[receiving the last dose of doxorubicin]	1.0	6	1	0	0
5997	295	4 group	[4 groups]	1.0	2	1	0	0
5998	295	interatrial shunting	[interatrial shunting]	1.0	2	2	2	2
5999	295	echocardiographic examination	[echocardiographic examination]	1.0	2	1	0	0
6000	295	crt-d recipient	[CRT-D recipients]	1.0	2	2	2	2
6001	295	update on cardiopulmonary exercise variable	[update on cardiopulmonary exercise variables]	1.0	5	1	0	0
6002	295	mr-proadm p	[MR-proADM p]	1.0	2	1	0	0
6003	295	test result	[test results]	1.0	2	1	0	0
6004	295	DXA result	[DXA results]	1.0	2	1	0	0
6005	295	neurohumoral blocker	[neurohumoral blockers]	1.0	2	1	0	0
6006	295	Global strain	[Global strain]	1.0	2	2	2	2
6007	295	neurohormonal system	[neurohormonal systems]	1.0	2	1	0	0
6008	295	26 site in North America	[26 sites in North America]	1.0	5	1	0	0
6009	295	artificial pulse	[artificial pulse]	1.0	2	1	0	0
6010	295	Diuretic use in heart failure	[Diuretic use in heart failure]	1.0	5	1	0	0
6011	295	short follow-up	[short follow-up]	1.0	2	1	0	0
6012	295	Periodic breathing with no heart beat	[Periodic breathing with no heart beat]	1.0	6	1	0	0
6013	295	plasma sample	[plasma samples]	1.0	2	2	1	1
6014	295	cation channel m7 TRPM7 channel mrna	[cation channel M7 TRPM7 channel mRNA]	1.0	6	1	0	0
6015	295	hospital day	[hospital days]	1.0	2	2	1	1
6016	295	global strain	[global strain]	1.0	2	2	2	2
6017	295	device implantation	[device implantation]	1.0	2	2	1	1
6018	295	translational repression	[translational repression]	1.0	2	1	0	0
6019	295	heterogeneous group of patient consist	[heterogeneous group of patients consisting]	1.0	5	1	0	0
6020	295	229 millileter	[229 mL]	1.0	2	1	0	0
6021	295	signalosome complex	[signalosome complex]	1.0	2	1	0	0
6022	295	Left ventricular assist device lvas	[Left ventricular assist devices LVADs]	1.0	5	1	0	0
6023	295	nursing intervention	[nursing interventions]	1.0	2	1	0	0
6024	295	heart failure with ejection fraction HFpEF	[Heart failure with ejection fraction HFpEF]	1.0	6	1	0	0
6025	295	CI 0.85	[CI 0.85]	1.0	2	1	0	0
6026	295	dose uptitration	[dose uptitration]	1.0	2	2	2	2
6027	295	prespecified criterion	[prespecified criteria]	1.0	2	1	0	0
6028	295	left ventricular LV systolic pressure	[left ventricular LV systolic pressure]	1.0	5	1	0	0
6029	295	three mode	[three modes]	1.0	2	1	0	0
6030	295	atrial structure	[atrial structure]	1.0	2	1	0	0
6031	295	survive a acute myocardial infarction AMI	[surviving an acute myocardial infarction AMI]	1.0	6	1	0	0
6032	295	one setting	[one setting]	1.0	2	1	0	0
6033	295	–17.4 point vs. 2.1 point	[–17.4 points vs. 2.1 points]	1.0	5	1	0	0
6034	295	useful tool for prognostic assessment	[useful tool for prognostic assessment]	1.0	5	1	0	0
6035	295	CI 0.45	[CI 0.45]	1.0	2	1	0	0
6036	295	Medical therapy	[Medical Therapies]	1.0	2	1	0	0
6037	295	hospital performance of readmission metric	[hospital performance of readmission metrics]	1.0	5	1	0	0
6038	295	Exercise capacity	[Exercise capacity]	1.0	2	1	0	0
6039	295	systolic strain	[systolic strain]	1.0	2	2	2	2
6040	295	CI 0.39	[CI 0.39]	1.0	2	1	0	0
6041	295	Clinical comparison	[Clinical comparisons]	1.0	2	1	0	0
6042	295	proteomics change	[proteomics changes]	1.0	2	2	2	2
6043	295	7 month	[7 months]	1.0	2	1	0	0
6044	295	same indication	[same indication]	1.0	2	1	0	0
6045	295	Sprague-Dawley rat	[Sprague-Dawley rats]	1.0	2	1	0	0
6046	295	≥2 nondiabete risk factor age man	[≥2 nondiabetes risk factors age men]	1.0	6	1	0	0
6047	295	β1ar downregulation	[β1AR downregulation]	1.0	2	1	0	0
6048	295	foundation of management of patient	[foundation of management of patients]	1.0	5	1	0	0
6049	295	spite of development in procedure	[spite of developments in procedure]	1.0	5	1	0	0
6050	295	data processing	[Data processing]	1.0	2	1	0	0
6051	295	cardiac catheterization	[cardiac catheterization]	1.0	2	2	1	1
6052	295	induce hyperkalemia in high-risk patient	[inducing hyperkalemia in high-risk patients]	1.0	5	1	0	0
6053	295	low eo-cfus	[lower EO-CFUs]	1.0	2	1	0	0
6054	295	important comorbidity such as anemia	[important comorbidities such as anemia]	1.0	5	1	0	0
6055	295	other outcome in patient with moderate	[other outcomes in patients with moderate]	1.0	6	1	0	0
6056	295	cardiac development	[cardiac development]	1.0	2	1	0	0
6057	295	cognitive function	[cognitive function]	1.0	2	1	0	0
6058	295	cardiac performance	[cardiac performance]	1.0	2	1	0	0
6059	295	proximal left anterior descend artery	[proximal left anterior descending artery]	1.0	5	1	0	0
6060	295	12 male	[12 male]	1.0	2	1	0	0
6061	295	plasma b-type natriuretic peptide bnp	[plasma B-type natriuretic peptide BNP]	1.0	5	1	0	0
6062	295	cost for patient with heart failure	[costs for patients with heart failure]	1.0	6	1	0	0
6063	295	heart failure in old adult	[heart failure in older adults]	1.0	5	1	0	0
6064	295	2101481 hospitalization	[2,101,481 hospitalizations]	1.0	2	1	0	0
6065	295	develop congestive heart failure CHF	[developing congestive heart failure CHF]	1.0	5	1	0	0
6066	295	Global longitudinal strain of left ventricle	[Global longitudinal strain of left ventricle]	1.0	6	1	0	0
6067	295	web-based program	[Web-based program]	1.0	2	1	0	0
6068	295	ERK1 signalling	[ERK1 signalling]	1.0	2	1	0	0
6069	295	Hazard ratio	[Hazard ratios]	1.0	2	2	1	1
6070	295	risk of acute heart failure	[risk of acute heart failure]	1.0	5	1	0	0
6071	295	hypothesis-generating finding	[hypothesis-generating findings]	1.0	2	1	0	0
6072	295	individual with acute RV failure	[Individuals with acute RV failure]	1.0	5	1	0	0
6073	295	messenger rna	[messenger RNA]	1.0	2	1	0	0
6074	295	New York heart Association classification	[New York Heart Association classification]	1.0	5	1	0	0
6075	295	onset hfref	[onset HFrEF]	1.0	2	2	2	2
6076	295	comparative effect of ventricular assist device	[Comparative effects of ventricular assist device]	1.0	6	1	0	0
6077	295	patient need at follow-up visit	[patient needs at follow-up visits]	1.0	5	1	0	0
6078	295	doppler mitral inflow velocity e-wave	[Doppler mitral inflow velocity E-wave]	1.0	5	1	0	0
6079	295	lvad therapy	[LVAD therapy]	1.0	2	1	0	0
6080	295	transmitral e-wave	[transmitral E-wave]	1.0	2	1	0	0
6081	295	Impact of frailty on HF risk	[Impact of frailty on HF risk]	1.0	6	1	0	0
6082	295	kidney infection without major complication	[kidney infection without major complications]	1.0	5	1	0	0
6083	295	high risk of death visit	[higher risk of death visit]	1.0	5	1	0	0
6084	295	patient with HF with ef	[patients with HF with EF]	1.0	5	1	0	0
6085	295	primary symptom	[primary symptom]	1.0	2	2	1	1
6086	295	patient consist after myocardial infarction	[patients consisting after myocardial infarction]	1.0	5	1	0	0
6087	295	mitral	[mitral]	1.0	1	11	9	9
6088	295	little hr reduction with beta-blocker therapy	[little HR reduction with beta-blocker therapy]	1.0	6	1	0	0
6089	295	severe hyponatremia	[severe hyponatremia]	1.0	2	1	0	0
6090	295	RM intervention	[RM interventions]	1.0	2	1	0	0
6091	295	other patient	[other patients]	1.0	2	1	0	0
6092	295	388.3 m	[388.3 ms]	1.0	2	1	0	0
6093	295	systolic function in hfpef patient	[systolic function in HFpEF patients]	1.0	5	1	0	0
6094	295	common emergency Department ED presentation	[common Emergency Department ED presentation]	1.0	5	1	0	0
6095	295	62 primary care clinician care	[62 primary care clinicians caring]	1.0	5	1	0	0
6096	295	CRT capability	[CRT capability]	1.0	2	1	0	0
6097	295	induction of a substantial subset	[induction of a substantial subset]	1.0	5	1	0	0
6098	295	multivariable model	[multivariable models]	1.0	2	1	0	0
6099	295	adult with a Fontan circulation	[adults with a Fontan circulation]	1.0	5	1	0	0
6100	295	obese patient	[obese patients]	1.0	2	2	2	2
6101	295	change in 7-day follow-up visit	[change in 7-day follow-up visits]	1.0	5	1	0	0
6102	295	low cd34+vegfr2	[lower CD34+VEGFR2]	1.0	2	1	0	0
6103	295	DAVID tool	[DAVID tools]	1.0	2	1	0	0
6104	295	little attention	[little attention]	1.0	2	1	0	0
6105	295	84 millileter	[84 mL]	1.0	2	1	0	0
6106	295	role determine the adaptive cardiac remodelling	[role determining the adaptive cardiac remodelling]	1.0	6	1	0	0
6107	295	mouse rad q65p the murine equivalent	[mouse Rad Q65P the murine equivalent]	1.0	6	1	0	0
6108	295	real-world setting	[real-world setting]	1.0	2	1	0	0
6109	295	9 patient	[9 patients]	1.0	2	1	0	0
6110	295	rate of annual ed visit	[rates of annual ED visits]	1.0	5	1	0	0
6111	295	nine patient	[nine patients]	1.0	2	1	0	0
6112	295	Clinical Practice	[Clinical Practice]	1.0	2	1	0	0
6113	295	adult patient undergo isolated heart transplant	[adult patients undergoing isolated heart transplant]	1.0	6	1	0	0
6114	295	ratio of systolic blood pressure	[ratio of systolic blood pressure]	1.0	5	1	0	0
6115	295	absolute minimal detectable change mdc value	[absolute minimal detectable change MDC values]	1.0	6	1	0	0
6116	295	rate-control treatment	[rate-control treatment]	1.0	2	1	0	0
6117	295	carry two increase in cardiac risk	[carrying two increase in cardiac risk]	1.0	6	1	0	0
6118	295	relation of preoperative serum albumin level	[Relation of preoperative serum albumin levels]	1.0	6	1	0	0
6119	295	ventricular mass	[ventricular mass]	1.0	2	1	0	0
6120	295	oxidative stress	[Oxidative stress]	1.0	2	2	1	1
6121	295	anti-inflammatory effect in the treatment	[anti-inflammatory effects in the treatment]	1.0	5	1	0	0
6122	295	prognostic power of various measure	[prognostic power of various measures]	1.0	5	1	0	0
6123	295	ring annuloplasty with a Physio Ring	[ring annuloplasty with a Physio Ring]	1.0	6	1	0	0
6124	295	obese zsf1	[obese ZSF1]	1.0	2	2	1	1
6125	295	nt-probnp level at the time	[NT-proBNP levels at the time]	1.0	5	1	0	0
6126	295	404 patient	[404 patients]	1.0	2	1	0	0
6127	295	slow increase in heart rate	[slower increase in heart rate]	1.0	5	1	0	0
6128	295	assess ventricular fill pressure in patient	[assessing ventricular filling pressure in patients]	1.0	6	1	0	0
6129	295	exercise duration	[exercise duration]	1.0	2	1	0	0
6130	295	human myocardium	[human myocardium]	1.0	2	1	0	0
6131	295	CHF p	[CHF p]	1.0	2	1	0	0
6132	295	above parameter	[above parameters]	1.0	2	1	0	0
6133	295	sympathetic control of heart rate	[sympathetic control of heart rate]	1.0	5	1	0	0
6134	295	all-cause mortality in heart failure	[all-cause mortality in heart failure]	1.0	5	1	0	0
6135	295	other etiology	[other etiologies]	1.0	2	1	0	0
6136	295	aa participant	[AA participants]	1.0	2	1	0	0
6137	295	worsen renal function WRF in EMPHASIS-HF	[worsening renal function WRF in EMPHASIS-HF]	1.0	6	1	0	0
6138	295	heart failure in the heart	[heart failure in the heart]	1.0	5	1	0	0
6139	295	invasive assessment	[invasive assessment]	1.0	2	2	2	2
6140	295	economic analysis	[Economic Analysis]	1.0	2	2	1	1
6141	295	2 molecular scaffold in heart pathology	[2 molecular scaffolds in heart pathology]	1.0	6	1	0	0
6142	295	mortality in heart failure HF	[mortality in heart failure HF]	1.0	5	1	0	0
6143	295	Cardiac amyloidosis about a atypical case	[Cardiac amyloidosis about an atypical case]	1.0	6	1	0	0
6144	295	chronic advanced heart failure patient	[chronic advanced heart failure patients]	1.0	5	2	1	1
6145	295	valvular regurgitation	[valvular regurgitation]	1.0	2	1	0	0
6146	295	overall summary	[overall summary]	1.0	2	1	0	0
6147	295	ejection fraction argument for hypo-response	[ejection fraction arguments for hypo-response]	1.0	5	1	0	0
6148	295	qrs width	[QRS width]	1.0	2	1	0	0
6149	295	least a level of CRF	[least a level of CRF]	1.0	5	1	0	0
6150	295	patient with heart failure irrespective	[patients with heart failure irrespective]	1.0	5	1	0	0
6151	295	selective heart rate reduction with ivabradine	[Selective heart rate reduction with ivabradine]	1.0	6	1	0	0
6152	295	western blot with site-specific monoclonal antibody	[Western blots with site-specific monoclonal antibodies]	1.0	6	1	0	0
6153	295	metabolic enzyme	[metabolic enzymes]	1.0	2	2	2	2
6154	295	significant value in HF risk prediction	[significant value in HF risk prediction]	1.0	6	1	0	0
6155	295	10.4 year	[10.4 years]	1.0	2	1	0	0
6156	295	consistent benefit	[consistent benefits]	1.0	2	1	0	0
6157	295	nervous system	[nervous system]	1.0	2	2	1	1
6158	295	myocardial remodelling	[myocardial remodelling]	1.0	2	1	0	0
6159	295	use a prospective HF registry	[Using a prospective HF registry]	1.0	5	1	0	0
6160	295	2.5 millileter	[2.5 mL]	1.0	2	1	0	0
6161	295	variation in the use of medication	[Variation in the use of medications]	1.0	6	1	0	0
6162	295	early treatment	[Early treatment]	1.0	2	2	2	2
6163	295	4±15 bpm	[4±15 bpm]	1.0	2	1	0	0
6164	295	major underlying mechanism of HFPEF	[major underlying mechanism of HFPEF]	1.0	5	1	0	0
6165	295	32 deficit	[32 deficits]	1.0	2	1	0	0
6166	295	Health Initiative	[Health Initiative]	1.0	2	2	2	2
6167	295	24 troponin	[24 troponin]	1.0	2	1	0	0
6168	295	severe hyponatremia in most country	[severe hyponatremia in most countries]	1.0	5	1	0	0
6169	295	HFPSI in affair HF clinic	[HFPSI in Affairs HF clinic]	1.0	5	1	0	0
6170	295	less hypertension	[less hypertension]	1.0	2	1	0	0
6171	295	available study	[available studies]	1.0	2	1	0	0
6172	295	1-day reduction in hospital length	[1-day reduction in hospital length]	1.0	5	1	0	0
6173	295	208 patient	[208 patients]	1.0	2	1	0	0
6174	295	reciprocal downregulation	[reciprocal downregulation]	1.0	2	1	0	0
6175	295	Patient in York heart Association	[Patients In York Heart Association]	1.0	5	1	0	0
6176	295	tomographic angiography	[tomographic angiography]	1.0	2	1	0	0
6177	295	stage d	[stage D]	1.0	2	1	0	0
6178	295	454 patient	[454 patients]	1.0	2	1	0	0
6179	295	gait therapy	[gait therapy]	1.0	2	2	2	2
6180	295	HF volume management between 2007	[HF volume management between 2007]	1.0	5	1	0	0
6181	295	adult with ejection fraction without inotrope	[adults with ejection fraction without inotropes]	1.0	6	1	0	0
6182	295	variance in future hospital mortality	[variance in future hospital mortality]	1.0	5	1	0	0
6183	295	fifty patient	[Fifty patients]	1.0	2	2	1	1
6184	295	nursing management	[Nursing Management]	1.0	2	1	0	0
6185	295	cachexia hazard ratio in univariate analysis	[cachexia hazard ratio in univariate analyses]	1.0	6	1	0	0
6186	295	meet specific inclusion include a egfr	[meeting specific inclusion including an eGFR]	1.0	6	1	0	0
6187	295	rate-control strategy	[rate-control strategies]	1.0	2	1	0	0
6188	295	irs2 protein	[IRS2 proteins]	1.0	2	1	0	0
6189	295	osteomedullary biopsy	[osteomedullary biopsy]	1.0	2	1	0	0
6190	295	209 HFrEF	[209 HFrEF]	1.0	2	1	0	0
6191	295	low apparent concentration circulate nt-probnp	[low apparent concentration circulating NT-proBNP]	1.0	5	1	0	0
6192	295	Hypertension DASH diet score with mortality	[Hypertension DASH diet scores with mortality]	1.0	6	1	0	0
6193	295	cardioverter-defibrillator device	[cardioverter-defibrillator device]	1.0	2	2	2	2
6194	295	convert enzyme inhibitor angiotensin receptor blocker	[converting enzyme inhibitors angiotensin receptor blockers]	1.0	6	1	0	0
6195	295	phosphomimic ser77	[phosphomimic Ser77]	1.0	2	1	0	0
6196	295	LV end systolic volume index	[LV end systolic volume index]	1.0	5	1	0	0
6197	295	pressure pasp	[pressure PASP]	1.0	2	2	2	2
6198	295	dialysis-dependent patient with heart failure	[dialysis-dependent patients with heart failure]	1.0	5	2	1	1
6199	295	management of patient with heart failure	[Management of patients with heart failure]	1.0	6	2	2	2
6200	295	growth factor	[growth factor]	1.0	2	2	2	2
6201	295	diet adherence	[diet adherence]	1.0	2	1	0	0
6202	295	3.1 cm	[3.1 cm]	1.0	2	1	0	0
6203	295	Cardiac function	[Cardiac function]	1.0	2	2	1	1
6204	295	diastolic mitral	[diastolic mitral]	1.0	2	2	1	1
6205	295	decision about implantable cardioverter-defibrillator deactivation	[decisions about implantable cardioverter-defibrillator deactivation]	1.0	5	1	0	0
6206	295	surgical revascularization	[Surgical revascularization]	1.0	2	1	0	0
6207	295	patient have heart failure HF	[patients having heart failure HF]	1.0	5	1	0	0
6208	295	doxorubicin treatment	[doxorubicin treatment]	1.0	2	1	0	0
6209	295	fundamental hypothesis	[fundamental hypothesis]	1.0	2	1	0	0
6210	295	therapeutic intervention	[therapeutic interventions]	1.0	2	2	1	1
6211	295	patient with acute coronary syndrome	[patients with acute coronary syndromes]	1.0	5	1	0	0
6212	295	HABC Battery	[HABC Battery]	1.0	2	1	0	0
6213	295	efficacy of mineralocorticoid receptor antagonist	[efficacy of mineralocorticoid receptor antagonists]	1.0	5	1	0	0
6214	295	high frequency of diabete mellitus	[higher frequency of diabetes mellitus]	1.0	5	1	0	0
6215	295	survival rate of patient with cardiomyopathy	[survival rates of patients with cardiomyopathy]	1.0	6	1	0	0
6216	295	transfusion in patient with heart disease	[transfusions in patients with heart disease]	1.0	6	1	0	0
6217	295	half of patient with heart failure	[Half of patients with heart failure]	1.0	6	1	0	0
6218	295	cardioprotective signal	[cardioprotective signaling]	1.0	2	1	0	0
6219	295	conflict result about the risk	[conflicting results about the risk]	1.0	5	1	0	0
6220	295	implementation of care transfer policy	[implementation of care transfer policy]	1.0	5	1	0	0
6221	295	ring annuloplasty for mitral regurgitation	[ring annuloplasty for mitral regurgitation]	1.0	5	2	2	2
6222	295	hypertensive hfpef	[hypertensive HFPEF]	1.0	2	2	1	1
6223	295	atp content	[ATP content]	1.0	2	1	0	0
6224	295	cardiomyocyte use the flux analyzer	[cardiomyocytes using the flux analyzer]	1.0	5	1	0	0
6225	295	p38alpha mapk	[p38alpha MAPK]	1.0	2	1	0	0
6226	295	receive ecmo	[receiving ECMO]	1.0	2	1	0	0
6227	295	device consideration	[device consideration]	1.0	2	1	0	0
6228	295	common language	[common language]	1.0	2	1	0	0
6229	295	robust predictor of subsequent HF	[robust predictor of subsequent HF]	1.0	5	1	0	0
6230	295	β-blocker at guideline-recommended target dose	[β-blockers at guideline-recommended target dose]	1.0	5	1	0	0
6231	295	with therapy range from medication	[With therapies ranging from medication]	1.0	5	1	0	0
6232	295	full potential	[full potential]	1.0	2	1	0	0
6233	295	negative predictive value of E	[negative predictive value of E]	1.0	5	1	0	0
6234	295	Clinical Excellence	[Clinical Excellence]	1.0	2	1	0	0
6235	295	data source MEDLINE database trial registry	[Data Sources MEDLINE databases trial registries]	1.0	6	1	0	0
6236	295	l-type current	[L-type currents]	1.0	2	1	0	0
6237	295	HF admission	[HF admissions]	1.0	2	1	0	0
6238	295	undergo chronic β-adrenergic receptor stimulation	[undergoing chronic β-adrenergic receptor stimulation]	1.0	5	1	0	0
6239	295	national effort	[national efforts]	1.0	2	1	0	0
6240	295	Health ABC	[Health ABC]	1.0	2	1	0	0
6241	295	progressive development of cardiac hypertrophy	[progressive development of cardiac hypertrophy]	1.0	5	1	0	0
6242	295	other potential predictor particularly biomarker	[other potential predictors particularly biomarkers]	1.0	5	1	0	0
6243	295	primary care	[primary care]	1.0	2	1	0	0
6244	295	deficit present out of deficit	[deficits present out of deficits]	1.0	5	1	0	0
6245	295	effect of CRT in patient	[effect of CRT in patients]	1.0	5	1	0	0
6246	295	1.73 m2	[1.73 m2]	1.0	2	1	0	0
6247	295	other prognostic factor at admission	[Other prognostic factors at admission]	1.0	5	1	0	0
6248	295	402 patient	[402 patients]	1.0	2	2	2	2
6249	295	index admission	[index admission]	1.0	2	2	1	1
6250	295	listing criterion	[listing criteria]	1.0	2	1	0	0
6251	295	multisite study	[multisite study]	1.0	2	2	1	1
6252	295	0.12 mg	[0.12 mg]	1.0	2	1	0	0
6253	295	sound mind	[sound mind]	1.0	2	1	0	0
6254	295	1113 pg	[1,113 pg]	1.0	2	1	0	0
6255	295	waste t-score	[wasting T-score]	1.0	2	1	0	0
6256	295	incidence of	[incidence of]	1.0	2	1	0	0
6257	295	effective treatment	[effective treatment]	1.0	2	1	0	0
6258	295	psoriasis patient	[Psoriasis patients]	1.0	2	2	1	1
6259	295	3.1 kg	[3.1 kg]	1.0	2	1	0	0
6260	295	20-week time	[20-week time]	1.0	2	1	0	0
6261	295	temporary support	[temporary support]	1.0	2	1	0	0
6262	295	arm cuff	[arm cuff]	1.0	2	1	0	0
6263	295	17 day range 6 day	[17 days range 6 days]	1.0	5	1	0	0
6264	295	Outcome of Exercise Training HF-ACTION	[Outcomes of Exercise Training HF-ACTION]	1.0	5	2	2	2
6265	295	sacubiltril valsartan	[sacubiltril valsartan]	1.0	2	1	0	0
6266	295	multimarker-based strategy	[multimarker-based strategy]	1.0	2	1	0	0
6267	295	human pluripotent stem cardiomyocyte hipsc-ct	[human pluripotent stem cardiomyocytes hiPSC-CMs]	1.0	5	1	0	0
6268	295	pulmonary arterial systolic pressure pasp	[pulmonary arterial systolic pressure PASP]	1.0	5	1	0	0
6269	295	absolute improvement	[absolute improvements]	1.0	2	1	0	0
6270	295	N-terminal pro-brain-type natriuretic peptide assessment	[N-terminal pro-brain-type natriuretic peptide assessment]	1.0	5	1	0	0
6271	295	t1 mapping	[T1 mapping]	1.0	2	1	0	0
6272	295	MEDLINE database clinical trial registry	[MEDLINE databases clinical trial registries]	1.0	5	1	0	0
6273	295	multiple myeloma	[multiple myeloma]	1.0	2	1	0	0
6274	295	30 minute	[30 min]	1.0	2	1	0	0
6275	295	0.36 mm	[0.36 mm]	1.0	2	1	0	0
6276	295	58 patient	[58 patients]	1.0	2	1	0	0
6277	295	1.3 millileter	[1.3 mL]	1.0	2	1	0	0
6278	295	1-year mortality in 90-day survivor	[1-year mortality in 90-day survivors]	1.0	5	1	0	0
6279	295	Cardiac magnetic resonance postcontrast t1 time	[Cardiac magnetic resonance postcontrast T1 time]	1.0	6	1	0	0
6280	295	low resting hr p value=0.033	[lower resting HR P value=0.033]	1.0	5	1	0	0
6281	295	all-cause death	[all-cause death]	1.0	2	2	1	1
6282	295	71 millileter	[71 mL]	1.0	2	1	0	0
6283	295	study group	[study group]	1.0	2	1	0	0
6284	295	poorly contract	[poorly contracting]	1.0	2	1	0	0
6285	295	adequate self-management training of patient	[adequate self-management training of patients]	1.0	5	1	0	0
6286	295	continuity equation	[continuity equation]	1.0	2	1	0	0
6287	295	rhythm strategy	[Rhythm strategies]	1.0	2	1	0	0
6288	295	268 inpatient record of patient	[268 inpatient records of patients]	1.0	5	1	0	0
6289	295	many rirnas	[many miRNAs]	1.0	2	1	0	0
6290	295	novel target	[novel targets]	1.0	2	1	0	0
6291	295	risk for the primary outcome	[risk for the primary outcome]	1.0	5	1	0	0
6292	295	primary cabg	[primary CABG]	1.0	2	1	0	0
6293	295	ven slope	[VEN slope]	1.0	2	1	0	0
6294	295	low bte	[lower BTES]	1.0	2	2	1	1
6295	295	hemoglobin in patient with heart failure	[Hemoglobin in patients with heart failure]	1.0	6	1	0	0
6296	295	Kaplan-Meier curve	[Kaplan-Meier curves]	1.0	2	2	1	1
6297	295	acute β-adrenoceptor blockade with esmolol	[acute β-adrenoceptor blockade with esmolol]	1.0	5	1	0	0
6298	295	tgf-β inhibition	[TGF-β inhibition]	1.0	2	1	0	0
6299	295	high muscle	[high muscle]	1.0	2	1	0	0
6300	295	investigate outcome of Exercise training hf-action	[Investigating Outcomes of Exercise Training HF-ACTION]	1.0	6	1	0	0
6301	295	medication regimen	[Medication regimen]	1.0	2	1	0	0
6302	295	≥60 millileter per 1.73 m 2	[≥60 mL per 1.73 m 2]	1.0	6	1	0	0
6303	295	significant improvement show minor improvement	[significant improvements showing minor improvement]	1.0	5	1	0	0
6304	295	improvement in nyha classification from class	[improvements in NYHA classification from class]	1.0	6	1	0	0
6305	295	pluripotency marker	[pluripotency marker]	1.0	2	2	2	2
6306	295	short-term exercise tolerance in patient	[short-term exercise tolerance in patients]	1.0	5	1	0	0
6307	295	bte with high exercise time	[BTES with higher exercise time]	1.0	5	1	0	0
6308	295	heart failure in Latin America	[heart failure in Latin America]	1.0	5	1	0	0
6309	295	mitral annulus velocity during systole s	[mitral annulus velocities during systole s]	1.0	6	1	0	0
6310	295	collagen deposition	[collagen deposition]	1.0	2	2	1	1
6311	295	doxorubicin-induced cardiotoxicity	[doxorubicin-induced cardiotoxicity]	1.0	2	1	0	0
6312	295	highlight the contribution of nursing care	[highlighting the contribution of nursing care]	1.0	6	1	0	0
6313	295	noncardiovascular diagnosis	[noncardiovascular diagnoses]	1.0	2	1	0	0
6314	295	use technique	[using techniques]	1.0	2	1	0	0
6315	295	significant decrease in LV fractional shortening	[significant decreases in LV fractional shortening]	1.0	6	1	0	0
6316	295	regard risk factor for the development	[regarding risk factors for the development]	1.0	6	1	0	0
6317	295	differential impact on hospital performance	[differential impact on hospital performance]	1.0	5	1	0	0
6318	295	cardiovascular function	[cardiovascular function]	1.0	2	2	2	2
6319	295	outcome for patient with heart failure	[outcomes for patients with heart failure]	1.0	6	1	0	0
6320	295	short-form quality of life domain	[Short-Form quality of life domains]	1.0	5	1	0	0
6321	295	stent occlusion	[stent occlusion]	1.0	2	1	0	0
6322	295	exercise than in the group	[exercise than in the group]	1.0	5	1	0	0
6323	295	2 minute	[2 minutes]	1.0	2	1	0	0
6324	295	preorder initiation	[pre initiation]	1.0	2	1	0	0
6325	295	21 month	[21 months]	1.0	2	1	0	0
6326	295	uptake of class i cpg recommendation	[uptake of class I CPG recommendations]	1.0	6	1	0	0
6327	295	normal LV ejection fraction of 0.70	[normal LV ejection fraction of 0.70]	1.0	6	1	0	0
6328	295	transduction pathway	[transduction pathways]	1.0	2	1	0	0
6329	295	data in patient with systolic function	[Data in patients with systolic function]	1.0	6	1	0	0
6330	295	alleviate the decrement of heart rate	[alleviating the decrement of heart rate]	1.0	6	1	0	0
6331	295	electrical stimulation	[electrical stimulation]	1.0	2	2	2	2
6332	295	favorable outcome at 1 year	[favorable outcome at 1 year]	1.0	5	1	0	0
6333	295	future of heart failure trial	[future of heart failure trials]	1.0	5	1	0	0
6334	295	future trial use hr variability	[Future trials using HR variability]	1.0	5	1	0	0
6335	295	hdl-mediated effect	[HDL-mediated effects]	1.0	2	2	2	2
6336	295	at nonidentification	[AT nonidentification]	1.0	2	1	0	0
6337	295	tachycardic response	[tachycardic response]	1.0	2	1	0	0
6338	295	iron homeostasis	[iron homeostasis]	1.0	2	1	0	0
6339	295	characteristic mortality	[characteristics mortality]	1.0	2	1	0	0
6340	295	3m potential	[3M Potential]	1.0	2	1	0	0
6341	295	median of 123 mm hg	[median of 123 mm Hg]	1.0	5	1	0	0
6342	295	restoration of cardiac plasma membrane level	[restoration of cardiac plasma membrane levels]	1.0	6	1	0	0
6343	295	2.1 17.6 millileter 2 p=0.01	[2.1 17.6 mL 2 P=0.01]	1.0	5	1	0	0
6344	295	left ventricular fill pressure response	[left ventricular filling pressure response]	1.0	5	1	0	0
6345	295	noninvasive assessment	[noninvasive assessments]	1.0	2	1	0	0
6346	295	unit cost	[unit costs]	1.0	2	1	0	0
6347	295	trastuzumab use	[trastuzumab use]	1.0	2	1	0	0
6348	295	125.6 minute	[125.6 minutes]	1.0	2	1	0	0
6349	295	new user	[new users]	1.0	2	2	2	2
6350	295	cardiopulmonary exercise testing with echocardiographic assessment	[Cardiopulmonary exercise testing with echocardiographic assessment]	1.0	6	1	0	0
6351	295	pharmacological armamentarium	[pharmacological armamentarium]	1.0	2	1	0	0
6352	295	significant value	[significant value]	1.0	2	2	2	2
6353	295	18 mg	[18 mg]	1.0	2	1	0	0
6354	295	transmitral e-wave early diastolic mitral velocity	[transmitral E-wave early diastolic mitral velocity]	1.0	6	1	0	0
6355	295	assembly of this three kinase	[assembly of these three kinases]	1.0	5	1	0	0
6356	295	treat Advanced HF a Multicenter Study	[Treating Advanced HF A Multicenter Study]	1.0	6	1	0	0
6357	295	stimulation of cell oxide production	[stimulation of cell oxide production]	1.0	5	1	0	0
6358	295	xanthine oxidase	[Xanthine oxidase]	1.0	2	2	2	2
6359	295	Rad Q65P	[Rad Q65P]	1.0	2	1	0	0
6360	295	inoperable chronic thromboembolic pulmonary hypertension	[inoperable chronic thromboembolic pulmonary hypertension]	1.0	5	1	0	0
6361	295	cardiovascular death for heart failure	[cardiovascular death for heart failure]	1.0	5	1	0	0
6362	295	large registry	[large registry]	1.0	2	1	0	0
6363	295	6 wk after the procedure	[6 wk after the procedures]	1.0	5	1	0	0
6364	295	normal reference	[normal reference]	1.0	2	1	0	0
6365	295	good performance	[good performance]	1.0	2	2	2	2
6366	295	Diuretic efficacy	[Diuretic efficacy]	1.0	2	1	0	0
6367	295	patient with HF under drug treatment	[patients with HF under drug treatment]	1.0	6	1	0	0
6368	295	nbdmard in this RA population	[nbDMARDs in this RA population]	1.0	5	1	0	0
6369	295	cross talk between this receptor	[cross talk between these receptors]	1.0	5	1	0	0
6370	295	10 lb in 1 year	[10 lb in 1 year]	1.0	5	1	0	0
6371	295	result in the suppression of signalling	[resulting in the suppression of signalling]	1.0	6	1	0	0
6372	295	18 female	[18 female]	1.0	2	1	0	0
6373	295	SAF cohort	[SAF cohort]	1.0	2	1	0	0
6374	295	signal transduction	[signal transduction]	1.0	2	2	2	2
6375	295	ARNI inhibitor angiotensin-receptor neprilysin inhibitor	[ARNI inhibitors angiotensin-receptor neprilysin inhibitors]	1.0	5	1	0	0
6376	295	eight week from myocardial infarction	[Eight weeks from myocardial infarction]	1.0	5	1	0	0
6377	295	common disorder	[common disorder]	1.0	2	1	0	0
6378	295	social mandate	[social mandate]	1.0	2	1	0	0
6379	295	4 patient	[4 patients]	1.0	2	1	0	0
6380	295	once during the index admission	[once during the index admission]	1.0	5	1	0	0
6381	295	70 bpm with beta-blocker therapy	[70 bpm with beta-blocker therapy]	1.0	5	1	0	0
6382	295	age risk	[age risk]	1.0	2	1	0	0
6383	295	myocyte diameter	[myocyte diameter]	1.0	2	1	0	0
6384	295	adverse outcome in other patient	[adverse outcomes in other patients]	1.0	5	1	0	0
6385	295	use a blood cell transfusion strategy	[using a blood cell transfusion strategy]	1.0	6	1	0	0
6386	295	infarction-related refractory right heart failure	[infarction-related refractory right heart failure]	1.0	5	1	0	0
6387	295	involve family	[involving families]	1.0	2	1	0	0
6388	295	odd ratio 1.76 even after adjustment	[odds ratio 1.76 even after adjustment]	1.0	6	1	0	0
6389	295	intestinal morphology	[intestinal morphology]	1.0	2	1	0	0
6390	295	acetylcholinesterase inhibition	[acetylcholinesterase inhibition]	1.0	2	1	0	0
6391	295	strain rate	[strain rate]	1.0	2	2	1	1
6392	295	patient age	[patients age]	1.0	2	2	2	2
6393	295	1620 patient	[1,620 patients]	1.0	2	1	0	0
6394	295	36284 patient	[36,284 patients]	1.0	2	1	0	0
6395	295	high score	[higher scores]	1.0	2	1	0	0
6396	295	LV function	[LV function]	1.0	2	2	1	1
6397	295	low natremia	[lower natremia]	1.0	2	1	0	0
6398	295	30 millileter per 1.73 m	[30 mL per 1.73 m]	1.0	5	2	1	1
6399	295	qt interval	[QT intervals]	1.0	2	2	2	2
6400	295	insight from the NCDR PINNACLE program	[Insights from the NCDR PINNACLE program]	1.0	6	1	0	0
6401	295	multiparametric score	[multiparametric score]	1.0	2	2	2	2
6402	295	early transmitral blood flow velocity	[early transmitral blood flow velocity]	1.0	5	1	0	0
6403	295	pneumonia PNA	[pneumonia PNA]	1.0	2	1	0	0
6404	295	independent predictor of long mortality	[independent predictor of long-term mortality]	1.0	5	1	0	0
6405	295	advanced stage of heart failure	[advanced stages of heart failure]	1.0	5	1	0	0
6406	295	bnp group	[BNP group]	1.0	2	2	2	2
6407	295	valid measure of health status	[valid measure of health status]	1.0	5	2	1	1
6408	295	cardiac energy	[cardiac energy]	1.0	2	1	0	0
6409	295	cell adhesion	[cell adhesion]	1.0	2	1	0	0
6410	295	important component	[important component]	1.0	2	2	2	2
6411	295	possible index	[possible index]	1.0	2	1	0	0
6412	295	diverse aspect of cardiac remodeling	[diverse aspects of cardiac remodeling]	1.0	5	1	0	0
6413	295	great reduction of sympathetic activity	[greater reduction of sympathetic activity]	1.0	5	1	0	0
6414	295	conjunction with a CentriMag rvad	[conjunction with a CentriMag RVAD]	1.0	5	1	0	0
6415	295	combination of the four remodeling aspect	[combinations of the four remodeling aspects]	1.0	6	1	0	0
6416	295	adoption of heart failure guideline lesson	[adoption of heart failure guidelines lessons]	1.0	6	1	0	0
6417	295	10 center	[10 centers]	1.0	2	1	0	0
6418	295	visit during the 2-year study period	[visits during the 2-year study period]	1.0	6	1	0	0
6419	295	disease severity	[disease severity]	1.0	2	1	0	0
6420	295	resting tension (Fpassive)-sarcomere length relation	[Resting tension (Fpassive)-sarcomere length relations]	1.0	5	1	0	0
6421	295	75 year of age with diabete	[75 years of age with diabetes]	1.0	6	1	0	0
6422	295	safety of mineralocorticoid receptor antagonist	[safety of mineralocorticoid receptor antagonists]	1.0	5	1	0	0
6423	295	evidence-based care	[Evidence-based care]	1.0	2	1	0	0
6424	295	early-activated septum	[early-activated septum]	1.0	2	1	0	0
6425	295	intermediate metabolism	[intermediate metabolism]	1.0	2	1	0	0
6426	295	inpatient admission	[inpatient admissions]	1.0	2	2	1	1
6427	295	only the obese ZSF1 group	[Only the obese ZSF1 groups]	1.0	5	1	0	0
6428	295	LV remodeling	[LV remodeling]	1.0	2	1	0	0
6429	295	cardiac magnetic resonance postcontrast t1 time	[cardiac magnetic resonance postcontrast T1 time]	1.0	6	1	0	0
6430	295	restrictive blood cell transfusion strategy	[restrictive blood cell transfusion strategy]	1.0	5	1	0	0
6431	295	ejection time	[ejection time]	1.0	2	2	2	2
6432	295	doxorubicin-induced heart failure in rat	[doxorubicin-induced heart failure in rats]	1.0	5	1	0	0
6433	295	vary combination of the remodeling aspect	[varying combinations of the remodeling aspects]	1.0	6	1	0	0
6434	295	LVET at entry 237 millisecond	[LVET at entry 237 milliseconds]	1.0	5	1	0	0
6435	295	heart Failure Patient Severity Index	[Heart Failure Patient Severity Index]	1.0	5	1	0	0
6436	295	double-blind trial	[double-blind trial]	1.0	2	1	0	0
6437	295	inhibit TGF-β receptor type I	[inhibiting TGF-β receptor type I]	1.0	5	1	0	0
6438	295	medication dose	[medication dose]	1.0	2	1	0	0
6439	295	adult medicine	[adult medicine]	1.0	2	1	0	0
6440	295	particularly reduce all-cause mortality for patient	[particularly reducing all-cause mortality for patients]	1.0	6	1	0	0
6441	295	extracorporeal membrane	[extracorporeal membrane]	1.0	2	2	1	1
6442	295	CV death	[CV death]	1.0	2	2	1	1
6443	295	paf-cpt in parallel with paf level	[PAF-CPT in parallel with PAF levels]	1.0	6	1	0	0
6444	295	optimal cutoff level of NT-proBNP	[optimal cutoff level of NT-proBNP]	1.0	5	1	0	0
6445	295	cardiac sympathetic activity in patient	[cardiac sympathetic activity in patients]	1.0	5	1	0	0
6446	295	prospective study evaluate implementation intervention	[prospective studies evaluating implementation interventions]	1.0	5	1	0	0
6447	295	postoperative normalization of albumin level	[postoperative normalization of albumin levels]	1.0	5	1	0	0
6448	295	outcome performance	[outcome performance]	1.0	2	1	0	0
6449	295	use of medication among outpatient	[use of medications among outpatients]	1.0	5	1	0	0
6450	295	aortic pressure	[aortic pressure]	1.0	2	1	0	0
6451	295	routine measurement of hr variability	[routine measurement of HR variability]	1.0	5	1	0	0
6452	295	PAF-CPT level	[PAF-CPT levels]	1.0	2	1	0	0
6453	295	clinical outcome such as hospitalisation	[clinical outcomes such as hospitalisations]	1.0	5	1	0	0
6454	295	background uncertain	[Background uncertain]	1.0	2	1	0	0
6455	295	grade recommendation	[Grade recommendation]	1.0	2	2	2	2
6456	295	urgent need	[urgent need]	1.0	2	1	0	0
6457	295	cardiac na	[cardiac Na]	1.0	2	2	1	1
6458	295	SRD brachial	[SRD brachial]	1.0	2	1	0	0
6459	295	eligible patient	[eligible patients]	1.0	2	2	2	2
6460	295	paradigm shift in the treatment	[paradigm shift in the treatment]	1.0	5	1	0	0
6461	295	other system	[other systems]	1.0	2	1	0	0
6462	295	oxygen flow	[oxygen flow]	1.0	2	2	1	1
6463	295	HF risk factor of country	[HF risk factors of countries]	1.0	5	2	1	1
6464	295	HF prediction	[HF prediction]	1.0	2	2	2	2
6465	295	univariable analysis	[univariable analysis]	1.0	2	1	0	0
6466	295	extracorporeal support	[extracorporeal support]	1.0	2	1	0	0
6467	295	system level	[systems level]	1.0	2	1	0	0
6468	295	exercise-induced pasp	[exercise-induced PASP]	1.0	2	1	0	0
6469	295	stable severe systolic heart failure	[stable severe systolic heart failure]	1.0	5	1	0	0
6470	295	left strain	[left strain]	1.0	2	2	2	2
6471	295	disease C	[disease C]	1.0	2	1	0	0
6472	295	pump thrombosis	[pump thrombosis]	1.0	2	1	0	0
6473	295	potentially beneficial new therapeutic approach	[potentially beneficial new therapeutic approach]	1.0	5	1	0	0
6474	295	hypothetical program	[hypothetical programs]	1.0	2	1	0	0
6475	295	β-blocker-induced enhancement of cardiac angiogenesis	[β-Blocker-induced enhancement of cardiac angiogenesis]	1.0	5	1	0	0
6476	295	CentriMag rvad	[CentriMag RVAD]	1.0	2	2	1	1
6477	295	peripheral oedema	[peripheral oedema]	1.0	2	1	0	0
6478	295	trial result	[trial results]	1.0	2	1	0	0
6479	295	measure the peak quadricep force	[measuring the peak quadriceps force]	1.0	5	1	0	0
6480	295	complicate AMI	[complicating AMI]	1.0	2	2	1	1
6481	295	prognostic resolution	[prognostic resolution]	1.0	2	1	0	0
6482	295	signal cascade	[signalling cascades]	1.0	2	1	0	0
6483	295	KCCQ domain	[KCCQ domains]	1.0	2	1	0	0
6484	295	epigenetic reader in cardiac biology	[epigenetic readers in cardiac biology]	1.0	5	1	0	0
6485	295	parasympathetic neurotransmission	[parasympathetic neurotransmission]	1.0	2	1	0	0
6486	295	23 patient in the VAD group	[23 patients in the VAD group]	1.0	6	1	0	0
6487	295	nosignificant change in control group p	[nosignificant changes in control group P]	1.0	6	1	0	0
6488	295	cardiac mrna level of inflammatory gene	[cardiac mRNA levels of inflammatory genes]	1.0	6	1	0	0
6489	295	psychometric profile	[psychometric profile]	1.0	2	1	0	0
6490	295	bad outcome	[worse outcomes]	1.0	2	1	0	0
6491	295	standard error of measurement value	[standard error of measurement value]	1.0	5	1	0	0
6492	295	RENASTUR cohort	[RENASTUR cohort]	1.0	2	1	0	0
6493	295	primary CABG	[primary CABG]	1.0	2	1	0	0
6494	295	heart block	[Heart block]	1.0	2	1	0	0
6495	295	perfusion of the carotid body	[perfusion of the carotid bodies]	1.0	5	1	0	0
6496	295	icd shock	[ICD shocks]	1.0	2	2	2	2
6497	295	top pathway	[top pathways]	1.0	2	1	0	0
6498	295	two Centers	[two Centers]	1.0	2	1	0	0
6499	295	electromechanical behavior of the heart	[electromechanical behavior of the heart]	1.0	5	1	0	0
6500	295	low limb	[lower limbs]	1.0	2	1	0	0
6501	295	additional progress	[Additional progress]	1.0	2	1	0	0
6502	295	management of patient with ras	[management of patients with RAS]	1.0	5	1	0	0
6503	295	262 psoriasis systemic ultra-violet treatment	[262 psoriasis systemic UV treatment]	1.0	5	1	0	0
6504	295	potential benefit with few adverse consequence	[potential benefit with few adverse consequences]	1.0	6	1	0	0
6505	295	Neprilysin inhibitor	[Neprilysin inhibitors]	1.0	2	1	0	0
6506	295	interaction effect	[interaction effect]	1.0	2	1	0	0
6507	295	chromatin hyperacetylation	[chromatin hyperacetylation]	1.0	2	1	0	0
6508	295	doxorubicin cardiotoxicity	[doxorubicin cardiotoxicity]	1.0	2	1	0	0
6509	295	parasympathetic control of the heart	[parasympathetic control of the heart]	1.0	5	1	0	0
6510	295	association with exercise training response	[association with exercise training response]	1.0	5	1	0	0
6511	295	standard care	[standard care]	1.0	2	1	0	0
6512	295	woman respectively	[women respectively]	1.0	2	1	0	0
6513	295	race by treatment interaction p=0.03	[race by treatment interaction P=0.03]	1.0	5	1	0	0
6514	295	exertional shortness	[Exertional Shortness]	1.0	2	1	0	0
6515	295	hf-related morbidity	[HF-related morbidity]	1.0	2	1	0	0
6516	295	remote monitoring	[Remote monitoring]	1.0	2	2	2	2
6517	295	g'mt-treated nyha	[GDMT-treated NYHA]	1.0	2	1	0	0
6518	295	65±12 year	[65±12 years]	1.0	2	1	0	0
6519	295	especially lyso-paf-at	[especially lyso-PAF-AT]	1.0	2	1	0	0
6520	295	selective beta-blocker	[selective beta-blockers]	1.0	2	1	0	0
6521	295	foundation describe a uniform nomenclature	[foundation describing a uniform nomenclature]	1.0	5	1	0	0
6522	295	bottleneck stenting	[bottleneck stenting]	1.0	2	1	0	0
6523	295	outcome of care for patient	[outcomes of care for patients]	1.0	5	1	0	0
6524	295	unique property	[unique property]	1.0	2	1	0	0
6525	295	sarcopenic range muscle waste t-score	[sarcopenic range muscle wasting T-score]	1.0	5	1	0	0
6526	295	few trial	[Few trials]	1.0	2	1	0	0
6527	295	HF-ACTION cohort	[HF-ACTION cohort]	1.0	2	1	0	0
6528	295	ischemic-hypertensive cardiomyiopathy	[ischemic-hypertensive cardiomyiopathy]	1.0	2	1	0	0
6529	296	characteristic	[characteristics]	0.9888888888888889	1	11	10	9
6530	297	beta-blocker	[beta-blocker]	0.9875	1	11	9	8
6531	298	nyha	[NYHA]	0.9857142857142858	1	11	8	7
6532	299	wall	[wall]	0.9833333333333334	1	11	7	6
6533	299	procedure	[procedure]	0.9833333333333334	1	11	7	6
6534	300	HFrEF	[HFrEF]	0.9800000000000001	1	11	6	5
6535	301	MI	[MI]	0.9750000000000001	1	11	5	4
6536	301	sex	[sex]	0.9750000000000001	1	11	5	4
6537	301	oxygen	[oxygen]	0.9750000000000001	1	11	10	8
6538	301	area	[area]	0.9750000000000001	1	11	10	8
6539	302	all-cause	[all-cause]	0.9714285714285714	1	11	9	7
6540	303	history	[history]	0.9666666666666667	1	12	7	3
6541	304	activation	[activation]	0.9571428571428572	1	11	10	7
6542	305	onset	[onset]	0.9500000000000001	1	11	6	4
6543	306	dopamine	[dopamine]	0.925	1	11	7	4
6544	307	CRF	[CRF]	0.9	1	10	4	4
6545	307	CV	[CV]	0.9	1	10	4	4
6546	307	MS	[MS]	0.9	1	10	3	3
6547	307	be	[r]	0.9	1	9	0	0
6548	307	system	[system]	0.9	1	10	9	9
6549	307	deficit	[deficit]	0.9	1	10	1	1
6550	308	correlation	[correlation]	0.8833333333333334	1	10	7	6
6551	309	HeartMate	[HeartMate]	0.875	1	10	10	8
6552	310	strain	[strain]	0.8714285714285714	1	10	9	7
6553	311	resonance	[resonance]	0.8666666666666667	1	10	8	6
6554	312	psoriasis	[psoriasis]	0.8500000000000001	1	10	3	2
6555	313	mmol	[mmol]	0.8400000000000001	1	10	8	5
6556	314	doxorubicin	[doxorubicin]	0.8	1	9	2	2
6557	314	energy	[energy]	0.8	1	9	4	4
6558	314	F	[F]	0.8	1	8	0	0
6559	314	comorbidity	[comorbidity]	0.8	1	9	4	4
6560	314	Mena	[Mena]	0.8	1	9	5	5
6561	314	LA	[LA]	0.8	1	9	2	2
6562	314	fat	[fat]	0.8	1	9	4	4
6563	314	bb	[BB]	0.8	1	10	8	4
6564	314	adjustment	[adjustment]	0.8	1	10	10	5
6565	314	KCCQ	[KCCQ]	0.8	1	9	3	3
6566	314	dose	[dose]	0.8	1	9	6	6
6567	314	phenotype	[phenotype]	0.8	1	10	8	4
6568	314	regard	[regard]	0.8	1	9	6	6
6569	314	prediction	[prediction]	0.8	1	9	1	1
6570	314	Medicare	[Medicare]	0.8	1	9	4	4
6571	314	nesiritide	[nesiritide]	0.8	1	10	6	3
6572	314	testosterone	[testosterone]	0.8	1	9	4	4
6573	314	self-care	[Self-Care]	0.8	1	9	5	5
6574	314	pathway	[pathway]	0.8	1	9	6	6
6575	314	child	[children]	0.8	1	10	4	2
6576	314	prevalence	[prevalence]	0.8	1	11	9	3
6577	314	contribution	[contribution]	0.8	1	9	8	8
6578	314	reference	[reference]	0.8	1	9	4	4
6579	314	tapse	[TAPSE]	0.8	1	9	5	5
6580	314	bet	[BET]	0.8	1	9	3	3
6581	315	wk	[wk]	0.7875000000000001	1	9	9	8
6582	316	etiology	[etiology]	0.7857142857142858	1	9	8	7
6583	317	nursing	[nursing]	0.78	1	9	6	5
6584	317	agent	[agent]	0.78	1	9	6	5
6585	317	phosphorylation	[phosphorylation]	0.78	1	9	6	5
6586	318	albumin	[albumin]	0.775	1	9	5	4
6587	319	tool	[tool]	0.7714285714285715	1	9	9	7
6588	320	growth	[growth]	0.7666666666666667	1	9	8	6
6589	320	variable	[variable]	0.7666666666666667	1	9	8	6
6590	321	nurse	[nurse]	0.76	1	9	7	5
6591	321	potential	[potential]	0.76	1	9	7	5
6592	321	pathophysiology	[pathophysiology]	0.76	1	9	7	5
6593	322	vad	[VAD]	0.75	1	9	3	2
6594	322	tone	[tone]	0.75	1	10	10	4
6595	323	need	[need]	0.7400000000000001	1	9	8	5
6596	324	composite	[composite]	0.7333333333333334	1	9	5	3
6597	325	L	[L]	0.7000000000000001	1	8	2	2
6598	325	l	[l]	0.7000000000000001	1	7	0	0
6599	325	mass	[mass]	0.7000000000000001	1	8	6	6
6600	325	transcription	[transcription]	0.7000000000000001	1	8	3	3
6601	325	report	[report]	0.7000000000000001	1	8	5	5
6602	325	lead	[leading]	0.7000000000000001	1	8	3	3
6603	325	animal	[animal]	0.7000000000000001	1	8	4	4
6604	325	filtration	[filtration]	0.7000000000000001	1	12	5	1
6605	325	resistance	[resistance]	0.7000000000000001	1	8	5	5
6606	325	sample	[sample]	0.7000000000000001	1	8	4	4
6607	325	tac	[TAC]	0.7000000000000001	1	8	2	2
6608	325	parameter	[parameter]	0.7000000000000001	1	8	6	6
6609	325	center	[center]	0.7000000000000001	1	8	6	6
6610	325	saxagliptin	[saxagliptin]	0.7000000000000001	1	8	4	4
6611	325	irs1	[IRS1]	0.7000000000000001	1	8	5	5
6612	325	irs2	[IRS2]	0.7000000000000001	1	8	3	3
6613	325	egfr	[eGFR]	0.7000000000000001	1	8	7	7
6614	325	aor	[aOR]	0.7000000000000001	1	8	1	1
6615	326	tissue	[tissue]	0.68	1	8	6	5
6616	326	investigation	[investigation]	0.68	1	8	6	5
6617	326	indication	[indication]	0.68	1	8	6	5
6618	326	process	[process]	0.68	1	8	6	5
6619	327	sitagliptin	[sitagliptin]	0.675	1	8	5	4
6620	327	cardiotoxicity	[cardiotoxicity]	0.675	1	8	5	4
6621	327	cost-effectiveness	[cost-effectiveness]	0.675	1	8	5	4
6622	328	stay	[stay]	0.6666666666666667	1	8	4	3
6623	329	iron	[iron]	0.66	1	8	7	5
6624	330	rs	[RS]	0.65	1	8	3	2
6625	330	cachexia	[cachexia]	0.65	1	8	6	4
6626	330	LVEF	[LVEF]	0.65	1	8	3	2
6627	330	diuretic	[diuretic]	0.65	1	8	3	2
6628	331	length	[length]	0.6400000000000001	1	8	8	5
6629	332	esrd	[ESRD]	0.6333333333333333	1	8	5	3
6630	332	NYHA	[NYHA]	0.6333333333333333	1	8	5	3
6631	333	e	[E]	0.6000000000000001	1	7	1	1
6632	333	s1pr1	[S1PR1]	0.6000000000000001	1	7	2	2
6633	333	HF-ACTION	[HF-ACTION]	0.6000000000000001	1	7	3	3
6634	333	CO	[CO]	0.6000000000000001	1	7	1	1
6635	333	Ie	[IE]	0.6000000000000001	1	6	0	0
6636	333	VA	[VA]	0.6000000000000001	1	6	0	0
6637	333	at	[AT]	0.6000000000000001	1	7	4	4
6638	333	eh	[EH]	0.6000000000000001	1	7	3	3
6639	333	ability	[ability]	0.6000000000000001	1	8	4	2
6640	333	mt	[MT]	0.6000000000000001	1	7	1	1
6641	333	or	[OR]	0.6000000000000001	1	6	0	0
6642	333	GLS	[GLS]	0.6000000000000001	1	7	1	1
6643	333	article	[article]	0.6000000000000001	1	7	2	2
6644	333	dietary	[dietary]	0.6000000000000001	1	7	5	5
6645	333	abnormality	[abnormalities]	0.6000000000000001	1	7	7	7
6646	333	inclusion	[inclusion]	0.6000000000000001	1	7	1	1
6647	333	comparison	[comparison]	0.6000000000000001	1	7	5	5
6648	333	importance	[importance]	0.6000000000000001	1	7	4	4
6649	333	trastuzumab	[trastuzumab]	0.6000000000000001	1	7	3	3
6650	333	l-type	[L-type]	0.6000000000000001	1	7	4	4
6651	333	aldosterone	[aldosterone]	0.6000000000000001	1	7	5	5
6652	333	pump	[pump]	0.6000000000000001	1	7	4	4
6653	333	c-kit	[c-Kit]	0.6000000000000001	1	7	6	6
6654	333	percent	[percent]	0.6000000000000001	1	7	6	6
6655	333	b-type	[B-type]	0.6000000000000001	1	8	8	4
6656	333	scn5a	[SCN5A]	0.6000000000000001	1	7	5	5
6657	333	rate-control	[rate-control]	0.6000000000000001	1	7	6	6
6658	333	summary	[summary]	0.6000000000000001	1	7	1	1
6659	333	vivo	[vivo]	0.6000000000000001	1	8	2	1
6660	333	β-ar	[β-AR]	0.6000000000000001	1	7	5	5
6661	333	rehospitalization	[rehospitalization]	0.6000000000000001	1	7	5	5
6662	333	STS	[STS]	0.6000000000000001	1	7	2	2
6663	333	test	[test]	0.6000000000000001	1	7	6	6
6664	333	training	[training]	0.6000000000000001	1	7	3	3
6665	333	barrier	[barrier]	0.6000000000000001	1	7	4	4
6666	333	laboratory	[laboratory]	0.6000000000000001	1	7	2	2
6667	333	bottleneck	[bottleneck]	0.6000000000000001	1	6	0	0
6668	333	myocardium	[myocardium]	0.6000000000000001	1	7	3	3
6669	333	rest	[rest]	0.6000000000000001	1	7	3	3
6670	333	meta-analysis	[meta-analysis]	0.6000000000000001	1	6	0	0
6671	333	enrollment	[enrollment]	0.6000000000000001	1	7	2	2
6672	333	stimulation	[stimulation]	0.6000000000000001	1	7	6	6
6673	333	user	[user]	0.6000000000000001	1	8	8	4
6674	333	pde2	[PDE2]	0.6000000000000001	1	7	7	7
6675	333	potassium	[potassium]	0.6000000000000001	1	7	2	2
6676	333	dash	[DASH]	0.6000000000000001	1	7	4	4
6677	333	atp	[ATP]	0.6000000000000001	1	7	5	5
6678	333	camp	[cAMP]	0.6000000000000001	1	7	3	3
6679	334	marker	[markers]	0.5833333333333334	1	7	7	6
6680	334	elastance	[elastance]	0.5833333333333334	1	7	7	6
6681	334	alteration	[alterations]	0.5833333333333334	1	7	7	6
6682	335	remodelling	[remodelling]	0.58	1	7	6	5
6683	335	mrna	[mRNA]	0.58	1	7	6	5
6684	335	action	[action]	0.58	1	7	6	5
6685	336	chromatin	[chromatin]	0.5750000000000001	1	7	5	4
6686	336	structure	[structure]	0.5750000000000001	1	7	5	4
6687	336	percentage	[percentage]	0.5750000000000001	1	7	5	4
6688	336	membrane	[membrane]	0.5750000000000001	1	7	5	4
6689	336	leaflet	[leaflet]	0.5750000000000001	1	7	5	4
6690	337	dialysis	[dialysis]	0.5666666666666668	1	7	4	3
6691	338	decline	[decline]	0.5599999999999999	1	7	7	5
6692	338	examination	[examination]	0.5599999999999999	1	7	7	5
6693	338	combination	[combination]	0.5599999999999999	1	7	7	5
6694	339	salt	[salt]	0.55	1	7	6	4
6695	339	NT-proBNP	[NT-proBNP]	0.55	1	7	3	2
6696	340	effectiveness	[effectiveness]	0.5333333333333334	1	8	8	3
6697	340	coupling	[coupling]	0.5333333333333334	1	8	8	3
6698	341	criterion	[criteria]	0.5333333333333333	1	7	5	3
6699	342	mean	[mean]	0.525	1	7	7	4
6700	343	fibrosis	[fibrosis]	0.5	1	6	2	2
6701	343	community	[community]	0.5	1	6	1	1
6702	343	CC	[CC]	0.5	1	6	2	2
6703	343	ET	[ET]	0.5	1	6	3	3
6704	343	PD	[PD]	0.5	1	6	2	2
6705	343	cm	[cm]	0.5	1	6	4	4
6706	343	cs	[CS]	0.5	1	6	1	1
6707	343	na	[Na]	0.5	1	6	3	3
6708	343	hemoglobin	[hemoglobin]	0.5	1	6	4	4
6709	343	pg	[pg]	0.5	1	6	6	6
6710	343	tm	[TM]	0.5	1	6	2	2
6711	343	FFM	[FFM]	0.5	1	5	0	0
6712	343	simulation	[simulation]	0.5	1	5	0	0
6713	343	BiVP	[BiVP]	0.5	1	5	0	0
6714	343	distance	[distance]	0.5	1	6	2	2
6715	343	inflammation	[inflammation]	0.5	1	5	0	0
6716	343	pyridostigmine	[pyridostigmine]	0.5	1	5	0	0
6717	343	Kansas	[Kansas]	0.5	1	6	2	2
6718	343	pilot	[pilot]	0.5	1	6	4	4
6719	343	Minnesota	[Minnesota]	0.5	1	6	5	5
6720	343	lad	[LAD]	0.5	1	6	1	1
6721	343	HRQoL	[HRQoL]	0.5	1	6	1	1
6722	343	LCX	[LCX]	0.5	1	6	2	2
6723	343	hfref	[HFrEF]	0.5	1	6	3	3
6724	343	mva	[MVA]	0.5	1	7	4	2
6725	343	atherosclerosis	[atherosclerosis]	0.5	1	6	4	4
6726	343	survivor	[survivors]	0.5	1	6	4	4
6727	343	presence	[presence]	0.5	1	9	8	2
6728	343	component	[component]	0.5	1	6	6	6
6729	343	rad	[Rad]	0.5	1	6	4	4
6730	343	transplantation	[transplantation]	0.5	1	6	1	1
6731	343	incident	[incident]	0.5	1	6	2	2
6732	343	stage	[stage]	0.5	1	6	4	4
6733	343	TNF	[TNF]	0.5	1	6	2	2
6734	343	work	[work]	0.5	1	6	3	3
6735	343	monitoring	[monitoring]	0.5	1	6	5	5
6736	343	metric	[metric]	0.5	1	6	5	5
6737	343	attention	[attention]	0.5	1	6	4	4
6738	343	contrast	[contrast]	0.5	1	6	1	1
6739	343	email	[e]	0.5	1	6	1	1
6740	343	insight	[insight]	0.5	1	6	4	4
6741	343	implementation	[implementation]	0.5	1	6	4	4
6742	343	basis	[basis]	0.5	1	7	6	3
6743	343	hypoalbuminemia	[hypoalbuminemia]	0.5	1	6	3	3
6744	343	alternative	[alternative]	0.5	1	6	5	5
6745	343	sham	[sham]	0.5	1	5	0	0
6746	343	application	[application]	0.5	1	6	3	3
6747	343	collagen	[collagen]	0.5	1	7	4	2
6748	343	breast	[breast]	0.5	1	6	2	2
6749	343	ring	[ring]	0.5	1	6	3	3
6750	343	country	[country]	0.5	1	6	1	1
6751	343	program	[program]	0.5	1	6	5	5
6752	343	sinus	[sinus]	0.5	1	6	4	4
6753	344	walk	[walk]	0.48	1	6	6	5
6754	344	interval	[interval]	0.48	1	6	6	5
6755	344	implication	[implications]	0.48	1	6	6	5
6756	344	endpoint	[endpoint]	0.48	1	6	6	5
6757	345	angiogenesis	[angiogenesis]	0.47500000000000003	1	6	5	4
6758	345	syndrome	[syndrome]	0.47500000000000003	1	6	5	4
6759	345	doppler	[Doppler]	0.47500000000000003	1	6	5	4
6760	345	titin	[titin]	0.47500000000000003	1	6	5	4
6761	345	crt-d	[CRT-D]	0.47500000000000003	1	6	5	4
6762	345	resource	[resource]	0.47500000000000003	1	6	5	4
6763	345	decade	[decade]	0.47500000000000003	1	6	5	4
6764	345	transition	[transition]	0.47500000000000003	1	6	5	4
6765	345	inhibition	[inhibition]	0.47500000000000003	1	6	5	4
6766	346	flow	[flow]	0.46666666666666673	1	6	4	3
6767	346	median	[median]	0.46666666666666673	1	6	4	3
6768	346	eo-cfus	[EO-CFUs]	0.46666666666666673	1	6	4	3
6769	347	City	[City]	0.4666666666666666	1	7	7	3
6770	347	bleed	[bleeding]	0.4666666666666666	1	7	7	3
6771	348	b	[B]	0.45	1	6	3	2
6772	348	β	[β]	0.45	1	6	3	2
6773	348	shock	[shock]	0.45	1	6	6	4
6774	348	purpose	[purpose]	0.45	1	8	7	2
6775	348	dilatation	[dilatation]	0.45	1	6	6	4
6776	348	worsen	[worsening]	0.45	1	6	6	4
6777	348	catheter	[catheter]	0.45	1	7	5	2
6778	348	duration	[duration]	0.45	1	7	5	2
6779	348	LVET	[LVET]	0.45	1	6	3	2
6780	348	ischemia	[ischemia]	0.45	1	6	6	4
6781	349	state	[state]	0.43333333333333335	1	6	5	3
6782	350	C	[C]	0.4	1	5	1	1
6783	350	N	[N]	0.4	1	5	2	2
6784	350	s	[s]	0.4	1	4	0	0
6785	350	information	[information]	0.4	1	5	5	5
6786	350	pacing	[pacing]	0.4	1	5	4	4
6787	350	CHM	[CHM]	0.4	1	5	1	1
6788	350	CPC	[CPCs]	0.4	1	5	1	1
6789	350	EF	[EF]	0.4	1	5	2	2
6790	350	Ea	[Ea]	0.4	1	5	2	2
6791	350	EMBASE	[EMBASE]	0.4	1	4	0	0
6792	350	fit	[fit]	0.4	1	5	3	3
6793	350	grow	[growing]	0.4	1	4	0	0
6794	350	ch	[CH]	0.4	1	5	2	2
6795	350	EMD	[EMD]	0.4	1	4	0	0
6796	350	hm	[HM]	0.4	1	5	4	4
6797	350	author	[authors]	0.4	1	4	0	0
6798	350	np	[NP]	0.4	1	5	2	2
6799	350	pro-b-type	[pro-B-type]	0.4	1	5	3	3
6800	350	atrial	[atrial]	0.4	1	5	2	2
6801	350	hHF	[hHF]	0.4	1	4	0	0
6802	350	weight	[weight]	0.4	1	5	2	2
6803	350	beta	[beta]	0.4	1	6	4	2
6804	350	outpatient	[outpatients]	0.4	1	5	2	2
6805	350	icd	[ICD]	0.4	1	5	4	4
6806	350	icu	[ICU]	0.4	1	5	3	3
6807	350	proteomics	[proteomics]	0.4	1	5	3	3
6808	350	uptitration	[uptitration]	0.4	1	5	3	3
6809	350	blocker	[blocker]	0.4	1	5	5	5
6810	350	JQ1	[JQ1]	0.4	1	5	1	1
6811	350	record	[records]	0.4	1	6	6	3
6812	350	prevention	[prevention]	0.4	1	5	5	5
6813	350	LVH	[LVH]	0.4	1	4	0	0
6814	350	progenitor	[progenitor]	0.4	1	5	3	3
6815	350	relevance	[relevance]	0.4	1	5	3	3
6816	350	e'septal	[e'septal]	0.4	1	4	0	0
6817	350	paf	[PAF]	0.4	1	5	2	2
6818	350	zsf1	[ZSF1]	0.4	1	5	4	4
6819	350	poc	[POC]	0.4	1	5	1	1
6820	350	Patient	[Patient]	0.4	1	5	4	4
6821	350	non-aa	[non-AA]	0.4	1	5	1	1
6822	350	nicorandil	[nicorandil]	0.4	1	4	0	0
6823	350	QTV	[QTV]	0.4	1	5	1	1
6824	350	hfvt(+)	[HFVT(+)]	0.4	1	4	0	0
6825	350	metabolism	[metabolism]	0.4	1	5	3	3
6826	350	HNorm	[HNorm]	0.4	1	4	0	0
6827	350	cutoff	[cutoff]	0.4	1	5	2	2
6828	350	University	[University]	0.4	1	4	0	0
6829	350	cardioverter	[cardioverter]	0.4	1	6	2	1
6830	350	telehealth	[telehealth]	0.4	1	4	0	0
6831	350	transfusion	[transfusion]	0.4	1	5	5	5
6832	350	progression	[progression]	0.4	1	5	2	2
6833	350	administration	[administration]	0.4	1	5	3	3
6834	350	β1ar	[β1AR]	0.4	1	5	4	4
6835	350	literature	[literature]	0.4	1	5	3	3
6836	350	Disease	[Disease]	0.4	1	5	2	2
6837	350	point	[point]	0.4	1	5	4	4
6838	350	stent	[stent]	0.4	1	5	4	4
6839	350	unit	[unit]	0.4	1	5	2	2
6840	350	neprilysin	[neprilysin]	0.4	1	5	2	2
6841	350	sign	[signs]	0.4	1	5	2	2
6842	350	bisphosphonate	[Bisphosphonate]	0.4	1	5	2	2
6843	350	ECCT	[ECCT]	0.4	1	5	3	3
6844	350	attenuation	[attenuation]	0.4	1	5	5	5
6845	350	ECMO	[ECMO]	0.4	1	5	1	1
6846	350	decongestion	[decongestion]	0.4	1	5	1	1
6847	350	rehabilitation	[rehabilitation]	0.4	1	6	4	2
6848	350	region	[region]	0.4	1	5	5	5
6849	350	method	[method]	0.4	1	5	1	1
6850	350	regurgitation	[regurgitation]	0.4	1	6	6	3
6851	350	cardiology	[cardiology]	0.4	1	5	2	2
6852	350	pneumonia	[pneumonia]	0.4	1	5	1	1
6853	350	auc	[AUC]	0.4	1	7	3	1
6854	350	defibrillator	[defibrillator]	0.4	1	5	5	5
6855	350	database	[databases]	0.4	1	5	5	5
6856	350	can	[Ca]	0.4	1	5	5	5
6857	351	relation	[Relation]	0.375	1	5	5	4
6858	351	impairment	[impairment]	0.375	1	5	5	4
6859	351	velocity	[velocity]	0.375	1	5	5	4
6860	351	implantation	[implantation]	0.375	1	5	5	4
6861	351	usefulness	[usefulness]	0.375	1	5	5	4
6862	351	Depression	[Depression]	0.375	1	5	5	4
6863	351	bpm	[bpm]	0.375	1	5	5	4
6864	352	understanding	[understanding]	0.3666666666666667	1	5	4	3
6865	352	DNA	[DNA]	0.3666666666666667	1	5	4	3
6866	352	athlete	[athletes]	0.3666666666666667	1	5	4	3
6867	352	millisecond	[milliseconds]	0.3666666666666667	1	5	4	3
6868	352	lesion	[lesion]	0.3666666666666667	1	5	4	3
6869	352	angiography	[angiography]	0.3666666666666667	1	5	4	3
6870	352	consequence	[consequence]	0.3666666666666667	1	5	4	3
6871	352	Hand2	[Hand2]	0.3666666666666667	1	5	4	3
6872	353	cm2	[cm2]	0.35000000000000003	1	6	5	2
6873	353	Bax	[Bax]	0.35000000000000003	1	5	3	2
6874	353	walking	[walking]	0.35000000000000003	1	6	5	2
6875	353	AF	[AF]	0.35000000000000003	1	5	3	2
6876	353	Trial	[Trial]	0.35000000000000003	1	6	5	2
6877	353	bundle	[bundle]	0.35000000000000003	1	5	3	2
6878	353	catheterization	[catheterization]	0.35000000000000003	1	5	3	2
6879	353	network	[network]	0.35000000000000003	1	5	3	2
6880	353	clinic	[clinic]	0.35000000000000003	1	5	3	2
6881	353	size	[size]	0.35000000000000003	1	5	3	2
6882	353	myofiber	[myofiber]	0.35000000000000003	1	5	3	2
6883	354	reserve	[reserve]	0.3333333333333333	1	5	5	3
6884	354	variation	[variation]	0.3333333333333333	1	5	5	3
6885	355	I	[I]	0.30000000000000004	1	4	3	3
6886	355	a	[AN]	0.30000000000000004	1	4	2	2
6887	355	q	[Q]	0.30000000000000004	1	4	2	2
6888	355	cms	[CMS]	0.30000000000000004	1	4	1	1
6889	355	cpr	[CPR]	0.30000000000000004	1	3	0	0
6890	355	BTT	[BTT]	0.30000000000000004	1	3	0	0
6891	355	vasopressin	[vasopressin]	0.30000000000000004	1	3	0	0
6892	355	CFI	[CFI]	0.30000000000000004	1	3	0	0
6893	355	ECMO+VAD	[ECMO+VAD]	0.30000000000000004	1	4	1	1
6894	355	progress	[progress]	0.30000000000000004	1	4	3	3
6895	355	FM	[FM]	0.30000000000000004	1	4	1	1
6896	355	IV	[IV]	0.30000000000000004	1	4	2	2
6897	355	gram	[g]	0.30000000000000004	1	4	4	4
6898	355	b-treated	[B-treated]	0.30000000000000004	1	4	3	3
6899	355	fes	[FES]	0.30000000000000004	1	4	1	1
6900	355	extent	[extent]	0.30000000000000004	1	5	2	1
6901	355	dL	[dL]	0.30000000000000004	1	3	0	0
6902	355	renal	[renal]	0.30000000000000004	1	4	3	3
6903	355	expenditure	[expenditure]	0.30000000000000004	1	4	4	4
6904	355	dl	[dl]	0.30000000000000004	1	3	0	0
6905	355	ec	[EC]	0.30000000000000004	1	4	1	1
6906	355	fm	[FM]	0.30000000000000004	1	4	1	1
6907	355	ERC	[ERC]	0.30000000000000004	1	3	0	0
6908	355	m2	[m2]	0.30000000000000004	1	4	1	1
6909	355	ph	[PH]	0.30000000000000004	1	4	1	1
6910	355	January	[January]	0.30000000000000004	1	4	1	1
6911	355	phase	[phase]	0.30000000000000004	1	4	4	4
6912	355	institution	[institution]	0.30000000000000004	1	4	4	4
6913	355	cgmp	[cGMP]	0.30000000000000004	1	4	1	1
6914	355	embolism	[embolism]	0.30000000000000004	1	6	6	2
6915	355	Development	[Development]	0.30000000000000004	1	3	0	0
6916	355	reverse	[reverse]	0.30000000000000004	1	5	4	2
6917	355	cxl-1020	[CXL-1020]	0.30000000000000004	1	3	0	0
6918	355	ies	[IEs]	0.30000000000000004	1	3	0	0
6919	355	HHD	[HHD]	0.30000000000000004	1	4	3	3
6920	355	multicenter	[Multicenter]	0.30000000000000004	1	4	1	1
6921	355	hypothesis	[hypothesis]	0.30000000000000004	1	4	1	1
6922	355	limitation	[LIMITATION]	0.30000000000000004	1	4	1	1
6923	355	pioglitazone	[pioglitazone]	0.30000000000000004	1	3	0	0
6924	355	downregulation	[downregulation]	0.30000000000000004	1	4	3	3
6925	355	covariate	[Covariate]	0.30000000000000004	1	4	3	3
6926	355	validity	[validity]	0.30000000000000004	1	4	3	3
6927	355	variant	[variants]	0.30000000000000004	1	4	4	4
6928	355	inhibitor	[inhibitor]	0.30000000000000004	1	4	3	3
6929	355	HFPSI	[HFPSI]	0.30000000000000004	1	4	1	1
6930	355	experience	[experience]	0.30000000000000004	1	4	4	4
6931	355	lyso-paf-at	[lyso-PAF-AT]	0.30000000000000004	1	4	2	2
6932	355	glycolysis	[glycolysis]	0.30000000000000004	1	3	0	0
6933	355	mdc	[MDC]	0.30000000000000004	1	4	1	1
6934	355	matrix	[matrix]	0.30000000000000004	1	4	4	4
6935	355	Bcl-2	[Bcl-2]	0.30000000000000004	1	4	2	2
6936	355	nps	[NPs]	0.30000000000000004	1	4	2	2
6937	355	urine	[urine]	0.30000000000000004	1	3	0	0
6938	355	recovery	[recovery]	0.30000000000000004	1	4	1	1
6939	355	phosphocreatine	[phosphocreatine]	0.30000000000000004	1	4	1	1
6940	355	pad	[PAD]	0.30000000000000004	1	4	2	2
6941	355	restriction	[restriction]	0.30000000000000004	1	4	4	4
6942	355	signalling	[signalling]	0.30000000000000004	1	4	2	2
6943	355	qol	[QOL]	0.30000000000000004	1	4	1	1
6944	355	CLCNKA	[CLCNKA]	0.30000000000000004	1	3	0	0
6945	355	HART	[HART]	0.30000000000000004	1	3	0	0
6946	355	future	[future]	0.30000000000000004	1	4	3	3
6947	355	grade	[Grade]	0.30000000000000004	1	4	4	4
6948	355	absence	[absence]	0.30000000000000004	1	5	4	2
6949	355	rwt	[RWT]	0.30000000000000004	1	3	0	0
6950	355	CHF-INV	[CHF-INV]	0.30000000000000004	1	3	0	0
6951	355	timing	[timing]	0.30000000000000004	1	4	3	3
6952	355	RAS	[RAS]	0.30000000000000004	1	4	3	3
6953	355	delay	[delay]	0.30000000000000004	1	4	4	4
6954	355	RGK	[RGK]	0.30000000000000004	1	3	0	0
6955	355	Outcome	[Outcomes]	0.30000000000000004	1	4	3	3
6956	355	efficiency	[efficiency]	0.30000000000000004	1	4	3	3
6957	355	SAF	[SAF]	0.30000000000000004	1	4	2	2
6958	355	Rad	[Rad]	0.30000000000000004	1	4	2	2
6959	355	harm	[harms]	0.30000000000000004	1	4	3	3
6960	355	SRD	[SRD]	0.30000000000000004	1	4	1	1
6961	355	alendronate	[alendronate]	0.30000000000000004	1	4	1	1
6962	355	Hum-Retn	[Hum-Retn]	0.30000000000000004	1	4	2	2
6963	355	STE	[STE]	0.30000000000000004	1	4	2	2
6964	355	anticoagulant	[anticoagulants]	0.30000000000000004	1	3	0	0
6965	355	revascularization	[revascularization]	0.30000000000000004	1	4	4	4
6966	355	participate	[participating]	0.30000000000000004	1	4	3	3
6967	355	Cochrane	[Cochrane]	0.30000000000000004	1	4	2	2
6968	355	angiotensin-converting	[angiotensin-converting]	0.30000000000000004	1	4	2	2
6969	355	TAC	[TAC]	0.30000000000000004	1	4	1	1
6970	355	SkM	[SkM]	0.30000000000000004	1	4	3	3
6971	355	rmsea	[RMSEA]	0.30000000000000004	1	3	0	0
6972	355	gender	[gender]	0.30000000000000004	1	4	1	1
6973	355	Seattle	[Seattle]	0.30000000000000004	1	3	0	0
6974	355	ARIC	[ARIC]	0.30000000000000004	1	4	1	1
6975	355	UPR	[UPR]	0.30000000000000004	1	3	0	0
6976	355	consensus	[consensus]	0.30000000000000004	1	4	2	2
6977	355	tachycardia	[tachycardia]	0.30000000000000004	1	4	2	2
6978	355	visit	[visit]	0.30000000000000004	1	4	4	4
6979	355	Nicorandil	[Nicorandil]	0.30000000000000004	1	4	1	1
6980	355	perturbation	[perturbations]	0.30000000000000004	1	4	3	3
6981	355	success	[success]	0.30000000000000004	1	4	4	4
6982	355	uninephrectomy	[uninephrectomy]	0.30000000000000004	1	4	1	1
6983	355	twist	[twist]	0.30000000000000004	1	3	0	0
6984	355	vitro	[vitro]	0.30000000000000004	1	4	1	1
6985	355	apoptosis	[apoptosis]	0.30000000000000004	1	4	1	1
6986	355	Cardiology	[Cardiology]	0.30000000000000004	1	3	0	0
6987	355	adherence	[adherence]	0.30000000000000004	1	4	2	2
6988	355	lung	[lung]	0.30000000000000004	1	4	1	1
6989	355	total	[total]	0.30000000000000004	1	11	8	1
6990	355	rirnas	[miRNAs]	0.30000000000000004	1	4	1	1
6991	355	site	[site]	0.30000000000000004	1	4	3	3
6992	355	circulate	[circulating]	0.30000000000000004	1	4	1	1
6993	355	means	[means]	0.30000000000000004	1	4	2	2
6994	355	part	[part]	0.30000000000000004	1	4	2	2
6995	355	arrhythmia	[arrhythmia]	0.30000000000000004	1	4	1	1
6996	355	chemotherapy	[chemotherapy]	0.30000000000000004	1	4	2	2
6997	355	Canada	[Canada]	0.30000000000000004	1	4	1	1
6998	355	clinician	[clinician]	0.30000000000000004	1	4	3	3
6999	355	enhancement	[enhancement]	0.30000000000000004	1	4	3	3
7000	355	Eplerenone	[Eplerenone]	0.30000000000000004	1	4	1	1
7001	355	June	[June]	0.30000000000000004	1	3	0	0
7002	355	significance	[significance]	0.30000000000000004	1	4	4	4
7003	355	n=11	[n=11]	0.30000000000000004	1	4	1	1
7004	355	pcwp	[PCWP]	0.30000000000000004	1	4	2	2
7005	355	CXL-1020	[CXL-1020]	0.30000000000000004	1	3	0	0
7006	355	medicare	[Medicare]	0.30000000000000004	1	4	2	2
7007	355	material	[material]	0.30000000000000004	1	4	1	1
7008	355	aas	[AAs]	0.30000000000000004	1	4	3	3
7009	355	other	[others]	0.30000000000000004	1	3	0	0
7010	355	air	[air]	0.30000000000000004	1	4	2	2
7011	355	rhythm-control	[rhythm-control]	0.30000000000000004	1	3	0	0
7012	355	t1-mapping	[T1-mapping]	0.30000000000000004	1	4	3	3
7013	355	latter	[latter]	0.30000000000000004	1	3	0	0
7014	355	bat	[BAT]	0.30000000000000004	1	4	1	1
7015	355	MADIT-CRT	[MADIT-CRT]	0.30000000000000004	1	3	0	0
7016	355	eGFR	[eGFR]	0.30000000000000004	1	5	2	1
7017	355	antiplatelet	[antiplatelet]	0.30000000000000004	1	4	1	1
7018	355	office	[office]	0.30000000000000004	1	3	0	0
7019	355	ANS	[ANS]	0.30000000000000004	1	4	2	2
7020	355	bte	[BTES]	0.30000000000000004	1	4	3	3
7021	355	contractility	[contractility]	0.30000000000000004	1	4	2	2
7022	356	perfusion	[perfusion]	0.2666666666666667	1	4	4	3
7023	356	problem	[problem]	0.2666666666666667	1	4	4	3
7024	357	DD	[DD]	0.25	1	4	3	2
7025	357	atrium	[atrium]	0.25	1	4	3	2
7026	357	UM	[UM]	0.25	1	4	3	2
7027	357	regulation	[regulation]	0.25	1	5	5	2
7028	357	deactivation	[deactivation]	0.25	1	4	3	2
7029	357	constriction	[constriction]	0.25	1	4	3	2
7030	357	antibody	[antibodies]	0.25	1	4	3	2
7031	357	strength	[strength]	0.25	1	4	3	2
7032	357	quality-of-life	[quality-of-life]	0.25	1	4	3	2
7033	357	Survival	[Survival]	0.25	1	4	3	2
7034	357	majority	[majority]	0.25	1	5	5	2
7035	357	Cardiomyopathy	[Cardiomyopathy]	0.25	1	5	5	2
7036	357	CABG	[CABG]	0.25	1	4	3	2
7037	357	frequency	[frequency]	0.25	1	4	3	2
7038	358	chelation	[chelation]	0.2	1	3	1	1
7039	358	order	[order]	0.2	1	2	0	0
7040	358	sympathovagal	[sympathovagal]	0.2	1	2	0	0
7041	358	porcine	[porcine]	0.2	1	2	0	0
7042	358	capita	[capita]	0.2	1	3	1	1
7043	358	TUNEL	[TUNEL]	0.2	1	2	0	0
7044	358	deg	[DEGs]	0.2	1	3	1	1
7045	358	average	[average]	0.2	1	3	2	2
7046	358	allopurinol	[allopurinol]	0.2	1	3	1	1
7047	358	paf-ah	[PAF-AH]	0.2	1	3	1	1
7048	358	dog	[dogs]	0.2	1	3	2	2
7049	358	tgf-β	[TGF-β]	0.2	1	3	3	3
7050	358	childhood	[childhood]	0.2	1	3	1	1
7051	358	modification	[modification]	0.2	1	3	2	2
7052	358	stem	[stem]	0.2	1	3	3	3
7053	358	DCM	[DCM]	0.2	1	4	2	1
7054	358	BB	[BB]	0.2	1	3	2	2
7055	358	CF	[CF]	0.2	1	3	2	2
7056	358	DT	[DT]	0.2	1	2	0	0
7057	358	EH	[EH]	0.2	1	2	0	0
7058	358	HH	[HH]	0.2	1	2	0	0
7059	358	DNx	[DNx]	0.2	1	3	2	2
7060	358	MR	[MR]	0.2	1	2	0	0
7061	358	QT	[QT]	0.2	1	3	1	1
7062	358	remain	[remaining]	0.2	1	3	1	1
7063	358	RA	[RA]	0.2	1	3	2	2
7064	358	RM	[RM]	0.2	1	3	2	2
7065	358	black	[Blacks]	0.2	1	2	0	0
7066	358	Sa	[Sa]	0.2	1	3	1	1
7067	358	carotid	[carotid]	0.2	1	3	1	1
7068	358	septum	[septum]	0.2	1	3	2	2
7069	358	grip	[grip]	0.2	1	3	2	2
7070	358	LBBB	[LBBB]	0.2	1	3	1	1
7071	358	al	[al]	0.2	1	2	0	0
7072	358	dt	[DT]	0.2	1	3	1	1
7073	358	ea	[Ea]	0.2	1	3	1	1
7074	358	go	[Go]	0.2	1	2	0	0
7075	358	form	[form]	0.2	1	4	4	2
7076	358	hg	[Hg]	0.2	1	3	2	2
7077	358	context	[context]	0.2	1	4	2	1
7078	358	ng	[ng]	0.2	1	3	2	2
7079	358	pb	[PB]	0.2	1	3	1	1
7080	358	pf	[PF]	0.2	1	2	0	0
7081	358	sham-inv	[sham-INV]	0.2	1	2	0	0
7082	358	bridge	[bridge]	0.2	1	3	1	1
7083	358	rr	[RR]	0.2	1	2	0	0
7084	358	sv	[SV]	0.2	1	3	2	2
7085	358	lvass	[LVAS]	0.2	1	3	1	1
7086	358	xo	[XO]	0.2	1	3	2	2
7087	358	power	[power]	0.2	1	3	3	3
7088	358	FES	[FES]	0.2	1	2	0	0
7089	358	Ees	[Ees]	0.2	1	2	0	0
7090	358	scale	[scale]	0.2	1	3	2	2
7091	358	reader	[reader]	0.2	1	3	2	2
7092	358	TgTetMena	[TgTetMena]	0.2	1	2	0	0
7093	358	discussion	[discussion]	0.2	1	3	2	2
7094	358	accounting	[accounting]	0.2	1	3	3	3
7095	358	wave	[wave]	0.2	1	2	0	0
7096	358	6-mwt	[6-MWT]	0.2	1	3	3	3
7097	358	Connecticut	[Connecticut]	0.2	1	2	0	0
7098	358	diastole	[diastole]	0.2	1	3	2	2
7099	358	Hospital	[Hospital]	0.2	1	3	2	2
7100	358	non-lbbb	[non-LBBB]	0.2	1	3	1	1
7101	358	preference	[preferences]	0.2	1	3	1	1
7102	358	kinase	[kinase]	0.2	1	3	3	3
7103	358	present	[presenting]	0.2	1	3	2	2
7104	358	(123)I-MIBG	[(123)I-MIBG]	0.2	1	2	0	0
7105	358	HCT	[HCT]	0.2	1	3	2	2
7106	358	abstract	[Abstract]	0.2	1	2	0	0
7107	358	Japan	[Japan]	0.2	1	2	0	0
7108	358	echocardiogram	[Echocardiograms]	0.2	1	3	2	2
7109	358	HNO	[HNO]	0.2	1	3	1	1
7110	358	production	[production]	0.2	1	3	2	2
7111	358	testing	[testing]	0.2	1	3	3	3
7112	358	rvad	[RVAD]	0.2	1	2	0	0
7113	358	Study	[Studies]	0.2	1	3	2	2
7114	358	demographic	[demographics]	0.2	1	3	1	1
7115	358	methylatropine	[methylatropine]	0.2	1	2	0	0
7116	358	randomization	[randomization]	0.2	1	2	0	0
7117	358	vehicle	[vehicle]	0.2	1	2	0	0
7118	358	shunt	[Shunt]	0.2	1	3	1	1
7119	358	medicine	[medicine]	0.2	1	3	3	3
7120	358	adjust	[adjusting]	0.2	1	4	4	2
7121	358	subset	[subset]	0.2	1	3	3	3
7122	358	Kaplan-Meier	[Kaplan-Meier]	0.2	1	3	2	2
7123	358	interatrial	[interatrial]	0.2	1	3	1	1
7124	358	lean	[lean]	0.2	1	3	1	1
7125	358	glucose	[glucose]	0.2	1	3	1	1
7126	358	bhlh	[bHLH]	0.2	1	2	0	0
7127	358	cav1.3	[CaV1.3]	0.2	1	2	0	0
7128	358	CINAHL	[CINAHL]	0.2	1	2	0	0
7129	358	technique	[technique]	0.2	1	3	2	2
7130	358	doctor	[doctors]	0.2	1	2	0	0
7131	358	va-rt	[VA-RT]	0.2	1	3	1	1
7132	358	situation	[situation]	0.2	1	3	3	3
7133	358	mice	[Mice]	0.2	1	2	0	0
7134	358	acetylcholinesterase	[acetylcholinesterase]	0.2	1	2	0	0
7135	358	VEGF	[VEGF]	0.2	1	3	1	1
7136	358	test-retest	[test-retest]	0.2	1	3	1	1
7137	358	vo2max	[VO2max]	0.2	1	3	3	3
7138	358	β-adrenoceptor	[β-adrenoceptor]	0.2	1	3	1	1
7139	358	Nucleolin	[Nucleolin]	0.2	1	3	1	1
7140	358	arrhythmias	[arrhythmias]	0.2	1	2	0	0
7141	358	psss	[PSSS]	0.2	1	3	1	1
7142	358	normalization	[normalization]	0.2	1	3	2	2
7143	358	crude	[crude]	0.2	1	3	1	1
7144	358	professional	[professionals]	0.2	1	3	1	1
7145	358	cd34+vegfr2	[CD34+VEGFR2]	0.2	1	3	1	1
7146	358	attrition	[attrition]	0.2	1	2	0	0
7147	358	vegf	[VEGF]	0.2	1	3	2	2
7148	358	actin	[actin]	0.2	1	3	1	1
7149	358	burden	[burden]	0.2	1	3	3	3
7150	358	Pyridostigmine	[Pyridostigmine]	0.2	1	2	0	0
7151	358	code	[codes]	0.2	1	2	0	0
7152	358	phospholamban	[phospholamban]	0.2	1	2	0	0
7153	358	SCHFI	[SCHFI]	0.2	1	2	0	0
7154	358	estimate	[estimates]	0.2	1	3	2	2
7155	358	ISrael	[ISrael]	0.2	1	2	0	0
7156	358	copd	[COPD]	0.2	1	3	2	2
7157	358	blot	[blot]	0.2	1	3	3	3
7158	358	raloxifene	[raloxifene]	0.2	1	2	0	0
7159	358	challenge	[challenge]	0.2	1	3	1	1
7160	358	pah	[PAH]	0.2	1	3	1	1
7161	358	medium	[medium]	0.2	1	3	1	1
7162	358	pig	[pigs]	0.2	1	3	2	2
7163	358	sulfonylurea	[sulfonylureas]	0.2	1	3	1	1
7164	358	e'lateral	[e'lateral]	0.2	1	2	0	0
7165	358	mixed-method	[mixed-methods]	0.2	1	2	0	0
7166	358	validation	[validation]	0.2	1	3	2	2
7167	358	induction	[induction]	0.2	1	4	4	2
7168	358	PNA	[PNA]	0.2	1	3	1	1
7169	358	perspective	[perspective]	0.2	1	3	3	3
7170	358	operating	[operating]	0.2	1	2	0	0
7171	358	operation	[operation]	0.2	1	2	0	0
7172	358	HABC	[HABC]	0.2	1	3	2	2
7173	358	bisoprolol	[bisoprolol]	0.2	1	3	3	3
7174	358	aspect	[aspects]	0.2	1	3	3	3
7175	358	swine	[swine]	0.2	1	2	0	0
7176	358	post-lvad	[post-LVAD]	0.2	1	3	2	2
7177	358	likelihood	[likelihood]	0.2	1	2	0	0
7178	358	participation	[participation]	0.2	1	3	2	2
7179	358	SCN5A	[SCN5A]	0.2	1	2	0	0
7180	358	assignment	[assignment]	0.2	1	2	0	0
7181	358	fluid	[fluid]	0.2	1	3	1	1
7182	358	hfvt(-)	[HFVT(-)]	0.2	1	3	1	1
7183	358	Québec	[Québec]	0.2	1	3	1	1
7184	358	Race	[Race]	0.2	1	2	0	0
7185	358	sensitivity	[sensitivity]	0.2	1	3	2	2
7186	358	feature	[features]	0.2	1	3	3	3
7187	358	afterload	[afterload]	0.2	1	3	3	3
7188	358	provider	[provider]	0.2	1	2	0	0
7189	358	ctnt	[cTnT]	0.2	1	4	2	1
7190	358	tta	[TTA]	0.2	1	3	2	2
7191	358	tug	[TUG]	0.2	1	2	0	0
7192	358	SVR	[SVR]	0.2	1	3	1	1
7193	358	concept	[concept]	0.2	1	3	3	3
7194	358	bypass	[bypass]	0.2	1	3	3	3
7195	358	tgtetmena	[TgTetMena]	0.2	1	3	1	1
7196	358	SDQT	[SDQT]	0.2	1	2	0	0
7197	358	BTES	[BTES]	0.2	1	3	1	1
7198	358	sodium	[sodium]	0.2	1	3	2	2
7199	358	deterioration	[deterioration]	0.2	1	3	3	3
7200	358	upr	[UPR]	0.2	1	3	2	2
7201	358	scaffold	[scaffold]	0.2	1	3	1	1
7202	358	isoproterenol	[isoproterenol]	0.2	1	2	0	0
7203	358	loss	[loss]	0.2	1	3	3	3
7204	358	microrna	[microRNAs]	0.2	1	3	2	2
7205	358	apex	[apex]	0.2	1	3	1	1
7206	358	ARNI	[ARNI]	0.2	1	3	2	2
7207	358	way	[way]	0.2	1	3	3	3
7208	358	feasibility	[feasibility]	0.2	1	3	2	2
7209	358	arrest	[arrest]	0.2	1	3	3	3
7210	358	protocol	[PROTOCOL]	0.2	1	3	1	1
7211	358	gait	[gait]	0.2	1	2	0	0
7212	358	option	[option]	0.2	1	3	3	3
7213	358	contribute	[contributing]	0.2	1	3	2	2
7214	358	sdqt	[SDQT]	0.2	1	3	1	1
7215	358	interpretation	[INTERPRETATION]	0.2	1	3	1	1
7216	358	interview	[interview]	0.2	1	3	2	2
7217	358	VVD	[VVD]	0.2	1	3	1	1
7218	358	brain	[brain]	0.2	1	2	0	0
7219	358	State	[States]	0.2	1	3	1	1
7220	358	WRF	[WRF]	0.2	1	3	1	1
7221	358	retrospective	[retrospective]	0.2	1	2	0	0
7222	358	focus	[focus]	0.2	1	3	2	2
7223	358	hscrp	[hsCRP]	0.2	1	2	0	0
7224	358	chart	[chart]	0.2	1	3	1	1
7225	358	antagonist	[antagonist]	0.2	1	3	1	1
7226	358	Raf-MEK1	[Raf-MEK1]	0.2	1	2	0	0
7227	358	p=0·016	[p=0·016]	0.2	1	2	0	0
7228	358	eNOS-Thr	[eNOS-Thr]	0.2	1	2	0	0
7229	358	aging	[aging]	0.2	1	2	0	0
7230	358	eplerenone	[eplerenone]	0.2	1	5	3	1
7231	358	Practice	[Practice]	0.2	1	3	1	1
7232	358	presentation	[Presentation]	0.2	1	3	2	2
7233	358	rationale	[RATIONALE]	0.2	1	3	1	1
7234	358	healthcare	[healthcare]	0.2	1	3	3	3
7235	358	nontrastuzumab	[nontrastuzumab]	0.2	1	2	0	0
7236	358	pre-hct	[pre-HCT]	0.2	1	3	2	2
7237	358	emean	[emean]	0.2	1	2	0	0
7238	358	North	[North]	0.2	1	2	0	0
7239	358	output	[output]	0.2	1	4	4	2
7240	358	proportion	[proportion]	0.2	1	4	4	2
7241	358	South	[South]	0.2	1	2	0	0
7242	358	Europe	[Europe]	0.2	1	2	0	0
7243	358	cystatin	[cystatin]	0.2	1	2	0	0
7244	358	Gill	[Gill]	0.2	1	2	0	0
7245	358	lvas	[LVADs]	0.2	1	5	3	1
7246	358	insulin-resistance	[insulin-resistance]	0.2	1	3	3	3
7247	358	obesity	[Obesity]	0.2	1	2	0	0
7248	358	turbulence	[turbulence]	0.2	1	2	0	0
7249	358	College	[College]	0.2	1	4	4	2
7250	358	propranolol	[propranolol]	0.2	1	2	0	0
7251	358	consultation	[consultation]	0.2	1	3	2	2
7252	358	midpapillary	[midpapillary]	0.2	1	2	0	0
7253	358	lp-pla2	[Lp-PLA2]	0.2	1	3	2	2
7254	358	east	[EAST]	0.2	1	3	1	1
7255	358	cardiologist	[cardiologist]	0.2	1	3	1	1
7256	358	domain	[domain]	0.2	1	3	2	2
7257	358	PDE2	[PDE2]	0.2	1	3	1	1
7258	358	March	[March]	0.2	1	2	0	0
7259	358	shotgun	[shotgun]	0.2	1	2	0	0
7260	358	DASH	[DASH]	0.2	1	3	1	1
7261	358	Assessment	[Assessment]	0.2	1	3	1	1
7262	358	July	[July]	0.2	1	3	1	1
7263	358	agreement	[agreement]	0.2	1	3	3	3
7264	358	creatinine	[creatinine]	0.2	1	3	2	2
7265	358	troponin	[troponin]	0.2	1	3	3	3
7266	358	family	[family]	0.2	1	3	2	2
7267	358	tonometry	[tonometry]	0.2	1	3	3	3
7268	358	quintile	[quintile]	0.2	1	3	1	1
7269	358	ecmo	[ECMO]	0.2	1	3	3	3
7270	358	liver	[liver]	0.2	1	3	1	1
7271	358	parallel	[parallel]	0.2	1	3	2	2
7272	358	Rotterdam	[Rotterdam]	0.2	1	2	0	0
7273	358	mutant	[mutant]	0.2	1	3	3	3
7274	358	exist	[existing]	0.2	1	2	0	0
7275	358	CentriMag	[CentriMag]	0.2	1	3	1	1
7276	358	assay	[assay]	0.2	1	3	2	2
7277	358	microstructure	[microstructure]	0.2	1	3	2	2
7278	358	nbdmard	[nbDMARD]	0.2	1	3	3	3
7279	358	kilogram	[kilogram]	0.2	1	3	1	1
7280	358	quartile	[quartile]	0.2	1	3	2	2
7281	358	perk	[PERK]	0.2	1	3	3	3
7282	358	infancy	[infancy]	0.2	1	2	0	0
7283	358	tolvaptan	[tolvaptan]	0.2	1	2	0	0
7284	358	sphingosine-1-phosphate	[sphingosine-1-phosphate]	0.2	1	3	2	2
7285	358	anthracycline	[anthracycline]	0.2	1	3	2	2
7286	358	people	[people]	0.2	1	3	3	3
7287	358	update	[update]	0.2	1	4	2	1
7288	358	definition	[definition]	0.2	1	3	2	2
7289	358	hospitalisation	[hospitalisation]	0.2	1	3	2	2
7290	358	mdc95	[MDC95]	0.2	1	2	0	0
7291	358	derivation	[derivation]	0.2	1	2	0	0
7292	358	acf	[ACF]	0.2	1	3	1	1
7293	358	acs	[ACS]	0.2	1	3	1	1
7294	358	acr	[ACR]	0.2	1	3	3	3
7295	358	chf-inv	[CHF-INV]	0.2	1	3	1	1
7296	358	defect	[defects]	0.2	1	2	0	0
7297	358	MEDLINE	[MEDLINE]	0.2	1	3	2	2
7298	358	ang	[ANG]	0.2	1	4	4	2
7299	358	intubation	[Intubation]	0.2	1	3	2	2
7300	358	refill	[refill]	0.2	1	2	0	0
7301	358	avd	[AVD]	0.2	1	3	1	1
7302	358	resting	[resting]	0.2	1	3	1	1
7303	358	depression	[depression]	0.2	1	3	1	1
7304	358	ACF	[ACF]	0.2	1	3	1	1
7305	358	ACP	[ACP]	0.2	1	3	1	1
7306	358	ss20	[SS20]	0.2	1	2	0	0
7307	358	breathing	[breathing]	0.2	1	3	3	3
7308	358	AHF	[AHF]	0.2	1	3	3	3
7309	358	bromodomain	[bromodomain]	0.2	1	3	2	2
7310	358	btt	[BTT]	0.2	1	3	1	1
7311	358	myocyte	[myocyte]	0.2	1	3	1	1
7312	358	fragment	[fragment]	0.2	1	3	3	3
7313	359	Beck	[Beck]	0.15000000000000002	1	3	3	2
7314	359	DXA	[DXA]	0.15000000000000002	1	3	3	2
7315	359	SR	[SR]	0.15000000000000002	1	3	3	2
7316	359	ai	[AI]	0.15000000000000002	1	3	3	2
7317	359	respiration	[respiration]	0.15000000000000002	1	3	3	2
7318	359	advance	[advances]	0.15000000000000002	1	3	3	2
7319	359	shortening	[shortening]	0.15000000000000002	1	3	3	2
7320	359	discrimination	[discrimination]	0.15000000000000002	1	3	3	2
7321	359	fee-for-service	[fee-for-service]	0.15000000000000002	1	3	3	2
7322	359	pathogenesis	[pathogenesis]	0.15000000000000002	1	3	3	2
7323	359	determination	[Determination]	0.15000000000000002	1	3	3	2
7324	359	elevation	[elevation]	0.15000000000000002	1	3	3	2
7325	359	exclusion	[exclusion]	0.15000000000000002	1	3	3	2
7326	359	t-score	[T-score]	0.15000000000000002	1	3	3	2
7327	359	maintenance	[maintenance]	0.15000000000000002	1	3	3	2
7328	359	indicator	[indicator]	0.15000000000000002	1	3	3	2
7329	359	compliance	[compliance]	0.15000000000000002	1	3	3	2
7330	359	goal	[goal]	0.15000000000000002	1	3	3	2
7331	360	-	[-]	0.1	1	1	0	0
7332	360	Nfat	[Nfat]	0.1	1	1	0	0
7333	360	A	[A]	0.1	1	1	0	0
7334	360	R	[R]	0.1	1	2	1	1
7335	360	T	[T]	0.1	1	1	0	0
7336	360	c	[C]	0.1	1	2	1	1
7337	360	pluripotency	[pluripotency]	0.1	1	2	1	1
7338	360	SUrvival	[SUrvival]	0.1	1	1	0	0
7339	360	HeartWare	[HeartWare]	0.1	1	2	2	2
7340	360	Dialysis	[Dialysis]	0.1	1	1	0	0
7341	360	ascend	[ascending]	0.1	1	1	0	0
7342	360	noncardiac	[noncardiac]	0.1	1	1	0	0
7343	360	late-onset	[late-onset]	0.1	1	2	1	1
7344	360	Age	[Age]	0.1	1	2	1	1
7345	360	Paradigm-hf	[PARADIGM-HF]	0.1	1	2	2	2
7346	360	MedLine	[MedLine]	0.1	1	1	0	0
7347	360	co.	[CO.]	0.1	1	2	1	1
7348	360	protection	[protection]	0.1	1	2	1	1
7349	360	renin-angiotensin	[renin-angiotensin]	0.1	1	2	1	1
7350	360	BMI	[BMI]	0.1	1	1	0	0
7351	360	Akt	[Akt]	0.1	1	1	0	0
7352	360	Bcl2	[Bcl2]	0.1	1	1	0	0
7353	360	rose	[ROSE]	0.1	1	2	1	1
7354	360	Ann	[Ann]	0.1	1	1	0	0
7355	360	Framingham	[Framingham]	0.1	1	2	1	1
7356	360	flux	[flux]	0.1	1	1	0	0
7357	360	Pro75-Arg76	[Pro75-Arg76]	0.1	1	1	0	0
7358	360	Sweden	[Sweden]	0.1	1	1	0	0
7359	360	micronutrient	[micronutrients]	0.1	1	1	0	0
7360	360	thigh	[thigh]	0.1	1	1	0	0
7361	360	budget	[budget]	0.1	1	1	0	0
7362	360	dyslipidemia	[dyslipidemia]	0.1	1	1	0	0
7363	360	consistency	[consistency]	0.1	1	2	2	2
7364	360	calreticulin	[calreticulin]	0.1	1	1	0	0
7365	360	Δ	[Δ]	0.1	1	1	0	0
7366	360	α	[α]	0.1	1	1	0	0
7367	360	etidronate	[etidronate]	0.1	1	2	1	1
7368	360	introduction	[Introduction]	0.1	1	1	0	0
7369	360	concentration	[concentration]	0.1	1	2	2	2
7370	360	CFA	[CFA]	0.1	1	2	1	1
7371	360	non-DNx	[non-DNx]	0.1	1	1	0	0
7372	360	e-wave	[E-wave]	0.1	1	2	2	2
7373	360	L-type	[L-type]	0.1	1	2	1	1
7374	360	therapeutics	[therapeutics]	0.1	1	2	1	1
7375	360	CIs	[CIs]	0.1	1	1	0	0
7376	360	(-)-erc	[(-)-ERC]	0.1	1	1	0	0
7377	360	'D	['D]	0.1	1	1	0	0
7378	360	attempt	[attempt]	0.1	1	1	0	0
7379	360	lying	[lying]	0.1	1	1	0	0
7380	360	curve	[curve]	0.1	1	2	2	2
7381	360	cogeneration	[cogeneration]	0.1	1	1	0	0
7382	360	drs	[DRS]	0.1	1	1	0	0
7383	360	fulfil	[fulfilling]	0.1	1	1	0	0
7384	360	case-fatality	[case-fatality]	0.1	1	2	1	1
7385	360	CVD	[CVD]	0.1	1	1	0	0
7386	360	male	[male]	0.1	1	2	1	1
7387	360	Australia	[Australia]	0.1	1	1	0	0
7388	360	interest	[interest]	0.1	1	1	0	0
7389	360	China	[China]	0.1	1	1	0	0
7390	360	step	[step]	0.1	1	2	1	1
7391	360	base	[base]	0.1	1	2	2	2
7392	360	theory	[theory]	0.1	1	1	0	0
7393	360	foundation	[foundation]	0.1	1	2	2	2
7394	360	Osprey	[Osprey]	0.1	1	1	0	0
7395	360	ecg	[ECG]	0.1	1	2	1	1
7396	360	ees	[Ees]	0.1	1	3	2	1
7397	360	advantage	[advantage]	0.1	1	2	2	2
7398	360	dtt]-insensitive	[DTT]-insensitive]	0.1	1	1	0	0
7399	360	valvular	[valvular]	0.1	1	1	0	0
7400	360	branch	[branch]	0.1	1	2	2	2
7401	360	version	[version]	0.1	1	1	0	0
7402	360	CA	[CA]	0.1	1	1	0	0
7403	360	case-control	[case-control]	0.1	1	1	0	0
7404	360	CH	[CH]	0.1	1	1	0	0
7405	360	CR	[CR]	0.1	1	1	0	0
7406	360	rs10927887	[rs10927887]	0.1	1	2	1	1
7407	360	EC	[EC]	0.1	1	2	2	2
7408	360	signalosome	[signalosome]	0.1	1	1	0	0
7409	360	education	[education]	0.1	1	2	1	1
7410	360	L.	[L.]	0.1	1	1	0	0
7411	360	Implantation	[Implantation]	0.1	1	1	0	0
7412	360	cardioprotection	[cardioprotection]	0.1	1	2	1	1
7413	360	CrI	[CrI]	0.1	1	2	1	1
7414	360	bridging	[bridging]	0.1	1	1	0	0
7415	360	pressure-volume	[pressure-volume]	0.1	1	1	0	0
7416	360	PF	[PF]	0.1	1	1	0	0
7417	360	anaesthesia	[anaesthesia]	0.1	1	1	0	0
7418	360	R.	[R.]	0.1	1	1	0	0
7419	360	RR	[RR]	0.1	1	1	0	0
7420	360	SH	[SH]	0.1	1	1	0	0
7421	360	Figure	[figure]	0.1	1	1	0	0
7422	360	UK	[UK]	0.1	1	1	0	0
7423	360	US	[US]	0.1	1	1	0	0
7424	360	duplicate	[duplicate]	0.1	1	1	0	0
7425	360	VT	[VT]	0.1	1	2	2	2
7426	360	WT	[WT]	0.1	1	1	0	0
7427	360	window	[window]	0.1	1	1	0	0
7428	360	physiology	[physiology]	0.1	1	1	0	0
7429	360	ECG	[ECG]	0.1	1	1	0	0
7430	360	pharmaceutical	[pharmaceuticals]	0.1	1	1	0	0
7431	360	NT-ProBNP	[NT-ProBNP]	0.1	1	1	0	0
7432	360	ECs	[ECs]	0.1	1	1	0	0
7433	360	nutrition	[nutrition]	0.1	1	2	2	2
7434	360	candidate	[candidate]	0.1	1	2	1	1
7435	360	nfat	[Nfat]	0.1	1	2	2	2
7436	360	assumption	[assumption]	0.1	1	1	0	0
7437	360	as	[AS]	0.1	1	2	1	1
7438	360	panel	[panel]	0.1	1	2	2	2
7439	360	ABCD	[ABCD]	0.1	1	1	0	0
7440	360	foot	[feet]	0.1	1	2	2	2
7441	360	cf	[CF]	0.1	1	1	0	0
7442	360	bradyarrhythmias	[bradyarrhythmias]	0.1	1	1	0	0
7443	360	language	[language]	0.1	1	2	2	2
7444	360	eg	[eg]	0.1	1	1	0	0
7445	360	et	[ET]	0.1	1	2	1	1
7446	360	i2	[I2]	0.1	1	1	0	0
7447	360	ic	[IC]	0.1	1	3	2	1
7448	360	ie	[ie]	0.1	1	1	0	0
7449	360	additive	[additive]	0.1	1	2	1	1
7450	360	ESC	[ESC]	0.1	1	1	0	0
7451	360	ka	[Ka]	0.1	1	1	0	0
7452	360	oxidation	[oxidation]	0.1	1	1	0	0
7453	360	disposition	[disposition]	0.1	1	1	0	0
7454	360	renin	[renin]	0.1	1	2	1	1
7455	360	lf	[LF]	0.1	1	1	0	0
7456	360	second	[seconds]	0.1	1	2	1	1
7457	360	NYHA-II	[NYHA-II]	0.1	1	1	0	0
7458	360	o2	[O2]	0.1	1	1	0	0
7459	360	discipline	[disciplines]	0.1	1	1	0	0
7460	360	METs	[METs]	0.1	1	2	2	2
7461	360	qt	[QT]	0.1	1	2	2	2
7462	360	rm	[RM]	0.1	1	2	1	1
7463	360	se	[se]	0.1	1	1	0	0
7464	360	sh	[SH]	0.1	1	2	1	1
7465	360	sr	[SR]	0.1	1	1	0	0
7466	360	up	[Up]	0.1	1	2	2	2
7467	360	plasticity	[plasticity]	0.1	1	2	1	1
7468	360	vo	[VO]	0.1	1	1	0	0
7469	360	outcome-monitoring	[outcome-monitoring]	0.1	1	1	0	0
7470	360	CHF-DNx	[CHF-DNx]	0.1	1	1	0	0
7471	360	force	[force]	0.1	1	1	0	0
7472	360	gem	[Gem]	0.1	1	1	0	0
7473	360	cα	[Cα]	0.1	1	2	1	1
7474	360	Zealand	[Zealand]	0.1	1	1	0	0
7475	360	hyperinsulinemia	[hyperinsulinemia]	0.1	1	1	0	0
7476	360	Maisel	[Maisel]	0.1	1	1	0	0
7477	360	7508t→a	[7508T→A]	0.1	1	1	0	0
7478	360	n=238	[n=238]	0.1	1	1	0	0
7479	360	epitope	[epitopes]	0.1	1	2	2	2
7480	360	phenylephrine	[phenylephrine]	0.1	1	1	0	0
7481	360	ingenuity	[ingenuity]	0.1	1	2	1	1
7482	360	pulmonary	[pulmonary]	0.1	1	1	0	0
7483	360	pediatrics	[pediatrics]	0.1	1	1	0	0
7484	360	implant	[implant]	0.1	1	1	0	0
7485	360	fiber	[fiber]	0.1	1	2	1	1
7486	360	hrqol	[HRQoL]	0.1	1	1	0	0
7487	360	gut	[gut]	0.1	1	1	0	0
7488	360	messenger	[messenger]	0.1	1	1	0	0
7489	360	anticoagulation	[anticoagulation]	0.1	1	2	1	1
7490	360	norepinephrine	[norepinephrine]	0.1	1	1	0	0
7491	360	Caspase-3	[Caspase-3]	0.1	1	2	1	1
7492	360	Placebo	[Placebo]	0.1	1	1	0	0
7493	360	clarity	[clarity]	0.1	1	1	0	0
7494	360	nonadherence	[nonadherence]	0.1	1	2	1	1
7495	360	nephropathy	[nephropathy]	0.1	1	1	0	0
7496	360	hfe	[HFE]	0.1	1	1	0	0
7497	360	lesson	[lessons]	0.1	1	2	1	1
7498	360	hgb	[Hgb]	0.1	1	2	1	1
7499	360	Fig	[Fig]	0.1	1	2	2	2
7500	360	hno	[HNO]	0.1	1	1	0	0
7501	360	nitrite	[nitrite]	0.1	1	1	0	0
7502	360	organ	[organ]	0.1	1	1	0	0
7503	360	n=120	[n=120]	0.1	1	1	0	0
7504	360	Ceballos	[Ceballos]	0.1	1	1	0	0
7505	360	Perkins	[Perkins]	0.1	1	1	0	0
7506	360	(123)i-meta-iodobenzylguanidine	[(123)I-meta-iodobenzylguanidine]	0.1	1	1	0	0
7507	360	ad-c	[Ad-C]	0.1	1	2	1	1
7508	360	chop	[CHOP]	0.1	1	1	0	0
7509	360	trigger	[trigger]	0.1	1	2	2	2
7510	360	mena	[Mena]	0.1	1	1	0	0
7511	360	breathlessness	[breathlessness]	0.1	1	1	0	0
7512	360	DAVID	[DAVID]	0.1	1	1	0	0
7513	360	sustainability	[sustainability]	0.1	1	1	0	0
7514	360	°c	[°C]	0.1	1	1	0	0
7515	360	hum-retn	[Hum-Retn]	0.1	1	1	0	0
7516	360	icc	[ICC]	0.1	1	2	2	2
7517	360	HEK	[HEK]	0.1	1	1	0	0
7518	360	ablation	[ablation]	0.1	1	1	0	0
7519	360	Society	[Society]	0.1	1	2	2	2
7520	360	Clin	[Clin]	0.1	1	1	0	0
7521	360	il6	[IL6]	0.1	1	1	0	0
7522	360	Dodson	[Dodson]	0.1	1	1	0	0
7523	360	immunohistochemistry	[immunohistochemistry]	0.1	1	1	0	0
7524	360	dementia	[dementia]	0.1	1	1	0	0
7525	360	p70s6k	[p70S6K]	0.1	1	1	0	0
7526	360	post	[post]	0.1	1	2	1	1
7527	360	post-aac	[post-AAC]	0.1	1	2	1	1
7528	360	respect	[respect]	0.1	1	1	0	0
7529	360	euthanization	[euthanization]	0.1	1	1	0	0
7530	360	income	[income]	0.1	1	2	2	2
7531	360	pre-pd	[pre-PD]	0.1	1	1	0	0
7532	360	ivc	[IVC]	0.1	1	2	1	1
7533	360	hfpsi	[HFPSI]	0.1	1	2	2	2
7534	360	property	[property]	0.1	1	2	2	2
7535	360	study-drug	[study-drug]	0.1	1	1	0	0
7536	360	Safety	[Safety]	0.1	1	2	2	2
7537	360	Aldactone	[Aldactone]	0.1	1	1	0	0
7538	360	ICD	[ICD]	0.1	1	1	0	0
7539	360	ERK1	[ERK1]	0.1	1	2	1	1
7540	360	telephone	[telephone]	0.1	1	2	1	1
7541	360	description	[Description]	0.1	1	1	0	0
7542	360	Hgb	[Hgb]	0.1	1	1	0	0
7543	360	plateau	[plateau]	0.1	1	1	0	0
7544	360	IL6	[IL6]	0.1	1	1	0	0
7545	360	rvpo	[RVPO]	0.1	1	2	1	1
7546	360	β-Blockade	[β-Blockade]	0.1	1	1	0	0
7547	360	n=431	[n=431]	0.1	1	1	0	0
7548	360	paf-cpt	[PAF-CPT]	0.1	1	2	1	1
7549	360	pay-for-performance	[pay-for-performance]	0.1	1	1	0	0
7550	360	Tolvaptan	[Tolvaptan]	0.1	1	1	0	0
7551	360	lactate	[lactate]	0.1	1	1	0	0
7552	360	colony-forming	[colony-forming]	0.1	1	1	0	0
7553	360	bolus	[bolus]	0.1	1	2	2	2
7554	360	fatigue	[fatigue]	0.1	1	1	0	0
7555	360	publication	[publications]	0.1	1	1	0	0
7556	360	cross	[cross]	0.1	1	2	1	1
7557	360	pulse	[pulse]	0.1	1	2	1	1
7558	360	specialty	[specialty]	0.1	1	1	0	0
7559	360	vary	[varying]	0.1	1	2	1	1
7560	360	access	[access]	0.1	1	2	1	1
7561	360	specificity	[specificity]	0.1	1	1	0	0
7562	360	atropine	[atropine]	0.1	1	2	1	1
7563	360	SEER-Medicare	[SEER-Medicare]	0.1	1	1	0	0
7564	360	NYHA-IIIb	[NYHA-IIIb]	0.1	1	3	2	1
7565	360	PSSS	[PSSS]	0.1	1	2	1	1
7566	360	lifesaving	[lifesaving]	0.1	1	1	0	0
7567	360	repolarization	[repolarization]	0.1	1	2	1	1
7568	360	Inc	[Inc]	0.1	1	1	0	0
7569	360	S1PR1	[S1PR1]	0.1	1	1	0	0
7570	360	would	[d]	0.1	1	2	1	1
7571	360	antitachycardia	[antitachycardia]	0.1	1	1	0	0
7572	360	mr-proanp	[MR-proANP]	0.1	1	1	0	0
7573	360	example	[example]	0.1	1	2	1	1
7574	360	feeding	[feeding]	0.1	1	1	0	0
7575	360	VA-RT	[VA-RT]	0.1	1	1	0	0
7576	360	ventricular	[Ventricular]	0.1	1	1	0	0
7577	360	cav1.2	[CaV1.2]	0.1	1	2	1	1
7578	360	capillary	[capillary]	0.1	1	2	1	1
7579	360	discontinuation	[discontinuation]	0.1	1	1	0	0
7580	360	citation	[citations]	0.1	1	1	0	0
7581	360	nonpace	[nonpace]	0.1	1	2	1	1
7582	360	knockdown	[knockdown]	0.1	1	2	1	1
7583	360	conjunction	[conjunction]	0.1	1	2	1	1
7584	360	mr-proadm	[MR-proADM]	0.1	1	2	1	1
7585	360	sport	[sport]	0.1	1	1	0	0
7586	360	scenario	[scenario]	0.1	1	2	2	2
7587	360	subproteome	[subproteome]	0.1	1	2	1	1
7588	360	fashion	[fashion]	0.1	1	1	0	0
7589	360	detergent	[detergent]	0.1	1	1	0	0
7590	360	shuttle	[shuttle]	0.1	1	2	1	1
7591	360	reliability	[reliability]	0.1	1	2	2	2
7592	360	murine	[murine]	0.1	1	2	1	1
7593	360	pause	[pause]	0.1	1	1	0	0
7594	360	August	[August]	0.1	1	1	0	0
7595	360	icd-hf	[ICD-HF]	0.1	1	1	0	0
7596	360	kccq	[KCCQ]	0.1	1	2	1	1
7597	360	stiffness	[stiffness]	0.1	1	2	1	1
7598	360	October	[Oct]	0.1	1	1	0	0
7599	360	Hogan	[Hogan]	0.1	1	1	0	0
7600	360	n=9	[n=9]	0.1	1	1	0	0
7601	360	T1-mapping	[T1-mapping]	0.1	1	1	0	0
7602	360	Sitagliptin	[Sitagliptin]	0.1	1	1	0	0
7603	360	vco2	[VCO2]	0.1	1	1	0	0
7604	360	Olmsted	[Olmsted]	0.1	1	1	0	0
7605	360	Addition	[Addition]	0.1	1	2	1	1
7606	360	differentiation	[differentiation]	0.1	1	2	1	1
7607	360	LC-MS	[LC-MS]	0.1	1	1	0	0
7608	360	receiver	[receiver]	0.1	1	2	1	1
7609	360	1515g→a	[1515G→A]	0.1	1	1	0	0
7610	360	self-management	[self-management]	0.1	1	2	1	1
7611	360	PubMed	[PubMed]	0.1	1	1	0	0
7612	360	Kir	[Kir]	0.1	1	1	0	0
7613	360	regulator	[regulator]	0.1	1	2	2	2
7614	360	vegetable	[vegetables]	0.1	1	1	0	0
7615	360	nonsurvivor	[nonsurvivors]	0.1	1	2	2	2
7616	360	MLHF	[MLHF]	0.1	1	2	1	1
7617	360	age-	[age-]	0.1	1	1	0	0
7618	360	pro2-leu3	[Pro2-Leu3]	0.1	1	1	0	0
7619	360	Edwards	[Edwards]	0.1	1	1	0	0
7620	360	COPD	[COPD]	0.1	1	1	0	0
7621	360	nmol	[nmol]	0.1	1	1	0	0
7622	360	post-dash	[post-DASH]	0.1	1	1	0	0
7623	360	tnf)α	[TNF)α]	0.1	1	1	0	0
7624	360	female	[female]	0.1	1	2	2	2
7625	360	viscoelastic	[viscoelastic]	0.1	1	1	0	0
7626	360	EPHESUS	[EPHESUS]	0.1	1	1	0	0
7627	360	postexercise	[postexercise]	0.1	1	1	0	0
7628	360	Caucasian	[Caucasian]	0.1	1	1	0	0
7629	360	turnaround	[turnaround]	0.1	1	1	0	0
7630	360	ultra-violet	[UV]	0.1	1	1	0	0
7631	360	ZSF1	[ZSF1]	0.1	1	2	2	2
7632	360	precipitate	[precipitating]	0.1	1	1	0	0
7633	360	CPET	[CPET]	0.1	1	2	1	1
7634	360	Taub	[Taub]	0.1	1	1	0	0
7635	360	nonprescribing	[nonprescribing]	0.1	1	3	2	1
7636	360	imaging	[imaging]	0.1	1	2	1	1
7637	360	thrombosis	[thrombosis]	0.1	1	1	0	0
7638	360	p38	[p38]	0.1	1	2	1	1
7639	360	delivery	[delivery]	0.1	1	1	0	0
7640	360	continuity	[continuity]	0.1	1	2	1	1
7641	360	colon	[colon]	0.1	1	1	0	0
7642	360	Fibrillation	[Fibrillation]	0.1	1	1	0	0
7643	360	MRI	[MRI]	0.1	1	1	0	0
7644	360	organization	[organizations]	0.1	1	1	0	0
7645	360	nut	[nuts]	0.1	1	1	0	0
7646	360	MVA	[MVA]	0.1	1	1	0	0
7647	360	adiponectin	[adiponectin]	0.1	1	3	2	1
7648	360	63c→g	[63C→G]	0.1	1	1	0	0
7649	360	terminal	[terminal]	0.1	1	1	0	0
7650	360	consideration	[consideration]	0.1	1	2	2	2
7651	360	vena	[vena]	0.1	1	1	0	0
7652	360	polytetrafluoroethylene	[polytetrafluoroethylene]	0.1	1	1	0	0
7653	360	May	[May]	0.1	1	1	0	0
7654	360	oht	[OHT]	0.1	1	1	0	0
7655	360	NHS	[NHS]	0.1	1	1	0	0
7656	360	Duke	[Duke]	0.1	1	1	0	0
7657	360	lipolysis	[Lipolysis]	0.1	1	1	0	0
7658	360	one	[one]	0.1	1	1	0	0
7659	360	S3991	[S3991]	0.1	1	1	0	0
7660	360	Zung	[Zung]	0.1	1	2	1	1
7661	360	futility	[futility]	0.1	1	1	0	0
7662	360	NOC	[NOC]	0.1	1	2	1	1
7663	360	mlhf	[MLHF]	0.1	1	1	0	0
7664	360	NPs	[NPs]	0.1	1	1	0	0
7665	360	optimization	[Optimization]	0.1	1	2	2	2
7666	360	inability	[inability]	0.1	1	1	0	0
7667	360	researcher	[researchers]	0.1	1	1	0	0
7668	360	come	[coming]	0.1	1	1	0	0
7669	360	cardiac-resynchronization	[Cardiac-resynchronization]	0.1	1	2	1	1
7670	360	adipokine	[adipokines]	0.1	1	1	0	0
7671	360	World	[World]	0.1	1	2	1	1
7672	360	core	[core]	0.1	1	1	0	0
7673	360	q65p	[Q65P]	0.1	1	1	0	0
7674	360	line	[line]	0.1	1	1	0	0
7675	360	link	[link]	0.1	1	2	2	2
7676	360	3-vessel	[3-vessel]	0.1	1	1	0	0
7677	360	TissueFAXS	[TissueFAXS]	0.1	1	1	0	0
7678	360	c-statistics	[C-statistics]	0.1	1	1	0	0
7679	360	with	[w]	0.1	1	2	1	1
7680	360	per	[per]	0.1	1	1	0	0
7681	360	vegfr2	[VEGFR2]	0.1	1	1	0	0
7682	360	ldl-cholesterol	[LDL-cholesterol]	0.1	1	1	0	0
7683	360	e'mean	[e'mean]	0.1	1	1	0	0
7684	360	OHT	[OHT]	0.1	1	2	1	1
7685	360	stenting	[stenting]	0.1	1	1	0	0
7686	360	pka	[PKA]	0.1	1	2	2	2
7687	360	blood-flow	[blood-flow]	0.1	1	1	0	0
7688	360	determinant	[determinant]	0.1	1	2	2	2
7689	360	sham-INV	[sham-INV]	0.1	1	1	0	0
7690	360	pna	[PNA]	0.1	1	1	0	0
7691	360	cytochrome	[cytochrome]	0.1	1	1	0	0
7692	360	ppr	[PPR]	0.1	1	2	2	2
7693	360	mmhg	[mmHg]	0.1	1	1	0	0
7694	360	substudy	[substudy]	0.1	1	2	1	1
7695	360	post-pd	[post-PD]	0.1	1	1	0	0
7696	360	zebrafish	[zebrafish]	0.1	1	1	0	0
7697	360	transmitral	[transmitral]	0.1	1	1	0	0
7698	360	pvf	[PVF]	0.1	1	1	0	0
7699	360	Resynchronization	[Resynchronization]	0.1	1	1	0	0
7700	360	murmur	[murmurs]	0.1	1	2	2	2
7701	360	uptake	[uptake]	0.1	1	2	2	2
7702	360	g-protein	[G-protein]	0.1	1	1	0	0
7703	360	6mwt	[6MWT]	0.1	1	2	1	1
7704	360	knowledge	[knowledge]	0.1	1	2	2	2
7705	360	California	[California]	0.1	1	1	0	0
7706	360	involvement	[involvement]	0.1	1	2	1	1
7707	360	slowness	[slowness]	0.1	1	1	0	0
7708	360	PDE	[PDE]	0.1	1	1	0	0
7709	360	Henry	[Henry]	0.1	1	1	0	0
7710	360	dipeptidyl	[dipeptidyl]	0.1	1	1	0	0
7711	360	guideline-heart	[Guideline-Heart]	0.1	1	1	0	0
7712	360	instance	[instance]	0.1	1	1	0	0
7713	360	occur	[occurring]	0.1	1	2	2	2
7714	360	PKA	[PKA]	0.1	1	2	1	1
7715	360	HEALTHSTAR	[HEALTHSTAR]	0.1	1	1	0	0
7716	360	gln27	[Gln27]	0.1	1	1	0	0
7717	360	PVF	[PVF]	0.1	1	1	0	0
7718	360	discrepancy	[discrepancy]	0.1	1	1	0	0
7719	360	caloric	[Caloric]	0.1	1	1	0	0
7720	360	x-ray	[X-ray]	0.1	1	2	1	1
7721	360	eseptal	[eseptal]	0.1	1	1	0	0
7722	360	raa	[RAAS]	0.1	1	1	0	0
7723	360	nephrectomy	[nephrectomy]	0.1	1	1	0	0
7724	360	early-onset	[early-onset]	0.1	1	2	2	2
7725	360	collateral	[collateral]	0.1	1	2	1	1
7726	360	health-care	[health-care]	0.1	1	1	0	0
7727	360	re-hospitalization	[re-hospitalization]	0.1	1	1	0	0
7728	360	carbohydrate	[carbohydrates]	0.1	1	1	0	0
7729	360	Pig	[Pigs]	0.1	1	1	0	0
7730	360	closure	[closure]	0.1	1	1	0	0
7731	360	tachy	[tachy]	0.1	1	1	0	0
7732	360	hnorm	[HNorm]	0.1	1	1	0	0
7733	360	ros	[ROS]	0.1	1	2	2	2
7734	360	t2d	[T2D]	0.1	1	2	1	1
7735	360	non-hf	[non-HF]	0.1	1	1	0	0
7736	360	immunoprecipitation	[immunoprecipitation]	0.1	1	1	0	0
7737	360	caspase-3	[caspase-3]	0.1	1	1	0	0
7738	360	sampling	[sampling]	0.1	1	1	0	0
7739	360	Pol	[Pol]	0.1	1	1	0	0
7740	360	organisation	[organisation]	0.1	1	1	0	0
7741	360	N-terminal	[N-terminal]	0.1	1	3	2	1
7742	360	Resynchronization-Defibrillation	[Resynchronization-Defibrillation]	0.1	1	2	2	2
7743	360	pattern	[pattern]	0.1	1	2	2	2
7744	360	disorder	[disorder]	0.1	1	2	1	1
7745	360	angina	[angina]	0.1	1	1	0	0
7746	360	RCT	[RCTs]	0.1	1	2	1	1
7747	360	completion	[completion]	0.1	1	2	1	1
7748	360	set	[set]	0.1	1	2	2	2
7749	360	hf-ref	[HF-REF]	0.1	1	2	1	1
7750	360	osteomedullary	[osteomedullary]	0.1	1	1	0	0
7751	360	reduce	[reducing]	0.1	1	1	0	0
7752	360	nucleolin	[nucleolin]	0.1	1	2	1	1
7753	360	RNA	[RNA]	0.1	1	1	0	0
7754	360	Alberta	[Alberta]	0.1	1	1	0	0
7755	360	myofilament	[myofilament]	0.1	1	1	0	0
7756	360	PKC-βII-Ser	[PKC-βII-Ser]	0.1	1	1	0	0
7757	360	CHF-NYHA-II	[CHF-NYHA-II]	0.1	1	1	0	0
7758	360	Ser23	[Ser23]	0.1	1	1	0	0
7759	360	pump-exchange	[pump-exchange]	0.1	1	1	0	0
7760	360	madit-crt	[MADIT-CRT]	0.1	1	1	0	0
7761	360	intraclass	[intraclass]	0.1	1	1	0	0
7762	360	RWT	[RWT]	0.1	1	1	0	0
7763	360	Lancet	[Lancet]	0.1	1	1	0	0
7764	360	prescription	[prescription]	0.1	1	1	0	0
7765	360	Hungary	[Hungary]	0.1	1	1	0	0
7766	360	sub-group	[sub-groups]	0.1	1	1	0	0
7767	360	Ser77	[Ser77]	0.1	1	1	0	0
7768	360	interplay	[interplay]	0.1	1	1	0	0
7769	360	Ser83	[Ser83]	0.1	1	2	1	1
7770	360	hand	[hand]	0.1	1	1	0	0
7771	360	Hypoalbuminemia	[Hypoalbuminemia]	0.1	1	1	0	0
7772	360	coagulability	[coagulability]	0.1	1	1	0	0
7773	360	exertion	[exertion]	0.1	1	2	1	1
7774	360	Ontario	[Ontario]	0.1	1	1	0	0
7775	360	RENASTUR	[RENASTUR]	0.1	1	1	0	0
7776	360	EMPHASIS-HF	[EMPHASIS-HF]	0.1	1	2	2	2
7777	360	(egfr)-group	[(eGFR)-group]	0.1	1	1	0	0
7778	360	start	[start]	0.1	1	2	2	2
7779	360	borderline	[borderline]	0.1	1	1	0	0
7780	360	recipient	[recipients]	0.1	1	2	1	1
7781	360	tapse-to-pasp	[TAPSE-to-PASP]	0.1	1	1	0	0
7782	360	Diuretic	[Diuretic]	0.1	1	2	2	2
7783	360	survive	[surviving]	0.1	1	1	0	0
7784	360	infusion	[infusion]	0.1	1	1	0	0
7785	360	water	[water]	0.1	1	1	0	0
7786	360	6-wk	[6-wk]	0.1	1	1	0	0
7787	360	food-frequency	[food-frequency]	0.1	1	1	0	0
7788	360	colleague	[colleagues]	0.1	1	1	0	0
7789	360	Sci	[Sci]	0.1	1	1	0	0
7790	360	methodology	[METHODOLOGY]	0.1	1	1	0	0
7791	360	Gln27	[Gln27]	0.1	1	1	0	0
7792	360	Arbor	[Arbor]	0.1	1	1	0	0
7793	360	macrophage	[Macrophages]	0.1	1	2	1	1
7794	360	term	[terms]	0.1	1	2	2	2
7795	360	right	[right]	0.1	1	1	0	0
7796	360	hemocompatibility	[hemocompatibility]	0.1	1	1	0	0
7797	360	December	[December]	0.1	1	1	0	0
7798	360	log2	[log2]	0.1	1	1	0	0
7799	360	Lokomat®	[Lokomat®]	0.1	1	2	2	2
7800	360	uti	[UTI]	0.1	1	2	2	2
7801	360	originate	[originating]	0.1	1	1	0	0
7802	360	TTA	[TTA]	0.1	1	2	2	2
7803	360	smoking	[smoking]	0.1	1	2	2	2
7804	360	TUG	[TUG]	0.1	1	1	0	0
7805	360	synchrony	[synchrony]	0.1	1	1	0	0
7806	360	loop	[loop]	0.1	1	1	0	0
7807	360	contraindication	[contraindications]	0.1	1	1	0	0
7808	360	utilization	[utilization]	0.1	1	1	0	0
7809	360	variability	[Variability]	0.1	1	2	1	1
7810	360	arg16	[Arg16]	0.1	1	1	0	0
7811	360	propensity-score	[propensity-score]	0.1	1	1	0	0
7812	360	threshold	[threshold]	0.1	1	2	2	2
7813	360	revision	[Revision]	0.1	1	3	2	1
7814	360	dpp-4	[DPP-4]	0.1	1	2	1	1
7815	360	adolescence	[adolescence]	0.1	1	1	0	0
7816	360	rs1799945	[rs1799945]	0.1	1	1	0	0
7817	360	Michigan	[Michigan]	0.1	1	1	0	0
7818	360	Epidemiology	[Epidemiology]	0.1	1	1	0	0
7819	360	vo2	[VO2]	0.1	1	2	1	1
7820	360	inroad	[inroads]	0.1	1	1	0	0
7821	360	concordance	[concordance]	0.1	1	1	0	0
7822	360	von	[von]	0.1	1	1	0	0
7823	360	degradation	[degradation]	0.1	1	1	0	0
7824	360	cTnT	[cTnT]	0.1	1	2	1	1
7825	360	renin-angiotensin-aldosterone	[renin-angiotensin-aldosterone]	0.1	1	1	0	0
7826	360	hypokalemia	[hypokalemia]	0.1	1	2	2	2
7827	360	Mammalian	[Mammalian]	0.1	1	2	1	1
7828	360	net-reclassification-improvement	[net-reclassification-improvement]	0.1	1	1	0	0
7829	360	rtq-pcr	[RTQ-PCR]	0.1	1	1	0	0
7830	360	incorporate	[incorporating]	0.1	1	1	0	0
7831	360	severity	[severity]	0.1	1	1	0	0
7832	360	VAD	[VAD]	0.1	1	2	1	1
7833	360	β-blockade	[β-blockade]	0.1	1	1	0	0
7834	360	topic	[topic]	0.1	1	2	1	1
7835	360	hyperlipidaemia	[hyperlipidaemia]	0.1	1	1	0	0
7836	360	actrn12610001087044	[ACTRN12610001087044]	0.1	1	1	0	0
7837	360	pacemaker	[pacemaker]	0.1	1	2	1	1
7838	360	decile	[decile]	0.1	1	2	1	1
7839	360	occlusion	[occlusion]	0.1	1	2	1	1
7840	360	2+)-pump	[2+)-pump]	0.1	1	3	2	1
7841	360	wrf	[WRF]	0.1	1	2	1	1
7842	360	portal	[portal]	0.1	1	1	0	0
7843	360	etiologic	[etiologic]	0.1	1	1	0	0
7844	360	expansion	[expansion]	0.1	1	1	0	0
7845	360	adaptation	[adaptation]	0.1	1	2	2	2
7846	360	decision-support	[decision-support]	0.1	1	1	0	0
7847	360	nodularity	[nodularity]	0.1	1	1	0	0
7848	360	Rem2	[Rem2]	0.1	1	1	0	0
7849	360	15-mL	[15-mL]	0.1	1	1	0	0
7850	360	Gene	[Gene]	0.1	1	3	2	1
7851	360	GDMT	[GDMT]	0.1	1	1	0	0
7852	360	confounder	[confounders]	0.1	1	2	2	2
7853	360	sound	[sound]	0.1	1	1	0	0
7854	360	translate	[translating]	0.1	1	1	0	0
7855	360	glu27	[Glu27]	0.1	1	1	0	0
7856	360	CORAL	[CORAL]	0.1	1	1	0	0
7857	360	cd133	[CD133]	0.1	1	1	0	0
7858	360	Retn	[Retn]	0.1	1	2	1	1
7859	360	Kaiser	[Kaiser]	0.1	1	1	0	0
7860	360	caspase	[Caspase]	0.1	1	2	1	1
7861	360	hypoxia	[hypoxia]	0.1	1	2	1	1
7862	360	sex-	[sex-]	0.1	1	1	0	0
7863	360	Community	[Communities]	0.1	1	1	0	0
7864	360	Lung	[Lung]	0.1	1	1	0	0
7865	360	American	[Americans]	0.1	1	2	2	2
7866	360	Cardiovascular	[Cardiovascular]	0.1	1	1	0	0
7867	360	30-day	[30-day]	0.1	1	2	2	2
7868	360	Tuscany	[Tuscany]	0.1	1	1	0	0
7869	360	molecule	[molecule]	0.1	1	1	0	0
7870	360	guidelines-heart	[Guidelines-Heart]	0.1	1	1	0	0
7871	360	defense	[defense]	0.1	1	1	0	0
7872	360	oxide	[oxide]	0.1	1	2	1	1
7873	360	effort	[effort]	0.1	1	2	1	1
7874	360	p=0·035	[p=0·035]	0.1	1	1	0	0
7875	360	histone	[histone]	0.1	1	2	2	2
7876	360	leu3-gly4	[Leu3-Gly4]	0.1	1	1	0	0
7877	360	AUCs	[AUCs]	0.1	1	2	1	1
7878	360	haplotype	[haplotype]	0.1	1	1	0	0
7879	360	breath-holding	[breath-holding]	0.1	1	1	0	0
7880	360	nad(p)	[NAD(P)]	0.1	1	1	0	0
7881	360	ethnicity	[ethnicity]	0.1	1	2	1	1
7882	360	dyspnea	[dyspnea]	0.1	1	2	1	1
7883	360	promise	[promise]	0.1	1	2	1	1
7884	360	Multicenter	[Multicenter]	0.1	1	2	2	2
7885	360	Medicaid	[Medicaid]	0.1	1	2	1	1
7886	360	permeability	[permeability]	0.1	1	1	0	0
7887	360	Latin	[Latin]	0.1	1	2	1	1
7888	360	binding	[binding]	0.1	1	2	2	2
7889	360	amplitude	[amplitude]	0.1	1	1	0	0
7890	360	Nonpublic	[Nonpublic]	0.1	1	1	0	0
7891	360	gdmt	[GDMT]	0.1	1	2	2	2
7892	360	gating	[gating]	0.1	1	1	0	0
7893	360	Dietary	[Dietary]	0.1	1	1	0	0
7894	360	eNOS-Ser	[eNOS-Ser]	0.1	1	2	2	2
7895	360	complicity	[complicity]	0.1	1	1	0	0
7896	360	neurohormone	[neurohormone]	0.1	1	2	1	1
7897	360	osteoporosis	[osteoporosis]	0.1	1	1	0	0
7898	360	hybrid	[hybrid]	0.1	1	1	0	0
7899	360	unanchor	[unanchors]	0.1	1	1	0	0
7900	360	tm24	[TM24]	0.1	1	1	0	0
7901	360	Association	[Association]	0.1	1	2	2	2
7902	360	U.S.	[U.S.]	0.1	1	1	0	0
7903	360	debate	[debate]	0.1	1	1	0	0
7904	360	sternotomy	[sternotomy]	0.1	1	2	2	2
7905	360	surrogate	[surrogate]	0.1	1	2	2	2
7906	360	driveline	[driveline]	0.1	1	2	2	2
7907	360	pathobiology	[pathobiology]	0.1	1	1	0	0
7908	360	radioenzymatic	[radioenzymatic]	0.1	1	1	0	0
7909	360	correction	[correction]	0.1	1	2	2	2
7910	360	thalassaemia	[thalassaemia]	0.1	1	1	0	0
7911	360	retn	[Retn]	0.1	1	1	0	0
7912	360	PASP	[PASP]	0.1	1	2	1	1
7913	360	Centers	[Centers]	0.1	1	2	2	2
7914	360	precede	[preceding]	0.1	1	1	0	0
7915	360	PRONTO	[PRONTO]	0.1	1	1	0	0
7916	360	auscultation	[auscultation]	0.1	1	1	0	0
7917	360	side	[side]	0.1	1	1	0	0
7918	360	Glu27	[Glu27]	0.1	1	1	0	0
7919	360	Spironolactone	[Spironolactone]	0.1	1	1	0	0
7920	360	gluconeogenesis	[gluconeogenesis]	0.1	1	1	0	0
7921	360	initiation	[initiation]	0.1	1	1	0	0
7922	360	mir-25	[miR-25]	0.1	1	2	2	2
7923	360	dissemination	[dissemination]	0.1	1	1	0	0
7924	360	leukocyte	[leukocytes]	0.1	1	1	0	0
7925	360	place	[place]	0.1	1	1	0	0
7926	360	observation	[observation]	0.1	1	2	1	1
7927	360	S12884	[S12884]	0.1	1	1	0	0
7928	360	lvet	[LVET]	0.1	1	1	0	0
7929	360	computing	[computing]	0.1	1	1	0	0
7930	360	match	[matching]	0.1	1	2	1	1
7931	360	Ciaraldi	[Ciaraldi]	0.1	1	1	0	0
7932	360	transduction	[transduction]	0.1	1	2	1	1
7933	360	centrifugal-flow	[centrifugal-flow]	0.1	1	1	0	0
7934	360	Dissemination	[Dissemination]	0.1	1	1	0	0
7935	360	November	[November]	0.1	1	1	0	0
7936	360	Phosphodiesterase-2	[Phosphodiesterase-2]	0.1	1	1	0	0
7937	360	aldactone	[Aldactone]	0.1	1	1	0	0
7938	360	possibility	[possibility]	0.1	1	2	1	1
7939	360	systole	[systole]	0.1	1	2	2	2
7940	360	Collaboration	[Collaboration]	0.1	1	1	0	0
7941	360	pace	[pace]	0.1	1	2	2	2
7942	360	prolapse	[prolapse]	0.1	1	1	0	0
7943	360	Congestive	[Congestive]	0.1	1	1	0	0
7944	360	cornerstone	[cornerstone]	0.1	1	2	2	2
7945	360	Calif	[Calif]	0.1	1	1	0	0
7946	360	chest	[chest]	0.1	1	2	1	1
7947	360	p38alpha	[p38alpha]	0.1	1	1	0	0
7948	360	recruitment	[recruitment]	0.1	1	1	0	0
7949	360	esmolol	[esmolol]	0.1	1	2	1	1
7950	360	centre	[centre]	0.1	1	2	2	2
7951	360	affair	[Affairs]	0.1	1	1	0	0
7952	360	Murphy	[Murphy]	0.1	1	1	0	0
7953	360	heartware	[HeartWare]	0.1	1	1	0	0
7954	360	profile	[profile]	0.1	1	2	2	2
7955	360	time-var	[time-varying]	0.1	1	1	0	0
7956	360	conduction	[conduction]	0.1	1	2	1	1
7957	360	s'lateral	[s'lateral]	0.1	1	2	1	1
7958	360	KCl-KI	[KCl-KI]	0.1	1	1	0	0
7959	360	hemostasis	[hemostasis]	0.1	1	2	1	1
7960	360	human	[humans]	0.1	1	2	1	1
7961	360	recognition	[recognition]	0.1	1	2	2	2
7962	360	rs8187710	[rs8187710]	0.1	1	1	0	0
7963	360	breath	[Breath]	0.1	1	1	0	0
7964	360	repeat	[repeat]	0.1	1	1	0	0
7965	360	circulation	[circulation]	0.1	1	2	2	2
7966	360	crossover	[crossover]	0.1	1	1	0	0
7967	360	collaboration	[collaboration]	0.1	1	2	1	1
7968	360	geometry	[geometry]	0.1	1	2	2	2
7969	360	tobacco	[tobacco]	0.1	1	2	1	1
7970	360	subdomain	[subdomains]	0.1	1	1	0	0
7971	360	Ehrlich	[Ehrlich]	0.1	1	1	0	0
7972	360	registry	[registry]	0.1	1	2	1	1
7973	360	ea=1.5	[Ea=1.5]	0.1	1	1	0	0
7974	360	washout	[washout]	0.1	1	2	2	2
7975	360	Naviaux	[Naviaux]	0.1	1	1	0	0
7976	360	Tran	[Trans]	0.1	1	1	0	0
7977	360	imbalance	[imbalance]	0.1	1	2	2	2
7978	360	myxomas	[Myxomas]	0.1	1	2	1	1
7979	360	science	[science]	0.1	1	1	0	0
7980	360	utility	[utility]	0.1	1	1	0	0
7981	360	hand-search	[hand-searching]	0.1	1	1	0	0
7982	360	descend	[descending]	0.1	1	1	0	0
7983	360	canine	[canine]	0.1	1	2	1	1
7984	360	pro6-gly7	[Pro6-Gly7]	0.1	1	1	0	0
7985	360	screening	[Screening]	0.1	1	1	0	0
7986	360	ad-flk	[Ad-Flk]	0.1	1	2	1	1
7987	360	new-onset	[new-onset]	0.1	1	1	0	0
7988	360	difference-in-differences	[difference-in-differences]	0.1	1	1	0	0
7989	360	Student	[Student]	0.1	1	1	0	0
7990	360	(drs)-stratified	[(DRS)-stratified]	0.1	1	1	0	0
7991	360	Hope	[Hope]	0.1	1	1	0	0
7992	360	ecct	[ECCT]	0.1	1	2	1	1
7993	360	p-value	[P-value]	0.1	1	1	0	0
7994	360	baroreflex	[Baroreflex]	0.1	1	1	0	0
7995	360	shift	[shift]	0.1	1	2	1	1
7996	360	10-eo-cfu	[10-EO-CFU]	0.1	1	1	0	0
7997	360	proteome	[proteome]	0.1	1	2	1	1
7998	360	flutter	[flutter]	0.1	1	1	0	0
7999	360	Texas	[Texas]	0.1	1	1	0	0
8000	360	September	[September]	0.1	1	2	2	2
8001	360	miR-25	[miR-25]	0.1	1	1	0	0
8002	360	ischemic	[ischemic]	0.1	1	1	0	0
8003	360	rise	[rise]	0.1	1	2	2	2
8004	360	length-force	[length-force]	0.1	1	1	0	0
8005	360	contention	[contention]	0.1	1	1	0	0
8006	360	PEVK	[PEVK]	0.1	1	1	0	0
8007	360	dhand	[dHAND]	0.1	1	1	0	0
8008	360	echo-doppler	[echo-Doppler]	0.1	1	2	2	2
8009	360	electrolyte	[electrolytes]	0.1	1	1	0	0
8010	360	smad	[Smad]	0.1	1	1	0	0
8011	360	stimulus	[stimuli]	0.1	1	2	2	2
8012	360	Denmark	[Denmark]	0.1	1	1	0	0
8013	360	n=22	[n=22]	0.1	1	1	0	0
8014	360	n=95	[n=95]	0.1	1	1	0	0
8015	360	ecmo+vad	[ECMO+VAD]	0.1	1	1	0	0
8016	360	riiα	[RIIα]	0.1	1	1	0	0
8017	360	survey	[surveys]	0.1	1	1	0	0
8018	360	regeneration	[regeneration]	0.1	1	1	0	0
8019	360	province	[province]	0.1	1	2	2	2
8020	360	chf-dnx	[CHF-DNx]	0.1	1	2	1	1
8021	360	N2Bus	[N2Bus]	0.1	1	1	0	0
8022	360	awareness	[awareness]	0.1	1	2	1	1
8023	360	epidemic	[epidemic]	0.1	1	2	2	2
8024	360	s'septal	[s'septal]	0.1	1	1	0	0
8025	360	destination	[destination]	0.1	1	2	1	1
8026	360	cha₂ds₂vasc	[CHA₂DS₂VASc]	0.1	1	1	0	0
8027	360	dapc	[DAPC]	0.1	1	2	1	1
8028	360	Care	[Care]	0.1	1	1	0	0
8029	360	distribution	[distribution]	0.1	1	3	2	1
8030	360	INTERMACS	[INTERMACS]	0.1	1	1	0	0
8031	360	vasodilator	[vasodilator]	0.1	1	2	1	1
8032	360	conversation	[conversations]	0.1	1	1	0	0
8033	360	CHF-NYHA-III	[CHF-NYHA-III]	0.1	1	1	0	0
8034	360	co-morbidity	[co-morbidity]	0.1	1	2	1	1
8035	360	VO2max	[VO2max]	0.1	1	1	0	0
8036	360	Anand	[Anand]	0.1	1	1	0	0
8037	360	sepsis	[sepsis]	0.1	1	1	0	0
8038	360	n-terminal	[N-terminal]	0.1	1	2	2	2
8039	360	working	[working]	0.1	1	1	0	0
8040	360	retention	[Retention]	0.1	1	1	0	0
8041	360	adjuvant	[adjuvant]	0.1	1	1	0	0
8042	360	prostate	[prostate]	0.1	1	1	0	0
8043	360	lipoprotein	[lipoprotein]	0.1	1	2	2	2
8044	360	isoprenaline	[isoprenaline]	0.1	1	2	1	1
8045	360	infection	[infection]	0.1	1	1	0	0
8046	360	pre-crt	[pre-CRT]	0.1	1	1	0	0
8047	360	choice	[choice]	0.1	1	2	2	2
8048	360	μg	[μg]	0.1	1	2	2	2
8049	360	propensity	[propensity]	0.1	1	2	1	1
8050	360	explant	[explant]	0.1	1	1	0	0
8051	360	treadmill	[treadmill]	0.1	1	2	1	1
8052	360	compete	[competing]	0.1	1	2	1	1
8053	360	home	[home]	0.1	1	2	1	1
8054	360	Paco2	[Paco2]	0.1	1	1	0	0
8055	360	i.p.	[i.p.]	0.1	1	1	0	0
8056	360	polymorphism	[polymorphisms]	0.1	1	1	0	0
8057	360	hour	[hours]	0.1	1	2	2	2
8058	360	clcnka	[CLCNKA]	0.1	1	1	0	0
8059	360	beagle	[beagle]	0.1	1	1	0	0
8060	360	ranking	[rankings]	0.1	1	1	0	0
8061	360	elateral	[elateral]	0.1	1	1	0	0
8062	360	conflict	[conflicting]	0.1	1	2	1	1
8063	360	hf-action	[HF-ACTION]	0.1	1	3	2	1
8064	360	nyha-iiib	[NYHA-IIIb]	0.1	1	1	0	0
8065	360	Inhibitor	[Inhibitor]	0.1	1	1	0	0
8066	360	consist	[consisting]	0.1	1	1	0	0
8067	360	PsycINFO	[PsycINFO]	0.1	1	1	0	0
8068	360	Night	[Nights]	0.1	1	1	0	0
8069	360	array	[array]	0.1	1	1	0	0
8070	360	adenosine	[adenosine]	0.1	1	2	1	1
8071	360	malondialdehyde	[malondialdehyde]	0.1	1	2	1	1
8072	360	consent	[consenting]	0.1	1	1	0	0
8073	360	SS20	[SS20]	0.1	1	1	0	0
8074	360	willebrand	[Willebrand]	0.1	1	2	1	1
8075	360	aim	[aim]	0.1	1	8	7	1
8076	360	nbDMARD	[nbDMARD]	0.1	1	1	0	0
8077	360	arm	[arm]	0.1	1	1	0	0
8078	360	at1	[AT1]	0.1	1	1	0	0
8079	360	tumor	[tumor]	0.1	1	2	1	1
8080	360	avp	[AVP]	0.1	1	2	1	1
8081	360	vagal	[vagal]	0.1	1	2	1	1
8082	360	Atrial	[Atrial]	0.1	1	1	0	0
8083	360	Arg83Gly	[Arg83Gly]	0.1	1	1	0	0
8084	360	ASTRONAUT	[ASTRONAUT]	0.1	1	1	0	0
8085	360	Irvine	[Irvine]	0.1	1	1	0	0
8086	360	Pleasanton	[Pleasanton]	0.1	1	1	0	0
8087	360	amount	[amount]	0.1	1	2	2	2
8088	360	Ramirez-Sanchez	[Ramirez-Sanchez]	0.1	1	1	0	0
8089	360	AAC	[AAC]	0.1	1	2	1	1
8090	360	ABC	[ABC]	0.1	1	2	1	1
8091	360	rs13058338	[rs13058338]	0.1	1	1	0	0
8092	360	ACS	[ACS]	0.1	1	2	1	1
8093	360	Doxorubicin	[Doxorubicin]	0.1	1	1	0	0
8094	360	lcz696	[LCZ696]	0.1	1	1	0	0
8095	360	AHA	[AHA]	0.1	1	2	1	1
8096	360	surface	[surface]	0.1	1	1	0	0
8097	360	AIM	[AIM]	0.1	1	1	0	0
8098	360	medicaid	[Medicaid]	0.1	1	1	0	0
8099	360	angii	[AngII]	0.1	1	2	1	1
8100	360	current	[currents]	0.1	1	1	0	0
8101	360	dyssynchrony	[dyssynchrony]	0.1	1	2	2	2
8102	360	migration	[migration]	0.1	1	1	0	0
8103	360	off-pump	[off-pump]	0.1	1	1	0	0
8104	360	ca2	[Ca2]	0.1	1	1	0	0
8105	360	hallmark	[hallmark]	0.1	1	3	2	1
8106	360	BAT	[BAT]	0.1	1	1	0	0
8107	360	p70S6K-Ser	[p70S6K-Ser]	0.1	1	1	0	0
8108	361	dose of doxorubicin	[dose of doxorubicin]	0.0	3	1	1	1
8109	361	ventricular assist system	[Ventricular Assist System]	0.0	3	1	1	1
8110	361	implication of metric choice for application	[Implications of metric choice for applications]	0.0	6	1	1	1
8111	361	ventricular biopsy	[ventricular biopsies]	0.0	2	1	1	1
8112	361	relative importance for DD	[relative importance for DD]	0.0	4	1	1	1
8113	361	iii HF	[III HF]	0.0	2	1	1	1
8114	361	arterial elastance end-systolic elastance ees	[arterial elastance end-systolic elastance Ees]	0.0	5	1	1	1
8115	361	sternotomy for valve procedure	[sternotomy for valve procedures]	0.0	4	1	1	1
8116	361	experimental research	[experimental research]	0.0	2	1	1	1
8117	361	decade of national effort	[decade of national efforts]	0.0	4	1	1	1
8118	361	CHM versus treatment	[CHM versus treatment]	0.0	3	1	1	1
8119	361	atrial peptide	[atrial peptide]	0.0	2	1	1	1
8120	361	conventional systolic parameter in af	[conventional systolic parameters in AF]	0.0	5	1	1	1
8121	361	group with heart failure	[groups with heart failure]	0.0	4	1	1	1
8122	361	Addition discrimination change in c-index	[Addition discrimination change in C-index]	0.0	5	1	1	1
8123	361	study sample with patient	[study sample with patients]	0.0	4	1	1	1
8124	361	bb dose versus mg daily dose	[BB dose versus mg daily dose]	0.0	6	1	1	1
8125	361	h-dko	[H-DKO]	0.0	1	1	1	1
8126	361	left remodeling	[left remodeling]	0.0	2	1	1	1
8127	361	target of heart failure research	[target of heart failure research]	0.0	5	1	1	1
8128	361	tta animal	[TTA animals]	0.0	2	1	1	1
8129	361	Excellence	[Excellence]	0.0	1	1	1	1
8130	361	endothelial cell ec	[endothelial cell EC]	0.0	3	1	1	1
8131	361	change with exercise main effect	[change with exercise main effect]	0.0	5	1	1	1
8132	361	independent correlate of increase	[independent correlates of increase]	0.0	4	1	1	1
8133	361	ethnic group	[ethnic groups]	0.0	2	1	1	1
8134	361	Biventricular support	[Biventricular support]	0.0	2	1	1	1
8135	361	LV pressure p	[LV pressure P]	0.0	3	1	1	1
8136	361	pulmonary arterial pressure pasp	[pulmonary arterial pressure PASP]	0.0	4	1	1	1
8137	361	patient with low ejection fraction	[patients with low ejection fraction]	0.0	5	1	1	1
8138	361	protein level	[protein levels]	0.0	2	1	1	1
8139	361	disclose prognosis	[disclosing prognosis]	0.0	2	1	1	1
8140	361	patient geometry	[patients geometry]	0.0	2	1	1	1
8141	361	characteristic use of evidence-based medication	[characteristics use of evidence-based medications]	0.0	5	1	1	1
8142	361	large control study	[larger control studies]	0.0	3	1	1	1
8143	361	atherosclerotic Lesion CORAL	[Atherosclerotic Lesions CORAL]	0.0	3	1	1	1
8144	361	relative value	[relative value]	0.0	2	1	1	1
8145	361	left function in cardiac volume overload	[left function in cardiac volume overload]	0.0	6	1	1	1
8146	361	CHF predictive model	[CHF predictive model]	0.0	3	1	1	1
8147	361	V	[V]	0.0	1	1	1	1
8148	361	Grading of recommendation Assessment methodology	[Grading of Recommendations Assessment methodology]	0.0	5	1	1	1
8149	361	turnaround time	[turnaround times]	0.0	2	1	1	1
8150	361	resuscitation	[resuscitation]	0.0	1	1	1	1
8151	361	review of preference	[review of preferences]	0.0	3	1	1	1
8152	361	telehealth system with care management	[telehealth system with care management]	0.0	5	1	1	1
8153	361	g	[G]	0.0	1	1	1	1
8154	361	h	[h]	0.0	1	1	1	1
8155	361	peritoneal dialysis for long management	[Peritoneal dialysis for long-term management]	0.0	5	1	1	1
8156	361	53 consecutive patient	[53 consecutive patients]	0.0	3	1	1	1
8157	361	man without a history	[men without a history]	0.0	4	1	1	1
8158	361	Depression scale	[Depression Scale]	0.0	2	1	1	1
8159	361	most common type	[most common type]	0.0	3	1	1	1
8160	361	troponin T cTnT	[troponin T cTnT]	0.0	3	1	1	1
8161	361	patient with a egfr	[patients with an eGFR]	0.0	4	1	1	1
8162	361	Practice Guideline CPG	[Practice Guideline CPG]	0.0	3	1	1	1
8163	361	use a start date	[using an start date]	0.0	4	1	1	1
8164	361	statistically significant change main effect	[statistically significant change main effect]	0.0	5	1	1	1
8165	361	low hazard	[lowest hazard]	0.0	2	1	1	1
8166	361	treatment of heart failure treatment	[treatment of heart failure treatment]	0.0	5	1	1	1
8167	361	key role of ERK1 molecular scaffold	[Key role of ERK1 molecular scaffolds]	0.0	6	1	1	1
8168	361	strong predictor	[strong predictor]	0.0	2	2	2	1
8169	361	morbidity especially in people	[morbidity especially in people]	0.0	4	1	1	1
8170	361	placebo for day in this trial	[placebo for days in this trial]	0.0	6	1	1	1
8171	361	fail Fontan	[failing Fontan]	0.0	2	1	1	1
8172	361	54 patient	[54 patients]	0.0	2	1	1	1
8173	361	net reclassification	[net reclassification]	0.0	2	2	2	1
8174	361	2 distinct receptor	[2 distinct receptors]	0.0	3	1	1	1
8175	361	qol outcome	[QOL outcome]	0.0	2	1	1	1
8176	361	relative risk RR	[relative risk RR]	0.0	3	1	1	1
8177	361	patient require HeartMate	[patients requiring HeartMate]	0.0	3	1	1	1
8178	361	measure of right ventricular reserve	[measure of right ventricular reserve]	0.0	5	1	1	1
8179	361	blocker at evaluation	[blockers at evaluation]	0.0	3	1	1	1
8180	361	arterial elastance ea end-systolic elastance	[arterial elastance Ea end-systolic elastance]	0.0	5	1	1	1
8181	361	ec coupling	[EC coupling]	0.0	2	1	1	1
8182	361	safety end	[safety end]	0.0	2	1	1	1
8183	361	indicate care of patient	[indicating care of patients]	0.0	4	1	1	1
8184	361	treat HF	[Treating HF]	0.0	2	1	1	1
8185	361	10 heart failure HF patient	[10 heart failure HF patients]	0.0	5	1	1	1
8186	361	left LV systolic pressure	[left LV systolic pressure]	0.0	4	1	1	1
8187	361	care clinician care	[care clinicians caring]	0.0	3	1	1	1
8188	361	transcriptional analysis	[transcriptional analysis]	0.0	2	1	1	1
8189	361	effect of (-)-epicatechin-rich cocoa	[effects of (-)-epicatechin-rich cocoa]	0.0	4	1	1	1
8190	361	novel antiadrenergic strategy in HF	[novel antiadrenergic strategy in HF]	0.0	5	1	1	1
8191	361	modify antirheumatic drug	[modifying antirheumatic drug]	0.0	3	1	1	1
8192	361	7.5 mg	[7.5 mg]	0.0	2	1	1	1
8193	361	cutoff level	[cutoff level]	0.0	2	1	1	1
8194	361	even with systolic function	[even with systolic function]	0.0	4	1	1	1
8195	361	ongoing Cardiovascular Outcome in Lesion	[ongoing Cardiovascular Outcomes in Lesions]	0.0	5	1	1	1
8196	361	play a major role	[playing a major role]	0.0	4	1	1	1
8197	361	Québec Canada	[Québec Canada]	0.0	2	1	1	1
8198	361	three patient	[three patients]	0.0	2	1	1	1
8199	361	ventricular base during baseline	[ventricular base during baseline]	0.0	4	1	1	1
8200	361	m age	[m age]	0.0	2	1	1	1
8201	361	correct nutrition function	[correcting nutrition function]	0.0	3	1	1	1
8202	361	independent hypothese addition μg	[independent hypotheses addition μg]	0.0	4	1	1	1
8203	361	descend artery	[descending artery]	0.0	2	1	1	1
8204	361	partial attenuation	[partial attenuation]	0.0	2	1	1	1
8205	361	change in hdl-induced	[changes in HDL-induced]	0.0	3	1	1	1
8206	361	constriction tac	[constriction TAC]	0.0	2	2	2	1
8207	361	depressive symptom Hospital anxiety	[depressive symptoms Hospital Anxiety]	0.0	4	1	1	1
8208	361	other prognostic factor	[Other prognostic factors]	0.0	3	1	1	1
8209	361	cancer	[cancers]	0.0	1	2	2	1
8210	361	week after AAC	[weeks after AAC]	0.0	3	1	1	1
8211	361	association of hHF	[associations of hHF]	0.0	3	1	1	1
8212	361	Skeletal muscle abnormality	[Skeletal muscle abnormalities]	0.0	3	1	1	1
8213	361	Bradycardia indicative of sympathetic tone	[Bradycardia indicative of sympathetic tone]	0.0	5	1	1	1
8214	361	Specific signalling pathway activate cardiac remodelling	[Specific signalling pathways activating cardiac remodelling]	0.0	6	1	1	1
8215	361	strong mortality predictor	[strong mortality predictors]	0.0	3	1	1	1
8216	361	rigorous investigation	[rigorous investigation]	0.0	2	1	1	1
8217	361	Patient perception of cardioverter-defibrillator deactivation discussion	[Patient perceptions of cardioverter-defibrillator deactivation discussions]	0.0	6	1	1	1
8218	361	doppler mitral inflow velocity	[Doppler mitral inflow velocity]	0.0	4	1	1	1
8219	361	difference among ef bnp	[difference among EF BNP]	0.0	4	1	1	1
8220	361	L-type channel isoform	[L-type channel isoforms]	0.0	3	1	1	1
8221	361	cardioverter-defibrillators	[cardioverter-defibrillators]	0.0	1	1	1	1
8222	361	specific inclusion	[specific inclusion]	0.0	2	1	1	1
8223	361	pressure relationship in heart failure	[pressure relationship in heart failure]	0.0	5	1	1	1
8224	361	partly a result	[partly a result]	0.0	3	1	1	1
8225	361	treatment of acute heart failure treatment	[treatment of acute heart failure treatment]	0.0	6	1	1	1
8226	361	predictor period versus 1	[predictor period versus 1]	0.0	4	1	1	1
8227	361	unique indication	[unique indication]	0.0	2	1	1	1
8228	361	objective institution	[Objective institution]	0.0	2	1	1	1
8229	361	predictor of all-cause mortality	[predictor of all-cause mortality]	0.0	4	1	1	1
8230	361	blot analysis	[blot analysis]	0.0	2	1	1	1
8231	361	cytoskeleton	[cytoskeleton]	0.0	1	1	1	1
8232	361	millileter p=0.01	[mL P=0.01]	0.0	2	1	1	1
8233	361	state of mitochondrial stress	[state of mitochondrial stress]	0.0	4	1	1	1
8234	361	need of resuscitation cpr	[need of resuscitation CPR]	0.0	4	1	1	1
8235	361	enzyme inhibitor angiotensin receptor blocker	[enzyme inhibitors angiotensin receptor blockers]	0.0	5	1	1	1
8236	361	two hundred HF patient hfref	[Two hundred HF patients HFrEF]	0.0	5	1	1	1
8237	361	derangement	[derangement]	0.0	1	1	1	1
8238	361	membrane oxygenation on function in child	[membrane oxygenation on function in children]	0.0	6	1	1	1
8239	361	lateral wall	[lateral wall]	0.0	2	1	1	1
8240	361	relevance of right ventricular reserve	[relevance of right ventricular reserve]	0.0	5	1	1	1
8241	361	difference in performance	[differences in performance]	0.0	3	1	1	1
8242	361	degree of MS early	[degree of MS early]	0.0	4	1	1	1
8243	361	co2	[CO2]	0.0	1	1	1	1
8244	361	index of right ventricular function	[index of right ventricular function]	0.0	5	1	1	1
8245	361	renal disease in outpatient	[renal disease in outpatients]	0.0	4	1	1	1
8246	361	grow subclass	[growing subclass]	0.0	2	1	1	1
8247	361	2 scaffold	[2 scaffolds]	0.0	2	1	1	1
8248	361	mg daily equivalent dose	[mg daily equivalent dose]	0.0	4	1	1	1
8249	361	level of epinephrine	[levels of epinephrine]	0.0	3	1	1	1
8250	361	end-point of all-cause mortality	[end-point of all-cause mortality]	0.0	4	1	1	1
8251	361	association between dysfunction	[association between dysfunction]	0.0	3	1	1	1
8252	361	reduction in the composite end-point	[reductions in the composite end-point]	0.0	5	1	1	1
8253	361	effect of ejection fraction on mortality	[effect of ejection fraction on mortality]	0.0	6	1	1	1
8254	361	trend toward day	[trend toward days]	0.0	3	1	1	1
8255	361	obese zsf1 rat	[obese ZSF1 rats]	0.0	3	1	1	1
8256	361	evaluate the change	[evaluating the changes]	0.0	3	1	1	1
8257	361	right ventricular plane systolic excursion tapse	[right ventricular plane systolic excursion TAPSE]	0.0	6	1	1	1
8258	361	–17.4 point	[–17.4 points]	0.0	2	1	1	1
8259	361	bone expression	[bone expression]	0.0	2	1	1	1
8260	361	increase in LV pressure	[increase in LV pressure]	0.0	4	1	1	1
8261	361	defense mechanism during stress	[defense mechanism during stress]	0.0	4	1	1	1
8262	361	basic relevance carry increase	[basic relevance carrying increase]	0.0	4	1	1	1
8263	361	database for all adult	[databases for all adults]	0.0	4	1	1	1
8264	361	function in chronic heart failure	[function in chronic heart failure]	0.0	5	1	1	1
8265	361	cardiac mena overexpression TTA comparable	[cardiac Mena overexpression TTA comparable]	0.0	5	1	1	1
8266	361	infarction-related right heart failure	[infarction-related right heart failure]	0.0	4	1	1	1
8267	361	reoperation	[reoperation]	0.0	1	1	1	1
8268	361	phosphorylation capacity	[phosphorylation capacity]	0.0	2	2	2	1
8269	361	record of surface ecg	[records of surface ECGs]	0.0	4	1	1	1
8270	361	extrapolate short-term outcome	[extrapolating short-term outcomes]	0.0	3	1	1	1
8271	361	similar risk of long mortality	[similar risk of long-term mortality]	0.0	5	1	1	1
8272	361	receptor antagonist tolvaptan	[receptor antagonist tolvaptan]	0.0	3	1	1	1
8273	361	include risk of blood glucose level	[including risk of blood glucose levels]	0.0	6	1	1	1
8274	361	subject with heart	[subjects with hearts]	0.0	3	1	1	1
8275	361	relationship with adverse CV event AF	[relationship with adverse CV events AF]	0.0	6	1	1	1
8276	361	heart failure treatment	[Heart Failure Treatment]	0.0	3	1	1	1
8277	361	undergo assist device lvad implantation	[undergoing assist device LVAD implantation]	0.0	5	1	1	1
8278	361	platelet-activating factor	[platelet-activating factor]	0.0	2	1	1	1
8279	361	prognostic relevance of ventricular contractile reserve	[prognostic relevance of ventricular contractile reserve]	0.0	6	1	1	1
8280	361	achievement of metabolism quotient	[achievement of metabolism quotient]	0.0	4	1	1	1
8281	361	true change	[true change]	0.0	2	1	1	1
8282	361	standard rehabilitation care on functional capacity	[standard rehabilitation care on functional capacity]	0.0	6	1	1	1
8283	361	prospective assessment of body composition	[prospective assessment of body composition]	0.0	5	1	1	1
8284	361	automatic defibrillator implantation	[Automatic Defibrillator Implantation]	0.0	3	1	1	1
8285	361	significant reduction in mortality	[significant reduction in mortality]	0.0	4	1	1	1
8286	361	p-value 0.001	[P-value 0.001]	0.0	2	1	1	1
8287	361	chloride	[chloride]	0.0	1	1	1	1
8288	361	cpg	[CPG]	0.0	1	1	1	1
8289	361	heart lack Nucleolin	[hearts lacking Nucleolin]	0.0	3	1	1	1
8290	361	present with a responsible diagnosis	[presenting with a responsible diagnosis]	0.0	5	1	1	1
8291	361	esrd patient-year	[ESRD patient-years]	0.0	2	1	1	1
8292	361	include nuclear factor of T cell	[including nuclear factor of T cells]	0.0	6	1	1	1
8293	361	develop malignancy	[developing malignancies]	0.0	2	1	1	1
8294	361	natriuretic peptide level	[Natriuretic peptide levels]	0.0	3	1	1	1
8295	361	Hereditary abnormality	[Hereditary abnormalities]	0.0	2	1	1	1
8296	361	multiacquisition	[Multiacquisition]	0.0	1	1	1	1
8297	361	characteristic eg	[characteristics eg]	0.0	2	1	1	1
8298	361	trastuzumab-related CHF among patient	[trastuzumab-related CHF among patients]	0.0	4	1	1	1
8299	361	care program	[care program]	0.0	2	2	2	1
8300	361	brain natriuretic peptide level pg	[brain natriuretic peptide levels pg]	0.0	5	1	1	1
8301	361	moderate evidence	[Moderate evidence]	0.0	2	1	1	1
8302	361	catheterisation with echocardiographic guidance	[catheterisation with echocardiographic guidance]	0.0	4	1	1	1
8303	361	decongestion end point	[decongestion end point]	0.0	3	1	1	1
8304	361	alendronate- patient respectively	[alendronate- patients respectively]	0.0	3	1	1	1
8305	361	increase refill compliance p for trend	[increasing refill compliance P for trend]	0.0	6	1	1	1
8306	361	heartmate ii	[HeartMate II]	0.0	2	1	1	1
8307	361	change dose of β-blocker	[changing doses of β-blocker]	0.0	4	1	1	1
8308	361	Global strain of ventricle	[Global strain of ventricle]	0.0	4	1	1	1
8309	361	Function	[Function]	0.0	1	1	1	1
8310	361	undergo DNx	[undergoing DNx]	0.0	2	1	1	1
8311	361	improvement of cardiac performance	[improvement of cardiac performance]	0.0	4	1	1	1
8312	361	predominantly mild disease	[predominantly mild disease]	0.0	3	1	1	1
8313	361	cardiac death in athlete under 35	[cardiac death in athletes under 35]	0.0	6	1	1	1
8314	361	more than a decade	[more than a decade]	0.0	4	1	1	1
8315	361	temporary RV support	[temporary RV support]	0.0	3	1	1	1
8316	361	type of continuous-flow lvas HeartMate	[types of continuous-flow LVADs HeartMate]	0.0	5	1	1	1
8317	361	left ventricular biopsy n=9	[left ventricular biopsies n=9]	0.0	4	1	1	1
8318	361	1.61 time	[1.61 times]	0.0	2	1	1	1
8319	361	discharge among patient	[discharge among patients]	0.0	3	1	1	1
8320	361	multicenter placebo-controlled trial of patient	[Multicenter placebo-controlled trial of patients]	0.0	5	1	1	1
8321	361	cardiac sodium current	[cardiac sodium current]	0.0	3	1	1	1
8322	361	transplant survival	[transplant survival]	0.0	2	1	1	1
8323	361	334 patient 224 man	[334 patients 224 men]	0.0	4	1	1	1
8324	361	change in follow-up visit	[change in follow-up visits]	0.0	4	1	1	1
8325	361	rare with.estimate range	[rare with.estimates ranging]	0.0	3	1	1	1
8326	361	ventricular-pulmonary coupling pulmonary vascular resistance	[ventricular-pulmonary coupling pulmonary vascular resistance]	0.0	5	1	1	1
8327	361	practice-level variation in use of medication	[Practice-level variation in use of medications]	0.0	6	1	1	1
8328	361	603 patient	[603 patients]	0.0	2	1	1	1
8329	361	prognostic information for a clinical outcome	[prognostic information for an clinical outcome]	0.0	6	1	1	1
8330	361	Diagnostic role in coronary artery disease	[Diagnostic role in coronary artery disease]	0.0	6	1	1	1
8331	361	heart failure in mouse	[heart failure in mice]	0.0	4	1	1	1
8332	361	ed visit year	[ED visits years]	0.0	3	1	1	1
8333	361	baseline serum	[baseline serum]	0.0	2	1	1	1
8334	361	4 wk effect	[4 wk effects]	0.0	3	1	1	1
8335	361	Latin America	[Latin America]	0.0	2	2	2	1
8336	361	patient with chronic disease copd	[patients with chronic disease COPD]	0.0	5	1	1	1
8337	361	hypertrophy a predictor of subsequent HF	[hypertrophy a predictor of subsequent HF]	0.0	6	1	1	1
8338	361	walk test of foot	[walk test of feet]	0.0	4	1	1	1
8339	361	clinical practice with this population	[clinical practice with these populations]	0.0	5	1	1	1
8340	361	element	[elements]	0.0	1	1	1	1
8341	361	web-system	[Web-system]	0.0	1	1	1	1
8342	361	end point of esrd	[end point of ESRD]	0.0	4	1	1	1
8343	361	reversible myocardial ischemia	[reversible myocardial ischemia]	0.0	3	1	1	1
8344	361	valve area	[valve area]	0.0	2	1	1	1
8345	361	tool for analysis a program	[Tools for Analysis A program]	0.0	5	1	1	1
8346	361	impact of ventricular assist device	[impact of ventricular assist device]	0.0	5	1	1	1
8347	361	simultaneous activation	[simultaneous activation]	0.0	2	1	1	1
8348	361	stable body weight	[stable body weight]	0.0	3	1	1	1
8349	361	creatine	[creatine]	0.0	1	2	2	1
8350	361	general model	[general models]	0.0	2	1	1	1
8351	361	clinical condition	[clinical conditions]	0.0	2	1	1	1
8352	361	all-cause hospitalization within the month	[all-cause hospitalization within the months]	0.0	5	1	1	1
8353	361	mean of m	[mean of m]	0.0	3	1	1	1
8354	361	fast subclass of disease	[fastest subclass of diseases]	0.0	4	1	1	1
8355	361	zsf1 with diet	[ZSF1 with diet]	0.0	3	1	1	1
8356	361	walk distance	[walk distance]	0.0	2	1	1	1
8357	361	frailty a indicator	[Frailty an indicator]	0.0	3	1	1	1
8358	361	hfpef patient aged year	[HFpEF patients aged years]	0.0	4	1	1	1
8359	361	Cardiomyopathy questionnaire	[Cardiomyopathy Questionnaire]	0.0	2	1	1	1
8360	361	2538 eligible patient	[2,538 eligible patients]	0.0	3	1	1	1
8361	361	use trichrome histologic analysis	[using trichrome histologic analysis]	0.0	4	1	1	1
8362	361	prevalence range	[prevalence ranging]	0.0	2	1	1	1
8363	361	PASP relationship	[PASP relationship]	0.0	2	1	1	1
8364	361	definition of the component	[definitions of the components]	0.0	4	1	1	1
8365	361	cardiac myocyte-specific mena overexpression	[cardiac myocyte-specific Mena overexpression]	0.0	4	1	1	1
8366	361	measure explain variation	[measures explaining variation]	0.0	3	1	1	1
8367	361	writer protein histone acetyltransferase	[writer proteins histone acetyltransferases]	0.0	4	1	1	1
8368	361	incident CVD	[incident CVD]	0.0	2	1	1	1
8369	361	transseptal catheterisation with guidance	[transseptal catheterisation with guidance]	0.0	4	1	1	1
8370	361	development among crt-d recipient	[development among CRT-D recipients]	0.0	4	1	1	1
8371	361	Student t	[Student t]	0.0	2	1	1	1
8372	361	group ii millileter per m	[group II mL per m]	0.0	5	1	1	1
8373	361	fat mass index	[fat mass index]	0.0	3	1	1	1
8374	361	several outcome study short-form quality	[several Outcomes Study Short-Form quality]	0.0	5	1	1	1
8375	361	vary regional strain contribution	[varying regional strain contributions]	0.0	4	1	1	1
8376	361	6-month event rate	[6-month event rates]	0.0	3	2	2	1
8377	361	CHF patient present	[CHF patients presenting]	0.0	3	1	1	1
8378	361	embryonic kidney cell	[embryonic kidney cells]	0.0	3	1	1	1
8379	361	frailty in heart failure	[frailty in heart failure]	0.0	4	1	1	1
8380	361	limit of agreement difference	[limits of agreement difference]	0.0	4	1	1	1
8381	361	connection between center	[connection between centers]	0.0	3	1	1	1
8382	361	treatment iron deficiency	[treatment iron deficiency]	0.0	3	1	1	1
8383	361	LV ejection fraction velocity	[LV ejection fraction velocity]	0.0	4	1	1	1
8384	361	with value	[with values]	0.0	2	1	1	1
8385	361	beta-adrenergic receptor β-ar	[beta-adrenergic receptor β-AR]	0.0	3	1	1	1
8386	361	ratio of blood flow velocity	[ratio of blood flow velocity]	0.0	5	1	1	1
8387	361	chronic arterial hypertension	[chronic arterial hypertension]	0.0	3	1	1	1
8388	361	common cause in young athlete	[common cause in young athletes]	0.0	5	1	1	1
8389	361	good diagnostic performance in patient	[good diagnostic performance in patients]	0.0	5	1	1	1
8390	361	demonstrate development	[demonstrating development]	0.0	2	1	1	1
8391	361	coronary artery ligation	[coronary artery ligation]	0.0	3	1	1	1
8392	361	use of device in heart failure	[use of devices in heart failure]	0.0	6	1	1	1
8393	361	intermediate outcome event	[intermediate outcomes events]	0.0	3	1	1	1
8394	361	restore mitochondrial phosphorylation capacity	[restoring mitochondrial phosphorylation capacity]	0.0	4	1	1	1
8395	361	elastance ea elastance ees	[elastance Ea elastance Ees]	0.0	4	1	1	1
8396	361	outcome versus millisecond	[outcome vs milliseconds]	0.0	3	1	1	1
8397	361	outcome hospitalization	[outcome hospitalization]	0.0	2	1	1	1
8398	361	cardiopulmonary resuscitation	[cardiopulmonary resuscitation]	0.0	2	1	1	1
8399	361	hazard of event for psoriasis	[hazards of events for psoriasis]	0.0	5	1	1	1
8400	361	long cost	[long-term costs]	0.0	2	1	1	1
8401	361	diagnostic test for HFpEF	[diagnostic test for HFpEF]	0.0	4	1	1	1
8402	361	LV volume LV	[LV volume LV]	0.0	3	1	1	1
8403	361	New York heart	[New York Heart]	0.0	3	1	1	1
8404	361	Medicare hospital	[Medicare hospital]	0.0	2	1	1	1
8405	361	Outcome of Exercise Training study	[Outcomes of Exercise Training study]	0.0	5	1	1	1
8406	361	final bb dose versus mg dose	[final BB dose versus mg dose]	0.0	6	1	1	1
8407	361	health service provision related	[health service provision related]	0.0	4	1	1	1
8408	361	optimal nt-probnp cutoff point	[optimal NT-proBNP cutoff point]	0.0	4	1	1	1
8409	361	internist p	[internists P]	0.0	2	1	1	1
8410	361	improvement show improvement	[improvements showing improvement]	0.0	3	1	1	1
8411	361	dual inhibition neprilysin block renin-angiotensin-aldosteron axis	[Dual inhibition neprilysin blocks renin-angiotensin-aldosteron axis]	0.0	6	1	1	1
8412	361	gait therapy with the Lokomat® system	[gait therapy with the Lokomat® system]	0.0	6	1	1	1
8413	361	impaired angiogenesis	[Impaired angiogenesis]	0.0	2	1	1	1
8414	361	non-biological disease nbdmard	[non-biological disease nbDMARD]	0.0	3	1	1	1
8415	361	difference between group patient	[difference between groups patients]	0.0	4	1	1	1
8416	361	subclinical atherosclerosis use model	[subclinical atherosclerosis using models]	0.0	4	1	1	1
8417	361	subset of gene	[subset of genes]	0.0	3	1	1	1
8418	361	wall infarction	[wall infarction]	0.0	2	1	1	1
8419	361	aerobic training intervention	[aerobic training intervention]	0.0	3	1	1	1
8420	361	serum sodium level	[serum sodium levels]	0.0	3	1	1	1
8421	361	especially in patient	[especially in patients]	0.0	3	1	1	1
8422	361	with.estimate range from 1	[with.estimates ranging from 1]	0.0	4	1	1	1
8423	361	thrombotic obstruction	[thrombotic obstruction]	0.0	2	1	1	1
8424	361	diagnostic biomarker	[diagnostic biomarkers]	0.0	2	1	1	1
8425	361	strict standard	[strict standards]	0.0	2	1	1	1
8426	361	avoid the central region	[avoiding the central region]	0.0	4	1	1	1
8427	361	further validation	[further validation]	0.0	2	1	1	1
8428	361	dapc protein complex	[DAPC protein complex]	0.0	3	1	1	1
8429	361	fitness CRF	[fitness CRF]	0.0	2	1	1	1
8430	361	influence on the financial burden	[influence on the financial burden]	0.0	5	1	1	1
8431	361	(31)p resonance spectroscopy	[(31)P resonance spectroscopy]	0.0	3	1	1	1
8432	361	range 18.6	[range 18.6]	0.0	2	1	1	1
8433	361	295 veteran	[295 veterans]	0.0	2	1	1	1
8434	361	wk per ounce	[wk per os]	0.0	3	1	1	1
8435	361	magnetic resonance t1 mapping	[magnetic resonance T1 mapping]	0.0	4	1	1	1
8436	361	vary atrioventricular delay	[varying atrioventricular delay]	0.0	3	1	1	1
8437	361	savings	[savings]	0.0	1	1	1	1
8438	361	risk develop malignancy	[risk developing malignancies]	0.0	3	1	1	1
8439	361	catheter ablation for fibrillation	[catheter ablation for fibrillation]	0.0	4	1	1	1
8440	361	track VA patient for month	[tracking VA patients for months]	0.0	5	1	1	1
8441	361	inhibition of growth factor VEGF	[inhibition of growth factor VEGF]	0.0	5	1	1	1
8442	361	petco2	[PETCO2]	0.0	1	1	1	1
8443	361	role of ERK1 2 scaffold	[role of ERK1 2 scaffolds]	0.0	5	1	1	1
8444	361	improvement of nt-probnp inflammatory biomarker	[improvement of NT-ProBNP inflammatory biomarkers]	0.0	5	1	1	1
8445	361	production of ec	[production of EC]	0.0	3	1	1	1
8446	361	measure frailty	[Measuring frailty]	0.0	2	1	1	1
8447	361	global ventricular longitudinal strain GLS	[global ventricular longitudinal strain GLS]	0.0	5	1	1	1
8448	361	safe pump-exchange technique	[safe pump-exchange technique]	0.0	3	1	1	1
8449	361	heart sound	[heart sound]	0.0	2	1	1	1
8450	361	6 month of follow-up	[6 months of follow-up]	0.0	4	1	1	1
8451	361	anti-neoplastic agent in the treatment	[anti-neoplastic agent in the treatment]	0.0	5	1	1	1
8452	361	consecutive ambulatory HF patient	[consecutive ambulatory HF patients]	0.0	4	1	1	1
8453	361	primary diagnosis	[primary diagnosis]	0.0	2	1	1	1
8454	361	Particular topic in heart failure concern	[Particular topics in heart failure concern]	0.0	6	1	1	1
8455	361	possible measure	[possible measure]	0.0	2	1	1	1
8456	361	high morbidity	[high morbidity]	0.0	2	1	1	1
8457	361	guidance under general anaesthesia	[guidance under general anaesthesia]	0.0	4	1	1	1
8458	361	similar risk	[similar risk]	0.0	2	1	1	1
8459	361	HF diagnosis	[HF diagnosis]	0.0	2	1	1	1
8460	361	result in the social support score	[resulting in the social support score]	0.0	6	1	1	1
8461	361	physician continuity death	[physician continuity death]	0.0	3	1	1	1
8462	361	describe a uniform nomenclature	[describing a uniform nomenclature]	0.0	4	1	1	1
8463	361	important tool	[important tool]	0.0	2	1	1	1
8464	361	serious event	[serious events]	0.0	2	1	1	1
8465	361	cardiac index 0.7 L	[cardiac index 0.7 L]	0.0	4	1	1	1
8466	361	14 study 2900 hm ii	[14 studies 2900 HM II]	0.0	5	1	1	1
8467	361	millisecond millisecond	[milliseconds milliseconds]	0.0	2	1	1	1
8468	361	systematic review of the effect	[systematic review of the effects]	0.0	5	1	1	1
8469	361	undergo resynchronization therapy with a defibrillator	[undergoing resynchronization therapy with a defibrillator]	0.0	6	1	1	1
8470	361	twenty-seven adult Fontan SAF patient	[Twenty-seven adult Fontan SAF patients]	0.0	5	1	1	1
8471	361	fundamental mechanism during insulin resistance	[fundamental mechanism during insulin resistance]	0.0	5	1	1	1
8472	361	transfusion protocol	[transfusion protocols]	0.0	2	1	1	1
8473	361	Study of predictor	[Studies of predictors]	0.0	3	1	1	1
8474	361	systolic ventricular ejection fraction HF	[systolic ventricular ejection fraction HF]	0.0	5	1	1	1
8475	361	regard the need in combination	[regarding the need in combination]	0.0	5	1	1	1
8476	361	performer	[performers]	0.0	1	2	2	1
8477	361	time 4 year	[time 4 years]	0.0	3	1	1	1
8478	361	survival of patient with preoperative hypoalbuminemia	[survival of patients with preoperative hypoalbuminemia]	0.0	6	1	1	1
8479	361	bnp in woman versus man	[BNP in women vs men]	0.0	5	1	1	1
8480	361	bnp level in patient	[BNP levels in patients]	0.0	4	1	1	1
8481	361	heterogeneity	[heterogeneity]	0.0	1	1	1	1
8482	361	chronic stable medical therapy GDMT	[chronic stable medical therapy GDMT]	0.0	5	1	1	1
8483	361	health outcome in male patient	[health outcomes in male patients]	0.0	5	1	1	1
8484	361	effect of type	[effects of types]	0.0	3	1	1	1
8485	361	additional benefit over conventional parameter	[additional benefit over conventional parameters]	0.0	5	1	1	1
8486	361	rehabilitation care	[rehabilitation care]	0.0	2	1	1	1
8487	361	hypertrophy eh	[hypertrophy EH]	0.0	2	1	1	1
8488	361	most common form	[most common form]	0.0	3	1	1	1
8489	361	great risk	[greater risk]	0.0	2	2	2	1
8490	361	several change include hypertrophy	[several changes including hypertrophy]	0.0	4	1	1	1
8491	361	mva of cm2	[MVA of cm2]	0.0	3	3	3	1
8492	361	body mass index ≥35 kg	[body mass index ≥35 kg]	0.0	5	1	1	1
8493	361	microrna in heart failure target	[MicroRNAs in heart failure targets]	0.0	5	1	1	1
8494	361	pilot project	[pilot project]	0.0	2	1	1	1
8495	361	east early treatment of fibrillation	[EAST Early treatment of fibrillation]	0.0	5	1	1	1
8496	361	study selection english-language trial in adult	[Study Selection English-language trials in adults]	0.0	6	1	1	1
8497	361	protein complex	[protein complex]	0.0	2	1	1	1
8498	361	afterload burden	[afterload burden]	0.0	2	1	1	1
8499	361	diagnostic role of BNP	[diagnostic roles of BNP]	0.0	4	1	1	1
8500	361	156 consecutive HF patient	[156 consecutive HF patients]	0.0	4	1	1	1
8501	361	replicate resource use from clinical trial	[replicating resource use from clinical trials]	0.0	6	1	1	1
8502	361	voluntary testimony	[voluntary testimonies]	0.0	2	1	1	1
8503	361	economic evaluation hm	[economic evaluations HM]	0.0	3	1	1	1
8504	361	Subgroup analysis of patient	[Subgroup analysis of patients]	0.0	4	1	1	1
8505	361	compete risk	[competing risk]	0.0	2	1	1	1
8506	361	first-in-man experience	[first-in-man experience]	0.0	2	1	1	1
8507	361	patient with artery disease cad	[patients with artery disease CAD]	0.0	5	1	1	1
8508	361	nuclear factor-κB	[nuclear factor-κB]	0.0	2	1	1	1
8509	361	vascular growth	[vascular growth]	0.0	2	1	1	1
8510	361	ARNI inhibitor neprilysin inhibitor	[ARNI inhibitors neprilysin inhibitors]	0.0	4	1	1	1
8511	361	hypertrophy ch	[hypertrophy CH]	0.0	2	1	1	1
8512	361	even on therapy include anticoagulation	[Even on therapy including anticoagulation]	0.0	5	1	1	1
8513	361	control heart rate	[controlling heart rate]	0.0	3	1	1	1
8514	361	achievement of metabolism peak quotient	[achievement of metabolism peak quotient]	0.0	5	1	1	1
8515	361	heart failure datum in Latin America	[Heart failure data in Latin America]	0.0	6	1	1	1
8516	361	distinct derangement albeit with ability	[distinct derangement albeit with ability]	0.0	5	1	1	1
8517	361	highly effective anti-neoplastic agent	[highly effective anti-neoplastic agent]	0.0	4	1	1	1
8518	361	trastuzumab-related cardiotoxicity among old patient	[Trastuzumab-related cardiotoxicity among older patients]	0.0	5	1	1	1
8519	361	heart pathology	[heart pathology]	0.0	2	1	1	1
8520	361	HeartMate ii device	[HeartMate II devices]	0.0	3	1	1	1
8521	361	dyssynchronous heart	[dyssynchronous heart]	0.0	2	1	1	1
8522	361	renal Lesion CORAL	[Renal Lesions CORAL]	0.0	3	1	1	1
8523	361	composite primary outcome	[composite primary outcome]	0.0	3	1	1	1
8524	361	hospital readmission	[hospital readmission]	0.0	2	1	1	1
8525	361	exercise capacity in patient with hfpef	[exercise capacity in patients with HFPEF]	0.0	6	1	1	1
8526	361	such as exercise programme	[such as exercise programmes]	0.0	4	1	1	1
8527	361	type regulatory riiα subunit expression	[type regulatory RIIα subunit expression]	0.0	5	1	1	1
8528	361	CV event in univariate model p	[CV events in univariate models p]	0.0	6	1	1	1
8529	361	HF in patient	[HF in patients]	0.0	3	1	1	1
8530	361	measure of quality for HF	[measures of quality for HF]	0.0	5	1	1	1
8531	361	valve procedure 1 valve replacement	[valve procedures 1 valve replacement]	0.0	5	1	1	1
8532	361	hospital facility	[hospital facilities]	0.0	2	1	1	1
8533	361	training per week	[trainings per week]	0.0	3	1	1	1
8534	361	dilatation improvement by ET	[dilatation improvement by ET]	0.0	4	1	1	1
8535	361	incident HF in participant aged	[incident HF in participants aged]	0.0	5	1	1	1
8536	361	third	[thirds]	0.0	1	1	1	1
8537	361	diagnosis of dysfunction	[diagnosis of dysfunction]	0.0	3	1	1	1
8538	361	first AMI	[first AMI]	0.0	2	1	1	1
8539	361	obese zsf1 with high-fat diet	[obese ZSF1 with high-fat diet]	0.0	5	1	1	1
8540	361	evaluation use simulation model	[evaluations using simulation models]	0.0	4	1	1	1
8541	361	four group of rat	[Four groups of rats]	0.0	4	1	1	1
8542	361	2.1 point	[2.1 points]	0.0	2	1	1	1
8543	361	interaction by EF	[interaction by EF]	0.0	3	1	1	1
8544	361	old patient with heart failure	[Older Patients With Heart Failure]	0.0	5	1	1	1
8545	361	antitumor	[antitumor]	0.0	1	1	1	1
8546	361	sarcoplasmic reticular can	[sarcoplasmic reticular Ca]	0.0	3	1	1	1
8547	361	relevance of contractile reserve in patient	[relevance of contractile reserve in patients]	0.0	6	1	1	1
8548	361	year of oht	[year of OHT]	0.0	3	1	1	1
8549	361	pro-brain natriuretic peptide	[pro-brain natriuretic peptide]	0.0	3	4	4	1
8550	361	2.1 kg	[2.1 kg]	0.0	2	1	1	1
8551	361	right plane excursion from the end	[right plane excursion from the end]	0.0	6	1	1	1
8552	361	dysfunction with conduction abnormality	[dysfunction with conduction abnormalities]	0.0	4	1	1	1
8553	361	sampling frame	[sampling frame]	0.0	2	1	1	1
8554	361	modest benefit for patient in study	[modest benefit for patients in studies]	0.0	6	1	1	1
8555	361	ventricular plane excursion tapse	[ventricular plane excursion TAPSE]	0.0	4	1	1	1
8556	361	multicenter double-blind placebo-controlled trial	[Multicenter double-blind placebo-controlled trial]	0.0	4	1	1	1
8557	361	gtpase	[GTPase]	0.0	1	1	1	1
8558	361	ingenuity pathway	[ingenuity pathway]	0.0	2	1	1	1
8559	361	addition indicate care of patient	[addition indicating care of patients]	0.0	5	1	1	1
8560	361	Biventricular	[Biventricular]	0.0	1	1	1	1
8561	361	promote fill	[promoting filling]	0.0	2	1	1	1
8562	361	HF year	[HF years]	0.0	2	1	1	1
8563	361	stable arterial hypertension medication	[stable arterial hypertension medication]	0.0	4	1	1	1
8564	361	culprit extend EMD	[culprit extending EMD]	0.0	3	1	1	1
8565	361	outcome versus 257 millisecond	[outcome vs 257 milliseconds]	0.0	4	1	1	1
8566	361	transplant program	[transplant programs]	0.0	2	1	1	1
8567	361	≤4.5 cm	[≤4.5 cm]	0.0	2	1	1	1
8568	361	rare with.estimate range in 50000	[rare with.estimates ranging in 50,000]	0.0	5	1	1	1
8569	361	223 patient	[223 patients]	0.0	2	1	1	1
8570	361	application of readmission metric	[applications of readmission metrics]	0.0	4	1	1	1
8571	361	diet n=11	[diet n=11]	0.0	2	1	1	1
8572	361	age of majority	[age of majority]	0.0	3	1	1	1
8573	361	downward regression line shift	[downward regression line shift]	0.0	4	1	1	1
8574	361	global left ventricular longitudinal strain GLS	[global left ventricular longitudinal strain GLS]	0.0	6	1	1	1
8575	361	25.6 kg	[25.6 kg]	0.0	2	1	1	1
8576	361	nucleotide content	[nucleotides contents]	0.0	2	1	1	1
8577	361	consent HF patient left ejection fraction	[consenting HF patients left ejection fraction]	0.0	6	1	1	1
8578	361	self-management counseling	[self-management counseling]	0.0	2	1	1	1
8579	361	mean duration of support	[mean duration of support]	0.0	4	1	1	1
8580	361	start after 10 week	[start After 10 weeks]	0.0	4	1	1	1
8581	361	reduce mortality	[reducing mortality]	0.0	2	1	1	1
8582	361	individual contribution of remodeling aspect	[individual contributions of remodeling aspects]	0.0	5	1	1	1
8583	361	use in patient with non-lbbb	[use in patients with non-LBBB]	0.0	5	1	1	1
8584	361	exercise testing guide exercise rehabilitation	[exercise testing guide exercise rehabilitation]	0.0	5	1	1	1
8585	361	child with heart failure	[children with heart failure]	0.0	4	2	2	1
8586	361	man mean 65±12 year	[men mean 65±12 years]	0.0	4	1	1	1
8587	361	open-label crossover study	[open-label crossover study]	0.0	3	1	1	1
8588	361	130 msec	[130 msec]	0.0	2	2	2	1
8589	361	die	[dying]	0.0	1	1	1	1
8590	361	treatment for acute myocardial infarction	[treatment for acute myocardial infarction]	0.0	5	1	1	1
8591	361	role scaffold	[role scaffolds]	0.0	2	1	1	1
8592	361	new review	[new review]	0.0	2	1	1	1
8593	361	twenty week	[Twenty weeks]	0.0	2	1	1	1
8594	361	diagnosis of clinical prognostic dysfunction	[diagnosis of clinical prognostic dysfunction]	0.0	5	1	1	1
8595	361	drug for heart failure	[drugs for heart failure]	0.0	4	1	1	1
8596	361	≤75 year	[≤75 years]	0.0	2	1	1	1
8597	361	include heart failure	[including heart failure]	0.0	3	1	1	1
8598	361	Magnet(®)	[Magnet(®)]	0.0	1	1	1	1
8599	361	outcome hospitalization for HF	[outcome hospitalization for HF]	0.0	4	1	1	1
8600	361	peptide ss31	[peptide SS31]	0.0	2	1	1	1
8601	361	with icc value	[with ICC values]	0.0	3	1	1	1
8602	361	cardiac rehabilitation care	[cardiac rehabilitation care]	0.0	3	1	1	1
8603	361	change in subproteome	[changes in subproteomes]	0.0	3	1	1	1
8604	361	irs1 irs2 gene double-knockout mouse	[IRS1 IRS2 gene double-knockout mice]	0.0	5	1	1	1
8605	361	absolute minimal change mdc value	[absolute minimal change MDC values]	0.0	5	1	1	1
8606	361	Postoperative survival of patient gram	[Postoperative survival of patients g]	0.0	5	1	1	1
8607	361	obese ZSF1 group	[obese ZSF1 groups]	0.0	3	1	1	1
8608	361	rate of hypertension	[rates of hypertension]	0.0	3	1	1	1
8609	361	Prognostic value of anaerobic threshold	[Prognostic value of anaerobic threshold]	0.0	5	1	1	1
8610	361	score of 44·3	[score of 44·3]	0.0	3	1	1	1
8611	361	2005 2008 composite	[2005 2008 composite]	0.0	3	1	1	1
8612	361	end-stage disease in outpatient	[end-stage disease in outpatients]	0.0	4	1	1	1
8613	361	possible suboptimal care	[possible suboptimal care]	0.0	3	1	1	1
8614	361	MRI scanner	[MRI scanner]	0.0	2	1	1	1
8615	361	epidemiology of infarction	[epidemiology of infarction]	0.0	3	1	1	1
8616	361	research investigation	[research investigations]	0.0	2	1	1	1
8617	361	data in patient	[Data in patients]	0.0	3	1	1	1
8618	361	interquartile range 22.8 with copd	[interquartile range 22.8 with COPD]	0.0	5	1	1	1
8619	361	n=44 925 ed visit age year	[n=44 925 ED visits age years]	0.0	6	1	1	1
8620	361	ICD patient	[ICD patients]	0.0	2	1	1	1
8621	361	quality measure for inpatient condition	[quality measures for inpatient conditions]	0.0	5	1	1	1
8622	361	odd ratio even after adjustment	[odds ratio even after adjustment]	0.0	5	1	1	1
8623	361	CKD	[CKD]	0.0	1	1	1	1
8624	361	myocardial change	[myocardial changes]	0.0	2	1	1	1
8625	361	leaflet opening	[leaflet opening]	0.0	2	2	2	1
8626	361	evidence of ventricular dyssynchrony	[evidence of ventricular dyssynchrony]	0.0	4	1	1	1
8627	361	mouse myocyte	[mouse myocytes]	0.0	2	1	1	1
8628	361	factor insight a Trial investigate outcome	[Factors Insights A Trial Investigating Outcomes]	0.0	6	1	1	1
8629	361	use regression analysis	[Using regression analysis]	0.0	3	1	1	1
8630	361	blood pressure median	[blood pressure median]	0.0	3	1	1	1
8631	361	peptide b-type natriuretic peptide	[peptide B-type natriuretic peptide]	0.0	4	1	1	1
8632	361	few symptom Hospital anxiety	[fewer symptoms Hospital Anxiety]	0.0	4	1	1	1
8633	361	cardiovascular risk factor in fit	[cardiovascular risk factors in fit]	0.0	5	1	1	1
8634	361	National trend for four common condition	[National trends for four common conditions]	0.0	6	1	1	1
8635	361	stable therapy	[stable therapy]	0.0	2	1	1	1
8636	361	construct	[construct]	0.0	1	1	1	1
8637	361	independent risk factor	[independent risk factor]	0.0	3	1	1	1
8638	361	over 20 clinical variable	[over 20 clinical variables]	0.0	4	1	1	1
8639	361	sickle cell disease	[sickle cell disease]	0.0	3	1	1	1
8640	361	secondary outcome from any cause	[secondary outcome from any cause]	0.0	5	1	1	1
8641	361	neutral result	[neutral results]	0.0	2	1	1	1
8642	361	left end-diastolic pressure	[left end-diastolic pressure]	0.0	3	1	1	1
8643	361	human pluripotent stem cardiomyocyte	[human pluripotent stem cardiomyocytes]	0.0	4	1	1	1
8644	361	balance	[balance]	0.0	1	4	4	1
8645	361	patient from the heart Function Clinic	[Patients from the Heart Function Clinic]	0.0	6	1	1	1
8646	361	7-day follow-up	[7-day follow-up]	0.0	2	1	1	1
8647	361	absolute detectable change value	[absolute detectable change values]	0.0	4	1	1	1
8648	361	rare with.estimate	[rare with.estimates]	0.0	2	1	1	1
8649	361	659 heart failure patient	[659 heart failure patients]	0.0	4	1	1	1
8650	361	relationship between RV function	[relationships between RV function]	0.0	4	1	1	1
8651	361	change between performance the percent	[change between performance the percent]	0.0	5	1	1	1
8652	361	cad involve the proximal descend artery	[CAD involving the proximal descending artery]	0.0	6	1	1	1
8653	361	such as myocardial infarction with expansion	[such as myocardial infarction with expansion]	0.0	6	1	1	1
8654	361	point vs. point	[points vs. points]	0.0	3	1	1	1
8655	361	institute mechanical support	[instituting mechanical support]	0.0	3	1	1	1
8656	361	CMS	[CMS]	0.0	1	1	1	1
8657	361	end-stage congestive heart failure CHF	[end-stage congestive heart failure CHF]	0.0	5	1	1	1
8658	361	CLCNKA polymorphism	[CLCNKA polymorphism]	0.0	2	1	1	1
8659	361	cause of morbidity in childhood	[cause of morbidity in childhood]	0.0	5	1	1	1
8660	361	postoperative month	[postoperative months]	0.0	2	1	1	1
8661	361	dnx	[DNx]	0.0	1	1	1	1
8662	361	Cardiovascular Society guideline	[Cardiovascular Society guidelines]	0.0	3	1	1	1
8663	361	survive a acute infarction AMI	[surviving an acute infarction AMI]	0.0	5	1	1	1
8664	361	chronotropic response	[chronotropic response]	0.0	2	1	1	1
8665	361	16 patient HDL	[16 patients HDL]	0.0	3	1	1	1
8666	361	presentation Cardiovascular Society guideline	[Presentation Cardiovascular Society guidelines]	0.0	4	1	1	1
8667	361	myocardial pde2	[myocardial PDE2]	0.0	2	1	1	1
8668	361	brain peptide BNP level 100 pg	[brain peptide BNP levels 100 pg]	0.0	6	1	1	1
8669	361	energy x-ray	[energy X-ray]	0.0	2	1	1	1
8670	361	risk of event in patient	[risk of events in patients]	0.0	5	1	1	1
8671	361	post-TAC cardiac deterioration	[post-TAC cardiac deterioration]	0.0	3	1	1	1
8672	361	eighty-one percent of visit	[Eighty-one percent of visits]	0.0	4	1	1	1
8673	361	Secondary outcome measure	[Secondary outcome measures]	0.0	3	1	1	1
8674	361	irs2 double-knockout l-dko	[IRS2 double-knockout L-DKO]	0.0	3	1	1	1
8675	361	hospital from January through September	[hospitals from January through September]	0.0	5	1	1	1
8676	361	fundamental definition of the component	[fundamental definitions of the components]	0.0	5	1	1	1
8677	361	professional from discipline	[professionals from disciplines]	0.0	3	1	1	1
8678	361	association between serial measurement	[association between serial measurements]	0.0	4	1	1	1
8679	361	Yorkshire	[Yorkshire]	0.0	1	1	1	1
8680	361	artery tonometry variable	[artery tonometry variables]	0.0	3	1	1	1
8681	361	clinical exercise test investigation	[clinical exercise test investigations]	0.0	4	1	1	1
8682	361	insulin receptor substrate	[insulin receptor substrates]	0.0	3	1	1	1
8683	361	reperfusion	[reperfusion]	0.0	1	1	1	1
8684	361	period of pulseless fibrillation	[period of pulseless fibrillation]	0.0	4	1	1	1
8685	361	TUNEL method	[TUNEL method]	0.0	2	1	1	1
8686	361	arrhythmia device	[arrhythmia devices]	0.0	2	1	1	1
8687	361	model use experimental procedure	[model using experimental procedures]	0.0	4	1	1	1
8688	361	proximal artery	[proximal artery]	0.0	2	1	1	1
8689	361	atp hr	[ATP HR]	0.0	2	1	1	1
8690	361	study 2900 hm ii	[studies 2900 HM II]	0.0	4	1	1	1
8691	361	odd ratio for event p=0.18	[odds ratios for events P=0.18]	0.0	5	1	1	1
8692	361	low mortality in woman	[lower mortality in women]	0.0	4	1	1	1
8693	361	management of diuretic volume overload	[management of diuretic volume overload]	0.0	5	1	1	1
8694	361	year hr	[years HR]	0.0	2	1	1	1
8695	361	CPG	[CPG]	0.0	1	1	1	1
8696	361	report demonstrate development of functional ms	[reports demonstrating development of functional MS]	0.0	6	1	1	1
8697	361	myofiber dynamic	[myofiber dynamics]	0.0	2	1	1	1
8698	361	measurement value of second	[measurement value of seconds]	0.0	4	1	1	1
8699	361	baseline hgb	[baseline Hgb]	0.0	2	1	1	1
8700	361	nontraumatic death	[nontraumatic death]	0.0	2	1	1	1
8701	361	event rate at event	[event rate at events]	0.0	4	1	1	1
8702	361	determinant of quality of life	[determinant of quality of life]	0.0	5	1	1	1
8703	361	8000 individual	[8000 individuals]	0.0	2	1	1	1
8704	361	baseline serum creatinine	[baseline serum creatinine]	0.0	3	1	1	1
8705	361	bridging therapy	[bridging therapy]	0.0	2	1	1	1
8706	361	beta-adrenergic receptor signal	[beta-adrenergic receptor signaling]	0.0	3	1	1	1
8707	361	particularly between a group	[particularly between a group]	0.0	4	1	1	1
8708	361	ventricular LV ejection fraction LVEF	[ventricular LV ejection fraction LVEF]	0.0	5	1	1	1
8709	361	status hospitalization	[status hospitalizations]	0.0	2	1	1	1
8710	361	strip	[strip]	0.0	1	1	1	1
8711	361	factor for clinical deterioration	[factor for clinical deterioration]	0.0	4	1	1	1
8712	361	include factor of T cell	[including factor of T cells]	0.0	5	1	1	1
8713	361	such as patient compliance	[such as patient compliance]	0.0	4	1	1	1
8714	361	protective effect of mitochondrial-targeted antioxidant	[protective effects of mitochondrial-targeted antioxidant]	0.0	5	1	1	1
8715	361	incubation of EC with HDL	[Incubation of EC with HDL]	0.0	5	1	1	1
8716	361	underlying trial	[underlying trials]	0.0	2	1	1	1
8717	361	hospitalization for heart failure	[hospitalization for heart failure]	0.0	4	1	1	1
8718	361	high-strength evidence	[high-strength evidence]	0.0	2	1	1	1
8719	361	heart Failure Trial RAFT	[Heart Failure Trial RAFT]	0.0	4	1	1	1
8720	361	protective role of s1pr1 gene therapy	[protective role of S1PR1 gene therapy]	0.0	6	1	1	1
8721	361	patient with chronic hf-ref	[patients with chronic HF-REF]	0.0	4	1	1	1
8722	361	use inhibitor c-kit	[using inhibitors c-Kit]	0.0	3	1	1	1
8723	361	other potential predictor biomarker	[other potential predictors biomarkers]	0.0	4	1	1	1
8724	361	analysis with egfr	[analysis with eGFR]	0.0	3	1	1	1
8725	361	thus provide information for a outcome	[thus providing information for an outcome]	0.0	6	1	1	1
8726	361	composite HF index	[composite HF index]	0.0	3	1	1	1
8727	361	valve procedure valve replacement	[valve procedures valve replacement]	0.0	4	1	1	1
8728	361	sv p	[SV p]	0.0	2	1	1	1
8729	361	C 'D HF	[C 'D HF]	0.0	3	1	1	1
8730	361	ventricular-pulmonary coupling vascular resistance p	[ventricular-pulmonary coupling vascular resistance P]	0.0	5	1	1	1
8731	361	low-risk group	[low-risk group]	0.0	2	1	1	1
8732	361	study with follow-up	[studies with follow-up]	0.0	3	1	1	1
8733	361	mechanism of dysfunction	[mechanism of dysfunction]	0.0	3	1	1	1
8734	361	case of survival	[case of survival]	0.0	3	1	1	1
8735	361	use of pro-b-type peptide assay	[use of pro-B-type peptide assays]	0.0	5	1	1	1
8736	361	improvement at stage	[improvement at stages]	0.0	3	1	1	1
8737	361	inoperable chronic pulmonary hypertension	[inoperable chronic pulmonary hypertension]	0.0	4	1	1	1
8738	361	fibrillation AF	[fibrillation AF]	0.0	2	1	1	1
8739	361	extracellular matrix of left biopsy n=9	[Extracellular matrix of left biopsies n=9]	0.0	6	1	1	1
8740	361	nyha functional class iii HF	[NYHA functional class III HF]	0.0	5	1	1	1
8741	361	include cancer of the prostate	[including cancer of the prostate]	0.0	5	1	1	1
8742	361	dose-related gradient	[dose-related gradient]	0.0	2	1	1	1
8743	361	atherosclerosis use general model	[atherosclerosis using general models]	0.0	4	1	1	1
8744	361	practice guideline grading system	[practice guidelines grading system]	0.0	4	1	1	1
8745	361	hospitalization with no difference	[hospitalizations with no difference]	0.0	4	1	1	1
8746	361	east treatment	[EAST treatment]	0.0	2	1	1	1
8747	361	patient with a follow-up	[patients with a follow-up]	0.0	4	1	1	1
8748	361	hospital in the quintile	[hospital in the quintile]	0.0	4	1	1	1
8749	361	finding of cause	[findings of causes]	0.0	3	1	1	1
8750	361	feature similar	[features similar]	0.0	2	1	1	1
8751	361	mild patient hospitalization	[Mild Patients Hospitalization]	0.0	3	1	1	1
8752	361	effect on peak oxygen Consumption	[Effect on Peak Oxygen Consumption]	0.0	5	1	1	1
8753	361	target in disease management	[targets in disease management]	0.0	4	1	1	1
8754	361	interagency	[Interagency]	0.0	1	1	1	1
8755	361	transition from hypertrophy	[transition from hypertrophy]	0.0	3	1	1	1
8756	361	economic evaluation hm use simulation model	[economic evaluations HM using simulation models]	0.0	6	1	1	1
8757	361	dearth	[dearth]	0.0	1	1	1	1
8758	361	routine tool	[routine tool]	0.0	2	1	1	1
8759	361	eGFR group iii	[eGFR group III]	0.0	3	1	1	1
8760	361	qrs duration of benefit	[QRS duration of benefit]	0.0	4	1	1	1
8761	361	muscle function	[muscle function]	0.0	2	1	1	1
8762	361	monitoring strategy	[monitoring strategies]	0.0	2	1	1	1
8763	361	4.9 year for alendronate- patient	[4.9 years for alendronate- patients]	0.0	5	1	1	1
8764	361	cell nitric oxide no production	[cell nitric oxide NO production]	0.0	5	1	1	1
8765	361	meaning	[meaning]	0.0	1	1	1	1
8766	361	coupling pulmonary vascular resistance p	[coupling pulmonary vascular resistance P]	0.0	5	1	1	1
8767	361	cholesterol	[cholesterol]	0.0	1	1	1	1
8768	361	band	[band]	0.0	1	1	1	1
8769	361	3-year event rate HF hospitalization	[3-year event rates HF hospitalization]	0.0	5	1	1	1
8770	361	manage clinically significant bleed	[managing clinically significant bleeding]	0.0	4	1	1	1
8771	361	measurement of peptide at the point	[Measurement of peptides at the point]	0.0	6	1	1	1
8772	361	Comparison of Outcome in Patient	[Comparison Of Outcomes In Patients]	0.0	5	1	1	1
8773	361	year of follow-up	[years of follow-up]	0.0	3	1	1	1
8774	361	rat mechanism of cardioprotection	[rats mechanism of cardioprotection]	0.0	4	1	1	1
8775	361	cardiac index L	[cardiac index L]	0.0	3	1	1	1
8776	361	shortcoming	[shortcomings]	0.0	1	1	1	1
8777	361	self-management training of patient	[self-management training of patients]	0.0	4	1	1	1
8778	361	reader in cardiac biology	[readers in cardiac biology]	0.0	4	1	1	1
8779	361	increase in lf ratio	[increase in LF ratio]	0.0	4	1	1	1
8780	361	important outcome in patient	[important outcomes in patients]	0.0	4	1	1	1
8781	361	right ejection fraction	[right ejection fraction]	0.0	3	1	1	1
8782	361	interagency registry	[Interagency Registry]	0.0	2	1	1	1
8783	361	invasive alternative	[invasive alternatives]	0.0	2	1	1	1
8784	361	lvass support	[LVAS support]	0.0	2	1	1	1
8785	361	secretion of arginine vasopressin	[secretion of arginine vasopressin]	0.0	4	1	1	1
8786	361	patient with coronary artery disease	[patients with coronary artery disease]	0.0	5	1	1	1
8787	361	dopamine on end point	[dopamine on end points]	0.0	4	1	1	1
8788	361	soluble ST2	[soluble ST2]	0.0	2	1	1	1
8789	361	blood urea	[blood urea]	0.0	2	1	1	1
8790	361	adult with symptomatic heart failure	[adults with symptomatic heart failure]	0.0	5	1	1	1
8791	361	renal function WRF	[renal function WRF]	0.0	3	1	1	1
8792	361	proximal LCX 2-vessel model	[proximal LCX 2-vessel model]	0.0	4	1	1	1
8793	361	isoenzyme paf-acetylhydrolase	[isoenzymes PAF-acetylhydrolase]	0.0	2	1	1	1
8794	361	ventricular ejection time complicate hypertension	[ventricular ejection time complicating hypertension]	0.0	5	1	1	1
8795	361	assessment of function	[assessment of function]	0.0	3	1	1	1
8796	361	rate among patient	[rates among patients]	0.0	3	1	1	1
8797	361	change in heart failure	[change in heart failure]	0.0	4	1	1	1
8798	361	4 hospital in New Jersey	[4 hospitals in New Jersey]	0.0	5	1	1	1
8799	361	Global longitudinal strain of ventricle	[Global longitudinal strain of ventricle]	0.0	5	1	1	1
8800	361	impairment with mortality	[impairment with mortality]	0.0	3	1	1	1
8801	361	abnormality in cardiovascular function	[abnormalities in cardiovascular function]	0.0	4	1	1	1
8802	361	cardiac sodium current in heart failure	[cardiac sodium current in heart failure]	0.0	6	1	1	1
8803	361	potential benefit with adverse consequence	[potential benefit with adverse consequences]	0.0	5	1	1	1
8804	361	74 patient	[74 patients]	0.0	2	1	1	1
8805	361	ng interquartile range	[ng interquartile range]	0.0	3	1	1	1
8806	361	alternative mrna splicing	[alternative mRNA splicing]	0.0	3	1	1	1
8807	361	risk factor for disease CVD	[risk factor for disease CVD]	0.0	5	1	1	1
8808	361	development of approach	[development of approaches]	0.0	3	2	2	1
8809	361	improvement in rate relative risk	[improvement in rate relative risk]	0.0	5	1	1	1
8810	361	other condition such as infarction	[other conditions such as infarction]	0.0	5	1	1	1
8811	361	z-score	[Z-score]	0.0	1	1	1	1
8812	361	treat patient	[treating patients]	0.0	2	3	3	1
8813	361	CardioPulmonary	[CardioPulmonary]	0.0	1	1	1	1
8814	361	risk-adjusted all-cause mortality	[risk-adjusted all-cause mortality]	0.0	3	1	1	1
8815	361	common form of arterial disease	[common form of arterial disease]	0.0	5	1	1	1
8816	361	development of cardiomyopathy	[development of cardiomyopathy]	0.0	3	1	1	1
8817	361	care of patient with this condition	[care of patients with this condition]	0.0	6	1	1	1
8818	361	3m	[3M]	0.0	1	1	1	1
8819	361	regulatory involvement of receptor kinase-2	[regulatory involvement of receptor kinase-2]	0.0	5	1	1	1
8820	361	b act	[B act]	0.0	2	1	1	1
8821	361	diabetic zsf1 rat	[diabetic ZSF1 rats]	0.0	3	1	1	1
8822	361	left midpapillary level	[left midpapillary level]	0.0	3	1	1	1
8823	361	safe effective off-pump sparing approach	[Safe effective off-pump sparing approach]	0.0	5	1	1	1
8824	361	myocarditis	[myocarditis]	0.0	1	1	1	1
8825	361	heterogeneous region	[heterogeneous region]	0.0	2	1	1	1
8826	361	Exercise test	[Exercise Testing]	0.0	2	1	1	1
8827	361	benefit over conventional parameter	[benefit over conventional parameters]	0.0	4	1	1	1
8828	361	130 consecutive patient	[130 consecutive patients]	0.0	3	1	1	1
8829	361	hazard ratio of 2.7	[hazard ratio of 2.7]	0.0	4	1	1	1
8830	361	isolated heart rate reduction with ivabradine	[isolated heart rate reduction with ivabradine]	0.0	6	1	1	1
8831	361	hazard ratio of 2.2	[hazard ratio of 2.2]	0.0	4	1	1	1
8832	361	small difference among ef bnp EF	[smallest difference among EF BNP EF]	0.0	6	1	1	1
8833	361	ventricular-pulmonary coupling pulmonary resistance p	[ventricular-pulmonary coupling pulmonary resistance P]	0.0	5	1	1	1
8834	361	institution for the treatment of HF	[institution for the treatment of HF]	0.0	6	1	1	1
8835	361	peak mitral flow velocity	[peak mitral flow velocity]	0.0	4	3	3	1
8836	361	clinical relevance	[clinical relevance]	0.0	2	1	1	1
8837	361	number of quarterly admission	[number of quarterly admissions]	0.0	4	1	1	1
8838	361	culprit extend EMD in HF	[culprit extending EMD in HF]	0.0	5	1	1	1
8839	361	problem with mortality	[problem with mortality]	0.0	3	1	1	1
8840	361	treatment target exercise status	[treatments targeting exercise status]	0.0	4	1	1	1
8841	361	twofold increase in lung weight	[twofold increase in lung weight]	0.0	5	1	1	1
8842	361	diet in disease	[diet in disease]	0.0	3	1	1	1
8843	361	Gene expression profile	[Gene expression profile]	0.0	3	1	1	1
8844	361	protective effect on cardiac function	[protective effects on cardiac function]	0.0	5	1	1	1
8845	361	sodium current in heart failure	[sodium current in heart failure]	0.0	5	1	1	1
8846	361	prospective multicenter trial with individual	[prospective multicenter trial with individuals]	0.0	5	1	1	1
8847	361	heart failure exacerbation	[heart failure exacerbation]	0.0	3	1	1	1
8848	361	modest benefit	[modest benefit]	0.0	2	1	1	1
8849	361	potential implication of promising biomarker	[potential implications of promising biomarkers]	0.0	5	1	1	1
8850	361	low resting hr	[lower resting HR]	0.0	3	1	1	1
8851	361	Circulatory	[Circulatory]	0.0	1	1	1	1
8852	361	incentive	[incentives]	0.0	1	1	1	1
8853	361	relate	[relating]	0.0	1	1	1	1
8854	361	conscious dog	[conscious dogs]	0.0	2	1	1	1
8855	361	Effect a analysis use medicare datum	[Effects a analysis using medicare data]	0.0	6	1	1	1
8856	361	aerobic exercise per week	[aerobic exercise per week]	0.0	4	1	1	1
8857	361	reciprocal regulation	[reciprocal regulation]	0.0	2	1	1	1
8858	361	ICD-HF	[ICD-HF]	0.0	1	1	1	1
8859	361	biology	[biology]	0.0	1	1	1	1
8860	361	2.1 millileter 2 p=0.01	[2.1 mL 2 P=0.01]	0.0	4	1	1	1
8861	361	even after multivariable adjustment	[even after multivariable adjustment]	0.0	4	1	1	1
8862	361	guideline-directed therapy	[guideline-directed therapy]	0.0	2	1	1	1
8863	361	p relative decrease	[P relative decrease]	0.0	3	1	1	1
8864	361	plasma nps	[plasma NPs]	0.0	2	1	1	1
8865	361	6 minute m vs. m	[6 min m vs. m]	0.0	5	1	1	1
8866	361	resistance SVR	[resistance SVR]	0.0	2	1	1	1
8867	361	little hr reduction	[little HR reduction]	0.0	3	1	1	1
8868	361	negative predictive value	[negative predictive value]	0.0	3	1	1	1
8869	361	cgmp signal	[cGMP signaling]	0.0	2	1	1	1
8870	361	prognostic relevance of right reserve	[prognostic relevance of right reserve]	0.0	5	1	1	1
8871	361	risk predictor for death	[risk predictor for death]	0.0	4	1	1	1
8872	361	model system of zebrafish	[model system of zebrafish]	0.0	4	1	1	1
8873	361	cachexia hazard ratio in analysis	[cachexia hazard ratio in analyses]	0.0	5	1	1	1
8874	361	two final model	[Two final models]	0.0	3	1	1	1
8875	361	three disease group heart failure	[three disease groups heart failure]	0.0	5	1	1	1
8876	361	common form of remodeling	[common forms of remodeling]	0.0	4	1	1	1
8877	361	with.estimate range in 50000	[with.estimates ranging in 50,000]	0.0	4	1	1	1
8878	361	long assist device	[long-term assist device]	0.0	3	1	1	1
8879	361	transoesophageal guidance under anaesthesia	[transoesophageal guidance under anaesthesia]	0.0	4	1	1	1
8880	361	hfpef with left ejection fraction	[HFpEF with left ejection fraction]	0.0	5	1	1	1
8881	361	oxygen pulse in four of patient	[oxygen pulse in four of patients]	0.0	6	1	1	1
8882	361	sternotomy for valve procedure valve replacement	[sternotomy for valve procedures valve replacement]	0.0	6	1	1	1
8883	361	achieve a moderate level	[achieving a moderate level]	0.0	4	1	1	1
8884	361	internal validity replicate resource use	[internal validity replicating resource use]	0.0	5	1	1	1
8885	361	individual with pulmonary disease	[individuals with pulmonary disease]	0.0	4	1	1	1
8886	361	pressure relationship	[pressure relationship]	0.0	2	1	1	1
8887	361	process redesign contextual framework	[Process Redesign contextual framework]	0.0	4	1	1	1
8888	361	experience implantable cardioverter-defibrillator shock at end	[experiencing implantable cardioverter-defibrillator shocks at end]	0.0	6	1	1	1
8889	361	common type of cardiac tumor	[common type of cardiac tumors]	0.0	5	1	1	1
8890	361	ventricular remodeling	[ventricular remodeling]	0.0	2	1	1	1
8891	361	re-activate transcription	[re-activating transcription]	0.0	2	1	1	1
8892	361	infarction in western Australia	[infarction in Western Australia]	0.0	4	1	1	1
8893	361	postexercise phosphocreatine resynthesis	[postexercise phosphocreatine resynthesis]	0.0	3	1	1	1
8894	361	impact of assist device	[impact of assist device]	0.0	4	1	1	1
8895	361	baseline exercise capacity METs	[baseline exercise capacity METs]	0.0	4	1	1	1
8896	361	function in EMPHASIS-HF	[function in EMPHASIS-HF]	0.0	3	1	1	1
8897	361	arterial systolic pressure relationship a index	[arterial systolic pressure relationship an index]	0.0	6	1	1	1
8898	361	resource utilization	[resource utilization]	0.0	2	1	1	1
8899	361	cardiac myocyte-specific mena overexpression TTA	[cardiac myocyte-specific Mena overexpression TTA]	0.0	5	1	1	1
8900	361	pure hno donor cxl-1020	[pure HNO donor CXL-1020]	0.0	4	1	1	1
8901	361	cardiovascular CV event AF	[cardiovascular CV events AF]	0.0	4	1	1	1
8902	361	cardiac hospital	[cardiac hospital]	0.0	2	1	1	1
8903	361	4 suburban hospital in Jersey	[4 suburban hospitals in Jersey]	0.0	5	1	1	1
8904	361	334 patient	[334 patients]	0.0	2	1	1	1
8905	361	quintile of hospital	[quintile of hospitals]	0.0	3	1	1	1
8906	361	bad quintile of performance	[worst quintile of performance]	0.0	4	1	1	1
8907	361	treatment with ivabradine exercise capacity	[treatment with ivabradine exercise capacity]	0.0	5	1	1	1
8908	361	elderly patient with CHF	[elderly patients with CHF]	0.0	4	1	1	1
8909	361	53 patient with ph	[53 patients with PH]	0.0	4	1	1	1
8910	361	similar benefit	[similar benefit]	0.0	2	1	1	1
8911	361	hospital programme	[hospital programmes]	0.0	2	1	1	1
8912	361	heart Failure database	[Heart Failure database]	0.0	3	1	1	1
8913	361	6 day	[6 days]	0.0	2	1	1	1
8914	361	Impact on inappropriate implantable cardioverter-defibrillator therapy	[Impact on inappropriate implantable cardioverter-defibrillator therapy]	0.0	6	1	1	1
8915	361	mammalian myocardium	[mammalian myocardium]	0.0	2	1	1	1
8916	361	large study sample with patient	[large study sample with patients]	0.0	5	1	1	1
8917	361	2.8 0.7 L	[2.8 0.7 L]	0.0	3	1	1	1
8918	361	variant consistent with report	[variants consistent with reports]	0.0	4	1	1	1
8919	361	seventy-seven case	[Seventy-seven cases]	0.0	2	1	1	1
8920	361	consecutive HF patient	[consecutive HF patients]	0.0	3	1	1	1
8921	361	considerable attention	[considerable attention]	0.0	2	1	1	1
8922	361	prevalent heart disease	[prevalent heart disease]	0.0	3	1	1	1
8923	361	Cardiovascular Outcome in renal Lesion	[Cardiovascular Outcomes in Renal Lesions]	0.0	5	1	1	1
8924	361	cardioverter-defibrillator therapy automatic defibrillator implantation	[cardioverter-defibrillator therapy Automatic Defibrillator Implantation]	0.0	5	1	1	1
8925	361	hospital mortality	[hospital mortality]	0.0	2	1	1	1
8926	361	transplant-ineligible patient as destination therapy	[transplant-ineligible patients as destination therapy]	0.0	5	1	1	1
8927	361	improvement show minor improvement	[improvements showing minor improvement]	0.0	4	1	1	1
8928	361	Impact of ejection fraction	[Impact of ejection fraction]	0.0	4	1	1	1
8929	361	few complication	[few complications]	0.0	2	1	1	1
8930	361	aas race by treatment interaction	[AAs race by treatment interaction]	0.0	5	1	1	1
8931	361	effectiveness for heart failure	[Effectiveness for heart failure]	0.0	4	1	1	1
8932	361	underlying pathophysiology	[underlying pathophysiology]	0.0	2	1	1	1
8933	361	nervous system modulation on QTV	[nervous system modulation on QTV]	0.0	5	1	1	1
8934	361	difference histologically control	[difference histologically control]	0.0	3	1	1	1
8935	361	significant change effect exercise	[significant change effect exercise]	0.0	4	1	1	1
8936	361	York heart Association classification	[York Heart Association classification]	0.0	4	1	1	1
8937	361	first-time diagnosis	[first-time diagnosis]	0.0	2	1	1	1
8938	361	inhibition of signal pathway	[inhibition of signaling pathway]	0.0	4	1	1	1
8939	361	evidence of benefit	[evidence of benefit]	0.0	3	1	1	1
8940	361	Society of Cardiology guideline definition	[Society of Cardiology guidelines definition]	0.0	5	1	1	1
8941	361	participation of apoptosis	[Participation of apoptosis]	0.0	3	1	1	1
8942	361	vascular growth factor protein	[vascular growth factor protein]	0.0	4	1	1	1
8943	361	form of disease	[form of disease]	0.0	3	1	1	1
8944	361	100 obese participant mean	[100 obese participants mean]	0.0	4	1	1	1
8945	361	baroreflex activation therapy	[Baroreflex Activation Therapy]	0.0	3	1	1	1
8946	361	evidence-based management	[evidence-based management]	0.0	2	1	1	1
8947	361	efficient RV function evaluation	[efficient RV function evaluation]	0.0	4	1	1	1
8948	361	development via effect	[development via effects]	0.0	3	1	1	1
8949	361	trial of patient	[trial of patients]	0.0	3	1	1	1
8950	361	difference between number of cell	[difference between numbers of cells]	0.0	5	1	1	1
8951	361	674 man	[674 men]	0.0	2	1	1	1
8952	361	composite quality measure for medical condition	[Composite quality measures for medical conditions]	0.0	6	1	1	1
8953	361	oscillation	[oscillations]	0.0	1	1	1	1
8954	361	health-related quality Minnesota live	[health-related quality Minnesota Living]	0.0	4	1	1	1
8955	361	hour of admission	[hours of admission]	0.0	3	1	1	1
8956	361	most area	[most areas]	0.0	2	1	1	1
8957	361	5.0 gram p=0.04	[5.0 g P=0.04]	0.0	3	1	1	1
8958	361	length nt-probnp molecule	[length NT-proBNP molecule]	0.0	3	1	1	1
8959	361	control HDL	[controls HDL]	0.0	2	1	1	1
8960	361	effect of 2 type HeartMate	[effects of 2 types HeartMate]	0.0	5	1	1	1
8961	361	event rate for infarction	[event rates for infarction]	0.0	4	1	1	1
8962	361	guideline-recommended drug for heart failure	[guideline-recommended drugs for heart failure]	0.0	5	1	1	1
8963	361	cocoa	[cocoa]	0.0	1	1	1	1
8964	361	after percutaneous revascularization	[After percutaneous revascularization]	0.0	3	1	1	1
8965	361	Nursing	[Nursing]	0.0	1	1	1	1
8966	361	artery stenosis RAS	[artery stenosis RAS]	0.0	3	1	1	1
8967	361	single test	[single test]	0.0	2	1	1	1
8968	361	small difference bnp in woman EF	[smallest difference BNP in women EF]	0.0	6	1	1	1
8969	361	BP	[BP]	0.0	1	1	1	1
8970	361	only in patient with s'lateral	[only in patients with s'lateral]	0.0	5	1	1	1
8971	361	assist device lvas	[assist devices LVADs]	0.0	3	3	3	1
8972	361	pre-specified analysis with egfr	[pre-specified analysis with eGFR]	0.0	4	1	1	1
8973	361	fibrillation for stroke prevention Trial	[fibrillation for Stroke prevention Trial]	0.0	5	1	1	1
8974	361	patient with recent onset HFrEF day	[patients with recent onset HFrEF days]	0.0	6	1	1	1
8975	361	patient with mean SD testosterone level	[patients with mean SD testosterone levels]	0.0	6	1	1	1
8976	361	TGF-β	[TGF-β]	0.0	1	1	1	1
8977	361	17 trial	[17 trials]	0.0	2	1	1	1
8978	361	dramatic induction	[dramatic induction]	0.0	2	1	1	1
8979	361	several gene related	[several genes related]	0.0	3	1	1	1
8980	361	development of insulin-resistance	[development of insulin-resistance]	0.0	3	1	1	1
8981	361	strata	[strata]	0.0	1	1	1	1
8982	361	especially m	[especially ms]	0.0	2	1	1	1
8983	361	experience of a receptor antagonist tolvaptan	[Experience of a receptor antagonist tolvaptan]	0.0	6	1	1	1
8984	361	high event rate 2.08 event	[highest event rate 2.08 events]	0.0	5	1	1	1
8985	361	ventricular support	[ventricular support]	0.0	2	1	1	1
8986	361	PKA subunit	[PKA subunits]	0.0	2	2	2	1
8987	361	relationship force	[relationship force]	0.0	2	1	1	1
8988	361	increase body	[increasing body]	0.0	2	1	1	1
8989	361	range with copd	[range with COPD]	0.0	3	1	1	1
8990	361	partial pressure of co2	[partial pressure of CO2]	0.0	4	1	1	1
8991	361	334 patient man	[334 patients men]	0.0	3	1	1	1
8992	361	age of the CHF patient	[age of the CHF patients]	0.0	5	1	1	1
8993	361	ed visit age year	[ED visits age years]	0.0	4	1	1	1
8994	361	R-R interval oscillation	[R-R interval oscillations]	0.0	3	1	1	1
8995	361	ejection fraction on mortality	[ejection fraction on mortality]	0.0	4	1	1	1
8996	361	power of measure	[power of measures]	0.0	3	1	1	1
8997	361	1.6 reason per patient	[1.6 reasons per patient]	0.0	4	1	1	1
8998	361	new target in disease management	[new targets in disease management]	0.0	5	1	1	1
8999	361	metoprolol irrespective of receptor haplotype	[metoprolol irrespective of receptor haplotype]	0.0	5	1	1	1
9000	361	confidence interval 0.60	[confidence interval 0.60]	0.0	3	1	1	1
9001	361	improvement in effective rate relative risk	[improvement in effective rate relative risk]	0.0	6	1	1	1
9002	361	index E ratio	[indices E ratio]	0.0	3	1	1	1
9003	361	3058 patient with ejection fraction HF	[3058 patients with ejection fraction HF]	0.0	6	1	1	1
9004	361	embolectomy	[embolectomy]	0.0	1	1	1	1
9005	361	symptomatic heart failure patient	[symptomatic heart failure patients]	0.0	4	1	1	1
9006	361	key enzyme	[key enzymes]	0.0	2	1	1	1
9007	361	sST2	[sST2]	0.0	1	1	1	1
9008	361	reliable biomarker in patient	[reliable biomarkers in patients]	0.0	4	1	1	1
9009	361	heartmate lvad	[HeartMate LVAD]	0.0	2	1	1	1
9010	361	insulin-resistance by 2 week post-aac	[insulin-resistance by 2 weeks post-AAC]	0.0	5	1	1	1
9011	361	low event rate at event	[lowest event rate at events]	0.0	5	1	1	1
9012	361	analysis of patient management intervention	[Analysis of Patient Management Interventions]	0.0	5	2	2	1
9013	361	outcome measure in prospective experimental research	[outcome measures in prospective experimental research]	0.0	6	1	1	1
9014	361	consent HF patient ejection fraction	[consenting HF patients ejection fraction]	0.0	5	1	1	1
9015	361	N-terminal proBNP NT-proBNP proanp MR-proANP	[N-terminal proBNP NT-proBNP proANP MR-proANP]	0.0	5	1	1	1
9016	361	hypertension diet	[hypertension diet]	0.0	2	1	1	1
9017	361	distinct population	[distinct populations]	0.0	2	1	1	1
9018	361	early outcome	[early outcomes]	0.0	2	1	1	1
9019	361	number of admission	[number of admissions]	0.0	3	1	1	1
9020	361	consecutive patient 209 HFrEF	[consecutive patients 209 HFrEF]	0.0	4	1	1	1
9021	361	paucity	[paucity]	0.0	1	1	1	1
9022	361	underlying characteristic use Cochrane effective Practice	[underlying characteristics using Cochrane Effective Practice]	0.0	6	1	1	1
9023	361	pde2 overexpression	[PDE2 overexpression]	0.0	2	1	1	1
9024	361	4.9 year	[4.9 years]	0.0	2	1	1	1
9025	361	artery disease pad	[artery disease PAD]	0.0	3	1	1	1
9026	361	multivariate logistic regression analysis	[multivariate logistic regression analysis]	0.0	4	1	1	1
9027	361	obese patient with stable hfpef	[obese patients with stable HFPEF]	0.0	5	1	1	1
9028	361	reliable mortality predictor in ICD-HF patient	[reliable mortality predictors in ICD-HF patients]	0.0	6	1	1	1
9029	361	relevance of right reserve	[relevance of right reserve]	0.0	4	1	1	1
9030	361	asymptomatic Fontan PF patient	[asymptomatic Fontan PF patients]	0.0	4	1	1	1
9031	361	membrane oxygenation in infarction-related heart failure	[membrane oxygenation in infarction-related heart failure]	0.0	6	1	1	1
9032	361	e-wave mitral annular velocity ratio	[E-wave mitral annular velocity ratio]	0.0	5	1	1	1
9033	361	urinary tract infection	[urinary tract infection]	0.0	3	1	1	1
9034	361	chromatin-mediated signal transduction	[chromatin-mediated signal transduction]	0.0	3	1	1	1
9035	361	involve the left artery	[involving the left artery]	0.0	4	1	1	1
9036	361	middle-aged athlete	[middle-aged athletes]	0.0	2	1	1	1
9037	361	flow pump	[flow pump]	0.0	2	1	1	1
9038	361	2.1 kg versus kg	[2.1 kg vs kg]	0.0	4	1	1	1
9039	361	nursing-sensitive outcome measure	[nursing-sensitive outcome measures]	0.0	3	1	1	1
9040	361	great risk of event	[greater risk of events]	0.0	4	1	1	1
9041	361	eov	[EOV]	0.0	1	1	1	1
9042	361	hypertension of mm hg	[hypertension of mm Hg]	0.0	4	1	1	1
9043	361	investigate Outcome multicenter study	[Investigating Outcomes multicenter study]	0.0	4	1	1	1
9044	361	low ventricular ejection fraction	[low ventricular ejection fraction]	0.0	4	1	1	1
9045	361	heart rate variability	[Heart rate variability]	0.0	3	1	1	1
9046	361	combination of the remodeling aspect	[combinations of the remodeling aspects]	0.0	5	1	1	1
9047	361	haemodynamic assessment	[haemodynamic assessment]	0.0	2	1	1	1
9048	361	future of advanced heart failure	[Future of advanced heart failure]	0.0	5	1	1	1
9049	361	statistically significant percent relative reduction	[statistically significant percent relative reduction]	0.0	5	1	1	1
9050	361	IL	[IL]	0.0	1	1	1	1
9051	361	outcome measure in future experimental research	[outcome measures in future experimental research]	0.0	6	1	1	1
9052	361	prognostic significance	[prognostic significance]	0.0	2	1	1	1
9053	361	management for acute HF	[management for acute HF]	0.0	4	1	1	1
9054	361	knowledge of abnormality	[knowledge of abnormalities]	0.0	3	1	1	1
9055	361	pre-specified subgroup analysis include quality	[pre-specified subgroup analyses including quality]	0.0	5	1	1	1
9056	361	study in practice setting	[studies in practice settings]	0.0	4	1	1	1
9057	361	endothelial function dilatation	[endothelial function dilatation]	0.0	3	1	1	1
9058	361	ventricular systolic function	[ventricular systolic function]	0.0	3	1	1	1
9059	361	common emergency Department presentation	[common Emergency Department presentation]	0.0	4	1	1	1
9060	361	heart failure in Hungary	[heart failure in Hungary]	0.0	4	1	1	1
9061	361	response protective role	[response protective role]	0.0	3	1	1	1
9062	361	low rate of death	[lower rates of death]	0.0	4	1	1	1
9063	361	heterogeneous group of patient	[heterogeneous group of patients]	0.0	4	1	1	1
9064	361	mitral valve area mva	[mitral valve area MVA]	0.0	4	1	1	1
9065	361	require surgery	[requiring surgery]	0.0	2	1	1	1
9066	361	modest clinical benefit	[modest clinical benefit]	0.0	3	1	1	1
9067	361	Mechanistic insight in heart failure	[Mechanistic insight in heart failure]	0.0	5	1	1	1
9068	361	presence of mild diastolic dysfunction	[presence of mild diastolic dysfunction]	0.0	5	1	1	1
9069	361	cardiac insulin-resistance by week	[cardiac insulin-resistance by weeks]	0.0	4	1	1	1
9070	361	N-terminal peptide assessment	[N-terminal peptide assessment]	0.0	3	1	1	1
9071	361	concentric hypertrophy in heart failure	[concentric hypertrophy in heart failure]	0.0	5	1	1	1
9072	361	role in HF	[role in HF]	0.0	3	1	1	1
9073	361	strong acid	[strong acid]	0.0	2	1	1	1
9074	361	norepinephrine-induced hypertrophic response	[norepinephrine-induced hypertrophic responses]	0.0	3	1	1	1
9075	361	consecutive patient aged year	[consecutive patients aged years]	0.0	4	1	1	1
9076	361	comorbidity in heart failure	[comorbidities in heart failure]	0.0	4	1	1	1
9077	361	3 evaluation	[3 evaluations]	0.0	2	1	1	1
9078	361	reduce all-cause mortality	[reducing all-cause mortality]	0.0	3	1	1	1
9079	361	reduce the primary endpoint	[reducing the primary endpoint]	0.0	4	1	1	1
9080	361	tone result in autonomic imbalance	[tone resulting in autonomic imbalance]	0.0	5	1	1	1
9081	361	reflect decrease period versus 1	[reflecting decreases period versus 1]	0.0	5	1	1	1
9082	361	pathway in patient	[pathways in patients]	0.0	3	1	1	1
9083	361	mechanism of cardiac dysfunction	[mechanism of cardiac dysfunction]	0.0	4	1	1	1
9084	361	arterial hypertension medication	[arterial hypertension medication]	0.0	3	1	1	1
9085	361	few symptom	[fewer symptoms]	0.0	2	1	1	1
9086	361	internal consistency among patient	[internal consistency among patients]	0.0	4	1	1	1
9087	361	screen	[Screening]	0.0	1	1	1	1
9088	361	role determine the adaptive remodelling	[role determining the adaptive remodelling]	0.0	5	1	1	1
9089	361	beta-blocker on the endpoint	[beta-blockers on the endpoint]	0.0	4	1	1	1
9090	361	perception	[perceptions]	0.0	1	1	1	1
9091	361	advanced heart failure patient	[advanced heart failure patients]	0.0	4	2	2	1
9092	361	left ventricular LV remodeling	[left ventricular LV remodeling]	0.0	4	1	1	1
9093	361	v.6.2	[v.6.2]	0.0	1	1	1	1
9094	361	large fluctuation	[larger fluctuations]	0.0	2	1	1	1
9095	361	heart dilatation after transverse aortic constriction	[heart dilatation after transverse aortic constriction]	0.0	6	1	1	1
9096	361	usefulness assess ventricular fill pressure	[Usefulness assessing ventricular filling pressure]	0.0	5	1	1	1
9097	361	123 mm hg	[123 mm Hg]	0.0	3	1	1	1
9098	361	contemporary heart failure population	[contemporary heart failure population]	0.0	4	1	1	1
9099	361	alter the gene expression profile	[altering the gene expression profile]	0.0	5	1	1	1
9100	361	β-blocker at target dose	[β-blockers at target dose]	0.0	4	1	1	1
9101	361	activity control	[activity controls]	0.0	2	1	1	1
9102	361	hfpsi use va-rt cohort	[HFPSI use VA-RT cohort]	0.0	4	1	1	1
9103	361	prognostic factor in disease	[prognostic factor in diseases]	0.0	4	1	1	1
9104	361	tool for analysis a web-based program	[Tools for Analysis A Web-based program]	0.0	6	1	1	1
9105	361	tricuspid plane excursion tapse	[tricuspid plane excursion TAPSE]	0.0	4	1	1	1
9106	361	role molecular scaffold in heart pathology	[role molecular scaffolds in heart pathology]	0.0	6	1	1	1
9107	361	protein content for SR can	[protein content for SR Ca]	0.0	5	1	1	1
9108	361	early-onset HF for HF	[early-onset HF for HF]	0.0	4	1	1	1
9109	361	peak can	[peak Ca]	0.0	2	1	1	1
9110	361	highly effective agent	[highly effective agent]	0.0	3	1	1	1
9111	361	heart association class	[Heart Association class]	0.0	3	1	1	1
9112	361	maximal power index	[maximal power index]	0.0	3	1	1	1
9113	361	total of subject	[total of subjects]	0.0	3	1	1	1
9114	361	74 patient with hfpef	[74 patients with HFPEF]	0.0	4	1	1	1
9115	361	benefit of anemia treatment	[benefits of anemia treatment]	0.0	4	1	1	1
9116	361	PB	[PB]	0.0	1	1	1	1
9117	361	many multisite study	[Many multisite studies]	0.0	3	1	1	1
9118	361	continuous relationship	[continuous relationship]	0.0	2	2	2	1
9119	361	significant consideration	[significant considerations]	0.0	2	1	1	1
9120	361	adjust decrease	[adjusting decrease]	0.0	2	1	1	1
9121	361	ventricular plane systolic excursion tapse	[ventricular plane systolic excursion TAPSE]	0.0	5	1	1	1
9122	361	artery ligation	[artery ligation]	0.0	2	1	1	1
9123	361	fifty-one percent	[Fifty-one percent]	0.0	2	1	1	1
9124	361	child with heart disease of HF	[children with heart disease of HF]	0.0	6	1	1	1
9125	361	pharmacologic study include calcium-sensin agent	[pharmacologic studies including calcium-sensitizing agents]	0.0	5	1	1	1
9126	361	potentially anti-inflammatory effect	[potentially anti-inflammatory effects]	0.0	3	1	1	1
9127	361	cardiac rehabilitation care on capacity	[cardiac rehabilitation care on capacity]	0.0	5	1	1	1
9128	361	current dietary recommendation	[Current dietary recommendations]	0.0	3	1	1	1
9129	361	295 veteran aged year	[295 veterans aged years]	0.0	4	1	1	1
9130	361	other staff	[other staff]	0.0	2	1	1	1
9131	361	rethink the quality	[Rethinking the quality]	0.0	3	1	1	1
9132	361	past year	[past years]	0.0	2	1	1	1
9133	361	prescribing of medication	[prescribing of medications]	0.0	3	1	1	1
9134	361	Safety of eplerenone analysis	[Safety of eplerenone analyses]	0.0	4	1	1	1
9135	361	relevance of reserve	[relevance of reserve]	0.0	3	1	1	1
9136	361	24 patient	[24 patients]	0.0	2	1	1	1
9137	361	add-on feature such as detection	[add-on features such as detection]	0.0	5	1	1	1
9138	361	1.6 second	[1.6 seconds]	0.0	2	1	1	1
9139	361	care hospital	[care hospital]	0.0	2	1	1	1
9140	361	care hospital for HF	[care hospital for HF]	0.0	4	1	1	1
9141	361	Global left ventricular systolic strain	[Global left ventricular systolic strain]	0.0	5	1	1	1
9142	361	radial strain	[radial strain]	0.0	2	1	1	1
9143	361	RI	[RI]	0.0	1	1	1	1
9144	361	aggressive medical treatment with vasodilator	[aggressive medical treatment with vasodilators]	0.0	5	1	1	1
9145	361	h-oxidase	[H-oxidase]	0.0	1	1	1	1
9146	361	fluctuation	[fluctuations]	0.0	1	1	1	1
9147	361	patient with ejection fraction 0.35	[patients with ejection fraction 0.35]	0.0	5	1	1	1
9148	361	chronic kidney disease	[chronic kidney disease]	0.0	3	1	1	1
9149	361	noncoding	[noncoding]	0.0	1	1	1	1
9150	361	stable situation	[stable situation]	0.0	2	1	1	1
9151	361	nursing-sensitive outcome change score	[Nursing-sensitive outcome change scores]	0.0	4	1	1	1
9152	361	heart failure in clinical practice	[heart failure in clinical practice]	0.0	5	1	1	1
9153	361	usefulness assess fill pressure	[Usefulness assessing filling pressure]	0.0	4	1	1	1
9154	361	occurrence within day	[Occurrence within days]	0.0	3	1	1	1
9155	361	follow-up of 21 month	[follow-up of 21 months]	0.0	4	1	1	1
9156	361	participant satisfaction	[participant satisfaction]	0.0	2	1	1	1
9157	361	chest model noninvasive surrogate	[chest model noninvasive surrogates]	0.0	4	1	1	1
9158	361	great number	[great number]	0.0	2	1	1	1
9159	361	heart failure in hypertension	[heart failure in hypertension]	0.0	4	1	1	1
9160	361	scaling	[scaling]	0.0	1	1	1	1
9161	361	looping	[looping]	0.0	1	1	1	1
9162	361	user of Saxagliptin	[Users of Saxagliptin]	0.0	3	1	1	1
9163	361	important contribution of abnormality	[important contribution of abnormalities]	0.0	4	1	1	1
9164	361	day p-value 0.001	[days P-value 0.001]	0.0	3	1	1	1
9165	361	150 minute of moderate-intensity exercise	[150 minutes of moderate-intensity exercise]	0.0	5	1	1	1
9166	361	consecutive patient with onset HFrEF day	[consecutive patients with onset HFrEF days]	0.0	6	1	1	1
9167	361	symptom in child	[symptoms in children]	0.0	3	1	1	1
9168	361	monocyte	[monocytes]	0.0	1	1	1	1
9169	361	alteration in SkM muscle structure	[alterations in SkM muscle structure]	0.0	5	1	1	1
9170	361	effective rate control	[effective rate control]	0.0	3	1	1	1
9171	361	reduction of na current	[reduction of Na current]	0.0	4	1	1	1
9172	361	confirmation on population	[confirmation on populations]	0.0	3	1	1	1
9173	361	tool for economic analysis a program	[Tools for Economic Analysis A program]	0.0	6	1	1	1
9174	361	basic bhlh transcription factor	[basic bHLH transcription factor]	0.0	4	1	1	1
9175	361	method of transverse constriction	[method of transverse constriction]	0.0	4	1	1	1
9176	361	role in signal transduction	[role in signal transduction]	0.0	4	1	1	1
9177	361	LV posterior wall thickness	[LV posterior wall thickness]	0.0	4	1	1	1
9178	361	efficacy of receptor antagonist	[efficacy of receptor antagonists]	0.0	4	1	1	1
9179	361	baseline egfr group	[Baseline eGFR group]	0.0	3	1	1	1
9180	361	mg hr 1.54	[mg HR 1.54]	0.0	3	1	1	1
9181	361	implantable cardioverter-defibrillator therapy defibrillator implantation	[implantable cardioverter-defibrillator therapy Defibrillator Implantation]	0.0	5	1	1	1
9182	361	care by antiarrhythmic drug	[care by antiarrhythmic drugs]	0.0	4	1	1	1
9183	361	need for strict standard	[need for strict standards]	0.0	4	1	1	1
9184	361	terminal stage	[terminal stage]	0.0	2	1	1	1
9185	361	hospital nationwide through September	[hospitals nationwide through September]	0.0	4	1	1	1
9186	361	diagnostic performance detect fill pressure	[diagnostic performance detecting filling pressures]	0.0	5	1	1	1
9187	361	ventricular tissue	[ventricular tissue]	0.0	2	1	1	1
9188	361	LCX late	[LCX later]	0.0	2	1	1	1
9189	361	more than 60000 patient	[more than 60,000 patients]	0.0	4	1	1	1
9190	361	benefit from implantable cardioverter defibrillator-CRT	[benefit from implantable cardioverter defibrillator-CRT]	0.0	5	1	1	1
9191	361	safety cohort study	[safety cohort study]	0.0	3	1	1	1
9192	361	economic evaluation hm ii	[economic evaluations HM II]	0.0	4	1	1	1
9193	361	extend EMD in the dyssynchronous heart	[extending EMD in the dyssynchronous heart]	0.0	6	1	1	1
9194	361	first result	[first results]	0.0	2	1	1	1
9195	361	several Medical outcome study	[several Medical Outcomes Study]	0.0	4	1	1	1
9196	361	small group	[small group]	0.0	2	1	1	1
9197	361	3 economic evaluation hm ii	[3 economic evaluations HM II]	0.0	5	1	1	1
9198	361	study of therapeutics include calcium-sensin agent	[studies of therapeutics including calcium-sensitizing agents]	0.0	6	1	1	1
9199	361	matrix of ventricular biopsy n=9	[matrix of ventricular biopsies n=9]	0.0	5	1	1	1
9200	361	phenotype of the Fontan	[phenotype of the Fontan]	0.0	4	1	1	1
9201	361	activation PKC-βII by HDL	[activation PKC-βII by HDL]	0.0	4	1	1	1
9202	361	common type of tumor	[common type of tumors]	0.0	4	1	1	1
9203	361	clinical effect	[clinical effects]	0.0	2	1	1	1
9204	361	Carvedilol	[Carvedilol]	0.0	1	1	1	1
9205	361	Minnesota quality	[Minnesota quality]	0.0	2	1	1	1
9206	361	combination of size reduction	[combination of size reduction]	0.0	4	2	2	1
9207	361	score of Minnesota quality	[score of Minnesota quality]	0.0	4	1	1	1
9208	361	outcome median	[outcome median]	0.0	2	1	1	1
9209	361	receive assist device support	[receiving assist device support]	0.0	4	1	1	1
9210	361	regional circumferential strain	[regional circumferential strain]	0.0	3	1	1	1
9211	361	low rate among patient	[lower rates among patients]	0.0	4	1	1	1
9212	361	k constant	[k constants]	0.0	2	1	1	1
9213	361	Catheter-based revascularization	[Catheter-based revascularization]	0.0	2	1	1	1
9214	361	life score	[life score]	0.0	2	1	1	1
9215	361	less benefit	[less benefit]	0.0	2	1	1	1
9216	361	ratio disclose prognosis	[ratio disclosing prognosis]	0.0	3	1	1	1
9217	361	Study of predictor after resynchronization therapy	[Studies of predictors after resynchronization therapy]	0.0	6	1	1	1
9218	361	thirty-seven hospital nationwide from January	[thirty-seven hospitals nationwide from January]	0.0	5	1	1	1
9219	361	outcome-monitoring phase mean	[outcome-monitoring phase mean]	0.0	3	1	1	1
9220	361	peptide level like other biomarker	[peptide levels like other biomarkers]	0.0	5	1	1	1
9221	361	activation of p70s6k	[activation of p70S6K]	0.0	3	1	1	1
9222	361	Patient Severity	[Patient Severity]	0.0	2	1	1	1
9223	361	favour of apoptosis	[favour of apoptosis]	0.0	3	1	1	1
9224	361	bet bromodomain-containing protein	[BET bromodomain-containing protein]	0.0	3	1	1	1
9225	361	24 telephone support programme	[24 telephone support programmes]	0.0	4	1	1	1
9226	361	T cell nfat	[T cells NFAT]	0.0	3	1	1	1
9227	361	agent in patient	[agents in patients]	0.0	3	1	1	1
9228	361	strain of ventricle	[strain of ventricle]	0.0	3	2	2	1
9229	361	experience cardioverter-defibrillator shock at end	[experiencing cardioverter-defibrillator shocks at end]	0.0	5	1	1	1
9230	361	sarcoplasmic reticular can 2+)-uptake	[sarcoplasmic reticular Ca 2+)-uptake]	0.0	4	1	1	1
9231	361	large study	[larger studies]	0.0	2	1	1	1
9232	361	change with regional strain contribution	[changes with regional strain contributions]	0.0	5	1	1	1
9233	361	mrna level of gene	[mRNA levels of genes]	0.0	4	1	1	1
9234	361	artery pressure increase by means	[artery pressure increase by means]	0.0	5	1	1	1
9235	361	low expenditure on health per capita	[lower expenditure on health per capita]	0.0	6	1	1	1
9236	361	few perioperative death	[few perioperative deaths]	0.0	3	1	1	1
9237	361	biomedical reason	[biomedical reasons]	0.0	2	2	2	1
9238	361	prognostic composite HF index	[prognostic composite HF index]	0.0	4	1	1	1
9239	361	similar incidence	[similar incidence]	0.0	2	1	1	1
9240	361	PKC-βII by HDL NYHA-IIIb	[PKC-βII by HDL NYHA-IIIb]	0.0	4	1	1	1
9241	361	case-control study	[case-control study]	0.0	2	1	1	1
9242	361	dipeptidyl peptidase-4	[dipeptidyl peptidase-4]	0.0	2	1	1	1
9243	361	use of antagonist	[use of antagonists]	0.0	3	1	1	1
9244	361	heart failure with impaired function	[heart failure with impaired function]	0.0	5	1	1	1
9245	361	improvement at stage of heart failure	[improvement at stages of heart failure]	0.0	6	1	1	1
9246	361	electrical stimulation of peripheral muscle	[electrical stimulation of peripheral muscles]	0.0	5	1	1	1
9247	361	improvement by β-adrenoceptor blockade at stage	[improvement by β-adrenoceptor blockade at stages]	0.0	6	1	1	1
9248	361	lyso-paf	[lyso-PAF]	0.0	1	1	1	1
9249	361	Cooper Center longitudinal Study	[Cooper Center Longitudinal Study]	0.0	4	1	1	1
9250	361	ST2 in patient	[ST2 in patients]	0.0	3	1	1	1
9251	361	cardiotoxicity a effective agent	[cardiotoxicity a effective agent]	0.0	4	1	1	1
9252	361	end-diastolic area index	[end-diastolic area index]	0.0	3	1	1	1
9253	361	arterial pressure pasp	[arterial pressure PASP]	0.0	3	1	1	1
9254	361	pace non-dnx	[pace non-DNx]	0.0	2	1	1	1
9255	361	chronic pulmonary arterial hypertension	[chronic pulmonary arterial hypertension]	0.0	4	1	1	1
9256	361	other agent	[other agents]	0.0	2	1	1	1
9257	361	fever	[fever]	0.0	1	2	2	1
9258	361	pg high bnp group	[pg high BNP group]	0.0	4	1	1	1
9259	361	Society of Cardiology	[Society of Cardiology]	0.0	3	1	1	1
9260	361	enhancement of angiogenesis	[enhancement of angiogenesis]	0.0	3	1	1	1
9261	361	Joanna Briggs Institute Evidence	[Joanna Briggs Institute Evidence]	0.0	4	1	1	1
9262	361	left descending	[left descending]	0.0	2	1	1	1
9263	361	patient in the VAD group	[patients in the VAD group]	0.0	5	1	1	1
9264	361	(egfr)-group I millileter	[(eGFR)-group I mL]	0.0	3	1	1	1
9265	361	clinical study hm ii	[clinical studies HM II]	0.0	4	1	1	1
9266	361	accessory pathway	[accessory pathways]	0.0	2	1	1	1
9267	361	filtration rate of egfr	[filtration rate of eGFR]	0.0	4	1	1	1
9268	361	stroke cha₂ds₂vasc score	[stroke CHA₂DS₂VASc score]	0.0	3	1	1	1
9269	361	European Society of Cardiology	[European Society of Cardiology]	0.0	4	1	1	1
9270	361	growth factor-β tgf-β signal level	[growth factor-β TGF-β signaling level]	0.0	5	1	1	1
9271	361	disease phase	[disease phase]	0.0	2	1	1	1
9272	361	patient with recent onset af	[patients with recent onset AF]	0.0	5	1	1	1
9273	361	patient with valve plasty	[patient with valve plasty]	0.0	4	1	1	1
9274	361	neurohormonal stimulation	[neurohormonal stimulation]	0.0	2	1	1	1
9275	361	myocardial matrix	[myocardial matrix]	0.0	2	1	1	1
9276	361	field of investigation	[field of investigation]	0.0	3	1	1	1
9277	361	detailed analysis of cardiac tissue	[Detailed analysis of cardiac tissue]	0.0	5	1	1	1
9278	361	lack murine resistin	[lacking murine resistin]	0.0	3	1	1	1
9279	361	neurological event-free rate	[neurological event-free rate]	0.0	3	1	1	1
9280	361	third heart sound	[third heart sound]	0.0	3	1	1	1
9281	361	catheterisation with guidance	[catheterisation with guidance]	0.0	3	1	1	1
9282	361	medical condition	[medical conditions]	0.0	2	1	1	1
9283	361	multicenter trial renal optimization strategy evaluation	[Multicenter trial Renal Optimization Strategies Evaluation]	0.0	6	1	1	1
9284	361	LV volume of 66 millileter	[LV volume of 66 mL]	0.0	5	1	1	1
9285	361	validate outcome measure in research	[Validating outcome measures in research]	0.0	5	1	1	1
9286	361	low volume	[lower volumes]	0.0	2	1	1	1
9287	361	simulation tool	[simulation tool]	0.0	2	1	1	1
9288	361	normal body mass index strata	[normal body mass index strata]	0.0	5	1	1	1
9289	361	systolic parameter	[systolic parameters]	0.0	2	1	1	1
9290	361	30 day p-value	[30 days P-value]	0.0	3	1	1	1
9291	361	pathology	[pathology]	0.0	1	1	1	1
9292	361	sitagliptin versus pioglitazone	[sitagliptin versus pioglitazone]	0.0	3	1	1	1
9293	361	heart disease of possible HF	[heart disease of possible HF]	0.0	5	1	1	1
9294	361	rrna	[rRNA]	0.0	1	1	1	1
9295	361	consecutive patient with recent onset	[consecutive patients with recent onset]	0.0	5	1	1	1
9296	361	left ventricular longitudinal systolic strain GLS	[left ventricular longitudinal systolic strain GLS]	0.0	6	1	1	1
9297	361	effect of doxorubicin	[effect of doxorubicin]	0.0	3	1	1	1
9298	361	10 HF patient	[10 HF patients]	0.0	3	1	1	1
9299	361	total of 569 individual	[total of 569 individuals]	0.0	4	1	1	1
9300	361	case-control analysis match	[case-control analysis matching]	0.0	3	1	1	1
9301	361	effect of system modulation	[effect of system modulation]	0.0	4	1	1	1
9302	361	925 ed visit	[925 ED visits]	0.0	3	1	1	1
9303	361	fifty patient with recent onset	[Fifty patients with recent onset]	0.0	5	1	1	1
9304	361	improvement of perturbation	[improvement of perturbations]	0.0	3	1	1	1
9305	361	pioglitazone for saxagliptin versus sulfonylurea	[pioglitazone for saxagliptin versus sulfonylureas]	0.0	5	1	1	1
9306	361	previous study investigate cachexia	[Previous studies investigating cachexia]	0.0	4	1	1	1
9307	361	response in activity (123)i-meta-iodobenzylguanidine	[response in activity (123)I-meta-iodobenzylguanidine]	0.0	4	1	1	1
9308	361	diastolic end diameter mean difference	[diastolic end diameter mean difference]	0.0	5	1	1	1
9309	361	right ventricular plane systolic excursion	[right ventricular plane systolic excursion]	0.0	5	1	1	1
9310	361	descriptive assessment	[descriptive assessment]	0.0	2	1	1	1
9311	361	literature search	[literature search]	0.0	2	1	1	1
9312	361	male gender	[male gender]	0.0	2	1	1	1
9313	361	fig	[Fig]	0.0	1	1	1	1
9314	361	health problem worldwide	[health problem worldwide]	0.0	3	1	1	1
9315	361	Subgroup	[Subgroup]	0.0	1	1	1	1
9316	361	distinct derangement	[distinct derangement]	0.0	2	1	1	1
9317	361	result of study with ARNI inhibitor	[results of studies with ARNI inhibitors]	0.0	6	1	1	1
9318	361	model use procedure	[model using procedures]	0.0	3	1	1	1
9319	361	reticulum	[reticulum]	0.0	1	1	1	1
9320	361	Mechanistic insight	[Mechanistic insight]	0.0	2	1	1	1
9321	361	involve 115 center	[involving 115 centers]	0.0	3	1	1	1
9322	361	Physio Ring	[Physio Ring]	0.0	2	1	1	1
9323	361	partial pressure	[partial pressure]	0.0	2	1	1	1
9324	361	hyperkalemia patient	[hyperkalemia patients]	0.0	2	1	1	1
9325	361	aa	[AA]	0.0	1	1	1	1
9326	361	single-arm multicenter study	[single-arm multicenter study]	0.0	3	1	1	1
9327	361	practice-level variation in use	[Practice-level variation in use]	0.0	4	1	1	1
9328	361	baseline ef	[baseline EF]	0.0	2	1	1	1
9329	361	20 812 consecutive patient	[20 812 consecutive patients]	0.0	4	1	1	1
9330	361	coronary occlusion	[coronary occlusion]	0.0	2	1	1	1
9331	361	receive PD	[receiving PD]	0.0	2	1	1	1
9332	361	effect on cumulative urine volume	[effect on cumulative urine volume]	0.0	5	2	2	1
9333	361	context of liver disease	[context of liver disease]	0.0	4	1	1	1
9334	361	addition of GLS	[addition of GLS]	0.0	3	1	1	1
9335	361	plasma b-type peptide level	[plasma B-type peptide levels]	0.0	4	1	1	1
9336	361	parameter in af	[parameters in AF]	0.0	3	1	1	1
9337	361	individual with obstructive pulmonary disease	[individuals with obstructive pulmonary disease]	0.0	5	1	1	1
9338	361	right ventricular area index	[right ventricular area index]	0.0	4	1	1	1
9339	361	reveal a mechanism of dysfunction	[revealing a mechanism of dysfunction]	0.0	5	1	1	1
9340	361	crucial role include factor	[crucial role including factor]	0.0	4	1	1	1
9341	361	Postoperative survival gram	[Postoperative survival g]	0.0	3	1	1	1
9342	361	grade moderate-quality evidence	[Grade moderate-quality evidence]	0.0	3	1	1	1
9343	361	additive for peak vo2	[additive for peak VO2]	0.0	4	1	1	1
9344	361	presence of mr	[presence of MR]	0.0	3	1	1	1
9345	361	actin cytoskeleton	[actin cytoskeleton]	0.0	2	1	1	1
9346	361	right ventricular annular plane excursion	[right ventricular annular plane excursion]	0.0	5	1	1	1
9347	361	β1ar overstimulation in heart failure	[β1AR overstimulation in heart failure]	0.0	5	1	1	1
9348	361	Comparison	[Comparison]	0.0	1	3	3	1
9349	361	validate outcome measure	[Validating outcome measures]	0.0	3	1	1	1
9350	361	trend for four common condition	[trends for four common conditions]	0.0	5	1	1	1
9351	361	interruption of neurohormonal system	[interruption of neurohormonal systems]	0.0	4	1	1	1
9352	361	insight in heart failure a study	[insight in heart failure a study]	0.0	6	1	1	1
9353	361	left ejection fraction p	[left ejection fraction P]	0.0	4	1	1	1
9354	361	iron-deficient adult patient	[iron-deficient adult patients]	0.0	3	1	1	1
9355	361	effect on mortality	[effect on mortality]	0.0	3	1	1	1
9356	361	monitoring a systematic review	[monitoring a systematic review]	0.0	4	1	1	1
9357	361	induction of hretn human resistin mrna	[induction of hRetn human resistin mRNA]	0.0	6	1	1	1
9358	361	multiacquisition t1-mapping MRI during respiration	[Multiacquisition T1-mapping MRI during respiration]	0.0	5	1	1	1
9359	361	cr	[CR]	0.0	1	1	1	1
9360	361	difference among ef median bnp EF	[difference among EF median BNP EF]	0.0	6	1	1	1
9361	361	Trial investigate Outcome study	[Trial Investigating Outcomes study]	0.0	4	1	1	1
9362	361	ventricular function in cardiac volume overload	[ventricular function in cardiac volume overload]	0.0	6	1	1	1
9363	361	month post-procedure	[months post-procedure]	0.0	2	1	1	1
9364	361	action the L-type channel isoform	[actions the L-type channel isoforms]	0.0	5	1	1	1
9365	361	high exercise	[higher exercise]	0.0	2	1	1	1
9366	361	recent onset HFrEF day	[recent onset HFrEF days]	0.0	4	1	1	1
9367	361	composite from any cause	[composite from any cause]	0.0	4	1	1	1
9368	361	hr 70 bpm	[HR 70 bpm]	0.0	3	1	1	1
9369	361	ventricular fill pressure response	[ventricular filling pressure response]	0.0	4	1	1	1
9370	361	derangement with hemodynamic feature	[derangement with hemodynamic features]	0.0	4	1	1	1
9371	361	many current predictor of mortality	[Many current predictors of mortality]	0.0	5	1	1	1
9372	361	reserve in patient with hypertension	[reserve in patients with hypertension]	0.0	5	2	2	1
9373	361	information for a unfavourable outcome	[information for an unfavourable outcome]	0.0	5	1	1	1
9374	361	tta tgtetmena mouse	[TTA TgTetMena mice]	0.0	3	1	1	1
9375	361	aortocaval fistula	[aortocaval fistula]	0.0	2	1	1	1
9376	361	psoriasis as a variable	[psoriasis as a variable]	0.0	4	1	1	1
9377	361	epitope p	[epitopes P]	0.0	2	1	1	1
9378	361	er	[ER]	0.0	1	1	1	1
9379	361	study-related event	[study-related events]	0.0	2	1	1	1
9380	361	np assessment of ED patient	[NP assessment of ED patients]	0.0	5	1	1	1
9381	361	674 man without a history	[674 men without a history]	0.0	5	1	1	1
9382	361	c57bl	[C57BL]	0.0	1	1	1	1
9383	361	agreement mean difference	[agreement mean difference]	0.0	3	1	1	1
9384	361	Left assist device lvas	[Left assist devices LVADs]	0.0	4	1	1	1
9385	361	staff responsible	[staff responsible]	0.0	2	1	1	1
9386	361	ventricular systolic function in volume overload	[ventricular systolic function in volume overload]	0.0	6	1	1	1
9387	361	follow 3-year event rate	[following 3-year event rates]	0.0	4	1	1	1
9388	361	prospective assessment	[prospective assessment]	0.0	2	1	1	1
9389	361	crucial target	[crucial target]	0.0	2	1	1	1
9390	361	electromechanical delay EMD the time	[electromechanical delay EMD the time]	0.0	5	1	1	1
9391	361	patient man year	[patients men years]	0.0	3	1	1	1
9392	361	ventricular RV annular plane excursion	[ventricular RV annular plane excursion]	0.0	5	1	1	1
9393	361	practice for a limited number	[practice for a limited number]	0.0	5	1	1	1
9394	361	patient with myxoma	[patient with myxoma]	0.0	3	1	1	1
9395	361	impaired right ventricular pump function	[impaired right ventricular pump function]	0.0	5	1	1	1
9396	361	1.02±0.18 mm for psoriasis	[1.02±0.18 mm for psoriasis]	0.0	4	1	1	1
9397	361	monitoring rm	[monitoring RM]	0.0	2	1	1	1
9398	361	effect of beta-blocker therapy	[effects of beta-blocker therapy]	0.0	4	1	1	1
9399	361	point-of-care	[Point-of-care]	0.0	1	1	1	1
9400	361	risk for HF	[risk for HF]	0.0	3	1	1	1
9401	361	gg	[GG]	0.0	1	1	1	1
9402	361	HF patient without VT	[HF patients without VT]	0.0	4	1	1	1
9403	361	level pg	[levels pg]	0.0	2	1	1	1
9404	361	splice	[splice]	0.0	1	2	2	1
9405	361	downregulation of multiple cardiac gene	[downregulation of multiple cardiac genes]	0.0	5	1	1	1
9406	361	downregulation of gene in HF	[downregulation of genes in HF]	0.0	5	1	1	1
9407	361	suboptimal care	[suboptimal care]	0.0	2	1	1	1
9408	361	CHF among patient	[CHF among patients]	0.0	3	1	1	1
9409	361	effect on the endpoint	[effects on the endpoint]	0.0	4	1	1	1
9410	361	new therapeutic target	[new therapeutic targets]	0.0	3	1	1	1
9411	361	potential of diuretic	[potential of diuretics]	0.0	3	1	1	1
9412	361	non-diastolic abnormality in cardiovascular function	[non-diastolic abnormalities in cardiovascular function]	0.0	5	1	1	1
9413	361	marker indicative of autonomic balance	[markers indicative of autonomic balance]	0.0	5	1	1	1
9414	361	time domain	[time domain]	0.0	2	1	1	1
9415	361	plasma b-type peptide	[plasma B-type peptide]	0.0	3	1	1	1
9416	361	kg with improvement in diuretic response	[kg with improvement in diuretic response]	0.0	6	1	1	1
9417	361	stem from cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[stemming from cardiomyopathies]	0.0	3	1	1	1
9418	361	regulator of growth	[regulator of growth]	0.0	3	1	1	1
9419	361	heart failure guideline	[heart failure guidelines]	0.0	3	1	1	1
9420	361	minute m vs. 1.5 m	[min m vs. 1.5 m]	0.0	5	1	1	1
9421	361	pulmonary hypertension medication	[pulmonary hypertension medication]	0.0	3	1	1	1
9422	361	benefit for patient	[benefit for patients]	0.0	3	1	1	1
9423	361	left LV ejection fraction LVEF	[left LV ejection fraction LVEF]	0.0	5	1	1	1
9424	361	pediatric support	[pediatric support]	0.0	2	1	1	1
9425	361	additive effect of a number	[additive effect of an number]	0.0	5	1	1	1
9426	361	increase refill compliance	[increasing refill compliance]	0.0	3	1	1	1
9427	361	predictor of long outcome	[predictor of long-term outcomes]	0.0	4	1	1	1
9428	361	secondary end point reflective	[secondary end points reflective]	0.0	4	1	1	1
9429	361	ventricular-pulmonary coupling resistance	[ventricular-pulmonary coupling resistance]	0.0	3	1	1	1
9430	361	r-like	[R-like]	0.0	1	1	1	1
9431	361	use cardiac resonance t1 mapping	[using cardiac resonance T1 mapping]	0.0	5	1	1	1
9432	361	manipulation of gene control	[manipulation of gene control]	0.0	4	1	1	1
9433	361	iv	[IV]	0.0	1	1	1	1
9434	361	β-blocker-induced enhancement	[β-Blocker-induced enhancement]	0.0	2	1	1	1
9435	361	require RV support	[requiring RV support]	0.0	3	1	1	1
9436	361	clinical study 2900 hm ii	[clinical studies 2900 HM II]	0.0	5	1	1	1
9437	361	Bradycardia	[Bradycardia]	0.0	1	1	1	1
9438	361	can 2 handling	[Ca 2 handling]	0.0	3	1	1	1
9439	361	age group of year	[age group of years]	0.0	4	1	1	1
9440	361	utilize testimony with nurse	[Utilizing testimonies with nurses]	0.0	4	1	1	1
9441	361	complication of therapy in HF	[complications of therapy in HF]	0.0	5	1	1	1
9442	361	occurrence	[Occurrence]	0.0	1	2	2	1
9443	361	originally part	[originally part]	0.0	2	1	1	1
9444	361	Clinician	[Clinician]	0.0	1	1	1	1
9445	361	readmission rate p	[readmission rates P]	0.0	3	1	1	1
9446	361	heart twist	[heart twist]	0.0	2	1	1	1
9447	361	high hospitalization rate	[higher hospitalization rates]	0.0	3	1	1	1
9448	361	two hundred HF patient	[Two hundred HF patients]	0.0	4	1	1	1
9449	361	mechanism during insulin resistance	[mechanism during insulin resistance]	0.0	4	1	1	1
9450	361	association with capacity	[Association with capacity]	0.0	3	1	1	1
9451	361	aortic constriction AAC	[aortic constriction AAC]	0.0	3	1	1	1
9452	361	kd	[Kd]	0.0	1	1	1	1
9453	361	safe off-pump sternal sparing approach	[Safe off-pump sternal sparing approach]	0.0	5	1	1	1
9454	361	30 millileter per m 2	[30 mL per m 2]	0.0	5	1	1	1
9455	361	binomial regression	[binomial regression]	0.0	2	1	1	1
9456	361	mean duration	[mean duration]	0.0	2	1	1	1
9457	361	Implantable cardioverter-defibrillators	[Implantable cardioverter-defibrillators]	0.0	2	1	1	1
9458	361	treatment of heart failure current treatment	[treatment of heart failure current treatment]	0.0	6	1	1	1
9459	361	B-type natriuretic peptide	[B-type natriuretic peptide]	0.0	3	1	1	1
9460	361	lb	[lb]	0.0	1	1	1	1
9461	361	fifty-four asymptomatic pediatric Fontan PF patient	[Fifty-four asymptomatic pediatric Fontan PF patients]	0.0	6	1	1	1
9462	361	argument for hypo-response	[arguments for hypo-response]	0.0	3	1	1	1
9463	361	low vascular resistance SVR index	[low vascular resistance SVR index]	0.0	5	1	1	1
9464	361	if-channel inhibition	[If-channel inhibition]	0.0	2	1	1	1
9465	361	hvad	[HVAD]	0.0	1	1	1	1
9466	361	sitagliptin versus pioglitazone for sitagliptin	[sitagliptin versus pioglitazone for sitagliptin]	0.0	5	1	1	1
9467	361	outcome in patient with moderate	[outcomes in patients with moderate]	0.0	5	1	1	1
9468	361	role for microrna rirnas	[role for microRNAs miRNAs]	0.0	4	1	1	1
9469	361	diverse aspect of remodeling	[diverse aspects of remodeling]	0.0	4	1	1	1
9470	361	g protein	[G proteins]	0.0	2	1	1	1
9471	361	day range 6 day	[days range 6 days]	0.0	4	1	1	1
9472	361	70 versus ≥70 bpm respectively p	[70 versus ≥70 bpm respectively P]	0.0	6	1	1	1
9473	361	global strain of left ventricle	[global strain of left ventricle]	0.0	5	1	1	1
9474	361	proteomics change in transverse constriction	[proteomics changes in transverse constriction]	0.0	5	1	1	1
9475	361	give rise in HF	[giving rise in HF]	0.0	4	1	1	1
9476	361	communication	[communication]	0.0	1	1	1	1
9477	361	prognostic dysfunction lead	[prognostic dysfunction leading]	0.0	3	1	1	1
9478	361	structurally normal heart HNorm	[structurally normal hearts HNorm]	0.0	4	1	1	1
9479	361	mo	[mo]	0.0	1	1	1	1
9480	361	ejection time complicate hypertension	[ejection time complicating hypertension]	0.0	4	1	1	1
9481	361	rehabilitation care on capacity	[rehabilitation care on capacity]	0.0	4	1	1	1
9482	361	heart failure with left ejection fraction	[Heart failure with left ejection fraction]	0.0	6	1	1	1
9483	361	presence of even mild dysfunction	[presence of even mild dysfunction]	0.0	5	1	1	1
9484	361	entry	[entry]	0.0	1	1	1	1
9485	361	serum level of peptide	[serum levels of peptide]	0.0	4	1	1	1
9486	361	event during the postoperative month	[events during the postoperative months]	0.0	5	1	1	1
9487	361	target individual	[targeting individuals]	0.0	2	1	1	1
9488	361	6 minute m	[6 min m]	0.0	3	1	1	1
9489	361	elevation in BNP	[elevations in BNP]	0.0	3	1	1	1
9490	361	no	[NO]	0.0	1	1	1	1
9491	361	p3	[P3]	0.0	1	1	1	1
9492	361	set of variable	[set of variables]	0.0	3	1	1	1
9493	361	new review of the effect	[new review of the effects]	0.0	5	1	1	1
9494	361	great benefit	[greater benefit]	0.0	2	1	1	1
9495	361	serum level of peptide bnp	[serum levels of peptide BNP]	0.0	5	1	1	1
9496	361	veteran aged year	[veterans aged years]	0.0	3	1	1	1
9497	361	history of infarction	[history of infarction]	0.0	3	2	2	1
9498	361	myocardial infarction with major complication	[myocardial infarction with major complications]	0.0	5	1	1	1
9499	361	state of stress	[state of stress]	0.0	3	1	1	1
9500	361	additional prognostic benefit	[additional prognostic benefit]	0.0	3	1	1	1
9501	361	impaired gene expression	[impaired gene expression]	0.0	3	1	1	1
9502	361	ischemic etiology	[ischemic etiology]	0.0	2	1	1	1
9503	361	endpoint of therapy	[endpoint of therapy]	0.0	3	1	1	1
9504	361	acute myocardial infarction in Australia	[acute myocardial infarction in Australia]	0.0	5	1	1	1
9505	361	transition marker	[transition markers]	0.0	2	1	1	1
9506	361	unidirectional interatrial shunting	[Unidirectional interatrial shunting]	0.0	3	1	1	1
9507	361	LCX 2-vessel model	[LCX 2-vessel model]	0.0	3	1	1	1
9508	361	first day	[first days]	0.0	2	1	1	1
9509	361	have heart failure HF	[having heart failure HF]	0.0	4	1	1	1
9510	361	use magnetic resonance t1 mapping	[using magnetic resonance T1 mapping]	0.0	5	1	1	1
9511	361	radial tonometry	[radial tonometry]	0.0	2	1	1	1
9512	361	renal optimization strategy	[Renal Optimization Strategies]	0.0	3	1	1	1
9513	361	156 HF patient ventricular ejection fraction	[156 HF patients ventricular ejection fraction]	0.0	6	1	1	1
9514	361	titin hypophosphorylation	[titin hypophosphorylation]	0.0	2	1	1	1
9515	361	importance in the pathophysiology	[importance in the pathophysiology]	0.0	4	1	1	1
9516	361	N termini	[N termini]	0.0	2	1	1	1
9517	361	decrease in re-hospitalization	[decrease in re-hospitalization]	0.0	3	1	1	1
9518	361	independent risk factor for disease	[independent risk factor for disease]	0.0	5	1	1	1
9519	361	proteomics analysis of pressure-overload-induced heart failure	[proteomics analysis of pressure-overload-induced heart failure]	0.0	6	1	1	1
9520	361	adverse CV event in model p	[adverse CV events in models p]	0.0	6	1	1	1
9521	361	e-wave diastolic mitral velocity	[E-wave diastolic mitral velocity]	0.0	4	1	1	1
9522	361	partial improvement at advanced stage	[partial improvement at advanced stages]	0.0	5	1	1	1
9523	361	effect on receptor β-ar signal	[effects on receptor β-AR signaling]	0.0	5	1	1	1
9524	361	global longitudinal strain GLS	[global longitudinal strain GLS]	0.0	4	1	1	1
9525	361	admission measurement	[admission measurement]	0.0	2	1	1	1
9526	361	self-care maintenance with success	[Self-Care Maintenance with success]	0.0	4	1	1	1
9527	361	encode a decoy vegf receptor	[encoding a decoy VEGF receptor]	0.0	5	1	1	1
9528	361	molecular pathway in patient	[molecular pathways in patients]	0.0	4	1	1	1
9529	361	ventricular contractile reserve in patient	[ventricular contractile reserve in patients]	0.0	5	2	2	1
9530	361	study investigate hf-related cachexia	[studies investigating HF-related cachexia]	0.0	4	1	1	1
9531	361	history of mitral valve plasty	[history of mitral valve plasty]	0.0	5	1	1	1
9532	361	index 0.7 L	[index 0.7 L]	0.0	3	1	1	1
9533	361	oppose	[opposing]	0.0	1	1	1	1
9534	361	outcome median versus 257 millisecond	[outcome median vs 257 milliseconds]	0.0	5	1	1	1
9535	361	assess fill pressure in patient	[assessing filling pressure in patients]	0.0	5	1	1	1
9536	361	cardiomyocyte-like cell	[cardiomyocyte-like cells]	0.0	2	1	1	1
9537	361	t2	[T2]	0.0	1	1	1	1
9538	361	Connecticut Health Center	[Connecticut Health Center]	0.0	3	1	1	1
9539	361	obstructive disease copd	[obstructive disease COPD]	0.0	3	1	1	1
9540	361	electrical stimulation fes	[electrical stimulation FES]	0.0	3	1	1	1
9541	361	2 type HeartMate	[2 types HeartMate]	0.0	3	1	1	1
9542	361	validation cohort of patient	[validation cohort of patients]	0.0	4	1	1	1
9543	361	myocyte from heart	[myocytes from hearts]	0.0	3	1	1	1
9544	361	walking in patient	[walking in patients]	0.0	3	1	1	1
9545	361	benefit over systolic parameter	[benefit over systolic parameters]	0.0	4	1	1	1
9546	361	decile of agreement	[deciles of agreement]	0.0	3	1	1	1
9547	361	total of man	[total of men]	0.0	3	1	1	1
9548	361	p-value for difference	[P-value for difference]	0.0	3	1	1	1
9549	361	mitochondrial stress	[mitochondrial stress]	0.0	2	1	1	1
9550	361	ss	[SS]	0.0	1	1	1	1
9551	361	decision	[decisions]	0.0	1	2	2	1
9552	361	deleterious effect on various process	[deleterious effects on various processes]	0.0	5	1	1	1
9553	361	dose of 18 mg	[dose of 18 mg]	0.0	4	1	1	1
9554	361	self-care maintenance	[Self-Care Maintenance]	0.0	2	1	1	1
9555	361	percutaneous intervention	[percutaneous intervention]	0.0	2	1	1	1
9556	361	patient man	[patients men]	0.0	2	1	1	1
9557	361	arterial coupling	[arterial coupling]	0.0	2	1	1	1
9558	361	reactivation	[reactivation]	0.0	1	1	1	1
9559	361	exclusion of trial	[Exclusion of trial]	0.0	3	1	1	1
9560	361	lipoprotein HDL	[lipoprotein HDL]	0.0	2	1	1	1
9561	361	pharmacologic study	[pharmacologic studies]	0.0	2	1	1	1
9562	361	bte all p	[BTES All P]	0.0	3	1	1	1
9563	361	non-dilated ventricle	[non-dilated ventricle]	0.0	2	1	1	1
9564	361	circulatory derangement with feature similar	[circulatory derangement with features similar]	0.0	5	1	1	1
9565	361	ventricular longitudinal strain GLS	[ventricular longitudinal strain GLS]	0.0	4	1	1	1
9566	361	insight into the potential as target	[insight into the potential as targets]	0.0	6	1	1	1
9567	361	effect of dopamine	[effect of dopamine]	0.0	3	1	1	1
9568	361	Cox proportional hazard regression modeling	[Cox proportional hazards regression modeling]	0.0	5	1	1	1
9569	361	with axis function	[with axis function]	0.0	3	1	1	1
9570	361	practice with this population	[practice with these populations]	0.0	4	1	1	1
9571	361	survival of patient gram	[survival of patients g]	0.0	4	1	1	1
9572	361	Michigan HF clinic	[Michigan HF clinic]	0.0	3	1	1	1
9573	361	type V cardiac na	[type V cardiac Na]	0.0	4	1	1	1
9574	361	reversal of cardiac dysfunction by metoprolol	[Reversal of cardiac dysfunction by metoprolol]	0.0	6	1	1	1
9575	361	common form of ventricular LV remodeling	[common forms of ventricular LV remodeling]	0.0	6	1	1	1
9576	361	total compliance tac	[total compliance TAC]	0.0	3	1	1	1
9577	361	instability of nitrite	[instability of nitrite]	0.0	3	1	1	1
9578	361	evidence of diastolic dysfunction	[evidence of diastolic dysfunction]	0.0	4	1	1	1
9579	361	involve ventricular assist device	[involving ventricular assist devices]	0.0	4	1	1	1
9580	361	daily practice with this population	[daily practice with these populations]	0.0	5	1	1	1
9581	361	left ejection fraction 0.35	[left ejection fraction 0.35]	0.0	4	1	1	1
9582	361	cross-talk between the heart	[Cross-talk between the heart]	0.0	4	1	1	1
9583	361	stable hypertension medication	[stable hypertension medication]	0.0	3	1	1	1
9584	361	favorable outcome at year	[favorable outcome at year]	0.0	4	1	1	1
9585	361	irs2 double-knockout	[IRS2 double-knockout]	0.0	2	1	1	1
9586	361	joint effect	[joint effect]	0.0	2	1	1	1
9587	361	gap	[gaps]	0.0	1	1	1	1
9588	361	gas	[gas]	0.0	1	1	1	1
9589	361	change in cardiomyocyte	[changes in cardiomyocytes]	0.0	3	1	1	1
9590	361	insight into prolonged delay	[insight into prolonged delay]	0.0	4	1	1	1
9591	361	guanylate	[guanylate]	0.0	1	1	1	1
9592	361	decrease in length of stay	[decrease in length of stay]	0.0	5	1	1	1
9593	361	uptitration of neurohumoral blocker	[uptitration of neurohumoral blockers]	0.0	4	1	1	1
9594	361	consecutive patient 224 man mean	[consecutive patients 224 men mean]	0.0	5	1	1	1
9595	361	final evaluation	[final evaluation]	0.0	2	1	1	1
9596	361	with.estimate	[with.estimates]	0.0	1	1	1	1
9597	361	carry two increase in risk	[carrying two increase in risk]	0.0	5	1	1	1
9598	361	transplant ineligible patient	[transplant ineligible patients]	0.0	3	1	1	1
9599	361	overview of the abnormality	[overview of the abnormalities]	0.0	4	1	1	1
9600	361	high 30-day survival rate	[high 30-day survival rates]	0.0	4	1	1	1
9601	361	participant contact	[participant contact]	0.0	2	1	1	1
9602	361	common characteristic use Cochrane Practice	[common characteristics using Cochrane Practice]	0.0	5	1	1	1
9603	361	undiagnosed heart disease	[undiagnosed heart disease]	0.0	3	1	1	1
9604	361	cost for patient	[costs for patients]	0.0	3	1	1	1
9605	361	tricuspid annular	[Tricuspid annular]	0.0	2	1	1	1
9606	361	seven problem	[seven problems]	0.0	2	1	1	1
9607	361	chronic stable guideline-directed therapy	[chronic stable guideline-directed therapy]	0.0	4	1	1	1
9608	361	patient with infarction	[patients with infarction]	0.0	3	1	1	1
9609	361	important defense mechanism during stress	[important defense mechanism during stress]	0.0	5	1	1	1
9610	361	impact of carvedilol	[impact of carvedilol]	0.0	3	1	1	1
9611	361	approach extrapolate short-term outcome	[approach extrapolating short-term outcomes]	0.0	4	1	1	1
9612	361	symptom cpet in 10 patient	[symptom CPET in 10 patients]	0.0	5	1	1	1
9613	361	analysis of cardiac tissue	[analysis of cardiac tissue]	0.0	4	1	1	1
9614	361	vs. 1.39 time	[vs. 1.39 times]	0.0	3	1	1	1
9615	361	chronic heart failure population	[chronic heart failure population]	0.0	4	1	1	1
9616	361	trend toward enrollment with dilatation	[trend toward enrollment with dilatation]	0.0	5	1	1	1
9617	361	several gene	[several genes]	0.0	2	1	1	1
9618	361	first acute myocardial infarction	[first acute myocardial infarction]	0.0	4	1	1	1
9619	361	association of Approaches	[associations of Approaches]	0.0	3	1	1	1
9620	361	other important outcome	[other important outcomes]	0.0	3	1	1	1
9621	361	pharmacologic management	[pharmacologic management]	0.0	2	1	1	1
9622	361	1.3 patient-year	[1.3 patient-years]	0.0	2	1	1	1
9623	361	pulmonary artery systolic pressure pasp increase	[pulmonary artery systolic pressure PASP increase]	0.0	6	1	1	1
9624	361	outcome such as heart failure	[outcomes such as heart failure]	0.0	5	1	1	1
9625	361	Particular topic of debate	[Particular topics of debate]	0.0	4	1	1	1
9626	361	strength as a independent predictor	[strength as an independent predictor]	0.0	5	1	1	1
9627	361	arterial tonometry	[arterial tonometry]	0.0	2	1	1	1
9628	361	4.4 mm hg	[4.4 mm Hg]	0.0	3	1	1	1
9629	361	subgroup at risk of hyperkalemia	[subgroups at risk of hyperkalemia]	0.0	5	1	1	1
9630	361	common inpatient condition	[common inpatient conditions]	0.0	3	1	1	1
9631	361	heart failure clinical study	[heart failure clinical studies]	0.0	4	1	1	1
9632	361	longitudinal systolic strain GLS	[longitudinal systolic strain GLS]	0.0	4	1	1	1
9633	361	2 hypothese addition 2 μg	[2 hypotheses addition 2 μg]	0.0	5	1	1	1
9634	361	evidence on effect of type	[evidence on effects of types]	0.0	5	1	1	1
9635	361	median follow-up of year	[median follow-up of years]	0.0	4	2	2	1
9636	361	death in the procedure	[deaths in the procedures]	0.0	4	1	1	1
9637	361	disease complex with therapeutics	[disease complex with therapeutics]	0.0	4	1	1	1
9638	361	median bnp level	[median BNP level]	0.0	3	1	1	1
9639	361	first myocardial infarction	[first myocardial infarction]	0.0	3	1	1	1
9640	361	english-language trial in adult with anemia	[English-language trials in adults with anemia]	0.0	6	1	1	1
9641	361	twofold increase	[twofold increase]	0.0	2	2	2	1
9642	361	alleviate the decrement	[alleviating the decrement]	0.0	3	1	1	1
9643	361	left LV myocyte	[left LV myocytes]	0.0	3	1	1	1
9644	361	1.6 reason p	[1.6 reasons P]	0.0	3	1	1	1
9645	361	get	[Get]	0.0	1	1	1	1
9646	361	early diastolic velocity 3.1 vs. 1.3	[early diastolic velocity 3.1 vs. 1.3]	0.0	6	1	1	1
9647	361	application of mitochondrial-targeted peptide drug	[application of mitochondrial-targeted peptide drugs]	0.0	5	1	1	1
9648	361	cardiovascular event p=0.18	[cardiovascular events P=0.18]	0.0	3	1	1	1
9649	361	Canadian access programme	[Canadian access programme]	0.0	3	1	1	1
9650	361	event rate at 0.53 event	[event rate at 0.53 events]	0.0	5	1	1	1
9651	361	participatory population-specific health intervention	[participatory population-specific health interventions]	0.0	4	1	1	1
9652	361	assessment of patient within day	[assessments of patients within days]	0.0	5	1	1	1
9653	361	development in procedure	[developments in procedure]	0.0	3	1	1	1
9654	361	significance of BNP	[significance of BNP]	0.0	3	1	1	1
9655	361	Coronary artery disease	[Coronary artery disease]	0.0	3	1	1	1
9656	361	initial class	[initial class]	0.0	2	1	1	1
9657	361	bad good quintile	[worst best quintile]	0.0	3	1	1	1
9658	361	full advantage	[full advantage]	0.0	2	1	1	1
9659	361	reduction in the number of admission	[reductions in the number of admissions]	0.0	6	1	1	1
9660	361	significant decline	[significant decline]	0.0	2	1	1	1
9661	361	104 mm hg	[104 mm Hg]	0.0	3	1	1	1
9662	361	factor at admission	[factors at admission]	0.0	3	1	1	1
9663	361	history with normal artery	[history with normal arteries]	0.0	4	1	1	1
9664	361	low mg	[low mg]	0.0	2	1	1	1
9665	361	relevance of reserve in patient	[relevance of reserve in patients]	0.0	5	1	1	1
9666	361	arterial hypertension pah	[arterial hypertension PAH]	0.0	3	1	1	1
9667	361	worsen GLS	[worsening GLS]	0.0	2	1	1	1
9668	361	fat mass FFM	[fat mass FFM]	0.0	3	1	1	1
9669	361	broad panel of assessment	[broad panel of assessments]	0.0	4	1	1	1
9670	361	reversible ischemia open stent	[reversible ischemia open stent]	0.0	4	1	1	1
9671	361	mitral valve tethering	[mitral valve tethering]	0.0	3	2	2	1
9672	361	use of the nervous system	[use of the nervous systems]	0.0	5	1	1	1
9673	361	systolic elastance	[systolic elastance]	0.0	2	1	1	1
9674	361	harm such as thromboembolism	[harms such as thromboembolism]	0.0	4	1	1	1
9675	361	especially in patient survive a infarction	[especially in patients surviving an infarction]	0.0	6	1	1	1
9676	361	2 type for btt patient	[2 types for BTT patients]	0.0	5	1	1	1
9677	361	2+)-uptake	[2+)-uptake]	0.0	1	1	1	1
9678	361	Renin-angiotensin-aldosterone system	[Renin-angiotensin-aldosterone system]	0.0	2	1	1	1
9679	361	VA health care system	[VA health care systems]	0.0	4	1	1	1
9680	361	ED setting	[ED settings]	0.0	2	1	1	1
9681	361	major safety measure	[major safety measures]	0.0	3	1	1	1
9682	361	corporeal membrane oxygenation	[corporeal membrane oxygenation]	0.0	3	1	1	1
9683	361	most common cause of hospitalization	[most common cause of hospitalization]	0.0	5	1	1	1
9684	361	acute cardiotoxicity	[acute cardiotoxicity]	0.0	2	1	1	1
9685	361	multicenter double-blind placebo-controlled trial of patient	[Multicenter double-blind placebo-controlled trial of patients]	0.0	6	1	1	1
9686	361	Outcome multicenter study	[Outcomes multicenter study]	0.0	3	1	1	1
9687	361	partial improvement at stage	[partial improvement at stages]	0.0	4	1	1	1
9688	361	woman undergo chemotherapy	[women undergoing chemotherapy]	0.0	3	1	1	1
9689	361	peripheral muscle	[peripheral muscles]	0.0	2	1	1	1
9690	361	deleterious effect on process	[deleterious effects on processes]	0.0	4	1	1	1
9691	361	standard in biomarker study	[standards in biomarker studies]	0.0	4	1	1	1
9692	361	right assist	[right assist]	0.0	2	1	1	1
9693	361	dopamine in heart failure with dysfunction	[dopamine in heart failure with dysfunction]	0.0	6	1	1	1
9694	361	typical pattern	[typical pattern]	0.0	2	1	1	1
9695	361	rest hr 70 bpm p	[resting HR 70 bpm P]	0.0	5	1	1	1
9696	361	myocty	[myoctyes]	0.0	1	1	1	1
9697	361	cardiac risk	[cardiac risk]	0.0	2	1	1	1
9698	361	patient aged	[Patients aged]	0.0	2	1	1	1
9699	361	perception of cardioverter-defibrillator deactivation discussion	[perceptions of cardioverter-defibrillator deactivation discussions]	0.0	5	1	1	1
9700	361	little influence on the overall burden	[little influence on the overall burden]	0.0	6	1	1	1
9701	361	von willebrand factor	[von Willebrand factor]	0.0	3	1	1	1
9702	361	datum on the potential of diuretic	[data on the potential of diuretics]	0.0	6	1	1	1
9703	361	low median activity p	[lower median activities P]	0.0	4	1	1	1
9704	361	transform growth factor yield	[transforming growth factor yield]	0.0	4	1	1	1
9705	361	ounce	[os]	0.0	1	1	1	1
9706	361	heart failure a disorder	[heart failure a disorder]	0.0	4	1	1	1
9707	361	acute ventricular pressure overload	[acute ventricular pressure overload]	0.0	4	1	1	1
9708	361	resting hr bpm	[resting HR bpm]	0.0	3	1	1	1
9709	361	major component	[major components]	0.0	2	1	1	1
9710	361	left ventricular diastolic end diameter difference	[left ventricular diastolic end diameter difference]	0.0	6	1	1	1
9711	361	beta blocker in onset hfref	[beta blockers in onset HFrEF]	0.0	5	1	1	1
9712	361	age 60 year	[age 60 years]	0.0	3	1	1	1
9713	361	end point of death	[end point of death]	0.0	4	1	1	1
9714	361	chronic guideline-directed medical therapy	[chronic guideline-directed medical therapy]	0.0	4	1	1	1
9715	361	small difference bnp in woman	[smallest difference BNP in women]	0.0	5	1	1	1
9716	361	model p	[models p]	0.0	2	1	1	1
9717	361	decrease in length	[decrease in length]	0.0	3	1	1	1
9718	361	arterial systolic pressure relationship	[arterial systolic pressure relationship]	0.0	4	1	1	1
9719	361	significant gap in impact	[significant gaps in impact]	0.0	4	1	1	1
9720	361	estimate capillary wedge pressure	[estimating capillary wedge pressure]	0.0	4	1	1	1
9721	361	race by treatment interaction	[race by treatment interaction]	0.0	4	1	1	1
9722	361	tonometric index	[tonometric indices]	0.0	2	1	1	1
9723	361	bnp level 100 pg	[BNP levels 100 pg]	0.0	4	1	1	1
9724	361	thigh muscle fat ratio	[thigh muscle fat ratio]	0.0	4	1	1	1
9725	361	inoperable thromboembolic hypertension	[inoperable thromboembolic hypertension]	0.0	3	1	1	1
9726	361	advanced management involve assist device	[advanced management involving assist devices]	0.0	5	1	1	1
9727	361	concentration of s ST2	[Concentrations of s ST2]	0.0	4	1	1	1
9728	361	patient with advanced organ failure	[patients with advanced organ failure]	0.0	5	1	1	1
9729	361	156 HF patient ejection fraction	[156 HF patients ejection fraction]	0.0	5	1	1	1
9730	361	increase refill compliance for etidronate p	[increasing refill compliance for etidronate P]	0.0	6	1	1	1
9731	361	function via echocardiography	[function via echocardiography]	0.0	3	1	1	1
9732	361	sensitive measure of mechanic	[sensitive measure of mechanics]	0.0	4	1	1	1
9733	361	collateral growth pattern	[collateral growth patterns]	0.0	3	1	1	1
9734	361	key event	[Key events]	0.0	2	1	1	1
9735	361	reference mean	[reference mean]	0.0	2	1	1	1
9736	361	improvement in egfr	[Improvement in eGFR]	0.0	3	1	1	1
9737	361	right atrial area cm	[right atrial area cm]	0.0	4	1	1	1
9738	361	time of HF year	[time of HF years]	0.0	4	1	1	1
9739	361	improve quality for patient	[improving quality for patients]	0.0	4	1	1	1
9740	361	trial of TNF antagonist	[trials of TNF antagonists]	0.0	4	1	1	1
9741	361	correction after assist device implantation	[correction after assist device implantation]	0.0	5	1	1	1
9742	361	over 80 year	[over 80 years]	0.0	3	1	1	1
9743	361	evidence from trial of intravenous iron	[evidence from trials of intravenous iron]	0.0	6	1	1	1
9744	361	conduct cost-effectiveness analysis	[conducting cost-effectiveness analyses]	0.0	3	1	1	1
9745	361	one model for myocardial ischemia	[one model for myocardial ischemia]	0.0	5	1	1	1
9746	361	nurse assessment of impairment	[nurse assessment of impairment]	0.0	4	1	1	1
9747	361	subject of this review	[subject of this review]	0.0	4	1	1	1
9748	361	apparently healthy volunteer	[apparently healthy volunteers]	0.0	3	1	1	1
9749	361	925 ed visit 76.4 year	[925 ED visits 76.4 years]	0.0	5	1	1	1
9750	361	exercise-induced pulmonary artery systolic pressure increase	[exercise-induced pulmonary artery systolic pressure increase]	0.0	6	1	1	1
9751	361	role of s1pr1 gene therapy	[role of S1PR1 gene therapy]	0.0	5	1	1	1
9752	361	interleukin receptor family	[interleukin receptor family]	0.0	3	1	1	1
9753	361	grade weak recommendation evidence	[Grade weak recommendation evidence]	0.0	4	1	1	1
9754	361	possible contribution	[possible contribution]	0.0	2	1	1	1
9755	361	out-patient follow-up	[out-patient follow-up]	0.0	2	1	1	1
9756	361	prognostic relevance of reserve	[prognostic relevance of reserve]	0.0	4	1	1	1
9757	361	Renin-angiotensin-aldosterone system inhibitor	[Renin-angiotensin-aldosterone system inhibitors]	0.0	3	1	1	1
9758	361	composite end-point in hfref	[composite end-point in HFrEF]	0.0	4	1	1	1
9759	361	component improve quality for patient	[component improving quality for patients]	0.0	5	1	1	1
9760	361	intracellular therapeutic strategy	[intracellular therapeutic strategy]	0.0	3	1	1	1
9761	361	rest hr bpm p	[resting HR bpm P]	0.0	4	1	1	1
9762	361	suggest t1 as possible biomarker	[suggesting T1 as possible biomarker]	0.0	5	1	1	1
9763	361	Global strain of left ventricle	[Global strain of left ventricle]	0.0	5	1	1	1
9764	361	inhibition neprilysin block renin-angiotensin-aldosteron axis	[inhibition neprilysin blocks renin-angiotensin-aldosteron axis]	0.0	5	1	1	1
9765	361	therapeutic concept	[therapeutic concepts]	0.0	2	1	1	1
9766	361	effect in the treatment	[effects in the treatment]	0.0	4	1	1	1
9767	361	western administrative health datum	[Western administrative health data]	0.0	4	1	1	1
9768	361	global gene expression	[global gene expression]	0.0	3	1	1	1
9769	361	8-fluo-cAMP	[8-fluo-cAMP]	0.0	1	1	1	1
9770	361	vascular endothelial growth	[vascular endothelial growth]	0.0	3	1	1	1
9771	361	oxidative phosphorylation	[oxidative phosphorylation]	0.0	2	1	1	1
9772	361	lack	[lack]	0.0	1	5	5	1
9773	361	effective off-pump sternal sparing approach	[effective off-pump sternal sparing approach]	0.0	5	1	1	1
9774	361	administrative health datum	[administrative health data]	0.0	3	1	1	1
9775	361	fifty-four pediatric Fontan patient	[Fifty-four pediatric Fontan patients]	0.0	4	1	1	1
9776	361	event rate at event p=0.001	[event rate at events P=0.001]	0.0	5	1	1	1
9777	361	dose-related benefit	[dose-related benefits]	0.0	2	1	1	1
9778	361	single center retrospective study	[single center retrospective study]	0.0	4	1	1	1
9779	361	influence on the burden	[influence on the burden]	0.0	4	1	1	1
9780	361	powerful composite HF index	[powerful composite HF index]	0.0	4	1	1	1
9781	361	epigenetic reader	[epigenetic readers]	0.0	2	1	1	1
9782	361	low-dose nesiritide μg	[low-dose nesiritide μg]	0.0	3	1	1	1
9783	361	LV systolic dysfunction	[LV systolic dysfunction]	0.0	3	1	1	1
9784	361	patient in the ECMO+VAD group	[patients in the ECMO+VAD group]	0.0	5	1	1	1
9785	361	mlhf total score	[MLHF total score]	0.0	3	1	1	1
9786	361	January 2000	[January 2000]	0.0	2	1	1	1
9787	361	intracellular therapeutic strategy in HF	[intracellular therapeutic strategy in HF]	0.0	5	1	1	1
9788	361	cross talk between cgmp signal	[cross talk between cGMP signaling]	0.0	5	1	1	1
9789	361	natremia	[natremia]	0.0	1	1	1	1
9790	361	type of heart failure	[types of heart failure]	0.0	4	1	1	1
9791	361	January 2009	[January 2009]	0.0	2	1	1	1
9792	361	lb in year	[lb in year]	0.0	3	1	1	1
9793	361	blockade of the system	[blockade of the system]	0.0	4	1	1	1
9794	361	epifluorescence	[epifluorescence]	0.0	1	1	1	1
9795	361	Organisation	[Organisation]	0.0	1	1	1	1
9796	361	subject with RA	[Subjects with RA]	0.0	3	1	1	1
9797	361	control study	[control studies]	0.0	2	1	1	1
9798	361	novel intracellular therapeutic strategy	[novel intracellular therapeutic strategy]	0.0	4	1	1	1
9799	361	total expenditure on health per capita	[total expenditure on health per capita]	0.0	6	1	1	1
9800	361	event stroke	[events stroke]	0.0	2	1	1	1
9801	361	272 consecutive patient	[272 consecutive patients]	0.0	3	1	1	1
9802	361	relationship with adverse CV event	[relationship with adverse CV events]	0.0	5	1	1	1
9803	361	quantification of myocardial t1	[quantification of myocardial T1]	0.0	4	1	1	1
9804	361	stroke prevention	[Stroke prevention]	0.0	2	1	1	1
9805	361	case mix after MI	[case mix after MI]	0.0	4	1	1	1
9806	361	1-day reduction	[1-day reduction]	0.0	2	1	1	1
9807	361	patient with New York heart Association	[Patients with New York Heart Association]	0.0	6	1	1	1
9808	361	outpatient assessment of patient	[outpatient assessments of patients]	0.0	4	1	1	1
9809	361	usefulness of tissue doppler imaging	[Usefulness of tissue Doppler imaging]	0.0	5	1	1	1
9810	361	emergency setting	[emergency setting]	0.0	2	1	1	1
9811	361	59.6 m	[59.6 m]	0.0	2	1	1	1
9812	361	compelling improvement	[compelling improvement]	0.0	2	1	1	1
9813	361	consecutive patient man	[consecutive patients men]	0.0	3	1	1	1
9814	361	ventricular end diameter mm mean difference	[ventricular end diameter mm mean difference]	0.0	6	1	1	1
9815	361	target the extreme N termini	[targeting the extreme N termini]	0.0	5	1	1	1
9816	361	automatic defibrillator	[Automatic Defibrillator]	0.0	2	1	1	1
9817	361	left anterior descend artery	[left anterior descending artery]	0.0	4	1	1	1
9818	361	deactivation preference	[deactivation preferences]	0.0	2	1	1	1
9819	361	development of strategy capable	[development of strategies capable]	0.0	4	1	1	1
9820	361	PD initiation almost 7 kg	[PD initiation almost 7 kg]	0.0	5	1	1	1
9821	361	understand	[Understanding]	0.0	1	1	1	1
9822	361	fast subclass	[fastest subclass]	0.0	2	1	1	1
9823	361	insight into electromechanical delay	[insight into electromechanical delay]	0.0	4	1	1	1
9824	361	receptor agonist treatment	[receptor agonist treatment]	0.0	3	1	1	1
9825	361	antiadrenergic therapeutic strategy in HF	[antiadrenergic therapeutic strategy in HF]	0.0	5	1	1	1
9826	361	information for a outcome	[information for an outcome]	0.0	4	1	1	1
9827	361	several poc system	[Several POC systems]	0.0	3	1	1	1
9828	361	interval between myocyte depolarization	[interval between myocyte depolarization]	0.0	4	1	1	1
9829	361	3 study of therapeutics	[3 studies of therapeutics]	0.0	4	1	1	1
9830	361	cachectic heart failure patient	[cachectic heart failure patients]	0.0	4	1	1	1
9831	361	poc testing of np	[POC testing of NP]	0.0	4	1	1	1
9832	361	involve the anterior descend artery	[involving the anterior descending artery]	0.0	5	1	1	1
9833	361	refractory heart failure CHF	[refractory heart failure CHF]	0.0	4	1	1	1
9834	361	end-stage disease	[end-stage disease]	0.0	2	1	1	1
9835	361	patient 224 man year	[patients 224 men years]	0.0	4	1	1	1
9836	361	257 millisecond	[257 milliseconds]	0.0	2	1	1	1
9837	361	echocardiographic evidence of dyssynchrony	[echocardiographic evidence of dyssynchrony]	0.0	4	1	1	1
9838	361	arterial elastance elastance ees	[arterial elastance elastance Ees]	0.0	4	1	1	1
9839	361	diagnostic feature such as detection	[diagnostic features such as detection]	0.0	5	1	1	1
9840	361	nutritional strategy with potentially anti-inflammatory effect	[nutritional strategies with potentially anti-inflammatory effects]	0.0	6	1	1	1
9841	361	remote monitoring after hospital discharge	[Remote monitoring after hospital discharge]	0.0	5	1	1	1
9842	361	relation between dysfunction	[Relation between dysfunction]	0.0	3	1	1	1
9843	361	experience between 2008	[experience between 2008]	0.0	3	1	1	1
9844	361	tricuspid valve	[tricuspid valve]	0.0	2	1	1	1
9845	361	improvement initiative	[improvement initiative]	0.0	2	2	2	1
9846	361	cause of systolic heart failure	[cause of systolic heart failure]	0.0	5	1	1	1
9847	361	healthy age-matched control	[healthy age-matched controls]	0.0	3	1	1	1
9848	361	risk RR of heart failure	[risk RR of heart failure]	0.0	5	1	1	1
9849	361	right ventricular RV plane systolic excursion	[right ventricular RV plane systolic excursion]	0.0	6	1	1	1
9850	361	first result of study	[first results of studies]	0.0	4	1	1	1
9851	361	remain index	[remaining indices]	0.0	2	1	1	1
9852	361	quality measure for medical condition	[quality measures for medical conditions]	0.0	5	1	1	1
9853	361	mr with LV dilatation	[MR with LV dilatation]	0.0	4	1	1	1
9854	361	use a HeartMate ii lvad	[using a HeartMate II LVAD]	0.0	5	1	1	1
9855	361	minor improvement	[minor improvement]	0.0	2	1	1	1
9856	361	ventricular end-diastolic area index 10.0 cm(2)	[ventricular end-diastolic area index 10.0 cm(2)]	0.0	6	1	1	1
9857	361	participate nurse	[participating nurses]	0.0	2	1	1	1
9858	361	fast grow subclass of disease	[fastest growing subclass of diseases]	0.0	5	1	1	1
9859	361	baseline sst2 status ≤35	[baseline sST2 status ≤35]	0.0	4	1	1	1
9860	361	contextual factor such as patient preference	[contextual factors such as patient preferences]	0.0	6	1	1	1
9861	361	left ventricular end diameter difference	[left ventricular end diameter difference]	0.0	5	1	1	1
9862	361	hypertension of 191 mm hg	[hypertension of 191 mm Hg]	0.0	5	1	1	1
9863	361	potential efficacy of therapeutic interatrial shunting	[potential efficacy of therapeutic interatrial shunting]	0.0	6	1	1	1
9864	361	incident HF in 2825 participant	[incident HF in 2825 participants]	0.0	5	1	1	1
9865	361	role of autonomic system activity	[role of autonomic system activity]	0.0	5	1	1	1
9866	361	primary endpoint of therapy	[primary endpoint of therapy]	0.0	4	1	1	1
9867	361	reclassification	[reclassification]	0.0	1	1	1	1
9868	361	consecutive ambulatory HF patient ejection fraction	[consecutive ambulatory HF patients ejection fraction]	0.0	6	1	1	1
9869	361	multivariate model a predictor	[multivariate model a predictor]	0.0	4	1	1	1
9870	361	trial of walking	[trial of walking]	0.0	3	1	1	1
9871	361	extend EMD in the fail heart	[extending EMD in the failing heart]	0.0	6	1	1	1
9872	361	concept appropriate in patient	[concept appropriate in patients]	0.0	4	1	1	1
9873	361	state of oxidative stress	[state of oxidative stress]	0.0	4	1	1	1
9874	361	month of artery bypass grafting	[months of artery bypass grafting]	0.0	5	1	1	1
9875	361	understanding of the mechanism	[understanding of the mechanism]	0.0	4	1	1	1
9876	361	moderate-intensity exercise per week	[moderate-intensity exercise per week]	0.0	4	1	1	1
9877	361	baseline covariate	[baseline covariates]	0.0	2	1	1	1
9878	361	vasopressin type receptor antagonist	[vasopressin type receptor antagonist]	0.0	4	1	1	1
9879	361	mild restriction	[mild restriction]	0.0	2	1	1	1
9880	361	diet score with heart failure	[diet scores with heart failure]	0.0	5	1	1	1
9881	361	magnetic resonance imaging	[magnetic resonance imaging]	0.0	3	1	1	1
9882	361	response in cardiac activity (123)i-meta-iodobenzylguanidine	[response in cardiac activity (123)I-meta-iodobenzylguanidine]	0.0	5	1	1	1
9883	361	low bnp group	[low BNP group]	0.0	3	1	1	1
9884	361	role of Mena in pathophysiology	[role of Mena in pathophysiology]	0.0	5	1	1	1
9885	361	central pattern generator	[central pattern generator]	0.0	3	1	1	1
9886	361	significant alteration	[significant alterations]	0.0	2	1	1	1
9887	361	retn gene Hum-Retn mouse	[Retn gene Hum-Retn mice]	0.0	4	1	1	1
9888	361	tachycardia indicative of vagal tone	[tachycardia indicative of vagal tone]	0.0	5	1	1	1
9889	361	10 HF patient without VT	[10 HF patients without VT]	0.0	5	1	1	1
9890	361	important prognostic indicator	[important prognostic indicator]	0.0	3	1	1	1
9891	361	insulin-signaling component	[insulin-signaling components]	0.0	2	1	1	1
9892	361	study of 20812 patient	[study of 20,812 patients]	0.0	4	1	1	1
9893	361	support score psss	[support score PSSS]	0.0	3	1	1	1
9894	361	novel antiadrenergic therapeutic strategy	[novel antiadrenergic therapeutic strategy]	0.0	4	1	1	1
9895	361	8 patient with CHF-NYHA-II	[8 patients with CHF-NYHA-II]	0.0	4	1	1	1
9896	361	impact on inappropriate therapy	[impact on inappropriate therapy]	0.0	4	1	1	1
9897	361	heart failure a preliminary study	[heart failure a preliminary study]	0.0	5	1	1	1
9898	361	Northwest	[Northwest]	0.0	1	1	1	1
9899	361	chronic stable therapy	[chronic stable therapy]	0.0	3	1	1	1
9900	361	hyponatremia	[hyponatremia]	0.0	1	1	1	1
9901	361	increase in life expectancy	[increase in life expectancy]	0.0	4	1	1	1
9902	361	novel stable hno donor	[novel stable HNO donor]	0.0	4	1	1	1
9903	361	main objective	[main objective]	0.0	2	1	1	1
9904	361	rehabilitation care on functional capacity	[rehabilitation care on functional capacity]	0.0	5	1	1	1
9905	361	time period	[time period]	0.0	2	1	1	1
9906	361	echocardiogram of the left midpapillary level	[Echocardiograms of the left midpapillary level]	0.0	6	1	1	1
9907	361	care surgery ACS consultation	[care surgery ACS consultations]	0.0	4	1	1	1
9908	361	animal model	[animal model]	0.0	2	1	1	1
9909	361	advanced chronic pulmonary disease	[advanced chronic pulmonary disease]	0.0	4	1	1	1
9910	361	marker indicative	[markers indicative]	0.0	2	1	1	1
9911	361	nf-κb	[NF-κB]	0.0	1	1	1	1
9912	361	useful technique	[useful technique]	0.0	2	1	1	1
9913	361	pressure overload rvpo	[pressure overload RVPO]	0.0	3	1	1	1
9914	361	grow epidemic	[growing epidemic]	0.0	2	1	1	1
9915	361	patient with hfpef geometry	[patients with HFpEF geometry]	0.0	4	1	1	1
9916	361	subject with heart HNorm	[subjects with hearts HNorm]	0.0	4	1	1	1
9917	361	Cardiac magnetic resonance postcontrast	[Cardiac magnetic resonance postcontrast]	0.0	4	1	1	1
9918	361	baseline CRF	[baseline CRF]	0.0	2	1	1	1
9919	361	Sham-INV	[Sham-INV]	0.0	1	1	1	1
9920	361	match for age	[matching for age]	0.0	3	1	1	1
9921	361	evidence of remodeling	[evidence of remodeling]	0.0	3	1	1	1
9922	361	association between treatment variation	[association between treatment variation]	0.0	4	1	1	1
9923	361	start a TNF antagonist	[starting a TNF antagonist]	0.0	4	1	1	1
9924	361	patient with CHF-NYHA-II	[patients with CHF-NYHA-II]	0.0	3	1	1	1
9925	361	HF death	[HF deaths]	0.0	2	1	1	1
9926	361	intracellular strategy in HF	[intracellular strategy in HF]	0.0	4	1	1	1
9927	361	mrna level result	[mRNA levels resulting]	0.0	3	1	1	1
9928	361	development after HCT	[development after HCT]	0.0	3	1	1	1
9929	361	generate variant	[generating variants]	0.0	2	1	1	1
9930	361	extreme decile of agreement	[extreme deciles of agreement]	0.0	4	1	1	1
9931	361	black patient	[black patients]	0.0	2	1	1	1
9932	361	cardiomyopathy include angiography	[cardiomyopathy including angiography]	0.0	3	1	1	1
9933	361	reversible ischemia	[reversible ischemia]	0.0	2	1	1	1
9934	361	suppression of signalling	[suppression of signalling]	0.0	3	1	1	1
9935	361	n=44 925 ed visit mean age	[n=44 925 ED visits mean age]	0.0	6	1	1	1
9936	361	Fontan patient	[Fontan patients]	0.0	2	1	1	1
9937	361	nyha classification from class	[NYHA classification from class]	0.0	4	1	1	1
9938	361	however a disease accounting	[however an disease accounting]	0.0	4	1	1	1
9939	361	insight into delay in heart failure	[insight into delay in heart failure]	0.0	6	1	1	1
9940	361	population within cardiac rehabilitation	[population within cardiac rehabilitation]	0.0	4	1	1	1
9941	361	mitral velocity 3.1 vs. 1.3	[mitral velocity 3.1 vs. 1.3]	0.0	5	1	1	1
9942	361	major cardiovascular complication	[major cardiovascular complications]	0.0	3	1	1	1
9943	361	diagnosis of clinical diastolic dysfunction	[diagnosis of clinical diastolic dysfunction]	0.0	5	1	1	1
9944	361	patient awareness of cardioverter-defibrillator deactivation discussion	[patient awareness of cardioverter-defibrillator deactivation discussions]	0.0	6	1	1	1
9945	361	multicenter defibrillator implantation	[Multicenter Defibrillator Implantation]	0.0	3	1	1	1
9946	361	natriuretic peptide b-type peptide	[natriuretic peptide B-type peptide]	0.0	4	1	1	1
9947	361	explant-derived cell	[explant-derived cells]	0.0	2	1	1	1
9948	361	involve the left descend artery	[involving the left descending artery]	0.0	5	1	1	1
9949	361	treat heart failure	[treating heart failure]	0.0	3	1	1	1
9950	361	short-term exercise tolerance	[short-term exercise tolerance]	0.0	3	1	1	1
9951	361	valve insufficiency	[valve insufficiency]	0.0	2	1	1	1
9952	361	obstruction of the right artery	[obstruction of the right artery]	0.0	5	1	1	1
9953	361	pharmacologic study of therapeutics	[pharmacologic studies of therapeutics]	0.0	4	1	1	1
9954	361	complementary model system	[complementary model system]	0.0	3	1	1	1
9955	361	b-treated rat	[B-treated rats]	0.0	2	1	1	1
9956	361	ejection fraction r=0.28	[ejection fraction R=0.28]	0.0	3	1	1	1
9957	361	Impact of physician continuity	[Impact of physician continuity]	0.0	4	1	1	1
9958	361	routine measurement	[routine measurement]	0.0	2	1	1	1
9959	361	LV ef	[LV EF]	0.0	2	1	1	1
9960	361	such ms	[such MS]	0.0	2	1	1	1
9961	361	LV with a volume index	[LV with an volume index]	0.0	5	1	1	1
9962	361	low no production	[lower NO production]	0.0	3	1	1	1
9963	361	cardioverter-defibrillator therapy defibrillator implantation	[cardioverter-defibrillator therapy Defibrillator Implantation]	0.0	4	1	1	1
9964	361	investigation in a canine model	[Investigation in a canine model]	0.0	5	1	1	1
9965	361	Collins	[Collins]	0.0	1	1	1	1
9966	361	assist device vad	[assist device VAD]	0.0	3	1	1	1
9967	361	insulin product	[insulin products]	0.0	2	1	1	1
9968	361	right coupling pulmonary vascular resistance	[right coupling pulmonary vascular resistance]	0.0	5	1	1	1
9969	361	PD initiation 7 kg	[PD initiation 7 kg]	0.0	4	1	1	1
9970	361	autonomic system activity on QTV	[autonomic system activity on QTV]	0.0	5	1	1	1
9971	361	future a surgery consensus report	[Future A Surgery Consensus Report]	0.0	5	1	1	1
9972	361	812 consecutive patient	[812 consecutive patients]	0.0	3	1	1	1
9973	361	evaluate predictor on ICD patient	[evaluating predictors on ICD patients]	0.0	5	1	1	1
9974	361	video	[video]	0.0	1	1	1	1
9975	361	therapy refractory shock	[therapy refractory shock]	0.0	3	1	1	1
9976	361	track VA patient	[tracking VA patients]	0.0	3	1	1	1
9977	361	lack Nucleolin	[lacking Nucleolin]	0.0	2	1	1	1
9978	361	definition of the distinctive component	[definitions of the distinctive components]	0.0	5	1	1	1
9979	361	study approximately 2900 hm	[studies approximately 2900 HM]	0.0	4	1	1	1
9980	361	patient in nyha class	[patients in NYHA class]	0.0	4	1	1	1
9981	361	end-diastolic dimension	[end-diastolic dimension]	0.0	2	1	1	1
9982	361	impaired energy metabolism gene expression	[impaired energy metabolism gene expression]	0.0	5	1	1	1
9983	361	63 predictor	[63 predictors]	0.0	2	1	1	1
9984	361	association between spironolactone use	[association between spironolactone use]	0.0	4	1	1	1
9985	361	156 consecutive ambulatory HF patient	[156 consecutive ambulatory HF patients]	0.0	5	1	1	1
9986	361	predictor period hazard ratio	[predictor period hazard ratio]	0.0	4	1	1	1
9987	361	trial RCT	[trials RCTs]	0.0	2	1	1	1
9988	361	hospital in the bad quintile	[hospital in the worst quintile]	0.0	5	1	1	1
9989	361	oral glucocorticoid dosage	[oral glucocorticoid dosage]	0.0	3	1	1	1
9990	361	participant mean	[participants mean]	0.0	2	1	1	1
9991	361	follow hospital stay	[following hospital stay]	0.0	3	1	1	1
9992	361	ratio of LV strain rate	[ratio of LV strain rate]	0.0	5	1	1	1
9993	361	2 hypothese addition	[2 hypotheses addition]	0.0	3	1	1	1
9994	361	inoperable chronic thromboembolic hypertension	[inoperable chronic thromboembolic hypertension]	0.0	4	1	1	1
9995	361	left assist device lvad	[left assist device LVAD]	0.0	4	1	1	1
9996	361	ejection fraction argument	[ejection fraction arguments]	0.0	3	1	1	1
9997	361	extend EMD with the aspect contribute	[extending EMD with the aspects contributing]	0.0	6	1	1	1
9998	361	determine the cardiac remodelling	[determining the cardiac remodelling]	0.0	4	1	1	1
9999	361	patient with a median follow-up	[patients with a median follow-up]	0.0	5	1	1	1
10000	361	consent HF patient	[consenting HF patients]	0.0	3	1	1	1
10001	361	patient-year	[patient-years]	0.0	1	1	1	1
10002	361	role in diverse aspect	[role in diverse aspects]	0.0	4	1	1	1
10003	361	sodium current in human heart failure	[sodium current in human heart failure]	0.0	6	1	1	1
10004	361	non-AAs	[non-AAs]	0.0	1	1	1	1
10005	361	CV event in atrial fibrillation	[CV events in atrial fibrillation]	0.0	5	1	1	1
10006	361	management of intrinsic dysfunction	[management of intrinsic dysfunction]	0.0	4	1	1	1
10007	361	time interval between myocyte depolarization	[time interval between myocyte depolarization]	0.0	5	1	1	1
10008	361	hemoglobin in patient	[Hemoglobin in patients]	0.0	3	1	1	1
10009	361	6-min	[6-min]	0.0	1	1	1	1
10010	361	use of the renin-angiotensin-aldosterone system	[use of the renin-angiotensin-aldosterone systems]	0.0	5	1	1	1
10011	361	involve the proximal left artery	[involving the proximal left artery]	0.0	5	1	1	1
10012	361	detailed transcriptional analysis	[Detailed transcriptional analysis]	0.0	3	1	1	1
10013	361	cachexia CC	[cachexia CC]	0.0	2	1	1	1
10014	361	old obese participant mean	[older obese participants mean]	0.0	4	1	1	1
10015	361	guideline-directed therapy GDMT	[guideline-directed therapy GDMT]	0.0	3	1	1	1
10016	361	play a role in patient	[playing a role in patients]	0.0	5	1	1	1
10017	361	relationship between length	[relationship between length]	0.0	3	1	1	1
10018	361	abnormal scn5a mrna splicing	[abnormal SCN5A mRNA splicing]	0.0	4	1	1	1
10019	361	great impact	[greater impact]	0.0	2	1	1	1
10020	361	daily clinical practice	[daily clinical practice]	0.0	3	1	1	1
10021	361	significant reduction in the end-point	[significant reductions in the end-point]	0.0	5	1	1	1
10022	361	useful tool	[useful tool]	0.0	2	1	1	1
10023	361	stage 3 kidney disease	[Stage 3 kidney disease]	0.0	4	1	1	1
10024	361	enzyme lyso-paf acetyltransferase	[enzymes lyso-PAF acetyltransferase]	0.0	3	1	1	1
10025	361	estimate LV fill pressure	[estimating LV filling pressure]	0.0	4	1	1	1
10026	361	RVPO	[RVPO]	0.0	1	1	1	1
10027	361	left assist device lvas	[left assist devices LVADs]	0.0	4	1	1	1
10028	361	vena cava IVC	[vena cava IVC]	0.0	3	1	1	1
10029	361	stage kidney disease	[Stage kidney disease]	0.0	3	1	1	1
10030	361	100 old obese participant	[100 older obese participants]	0.0	4	1	1	1
10031	361	outcome in patient with fibrillation	[outcomes in patients with fibrillation]	0.0	5	1	1	1
10032	361	english-language trial in adult	[English-language trials in adults]	0.0	4	1	1	1
10033	361	Effect of cardiac support on function	[Effects of cardiac support on function]	0.0	6	1	1	1
10034	361	range with copd n=95	[range with COPD n=95]	0.0	4	1	1	1
10035	361	restore phosphorylation capacity	[restoring phosphorylation capacity]	0.0	3	1	1	1
10036	361	survive a myocardial infarction AMI	[surviving an myocardial infarction AMI]	0.0	5	1	1	1
10037	361	type regulatory riiα	[type regulatory RIIα]	0.0	3	1	1	1
10038	361	use metric for disease group	[using metrics for disease groups]	0.0	5	1	1	1
10039	361	factor such as patient preference	[factors such as patient preferences]	0.0	5	1	1	1
10040	361	infarction patient with heart failure	[infarction patients with heart failure]	0.0	5	1	1	1
10041	361	rate risk	[rate risk]	0.0	2	1	1	1
10042	361	acute autonomic system modulation	[acute autonomic system modulation]	0.0	4	1	1	1
10043	361	delay the time interval	[delay the time interval]	0.0	4	1	1	1
10044	361	criteriabased institution of PD	[criteriabased institution of PD]	0.0	4	1	1	1
10045	361	cause of heart failure HF	[cause of heart failure HF]	0.0	5	1	1	1
10046	361	treatment target abnormal exercise hemodynamic status	[treatments targeting abnormal exercise hemodynamic status]	0.0	6	1	1	1
10047	361	patient with shortness of breath	[Patients With Shortness of Breath]	0.0	5	1	1	1
10048	361	treatment treatment	[treatment treatment]	0.0	2	1	1	1
10049	361	estimate the jugular pressure	[Estimating the jugular pressure]	0.0	4	1	1	1
10050	361	14 study 2900 hm	[14 studies 2900 HM]	0.0	4	1	1	1
10051	361	regard effective treatment of adult	[regarding effective treatment of adults]	0.0	5	1	1	1
10052	361	therapy hr 0.87	[therapy HR 0.87]	0.0	3	1	1	1
10053	361	high consistency	[high consistency]	0.0	2	1	1	1
10054	361	beat	[beats]	0.0	1	1	1	1
10055	361	molecular analysis	[molecular analysis]	0.0	2	1	1	1
10056	361	less severe dilatation	[less severe dilatation]	0.0	3	1	1	1
10057	361	Australian administrative health datum	[Australian administrative health data]	0.0	4	1	1	1
10058	361	patient with the coronary syndrome	[patients with the coronary syndrome]	0.0	5	1	1	1
10059	361	2.1 millileter p=0.01	[2.1 mL P=0.01]	0.0	3	1	1	1
10060	361	metabolic change	[metabolic changes]	0.0	2	1	1	1
10061	361	tract infection uti	[tract infection UTI]	0.0	3	1	1	1
10062	361	chronic medical therapy GDMT	[chronic medical therapy GDMT]	0.0	4	1	1	1
10063	361	New Zealand rabbit undergo DNx	[New Zealand rabbits undergoing DNx]	0.0	5	1	1	1
10064	361	exercise capacity in patient	[exercise capacity in patients]	0.0	4	1	1	1
10065	361	use procedure	[using procedures]	0.0	2	1	1	1
10066	361	behavior of the heart	[behavior of the heart]	0.0	4	1	1	1
10067	361	stable medical therapy GDMT	[stable medical therapy GDMT]	0.0	4	1	1	1
10068	361	20812 patient with infarction	[20,812 patients with infarction]	0.0	4	1	1	1
10069	361	death hospitalization	[death hospitalization]	0.0	2	1	1	1
10070	361	improve muscle function	[improving muscle function]	0.0	3	1	1	1
10071	361	economic climate	[economic climate]	0.0	2	1	1	1
10072	361	little impact on gross development	[little impact on gross development]	0.0	5	1	1	1
10073	361	334 consecutive patient man year	[334 consecutive patients men years]	0.0	5	1	1	1
10074	361	moderate high-strength evidence	[Moderate high-strength evidence]	0.0	3	1	1	1
10075	361	presumably decrease risk of HF mortality	[presumably decreasing risk of HF mortality]	0.0	6	1	1	1
10076	361	pGE2-mediated effect on receptor signal	[PDE2-mediated effects on receptor signaling]	0.0	5	1	1	1
10077	361	Chronic β-ar stimulation	[Chronic β-AR stimulation]	0.0	3	1	1	1
10078	361	total of individual	[total of individuals]	0.0	3	1	1	1
10079	361	diagnosis of prognostic dysfunction	[diagnosis of prognostic dysfunction]	0.0	4	1	1	1
10080	361	experience distressing implantable cardioverter-defibrillator shock	[experiencing distressing implantable cardioverter-defibrillator shocks]	0.0	5	1	1	1
10081	361	fifty consecutive patient with onset	[Fifty consecutive patients with onset]	0.0	5	1	1	1
10082	361	evidence-based practice	[evidence-based practices]	0.0	2	1	1	1
10083	361	analysis of a chromatin subproteome	[analysis of a chromatin subproteome]	0.0	5	1	1	1
10084	361	estimate the pressure	[Estimating the pressure]	0.0	3	1	1	1
10085	361	Functional electrical stimulation of muscle	[Functional electrical stimulation of muscles]	0.0	5	1	1	1
10086	361	reduce all-cause mortality for patient	[reducing all-cause mortality for patients]	0.0	5	1	1	1
10087	361	gene program in heart failure	[gene programs in heart failure]	0.0	5	1	1	1
10088	361	2825 participant aged	[2825 participants aged]	0.0	3	1	1	1
10089	361	type V voltage-gated na	[type V voltage-gated Na]	0.0	4	1	1	1
10090	361	underlying mechanism of HFPEF	[underlying mechanism of HFPEF]	0.0	4	1	1	1
10091	361	outcome study short-form quality	[Outcomes Study Short-Form quality]	0.0	4	1	1	1
10092	361	left systolic function in volume overload	[left systolic function in volume overload]	0.0	6	1	1	1
10093	361	early velocity 3.1 vs. 1.3	[early velocity 3.1 vs. 1.3]	0.0	5	1	1	1
10094	361	small difference median bnp EF	[smallest difference median BNP EF]	0.0	5	1	1	1
10095	361	self-management training	[self-management training]	0.0	2	1	1	1
10096	361	cost-effectiveness ratio from user input	[cost-effectiveness ratios from user inputs]	0.0	5	1	1	1
10097	361	patient hospitalization	[Patients Hospitalization]	0.0	2	1	1	1
10098	361	risk than the rest	[risk than the rest]	0.0	4	1	1	1
10099	361	risk develop hyperkalemia	[risk developing hyperkalemia]	0.0	3	1	1	1
10100	361	select control	[selecting controls]	0.0	2	1	1	1
10101	361	early annular velocity 3.1	[early annular velocity 3.1]	0.0	4	1	1	1
10102	361	334 patient man mean year	[334 patients men mean years]	0.0	5	1	1	1
10103	361	self-reported physical activity	[self-reported physical activity]	0.0	3	1	1	1
10104	361	outcome p	[outcomes P]	0.0	2	1	1	1
10105	361	use a improvement database	[Using a improvement database]	0.0	4	1	1	1
10106	361	ratio early mitral annulus velocity	[ratio early mitral annulus velocity]	0.0	5	1	1	1
10107	361	vivo RV length-force	[vivo RV length-force]	0.0	3	1	1	1
10108	361	myocyte-specific mena overexpression comparable	[myocyte-specific Mena overexpression comparable]	0.0	4	1	1	1
10109	361	overwhelming contribution	[overwhelming contribution]	0.0	2	1	1	1
10110	361	artery occlusion	[artery occlusion]	0.0	2	1	1	1
10111	361	increase for acute infarction	[increase for acute infarction]	0.0	4	1	1	1
10112	361	assessment of patient	[assessments of patients]	0.0	3	1	1	1
10113	361	mouse heart failure HF	[mouse heart failure HF]	0.0	4	1	1	1
10114	361	n=100	[n=100]	0.0	1	1	1	1
10115	361	achievement of anaerobic metabolism quotient	[achievement of anaerobic metabolism quotient]	0.0	5	1	1	1
10116	361	other important outcome in patient	[other important outcomes in patients]	0.0	5	1	1	1
10117	361	sustain the workload	[sustaining the workload]	0.0	3	1	1	1
10118	361	10 heart failure patient	[10 heart failure patients]	0.0	4	1	1	1
10119	361	patient as destination therapy dt	[patients as destination therapy DT]	0.0	5	1	1	1
10120	361	group millileter per m	[group mL per m]	0.0	4	1	1	1
10121	361	event for psoriasis	[events for psoriasis]	0.0	3	1	1	1
10122	361	123 mm	[123 mm]	0.0	2	1	1	1
10123	361	case mix	[case mix]	0.0	2	1	1	1
10124	361	group iv	[group IV]	0.0	2	1	1	1
10125	361	positive effect in vivo	[positive effects in vivo]	0.0	4	1	1	1
10126	361	possible mechanism of cardioprotection	[possible mechanism of cardioprotection]	0.0	4	1	1	1
10127	361	improve the prognosis of patient	[improving the prognosis of patients]	0.0	5	1	1	1
10128	361	matrix use resonance t1 mapping	[matrix using resonance T1 mapping]	0.0	5	1	1	1
10129	361	bmi-matched healthy volunteer	[BMI-matched healthy volunteers]	0.0	3	1	1	1
10130	361	group ii	[group II]	0.0	2	1	1	1
10131	361	catabolism	[catabolism]	0.0	1	1	1	1
10132	361	function in hfpef patient	[function in HFpEF patients]	0.0	4	1	1	1
10133	361	Large-scale multicenter trial with 8000 individual	[Large-scale multicenter trial with 8000 individuals]	0.0	6	1	1	1
10134	361	METs vs. 5.7 METs	[METs vs. 5.7 METs]	0.0	4	1	1	1
10135	361	ejection time complicate precapillary hypertension	[ejection time complicating precapillary hypertension]	0.0	5	1	1	1
10136	361	patient with hr bpm	[patients with HR bpm]	0.0	4	1	1	1
10137	361	Biventricular support use a HeartMate lvad	[Biventricular support using a HeartMate LVAD]	0.0	6	1	1	1
10138	361	3 trial of iron	[3 trials of iron]	0.0	4	1	1	1
10139	361	magnetic resonance imaging include t1 mapping	[magnetic resonance imaging including T1 mapping]	0.0	6	1	1	1
10140	361	large cardiomyopathy cohort	[large cardiomyopathy cohort]	0.0	3	1	1	1
10141	361	CI for sitagliptin for sitagliptin	[CI for sitagliptin for sitagliptin]	0.0	5	1	1	1
10142	361	median activity of lyso-paf-at p	[median activities of lyso-PAF-AT P]	0.0	5	1	1	1
10143	361	only modest effect	[only modest effects]	0.0	3	1	1	1
10144	361	user input	[user inputs]	0.0	2	1	1	1
10145	361	nonglycosylated epitope p	[nonglycosylated epitopes P]	0.0	3	1	1	1
10146	361	factor-β tgf-β	[factor-β TGF-β]	0.0	2	1	1	1
10147	361	cardiac progenitor function	[cardiac progenitor function]	0.0	3	1	1	1
10148	361	malignancy	[malignancies]	0.0	1	1	1	1
10149	361	underperfusion result	[underperfusion resulting]	0.0	2	1	1	1
10150	361	day p-value	[days P-value]	0.0	2	1	1	1
10151	361	effect of natriuretic peptide	[effect of natriuretic peptides]	0.0	4	1	1	1
10152	361	principle of treatment	[principles of treatment]	0.0	3	1	1	1
10153	361	predictor of long mortality	[predictor of long-term mortality]	0.0	4	1	1	1
10154	361	somewhat good prognostic information	[somewhat better prognostic information]	0.0	4	1	1	1
10155	361	blockade	[blockade]	0.0	1	1	1	1
10156	361	Procedure	[Procedure]	0.0	1	1	1	1
10157	361	strain as a predictor of event	[strain as a predictor of events]	0.0	6	1	1	1
10158	361	condition such as infarction	[conditions such as infarction]	0.0	4	1	1	1
10159	361	average follow-up of month	[average follow-up of months]	0.0	4	1	1	1
10160	361	nonfunctional channel	[nonfunctional channels]	0.0	2	1	1	1
10161	361	normal artery	[normal arteries]	0.0	2	1	1	1
10162	361	validate outcome measure in future research	[Validating outcome measures in future research]	0.0	6	1	1	1
10163	361	population-based study	[population-based study]	0.0	2	1	1	1
10164	361	ventricular tricuspid plane systolic excursion tapse	[ventricular tricuspid plane systolic excursion TAPSE]	0.0	6	1	1	1
10165	361	diastolic mitral annulus velocity E	[diastolic mitral annulus velocity E]	0.0	5	1	1	1
10166	361	cxl-1051	[CXL-1051]	0.0	1	1	1	1
10167	361	albeit with ability	[albeit with ability]	0.0	3	1	1	1
10168	361	evidence from 3 trial of iron	[evidence from 3 trials of iron]	0.0	6	1	1	1
10169	361	relationship between qrs	[relationship between QRS]	0.0	3	1	1	1
10170	361	mortality at year	[mortality at years]	0.0	3	1	1	1
10171	361	major cause of heart failure	[major cause of heart failure]	0.0	5	1	1	1
10172	361	indeterminable threshold	[indeterminable threshold]	0.0	2	1	1	1
10173	361	developmental impairment	[developmental impairment]	0.0	2	1	1	1
10174	361	channel mrna	[channel mRNA]	0.0	2	2	2	1
10175	361	left ventricular systolic pressure	[left ventricular systolic pressure]	0.0	4	1	1	1
10176	361	two increase in cardiac risk	[two increase in cardiac risk]	0.0	5	1	1	1
10177	361	24 per cent with death occur	[24 per cent with deaths occurring]	0.0	6	1	1	1
10178	361	x-ray absorptiometry DXA	[x-ray absorptiometry DXA]	0.0	3	1	1	1
10179	361	model a predictor	[model a predictor]	0.0	3	1	1	1
10180	361	efficiency slope	[efficiency slope]	0.0	2	1	1	1
10181	361	pulmonary systolic pressure relationship a index	[pulmonary systolic pressure relationship an index]	0.0	6	1	1	1
10182	361	population of anthracycline	[population of anthracycline]	0.0	3	1	1	1
10183	361	average of month	[average of months]	0.0	3	1	1	1
10184	361	hfref hazard ratio	[HFrEF hazard ratio]	0.0	3	1	1	1
10185	361	estimate pulmonary capillary wedge pressure pcwp	[estimating pulmonary capillary wedge pressure PCWP]	0.0	6	1	1	1
10186	361	follow β-ar stimulation	[following β-AR stimulation]	0.0	3	1	1	1
10187	361	decrease in septum thickness	[decreases in septum thickness]	0.0	4	1	1	1
10188	361	prospective multicenter trial Paradigm-hf with individual	[prospective multicenter trial PARADIGM-HF with individuals]	0.0	6	1	1	1
10189	361	important implication	[important implications]	0.0	2	1	1	1
10190	361	co. lack	[CO. Lack]	0.0	2	1	1	1
10191	361	elderly male patient	[elderly male patients]	0.0	3	1	1	1
10192	361	diagnosis of cardiomyiopathy	[diagnosis of cardiomyiopathy]	0.0	3	1	1	1
10193	361	patient with HF of etiology	[patients with HF of etiology]	0.0	5	1	1	1
10194	361	receive the last dose	[receiving the last dose]	0.0	4	1	1	1
10195	361	inappropriate shock therapy	[inappropriate shock therapy]	0.0	3	1	1	1
10196	361	evaluation hm	[evaluations HM]	0.0	2	1	1	1
10197	361	tool for prognostic assessment	[tool for prognostic assessment]	0.0	4	1	1	1
10198	361	effect of 2 type	[effects of 2 types]	0.0	4	1	1	1
10199	361	plasma n-terminal pro-b-type peptide	[plasma N-terminal pro-B-type peptide]	0.0	4	1	1	1
10200	361	matrix use cardiac resonance t1 mapping	[matrix using cardiac resonance T1 mapping]	0.0	6	1	1	1
10201	361	biomarker for HFPEF	[biomarker for HFPEF]	0.0	3	1	1	1
10202	361	effective target	[effective target]	0.0	2	1	1	1
10203	361	metric choice	[metric choice]	0.0	2	1	1	1
10204	361	Joanna	[Joanna]	0.0	1	1	1	1
10205	361	heterogenous improvement	[Heterogenous improvement]	0.0	2	1	1	1
10206	361	role in aspect	[role in aspects]	0.0	3	1	1	1
10207	361	difference among ef bnp EF	[difference among EF BNP EF]	0.0	5	1	1	1
10208	361	ring implantation	[ring implantation]	0.0	2	1	1	1
10209	361	coupling resistance	[coupling resistance]	0.0	2	1	1	1
10210	361	direct interaction	[direct interaction]	0.0	2	1	1	1
10211	361	normal LV ejection fraction	[normal LV ejection fraction]	0.0	4	1	1	1
10212	361	predictor of outcome period	[predictor of outcome period]	0.0	4	1	1	1
10213	361	carotid baroreflex activation	[carotid baroreflex activation]	0.0	3	1	1	1
10214	361	skinfold	[skinfold]	0.0	1	1	1	1
10215	361	application of peptide drug	[application of peptide drugs]	0.0	4	1	1	1
10216	361	N-terminal pro-b-type natriuretic peptide nt-probnp	[N-terminal pro-B-type natriuretic peptide NT-proBNP]	0.0	5	1	1	1
10217	361	diminish the xo-mediated ros effect	[diminishing the XO-mediated ROS effects]	0.0	5	1	1	1
10218	361	trend for four condition	[trends for four conditions]	0.0	4	1	1	1
10219	361	stable hno donor	[stable HNO donor]	0.0	3	1	1	1
10220	361	medical management of HF	[medical management of HF]	0.0	4	1	1	1
10221	361	anterior descending lad	[anterior descending LAD]	0.0	3	1	1	1
10222	361	validate nursing-sensitive outcome measure in research	[Validating nursing-sensitive outcome measures in research]	0.0	6	1	1	1
10223	361	magnetic resonance t1 time hazard ratio	[magnetic resonance T1 time hazard ratio]	0.0	6	1	1	1
10224	361	failure CRF	[failure CRF]	0.0	2	1	1	1
10225	361	frequency of follow-up visit	[frequency of follow-up visits]	0.0	4	2	2	1
10226	361	option in end-stage heart failure	[option in end-stage heart failure]	0.0	5	1	1	1
10227	361	event during the first month	[events during the first months]	0.0	5	1	1	1
10228	361	periodic breathing pb	[periodic breathing PB]	0.0	3	1	1	1
10229	361	malfunction	[malfunctioning]	0.0	1	1	1	1
10230	361	Survival after assist device	[Survival after assist device]	0.0	4	1	1	1
10231	361	left ventricular end diameter mean difference	[left ventricular end diameter mean difference]	0.0	6	1	1	1
10232	361	activity of lyso-paf-at	[activities of lyso-PAF-AT]	0.0	3	1	1	1
10233	361	millileter odd ratio 1.76	[ml odds ratio 1.76]	0.0	4	1	1	1
10234	361	high quartile	[highest quartile]	0.0	2	1	1	1
10235	361	structural heart disease	[structural heart disease]	0.0	3	1	1	1
10236	361	excellent risk stratification between a group	[excellent risk stratification between a group]	0.0	6	1	1	1
10237	361	lvad support	[LVAD support]	0.0	2	2	2	1
10238	361	noncardiovascular drug	[noncardiovascular drugs]	0.0	2	1	1	1
10239	361	receptor neprilysin	[receptor neprilysin]	0.0	2	1	1	1
10240	361	bundle-branch	[bundle-branch]	0.0	1	1	1	1
10241	361	efficacy of a HNO donor	[efficacy of a HNO donor]	0.0	5	1	1	1
10242	361	measure of HF	[measure of HF]	0.0	3	1	1	1
10243	361	reduction in the end-point	[reductions in the end-point]	0.0	4	1	1	1
10244	361	diagnosis role of clinical doppler echocardiography	[Diagnosis role of clinical Doppler echocardiography]	0.0	6	1	1	1
10245	361	major predictor of event	[major predictor of events]	0.0	4	1	1	1
10246	361	extracellular matrix of biopsy	[Extracellular matrix of biopsies]	0.0	4	1	1	1
10247	361	right heart Foundation	[Right Heart Foundation]	0.0	3	1	1	1
10248	361	relevance of right ventricular contractile reserve	[relevance of right ventricular contractile reserve]	0.0	6	1	1	1
10249	361	HF hospitalization hr 1.58	[HF hospitalization HR 1.58]	0.0	4	1	1	1
10250	361	myocardial infarction with complication	[myocardial infarction with complications]	0.0	4	1	1	1
10251	361	multisite study in practice setting	[multisite studies in practice settings]	0.0	5	1	1	1
10252	361	trichrome histologic analysis	[trichrome histologic analysis]	0.0	3	1	1	1
10253	361	activity p	[activities P]	0.0	2	1	1	1
10254	361	diastolic mitral flow	[diastolic mitral flow]	0.0	3	1	1	1
10255	361	decline in function	[decline in function]	0.0	3	1	1	1
10256	361	enormous clinical burden	[enormous clinical burden]	0.0	3	1	1	1
10257	361	beta1-adrenergic	[beta1-adrenergic]	0.0	1	1	1	1
10258	361	national income per capita	[national income per capita]	0.0	4	1	1	1
10259	361	effect of assist device	[effects of assist device]	0.0	4	1	1	1
10260	361	echocardiographic evidence of ventricular dyssynchrony	[echocardiographic evidence of ventricular dyssynchrony]	0.0	5	1	1	1
10261	361	adult with anemia	[adults with anemia]	0.0	3	1	1	1
10262	361	support score	[support score]	0.0	2	1	1	1
10263	361	type regulatory	[type regulatory]	0.0	2	1	1	1
10264	361	cystatin c	[cystatin C]	0.0	2	2	2	1
10265	361	group millileter per m 2	[group mL per m 2]	0.0	5	1	1	1
10266	361	global ventricular longitudinal systolic strain	[global ventricular longitudinal systolic strain]	0.0	5	1	1	1
10267	361	patient maintain sinus rhythm	[patients maintaining sinus rhythm]	0.0	4	1	1	1
10268	361	individual with congestive heart failure	[individuals with congestive heart failure]	0.0	5	1	1	1
10269	361	adoption of heart failure guideline	[adoption of heart failure guidelines]	0.0	5	1	1	1
10270	361	beta-blocker on cardiac sympathetic activity	[beta-blockers on cardiac sympathetic activity]	0.0	5	1	1	1
10271	361	high level of support	[higher levels of support]	0.0	4	1	1	1
10272	361	maladaptive process	[maladaptive processes]	0.0	2	1	1	1
10273	361	test-retest reliability in patient	[test-retest reliability in patients]	0.0	4	1	1	1
10274	361	coupling pulmonary resistance p	[coupling pulmonary resistance P]	0.0	4	1	1	1
10275	361	patient with ischemic cardiomyopathy	[patients with ischemic cardiomyopathy]	0.0	4	1	1	1
10276	361	severe perturbation	[severe perturbations]	0.0	2	1	1	1
10277	361	catheter ablation of atrial fibrillation	[catheter ablation of atrial fibrillation]	0.0	5	1	1	1
10278	361	infarction-related refractory heart failure	[infarction-related refractory heart failure]	0.0	4	1	1	1
10279	361	60 year p=0.016	[60 years P=0.016]	0.0	3	1	1	1
10280	361	ratio good	[ratio better]	0.0	2	1	1	1
10281	361	short-term improvement in functioning of treatment	[short-term improvements in functioning of treatments]	0.0	6	1	1	1
10282	361	trial registry	[trial registries]	0.0	2	1	1	1
10283	361	treatment for infarction	[treatment for infarction]	0.0	3	1	1	1
10284	361	thirty-seven hospital from January through September	[thirty-seven hospitals from January through September]	0.0	6	1	1	1
10285	361	Minnesota resident	[Minnesota residents]	0.0	2	1	1	1
10286	361	examine outcome	[examining outcomes]	0.0	2	1	1	1
10287	361	subgroup of patient at risk	[subgroups of patients at risk]	0.0	5	1	1	1
10288	361	common form of disease	[common form of disease]	0.0	4	1	1	1
10289	361	heart failure index	[Heart Failure Index]	0.0	3	1	1	1
10290	361	complicate hypertension	[complicating hypertension]	0.0	2	1	1	1
10291	361	Health Insurance Board	[Health Insurance Board]	0.0	3	1	1	1
10292	361	consecutive patient with ejection fraction	[consecutive patients with ejection fraction]	0.0	5	1	1	1
10293	361	reversal by metoprolol in heart failure	[Reversal by metoprolol in heart failure]	0.0	6	1	1	1
10294	361	understand of heart failure HF	[Understanding of heart failure HF]	0.0	5	1	1	1
10295	361	treatment for end-stage heart failure	[treatment for end-stage heart failure]	0.0	5	1	1	1
10296	361	amelioration	[amelioration]	0.0	1	1	1	1
10297	361	Minnesota resident with HF	[Minnesota residents with HF]	0.0	4	1	1	1
10298	361	biopsy	[biopsies]	0.0	1	1	1	1
10299	361	low cardiovascular event rate	[lowest cardiovascular event rate]	0.0	4	1	1	1
10300	361	restore capacity for CF lvad patient	[restoring capacity for CF LVAD patients]	0.0	6	1	1	1
10301	361	cross-talk in cachectic heart failure patient	[Cross-talk in cachectic heart failure patients]	0.0	6	1	1	1
10302	361	mitral stenosis MS	[mitral stenosis MS]	0.0	3	1	1	1
10303	361	capillary perfusion	[capillary perfusion]	0.0	2	1	1	1
10304	361	support for the concept	[support for the concept]	0.0	4	1	1	1
10305	361	decongestion end	[decongestion end]	0.0	2	1	1	1
10306	361	start date	[start date]	0.0	2	1	1	1
10307	361	also in patient with heart failure	[also in patients with heart failure]	0.0	6	1	1	1
10308	361	aspect contribute insignificantly	[aspects contributing insignificantly]	0.0	3	1	1	1
10309	361	undergo anthracycline-containing chemotherapy	[undergoing anthracycline-containing chemotherapy]	0.0	3	1	1	1
10310	361	study include RELAX-AHF	[studies including RELAX-AHF]	0.0	3	1	1	1
10311	361	training period with three training	[training period with three trainings]	0.0	5	1	1	1
10312	361	rate for outpatient	[rates for outpatients]	0.0	3	1	1	1
10313	361	commissioning of hospital programme	[commissioning of hospital programmes]	0.0	4	1	1	1
10314	361	irs2 gene	[IRS2 gene]	0.0	2	1	1	1
10315	361	primary outcome hospitalization	[primary outcome hospitalization]	0.0	3	1	1	1
10316	361	receptor signal in cardiomyocyte	[receptor signaling in cardiomyocytes]	0.0	4	1	1	1
10317	361	development of strategy	[development of strategies]	0.0	3	1	1	1
10318	361	10.0 cm(2)	[10.0 cm(2)]	0.0	2	1	1	1
10319	361	include angiography	[including angiography]	0.0	2	1	1	1
10320	361	systemic resistance	[systemic resistance]	0.0	2	1	1	1
10321	361	cardiomyopathy include negative angiography	[cardiomyopathy including negative angiography]	0.0	4	1	1	1
10322	361	transmitral e-wave early mitral annular velocity	[transmitral E-wave early mitral annular velocity]	0.0	6	1	1	1
10323	361	right ventricular tricuspid annular plane excursion	[right ventricular tricuspid annular plane excursion]	0.0	6	1	1	1
10324	361	multicenter trial optimization strategy evaluation	[Multicenter trial Optimization Strategies Evaluation]	0.0	5	1	1	1
10325	361	determine individualized assessment	[determining individualized assessment]	0.0	3	1	1	1
10326	361	subspecialty group	[subspecialty groups]	0.0	2	1	1	1
10327	361	NCDR PINNACLE program	[NCDR PINNACLE program]	0.0	3	1	1	1
10328	361	patient with first acute infarction	[patients with first acute infarction]	0.0	5	1	1	1
10329	361	risk of mortality as patient	[risk of mortality as patients]	0.0	5	1	1	1
10330	361	cause in young athlete	[cause in young athletes]	0.0	4	1	1	1
10331	361	20 cm 2	[20 cm 2]	0.0	3	1	1	1
10332	361	hypertensive heart failure	[hypertensive heart failure]	0.0	3	1	1	1
10333	361	propensity analysis	[propensity analyses]	0.0	2	1	1	1
10334	361	Doppler echocardiography	[Doppler echocardiography]	0.0	2	1	1	1
10335	361	risk of outcome	[risk of outcomes]	0.0	3	1	1	1
10336	361	readmission rate use three metric	[readmission rates using three metrics]	0.0	5	1	1	1
10337	361	potential application of peptide drug	[potential application of peptide drugs]	0.0	5	1	1	1
10338	361	positron	[positron]	0.0	1	1	1	1
10339	361	crossover study	[crossover study]	0.0	2	1	1	1
10340	361	management stem	[Management stemming]	0.0	2	1	1	1
10341	361	participation during the development	[Participation during the development]	0.0	4	1	1	1
10342	361	treatment of atrial fibrillation	[treatment of Atrial fibrillation]	0.0	4	2	2	1
10343	361	dysfunction in pathway	[dysfunction in pathways]	0.0	3	1	1	1
10344	361	validity of scale	[validity of scales]	0.0	3	1	1	1
10345	361	simultaneous activation of β1ar	[simultaneous activation of β1ARs]	0.0	4	1	1	1
10346	361	few death in the experimental procedure	[few deaths in the experimental procedures]	0.0	6	1	1	1
10347	361	regulator in cardiomyocyte	[regulator in cardiomyocytes]	0.0	3	1	1	1
10348	361	group Wistar-Kyoto	[groups Wistar-Kyoto]	0.0	2	1	1	1
10349	361	various measure of hr dynamic	[Various measures of HR dynamics]	0.0	5	1	1	1
10350	361	indicator of status	[indicators of status]	0.0	3	1	1	1
10351	361	N-terminal pro-brain-type peptide assessment	[N-terminal pro-brain-type peptide assessment]	0.0	4	1	1	1
10352	361	change value	[change values]	0.0	2	1	1	1
10353	361	reason prescribe guideline-recommended medication	[Reasons prescribing guideline-recommended medications]	0.0	4	1	1	1
10354	361	aim of the study	[aim of the study]	0.0	4	1	1	1
10355	361	symptom cpet	[symptom CPET]	0.0	2	1	1	1
10356	361	effective elastance elastance	[Effective elastance elastance]	0.0	3	1	1	1
10357	361	recommendation for advanced management	[Recommendations for advanced management]	0.0	4	1	1	1
10358	361	cardiac gene control	[cardiac gene control]	0.0	3	1	1	1
10359	361	World Health Organization criterion for cardiomyopathy	[World Health Organization criteria for cardiomyopathy]	0.0	6	1	1	1
10360	361	t2d type	[T2D Type]	0.0	2	1	1	1
10361	361	follow ring annuloplasty for mr	[following ring annuloplasty for MR]	0.0	5	1	1	1
10362	361	subject with heart failure attributable	[subjects with heart failure attributable]	0.0	5	1	1	1
10363	361	tidal respiration for quantification	[tidal respiration for quantification]	0.0	4	1	1	1
10364	361	respiration for quantification	[respiration for quantification]	0.0	3	1	1	1
10365	361	York heart Association class ii	[York Heart Association class II]	0.0	5	1	1	1
10366	361	statistically significant 42 percent reduction	[statistically significant 42 percent reduction]	0.0	5	1	1	1
10367	361	quality for HF	[quality for HF]	0.0	3	1	1	1
10368	361	large-scale trial	[large-scale trial]	0.0	2	1	1	1
10369	361	care surgery consultation in recipient	[care surgery consultations in recipients]	0.0	5	1	1	1
10370	361	stenosis	[stenosis]	0.0	1	1	1	1
10371	361	benefit for patient in small study	[benefit for patients in small studies]	0.0	6	1	1	1
10372	361	hazard ratio of 0.67	[hazard ratios of 0.67]	0.0	4	1	1	1
10373	361	change during rvpo	[changes During RVPO]	0.0	3	1	1	1
10374	361	fluorescence resonance	[fluorescence resonance]	0.0	2	1	1	1
10375	361	five patient IL	[five patients IL]	0.0	3	1	1	1
10376	361	prospective multicenter trial with 8000 individual	[prospective multicenter trial with 8000 individuals]	0.0	6	1	1	1
10377	361	telephone support	[telephone support]	0.0	2	1	1	1
10378	361	circulate plasma NE	[circulating plasma NE]	0.0	3	1	1	1
10379	361	hypoxia activator	[hypoxia activators]	0.0	2	1	1	1
10380	361	diet score p trend=0.08	[diet score P trend=0.08]	0.0	4	1	1	1
10381	361	refill compliance p	[refill compliance P]	0.0	3	1	1	1
10382	361	PAF-CPT	[PAF-CPT]	0.0	1	1	1	1
10383	361	right ventricular plane excursion tapse	[right ventricular plane excursion TAPSE]	0.0	5	1	1	1
10384	361	14 patient	[14 patients]	0.0	2	1	1	1
10385	361	trial of intravenous iron	[trials of intravenous iron]	0.0	4	1	1	1
10386	361	patient with the acute syndrome	[patients with the acute syndrome]	0.0	5	1	1	1
10387	361	frequency of diabete mellitus	[frequency of diabetes mellitus]	0.0	4	1	1	1
10388	361	bb dose versus 50 mg dose	[BB dose versus 50 mg dose]	0.0	6	1	1	1
10389	361	human embryonic kidney cell overexpress β1ar	[human embryonic kidney cells overexpressing β1AR]	0.0	6	1	1	1
10390	361	tract infection	[tract infection]	0.0	2	1	1	1
10391	361	fundamental mechanism	[fundamental mechanism]	0.0	2	1	1	1
10392	361	Black race in patient with HF	[Black race in patients with HF]	0.0	6	1	1	1
10393	361	pulse sequence	[pulse sequence]	0.0	2	1	1	1
10394	361	257 millisecond millisecond	[257 milliseconds milliseconds]	0.0	3	1	1	1
10395	361	tool a web-based program	[Tools A Web-based program]	0.0	4	1	1	1
10396	361	common form of ventricular remodeling	[common forms of ventricular remodeling]	0.0	5	1	1	1
10397	361	Coding	[Coding]	0.0	1	1	1	1
10398	361	transplant in child	[transplants in children]	0.0	3	1	1	1
10399	361	renal artery	[Renal artery]	0.0	2	1	1	1
10400	361	contribution of remodeling aspect	[contributions of remodeling aspects]	0.0	4	1	1	1
10401	361	total of psoriasis	[total of psoriasis]	0.0	3	1	1	1
10402	361	onset HFrEF day	[onset HFrEF days]	0.0	3	1	1	1
10403	361	subgroup analysis	[subgroup analyses]	0.0	2	1	1	1
10404	361	electrocardiographer	[electrocardiographers]	0.0	1	1	1	1
10405	361	heart failure patient with respect	[heart failure patients with respect]	0.0	5	1	1	1
10406	361	potential benefit with consequence	[potential benefit with consequences]	0.0	4	1	1	1
10407	361	clinical CHF model	[clinical CHF model]	0.0	3	1	1	1
10408	361	patient with hfpef treatment	[patients with HFpEF treatment]	0.0	4	1	1	1
10409	361	indicator in heart failure	[indicator in heart failure]	0.0	4	1	1	1
10410	361	use 2005 2008 performance	[using 2005 2008 performance]	0.0	4	1	1	1
10411	361	several outcome study	[several Outcomes Study]	0.0	3	1	1	1
10412	361	postoperative normalization	[postoperative normalization]	0.0	2	1	1	1
10413	361	crude rate of hyperkalemia	[Crude rates of hyperkalemia]	0.0	4	1	1	1
10414	361	2 type of lvas	[2 types of LVADs]	0.0	4	1	1	1
10415	361	early-onset HF	[early-onset HF]	0.0	2	1	1	1
10416	361	beta-blocker on cardiac activity	[beta-blockers on cardiac activity]	0.0	4	1	1	1
10417	361	consistency among patient with hfpef α=0.96	[consistency among patients with HFpEF α=0.96]	0.0	6	1	1	1
10418	361	study sample	[study sample]	0.0	2	1	1	1
10419	361	infarction MI	[infarction MI]	0.0	2	1	1	1
10420	361	exercise time test	[exercise time tests]	0.0	3	1	1	1
10421	361	long-standing af	[long-standing AF]	0.0	2	1	1	1
10422	361	refractory HF	[refractory HF]	0.0	2	1	1	1
10423	361	provide information	[providing information]	0.0	2	1	1	1
10424	361	provision of treatment	[provision of treatment]	0.0	3	1	1	1
10425	361	carry increase in risk	[carrying increase in risk]	0.0	4	1	1	1
10426	361	kidney injury during spironolactone use	[kidney injury during spironolactone use]	0.0	5	1	1	1
10427	361	Medicare 30-day readmission	[Medicare 30-day readmission]	0.0	3	1	1	1
10428	361	still a effective agent	[still a effective agent]	0.0	4	1	1	1
10429	361	have predictor	[having predictor]	0.0	2	1	1	1
10430	361	most common type of tumor	[most common type of tumors]	0.0	5	1	1	1
10431	361	hdl-induced no production	[HDL-induced NO production]	0.0	3	1	1	1
10432	361	arterial coupling pulmonary vascular resistance	[arterial coupling pulmonary vascular resistance]	0.0	5	1	1	1
10433	361	short walk distance	[shorter walk distance]	0.0	3	1	1	1
10434	361	quintile of performance	[quintile of performance]	0.0	3	1	1	1
10435	361	post-myocardial infarction heart	[post-myocardial infarction heart]	0.0	3	1	1	1
10436	361	trend toward a inverse association	[trend toward an inverse association]	0.0	5	1	1	1
10437	361	CI for sitagliptin CI for sitagliptin	[CI for sitagliptin CI for sitagliptin]	0.0	6	1	1	1
10438	361	fashion alteration	[fashion alterations]	0.0	2	1	1	1
10439	361	benefit over clinical systolic parameter	[benefit over clinical systolic parameters]	0.0	5	1	1	1
10440	361	multivariate Cox proportional hazard	[multivariate Cox proportional hazards]	0.0	4	1	1	1
10441	361	descending	[descending]	0.0	1	1	1	1
10442	361	ed visit 76.4 year	[ED visits 76.4 years]	0.0	4	1	1	1
10443	361	functional etiology	[functional etiology]	0.0	2	1	1	1
10444	361	spite	[spite]	0.0	1	1	1	1
10445	361	effect exercise	[effect exercise]	0.0	2	1	1	1
10446	361	biomarker of stimulation	[Biomarkers of stimulation]	0.0	3	1	1	1
10447	361	atrial explant-derived c-kit	[atrial explant-derived c-Kit]	0.0	3	1	1	1
10448	361	ratio mitral annulus velocity	[ratio mitral annulus velocity]	0.0	4	1	1	1
10449	361	National trend for condition	[National trends for conditions]	0.0	4	1	1	1
10450	361	heart Failure Questionnaire	[Heart Failure Questionnaire]	0.0	3	2	2	1
10451	361	aldactone evaluation study RALES	[Aldactone Evaluation Study RALES]	0.0	4	1	1	1
10452	361	conventional clinical parameter in af	[conventional clinical parameters in AF]	0.0	5	1	1	1
10453	361	induce hyperkalemia	[inducing hyperkalemia]	0.0	2	1	1	1
10454	361	twenty-seven study	[Twenty-seven studies]	0.0	2	1	1	1
10455	361	cha₂ds₂vasc score	[CHA₂DS₂VASc score]	0.0	2	1	1	1
10456	361	difference among the group	[difference among the groups]	0.0	4	1	1	1
10457	361	matrix of left ventricular biopsy n=9	[matrix of left ventricular biopsies n=9]	0.0	6	1	1	1
10458	361	artery calcium score	[artery calcium scores]	0.0	3	1	1	1
10459	361	composite HF index p	[composite HF index P]	0.0	4	1	1	1
10460	361	mortality all hazard ratio	[mortality all hazard ratios]	0.0	4	1	1	1
10461	361	Diagnostic role	[Diagnostic role]	0.0	2	1	1	1
10462	361	functional decline atrial c-kit	[functional decline atrial c-Kit]	0.0	4	1	1	1
10463	361	patient man 65±12 year	[patients men 65±12 years]	0.0	4	1	1	1
10464	361	classification of Disease	[Classification of Diseases]	0.0	3	1	1	1
10465	361	crucial problem of cardiology	[crucial problem of cardiology]	0.0	4	1	1	1
10466	361	develop certain malignancy	[developing certain malignancies]	0.0	3	1	1	1
10467	361	LV mass 42.4 gram	[LV mass 42.4 g]	0.0	4	1	1	1
10468	361	pde2 activity	[PDE2 activity]	0.0	2	1	1	1
10469	361	patient with pulmonary disease copd	[patients with pulmonary disease COPD]	0.0	5	1	1	1
10470	361	membrane oxygenation in refractory heart failure	[membrane oxygenation in refractory heart failure]	0.0	6	1	1	1
10471	361	include the establishment	[including the establishment]	0.0	3	1	1	1
10472	361	evidence from trial of iron	[evidence from trials of iron]	0.0	5	1	1	1
10473	361	descend coronary artery occlusion	[descending coronary artery occlusion]	0.0	4	1	1	1
10474	361	common problem	[common problem]	0.0	2	1	1	1
10475	361	≥5 mg hr	[≥5 mg HR]	0.0	3	1	1	1
10476	361	cardiomyiopathy	[cardiomyiopathy]	0.0	1	1	1	1
10477	361	heart failure patient ejection fraction	[heart failure patients ejection fraction]	0.0	5	1	1	1
10478	361	brief insight	[brief insight]	0.0	2	1	1	1
10479	361	factorial trial	[factorial trial]	0.0	2	1	1	1
10480	361	effect of nicorandil	[effect of nicorandil]	0.0	3	1	1	1
10481	361	combine salt loading	[combining salt loading]	0.0	3	1	1	1
10482	361	transcription factor network	[transcription factor networks]	0.0	3	1	1	1
10483	361	urgent all-cause	[urgent all-cause]	0.0	2	1	1	1
10484	361	8656 user of a nbdmard	[8656 users of a nbDMARD]	0.0	5	1	1	1
10485	361	method of constriction tac	[method of constriction TAC]	0.0	4	1	1	1
10486	361	Organisation of Care	[Organisation of Care]	0.0	3	1	1	1
10487	361	ventricle RV	[ventricle RV]	0.0	2	1	1	1
10488	361	anterior descending	[anterior descending]	0.0	2	1	1	1
10489	361	ion	[ion]	0.0	1	1	1	1
10490	361	effect of if-channel inhibition on status	[Effect of If-channel inhibition on status]	0.0	6	1	1	1
10491	361	chronic guideline-directed medical therapy GDMT	[chronic guideline-directed medical therapy GDMT]	0.0	5	1	1	1
10492	361	less severe dysfunction	[less severe dysfunction]	0.0	3	1	1	1
10493	361	cardioprotection via inhibition	[cardioprotection via inhibition]	0.0	3	1	1	1
10494	361	scenario of expenditure	[scenario of expenditure]	0.0	3	1	1	1
10495	361	passive constant	[passive constants]	0.0	2	1	1	1
10496	361	target the N termini	[targeting the N termini]	0.0	4	1	1	1
10497	361	response in cardiac activity	[response in cardiac activity]	0.0	4	1	1	1
10498	361	excellent ability	[excellent ability]	0.0	2	1	1	1
10499	361	sr can	[SR Ca]	0.0	2	1	1	1
10500	361	apparent nt-probnp concentration	[apparent NT-proBNP concentration]	0.0	3	1	1	1
10501	361	nontrastuzumab user hazard ratio	[nontrastuzumab users hazard ratio]	0.0	4	1	1	1
10502	361	achievement of metabolism	[achievement of metabolism]	0.0	3	1	1	1
10503	361	human left ventricular LV myocyte	[human left ventricular LV myocytes]	0.0	5	1	1	1
10504	361	gly16 haplotype	[Gly16 haplotype]	0.0	2	1	1	1
10505	361	statistical standard	[statistical standards]	0.0	2	1	1	1
10506	361	financial burden	[financial burden]	0.0	2	1	1	1
10507	361	dtt]-insensitive cdp	[DTT]-insensitive CDP]	0.0	2	1	1	1
10508	361	risk of hyperkalemia patient	[risk of hyperkalemia patients]	0.0	4	1	1	1
10509	361	34 follow-up period	[34 follow-up period]	0.0	3	1	1	1
10510	361	odd die in day p-value	[odds dying in days P-value]	0.0	5	1	1	1
10511	361	anaerobic metabolism	[anaerobic metabolism]	0.0	2	1	1	1
10512	361	large-scale study	[large-scale studies]	0.0	2	1	1	1
10513	361	6-week follow-up period	[6-week follow-up period]	0.0	3	1	1	1
10514	361	normal sized LV	[normal sized LV]	0.0	3	1	1	1
10515	361	sarcoplasmic SR can	[sarcoplasmic SR Ca]	0.0	3	1	1	1
10516	361	treadmill testing	[treadmill testing]	0.0	2	1	1	1
10517	361	follow event rate	[following event rates]	0.0	3	1	1	1
10518	361	improvement between baseline exercise capacity	[improvement between baseline exercise capacity]	0.0	5	1	1	1
10519	361	conventional parameter	[conventional parameters]	0.0	2	1	1	1
10520	361	difference bnp in woman EF	[difference BNP in women EF]	0.0	5	1	1	1
10521	361	population in South Dakota	[population in South Dakota]	0.0	4	1	1	1
10522	361	ventricular systolic strain as a predictor	[ventricular systolic strain as a predictor]	0.0	6	1	1	1
10523	361	geometry no LV hypertrophy	[geometry no LV hypertrophy]	0.0	4	1	1	1
10524	361	bpm respectively p	[bpm respectively P]	0.0	3	1	1	1
10525	361	acute system modulation	[acute system modulation]	0.0	3	1	1	1
10526	361	significant cost savings	[significant cost savings]	0.0	3	1	1	1
10527	361	nonadherence vs. old	[nonadherence vs. oldest]	0.0	3	1	1	1
10528	361	significant percent reduction	[significant percent reduction]	0.0	3	1	1	1
10529	361	citrate	[citrate]	0.0	1	1	1	1
10530	361	ventricular assist device use	[ventricular assist device use]	0.0	4	1	1	1
10531	361	multicenter double-blind trial	[Multicenter double-blind trial]	0.0	3	1	1	1
10532	361	transcatheter approach	[transcatheter approaches]	0.0	2	1	1	1
10533	361	require HeartMate ii	[requiring HeartMate II]	0.0	3	1	1	1
10534	361	outpatient assessment within 7 day	[outpatient assessments within 7 days]	0.0	5	1	1	1
10535	361	812 patient aged year	[812 patients aged years]	0.0	4	1	1	1
10536	361	progenitor function	[progenitor function]	0.0	2	1	1	1
10537	361	independent hypothese addition 2 μg	[independent hypotheses addition 2 μg]	0.0	5	1	1	1
10538	361	right ventricular RV tricuspid plane excursion	[right ventricular RV tricuspid plane excursion]	0.0	6	1	1	1
10539	361	presence of N form	[presence of N forms]	0.0	4	1	1	1
10540	361	function assessment	[function assessment]	0.0	2	1	1	1
10541	361	impact of assist device vad	[impact of assist device VAD]	0.0	5	1	1	1
10542	361	pulse-wave	[pulse-wave]	0.0	1	1	1	1
10543	361	black ethnicity	[black ethnicity]	0.0	2	1	1	1
10544	361	role of s1pr1 cardiac gene therapy	[role of S1PR1 cardiac gene therapy]	0.0	6	1	1	1
10545	361	protein Nucleolin	[proteins Nucleolin]	0.0	2	1	1	1
10546	361	70 bpm respectively p	[70 bpm respectively P]	0.0	4	1	1	1
10547	361	HRV	[HRV]	0.0	1	1	1	1
10548	361	man year	[men years]	0.0	2	1	1	1
10549	361	Outcome multicenter study of exercise training	[Outcomes multicenter study of exercise training]	0.0	6	1	1	1
10550	361	Catheter-based percutaneous revascularization	[Catheter-based percutaneous revascularization]	0.0	3	1	1	1
10551	361	acid	[acid]	0.0	1	1	1	1
10552	361	assist device with right support	[assist device with right support]	0.0	5	1	1	1
10553	361	inhibition of l-type ca2	[inhibition of L-type Ca2]	0.0	4	1	1	1
10554	361	hospital volume	[hospital volume]	0.0	2	1	1	1
10555	361	prognostic marker hazard ratio	[prognostic markers hazard ratio]	0.0	4	1	1	1
10556	361	global ventricular systolic strain	[global ventricular systolic strain]	0.0	4	1	1	1
10557	361	acceptable validity replicate resource use	[acceptable validity replicating resource use]	0.0	5	1	1	1
10558	361	cardiac procedure	[cardiac procedures]	0.0	2	1	1	1
10559	361	20 consecutive patient aged year	[20 consecutive patients aged years]	0.0	5	1	1	1
10560	361	nomenclature for failure	[nomenclature for failure]	0.0	3	1	1	1
10561	361	β-myosin chain	[β-myosin chain]	0.0	2	1	1	1
10562	361	parallel with a average	[parallel with an average]	0.0	4	1	1	1
10563	361	patient man mean	[patients men mean]	0.0	3	1	1	1
10564	361	treatment interaction p=0.03	[treatment interaction P=0.03]	0.0	3	1	1	1
10565	361	end-tidal co2	[end-tidal CO2]	0.0	2	1	1	1
10566	361	difference in presentation	[differences in presentation]	0.0	3	1	1	1
10567	361	unfavorable outcome versus millisecond	[unfavorable outcome vs milliseconds]	0.0	4	1	1	1
10568	361	Echocardiographic predictor of reverse remodeling	[Echocardiographic predictors of reverse remodeling]	0.0	5	1	1	1
10569	361	patient experience cardioverter-defibrillator shock	[patients experiencing cardioverter-defibrillator shocks]	0.0	4	1	1	1
10570	361	simple procedure	[simple procedures]	0.0	2	1	1	1
10571	361	difference bnp EF	[difference BNP EF]	0.0	3	1	1	1
10572	361	common type of benign tumor	[common type of benign tumors]	0.0	5	1	1	1
10573	361	similar improvement	[Similar improvements]	0.0	2	1	1	1
10574	361	liver texture change	[liver texture changes]	0.0	3	1	1	1
10575	361	duration of mechanical support	[duration of mechanical support]	0.0	4	1	1	1
10576	361	Republic	[Republic]	0.0	1	1	1	1
10577	361	natriuretic	[natriuretic]	0.0	1	1	1	1
10578	361	myofilament can sensitivity	[myofilament Ca sensitivity]	0.0	3	1	1	1
10579	361	Evidence	[Evidence]	0.0	1	1	1	1
10580	361	cohort systolic heart failure	[cohort systolic heart failure]	0.0	4	1	1	1
10581	361	acute care surgery ACS	[acute care surgery ACS]	0.0	4	1	1	1
10582	361	Exercise time	[Exercise time]	0.0	2	1	1	1
10583	361	gross development	[gross development]	0.0	2	1	1	1
10584	361	body mass index kg	[body mass index kg]	0.0	4	1	1	1
10585	361	practice within domain	[practice within domain]	0.0	3	1	1	1
10586	361	follow ring annuloplasty	[following ring annuloplasty]	0.0	3	1	1	1
10587	361	trastuzumab administration	[trastuzumab administration]	0.0	2	1	1	1
10588	361	end-tidal co2 petco2	[end-tidal CO2 PETCO2]	0.0	3	1	1	1
10589	361	human heart	[human hearts]	0.0	2	1	1	1
10590	361	promote fill during exercise in subject	[promoting filling during exercise in subjects]	0.0	6	1	1	1
10591	361	average length 37	[average length 37]	0.0	3	1	1	1
10592	361	o2 consumption	[O2 consumption]	0.0	2	1	1	1
10593	361	arterial elastance Ea	[arterial elastance Ea]	0.0	3	1	1	1
10594	361	effect analysis	[effects analysis]	0.0	2	1	1	1
10595	361	Multicenter Defibrillator	[Multicenter Defibrillator]	0.0	2	1	1	1
10596	361	development of new approach	[development of new approaches]	0.0	4	1	1	1
10597	361	few depressive symptom	[fewer depressive symptoms]	0.0	3	1	1	1
10598	361	obstructive pulmonary disease copd	[obstructive pulmonary disease COPD]	0.0	4	1	1	1
10599	361	median filtration rate	[median filtration rate]	0.0	3	1	1	1
10600	361	pharmacologic management for HF	[pharmacologic management for HF]	0.0	4	1	1	1
10601	361	trend in HF	[trends in HF]	0.0	3	1	1	1
10602	361	heart dilatation after transverse constriction	[heart dilatation after transverse constriction]	0.0	5	1	1	1
10603	361	shorten	[shortening]	0.0	1	1	1	1
10604	361	Witness	[Witness]	0.0	1	2	2	1
10605	361	symptom maximal cpet	[symptom maximal CPET]	0.0	3	1	1	1
10606	361	albumin concentration gram	[albumin concentration g]	0.0	3	1	1	1
10607	361	Extracorporeal membrane oxygenation as bridge	[Extracorporeal membrane oxygenation as bridge]	0.0	5	1	1	1
10608	361	2 type	[2 types]	0.0	2	1	1	1
10609	361	chemotherapy-induced heart failure	[chemotherapy-induced heart failure]	0.0	3	1	1	1
10610	361	aerobic training period	[aerobic training period]	0.0	3	1	1	1
10611	361	armamentarium	[armamentarium]	0.0	1	1	1	1
10612	361	wild type	[wild type]	0.0	2	1	1	1
10613	361	ongoing Cardiovascular Outcome	[ongoing Cardiovascular Outcomes]	0.0	3	1	1	1
10614	361	systolic function in cardiac volume overload	[systolic function in cardiac volume overload]	0.0	6	1	1	1
10615	361	ventricular diastolic end diameter mm difference	[ventricular diastolic end diameter mm difference]	0.0	6	1	1	1
10616	361	16 patient with CHF-NYHA-III	[16 patients with CHF-NYHA-III]	0.0	4	1	1	1
10617	361	blood glucose	[blood glucose]	0.0	2	1	1	1
10618	361	develop malignancy include cancer	[developing malignancies including cancer]	0.0	4	1	1	1
10619	361	gender odd ratio	[gender odds ratio]	0.0	3	1	1	1
10620	361	filtration rate 60 millileter	[filtration rate 60 ml]	0.0	4	1	1	1
10621	361	plane excursion tapse from the end	[plane excursion TAPSE from the end]	0.0	6	1	1	1
10622	361	right plane systolic excursion	[right plane systolic excursion]	0.0	4	1	1	1
10623	361	NCDR PINNACLE	[NCDR PINNACLE]	0.0	2	1	1	1
10624	361	Postoperative survival of patient 3.5 gram	[Postoperative survival of patients 3.5 g]	0.0	6	1	1	1
10625	361	background in heart failure patient	[background in heart failure patients]	0.0	5	1	1	1
10626	361	significant change in mlhf score	[significant change in MLHF score]	0.0	5	1	1	1
10627	361	brachial pressure 155 35	[brachial pressure 155 35]	0.0	4	1	1	1
10628	361	determine the adaptive cardiac remodelling	[determining the adaptive cardiac remodelling]	0.0	5	1	1	1
10629	361	assembly of this kinase	[assembly of these kinases]	0.0	4	1	1	1
10630	361	consecutive HF patient ejection fraction	[consecutive HF patients ejection fraction]	0.0	5	1	1	1
10631	361	real-time hfpsi use	[real-time HFPSI use]	0.0	3	1	1	1
10632	361	single-arm prospective study	[single-arm prospective study]	0.0	3	1	1	1
10633	361	workload	[workload]	0.0	1	1	1	1
10634	361	literature in the language	[literature in the language]	0.0	4	1	1	1
10635	361	quality HRQoL	[quality HRQoL]	0.0	2	1	1	1
10636	361	treatment median	[treatment median]	0.0	2	1	1	1
10637	361	factor for deterioration	[factor for deterioration]	0.0	3	1	1	1
10638	361	patient with York heart Association	[Patients with York Heart Association]	0.0	5	1	1	1
10639	361	such as acute myocardial infarction	[such as acute myocardial infarction]	0.0	5	1	1	1
10640	361	limited amount of recent datum	[limited amount of recent data]	0.0	5	1	1	1
10641	361	data support	[Data supporting]	0.0	2	1	1	1
10642	361	sample COPD	[sample COPD]	0.0	2	1	1	1
10643	361	fifty-four predominantly asymptomatic pediatric Fontan patient	[Fifty-four predominantly asymptomatic pediatric Fontan patients]	0.0	6	1	1	1
10644	361	safety monitoring	[safety monitoring]	0.0	2	1	1	1
10645	361	healthy control HDL	[healthy controls HDL]	0.0	3	1	1	1
10646	361	key outcome	[Key outcomes]	0.0	2	1	1	1
10647	361	systolic annulus velocity Sa	[systolic annulus velocity Sa]	0.0	4	1	1	1
10648	361	possible suboptimal care of patient	[possible suboptimal care of patients]	0.0	5	1	1	1
10649	361	predictor of subsequent HF	[predictor of subsequent HF]	0.0	4	1	1	1
10650	361	patient geometry no LV hypertrophy	[patients geometry no LV hypertrophy]	0.0	5	1	1	1
10651	361	evidence from 6 trial	[evidence from 6 trials]	0.0	4	1	1	1
10652	361	echocardiographic guidance	[echocardiographic guidance]	0.0	2	1	1	1
10653	361	therapeutic potential of a strategy	[therapeutic potential of a strategy]	0.0	5	1	1	1
10654	361	use the method of constriction tac	[using the method of constriction TAC]	0.0	6	1	1	1
10655	361	ventricular ejection fraction r=0.28	[ventricular ejection fraction R=0.28]	0.0	4	1	1	1
10656	361	decrease in LV shortening	[decreases in LV shortening]	0.0	4	1	1	1
10657	361	predictor a review	[Predictors a review]	0.0	3	1	1	1
10658	361	April	[April]	0.0	1	1	1	1
10659	361	chamber patterning	[chamber patterning]	0.0	2	1	1	1
10660	361	22.9±5.0 month	[22.9±5.0 months]	0.0	2	1	1	1
10661	361	sphingosine-1-phosphate receptor s1pr1	[sphingosine-1-phosphate receptor S1PR1]	0.0	3	1	1	1
10662	361	major database	[major databases]	0.0	2	1	1	1
10663	361	mitral velocity 3.1	[mitral velocity 3.1]	0.0	3	1	1	1
10664	361	egfr 60 year	[eGFR 60 years]	0.0	3	1	1	1
10665	361	ventricular RV plane systolic excursion	[ventricular RV plane systolic excursion]	0.0	5	1	1	1
10666	361	number of hospital day	[number of hospital days]	0.0	4	1	1	1
10667	361	bisphophonate	[bisphophonates]	0.0	1	1	1	1
10668	361	exercise training exercise	[exercise training exercise]	0.0	3	1	1	1
10669	361	a subunit	[A subunit]	0.0	2	1	1	1
10670	361	ventricular area index 10.0 cm(2)	[ventricular area index 10.0 cm(2)]	0.0	5	1	1	1
10671	361	high mortality than cancer	[higher mortality than cancers]	0.0	4	1	1	1
10672	361	with therapy range	[With therapies ranging]	0.0	3	1	1	1
10673	361	subject with normal heart	[subjects with normal hearts]	0.0	4	1	1	1
10674	361	malignancy include cancer of the prostate	[malignancies including cancer of the prostate]	0.0	6	1	1	1
10675	361	small difference median bnp	[smallest difference median BNP]	0.0	4	1	1	1
10676	361	fibrillation af	[fibrillation AF]	0.0	2	3	3	1
10677	361	patient with systolic function	[patients with systolic function]	0.0	4	1	1	1
10678	361	patient with the syndrome	[patients with the syndrome]	0.0	4	1	1	1
10679	361	end diameter mm difference	[end diameter mm difference]	0.0	4	1	1	1
10680	361	LVET at entry millisecond	[LVET at entry milliseconds]	0.0	4	1	1	1
10681	361	sham-dnx	[sham-DNx]	0.0	1	1	1	1
10682	361	Circulatory performance goal	[Circulatory performance goal]	0.0	3	1	1	1
10683	361	study investigate cachexia	[studies investigating cachexia]	0.0	3	1	1	1
10684	361	adverse neurological event-free rate	[adverse neurological event-free rate]	0.0	4	1	1	1
10685	361	off-pump sternal sparing approach	[off-pump sternal sparing approach]	0.0	4	1	1	1
10686	361	tgf-β signal	[TGF-β signaling]	0.0	2	1	1	1
10687	361	fourteen database	[Fourteen databases]	0.0	2	1	1	1
10688	361	trend in heart failure	[trends in heart failure]	0.0	4	1	1	1
10689	361	end point for HF	[end point for HF]	0.0	4	1	1	1
10690	361	isolated heart transplant	[isolated heart transplant]	0.0	3	1	1	1
10691	361	conclusions—low-volume	[Conclusions—Low-volume]	0.0	1	1	1	1
10692	361	medication use	[medication use]	0.0	2	1	1	1
10693	361	20 812 consecutive patient aged year	[20 812 consecutive patients aged years]	0.0	6	1	1	1
10694	361	effect of antioxidant on function	[effects of antioxidant on function]	0.0	5	1	1	1
10695	361	urban medical center	[urban medical center]	0.0	3	1	1	1
10696	361	absolute value	[absolute value]	0.0	2	2	2	1
10697	361	transfusion in patient	[transfusions in patients]	0.0	3	1	1	1
10698	361	unfavorable outcome versus millisecond millisecond	[unfavorable outcome vs milliseconds milliseconds]	0.0	5	1	1	1
10699	361	(31)p	[(31)P]	0.0	1	1	1	1
10700	361	chronic kidney disease filtration rate	[chronic kidney disease filtration rate]	0.0	5	1	1	1
10701	361	population within rehabilitation	[population within rehabilitation]	0.0	3	1	1	1
10702	361	asymptomatic Fontan patient	[asymptomatic Fontan patients]	0.0	3	1	1	1
10703	361	underlying characteristic	[underlying characteristics]	0.0	2	1	1	1
10704	361	odd ratio for event	[odds ratios for events]	0.0	4	1	1	1
10705	361	favorable change in diastolic function	[favorable changes in diastolic function]	0.0	5	1	1	1
10706	361	predictor of favorable outcome period	[predictor of favorable outcome period]	0.0	5	1	1	1
10707	361	diverse aspect	[diverse aspects]	0.0	2	1	1	1
10708	361	implication of promising biomarker	[implications of promising biomarkers]	0.0	4	1	1	1
10709	361	diuretic severe-end-stage HF	[diuretic severe-end-stage HF]	0.0	3	1	1	1
10710	361	positive effect of b	[positive effects of B]	0.0	4	1	1	1
10711	361	prediction rule for cad	[prediction rule for CAD]	0.0	4	1	1	1
10712	361	other aspect of remodeling	[other aspects of remodeling]	0.0	4	1	1	1
10713	361	outcome measure in research	[outcome measures in research]	0.0	4	1	1	1
10714	361	total of 262 psoriasis	[total of 262 psoriasis]	0.0	4	1	1	1
10715	361	tactic	[tactics]	0.0	1	1	1	1
10716	361	increase of millileter	[increase of mL]	0.0	3	1	1	1
10717	361	index versus 2.8 0.7 L	[index versus 2.8 0.7 L]	0.0	5	1	1	1
10718	361	detailed analysis of tissue	[Detailed analysis of tissue]	0.0	4	1	1	1
10719	361	treatment in patient a systematic review	[Treatment in patients a systematic review]	0.0	6	1	1	1
10720	361	ventricular annular plane excursion tapse	[ventricular annular plane excursion TAPSE]	0.0	5	1	1	1
10721	361	42.4 gram p=0.04	[42.4 g P=0.04]	0.0	3	1	1	1
10722	361	left ventricular remodeling	[left ventricular remodeling]	0.0	3	1	1	1
10723	361	0.92 event	[0.92 events]	0.0	2	1	1	1
10724	361	cardiotoxicity among patient with breast cancer	[cardiotoxicity among patients with breast cancer]	0.0	6	1	1	1
10725	361	optimization strategy evaluation rose	[Optimization Strategies Evaluation ROSE]	0.0	4	1	1	1
10726	361	end-point in hfref	[end-point in HFrEF]	0.0	3	1	1	1
10727	361	optimize cardiac progenitor function	[optimizing cardiac progenitor function]	0.0	4	1	1	1
10728	361	clinical burden in medicine	[clinical burden in medicine]	0.0	4	1	1	1
10729	361	multicenter trial Paradigm-hf with individual	[multicenter trial PARADIGM-HF with individuals]	0.0	5	1	1	1
10730	361	consensus report	[consensus report]	0.0	2	1	1	1
10731	361	right area index	[right area index]	0.0	3	1	1	1
10732	361	plasma membrane level of s1pr1	[plasma membrane levels of S1PR1]	0.0	5	1	1	1
10733	361	right ventricular annular plane systolic excursion	[right ventricular annular plane systolic excursion]	0.0	6	1	1	1
10734	361	New Zealand rabbit	[New Zealand rabbits]	0.0	3	1	1	1
10735	361	male gender odd ratio	[male gender odds ratio]	0.0	4	1	1	1
10736	361	rate of hyperkalemia	[rates of hyperkalemia]	0.0	3	1	1	1
10737	361	outcome of catheter ablation of fibrillation	[outcomes of catheter ablation of fibrillation]	0.0	6	1	1	1
10738	361	data in patient with function	[Data in patients with function]	0.0	5	1	1	1
10739	361	1-day decrease in length	[1-day decrease in length]	0.0	4	1	1	1
10740	361	Comparison heart Failure	[Comparison Heart Failure]	0.0	3	1	1	1
10741	361	decade of effort	[decade of efforts]	0.0	3	1	1	1
10742	361	toxicity	[toxicity]	0.0	1	1	1	1
10743	361	CV event in univariate model	[CV events in univariate models]	0.0	5	1	1	1
10744	361	velocity 3.1	[velocity 3.1]	0.0	2	1	1	1
10745	361	complicate precapillary hypertension	[complicating precapillary hypertension]	0.0	3	1	1	1
10746	361	level 100 pg	[levels 100 pg]	0.0	3	1	1	1
10747	361	dual inhibition of at1 receptor	[Dual inhibition of AT1 receptors]	0.0	5	1	1	1
10748	361	condition such as myocardial infarction	[conditions such as myocardial infarction]	0.0	5	1	1	1
10749	361	surgical treatment	[Surgical treatment]	0.0	2	1	1	1
10750	361	dysfunction in heart failure	[dysfunction in heart failure]	0.0	4	1	1	1
10751	361	global left longitudinal systolic strain	[global left longitudinal systolic strain]	0.0	5	1	1	1
10752	361	Sprague-Dawley	[Sprague-Dawley]	0.0	1	1	1	1
10753	361	plane systolic excursion	[plane systolic excursion]	0.0	3	1	1	1
10754	361	14 day	[14 days]	0.0	2	1	1	1
10755	361	use small-molecule inhibitor	[using small-molecule inhibitors]	0.0	3	1	1	1
10756	361	pulmonary arterial hypertension medication	[pulmonary arterial hypertension medication]	0.0	4	1	1	1
10757	361	throughput	[throughput]	0.0	1	1	1	1
10758	361	tobacco use	[tobacco use]	0.0	2	1	1	1
10759	361	left mechanic	[left mechanics]	0.0	2	1	1	1
10760	361	change in most subject	[changes in most subjects]	0.0	4	1	1	1
10761	361	change the percent of hospital	[change the percent of hospitals]	0.0	5	1	1	1
10762	361	combination into a score	[Combination into an score]	0.0	4	1	1	1
10763	361	year after discharge	[year after discharge]	0.0	3	1	1	1
10764	361	outcome of cardiovascular death	[outcome of cardiovascular death]	0.0	4	1	1	1
10765	361	participant with heart failure	[participants with heart failure]	0.0	4	1	1	1
10766	361	care surgery consultation include inotrope	[care surgery consultations including inotropes]	0.0	5	1	1	1
10767	361	add-on feature	[add-on features]	0.0	2	1	1	1
10768	361	Mechanistic insight into prolonged delay	[Mechanistic insight into prolonged delay]	0.0	5	1	1	1
10769	361	model of dyssynchronous canine electromechanic	[models of dyssynchronous canine electromechanics]	0.0	5	1	1	1
10770	361	panel of 3 electrocardiographer	[panel of 3 electrocardiographers]	0.0	4	1	1	1
10771	361	include cardiac hypertrophy	[including cardiac hypertrophy]	0.0	3	1	1	1
10772	361	neprilysin block renin-angiotensin-aldosteron	[neprilysin blocks renin-angiotensin-aldosteron]	0.0	3	1	1	1
10773	361	360 patient	[360 patients]	0.0	2	1	1	1
10774	361	cardiac hypertrophy a predictor	[cardiac hypertrophy a predictor]	0.0	4	1	1	1
10775	361	Ethics	[Ethics]	0.0	1	1	1	1
10776	361	prognosis in patient	[prognosis in patients]	0.0	3	1	1	1
10777	361	difference in the percentage	[difference in the percentage]	0.0	4	1	1	1
10778	361	HF for late-onset HF	[HF for late-onset HF]	0.0	4	1	1	1
10779	361	GSE9128	[GSE9128]	0.0	1	1	1	1
10780	361	other biomarker	[other biomarkers]	0.0	2	1	1	1
10781	361	LV mass	[LV mass]	0.0	2	1	1	1
10782	361	pde2 overexpression in cardiomyocyte	[PDE2 overexpression in cardiomyocytes]	0.0	4	1	1	1
10783	361	g'mt-treated nyha class	[GDMT-treated NYHA class]	0.0	3	1	1	1
10784	361	925 ed visit age	[925 ED visits age]	0.0	4	1	1	1
10785	361	practice-level variation in rate for outpatient	[practice-level variation in rates for outpatients]	0.0	6	1	1	1
10786	361	deficit present	[deficits present]	0.0	2	1	1	1
10787	361	9868 participant without HF	[9868 participants without HF]	0.0	4	1	1	1
10788	361	5.7 METs	[5.7 METs]	0.0	2	1	1	1
10789	361	beta-blocker hypo-response	[beta-blocker hypo-response]	0.0	2	1	1	1
10790	361	if-channel inhibition on status	[If-channel inhibition on status]	0.0	4	1	1	1
10791	361	relevance of ventricular reserve	[relevance of ventricular reserve]	0.0	4	1	1	1
10792	361	Magnet(®) research	[Magnet(®) research]	0.0	2	1	1	1
10793	361	hallmark of type diabete	[hallmark of type diabetes]	0.0	4	1	1	1
10794	361	of stenting	[of stenting]	0.0	2	1	1	1
10795	361	period of fibrillation pvf	[period of fibrillation PVF]	0.0	4	1	1	1
10796	361	role in stable coronary artery disease	[role in stable coronary artery disease]	0.0	6	1	1	1
10797	361	repolarization instability in patient	[repolarization instability in patients]	0.0	4	1	1	1
10798	361	age of patient	[age of patients]	0.0	3	1	1	1
10799	361	24 per cent with death	[24 per cent with deaths]	0.0	5	1	1	1
10800	361	pulmonary resistance hazard ratio	[pulmonary resistance hazard ratio]	0.0	4	1	1	1
10801	361	impaired metabolic gene expression	[impaired metabolic gene expression]	0.0	4	1	1	1
10802	361	cell oxide no production	[cell oxide NO production]	0.0	4	1	1	1
10803	361	other cardiovascular risk factor	[Other cardiovascular risk factors]	0.0	4	1	1	1
10804	361	top NOC outcome	[top NOC outcomes]	0.0	3	1	1	1
10805	361	most heart failure risk stratification model	[Most heart failure risk stratification models]	0.0	6	1	1	1
10806	361	biomarker-guided trial design	[biomarker-guided trial design]	0.0	3	1	1	1
10807	361	Specific signalling pathway activate remodelling	[Specific signalling pathways activating remodelling]	0.0	5	1	1	1
10808	361	early medical management of HF	[early medical management of HF]	0.0	5	1	1	1
10809	361	follow-up of 2.4 year	[follow-up of 2.4 years]	0.0	4	1	1	1
10810	361	final bb dose	[final BB dose]	0.0	3	1	1	1
10811	361	high sv	[higher SV]	0.0	2	1	1	1
10812	361	thus provide information	[thus providing information]	0.0	3	1	1	1
10813	361	error of measurement	[error of measurement]	0.0	3	2	2	1
10814	361	waist	[waist]	0.0	1	1	1	1
10815	361	idiopathic cardiomyopathy cohort	[idiopathic cardiomyopathy cohort]	0.0	3	1	1	1
10816	361	worsen function	[worsening function]	0.0	2	1	1	1
10817	361	assessment include stress echocardiography	[assessments including stress echocardiography]	0.0	4	1	1	1
10818	361	17.6 millileter	[17.6 mL]	0.0	2	1	1	1
10819	361	subclinical atherosclerosis	[subclinical atherosclerosis]	0.0	2	1	1	1
10820	361	idiopathic cardiomyopathy include coronary angiography	[idiopathic cardiomyopathy including coronary angiography]	0.0	5	1	1	1
10821	361	4.2 METs vs. METs	[4.2 METs vs. METs]	0.0	4	1	1	1
10822	361	primary diagnosis ejection fraction	[primary diagnosis ejection fraction]	0.0	4	1	1	1
10823	361	outcome trial	[outcomes trial]	0.0	2	1	1	1
10824	361	reversal of alteration	[reversal of alterations]	0.0	3	1	1	1
10825	361	bnp in woman	[BNP in women]	0.0	3	1	1	1
10826	361	kappa	[kappa]	0.0	1	2	2	1
10827	361	right ventricular tricuspid plane excursion	[right ventricular tricuspid plane excursion]	0.0	5	1	1	1
10828	361	current knowledge on use	[current knowledge on use]	0.0	4	1	1	1
10829	361	ventricular tricuspid plane excursion	[ventricular tricuspid plane excursion]	0.0	4	1	1	1
10830	361	predict CRT response	[predicting CRT response]	0.0	3	1	1	1
10831	361	echocardiographic score predict CRT response	[echocardiographic score predicting CRT response]	0.0	5	1	1	1
10832	361	b-type peptide level	[B-type peptide levels]	0.0	3	1	1	1
10833	361	Sudden death in athlete under 35	[Sudden death in athletes under 35]	0.0	6	1	1	1
10834	361	serial measurement	[serial measurements]	0.0	2	1	1	1
10835	361	2331 patient with ejection fraction	[2331 patients with ejection fraction]	0.0	5	1	1	1
10836	361	precise role of Mena	[precise role of Mena]	0.0	4	1	1	1
10837	361	reflect decrease in heart mortality	[reflecting decreases in heart mortality]	0.0	5	1	1	1
10838	361	70 versus ≥70 bpm 17.5±5.5	[70 versus ≥70 bpm 17.5±5.5]	0.0	5	1	1	1
10839	361	evaluate the effect of intervention	[evaluating the effect of interventions]	0.0	5	1	1	1
10840	361	low muscle mass	[Low muscle mass]	0.0	3	1	1	1
10841	361	entire cohort	[entire cohort]	0.0	2	1	1	1
10842	361	catheter ablation in patient	[catheter ablation in patients]	0.0	4	1	1	1
10843	361	resynchronization therapy in patient	[resynchronization therapy in patients]	0.0	4	1	1	1
10844	361	early diastolic mitral annular velocity 3.1	[early diastolic mitral annular velocity 3.1]	0.0	6	1	1	1
10845	361	3 evaluation hm use simulation model	[3 evaluations HM using simulation models]	0.0	6	1	1	1
10846	361	trials-Enriching patient identification by Collins	[trials-Enriching patient identification by Collins]	0.0	5	1	1	1
10847	361	reader in biology	[readers in biology]	0.0	3	1	1	1
10848	361	pattern generator	[pattern generator]	0.0	2	1	1	1
10849	361	strategy with potentially anti-inflammatory effect	[strategies with potentially anti-inflammatory effects]	0.0	5	1	1	1
10850	361	Catheter-based revascularization with angioplasty	[Catheter-based revascularization with angioplasty]	0.0	4	1	1	1
10851	361	restoration of high-density lipoprotein property	[restoration of high-density lipoprotein properties]	0.0	5	1	1	1
10852	361	early risk	[early risk]	0.0	2	1	1	1
10853	361	veteran	[veterans]	0.0	1	1	1	1
10854	361	effect of mitochondrial-targeted antioxidant	[effects of mitochondrial-targeted antioxidant]	0.0	4	1	1	1
10855	361	therapeutic target for heart failure	[therapeutic targets for heart failure]	0.0	5	1	1	1
10856	361	left biopsy	[left biopsies]	0.0	2	1	1	1
10857	361	autopsy	[autopsy]	0.0	1	1	1	1
10858	361	case of long survival	[case of long-term survival]	0.0	4	1	1	1
10859	361	925 ed visit year	[925 ED visits years]	0.0	4	1	1	1
10860	361	strategy with anti-inflammatory effect	[strategies with anti-inflammatory effects]	0.0	4	1	1	1
10861	361	left systolic pressure	[left systolic pressure]	0.0	3	1	1	1
10862	361	random-effect model	[random-effects models]	0.0	2	1	1	1
10863	361	versus without left ejection fraction	[versus without left ejection fraction]	0.0	5	1	1	1
10864	361	few procedure	[fewer procedures]	0.0	2	1	1	1
10865	361	transplant patient	[transplant patients]	0.0	2	1	1	1
10866	361	sarcoplasmic can	[sarcoplasmic Ca]	0.0	2	1	1	1
10867	361	impact in patient with HFrEF	[impact in patients with HFrEF]	0.0	5	1	1	1
10868	361	enormous burden	[enormous burden]	0.0	2	1	1	1
10869	361	possibly the burden	[possibly the burden]	0.0	3	1	1	1
10870	361	multicenter clinical trial of 360 patient	[Multicenter clinical trial of 360 patients]	0.0	6	1	1	1
10871	361	brachial pressure	[brachial pressure]	0.0	2	1	1	1
10872	361	lesion in the major branch	[lesions in the major branches]	0.0	5	1	1	1
10873	361	speckle tracking echocardiography	[speckle tracking echocardiography]	0.0	3	1	1	1
10874	361	result with a mva	[resulting with an MVA]	0.0	4	1	1	1
10875	361	patient aged 62.4 year	[patients aged 62.4 years]	0.0	4	1	1	1
10876	361	fundamental definition	[fundamental definitions]	0.0	2	1	1	1
10877	361	fifty patient with recent onset HFrEF	[Fifty patients with recent onset HFrEF]	0.0	6	1	1	1
10878	361	powerful composite HF index p	[powerful composite HF index P]	0.0	5	1	1	1
10879	361	optimization of fill time	[optimization of filling time]	0.0	4	1	1	1
10880	361	autonomic nervous system activity	[autonomic nervous system activity]	0.0	4	1	1	1
10881	361	ischemic sample	[ischemic samples]	0.0	2	1	1	1
10882	361	physical exertion	[physical exertion]	0.0	2	1	1	1
10883	361	icu mortality median stay	[ICU mortality median stay]	0.0	4	1	1	1
10884	361	hypertension medication	[hypertension medication]	0.0	2	1	1	1
10885	361	understanding of the structure	[understanding of the structure]	0.0	4	1	1	1
10886	361	independent role in HF	[independent role in HF]	0.0	4	1	1	1
10887	361	plasma membrane level	[plasma membrane levels]	0.0	3	1	1	1
10888	361	important role in the pathogenesis	[important role in the pathogenesis]	0.0	5	1	1	1
10889	361	adenine nucleotide	[adenine nucleotides]	0.0	2	2	2	1
10890	361	consecutive patient HFrEF	[consecutive patients HFrEF]	0.0	3	1	1	1
10891	361	3 study of therapeutics include agent	[3 studies of therapeutics including agents]	0.0	6	1	1	1
10892	361	LV pressure in week	[LV pressure in weeks]	0.0	4	1	1	1
10893	361	prognosis of a cardiomyopathy cohort	[prognosis of a cardiomyopathy cohort]	0.0	5	1	1	1
10894	361	gene between non-ischemic heart failure sample	[genes between non-ischemic heart failure samples]	0.0	6	1	1	1
10895	361	kg versus kg	[kg vs kg]	0.0	3	1	1	1
10896	361	8.4 mm hg	[8.4 mm Hg]	0.0	3	1	1	1
10897	361	heart failure patient left ejection fraction	[heart failure patients left ejection fraction]	0.0	6	1	1	1
10898	361	predominantly asymptomatic pediatric Fontan patient	[predominantly asymptomatic pediatric Fontan patients]	0.0	5	1	1	1
10899	361	reduction in exercise-induced increase	[reduction in exercise-induced increase]	0.0	4	1	1	1
10900	361	participant without HF	[participants without HF]	0.0	3	1	1	1
10901	361	partial improvement of performance	[partial improvement of performance]	0.0	4	1	1	1
10902	361	c statistic	[C statistic]	0.0	2	1	1	1
10903	361	tachycardia indicative of cardiac tone	[tachycardia indicative of cardiac tone]	0.0	5	1	1	1
10904	361	infarction patient	[infarction patients]	0.0	2	1	1	1
10905	361	fifty-four predominantly asymptomatic Fontan PF patient	[Fifty-four predominantly asymptomatic Fontan PF patients]	0.0	6	1	1	1
10906	361	increase refill compliance for etidronate	[increasing refill compliance for etidronate]	0.0	5	1	1	1
10907	361	component of the dapc	[components of the DAPC]	0.0	4	1	1	1
10908	361	bnp level with the difference	[BNP levels with the difference]	0.0	5	1	1	1
10909	361	datum on the potential	[data on the potential]	0.0	4	1	1	1
10910	361	hypertrophy a predictor	[hypertrophy a predictor]	0.0	3	1	1	1
10911	361	effective arterial elastance	[effective arterial elastance]	0.0	3	1	1	1
10912	361	2538 patient	[2,538 patients]	0.0	2	1	1	1
10913	361	ANOVA	[ANOVA]	0.0	1	1	1	1
10914	361	social support score	[social support score]	0.0	3	1	1	1
10915	361	Survival after assist device with support	[Survival after assist device with support]	0.0	6	1	1	1
10916	361	screen with a ecg in athlete	[Screening with a ECG in athletes]	0.0	6	1	1	1
10917	361	majority of candidate	[majority of candidates]	0.0	3	1	1	1
10918	361	sodium current in systolic heart failure	[sodium current in systolic heart failure]	0.0	6	1	1	1
10919	361	different US healthcare programme	[different US healthcare programmes]	0.0	4	1	1	1
10920	361	improvement database	[improvement database]	0.0	2	1	1	1
10921	361	insufficiency	[insufficiency]	0.0	1	1	1	1
10922	361	time of surgery	[time of surgery]	0.0	3	1	1	1
10923	361	demonstrate development of ms	[demonstrating development of MS]	0.0	4	1	1	1
10924	361	insulin-resistance by week post-aac	[insulin-resistance by weeks post-AAC]	0.0	4	1	1	1
10925	361	left assist device lvad implantation	[left assist device LVAD implantation]	0.0	5	1	1	1
10926	361	molecular process	[molecular processes]	0.0	2	1	1	1
10927	361	valve opening with a valve area	[valve opening with a valve area]	0.0	6	1	1	1
10928	361	left ventricular ejection fraction difference	[left ventricular ejection fraction difference]	0.0	5	1	1	1
10929	361	mitral inflow	[mitral inflow]	0.0	2	1	1	1
10930	361	membrane oxygenation in heart failure	[membrane oxygenation in heart failure]	0.0	5	1	1	1
10931	361	saxagliptin versus pioglitazone	[saxagliptin versus pioglitazone]	0.0	3	1	1	1
10932	361	relevance carry increase	[relevance carrying increase]	0.0	3	1	1	1
10933	361	contact	[contact]	0.0	1	1	1	1
10934	361	Global ventricular longitudinal systolic strain	[Global ventricular longitudinal systolic strain]	0.0	5	1	1	1
10935	361	novel intracellular strategy in HF	[novel intracellular strategy in HF]	0.0	5	1	1	1
10936	361	annulus velocity during systole s	[annulus velocities during systole s]	0.0	5	1	1	1
10937	361	treatment with vasodilator	[treatment with vasodilators]	0.0	3	1	1	1
10938	361	fifty-four asymptomatic pediatric Fontan patient	[Fifty-four asymptomatic pediatric Fontan patients]	0.0	5	1	1	1
10939	361	participant aged 70 year	[participants aged 70 years]	0.0	4	1	1	1
10940	361	peptide level	[peptide levels]	0.0	2	1	1	1
10941	361	myocardial extracellular matrix	[myocardial extracellular matrix]	0.0	3	1	1	1
10942	361	arbitrary start date	[arbitrary start date]	0.0	3	1	1	1
10943	361	inpatient record of patient	[inpatient records of patients]	0.0	4	1	1	1
10944	361	left function in volume overload	[left function in volume overload]	0.0	5	1	1	1
10945	361	anxiety	[anxiety]	0.0	1	1	1	1
10946	361	Clinical sign	[Clinical signs]	0.0	2	1	1	1
10947	361	IVC	[IVC]	0.0	1	1	1	1
10948	361	biopsy n=9	[biopsies n=9]	0.0	2	1	1	1
10949	361	ventricular mechanic	[ventricular mechanics]	0.0	2	1	1	1
10950	361	annular plane excursion	[annular plane excursion]	0.0	3	1	1	1
10951	361	heart failure in adult	[heart failure in adults]	0.0	4	1	1	1
10952	361	explant c-kit	[explant c-Kit]	0.0	2	1	1	1
10953	361	inhibition of growth factor signal	[inhibition of growth factor signaling]	0.0	5	1	1	1
10954	361	mild heart failure HF patient	[mild heart failure HF patients]	0.0	5	1	1	1
10955	361	significant effect	[significant effect]	0.0	2	4	4	1
10956	361	lvad support on survival	[LVAD support on survival]	0.0	4	1	1	1
10957	361	patient 224 man mean	[patients 224 men mean]	0.0	4	1	1	1
10958	361	left ejection fraction HF	[left ejection fraction HF]	0.0	4	1	1	1
10959	361	relevance of right reserve in patient	[relevance of right reserve in patients]	0.0	6	1	1	1
10960	361	3 study include calcium-sensin agent	[3 studies including calcium-sensitizing agents]	0.0	5	1	1	1
10961	361	HFrEF day	[HFrEF days]	0.0	2	1	1	1
10962	361	corporeal membrane oxygenation ecmo	[corporeal membrane oxygenation ECMO]	0.0	4	1	1	1
10963	361	survival in patient	[survival in patients]	0.0	3	1	1	1
10964	361	38 control	[38 controls]	0.0	2	1	1	1
10965	361	xo-mediated ros effect	[XO-mediated ROS effects]	0.0	3	1	1	1
10966	361	decoy	[decoy]	0.0	1	1	1	1
10967	361	suggest angiogenesis	[suggesting angiogenesis]	0.0	2	1	1	1
10968	361	frailty on HF risk	[frailty on HF risk]	0.0	4	1	1	1
10969	361	strain contribution	[strain contributions]	0.0	2	1	1	1
10970	361	significant decrease from a average	[significant decrease from an average]	0.0	5	1	1	1
10971	361	T cell	[T cells]	0.0	2	1	1	1
10972	361	factor in disease	[factor in diseases]	0.0	3	1	1	1
10973	361	increase in the ratio	[increase in the ratio]	0.0	4	1	1	1
10974	361	outcome study	[Outcomes Study]	0.0	2	1	1	1
10975	361	remote monitoring strategy	[Remote monitoring strategies]	0.0	3	1	1	1
10976	361	hfpef α=0.96 for summary	[HFpEF α=0.96 for summary]	0.0	4	1	1	1
10977	361	manage significant bleed	[managing significant bleeding]	0.0	3	1	1	1
10978	361	6-minute walk test 6-mwt	[6-minute walk test 6-MWT]	0.0	4	1	1	1
10979	361	70 bpm 17.5±5.5 versus millileter	[70 bpm 17.5±5.5 versus mL]	0.0	5	1	1	1
10980	361	type regulatory subunit expression	[type regulatory subunit expression]	0.0	4	1	1	1
10981	361	hemolysis	[hemolysis]	0.0	1	1	1	1
10982	361	overexpression	[overexpression]	0.0	1	1	1	1
10983	361	Exercise Training	[Exercise Training]	0.0	2	2	2	1
10984	361	42 percent reduction	[42 percent reduction]	0.0	3	1	1	1
10985	361	poor support	[Poor support]	0.0	2	1	1	1
10986	361	model of nonfailing canine electromechanic	[models of nonfailing canine electromechanics]	0.0	5	1	1	1
10987	361	resistin level similar	[resistin levels similar]	0.0	3	1	1	1
10988	361	intervention during the trial	[interventions during the trial]	0.0	4	1	1	1
10989	361	short-term treatment with a contribution	[short-term treatment with a contribution]	0.0	5	1	1	1
10990	361	low HF mortality risk	[lower HF mortality risk]	0.0	4	1	1	1
10991	361	interaction between race training	[interaction between race training]	0.0	4	1	1	1
10992	361	death in athlete under 35	[death in athletes under 35]	0.0	5	1	1	1
10993	361	cohort study with a control group	[cohort studies with a control group]	0.0	6	1	1	1
10994	361	index of right function	[index of right function]	0.0	4	1	1	1
10995	361	treatment of post-lvad ai	[treatment of post-LVAD AI]	0.0	4	1	1	1
10996	361	abnormal can handling in dyssynchronous HF	[abnormal Ca handling in dyssynchronous HF]	0.0	6	1	1	1
10997	361	serum sodium	[serum sodium]	0.0	2	1	1	1
10998	361	world	[world]	0.0	1	1	1	1
10999	361	absolute minimal detectable change value	[absolute minimal detectable change values]	0.0	5	1	1	1
11000	361	Renal	[Renal]	0.0	1	1	1	1
11001	361	70 versus ≥70 bpm p	[70 versus ≥70 bpm P]	0.0	5	1	1	1
11002	361	similar rate	[similar rates]	0.0	2	1	1	1
11003	361	infarction with major complication	[infarction with major complications]	0.0	4	1	1	1
11004	361	internal validity	[internal validity]	0.0	2	1	1	1
11005	361	application in the setting	[application in the setting]	0.0	4	1	1	1
11006	361	local cardiology service	[local cardiology services]	0.0	3	1	1	1
11007	361	association with mortality	[association with mortality]	0.0	3	1	1	1
11008	361	antiadrenergic strategy in HF	[antiadrenergic strategy in HF]	0.0	4	1	1	1
11009	361	minute of moderate-intensity aerobic exercise	[minutes of moderate-intensity aerobic exercise]	0.0	5	1	1	1
11010	361	absolute minimal change value	[absolute minimal change values]	0.0	4	1	1	1
11011	361	filtration rate of 15 millileter	[filtration rate of 15 mL]	0.0	5	2	2	1
11012	361	commissioning	[commissioning]	0.0	1	1	1	1
11013	361	adult wistar rat	[adult Wistar rats]	0.0	3	1	1	1
11014	361	high filtration rate	[higher filtration rate]	0.0	3	1	1	1
11015	361	cardiac activity by ((123)i-mibg	[cardiac activity by ((123)I-MIBG]	0.0	4	1	1	1
11016	361	262 psoriasis	[262 psoriasis]	0.0	2	1	1	1
11017	361	chronic guideline-directed therapy GDMT	[chronic guideline-directed therapy GDMT]	0.0	4	1	1	1
11018	361	multicenter clinical trial of patient	[Multicenter clinical trial of patients]	0.0	5	1	1	1
11019	361	Comparison of Outcome	[Comparison Of Outcomes]	0.0	3	1	1	1
11020	361	adverse cardiovascular CV event AF	[adverse cardiovascular CV events AF]	0.0	5	1	1	1
11021	361	ten-year experience with criterion transplantation	[Ten-year experience with criteria transplantation]	0.0	5	1	1	1
11022	361	hospital nationwide from January	[hospitals nationwide from January]	0.0	4	1	1	1
11023	361	death in the CRT group	[deaths in the CRT group]	0.0	5	1	1	1
11024	361	adequacy	[adequacy]	0.0	1	1	1	1
11025	361	severe LV dysfunction	[severe LV dysfunction]	0.0	3	1	1	1
11026	361	significant predictor of mortality	[significant predictor of mortality]	0.0	4	1	1	1
11027	361	time interval between depolarization	[time interval between depolarization]	0.0	4	1	1	1
11028	361	many predictor	[Many predictors]	0.0	2	1	1	1
11029	361	H-DKO	[H-DKO]	0.0	1	1	1	1
11030	361	hyperkalemia in American	[hyperkalemia in Americans]	0.0	3	1	1	1
11031	361	screen with a 12-lead ecg	[Screening with a 12-lead ECG]	0.0	5	1	1	1
11032	361	result in imbalance	[resulting in imbalance]	0.0	3	1	1	1
11033	361	most common cause in athlete	[most common cause in athletes]	0.0	5	1	1	1
11034	361	cyclic guanosine monophosphate	[cyclic guanosine monophosphate]	0.0	3	1	1	1
11035	361	collagen density	[collagen density]	0.0	2	1	1	1
11036	361	after coronary revascularization	[After coronary revascularization]	0.0	3	1	1	1
11037	361	form of heart failure	[form of heart failure]	0.0	4	1	1	1
11038	361	increase in LV end-diastolic pressure	[increase in LV end-diastolic pressure]	0.0	5	1	1	1
11039	361	cm 2	[cm 2]	0.0	2	1	1	1
11040	361	Medicare readmission	[Medicare readmission]	0.0	2	1	1	1
11041	361	multicenter double-blind clinical trial of patient	[Multicenter double-blind clinical trial of patients]	0.0	6	1	1	1
11042	361	prognostic ability	[prognostic ability]	0.0	2	1	1	1
11043	361	valve plasty for degenerative regurgitation	[valve plasty for degenerative regurgitation]	0.0	5	1	1	1
11044	361	investigate Outcome of Exercise Training study	[Investigating Outcomes of Exercise Training study]	0.0	6	1	1	1
11045	361	conscious dog with HF	[conscious dogs with HF]	0.0	4	1	1	1
11046	361	strike difference	[striking differences]	0.0	2	1	1	1
11047	361	economic impact	[economic impact]	0.0	2	1	1	1
11048	361	support on function in child	[support on function in children]	0.0	5	1	1	1
11049	361	psychosocial factor insight from heart failure	[Psychosocial Factors Insights From Heart Failure]	0.0	6	1	1	1
11050	361	myosin binding protein-C phosphorylation	[myosin binding protein-C phosphorylation]	0.0	4	1	1	1
11051	361	pace dnx	[pace DNx]	0.0	2	1	1	1
11052	361	manage significant gastrointestinal bleed	[managing significant gastrointestinal bleeding]	0.0	4	1	1	1
11053	361	indication for ms	[indication for MS]	0.0	3	1	1	1
11054	361	cumulative dose of mg	[cumulative dose of mg]	0.0	4	1	1	1
11055	361	measure of left ventricular mechanic	[measure of left ventricular mechanics]	0.0	5	1	1	1
11056	361	reversibility	[reversibility]	0.0	1	1	1	1
11057	361	resonance postcontrast t1 time	[resonance postcontrast T1 time]	0.0	4	2	2	1
11058	361	usefulness assess fill pressure in patient	[Usefulness assessing filling pressure in patients]	0.0	6	1	1	1
11059	361	trichrome analysis	[trichrome analysis]	0.0	2	1	1	1
11060	361	develop heart failure CHF	[developing heart failure CHF]	0.0	4	1	1	1
11061	361	HF trial	[HF trials]	0.0	2	1	1	1
11062	361	protection from hypertrophic response	[protection from hypertrophic responses]	0.0	4	1	1	1
11063	361	impact on morphological development	[impact on morphological development]	0.0	4	1	1	1
11064	361	heart failure guideline lesson	[heart failure guidelines lessons]	0.0	4	1	1	1
11065	361	exercise capacity in obese patient	[exercise capacity in obese patients]	0.0	5	1	1	1
11066	361	readmission metric	[readmission metrics]	0.0	2	2	2	1
11067	361	survival in ED patient	[survival in ED patients]	0.0	4	1	1	1
11068	361	response in activity by ((123)i-mibg	[response in activity by ((123)I-MIBG]	0.0	5	1	1	1
11069	361	occurrence within 90 day	[Occurrence within 90 days]	0.0	4	1	1	1
11070	361	manage gastrointestinal bleed	[managing gastrointestinal bleeding]	0.0	3	1	1	1
11071	361	SR can 2+)-pump	[SR Ca 2+)-pump]	0.0	3	2	2	1
11072	361	anterior descend artery occlusion	[anterior descending artery occlusion]	0.0	4	1	1	1
11073	361	cause of mortality in society	[cause of mortality in society]	0.0	5	2	2	1
11074	361	Global left ventricular longitudinal systolic strain	[Global left ventricular longitudinal systolic strain]	0.0	6	1	1	1
11075	361	interatrial shunting for treatment	[interatrial shunting for treatment]	0.0	4	1	1	1
11076	361	nondiabete risk factor	[nondiabetes risk factors]	0.0	3	1	1	1
11077	361	hospitalization for syndrome	[hospitalization for syndromes]	0.0	3	1	1	1
11078	361	TGF-β receptor type	[TGF-β receptor type]	0.0	3	1	1	1
11079	361	hospital length	[hospital length]	0.0	2	1	1	1
11080	361	cell ec oxide production	[cell EC oxide production]	0.0	4	1	1	1
11081	361	accurate risk stratification appropriate	[accurate risk stratification appropriate]	0.0	4	1	1	1
11082	361	low stimulation at eNOS-Ser	[lower stimulation at eNOS-Ser]	0.0	4	1	1	1
11083	361	vasopeptidase	[vasopeptidase]	0.0	1	1	1	1
11084	361	group iv millileter per m	[group IV mL per m]	0.0	5	1	1	1
11085	361	spontaneous ventricular tachycardia	[spontaneous ventricular tachycardia]	0.0	3	1	1	1
11086	361	oxidative phosphorylation capacity	[oxidative phosphorylation capacity]	0.0	3	2	2	1
11087	361	af type other than persistent af	[AF type other than persistent AF]	0.0	6	1	1	1
11088	361	strategy for the treatment	[strategies for the treatment]	0.0	4	1	1	1
11089	361	exercise training in HF	[exercise training in HF]	0.0	4	1	1	1
11090	361	malfunction HeartMate lvas	[malfunctioning HeartMate LVADs]	0.0	3	1	1	1
11091	361	rationale of the treatment	[rationale of the treatment]	0.0	4	1	1	1
11092	361	interview with care clinician	[interviews with care clinicians]	0.0	4	1	1	1
11093	361	age-matched control	[age-matched controls]	0.0	2	1	1	1
11094	361	acceptable alternative	[acceptable alternative]	0.0	2	1	1	1
11095	361	cardiac transplant in child	[cardiac transplants in children]	0.0	4	1	1	1
11096	361	admission for individual with disease	[admissions for individuals with disease]	0.0	5	1	1	1
11097	361	high sv p	[higher SV p]	0.0	3	1	1	1
11098	361	decade of acute heart failure	[decade of acute heart failure]	0.0	5	1	1	1
11099	361	hallmark of type	[hallmark of type]	0.0	3	1	1	1
11100	361	solely a consequence	[solely a consequence]	0.0	3	1	1	1
11101	361	activation of p70s6k PKC-βII	[activation of p70S6K PKC-βII]	0.0	4	1	1	1
11102	361	mrna level for β-myosin chain	[mRNA level for β-myosin chain]	0.0	5	1	1	1
11103	361	future research	[future research]	0.0	2	1	1	1
11104	361	postmarketing trial	[postmarketing trials]	0.0	2	1	1	1
11105	361	acceptable validity	[acceptable validity]	0.0	2	1	1	1
11106	361	form of left ventricular LV remodeling	[forms of left ventricular LV remodeling]	0.0	6	1	1	1
11107	361	unloading	[unloading]	0.0	1	1	1	1
11108	361	single success rate	[single success rates]	0.0	3	1	1	1
11109	361	describe trend	[describing trends]	0.0	2	1	1	1
11110	361	equivalent outcome	[equivalent outcomes]	0.0	2	1	1	1
11111	361	indicate possible care	[indicating possible care]	0.0	3	1	1	1
11112	361	follow acute β-ar stimulation	[following acute β-AR stimulation]	0.0	4	1	1	1
11113	361	system modulation on QTV	[system modulation on QTV]	0.0	4	1	1	1
11114	361	patient on diuretic	[patients on diuretics]	0.0	3	1	1	1
11115	361	study with ARNI inhibitor	[studies with ARNI inhibitors]	0.0	4	1	1	1
11116	361	change from enrollment	[change from enrollment]	0.0	3	1	1	1
11117	361	regard the role	[regarding the role]	0.0	3	1	1	1
11118	361	diagnosis role of doppler echocardiography	[Diagnosis role of Doppler echocardiography]	0.0	5	1	1	1
11119	361	consensus regard the form	[consensus regarding the forms]	0.0	4	1	1	1
11120	361	frailty a important indicator	[Frailty an important indicator]	0.0	4	1	1	1
11121	361	particularly between a large group	[particularly between a large group]	0.0	5	1	1	1
11122	361	cardiac plasma	[cardiac plasma]	0.0	2	1	1	1
11123	361	CHF among old patient	[CHF among older patients]	0.0	4	1	1	1
11124	361	year for patient	[years for patients]	0.0	3	1	1	1
11125	361	flow cf	[flow CF]	0.0	2	1	1	1
11126	361	American heart Association guideline	[American Heart Association guidelines]	0.0	4	1	1	1
11127	361	low-quality evidence	[low-quality evidence]	0.0	2	1	1	1
11128	361	decrease in insulin-stimulated rate	[decrease in insulin-stimulated rates]	0.0	4	1	1	1
11129	361	(egfr)-group I millileter per m 2	[(eGFR)-group I mL per m 2]	0.0	6	1	1	1
11130	361	LV wall thickness	[LV wall thickness]	0.0	3	1	1	1
11131	361	cardioverter-defibrillators icd	[cardioverter-defibrillators ICDs]	0.0	2	1	1	1
11132	361	nursing-sensitive outcome measure in future research	[nursing-sensitive outcome measures in future research]	0.0	6	1	1	1
11133	361	vivo assessment	[vivo assessment]	0.0	2	1	1	1
11134	361	low 50 mg dose	[low 50 mg dose]	0.0	4	1	1	1
11135	361	therapy GDMT	[therapy GDMT]	0.0	2	1	1	1
11136	361	47 percent	[47 percent]	0.0	2	1	1	1
11137	361	type receptor antagonist	[type receptor antagonist]	0.0	3	1	1	1
11138	361	adjust for over 20 variable	[adjusting for over 20 variables]	0.0	5	1	1	1
11139	361	median glomerular filtration rate	[median glomerular filtration rate]	0.0	4	1	1	1
11140	361	microarray	[microarray]	0.0	1	1	1	1
11141	361	Approaches	[Approaches]	0.0	1	1	1	1
11142	361	treatment of anemia a review	[Treatment of anemia a review]	0.0	5	1	1	1
11143	361	significant change main effect	[significant change main effect]	0.0	4	1	1	1
11144	361	CardioPulmonary Exercise test guide	[CardioPulmonary Exercise Testing guide]	0.0	4	1	1	1
11145	361	precise role	[precise role]	0.0	2	1	1	1
11146	361	effect with ivabradine	[effects with ivabradine]	0.0	3	1	1	1
11147	361	global left strain GLS	[global left strain GLS]	0.0	4	1	1	1
11148	361	feedback	[feedback]	0.0	1	1	1	1
11149	361	Cardiovascular Society	[Cardiovascular Society]	0.0	2	1	1	1
11150	361	protective effect of exercise training	[Protective effects of exercise training]	0.0	5	1	1	1
11151	361	calcium-sensin	[calcium-sensitizing]	0.0	1	1	1	1
11152	361	disease nbdmard	[disease nbDMARD]	0.0	2	1	1	1
11153	361	reference value z-score	[reference values Z-score]	0.0	3	1	1	1
11154	361	component regulate cellular metabolism	[components regulating cellular metabolism]	0.0	4	1	1	1
11155	361	Mechanistic insight in dyssynchronous heart failure	[Mechanistic insight in dyssynchronous heart failure]	0.0	6	1	1	1
11156	361	no production	[NO production]	0.0	2	1	1	1
11157	361	151 subject with heart failure	[151 subjects with heart failure]	0.0	5	1	1	1
11158	361	syndrome of heart failure	[syndrome of heart failure]	0.0	4	1	1	1
11159	361	use a approach	[using a approach]	0.0	3	1	1	1
11160	361	enzyme over a 6-week follow-up period	[enzymes over a 6-week follow-up period]	0.0	6	1	1	1
11161	361	circulatory derangement albeit with ability	[circulatory derangement albeit with ability]	0.0	5	1	1	1
11162	361	basic relevance carry two increase	[basic relevance carrying two increase]	0.0	5	1	1	1
11163	361	(egfr)-group I	[(eGFR)-group I]	0.0	2	1	1	1
11164	361	15 millileter odd ratio 1.76	[15 ml odds ratio 1.76]	0.0	5	1	1	1
11165	361	abdominal aortic constriction	[abdominal aortic constriction]	0.0	3	1	1	1
11166	361	longitudinal analysis	[longitudinal analysis]	0.0	2	1	1	1
11167	361	HF study	[HF studies]	0.0	2	1	1	1
11168	361	clinical trial design	[clinical trial design]	0.0	3	1	1	1
11169	361	monitoring device	[monitoring devices]	0.0	2	1	1	1
11170	361	adult patient with Fontan circulation	[adult patients with Fontan circulation]	0.0	5	1	1	1
11171	361	patient with outcome	[patients with outcome]	0.0	3	1	1	1
11172	361	elastance elastance ees	[elastance elastance Ees]	0.0	3	1	1	1
11173	361	suggest t1 as biomarker	[suggesting T1 as biomarker]	0.0	4	1	1	1
11174	361	largely because of the prevalence	[largely because of the prevalence]	0.0	5	1	1	1
11175	361	unfavorable outcome median	[unfavorable outcome median]	0.0	3	1	1	1
11176	361	interaction=0.032	[interaction=0.032]	0.0	1	1	1	1
11177	361	area cm	[area cm]	0.0	2	1	1	1
11178	361	health service provision	[health service provision]	0.0	3	1	1	1
11179	361	determinant of quality	[determinant of quality]	0.0	3	1	1	1
11180	361	relation between renal dysfunction within month	[Relation between renal dysfunction within months]	0.0	6	1	1	1
11181	361	prognostic information than the other	[prognostic information than the others]	0.0	5	1	1	1
11182	361	glomerular filtration rate egfr	[glomerular filtration rate eGFR]	0.0	4	1	1	1
11183	361	ischemic regurgitation mr	[ischemic regurgitation MR]	0.0	3	1	1	1
11184	361	refractory severe-end-stage HF	[refractory severe-end-stage HF]	0.0	3	1	1	1
11185	361	other aspect contribute insignificantly	[other aspects contributing insignificantly]	0.0	4	1	1	1
11186	361	care by drug	[care by drugs]	0.0	3	1	1	1
11187	361	incremental cost-effectiveness ratio	[incremental cost-effectiveness ratios]	0.0	3	1	1	1
11188	361	end point reflective of decongestion	[end points reflective of decongestion]	0.0	5	1	1	1
11189	361	reduction of na	[reduction of Na]	0.0	3	1	1	1
11190	361	hazard ratio for 1-year mortality	[hazard ratio for 1-year mortality]	0.0	5	1	1	1
11191	361	therapeutic treatment target exercise hemodynamic status	[therapeutic treatments targeting exercise hemodynamic status]	0.0	6	1	1	1
11192	361	risk factor for health	[risk factor for health]	0.0	4	1	1	1
11193	361	patient with bte	[patients with BTES]	0.0	3	1	1	1
11194	361	total sample COPD	[total sample COPD]	0.0	3	1	1	1
11195	361	method of transverse aortic constriction	[method of transverse aortic constriction]	0.0	5	1	1	1
11196	361	prognostic benefit over conventional parameter	[prognostic benefit over conventional parameters]	0.0	5	1	1	1
11197	361	14 study	[14 studies]	0.0	2	1	1	1
11198	361	crude case-fatality rate	[crude case-fatality rate]	0.0	3	1	1	1
11199	361	interruption of system	[interruption of systems]	0.0	3	1	1	1
11200	361	key biosynthetic enzyme	[key biosynthetic enzymes]	0.0	3	1	1	1
11201	361	absolute increase in rehospitalization	[absolute increase in rehospitalization]	0.0	4	1	1	1
11202	361	long value	[long-term value]	0.0	2	1	1	1
11203	361	quality-of-life score point vs. point	[quality-of-life score points vs. points]	0.0	5	1	1	1
11204	361	effective agent in the treatment	[effective agent in the treatment]	0.0	5	1	1	1
11205	361	duration of cardiac support	[duration of cardiac support]	0.0	4	1	1	1
11206	361	predictor a systematic review	[Predictors a systematic review]	0.0	4	1	1	1
11207	361	LV end-diastolic	[LV end-diastolic]	0.0	2	1	1	1
11208	361	trial the effect	[trial the effects]	0.0	3	1	1	1
11209	361	HF mortality risk in man	[HF mortality risk in men]	0.0	5	1	1	1
11210	361	systolic strain GLS	[systolic strain GLS]	0.0	3	1	1	1
11211	361	acute infarction with complication	[acute infarction with complications]	0.0	4	1	1	1
11212	361	longitudinal systolic strain as a predictor	[longitudinal systolic strain as a predictor]	0.0	6	1	1	1
11213	361	positive effect on function	[positive effects on function]	0.0	4	1	1	1
11214	361	monitoring after hospital discharge	[monitoring after hospital discharge]	0.0	4	1	1	1
11215	361	hallmark of type 2	[hallmark of type 2]	0.0	4	1	1	1
11216	361	extracellular matrix of biopsy n=9	[Extracellular matrix of biopsies n=9]	0.0	5	1	1	1
11217	361	testimony	[testimonies]	0.0	1	1	1	1
11218	361	30-day readmission rate use metric	[30-day readmission rates using metrics]	0.0	5	1	1	1
11219	361	prediction rule have predictor	[prediction rule having predictor]	0.0	4	1	1	1
11220	361	caspase expression	[caspase expression]	0.0	2	1	1	1
11221	361	examine long outcome	[examining long-term outcomes]	0.0	3	1	1	1
11222	361	platelet-activating	[platelet-activating]	0.0	1	1	1	1
11223	361	month after discharge 5336	[month after discharge 5336]	0.0	4	1	1	1
11224	361	involve the descend artery	[involving the descending artery]	0.0	4	1	1	1
11225	361	usually the result of lesion	[usually the result of lesions]	0.0	5	1	1	1
11226	361	predictor use regression	[predictor using regression]	0.0	3	1	1	1
11227	361	gtpase rac1 activity	[GTPase Rac1 activity]	0.0	3	1	1	1
11228	361	relationship with CV event AF	[relationship with CV events AF]	0.0	5	1	1	1
11229	361	bnp in woman EF	[BNP in women EF]	0.0	4	1	1	1
11230	361	multisystem disease	[multisystem disease]	0.0	2	1	1	1
11231	361	ventricular ejection fraction mean difference	[ventricular ejection fraction mean difference]	0.0	5	1	1	1
11232	361	Left ejection time complicate precapillary hypertension	[Left ejection time complicating precapillary hypertension]	0.0	6	1	1	1
11233	361	standard cardiac rehabilitation care	[standard cardiac rehabilitation care]	0.0	4	1	1	1
11234	361	108 hfpef with ejection fraction	[108 HFpEF with ejection fraction]	0.0	5	1	1	1
11235	361	millileter odd ratio after adjustment	[ml odds ratio after adjustment]	0.0	5	1	1	1
11236	361	odd ratio of 6.77	[odds ratio of 6.77]	0.0	4	1	1	1
11237	361	PD on status hospitalization	[PD on status hospitalizations]	0.0	4	1	1	1
11238	361	element of intervention	[elements of interventions]	0.0	3	1	1	1
11239	361	non-survivor year versus 72.83	[non-survivors years vs 72.83]	0.0	4	1	1	1
11240	361	group with high mortality	[group with high mortality]	0.0	4	1	1	1
11241	361	measure of capacity	[measures of capacity]	0.0	3	1	1	1
11242	361	predictor biomarker	[predictors biomarkers]	0.0	2	1	1	1
11243	361	pathological gene expression programme	[pathological gene expression programme]	0.0	4	1	1	1
11244	361	telehealth technology	[telehealth technology]	0.0	2	1	1	1
11245	361	cause especially among the elderly	[cause especially among the elderly]	0.0	5	1	1	1
11246	361	highlight dysfunction	[highlighting dysfunction]	0.0	2	1	1	1
11247	361	right ventricular area index cm(2)	[right ventricular area index cm(2)]	0.0	5	1	1	1
11248	361	nt-pro	[NT-pro]	0.0	1	1	1	1
11249	361	Adherence	[Adherence]	0.0	1	1	1	1
11250	361	track VA patient for 6 month	[tracking VA patients for 6 months]	0.0	6	1	1	1
11251	361	absolute detectable change mdc	[absolute detectable change MDC]	0.0	4	1	1	1
11252	361	distinct g-protein-coupled receptor	[distinct G-protein-coupled receptors]	0.0	3	1	1	1
11253	361	contribution of abnormality	[contribution of abnormalities]	0.0	3	1	1	1
11254	361	per cent with death occur	[per cent with deaths occurring]	0.0	5	1	1	1
11255	361	20812 patient	[20,812 patients]	0.0	2	1	1	1
11256	361	agent in the treatment	[agent in the treatment]	0.0	4	1	1	1
11257	361	rabbit	[rabbits]	0.0	1	1	1	1
11258	361	involve the proximal left descend artery	[involving the proximal left descending artery]	0.0	6	1	1	1
11259	361	certain malignancy include cancer	[certain malignancies including cancer]	0.0	4	1	1	1
11260	361	gross morphological development	[gross morphological development]	0.0	3	1	1	1
11261	361	cardiac resonance t1 mapping	[cardiac resonance T1 mapping]	0.0	4	1	1	1
11262	361	3 economic evaluation use simulation model	[3 economic evaluations using simulation models]	0.0	6	1	1	1
11263	361	14 clinical study approximately 2900 hm	[14 clinical studies approximately 2900 HM]	0.0	6	1	1	1
11264	361	156 consent ambulatory HF patient	[156 consenting ambulatory HF patients]	0.0	5	1	1	1
11265	361	guideline-directed medical therapy GDMT	[guideline-directed medical therapy GDMT]	0.0	4	1	1	1
11266	361	nt-probnp concentration	[NT-proBNP concentration]	0.0	2	1	1	1
11267	361	high internal consistency among patient	[high internal consistency among patients]	0.0	5	1	1	1
11268	361	current ongoing Cardiovascular Outcome	[current ongoing Cardiovascular Outcomes]	0.0	4	1	1	1
11269	361	myocyte-specific mena overexpression TTA	[myocyte-specific Mena overexpression TTA]	0.0	4	1	1	1
11270	361	mortality predictor	[mortality predictors]	0.0	2	1	1	1
11271	361	investigation for onset heart failure	[investigations for onset heart failure]	0.0	5	1	1	1
11272	361	longitudinal outcome-monitoring phase mean month	[longitudinal outcome-monitoring phase mean months]	0.0	5	1	1	1
11273	361	clinical composite response p=0.02	[clinical composite response P=0.02]	0.0	4	1	1	1
11274	361	Mena overexpression	[Mena overexpression]	0.0	2	1	1	1
11275	361	prospective datum	[prospective data]	0.0	2	1	1	1
11276	361	hypothese	[hypotheses]	0.0	1	1	1	1
11277	361	important contribution	[important contribution]	0.0	2	1	1	1
11278	361	study selection trial	[Study Selection trials]	0.0	3	1	1	1
11279	361	rheumatoid	[rheumatoid]	0.0	1	1	1	1
11280	361	autopsy sample	[autopsy samples]	0.0	2	1	1	1
11281	361	Institute	[Institute]	0.0	1	1	1	1
11282	361	effect on the number	[effect on the number]	0.0	4	1	1	1
11283	361	hr 70 versus ≥70 bpm	[HR 70 versus ≥70 bpm]	0.0	5	1	1	1
11284	361	adverse activation	[adverse activation]	0.0	2	1	1	1
11285	361	multicenter automatic defibrillator implantation resynchronization therapy	[Multicenter Automatic Defibrillator Implantation Resynchronization Therapy]	0.0	6	1	1	1
11286	361	inhibitory action on cav1.2	[inhibitory actions on CaV1.2]	0.0	4	1	1	1
11287	361	such as acute infarction	[such as acute infarction]	0.0	4	1	1	1
11288	361	uti with complication	[UTI with complications]	0.0	3	1	1	1
11289	361	trigger of myocardial infarction	[trigger of myocardial infarction]	0.0	4	1	1	1
11290	361	important factor	[important factor]	0.0	2	1	1	1
11291	361	1.6 vs. 0.8 reason	[1.6 vs. 0.8 reasons]	0.0	4	1	1	1
11292	361	diagnostic role in patient	[diagnostic roles in patients]	0.0	4	1	1	1
11293	361	obese participant	[obese participants]	0.0	2	1	1	1
11294	361	fundamental mechanism of dysfunction	[fundamental mechanism of dysfunction]	0.0	4	1	1	1
11295	361	patient with first infarction	[patients with first infarction]	0.0	4	1	1	1
11296	361	patient with left LV ejection fraction	[patients with left LV ejection fraction]	0.0	6	1	1	1
11297	361	regard treatment	[regarding treatment]	0.0	2	1	1	1
11298	361	heart mortality	[heart mortality]	0.0	2	1	1	1
11299	361	change mdc value	[change MDC values]	0.0	3	1	1	1
11300	361	exercise training on function	[exercise training on function]	0.0	4	1	1	1
11301	361	old obese participant	[older obese participants]	0.0	3	1	1	1
11302	361	patient with CHF-NYHA-III HDL	[patients with CHF-NYHA-III HDL]	0.0	4	1	1	1
11303	361	site riiα Ser96	[site RIIα Ser96]	0.0	3	1	1	1
11304	361	day p-value for difference 0.001	[days P-value for difference 0.001]	0.0	5	1	1	1
11305	361	hand-search article	[hand-searching articles]	0.0	2	1	1	1
11306	361	0.5 kg	[0.5 kg]	0.0	2	1	1	1
11307	361	routine clinical tool	[routine clinical tool]	0.0	3	1	1	1
11308	361	several pathological change include hypertrophy	[several pathological changes including hypertrophy]	0.0	5	1	1	1
11309	361	multivariate Cox	[multivariate Cox]	0.0	2	1	1	1
11310	361	good diagnostic performance only in patient	[good diagnostic performance only in patients]	0.0	6	1	1	1
11311	361	26 site	[26 sites]	0.0	2	1	1	1
11312	361	option in heart failure CHF	[option in heart failure CHF]	0.0	5	1	1	1
11313	361	longitudinal strain as a predictor	[longitudinal strain as a predictor]	0.0	5	1	1	1
11314	361	heart beat	[heart beat]	0.0	2	1	1	1
11315	361	enzyme over a follow-up period	[enzymes over a follow-up period]	0.0	5	1	1	1
11316	361	child with heart disease	[children with heart disease]	0.0	4	1	1	1
11317	361	proximal circumflex	[proximal circumflex]	0.0	2	1	1	1
11318	361	diastolic end diameter mm	[diastolic end diameter mm]	0.0	4	1	1	1
11319	361	role in the pathogenesis	[role in the pathogenesis]	0.0	4	1	1	1
11320	361	method of constriction	[method of constriction]	0.0	3	1	1	1
11321	361	large hr reduction 17±22	[larger HR reduction 17±22]	0.0	4	1	1	1
11322	361	western blot with monoclonal antibody	[Western blots with monoclonal antibodies]	0.0	5	1	1	1
11323	361	validation in large study	[validation in larger studies]	0.0	4	1	1	1
11324	361	ras-blocker	[RAS-blocker]	0.0	1	1	1	1
11325	361	model vary combination	[models varying combinations]	0.0	3	1	1	1
11326	361	functional decline explant-derived c-kit	[functional decline explant-derived c-Kit]	0.0	4	1	1	1
11327	361	growth in the setting of disease	[growth in the setting of disease]	0.0	6	1	1	1
11328	361	72 study evaluate predictor	[72 studies evaluating predictors]	0.0	4	1	1	1
11329	361	concentrate	[concentrating]	0.0	1	1	1	1
11330	361	increase in heart rate	[increase in heart rate]	0.0	4	1	1	1
11331	361	obstruction of the coronary artery	[obstruction of the coronary artery]	0.0	5	1	1	1
11332	361	bad heart failure-related qol	[worse heart failure-related QOL]	0.0	4	1	1	1
11333	361	r-like er kinase	[R-like ER kinase]	0.0	3	1	1	1
11334	361	Main etiology	[Main etiologies]	0.0	2	1	1	1
11335	361	evaluate implementation intervention	[evaluating implementation interventions]	0.0	3	1	1	1
11336	361	handling	[handling]	0.0	1	1	1	1
11337	361	cost-minimization approach	[cost-minimization approach]	0.0	2	1	1	1
11338	361	ventricular contractile function	[ventricular contractile function]	0.0	3	1	1	1
11339	361	variant consistent	[variants consistent]	0.0	2	1	1	1
11340	361	arterial compliance tac	[arterial compliance TAC]	0.0	3	1	1	1
11341	361	post-myocardial infarction patient	[post-myocardial infarction patients]	0.0	3	1	1	1
11342	361	additive impact	[additive impact]	0.0	2	1	1	1
11343	361	include sample	[including samples]	0.0	2	1	1	1
11344	361	defibrillator crt-d	[defibrillator CRT-D]	0.0	2	1	1	1
11345	361	circulate fragment of N-terminal pro-b-type peptide	[Circulating fragments of N-terminal pro-B-type peptides]	0.0	6	1	1	1
11346	361	phenotype of hypertrophy	[phenotype of hypertrophy]	0.0	3	1	1	1
11347	361	risk factor for cardiovascular health	[risk factor for cardiovascular health]	0.0	5	1	1	1
11348	361	ed visit for CHF rate	[ED visits for CHF rates]	0.0	5	1	1	1
11349	361	such as time-domain	[such as time-domain]	0.0	3	1	1	1
11350	361	attenuation of proteomic alteration	[attenuation of proteomic alterations]	0.0	4	1	1	1
11351	361	susceptibility in survivor	[susceptibility in survivors]	0.0	3	1	1	1
11352	361	describe trend after MI	[describing trends after MI]	0.0	4	1	1	1
11353	361	complication in HF	[complications in HF]	0.0	3	1	1	1
11354	361	nyha class iii HF	[NYHA class III HF]	0.0	4	1	1	1
11355	361	promising field	[promising field]	0.0	2	1	1	1
11356	361	right arterial coupling	[right arterial coupling]	0.0	3	1	1	1
11357	361	information regard condition	[information regarding conditions]	0.0	3	1	1	1
11358	361	antagomir	[antagomir]	0.0	1	1	1	1
11359	361	catecholamine	[catecholamine]	0.0	1	1	1	1
11360	361	worsen renal function WRF	[worsening renal function WRF]	0.0	4	1	1	1
11361	361	STS HH hr interval CrI	[STS HH HR interval CrI]	0.0	5	1	1	1
11362	361	low socioeconomic status	[lower socioeconomic status]	0.0	3	1	1	1
11363	361	right end-diastolic area index 10.0 cm(2)	[right end-diastolic area index 10.0 cm(2)]	0.0	6	1	1	1
11364	361	presence with physiological proteolysis	[presence with physiological proteolysis]	0.0	4	1	1	1
11365	361	diagnostic strategy	[diagnostic strategies]	0.0	2	1	1	1
11366	361	bpm 17.5±5.5 versus millileter respectively p	[bpm 17.5±5.5 versus mL respectively P]	0.0	6	1	1	1
11367	361	cohort heart failure	[cohort heart failure]	0.0	3	1	1	1
11368	361	improvement of nt-probnp biomarker	[improvement of NT-ProBNP biomarkers]	0.0	4	1	1	1
11369	361	refractory shock	[refractory shock]	0.0	2	1	1	1
11370	361	Moderate-strength evidence from trial of iron	[Moderate-strength evidence from trials of iron]	0.0	6	1	1	1
11371	361	impact on effect	[impact on effects]	0.0	3	1	1	1
11372	361	Modification code 402.x1	[Modification codes 402.x1]	0.0	3	1	1	1
11373	361	population-based study of patient	[population-based study of patients]	0.0	4	1	1	1
11374	361	left anterior descend artery occlusion	[left anterior descending artery occlusion]	0.0	5	1	1	1
11375	361	patient with systolic ejection fraction HF	[patients with systolic ejection fraction HF]	0.0	6	1	1	1
11376	361	hypertension of 191 104 mm hg	[hypertension of 191 104 mm Hg]	0.0	6	1	1	1
11377	361	two patient	[two patients]	0.0	2	1	1	1
11378	361	0.7 L	[0.7 L]	0.0	2	1	1	1
11379	361	L 2	[L 2]	0.0	2	1	1	1
11380	361	wall rs p	[wall RS P]	0.0	3	1	1	1
11381	361	arterial systolic pressure pasp	[arterial systolic pressure PASP]	0.0	4	1	1	1
11382	361	impact on development	[impact on development]	0.0	3	1	1	1
11383	361	change the percent	[change the percent]	0.0	3	1	1	1
11384	361	function end point	[function end point]	0.0	3	1	1	1
11385	361	randomized control study	[randomized control studies]	0.0	3	1	1	1
11386	361	cardiac t2 value	[cardiac T2 values]	0.0	3	1	1	1
11387	361	severe LV systolic dysfunction	[severe LV systolic dysfunction]	0.0	4	1	1	1
11388	361	eGFR group	[eGFR group]	0.0	2	1	1	1
11389	361	heart failure with systolic function	[heart failure with systolic function]	0.0	5	1	1	1
11390	361	ventricular-pulmonary arterial coupling vascular resistance	[ventricular-pulmonary arterial coupling vascular resistance]	0.0	5	1	1	1
11391	361	drug treatment	[drug treatment]	0.0	2	1	1	1
11392	361	detect fibrosis	[detecting fibrosis]	0.0	2	1	1	1
11393	361	relationship with cardiovascular CV event AF	[relationship with cardiovascular CV events AF]	0.0	6	1	1	1
11394	361	accurate recognition of disease	[accurate recognition of disease]	0.0	4	1	1	1
11395	361	14 study approximately 2900 hm	[14 studies approximately 2900 HM]	0.0	5	1	1	1
11396	361	Cochrane effective Practice	[Cochrane Effective Practice]	0.0	3	1	1	1
11397	361	effect of ventricular assist device	[effects of ventricular assist device]	0.0	5	1	1	1
11398	361	heart of fish	[hearts of fish]	0.0	3	1	1	1
11399	361	antiadrenergic strategy	[antiadrenergic strategy]	0.0	2	1	1	1
11400	361	heart Association AHA	[Heart Association AHA]	0.0	3	1	1	1
11401	361	non-AAs with New York heart Association	[non-AAs with New York Heart Association]	0.0	6	1	1	1
11402	361	end diameter mm mean difference	[end diameter mm mean difference]	0.0	5	1	1	1
11403	361	angiotensin convert	[angiotensin converting]	0.0	2	1	1	1
11404	361	β-adrenergic	[β-adrenergic]	0.0	1	1	1	1
11405	361	improve the prognosis	[improving the prognosis]	0.0	3	1	1	1
11406	361	n=44 925 ed visit 76.4 year	[n=44 925 ED visits 76.4 years]	0.0	6	1	1	1
11407	361	cell ec oxide no production	[cell EC oxide NO production]	0.0	5	1	1	1
11408	361	mouse model	[mouse model]	0.0	2	1	1	1
11409	361	perioperative death	[perioperative deaths]	0.0	2	1	1	1
11410	361	2 treatment strategy	[2 treatment strategies]	0.0	3	1	1	1
11411	361	elderly people	[elderly people]	0.0	2	1	1	1
11412	361	minute of aerobic exercise	[minutes of aerobic exercise]	0.0	4	1	1	1
11413	361	red blood cell transfusion strategy	[red blood cell transfusion strategy]	0.0	5	1	1	1
11414	361	detectable change value	[detectable change values]	0.0	3	1	1	1
11415	361	intravenous bolus	[intravenous bolus]	0.0	2	1	1	1
11416	361	2331 patient with ventricular ejection fraction	[2331 patients with ventricular ejection fraction]	0.0	6	1	1	1
11417	361	gene expression profiling	[Gene expression profiling]	0.0	3	1	1	1
11418	361	cardiopulmonary	[Cardiopulmonary]	0.0	1	1	1	1
11419	361	vegf pathway	[VEGF pathway]	0.0	2	1	1	1
11420	361	decrease period	[decreases period]	0.0	2	1	1	1
11421	361	trial of Nordic walking with moderate	[trial of Nordic walking with moderate]	0.0	6	1	1	1
11422	361	healthy control animal	[healthy control animals]	0.0	3	1	1	1
11423	361	potential of a multimarker-based strategy	[potential of a multimarker-based strategy]	0.0	5	1	1	1
11424	361	treatment option	[treatment options]	0.0	2	1	1	1
11425	361	framework determine assessment	[framework determining assessment]	0.0	3	1	1	1
11426	361	finding of cause of ms	[findings of causes of MS]	0.0	5	1	1	1
11427	361	brachial systolic pressure	[brachial systolic pressure]	0.0	3	1	1	1
11428	361	rest hr 70 bpm	[resting HR 70 bpm]	0.0	4	1	1	1
11429	361	3-year mortality rate	[3-year mortality rates]	0.0	3	1	1	1
11430	361	thirty-seven hospital through September	[thirty-seven hospitals through September]	0.0	4	1	1	1
11431	361	catheter ablation for fibrillation af	[catheter ablation for fibrillation AF]	0.0	5	1	1	1
11432	361	valve plasty for mitral regurgitation	[valve plasty for mitral regurgitation]	0.0	5	1	1	1
11433	361	early management of HF in infancy	[early management of HF in infancy]	0.0	6	1	1	1
11434	361	treatment alone	[treatment alone]	0.0	2	2	2	1
11435	361	pre-specified subgroup analysis	[pre-specified subgroup analyses]	0.0	3	1	1	1
11436	361	disease modify antirheumatic drug nbdmard	[disease modifying antirheumatic drug nbDMARD]	0.0	5	1	1	1
11437	361	event rate hr	[event rate HR]	0.0	3	1	1	1
11438	361	peptide bnp	[peptide BNP]	0.0	2	1	1	1
11439	361	strategy in HF	[strategy in HF]	0.0	3	1	1	1
11440	361	tricuspid plane systolic excursion	[tricuspid plane systolic excursion]	0.0	4	1	1	1
11441	361	play a role	[playing a role]	0.0	3	1	1	1
11442	361	LV end-diastolic volume of millileter	[LV end-diastolic volume of mL]	0.0	5	1	1	1
11443	361	stable systolic HF	[stable systolic HF]	0.0	3	1	1	1
11444	361	diastolic index ratio	[diastolic indices ratio]	0.0	3	1	1	1
11445	361	such as pressure ulcer	[such as pressure ulcers]	0.0	4	1	1	1
11446	361	global ventricular longitudinal strain	[global ventricular longitudinal strain]	0.0	4	1	1	1
11447	361	indicator in patient	[indicator in patients]	0.0	3	1	1	1
11448	361	center retrospective	[center retrospective]	0.0	2	1	1	1
11449	361	disease with comorbidity	[disease with comorbidities]	0.0	3	1	1	1
11450	361	potential effectiveness	[potential effectiveness]	0.0	2	1	1	1
11451	361	composite quality measure for common condition	[Composite quality measures for common conditions]	0.0	6	1	1	1
11452	361	cluster	[Cluster]	0.0	1	1	1	1
11453	361	ventricular pressure overload rvpo	[ventricular pressure overload RVPO]	0.0	4	1	1	1
11454	361	leg	[leg]	0.0	1	1	1	1
11455	361	significant predictor of post-transplant mortality	[significant predictor of post-transplant mortality]	0.0	5	1	1	1
11456	361	20 consecutive patient aged 40 year	[20 consecutive patients aged 40 years]	0.0	6	1	1	1
11457	361	nonselective β-blocker	[nonselective β-blocker]	0.0	2	1	1	1
11458	361	peak o2	[peak o2]	0.0	2	1	1	1
11459	361	exercise training ET on function	[exercise training ET on function]	0.0	5	1	1	1
11460	361	heart disease of HF	[heart disease of HF]	0.0	4	1	1	1
11461	361	prescription rate	[prescription rates]	0.0	2	1	1	1
11462	361	undergo mt	[undergoing MT]	0.0	2	2	2	1
11463	361	revascularization artery bypass surgery	[revascularization artery bypass surgery]	0.0	4	1	1	1
11464	361	criterion transplantation	[criteria transplantation]	0.0	2	1	1	1
11465	361	infarction-related heart failure	[infarction-related heart failure]	0.0	3	1	1	1
11466	361	prognostic benefit	[prognostic benefit]	0.0	2	1	1	1
11467	361	hazard ratio for early-onset HF	[hazard ratios for early-onset HF]	0.0	5	1	1	1
11468	361	marker of SkM growth	[markers of SkM growth]	0.0	4	1	1	1
11469	361	hypotension without a need	[hypotension without a need]	0.0	4	1	1	1
11470	361	measure of HF in patient	[measure of HF in patients]	0.0	5	1	1	1
11471	361	Addition discrimination	[Addition discrimination]	0.0	2	1	1	1
11472	361	dearth of biomarker-guided trial	[dearth of biomarker-guided trials]	0.0	4	1	1	1
11473	361	portion of the health-care budget	[portion of the health-care budget]	0.0	5	1	1	1
11474	361	two-center pilot project	[two-center pilot project]	0.0	3	1	1	1
11475	361	responsiveness	[responsiveness]	0.0	1	1	1	1
11476	361	outcome change	[outcome change]	0.0	2	1	1	1
11477	361	patient with acute infarction	[patients with acute infarction]	0.0	4	1	1	1
11478	361	interquartile range 22.8 with copd n=95	[interquartile range 22.8 with COPD n=95]	0.0	6	1	1	1
11479	361	index score p	[index score P]	0.0	3	1	1	1
11480	361	year of age with diabete	[years of age with diabetes]	0.0	5	1	1	1
11481	361	rate of change in pressure development	[rates of changes in pressure development]	0.0	6	1	1	1
11482	361	severe refractory heart failure	[severe refractory heart failure]	0.0	4	1	1	1
11483	361	valve area of cm2	[valve area of cm2]	0.0	4	1	1	1
11484	361	70 bpm 17.5±5.5 versus millileter p	[70 bpm 17.5±5.5 versus mL P]	0.0	6	1	1	1
11485	361	demographic characteristic use of medication	[demographic characteristics use of medications]	0.0	5	1	1	1
11486	361	incidence of disease in outpatient	[Incidence of disease in outpatients]	0.0	5	1	1	1
11487	361	Multicenter Study	[Multicenter Study]	0.0	2	1	1	1
11488	361	information for a unfavourable clinical outcome	[information for an unfavourable clinical outcome]	0.0	6	1	1	1
11489	361	insurance	[insurance]	0.0	1	1	1	1
11490	361	heart failure related	[heart failure related]	0.0	3	1	1	1
11491	361	cardiac response role	[cardiac response role]	0.0	3	1	1	1
11492	361	patient with advanced disease	[patients with advanced disease]	0.0	4	1	1	1
11493	361	most important component	[most important component]	0.0	3	1	1	1
11494	361	pressure 18	[pressure 18]	0.0	2	1	1	1
11495	361	membrane oxygenation in right heart failure	[membrane oxygenation in right heart failure]	0.0	6	1	1	1
11496	361	evaluate the effect	[evaluating the effect]	0.0	3	1	1	1
11497	361	resistance SVR index	[resistance SVR index]	0.0	3	1	1	1
11498	361	Systolic dysfunction	[Systolic dysfunction]	0.0	2	1	1	1
11499	361	artery pressure pasp increase by means	[artery pressure PASP increase by means]	0.0	6	1	1	1
11500	361	also evaluate the effect	[also evaluating the effect]	0.0	4	1	1	1
11501	361	Cardiac function among patient with shortness	[Cardiac Function Among Patients With Shortness]	0.0	6	1	1	1
11502	361	clinical effect of type	[clinical effects of types]	0.0	4	1	1	1
11503	361	possible care	[possible care]	0.0	2	1	1	1
11504	361	recent onset	[recent onset]	0.0	2	1	1	1
11505	361	strong reliable mortality predictor	[strong reliable mortality predictors]	0.0	4	1	1	1
11506	361	70 bpm p	[70 bpm P]	0.0	3	1	1	1
11507	361	402 patient with hfpef	[402 patients with HFpEF]	0.0	4	1	1	1
11508	361	trigger for excitation-contraction coupling	[trigger for excitation-contraction coupling]	0.0	4	1	1	1
11509	361	disease CVD	[disease CVD]	0.0	2	1	1	1
11510	361	Study of predictor of response	[Studies of predictors of response]	0.0	5	1	1	1
11511	361	cardiac growth in the setting	[cardiac growth in the setting]	0.0	5	1	1	1
11512	361	myocardial ischemia stent	[myocardial ischemia stent]	0.0	3	1	1	1
11513	361	ras blocker	[RAS blockers]	0.0	2	1	1	1
11514	361	Canadian Cardiovascular Society guideline	[Canadian Cardiovascular Society guidelines]	0.0	4	1	1	1
11515	361	gating movement	[gating movement]	0.0	2	1	1	1
11516	361	adult Fontan patient	[adult Fontan patients]	0.0	3	1	1	1
11517	361	administration of pyridostigmine	[administration of pyridostigmine]	0.0	3	1	1	1
11518	361	adverse CV event in fibrillation	[adverse CV events in fibrillation]	0.0	5	1	1	1
11519	361	understanding of the role	[understanding of the role]	0.0	4	1	1	1
11520	361	great reduction	[greater reduction]	0.0	2	1	1	1
11521	361	survive a myocardial infarction	[surviving an myocardial infarction]	0.0	4	1	1	1
11522	361	recovery period of BP	[recovery period of BP]	0.0	4	1	1	1
11523	361	difference median bnp	[difference median BNP]	0.0	3	1	1	1
11524	361	human stem cardiomyocyte	[human stem cardiomyocytes]	0.0	3	1	1	1
11525	361	New York heart Association class hr	[New York Heart Association class HR]	0.0	6	1	1	1
11526	361	heart failure patient with ventricular tachycardia	[heart failure patients with ventricular tachycardia]	0.0	6	1	1	1
11527	361	co. lack of correlation	[CO. Lack of correlation]	0.0	4	1	1	1
11528	361	Impact of physician continuity death	[Impact of physician continuity death]	0.0	5	1	1	1
11529	361	monitoring after recent hospital discharge	[monitoring after recent hospital discharge]	0.0	5	1	1	1
11530	361	development of myocardial event	[development of myocardial events]	0.0	4	1	1	1
11531	361	nitroxyl donor salt	[nitroxyl donor salt]	0.0	3	1	1	1
11532	361	calcium	[calcium]	0.0	1	1	1	1
11533	361	participate in a study	[Participating in a study]	0.0	4	1	1	1
11534	361	skeletal muscle sarcomere	[skeletal muscle sarcomere]	0.0	3	1	1	1
11535	361	Safety of eplerenone in patient	[Safety of eplerenone in patients]	0.0	5	1	1	1
11536	361	mitral e wave ratio	[mitral E wave ratio]	0.0	4	1	1	1
11537	361	elastance Ea	[elastance Ea]	0.0	2	1	1	1
11538	361	study selection english-language trial	[Study Selection English-language trials]	0.0	4	1	1	1
11539	361	post-hct CHF	[post-HCT CHF]	0.0	2	1	1	1
11540	361	consistent approach extrapolate outcome	[consistent approach extrapolating outcomes]	0.0	4	1	1	1
11541	361	composite end point	[composite end point]	0.0	3	1	1	1
11542	361	eight healthy control	[eight healthy controls]	0.0	3	1	1	1
11543	361	enhancement of care	[Enhancement of care]	0.0	3	1	1	1
11544	361	odd ratio for mortality	[odds ratio for mortality]	0.0	4	1	1	1
11545	361	3-year event rate	[3-year event rates]	0.0	3	1	1	1
11546	361	diastolic dysfunction lead	[diastolic dysfunction leading]	0.0	3	1	1	1
11547	361	characteristic of eh	[characteristics of EH]	0.0	3	1	1	1
11548	361	determination treatment strategy	[Determination treatment strategies]	0.0	3	1	1	1
11549	361	time year	[time years]	0.0	2	1	1	1
11550	361	progressive loss of fat mass	[progressive loss of fat mass]	0.0	5	1	1	1
11551	361	1.61 1.39 time	[1.61 1.39 times]	0.0	3	1	1	1
11552	361	change with strain contribution	[changes with strain contributions]	0.0	4	1	1	1
11553	361	evaluate 63 predictor	[evaluating 63 predictors]	0.0	3	1	1	1
11554	361	cardiac response	[cardiac response]	0.0	2	1	1	1
11555	361	LV dimension	[LV dimension]	0.0	2	1	1	1
11556	361	moderate high-strength evidence from 17 trial	[Moderate high-strength evidence from 17 trials]	0.0	6	1	1	1
11557	361	receptor activation	[receptor activation]	0.0	2	1	1	1
11558	361	finding a Trial investigate outcome	[findings a Trial Investigating Outcomes]	0.0	5	1	1	1
11559	361	emphasize the importance	[emphasizing the importance]	0.0	3	1	1	1
11560	361	oxygen pulse range in four	[oxygen pulse range in four]	0.0	5	1	1	1
11561	361	central blood pressure via arterial tonometry	[central blood pressure via arterial tonometry]	0.0	6	1	1	1
11562	361	effective rate relative risk	[effective rate relative risk]	0.0	4	1	1	1
11563	361	log	[log]	0.0	1	1	1	1
11564	361	cardiac magnetic resonance imaging	[cardiac magnetic resonance imaging]	0.0	4	1	1	1
11565	361	avoid the region	[avoiding the region]	0.0	3	1	1	1
11566	361	Study of echocardiographic predictor of response	[Studies of echocardiographic predictors of response]	0.0	6	1	1	1
11567	361	systolic HF of etiology	[systolic HF of etiology]	0.0	4	2	2	1
11568	361	possibly worsen	[possibly worsening]	0.0	2	1	1	1
11569	361	Australian health datum	[Australian health data]	0.0	3	1	1	1
11570	361	arthritis start a TNF antagonist	[arthritis starting a TNF antagonist]	0.0	5	1	1	1
11571	361	outcome-monitoring phase mean 22.9±5.0 month	[outcome-monitoring phase mean 22.9±5.0 months]	0.0	5	1	1	1
11572	361	academic medical center	[academic medical center]	0.0	3	1	1	1
11573	361	independent marker hazard ratio	[independent markers hazard ratio]	0.0	4	1	1	1
11574	361	examine the safety measure	[examining the safety measures]	0.0	4	1	1	1
11575	361	reporting on quality	[reporting on quality]	0.0	3	1	1	1
11576	361	systematic monitoring of lvad use	[systematic monitoring of LVAD use]	0.0	5	1	1	1
11577	361	symptomatic adult Fontan SAF patient	[symptomatic adult Fontan SAF patients]	0.0	5	1	1	1
11578	361	extend EMD in dyssynchronous HF	[extending EMD in dyssynchronous HF]	0.0	5	1	1	1
11579	361	20 812 patient aged year	[20 812 patients aged years]	0.0	5	1	1	1
11580	361	myocardial infarction-both n	[myocardial infarction-both n]	0.0	3	1	1	1
11581	361	subpulmonary ventricle	[subpulmonary ventricle]	0.0	2	1	1	1
11582	361	hypertension patient	[hypertension patients]	0.0	2	2	2	1
11583	361	transoesophageal guidance	[transoesophageal guidance]	0.0	2	1	1	1
11584	361	fifty-four pediatric Fontan PF patient	[Fifty-four pediatric Fontan PF patients]	0.0	5	1	1	1
11585	361	E ratio	[E ratios]	0.0	2	1	1	1
11586	361	ejection fraction r=0.28 p=0.01	[ejection fraction R=0.28 P=0.01]	0.0	4	1	1	1
11587	361	array of procedure	[array of procedures]	0.0	3	1	1	1
11588	361	symptom maximal cpet in patient	[symptom maximal CPET in patients]	0.0	5	1	1	1
11589	361	restoration of lipoprotein functional property	[restoration of lipoprotein functional properties]	0.0	5	1	1	1
11590	361	4-year survival of patient	[4-year survival of patients]	0.0	4	1	1	1
11591	361	important cause of morbidity	[important cause of morbidity]	0.0	4	1	1	1
11592	361	heart resonance imaging	[heart resonance imaging]	0.0	3	1	1	1
11593	361	data source MEDLINE database	[Data Sources MEDLINE databases]	0.0	4	1	1	1
11594	361	cardiac insulin-resistance post-aac	[cardiac insulin-resistance post-AAC]	0.0	3	1	1	1
11595	361	distinct receptor	[distinct receptors]	0.0	2	1	1	1
11596	361	right atrial area cm 2	[right atrial area cm 2]	0.0	5	1	1	1
11597	361	short-term improvement	[short-term improvements]	0.0	2	1	1	1
11598	361	achieve a level of CRF	[achieving a level of CRF]	0.0	5	1	1	1
11599	361	remain in decile of agreement	[remaining in deciles of agreement]	0.0	5	1	1	1
11600	361	participant aged year	[participants aged years]	0.0	3	1	1	1
11601	361	include calcium-sensin agent of endothelin	[including calcium-sensitizing agents of endothelin]	0.0	5	1	1	1
11602	361	heart rate hr reduction	[heart rate HR reduction]	0.0	4	1	1	1
11603	361	global systolic strain GLS	[global systolic strain GLS]	0.0	4	1	1	1
11604	361	HF patient without spontaneous VT hfvt(-)	[HF patients without spontaneous VT HFVT(-)]	0.0	6	1	1	1
11605	361	detectable change	[detectable change]	0.0	2	1	1	1
11606	361	Q65P	[Q65P]	0.0	1	1	1	1
11607	361	particularly between a low-risk group	[particularly between a low-risk group]	0.0	5	1	1	1
11608	361	left longitudinal systolic strain GLS	[left longitudinal systolic strain GLS]	0.0	5	1	1	1
11609	361	patient awareness	[patient awareness]	0.0	2	1	1	1
11610	361	kcal	[kcal]	0.0	1	1	1	1
11611	361	utilize voluntary testimony	[Utilizing voluntary testimonies]	0.0	3	1	1	1
11612	361	signalling pathway activate adaptive cardiac remodelling	[signalling pathways activating adaptive cardiac remodelling]	0.0	6	1	1	1
11613	361	effective rate risk	[effective rate risk]	0.0	3	1	1	1
11614	361	correlate	[correlates]	0.0	1	1	1	1
11615	361	individual with RV failure	[Individuals with RV failure]	0.0	4	1	1	1
11616	361	report demonstrate development of ms	[reports demonstrating development of MS]	0.0	5	1	1	1
11617	361	Q66P	[Q66P]	0.0	1	2	2	1
11618	361	end-of-life treatment preference	[end-of-life treatment preferences]	0.0	3	1	1	1
11619	361	factor insight	[Factors Insights]	0.0	2	1	1	1
11620	361	intensive transition	[intensive transitions]	0.0	2	2	2	1
11621	361	low risk	[lower risk]	0.0	2	1	1	1
11622	361	surgery month	[surgery months]	0.0	2	1	1	1
11623	361	nosignificant change in control group	[nosignificant changes in control group]	0.0	5	1	1	1
11624	361	acceptable internal validity	[acceptable internal validity]	0.0	3	1	1	1
11625	361	index ratio of LV strain rate	[indices ratio of LV strain rate]	0.0	6	1	1	1
11626	361	effect of exercise training on function	[effects of exercise training on function]	0.0	6	1	1	1
11627	361	institute support	[instituting support]	0.0	2	1	1	1
11628	361	treatment a review	[Treatment a review]	0.0	3	1	1	1
11629	361	RA population	[RA population]	0.0	2	1	1	1
11630	361	collagen density of the left ventricle	[collagen density of the left ventricle]	0.0	6	1	1	1
11631	361	open without any lesion	[opening without any lesion]	0.0	4	1	1	1
11632	361	gas analysis	[gas analysis]	0.0	2	1	1	1
11633	361	need of cardiopulmonary resuscitation	[need of cardiopulmonary resuscitation]	0.0	4	1	1	1
11634	361	exist measure	[existing measures]	0.0	2	1	1	1
11635	361	patient receive cardioverter defibrillator-CRT	[patients receiving cardioverter defibrillator-CRT]	0.0	4	1	1	1
11636	361	various measure such as time-domain measure	[Various measures such as time-domain measures]	0.0	6	1	1	1
11637	361	intraclass correlation	[intraclass correlation]	0.0	2	1	1	1
11638	361	underperfusion result in the activation	[underperfusion resulting in the activation]	0.0	5	1	1	1
11639	361	history of disease	[history of disease]	0.0	3	1	1	1
11640	361	large idiopathic cohort	[large idiopathic cohort]	0.0	3	1	1	1
11641	361	serum cystatin	[serum cystatin]	0.0	2	1	1	1
11642	361	improve capacity	[improving capacity]	0.0	2	1	1	1
11643	361	HeartMate ventricular assist system LVAS	[HeartMate ventricular assist system LVAS]	0.0	5	1	1	1
11644	361	death confidence interval	[death confidence interval]	0.0	3	1	1	1
11645	361	nyha class iiib symptom	[NYHA class IIIB symptoms]	0.0	4	1	1	1
11646	361	twenty-seven study patient	[Twenty-seven studies patients]	0.0	3	1	1	1
11647	361	steady improvement	[steady improvement]	0.0	2	1	1	1
11648	361	moderate high-strength evidence from trial	[Moderate high-strength evidence from trials]	0.0	5	1	1	1
11649	361	day of acs consultation	[days of ACS consultation]	0.0	4	1	1	1
11650	361	role for microrna	[role for microRNAs]	0.0	3	1	1	1
11651	361	3-min record	[3-min records]	0.0	2	1	1	1
11652	361	trial in acute HF	[trials in acute HF]	0.0	4	1	1	1
11653	361	remodeling cr	[remodeling CR]	0.0	2	1	1	1
11654	361	difference in outcome rating	[difference in outcome ratings]	0.0	4	1	1	1
11655	361	Seattle heart failure Model score	[Seattle Heart Failure Model scores]	0.0	5	1	1	1
11656	361	reliable biomarker	[reliable biomarkers]	0.0	2	1	1	1
11657	361	support device	[support devices]	0.0	2	1	1	1
11658	361	action of Rad on cav1.2	[actions of Rad on CaV1.2]	0.0	5	1	1	1
11659	361	response in activity	[response in activity]	0.0	3	1	1	1
11660	361	benefit from cardioverter defibrillator-CRT	[benefit from cardioverter defibrillator-CRT]	0.0	4	1	1	1
11661	361	cAMP-dependent protein kinase	[cAMP-dependent protein kinase]	0.0	3	1	1	1
11662	361	visit during the study period	[visits during the study period]	0.0	5	1	1	1
11663	361	10 HF patient without VT hfvt(-)	[10 HF patients without VT HFVT(-)]	0.0	6	1	1	1
11664	361	hfpsi use	[HFPSI use]	0.0	2	1	1	1
11665	361	exercise per week	[exercise per week]	0.0	3	1	1	1
11666	361	advance in treatment for infarction AMI	[Advances in treatment for infarction AMI]	0.0	6	1	1	1
11667	361	activation of β1ar in a myocyte	[activation of β1ARs in a myocyte]	0.0	6	1	1	1
11668	361	ventricular biopsy n=9	[ventricular biopsies n=9]	0.0	3	1	1	1
11669	361	gene related	[genes related]	0.0	2	1	1	1
11670	361	receptor neprilysin inhibitor	[receptor neprilysin inhibitor]	0.0	3	1	1	1
11671	361	particularly in patient	[particularly in patients]	0.0	3	1	1	1
11672	361	nesiritide μg	[nesiritide μg]	0.0	2	1	1	1
11673	361	cause of cardiovascular morbidity	[cause of cardiovascular morbidity]	0.0	4	1	1	1
11674	361	mitochondrial change	[mitochondrial changes]	0.0	2	1	1	1
11675	361	heart failure at rest	[heart failure at rest]	0.0	4	1	1	1
11676	361	schfi	[SCHFI]	0.0	1	1	1	1
11677	361	vascular resistance p	[vascular resistance P]	0.0	3	1	1	1
11678	361	systolic leaflet motion	[systolic leaflet motions]	0.0	3	1	1	1
11679	361	heart transplant recipient	[heart transplant recipients]	0.0	3	1	1	1
11680	361	transplant n=36	[transplant n=36]	0.0	2	1	1	1
11681	361	role 2 scaffold in heart pathology	[role 2 scaffolds in heart pathology]	0.0	6	1	1	1
11682	361	study in HF	[studies in HF]	0.0	3	1	1	1
11683	361	kccq category among patient	[KCCQ category among patients]	0.0	4	1	1	1
11684	361	performance detect fill pressure	[performance detecting filling pressures]	0.0	4	1	1	1
11685	361	ratio mitral annulus velocity E	[ratio mitral annulus velocity E]	0.0	5	1	1	1
11686	361	population-based study of 20812 patient	[population-based study of 20,812 patients]	0.0	5	1	1	1
11687	361	trials-Enriching patient identification	[trials-Enriching patient identification]	0.0	3	1	1	1
11688	361	change main effect	[change main effect]	0.0	3	1	1	1
11689	361	tool for economic Analysis	[Tools for Economic Analysis]	0.0	4	1	1	1
11690	361	annular plane excursion tapse	[annular plane excursion TAPSE]	0.0	4	1	1	1
11691	361	tachycardia indicative of tone	[tachycardia indicative of tone]	0.0	4	1	1	1
11692	361	bridging therapy in patient	[bridging therapy in patients]	0.0	4	1	1	1
11693	361	association of cognitive impairment	[association of cognitive impairment]	0.0	4	1	1	1
11694	361	global change in subproteome	[global changes in subproteomes]	0.0	4	1	1	1
11695	361	clinical parameter	[clinical parameters]	0.0	2	1	1	1
11696	361	extend EMD in HF	[extending EMD in HF]	0.0	4	1	1	1
11697	361	resistin in chemotherapy-induced heart failure	[resistin in chemotherapy-induced heart failure]	0.0	5	1	1	1
11698	361	bpm 17.5±5.5 versus 14.4±3.3 millileter	[bpm 17.5±5.5 versus 14.4±3.3 mL]	0.0	5	1	1	1
11699	361	treatment with ejection fraction hfpef	[treatment with ejection fraction HFpEF]	0.0	5	1	1	1
11700	361	individual with obstructive disease	[individuals with obstructive disease]	0.0	4	1	1	1
11701	361	Impact of qrs morphology	[Impact of QRS morphology]	0.0	4	1	1	1
11702	361	direct observation	[Direct observation]	0.0	2	1	1	1
11703	361	bleed in patient	[bleeding in patients]	0.0	3	1	1	1
11704	361	impact of et	[impact of ET]	0.0	3	1	1	1
11705	361	soluble	[Soluble]	0.0	1	1	1	1
11706	361	9 subject with heart HNorm	[9 subjects with hearts HNorm]	0.0	5	1	1	1
11707	361	heart failure of unclear etiology	[heart failure of unclear etiology]	0.0	5	1	1	1
11708	361	pulmonary hypertension ph	[pulmonary hypertension PH]	0.0	3	1	1	1
11709	361	study include calcium-sensin agent of endothelin	[studies including calcium-sensitizing agents of endothelin]	0.0	6	1	1	1
11710	361	absolute change the percent remain	[absolute change the percent remaining]	0.0	5	1	1	1
11711	361	participant without HF area	[participants without HF area]	0.0	4	1	1	1
11712	361	ventricular ejection fraction p=0.01	[ventricular ejection fraction P=0.01]	0.0	4	1	1	1
11713	361	difference in that parameter	[differences in those parameters]	0.0	4	1	1	1
11714	361	outcome at 1 year	[outcome at 1 year]	0.0	4	1	1	1
11715	361	period hazard ratio	[period hazard ratio]	0.0	3	1	1	1
11716	361	diastolic velocity 3.1	[diastolic velocity 3.1]	0.0	3	1	1	1
11717	361	common cause of death	[common cause of death]	0.0	4	1	1	1
11718	361	information than the other	[information than the others]	0.0	4	1	1	1
11719	361	clinical relevance in hypertension patient	[clinical relevance in hypertension patients]	0.0	5	1	1	1
11720	361	European Society	[European Society]	0.0	2	1	1	1
11721	361	require revision by open surgery	[requiring revision by open surgery]	0.0	5	1	1	1
11722	361	level of CRF	[level of CRF]	0.0	3	1	1	1
11723	361	often in the context	[often in the context]	0.0	4	1	1	1
11724	361	skinfold thickness	[skinfold thickness]	0.0	2	1	1	1
11725	361	partial pressure of co2 petco2	[partial pressure of CO2 PETCO2]	0.0	5	1	1	1
11726	361	vasopressin in heart failure	[vasopressin in heart failure]	0.0	4	1	1	1
11727	361	action on camp production	[action on cAMP production]	0.0	4	1	1	1
11728	361	proof-of-principle cohort	[proof-of-principle cohort]	0.0	2	1	1	1
11729	361	two type	[two types]	0.0	2	1	1	1
11730	361	334 patient 224 man year	[334 patients 224 men years]	0.0	5	1	1	1
11731	361	reversal of dysfunction	[Reversal of dysfunction]	0.0	3	1	1	1
11732	361	metoprolol irrespective	[metoprolol irrespective]	0.0	2	1	1	1
11733	361	va-rt cohort	[VA-RT cohort]	0.0	2	1	1	1
11734	361	angiotensin receptor antagonist	[angiotensin receptor antagonist]	0.0	3	1	1	1
11735	361	individual with chronic obstructive disease	[individuals with chronic obstructive disease]	0.0	5	1	1	1
11736	361	extracorporeal membrane oxygenation membrane support	[extracorporeal membrane oxygenation membrane support]	0.0	5	1	1	1
11737	361	man mean	[men mean]	0.0	2	1	1	1
11738	361	ventricular end diameter mm difference	[ventricular end diameter mm difference]	0.0	5	1	1	1
11739	361	colony-forming unit eo-cfus	[colony-forming units EO-CFUs]	0.0	3	1	1	1
11740	361	bnp level pg low bnp group	[BNP levels pg low BNP group]	0.0	6	1	1	1
11741	361	coupling in hypertensive hfpef	[coupling in hypertensive HFPEF]	0.0	4	1	1	1
11742	361	life domain	[life domains]	0.0	2	1	1	1
11743	361	26 cm	[26 cm]	0.0	2	1	1	1
11744	361	trend with dilatation	[trend with dilatation]	0.0	3	1	1	1
11745	361	viable option	[viable option]	0.0	2	1	1	1
11746	361	classification	[Classification]	0.0	1	1	1	1
11747	361	test-retest reliability of the up test	[test-retest reliability of the Up test]	0.0	6	1	1	1
11748	361	wk of pyridostigmine administration	[wk of pyridostigmine administration]	0.0	4	1	1	1
11749	361	compliance tac	[compliance TAC]	0.0	2	1	1	1
11750	361	field	[field]	0.0	1	1	1	1
11751	361	condition such as acute infarction	[conditions such as acute infarction]	0.0	5	1	1	1
11752	361	Health ABC performance Battery	[Health ABC Performance Battery]	0.0	4	1	1	1
11753	361	community-based cohort with incident	[community-based cohort with incident]	0.0	4	1	1	1
11754	361	16 healthy control	[16 healthy controls]	0.0	3	1	1	1
11755	361	delay avd	[delay AVD]	0.0	2	1	1	1
11756	361	aggressive protocol	[aggressive protocols]	0.0	2	1	1	1
11757	361	enrichment analysis	[enrichment analysis]	0.0	2	2	2	1
11758	361	few cardiac procedure	[fewer cardiac procedures]	0.0	3	1	1	1
11759	361	patient with Fontan circulation	[patients with Fontan circulation]	0.0	4	1	1	1
11760	361	bnp level 100 pg bnp group	[BNP levels 100 pg BNP group]	0.0	6	1	1	1
11761	361	randomized trial of walking in patient	[Randomized trial of walking in patients]	0.0	6	1	1	1
11762	361	good prognostic information	[better prognostic information]	0.0	3	1	1	1
11763	361	concept appropriate	[concept appropriate]	0.0	2	1	1	1
11764	361	47 percent of hospital	[47 percent of hospitals]	0.0	4	1	1	1
11765	361	primary outcome over month	[primary outcome over months]	0.0	4	1	1	1
11766	361	heart lesion	[heart lesions]	0.0	2	1	1	1
11767	361	maq	[mEq]	0.0	1	1	1	1
11768	361	evidence of left dyssynchrony	[evidence of left dyssynchrony]	0.0	4	1	1	1
11769	361	pulmonary systolic pressure pasp	[pulmonary systolic pressure PASP]	0.0	4	1	1	1
11770	361	ICD-HF patient	[ICD-HF patients]	0.0	2	1	1	1
11771	361	index versus 2.8 0.7 L 2	[index versus 2.8 0.7 L 2]	0.0	6	1	1	1
11772	361	cardiovascular reserve	[cardiovascular reserve]	0.0	2	1	1	1
11773	361	bivp	[BiVP]	0.0	1	1	1	1
11774	361	measurement value	[measurement value]	0.0	2	1	1	1
11775	361	334 patient man 65±12 year	[334 patients men 65±12 years]	0.0	5	1	1	1
11776	361	hazard ratio for peak o2	[hazard ratio for peak o2]	0.0	5	1	1	1
11777	361	patient 224 man	[patients 224 men]	0.0	3	1	1	1
11778	361	year q	[years Q]	0.0	2	1	1	1
11779	361	year p	[years p]	0.0	2	1	1	1
11780	361	double-blind feasibility study	[double-blind feasibility study]	0.0	3	1	1	1
11781	361	modest clinical benefit for patient	[modest clinical benefit for patients]	0.0	5	1	1	1
11782	361	ejection fraction after infarction	[ejection fraction after infarction]	0.0	4	1	1	1
11783	361	advanced organ failure	[advanced organ failure]	0.0	3	1	1	1
11784	361	improvement of performance by β-adrenoceptor blockade	[improvement of performance by β-adrenoceptor blockade]	0.0	6	1	1	1
11785	361	patient have hfpef gender	[patients having HFpEF gender]	0.0	4	1	1	1
11786	361	transcatheter valve procedure	[transcatheter valve procedure]	0.0	3	1	1	1
11787	361	haplotype status	[haplotype status]	0.0	2	1	1	1
11788	361	nutritional strategy with anti-inflammatory effect	[nutritional strategies with anti-inflammatory effects]	0.0	5	1	1	1
11789	361	total compliance	[total compliance]	0.0	2	1	1	1
11790	361	capillary wedge	[capillary wedge]	0.0	2	1	1	1
11791	361	mortality among woman with HF	[mortality among women with HF]	0.0	5	1	1	1
11792	361	Effect of support on function	[Effects of support on function]	0.0	5	1	1	1
11793	361	improvement of biomarker	[improvement of biomarkers]	0.0	3	1	1	1
11794	361	quantification of t1	[quantification of T1]	0.0	3	1	1	1
11795	361	right ventricular ejection fraction r=0.28	[right ventricular ejection fraction R=0.28]	0.0	5	1	1	1
11796	361	can 2 handling in HF	[Ca 2 handling in HF]	0.0	5	1	1	1
11797	361	cardiac magnetic resonance t1 mapping	[cardiac magnetic resonance T1 mapping]	0.0	5	1	1	1
11798	361	valve plasty for regurgitation	[valve plasty for regurgitation]	0.0	4	1	1	1
11799	361	first acute infarction in Australia	[first acute infarction in Australia]	0.0	5	1	1	1
11800	361	10000 pair	[10,000 pairs]	0.0	2	1	1	1
11801	361	index ratio at diastole	[indices ratio at diastole]	0.0	4	1	1	1
11802	361	insight into delay	[insight into delay]	0.0	3	1	1	1
11803	361	10 patient	[10 patients]	0.0	2	1	1	1
11804	361	essential role	[essential role]	0.0	2	1	1	1
11805	361	acf group	[ACF groups]	0.0	2	1	1	1
11806	361	ischemic event in patient	[ischemic events in patients]	0.0	4	1	1	1
11807	361	hr variability measure	[HR variability measures]	0.0	3	1	1	1
11808	361	risk for hyperkalemia	[risk for hyperkalemia]	0.0	3	2	2	1
11809	361	health intervention	[health interventions]	0.0	2	1	1	1
11810	361	patient with obstructive pulmonary disease	[patients with obstructive pulmonary disease]	0.0	5	1	1	1
11811	361	enhancement of cardiac angiogenesis	[enhancement of cardiac angiogenesis]	0.0	4	1	1	1
11812	361	Left ejection time complicate pulmonary hypertension	[Left ejection time complicating pulmonary hypertension]	0.0	6	1	1	1
11813	361	cation channel m7	[cation channel M7]	0.0	3	1	1	1
11814	361	heart failure-related qol outcome	[heart failure-related QOL outcome]	0.0	4	1	1	1
11815	361	emphasis-hf study subgroup	[EMPHASIS-HF study subgroups]	0.0	3	1	1	1
11816	361	tumor necrosis	[tumor necrosis]	0.0	2	1	1	1
11817	361	dietary pattern	[dietary patterns]	0.0	2	1	1	1
11818	361	use the method	[using the method]	0.0	3	1	1	1
11819	361	treatment of diuretic HF	[treatment of diuretic HF]	0.0	4	1	1	1
11820	361	multicenter placebo-controlled trial	[Multicenter placebo-controlled trial]	0.0	3	1	1	1
11821	361	CI for sitagliptin	[CI for sitagliptin]	0.0	3	1	1	1
11822	361	proteolysis between pro2-leu3	[proteolysis between Pro2-Leu3]	0.0	3	1	1	1
11823	361	Cardiac overexpression	[Cardiac overexpression]	0.0	2	1	1	1
11824	361	high-strength evidence from 17 trial	[high-strength evidence from 17 trials]	0.0	5	1	1	1
11825	361	patch	[patch]	0.0	1	1	1	1
11826	361	velocity of shortening	[velocity of shortening]	0.0	3	1	1	1
11827	361	spironolactone use from 2006	[spironolactone use from 2006]	0.0	4	1	1	1
11828	361	peak early diastolic flow velocity	[peak early diastolic flow velocity]	0.0	5	2	2	1
11829	361	furosemide	[furosemide]	0.0	1	2	2	1
11830	361	Effect of support	[Effects of support]	0.0	3	1	1	1
11831	361	resident	[residents]	0.0	1	1	1	1
11832	361	use general model	[using general models]	0.0	3	1	1	1
11833	361	pharmacologic study include agent of endothelin	[pharmacologic studies including agents of endothelin]	0.0	6	1	1	1
11834	361	risk stratification between a group	[risk stratification between a group]	0.0	5	1	1	1
11835	361	CHF-NYHA-IIIb	[CHF-NYHA-IIIb]	0.0	1	1	1	1
11836	361	finding a Trial	[findings a Trial]	0.0	3	1	1	1
11837	361	receive membrane oxygenation membrane support	[receiving membrane oxygenation membrane support]	0.0	5	1	1	1
11838	361	detect at	[detecting AT]	0.0	2	1	1	1
11839	361	mortality at 4 year after hospitalization	[mortality at 4 years after hospitalization]	0.0	6	1	1	1
11840	361	afterload of the heart	[afterload of the heart]	0.0	4	1	1	1
11841	361	management stem from ischemic cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[Management stemming from ischemic cardiomyopathies]	0.0	5	1	1	1
11842	361	tachycardia in response	[tachycardia in response]	0.0	3	1	1	1
11843	361	artery pressure pasp increase	[artery pressure PASP increase]	0.0	4	1	1	1
11844	361	post-transplant	[post-transplant]	0.0	1	1	1	1
11845	361	significant improvement show improvement	[significant improvements showing improvement]	0.0	4	1	1	1
11846	361	venous event	[venous events]	0.0	2	1	1	1
11847	361	morbidity in elderly people	[morbidity in elderly people]	0.0	4	1	1	1
11848	361	system event	[system events]	0.0	2	1	1	1
11849	361	LV fibrosis	[LV fibrosis]	0.0	2	1	1	1
11850	361	physician a difference	[physicians a difference]	0.0	3	1	1	1
11851	361	o-1	[O-1]	0.0	1	1	1	1
11852	361	all-cause hospitalization in HF clinic outpatient	[all-cause hospitalization in HF clinic outpatients]	0.0	6	2	2	1
11853	361	mitochondrial-targeted peptide	[mitochondrial-targeted peptides]	0.0	2	1	1	1
11854	361	PKC-βII by HDL	[PKC-βII by HDL]	0.0	3	1	1	1
11855	361	risk factor on HF mortality	[risk factors on HF mortality]	0.0	5	1	1	1
11856	361	Obese patient with heart failure	[Obese Patients With Heart Failure]	0.0	5	1	1	1
11857	361	aim of this multicenter study	[aim of this multicenter study]	0.0	5	1	1	1
11858	361	number of apoptotic cell	[numbers of apoptotic cells]	0.0	4	1	1	1
11859	361	E email	[E e]	0.0	2	1	1	1
11860	361	user of bisphosphonate	[users of bisphosphonates]	0.0	3	1	1	1
11861	361	large-scale randomised study	[large-scale randomised studies]	0.0	3	1	1	1
11862	361	ventricular RV failure	[ventricular RV failure]	0.0	3	1	1	1
11863	361	complicate pulmonary hypertension	[complicating pulmonary hypertension]	0.0	3	1	1	1
11864	361	robot-assisted gait therapy	[robot-assisted gait therapy]	0.0	3	1	1	1
11865	361	LV contractility	[LV contractility]	0.0	2	1	1	1
11866	361	major mechanism	[major mechanism]	0.0	2	1	1	1
11867	361	open	[opening]	0.0	1	1	1	1
11868	361	KCCQ summary	[KCCQ Summary]	0.0	2	1	1	1
11869	361	gastrointestinal bleed in patient	[Gastrointestinal bleeding in patients]	0.0	4	1	1	1
11870	361	adjustment for variable	[adjustment for variables]	0.0	3	1	1	1
11871	361	ph with heart failure	[PH with heart failure]	0.0	4	2	2	1
11872	361	appropriate investigation	[appropriate investigations]	0.0	2	1	1	1
11873	361	patient a Trial investigate outcome	[patients A Trial Investigating Outcomes]	0.0	5	1	1	1
11874	361	elastance ea	[elastance Ea]	0.0	2	1	1	1
11875	361	effectiveness as a adjunctive treatment	[Effectiveness as an adjunctive treatment]	0.0	5	1	1	1
11876	361	bb therapy	[BB therapy]	0.0	2	1	1	1
11877	361	benefit for patient in retrospective study	[benefit for patients in retrospective studies]	0.0	6	1	1	1
11878	361	target in the treatment	[target in the treatment]	0.0	4	1	1	1
11879	361	regard the need	[regarding the need]	0.0	3	1	1	1
11880	361	70 bpm 17.5±5.5 versus 14.4±3.3 millileter	[70 bpm 17.5±5.5 versus 14.4±3.3 mL]	0.0	6	1	1	1
11881	361	occur within day	[occurring within days]	0.0	3	1	1	1
11882	361	right arterial coupling resistance	[right arterial coupling resistance]	0.0	4	1	1	1
11883	361	left diastolic end diameter mm difference	[left diastolic end diameter mm difference]	0.0	6	1	1	1
11884	361	excitation-contraction	[excitation-contraction]	0.0	1	1	1	1
11885	361	adverse CV event in univariate model	[adverse CV events in univariate models]	0.0	6	1	1	1
11886	361	high cardiovascular event rate	[highest cardiovascular event rate]	0.0	4	1	1	1
11887	361	isoenzyme	[isoenzymes]	0.0	1	1	1	1
11888	361	renal underperfusion	[renal underperfusion]	0.0	2	1	1	1
11889	361	receive the dose	[receiving the dose]	0.0	3	1	1	1
11890	361	cell transplantation	[cell transplantation]	0.0	2	1	1	1
11891	361	usefulness in HF	[usefulness in HF]	0.0	3	1	1	1
11892	361	abnormal can 2 handling	[abnormal Ca 2 handling]	0.0	4	1	1	1
11893	361	cardiac resonance postcontrast	[cardiac resonance postcontrast]	0.0	3	1	1	1
11894	361	Impact on the clinical response	[Impact on the clinical response]	0.0	5	1	1	1
11895	361	contribution of atherosclerotic cad	[contribution of atherosclerotic CAD]	0.0	4	1	1	1
11896	361	administrative database	[administrative databases]	0.0	2	1	1	1
11897	361	spironolactone dose	[spironolactone dose]	0.0	2	1	1	1
11898	361	disease copd	[disease COPD]	0.0	2	1	1	1
11899	361	induction of scn5a variant	[Induction of SCN5A variants]	0.0	4	1	1	1
11900	361	aspect of cardiac remodeling	[aspects of cardiac remodeling]	0.0	4	1	1	1
11901	361	camp production	[cAMP production]	0.0	2	1	1	1
11902	361	Extracorporeal membrane oxygenation	[Extracorporeal membrane oxygenation]	0.0	3	1	1	1
11903	361	system activity on QTV	[system activity on QTV]	0.0	4	1	1	1
11904	361	late-onset day	[late-onset days]	0.0	2	1	1	1
11905	361	Potent inhibition of l-type ca2	[Potent inhibition of L-type Ca2]	0.0	5	1	1	1
11906	361	2 μg	[2 μg]	0.0	2	1	1	1
11907	361	HF a Multicenter Study	[HF A Multicenter Study]	0.0	4	1	1	1
11908	361	pharmacological treatment of heart failure	[Pharmacological treatment of heart failure]	0.0	5	1	1	1
11909	361	low-volume physician	[low-volume physicians]	0.0	2	1	1	1
11910	361	beneficial outcome	[beneficial outcomes]	0.0	2	1	1	1
11911	361	Szeto-Schiller	[Szeto-Schiller]	0.0	1	1	1	1
11912	361	patient above the bnp level	[patients above the BNP level]	0.0	5	1	1	1
11913	361	LV mass versus 5.0 42.4 gram	[LV mass versus 5.0 42.4 g]	0.0	6	1	1	1
11914	361	value of anaerobic threshold	[value of anaerobic threshold]	0.0	4	1	1	1
11915	361	absolute change value	[absolute change values]	0.0	3	1	1	1
11916	361	albumin concentration ≥3.5 gram	[albumin concentration ≥3.5 g]	0.0	4	1	1	1
11917	361	incubation of EC	[Incubation of EC]	0.0	3	1	1	1
11918	361	hyperacetylation	[hyperacetylation]	0.0	1	1	1	1
11919	361	comprise hospitalization for acute syndrome	[comprising hospitalization for acute syndromes]	0.0	5	1	1	1
11920	361	echocardiographic predictor after resynchronization therapy	[echocardiographic predictors after resynchronization therapy]	0.0	5	1	1	1
11921	361	treatment for myocardial infarction	[treatment for myocardial infarction]	0.0	4	1	1	1
11922	361	proteomics change in aortic constriction	[proteomics changes in aortic constriction]	0.0	5	1	1	1
11923	361	molecular scaffold	[molecular scaffolds]	0.0	2	1	1	1
11924	361	decline atrial c-kit	[decline atrial c-Kit]	0.0	3	1	1	1
11925	361	vo2 max	[VO2 max]	0.0	2	1	1	1
11926	361	SD testosterone level	[SD testosterone levels]	0.0	3	1	1	1
11927	361	c57bl 6	[C57BL 6]	0.0	2	1	1	1
11928	361	total of psoriasis ultra-violet treatment	[total of psoriasis UV treatment]	0.0	5	1	1	1
11929	361	abnormal exercise hemodynamic status	[abnormal exercise hemodynamic status]	0.0	4	1	1	1
11930	361	high risk of hyperkalemia	[high risk of hyperkalemia]	0.0	4	1	1	1
11931	361	hfpef p	[HFpEF P]	0.0	2	1	1	1
11932	361	study include agent	[studies including agents]	0.0	3	1	1	1
11933	361	include tool regard the need	[including tools regarding the need]	0.0	5	1	1	1
11934	361	revascularization hazard ratio	[revascularization hazard ratio]	0.0	3	1	1	1
11935	361	left base	[left base]	0.0	2	1	1	1
11936	361	absence of artery disease	[absence of artery disease]	0.0	4	1	1	1
11937	361	evidence of dysfunction LV relaxation	[evidence of dysfunction LV relaxation]	0.0	5	1	1	1
11938	361	bundle-branch block	[bundle-branch block]	0.0	2	1	1	1
11939	361	1 trial	[1 trial]	0.0	2	1	1	1
11940	361	patient 224 man mean year	[patients 224 men mean years]	0.0	5	1	1	1
11941	361	determinant of survival	[determinants of survival]	0.0	3	1	1	1
11942	361	institution for the treatment	[institution for the treatment]	0.0	4	1	1	1
11943	361	neprilysin block	[neprilysin blocks]	0.0	2	1	1	1
11944	361	receptor signal	[receptor signaling]	0.0	2	1	1	1
11945	361	trials-Enriching patient	[trials-Enriching patient]	0.0	2	1	1	1
11946	361	improvement in prognosis	[improvement in prognosis]	0.0	3	1	1	1
11947	361	quality indicator	[quality indicators]	0.0	2	1	1	1
11948	361	heart failure-related qol	[heart failure-related QOL]	0.0	3	1	1	1
11949	361	Survival after left assist device	[Survival after left assist device]	0.0	5	1	1	1
11950	361	period of 3.4 year	[period of 3.4 years]	0.0	4	1	1	1
11951	361	index beat	[index beat]	0.0	2	1	1	1
11952	361	diastolic valve tethering	[diastolic valve tethering]	0.0	3	2	2	1
11953	361	death occur within day	[deaths occurring within days]	0.0	4	1	1	1
11954	361	HeartMate 3	[HeartMate 3]	0.0	2	1	1	1
11955	361	heart failure a computational study	[heart failure a computational study]	0.0	5	1	1	1
11956	361	medicare fee-for-service beneficiary	[medicare fee-for-service beneficiaries]	0.0	3	1	1	1
11957	361	reticular SR can	[reticular SR Ca]	0.0	3	1	1	1
11958	361	percent remain	[percent remaining]	0.0	2	1	1	1
11959	361	100 old participant	[100 older participants]	0.0	3	1	1	1
11960	361	ongoing gdmt for month	[ongoing GDMT for months]	0.0	4	1	1	1
11961	361	pump function	[pump function]	0.0	2	1	1	1
11962	361	index score value	[index score value]	0.0	3	1	1	1
11963	361	association of hypoalbuminemia with mortality	[association of hypoalbuminemia with mortality]	0.0	5	1	1	1
11964	361	(Fpassive)-sarcomere	[(Fpassive)-sarcomere]	0.0	1	1	1	1
11965	361	include good tool for risk stratification	[including better tools for risk stratification]	0.0	6	1	1	1
11966	361	symptom maximal cpet in 10 patient	[symptom maximal CPET in 10 patients]	0.0	6	1	1	1
11967	361	function in volume overload	[function in volume overload]	0.0	4	1	1	1
11968	361	556 patient	[556 patients]	0.0	2	1	1	1
11969	361	effect of cocoa	[effects of cocoa]	0.0	3	1	1	1
11970	361	however a analysis	[However a analysis]	0.0	3	1	1	1
11971	361	panel of noninvasive assessment	[panel of noninvasive assessments]	0.0	4	1	1	1
11972	361	receive carvedilol	[receiving carvedilol]	0.0	2	2	2	1
11973	361	left LV pressure	[left LV pressure]	0.0	3	1	1	1
11974	361	significant predictor	[significant predictor]	0.0	2	1	1	1
11975	361	change with exercise effect	[change with exercise effect]	0.0	4	1	1	1
11976	361	therapeutic implication of promising biomarker	[therapeutic implications of promising biomarkers]	0.0	5	1	1	1
11977	361	cascade	[cascades]	0.0	1	1	1	1
11978	361	promote cardiac fill in subject	[promoting cardiac filling in subjects]	0.0	5	1	1	1
11979	361	cardiac index L 2	[cardiac index L 2]	0.0	4	1	1	1
11980	361	exercise-induced artery pressure pasp increase	[exercise-induced artery pressure PASP increase]	0.0	5	1	1	1
11981	361	paf of enzyme in patient	[PAF of enzymes in patients]	0.0	5	1	1	1
11982	361	ecg in athlete	[ECG in athletes]	0.0	3	1	1	1
11983	361	9 subject with normal heart HNorm	[9 subjects with normal hearts HNorm]	0.0	6	1	1	1
11984	361	interatrial shunting for treatment of patient	[interatrial shunting for treatment of patients]	0.0	6	1	1	1
11985	361	diagnosis of diastolic dysfunction lead	[diagnosis of diastolic dysfunction leading]	0.0	5	1	1	1
11986	361	mortality than cancer	[mortality than cancers]	0.0	3	1	1	1
11987	361	attenuation of global proteomics change	[attenuation of global proteomics changes]	0.0	5	1	1	1
11988	361	further validation in study	[further validation in studies]	0.0	4	1	1	1
11989	361	significant improvement in capacity	[significant improvement in capacity]	0.0	4	1	1	1
11990	361	management stem from cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[Management stemming from cardiomyopathies]	0.0	4	1	1	1
11991	361	difference control	[difference control]	0.0	2	1	1	1
11992	361	patient with filtration rate	[patients with filtration rate]	0.0	4	1	1	1
11993	361	study drug	[study drugs]	0.0	2	1	1	1
11994	361	systolic HF tissue sample	[systolic HF tissue samples]	0.0	4	1	1	1
11995	361	pediatric Fontan PF patient	[pediatric Fontan PF patients]	0.0	4	1	1	1
11996	361	blood pressure via radial arterial tonometry	[blood pressure via radial arterial tonometry]	0.0	6	1	1	1
11997	361	signalling pathway activate cardiac remodelling	[signalling pathways activating cardiac remodelling]	0.0	5	1	1	1
11998	361	ventricular plane systolic excursion	[ventricular plane systolic excursion]	0.0	4	1	1	1
11999	361	adjuvant setting	[adjuvant setting]	0.0	2	1	1	1
12000	361	patient management	[Patient Management]	0.0	2	2	2	1
12001	361	relationship between function	[Relationships between function]	0.0	3	1	1	1
12002	361	ventricular-pulmonary arterial coupling resistance p	[ventricular-pulmonary arterial coupling resistance P]	0.0	5	1	1	1
12003	361	high muscle strip stiffness	[high muscle strip stiffness]	0.0	4	1	1	1
12004	361	endothelial growth factor protein	[endothelial growth factor protein]	0.0	4	1	1	1
12005	361	change in mlhf total score	[change in MLHF total score]	0.0	5	1	1	1
12006	361	ventricular RV function	[ventricular RV function]	0.0	3	1	1	1
12007	361	nonstandardized pro-b-type natriuretic peptide	[nonstandardized pro-B-type natriuretic peptide]	0.0	4	1	1	1
12008	361	phenotype of the fail Fontan	[phenotype of the failing Fontan]	0.0	5	1	1	1
12009	361	heart failure HF patient with tachycardia	[heart failure HF patients with tachycardia]	0.0	6	1	1	1
12010	361	result in the activation	[resulting in the activation]	0.0	4	1	1	1
12011	361	ventricular strain as a predictor	[ventricular strain as a predictor]	0.0	5	1	1	1
12012	361	hr 1.58 CI	[HR 1.58 CI]	0.0	3	1	1	1
12013	361	insight from heart failure	[Insights From Heart Failure]	0.0	4	1	1	1
12014	361	grade recommendation low-quality evidence	[Grade recommendation low-quality evidence]	0.0	4	1	1	1
12015	361	ventricular ejection fraction on mortality	[ventricular ejection fraction on mortality]	0.0	5	1	1	1
12016	361	Extracorporeal membrane oxygenation in heart failure	[Extracorporeal membrane oxygenation in heart failure]	0.0	6	1	1	1
12017	361	function flow-mediated dilatation	[function flow-mediated dilatation]	0.0	3	1	1	1
12018	361	risk stratification between a low-risk group	[risk stratification between a low-risk group]	0.0	6	1	1	1
12019	361	multiple abnormality in function	[multiple abnormalities in function]	0.0	4	1	1	1
12020	361	disease modify antirheumatic drug	[disease modifying antirheumatic drug]	0.0	4	1	1	1
12021	361	high admission median bnp level	[higher admission median BNP levels]	0.0	5	1	1	1
12022	361	outpatient assessment of patient within day	[outpatient assessments of patients within days]	0.0	6	1	1	1
12023	361	medical resource	[medical resources]	0.0	2	1	1	1
12024	361	mri-based model of canine electromechanic	[MRI-based models of canine electromechanics]	0.0	5	1	1	1
12025	361	concentric ventricular hypertrophy	[concentric ventricular hypertrophy]	0.0	3	1	1	1
12026	361	myocardial phosphodiesterase-2	[myocardial phosphodiesterase-2]	0.0	2	1	1	1
12027	361	advanced copd n=95	[advanced COPD n=95]	0.0	3	1	1	1
12028	361	rapid onset	[rapid onset]	0.0	2	1	1	1
12029	361	17.6 millileter p=0.01	[17.6 mL P=0.01]	0.0	3	1	1	1
12030	361	gdmt alone control group	[GDMT alone control group]	0.0	4	1	1	1
12031	361	all-cause mortality after hospitalization	[All-cause mortality after hospitalization]	0.0	4	1	1	1
12032	361	effectiveness as a treatment for cardiomyopathy	[Effectiveness as an treatment for cardiomyopathy]	0.0	6	1	1	1
12033	361	reveal a mechanism of cardiac dysfunction	[revealing a mechanism of cardiac dysfunction]	0.0	6	1	1	1
12034	361	modest effect	[modest effects]	0.0	2	1	1	1
12035	361	risk of outcome in patient	[risk of outcomes in patients]	0.0	5	1	1	1
12036	361	permanent periodic breathing	[permanent periodic breathing]	0.0	3	1	1	1
12037	361	Eplerenone Post	[Eplerenone Post]	0.0	2	1	1	1
12038	361	23 mm hg	[23 mm Hg]	0.0	3	1	1	1
12039	361	model use datum	[models using data]	0.0	3	1	1	1
12040	361	stressor	[stressors]	0.0	1	1	1	1
12041	361	rate of death among patient	[rates of death among patients]	0.0	5	1	1	1
12042	361	antibody target the N termini	[antibodies targeting the N termini]	0.0	5	1	1	1
12043	361	treat HF a Multicenter Study	[Treating HF A Multicenter Study]	0.0	5	1	1	1
12044	361	1.39 year	[1.39 years]	0.0	2	1	1	1
12045	361	severe hyponatremia in country	[severe hyponatremia in countries]	0.0	4	1	1	1
12046	361	patient have HFrEF	[patients having HFrEF]	0.0	3	1	1	1
12047	361	patient aged year with heart failure	[patients aged years with heart failure]	0.0	6	1	1	1
12048	361	dysbalance	[dysbalance]	0.0	1	1	1	1
12049	361	sarcoplasmic SR can 2+)-uptake	[sarcoplasmic SR Ca 2+)-uptake]	0.0	4	1	1	1
12050	361	10-cell decrease	[10-cell decrease]	0.0	2	1	1	1
12051	361	home telemonitoring include monitoring device	[home telemonitoring including monitoring devices]	0.0	5	1	1	1
12052	361	type for btt patient	[types for BTT patients]	0.0	4	1	1	1
12053	361	heart failure.	[heart failure.]	0.0	2	1	1	1
12054	361	AMI mortality rate	[AMI mortality rates]	0.0	3	1	1	1
12055	361	noninvasive surrogate for change	[noninvasive surrogates for changes]	0.0	4	1	1	1
12056	361	reader bromodomain protein	[readers bromodomain proteins]	0.0	3	1	1	1
12057	361	two distinct population	[two distinct populations]	0.0	3	1	1	1
12058	361	certain malignancy	[certain malignancies]	0.0	2	1	1	1
12059	361	susceptibility in survivor of cell transplantation	[susceptibility in survivors of cell transplantation]	0.0	6	1	1	1
12060	361	One-year rate by kccq category	[One-year rates by KCCQ category]	0.0	5	1	1	1
12061	361	significant decrease in rate	[significant decrease in rates]	0.0	4	1	1	1
12062	361	importance of dysfunction	[importance of dysfunction]	0.0	3	1	1	1
12063	361	microrna target in disease management	[MicroRNAs targets in disease management]	0.0	5	1	1	1
12064	361	wk of treatment	[wk of treatment]	0.0	3	1	1	1
12065	361	nursing care	[nursing care]	0.0	2	3	3	1
12066	361	3 study	[3 studies]	0.0	2	1	1	1
12067	361	nutritional strategy with effect	[nutritional strategies with effects]	0.0	4	1	1	1
12068	361	hospitalization in severe heart failure	[hospitalizations in severe heart failure]	0.0	5	1	1	1
12069	361	reactivation of embryonic gene program	[reactivation of embryonic gene programs]	0.0	5	1	1	1
12070	361	National Inpatient Registry	[National Inpatient Registry]	0.0	3	1	1	1
12071	361	left-to-right interatrial shunting for treatment	[left-to-right interatrial shunting for treatment]	0.0	5	1	1	1
12072	361	predict CV event in univariate model	[predicting CV events in univariate models]	0.0	6	1	1	1
12073	361	resistance training of the limb	[resistance training of the limbs]	0.0	5	1	1	1
12074	361	Hypertension DASH	[Hypertension DASH]	0.0	2	1	1	1
12075	361	even mild clinical dysfunction	[even mild clinical dysfunction]	0.0	4	1	1	1
12076	361	include good tool	[including better tools]	0.0	3	1	1	1
12077	361	variant of gene	[variants of genes]	0.0	3	1	1	1
12078	361	reduction in mortality for patient	[reduction in mortality for patients]	0.0	5	1	1	1
12079	361	pulmonary arterial systolic pressure relationship	[pulmonary arterial systolic pressure relationship]	0.0	5	1	1	1
12080	361	concentration circulate nt-probnp	[concentration circulating NT-proBNP]	0.0	3	1	1	1
12081	361	BiVP setting	[BiVP setting]	0.0	2	1	1	1
12082	361	long survival of patient	[long-term survival of patients]	0.0	4	1	1	1
12083	361	high internal consistency	[high internal consistency]	0.0	3	1	1	1
12084	361	function in child	[function in children]	0.0	3	2	2	1
12085	361	discharge diagnosis	[discharge diagnosis]	0.0	2	1	1	1
12086	361	perioperative death in the procedure	[perioperative deaths in the procedures]	0.0	5	1	1	1
12087	361	practice-level variation in rate of treatment	[practice-level variation in rates of treatment]	0.0	6	1	1	1
12088	361	reason per patient	[reasons per patient]	0.0	3	1	1	1
12089	361	insulin-resistance by week	[insulin-resistance by weeks]	0.0	3	1	1	1
12090	361	such as infarction	[such as infarction]	0.0	3	1	1	1
12091	361	2.1 millileter	[2.1 mL]	0.0	2	1	1	1
12092	361	Mena deletion	[Mena deletion]	0.0	2	1	1	1
12093	361	successful mitral valve plasty	[successful mitral valve plasty]	0.0	4	1	1	1
12094	361	(egfr)-group I ≥60 millileter per m	[(eGFR)-group I ≥60 mL per m]	0.0	6	1	1	1
12095	361	heart failure HF datum	[Heart failure HF data]	0.0	4	1	1	1
12096	361	effective elastance end-systolic elastance	[Effective elastance end-systolic elastance]	0.0	4	1	1	1
12097	361	potential implication of biomarker	[potential implications of biomarkers]	0.0	4	1	1	1
12098	361	management of HF	[management of HF]	0.0	3	1	1	1
12099	361	patient with infarction in Australia	[patients with infarction in Australia]	0.0	5	1	1	1
12100	361	patient with evaluable plasma sample	[patients with evaluable plasma samples]	0.0	5	1	1	1
12101	361	suggest postcontrast t1 as possible biomarker	[suggesting postcontrast T1 as possible biomarker]	0.0	6	1	1	1
12102	361	human pluripotent stem	[human pluripotent stem]	0.0	3	1	1	1
12103	361	very few complication	[very few complications]	0.0	3	1	1	1
12104	361	decoy vegf receptor	[decoy VEGF receptor]	0.0	3	1	1	1
12105	361	patient with clinically stable hfpef	[patients with clinically stable HFPEF]	0.0	5	1	1	1
12106	361	cardiopulmonary exercise testing with assessment	[Cardiopulmonary exercise testing with assessment]	0.0	5	1	1	1
12107	361	single-centre trial	[single-centre trial]	0.0	2	1	1	1
12108	361	high cardiovascular event rate event	[highest cardiovascular event rate events]	0.0	5	1	1	1
12109	361	subset of patient	[subset of patients]	0.0	3	1	1	1
12110	361	Echocardiographic predictor after resynchronization therapy	[Echocardiographic predictors after resynchronization therapy]	0.0	5	1	1	1
12111	361	relevant article	[relevant articles]	0.0	2	1	1	1
12112	361	1,045 patient	[1,045 patients]	0.0	2	1	1	1
12113	361	recommendation for management	[Recommendations for management]	0.0	3	1	1	1
12114	361	relation of serum albumin level	[Relation of serum albumin levels]	0.0	5	1	1	1
12115	361	undergo assist device implantation	[undergoing assist device implantation]	0.0	4	2	2	1
12116	361	defense mechanism	[defense mechanism]	0.0	2	1	1	1
12117	361	impact on hospital performance	[impact on hospital performance]	0.0	4	1	1	1
12118	361	4 wk of pyridostigmine administration	[4 wk of pyridostigmine administration]	0.0	5	1	1	1
12119	361	body mass index of black ethnicity	[body mass index of black ethnicity]	0.0	6	1	1	1
12120	361	ACS procedure	[ACS procedures]	0.0	2	1	1	1
12121	361	hemodynamics	[hemodynamics]	0.0	1	1	1	1
12122	361	Differential effect of nonselective versus beta-blocker	[Differential effects of nonselective versus beta-blockers]	0.0	6	1	1	1
12123	361	investigate the role	[Investigating the role]	0.0	3	1	1	1
12124	361	vascular growth factor blockade	[Vascular growth factor blockade]	0.0	4	1	1	1
12125	361	cardiac resonance imaging include t1 mapping	[cardiac resonance imaging including T1 mapping]	0.0	6	1	1	1
12126	361	health care expenditure	[health care expenditures]	0.0	3	1	1	1
12127	361	LV mass gram	[LV mass g]	0.0	3	1	1	1
12128	361	research initiative	[research initiatives]	0.0	2	1	1	1
12129	361	eGFR group IV	[eGFR group IV]	0.0	3	1	1	1
12130	361	ventricular dysfunction reverse	[vEntricular dysfunction REVERSE]	0.0	3	1	1	1
12131	361	ongoing gdmt alone	[ongoing GDMT alone]	0.0	3	1	1	1
12132	361	t2 value	[T2 values]	0.0	2	1	1	1
12133	361	multicenter double-blind trial of 360 patient	[Multicenter double-blind trial of 360 patients]	0.0	6	1	1	1
12134	361	cause of death during sport	[cause of death during sport]	0.0	5	1	1	1
12135	361	safety of eplerenone	[safety of eplerenone]	0.0	3	1	1	1
12136	361	etiology of HF	[etiologies of HF]	0.0	3	1	1	1
12137	361	plasma n-terminal pro-b-type natriuretic peptide	[plasma N-terminal pro-B-type natriuretic peptide]	0.0	5	1	1	1
12138	361	last decade of heart failure	[last decade of heart failure]	0.0	5	1	1	1
12139	361	accurate risk stratification with heart failure	[accurate risk stratification with heart failure]	0.0	6	1	1	1
12140	361	Grading	[Grading]	0.0	1	1	1	1
12141	361	insight a Trial	[Insights A Trial]	0.0	3	1	1	1
12142	361	high-density lipoprotein property	[high-density lipoprotein properties]	0.0	3	1	1	1
12143	361	echocardiogram of the midpapillary level	[Echocardiograms of the midpapillary level]	0.0	5	1	1	1
12144	361	remote monitoring after recent hospital discharge	[Remote monitoring after recent hospital discharge]	0.0	6	1	1	1
12145	361	fast turnaround time	[faster turnaround times]	0.0	3	1	1	1
12146	361	novel HNO donor	[novel HNO donor]	0.0	3	1	1	1
12147	361	Swedish web-system for enhancement	[Swedish Web-system for Enhancement]	0.0	4	1	1	1
12148	361	result about the risk	[results about the risk]	0.0	4	1	1	1
12149	361	case cohort analysis	[case cohort analysis]	0.0	3	1	1	1
12150	361	first month after discharge	[first month after discharge]	0.0	4	1	1	1
12151	361	inhibition on hemodynamic status	[inhibition on hemodynamic status]	0.0	4	1	1	1
12152	361	high rate potassium	[higher rates potassium]	0.0	3	1	1	1
12153	361	performance of the prediction rule	[performance of the prediction rule]	0.0	5	1	1	1
12154	361	inhibition of vascular growth factor	[inhibition of vascular growth factor]	0.0	5	1	1	1
12155	361	group of rat Wistar-Kyoto	[groups of rats Wistar-Kyoto]	0.0	4	1	1	1
12156	361	analysis of cardiac tissue from mouse	[analysis of cardiac tissue from mice]	0.0	6	1	1	1
12157	361	Postoperative normalization	[Postoperative normalization]	0.0	2	1	1	1
12158	361	aldactone evaluation	[Aldactone Evaluation]	0.0	2	1	1	1
12159	361	clinical practice guideline grading system	[clinical practice guidelines grading system]	0.0	5	1	1	1
12160	361	hospitalization for acute syndrome	[hospitalization for acute syndromes]	0.0	4	1	1	1
12161	361	role of system activity	[role of system activity]	0.0	4	1	1	1
12162	361	heart sound in the apex	[heart sound in the apex]	0.0	5	1	1	1
12163	361	accurate recognition	[accurate recognition]	0.0	2	1	1	1
12164	361	powerful predictor period hazard ratio	[powerful predictor period hazard ratio]	0.0	5	1	1	1
12165	361	extensive functional characterization	[extensive functional characterization]	0.0	3	1	1	1
12166	361	elevation in resistin	[elevation in resistin]	0.0	3	1	1	1
12167	361	low e wave ratio	[lower E wave ratio]	0.0	4	1	1	1
12168	361	major neurological event-free rate	[major neurological event-free rate]	0.0	4	1	1	1
12169	361	prediction rule have ≥1 predictor	[prediction rule having ≥1 predictor]	0.0	5	1	1	1
12170	361	net	[net]	0.0	1	2	2	1
12171	361	brain natriuretic peptide BNP level	[brain natriuretic peptide BNP levels]	0.0	5	1	1	1
12172	361	renal function in heart failure	[renal function in heart failure]	0.0	5	1	1	1
12173	361	group ii millileter per m 2	[group II mL per m 2]	0.0	6	1	1	1
12174	361	favorable event profile	[favorable event profile]	0.0	3	1	1	1
12175	361	atrial c-kit	[atrial c-Kit]	0.0	2	1	1	1
12176	361	global left longitudinal strain	[global left longitudinal strain]	0.0	4	1	1	1
12177	361	SkM structure	[SkM structure]	0.0	2	1	1	1
12178	361	penalty for rate	[penalties for rates]	0.0	3	1	1	1
12179	361	ST2 level with functional capacity	[ST2 levels with functional capacity]	0.0	5	1	1	1
12180	361	beta-blocker therapy on function	[beta-blocker therapy on function]	0.0	4	1	1	1
12181	361	abnormal t2	[Abnormal T2]	0.0	2	1	1	1
12182	361	heart failure ed visit age	[heart failure ED visits age]	0.0	5	1	1	1
12183	361	suburban hospital	[suburban hospitals]	0.0	2	1	1	1
12184	361	form of nt-probnp	[forms of NT-proBNP]	0.0	3	1	1	1
12185	361	still a anti-neoplastic agent	[still a anti-neoplastic agent]	0.0	4	1	1	1
12186	361	activation of p38α protein kinase	[activation of p38α protein kinase]	0.0	5	1	1	1
12187	361	age-matched reference value	[age-matched reference values]	0.0	3	1	1	1
12188	361	home telemonitoring with support	[home telemonitoring with support]	0.0	4	1	1	1
12189	361	ef≤	[EF≤]	0.0	1	1	1	1
12190	361	means improve muscle function	[means improving muscle function]	0.0	4	1	1	1
12191	361	valve repair	[valve repairs]	0.0	2	1	1	1
12192	361	large animal model of ischemia	[large animal model of ischemia]	0.0	5	1	1	1
12193	361	brain natriuretic peptide level 100 pg	[brain natriuretic peptide levels 100 pg]	0.0	6	1	1	1
12194	361	patient-operated device	[patient-operated device]	0.0	2	1	1	1
12195	361	ventricular plane excursion	[ventricular plane excursion]	0.0	3	1	1	1
12196	361	physician follow-up after discharge	[physician follow-up after discharge]	0.0	4	2	2	1
12197	361	Clinical Modification code	[Clinical Modification codes]	0.0	3	1	1	1
12198	361	screen with a ecg	[Screening with a ECG]	0.0	4	1	1	1
12199	361	right end-diastolic area index	[right end-diastolic area index]	0.0	4	1	1	1
12200	361	Patient management	[Patient Management]	0.0	2	1	1	1
12201	361	peak quadricep force range	[peak quadriceps force range]	0.0	4	1	1	1
12202	361	range 22.8 with copd n=95	[range 22.8 with COPD n=95]	0.0	5	1	1	1
12203	361	kv4.3 mrna level	[Kv4.3 mRNA levels]	0.0	3	1	1	1
12204	361	decline atrial explant-derived c-kit	[decline atrial explant-derived c-Kit]	0.0	4	1	1	1
12205	361	effect of b act	[effects of B act]	0.0	4	1	1	1
12206	361	alternative for this population	[alternative for this population]	0.0	4	1	1	1
12207	361	increase for infarction AMI	[increase for infarction AMI]	0.0	4	1	1	1
12208	361	treatment for acute infarction AMI	[treatment for acute infarction AMI]	0.0	5	1	1	1
12209	361	crucial role in signal transduction	[crucial role in signal transduction]	0.0	5	1	1	1
12210	361	oxygen pulse in four	[oxygen pulse in four]	0.0	4	1	1	1
12211	361	abnormality in function	[abnormalities in function]	0.0	3	1	1	1
12212	361	relaxation	[relaxation]	0.0	1	1	1	1
12213	361	follow-up of 19.8±10.4 year	[follow-up of 19.8±10.4 years]	0.0	4	1	1	1
12214	361	Obese patient	[Obese Patients]	0.0	2	1	1	1
12215	361	lack resistin	[lacking resistin]	0.0	2	1	1	1
12216	361	transplant ECCT	[transplant ECCT]	0.0	2	1	1	1
12217	361	event profile	[event profile]	0.0	2	1	1	1
12218	361	overview of clinical trial design	[overview of clinical trial design]	0.0	5	1	1	1
12219	361	double mutant	[double mutant]	0.0	2	1	1	1
12220	361	positive effect on cardiac function	[positive effects on cardiac function]	0.0	5	1	1	1
12221	361	failure from cardiomyopathic restriction	[failure from cardiomyopathic restriction]	0.0	4	1	1	1
12222	361	support use a HeartMate ii lvad	[support using a HeartMate II LVAD]	0.0	6	1	1	1
12223	361	effect follow acute β-ar stimulation	[effect following acute β-AR stimulation]	0.0	5	1	1	1
12224	361	Effect of mechanical cardiac support	[Effects of mechanical cardiac support]	0.0	5	1	1	1
12225	361	right ventricular-pulmonary coupling pulmonary resistance	[right ventricular-pulmonary coupling pulmonary resistance]	0.0	5	1	1	1
12226	361	reversible myocardial ischemia stent	[reversible myocardial ischemia stent]	0.0	4	1	1	1
12227	361	patient with chronic HF	[patients with chronic HF]	0.0	4	1	1	1
12228	361	LV volume of millileter	[LV volume of mL]	0.0	4	1	1	1
12229	361	induce hyperkalemia in patient	[inducing hyperkalemia in patients]	0.0	4	1	1	1
12230	361	patient irrespective	[patients irrespective]	0.0	2	1	1	1
12231	361	epicatechin	[epicatechin]	0.0	1	1	1	1
12232	361	key gene related	[key genes related]	0.0	3	1	1	1
12233	361	dual energy x-ray absorptiometry	[dual energy X-ray absorptiometry]	0.0	4	1	1	1
12234	361	endothelin	[endothelin]	0.0	1	1	1	1
12235	361	recovery period	[recovery period]	0.0	2	1	1	1
12236	361	multicenter trial Paradigm-hf	[multicenter trial PARADIGM-HF]	0.0	3	1	1	1
12237	361	right ventricular-pulmonary arterial coupling resistance	[right ventricular-pulmonary arterial coupling resistance]	0.0	5	1	1	1
12238	361	multiple N fragment	[multiple N fragments]	0.0	3	1	1	1
12239	361	unidirectional left-to-right interatrial shunting	[Unidirectional left-to-right interatrial shunting]	0.0	4	1	1	1
12240	361	event p=0.18	[events P=0.18]	0.0	2	1	1	1
12241	361	association among cardiorespiratory fitness CRF	[associations among cardiorespiratory fitness CRF]	0.0	5	1	1	1
12242	361	normal fill pressure	[normal filling pressures]	0.0	3	1	1	1
12243	361	minute 59.6 m	[min 59.6 m]	0.0	3	1	1	1
12244	361	right tricuspid plane systolic excursion tapse	[right tricuspid plane systolic excursion TAPSE]	0.0	6	1	1	1
12245	361	right annular plane excursion tapse	[right annular plane excursion TAPSE]	0.0	5	1	1	1
12246	361	evidence on clinical effect	[evidence on clinical effects]	0.0	4	1	1	1
12247	361	national trend	[national trends]	0.0	2	1	1	1
12248	361	global ventricular systolic strain GLS	[global ventricular systolic strain GLS]	0.0	5	1	1	1
12249	361	noninvasive surrogate for change in co.	[noninvasive surrogates for changes in CO.]	0.0	6	1	1	1
12250	361	electronic database include MEDLINE	[electronic databases including MEDLINE]	0.0	4	1	1	1
12251	361	rheumatic cause	[rheumatic causes]	0.0	2	1	1	1
12252	361	rapid R-R interval oscillation	[rapid R-R interval oscillations]	0.0	4	1	1	1
12253	361	monitoring of lvad use	[monitoring of LVAD use]	0.0	4	1	1	1
12254	361	outcome median versus millisecond millisecond	[outcome median vs milliseconds milliseconds]	0.0	5	1	1	1
12255	361	insight into the potential of rirnas	[insight into the potential of miRNAs]	0.0	6	1	1	1
12256	361	arterial elastance ea end-systolic elastance ees	[arterial elastance Ea end-systolic elastance Ees]	0.0	6	1	1	1
12257	361	incidence outcome after infarction	[incidence outcomes after infarction]	0.0	4	1	1	1
12258	361	hr reduction 17±22	[HR reduction 17±22]	0.0	3	1	1	1
12259	361	anti-neoplastic agent	[anti-neoplastic agent]	0.0	2	1	1	1
12260	361	ARIC HF model	[ARIC HF model]	0.0	3	1	1	1
12261	361	right ventricular area change	[right ventricular area change]	0.0	4	1	1	1
12262	361	((123)i-mibg	[((123)I-MIBG]	0.0	1	1	1	1
12263	361	impaired cardiac gene expression	[impaired cardiac gene expression]	0.0	4	1	1	1
12264	361	index of function	[index of function]	0.0	3	1	1	1
12265	361	activate adaptive remodelling	[activating adaptive remodelling]	0.0	3	1	1	1
12266	361	pathological stress	[pathological stress]	0.0	2	1	1	1
12267	361	sympathetic tone result	[sympathetic tone resulting]	0.0	3	1	1	1
12268	361	slow increase	[slower increase]	0.0	2	1	1	1
12269	361	total of 674 man	[total of 674 men]	0.0	4	1	1	1
12270	361	relation of hemoglobin	[relation of hemoglobin]	0.0	3	1	1	1
12271	361	etiology of MR	[etiology of MR]	0.0	3	1	1	1
12272	361	young reference mean	[young reference mean]	0.0	3	1	1	1
12273	361	mortality at year after hospitalization	[mortality at years after hospitalization]	0.0	5	1	1	1
12274	361	CI for HF	[CI for HF]	0.0	3	1	1	1
12275	361	peptide b-type peptide	[peptide B-type peptide]	0.0	3	1	1	1
12276	361	Global ventricular strain as a predictor	[Global ventricular strain as a predictor]	0.0	6	1	1	1
12277	361	survival from the time of inclusion	[survival from the time of inclusion]	0.0	6	1	1	1
12278	361	incident HF in participant	[incident HF in participants]	0.0	4	1	1	1
12279	361	amount of datum	[amount of data]	0.0	3	1	1	1
12280	361	error of measurement value	[error of measurement value]	0.0	4	1	1	1
12281	361	regard the form	[regarding the forms]	0.0	3	1	1	1
12282	361	right ventricular pressure overload rvpo	[right ventricular pressure overload RVPO]	0.0	5	1	1	1
12283	361	right tricuspid annular plane excursion tapse	[right tricuspid annular plane excursion TAPSE]	0.0	6	1	1	1
12284	361	right coupling pulmonary resistance p	[right coupling pulmonary resistance P]	0.0	5	1	1	1
12285	361	feature such as early detection	[features such as early detection]	0.0	5	1	1	1
12286	361	atherosclerosis use linear model	[atherosclerosis using linear models]	0.0	4	1	1	1
12287	361	reperfusion therapy	[reperfusion therapy]	0.0	2	1	1	1
12288	361	eligibility	[eligibility]	0.0	1	1	1	1
12289	361	transseptal catheterisation with echocardiographic guidance	[transseptal catheterisation with echocardiographic guidance]	0.0	5	1	1	1
12290	361	basis end-diastolic pressure	[basis end-diastolic pressure]	0.0	3	1	1	1
12291	361	investigate Outcome study of exercise training	[Investigating Outcomes study of exercise training]	0.0	6	1	1	1
12292	361	few adverse consequence	[few adverse consequences]	0.0	3	1	1	1
12293	361	Prognostic value	[Prognostic value]	0.0	2	1	1	1
12294	361	100 pg high bnp group	[100 pg high BNP group]	0.0	5	1	1	1
12295	361	reflect decrease	[reflecting decreases]	0.0	2	1	1	1
12296	361	consecutive patient man mean	[consecutive patients men mean]	0.0	4	1	1	1
12297	361	CI millileter	[CI ml]	0.0	2	1	1	1
12298	361	diastolic velocity 3.1 vs. 1.3	[diastolic velocity 3.1 vs. 1.3]	0.0	5	1	1	1
12299	361	renal impairment	[renal impairment]	0.0	2	1	1	1
12300	361	predict performer	[predicting performers]	0.0	2	1	1	1
12301	361	nri	[NRI]	0.0	1	1	1	1
12302	361	probability	[probability]	0.0	1	1	1	1
12303	361	heart-specific irs1 irs2 gene double-knockout mouse	[heart-specific IRS1 IRS2 gene double-knockout mice]	0.0	6	1	1	1
12304	361	score of 13	[score of 13]	0.0	3	1	1	1
12305	361	hand grip strength 2.1 kg	[hand grip strength 2.1 kg]	0.0	5	1	1	1
12306	361	useful mouse HF model	[useful mouse HF model]	0.0	4	1	1	1
12307	361	diastolic failure from restriction	[diastolic failure from restriction]	0.0	4	1	1	1
12308	361	β1ar in a myocyte	[β1ARs in a myocyte]	0.0	4	1	1	1
12309	361	York heart Association functional class	[York Heart Association functional class]	0.0	5	1	1	1
12310	361	optimization strategy	[Optimization Strategies]	0.0	2	1	1	1
12311	361	decline in adverse event rate	[decline in adverse event rates]	0.0	5	1	1	1
12312	361	age of participant	[age of participants]	0.0	3	1	1	1
12313	361	effectiveness of rhythm control therapy	[effectiveness of rhythm control therapy]	0.0	5	1	1	1
12314	361	m vs. 1.5 m	[m vs. 1.5 m]	0.0	4	1	1	1
12315	361	ejection time LVET	[ejection time LVET]	0.0	3	1	1	1
12316	361	embryonic kidney 293 cell	[embryonic kidney 293 cells]	0.0	4	1	1	1
12317	361	right tricuspid annular plane systolic excursion	[right tricuspid annular plane systolic excursion]	0.0	6	1	1	1
12318	361	strict standard in biomarker study	[strict standards in biomarker studies]	0.0	5	1	1	1
12319	361	hospitalization a consecutive case series	[hospitalizations a consecutive case series]	0.0	5	1	1	1
12320	361	Large-scale prospective multicenter trial Paradigm-hf	[Large-scale prospective multicenter trial PARADIGM-HF]	0.0	5	1	1	1
12321	361	treatment of refractory HF	[treatment of refractory HF]	0.0	4	1	1	1
12322	361	stage chronic kidney disease CKD	[Stage chronic kidney disease CKD]	0.0	5	1	1	1
12323	361	low concentration circulate nt-probnp	[low concentration circulating NT-proBNP]	0.0	4	1	1	1
12324	361	most common cause	[most common cause]	0.0	3	3	3	1
12325	361	mean SD	[mean SD]	0.0	2	1	1	1
12326	361	subject with structurally normal heart HNorm	[subjects with structurally normal hearts HNorm]	0.0	6	1	1	1
12327	361	various form in the circulation	[various forms in the circulation]	0.0	5	1	1	1
12328	361	predictor particularly biomarker	[predictors particularly biomarkers]	0.0	3	1	1	1
12329	361	atherosclerosis risk	[Atherosclerosis Risk]	0.0	2	1	1	1
12330	361	stimulation of phosphorylation at eNOS-Ser	[stimulation of phosphorylation at eNOS-Ser]	0.0	5	1	1	1
12331	361	timing of infarction	[timing of infarction]	0.0	3	1	1	1
12332	361	HF prediction model	[HF prediction model]	0.0	3	1	1	1
12333	361	Cardiac resynchronization	[Cardiac Resynchronization]	0.0	2	1	1	1
12334	361	rotor	[rotor]	0.0	1	1	1	1
12335	361	exercise tolerance in patient	[exercise tolerance in patients]	0.0	4	1	1	1
12336	361	cause of the array	[causes of the array]	0.0	4	1	1	1
12337	361	multiparametric score predict CRT response	[multiparametric score predicting CRT response]	0.0	5	1	1	1
12338	361	beneficial impact	[beneficial impact]	0.0	2	1	1	1
12339	361	important determinant	[important determinants]	0.0	2	1	1	1
12340	361	important disease accounting	[important disease accounting]	0.0	3	1	1	1
12341	361	patient undergo lvad implantation	[patients undergoing LVAD implantation]	0.0	4	1	1	1
12342	361	low total expenditure	[lower total expenditure]	0.0	3	2	2	1
12343	361	important risk factor	[important risk factors]	0.0	3	1	1	1
12344	361	Impact	[Impact]	0.0	1	6	6	1
12345	361	cell expansion	[cell expansion]	0.0	2	1	1	1
12346	361	right ventricular-pulmonary coupling resistance	[right ventricular-pulmonary coupling resistance]	0.0	4	1	1	1
12347	361	HF patient left ventricular ejection fraction	[HF patients left ventricular ejection fraction]	0.0	6	1	1	1
12348	361	extensive functional characterization of one	[extensive functional characterization of one]	0.0	5	1	1	1
12349	361	cost-effectiveness analysis	[cost-effectiveness analyses]	0.0	2	1	1	1
12350	361	distinct circulatory derangement with feature	[distinct circulatory derangement with features]	0.0	5	1	1	1
12351	361	successful approach	[Successful approaches]	0.0	2	1	1	1
12352	361	ventricular tricuspid annular plane excursion	[ventricular tricuspid annular plane excursion]	0.0	5	1	1	1
12353	361	reference datum	[reference data]	0.0	2	1	1	1
12354	361	single center retrospective observational study	[single center retrospective observational study]	0.0	5	1	1	1
12355	361	end-diastolic volume index	[end-diastolic volume index]	0.0	3	2	2	1
12356	361	three training	[three trainings]	0.0	2	1	1	1
12357	361	relevance carry increase in risk	[relevance carrying increase in risk]	0.0	5	1	1	1
12358	361	N-terminal peptide	[N-terminal peptide]	0.0	2	3	3	1
12359	361	three disease group	[three disease groups]	0.0	3	1	1	1
12360	361	baseline sdqt-to-sdrr ratio	[baseline SDQT-to-SDRR ratio]	0.0	3	1	1	1
12361	361	play a role in the progression	[playing a role in the progression]	0.0	6	1	1	1
12362	361	outcome for disease	[outcomes for diseases]	0.0	3	1	1	1
12363	361	tricuspid plane excursion from the end	[tricuspid plane excursion from the end]	0.0	6	1	1	1
12364	361	right heart failure in pulmonary hypertension	[right heart failure in pulmonary hypertension]	0.0	6	1	1	1
12365	361	heart in model	[hearts in models]	0.0	3	1	1	1
12366	361	strong predictor of all-cause mortality	[strong predictor of all-cause mortality]	0.0	5	1	1	1
12367	361	diminish the ros effect	[diminishing the ROS effects]	0.0	4	1	1	1
12368	361	open without any organic lesion	[opening without any organic lesion]	0.0	5	1	1	1
12369	361	catheterisation with guidance under anaesthesia	[catheterisation with guidance under anaesthesia]	0.0	5	1	1	1
12370	361	day than medium	[days than medium]	0.0	3	1	1	1
12371	361	LV mass versus 5.0 gram	[LV mass versus 5.0 g]	0.0	5	1	1	1
12372	361	large fluctuation in qt interval	[larger fluctuations in QT intervals]	0.0	5	1	1	1
12373	361	few perioperative death in the procedure	[few perioperative deaths in the procedures]	0.0	6	1	1	1
12374	361	pulmonary arterial hypertension pah	[pulmonary arterial hypertension PAH]	0.0	4	1	1	1
12375	361	province of Alberta	[province of Alberta]	0.0	3	1	1	1
12376	361	Medicare Service CMS	[Medicare Services CMS]	0.0	3	1	1	1
12377	361	aberrant reactivation	[aberrant reactivation]	0.0	2	1	1	1
12378	361	destination therapy dt	[destination therapy DT]	0.0	3	1	1	1
12379	361	target gene	[target genes]	0.0	2	1	1	1
12380	361	median activity of lyso-paf-at	[median activities of lyso-PAF-AT]	0.0	4	1	1	1
12381	361	hospital in the good quintile	[hospital in the best quintile]	0.0	5	1	1	1
12382	361	44 man	[44 men]	0.0	2	1	1	1
12383	361	relationship with adverse cardiovascular CV event	[relationship with adverse cardiovascular CV events]	0.0	6	1	1	1
12384	361	potentially promising biomarker HF	[potentially promising biomarker HF]	0.0	4	1	1	1
12385	361	common form of heart failure	[common form of heart failure]	0.0	5	1	1	1
12386	361	consecutive patient undergo lvad implantation	[consecutive patients undergoing LVAD implantation]	0.0	5	1	1	1
12387	361	patient with shortness	[Patients With Shortness]	0.0	3	1	1	1
12388	361	Global systolic strain	[Global systolic strain]	0.0	3	1	1	1
12389	361	heart failure patient with spontaneous tachycardia	[heart failure patients with spontaneous tachycardia]	0.0	6	1	1	1
12390	361	assessment of myocardial function	[assessment of myocardial function]	0.0	4	1	1	1
12391	361	three readmission metric all-cause readmission	[three readmission metrics all-cause readmission]	0.0	5	1	1	1
12392	361	vary strain contribution	[varying strain contributions]	0.0	3	1	1	1
12393	361	end point of mortality	[end point of mortality]	0.0	4	1	1	1
12394	361	overexpress Hand2	[overexpressing Hand2]	0.0	2	1	1	1
12395	361	moderate-intensity exercise	[moderate-intensity exercise]	0.0	2	1	1	1
12396	361	rate ratio	[rate ratio]	0.0	2	2	2	1
12397	361	right ejection fraction r=0.28	[right ejection fraction R=0.28]	0.0	4	1	1	1
12398	361	coupling in hfpef	[coupling in HFPEF]	0.0	3	1	1	1
12399	361	nosignificant change	[nosignificant changes]	0.0	2	1	1	1
12400	361	anterior	[anterior]	0.0	1	1	1	1
12401	361	circulatory arrest	[circulatory arrest]	0.0	2	1	1	1
12402	361	search	[search]	0.0	1	1	1	1
12403	361	relationship with CV event	[relationship with CV events]	0.0	4	1	1	1
12404	361	significant change main effect exercise	[significant change main effect exercise]	0.0	5	1	1	1
12405	361	pulmonary artery pressure pasp increase	[pulmonary artery pressure PASP increase]	0.0	5	1	1	1
12406	361	rate of glycolysis	[rates of glycolysis]	0.0	3	1	1	1
12407	361	(egfr)-group I millileter per m	[(eGFR)-group I mL per m]	0.0	5	1	1	1
12408	361	cumulative dose	[cumulative dose]	0.0	2	1	1	1
12409	361	patient with hfpef for summary	[patients with HFpEF for summary]	0.0	5	1	1	1
12410	361	symptomatic ai	[symptomatic AI]	0.0	2	1	1	1
12411	361	ventricular annular plane systolic excursion	[ventricular annular plane systolic excursion]	0.0	5	1	1	1
12412	361	obstruction of the artery	[obstruction of the artery]	0.0	4	1	1	1
12413	361	involve the artery	[involving the artery]	0.0	3	1	1	1
12414	361	resonance t1 time hazard ratio	[resonance T1 time hazard ratio]	0.0	5	1	1	1
12415	361	level 100 pg bnp group	[levels 100 pg BNP group]	0.0	5	1	1	1
12416	361	Global left longitudinal strain	[Global left longitudinal strain]	0.0	4	1	1	1
12417	361	guanosine	[guanosine]	0.0	1	1	1	1
12418	361	endopeptidase	[endopeptidase]	0.0	1	1	1	1
12419	361	kg ip	[kg ip]	0.0	2	1	1	1
12420	361	median ejection fraction	[median ejection fraction]	0.0	3	1	1	1
12421	361	pressure development	[pressure development]	0.0	2	1	1	1
12422	361	delay EMD the time interval	[delay EMD the time interval]	0.0	5	1	1	1
12423	361	change between performance	[change between performance]	0.0	3	1	1	1
12424	361	annual ed visit	[annual ED visits]	0.0	3	1	1	1
12425	361	millileter vs. millileter	[ml vs. ml]	0.0	3	1	1	1
12426	361	dearth of trial	[dearth of trials]	0.0	3	1	1	1
12427	361	phosphodiesterase-2 pde2	[phosphodiesterase-2 PDE2]	0.0	2	1	1	1
12428	361	reversal by metoprolol	[Reversal by metoprolol]	0.0	3	1	1	1
12429	361	insulin-resistance post-aac	[insulin-resistance post-AAC]	0.0	2	1	1	1
12430	361	patient with a implantable cardioverter-defibrillator	[Patients with an implantable cardioverter-defibrillator]	0.0	5	1	1	1
12431	361	parasympathetic control	[parasympathetic control]	0.0	2	1	1	1
12432	361	end-stage renal disease	[end-stage renal disease]	0.0	3	1	1	1
12433	361	benefit over clinical parameter	[benefit over clinical parameters]	0.0	4	1	1	1
12434	361	atherosclerotic Lesion	[Atherosclerotic Lesions]	0.0	2	1	1	1
12435	361	single-centre trial the effect	[single-centre trial the effects]	0.0	4	1	1	1
12436	361	correction of valve insufficiency	[correction of valve insufficiency]	0.0	4	1	1	1
12437	361	ejection fraction in York heart Association	[ejection fraction in York Heart Association]	0.0	6	1	1	1
12438	361	beneficial new therapeutic approach	[beneficial new therapeutic approach]	0.0	4	1	1	1
12439	361	LV mass gram p=0.04	[LV mass g P=0.04]	0.0	4	1	1	1
12440	361	right RV failure after the insertion	[Right RV failure after the insertion]	0.0	6	1	1	1
12441	361	home telemonitoring tm with support	[home telemonitoring TM with support]	0.0	5	1	1	1
12442	361	defibrillator implantation with resynchronization therapy	[Defibrillator Implantation With Resynchronization Therapy]	0.0	5	1	1	1
12443	361	association between measurement of CPC	[association between measurements of CPCs]	0.0	5	1	1	1
12444	361	evaluation hm use simulation model	[evaluations HM using simulation models]	0.0	5	1	1	1
12445	361	s1pr1 gene therapy	[S1PR1 gene therapy]	0.0	3	1	1	1
12446	361	hospital clustering	[hospital clustering]	0.0	2	1	1	1
12447	361	reporting	[reporting]	0.0	1	1	1	1
12448	361	pb characteristic	[PB characteristics]	0.0	2	1	1	1
12449	361	murine equivalent	[murine equivalent]	0.0	2	1	1	1
12450	361	41-year-old man with arrest	[41-year-old man with arrest]	0.0	4	1	1	1
12451	361	total of 293	[total of 293]	0.0	3	1	1	1
12452	361	overall improvement for patient	[overall improvements for patients]	0.0	4	1	1	1
12453	361	amino-terminal natriuretic peptide	[amino-terminal natriuretic peptide]	0.0	3	1	1	1
12454	361	attenuation of tac-induced proteomic alteration	[attenuation of TAC-induced proteomic alterations]	0.0	5	1	1	1
12455	361	type of continuous-flow lvas	[types of continuous-flow LVADs]	0.0	4	1	1	1
12456	361	average follow-up	[average follow-up]	0.0	2	1	1	1
12457	361	nervous system activity on QTV	[nervous system activity on QTV]	0.0	5	1	1	1
12458	361	relationship between ventricular function	[Relationships between ventricular function]	0.0	4	1	1	1
12459	361	restore oxidative phosphorylation capacity	[restoring oxidative phosphorylation capacity]	0.0	4	1	1	1
12460	361	brain peptide level	[brain peptide levels]	0.0	3	1	1	1
12461	361	14 clinical study	[14 clinical studies]	0.0	3	1	1	1
12462	361	rate by kccq category among patient	[rates by KCCQ category among patients]	0.0	6	1	1	1
12463	361	common form of left ventricular remodeling	[common forms of left ventricular remodeling]	0.0	6	1	1	1
12464	361	fragment of N-terminal pro-b-type peptide	[fragments of N-terminal pro-B-type peptides]	0.0	5	1	1	1
12465	361	patient with advanced disease copd	[patients with advanced disease COPD]	0.0	5	1	1	1
12466	361	β-blocker therapy	[β-blockers therapy]	0.0	2	1	1	1
12467	361	impact on hdl-mediated protective effect	[impact on HDL-mediated protective effects]	0.0	5	1	1	1
12468	361	transoesophageal echocardiographic guidance under anaesthesia	[transoesophageal echocardiographic guidance under anaesthesia]	0.0	5	1	1	1
12469	361	LV volume LV end-systolic volume	[LV volume LV end-systolic volume]	0.0	5	1	1	1
12470	361	have HFrEF	[having HFrEF]	0.0	2	1	1	1
12471	361	pediatric heart failure	[pediatric heart failure]	0.0	3	1	1	1
12472	361	angiogenesis in the infarction heart	[angiogenesis in the infarction heart]	0.0	5	1	1	1
12473	361	year of follow-up 1385	[years of follow-up 1385]	0.0	4	1	1	1
12474	361	heart mass	[heart mass]	0.0	2	1	1	1
12475	361	rate constant	[rate constant]	0.0	2	1	1	1
12476	361	bad versus good quintile	[worst versus best quintile]	0.0	4	1	1	1
12477	361	insight on the contribution of nursing	[insight on the contribution of nursing]	0.0	6	1	1	1
12478	361	outcome of catheter ablation	[outcomes of catheter ablation]	0.0	4	1	1	1
12479	361	with therapy	[With therapies]	0.0	2	1	1	1
12480	361	≥60 millileter per 1.73 m	[≥60 mL per 1.73 m]	0.0	5	1	1	1
12481	361	normal systolic function	[normal systolic function]	0.0	3	1	1	1
12482	361	explain variation	[explaining variation]	0.0	2	1	1	1
12483	361	anaerobic metabolism peak quotient	[anaerobic metabolism peak quotient]	0.0	4	1	1	1
12484	361	14.0 millileter vs. millileter	[14.0 ml vs. ml]	0.0	4	1	1	1
12485	361	circumstance common	[circumstances common]	0.0	2	1	1	1
12486	361	first-in-man evidence for usefulness	[first-in-man evidence for usefulness]	0.0	4	1	1	1
12487	361	extracellular matrix use resonance t1 mapping	[extracellular matrix using resonance T1 mapping]	0.0	6	1	1	1
12488	361	diastolic index E ratio	[diastolic indices E ratio]	0.0	4	1	1	1
12489	361	preliminary datum for health outcome	[preliminary data for health outcomes]	0.0	5	1	1	1
12490	361	possible cause	[possible causes]	0.0	2	1	1	1
12491	361	disease from the general population	[disease from the general population]	0.0	5	1	1	1
12492	361	occurrence of HF	[Occurrence of HF]	0.0	3	1	1	1
12493	361	treatment a systematic review	[Treatment a systematic review]	0.0	4	1	1	1
12494	361	main cause of hospitalization	[main cause of hospitalization]	0.0	4	1	1	1
12495	361	serum factor	[serum factors]	0.0	2	1	1	1
12496	361	other predictor particularly biomarker	[other predictors particularly biomarkers]	0.0	4	1	1	1
12497	361	assessment of body composition	[assessment of body composition]	0.0	4	1	1	1
12498	361	CHM versus biomedical treatment	[CHM versus biomedical treatment]	0.0	4	1	1	1
12499	361	study of patient	[study of patients]	0.0	3	1	1	1
12500	361	60000 patient across hospital	[60,000 patients across hospitals]	0.0	4	1	1	1
12501	361	human systolic HF tissue sample	[human systolic HF tissue samples]	0.0	5	1	1	1
12502	361	primary endpoint death	[primary endpoint death]	0.0	3	1	1	1
12503	361	zsf1 with high-fat diet n=11	[ZSF1 with high-fat diet n=11]	0.0	5	1	1	1
12504	361	Southeastern Minnesota resident	[Southeastern Minnesota residents]	0.0	3	1	1	1
12505	361	standard practice for a limited number	[standard practice for a limited number]	0.0	6	1	1	1
12506	361	neoangiogenesis	[neoangiogenesis]	0.0	1	1	1	1
12507	361	target effector molecule	[targeting effector molecules]	0.0	3	1	1	1
12508	361	apparent concentration	[apparent concentration]	0.0	2	1	1	1
12509	361	day after MI	[days after MI]	0.0	3	1	1	1
12510	361	N fragment	[N fragments]	0.0	2	1	1	1
12511	361	Aldactone evaluation Study	[Aldactone Evaluation Study]	0.0	3	1	1	1
12512	361	control of heart rate	[control of heart rate]	0.0	4	1	1	1
12513	361	use general linear model	[using general linear models]	0.0	4	1	1	1
12514	361	Clinical symptom	[Clinical symptoms]	0.0	2	1	1	1
12515	361	HF with left ejection fraction	[HF with left ejection fraction]	0.0	5	1	1	1
12516	361	mortality after hospitalization	[mortality after hospitalization]	0.0	3	1	1	1
12517	361	practice rate with enzyme inhibitor	[Practice rates with enzyme inhibitors]	0.0	5	1	1	1
12518	361	heart failure-related qol co-primary outcome	[heart failure-related QOL co-primary outcome]	0.0	5	1	1	1
12519	361	proportion of deficit	[proportion of deficits]	0.0	3	1	1	1
12520	361	additive effect	[additive effect]	0.0	2	1	1	1
12521	361	incubation with HDL NYHA-IIIb	[Incubation with HDL NYHA-IIIb]	0.0	4	1	1	1
12522	361	decade of heart failure	[decade of heart failure]	0.0	4	1	1	1
12523	361	HF respectively	[HF respectively]	0.0	2	1	1	1
12524	361	evidence from 3 trial	[evidence from 3 trials]	0.0	4	1	1	1
12525	361	consecutive consent HF patient	[consecutive consenting HF patients]	0.0	4	1	1	1
12526	361	20 812 patient aged 40 year	[20 812 patients aged 40 years]	0.0	6	1	1	1
12527	361	highlight the contribution	[highlighting the contribution]	0.0	3	1	1	1
12528	361	affect the level	[affecting the levels]	0.0	3	1	1	1
12529	361	study hm ii	[studies HM II]	0.0	3	1	1	1
12530	361	heart failure patient with tachycardia hfvt(+)	[heart failure patients with tachycardia HFVT(+)]	0.0	6	1	1	1
12531	361	incident HF in 2825 participant aged	[incident HF in 2825 participants aged]	0.0	6	1	1	1
12532	361	underlie this defect	[underlying these defects]	0.0	3	1	1	1
12533	361	diastolic index	[diastolic indices]	0.0	2	1	1	1
12534	361	low total expenditure on health	[lower total expenditure on health]	0.0	5	2	2	1
12535	361	high-fat diet	[high-fat diet]	0.0	2	1	1	1
12536	361	human resistin in chemotherapy-induced heart failure	[Human resistin in chemotherapy-induced heart failure]	0.0	6	1	1	1
12537	361	resistin level in breast cancer patient	[resistin levels in breast cancer patients]	0.0	6	1	1	1
12538	361	excitation-contraction coupling	[excitation-contraction coupling]	0.0	2	1	1	1
12539	361	role scaffold in heart pathology	[role scaffolds in heart pathology]	0.0	5	1	1	1
12540	361	internist	[internists]	0.0	1	1	1	1
12541	361	inhibition signal	[inhibition signaling]	0.0	2	1	1	1
12542	361	trial of Nordic walking	[trial of Nordic walking]	0.0	4	1	1	1
12543	361	ser77	[Ser77]	0.0	1	1	1	1
12544	361	post-TAC	[post-TAC]	0.0	1	1	1	1
12545	361	global left strain	[global left strain]	0.0	3	1	1	1
12546	361	complication stroke	[complications stroke]	0.0	2	1	1	1
12547	361	rad variant	[Rad variant]	0.0	2	2	2	1
12548	361	MR-proANP	[MR-proANP]	0.0	1	1	1	1
12549	361	effectiveness of medicine as a treatment	[Effectiveness of medicine as an treatment]	0.0	6	1	1	1
12550	361	ser83	[Ser83]	0.0	1	1	1	1
12551	361	ivabradine-treated patient	[ivabradine-treated patients]	0.0	2	1	1	1
12552	361	acetylcholinesterase inhibitor	[acetylcholinesterase inhibitor]	0.0	2	1	1	1
12553	361	body mass index strata p	[body mass index strata P]	0.0	5	1	1	1
12554	361	interval CrI	[interval CrI]	0.0	2	1	1	1
12555	361	participation during the development of cardiomyopathy	[Participation during the development of cardiomyopathy]	0.0	6	1	1	1
12556	361	development among study patient	[development among study patients]	0.0	4	1	1	1
12557	361	pressure of end-tidal co2	[pressure of end-tidal CO2]	0.0	4	1	1	1
12558	361	participant low-dose dopamine	[participants low-dose dopamine]	0.0	3	1	1	1
12559	361	albumin concentration	[albumin concentration]	0.0	2	1	1	1
12560	361	effect on macrophage	[effects on macrophages]	0.0	3	1	1	1
12561	361	treatment of patient	[treatment of patients]	0.0	3	1	1	1
12562	361	follow-up duration	[follow-up duration]	0.0	2	1	1	1
12563	361	median exercise-induced pasp increase	[median exercise-induced PASP increase]	0.0	4	1	1	1
12564	361	implementation intervention	[implementation interventions]	0.0	2	1	1	1
12565	361	comorbidity such as anemia	[comorbidities such as anemia]	0.0	4	1	1	1
12566	361	cardiac troponin T	[cardiac troponin T]	0.0	3	1	1	1
12567	361	402 patient geometry no LV hypertrophy	[402 patients geometry no LV hypertrophy]	0.0	6	1	1	1
12568	361	odd die	[odds dying]	0.0	2	1	1	1
12569	361	require revision for valve replacement	[requiring revision for valve replacement]	0.0	5	1	1	1
12570	361	renal underperfusion result	[renal underperfusion resulting]	0.0	3	1	1	1
12571	361	cation	[cation]	0.0	1	1	1	1
12572	361	extend EMD with the other aspect	[extending EMD with the other aspects]	0.0	6	1	1	1
12573	361	result in autonomic imbalance	[resulting in autonomic imbalance]	0.0	4	1	1	1
12574	361	significant effect on quality	[significant effect on quality]	0.0	4	1	1	1
12575	361	high serum level	[higher serum levels]	0.0	3	2	2	1
12576	361	system proteomics	[Systems proteomics]	0.0	2	1	1	1
12577	361	delay EMD the time	[delay EMD the time]	0.0	4	1	1	1
12578	361	achieve a moderate level of CRF	[achieving a moderate level of CRF]	0.0	6	1	1	1
12579	361	early diastolic velocity 3.1	[early diastolic velocity 3.1]	0.0	4	1	1	1
12580	361	side effect	[side effects]	0.0	2	1	1	1
12581	361	early-outgrowth colony-forming unit	[early-outgrowth colony-forming units]	0.0	3	1	1	1
12582	361	334 consecutive patient 224 man	[334 consecutive patients 224 men]	0.0	5	1	1	1
12583	361	effective arterial elastance ea elastance ees	[Effective arterial elastance Ea elastance Ees]	0.0	6	1	1	1
12584	361	significant difference between group patient	[significant difference between groups patients]	0.0	5	1	1	1
12585	361	basic relevance	[basic relevance]	0.0	2	1	1	1
12586	361	western blot with antibody	[Western blots with antibodies]	0.0	4	1	1	1
12587	361	treatment with SS31	[treatment with SS31]	0.0	3	1	1	1
12588	361	year p=0.016	[years P=0.016]	0.0	2	1	1	1
12589	361	circulate nt-probnp concentration	[circulating NT-proBNP concentration]	0.0	3	1	1	1
12590	361	metabolism peak quotient	[metabolism peak quotient]	0.0	3	1	1	1
12591	361	use of nonstandardized pro-b-type peptide	[use of nonstandardized pro-B-type peptide]	0.0	5	1	1	1
12592	361	N-terminal proBNP midregional proanp	[N-terminal proBNP midregional proANP]	0.0	4	1	1	1
12593	361	up test in patient	[Up test in patients]	0.0	4	1	1	1
12594	361	good understanding	[better understanding]	0.0	2	1	1	1
12595	361	insight on the contribution	[insight on the contribution]	0.0	4	1	1	1
12596	361	metabolism respiratory quotient	[metabolism respiratory quotient]	0.0	3	1	1	1
12597	361	cardiac growth	[cardiac growth]	0.0	2	1	1	1
12598	361	measurement of flow velocity	[measurement of flow velocities]	0.0	4	1	1	1
12599	361	vector	[vector]	0.0	1	1	1	1
12600	361	range muscle waste	[range muscle wasting]	0.0	3	1	1	1
12601	361	opposing response	[opposing responses]	0.0	2	1	1	1
12602	361	non-survivor 64.26 year versus 72.83	[non-survivors 64.26 years vs 72.83]	0.0	5	1	1	1
12603	361	4.6 year of follow-up	[4.6 years of follow-up]	0.0	4	1	1	1
12604	361	failure from restriction	[failure from restriction]	0.0	3	1	1	1
12605	361	diagnosis of dysfunction lead	[diagnosis of dysfunction leading]	0.0	4	1	1	1
12606	361	nonidentification	[Nonidentification]	0.0	1	1	1	1
12607	361	LV index	[LV indices]	0.0	2	1	1	1
12608	361	support on renal function	[support on renal function]	0.0	4	1	1	1
12609	361	magnetic resonance t1 time	[magnetic resonance T1 time]	0.0	4	1	1	1
12610	361	include death heart failure	[including death heart failure]	0.0	4	1	1	1
12611	361	artery pressure increase	[artery pressure increase]	0.0	3	1	1	1
12612	361	epigenetic eraser	[epigenetic erasers]	0.0	2	1	1	1
12613	361	Hypertension DASH diet score	[Hypertension DASH diet scores]	0.0	4	1	1	1
12614	361	lyso-paf acetyltransferase	[lyso-PAF acetyltransferase]	0.0	2	1	1	1
12615	361	urban area	[urban areas]	0.0	2	1	1	1
12616	361	investigate outcome in Exercise training	[Investigating Outcomes in Exercise TraiNing]	0.0	5	1	1	1
12617	361	worsen renal function in EMPHASIS-HF	[worsening renal function in EMPHASIS-HF]	0.0	5	1	1	1
12618	361	briefing	[briefing]	0.0	1	1	1	1
12619	361	follow-up of 10.4 year	[follow-up of 10.4 years]	0.0	4	1	1	1
12620	361	arterial coupling pulmonary resistance	[arterial coupling pulmonary resistance]	0.0	4	1	1	1
12621	361	diverse cohort heart failure	[diverse cohort heart failure]	0.0	4	1	1	1
12622	361	transplant patient receive PD	[transplant patients receiving PD]	0.0	4	1	1	1
12623	361	mena overexpression	[Mena overexpression]	0.0	2	1	1	1
12624	361	site riiα	[site RIIα]	0.0	2	1	1	1
12625	361	recommendation for cardioverter-defibrillator deactivation discussion	[recommendation for cardioverter-defibrillator deactivation discussions]	0.0	5	1	1	1
12626	361	function with echocardiographic measure	[function with echocardiographic measures]	0.0	4	1	1	1
12627	361	g-protein coupling	[G-protein coupling]	0.0	2	1	1	1
12628	361	association among fitness	[associations among fitness]	0.0	3	1	1	1
12629	361	abnormality of different region	[abnormalities of different regions]	0.0	4	1	1	1
12630	361	development among patient	[development among patients]	0.0	3	1	1	1
12631	361	right contractile function	[right contractile function]	0.0	3	1	1	1
12632	361	patient with s'lateral	[patients with s'lateral]	0.0	3	1	1	1
12633	361	Doppler	[Doppler]	0.0	1	1	1	1
12634	361	key role scaffold	[Key role scaffolds]	0.0	3	1	1	1
12635	361	care for patient	[care for patients]	0.0	3	1	1	1
12636	361	study approximately 2900 hm ii	[studies approximately 2900 HM II]	0.0	5	1	1	1
12637	361	walk test 6mwt	[walk test 6MWT]	0.0	3	1	1	1
12638	361	common reason	[common reasons]	0.0	2	1	1	1
12639	361	learning	[Learning]	0.0	1	1	1	1
12640	361	prospective HF registry	[prospective HF registry]	0.0	3	1	1	1
12641	361	heart Function Clinic	[Heart Function Clinic]	0.0	3	1	1	1
12642	361	similar index	[similar index]	0.0	2	1	1	1
12643	361	Mechanistic insight into delay	[Mechanistic insight into delay]	0.0	4	1	1	1
12644	361	stimulation at eNOS-Ser	[stimulation at eNOS-Ser]	0.0	3	1	1	1
12645	361	detrimental alteration in microstructure	[detrimental alterations in microstructure]	0.0	4	1	1	1
12646	361	2.1 17.6 millileter	[2.1 17.6 mL]	0.0	3	1	1	1
12647	361	16 control HDL	[16 controls HDL]	0.0	3	1	1	1
12648	361	male wistar rat	[male Wistar rats]	0.0	3	1	1	1
12649	361	low-volume institution	[low-volume institutions]	0.0	2	1	1	1
12650	361	patient with unfavorable outcome median	[patients with unfavorable outcome median]	0.0	5	1	1	1
12651	361	low walking distance	[lower walking distance]	0.0	3	1	1	1
12652	361	stable therapy GDMT	[stable therapy GDMT]	0.0	3	1	1	1
12653	361	composite endpoint	[composite endpoint]	0.0	2	1	1	1
12654	361	ventricular pump function	[ventricular pump function]	0.0	3	1	1	1
12655	361	peak vo2 joint effect	[peak VO2 joint effect]	0.0	4	1	1	1
12656	361	percent reduction in readmission rate	[percent reduction in readmission rate]	0.0	5	1	1	1
12657	361	catabolic isoenzyme	[catabolic isoenzymes]	0.0	2	1	1	1
12658	361	hospitalization in refractory heart failure	[hospitalizations in refractory heart failure]	0.0	5	1	1	1
12659	361	major adverse neurological rate	[major adverse neurological rate]	0.0	4	1	1	1
12660	361	right tricuspid plane systolic excursion	[right tricuspid plane systolic excursion]	0.0	5	1	1	1
12661	361	global ventricular longitudinal systolic strain GLS	[global ventricular longitudinal systolic strain GLS]	0.0	6	1	1	1
12662	361	connection	[connection]	0.0	1	1	1	1
12663	361	group ii millileter per 1.73 m	[group II mL per 1.73 m]	0.0	6	1	1	1
12664	361	nitric oxide	[nitric oxide]	0.0	2	1	1	1
12665	361	parallel with attenuation	[parallel with attenuation]	0.0	3	1	1	1
12666	361	group ii 30 millileter	[group II 30 mL]	0.0	4	1	1	1
12667	361	66 year	[66 years]	0.0	2	1	1	1
12668	361	low lvef	[lower LVEF]	0.0	2	1	1	1
12669	361	low gross income	[lower gross income]	0.0	3	1	1	1
12670	361	16 control	[16 controls]	0.0	2	1	1	1
12671	361	acf in the rat	[ACF in the rat]	0.0	4	1	1	1
12672	361	detectable change mdc	[detectable change MDC]	0.0	3	1	1	1
12673	361	previous study	[Previous studies]	0.0	2	1	1	1
12674	361	cardiac metabolic gene expression	[cardiac metabolic gene expression]	0.0	4	1	1	1
12675	361	strength of race	[strength of race]	0.0	3	1	1	1
12676	361	potential efficacy	[potential efficacy]	0.0	2	1	1	1
12677	361	one million people in the UK	[one million people in the UK]	0.0	6	1	1	1
12678	361	relation in patient	[relations in patients]	0.0	3	1	1	1
12679	361	≥2 nondiabete risk factor age	[≥2 nondiabetes risk factors age]	0.0	5	1	1	1
12680	361	first HF	[first HF]	0.0	2	1	1	1
12681	361	day range	[days range]	0.0	2	1	1	1
12682	361	health datum	[health data]	0.0	2	1	1	1
12683	361	β-myosin	[β-myosin]	0.0	1	1	1	1
12684	361	cardiac support on function	[cardiac support on function]	0.0	4	1	1	1
12685	361	553 saxagliptin user	[553 saxagliptin users]	0.0	3	1	1	1
12686	361	Effect of biventricular pacing	[Effects of biventricular pacing]	0.0	4	1	1	1
12687	361	implication of choice for application	[Implications of choice for applications]	0.0	5	1	1	1
12688	361	for fail heart	[for failing hearts]	0.0	3	1	1	1
12689	361	kidney cell overexpress β1ar	[kidney cells overexpressing β1AR]	0.0	4	1	1	1
12690	361	underlying characteristic eg	[underlying characteristics eg]	0.0	3	1	1	1
12691	361	Large-scale multicenter trial with individual	[Large-scale multicenter trial with individuals]	0.0	5	1	1	1
12692	361	referral	[referral]	0.0	1	1	1	1
12693	361	human-to-machine	[human-to-machine]	0.0	1	1	1	1
12694	361	peptide system	[peptide system]	0.0	2	1	1	1
12695	361	complex situation in pediatrics	[complex situations in pediatrics]	0.0	4	1	1	1
12696	361	hfpef with ventricular ejection fraction	[HFpEF with ventricular ejection fraction]	0.0	5	1	1	1
12697	361	major cause of death	[major cause of death]	0.0	4	1	1	1
12698	361	risk of HF mortality	[risk of HF mortality]	0.0	4	1	1	1
12699	361	patient with acute syndrome	[patients with acute syndromes]	0.0	4	1	1	1
12700	361	improve quality	[improving quality]	0.0	2	1	1	1
12701	361	underlying mechanism	[underlying mechanism]	0.0	2	1	1	1
12702	361	body fat distribution	[body fat distribution]	0.0	3	1	1	1
12703	361	btt patient	[BTT patients]	0.0	2	1	1	1
12704	361	complication of therapy in end-stage HF	[complications of therapy in end-stage HF]	0.0	6	1	1	1
12705	361	72 study evaluate 63 predictor	[72 studies evaluating 63 predictors]	0.0	5	1	1	1
12706	361	chf-developed animal	[CHF-developed animals]	0.0	2	1	1	1
12707	361	few consequence	[few consequences]	0.0	2	1	1	1
12708	361	use of pro-b-type peptide	[use of pro-B-type peptide]	0.0	4	1	1	1
12709	361	diuretic refractory HF	[diuretic refractory HF]	0.0	3	1	1	1
12710	361	pulmonary capillary wedge pressure pcwp	[pulmonary capillary wedge pressure PCWP]	0.0	5	1	1	1
12711	361	clinical effect of 2 type	[clinical effects of 2 types]	0.0	5	1	1	1
12712	361	bnp in woman versus man EF	[BNP in women vs men EF]	0.0	6	1	1	1
12713	361	treatment target abnormal exercise status	[treatments targeting abnormal exercise status]	0.0	5	1	1	1
12714	361	dearth of clinical trial	[dearth of clinical trials]	0.0	4	1	1	1
12715	361	benefit with few adverse consequence	[benefit with few adverse consequences]	0.0	5	1	1	1
12716	361	procedure for	[procedures for]	0.0	2	1	1	1
12717	361	q66p	[Q66P]	0.0	1	1	1	1
12718	361	proximal left descending lad	[proximal left descending LAD]	0.0	4	1	1	1
12719	361	2374428 ED visit	[2,374,428 ED visits]	0.0	3	1	1	1
12720	361	Global strain as a major predictor	[Global strain as a major predictor]	0.0	6	1	1	1
12721	361	other potential predictor	[other potential predictors]	0.0	3	1	1	1
12722	361	diagnosis of systolic HF	[diagnosis of systolic HF]	0.0	4	1	1	1
12723	361	high performer	[high performers]	0.0	2	2	2	1
12724	361	plasma catecholamine	[plasma catecholamines]	0.0	2	1	1	1
12725	361	patient with ejection fraction HF	[patients with ejection fraction HF]	0.0	5	1	1	1
12726	361	multicenter placebo-controlled clinical trial	[Multicenter placebo-controlled clinical trial]	0.0	4	1	1	1
12727	361	ed visit mean age	[ED visits mean age]	0.0	4	1	1	1
12728	361	grow population within rehabilitation	[growing population within rehabilitation]	0.0	4	1	1	1
12729	361	limb	[limbs]	0.0	1	1	1	1
12730	361	autonomic modulation of repolarization instability	[Autonomic modulation of repolarization instability]	0.0	5	1	1	1
12731	361	44 man without a history	[44 men without a history]	0.0	5	1	1	1
12732	361	chronic obstructive pulmonary disease copd	[chronic obstructive pulmonary disease COPD]	0.0	5	1	1	1
12733	361	observational cohort study	[observational cohort studies]	0.0	3	1	1	1
12734	361	good diagnostic performance detect fill pressure	[good diagnostic performance detecting filling pressures]	0.0	6	1	1	1
12735	361	relation between renal dysfunction	[Relation between renal dysfunction]	0.0	4	1	1	1
12736	361	ejection time in heart failure	[ejection time in heart failure]	0.0	5	1	1	1
12737	361	year versus 72.83 year	[years vs 72.83 years]	0.0	4	1	1	1
12738	361	patient with left ejection fraction 0.35	[patients with left ejection fraction 0.35]	0.0	6	1	1	1
12739	361	Black race in patient	[Black race in patients]	0.0	4	1	1	1
12740	361	even low volume of exercise	[even lower volumes of exercise]	0.0	5	1	1	1
12741	361	method of aortic constriction tac	[method of aortic constriction TAC]	0.0	5	1	1	1
12742	361	topic in paediatric heart failure concern	[topics in paediatric heart failure concern]	0.0	6	1	1	1
12743	361	Cardiovascular Outcome in Lesion	[Cardiovascular Outcomes in Lesions]	0.0	4	1	1	1
12744	361	lung weight in acf group	[lung weight in ACF groups]	0.0	5	1	1	1
12745	361	vascular growth factor VEGF	[vascular growth factor VEGF]	0.0	4	1	1	1
12746	361	heart failure among person	[heart failure among persons]	0.0	4	1	1	1
12747	361	change with treatment	[change with treatment]	0.0	3	1	1	1
12748	361	mediator of insulin resistance	[mediator of insulin resistance]	0.0	4	1	1	1
12749	361	low CRF category	[low CRF categories]	0.0	3	1	1	1
12750	361	long follow-up	[long-term follow-up]	0.0	2	1	1	1
12751	361	improvement by β-adrenoceptor blockade	[improvement by β-adrenoceptor blockade]	0.0	4	1	1	1
12752	361	benign tumor	[benign tumors]	0.0	2	1	1	1
12753	361	diffuse change	[diffuse changes]	0.0	2	1	1	1
12754	361	grade systolic	[grade systolic]	0.0	2	1	1	1
12755	361	Excessive secretion	[Excessive secretion]	0.0	2	1	1	1
12756	361	derangement albeit with ability	[derangement albeit with ability]	0.0	4	1	1	1
12757	361	reduce Ea	[reducing Ea]	0.0	2	1	1	1
12758	361	modify drug	[modifying drug]	0.0	2	1	1	1
12759	361	resonance postcontrast	[resonance postcontrast]	0.0	2	2	2	1
12760	361	month after primary cabg	[months after primary CABG]	0.0	4	1	1	1
12761	361	functioning of evidence-based treatment	[functioning of evidence-based treatments]	0.0	4	1	1	1
12762	361	even volume of exercise	[even volumes of exercise]	0.0	4	1	1	1
12763	361	severe refractory congestive heart failure	[severe refractory congestive heart failure]	0.0	5	1	1	1
12764	361	major insulin-signaling component	[major insulin-signaling components]	0.0	3	1	1	1
12765	361	statistically significant percent reduction	[statistically significant percent reduction]	0.0	4	1	1	1
12766	361	ventricular longitudinal systolic strain GLS	[ventricular longitudinal systolic strain GLS]	0.0	5	1	1	1
12767	361	urgent transplant	[urgent transplant]	0.0	2	1	1	1
12768	361	listing	[listing]	0.0	1	1	1	1
12769	361	correction after left assist device implantation	[correction after left assist device implantation]	0.0	6	1	1	1
12770	361	patient with fail Fontan circulation	[patients with failing Fontan circulation]	0.0	5	1	1	1
12771	361	group 30 millileter per m	[group 30 mL per m]	0.0	5	1	1	1
12772	361	up tug test	[Up TUG test]	0.0	3	1	1	1
12773	361	acute autonomic nervous system modulation	[acute autonomic nervous system modulation]	0.0	5	1	1	1
12774	361	perhaps the component	[perhaps the component]	0.0	3	1	1	1
12775	361	predictive validity	[Predictive validity]	0.0	2	1	1	1
12776	361	108 hfpef with left ejection fraction	[108 HFpEF with left ejection fraction]	0.0	6	1	1	1
12777	361	use hr	[use HR]	0.0	2	1	1	1
12778	361	rat cardiomyocyte	[rat cardiomyocytes]	0.0	2	1	1	1
12779	361	mild dysfunction	[mild dysfunction]	0.0	2	1	1	1
12780	361	protein kinase pka	[protein kinase PKA]	0.0	3	1	1	1
12781	361	function in heart failure with function	[function in heart failure with function]	0.0	6	1	1	1
12782	361	estimate pulmonary capillary wedge pressure	[estimating pulmonary capillary wedge pressure]	0.0	5	1	1	1
12783	361	measure np level	[measuring NP levels]	0.0	3	1	1	1
12784	361	special access programme	[special access programme]	0.0	3	1	1	1
12785	361	ratio of blood pressure	[ratio of blood pressure]	0.0	4	1	1	1
12786	361	repeat evaluation	[repeat evaluations]	0.0	2	1	1	1
12787	361	patient with ventricular LV ejection fraction	[patients with ventricular LV ejection fraction]	0.0	6	1	1	1
12788	361	2825 participant	[2825 participants]	0.0	2	1	1	1
12789	361	most common reason	[most common reasons]	0.0	3	1	1	1
12790	361	contribution of hf-induced remodeling aspect	[contributions of HF-induced remodeling aspects]	0.0	5	1	1	1
12791	361	early velocity 3.1	[early velocity 3.1]	0.0	3	1	1	1
12792	361	comment on the role	[Comments on the role]	0.0	4	1	1	1
12793	361	cardioverter-defibrillator deactivation discussion a study	[cardioverter-defibrillator deactivation discussions A study]	0.0	5	1	1	1
12794	361	contractility of the ventricle	[contractility of the ventricle]	0.0	4	1	1	1
12795	361	A peptide	[A peptides]	0.0	2	1	1	1
12796	361	diuretic volume overload	[diuretic volume overload]	0.0	3	1	1	1
12797	361	secondary outcome of death	[secondary outcome of death]	0.0	4	1	1	1
12798	361	8 day	[8 days]	0.0	2	1	1	1
12799	361	cardiovascular event in patient	[cardiovascular events in patients]	0.0	4	1	1	1
12800	361	septum systolic thickness	[septum systolic thickness]	0.0	3	1	1	1
12801	361	role support patient	[role supporting patients]	0.0	3	1	1	1
12802	361	Campbell	[Campbell]	0.0	1	1	1	1
12803	361	epigenetic writer protein	[epigenetic writer proteins]	0.0	3	1	1	1
12804	361	ventricular ejection fraction LVEF	[ventricular ejection fraction LVEF]	0.0	4	1	1	1
12805	361	right heart Foundation work Group	[Right Heart Foundation Working Group]	0.0	5	1	1	1
12806	361	early physician follow-up	[Early physician follow-up]	0.0	3	2	2	1
12807	361	participant without prevalent HF	[participants without prevalent HF]	0.0	4	1	1	1
12808	361	systolic mitral annulus velocity	[systolic mitral annulus velocity]	0.0	4	1	1	1
12809	361	most powerful predictor	[most powerful predictor]	0.0	3	1	1	1
12810	361	time-dependent Cox regression analysis	[time-dependent Cox regression analysis]	0.0	4	1	1	1
12811	361	ventricular annular plane excursion	[ventricular annular plane excursion]	0.0	4	1	1	1
12812	361	change in stable heart failure	[change in stable heart failure]	0.0	5	1	1	1
12813	361	cardiac remodelling	[cardiac remodelling]	0.0	2	2	2	1
12814	361	onset af	[onset AF]	0.0	2	1	1	1
12815	361	right dysfunction	[right dysfunction]	0.0	2	1	1	1
12816	361	23 patient	[23 patients]	0.0	2	1	1	1
12817	361	other population	[other populations]	0.0	2	1	1	1
12818	361	International classification	[International Classification]	0.0	2	1	1	1
12819	361	achieve at least a moderate level	[achieving at least a moderate level]	0.0	6	1	1	1
12820	361	live	[Living]	0.0	1	1	1	1
12821	361	6-minute hall	[6-minute hall]	0.0	2	1	1	1
12822	361	protein kinase signal downstream	[protein kinase signaling downstream]	0.0	4	1	1	1
12823	361	risk as patient	[risk as patients]	0.0	3	1	1	1
12824	361	HF patient hfref	[HF patients HFrEF]	0.0	3	1	1	1
12825	361	Cochrane Practice	[Cochrane Practice]	0.0	2	1	1	1
12826	361	volume of exercise below this recommendation	[volumes of exercise below these recommendations]	0.0	6	1	1	1
12827	361	potential as therapeutic target	[potential as therapeutic targets]	0.0	4	1	1	1
12828	361	chronic kidney disease glomerular filtration rate	[chronic kidney disease glomerular filtration rate]	0.0	6	1	1	1
12829	361	high CRF category	[high CRF categories]	0.0	3	1	1	1
12830	361	hospitalization in heart failure	[hospitalizations in heart failure]	0.0	4	1	1	1
12831	361	diagnosis role	[Diagnosis role]	0.0	2	1	1	1
12832	361	presence of oedema	[presence of oedema]	0.0	3	1	1	1
12833	361	early beneficial outcome	[early beneficial outcomes]	0.0	3	1	1	1
12834	361	most responsible diagnosis	[most responsible diagnosis]	0.0	3	1	1	1
12835	361	recommendation for application	[Recommendations for application]	0.0	3	1	1	1
12836	361	prognostic relevance	[prognostic relevance]	0.0	2	1	1	1
12837	361	presentation Society guideline	[Presentation Society guidelines]	0.0	3	1	1	1
12838	361	profile of paf enzyme	[profile of PAF enzymes]	0.0	4	1	1	1
12839	361	pef	[pEF]	0.0	1	1	1	1
12840	361	advanced pulmonary disease	[advanced pulmonary disease]	0.0	3	1	1	1
12841	361	impact on patient	[impact on patients]	0.0	3	1	1	1
12842	361	mitral regurgitation mr	[mitral regurgitation MR]	0.0	3	1	1	1
12843	361	patient in study	[patients in studies]	0.0	3	1	1	1
12844	361	diverse cohort with incident	[diverse cohort with incident]	0.0	4	1	1	1
12845	361	range day	[range days]	0.0	2	1	1	1
12846	361	five death occur	[five deaths occurring]	0.0	3	1	1	1
12847	361	replicate resource use from trial	[replicating resource use from trials]	0.0	5	1	1	1
12848	361	incidence of end-stage renal disease	[Incidence of end-stage renal disease]	0.0	5	1	1	1
12849	361	patient 200	[patients 200]	0.0	2	1	1	1
12850	361	further study with follow-up	[further studies with follow-up]	0.0	4	1	1	1
12851	361	loss of scn5a	[loss of SCN5A]	0.0	3	1	1	1
12852	361	Age-dependent effect of ejection fraction	[Age-dependent effect of ejection fraction]	0.0	5	1	1	1
12853	361	tachycardia storm	[tachycardia storm]	0.0	2	1	1	1
12854	361	signalling pathway activate adaptive remodelling	[signalling pathways activating adaptive remodelling]	0.0	5	1	1	1
12855	361	catheterisation	[catheterisation]	0.0	1	1	1	1
12856	361	50 mg daily dose	[50 mg daily dose]	0.0	4	1	1	1
12857	361	right coupling resistance	[right coupling resistance]	0.0	3	1	1	1
12858	361	millileter in peak vo2	[mL in peak VO2]	0.0	4	1	1	1
12859	361	early physician	[Early physician]	0.0	2	1	1	1
12860	361	include anticoagulation	[including anticoagulation]	0.0	2	1	1	1
12861	361	334 consecutive patient man	[334 consecutive patients men]	0.0	4	1	1	1
12862	361	prescribe guideline-recommended medication	[prescribing guideline-recommended medications]	0.0	3	1	1	1
12863	361	conditioning for patient with heart failure	[conditioning for patients with heart failure]	0.0	6	1	1	1
12864	361	preorder	[pre]	0.0	1	1	1	1
12865	361	HF patient ejection fraction	[HF patients ejection fraction]	0.0	4	1	1	1
12866	361	testing of biomarker	[testing of biomarkers]	0.0	3	1	1	1
12867	361	add-on feature such as early detection	[add-on features such as early detection]	0.0	6	1	1	1
12868	361	Cytoscape	[Cytoscape]	0.0	1	1	1	1
12869	361	favorable change in function	[favorable changes in function]	0.0	4	1	1	1
12870	361	treadmill testing vo2max oxygen consumption	[treadmill testing VO2max oxygen consumption]	0.0	5	1	1	1
12871	361	predictor of remodeling	[predictors of remodeling]	0.0	3	1	1	1
12872	361	g-protein-coupled receptor	[G-protein-coupled receptors]	0.0	2	1	1	1
12873	361	role in pathogenesis	[role in pathogenesis]	0.0	3	1	1	1
12874	361	impaired pump function	[impaired pump function]	0.0	3	1	1	1
12875	361	common consensus regard the form	[common consensus regarding the forms]	0.0	5	1	1	1
12876	361	mm hg Fig 1B	[mm Hg Fig 1B]	0.0	4	1	1	1
12877	361	diagnosis ejection fraction	[diagnosis ejection fraction]	0.0	3	1	1	1
12878	361	acute nervous system modulation	[acute nervous system modulation]	0.0	4	1	1	1
12879	361	absolute detectable change mdc value	[absolute detectable change MDC values]	0.0	5	1	1	1
12880	361	refractory end-stage heart failure	[refractory end-stage heart failure]	0.0	4	1	1	1
12881	361	hand grip strength from baseline	[hand grip strength from baseline]	0.0	5	1	1	1
12882	361	Large-scale multicenter trial Paradigm-hf	[Large-scale multicenter trial PARADIGM-HF]	0.0	4	1	1	1
12883	361	millileter increase in vo2max	[mL increase in VO2max]	0.0	4	1	1	1
12884	361	care group hazard ratio	[care group hazard ratio]	0.0	4	1	1	1
12885	361	reversal of alteration in microstructure	[reversal of alterations in microstructure]	0.0	5	1	1	1
12886	361	potential usefulness in such patient	[potential usefulness in such patients]	0.0	5	1	1	1
12887	361	chemotherapy-induced heart failure in mouse	[chemotherapy-induced heart failure in mice]	0.0	5	1	1	1
12888	361	hand grip strength	[hand grip strength]	0.0	3	1	1	1
12889	361	sample from the first	[sample from the first]	0.0	4	1	1	1
12890	361	with.estimate range from 1 in 50000	[with.estimates ranging from 1 in 50,000]	0.0	6	1	1	1
12891	361	optimal therapy include anticoagulation	[optimal therapy including anticoagulation]	0.0	4	1	1	1
12892	361	advanced obstructive disease copd	[advanced obstructive disease COPD]	0.0	4	1	1	1
12893	361	remote monitoring a review	[Remote monitoring a review]	0.0	4	1	1	1
12894	361	odd ratio for cardiovascular event p=0.18	[odds ratios for cardiovascular events P=0.18]	0.0	6	1	1	1
12895	361	maximal exercise test	[maximal exercise test]	0.0	3	1	1	1
12896	361	defibrillator-only therapy hr	[defibrillator-only therapy HR]	0.0	3	1	1	1
12897	361	hretn human resistin	[hRetn human resistin]	0.0	3	1	1	1
12898	361	setting for management	[settings for management]	0.0	3	1	1	1
12899	361	small difference among ef	[smallest difference among EF]	0.0	4	1	1	1
12900	361	follow-up with cardiology service	[follow-up with cardiology services]	0.0	4	1	1	1
12901	361	good performance detect normal fill pressure	[good performance detecting normal filling pressures]	0.0	6	1	1	1
12902	361	gdmt treatment group for month	[GDMT treatment group for months]	0.0	5	1	1	1
12903	361	transcriptional analysis of tissue from mouse	[transcriptional analysis of tissue from mice]	0.0	6	1	1	1
12904	361	stage chronic kidney disease	[Stage chronic kidney disease]	0.0	4	1	1	1
12905	361	various form of nt-probnp	[various forms of NT-proBNP]	0.0	4	1	1	1
12906	361	HF hospital	[HF hospital]	0.0	2	1	1	1
12907	361	disease modify drug	[disease modifying drug]	0.0	3	1	1	1
12908	361	atrial area 20 cm	[atrial area 20 cm]	0.0	4	1	1	1
12909	361	result of congenital lesion	[result of congenital lesions]	0.0	4	1	1	1
12910	361	systemic blood pressure	[systemic blood pressure]	0.0	3	1	1	1
12911	361	type HeartMate for btt patient	[types HeartMate for BTT patients]	0.0	5	1	1	1
12912	361	chronic β-adrenergic receptor stimulation	[chronic β-adrenergic receptor stimulation]	0.0	4	1	1	1
12913	361	improvement in clinical composite response	[improvements in clinical composite response]	0.0	5	1	1	1
12914	361	global left ventricular strain GLS	[global left ventricular strain GLS]	0.0	5	1	1	1
12915	361	medical staff responsible for patient care	[medical staff responsible for patient care]	0.0	6	1	1	1
12916	361	patient short-term treatment	[patients short-term treatment]	0.0	3	1	1	1
12917	361	prognostic information for a unfavourable outcome	[prognostic information for an unfavourable outcome]	0.0	6	1	1	1
12918	361	with long axis function	[with long axis function]	0.0	4	1	1	1
12919	361	implantable arrhythmia device	[implantable arrhythmia devices]	0.0	3	1	1	1
12920	361	control of the heart	[control of the heart]	0.0	4	1	1	1
12921	361	well-recognised risk factor	[well-recognised risk factor]	0.0	3	1	1	1
12922	361	venous pressure 18	[venous pressure 18]	0.0	3	1	1	1
12923	361	fat free mass	[fat free mass]	0.0	3	1	1	1
12924	361	evaluation hm ii use simulation model	[evaluations HM II using simulation models]	0.0	6	1	1	1
12925	361	hypertrophy a predictor of HF	[hypertrophy a predictor of HF]	0.0	5	1	1	1
12926	361	form of ventricular remodeling	[forms of ventricular remodeling]	0.0	4	1	1	1
12927	361	abnormality of region	[abnormalities of regions]	0.0	3	1	1	1
12928	361	effect on various process	[effects on various processes]	0.0	4	1	1	1
12929	361	elevation nt-probnp level	[elevations NT-proBNP levels]	0.0	3	1	1	1
12930	361	ventricular area change	[ventricular area change]	0.0	3	1	1	1
12931	361	patient as control	[patients as control]	0.0	3	1	1	1
12932	361	infarction-both n	[infarction-both n]	0.0	2	1	1	1
12933	361	strain rs	[strain RS]	0.0	2	1	1	1
12934	361	doppler echocardiography	[Doppler echocardiography]	0.0	2	1	1	1
12935	361	ventricular assist system treat HF	[Ventricular Assist System Treating HF]	0.0	5	1	1	1
12936	361	time span	[time span]	0.0	2	1	1	1
12937	361	significant improvement in effective rate	[significant improvement in effective rate]	0.0	5	1	1	1
12938	361	ultimately target effector molecule	[ultimately targeting effector molecules]	0.0	4	1	1	1
12939	361	central blood pressure	[central blood pressure]	0.0	3	1	1	1
12940	361	circumflex artery	[circumflex artery]	0.0	2	1	1	1
12941	361	anterior descend artery	[anterior descending artery]	0.0	3	1	1	1
12942	361	improvement in shuttle walk test	[improvements in shuttle walk test]	0.0	5	1	1	1
12943	361	LV index LV ejection fraction	[LV indices LV ejection fraction]	0.0	5	1	1	1
12944	361	good performance only in patient	[good performance only in patients]	0.0	5	1	1	1
12945	361	saxagliptin versus sulfonylurea	[saxagliptin versus sulfonylureas]	0.0	3	1	1	1
12946	361	symptom despite maximal treatment	[symptoms despite maximal treatment]	0.0	4	1	1	1
12947	361	ventricular tricuspid plane systolic excursion	[ventricular tricuspid plane systolic excursion]	0.0	5	1	1	1
12948	361	reality	[reality]	0.0	1	1	1	1
12949	361	adverse neurological rate	[adverse neurological rate]	0.0	3	1	1	1
12950	361	factor in heart failure	[factor in heart failure]	0.0	4	1	1	1
12951	361	3 pharmacologic study of therapeutics	[3 pharmacologic studies of therapeutics]	0.0	5	1	1	1
12952	361	chronic stable therapy GDMT	[chronic stable therapy GDMT]	0.0	4	1	1	1
12953	361	Impact of frailty	[Impact of frailty]	0.0	3	1	1	1
12954	361	fetal gene program	[fetal gene program]	0.0	3	1	1	1
12955	361	history with coronary artery	[history with coronary arteries]	0.0	4	1	1	1
12956	361	range in 50000	[ranging in 50,000]	0.0	3	1	1	1
12957	361	prognostic benefit over clinical parameter	[prognostic benefit over clinical parameters]	0.0	5	1	1	1
12958	361	activation PKC-βII by HDL NYHA-IIIb	[activation PKC-βII by HDL NYHA-IIIb]	0.0	5	1	1	1
12959	361	non-AAs with York heart Association NYHA	[non-AAs with York Heart Association NYHA]	0.0	6	1	1	1
12960	361	cardiac mena overexpression TTA	[cardiac Mena overexpression TTA]	0.0	4	1	1	1
12961	361	fifty consecutive patient with recent onset	[Fifty consecutive patients with recent onset]	0.0	6	1	1	1
12962	361	brain peptide level 100 pg	[brain peptide levels 100 pg]	0.0	5	1	1	1
12963	361	pharmacologic target	[pharmacologic targets]	0.0	2	1	1	1
12964	361	need for statistical standard	[need for statistical standards]	0.0	4	1	1	1
12965	361	global left ventricular systolic strain	[global left ventricular systolic strain]	0.0	5	1	1	1
12966	361	ventricular area index	[ventricular area index]	0.0	3	1	1	1
12967	361	year for patient respectively	[years for patients respectively]	0.0	4	1	1	1
12968	361	beneficial new approach	[beneficial new approach]	0.0	3	1	1	1
12969	361	echocardiographic predictor	[echocardiographic predictors]	0.0	2	1	1	1
12970	361	current knowledge on diuretic use	[current knowledge on diuretic use]	0.0	5	1	1	1
12971	361	demonstrate development follow ring annuloplasty	[demonstrating development following ring annuloplasty]	0.0	5	1	1	1
12972	361	proximal anterior descending	[proximal anterior descending]	0.0	3	1	1	1
12973	361	patient with LV ejection fraction	[patients with LV ejection fraction]	0.0	5	1	1	1
12974	361	Bioinformatic analysis	[Bioinformatic analysis]	0.0	2	1	1	1
12975	361	unfavorable outcome versus 257 millisecond	[unfavorable outcome vs 257 milliseconds]	0.0	5	1	1	1
12976	361	downregulation of multiple gene	[downregulation of multiple genes]	0.0	4	1	1	1
12977	361	icd patient	[ICD patients]	0.0	2	1	1	1
12978	361	still a agent	[still a agent]	0.0	3	1	1	1
12979	361	mortality after hospitalization for HF	[mortality after hospitalization for HF]	0.0	5	1	1	1
12980	361	ejection fraction 0.35	[ejection fraction 0.35]	0.0	3	1	1	1
12981	361	single-arm analysis	[single-arm analysis]	0.0	2	1	1	1
12982	361	crude case-fatality rate for patient	[crude case-fatality rate for patients]	0.0	5	1	1	1
12983	361	fatty	[fatty]	0.0	1	1	1	1
12984	361	Witness with anemia	[Witness with anemia]	0.0	3	1	1	1
12985	361	vegf expression	[VEGF expression]	0.0	2	1	1	1
12986	361	variation in rate for outpatient	[variation in rates for outpatients]	0.0	5	1	1	1
12987	361	ventricular ejection time complicate precapillary hypertension	[ventricular ejection time complicating precapillary hypertension]	0.0	6	1	1	1
12988	361	undergo heart transplant	[undergoing heart transplant]	0.0	3	1	1	1
12989	361	quality of life HRQoL	[quality of life HRQoL]	0.0	4	1	1	1
12990	361	cardiac stress	[cardiac stress]	0.0	2	1	1	1
12991	361	mm for psoriasis	[mm for psoriasis]	0.0	3	1	1	1
12992	361	improvement in nyha classification	[improvements in NYHA classification]	0.0	4	1	1	1
12993	361	low apparent concentration	[low apparent concentration]	0.0	3	1	1	1
12994	361	National trend	[National trends]	0.0	2	1	1	1
12995	361	frequent comorbidity	[frequent comorbidities]	0.0	2	1	1	1
12996	361	choice for application	[choice for applications]	0.0	3	1	1	1
12997	361	mechanical support on function	[mechanical support on function]	0.0	4	1	1	1
12998	361	thirty-seven hospital nationwide through September	[thirty-seven hospitals nationwide through September]	0.0	5	1	1	1
12999	361	different type	[different types]	0.0	2	1	1	1
13000	361	atpase	[ATPase]	0.0	1	1	1	1
13001	361	disappointment in phase	[disappointments in phase]	0.0	3	1	1	1
13002	361	include agent of endothelin	[including agents of endothelin]	0.0	4	1	1	1
13003	361	microrna in heart failure new target	[MicroRNAs in heart failure new targets]	0.0	6	1	1	1
13004	361	important role for microrna	[important role for microRNAs]	0.0	4	1	1	1
13005	361	patient with arthritis	[patients with arthritis]	0.0	3	1	1	1
13006	361	risk of adverse outcome in patient	[risk of adverse outcomes in patients]	0.0	6	1	1	1
13007	361	Bax protein	[Bax proteins]	0.0	2	1	1	1
13008	361	require revision	[requiring revision]	0.0	2	1	1	1
13009	361	mir-25 by a antagomir	[miR-25 by a antagomir]	0.0	4	1	1	1
13010	361	per cent with death	[per cent with deaths]	0.0	4	1	1	1
13011	361	ejection fraction p	[ejection fraction P]	0.0	3	1	1	1
13012	361	predict adverse CV event in model	[predicting adverse CV events in models]	0.0	6	1	1	1
13013	361	two third of patient	[two thirds of patients]	0.0	4	1	1	1
13014	361	right mass removal	[right mass removal]	0.0	3	1	1	1
13015	361	Impact after discharge among patient	[Impact after discharge among patients]	0.0	5	1	1	1
13016	361	increase in lung weight p	[increase in lung weight P]	0.0	5	1	1	1
13017	361	cause in athlete	[cause in athletes]	0.0	3	1	1	1
13018	361	pediatric mechanical support	[pediatric mechanical support]	0.0	3	1	1	1
13019	361	CV event in fibrillation	[CV events in fibrillation]	0.0	4	1	1	1
13020	361	glucocorticoid dosage prior HF hospitalisation	[glucocorticoid dosage prior HF hospitalisations]	0.0	5	1	1	1
13021	361	adverse event evaluation	[adverse events evaluation]	0.0	3	1	1	1
13022	361	HF under drug treatment	[HF under drug treatment]	0.0	4	1	1	1
13023	361	human embryonic kidney 293 cell	[human embryonic kidney 293 cells]	0.0	5	1	1	1
13024	361	option in congestive heart failure	[option in congestive heart failure]	0.0	5	1	1	1
13025	361	heart failure visit	[heart failure visits]	0.0	3	1	1	1
13026	361	cytoskeletal actin dynamic	[cytoskeletal actin dynamics]	0.0	3	1	1	1
13027	361	group with mortality	[group with mortality]	0.0	3	1	1	1
13028	361	risk of arrhythmia event	[risk of arrhythmia events]	0.0	4	1	1	1
13029	361	furosemide dose	[furosemide dose]	0.0	2	2	2	1
13030	361	prognostic relevance of right ventricular reserve	[prognostic relevance of right ventricular reserve]	0.0	6	1	1	1
13031	361	protein kinase a	[protein kinase A]	0.0	3	1	1	1
13032	361	effect on effective rate	[effects on effective rate]	0.0	4	1	1	1
13033	361	predictor of reverse remodeling	[predictors of reverse remodeling]	0.0	4	1	1	1
13034	361	18 year	[18 years]	0.0	2	1	1	1
13035	361	assist device with ventricular support	[assist device with ventricular support]	0.0	5	1	1	1
13036	361	multivariable adjustment hazard ratio	[multivariable adjustment hazard ratio]	0.0	4	1	1	1
13037	361	eighty-one percent	[Eighty-one percent]	0.0	2	1	1	1
13038	361	device-related event	[device-related events]	0.0	2	1	1	1
13039	361	progression of HF	[progression of HF]	0.0	3	1	1	1
13040	361	alteration in microstructure	[alterations in microstructure]	0.0	3	1	1	1
13041	361	use the implementation	[using the implementation]	0.0	3	1	1	1
13042	361	surrogate for change during rvpo	[surrogates for changes During RVPO]	0.0	5	1	1	1
13043	361	model use simple procedure	[model using simple procedures]	0.0	4	1	1	1
13044	361	use Cox regression analysis	[Using Cox regression analysis]	0.0	4	1	1	1
13045	361	GLS hr	[GLS HR]	0.0	2	1	1	1
13046	361	ventricular-pulmonary coupling vascular resistance	[ventricular-pulmonary coupling vascular resistance]	0.0	4	1	1	1
13047	361	protection from response	[protection from responses]	0.0	3	1	1	1
13048	361	somewhat good information than the other	[somewhat better information than the others]	0.0	6	1	1	1
13049	361	age of the entire cohort	[age of the entire cohort]	0.0	5	1	1	1
13050	361	hr 1.54	[HR 1.54]	0.0	2	1	1	1
13051	361	hr 1.58	[HR 1.58]	0.0	2	1	1	1
13052	361	net savings	[net savings]	0.0	2	1	1	1
13053	361	value for heart failure	[value for heart failure]	0.0	4	1	1	1
13054	361	odd of future July	[odds of future July]	0.0	4	1	1	1
13055	361	foundation describe a nomenclature	[foundation describing a nomenclature]	0.0	4	1	1	1
13056	361	group iv 15 millileter	[group IV 15 mL]	0.0	4	1	1	1
13057	361	p38α	[p38α]	0.0	1	1	1	1
13058	361	heart transplantation OHT	[heart transplantation OHT]	0.0	3	1	1	1
13059	361	monitoring after hospital discharge a review	[monitoring after hospital discharge a review]	0.0	6	1	1	1
13060	361	6 fragment	[6 fragments]	0.0	2	1	1	1
13061	361	acute infarction AMI with complication	[acute infarction AMI with complications]	0.0	5	1	1	1
13062	361	hr 1.41	[HR 1.41]	0.0	2	1	1	1
13063	361	hr 1.46	[HR 1.46]	0.0	2	1	1	1
13064	361	clinical study 2900 hm	[clinical studies 2900 HM]	0.0	4	1	1	1
13065	361	thereby decrease risk	[thereby decreasing risk]	0.0	3	1	1	1
13066	361	irs2 double-knockout mouse	[IRS2 double-knockout mice]	0.0	3	1	1	1
13067	361	entry 237 millisecond	[entry 237 milliseconds]	0.0	3	1	1	1
13068	361	detrimental alteration in SkM structure	[detrimental alterations in SkM structure]	0.0	5	1	1	1
13069	361	effectiveness of herbal medicine CHM	[effectiveness of herbal medicine CHM]	0.0	5	1	1	1
13070	361	univariate model	[univariate models]	0.0	2	1	1	1
13071	361	Olmsted County	[Olmsted County]	0.0	2	1	1	1
13072	361	RV decompensation	[RV decompensation]	0.0	2	1	1	1
13073	361	outcome in Exercise training hf-action	[Outcomes in Exercise TraiNing HF-ACTION]	0.0	5	1	1	1
13074	361	comment on baroreflex activation therapy	[Comment on Baroreflex Activation Therapy]	0.0	5	1	1	1
13075	361	pathway alteration	[pathway alterations]	0.0	2	1	1	1
13076	361	thereby presumably decrease risk	[thereby presumably decreasing risk]	0.0	4	1	1	1
13077	361	regulatory subunit	[regulatory subunit]	0.0	2	1	1	1
13078	361	previous spironolactone use	[previous spironolactone use]	0.0	3	1	1	1
13079	361	impact of heart resonance imaging	[impact of heart resonance imaging]	0.0	5	1	1	1
13080	361	patient with low co-morbidity burden	[patients with low co-morbidity burden]	0.0	5	1	1	1
13081	361	patient with onset	[patients with onset]	0.0	3	1	1	1
13082	361	tool a program	[Tools A program]	0.0	3	1	1	1
13083	361	index E	[indices E]	0.0	2	1	1	1
13084	361	index L	[index L]	0.0	2	1	1	1
13085	361	combination of annular size reduction	[combination of annular size reduction]	0.0	5	2	2	1
13086	361	Robot-assisted training	[Robot-assisted training]	0.0	2	1	1	1
13087	361	180 day	[180 days]	0.0	2	1	1	1
13088	361	diagnosis of myocarditis	[diagnosis of myocarditis]	0.0	3	1	1	1
13089	361	potential for effect on process	[potential for effects on processes]	0.0	5	1	1	1
13090	361	potential usefulness in HF	[potential usefulness in HF]	0.0	4	1	1	1
13091	361	implication of biomarker in heart failure	[implications of biomarkers in heart failure]	0.0	6	1	1	1
13092	361	six thousand five hundred hospital nationwide	[Six thousand five hundred hospitals nationwide]	0.0	6	1	1	1
13093	361	meet specific inclusion	[meeting specific inclusion]	0.0	3	1	1	1
13094	361	discussion about end-of-life treatment preference	[discussions about end-of-life treatment preferences]	0.0	5	1	1	1
13095	361	gene deg	[genes DEGs]	0.0	2	1	1	1
13096	361	ventricular-pulmonary arterial coupling pulmonary resistance	[ventricular-pulmonary arterial coupling pulmonary resistance]	0.0	5	1	1	1
13097	361	success in trial	[success in trials]	0.0	3	1	1	1
13098	361	identify hospital	[identifying hospitals]	0.0	2	1	1	1
13099	361	high rate of hyperkalemia	[higher rates of hyperkalemia]	0.0	4	1	1	1
13100	361	hypothese addition of dopamine μg	[hypotheses addition of dopamine μg]	0.0	5	1	1	1
13101	361	CI for early HF	[CI for early HF]	0.0	4	1	1	1
13102	361	right arterial coupling vascular resistance	[right arterial coupling vascular resistance]	0.0	5	1	1	1
13103	361	inhibition by a rad variant	[inhibition by a Rad variant]	0.0	5	1	1	1
13104	361	practice-level variation	[Practice-level variation]	0.0	2	2	2	1
13105	361	myocardial n	[myocardial n]	0.0	2	1	1	1
13106	361	heart failure in male mouse	[heart failure in male mice]	0.0	5	1	1	1
13107	361	diagnostic device	[diagnostic devices]	0.0	2	1	1	1
13108	361	distinct derangement with hemodynamic feature	[distinct derangement with hemodynamic features]	0.0	5	1	1	1
13109	361	patient with ventricular ejection fraction HF	[patients with ventricular ejection fraction HF]	0.0	6	1	1	1
13110	361	effect of lvef	[effect of LVEF]	0.0	3	1	1	1
13111	361	42.4 gram	[42.4 g]	0.0	2	1	1	1
13112	361	effective off-pump sparing approach	[effective off-pump sparing approach]	0.0	4	1	1	1
13113	361	variation in rate of treatment	[variation in rates of treatment]	0.0	5	1	1	1
13114	361	One-year event-free rate by kccq category	[One-year event-free rates by KCCQ category]	0.0	6	1	1	1
13115	361	heart failure questionnaire	[Heart Failure Questionnaire]	0.0	3	1	1	1
13116	361	common element of intervention	[common elements of interventions]	0.0	4	1	1	1
13117	361	finding of rheumatic cause	[findings of rheumatic causes]	0.0	4	1	1	1
13118	361	brain peptide BNP level pg	[brain peptide BNP levels pg]	0.0	5	1	1	1
13119	361	usefulness of resynchronization therapy in patient	[Usefulness of resynchronization therapy in patients]	0.0	6	1	1	1
13120	361	24 telephone support STS	[24 telephone support STS]	0.0	4	1	1	1
13121	361	mrna splicing	[mRNA splicing]	0.0	2	1	1	1
13122	361	man with arrest	[man with arrest]	0.0	3	1	1	1
13123	361	use International Classification	[using International Classification]	0.0	3	1	1	1
13124	361	medical staff	[medical staff]	0.0	2	1	1	1
13125	361	use three metric	[using three metrics]	0.0	3	1	1	1
13126	361	mlhf score	[MLHF score]	0.0	2	1	1	1
13127	361	useful tool for assessment	[useful tool for assessment]	0.0	4	1	1	1
13128	361	component improve quality	[component improving quality]	0.0	3	1	1	1
13129	361	lack of improvement	[lack of improvement]	0.0	3	1	1	1
13130	361	ED visit 32036	[ED visits 32,036]	0.0	3	1	1	1
13131	361	account	[account]	0.0	1	1	1	1
13132	361	myocyte-specific mena overexpression	[myocyte-specific Mena overexpression]	0.0	3	1	1	1
13133	361	106 outcome	[106 outcomes]	0.0	2	1	1	1
13134	361	state like South Dakota	[state like South Dakota]	0.0	4	1	1	1
13135	361	exercise patient	[exercise patients]	0.0	2	1	1	1
13136	361	use of pro-b-type peptide nt-probnp	[use of pro-B-type peptide NT-proBNP]	0.0	5	1	1	1
13137	361	differential effect of LVEF	[differential effect of LVEF]	0.0	4	1	1	1
13138	361	three variant consistent	[three variants consistent]	0.0	3	1	1	1
13139	361	patient HDL before et	[patients HDL before ET]	0.0	4	1	1	1
13140	361	few pdrelated complication	[few PDrelated complications]	0.0	3	1	1	1
13141	361	10 lb in year	[10 lb in year]	0.0	4	1	1	1
13142	361	type regulatory catalytic subunit expression	[type regulatory catalytic subunit expression]	0.0	5	1	1	1
13143	361	die in 30 day p-value 0.001	[dying in 30 days P-value 0.001]	0.0	6	1	1	1
13144	361	LV myocyte	[LV myocytes]	0.0	2	1	1	1
13145	361	undergo lvad implantation at institution	[undergoing LVAD implantation at institution]	0.0	5	1	1	1
13146	361	involve the proximal artery	[involving the proximal artery]	0.0	4	1	1	1
13147	361	ventricular RV tricuspid plane excursion tapse	[ventricular RV tricuspid plane excursion TAPSE]	0.0	6	1	1	1
13148	361	renal denervation in CHF patient	[Renal denervation in CHF patients]	0.0	5	1	1	1
13149	361	factor in cardiovascular disease	[factor in cardiovascular diseases]	0.0	4	1	1	1
13150	361	telephone support STS	[telephone support STS]	0.0	3	1	1	1
13151	361	myocardial t1	[myocardial T1]	0.0	2	1	1	1
13152	361	strain cs	[strain CS]	0.0	2	1	1	1
13153	361	heart rate variation	[heart rate variation]	0.0	3	1	1	1
13154	361	alteration by the peptide ss31	[alterations by the peptide SS31]	0.0	5	1	1	1
13155	361	effect of HRQoL	[effects of HRQoL]	0.0	3	1	1	1
13156	361	value in HF risk prediction	[value in HF risk prediction]	0.0	5	1	1	1
13157	361	cardiac rehabilitation care on functional capacity	[cardiac rehabilitation care on functional capacity]	0.0	6	1	1	1
13158	361	prognosis of a cohort	[prognosis of a cohort]	0.0	4	1	1	1
13159	361	self-reported activity	[self-reported activity]	0.0	2	1	1	1
13160	361	RV fiber shortening	[RV fiber shortening]	0.0	3	1	1	1
13161	361	comorbid condition	[comorbid conditions]	0.0	2	1	1	1
13162	361	benefit for patient in study	[benefit for patients in studies]	0.0	5	1	1	1
13163	361	York heart Association class I	[York Heart Association class I]	0.0	5	1	1	1
13164	361	loss of irs1	[loss of IRS1]	0.0	3	1	1	1
13165	361	Sudden cardiac death in athlete	[Sudden cardiac death in athletes]	0.0	5	1	1	1
13166	361	70 bpm 17.5±5.5 respectively p	[70 bpm 17.5±5.5 respectively P]	0.0	5	1	1	1
13167	361	hr 70 versus ≥70	[HR 70 versus ≥70]	0.0	4	1	1	1
13168	361	low rate of atp	[lower rate of ATP]	0.0	4	1	1	1
13169	361	PAF	[PAF]	0.0	1	1	1	1
13170	361	series	[series]	0.0	1	1	1	1
13171	361	heart failure in patient present	[heart failure in patients presenting]	0.0	5	1	1	1
13172	361	include low risk	[including lower risk]	0.0	3	1	1	1
13173	361	high relevance	[high relevance]	0.0	2	1	1	1
13174	361	130 patient with a ejection fraction	[130 patients with a ejection fraction]	0.0	6	1	1	1
13175	361	novel strategy	[novel strategy]	0.0	2	1	1	1
13176	361	more hypokalemia	[more hypokalemia]	0.0	2	1	1	1
13177	361	cardiopulmonary resuscitation cpr	[cardiopulmonary resuscitation CPR]	0.0	3	1	1	1
13178	361	patient 209 HFrEF	[patients 209 HFrEF]	0.0	3	1	1	1
13179	361	extensive characterization of one	[extensive characterization of one]	0.0	4	1	1	1
13180	361	physiological proteolysis	[physiological proteolysis]	0.0	2	1	1	1
13181	361	short-term treatment with ivabradine exercise capacity	[short-term treatment with ivabradine exercise capacity]	0.0	6	1	1	1
13182	361	rEF	[rEF]	0.0	1	1	1	1
13183	361	heart Foundation work Group	[Heart Foundation Working Group]	0.0	4	1	1	1
13184	361	defibrillator implantation resynchronization therapy	[Defibrillator Implantation Resynchronization Therapy]	0.0	4	1	1	1
13185	361	dobutamine	[Dobutamine]	0.0	1	2	2	1
13186	361	symptom of heart failure despite treatment	[symptoms of heart failure despite treatment]	0.0	6	1	1	1
13187	361	low volume of exercise	[lower volumes of exercise]	0.0	4	1	1	1
13188	361	high bnp level with the difference	[higher BNP levels with the difference]	0.0	6	1	1	1
13189	361	Median age of the cohort	[Median age of the cohort]	0.0	5	1	1	1
13190	361	web-system in heart disease	[Web-system in Heart disease]	0.0	4	1	1	1
13191	361	result in acute HF trial	[results in acute HF trials]	0.0	5	1	1	1
13192	361	mild heart failure patient	[mild heart failure patients]	0.0	4	1	1	1
13193	361	training period with training	[training period with trainings]	0.0	4	1	1	1
13194	361	3 mg	[3 mg]	0.0	2	1	1	1
13195	361	thus provide prognostic information	[thus providing prognostic information]	0.0	4	1	1	1
13196	361	fifty-four Fontan patient	[Fifty-four Fontan patients]	0.0	3	1	1	1
13197	361	Systolic ventricular dysfunction	[Systolic vEntricular dysfunction]	0.0	3	1	1	1
13198	361	incidence outcome	[incidence outcomes]	0.0	2	1	1	1
13199	361	LCZ696	[LCZ696]	0.0	1	1	1	1
13200	361	trigger of infarction	[trigger of infarction]	0.0	3	1	1	1
13201	361	recognition of advanced disease	[recognition of advanced disease]	0.0	4	1	1	1
13202	361	24-hour systolic pressure 155	[24-hour systolic pressure 155]	0.0	4	1	1	1
13203	361	dyssynchronous nonfailing canine electromechanic	[dyssynchronous nonfailing canine electromechanics]	0.0	4	1	1	1
13204	361	important cause	[important cause]	0.0	2	1	1	1
13205	361	oxygen pulse range	[oxygen pulse range]	0.0	3	1	1	1
13206	361	important component improve quality	[important component improving quality]	0.0	4	1	1	1
13207	361	MPSMS	[MPSMS]	0.0	1	1	1	1
13208	361	consequence of remodelling	[consequence of remodelling]	0.0	3	1	1	1
13209	361	risk factor for outcome	[risk factor for outcomes]	0.0	4	1	1	1
13210	361	patient IL 0.5 mg	[patients IL 0.5 mg]	0.0	4	1	1	1
13211	361	receptor β-ar signal	[receptor β-AR signaling]	0.0	3	1	1	1
13212	361	potential therapeutic implication of biomarker	[potential therapeutic implications of biomarkers]	0.0	5	1	1	1
13213	361	mitochondrial V activity	[mitochondrial V activity]	0.0	3	1	1	1
13214	361	biomarker hscrp	[biomarkers hsCRP]	0.0	2	1	1	1
13215	361	database include MEDLINE	[databases including MEDLINE]	0.0	3	1	1	1
13216	361	resistance p	[resistance P]	0.0	2	1	1	1
13217	361	epidemic of heart failure	[epidemic of heart failure]	0.0	4	1	1	1
13218	361	effect on beta-adrenergic receptor signal	[effects on beta-adrenergic receptor signaling]	0.0	5	1	1	1
13219	361	amino-terminal pro-b-type peptide	[amino-terminal pro-B-type peptide]	0.0	3	1	1	1
13220	361	investigate Outcome	[Investigating Outcomes]	0.0	2	2	2	1
13221	361	such as myocardial infarction	[such as myocardial infarction]	0.0	4	1	1	1
13222	361	injection	[injections]	0.0	1	1	1	1
13223	361	cardiotoxicity among old patient	[cardiotoxicity among older patients]	0.0	4	1	1	1
13224	361	diastolic index E ratio at diastole	[diastolic indices E ratio at diastole]	0.0	6	1	1	1
13225	361	dramatic induction of hretn resistin mrna	[dramatic induction of hRetn resistin mRNA]	0.0	6	1	1	1
13226	361	meet inclusion include a egfr	[meeting inclusion including an eGFR]	0.0	5	1	1	1
13227	361	excellent risk stratification	[excellent risk stratification]	0.0	3	1	1	1
13228	361	decrease risk of HF mortality	[decreasing risk of HF mortality]	0.0	5	1	1	1
13229	361	patient in small study	[patients in small studies]	0.0	4	1	1	1
13230	361	quality measure for common inpatient condition	[quality measures for common inpatient conditions]	0.0	6	1	1	1
13231	361	Health Organization	[Health Organization]	0.0	2	1	1	1
13232	361	left dilatation	[left dilatation]	0.0	2	1	1	1
13233	361	many study	[Many studies]	0.0	2	1	1	1
13234	361	disease in outpatient	[disease in outpatients]	0.0	3	1	1	1
13235	361	right coupling vascular resistance p	[right coupling vascular resistance P]	0.0	5	1	1	1
13236	361	result from the propensity analysis	[Results from the propensity analyses]	0.0	5	1	1	1
13237	361	midpapillary level	[midpapillary level]	0.0	2	1	1	1
13238	361	determine the remodelling	[determining the remodelling]	0.0	3	1	1	1
13239	361	culprit	[culprit]	0.0	1	1	1	1
13240	361	Titin	[Titin]	0.0	1	1	1	1
13241	361	strong mortality predictor in ICD-HF patient	[strong mortality predictors in ICD-HF patients]	0.0	6	1	1	1
13242	361	user of a nbdmard	[users of a nbDMARD]	0.0	4	1	1	1
13243	361	Genetic susceptibility	[Genetic susceptibility]	0.0	2	1	1	1
13244	361	timing of patient enrollment	[timing of patient enrollment]	0.0	4	1	1	1
13245	361	negative regression model	[negative regression models]	0.0	3	1	1	1
13246	361	hypo-response	[hypo-response]	0.0	1	1	1	1
13247	361	use within the time frame	[use within the time frame]	0.0	5	1	1	1
13248	361	cardiac resynchronization therapy in patient	[cardiac resynchronization therapy in patients]	0.0	5	1	1	1
13249	361	heart failure prone	[heart failure prone]	0.0	3	1	1	1
13250	361	myocardial angiogenesis	[myocardial angiogenesis]	0.0	2	1	1	1
13251	361	STE analysis of strain cs	[STE analysis of strain CS]	0.0	5	1	1	1
13252	361	successful valve plasty for mr	[successful valve plasty for MR]	0.0	5	2	2	1
13253	361	member	[member]	0.0	1	1	1	1
13254	361	hospital rate for HF patient	[hospital rates for HF patients]	0.0	5	1	1	1
13255	361	baseline ST2 level	[baseline ST2 level]	0.0	3	1	1	1
13256	361	saxagliptin for saxagliptin	[saxagliptin for saxagliptin]	0.0	3	1	1	1
13257	361	low von willebrand factor concentration	[lower von Willebrand factor concentrations]	0.0	5	1	1	1
13258	361	individual contribution	[individual contributions]	0.0	2	1	1	1
13259	361	human left LV myocyte	[human left LV myocytes]	0.0	4	1	1	1
13260	361	large low-risk group	[large low-risk group]	0.0	3	1	1	1
13261	361	mg dose of metoprolol succinate	[mg dose of metoprolol succinate]	0.0	5	1	1	1
13262	361	β-blocker dose	[β-blocker dose]	0.0	2	1	1	1
13263	361	especially in people	[especially in people]	0.0	3	1	1	1
13264	361	trichrome	[trichrome]	0.0	1	1	1	1
13265	361	record of patient	[records of patients]	0.0	3	1	1	1
13266	361	thirteen patient	[Thirteen patients]	0.0	2	1	1	1
13267	361	blot with site-specific antibody	[blots with site-specific antibodies]	0.0	4	1	1	1
13268	361	cardiac plasma membrane level	[cardiac plasma membrane levels]	0.0	4	1	1	1
13269	361	HeartMate insertion	[HeartMate insertion]	0.0	2	1	1	1
13270	361	prognostic relevance of contractile reserve	[prognostic relevance of contractile reserve]	0.0	5	1	1	1
13271	361	right coupling pulmonary resistance	[right coupling pulmonary resistance]	0.0	4	1	1	1
13272	361	VA patient	[VA patients]	0.0	2	1	1	1
13273	361	high morbidity in elderly people	[high morbidity in elderly people]	0.0	5	1	1	1
13274	361	history of fibrillation	[history of fibrillation]	0.0	3	1	1	1
13275	361	repeat procedure	[repeat procedures]	0.0	2	1	1	1
13276	361	coupling pulmonary resistance	[coupling pulmonary resistance]	0.0	3	1	1	1
13277	361	presence of scale dimension	[presence of scale dimensions]	0.0	4	1	1	1
13278	361	fragment of nt-probnp	[fragments of NT-proBNP]	0.0	3	1	1	1
13279	361	higher-than-expected rate	[higher-than-expected rates]	0.0	2	1	1	1
13280	361	effect of inhibition on hemodynamic status	[Effect of inhibition on hemodynamic status]	0.0	6	1	1	1
13281	361	effective evidence-based therapy	[effective evidence-based therapies]	0.0	3	1	1	1
13282	361	Functional stimulation of muscle	[Functional stimulation of muscles]	0.0	4	1	1	1
13283	361	4 suburban hospital	[4 suburban hospitals]	0.0	3	1	1	1
13284	361	cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[cardiomyopathies]	0.0	1	1	1	1
13285	361	psychosocial factor insight a Trial	[Psychosocial Factors Insights A Trial]	0.0	5	1	1	1
13286	361	survival in patient require lvad	[survival in patients requiring LVAD]	0.0	5	1	1	1
13287	361	respectively p for trend	[respectively P for trend]	0.0	4	1	1	1
13288	361	Medicare Service	[Medicare Services]	0.0	2	1	1	1
13289	361	abundance	[abundance]	0.0	1	1	1	1
13290	361	2900 hm	[2900 HM]	0.0	2	1	1	1
13291	361	mena overexpression comparable	[Mena overexpression comparable]	0.0	3	1	1	1
13292	361	chronic acf	[chronic ACF]	0.0	2	1	1	1
13293	361	120 patient with pad	[120 patients with PAD]	0.0	4	1	1	1
13294	361	role in cardiac pathophysiology	[role in cardiac pathophysiology]	0.0	4	1	1	1
13295	361	HFpEF population	[HFpEF population]	0.0	2	1	1	1
13296	361	occurrence of HF within 90 day	[Occurrence of HF within 90 days]	0.0	6	1	1	1
13297	361	differential response in cardiac activity	[differential response in cardiac activity]	0.0	5	1	1	1
13298	361	screening patient for ras	[Screening patients for RAS]	0.0	4	1	1	1
13299	361	various disease	[various diseases]	0.0	2	1	1	1
13300	361	HF risk factor include risk	[HF risk factors including risk]	0.0	5	1	1	1
13301	361	57±22 month	[57±22 months]	0.0	2	1	1	1
13302	361	inoperable pulmonary hypertension	[inoperable pulmonary hypertension]	0.0	3	1	1	1
13303	361	play a major role in patient	[playing a major role in patients]	0.0	6	1	1	1
13304	361	gdmt alone	[GDMT alone]	0.0	2	1	1	1
13305	361	unidirectional left-to-right interatrial shunting for treatment	[Unidirectional left-to-right interatrial shunting for treatment]	0.0	6	1	1	1
13306	361	early mitral velocity 3.1 vs. 1.3	[early mitral velocity 3.1 vs. 1.3]	0.0	6	1	1	1
13307	361	restorative effect of cocoa	[restorative effects of cocoa]	0.0	4	1	1	1
13308	361	log2 ng	[log2 ng]	0.0	2	1	1	1
13309	361	quality qol	[quality QOL]	0.0	2	1	1	1
13310	361	812 patient aged 40 year	[812 patients aged 40 years]	0.0	5	1	1	1
13311	361	rural South Dakota	[rural South Dakota]	0.0	3	1	1	1
13312	361	patient with chronic pulmonary disease	[patients with chronic pulmonary disease]	0.0	5	1	1	1
13313	361	low egfr	[low eGFR]	0.0	2	1	1	1
13314	361	result of study	[results of studies]	0.0	3	1	1	1
13315	361	marker hazard ratio for peak o2	[markers hazard ratio for peak o2]	0.0	6	1	1	1
13316	361	low expenditure on health	[lower expenditure on health]	0.0	4	2	2	1
13317	361	independent predictor of cad	[independent predictors of CAD]	0.0	4	1	1	1
13318	361	avoid the region of this molecule	[avoiding the region of this molecule]	0.0	6	1	1	1
13319	361	circulate mediator	[circulating mediator]	0.0	2	1	1	1
13320	361	improvement of cardiac performance at stage	[improvement of cardiac performance at stages]	0.0	6	1	1	1
13321	361	other staff responsible	[other staff responsible]	0.0	3	1	1	1
13322	361	circumferential strain	[circumferential strain]	0.0	2	1	1	1
13323	361	result in the support score psss	[resulting in the support score PSSS]	0.0	6	1	1	1
13324	361	hr bpm	[HR bpm]	0.0	2	1	1	1
13325	361	function in pediatric heart failure	[function in pediatric heart failure]	0.0	5	1	1	1
13326	361	array of procedure for	[array of procedures for]	0.0	4	1	1	1
13327	361	first-in-man evidence	[first-in-man evidence]	0.0	2	1	1	1
13328	361	index of ventricular contractile function	[index of ventricular contractile function]	0.0	5	1	1	1
13329	361	deleterious effect	[deleterious effects]	0.0	2	1	1	1
13330	361	fat body mass ratio	[fat body mass ratio]	0.0	4	1	1	1
13331	361	continuous relationship between qrs	[continuous relationship between QRS]	0.0	4	1	1	1
13332	361	nomenclature	[nomenclature]	0.0	1	1	1	1
13333	361	LV pressure of mm	[LV pressure of mm]	0.0	4	1	1	1
13334	361	subscale	[subscales]	0.0	1	1	1	1
13335	361	62 care clinician care	[62 care clinicians caring]	0.0	4	1	1	1
13336	361	consecutive patient man 65±12 year	[consecutive patients men 65±12 years]	0.0	5	1	1	1
13337	361	first myocardial infarction in Australia	[first myocardial infarction in Australia]	0.0	5	1	1	1
13338	361	quantitative analysis	[quantitative analysis]	0.0	2	1	1	1
13339	361	World Health Organization criterion	[World Health Organization criteria]	0.0	4	1	1	1
13340	361	ventricular pacing	[ventricular pacing]	0.0	2	1	1	1
13341	361	antioxidant	[antioxidant]	0.0	1	1	1	1
13342	361	beneficial effect of HRQoL	[beneficial effects of HRQoL]	0.0	4	1	1	1
13343	361	health per capita	[health per capita]	0.0	3	2	2	1
13344	361	cause of nontraumatic death	[cause of nontraumatic death]	0.0	4	1	1	1
13345	361	indicator in heart failure HF	[indicator in heart failure HF]	0.0	5	1	1	1
13346	361	regard condition in Turkey	[regarding conditions in Turkey]	0.0	4	1	1	1
13347	361	Cox model	[Cox models]	0.0	2	1	1	1
13348	361	evidence of diastolic dysfunction LV relaxation	[evidence of diastolic dysfunction LV relaxation]	0.0	6	1	1	1
13349	361	coupling vascular resistance p	[coupling vascular resistance P]	0.0	4	1	1	1
13350	361	promote pause release during pathological stress	[promoting pause release during pathological stress]	0.0	6	1	1	1
13351	361	low systemic resistance index	[low systemic resistance index]	0.0	4	1	1	1
13352	361	lean body mass	[lean body mass]	0.0	3	1	1	1
13353	361	excitation-contraction ec coupling	[excitation-contraction EC coupling]	0.0	3	1	1	1
13354	361	right RV failure	[Right RV failure]	0.0	3	1	1	1
13355	361	ventricular end diameter mean difference	[ventricular end diameter mean difference]	0.0	5	1	1	1
13356	361	TRPM7	[TRPM7]	0.0	1	1	1	1
13357	361	composite response p=0.02	[composite response P=0.02]	0.0	3	1	1	1
13358	361	infarction a community study	[infarction a community study]	0.0	4	1	1	1
13359	361	effective therapy	[effective therapies]	0.0	2	1	1	1
13360	361	patient with a cardioverter-defibrillator	[Patients with an cardioverter-defibrillator]	0.0	4	1	1	1
13361	361	heart failure hr	[heart failure HR]	0.0	3	1	1	1
13362	361	little influence	[little influence]	0.0	2	1	1	1
13363	361	follow-up of 2.5 year	[follow-up of 2.5 years]	0.0	4	2	2	1
13364	361	ventricular end-diastolic area index	[ventricular end-diastolic area index]	0.0	4	1	1	1
13365	361	growth factor protein	[growth factor protein]	0.0	3	1	1	1
13366	361	blood pressure via radial tonometry	[blood pressure via radial tonometry]	0.0	5	1	1	1
13367	361	change with treatment in exertional increase	[change with treatment in exertional increase]	0.0	6	1	1	1
13368	361	patient require support	[patients requiring support]	0.0	3	1	1	1
13369	361	artery systolic pressure increase	[artery systolic pressure increase]	0.0	4	1	1	1
13370	361	hospitalization for coronary syndrome	[hospitalization for coronary syndromes]	0.0	4	1	1	1
13371	361	day of follow-up	[days of follow-up]	0.0	3	1	1	1
13372	361	achievement of anaerobic metabolism	[achievement of anaerobic metabolism]	0.0	4	1	1	1
13373	361	reduction in the number from baseline	[reductions in the number from baseline]	0.0	6	1	1	1
13374	361	patient have hfpef	[patients having HFpEF]	0.0	3	1	1	1
13375	361	outcome event	[outcomes events]	0.0	2	1	1	1
13376	361	925 ed visit age 76.4 year	[925 ED visits age 76.4 years]	0.0	6	1	1	1
13377	361	angiotensin receptor blocker use	[angiotensin receptor blocker use]	0.0	4	1	1	1
13378	361	marker hazard ratio	[markers hazard ratio]	0.0	3	1	1	1
13379	361	renin-angiotensin system blocker	[renin-angiotensin system blocker]	0.0	3	1	1	1
13380	361	treatment of cancer	[treatment of cancers]	0.0	3	1	1	1
13381	361	comparison significant	[comparisons significant]	0.0	2	1	1	1
13382	361	LV ejection fraction LVEF	[LV ejection fraction LVEF]	0.0	4	1	1	1
13383	361	selective beta-blocker on cardiac activity	[selective beta-blockers on cardiac activity]	0.0	5	1	1	1
13384	361	attenuation of mitochondrial proteome change	[attenuation of mitochondrial proteome changes]	0.0	5	1	1	1
13385	361	1:1 propensity analysis	[1:1 propensity analyses]	0.0	3	1	1	1
13386	361	2 hypothese addition of dopamine	[2 hypotheses addition of dopamine]	0.0	5	1	1	1
13387	361	proangiogenic effect via activation	[proangiogenic effects via activation]	0.0	4	1	1	1
13388	361	100 old participant mean	[100 older participants mean]	0.0	4	1	1	1
13389	361	ratio at diastole	[ratio at diastole]	0.0	3	1	1	1
13390	361	transseptal catheterisation	[transseptal catheterisation]	0.0	2	1	1	1
13391	361	type 2 receptor antagonist	[type 2 receptor antagonist]	0.0	4	1	1	1
13392	361	important trigger of myocardial infarction	[important trigger of myocardial infarction]	0.0	5	1	1	1
13393	361	stimulation of muscle	[stimulation of muscles]	0.0	3	1	1	1
13394	361	Prospective pilot project	[Prospective pilot project]	0.0	3	1	1	1
13395	361	volunteers--a pilot study	[volunteers--a pilot study]	0.0	3	1	1	1
13396	361	denervation in CHF patient	[denervation in CHF patients]	0.0	4	1	1	1
13397	361	dopamine in heart failure	[dopamine in heart failure]	0.0	4	1	1	1
13398	361	hospital rate	[hospital rates]	0.0	2	1	1	1
13399	361	thus give rise	[thus giving rise]	0.0	3	1	1	1
13400	361	improvement in clinical composite response p=0.02	[improvements in clinical composite response P=0.02]	0.0	6	1	1	1
13401	361	range with advanced copd	[range with advanced COPD]	0.0	4	1	1	1
13402	361	left ventricular strain GLS	[left ventricular strain GLS]	0.0	4	1	1	1
13403	361	diuretic use	[diuretic use]	0.0	2	1	1	1
13404	361	mouse ventricular myocyte	[mouse ventricular myocytes]	0.0	3	1	1	1
13405	361	stable guideline-directed medical therapy GDMT	[stable guideline-directed medical therapy GDMT]	0.0	5	1	1	1
13406	361	insulin exposure	[insulin exposure]	0.0	2	1	1	1
13407	361	heart circulation	[heart circulation]	0.0	2	1	1	1
13408	361	cardiac activity in patient	[cardiac activity in patients]	0.0	4	1	1	1
13409	361	other clinician	[other clinicians]	0.0	2	1	1	1
13410	361	remain in extreme decile	[remaining in extreme deciles]	0.0	4	1	1	1
13411	361	clinical model	[clinical models]	0.0	2	1	1	1
13412	361	brachial systolic pressure 155	[brachial systolic pressure 155]	0.0	4	1	1	1
13413	361	0.2 millileter in peak vo2	[0.2 mL in peak VO2]	0.0	5	1	1	1
13414	361	cardioprotective effect	[cardioprotective effect]	0.0	2	1	1	1
13415	361	Modification code	[Modification codes]	0.0	2	1	1	1
13416	361	lesion in the branch	[lesions in the branches]	0.0	4	1	1	1
13417	361	change with exercise	[change with exercise]	0.0	3	1	1	1
13418	361	antitachycardia pacing	[antitachycardia pacing]	0.0	2	1	1	1
13419	361	Health Buddy	[Health Buddy]	0.0	2	3	3	1
13420	361	problem with high mortality	[problem with high mortality]	0.0	4	1	1	1
13421	361	affair HF clinic	[Affairs HF clinic]	0.0	3	1	1	1
13422	361	trigger of acute infarction	[trigger of acute infarction]	0.0	4	1	1	1
13423	361	utilize voluntary testimony with nurse	[Utilizing voluntary testimonies with nurses]	0.0	5	1	1	1
13424	361	metoprolol mg	[metoprolol mg]	0.0	2	1	1	1
13425	361	decision about cardioverter-defibrillator deactivation	[decisions about cardioverter-defibrillator deactivation]	0.0	4	1	1	1
13426	361	increase in LV pressure p	[increase in LV pressure P]	0.0	5	1	1	1
13427	361	24-hour systolic pressure 155 35	[24-hour systolic pressure 155 35]	0.0	5	1	1	1
13428	361	infarction AMI with major complication	[infarction AMI with major complications]	0.0	5	1	1	1
13429	361	concentrate on the mechanism	[concentrating on the mechanisms]	0.0	4	1	1	1
13430	361	other pre-specified subgroup analysis	[other pre-specified subgroup analyses]	0.0	4	1	1	1
13431	361	class i cpg recommendation	[class I CPG recommendations]	0.0	4	1	1	1
13432	361	component improve quality of care	[component improving quality of care]	0.0	5	1	1	1
13433	361	risk factor for disease	[risk factor for disease]	0.0	4	1	1	1
13434	361	most subject	[most subjects]	0.0	2	1	1	1
13435	361	poc system measure np level	[POC systems measuring NP levels]	0.0	5	1	1	1
13436	361	patient with hr 70 bpm	[patients with HR 70 bpm]	0.0	5	1	1	1
13437	361	Sham-Innervated	[Sham-Innervated]	0.0	1	1	1	1
13438	361	quantification	[quantification]	0.0	1	1	1	1
13439	361	proangiogenic effect	[proangiogenic effects]	0.0	2	1	1	1
13440	361	long continuity	[long-term continuity]	0.0	2	1	1	1
13441	361	describe a nomenclature for failure	[describing a nomenclature for failure]	0.0	5	1	1	1
13442	361	transplant ECCT program	[transplant ECCT programs]	0.0	3	1	1	1
13443	361	promote pause release	[promoting pause release]	0.0	3	1	1	1
13444	361	several marker indicative of balance	[several markers indicative of balance]	0.0	5	1	1	1
13445	361	ejection fraction mean difference	[ejection fraction mean difference]	0.0	4	1	1	1
13446	361	great self-reported activity	[greater self-reported activity]	0.0	3	1	1	1
13447	361	direct interaction between this receptor	[direct interaction between these receptors]	0.0	5	1	1	1
13448	361	global left systolic strain	[global left systolic strain]	0.0	4	1	1	1
13449	361	important trigger	[important trigger]	0.0	2	1	1	1
13450	361	late-activated wall	[late-activated wall]	0.0	2	1	1	1
13451	361	response in sympathetic activity	[response in sympathetic activity]	0.0	4	1	1	1
13452	361	country include the State	[countries including the States]	0.0	4	1	1	1
13453	361	single-center chart review	[single-center chart review]	0.0	3	1	1	1
13454	361	symptom cpet in patient	[symptom CPET in patients]	0.0	4	1	1	1
13455	361	conscious New Zealand White rabbit	[conscious New Zealand White rabbits]	0.0	5	1	1	1
13456	361	pluripotent stem cardiomyocyte hipsc-ct	[pluripotent stem cardiomyocytes hiPSC-CMs]	0.0	4	1	1	1
13457	361	severe ventricular dilatation	[severe ventricular dilatation]	0.0	3	1	1	1
13458	361	differential relation between CPC	[differential relations between CPCs]	0.0	4	1	1	1
13459	361	pulmonary artery pressure increase	[pulmonary artery pressure increase]	0.0	4	1	1	1
13460	361	7 day in this trial	[7 days in this trial]	0.0	5	1	1	1
13461	361	care group	[care group]	0.0	2	1	1	1
13462	361	parallel-group trial	[parallel-group trial]	0.0	2	1	1	1
13463	361	impact on quality HRQoL	[impact on quality HRQoL]	0.0	4	1	1	1
13464	361	anterior leaflet opening	[anterior leaflet opening]	0.0	3	2	2	1
13465	361	17.6 millileter 2 p=0.01	[17.6 mL 2 P=0.01]	0.0	4	1	1	1
13466	361	potential of rirnas	[potential of miRNAs]	0.0	3	1	1	1
13467	361	pro-brain peptide	[pro-brain peptide]	0.0	2	3	3	1
13468	361	ischemic cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[ischemic cardiomyopathies]	0.0	2	1	1	1
13469	361	stable guideline-directed therapy GDMT	[stable guideline-directed therapy GDMT]	0.0	4	1	1	1
13470	361	dyssynchronous canine electromechanic	[dyssynchronous canine electromechanics]	0.0	3	1	1	1
13471	361	normal albumin concentration gram	[normal albumin concentration g]	0.0	4	1	1	1
13472	361	report demonstrate development	[reports demonstrating development]	0.0	3	1	1	1
13473	361	dual inhibition	[Dual inhibition]	0.0	2	1	1	1
13474	361	chronic therapy GDMT	[chronic therapy GDMT]	0.0	3	1	1	1
13475	361	trend toward enrollment of patient	[trend toward enrollment of patients]	0.0	5	1	1	1
13476	361	trial in adult	[trials in adults]	0.0	3	1	1	1
13477	361	64.26 year	[64.26 years]	0.0	2	1	1	1
13478	361	modification of pka subunit	[modification of PKA subunits]	0.0	4	1	1	1
13479	361	hr reduction with beta-blocker therapy	[HR reduction with beta-blocker therapy]	0.0	5	1	1	1
13480	361	stimulation of phosphorylation	[stimulation of phosphorylation]	0.0	3	1	1	1
13481	361	heart failure risk stratification model	[heart failure risk stratification models]	0.0	5	1	1	1
13482	361	full advantage of the turnaround time	[full advantage of the turnaround times]	0.0	6	1	1	1
13483	361	bpm 17.5±5.5 versus millileter	[bpm 17.5±5.5 versus mL]	0.0	4	1	1	1
13484	361	kidney disease median filtration rate	[kidney disease median filtration rate]	0.0	5	1	1	1
13485	361	ras dose increase	[RAS dose increase]	0.0	3	1	1	1
13486	361	ischaemia	[ischaemia]	0.0	1	1	1	1
13487	361	gene in HF	[genes in HF]	0.0	3	1	1	1
13488	361	difference bnp in woman versus man	[difference BNP in women vs men]	0.0	6	1	1	1
13489	361	arterial coupling vascular resistance p	[arterial coupling vascular resistance P]	0.0	5	1	1	1
13490	361	endothelial growth factor VEGF	[endothelial growth factor VEGF]	0.0	4	1	1	1
13491	361	individual with chronic heart failure	[individuals with chronic heart failure]	0.0	5	1	1	1
13492	361	transmitral e-wave mitral annular velocity ratio	[transmitral E-wave mitral annular velocity ratio]	0.0	6	1	1	1
13493	361	hazard ratio in univariate analysis	[hazard ratio in univariate analyses]	0.0	5	1	1	1
13494	361	left descending lad	[left descending LAD]	0.0	3	1	1	1
13495	361	class nyha ii-iii with bnp	[class NYHA II-III with BNP]	0.0	5	1	1	1
13496	361	care poc	[care POC]	0.0	2	1	1	1
13497	361	mg·kg(-1)·day(-1)	[mg·kg(-1)·day(-1)]	0.0	1	1	1	1
13498	361	new ai	[new AI]	0.0	2	1	1	1
13499	361	regulator of cytoskeletal actin dynamic	[regulator of cytoskeletal actin dynamics]	0.0	5	1	1	1
13500	361	survival through year	[survival through years]	0.0	3	1	1	1
13501	361	emergency Department presentation	[Emergency Department presentation]	0.0	3	1	1	1
13502	361	additional model	[additional models]	0.0	2	1	1	1
13503	361	effectiveness of bisoprolol	[effectiveness of bisoprolol]	0.0	3	1	1	1
13504	361	improvement of performance at advanced stage	[improvement of performance at advanced stages]	0.0	6	1	1	1
13505	361	elastance ees	[elastance Ees]	0.0	2	1	1	1
13506	361	addition prior stroke score	[addition prior stroke score]	0.0	4	1	1	1
13507	361	successful valve plasty for regurgitation	[successful valve plasty for regurgitation]	0.0	5	1	1	1
13508	361	akt→forkhead box class	[Akt→forkhead box class]	0.0	3	1	1	1
13509	361	range muscle waste t-score	[range muscle wasting T-score]	0.0	4	1	1	1
13510	361	system proteomics of chromatin	[Systems proteomics of chromatin]	0.0	4	1	1	1
13511	361	death occur	[deaths occurring]	0.0	2	1	1	1
13512	361	mm hg SD	[mm Hg SD]	0.0	3	1	1	1
13513	361	plasma b-type natriuretic peptide	[plasma B-type natriuretic peptide]	0.0	4	1	1	1
13514	361	mandatory monitoring of lvad use	[mandatory monitoring of LVAD use]	0.0	5	1	1	1
13515	361	blood pressure via tonometry	[blood pressure via tonometry]	0.0	4	1	1	1
13516	361	play a role particularly in patient	[playing a role particularly in patients]	0.0	6	1	1	1
13517	361	relative lean mass index	[relative lean mass index]	0.0	4	1	1	1
13518	361	relationship between right function	[Relationships between right function]	0.0	4	1	1	1
13519	361	catecholamine infusion	[catecholamine infusions]	0.0	2	1	1	1
13520	361	ST2 level a Trial	[ST2 levels A Trial]	0.0	4	1	1	1
13521	361	clinical burden in adult medicine	[clinical burden in adult medicine]	0.0	5	1	1	1
13522	361	HeartMate 3 assist system	[HeartMate 3 assist system]	0.0	4	1	1	1
13523	361	exercise capacity in old patient	[exercise capacity in older patients]	0.0	5	1	1	1
13524	361	patient with coronary syndrome	[patients with coronary syndromes]	0.0	4	1	1	1
13525	361	economic evaluation use simulation model	[economic evaluations using simulation models]	0.0	5	1	1	1
13526	361	modest reduction	[modest reduction]	0.0	2	1	1	1
13527	361	abdominal constriction AAC	[abdominal constriction AAC]	0.0	3	1	1	1
13528	361	knockdown of nucleolin	[knockdown of nucleolin]	0.0	3	1	1	1
13529	361	inhibition of at1 receptor	[inhibition of AT1 receptors]	0.0	4	1	1	1
13530	361	low national income per capita	[lower national income per capita]	0.0	5	1	1	1
13531	361	modest benefit for patient	[modest benefit for patients]	0.0	4	1	1	1
13532	361	diastolic end diameter mm difference	[diastolic end diameter mm difference]	0.0	5	1	1	1
13533	361	aldosterone antagonist therapy	[aldosterone antagonist therapy]	0.0	3	1	1	1
13534	361	Functional stimulation of peripheral muscle	[Functional stimulation of peripheral muscles]	0.0	5	1	1	1
13535	361	9 subject	[9 subjects]	0.0	2	1	1	1
13536	361	post-TAC functional deterioration	[post-TAC functional deterioration]	0.0	3	1	1	1
13537	361	abnormal exercise status	[abnormal exercise status]	0.0	3	1	1	1
13538	361	information on implantable cardioverter-defibrillator deactivation	[information on implantable cardioverter-defibrillator deactivation]	0.0	5	1	1	1
13539	361	few procedure 146	[fewer procedures 146]	0.0	3	1	1	1
13540	361	rate of hyperkalemia potassium	[rates of hyperkalemia potassium]	0.0	4	1	1	1
13541	361	factor-κB nf-κb	[factor-κB NF-κB]	0.0	2	1	1	1
13542	361	left strain as a predictor	[left strain as a predictor]	0.0	5	1	1	1
13543	361	drug in the rate-control group	[drugs in the rate-control group]	0.0	5	1	1	1
13544	361	early diastolic annular velocity 3.1	[early diastolic annular velocity 3.1]	0.0	5	1	1	1
13545	361	undergo ventricular assist device lvad implantation	[undergoing ventricular assist device LVAD implantation]	0.0	6	1	1	1
13546	361	relation between preoperative dysfunction	[Relation between preoperative dysfunction]	0.0	4	1	1	1
13547	361	restriction diet	[restriction diet]	0.0	2	1	1	1
13548	361	HeartMate 3 ventricular assist system	[HeartMate 3 ventricular assist system]	0.0	5	1	1	1
13549	361	grade weak recommendation	[Grade weak recommendation]	0.0	3	1	1	1
13550	361	York heart Association functional class hr	[York Heart Association functional class HR]	0.0	6	1	1	1
13551	361	Patient Safety Monitoring System	[Patient Safety Monitoring System]	0.0	4	1	1	1
13552	361	patient have hfpef male gender	[patients having HFpEF male gender]	0.0	5	1	1	1
13553	361	systematic search	[systematic search]	0.0	2	1	1	1
13554	361	nitroxyl HNO donor	[nitroxyl HNO donor]	0.0	3	1	1	1
13555	361	patient consist	[patients consisting]	0.0	2	1	1	1
13556	361	attenuate remodeling	[attenuating remodeling]	0.0	2	1	1	1
13557	361	μmol	[μmol]	0.0	1	1	1	1
13558	361	congestion	[congestion]	0.0	1	1	1	1
13559	361	improvement in effective rate	[improvement in effective rate]	0.0	4	1	1	1
13560	361	2 rupture	[2 ruptures]	0.0	2	1	1	1
13561	361	accurate risk stratification	[accurate risk stratification]	0.0	3	1	1	1
13562	361	Exercise test CPET	[Exercise Testing CPET]	0.0	3	1	1	1
13563	361	effective arterial elastance ea elastance	[Effective arterial elastance Ea elastance]	0.0	5	1	1	1
13564	361	19 non-diabetic patient	[19 non-diabetic patients]	0.0	3	1	1	1
13565	361	echocardiographic predictor of response	[echocardiographic predictors of response]	0.0	4	1	1	1
13566	361	first hospitalization	[first hospitalization]	0.0	2	1	1	1
13567	361	evidence from trial of agent therapy	[evidence from trials of agent therapy]	0.0	6	1	1	1
13568	361	result in a sv p	[resulting in a SV p]	0.0	5	1	1	1
13569	361	hallmark of chronic heart failure	[hallmark of chronic heart failure]	0.0	5	1	1	1
13570	361	institution of PD	[institution of PD]	0.0	3	1	1	1
13571	361	patient with advanced copd	[patients with advanced COPD]	0.0	4	1	1	1
13572	361	all-cause mortality at year	[All-cause mortality at years]	0.0	4	1	1	1
13573	361	icu mortality	[ICU mortality]	0.0	2	1	1	1
13574	361	implication of choice	[Implications of choice]	0.0	3	1	1	1
13575	361	impairment at hospitalization	[impairment at hospitalization]	0.0	3	1	1	1
13576	361	b-type peptide level in patient	[B-type peptide levels in patients]	0.0	5	1	1	1
13577	361	Cardiac resonance postcontrast	[Cardiac resonance postcontrast]	0.0	3	1	1	1
13578	361	characteristic of adult with heart failure	[characteristics of adults with heart failure]	0.0	6	1	1	1
13579	361	hr CI 1.27	[HR CI 1.27]	0.0	3	1	1	1
13580	361	69 year	[69 years]	0.0	2	1	1	1
13581	361	artery bypass grafting CABG	[artery bypass grafting CABG]	0.0	4	1	1	1
13582	361	echocardiographic evidence of left dyssynchrony	[echocardiographic evidence of left dyssynchrony]	0.0	5	1	1	1
13583	361	trend toward enrollment	[trend toward enrollment]	0.0	3	1	1	1
13584	361	54 patient aged year	[54 patients aged years]	0.0	4	1	1	1
13585	361	ventricular ejection fraction lvef	[ventricular ejection fraction LVEF]	0.0	4	1	1	1
13586	361	capillary wedge pressure pcwp	[capillary wedge pressure PCWP]	0.0	4	1	1	1
13587	361	language on anemia	[language on anemia]	0.0	3	1	1	1
13588	361	quality of outcome measure	[quality of outcome measures]	0.0	4	1	1	1
13589	361	156 HF patient	[156 HF patients]	0.0	3	1	1	1
13590	361	VVD variation	[VVD variation]	0.0	2	1	1	1
13591	361	transmitral e-wave mitral velocity ratio	[transmitral E-wave mitral velocity ratio]	0.0	5	1	1	1
13592	361	rest hr 70	[resting HR 70]	0.0	3	1	1	1
13593	361	1.05 mg	[1.05 mg]	0.0	2	1	1	1
13594	361	complication in end-stage HF	[complications in end-stage HF]	0.0	4	1	1	1
13595	361	within-day test-retest reliability in patient	[Within-day test-retest reliability in patients]	0.0	5	1	1	1
13596	361	downregulation of gene	[downregulation of genes]	0.0	3	1	1	1
13597	361	Global longitudinal systolic strain	[Global longitudinal systolic strain]	0.0	4	1	1	1
13598	361	high exercise time	[higher exercise time]	0.0	3	1	1	1
13599	361	even after adjustment hazard ratio	[even after adjustment hazard ratio]	0.0	5	1	1	1
13600	361	hfpef for summary	[HFpEF for summary]	0.0	3	1	1	1
13601	361	experience of a receptor antagonist	[Experience of a receptor antagonist]	0.0	5	1	1	1
13602	361	Organisation Taxonomy	[Organisation Taxonomy]	0.0	2	1	1	1
13603	361	even with function	[even with function]	0.0	3	1	1	1
13604	361	animal model of ischemia	[animal model of ischemia]	0.0	4	1	1	1
13605	361	high dose	[higher doses]	0.0	2	1	1	1
13606	361	area change	[area change]	0.0	2	1	1	1
13607	361	level of serum factor	[levels of serum factors]	0.0	4	1	1	1
13608	361	cachexia hazard ratio	[cachexia hazard ratio]	0.0	3	1	1	1
13609	361	broad discussion	[broader discussions]	0.0	2	1	1	1
13610	361	catheterisation with transoesophageal guidance	[catheterisation with transoesophageal guidance]	0.0	4	1	1	1
13611	361	prognostic power	[prognostic power]	0.0	2	1	1	1
13612	361	man mean year	[men mean years]	0.0	3	1	1	1
13613	361	chronic renal failure	[chronic renal failure]	0.0	3	1	1	1
13614	361	tendency	[tendency]	0.0	1	1	1	1
13615	361	unidirectional interatrial shunting for treatment	[Unidirectional interatrial shunting for treatment]	0.0	5	1	1	1
13616	361	risk RR	[risk RR]	0.0	2	1	1	1
13617	361	health-care budget	[health-care budget]	0.0	2	1	1	1
13618	361	hallmark of heart failure	[hallmark of heart failure]	0.0	4	1	1	1
13619	361	special intervention	[special interventions]	0.0	2	1	1	1
13620	361	include a egfr	[including an eGFR]	0.0	3	1	1	1
13621	361	non-diastolic abnormality in function	[non-diastolic abnormalities in function]	0.0	4	1	1	1
13622	361	disappointment	[disappointments]	0.0	1	1	1	1
13623	361	patient with organ failure	[patients with organ failure]	0.0	4	1	1	1
13624	361	urine volume decongestion end point	[urine volume decongestion end point]	0.0	5	1	1	1
13625	361	blot with site-specific monoclonal antibody	[blots with site-specific monoclonal antibodies]	0.0	5	1	1	1
13626	361	such as thromboembolism	[such as thromboembolism]	0.0	3	1	1	1
13627	361	embryonic kidney 293 cell overexpress β1ar	[embryonic kidney 293 cells overexpressing β1AR]	0.0	6	1	1	1
13628	361	failure of reserve	[failure of reserve]	0.0	3	1	1	1
13629	361	update on exercise variable	[update on exercise variables]	0.0	4	1	1	1
13630	361	case with pre-hct germline DNA	[cases with pre-HCT germline DNA]	0.0	5	1	1	1
13631	361	mouse heart failure	[mouse heart failure]	0.0	3	1	1	1
13632	361	assessment within 7 day	[assessments within 7 days]	0.0	4	1	1	1
13633	361	age subject from the population	[age subjects from the population]	0.0	5	1	1	1
13634	361	value of standard error	[Values of standard error]	0.0	4	1	1	1
13635	361	open allocation ratio	[open allocation ratio]	0.0	3	1	1	1
13636	361	activity of lyso-paf-at p	[activities of lyso-PAF-AT P]	0.0	4	1	1	1
13637	361	include factor	[including factor]	0.0	2	1	1	1
13638	361	even in patient	[even in patients]	0.0	3	1	1	1
13639	361	blood glucose level	[blood glucose levels]	0.0	3	1	1	1
13640	361	predictor for the development	[predictors for the development]	0.0	4	1	1	1
13641	361	increase in risk	[increase in risk]	0.0	3	1	1	1
13642	361	neprilysin block renin-angiotensin-aldosteron ras	[neprilysin blocks renin-angiotensin-aldosteron RAS]	0.0	4	1	1	1
13643	361	vary delay	[varying delay]	0.0	2	1	1	1
13644	361	sarcopenic range muscle waste	[sarcopenic range muscle wasting]	0.0	4	1	1	1
13645	361	evidence of dysfunction impaired LV relaxation	[evidence of dysfunction impaired LV relaxation]	0.0	6	1	1	1
13646	361	usefulness of CRT in patient	[usefulness of CRT in patients]	0.0	5	1	1	1
13647	361	physician s	[physician s]	0.0	2	1	1	1
13648	361	pulmonary pressure relationship a index	[pulmonary pressure relationship an index]	0.0	5	1	1	1
13649	361	physician p	[physicians P]	0.0	2	1	1	1
13650	361	heart failure with peritoneal dialysis	[heart failure with peritoneal dialysis]	0.0	5	1	1	1
13651	361	Fontan in a population	[Fontan in an population]	0.0	4	1	1	1
13652	361	hipsc-ct	[hiPSC-CMs]	0.0	1	1	1	1
13653	361	LV diameter	[LV diameter]	0.0	2	1	1	1
13654	361	change effect	[change effect]	0.0	2	1	1	1
13655	361	require HeartMate	[requiring HeartMate]	0.0	2	1	1	1
13656	361	postmenopausal woman	[postmenopausal women]	0.0	2	1	1	1
13657	361	stage of CHF	[stage of CHF]	0.0	3	1	1	1
13658	361	gram p=0.04	[g P=0.04]	0.0	2	1	1	1
13659	361	hretn resistin	[hRetn resistin]	0.0	2	1	1	1
13660	361	detect early myocardial fibrosis	[detecting early myocardial fibrosis]	0.0	4	1	1	1
13661	361	Global ventricular systolic strain	[Global ventricular systolic strain]	0.0	4	1	1	1
13662	361	spontaneous dysfunction	[spontaneous dysfunction]	0.0	2	1	1	1
13663	361	hypertrophy in heart failure	[hypertrophy in heart failure]	0.0	4	1	1	1
13664	361	College ACP	[College ACP]	0.0	2	1	1	1
13665	361	inflammatory gene	[inflammatory genes]	0.0	2	1	1	1
13666	361	262 psoriasis ultra-violet treatment	[262 psoriasis UV treatment]	0.0	4	1	1	1
13667	361	disease include heart failure	[disease including heart failure]	0.0	4	1	1	1
13668	361	measure explain variation in mortality	[measures explaining variation in mortality]	0.0	5	1	1	1
13669	361	particularly in institution	[particularly in institutions]	0.0	3	1	1	1
13670	361	peak oxygen Consumption	[Peak Oxygen Consumption]	0.0	3	1	1	1
13671	361	mode	[modes]	0.0	1	1	1	1
13672	361	myocardial infarction AMI with complication	[myocardial infarction AMI with complications]	0.0	5	1	1	1
13673	361	event ies	[events IEs]	0.0	2	1	1	1
13674	361	R-R	[R-R]	0.0	1	1	1	1
13675	361	progressive development of hypertrophy	[progressive development of hypertrophy]	0.0	4	1	1	1
13676	361	information on cardioverter-defibrillator deactivation	[information on cardioverter-defibrillator deactivation]	0.0	4	1	1	1
13677	361	etiologic cause	[etiologic causes]	0.0	2	1	1	1
13678	361	range 22.8 with advanced copd n=95	[range 22.8 with advanced COPD n=95]	0.0	6	1	1	1
13679	361	predictor of hospitalization in patient	[predictors of hospitalization in patients]	0.0	5	1	1	1
13680	361	diastolic failure	[diastolic failure]	0.0	2	1	1	1
13681	361	prognosis of cardiomyopathy	[prognosis of cardiomyopathy]	0.0	3	1	1	1
13682	361	blood flow velocity	[blood flow velocity]	0.0	3	1	1	1
13683	361	frailty for heart failure in adult	[Frailty for heart failure in adults]	0.0	6	1	1	1
13684	361	reticular can	[reticular Ca]	0.0	2	1	1	1
13685	361	cohort of all adult	[cohort of all adults]	0.0	4	1	1	1
13686	361	susceptibility	[susceptibility]	0.0	1	1	1	1
13687	361	patient with a implantable defibrillator	[patients with an implantable defibrillator]	0.0	5	1	1	1
13688	361	rapid ventricular pacing	[rapid ventricular pacing]	0.0	3	1	1	1
13689	361	briefing report	[briefing reports]	0.0	2	1	1	1
13690	361	cutoff level of NT-proBNP	[cutoff level of NT-proBNP]	0.0	4	1	1	1
13691	361	favour	[favour]	0.0	1	1	1	1
13692	361	Outcome of Exercise Training HF-ACTION study	[Outcomes of Exercise Training HF-ACTION study]	0.0	6	1	1	1
13693	361	sensitive measure of left mechanic	[sensitive measure of left mechanics]	0.0	5	1	1	1
13694	361	year for alendronate- patient	[years for alendronate- patients]	0.0	4	1	1	1
13695	361	nris	[NRIs]	0.0	1	1	1	1
13696	361	ischemic abdominal problem	[ischemic abdominal problems]	0.0	3	1	1	1
13697	361	annulus	[annulus]	0.0	1	2	2	1
13698	361	30 year	[30 years]	0.0	2	1	1	1
13699	361	study 2900 hm	[studies 2900 HM]	0.0	3	1	1	1
13700	361	ST2 level with capacity	[ST2 levels with capacity]	0.0	4	1	1	1
13701	361	consecutive patient with ph	[consecutive patients with PH]	0.0	4	1	1	1
13702	361	cardiac tumor	[cardiac tumors]	0.0	2	1	1	1
13703	361	20 patient aged 40 year	[20 patients aged 40 years]	0.0	5	1	1	1
13704	361	exercise-induced artery pressure increase	[exercise-induced artery pressure increase]	0.0	4	1	1	1
13705	361	partial improvement	[partial improvement]	0.0	2	1	1	1
13706	361	STS HH credible interval	[STS HH credible interval]	0.0	4	1	1	1
13707	361	4 heart failure sample	[4 heart failure samples]	0.0	4	1	1	1
13708	361	surgical correction	[Surgical correction]	0.0	2	1	1	1
13709	361	target nonglycosylated epitope	[targeting nonglycosylated epitopes]	0.0	3	1	1	1
13710	361	10 NOC outcome	[10 NOC outcomes]	0.0	3	1	1	1
13711	361	College ACC	[College ACC]	0.0	2	1	1	1
13712	361	negative effect	[negative effect]	0.0	2	1	1	1
13713	361	Safety analysis	[Safety analyses]	0.0	2	1	1	1
13714	361	right RV function	[right RV function]	0.0	3	1	1	1
13715	361	no production by EC	[NO production by EC]	0.0	4	1	1	1
13716	361	good performance in patient	[good performance in patients]	0.0	4	1	1	1
13717	361	cm(2)	[cm(2)]	0.0	1	1	1	1
13718	361	mechanism of HFPEF	[mechanism of HFPEF]	0.0	3	1	1	1
13719	361	enrichment	[enrichment]	0.0	1	2	2	1
13720	361	evaluation of the surgical indication	[evaluation of the surgical indications]	0.0	5	1	1	1
13721	361	low risk develop malignancy	[lower risk developing malignancies]	0.0	4	1	1	1
13722	361	measurement at the point	[Measurement at the point]	0.0	4	1	1	1
13723	361	consent ambulatory HF patient ejection fraction	[consenting ambulatory HF patients ejection fraction]	0.0	6	1	1	1
13724	361	203 HeartMate device	[203 HeartMate devices]	0.0	3	1	1	1
13725	361	Outcome study of exercise training	[Outcomes study of exercise training]	0.0	5	1	1	1
13726	361	improvement of performance	[improvement of performance]	0.0	3	1	1	1
13727	361	124 sitagliptin user	[124 sitagliptin users]	0.0	3	1	1	1
13728	361	include agent	[including agents]	0.0	2	1	1	1
13729	361	output CO	[output CO]	0.0	2	1	1	1
13730	361	small difference bnp	[smallest difference BNP]	0.0	3	1	1	1
13731	361	group 30 millileter	[group 30 mL]	0.0	3	1	1	1
13732	361	distinct circulatory derangement	[distinct circulatory derangement]	0.0	3	1	1	1
13733	361	model of canine electromechanic	[models of canine electromechanics]	0.0	4	1	1	1
13734	361	anterior descend coronary artery occlusion	[anterior descending coronary artery occlusion]	0.0	5	1	1	1
13735	361	impact of management	[impact of management]	0.0	3	1	1	1
13736	361	first-in-man evidence for usefulness in HF	[first-in-man evidence for usefulness in HF]	0.0	6	1	1	1
13737	361	defibrillator-only therapy	[defibrillator-only therapy]	0.0	2	1	1	1
13738	361	index versus 2.8 L	[index versus 2.8 L]	0.0	4	1	1	1
13739	361	heart failure a descriptive study	[heart failure a descriptive study]	0.0	5	1	1	1
13740	361	200 minute	[200 minutes]	0.0	2	1	1	1
13741	361	receive guideline-recommended drug	[receiving guideline-recommended drugs]	0.0	3	1	1	1
13742	361	paediatric cardiac transplant	[paediatric cardiac transplants]	0.0	3	1	1	1
13743	361	consecutive patient 224 man year	[consecutive patients 224 men years]	0.0	5	1	1	1
13744	361	chordal rupture	[chordal ruptures]	0.0	2	1	1	1
13745	361	ventricular RV plane systolic excursion tapse	[ventricular RV plane systolic excursion TAPSE]	0.0	6	1	1	1
13746	361	clinical status hospitalization	[clinical status hospitalizations]	0.0	3	1	1	1
13747	361	non-AAs with York heart Association class	[non-AAs with York Heart Association class]	0.0	6	1	1	1
13748	361	practice-level variation insight	[Practice-level variation Insights]	0.0	3	1	1	1
13749	361	national trend in adverse event rate	[national trends in adverse event rates]	0.0	6	1	1	1
13750	361	detect myocardial fibrosis	[detecting myocardial fibrosis]	0.0	3	1	1	1
13751	361	trend in patient safety	[trends in patient safety]	0.0	4	1	1	1
13752	361	24 telephone support	[24 telephone support]	0.0	3	1	1	1
13753	361	chelation choice	[chelation choices]	0.0	2	2	2	1
13754	361	risk for event	[risk for events]	0.0	3	1	1	1
13755	361	brief hypothermic arrest	[brief hypothermic arrest]	0.0	3	1	1	1
13756	361	view	[view]	0.0	1	1	1	1
13757	361	change in control group p	[changes in control group P]	0.0	5	1	1	1
13758	361	grade 2	[grade 2]	0.0	2	1	1	1
13759	361	Low-dose dopamine in heart failure	[Low-dose dopamine in heart failure]	0.0	5	1	1	1
13760	361	multiple gene	[multiple genes]	0.0	2	1	1	1
13761	361	analysis of tissue	[analysis of tissue]	0.0	3	1	1	1
13762	361	reveal a mechanism	[revealing a mechanism]	0.0	3	1	1	1
13763	361	molecular scaffold in heart pathology	[molecular scaffolds in heart pathology]	0.0	5	1	1	1
13764	361	role of PDE2	[role of PDE2]	0.0	3	1	1	1
13765	361	2331 patient	[2331 patients]	0.0	2	2	2	1
13766	361	mortality in heart failure	[mortality in heart failure]	0.0	4	1	1	1
13767	361	HF in infancy	[HF in infancy]	0.0	3	1	1	1
13768	361	instability	[instability]	0.0	1	1	1	1
13769	361	chronic organ failure	[chronic organ failure]	0.0	3	1	1	1
13770	361	cation channel m7 channel mrna	[cation channel M7 channel mRNA]	0.0	5	1	1	1
13771	361	partial improvement of performance at stage	[partial improvement of performance at stages]	0.0	6	1	1	1
13772	361	enrollment of patient	[enrollment of patients]	0.0	3	1	1	1
13773	361	bisphophonate crude rr	[bisphophonates crude RR]	0.0	3	1	1	1
13774	361	significant portion	[significant portion]	0.0	2	1	1	1
13775	361	non-AAs with York heart Association	[non-AAs with York Heart Association]	0.0	5	1	1	1
13776	361	overall icu mortality	[Overall ICU mortality]	0.0	3	1	1	1
13777	361	insulin-resistance by 2 week	[insulin-resistance by 2 weeks]	0.0	4	1	1	1
13778	361	result of lesion	[result of lesions]	0.0	3	1	1	1
13779	361	care of patient	[care of patients]	0.0	3	1	1	1
13780	361	energy x-ray absorptiometry DXA	[energy X-ray absorptiometry DXA]	0.0	4	1	1	1
13781	361	use metric	[using metrics]	0.0	2	1	1	1
13782	361	treatment measure	[treatment measure]	0.0	2	1	1	1
13783	361	Large-scale prospective multicenter trial	[Large-scale prospective multicenter trial]	0.0	4	1	1	1
13784	361	impact on protective effect	[impact on protective effects]	0.0	4	1	1	1
13785	361	HeartMate ventricular assist system	[HeartMate ventricular assist system]	0.0	4	1	1	1
13786	361	millileter increase	[mL increase]	0.0	2	1	1	1
13787	361	heart failure with systolic dysfunction	[heart failure with systolic dysfunction]	0.0	5	1	1	1
13788	361	predictor of severe cad	[predictors of severe CAD]	0.0	4	1	1	1
13789	361	bone	[bone]	0.0	1	1	1	1
13790	361	two multivariate model	[Two multivariate models]	0.0	3	1	1	1
13791	361	HF patient ventricular ejection fraction	[HF patients ventricular ejection fraction]	0.0	5	1	1	1
13792	361	odd ratio p	[odds ratio P]	0.0	3	1	1	1
13793	361	trend in adverse event rate	[trends in adverse event rates]	0.0	5	1	1	1
13794	361	final diagnosis of myeloma	[final diagnosis of myeloma]	0.0	4	1	1	1
13795	361	pulmonary pressure pasp	[pulmonary pressure PASP]	0.0	3	1	1	1
13796	361	guideline definition of HFPEF	[guidelines definition of HFPEF]	0.0	4	1	1	1
13797	361	surrogate for change in co.	[surrogates for changes in CO.]	0.0	5	1	1	1
13798	361	Cox hazard	[Cox hazards]	0.0	2	1	1	1
13799	361	improvement in function	[improvement in function]	0.0	3	1	1	1
13800	361	37 patient	[37 patients]	0.0	2	1	1	1
13801	361	age subject	[age subjects]	0.0	2	1	1	1
13802	361	patient with prior disease	[patients with prior disease]	0.0	4	1	1	1
13803	361	gene-targeted Hand2 mouse	[gene-targeted Hand2 mice]	0.0	3	1	1	1
13804	361	early mitral annulus velocity	[early mitral annulus velocity]	0.0	4	1	1	1
13805	361	impact on quality of life	[impact on quality of life]	0.0	5	1	1	1
13806	361	reach significance	[reaching significance]	0.0	2	1	1	1
13807	361	adenylyl cyclase	[adenylyl cyclase]	0.0	2	1	1	1
13808	361	most common cause of death	[most common cause of death]	0.0	5	1	1	1
13809	361	patient with dyspnea	[patients with dyspnea]	0.0	3	1	1	1
13810	361	twenty-seven study with 1887	[Twenty-seven studies with 1887]	0.0	4	1	1	1
13811	361	generation	[generation]	0.0	1	1	1	1
13812	361	right area change	[right area change]	0.0	3	1	1	1
13813	361	use the surgical method	[using the surgical method]	0.0	4	1	1	1
13814	361	unique state	[unique states]	0.0	2	1	1	1
13815	361	novel pure hno donor	[novel pure HNO donor]	0.0	4	1	1	1
13816	361	heart failure sample	[heart failure samples]	0.0	3	2	2	1
13817	361	factor in patient	[factor in patients]	0.0	3	1	1	1
13818	361	event in heart failure	[events in heart failure]	0.0	4	1	1	1
13819	361	insight into the potential	[insight into the potential]	0.0	4	1	1	1
13820	361	72 study	[72 studies]	0.0	2	1	1	1
13821	361	prevalence of disease	[prevalence of disease]	0.0	3	1	1	1
13822	361	effect on various physiologic process	[effects on various physiologic processes]	0.0	5	1	1	1
13823	361	univariate analysis	[univariate analyses]	0.0	2	1	1	1
13824	361	Potent inhibition	[Potent inhibition]	0.0	2	1	1	1
13825	361	damage	[damage]	0.0	1	1	1	1
13826	361	patient with exertional shortness	[Patients With Exertional Shortness]	0.0	4	1	1	1
13827	361	multiple non-diastolic abnormality	[multiple non-diastolic abnormalities]	0.0	3	1	1	1
13828	361	week from myocardial infarction	[weeks from myocardial infarction]	0.0	4	1	1	1
13829	361	infarction heart failure patient	[infarction heart failure patients]	0.0	4	1	1	1
13830	361	stable systolic heart failure	[stable systolic heart failure]	0.0	4	1	1	1
13831	361	Global longitudinal strain as a predictor	[Global longitudinal strain as a predictor]	0.0	6	1	1	1
13832	361	two Cox hazard model	[Two Cox hazards models]	0.0	4	1	1	1
13833	361	restorative effect	[restorative effects]	0.0	2	1	1	1
13834	361	right annular plane systolic excursion tapse	[right annular plane systolic excursion TAPSE]	0.0	6	1	1	1
13835	361	Global left strain as a predictor	[Global left strain as a predictor]	0.0	6	1	1	1
13836	361	intermediate odd ratio for event p=0.18	[intermediate odds ratios for events P=0.18]	0.0	6	1	1	1
13837	361	Echocardiographic predictor after cardiac resynchronization therapy	[Echocardiographic predictors after cardiac resynchronization therapy]	0.0	6	1	1	1
13838	361	prior month	[prior months]	0.0	2	1	1	1
13839	361	lifesaving drug	[lifesaving drugs]	0.0	2	1	1	1
13840	361	150000 population in South Dakota	[150,000 population in South Dakota]	0.0	5	1	1	1
13841	361	8656 user	[8656 users]	0.0	2	1	1	1
13842	361	central blood pressure via tonometry	[central blood pressure via tonometry]	0.0	5	1	1	1
13843	361	CI 9.4	[CI 9.4]	0.0	2	1	1	1
13844	361	symptom of chronic hfpef	[symptom of chronic HFPEF]	0.0	4	1	1	1
13845	361	technique detect early fibrosis	[technique detecting early fibrosis]	0.0	4	1	1	1
13846	361	lead cause of mortality	[leading cause of mortality]	0.0	4	2	2	1
13847	361	walking distance peak	[walking distance peak]	0.0	3	1	1	1
13848	361	response in sympathetic activity (123)i-meta-iodobenzylguanidine	[response in sympathetic activity (123)I-meta-iodobenzylguanidine]	0.0	5	1	1	1
13849	361	explain variation in mortality	[explaining variation in mortality]	0.0	4	1	1	1
13850	361	kidney disease glomerular filtration rate	[kidney disease glomerular filtration rate]	0.0	5	1	1	1
13851	361	mitochondrial dysfunction in heart failure	[mitochondrial dysfunction in heart failure]	0.0	5	1	1	1
13852	361	remote monitoring rm	[Remote monitoring RM]	0.0	3	1	1	1
13853	361	novel hno donor	[novel HNO donor]	0.0	3	1	1	1
13854	361	baseline exercise capacity	[baseline exercise capacity]	0.0	3	1	1	1
13855	361	heart failure glomerular filtration rate	[heart failure glomerular filtration rate]	0.0	5	1	1	1
13856	361	human kidney 293 cell overexpress β1ar	[human kidney 293 cells overexpressing β1AR]	0.0	6	1	1	1
13857	361	single important component	[single important component]	0.0	3	1	1	1
13858	361	delay EMD	[delay EMD]	0.0	2	1	1	1
13859	361	Clinical Modification	[Clinical Modification]	0.0	2	1	1	1
13860	361	potential predictor	[potential predictors]	0.0	2	1	1	1
13861	361	symptomatic adult Fontan patient	[symptomatic adult Fontan patients]	0.0	4	1	1	1
13862	361	predict CV event in model	[predicting CV events in models]	0.0	5	1	1	1
13863	361	clinical prognostic diastolic dysfunction	[clinical prognostic diastolic dysfunction]	0.0	4	1	1	1
13864	361	decrease albumin level	[decreasing albumin levels]	0.0	3	1	1	1
13865	361	patient with qrs m	[patients with QRS ms]	0.0	4	1	1	1
13866	361	metoprolol in heart failure	[metoprolol in heart failure]	0.0	4	1	1	1
13867	361	follow-up period of year	[follow-up period of years]	0.0	4	1	1	1
13868	361	most powerful predictor of outcome	[most powerful predictor of outcome]	0.0	5	1	1	1
13869	361	24-hour brachial pressure 155 35	[24-hour brachial pressure 155 35]	0.0	5	1	1	1
13870	361	incorporate a rotor	[incorporating a rotor]	0.0	3	1	1	1
13871	361	morphological development	[morphological development]	0.0	2	1	1	1
13872	361	event rate in the UM cohort	[event rates in the UM cohorts]	0.0	6	2	2	1
13873	361	catheter ablation for atrial fibrillation	[catheter ablation for atrial fibrillation]	0.0	5	1	1	1
13874	361	patient undergo lvad implantation at institution	[patients undergoing LVAD implantation at institution]	0.0	6	1	1	1
13875	361	include monitoring device	[including monitoring devices]	0.0	3	1	1	1
13876	361	risk hr	[risk HR]	0.0	2	1	1	1
13877	361	commoner	[commoner]	0.0	1	1	1	1
13878	361	minute of exercise per week	[minutes of exercise per week]	0.0	5	1	1	1
13879	361	group iv millileter	[group IV mL]	0.0	3	1	1	1
13880	361	biventricular pacing on heart twist	[biventricular pacing on heart twist]	0.0	5	1	1	1
13881	361	patient with hfpef short-term treatment	[patients with HFpEF short-term treatment]	0.0	5	1	1	1
13882	361	One-year rate	[One-year rates]	0.0	2	1	1	1
13883	361	evaluate predictor on 257692 ICD patient	[evaluating predictors on 257,692 ICD patients]	0.0	6	1	1	1
13884	361	early-onset day after MI	[early-onset days after MI]	0.0	4	1	1	1
13885	361	update on exercise parameter	[update on exercise parameters]	0.0	4	1	1	1
13886	361	large animal model	[large animal model]	0.0	3	1	1	1
13887	361	dysfunction lead	[dysfunction leading]	0.0	2	1	1	1
13888	361	derangement with feature	[derangement with features]	0.0	3	1	1	1
13889	361	patient with obstructive disease	[patients with obstructive disease]	0.0	4	1	1	1
13890	361	cation channel m7 TRPM7	[cation channel M7 TRPM7]	0.0	4	1	1	1
13891	361	systolic pressure relationship	[systolic pressure relationship]	0.0	3	1	1	1
13892	361	pressure relationship a index	[pressure relationship an index]	0.0	4	1	1	1
13893	361	Effect of support on renal function	[Effects of support on renal function]	0.0	6	1	1	1
13894	361	ef ef≤	[EF EF≤]	0.0	2	1	1	1
13895	361	bad qol outcome	[worse QOL outcome]	0.0	3	1	1	1
13896	361	rapid right pacing	[rapid right pacing]	0.0	3	1	1	1
13897	361	300 m	[300 ms]	0.0	2	1	1	1
13898	361	myxomas in the atrium	[Myxomas in the atrium]	0.0	4	1	1	1
13899	361	wk after the procedure	[wk after the procedures]	0.0	4	1	1	1
13900	361	effect of carvedilol	[effects of carvedilol]	0.0	3	1	1	1
13901	361	powerful independent predictor period	[powerful independent predictor period]	0.0	4	1	1	1
13902	361	bundle branch block pattern	[bundle branch block pattern]	0.0	4	1	1	1
13903	361	biosynthetic enzyme lyso-paf acetyltransferase	[biosynthetic enzymes lyso-PAF acetyltransferase]	0.0	4	1	1	1
13904	361	myocardial ischemic event	[myocardial ischemic events]	0.0	3	1	1	1
13905	361	include normal sample	[including normal samples]	0.0	3	1	1	1
13906	361	arterial elastance elastance	[arterial elastance elastance]	0.0	3	1	1	1
13907	361	risk among user	[Risk Among Users]	0.0	3	1	1	1
13908	361	usefulness of resynchronization therapy	[Usefulness of resynchronization therapy]	0.0	4	1	1	1
13909	361	β2-adrenergic receptor haplotype	[β2-adrenergic receptor haplotype]	0.0	3	2	2	1
13910	361	cad involve the proximal left artery	[CAD involving the proximal left artery]	0.0	6	1	1	1
13911	361	atrial area cm 2	[atrial area cm 2]	0.0	4	1	1	1
13912	361	156 HF patient left ejection fraction	[156 HF patients left ejection fraction]	0.0	6	1	1	1
13913	361	improve uptake	[improving uptake]	0.0	2	1	1	1
13914	361	nitroxyl donor	[nitroxyl donor]	0.0	2	1	1	1
13915	361	New Zealand White rabbit	[New Zealand White rabbits]	0.0	4	1	1	1
13916	361	matrix use magnetic resonance t1 mapping	[matrix using magnetic resonance T1 mapping]	0.0	6	1	1	1
13917	361	documentation	[documentation]	0.0	1	1	1	1
13918	361	nomenclature for right failure	[nomenclature for right failure]	0.0	4	1	1	1
13919	361	nurse assessment	[nurse assessment]	0.0	2	1	1	1
13920	361	life support	[life support]	0.0	2	1	1	1
13921	361	conditional Hand2 mouse	[conditional Hand2 mice]	0.0	3	1	1	1
13922	361	beta blocker on exercise capacity	[beta blockers on exercise capacity]	0.0	5	1	1	1
13923	361	epidemiology of infarction MI	[epidemiology of infarction MI]	0.0	4	1	1	1
13924	361	process of care	[processes of care]	0.0	3	1	1	1
13925	361	group 30 millileter per 1.73 m	[group 30 mL per 1.73 m]	0.0	6	1	1	1
13926	361	≥70 year p	[≥70 years p]	0.0	3	1	1	1
13927	361	hypertension p=0.049	[hypertension P=0.049]	0.0	2	1	1	1
13928	361	CRT off	[CRT OFF]	0.0	2	1	1	1
13929	361	severe end-stage HF	[severe end-stage HF]	0.0	3	1	1	1
13930	361	responsible diagnosis	[responsible diagnosis]	0.0	2	1	1	1
13931	361	result in many HF trial	[results in many HF trials]	0.0	5	1	1	1
13932	361	treatment in adult patient	[treatment in adult patients]	0.0	4	1	1	1
13933	361	Age-dependent effect	[Age-dependent effect]	0.0	2	1	1	1
13934	361	modestly low mortality	[modestly lower mortality]	0.0	3	1	1	1
13935	361	riα	[RIα]	0.0	1	1	1	1
13936	361	non-urbanized state	[non-urbanized state]	0.0	2	1	1	1
13937	361	right tricuspid plane excursion	[right tricuspid plane excursion]	0.0	4	1	1	1
13938	361	correlation coefficient	[correlation coefficient]	0.0	2	1	1	1
13939	361	optimal management	[optimal management]	0.0	2	1	1	1
13940	361	resynchronization therapy with a defibrillator crt-d	[resynchronization therapy with a defibrillator CRT-D]	0.0	6	1	1	1
13941	361	pair of cohort	[pairs of cohorts]	0.0	3	1	1	1
13942	361	atrium mass	[atrium mass]	0.0	2	1	1	1
13943	361	care clinician	[care clinicians]	0.0	2	1	1	1
13944	361	quality indicator include mortality	[quality indicators including mortality]	0.0	4	1	1	1
13945	361	Clinical characteristic of adult	[Clinical characteristics of adults]	0.0	4	1	1	1
13946	361	LV end-diastolic pressure in week	[LV end-diastolic pressure in weeks]	0.0	5	1	1	1
13947	361	heart failure stent	[heart failure stent]	0.0	3	1	1	1
13948	361	268 record	[268 records]	0.0	2	1	1	1
13949	361	20812 patient with first infarction	[20,812 patients with first infarction]	0.0	5	1	1	1
13950	361	aas 4.32±0.54-4.31±0.49 race	[AAs 4.32±0.54-4.31±0.49 race]	0.0	3	1	1	1
13951	361	Outcome study	[Outcomes study]	0.0	2	1	1	1
13952	361	six thousand five hundred hospital	[Six thousand five hundred hospitals]	0.0	5	1	1	1
13953	361	relation between dysfunction within three month	[Relation between dysfunction within three months]	0.0	6	1	1	1
13954	361	dog with microembolization-induced HF	[dogs with microembolization-induced HF]	0.0	4	1	1	1
13955	361	follow infarction	[following infarction]	0.0	2	1	1	1
13956	361	various form	[various forms]	0.0	2	1	1	1
13957	361	lf ratio in the chf-inv	[LF ratio in the CHF-INV]	0.0	5	1	1	1
13958	361	Effect a longitudinal analysis	[Effects a longitudinal analysis]	0.0	4	1	1	1
13959	361	response role	[response role]	0.0	2	1	1	1
13960	361	improvement domain	[improvement domains]	0.0	2	1	1	1
13961	361	York heart Association class iii	[York Heart Association class III]	0.0	5	2	2	1
13962	361	improvement nt-probnp	[improvement NT-ProBNP]	0.0	2	1	1	1
13963	361	routine tool for risk stratification	[routine tool for risk stratification]	0.0	5	1	1	1
13964	361	median m	[median ms]	0.0	2	1	1	1
13965	361	canine electromechanic	[canine electromechanics]	0.0	2	1	1	1
13966	361	Eplerenone Post infarction	[Eplerenone Post infarction]	0.0	3	1	1	1
13967	361	significant change with exercise	[significant change with exercise]	0.0	4	1	1	1
13968	361	manage bleed in this population	[managing bleeding in this population]	0.0	5	1	1	1
13969	361	signalling pathway activate remodelling	[signalling pathways activating remodelling]	0.0	4	1	1	1
13970	361	peak diastolic mitral flow velocity	[peak diastolic mitral flow velocity]	0.0	5	3	3	1
13971	361	prior HF hospitalisation	[prior HF hospitalisations]	0.0	3	1	1	1
13972	361	low 50 mg equivalent dose	[low 50 mg equivalent dose]	0.0	5	1	1	1
13973	361	cause of death in athlete	[cause of death in athletes]	0.0	5	1	1	1
13974	361	remodelling of the heart	[remodelling of the heart]	0.0	4	1	1	1
13975	361	new-onset esrd from the Registry	[new-onset ESRD from the Registry]	0.0	5	1	1	1
13976	361	peak vo2 effect	[peak VO2 effect]	0.0	3	1	1	1
13977	361	Functional mitral stenosis	[Functional mitral stenosis]	0.0	3	1	1	1
13978	361	egfr millileter	[eGFR mL]	0.0	2	1	1	1
13979	361	use resonance t1 mapping	[using resonance T1 mapping]	0.0	4	1	1	1
13980	361	overall burden	[overall burden]	0.0	2	1	1	1
13981	361	body mass index kg of ethnicity	[body mass index kg of ethnicity]	0.0	6	1	1	1
13982	361	Cardiac resonance t1 time hazard ratio	[Cardiac resonance T1 time hazard ratio]	0.0	6	1	1	1
13983	361	CHM versus treatment alone	[CHM versus treatment alone]	0.0	4	1	1	1
13984	361	several marker	[several markers]	0.0	2	1	1	1
13985	361	end diameter difference	[end diameter difference]	0.0	3	1	1	1
13986	361	Clinical characteristic the charm programme Candesartan	[Clinical characteristics The CHARM programme Candesartan]	0.0	6	1	1	1
13987	361	Aerobic Exercise	[Aerobic Exercise]	0.0	2	1	1	1
13988	361	renal optimization strategy evaluation	[Renal Optimization Strategies Evaluation]	0.0	4	1	1	1
13989	361	end-point	[end-point]	0.0	1	1	1	1
13990	361	group iv millileter per 1.73 m	[group IV mL per 1.73 m]	0.0	6	1	1	1
13991	361	small-molecule inhibitor	[small-molecule inhibitors]	0.0	2	1	1	1
13992	361	156 ambulatory HF patient ejection fraction	[156 ambulatory HF patients ejection fraction]	0.0	6	1	1	1
13993	361	Kidney	[Kidney]	0.0	1	1	1	1
13994	361	4.9 year for patient respectively	[4.9 years for patients respectively]	0.0	5	1	1	1
13995	361	annulus velocity during systole	[annulus velocities during systole]	0.0	4	1	1	1
13996	361	common Procedure	[Common Procedure]	0.0	2	1	1	1
13997	361	remote monitoring a systematic review	[Remote monitoring a systematic review]	0.0	5	1	1	1
13998	361	left ventricular systolic strain GLS	[left ventricular systolic strain GLS]	0.0	5	1	1	1
13999	361	emergency catheterization	[emergency catheterization]	0.0	2	1	1	1
14000	361	(egfr)-group I ≥60 millileter	[(eGFR)-group I ≥60 mL]	0.0	4	1	1	1
14001	361	Mechanistic insight into electromechanical delay	[Mechanistic insight into electromechanical delay]	0.0	5	1	1	1
14002	361	20 patient aged year	[20 patients aged years]	0.0	4	1	1	1
14003	361	other predictor	[other predictors]	0.0	2	1	1	1
14004	361	rate of guideline-recommended treatment	[rates of guideline-recommended treatment]	0.0	4	1	1	1
14005	361	enzyme inhibitor intolerance	[enzyme inhibitors intolerance]	0.0	3	1	1	1
14006	361	use a HeartMate lvad	[using a HeartMate LVAD]	0.0	4	1	1	1
14007	361	acute right pressure overload rvpo	[acute right pressure overload RVPO]	0.0	5	1	1	1
14008	361	mm for psoriasis for reference subject	[mm for psoriasis for reference subjects]	0.0	6	1	1	1
14009	361	223 patient age	[223 patients age]	0.0	3	1	1	1
14010	361	8656 new user	[8656 new users]	0.0	3	1	1	1
14011	361	urban academic center	[urban academic center]	0.0	3	1	1	1
14012	361	severe hypertension of 191 mm hg	[severe hypertension of 191 mm Hg]	0.0	6	1	1	1
14013	361	scn5a variant with angii	[SCN5A variants with AngII]	0.0	4	1	1	1
14014	361	practice setting	[practice settings]	0.0	2	1	1	1
14015	361	year respectively p	[years respectively p]	0.0	3	1	1	1
14016	361	Study of echocardiographic predictor	[Studies of echocardiographic predictors]	0.0	4	1	1	1
14017	361	neonatal rat cardiomyocyte	[neonatal rat cardiomyocytes]	0.0	3	1	1	1
14018	361	insight in heart failure	[insight in heart failure]	0.0	4	1	1	1
14019	361	survival study	[SurvIval Study]	0.0	2	1	1	1
14020	361	nursing-sensitive outcome change	[Nursing-sensitive outcome change]	0.0	3	1	1	1
14021	361	biomarker-guided trial	[biomarker-guided trials]	0.0	2	1	1	1
14022	361	current practice	[current practice]	0.0	2	1	1	1
14023	361	mortality in society	[mortality in society]	0.0	3	2	2	1
14024	361	observation at the time of surgery	[observation at the time of surgery]	0.0	6	1	1	1
14025	361	Clinical Practice Guideline recommendation	[Clinical Practice Guideline recommendations]	0.0	4	1	1	1
14026	361	common cause in athlete	[common cause in athletes]	0.0	4	1	1	1
14027	361	dipeptidyl peptidase-4 inhibitor	[dipeptidyl peptidase-4 inhibitors]	0.0	3	1	1	1
14028	361	oxide no	[oxide NO]	0.0	2	1	1	1
14029	361	risk stratification of patient appropriate	[risk stratification of patient appropriate]	0.0	5	1	1	1
14030	361	ring annuloplasty for regurgitation mr	[ring annuloplasty for regurgitation MR]	0.0	5	1	1	1
14031	361	difference between number in any	[difference between numbers in any]	0.0	5	1	1	1
14032	361	hno donor in myocty	[HNO donor in myoctyes]	0.0	4	1	1	1
14033	361	muscle strip stiffness	[muscle strip stiffness]	0.0	3	1	1	1
14034	361	2 molecular scaffold	[2 molecular scaffolds]	0.0	3	1	1	1
14035	361	trial of walking with moderate	[trial of walking with moderate]	0.0	5	1	1	1
14036	361	9868 participant area	[9868 participants area]	0.0	3	1	1	1
14037	361	link between air pollution	[link between air pollution]	0.0	4	1	1	1
14038	361	paf of enzyme	[PAF of enzymes]	0.0	3	1	1	1
14039	361	usefulness of CRT	[usefulness of CRT]	0.0	3	1	1	1
14040	361	perhaps the single important component	[perhaps the single important component]	0.0	5	1	1	1
14041	361	treatment for myocardial infarction AMI	[treatment for myocardial infarction AMI]	0.0	5	1	1	1
14042	361	rose acute heart failure	[ROSE acute heart failure]	0.0	4	1	1	1
14043	361	medical hospitalization in HF clinic outpatient	[medical hospitalization in HF clinic outpatients]	0.0	6	2	2	1
14044	361	Postoperative survival	[Postoperative survival]	0.0	2	1	1	1
14045	361	age of the cohort	[age of the cohort]	0.0	4	1	1	1
14046	361	156 consecutive consent HF patient	[156 consecutive consenting HF patients]	0.0	5	1	1	1
14047	361	beta receptor	[beta receptor]	0.0	2	1	1	1
14048	361	cardiovascular event rate event	[cardiovascular event rate events]	0.0	4	1	1	1
14049	361	constant	[constants]	0.0	1	1	1	1
14050	361	moderate level of CRF	[moderate level of CRF]	0.0	4	1	1	1
14051	361	target for heart failure	[targets for heart failure]	0.0	4	1	1	1
14052	361	nursing terminology	[nursing terminologies]	0.0	2	1	1	1
14053	361	partial improvement by β-adrenoceptor blockade	[partial improvement by β-adrenoceptor blockade]	0.0	5	1	1	1
14054	361	Physio Ring of size	[Physio Ring of size]	0.0	4	1	1	1
14055	361	peak diastolic flow velocity	[peak diastolic flow velocity]	0.0	4	2	2	1
14056	361	cardiac arrhythmia device	[cardiac arrhythmia devices]	0.0	3	1	1	1
14057	361	even with normal function	[even with normal function]	0.0	4	1	1	1
14058	361	remarkable role	[remarkable role]	0.0	2	1	1	1
14059	361	only at dose	[only at doses]	0.0	3	1	1	1
14060	361	estimate capillary wedge pressure pcwp	[estimating capillary wedge pressure PCWP]	0.0	5	1	1	1
14061	361	individual association among fitness	[individual associations among fitness]	0.0	4	1	1	1
14062	361	early-onset 0 day	[early-onset 0 days]	0.0	3	1	1	1
14063	361	double-blind ratio	[double-blind ratio]	0.0	2	1	1	1
14064	361	right ventricular RV plane excursion tapse	[right ventricular RV plane excursion TAPSE]	0.0	6	1	1	1
14065	361	day in this trial	[days in this trial]	0.0	4	1	1	1
14066	361	efficacy end	[efficacy end]	0.0	2	1	1	1
14067	361	year in 2011	[years in 2011]	0.0	3	1	1	1
14068	361	consecutive consent ambulatory HF patient	[consecutive consenting ambulatory HF patients]	0.0	5	1	1	1
14069	361	matrix of ventricular biopsy	[matrix of ventricular biopsies]	0.0	4	1	1	1
14070	361	national income	[national income]	0.0	2	1	1	1
14071	361	denervation DNx in CHF patient	[denervation DNx in CHF patients]	0.0	5	1	1	1
14072	361	sparing	[sparing]	0.0	1	1	1	1
14073	361	nervous system modulation	[nervous system modulation]	0.0	3	1	1	1
14074	361	heart failure mouse model	[heart failure mice model]	0.0	4	1	1	1
14075	361	common cause of ras	[common cause of RAS]	0.0	4	1	1	1
14076	361	mri-based model of dyssynchronous canine electromechanic	[MRI-based models of dyssynchronous canine electromechanics]	0.0	6	1	1	1
14077	361	urinary tract	[urinary tract]	0.0	2	1	1	1
14078	361	RALES	[RALES]	0.0	1	1	1	1
14079	361	dysfunction impaired LV relaxation	[dysfunction impaired LV relaxation]	0.0	4	1	1	1
14080	361	objective institution of PD	[Objective institution of PD]	0.0	4	1	1	1
14081	361	indicator 6-mwt	[indicators 6-MWT]	0.0	2	1	1	1
14082	361	dacron patch closure	[Dacron patch closure]	0.0	3	1	1	1
14083	361	predominantly asymptomatic Fontan patient	[predominantly asymptomatic Fontan patients]	0.0	4	1	1	1
14084	361	vivo perfusion	[vivo perfusion]	0.0	2	1	1	1
14085	361	decrement of heart rate	[decrement of heart rate]	0.0	4	1	1	1
14086	361	HF remodeling aspect	[HF remodeling aspects]	0.0	3	1	1	1
14087	361	limited amount of datum	[limited amount of data]	0.0	4	1	1	1
14088	361	risk among New user	[Risk Among New Users]	0.0	4	1	1	1
14089	361	subset of hfpef	[subset of HFpEF]	0.0	3	1	1	1
14090	361	20812 patient with acute infarction	[20,812 patients with acute infarction]	0.0	5	1	1	1
14091	361	at1 receptor	[AT1 receptors]	0.0	2	1	1	1
14092	361	RV support	[RV support]	0.0	2	1	1	1
14093	361	nondiabete risk factor age	[nondiabetes risk factors age]	0.0	4	1	1	1
14094	361	echocardiographic evidence	[echocardiographic evidence]	0.0	2	1	1	1
14095	361	mortality for patient	[mortality for patients]	0.0	3	1	1	1
14096	361	trial use hr variability	[trials using HR variability]	0.0	4	1	1	1
14097	361	death in patient	[death in patients]	0.0	3	1	1	1
14098	361	analysis match for age	[analysis matching for age]	0.0	4	1	1	1
14099	361	aldactone evaluation study	[Aldactone Evaluation Study]	0.0	3	1	1	1
14100	361	even with ventricular function	[even with ventricular function]	0.0	4	1	1	1
14101	361	impaired angiogenesis in the infarction heart	[Impaired angiogenesis in the infarction heart]	0.0	6	1	1	1
14102	361	study-related serious event	[study-related serious events]	0.0	3	1	1	1
14103	361	pGE2-mediated effect	[PDE2-mediated effects]	0.0	2	1	1	1
14104	361	correlation between change in hdl-induced	[correlation between changes in HDL-induced]	0.0	5	1	1	1
14105	361	pair of virtual cohort	[pairs of virtual cohorts]	0.0	4	1	1	1
14106	361	24 per cent with five death	[24 per cent with five deaths]	0.0	6	1	1	1
14107	361	clinical follow-up	[clinical follow-up]	0.0	2	1	1	1
14108	361	HF concurrent	[HF concurrent]	0.0	2	1	1	1
14109	361	composite quality measure for condition	[Composite quality measures for conditions]	0.0	5	1	1	1
14110	361	expression of variant	[expression of variants]	0.0	3	1	1	1
14111	361	Olmsted County Minnesota	[Olmsted County Minnesota]	0.0	3	1	1	1
14112	361	alcohol	[alcohol]	0.0	1	1	1	1
14113	361	over 20 variable	[over 20 variables]	0.0	3	1	1	1
14114	361	potential contribution	[potential contribution]	0.0	2	1	1	1
14115	361	Toronto Canada	[Toronto Canada]	0.0	2	1	1	1
14116	361	knowledge of nutritional abnormality	[knowledge of nutritional abnormalities]	0.0	4	1	1	1
14117	361	low 50 mg daily dose	[low 50 mg daily dose]	0.0	5	1	1	1
14118	361	context of HF	[context of HF]	0.0	3	1	1	1
14119	361	ventricular diastolic end diameter difference	[ventricular diastolic end diameter difference]	0.0	5	1	1	1
14120	361	benefit of treatment	[benefits of treatments]	0.0	3	1	1	1
14121	361	adjust for clinical variable	[adjusting for clinical variables]	0.0	4	1	1	1
14122	361	porcine model of myocardial ischemia	[porcine model of myocardial ischemia]	0.0	5	1	1	1
14123	361	electrical stimulation of muscle	[electrical stimulation of muscles]	0.0	4	1	1	1
14124	361	peak quadricep force in all participant	[peak quadriceps force in all participants]	0.0	6	1	1	1
14125	361	coprimary	[Coprimary]	0.0	1	1	1	1
14126	361	enhance neoangiogenesis in the heart	[enhancing neoangiogenesis in the heart]	0.0	5	1	1	1
14127	361	downward regression line	[downward regression line]	0.0	3	1	1	1
14128	361	dosage	[dosage]	0.0	1	1	1	1
14129	361	follow-up of 541 day	[follow-up of 541 days]	0.0	4	1	1	1
14130	361	gene induction	[gene induction]	0.0	2	1	1	1
14131	361	diastolic mitral annulus velocity	[diastolic mitral annulus velocity]	0.0	4	1	1	1
14132	361	co2 petco2	[CO2 PETCO2]	0.0	2	1	1	1
14133	361	however without a need	[however without a need]	0.0	4	1	1	1
14134	361	non-survivor	[non-survivors]	0.0	1	1	1	1
14135	361	Bradycardia indicative	[Bradycardia indicative]	0.0	2	1	1	1
14136	361	advanced chronic disease copd	[advanced chronic disease COPD]	0.0	4	1	1	1
14137	361	result in a sv	[resulting in a SV]	0.0	4	1	1	1
14138	361	brain natriuretic peptide BNP level pg	[brain natriuretic peptide BNP levels pg]	0.0	6	1	1	1
14139	361	1.6 reason	[1.6 reasons]	0.0	2	1	1	1
14140	361	blot with monoclonal antibody	[blots with monoclonal antibodies]	0.0	4	1	1	1
14141	361	12-lead ecg in athlete	[12-lead ECG in athletes]	0.0	4	1	1	1
14142	361	cell differentiation toward cell in vitro	[cell differentiation toward cells in vitro]	0.0	6	1	1	1
14143	361	effect on urine volume	[effect on urine volume]	0.0	4	2	2	1
14144	361	64.26 year year	[64.26 years years]	0.0	3	1	1	1
14145	361	outcome in Exercise training	[Outcomes in Exercise TraiNing]	0.0	4	1	1	1
14146	361	however a disease	[however an disease]	0.0	3	1	1	1
14147	361	global strain of ventricle	[global strain of ventricle]	0.0	4	1	1	1
14148	361	flow reserve measurement	[flow reserve measurements]	0.0	3	1	1	1
14149	361	group millileter per 1.73 m 2	[group mL per 1.73 m 2]	0.0	6	1	1	1
14150	361	significant lesion in the branch	[significant lesions in the branches]	0.0	5	1	1	1
14151	361	224 man 65±12 year	[224 men 65±12 years]	0.0	4	1	1	1
14152	361	right coupling resistance p	[right coupling resistance P]	0.0	4	1	1	1
14153	361	statistically significant change effect	[statistically significant change effect]	0.0	4	1	1	1
14154	361	research question	[research questions]	0.0	2	1	1	1
14155	361	haematopoietic	[Haematopoietic]	0.0	1	1	1	1
14156	361	17 day range day	[17 days range days]	0.0	4	1	1	1
14157	361	reversible ischemia stent	[reversible ischemia stent]	0.0	3	1	1	1
14158	361	relevance in pulmonary hypertension patient	[relevance in pulmonary hypertension patients]	0.0	5	1	1	1
14159	361	ed visit age 76.4 year	[ED visits age 76.4 years]	0.0	5	1	1	1
14160	361	worsen of disease	[worsening of disease]	0.0	3	1	1	1
14161	361	significant amelioration	[significant amelioration]	0.0	2	1	1	1
14162	361	modestly low mortality with HF	[modestly lower mortality with HF]	0.0	5	1	1	1
14163	361	overexpress β1ar	[overexpressing β1AR]	0.0	2	1	1	1
14164	361	use experimental procedure	[using experimental procedures]	0.0	3	1	1	1
14165	361	interview with primary care clinician	[interviews with primary care clinicians]	0.0	5	1	1	1
14166	361	human ventricular LV myocyte	[human ventricular LV myocytes]	0.0	4	1	1	1
14167	361	DD of collagen deposition	[DD of collagen deposition]	0.0	4	1	1	1
14168	361	debilitating disease	[debilitating disease]	0.0	2	1	1	1
14169	361	transform growth factor-β signal level	[transforming growth factor-β signaling level]	0.0	5	1	1	1
14170	361	272 patient	[272 patients]	0.0	2	1	1	1
14171	361	proximal LCX	[proximal LCX]	0.0	2	1	1	1
14172	361	volume status	[volume status]	0.0	2	1	1	1
14173	361	minimal change value	[minimal change values]	0.0	3	1	1	1
14174	361	adaptive response	[adaptive response]	0.0	2	1	1	1
14175	361	ecg parameter	[ECG parameters]	0.0	2	1	1	1
14176	361	HeartMate ii lvas	[HeartMate II LVADs]	0.0	3	1	1	1
14177	361	subclinical atherosclerosis use general model	[subclinical atherosclerosis using general models]	0.0	5	1	1	1
14178	361	behavioural-change	[behavioural-change]	0.0	1	1	1	1
14179	361	flow-mediated dilatation improvement	[flow-mediated dilatation improvement]	0.0	3	1	1	1
14180	361	benefit over parameter	[benefit over parameters]	0.0	3	1	1	1
14181	361	left descend artery	[left descending artery]	0.0	3	1	1	1
14182	361	Effect of mechanical support	[Effects of mechanical support]	0.0	4	1	1	1
14183	361	precapillary hypertension	[precapillary hypertension]	0.0	2	1	1	1
14184	361	direct renin inhibitor	[direct renin inhibitors]	0.0	3	1	1	1
14185	361	type ii	[type II]	0.0	2	1	1	1
14186	361	cardiac na current during HF	[cardiac Na current during HF]	0.0	5	1	1	1
14187	361	device in heart failure	[devices in heart failure]	0.0	4	1	1	1
14188	361	chronic failure CRF	[chronic failure CRF]	0.0	3	1	1	1
14189	361	multicenter trial of 360 patient	[Multicenter trial of 360 patients]	0.0	5	1	1	1
14190	361	mitral valve area	[mitral valve area]	0.0	3	1	1	1
14191	361	≥2 nondiabete risk factor	[≥2 nondiabetes risk factors]	0.0	4	1	1	1
14192	361	systemic event evaluation	[systemic events evaluation]	0.0	3	1	1	1
14193	361	hemoglobin with hrqol change	[hemoglobin with HRQoL changes]	0.0	4	1	1	1
14194	361	insulin receptor substrate 1	[insulin receptor substrates 1]	0.0	4	1	1	1
14195	361	left anterior	[left anterior]	0.0	2	1	1	1
14196	361	level of Mena	[levels of Mena]	0.0	3	1	1	1
14197	361	perturbation in component	[perturbations in components]	0.0	3	1	1	1
14198	361	neprilysin inhibitor	[neprilysin inhibitors]	0.0	2	1	1	1
14199	361	2-vessel cad	[2-vessel CAD]	0.0	2	1	1	1
14200	361	measurement of CPC	[measurements of CPCs]	0.0	3	1	1	1
14201	361	descend artery occlusion	[descending artery occlusion]	0.0	3	1	1	1
14202	361	nonsignificant trend	[nonsignificant trend]	0.0	2	1	1	1
14203	361	amount of recent datum	[amount of recent data]	0.0	4	1	1	1
14204	361	use Cox hazard model	[using Cox hazards models]	0.0	4	1	1	1
14205	361	acute β-adrenoceptor blockade	[acute β-adrenoceptor blockade]	0.0	3	1	1	1
14206	361	Pediatric heart failure	[Pediatric heart failure]	0.0	3	1	1	1
14207	361	20 patient	[20 patients]	0.0	2	1	1	1
14208	361	insight a Trial investigate outcome	[Insights A Trial Investigating Outcomes]	0.0	5	1	1	1
14209	361	reliable diagnostic biomarker in patient	[reliable diagnostic biomarkers in patients]	0.0	5	1	1	1
14210	361	role in pathophysiology	[role in pathophysiology]	0.0	3	1	1	1
14211	361	beta-blocker dose	[Beta-blocker dose]	0.0	2	1	1	1
14212	361	Postoperative survival 3.5 gram	[Postoperative survival 3.5 g]	0.0	4	1	1	1
14213	361	bromodomain-containing	[bromodomain-containing]	0.0	1	1	1	1
14214	361	association between support	[association between support]	0.0	3	1	1	1
14215	361	function among patient with exertional shortness	[Function Among Patients With Exertional Shortness]	0.0	6	1	1	1
14216	361	site specific riiα	[site specific RIIα]	0.0	3	1	1	1
14217	361	statistical standard in biomarker study	[statistical standards in biomarker studies]	0.0	5	1	1	1
14218	361	accounting for the cost	[accounting for the cost]	0.0	4	1	1	1
14219	361	time of HF	[time of HF]	0.0	3	1	1	1
14220	361	result in a ms	[resulting in a MS]	0.0	4	1	1	1
14221	361	Preventable readmission	[Preventable Readmission]	0.0	2	1	1	1
14222	361	microrna in heart failure	[MicroRNAs in heart failure]	0.0	4	1	1	1
14223	361	remote conditioning for patient	[Remote conditioning for patients]	0.0	4	1	1	1
14224	361	internal consistency among patient with hfpef	[internal consistency among patients with HFpEF]	0.0	6	1	1	1
14225	361	International heart Foundation work Group	[International Heart Foundation Working Group]	0.0	5	1	1	1
14226	361	saxagliptin versus sitagliptin	[saxagliptin versus sitagliptin]	0.0	3	1	1	1
14227	361	pulmonary arterial pressure relationship a index	[pulmonary arterial pressure relationship an index]	0.0	6	1	1	1
14228	361	diastolic dysfunction in patient	[diastolic dysfunction in patients]	0.0	4	1	1	1
14229	361	socioeconomic status versus white	[socioeconomic status versus whites]	0.0	4	1	1	1
14230	361	production by EC	[production by EC]	0.0	3	1	1	1
14231	361	differential response in sympathetic activity	[differential response in sympathetic activity]	0.0	5	1	1	1
14232	361	key role molecular scaffold	[Key role molecular scaffolds]	0.0	4	1	1	1
14233	361	pulseless fibrillation pvf	[pulseless fibrillation PVF]	0.0	3	1	1	1
14234	361	nonstandardized pro-b-type peptide nt-probnp	[nonstandardized pro-B-type peptide NT-proBNP]	0.0	4	1	1	1
14235	361	problem of cardiology	[problem of cardiology]	0.0	3	1	1	1
14236	361	eligible patient with a follow-up	[eligible patients with a follow-up]	0.0	5	1	1	1
14237	361	systolic ejection fraction HF	[systolic ejection fraction HF]	0.0	4	1	1	1
14238	361	low activity of lyso-paf-at p	[lower activities of lyso-PAF-AT P]	0.0	5	1	1	1
14239	361	congestive heart failure with dialysis	[congestive heart failure with dialysis]	0.0	5	1	1	1
14240	361	great weight loss	[greater weight loss]	0.0	3	1	1	1
14241	361	receive angiotensin-converting enzyme inhibitor	[receiving angiotensin-converting enzyme inhibitors]	0.0	4	1	1	1
14242	361	aggressive treatment	[aggressive treatment]	0.0	2	3	3	1
14243	361	1.02±0.18 mm	[1.02±0.18 mm]	0.0	2	1	1	1
14244	361	reduce the risk of event	[reducing the risk of events]	0.0	5	1	1	1
14245	361	sensitive measure of ventricular mechanic	[sensitive measure of ventricular mechanics]	0.0	5	1	1	1
14246	361	atrial peptide b-type natriuretic peptide	[atrial peptide B-type natriuretic peptide]	0.0	5	1	1	1
14247	361	elastance elastance	[elastance elastance]	0.0	2	1	1	1
14248	361	functional characterization	[functional characterization]	0.0	2	1	1	1
14249	361	heart failure patient from Italy	[heart failure patients from Italy]	0.0	5	1	1	1
14250	361	holosystolic	[holosystolic]	0.0	1	1	1	1
14251	361	total of 44 man	[total of 44 men]	0.0	4	1	1	1
14252	361	chronic heart failure with dysfunction	[chronic heart failure with dysfunction]	0.0	5	1	1	1
14253	361	participant aged	[participants aged]	0.0	2	1	1	1
14254	361	resonance angiography	[resonance angiography]	0.0	2	1	1	1
14255	361	strategy with effect in the treatment	[strategies with effects in the treatment]	0.0	6	1	1	1
14256	361	cardiac support on renal function	[cardiac support on renal function]	0.0	5	1	1	1
14257	361	common characteristic eg	[common characteristics eg]	0.0	3	1	1	1
14258	361	increase in lung weight	[increase in lung weight]	0.0	4	1	1	1
14259	361	consecutive patient man year	[consecutive patients men years]	0.0	4	1	1	1
14260	361	increase in tone	[increase in tone]	0.0	3	1	1	1
14261	361	812 consecutive patient aged year	[812 consecutive patients aged years]	0.0	5	1	1	1
14262	361	pharmacological treatment of acute heart failure	[Pharmacological treatment of acute heart failure]	0.0	6	1	1	1
14263	361	Ser96	[Ser96]	0.0	1	1	1	1
14264	361	three variant	[three variants]	0.0	2	1	1	1
14265	361	Diagnostic role in artery disease	[Diagnostic role in artery disease]	0.0	5	1	1	1
14266	361	decrease in heart mortality period	[decreases in heart mortality period]	0.0	5	1	1	1
14267	361	underlying characteristic eg use Cochrane Practice	[underlying characteristics eg using Cochrane Practice]	0.0	6	1	1	1
14268	361	primary care clinician	[primary care clinicians]	0.0	3	1	1	1
14269	361	contribute insignificantly	[contributing insignificantly]	0.0	2	1	1	1
14270	361	model alone	[models alone]	0.0	2	1	1	1
14271	361	hospitalization in heart failure with dialysis	[hospitalizations in heart failure with dialysis]	0.0	6	1	1	1
14272	361	N-terminal proBNP proanp MR-proANP	[N-terminal proBNP proANP MR-proANP]	0.0	4	1	1	1
14273	361	pb characteristic period	[PB characteristics period]	0.0	3	1	1	1
14274	361	adjustment for baseline characteristic	[adjustment for baseline characteristics]	0.0	4	1	1	1
14275	361	erythropoiesis-stimulating agent in patient	[erythropoiesis-stimulating agents in patients]	0.0	4	1	1	1
14276	361	global change	[global changes]	0.0	2	1	1	1
14277	361	heart dilatation after aortic constriction tac	[heart dilatation after aortic constriction TAC]	0.0	6	1	1	1
14278	361	favorable change	[favorable changes]	0.0	2	1	1	1
14279	361	early-onset day	[early-onset days]	0.0	2	1	1	1
14280	361	role of ERK1 2 molecular scaffold	[role of ERK1 2 molecular scaffolds]	0.0	6	1	1	1
14281	361	66.6 year	[66.6 years]	0.0	2	1	1	1
14282	361	Black race	[Black race]	0.0	2	1	1	1
14283	361	analysis of microarray datum	[analysis of microarray data]	0.0	4	1	1	1
14284	361	form of peripheral arterial disease	[form of peripheral arterial disease]	0.0	5	1	1	1
14285	361	multivariate Cox hazard	[multivariate Cox hazards]	0.0	3	1	1	1
14286	361	adult patient undergo heart transplant	[adult patients undergoing heart transplant]	0.0	5	1	1	1
14287	361	LV ejection fraction of 0.70	[LV ejection fraction of 0.70]	0.0	5	1	1	1
14288	361	separate scale dimension	[separate scale dimensions]	0.0	3	1	1	1
14289	361	other aspect contribute	[other aspects contributing]	0.0	3	1	1	1
14290	361	health outcome in elderly patient	[health outcomes in elderly patients]	0.0	5	1	1	1
14291	361	diagnostic performance in patient	[diagnostic performance in patients]	0.0	4	1	1	1
14292	361	risk mmol	[risk mmol]	0.0	2	1	1	1
14293	361	intracellular antiadrenergic strategy in HF	[intracellular antiadrenergic strategy in HF]	0.0	5	1	1	1
14294	361	level of support	[levels of support]	0.0	3	1	1	1
14295	361	circulate progenitor cell	[circulating progenitor cells]	0.0	3	1	1	1
14296	361	non-survivor 64.26 year	[non-survivors 64.26 years]	0.0	3	1	1	1
14297	361	difference median bnp in woman EF	[difference median BNP in women EF]	0.0	6	1	1	1
14298	361	soluble concentration	[Soluble concentrations]	0.0	2	1	1	1
14299	361	persistent af patient	[persistent AF patients]	0.0	3	1	1	1
14300	361	evaluate predictor	[evaluating predictors]	0.0	2	1	1	1
14301	361	treatment in adult	[treatments in adults]	0.0	3	1	1	1
14302	361	ventricle in heart failure	[ventricle in heart failure]	0.0	4	1	1	1
14303	361	growth in the setting	[growth in the setting]	0.0	4	1	1	1
14304	361	component of the outcome	[component of the outcome]	0.0	4	1	1	1
14305	361	category	[categories]	0.0	1	2	2	1
14306	361	fashion alteration in marker	[fashion alterations in markers]	0.0	4	1	1	1
14307	361	Subgroup analysis	[Subgroup analysis]	0.0	2	1	1	1
14308	361	experience of a vasopressin receptor antagonist	[Experience of a vasopressin receptor antagonist]	0.0	6	1	1	1
14309	361	use rat cardiomyocyte	[Using rat cardiomyocytes]	0.0	3	1	1	1
14310	361	half	[Half]	0.0	1	2	2	1
14311	361	function in HFpEF	[function in HFpEF]	0.0	3	1	1	1
14312	361	automatic defibrillator implantation Cardiac resynchronization therapy	[Automatic Defibrillator Implantation Cardiac Resynchronization Therapy]	0.0	6	1	1	1
14313	361	rat risk model	[rat risk model]	0.0	3	1	1	1
14314	361	10 transplant patient	[10 transplant patients]	0.0	3	1	1	1
14315	361	tissue from mouse	[tissue from mice]	0.0	3	1	1	1
14316	361	compare b-treated with fail heart	[comparing B-treated with failing hearts]	0.0	5	1	1	1
14317	361	hall	[hall]	0.0	1	1	1	1
14318	361	272 patient undergo lvad implantation	[272 patients undergoing LVAD implantation]	0.0	5	1	1	1
14319	361	2 hypothese addition μg	[2 hypotheses addition μg]	0.0	4	1	1	1
14320	361	66.6 year versus year	[66.6 years versus years]	0.0	4	1	1	1
14321	361	surgical method of aortic constriction	[surgical method of aortic constriction]	0.0	5	1	1	1
14322	361	right ventricular RV failure	[Right ventricular RV failure]	0.0	4	1	1	1
14323	361	arrhythmia event	[arrhythmia events]	0.0	2	1	1	1
14324	361	difference bnp in woman	[difference BNP in women]	0.0	4	1	1	1
14325	361	post-transplant mortality	[post-transplant mortality]	0.0	2	1	1	1
14326	361	Echocardiographic predictor of remodeling	[Echocardiographic predictors of remodeling]	0.0	4	1	1	1
14327	361	surgery consensus report	[Surgery Consensus Report]	0.0	3	1	1	1
14328	361	outcome measure in experimental research	[outcome measures in experimental research]	0.0	5	1	1	1
14329	361	use Cochrane Practice	[using Cochrane Practice]	0.0	3	1	1	1
14330	361	race in patient	[race in patients]	0.0	3	1	1	1
14331	361	global attenuation of alteration	[global attenuation of alterations]	0.0	4	1	1	1
14332	361	cardiac energy metabolism gene expression	[cardiac energy metabolism gene expression]	0.0	5	1	1	1
14333	361	abnormal can handling in HF	[abnormal Ca handling in HF]	0.0	5	1	1	1
14334	361	progression in rat	[progression in rats]	0.0	3	1	1	1
14335	361	concomitant downregulation	[concomitant downregulation]	0.0	2	1	1	1
14336	361	therapeutic treatment target exercise status	[therapeutic treatments targeting exercise status]	0.0	5	1	1	1
14337	361	use simulation model	[using simulation models]	0.0	3	1	1	1
14338	361	experience under the indication	[Experience under the indication]	0.0	4	1	1	1
14339	361	history of successful valve plasty	[history of successful valve plasty]	0.0	5	1	1	1
14340	361	qrs 160 m	[QRS 160 ms]	0.0	3	1	1	1
14341	361	cad involve the anterior descend artery	[CAD involving the anterior descending artery]	0.0	6	1	1	1
14342	361	2 independent hypothese	[2 independent hypotheses]	0.0	3	1	1	1
14343	361	one centre	[one centre]	0.0	2	1	1	1
14344	361	myocardial event in patient	[myocardial events in patients]	0.0	4	1	1	1
14345	361	recently for patient	[recently for patients]	0.0	3	1	1	1
14346	361	membrane oxygenation ecmo on renal function	[membrane oxygenation ECMO on renal function]	0.0	6	1	1	1
14347	361	prospective multicenter study	[prospective multicenter study]	0.0	3	1	1	1
14348	361	log-rank	[log-rank]	0.0	1	1	1	1
14349	361	HF clinic outpatient	[HF clinic outpatients]	0.0	3	2	2	1
14350	361	70 versus ≥70 bpm	[70 versus ≥70 bpm]	0.0	4	1	1	1
14351	361	effect of type HeartMate	[effects of types HeartMate]	0.0	4	1	1	1
14352	361	two hundred ninety-three HF patient	[Two hundred ninety-three HF patients]	0.0	5	1	1	1
14353	361	minute m vs. m	[min m vs. m]	0.0	4	1	1	1
14354	361	multivariate assessment	[multivariate assessment]	0.0	2	1	1	1
14355	361	RIα	[RIα]	0.0	1	1	1	1
14356	361	Beneficial effect	[Beneficial effect]	0.0	2	1	1	1
14357	361	decrease period versus 1	[decreases period versus 1]	0.0	4	1	1	1
14358	361	Center	[Center]	0.0	1	1	1	1
14359	361	day of inclusion	[days of inclusion]	0.0	3	1	1	1
14360	361	cardioverter-defibrillator deactivation discussion	[cardioverter-defibrillator deactivation discussions]	0.0	3	4	4	1
14361	361	infarction in Australia	[infarction in Australia]	0.0	3	1	1	1
14362	361	human-to-machine interface	[human-to-machine interface]	0.0	2	1	1	1
14363	361	ros effect	[ROS effects]	0.0	2	1	1	1
14364	361	end diameter mean difference	[end diameter mean difference]	0.0	4	1	1	1
14365	361	right ventricular tricuspid plane systolic excursion	[right ventricular tricuspid plane systolic excursion]	0.0	6	1	1	1
14366	361	Biventricular pacing	[Biventricular pacing]	0.0	2	1	1	1
14367	361	plane excursion from the end	[plane excursion from the end]	0.0	5	1	1	1
14368	361	Rem	[Rem]	0.0	1	1	1	1
14369	361	year versus year	[years versus years]	0.0	3	1	1	1
14370	361	heart failure patient with tachycardia	[heart failure patients with tachycardia]	0.0	5	1	1	1
14371	361	mass removal	[mass removal]	0.0	2	1	1	1
14372	361	statistically significant change with exercise	[statistically significant change with exercise]	0.0	5	1	1	1
14373	361	heavy chain	[heavy chain]	0.0	2	1	1	1
14374	361	ventricular ejection time complicate pulmonary hypertension	[ventricular ejection time complicating pulmonary hypertension]	0.0	6	1	1	1
14375	361	right ventricular-pulmonary arterial coupling	[right ventricular-pulmonary arterial coupling]	0.0	4	1	1	1
14376	361	chronic pulmonary hypertension pah	[chronic pulmonary hypertension PAH]	0.0	4	1	1	1
14377	361	lipoprotein property	[lipoprotein properties]	0.0	2	1	1	1
14378	361	cell differentiation toward cardiomyocyte-like cell	[cell differentiation toward cardiomyocyte-like cells]	0.0	5	1	1	1
14379	361	powerful prognostic composite HF index	[powerful prognostic composite HF index]	0.0	5	1	1	1
14380	361	LV myocyte with volume overload	[LV myocytes with volume overload]	0.0	5	1	1	1
14381	361	low activity of lyso-paf-at	[lower activities of lyso-PAF-AT]	0.0	4	1	1	1
14382	361	reveal a fundamental mechanism	[revealing a fundamental mechanism]	0.0	4	1	1	1
14383	361	inhibitory action	[inhibitory actions]	0.0	2	1	1	1
14384	361	economic model	[economic models]	0.0	2	1	1	1
14385	361	evidence on association	[evidence on associations]	0.0	3	1	1	1
14386	361	CV event in model p	[CV events in models p]	0.0	5	1	1	1
14387	361	severe impairment	[severe impairment]	0.0	2	1	1	1
14388	361	sitagliptin versus sulfonylurea for sitagliptin	[sitagliptin versus sulfonylureas for sitagliptin]	0.0	5	1	1	1
14389	361	patient with hr 70	[patients with HR 70]	0.0	4	1	1	1
14390	361	severe dilatation during the year	[severe dilatation during the years]	0.0	5	1	1	1
14391	361	simple tool	[simple tool]	0.0	2	1	1	1
14392	361	current Cardiovascular Outcome	[current Cardiovascular Outcomes]	0.0	3	1	1	1
14393	361	measure hospital change	[measuring hospital change]	0.0	3	1	1	1
14394	361	resonance imaging on chelation choice	[resonance imaging on chelation choices]	0.0	5	1	1	1
14395	361	cardiac insulin-resistance by week post-aac	[cardiac insulin-resistance by weeks post-AAC]	0.0	5	1	1	1
14396	361	longitudinal outcome-monitoring phase	[longitudinal outcome-monitoring phase]	0.0	3	1	1	1
14397	361	animal model of chronic ischemia	[animal model of chronic ischemia]	0.0	5	1	1	1
14398	361	Impact on implantable cardioverter-defibrillator therapy	[Impact on implantable cardioverter-defibrillator therapy]	0.0	5	1	1	1
14399	361	major predictor	[major predictor]	0.0	2	1	1	1
14400	361	low skeletal muscle mass	[Low skeletal muscle mass]	0.0	4	1	1	1
14401	361	individual with cardiomyopathy	[individuals with cardiomyopathy]	0.0	3	1	1	1
14402	361	incidence of HF	[incidence of HF]	0.0	3	1	1	1
14403	361	study of exercise training in HF	[study of exercise training in HF]	0.0	6	1	1	1
14404	361	adverse consequence	[adverse consequences]	0.0	2	1	1	1
14405	361	projection	[Projections]	0.0	1	1	1	1
14406	361	HFrEF versus HFpEF	[HFrEF versus HFpEF]	0.0	3	1	1	1
14407	361	predominantly asymptomatic Fontan PF patient	[predominantly asymptomatic Fontan PF patients]	0.0	5	1	1	1
14408	361	24-hour brachial systolic pressure 155	[24-hour brachial systolic pressure 155]	0.0	5	1	1	1
14409	361	prescribe medication with heart failure	[prescribing medications with heart failure]	0.0	5	1	1	1
14410	361	useful technique detect early fibrosis	[useful technique detecting early fibrosis]	0.0	5	1	1	1
14411	361	ongoing gdmt for 6 month	[ongoing GDMT for 6 months]	0.0	5	1	1	1
14412	361	consent ambulatory HF patient	[consenting ambulatory HF patients]	0.0	4	1	1	1
14413	361	clinical study approximately 2900 hm	[clinical studies approximately 2900 HM]	0.0	5	1	1	1
14414	361	patient with a left ejection fraction	[patients with a left ejection fraction]	0.0	6	1	1	1
14415	361	LV contractility lvef	[LV contractility LVEF]	0.0	3	1	1	1
14416	361	heart failure filtration rate	[heart failure filtration rate]	0.0	4	1	1	1
14417	361	metabolic gene expression	[metabolic gene expression]	0.0	3	1	1	1
14418	361	sandwich alphalisa® immunoassay	[sandwich AlphaLISA® immunoassays]	0.0	3	1	1	1
14419	361	Cardiovascular Disease Registry	[Cardiovascular Disease Registry]	0.0	3	1	1	1
14420	361	patient with onset af	[patients with onset AF]	0.0	4	1	1	1
14421	361	number of cell	[numbers of cells]	0.0	3	1	1	1
14422	361	hf-related cachexia	[HF-related cachexia]	0.0	2	1	1	1
14423	361	Medical outcome study	[Medical Outcomes Study]	0.0	3	1	1	1
14424	361	af type other than af	[AF type other than AF]	0.0	5	1	1	1
14425	361	prospective multicenter trial	[prospective multicenter trial]	0.0	3	1	1	1
14426	361	ventricular-pulmonary coupling	[ventricular-pulmonary coupling]	0.0	2	1	1	1
14427	361	10 HF patient without spontaneous VT	[10 HF patients without spontaneous VT]	0.0	6	1	1	1
14428	361	Effect of cardiac support	[Effects of cardiac support]	0.0	4	1	1	1
14429	361	rate relative risk	[rate relative risk]	0.0	3	1	1	1
14430	361	minute of moderate-intensity exercise	[minutes of moderate-intensity exercise]	0.0	4	1	1	1
14431	361	morphology	[morphology]	0.0	1	1	1	1
14432	361	use the Grading Assessment methodology	[using the Grading Assessment methodology]	0.0	5	1	1	1
14433	361	valve tethering	[valve tethering]	0.0	2	2	2	1
14434	361	self-identified patient	[self-identified patients]	0.0	2	1	1	1
14435	361	single diagnostic test	[single diagnostic test]	0.0	3	1	1	1
14436	361	particularly reduce all-cause mortality	[particularly reducing all-cause mortality]	0.0	4	1	1	1
14437	361	mandatory systematic monitoring	[mandatory systematic monitoring]	0.0	3	1	1	1
14438	361	significant decrease in LV shortening	[significant decreases in LV shortening]	0.0	5	1	1	1
14439	361	spontaneous tachycardia	[spontaneous tachycardia]	0.0	2	1	1	1
14440	361	prognostic assessment in hypertension patient	[prognostic assessment in hypertension patients]	0.0	5	1	1	1
14441	361	patient with left ejection fraction HF	[patients with left ejection fraction HF]	0.0	6	1	1	1
14442	361	use practice guideline grading system	[using practice guidelines grading system]	0.0	5	1	1	1
14443	361	ef≥50	[EF≥50]	0.0	1	1	1	1
14444	361	drs decile	[DRS deciles]	0.0	2	1	1	1
14445	361	implantable cardioverter-defibrillator shock	[implantable cardioverter-defibrillator shocks]	0.0	3	1	1	1
14446	361	Nursing Outcome Classification	[Nursing Outcomes Classification]	0.0	3	1	1	1
14447	361	eraser histone deacetylase	[erasers histone deacetylases]	0.0	3	1	1	1
14448	361	prospective experimental research	[prospective experimental research]	0.0	3	1	1	1
14449	361	low ejection fraction	[low ejection fraction]	0.0	3	1	1	1
14450	361	survivor of cell transplantation	[survivors of cell transplantation]	0.0	4	1	1	1
14451	361	renal chloride	[renal chloride]	0.0	2	1	1	1
14452	361	ST2 level	[ST2 levels]	0.0	2	1	1	1
14453	361	5 patient as control	[5 patients as control]	0.0	4	1	1	1
14454	361	MEDLINE database trial registry	[MEDLINE databases trial registries]	0.0	4	1	1	1
14455	361	assessment in pulmonary hypertension patient	[assessment in pulmonary hypertension patients]	0.0	5	1	1	1
14456	361	evidence-based therapy	[evidence-based therapies]	0.0	2	1	1	1
14457	361	temporary right support	[temporary right support]	0.0	3	1	1	1
14458	361	consequence of heart rate variation	[consequence of heart rate variation]	0.0	5	1	1	1
14459	361	mg dose	[mg dose]	0.0	2	1	1	1
14460	361	downregulation of cardiac gene	[downregulation of cardiac genes]	0.0	4	1	1	1
14461	361	biomarker HF	[biomarker HF]	0.0	2	1	1	1
14462	361	right support	[right support]	0.0	2	1	1	1
14463	361	select end point	[selecting end points]	0.0	3	1	1	1
14464	361	porcine model of ischemia	[porcine model of ischemia]	0.0	4	1	1	1
14465	361	reflect R-R interval oscillation	[reflecting R-R interval oscillations]	0.0	4	1	1	1
14466	361	p .001 decrease	[P .001 decrease]	0.0	3	1	1	1
14467	361	patient factor	[patient factors]	0.0	2	1	1	1
14468	361	outcome related	[outcomes related]	0.0	2	1	1	1
14469	361	s1pr1 agonist	[S1PR1 agonist]	0.0	2	1	1	1
14470	361	fifty patient with onset HFrEF day	[Fifty patients with onset HFrEF days]	0.0	6	1	1	1
14471	361	predict CV event in model p	[predicting CV events in models p]	0.0	6	1	1	1
14472	361	Buddy	[Buddy]	0.0	1	1	1	1
14473	361	modern rhythm control therapy	[modern rhythm control therapy]	0.0	4	1	1	1
14474	361	term of medication	[terms of medication]	0.0	3	1	1	1
14475	361	old participant mean	[older participants mean]	0.0	3	1	1	1
14476	361	acute infarction with major complication	[acute infarction with major complications]	0.0	5	1	1	1
14477	361	important indicator	[important indicator]	0.0	2	1	1	1
14478	361	advanced management	[advanced management]	0.0	2	1	1	1
14479	361	IL mg	[IL mg]	0.0	2	1	1	1
14480	361	high heart rate	[higher heart rate]	0.0	3	1	1	1
14481	361	Aldactone evaluation	[Aldactone Evaluation]	0.0	2	1	1	1
14482	361	characteristic use of medication	[characteristics use of medications]	0.0	4	1	1	1
14483	361	right plane excursion tapse	[right plane excursion TAPSE]	0.0	4	1	1	1
14484	361	high morbidity in people	[high morbidity in people]	0.0	4	1	1	1
14485	361	prior n	[prior n]	0.0	2	1	1	1
14486	361	45 death	[45 deaths]	0.0	2	1	1	1
14487	361	necessitate a understanding of the mechanism	[necessitating a understanding of the mechanism]	0.0	6	1	1	1
14488	361	composite measure of quality	[Composite measures of quality]	0.0	4	1	1	1
14489	361	patient ecct	[patients ECCT]	0.0	2	1	1	1
14490	361	effective elastance ea elastance	[Effective elastance Ea elastance]	0.0	4	1	1	1
14491	361	n=44 925 ed visit year	[n=44 925 ED visits years]	0.0	5	1	1	1
14492	361	lack of achievement	[lack of achievement]	0.0	3	1	1	1
14493	361	area index cm(2)	[area index cm(2)]	0.0	3	1	1	1
14494	361	impaired LV relaxation	[impaired LV relaxation]	0.0	3	1	1	1
14495	361	speckle	[speckle]	0.0	1	1	1	1
14496	361	case mix of HF	[case mix of HF]	0.0	4	1	1	1
14497	361	target nonglycosylated epitope p	[targeting nonglycosylated epitopes P]	0.0	4	1	1	1
14498	361	chest model	[chest model]	0.0	2	1	1	1
14499	361	incessant tachycardia storm	[incessant tachycardia storm]	0.0	3	1	1	1
14500	361	contemporary use	[Contemporary use]	0.0	2	1	1	1
14501	361	diastolic annular velocity 3.1 vs. 1.3	[diastolic annular velocity 3.1 vs. 1.3]	0.0	6	1	1	1
14502	361	key role 2 scaffold	[Key role 2 scaffolds]	0.0	4	1	1	1
14503	361	surgical method of transverse constriction	[surgical method of transverse constriction]	0.0	5	1	1	1
14504	361	race in patient with chronic HF	[race in patients with chronic HF]	0.0	6	1	1	1
14505	361	2825 participant aged year	[2825 participants aged years]	0.0	4	1	1	1
14506	361	promising target for the prevention	[promising targets for the prevention]	0.0	5	1	1	1
14507	361	follow-up of day	[follow-up of days]	0.0	3	1	1	1
14508	361	characterization of one of this protein	[characterization of one of these proteins]	0.0	6	1	1	1
14509	361	ed visit age	[ED visits age]	0.0	3	1	1	1
14510	361	can handling in dyssynchronous HF	[Ca handling in dyssynchronous HF]	0.0	5	1	1	1
14511	361	individual with disease	[individuals with disease]	0.0	3	1	1	1
14512	361	Centre	[Centre]	0.0	1	1	1	1
14513	361	human ventricular HF tissue sample	[human ventricular HF tissue samples]	0.0	5	1	1	1
14514	361	ejection fraction p=0.01	[ejection fraction P=0.01]	0.0	3	1	1	1
14515	361	t2d type diabete	[T2D Type diabetes]	0.0	3	1	1	1
14516	361	potential usefulness in patient	[potential usefulness in patients]	0.0	4	1	1	1
14517	361	patient functional class	[Patients functional class]	0.0	3	1	1	1
14518	361	disease group heart failure	[disease groups heart failure]	0.0	4	1	1	1
14519	361	datum for key health outcome	[data for key health outcomes]	0.0	5	1	1	1
14520	361	concern	[concerns]	0.0	1	1	1	1
14521	361	center for Medicare 30-day readmission	[Centers for Medicare 30-day readmission]	0.0	5	1	1	1
14522	361	enormous burden in medicine	[enormous burden in medicine]	0.0	4	1	1	1
14523	361	association with postoperative mortality	[association with postoperative mortality]	0.0	4	1	1	1
14524	361	effect of inhibition on status	[Effect of inhibition on status]	0.0	5	1	1	1
14525	361	promote transcriptional pause release	[promoting transcriptional pause release]	0.0	4	1	1	1
14526	361	812 consecutive patient aged 40 year	[812 consecutive patients aged 40 years]	0.0	6	1	1	1
14527	361	inhospital outcome	[inhospital outcomes]	0.0	2	1	1	1
14528	361	age sex fraction	[age sex fraction]	0.0	3	1	1	1
14529	361	World Health Organization	[World Health Organization]	0.0	3	1	1	1
14530	361	heart failure ed visit year	[heart failure ED visits years]	0.0	5	1	1	1
14531	361	even with normal systolic function	[even with normal systolic function]	0.0	5	1	1	1
14532	361	impact in patient	[impact in patients]	0.0	3	1	1	1
14533	361	Impact on cardioverter-defibrillator therapy	[Impact on cardioverter-defibrillator therapy]	0.0	4	1	1	1
14534	361	overview of biomarker-guided trial design	[overview of biomarker-guided trial design]	0.0	5	1	1	1
14535	361	heart circulatory failure	[heart circulatory failure]	0.0	3	1	1	1
14536	361	N form circulate nt-probnp	[N forms circulating NT-proBNP]	0.0	4	1	1	1
14537	361	wasting	[Wasting]	0.0	1	1	1	1
14538	361	novel therapeutic target	[novel therapeutic targets]	0.0	3	1	1	1
14539	361	basis of ventricle	[basis of ventricle]	0.0	3	1	1	1
14540	361	mri-based model	[MRI-based models]	0.0	2	1	1	1
14541	361	battery	[Battery]	0.0	1	2	2	1
14542	361	cross-talk in heart failure patient	[Cross-talk in heart failure patients]	0.0	5	1	1	1
14543	361	video edge	[video edge]	0.0	2	1	1	1
14544	361	major health problem worldwide	[major health problem worldwide]	0.0	4	1	1	1
14545	361	icu mortality stay	[ICU mortality stay]	0.0	3	1	1	1
14546	361	14 clinical study 2900 hm ii	[14 clinical studies 2900 HM II]	0.0	6	1	1	1
14547	361	thirty-seven hospital from January	[thirty-seven hospitals from January]	0.0	4	1	1	1
14548	361	tricuspid	[Tricuspid]	0.0	1	1	1	1
14549	361	potentially beneficial therapeutic approach	[potentially beneficial therapeutic approach]	0.0	4	1	1	1
14550	361	cardiotoxicity still a agent	[cardiotoxicity still a agent]	0.0	4	1	1	1
14551	361	occur rad variant q66p	[occurring Rad variant Q66P]	0.0	4	1	1	1
14552	361	aspect of remodeling contribute	[aspects of remodeling contributing]	0.0	4	1	1	1
14553	361	Nursing Outcome Classification NOC	[Nursing Outcomes Classification NOC]	0.0	4	1	1	1
14554	361	patient with atrial myxoma	[patient with atrial myxoma]	0.0	4	1	1	1
14555	361	peptide level like biomarker	[peptide levels like biomarkers]	0.0	4	1	1	1
14556	361	plasma norepinephrine	[plasma norepinephrine]	0.0	2	1	1	1
14557	361	Spearman correlation	[Spearman correlations]	0.0	2	1	1	1
14558	361	diastole with transmitral flow	[diastole with transmitral flow]	0.0	4	1	1	1
14559	361	egfr 30 millileter	[eGFR 30 mL]	0.0	3	1	1	1
14560	361	range with advanced copd n=95	[range with advanced COPD n=95]	0.0	5	1	1	1
14561	361	Impact on inappropriate cardioverter-defibrillator therapy	[Impact on inappropriate cardioverter-defibrillator therapy]	0.0	5	1	1	1
14562	361	mortality in this population	[mortality in this population]	0.0	4	1	1	1
14563	361	emergency Department ED	[Emergency Department ED]	0.0	3	1	1	1
14564	361	cardiac hypertrophic response	[cardiac hypertrophic response]	0.0	3	1	1	1
14565	361	autonomic system modulation	[autonomic system modulation]	0.0	3	1	1	1
14566	361	most study	[most studies]	0.0	2	1	1	1
14567	361	resting hr p value=0.033	[resting HR P value=0.033]	0.0	4	1	1	1
14568	361	predictor of mortality after admission	[predictor of mortality after admission]	0.0	5	1	1	1
14569	361	health status symptom	[health status symptoms]	0.0	3	1	1	1
14570	361	subgroup analysis include quality	[subgroup analyses including quality]	0.0	4	1	1	1
14571	361	circumflex artery LCX	[circumflex artery LCX]	0.0	3	1	1	1
14572	361	inoperable hypertension	[inoperable hypertension]	0.0	2	1	1	1
14573	361	die in day p-value	[dying in days P-value]	0.0	4	1	1	1
14574	361	RAAS	[RAAS]	0.0	1	1	1	1
14575	361	New Zealand White rabbit undergo DNx	[New Zealand White rabbits undergoing DNx]	0.0	6	1	1	1
14576	361	hospital through September	[hospitals through September]	0.0	3	1	1	1
14577	361	death in athlete	[death in athletes]	0.0	3	1	1	1
14578	361	right ejection fraction r=0.28 p=0.01	[right ejection fraction R=0.28 P=0.01]	0.0	5	1	1	1
14579	361	comanagement with clinician	[comanagement with clinicians]	0.0	3	1	1	1
14580	361	validate outcome measure in prospective research	[Validating outcome measures in prospective research]	0.0	6	1	1	1
14581	361	gdmt for month	[GDMT for months]	0.0	3	1	1	1
14582	361	adult Fontan SAF patient	[adult Fontan SAF patients]	0.0	4	1	1	1
14583	361	physiologic process	[physiologic processes]	0.0	2	1	1	1
14584	361	coupling pulmonary vascular resistance	[coupling pulmonary vascular resistance]	0.0	4	1	1	1
14585	361	accurate risk stratification of patient	[accurate risk stratification of patient]	0.0	5	1	1	1
14586	361	B-type peptide BNP	[B-type peptide BNP]	0.0	3	1	1	1
14587	361	more concrete datum	[more concrete data]	0.0	3	1	1	1
14588	361	interesting concept	[interesting concepts]	0.0	2	1	1	1
14589	361	wistar rat	[Wistar rats]	0.0	2	1	1	1
14590	361	140 mm	[140 mm]	0.0	2	1	1	1
14591	361	rose heart failure trial	[ROSE heart failure trial]	0.0	4	1	1	1
14592	361	other risk factor	[Other risk factors]	0.0	3	1	1	1
14593	361	systolic	[systolic]	0.0	1	1	1	1
14594	361	functional efficacy	[functional efficacy]	0.0	2	1	1	1
14595	361	diagnostic performance in patient with s'lateral	[diagnostic performance in patients with s'lateral]	0.0	6	1	1	1
14596	361	factor in patient with ph	[factor in patients with PH]	0.0	5	1	1	1
14597	361	post-TAC deterioration	[post-TAC deterioration]	0.0	2	1	1	1
14598	361	difference median bnp EF	[difference median BNP EF]	0.0	4	1	1	1
14599	361	patient with severe hypertension	[patients with severe hypertension]	0.0	4	2	2	1
14600	361	percent remain in decile	[percent remaining in deciles]	0.0	4	1	1	1
14601	361	target sodium	[target sodium]	0.0	2	1	1	1
14602	361	global longitudinal systolic strain GLS	[global longitudinal systolic strain GLS]	0.0	5	1	1	1
14603	361	alteration in SkM structure	[alterations in SkM structure]	0.0	4	1	1	1
14604	361	pulmonary vascular resistance p	[pulmonary vascular resistance P]	0.0	4	1	1	1
14605	361	anti-inflammatory effect	[anti-inflammatory effects]	0.0	2	1	1	1
14606	361	clinical outcome in patient	[clinical outcome in patients]	0.0	4	1	1	1
14607	361	wall thickness	[wall thickness]	0.0	2	1	1	1
14608	361	chronic heart failure with function	[chronic heart failure with function]	0.0	5	1	1	1
14609	361	left end diameter mm	[left end diameter mm]	0.0	4	1	1	1
14610	361	Practice Guideline CPG recommendation	[Practice Guideline CPG recommendations]	0.0	4	1	1	1
14611	361	heart failure attributable	[heart failure attributable]	0.0	3	1	1	1
14612	361	major adverse event-free rate	[major adverse event-free rate]	0.0	4	1	1	1
14613	361	patient with cardiomyopathy ic	[patients with cardiomyopathy IC]	0.0	4	1	1	1
14614	361	effect follow β-ar stimulation	[effect following β-AR stimulation]	0.0	4	1	1	1
14615	361	transplant patient receive PD solely	[transplant patients receiving PD solely]	0.0	5	1	1	1
14616	361	Survival after ventricular assist device	[Survival after ventricular assist device]	0.0	5	1	1	1
14617	361	measure in patient with hfpef	[measure in patients with HFpEF]	0.0	5	1	1	1
14618	361	powerful predictor	[powerful predictor]	0.0	2	1	1	1
14619	361	low systemic vascular resistance index	[low systemic vascular resistance index]	0.0	5	1	1	1
14620	361	left bundle branch	[left bundle branch]	0.0	3	1	1	1
14621	361	2 independent hypothese addition μg	[2 independent hypotheses addition μg]	0.0	5	1	1	1
14622	361	month after discharge	[month after discharge]	0.0	3	1	1	1
14623	361	National trend for four condition	[National trends for four conditions]	0.0	5	1	1	1
14624	361	fifty consecutive patient	[Fifty consecutive patients]	0.0	3	1	1	1
14625	361	PF mean	[PF mean]	0.0	2	1	1	1
14626	361	suboptimal care of patient	[suboptimal care of patients]	0.0	4	1	1	1
14627	361	importance for myocardial DD	[importance for myocardial DD]	0.0	4	1	1	1
14628	361	eight week	[Eight weeks]	0.0	2	1	1	1
14629	361	statistically significant improvement	[statistically significant improvement]	0.0	3	1	1	1
14630	361	endothelial cell nitric oxide production	[endothelial cell nitric oxide production]	0.0	5	1	1	1
14631	361	target abnormal exercise hemodynamic status	[targeting abnormal exercise hemodynamic status]	0.0	5	1	1	1
14632	361	valve oversewing	[valve oversewing]	0.0	2	1	1	1
14633	361	end point hazard ratio	[end point hazard ratio]	0.0	4	1	1	1
14634	361	taxonomy	[taxonomy]	0.0	1	1	1	1
14635	361	sacubiltril	[sacubiltril]	0.0	1	1	1	1
14636	361	reduction of tone	[reduction of tone]	0.0	3	1	1	1
14637	361	diastolic blood pressure	[diastolic blood pressure]	0.0	3	1	1	1
14638	361	RAFT	[RAFT]	0.0	1	1	1	1
14639	361	low fat body mass ratio	[lower fat body mass ratio]	0.0	5	1	1	1
14640	361	period of ventricular fibrillation	[period of ventricular fibrillation]	0.0	4	1	1	1
14641	361	restoration	[restoration]	0.0	1	2	2	1
14642	361	arterial pressure relationship a index	[arterial pressure relationship an index]	0.0	5	1	1	1
14643	361	biomarker in patient with heart failure	[biomarkers in patients with heart failure]	0.0	6	1	1	1
14644	361	add-on diagnostic feature	[add-on diagnostic features]	0.0	3	1	1	1
14645	361	gross income per capita	[gross income per capita]	0.0	4	1	1	1
14646	361	priority	[priorities]	0.0	1	1	1	1
14647	361	such as patient preference	[such as patient preferences]	0.0	4	1	1	1
14648	361	week of diet	[weeks of diet]	0.0	3	1	1	1
14649	361	low left ejection fraction	[low left ejection fraction]	0.0	4	1	1	1
14650	361	increase number	[increasing number]	0.0	2	1	1	1
14651	361	efficacy of left-to-right interatrial shunting	[efficacy of left-to-right interatrial shunting]	0.0	5	1	1	1
14652	361	pacing on left heart twist	[pacing on left heart twist]	0.0	5	1	1	1
14653	361	distinct subset	[distinct subset]	0.0	2	1	1	1
14654	361	Moderate-strength evidence	[Moderate-strength evidence]	0.0	2	1	1	1
14655	361	correlation between change no production	[correlation between changes NO production]	0.0	5	1	1	1
14656	361	key health outcome in patient	[key health outcomes in patients]	0.0	5	1	1	1
14657	361	tapse as measure	[TAPSE as measures]	0.0	3	1	1	1
14658	361	all-cause hospitalization within the prior month	[all-cause hospitalization within the prior months]	0.0	6	1	1	1
14659	361	hospitalization in severe congestive heart failure	[hospitalizations in severe congestive heart failure]	0.0	6	1	1	1
14660	361	cardiac activity (123)i-meta-iodobenzylguanidine	[cardiac activity (123)I-meta-iodobenzylguanidine]	0.0	3	1	1	1
14661	361	acute pressure overload rvpo	[acute pressure overload RVPO]	0.0	4	1	1	1
14662	361	action on cav1.2	[actions on CaV1.2]	0.0	3	1	1	1
14663	361	tomography	[tomography]	0.0	1	1	1	1
14664	361	serum level of creatinine	[serum levels of creatinine]	0.0	4	1	1	1
14665	361	outcome in other patient	[outcomes in other patients]	0.0	4	1	1	1
14666	361	group of patient consist	[group of patients consisting]	0.0	4	1	1	1
14667	361	sub-sample	[sub-sample]	0.0	1	1	1	1
14668	361	sitagliptin CI for sitagliptin	[sitagliptin CI for sitagliptin]	0.0	4	1	1	1
14669	361	therapeutic left-to-right interatrial shunting	[therapeutic left-to-right interatrial shunting]	0.0	4	1	1	1
14670	361	approximately 3000 patient	[approximately 3,000 patients]	0.0	3	1	1	1
14671	361	nucleotide	[nucleotides]	0.0	1	1	1	1
14672	361	central blood pressure via radial tonometry	[central blood pressure via radial tonometry]	0.0	6	1	1	1
14673	361	volume of exercise	[volumes of exercise]	0.0	3	1	1	1
14674	361	11 587 new user	[11 587 new users]	0.0	4	1	1	1
14675	361	participant with heart failure dopamine	[participants with heart failure dopamine]	0.0	5	1	1	1
14676	361	LV assist	[LV assist]	0.0	2	3	3	1
14677	361	incubation	[Incubation]	0.0	1	1	1	1
14678	361	effective elastance ea end-systolic elastance ees	[Effective elastance Ea end-systolic elastance Ees]	0.0	6	1	1	1
14679	361	study evaluate predictor on ICD patient	[studies evaluating predictors on ICD patients]	0.0	6	1	1	1
14680	361	aggressive treatment for HF with vasodilator	[aggressive treatment for HF with vasodilators]	0.0	6	1	1	1
14681	361	criteriabased institution	[criteriabased institution]	0.0	2	1	1	1
14682	361	Medicare beneficiary	[Medicare beneficiaries]	0.0	2	1	1	1
14683	361	most powerful independent predictor	[most powerful independent predictor]	0.0	4	1	1	1
14684	361	careful evaluation of the indication	[careful evaluation of the indications]	0.0	5	1	1	1
14685	361	undergo left assist device lvad implantation	[undergoing left assist device LVAD implantation]	0.0	6	1	1	1
14686	361	age group 20	[age groups 20]	0.0	3	1	1	1
14687	361	stage of heart failure	[stages of heart failure]	0.0	4	1	1	1
14688	361	panel of electrocardiographer	[panel of electrocardiographers]	0.0	3	1	1	1
14689	361	independent hypothese addition	[independent hypotheses addition]	0.0	3	1	1	1
14690	361	universal definition	[universal definition]	0.0	2	1	1	1
14691	361	4 expression	[4 expression]	0.0	2	1	1	1
14692	361	undergo vad	[undergoing VAD]	0.0	2	1	1	1
14693	361	Outcome of Exercise Training	[Outcomes of Exercise Training]	0.0	4	2	2	1
14694	361	orthotopic heart transplantation	[Orthotopic heart transplantation]	0.0	3	1	1	1
14695	361	ventricular ejection fraction 0.35	[ventricular ejection fraction 0.35]	0.0	4	1	1	1
14696	361	effect of a number	[effect of an number]	0.0	4	1	1	1
14697	361	evidence of dyssynchrony	[evidence of dyssynchrony]	0.0	3	1	1	1
14698	361	metabolic change in the development	[metabolic changes in the development]	0.0	5	1	1	1
14699	361	patient experience distressing cardioverter-defibrillator shock	[patients experiencing distressing cardioverter-defibrillator shocks]	0.0	5	1	1	1
14700	361	severe dysfunction	[severe dysfunction]	0.0	2	1	1	1
14701	361	GRADE	[GRADE]	0.0	1	1	1	1
14702	361	common underlying characteristic use Cochrane Practice	[common underlying characteristics using Cochrane Practice]	0.0	6	1	1	1
14703	361	SkM skeletal muscle	[SkM skeletal muscle]	0.0	3	1	1	1
14704	361	correlation between change	[correlation between changes]	0.0	3	1	1	1
14705	361	beta-blocker therapy in heart failure	[beta-blocker therapy in heart failure]	0.0	5	1	1	1
14706	361	peak flow velocity	[peak flow velocity]	0.0	3	2	2	1
14707	361	major neurological rate	[major neurological rate]	0.0	3	1	1	1
14708	361	prevention strategy	[prevention strategies]	0.0	2	1	1	1
14709	361	percent of hospital in a decile	[percent of hospitals in an decile]	0.0	6	1	1	1
14710	361	23.7 ng range 18.6	[23.7 ng range 18.6]	0.0	4	1	1	1
14711	361	trial with moderate	[trial with moderate]	0.0	3	1	1	1
14712	361	individual with chronic pulmonary disease	[individuals with chronic pulmonary disease]	0.0	5	1	1	1
14713	361	hospital in Jersey	[hospitals in Jersey]	0.0	3	1	1	1
14714	361	modification of diet in disease	[modification of diet in disease]	0.0	5	1	1	1
14715	361	limited amount	[limited amount]	0.0	2	1	1	1
14716	361	novel intracellular strategy	[novel intracellular strategy]	0.0	3	1	1	1
14717	361	glucocorticoid dosage	[glucocorticoid dosage]	0.0	2	1	1	1
14718	361	process redesign framework	[Process Redesign framework]	0.0	3	1	1	1
14719	361	8000 individual with heart failure	[8000 individuals with heart failure]	0.0	5	1	1	1
14720	361	myocardial matrix use resonance t1 mapping	[myocardial matrix using resonance T1 mapping]	0.0	6	1	1	1
14721	361	advance in treatment for myocardial infarction	[Advances in treatment for myocardial infarction]	0.0	6	1	1	1
14722	361	arterial coupling vascular resistance	[arterial coupling vascular resistance]	0.0	4	1	1	1
14723	361	acute right ventricular pressure overload	[acute right ventricular pressure overload]	0.0	5	1	1	1
14724	361	artery bypass surgery	[artery bypass surgery]	0.0	3	1	1	1
14725	361	collaboration of professional	[collaboration of professionals]	0.0	3	1	1	1
14726	361	ARNI inhibitor	[ARNI inhibitors]	0.0	2	1	1	1
14727	361	provide prognostic information	[providing prognostic information]	0.0	3	1	1	1
14728	361	noncoding rna	[noncoding RNAs]	0.0	2	1	1	1
14729	361	risk for outcome	[risk for outcomes]	0.0	3	1	1	1
14730	361	use inhibitor	[using inhibitors]	0.0	2	1	1	1
14731	361	development follow ring annuloplasty for mr	[development following ring annuloplasty for MR]	0.0	6	1	1	1
14732	361	suggest postcontrast t1	[suggesting postcontrast T1]	0.0	3	1	1	1
14733	361	treatment for anemia	[treatments for anemia]	0.0	3	1	1	1
14734	361	system neurological event	[system neurological events]	0.0	3	1	1	1
14735	361	adaptation of the myocardium	[adaptation of the myocardium]	0.0	4	1	1	1
14736	361	rad variant q66p	[Rad variant Q66P]	0.0	3	1	1	1
14737	361	17 day	[17 days]	0.0	2	1	1	1
14738	361	leg strength	[leg strength]	0.0	2	1	1	1
14739	361	angiotensin-converting enzyme	[angiotensin-converting enzyme]	0.0	2	1	1	1
14740	361	ventricular strain GLS	[ventricular strain GLS]	0.0	3	1	1	1
14741	361	pde2 inhibition	[PDE2 inhibition]	0.0	2	1	1	1
14742	361	treatment variation	[treatment variation]	0.0	2	1	1	1
14743	361	significant improvement in rate risk	[significant improvement in rate risk]	0.0	5	1	1	1
14744	361	ventricular dyssynchrony	[ventricular dyssynchrony]	0.0	2	1	1	1
14745	361	background for aldosterone antagonist therapy	[background for aldosterone antagonist therapy]	0.0	5	1	1	1
14746	361	validate outcome measure in experimental research	[Validating outcome measures in experimental research]	0.0	6	1	1	1
14747	361	Soluble ST2 in patient	[Soluble ST2 in patients]	0.0	4	1	1	1
14748	361	chronic failure	[chronic failure]	0.0	2	1	1	1
14749	361	maximal medical treatment	[maximal medical treatment]	0.0	3	1	1	1
14750	361	express resistin	[expressing resistin]	0.0	2	1	1	1
14751	361	test a device	[testing a device]	0.0	3	1	1	1
14752	361	assessment of patient within 7 day	[assessments of patients within 7 days]	0.0	6	1	1	1
14753	361	drug-untreated heart	[drug-untreated hearts]	0.0	2	1	1	1
14754	361	risk stratification with heart failure appropriate	[risk stratification with heart failure appropriate]	0.0	6	1	1	1
14755	361	β-blocker metoprolol	[β-blocker metoprolol]	0.0	2	1	1	1
14756	361	effect in vivo	[effects in vivo]	0.0	3	1	1	1
14757	361	median ventricular ejection fraction	[median ventricular ejection fraction]	0.0	4	1	1	1
14758	361	Hazard	[Hazard]	0.0	1	2	2	1
14759	361	trial of Nordic walking in patient	[trial of Nordic walking in patients]	0.0	6	1	1	1
14760	361	4 hospital in Jersey	[4 hospitals in Jersey]	0.0	4	1	1	1
14761	361	334 patient man mean	[334 patients men mean]	0.0	4	1	1	1
14762	361	ng range	[ng range]	0.0	2	1	1	1
14763	361	severe dilatation	[severe dilatation]	0.0	2	1	1	1
14764	361	staff	[staff]	0.0	1	1	1	1
14765	361	body mass index category	[body mass index categories]	0.0	4	1	1	1
14766	361	vary delay avd	[varying delay AVD]	0.0	3	1	1	1
14767	361	determine the adaptive remodelling	[determining the adaptive remodelling]	0.0	4	1	1	1
14768	361	study include calcium-sensin agent	[studies including calcium-sensitizing agents]	0.0	4	1	1	1
14769	361	value of indeterminable anaerobic threshold	[value of indeterminable anaerobic threshold]	0.0	5	1	1	1
14770	361	trend for condition	[trends for conditions]	0.0	3	1	1	1
14771	361	interventricular delay	[interventricular delay]	0.0	2	1	1	1
14772	361	SDRR	[SDRR]	0.0	1	1	1	1
14773	361	hospital longitudinal change	[hospital longitudinal change]	0.0	3	1	1	1
14774	361	constriction AAC	[constriction AAC]	0.0	2	1	1	1
14775	361	role in aspect of remodeling	[role in aspects of remodeling]	0.0	5	1	1	1
14776	361	brd4	[BRD4]	0.0	1	1	1	1
14777	361	plasma b-type peptide bnp	[plasma B-type peptide BNP]	0.0	4	1	1	1
14778	361	respiratory quotient	[respiratory quotient]	0.0	2	1	1	1
14779	361	measure such as time-domain measure	[measures such as time-domain measures]	0.0	5	1	1	1
14780	361	intraclass correlation coefficient	[intraclass correlation coefficient]	0.0	3	1	1	1
14781	361	angiotensin ii receptor	[angiotensin II receptor]	0.0	3	1	1	1
14782	361	effect with a familiar physician	[effect with a familiar physician]	0.0	5	1	1	1
14783	361	patient present	[patients presenting]	0.0	2	1	1	1
14784	361	angioplasty	[angioplasty]	0.0	1	1	1	1
14785	361	nyha class iv	[NYHA class IV]	0.0	3	1	1	1
14786	361	Obese old patient	[Obese Older Patients]	0.0	3	1	1	1
14787	361	hospital nationwide	[hospitals nationwide]	0.0	2	1	1	1
14788	361	institution of PD for the treatment	[institution of PD for the treatment]	0.0	6	1	1	1
14789	361	revascularization artery bypass surgery hazard ratio	[revascularization artery bypass surgery hazard ratio]	0.0	6	1	1	1
14790	361	develop congestive heart failure	[developing congestive heart failure]	0.0	4	1	1	1
14791	361	peak early flow velocity	[peak early flow velocity]	0.0	4	2	2	1
14792	361	benefit over conventional systolic parameter	[benefit over conventional systolic parameters]	0.0	5	1	1	1
14793	361	dose of JQ1	[doses of JQ1]	0.0	3	1	1	1
14794	361	treatment for patient	[treatment for patients]	0.0	3	1	1	1
14795	361	l-type channel activity	[L-type channel activity]	0.0	3	1	1	1
14796	361	potassium mmol	[potassium mmol]	0.0	2	1	1	1
14797	361	end-diastolic	[end-diastolic]	0.0	1	1	1	1
14798	361	hospitalization in HF clinic outpatient	[hospitalization in HF clinic outpatients]	0.0	5	2	2	1
14799	361	survival of patient with hypoalbuminemia	[survival of patients with hypoalbuminemia]	0.0	5	1	1	1
14800	361	relation between preoperative renal dysfunction	[Relation between preoperative renal dysfunction]	0.0	5	1	1	1
14801	361	hospital-to-home	[Hospital-to-Home]	0.0	1	1	1	1
14802	361	rose heart failure	[ROSE heart failure]	0.0	3	1	1	1
14803	361	discussion about treatment preference	[discussions about treatment preferences]	0.0	4	1	1	1
14804	361	direct effect	[direct effects]	0.0	2	1	1	1
14805	361	effect of this therapy	[effects of this therapy]	0.0	4	1	1	1
14806	361	change in ventricular diastolic function	[changes in ventricular diastolic function]	0.0	5	1	1	1
14807	361	gap in impact	[gaps in impact]	0.0	3	1	1	1
14808	361	ventricular fibrillation pvf	[ventricular fibrillation PVF]	0.0	3	1	1	1
14809	361	patient with anemia	[patients with anemia]	0.0	3	1	1	1
14810	361	global left longitudinal systolic strain GLS	[global left longitudinal systolic strain GLS]	0.0	6	1	1	1
14811	361	strong predictor after admission	[strong predictor after admission]	0.0	4	1	1	1
14812	361	Cox proportional hazard	[Cox proportional hazards]	0.0	3	1	1	1
14813	361	experience under the unique indication	[Experience under the unique indication]	0.0	5	1	1	1
14814	361	abnormal can 2 handling in HF	[abnormal Ca 2 handling in HF]	0.0	6	1	1	1
14815	361	improve survival rate of patient	[Improving survival rates of patients]	0.0	5	1	1	1
14816	361	treatment of hyponatremia	[treatment of hyponatremia]	0.0	3	1	1	1
14817	361	cumulative administration of doxorubicin	[cumulative administration of doxorubicin]	0.0	4	1	1	1
14818	361	CardioPulmonary Exercise test CPET guide	[CardioPulmonary Exercise Testing CPET guide]	0.0	5	1	1	1
14819	361	form of remodeling	[forms of remodeling]	0.0	3	1	1	1
14820	361	trichrome blue histologic analysis	[trichrome blue histologic analysis]	0.0	4	1	1	1
14821	361	Transoesophageal	[Transoesophageal]	0.0	1	1	1	1
14822	361	crucial problem	[crucial problem]	0.0	2	1	1	1
14823	361	function among patient with shortness	[Function Among Patients With Shortness]	0.0	5	1	1	1
14824	361	outpatient with systolic HF	[outpatients with systolic HF]	0.0	4	1	1	1
14825	361	onset follow myocardial infarction	[onset following myocardial infarction]	0.0	4	1	1	1
14826	361	268 record of patient	[268 records of patients]	0.0	4	1	1	1
14827	361	promote fill especially in subject	[promoting filling especially in subjects]	0.0	5	1	1	1
14828	361	early HF	[early HF]	0.0	2	1	1	1
14829	361	LV shortening	[LV shortening]	0.0	2	1	1	1
14830	361	male patient with SD testosterone level	[Male patients with SD testosterone levels]	0.0	6	1	1	1
14831	361	therapy with beta blockade	[therapy with beta blockade]	0.0	4	1	1	1
14832	361	pcwp estimation	[PCWP estimation]	0.0	2	1	1	1
14833	361	defibrillator implantation with Cardiac resynchronization therapy	[Defibrillator Implantation With Cardiac Resynchronization Therapy]	0.0	6	1	1	1
14834	361	cardiotoxicity among patient	[cardiotoxicity among patients]	0.0	3	1	1	1
14835	361	receptor β-ar	[receptor β-AR]	0.0	2	1	1	1
14836	361	50 μmol	[50 μmol]	0.0	2	1	1	1
14837	361	major determinant of quality	[major determinant of quality]	0.0	4	1	1	1
14838	361	cardiac volume index	[cardiac volume index]	0.0	3	1	1	1
14839	361	practice guideline from the College	[practice guideline from the College]	0.0	5	1	1	1
14840	361	mrna level for SR can	[mRNA levels for SR Ca]	0.0	5	1	1	1
14841	361	Modification	[Modification]	0.0	1	1	1	1
14842	361	1-day decrease	[1-day decrease]	0.0	2	1	1	1
14843	361	College of physician ACP	[College of Physicians ACP]	0.0	4	1	1	1
14844	361	little impact on development	[little impact on development]	0.0	4	1	1	1
14845	361	mild clinical dysfunction	[mild clinical dysfunction]	0.0	3	1	1	1
14846	361	meta-analy	[meta-analyses]	0.0	1	1	1	1
14847	361	use trichrome analysis	[using trichrome analysis]	0.0	3	1	1	1
14848	361	porcine model of reversible ischemia	[porcine model of reversible ischemia]	0.0	5	1	1	1
14849	361	peripheral artery disease	[peripheral artery disease]	0.0	3	1	1	1
14850	361	independent association	[independent association]	0.0	2	1	1	1
14851	361	patient in the CRT group	[patients in the CRT group]	0.0	5	1	1	1
14852	361	100 mg·kg(-1)·day(-1)	[100 mg·kg(-1)·day(-1)]	0.0	2	1	1	1
14853	361	require isolated lvad	[requiring isolated LVAD]	0.0	3	1	1	1
14854	361	clinical tool for risk stratification	[clinical tool for risk stratification]	0.0	5	1	1	1
14855	361	symptomatic heart failure	[symptomatic heart failure]	0.0	3	1	1	1
14856	361	microrna new target	[MicroRNAs new targets]	0.0	3	1	1	1
14857	361	STS HH hr interval	[STS HH HR interval]	0.0	4	1	1	1
14858	361	HF volume management	[HF volume management]	0.0	3	1	1	1
14859	361	exercise-induced artery pressure increase by means	[exercise-induced artery pressure increase by means]	0.0	6	1	1	1
14860	361	grain	[grain]	0.0	1	1	1	1
14861	361	waste	[wasting]	0.0	1	1	1	1
14862	361	left diastolic end diameter difference	[left diastolic end diameter difference]	0.0	5	1	1	1
14863	361	include the State	[including the States]	0.0	3	1	1	1
14864	361	proximal left artery	[proximal left artery]	0.0	3	1	1	1
14865	361	subject with heart failure	[subjects with heart failure]	0.0	4	1	1	1
14866	361	Cardiac symptom	[Cardiac symptoms]	0.0	2	1	1	1
14867	361	prognostic relevance of reserve in patient	[prognostic relevance of reserve in patients]	0.0	6	1	1	1
14868	361	3 pharmacologic study	[3 pharmacologic studies]	0.0	3	1	1	1
14869	361	circumferential strain cs	[circumferential strain CS]	0.0	3	1	1	1
14870	361	left strain GLS	[left strain GLS]	0.0	3	1	1	1
14871	361	placebo for day	[placebo for days]	0.0	3	1	1	1
14872	361	comment for the treatment	[Comment for the Treatment]	0.0	4	1	1	1
14873	361	major insulin-signaling component regulate metabolism	[major insulin-signaling components regulating metabolism]	0.0	5	1	1	1
14874	361	patient with acute myocardial infarction	[patients with acute myocardial infarction]	0.0	5	1	1	1
14875	361	post hoc	[post hoc]	0.0	2	1	1	1
14876	361	hospitalization within the prior 1 month	[hospitalization within the prior 1 months]	0.0	6	1	1	1
14877	361	dpp-4 inhibitor	[DPP-4 inhibitors]	0.0	2	1	1	1
14878	361	low egfr year	[low eGFR years]	0.0	3	1	1	1
14879	361	form in the circulation	[forms in the circulation]	0.0	4	1	1	1
14880	361	paradigm	[paradigm]	0.0	1	1	1	1
14881	361	16 patient with CHF-NYHA-III HDL	[16 patients with CHF-NYHA-III HDL]	0.0	5	1	1	1
14882	361	regard condition	[regarding conditions]	0.0	2	1	1	1
14883	361	HF ejection fraction	[HF ejection fractions]	0.0	3	1	1	1
14884	361	prospective datum on the potential	[prospective data on the potential]	0.0	5	1	1	1
14885	361	system adverse neurological event	[system adverse neurological events]	0.0	4	1	1	1
14886	361	cost-effectiveness analysis of disease management program	[cost-effectiveness analyses of disease management programs]	0.0	6	1	1	1
14887	361	change in mlhf score	[change in MLHF score]	0.0	4	1	1	1
14888	361	paradox	[paradox]	0.0	1	1	1	1
14889	361	zsf1 with diet n=11	[ZSF1 with diet n=11]	0.0	4	1	1	1
14890	361	arginine vasopressin avp	[arginine vasopressin AVP]	0.0	3	1	1	1
14891	361	concentration of ST2	[Concentrations of ST2]	0.0	3	1	1	1
14892	361	cgmp synthesis	[cGMP synthesis]	0.0	2	1	1	1
14893	361	phospholipase	[phospholipase]	0.0	1	1	1	1
14894	361	differential effect	[differential effect]	0.0	2	2	2	1
14895	361	low HF mortality	[lower HF mortality]	0.0	3	1	1	1
14896	361	assessment of this patient	[assessment of these patients]	0.0	4	1	1	1
14897	361	bolus of metoprolol	[bolus of metoprolol]	0.0	3	1	1	1
14898	361	improvement in functioning	[improvements in functioning]	0.0	3	1	1	1
14899	361	further review	[further review]	0.0	2	1	1	1
14900	361	proximal anterior descend artery	[proximal anterior descending artery]	0.0	4	1	1	1
14901	361	membrane oxygenation as bridge	[membrane oxygenation as bridge]	0.0	4	1	1	1
14902	361	user of bisphophonate	[users of bisphophonates]	0.0	3	1	1	1
14903	361	edema	[edema]	0.0	1	1	1	1
14904	361	demonstrate development of functional ms	[demonstrating development of functional MS]	0.0	5	1	1	1
14905	361	volume overload vo of regurgitation	[volume overload VO of regurgitation]	0.0	5	1	1	1
14906	361	significantly large hr reduction 17±22	[significantly larger HR reduction 17±22]	0.0	5	1	1	1
14907	361	distinct derangement with feature	[distinct derangement with features]	0.0	4	1	1	1
14908	361	major trial	[Major trials]	0.0	2	1	1	1
14909	361	heart failure of etiology	[heart failure of etiology]	0.0	4	1	1	1
14910	361	cardioverter-defibrillator therapy multicenter defibrillator implantation	[cardioverter-defibrillator therapy Multicenter Defibrillator Implantation]	0.0	5	1	1	1
14911	361	patient treatment	[patients treatment]	0.0	2	1	1	1
14912	361	same exercise time	[same exercise time]	0.0	3	1	1	1
14913	361	outcome such as hospitalisation	[outcomes such as hospitalisations]	0.0	4	1	1	1
14914	361	receptor agonist	[receptor agonist]	0.0	2	1	1	1
14915	361	four remodeling aspect	[four remodeling aspects]	0.0	3	1	1	1
14916	361	chronic arterial hypertension pah	[chronic arterial hypertension PAH]	0.0	4	1	1	1
14917	361	adjustment for patient characteristic	[adjustment for patient characteristics]	0.0	4	1	1	1
14918	361	possible care of patient	[possible care of patients]	0.0	4	1	1	1
14919	361	predictor on 257692 ICD patient	[predictors on 257,692 ICD patients]	0.0	5	1	1	1
14920	361	major underlying mechanism	[major underlying mechanism]	0.0	3	1	1	1
14921	361	subgroup of child	[subgroup of children]	0.0	3	1	1	1
14922	361	Inventory	[Inventory]	0.0	1	1	1	1
14923	361	well-being in all participant	[well-being in all participants]	0.0	4	1	1	1
14924	361	national attention	[national attention]	0.0	2	1	1	1
14925	361	full medicare coverage	[full Medicare coverage]	0.0	3	1	1	1
14926	361	addition indicate suboptimal care	[addition indicating suboptimal care]	0.0	4	1	1	1
14927	361	heart failure research	[heart failure research]	0.0	3	1	1	1
14928	361	difference in the ability	[difference in the ability]	0.0	4	1	1	1
14929	361	STS HH hr credible interval	[STS HH HR credible interval]	0.0	5	1	1	1
14930	361	Global ventricular strain	[Global ventricular strain]	0.0	3	1	1	1
14931	361	von willebrand factor concentration in Arg16	[von Willebrand factor concentrations in Arg16]	0.0	6	1	1	1
14932	361	potential application	[potential application]	0.0	2	1	1	1
14933	361	incidence in mt vad group	[incidence in MT VAD groups]	0.0	5	1	1	1
14934	361	pulmonary artery systolic pressure increase	[pulmonary artery systolic pressure increase]	0.0	5	1	1	1
14935	361	role in stable artery disease	[role in stable artery disease]	0.0	5	1	1	1
14936	361	receive the dose of doxorubicin	[receiving the dose of doxorubicin]	0.0	5	1	1	1
14937	361	substantial subset of gene	[substantial subset of genes]	0.0	4	1	1	1
14938	361	advanced chronic obstructive disease	[advanced chronic obstructive disease]	0.0	4	1	1	1
14939	361	conventional parameter in af	[conventional parameters in AF]	0.0	4	1	1	1
14940	361	independent predictor period versus 1	[independent predictor period versus 1]	0.0	5	1	1	1
14941	361	autonomic nervous system modulation	[autonomic nervous system modulation]	0.0	4	1	1	1
14942	361	study of patient with infarction	[study of patients with infarction]	0.0	5	1	1	1
14943	361	24-hour brachial pressure 155	[24-hour brachial pressure 155]	0.0	4	1	1	1
14944	361	independent predictor period hazard ratio	[independent predictor period hazard ratio]	0.0	5	1	1	1
14945	361	neurohormonal activation	[neurohormonal activation]	0.0	2	1	1	1
14946	361	burden because of the prevalence	[burden because of the prevalence]	0.0	5	1	1	1
14947	361	nt-probnp cutoff	[NT-proBNP cutoff]	0.0	2	1	1	1
14948	361	15 millileter odd ratio	[15 ml odds ratio]	0.0	4	1	1	1
14949	361	maximum oxygen consumption	[maximum oxygen consumption]	0.0	3	1	1	1
14950	361	intermediate odd ratio	[intermediate odds ratios]	0.0	3	1	1	1
14951	361	mechanical support on renal function	[mechanical support on renal function]	0.0	5	1	1	1
14952	361	determinant of quality qol	[determinant of quality QOL]	0.0	4	1	1	1
14953	361	heart failure ed visit	[heart failure ED visits]	0.0	4	1	1	1
14954	361	scar	[scar]	0.0	1	1	1	1
14955	361	fit versus man	[fit versus men]	0.0	3	1	1	1
14956	361	risk develop congestive heart failure	[risk developing congestive heart failure]	0.0	5	1	1	1
14957	361	randomization group	[randomization group]	0.0	2	1	1	1
14958	361	risk stratification between a large group	[risk stratification between a large group]	0.0	6	1	1	1
14959	361	patient with ventricular ejection fraction 0.35	[patients with ventricular ejection fraction 0.35]	0.0	6	1	1	1
14960	361	target audience	[target audience]	0.0	2	1	1	1
14961	361	metabolism quotient	[metabolism quotient]	0.0	2	1	1	1
14962	361	ambulatory HF patient ventricular ejection fraction	[ambulatory HF patients ventricular ejection fraction]	0.0	6	1	1	1
14963	361	difference at the exercise time	[difference at the exercise time]	0.0	5	1	1	1
14964	361	first infarction in western Australia	[first infarction in Western Australia]	0.0	5	1	1	1
14965	361	heart study	[Heart Study]	0.0	2	1	1	1
14966	361	increase for infarction	[increase for infarction]	0.0	3	1	1	1
14967	361	right ventricular RV annular plane excursion	[right ventricular RV annular plane excursion]	0.0	6	1	1	1
14968	361	change in ventricular function	[changes in ventricular function]	0.0	4	1	1	1
14969	361	lack of datum	[lack of data]	0.0	3	1	1	1
14970	361	matrix of left ventricular biopsy	[matrix of left ventricular biopsies]	0.0	5	1	1	1
14971	361	hospitalization within the prior month	[hospitalization within the prior months]	0.0	5	1	1	1
14972	361	mortality predictor in ICD-HF patient	[mortality predictors in ICD-HF patients]	0.0	5	1	1	1
14973	361	use metric for three disease group	[using metrics for three disease groups]	0.0	6	1	1	1
14974	361	prognostic benefit over systolic parameter	[prognostic benefit over systolic parameters]	0.0	5	1	1	1
14975	361	investigate cachexia	[investigating cachexia]	0.0	2	1	1	1
14976	361	treatment in patient a review	[Treatment in patients a review]	0.0	5	1	1	1
14977	361	egfr year	[eGFR years]	0.0	2	1	1	1
14978	361	survive a acute infarction	[surviving an acute infarction]	0.0	4	1	1	1
14979	361	reduction in LV end volume index	[reductions in LV end volume index]	0.0	6	1	1	1
14980	361	kccq category	[KCCQ category]	0.0	2	1	1	1
14981	361	AMI admission	[AMI admission]	0.0	2	1	1	1
14982	361	cardiac gene in HF	[cardiac genes in HF]	0.0	4	1	1	1
14983	361	stage 3 kidney disease CKD	[Stage 3 kidney disease CKD]	0.0	5	1	1	1
14984	361	heart failure with ventricular ejection fraction	[Heart failure with ventricular ejection fraction]	0.0	6	1	1	1
14985	361	LV dimension p	[LV dimension P]	0.0	3	1	1	1
14986	361	mechanic	[mechanics]	0.0	1	1	1	1
14987	361	experience implantable cardioverter-defibrillator shock	[experiencing implantable cardioverter-defibrillator shocks]	0.0	4	1	1	1
14988	361	risk hazard ratio	[risk hazard ratio]	0.0	3	1	1	1
14989	361	np assessment	[NP assessment]	0.0	2	1	1	1
14990	361	other condition such as myocardial infarction	[other conditions such as myocardial infarction]	0.0	6	1	1	1
14991	361	natriuretic peptide b-type natriuretic peptide	[natriuretic peptide B-type natriuretic peptide]	0.0	5	1	1	1
14992	361	stimulation fes	[stimulation FES]	0.0	2	1	1	1
14993	361	change in c-index	[change in C-index]	0.0	3	1	1	1
14994	361	6 minute 59.6 m	[6 min 59.6 m]	0.0	4	1	1	1
14995	361	fifty-four asymptomatic Fontan PF patient	[Fifty-four asymptomatic Fontan PF patients]	0.0	5	1	1	1
14996	361	independent marker	[independent markers]	0.0	2	1	1	1
14997	361	datum from trial	[data from trials]	0.0	3	1	1	1
14998	361	time-varying covariate	[time-varying covariates]	0.0	2	1	1	1
14999	361	range 6 day	[range 6 days]	0.0	3	1	1	1
15000	361	Gene expression	[Gene expression]	0.0	2	1	1	1
15001	361	normal geometry	[normal geometry]	0.0	2	1	1	1
15002	361	tricuspid annular plane excursion tapse	[tricuspid annular plane excursion TAPSE]	0.0	5	1	1	1
15003	361	150 minute of aerobic exercise	[150 minutes of aerobic exercise]	0.0	5	1	1	1
15004	361	all-cause mortality hazard ratio	[all-cause mortality hazard ratio]	0.0	4	1	1	1
15005	361	insulin product from 2006	[insulin products from 2006]	0.0	4	1	1	1
15006	361	activator	[activators]	0.0	1	1	1	1
15007	361	activity by ((123)i-mibg	[activity by ((123)I-MIBG]	0.0	3	1	1	1
15008	361	type ii regulatory	[type II regulatory]	0.0	3	1	1	1
15009	361	increase in cardiac risk	[increase in cardiac risk]	0.0	4	1	1	1
15010	361	treat patient with heart failure	[treating patients with heart failure]	0.0	5	1	1	1
15011	361	family of reader protein	[family of reader proteins]	0.0	4	1	1	1
15012	361	determinant of long survival	[determinants of long-term survival]	0.0	4	1	1	1
15013	361	receive PD for HF volume management	[receiving PD for HF volume management]	0.0	6	1	1	1
15014	361	incidence of end-stage disease	[Incidence of end-stage disease]	0.0	4	1	1	1
15015	361	proteomics change in constriction	[proteomics changes in constriction]	0.0	4	1	1	1
15016	361	annular velocity 3.1	[annular velocity 3.1]	0.0	3	1	1	1
15017	361	clinical dysfunction lead	[clinical dysfunction leading]	0.0	3	1	1	1
15018	361	transition of care program	[transitions of care program]	0.0	4	2	2	1
15019	361	predictor of remodeling after resynchronization therapy	[predictors of remodeling after resynchronization therapy]	0.0	6	1	1	1
15020	361	department in a university hospital	[Department in a university hospital]	0.0	5	1	1	1
15021	361	relation within month	[Relation within months]	0.0	3	1	1	1
15022	361	use of poc testing	[use of POC testing]	0.0	4	1	1	1
15023	361	Left assist device	[Left assist devices]	0.0	3	1	1	1
15024	361	Differential effect	[Differential effects]	0.0	2	1	1	1
15025	361	6 trial	[6 trials]	0.0	2	1	1	1
15026	361	low income	[lower income]	0.0	2	1	1	1
15027	361	patient management intervention	[Patient Management Interventions]	0.0	3	2	2	1
15028	361	study include agent of endothelin	[studies including agents of endothelin]	0.0	5	1	1	1
15029	361	2 type of lvas HeartMate	[2 types of LVADs HeartMate]	0.0	5	1	1	1
15030	361	cohort with incident	[cohort with incident]	0.0	3	1	1	1
15031	361	nutritional strategy	[nutritional strategies]	0.0	2	1	1	1
15032	361	cause of ms	[causes of MS]	0.0	3	1	1	1
15033	361	significant gastrointestinal bleed	[significant gastrointestinal bleeding]	0.0	3	1	1	1
15034	361	analysis of subgroup of patient	[analysis of subgroups of patients]	0.0	5	1	1	1
15035	361	naturally occur rad variant	[naturally occurring Rad variant]	0.0	4	1	1	1
15036	361	histone acetyltransferase	[histone acetyltransferases]	0.0	2	1	1	1
15037	361	ninety-three HF patient	[ninety-three HF patients]	0.0	3	1	1	1
15038	361	camp level	[cAMP levels]	0.0	2	1	1	1
15039	361	334 consecutive patient	[334 consecutive patients]	0.0	3	1	1	1
15040	361	traditional heart failure	[traditional heart failure]	0.0	3	1	1	1
15041	361	diastolic fill time	[diastolic filling time]	0.0	3	1	1	1
15042	361	risk factor such as diabete mellitus	[risk factors such as diabetes mellitus]	0.0	6	1	1	1
15043	361	nondiabete	[nondiabetes]	0.0	1	1	1	1
15044	361	ven	[VEN]	0.0	1	1	1	1
15045	361	Global ventricular longitudinal strain	[Global ventricular longitudinal strain]	0.0	4	1	1	1
15046	361	beta-adrenergic receptor signal in cardiomyocyte	[beta-adrenergic receptor signaling in cardiomyocytes]	0.0	5	1	1	1
15047	361	only a limited amount of datum	[only a limited amount of data]	0.0	6	1	1	1
15048	361	high rate	[higher rate]	0.0	2	2	2	1
15049	361	regulatory involvement	[regulatory involvement]	0.0	2	1	1	1
15050	361	NOC outcome	[NOC outcomes]	0.0	2	1	1	1
15051	361	disappearance	[disappearance]	0.0	1	1	1	1
15052	361	diagnosis of HF	[diagnosis of HF]	0.0	3	1	1	1
15053	361	surgical method of constriction	[surgical method of constriction]	0.0	4	1	1	1
15054	361	systemic vascular resistance index	[systemic vascular resistance index]	0.0	4	1	1	1
15055	361	national trend in event rate	[national trends in event rates]	0.0	5	1	1	1
15056	361	provision	[provision]	0.0	1	1	1	1
15057	361	change in Paco2	[change in Paco2]	0.0	3	1	1	1
15058	361	insertion	[insertion]	0.0	1	1	1	1
15059	361	quasi-experiment	[quasi-experiment]	0.0	1	1	1	1
15060	361	neprilysin block renin-angiotensin-aldosteron ras axis	[neprilysin blocks renin-angiotensin-aldosteron RAS axis]	0.0	5	1	1	1
15061	361	neurological rate	[neurological rate]	0.0	2	1	1	1
15062	361	morbidity in people	[morbidity in people]	0.0	3	1	1	1
15063	361	systemic resistance index	[systemic resistance index]	0.0	3	1	1	1
15064	361	high serum level of peptide	[higher serum levels of peptide]	0.0	5	1	1	1
15065	361	risk of adverse outcome	[risk of adverse outcomes]	0.0	4	1	1	1
15066	361	quantification of t1 in swine	[quantification of T1 in swine]	0.0	5	1	1	1
15067	361	subset of phenylephrine-induced gene	[subset of phenylephrine-induced genes]	0.0	4	1	1	1
15068	361	anaerobic metabolism quotient	[anaerobic metabolism quotient]	0.0	3	1	1	1
15069	361	endothelial growth factor	[endothelial growth factor]	0.0	3	1	1	1
15070	361	assist device lvad implantation	[assist device LVAD implantation]	0.0	4	1	1	1
15071	361	careful management	[careful management]	0.0	2	1	1	1
15072	361	require revision for aortic valve replacement	[requiring revision for aortic valve replacement]	0.0	6	1	1	1
15073	361	four HF remodeling aspect	[four HF remodeling aspects]	0.0	4	1	1	1
15074	361	February	[February]	0.0	1	1	1	1
15075	361	odd of future	[odds of future]	0.0	3	1	1	1
15076	361	benefit in the prediction	[benefit in the prediction]	0.0	4	1	1	1
15077	361	patient with qrs	[patients with QRS]	0.0	3	1	1	1
15078	361	Outcome of Exercise Training multicenter study	[Outcomes of Exercise Training multicenter study]	0.0	6	1	1	1
15079	361	diastolic end diameter difference	[diastolic end diameter difference]	0.0	4	1	1	1
15080	361	reduction in the number	[reductions in the number]	0.0	4	1	1	1
15081	361	correction of aortic valve insufficiency	[correction of aortic valve insufficiency]	0.0	5	1	1	1
15082	361	cardiac disease	[cardiac disease]	0.0	2	1	1	1
15083	361	include fat	[including fat]	0.0	2	1	1	1
15084	361	absolute increase	[absolute increase]	0.0	2	1	1	1
15085	361	cardioverter-defibrillator deactivation preference	[cardioverter-defibrillator deactivation preferences]	0.0	3	1	1	1
15086	361	aspect contribute	[aspects contributing]	0.0	2	1	1	1
15087	361	form of arterial disease	[form of arterial disease]	0.0	4	1	1	1
15088	361	VEGF signal pathway	[VEGF signaling pathway]	0.0	3	1	1	1
15089	361	regard the role of stenting	[regarding the role of stenting]	0.0	5	1	1	1
15090	361	array of diagnostic procedure	[array of diagnostic procedures]	0.0	4	1	1	1
15091	361	alteration in sarcomeric microstructure	[alterations in sarcomeric microstructure]	0.0	4	1	1	1
15092	361	protective effect of exercise training ET	[Protective effects of exercise training ET]	0.0	6	1	1	1
15093	361	New user	[New Users]	0.0	2	1	1	1
15094	361	management of patient stem	[Management of patients stemming]	0.0	4	1	1	1
15095	361	high clinical relevance	[high clinical relevance]	0.0	3	1	1	1
15096	361	with.estimate range	[with.estimates ranging]	0.0	2	1	1	1
15097	361	cardiovascular event during the month	[cardiovascular events during the months]	0.0	5	1	1	1
15098	361	cause of HF	[cause of HF]	0.0	3	2	2	1
15099	361	cardiology service	[cardiology services]	0.0	2	1	1	1
15100	361	number from baseline	[number from baseline]	0.0	3	1	1	1
15101	361	persistent af	[persistent AF]	0.0	2	1	1	1
15102	361	2 drs decile	[2 DRS deciles]	0.0	3	1	1	1
15103	361	nyha classification	[NYHA classification]	0.0	2	1	1	1
15104	361	biomarker of cardiotoxicity	[biomarker of cardiotoxicity]	0.0	3	1	1	1
15105	361	involvement of g-protein-coupled receptor kinase-2	[involvement of G-protein-coupled receptor kinase-2]	0.0	5	1	1	1
15106	361	woman with a history	[women with a history]	0.0	4	1	1	1
15107	361	10000 pair of cohort	[10,000 pairs of cohorts]	0.0	4	1	1	1
15108	361	vascular resistance SVR	[vascular resistance SVR]	0.0	3	1	1	1
15109	361	acute HF year	[acute HF years]	0.0	3	1	1	1
15110	361	subclinical atherosclerosis use linear model	[subclinical atherosclerosis using linear models]	0.0	5	1	1	1
15111	361	reduce the endpoint	[reducing the endpoint]	0.0	3	1	1	1
15112	361	relevance in hypertension patient	[relevance in hypertension patients]	0.0	4	1	1	1
15113	361	Clinical Practice Guideline	[Clinical Practice Guideline]	0.0	3	1	1	1
15114	361	median pasp	[median PASP]	0.0	2	1	1	1
15115	361	predictor on ICD patient	[predictors on ICD patients]	0.0	4	1	1	1
15116	361	change with vary strain contribution	[changes with varying strain contributions]	0.0	5	1	1	1
15117	361	amyloidosis	[amyloidosis]	0.0	1	1	1	1
15118	361	peritoneal dialysis PD for management	[Peritoneal dialysis PD for management]	0.0	5	1	1	1
15119	361	characteristic use	[characteristics use]	0.0	2	1	1	1
15120	361	Low-dose dopamine	[Low-dose dopamine]	0.0	2	1	1	1
15121	361	bad heart failure-related qol outcome	[worse heart failure-related QOL outcome]	0.0	5	1	1	1
15122	361	trend toward a association	[trend toward an association]	0.0	4	1	1	1
15123	361	type of cardiac benign tumor	[type of cardiac benign tumors]	0.0	5	1	1	1
15124	361	bb dose versus mg equivalent dose	[BB dose versus mg equivalent dose]	0.0	6	1	1	1
15125	361	predictor of HF	[predictor of HF]	0.0	3	1	1	1
15126	361	common cause of hospitalization	[common cause of hospitalization]	0.0	4	1	1	1
15127	361	gdmt treatment group	[GDMT treatment group]	0.0	3	1	1	1
15128	361	association with mortality in patient	[association with mortality in patients]	0.0	5	1	1	1
15129	361	β-myosin heavy chain	[β-myosin heavy chain]	0.0	3	1	1	1
15130	361	knowledge on use in HF	[knowledge on use in HF]	0.0	5	1	1	1
15131	361	drug-free success rate	[drug-free success rates]	0.0	3	1	1	1
15132	361	development of functional ms	[development of functional MS]	0.0	4	1	1	1
15133	361	western health datum	[Western health data]	0.0	3	1	1	1
15134	361	old participant	[older participants]	0.0	2	1	1	1
15135	361	target dose for beta-blocker therapy	[target doses for beta-blocker therapy]	0.0	5	1	1	1
15136	361	inferior vena cava	[inferior vena cava]	0.0	3	1	1	1
15137	361	performance only in patient	[performance only in patients]	0.0	4	1	1	1
15138	361	generation nt-probnp assay	[generation NT-proBNP assay]	0.0	3	1	1	1
15139	361	first postoperative month	[first postoperative months]	0.0	3	1	1	1
15140	361	symptom Beck	[symptoms Beck]	0.0	2	1	1	1
15141	361	reduction in LV volume	[reduction in LV volume]	0.0	4	1	1	1
15142	361	community-based cohort	[community-based cohort]	0.0	2	1	1	1
15143	361	metabolic risk factor	[metabolic risk factors]	0.0	3	1	1	1
15144	361	outcome measure in future prospective research	[outcome measures in future prospective research]	0.0	6	1	1	1
15145	361	patient man mean 65±12 year	[patients men mean 65±12 years]	0.0	5	1	1	1
15146	361	dietary measure	[dietary measures]	0.0	2	1	1	1
15147	361	metric choice for application	[metric choice for applications]	0.0	4	1	1	1
15148	361	reveal a mechanism during insulin resistance	[revealing a mechanism during insulin resistance]	0.0	6	1	1	1
15149	361	target for the prevention of HF	[targets for the prevention of HF]	0.0	6	1	1	1
15150	361	use a antagonist	[using an antagonist]	0.0	3	1	1	1
15151	361	Lokomat® system	[Lokomat® system]	0.0	2	1	1	1
15152	361	agreement difference	[agreement difference]	0.0	2	1	1	1
15153	361	4.5 second	[4.5 seconds]	0.0	2	1	1	1
15154	361	also in patient	[also in patients]	0.0	3	1	1	1
15155	361	decade of heart failure HF	[decade of heart failure HF]	0.0	5	1	1	1
15156	361	relevance of right contractile reserve	[relevance of right contractile reserve]	0.0	5	1	1	1
15157	361	impact of ras uptitration	[impact of RAS uptitrations]	0.0	4	1	1	1
15158	361	LV end-diastolic volume LV volume	[LV end-diastolic volume LV volume]	0.0	5	1	1	1
15159	361	exist quality indicator	[existing quality indicators]	0.0	3	1	1	1
15160	361	new-onset severe ai require intervention	[new-onset severe AI requiring intervention]	0.0	5	1	1	1
15161	361	stem cell source	[stem cell source]	0.0	3	1	1	1
15162	361	adjust for covariate	[adjusting for covariates]	0.0	3	1	1	1
15163	361	24-hour pressure 155 35	[24-hour pressure 155 35]	0.0	4	1	1	1
15164	361	dystrophin-associated protein complex	[dystrophin-associated protein complex]	0.0	3	1	1	1
15165	361	Cooper Center Study	[Cooper Center Study]	0.0	3	1	1	1
15166	361	uptitration of blocker	[uptitration of blockers]	0.0	3	1	1	1
15167	361	LV volume LV volume	[LV volume LV volume]	0.0	4	1	1	1
15168	361	carry increase in cardiac risk	[carrying increase in cardiac risk]	0.0	5	1	1	1
15169	361	addition of dopamine 2 μg	[addition of dopamine 2 μg]	0.0	5	1	1	1
15170	361	suggest a surrogate	[suggesting a surrogate]	0.0	3	1	1	1
15171	361	low 6-minute walking distance	[lower 6-minute walking distance]	0.0	4	1	1	1
15172	361	g'mt-treated nyha class iii HF	[GDMT-treated NYHA class III HF]	0.0	5	1	1	1
15173	361	diagnostic performance only in patient	[diagnostic performance only in patients]	0.0	5	1	1	1
15174	361	body composition a study	[body composition a study]	0.0	4	1	1	1
15175	361	heart dilatation after constriction tac	[heart dilatation after constriction TAC]	0.0	5	1	1	1
15176	361	specific strategy	[specific strategies]	0.0	2	1	1	1
15177	361	effect on heart failure	[effects on heart failure]	0.0	4	1	1	1
15178	361	new systematic review	[new systematic review]	0.0	3	1	1	1
15179	361	334 patient man year	[334 patients men years]	0.0	4	1	1	1
15180	361	pf cohort	[PF cohort]	0.0	2	1	1	1
15181	361	interquartile range with advanced copd	[interquartile range with advanced COPD]	0.0	5	1	1	1
15182	361	Inpatient Registry	[Inpatient Registry]	0.0	2	1	1	1
15183	361	synthase	[synthase]	0.0	1	1	1	1
15184	361	therapy shock	[therapy shock]	0.0	2	1	1	1
15185	361	fragment nt-probnp	[fragment NT-proBNP]	0.0	2	1	1	1
15186	361	msec	[msec]	0.0	1	2	2	1
15187	361	e-wave early diastolic mitral annular velocity	[E-wave early diastolic mitral annular velocity]	0.0	6	1	1	1
15188	361	Impact of physician continuity after discharge	[Impact of physician continuity after discharge]	0.0	6	1	1	1
15189	361	admission nt-probnp	[admission NT-proBNP]	0.0	2	1	1	1
15190	361	abnormal t2 value	[Abnormal T2 values]	0.0	3	1	1	1
15191	361	coronary artery bypass surgery	[coronary artery bypass surgery]	0.0	4	1	1	1
15192	361	pro-brain-type peptide assessment	[pro-brain-type peptide assessment]	0.0	3	1	1	1
15193	361	pacing period	[pacing period]	0.0	2	1	1	1
15194	361	powerful predictor period versus 1	[powerful predictor period versus 1]	0.0	5	1	1	1
15195	361	heart failure in child	[heart failure in children]	0.0	4	1	1	1
15196	361	conventional clinical parameter	[conventional clinical parameters]	0.0	3	1	1	1
15197	361	fluid overload	[fluid overload]	0.0	2	2	2	1
15198	361	ejection fraction difference	[ejection fraction difference]	0.0	3	1	1	1
15199	361	myocardial infarction in Australia	[myocardial infarction in Australia]	0.0	4	1	1	1
15200	361	beta-dependent yield	[beta-dependent yield]	0.0	2	1	1	1
15201	361	interval between depolarization	[interval between depolarization]	0.0	3	1	1	1
15202	361	many predictor of mortality	[Many predictors of mortality]	0.0	4	1	1	1
15203	361	death occur within 30 day	[deaths occurring within 30 days]	0.0	5	1	1	1
15204	361	sinus rhythm hazard ratio	[sinus rhythm hazard ratio]	0.0	4	1	1	1
15205	361	exercise-induced artery systolic pressure pasp increase	[exercise-induced artery systolic pressure PASP increase]	0.0	6	1	1	1
15206	361	cad involve the artery	[CAD involving the artery]	0.0	4	1	1	1
15207	361	patient with a defibrillator	[patients with an defibrillator]	0.0	4	1	1	1
15208	361	cell in vitro	[cells in vitro]	0.0	3	1	1	1
15209	361	interatrial shunt	[interatrial shunt]	0.0	2	1	1	1
15210	361	low mg daily dose	[low mg daily dose]	0.0	4	1	1	1
15211	361	loop diuretic	[loop diuretics]	0.0	2	1	1	1
15212	361	muscle abnormality	[muscle abnormalities]	0.0	2	1	1	1
15213	361	doxorubicin kg ip	[doxorubicin kg ip]	0.0	3	1	1	1
15214	361	guideline definition	[guidelines definition]	0.0	2	1	1	1
15215	361	0.005 μg	[0.005 μg]	0.0	2	1	1	1
15216	361	mortality than several cancer	[mortality than several cancers]	0.0	4	1	1	1
15217	361	median activity p	[median activities P]	0.0	3	1	1	1
15218	361	muscle sarcomere structure in patient	[muscle sarcomere structure in patients]	0.0	5	1	1	1
15219	361	excessive β-ar drive	[excessive β-AR drive]	0.0	3	1	1	1
15220	361	infarcted animal	[infarcted animals]	0.0	2	1	1	1
15221	361	anaerobic metabolism respiratory quotient	[anaerobic metabolism respiratory quotient]	0.0	4	1	1	1
15222	361	renal atherosclerotic Lesion	[Renal Atherosclerotic Lesions]	0.0	3	1	1	1
15223	361	mena overexpression TTA	[Mena overexpression TTA]	0.0	3	1	1	1
15224	361	event rate between 2005	[event rates between 2005]	0.0	4	1	1	1
15225	361	quick pump-exchange technique	[quick pump-exchange technique]	0.0	3	1	1	1
15226	361	end-stage congestive heart failure	[end-stage congestive heart failure]	0.0	4	1	1	1
15227	361	quality improvement database	[quality improvement database]	0.0	3	1	1	1
15228	361	risk develop heart failure CHF	[risk developing heart failure CHF]	0.0	5	1	1	1
15229	361	oxide donor	[oxide donors]	0.0	2	1	1	1
15230	361	myosin	[myosin]	0.0	1	1	1	1
15231	361	healthy heart muscle cell	[healthy heart muscle cells]	0.0	4	1	1	1
15232	361	validity of the KCCQ summary score	[validity of the KCCQ Summary scores]	0.0	6	1	1	1
15233	361	adult with ejection fraction	[adults with ejection fraction]	0.0	4	1	1	1
15234	361	pathophysiology of heart failure	[pathophysiology of heart failure]	0.0	4	1	1	1
15235	361	normal LV	[normal LV]	0.0	2	1	1	1
15236	361	membrane oxygenation membrane support	[membrane oxygenation membrane support]	0.0	4	1	1	1
15237	361	improvement in composite response	[improvements in composite response]	0.0	4	1	1	1
15238	361	bromodomain protein	[bromodomain proteins]	0.0	2	1	1	1
15239	361	region of this molecule	[region of this molecule]	0.0	4	1	1	1
15240	361	reflect decrease in heart failure-related mortality	[reflecting decreases in heart failure-related mortality]	0.0	6	1	1	1
15241	361	death visit	[death visit]	0.0	2	1	1	1
15242	361	patient gender	[patients gender]	0.0	2	1	1	1
15243	361	disease from the population	[disease from the population]	0.0	4	1	1	1
15244	361	many current predictor	[Many current predictors]	0.0	3	1	1	1
15245	361	common cause among the elderly	[common cause among the elderly]	0.0	5	1	1	1
15246	361	gata4	[GATA4]	0.0	1	1	1	1
15247	361	11 kg	[11 kg]	0.0	2	1	1	1
15248	361	use a metric	[using a metric]	0.0	3	1	1	1
15249	361	Cox hazard regression modeling	[Cox hazards regression modeling]	0.0	4	1	1	1
15250	361	antagonize excessive β-ar drive	[antagonizing excessive β-AR drive]	0.0	4	1	1	1
15251	361	give rise in dyssynchronous HF	[giving rise in dyssynchronous HF]	0.0	5	1	1	1
15252	361	cumulative administration in rat	[cumulative administration in rats]	0.0	4	1	1	1
15253	361	fast subclass of cardiovascular disease	[fastest subclass of cardiovascular diseases]	0.0	5	1	1	1
15254	361	ventricular tricuspid annular plane systolic excursion	[ventricular tricuspid annular plane systolic excursion]	0.0	6	1	1	1
15255	361	significant bleed	[significant bleeding]	0.0	2	1	1	1
15256	361	inhibition of growth factor	[inhibition of growth factor]	0.0	4	1	1	1
15257	361	left ejection fraction difference	[left ejection fraction difference]	0.0	4	1	1	1
15258	361	change in measure	[change in measures]	0.0	3	1	1	1
15259	361	attenuation of proteome change	[attenuation of proteome changes]	0.0	4	1	1	1
15260	361	cardiac chromatin	[cardiac chromatin]	0.0	2	1	1	1
15261	361	st-segment-elevation	[ST-segment-elevation]	0.0	1	1	1	1
15262	361	cAMP-dependent protein kinase pka	[cAMP-dependent protein kinase PKA]	0.0	4	1	1	1
15263	361	value of threshold in heart failure	[value of threshold in heart failure]	0.0	6	1	1	1
15264	361	undergo renal DNx	[undergoing renal DNx]	0.0	3	1	1	1
15265	361	evaluate 63 predictor on ICD patient	[evaluating 63 predictors on ICD patients]	0.0	6	1	1	1
15266	361	patient with recent onset HFrEF	[patients with recent onset HFrEF]	0.0	5	1	1	1
15267	361	dysfunction in patient	[dysfunction in patients]	0.0	3	1	1	1
15268	361	severe systolic heart failure	[severe systolic heart failure]	0.0	4	1	1	1
15269	361	program with testosterone supplementation	[program with testosterone supplementation]	0.0	4	1	1	1
15270	361	independent correlate	[independent correlates]	0.0	2	1	1	1
15271	361	use trichrome blue analysis	[using trichrome blue analysis]	0.0	4	1	1	1
15272	361	percentage of collagen	[percentage of collagen]	0.0	3	2	2	1
15273	361	mild patient	[Mild Patients]	0.0	2	1	1	1
15274	361	parallel with global attenuation	[parallel with global attenuation]	0.0	4	1	1	1
15275	361	cardiac myocyte-specific mena overexpression comparable	[cardiac myocyte-specific Mena overexpression comparable]	0.0	5	1	1	1
15276	361	cell death	[cell death]	0.0	2	1	1	1
15277	361	technique detect fibrosis	[technique detecting fibrosis]	0.0	3	1	1	1
15278	361	heart failure HF population	[heart failure HF population]	0.0	4	1	1	1
15279	361	requirement	[requirement]	0.0	1	1	1	1
15280	361	hr bpm p	[HR bpm P]	0.0	3	1	1	1
15281	361	report demonstrate development follow ring annuloplasty	[reports demonstrating development following ring annuloplasty]	0.0	6	1	1	1
15282	361	economic evaluation	[economic evaluations]	0.0	2	1	1	1
15283	361	Global left systolic strain	[Global left systolic strain]	0.0	4	1	1	1
15284	361	people in the UK	[people in the UK]	0.0	4	1	1	1
15285	361	advancement of the state	[advancement of the state]	0.0	4	1	1	1
15286	361	atherosclerosis use model	[atherosclerosis using models]	0.0	3	1	1	1
15287	361	other predictor biomarker	[other predictors biomarkers]	0.0	3	1	1	1
15288	361	Szeto-Schiller ss	[Szeto-Schiller SS]	0.0	2	1	1	1
15289	361	alteration in energy metabolism	[alterations in energy metabolism]	0.0	4	1	1	1
15290	361	stenotic physiology	[stenotic physiology]	0.0	2	1	1	1
15291	361	oxygen pulse	[oxygen pulse]	0.0	2	1	1	1
15292	361	2+)-pump function	[2+)-pump function]	0.0	2	1	1	1
15293	361	namely renin inhibitor	[namely renin inhibitors]	0.0	3	1	1	1
15294	361	trigger of acute myocardial infarction	[trigger of acute myocardial infarction]	0.0	5	1	1	1
15295	361	egfr millileter per m	[eGFR mL per m]	0.0	4	1	1	1
15296	361	cost-effective health intervention	[cost-effective health interventions]	0.0	3	1	1	1
15297	361	estimate the venous pressure	[Estimating the venous pressure]	0.0	4	1	1	1
15298	361	mechanism of disease	[mechanisms of disease]	0.0	3	1	1	1
15299	361	outcome versus millisecond millisecond	[outcome vs milliseconds milliseconds]	0.0	4	1	1	1
15300	361	key gene	[key genes]	0.0	2	1	1	1
15301	361	change in function	[changes in function]	0.0	3	1	1	1
15302	361	follow-up datum	[follow-up data]	0.0	2	1	1	1
15303	361	arterial elastance ea elastance	[arterial elastance Ea elastance]	0.0	4	1	1	1
15304	361	atherosclerosis use general linear model	[atherosclerosis using general linear models]	0.0	5	1	1	1
15305	361	acute infarction in Australia	[acute infarction in Australia]	0.0	4	1	1	1
15306	361	generate variant encode channel	[generating variants encoding channels]	0.0	4	1	1	1
15307	361	status versus white	[status versus whites]	0.0	3	1	1	1
15308	361	require surgical intervention	[requiring surgical intervention]	0.0	3	1	1	1
15309	361	provide information for a outcome	[providing information for an outcome]	0.0	5	1	1	1
15310	361	death during sport	[death during sport]	0.0	3	1	1	1
15311	361	usual care by drug	[usual care by drugs]	0.0	4	1	1	1
15312	361	abdominal constriction	[abdominal constriction]	0.0	2	1	1	1
15313	361	electrocardiographic device	[electrocardiographic device]	0.0	2	1	1	1
15314	361	reader protein	[reader proteins]	0.0	2	1	1	1
15315	361	major HF remodeling aspect	[major HF remodeling aspects]	0.0	4	1	1	1
15316	361	assessment within day	[assessments within days]	0.0	3	1	1	1
15317	361	group patient p	[groups patients P]	0.0	3	1	1	1
15318	361	incidence of end-stage disease in outpatient	[Incidence of end-stage disease in outpatients]	0.0	6	1	1	1
15319	361	hfpef n=100	[HFPEF n=100]	0.0	2	1	1	1
15320	361	ef hfref	[EF HFrEF]	0.0	2	1	1	1
15321	361	muscle pump	[muscle pump]	0.0	2	1	1	1
15322	361	β-blocker bb	[β-blocker BB]	0.0	2	1	1	1
15323	361	systolic heart failure in practice	[systolic heart failure in practice]	0.0	5	1	1	1
15324	361	right ventricular-pulmonary coupling vascular resistance	[right ventricular-pulmonary coupling vascular resistance]	0.0	5	1	1	1
15325	361	irs2 gene double-knockout h-dko	[IRS2 gene double-knockout H-DKO]	0.0	4	1	1	1
15326	361	white	[whites]	0.0	1	1	1	1
15327	361	counterpart	[counterparts]	0.0	1	1	1	1
15328	361	first-in-class inhibitor	[first-in-class inhibitor]	0.0	2	1	1	1
15329	361	long administration	[long-term administration]	0.0	2	1	1	1
15330	361	potential implication	[potential implications]	0.0	2	1	1	1
15331	361	energy metabolism gene expression	[energy metabolism gene expression]	0.0	4	1	1	1
15332	361	objective institution for the treatment	[Objective institution for the treatment]	0.0	5	1	1	1
15333	361	epidemiology of myocardial infarction	[epidemiology of myocardial infarction]	0.0	4	1	1	1
15334	361	brain natriuretic peptide BNP	[brain natriuretic peptide BNP]	0.0	4	1	1	1
15335	361	cardiac biology	[cardiac biology]	0.0	2	1	1	1
15336	361	metabolism peak respiratory quotient	[metabolism peak respiratory quotient]	0.0	4	1	1	1
15337	361	rac1	[Rac1]	0.0	1	1	1	1
15338	361	manipulation of cardiac gene control	[manipulation of cardiac gene control]	0.0	5	1	1	1
15339	361	cardiac-resynchronization therapy in heart failure	[Cardiac-resynchronization therapy in heart failure]	0.0	5	1	1	1
15340	361	consecutive patient with a ejection fraction	[consecutive patients with a ejection fraction]	0.0	6	1	1	1
15341	361	follow a admission	[following an admission]	0.0	3	1	1	1
15342	361	denervation	[denervation]	0.0	1	1	1	1
15343	361	more concrete datum regard the role	[more concrete data regarding the role]	0.0	6	1	1	1
15344	361	use assay	[use assays]	0.0	2	1	1	1
15345	361	admission median bnp level	[admission median BNP levels]	0.0	4	1	1	1
15346	361	4 week	[4 weeks]	0.0	2	1	1	1
15347	361	community-based cohort heart failure	[community-based cohort heart failure]	0.0	4	1	1	1
15348	361	exercise below this recommendation	[exercise below these recommendations]	0.0	4	1	1	1
15349	361	heart failure concern	[heart failure concern]	0.0	3	1	1	1
15350	361	beneficial therapeutic approach	[beneficial therapeutic approach]	0.0	3	1	1	1
15351	361	spite of development	[spite of developments]	0.0	3	1	1	1
15352	361	man 65±12 year	[men 65±12 years]	0.0	3	1	1	1
15353	361	inhibition neprilysin block renin-angiotensin-aldosteron ras axis	[inhibition neprilysin blocks renin-angiotensin-aldosteron RAS axis]	0.0	6	1	1	1
15354	361	affect contractility	[affecting contractility]	0.0	2	1	1	1
15355	361	extend EMD with the aspect	[extending EMD with the aspects]	0.0	5	1	1	1
15356	361	need for standard	[need for standards]	0.0	3	1	1	1
15357	361	implantation with resynchronization therapy	[Implantation With Resynchronization Therapy]	0.0	4	1	1	1
15358	361	indicate care	[indicating care]	0.0	2	1	1	1
15359	361	angiotensin receptor neprilysin inhibitor	[angiotensin receptor neprilysin inhibitor]	0.0	4	1	1	1
15360	361	body fat	[body fat]	0.0	2	1	1	1
15361	361	patient across hospital	[patients across hospitals]	0.0	3	1	1	1
15362	361	versus without ejection fraction	[versus without ejection fraction]	0.0	4	1	1	1
15363	361	gross national income	[gross national income]	0.0	3	1	1	1
15364	361	presence of dysfunction in patient	[Presence of dysfunction in patients]	0.0	5	1	1	1
15365	361	prevalence of risk factor	[prevalence of risk factors]	0.0	4	1	1	1
15366	361	electron	[electron]	0.0	1	1	1	1
15367	361	patient with chronic disease	[patients with chronic disease]	0.0	4	1	1	1
15368	361	independent hypothese addition of dopamine	[independent hypotheses addition of dopamine]	0.0	5	1	1	1
15369	361	attenuation of tac-induced alteration	[attenuation of TAC-induced alterations]	0.0	4	1	1	1
15370	361	TAPSE relationship	[TAPSE relationship]	0.0	2	1	1	1
15371	361	e-wave early diastolic mitral velocity ratio	[E-wave early diastolic mitral velocity ratio]	0.0	6	1	1	1
15372	361	Soluble ST2 in ambulatory patient	[Soluble ST2 in ambulatory patients]	0.0	5	1	1	1
15373	361	subclass of cardiovascular disease	[subclass of cardiovascular diseases]	0.0	4	1	1	1
15374	361	low systemic resistance SVR index	[low systemic resistance SVR index]	0.0	5	1	1	1
15375	361	portion	[portion]	0.0	1	1	1	1
15376	361	patient survive a acute infarction	[patients surviving an acute infarction]	0.0	5	1	1	1
15377	361	925 ed visit mean age	[925 ED visits mean age]	0.0	5	1	1	1
15378	361	left ejection fraction on mortality	[left ejection fraction on mortality]	0.0	5	1	1	1
15379	361	change in serum cystatin c	[change in serum cystatin C]	0.0	5	1	1	1
15380	361	eight week from infarction	[Eight weeks from infarction]	0.0	4	1	1	1
15381	361	ventricular ejection time in heart failure	[ventricular ejection time in heart failure]	0.0	6	1	1	1
15382	361	major component regulate metabolism	[major components regulating metabolism]	0.0	4	1	1	1
15383	361	reduce the primary composite endpoint	[reducing the primary composite endpoint]	0.0	5	1	1	1
15384	361	qrs morphology on outcome	[QRS morphology on outcomes]	0.0	4	1	1	1
15385	361	renal function in EMPHASIS-HF	[renal function in EMPHASIS-HF]	0.0	4	1	1	1
15386	361	improve process	[improving processes]	0.0	2	1	1	1
15387	361	web	[web]	0.0	1	1	1	1
15388	361	3.5-fold risk	[3.5-fold risk]	0.0	2	1	1	1
15389	361	co-morbidity burden	[co-morbidity burden]	0.0	2	1	1	1
15390	361	thirty-seven hospital nationwide	[thirty-seven hospitals nationwide]	0.0	3	1	1	1
15391	361	26 study	[26 studies]	0.0	2	1	1	1
15392	361	advanced chronic pulmonary disease copd	[advanced chronic pulmonary disease COPD]	0.0	5	1	1	1
15393	361	climate	[climate]	0.0	1	1	1	1
15394	361	hospital in New Jersey	[hospitals in New Jersey]	0.0	4	1	1	1
15395	361	Discharge	[Discharge]	0.0	1	1	1	1
15396	361	prediction rule have independent predictor	[prediction rule having independent predictor]	0.0	5	1	1	1
15397	361	156 consecutive HF patient ejection fraction	[156 consecutive HF patients ejection fraction]	0.0	6	1	1	1
15398	361	filtration rate egfr	[filtration rate eGFR]	0.0	3	1	1	1
15399	361	beat-to-beat qt interval	[beat-to-beat QT intervals]	0.0	3	1	1	1
15400	361	group of sample	[groups of samples]	0.0	3	1	1	1
15401	361	low-strength evidence from trial	[Low-strength evidence from trials]	0.0	4	1	1	1
15402	361	total arterial compliance	[total arterial compliance]	0.0	3	1	1	1
15403	361	left atrial area	[left atrial area]	0.0	3	1	1	1
15404	361	site in North America	[sites in North America]	0.0	4	1	1	1
15405	361	change main effect exercise	[change main effect exercise]	0.0	4	1	1	1
15406	361	nurse leader	[nurse leaders]	0.0	2	1	1	1
15407	361	role in chromatin-mediated signal transduction	[role in chromatin-mediated signal transduction]	0.0	5	1	1	1
15408	361	association between measurement	[association between measurements]	0.0	3	1	1	1
15409	361	Spearman	[Spearman]	0.0	1	1	1	1
15410	361	N-terminal pro-b-type	[N-terminal pro-B-type]	0.0	2	1	1	1
15411	361	patient normal geometry	[patients normal geometry]	0.0	3	1	1	1
15412	361	year versus 72.83	[years vs 72.83]	0.0	3	1	1	1
15413	361	postoperative mortality	[postoperative mortality]	0.0	2	1	1	1
15414	361	improvement in rate risk	[improvement in rate risk]	0.0	4	1	1	1
15415	361	common cause of nontraumatic death	[common cause of nontraumatic death]	0.0	5	1	1	1
15416	361	low all-cause mortality	[lower all-cause mortality]	0.0	3	1	1	1
15417	361	cardiopulmonary exercise	[Cardiopulmonary exercise]	0.0	2	1	1	1
15418	361	use Classification	[using Classification]	0.0	2	1	1	1
15419	361	low risk develop certain malignancy	[lower risk developing certain malignancies]	0.0	5	1	1	1
15420	361	14 study approximately 2900 hm ii	[14 studies approximately 2900 HM II]	0.0	6	1	1	1
15421	361	parallel with paf level	[parallel with PAF levels]	0.0	4	1	1	1
15422	361	trend in patient safety for condition	[trends in patient safety for conditions]	0.0	6	1	1	1
15423	361	effect of LVEF	[effect of LVEF]	0.0	3	1	1	1
15424	361	referral centre	[referral centre]	0.0	2	1	1	1
15425	361	transseptal catheterisation with transoesophageal guidance	[transseptal catheterisation with transoesophageal guidance]	0.0	5	1	1	1
15426	361	patient HFrEF	[patients HFrEF]	0.0	2	1	1	1
15427	361	donor	[donors]	0.0	1	1	1	1
15428	361	study evaluate implementation intervention	[studies evaluating implementation interventions]	0.0	4	1	1	1
15429	361	Soluble ST2	[Soluble ST2]	0.0	2	1	1	1
15430	361	old woman with a history	[older women with a history]	0.0	5	1	1	1
15431	361	Kv4.3	[Kv4.3]	0.0	1	1	1	1
15432	361	exercise variable exercise ventilation eov	[exercise variables exercise ventilation EOV]	0.0	5	1	1	1
15433	361	inotropic effect follow β-ar stimulation	[inotropic effect following β-AR stimulation]	0.0	5	1	1	1
15434	361	comprise hospitalization	[comprising hospitalization]	0.0	2	1	1	1
15435	361	angiogenesis in heart failure	[angiogenesis in heart failure]	0.0	4	1	1	1
15436	361	early mitral annulus velocity E	[early mitral annulus velocity E]	0.0	5	1	1	1
15437	361	ventricular LV ejection fraction hfpef	[ventricular LV ejection fraction HFpEF]	0.0	5	1	1	1
15438	361	interquartile range 22.8 with advanced copd	[interquartile range 22.8 with advanced COPD]	0.0	6	1	1	1
15439	361	role of bet	[role of BETs]	0.0	3	1	1	1
15440	361	extrapolate outcome	[extrapolating outcomes]	0.0	2	1	1	1
15441	361	variance	[variance]	0.0	1	1	1	1
15442	361	adenine	[adenine]	0.0	1	1	1	1
15443	361	off-pump sparing approach for HeartMate exchange	[off-pump sparing approach for HeartMate exchange]	0.0	6	1	1	1
15444	361	percent relative reduction	[percent relative reduction]	0.0	3	1	1	1
15445	361	emergency room	[emergency room]	0.0	2	1	1	1
15446	361	hypertrophic response role	[hypertrophic response role]	0.0	3	1	1	1
15447	361	effect of if-channel inhibition	[Effect of If-channel inhibition]	0.0	4	1	1	1
15448	361	dysfunction LV ef	[dysfunction LV EF]	0.0	3	1	1	1
15449	361	patient with myocardial infarction	[patients with myocardial infarction]	0.0	4	1	1	1
15450	361	oxidation of glucose	[oxidation of glucose]	0.0	3	1	1	1
15451	361	alteration in marker	[alterations in markers]	0.0	3	1	1	1
15452	361	non-biological disease	[non-biological disease]	0.0	2	1	1	1
15453	361	use of angiotensin	[use of angiotensin]	0.0	3	1	1	1
15454	361	inhibition on status	[inhibition on status]	0.0	3	1	1	1
15455	361	impact of carvedilol on therapy	[impact of carvedilol on therapy]	0.0	5	1	1	1
15456	361	age-by-LVEF interaction	[age-by-LVEF interaction]	0.0	2	1	1	1
15457	361	all-cause mortality at year after hospitalization	[All-cause mortality at years after hospitalization]	0.0	6	1	1	1
15458	361	such as infarction with future expansion	[such as infarction with future expansion]	0.0	6	1	1	1
15459	361	datum for health outcome	[data for health outcomes]	0.0	4	1	1	1
15460	361	circulate fragment in plasma	[Circulating fragments in plasma]	0.0	4	1	1	1
15461	361	redesign	[Redesign]	0.0	1	1	1	1
15462	361	receive drug	[receiving drugs]	0.0	2	1	1	1
15463	361	month p=0·035	[months p=0·035]	0.0	2	1	1	1
15464	361	cardiac balance	[cardiac balance]	0.0	2	2	2	1
15465	361	home telemonitoring	[home telemonitoring]	0.0	2	1	1	1
15466	361	mixed-method study of 295 veteran	[Mixed-methods study of 295 veterans]	0.0	5	1	1	1
15467	361	10.7 nmol	[10.7 nmol]	0.0	2	1	1	1
15468	361	reduction in mva	[reduction in MVA]	0.0	3	1	1	1
15469	361	survival of patient 3.5 gram	[survival of patients 3.5 g]	0.0	5	1	1	1
15470	361	automatic defibrillator implantation resynchronization therapy	[Automatic Defibrillator Implantation Resynchronization Therapy]	0.0	5	1	1	1
15471	361	HF 4 year	[HF 4 years]	0.0	3	1	1	1
15472	361	stable condition	[stable conditions]	0.0	2	1	1	1
15473	361	right heart failure in hypertension	[right heart failure in hypertension]	0.0	5	1	1	1
15474	361	detailed analysis of tissue from mouse	[Detailed analysis of tissue from mice]	0.0	6	1	1	1
15475	361	patient normal geometry no LV hypertrophy	[patients normal geometry no LV hypertrophy]	0.0	6	1	1	1
15476	361	refractory heart failure with dialysis	[refractory heart failure with dialysis]	0.0	5	1	1	1
15477	361	evaluation hm ii	[evaluations HM II]	0.0	3	1	1	1
15478	361	clinical response	[clinical response]	0.0	2	1	1	1
15479	361	effect of peptide	[effect of peptides]	0.0	3	1	1	1
15480	361	even in the presence	[even in the presence]	0.0	4	1	1	1
15481	361	tumor necrosis factor	[tumor necrosis factor]	0.0	3	1	1	1
15482	361	still a agent in the treatment	[still a agent in the treatment]	0.0	6	1	1	1
15483	361	idiopathic cardiomyopathy include angiography	[idiopathic cardiomyopathy including angiography]	0.0	4	1	1	1
15484	361	Fontan PF	[Fontan PF]	0.0	2	1	1	1
15485	361	die in day p-value 0.001	[dying in days P-value 0.001]	0.0	5	1	1	1
15486	361	aggressive medical treatment	[aggressive medical treatment]	0.0	3	3	3	1
15487	361	volume index of millileter	[volume index of mL]	0.0	4	2	2	1
15488	361	end-diastolic area index cm(2)	[end-diastolic area index cm(2)]	0.0	4	1	1	1
15489	361	ventricular hypertrophy	[ventricular hypertrophy]	0.0	2	1	1	1
15490	361	American AAs	[Americans AAs]	0.0	2	1	1	1
15491	361	characteristic eg use Cochrane Practice	[characteristics eg using Cochrane Practice]	0.0	5	1	1	1
15492	361	variation in rate of guideline-recommended treatment	[variation in rates of guideline-recommended treatment]	0.0	6	1	1	1
15493	361	human stem cardiomyocyte hipsc-ct	[human stem cardiomyocytes hiPSC-CMs]	0.0	4	1	1	1
15494	361	effect on quality of life	[effect on quality of life]	0.0	5	1	1	1
15495	361	receive this agent	[receiving these agents]	0.0	3	1	1	1
15496	361	3.01 year	[3.01 years]	0.0	2	1	1	1
15497	361	contribution of poc measurement	[contribution of POC measurement]	0.0	4	1	1	1
15498	361	excitation-contraction coupling in the myocardium	[excitation-contraction coupling in the myocardium]	0.0	5	1	1	1
15499	361	mortality effect	[mortality effects]	0.0	2	1	1	1
15500	361	correlate of increase	[correlates of increase]	0.0	3	1	1	1
15501	361	reduction of sympathetic activity	[reduction of sympathetic activity]	0.0	4	1	1	1
15502	361	practice of rhythm control	[practice of rhythm control]	0.0	4	1	1	1
15503	361	hfpef for overall summary	[HFpEF for overall summary]	0.0	4	1	1	1
15504	361	fat lean body mass ratio	[fat lean body mass ratio]	0.0	5	1	1	1
15505	361	Costing	[Costing]	0.0	1	1	1	1
15506	361	change with treatment in the ratio	[change with treatment in the ratio]	0.0	6	1	1	1
15507	361	β-adrenergic receptor stimulation	[β-adrenergic receptor stimulation]	0.0	3	1	1	1
15508	361	role of BNP	[roles of BNP]	0.0	3	1	1	1
15509	361	complex set	[complex set]	0.0	2	1	1	1
15510	361	four-week training period	[four-week training period]	0.0	3	1	1	1
15511	361	diastolic mitral annular velocity 3.1	[diastolic mitral annular velocity 3.1]	0.0	5	1	1	1
15512	361	change in gene expression	[changes in gene expression]	0.0	4	1	1	1
15513	361	Differential effect of nonselective	[Differential effects of nonselective]	0.0	4	1	1	1
15514	361	major adverse rate	[major adverse rate]	0.0	3	1	1	1
15515	361	HF hospitalization rate	[HF hospitalization rates]	0.0	3	1	1	1
15516	361	need of resuscitation	[need of resuscitation]	0.0	3	1	1	1
15517	361	two model	[Two models]	0.0	2	1	1	1
15518	361	improvement in 6-minute	[improvement in 6-minute]	0.0	3	1	1	1
15519	361	effect of nonselective versus selective beta-blocker	[effects of nonselective versus selective beta-blockers]	0.0	6	1	1	1
15520	361	function dilatation	[function dilatation]	0.0	2	1	1	1
15521	361	ng interquartile range 18.6	[ng interquartile range 18.6]	0.0	4	1	1	1
15522	361	ischemic right heart failure	[ischemic right heart failure]	0.0	4	1	1	1
15523	361	group patient	[groups patients]	0.0	2	1	1	1
15524	361	Potent inhibition by a rad variant	[Potent inhibition by a Rad variant]	0.0	6	1	1	1
15525	361	significant difference between number	[significant difference between numbers]	0.0	4	1	1	1
15526	361	manipulation	[manipulation]	0.0	1	1	1	1
15527	361	actin dynamic	[actin dynamics]	0.0	2	1	1	1
15528	361	cardiac mrna level of gene	[cardiac mRNA levels of genes]	0.0	5	1	1	1
15529	361	first-in-man evidence for potential usefulness	[first-in-man evidence for potential usefulness]	0.0	5	1	1	1
15530	361	remote ischemic conditioning for patient	[Remote ischemic conditioning for patients]	0.0	5	1	1	1
15531	361	Cardiac resonance postcontrast t1 time	[Cardiac resonance postcontrast T1 time]	0.0	5	1	1	1
15532	361	CRT response	[CRT response]	0.0	2	1	1	1
15533	361	hretn mrna	[hRetn mRNA]	0.0	2	1	1	1
15534	361	right atrial area 20 cm	[right atrial area 20 cm]	0.0	5	1	1	1
15535	361	screening patient with doppler ultrasonography	[Screening patients with Doppler ultrasonography]	0.0	5	1	1	1
15536	361	nursing-sensitive outcome change score for adult	[Nursing-sensitive outcome change scores for adults]	0.0	6	1	1	1
15537	361	study evaluate 63 predictor	[studies evaluating 63 predictors]	0.0	4	1	1	1
15538	361	recommendation for management involve assist device	[Recommendations for management involving assist devices]	0.0	6	1	1	1
15539	361	right fractional area change	[right fractional area change]	0.0	4	1	1	1
15540	361	evaluation of the strength	[evaluation of the strength]	0.0	4	1	1	1
15541	361	high-strength evidence from trial	[high-strength evidence from trials]	0.0	4	1	1	1
15542	361	expenditure on health per capita	[expenditure on health per capita]	0.0	5	2	2	1
15543	361	human stem	[human stem]	0.0	2	1	1	1
15544	361	cardiomyopathy all p	[cardiomyopathy all p]	0.0	3	1	1	1
15545	361	use Nursing Outcome Classification	[using Nursing Outcomes Classification]	0.0	4	1	1	1
15546	361	pre-participation	[pre-participation]	0.0	1	1	1	1
15547	361	scenario of low expenditure	[scenario of lower expenditure]	0.0	4	1	1	1
15548	361	kg in the exercise	[kg in the exercise]	0.0	4	1	1	1
15549	361	physician follow-up	[physician follow-up]	0.0	2	2	2	1
15550	361	complex situation	[complex situations]	0.0	2	1	1	1
15551	361	survival of patient with hypoalbuminemia gram	[survival of patients with hypoalbuminemia g]	0.0	6	1	1	1
15552	361	off-pump sparing approach	[off-pump sparing approach]	0.0	3	1	1	1
15553	361	mean pressure gradient	[mean pressure gradient]	0.0	3	3	3	1
15554	361	belief	[beliefs]	0.0	1	1	1	1
15555	361	manage gastrointestinal bleed in this population	[managing gastrointestinal bleeding in this population]	0.0	6	1	1	1
15556	361	sixteen York heart Association Class	[Sixteen York Heart Association Class]	0.0	5	1	1	1
15557	361	important defense mechanism	[important defense mechanism]	0.0	3	1	1	1
15558	361	risk stratification particularly between a group	[risk stratification particularly between a group]	0.0	6	1	1	1
15559	361	role determine the cardiac remodelling	[role determining the cardiac remodelling]	0.0	5	1	1	1
15560	361	perhaps the most important component	[perhaps the most important component]	0.0	5	1	1	1
15561	361	Large-scale multicenter trial	[Large-scale multicenter trial]	0.0	3	1	1	1
15562	361	Shah	[Shah]	0.0	1	1	1	1
15563	361	great risk than the rest	[greater risk than the rest]	0.0	5	1	1	1
15564	361	clinical prognostic dysfunction lead	[clinical prognostic dysfunction leading]	0.0	4	1	1	1
15565	361	mm for reference subject	[mm for reference subjects]	0.0	4	1	1	1
15566	361	study of therapeutics	[studies of therapeutics]	0.0	3	1	1	1
15567	361	endopeptidase inhibitor	[endopeptidase inhibitors]	0.0	2	1	1	1
15568	361	impact of et on effect	[impact of ET on effects]	0.0	5	1	1	1
15569	361	Prognostic value of threshold	[Prognostic value of threshold]	0.0	4	1	1	1
15570	361	fluorescence	[fluorescence]	0.0	1	1	1	1
15571	361	limit	[limits]	0.0	1	1	1	1
15572	361	sample with icc value	[sample with ICC values]	0.0	4	1	1	1
15573	361	most powerful independent predictor period	[most powerful independent predictor period]	0.0	5	1	1	1
15574	361	severe systolic dysfunction	[severe systolic dysfunction]	0.0	3	1	1	1
15575	361	multicenter double-blind placebo-controlled clinical trial	[Multicenter double-blind placebo-controlled clinical trial]	0.0	5	1	1	1
15576	361	role of ERK1 molecular scaffold	[role of ERK1 molecular scaffolds]	0.0	5	1	1	1
15577	361	cardiac transplant ECCT	[cardiac transplant ECCT]	0.0	3	1	1	1
15578	361	dose of β-blocker bb	[doses of β-blocker BB]	0.0	4	1	1	1
15579	361	ventricular RV tricuspid plane excursion	[ventricular RV tricuspid plane excursion]	0.0	5	1	1	1
15580	361	millileter vs. 17.0 millileter	[ml vs. 17.0 ml]	0.0	4	1	1	1
15581	361	center retrospective observational study	[center retrospective observational study]	0.0	4	1	1	1
15582	361	14 clinical study hm	[14 clinical studies HM]	0.0	4	1	1	1
15583	361	independent prognostic role	[independent prognostic role]	0.0	3	1	1	1
15584	361	university hospital	[university hospital]	0.0	2	1	1	1
15585	361	final diagnosis	[final diagnosis]	0.0	2	1	1	1
15586	361	evidence from 17 trial	[evidence from 17 trials]	0.0	4	1	1	1
15587	361	use of device	[use of devices]	0.0	3	1	1	1
15588	361	province of Québec	[province of Québec]	0.0	3	1	1	1
15589	361	relationship with cardiovascular CV event	[relationship with cardiovascular CV events]	0.0	5	1	1	1
15590	361	severe-end-stage HF	[severe-end-stage HF]	0.0	2	1	1	1
15591	361	undergo resynchronization therapy	[undergoing resynchronization therapy]	0.0	3	1	1	1
15592	361	influence on the overall burden	[influence on the overall burden]	0.0	5	1	1	1
15593	361	manage bleed	[managing bleeding]	0.0	2	1	1	1
15594	361	surface ecg	[surface ECGs]	0.0	2	1	1	1
15595	361	influx	[influx]	0.0	1	1	1	1
15596	361	short-form	[Short-Form]	0.0	1	1	1	1
15597	361	grow subclass of disease	[growing subclass of diseases]	0.0	4	1	1	1
15598	361	training intervention with feedback	[training intervention with feedback]	0.0	4	1	1	1
15599	361	early HF respectively	[early HF respectively]	0.0	3	1	1	1
15600	361	left artery	[left artery]	0.0	2	1	1	1
15601	361	survival gram	[survival g]	0.0	2	1	1	1
15602	361	perspective use a approach	[perspective using a approach]	0.0	4	1	1	1
15603	361	eight age-matched control	[eight age-matched controls]	0.0	3	1	1	1
15604	361	tertiary referral centre	[tertiary referral centre]	0.0	3	1	1	1
15605	361	4 hospital	[4 hospitals]	0.0	2	1	1	1
15606	361	system activity	[system activity]	0.0	2	1	1	1
15607	361	New user of Saxagliptin	[New Users of Saxagliptin]	0.0	4	1	1	1
15608	361	left end diameter difference	[left end diameter difference]	0.0	4	1	1	1
15609	361	European Society guideline definition	[European Society guidelines definition]	0.0	4	1	1	1
15610	361	left end diameter mean difference	[left end diameter mean difference]	0.0	5	1	1	1
15611	361	randomized trial with moderate	[Randomized trial with moderate]	0.0	4	1	1	1
15612	361	difference among ef bnp in woman	[difference among EF BNP in women]	0.0	6	1	1	1
15613	361	Connecticut Health Center patient	[Connecticut Health Center patients]	0.0	4	1	1	1
15614	361	inhibitor c-kit	[inhibitors c-Kit]	0.0	2	1	1	1
15615	361	Raf-MEK1 scaffold protein	[Raf-MEK1 scaffold proteins]	0.0	3	1	1	1
15616	361	redo sternotomy for valve procedure	[redo sternotomy for valve procedures]	0.0	5	1	1	1
15617	361	dopamine on secondary end point	[dopamine on secondary end points]	0.0	5	1	1	1
15618	361	respective pathway	[respective pathways]	0.0	2	1	1	1
15619	361	variant encode channel	[variants encoding channels]	0.0	3	1	1	1
15620	361	aim of this single-arm study	[aim of this single-arm study]	0.0	5	1	1	1
15621	361	trend in event rate	[trends in event rates]	0.0	4	1	1	1
15622	361	cardiac transplant program	[cardiac transplant programs]	0.0	3	1	1	1
15623	361	participant without prevalent HF area	[participants without prevalent HF area]	0.0	5	1	1	1
15624	361	underlying DD	[underlying DD]	0.0	2	1	1	1
15625	361	clinical outcome use a antagonist	[clinical outcomes using an antagonist]	0.0	5	1	1	1
15626	361	disease group heart failure HF	[disease groups heart failure HF]	0.0	5	1	1	1
15627	361	use a cutoff	[Using a cutoff]	0.0	3	1	1	1
15628	361	telephone support programme	[telephone support programmes]	0.0	3	1	1	1
15629	361	activator of scn5a mrna splicing	[activators of SCN5A mRNA splicing]	0.0	5	1	1	1
15630	361	global longitudinal systolic strain	[global longitudinal systolic strain]	0.0	4	1	1	1
15631	361	kd for the mutant	[Kd for the mutant]	0.0	4	1	1	1
15632	361	extensive change	[extensive changes]	0.0	2	1	1	1
15633	361	Ea p	[Ea p]	0.0	2	1	1	1
15634	361	most appropriate investigation	[most appropriate investigations]	0.0	3	1	1	1
15635	361	lf ratio	[LF ratio]	0.0	2	1	1	1
15636	361	prevalence of bnp level	[prevalence of BNP levels]	0.0	4	1	1	1
15637	361	Fontan PF patient	[Fontan PF patients]	0.0	3	1	1	1
15638	361	predictor of event	[predictor of events]	0.0	3	1	1	1
15639	361	use random-effect model	[using random-effects models]	0.0	3	1	1	1
15640	361	other condition such as acute infarction	[other conditions such as acute infarction]	0.0	6	1	1	1
15641	361	result in a significant ms	[resulting in a significant MS]	0.0	5	1	1	1
15642	361	steady improvement in eGFR	[steady improvement in eGFR]	0.0	4	1	1	1
15643	361	median of year	[median of years]	0.0	3	1	1	1
15644	361	include coronary angiography	[including coronary angiography]	0.0	3	1	1	1
15645	361	complication in severe end-stage HF	[complications in severe end-stage HF]	0.0	5	1	1	1
15646	361	heart failure with outcome	[heart failure with outcomes]	0.0	4	1	1	1
15647	361	restrict the leaflet opening	[restricting the leaflet opening]	0.0	4	2	2	1
15648	361	setting of disease	[setting of disease]	0.0	3	1	1	1
15649	361	fourteen electronic database	[Fourteen electronic databases]	0.0	3	1	1	1
15650	361	global longitudinal strain of ventricle	[global longitudinal strain of ventricle]	0.0	5	1	1	1
15651	361	require temporary RV support	[requiring temporary RV support]	0.0	4	1	1	1
15652	361	suggest t1 as biomarker for HFPEF	[suggesting T1 as biomarker for HFPEF]	0.0	6	1	1	1
15653	361	grow subclass of cardiovascular disease	[growing subclass of cardiovascular diseases]	0.0	5	1	1	1
15654	361	Safety of eplerenone	[Safety of eplerenone]	0.0	3	1	1	1
15655	361	gdmt control group	[GDMT control group]	0.0	3	1	1	1
15656	361	adverse outcome in patient	[adverse outcomes in patients]	0.0	4	1	1	1
15657	361	intact heart	[intact hearts]	0.0	2	1	1	1
15658	361	rate of treatment	[rates of treatment]	0.0	3	1	1	1
15659	361	cardiovascular CV event	[cardiovascular CV events]	0.0	3	1	1	1
15660	361	LV mass 42.4 gram p=0.04	[LV mass 42.4 g P=0.04]	0.0	5	1	1	1
15661	361	diagnosis of prognostic diastolic dysfunction	[diagnosis of prognostic diastolic dysfunction]	0.0	5	1	1	1
15662	361	overexpression of Mammalian	[overexpression of Mammalian]	0.0	3	1	1	1
15663	361	characteristic of adult the charm programme	[characteristics of adults The CHARM programme]	0.0	6	1	1	1
15664	361	strategy capable	[strategies capable]	0.0	2	1	1	1
15665	361	decrease in heart failure-related mortality	[decreases in heart failure-related mortality]	0.0	5	1	1	1
15666	361	Cost-Effectiveness	[Cost-Effectiveness]	0.0	1	1	1	1
15667	361	testosterone group	[testosterone group]	0.0	2	1	1	1
15668	361	serum level	[serum levels]	0.0	2	2	2	1
15669	361	potential predictor particularly biomarker	[potential predictors particularly biomarkers]	0.0	4	1	1	1
15670	361	patient with plasma sample	[patients with plasma samples]	0.0	4	1	1	1
15671	361	more recently for patient	[more recently for patients]	0.0	4	1	1	1
15672	361	modulation	[modulation]	0.0	1	1	1	1
15673	361	variable exercise	[variables exercise]	0.0	2	1	1	1
15674	361	chronic disease copd	[chronic disease COPD]	0.0	3	1	1	1
15675	361	tac-induced alteration	[TAC-induced alterations]	0.0	2	1	1	1
15676	361	LV systolic index	[LV systolic indices]	0.0	3	1	1	1
15677	361	effectiveness as a treatment	[Effectiveness as an treatment]	0.0	4	1	1	1
15678	361	right end-diastolic area index cm(2)	[right end-diastolic area index cm(2)]	0.0	5	1	1	1
15679	361	human kidney	[human kidney]	0.0	2	1	1	1
15680	361	marker indicative of balance	[markers indicative of balance]	0.0	4	1	1	1
15681	361	determine assessment	[determining assessment]	0.0	2	1	1	1
15682	361	extracellular matrix of ventricular biopsy n=9	[Extracellular matrix of ventricular biopsies n=9]	0.0	6	1	1	1
15683	361	protein change	[protein changes]	0.0	2	1	1	1
15684	361	substrate	[substrate]	0.0	1	1	1	1
15685	361	use multivariate regression analysis	[Using multivariate regression analysis]	0.0	4	1	1	1
15686	361	collagen density of the ventricle	[collagen density of the ventricle]	0.0	5	1	1	1
15687	361	multiple cardiac gene	[multiple cardiac genes]	0.0	3	1	1	1
15688	361	individual scale	[individual scales]	0.0	2	1	1	1
15689	361	effect on receptor signal in cardiomyocyte	[effects on receptor signaling in cardiomyocytes]	0.0	6	1	1	1
15690	361	predictor after resynchronization therapy CRT	[predictors after resynchronization therapy CRT]	0.0	5	1	1	1
15691	361	community of population	[community of population]	0.0	3	1	1	1
15692	361	rehospitalization of percentage point	[rehospitalization of percentage points]	0.0	4	1	1	1
15693	361	AlphaLISA	[AlphaLISA]	0.0	1	1	1	1
15694	361	evidence for usefulness	[evidence for usefulness]	0.0	3	1	1	1
15695	361	left dyssynchrony	[left dyssynchrony]	0.0	2	1	1	1
15696	361	decrease in heart mortality	[decreases in heart mortality]	0.0	4	1	1	1
15697	361	aortic constriction tac	[aortic constriction TAC]	0.0	3	2	2	1
15698	361	size reduction by surgery	[size reduction by surgery]	0.0	4	2	2	1
15699	361	atrial area 20 cm 2	[atrial area 20 cm 2]	0.0	5	1	1	1
15700	361	receiver operating characteristic curve	[receiver operating characteristic curve]	0.0	4	2	2	1
15701	361	uptitration after a HF hospitalization	[uptitration after an HF hospitalization]	0.0	5	1	1	1
15702	361	advantage of the turnaround time	[advantage of the turnaround times]	0.0	5	1	1	1
15703	361	improve physician adherence	[improving physician adherence]	0.0	3	1	1	1
15704	361	HF registry	[HF registry]	0.0	2	1	1	1
15705	361	76.4 year	[76.4 years]	0.0	2	1	1	1
15706	361	Outcome study-a multicenter study	[Outcomes study-a multicenter study]	0.0	4	1	1	1
15707	361	measure in patient	[measure in patients]	0.0	3	1	1	1
15708	361	Patient perception	[Patient perceptions]	0.0	2	1	1	1
15709	361	mild clinical diastolic dysfunction	[mild clinical diastolic dysfunction]	0.0	4	1	1	1
15710	361	pediatric Fontan patient	[pediatric Fontan patients]	0.0	3	1	1	1
15711	361	discrimination change	[discrimination change]	0.0	2	1	1	1
15712	361	patient undergo procedure	[patients undergoing procedures]	0.0	3	1	1	1
15713	361	dilated cardiomyopathy	[dilated cardiomyopathy]	0.0	2	1	1	1
15714	361	zsf1 group	[ZSF1 groups]	0.0	2	1	1	1
15715	361	trial of blood transfusion	[trials of blood transfusions]	0.0	4	1	1	1
15716	361	few CHF patient	[fewer CHF patients]	0.0	3	1	1	1
15717	361	strategy with effect	[strategies with effects]	0.0	3	1	1	1
15718	361	pump function despite a hypertension medication	[pump function despite a hypertension medication]	0.0	6	1	1	1
15719	361	differential impact	[differential impact]	0.0	2	1	1	1
15720	361	HeartMate device	[HeartMate devices]	0.0	2	1	1	1
15721	361	Registry	[Registry]	0.0	1	1	1	1
15722	361	interactor	[Interactors]	0.0	1	1	1	1
15723	361	synthase activation	[synthase activation]	0.0	2	1	1	1
15724	361	significant improvement in clinical composite response	[significant improvements in clinical composite response]	0.0	6	1	1	1
15725	361	advance in treatment for acute infarction	[Advances in treatment for acute infarction]	0.0	6	1	1	1
15726	361	electromechanical behavior	[electromechanical behavior]	0.0	2	1	1	1
15727	361	physician in health	[Physicians in health]	0.0	3	1	1	1
15728	361	decrease from a average	[decrease from an average]	0.0	4	1	1	1
15729	361	activity in patient	[activity in patients]	0.0	3	1	1	1
15730	361	CHF inhibition	[CHF Inhibition]	0.0	2	1	1	1
15731	361	risk for RV failure	[risk for RV failure]	0.0	4	1	1	1
15732	361	accessory	[accessory]	0.0	1	1	1	1
15733	361	ischemic conditioning for patient	[ischemic conditioning for patients]	0.0	4	1	1	1
15734	361	beagle dog	[beagle dogs]	0.0	2	1	1	1
15735	361	relation within three month	[Relation within three months]	0.0	4	1	1	1
15736	361	decrease from a average 3.2	[decrease from an average 3.2]	0.0	5	1	1	1
15737	361	signalling protein	[signalling proteins]	0.0	2	1	1	1
15738	361	reflect decrease in heart mortality period	[reflecting decreases in heart mortality period]	0.0	6	1	1	1
15739	361	saxagliptin versus sulfonylurea for saxagliptin	[saxagliptin versus sulfonylureas for saxagliptin]	0.0	5	1	1	1
15740	361	age-dependent increase	[age-dependent increase]	0.0	2	1	1	1
15741	361	distressing cardioverter-defibrillator shock	[distressing cardioverter-defibrillator shocks]	0.0	3	1	1	1
15742	361	moderate-quality evidence	[moderate-quality evidence]	0.0	2	1	1	1
15743	361	fill flow volume	[filling flow volume]	0.0	3	1	1	1
15744	361	vasopressin type	[vasopressin type]	0.0	2	1	1	1
15745	361	cardiovascular condition	[cardiovascular conditions]	0.0	2	1	1	1
15746	361	contract	[contracting]	0.0	1	1	1	1
15747	361	muscle mass t-score	[muscle mass T-score]	0.0	3	1	1	1
15748	361	documentation of reason	[documentation of reasons]	0.0	3	1	1	1
15749	361	profound change	[profound change]	0.0	2	1	1	1
15750	361	predictor of mortality a review	[Predictors of mortality a review]	0.0	5	1	1	1
15751	361	LV end	[LV end]	0.0	2	1	1	1
15752	361	risk of Ie in patient	[risk of IE in patients]	0.0	5	1	1	1
15753	361	mortality at the bad	[mortality at the worst]	0.0	4	1	1	1
15754	361	describe a nomenclature	[describing a nomenclature]	0.0	3	1	1	1
15755	361	stimulation of peripheral muscle	[stimulation of peripheral muscles]	0.0	4	1	1	1
15756	361	perhaps the single component	[perhaps the single component]	0.0	4	1	1	1
15757	361	guideline-recommended care	[guideline-recommended care]	0.0	2	1	1	1
15758	361	iron use	[iron use]	0.0	2	1	1	1
15759	361	respiration for quantification of t1	[respiration for quantification of T1]	0.0	5	1	1	1
15760	361	information on cardioverter-defibrillator deactivation at implant	[information on cardioverter-defibrillator deactivation at implant]	0.0	6	1	1	1
15761	361	cardiac plasma membrane	[cardiac plasma membrane]	0.0	3	1	1	1
15762	361	paediatric transplant	[paediatric transplants]	0.0	2	1	1	1
15763	361	little impact	[little impact]	0.0	2	1	1	1
15764	361	growth factor blockade	[growth factor blockade]	0.0	3	1	1	1
15765	361	year for alendronate- patient respectively	[years for alendronate- patients respectively]	0.0	5	1	1	1
15766	361	cardiotoxicity a anti-neoplastic agent	[cardiotoxicity a anti-neoplastic agent]	0.0	4	1	1	1
15767	361	large limit	[large limits]	0.0	2	1	1	1
15768	361	objective criteriabased institution for the treatment	[Objective criteriabased institution for the treatment]	0.0	6	1	1	1
15769	361	onset of	[onset of]	0.0	2	1	1	1
15770	361	other subgroup analysis	[other subgroup analyses]	0.0	3	1	1	1
15771	361	adverse event-free rate	[adverse event-free rate]	0.0	3	1	1	1
15772	361	tachycardia indicative	[tachycardia indicative]	0.0	2	1	1	1
15773	361	subclass of disease	[subclass of diseases]	0.0	3	1	1	1
15774	361	patient at risk for hyperkalemia	[patients at risk for hyperkalemia]	0.0	5	2	2	1
15775	361	charm programme Candesartan	[CHARM programme Candesartan]	0.0	3	1	1	1
15776	361	confounding	[confounding]	0.0	1	1	1	1
15777	361	risk of stroke	[risk of stroke]	0.0	3	1	1	1
15778	361	patient consist after infarction	[patients consisting after infarction]	0.0	4	1	1	1
15779	361	use convert enzyme inhibitor	[use converting enzyme inhibitors]	0.0	4	1	1	1
15780	361	primary oscillation	[primary oscillations]	0.0	2	1	1	1
15781	361	treatment period	[treatment period]	0.0	2	1	1	1
15782	361	marker hazard ratio for peak	[markers hazard ratio for peak]	0.0	5	1	1	1
15783	361	common syndrome of heart failure	[common syndrome of heart failure]	0.0	5	1	1	1
15784	361	thromboembolic pulmonary hypertension	[thromboembolic pulmonary hypertension]	0.0	3	1	1	1
15785	361	promising biomarker HF	[promising biomarker HF]	0.0	3	1	1	1
15786	361	autonomic modulation	[Autonomic modulation]	0.0	2	1	1	1
15787	361	spontaneous tachycardia hfvt(+)	[spontaneous tachycardia HFVT(+)]	0.0	3	1	1	1
15788	361	β1ar overstimulation	[β1AR overstimulation]	0.0	2	1	1	1
15789	361	2:1 ratio	[2:1 ratio]	0.0	2	1	1	1
15790	361	cell ec	[cell EC]	0.0	2	1	1	1
15791	361	Clinical Practice Guideline CPG	[Clinical Practice Guideline CPG]	0.0	4	1	1	1
15792	361	relation in patient with without diabete	[relations in patients with without diabetes]	0.0	6	1	1	1
15793	361	Bradycardia indicative of cardiac tone	[Bradycardia indicative of cardiac tone]	0.0	5	1	1	1
15794	361	coronary artery occlusion	[coronary artery occlusion]	0.0	3	1	1	1
15795	361	therapeutic treatment target abnormal exercise status	[therapeutic treatments targeting abnormal exercise status]	0.0	6	1	1	1
15796	361	median bnp in woman	[median BNP in women]	0.0	4	1	1	1
15797	361	even with systolic ventricular function	[even with systolic ventricular function]	0.0	5	1	1	1
15798	361	incidence of disease	[Incidence of disease]	0.0	3	1	1	1
15799	361	Echocardiographic predictor	[Echocardiographic predictors]	0.0	2	1	1	1
15800	361	human embryonic kidney cell	[human embryonic kidney cells]	0.0	4	1	1	1
15801	361	ventricular tachycardia	[ventricular tachycardia]	0.0	2	1	1	1
15802	361	HF hospitalization hr CI	[HF hospitalization HR CI]	0.0	4	1	1	1
15803	361	millileter 2 p=0.01	[mL 2 P=0.01]	0.0	3	1	1	1
15804	361	carotid intima-media	[carotid intima-media]	0.0	2	1	1	1
15805	361	income per capita	[income per capita]	0.0	3	1	1	1
15806	361	treatment in increase	[treatment in increase]	0.0	3	1	1	1
15807	361	superior hospital	[superior hospitals]	0.0	2	1	1	1
15808	361	admission for individual	[admissions for individuals]	0.0	3	1	1	1
15809	361	quality measure for common medical condition	[quality measures for common medical conditions]	0.0	6	1	1	1
15810	361	p38α protein kinase	[p38α protein kinase]	0.0	3	1	1	1
15811	361	activate remodelling	[activating remodelling]	0.0	2	1	1	1
15812	361	derangement with feature similar	[derangement with features similar]	0.0	4	1	1	1
15813	361	proximal LCX late	[proximal LCX later]	0.0	3	1	1	1
15814	361	control for characteristic	[controlling for characteristics]	0.0	3	1	1	1
15815	361	point vs. 2.1 point	[points vs. 2.1 points]	0.0	4	1	1	1
15816	361	man with cardiac arrest	[man with cardiac arrest]	0.0	4	1	1	1
15817	361	use the method of transverse constriction	[using the method of transverse constriction]	0.0	6	1	1	1
15818	361	allopurinol mg·kg(-1)·day(-1)	[allopurinol mg·kg(-1)·day(-1)]	0.0	2	1	1	1
15819	361	risk of cardiac event	[risk of cardiac events]	0.0	4	1	1	1
15820	361	dysfunction with LV fill pressure	[dysfunction with LV filling pressures]	0.0	5	1	1	1
15821	361	20 clinical variable	[20 clinical variables]	0.0	3	1	1	1
15822	361	other measure	[other measures]	0.0	2	1	1	1
15823	361	reduction in lvef hazard ratio	[reduction in LVEF hazard ratio]	0.0	5	1	1	1
15824	361	therefore of value	[therefore of value]	0.0	3	1	1	1
15825	361	novel strategy in HF	[novel strategy in HF]	0.0	4	1	1	1
15826	361	plane excursion tapse	[plane excursion TAPSE]	0.0	3	1	1	1
15827	361	independent predictor period	[independent predictor period]	0.0	3	1	1	1
15828	361	brain peptide level pg	[brain peptide levels pg]	0.0	4	1	1	1
15829	361	trend with severe ventricular dilatation	[trend with severe ventricular dilatation]	0.0	5	1	1	1
15830	361	form of left ventricular remodeling	[forms of left ventricular remodeling]	0.0	5	1	1	1
15831	361	end point reflective	[end points reflective]	0.0	3	1	1	1
15832	361	prognosis of a idiopathic cohort	[prognosis of a idiopathic cohort]	0.0	5	1	1	1
15833	361	characteristic use Cochrane effective Practice	[characteristics using Cochrane Effective Practice]	0.0	5	1	1	1
15834	361	score for prediction	[score for prediction]	0.0	3	1	1	1
15835	361	hospital volume group	[hospital volume groups]	0.0	3	2	2	1
15836	361	risk in patient	[risk in patients]	0.0	3	1	1	1
15837	361	population of patient	[populations of patients]	0.0	3	1	1	1
15838	361	outcome for patient undergo procedure	[outcomes for patients undergoing procedures]	0.0	5	1	1	1
15839	361	medical treatment with vasodilator	[medical treatment with vasodilators]	0.0	4	1	1	1
15840	361	regard referral	[regarding referrals]	0.0	2	1	1	1
15841	361	early fibrosis	[early fibrosis]	0.0	2	1	1	1
15842	361	79.9 year	[79.9 years]	0.0	2	1	1	1
15843	361	surrogate of catabolism	[surrogate of catabolism]	0.0	3	1	1	1
15844	361	heart failure phenotype	[heart failure phenotypes]	0.0	3	1	1	1
15845	361	training for heart failure patient	[training for heart failure patients]	0.0	5	1	1	1
15846	361	common characteristic use Cochrane effective Practice	[common characteristics using Cochrane Effective Practice]	0.0	6	1	1	1
15847	361	stem cardiomyocyte	[stem cardiomyocytes]	0.0	2	1	1	1
15848	361	hospital readmission reduction program	[hospital readmission reduction program]	0.0	4	1	1	1
15849	361	central venous pressure	[central venous pressure]	0.0	3	1	1	1
15850	361	outcome change score for adult	[outcome change scores for adults]	0.0	5	1	1	1
15851	361	3 evaluation hm	[3 evaluations HM]	0.0	3	1	1	1
15852	361	patient with stable hfpef	[patients with stable HFPEF]	0.0	4	1	1	1
15853	361	Analysis	[Analysis]	0.0	1	1	1	1
15854	361	elastance end-systolic elastance ees	[elastance end-systolic elastance Ees]	0.0	4	1	1	1
15855	361	small difference	[smallest difference]	0.0	2	1	1	1
15856	361	randomized aldactone evaluation study	[Randomized Aldactone Evaluation Study]	0.0	4	1	1	1
15857	361	such as obesity	[such as obesity]	0.0	3	1	1	1
15858	361	baseline egfr group ii	[Baseline eGFR group II]	0.0	4	1	1	1
15859	361	effect of a increase number	[effect of an increasing number]	0.0	5	1	1	1
15860	361	evaluable plasma sample	[evaluable plasma samples]	0.0	3	1	1	1
15861	361	defence	[defence]	0.0	1	1	1	1
15862	361	clinical effect of type HeartMate	[clinical effects of types HeartMate]	0.0	5	1	1	1
15863	361	inhibitory action of Rad	[inhibitory actions of Rad]	0.0	4	1	1	1
15864	361	attenuation of alteration	[attenuation of alterations]	0.0	3	1	1	1
15865	361	outcome after resynchronization therapy	[outcomes after resynchronization therapy]	0.0	4	1	1	1
15866	361	recent enrollment period	[recent enrollment period]	0.0	3	1	1	1
15867	361	annular size reduction for mr	[annular size reduction for MR]	0.0	5	1	1	1
15868	361	short-term improvement in functioning	[short-term improvements in functioning]	0.0	4	1	1	1
15869	361	patient with CHF-NYHA-III HDL before et	[patients with CHF-NYHA-III HDL before ET]	0.0	6	1	1	1
15870	361	variation in rate	[variation in rates]	0.0	3	1	1	1
15871	361	performance only in patient with s'lateral	[performance only in patients with s'lateral]	0.0	6	1	1	1
15872	361	stable hno donor cxl-1020	[stable HNO donor CXL-1020]	0.0	4	1	1	1
15873	361	inflammatory IL6 hscrp biomarker	[inflammatory IL6 hsCRP biomarkers]	0.0	4	1	1	1
15874	361	induction of a subset	[induction of a subset]	0.0	4	1	1	1
15875	361	diastolic end diameter mm mean difference	[diastolic end diameter mm mean difference]	0.0	6	1	1	1
15876	361	current treatment	[current treatment]	0.0	2	1	1	1
15877	361	few death in the procedure	[few deaths in the procedures]	0.0	5	1	1	1
15878	361	Addition of HABC battery score	[Addition of HABC Battery scores]	0.0	5	1	1	1
15879	361	right ventricular-pulmonary coupling resistance p	[right ventricular-pulmonary coupling resistance P]	0.0	5	1	1	1
15880	361	ventricular systolic HF tissue sample	[ventricular systolic HF tissue samples]	0.0	5	1	1	1
15881	361	severe heart failure with dialysis	[severe heart failure with dialysis]	0.0	5	1	1	1
15882	361	acetyl-lysine reader protein	[acetyl-lysine reader proteins]	0.0	3	1	1	1
15883	361	patient with albumin level	[patients with albumin levels]	0.0	4	1	1	1
15884	361	standard	[standards]	0.0	1	1	1	1
15885	361	chronic pulmonary disease copd	[chronic pulmonary disease COPD]	0.0	4	1	1	1
15886	361	flow velocity e	[flow velocities E]	0.0	3	1	1	1
15887	361	credible interval CrI	[credible interval CrI]	0.0	3	1	1	1
15888	361	resynchronization reverse	[REsynchronization reVErses]	0.0	2	1	1	1
15889	361	refractory right heart failure	[refractory right heart failure]	0.0	4	1	1	1
15890	361	high-fat diet n=11	[high-fat diet n=11]	0.0	3	1	1	1
15891	361	trial of iron	[trials of iron]	0.0	3	1	1	1
15892	361	percutaneous coronary intervention	[percutaneous coronary intervention]	0.0	3	1	1	1
15893	361	potentiate the response	[potentiating the response]	0.0	3	1	1	1
15894	361	results—retrospective cohort	[Results—Retrospective cohort]	0.0	2	1	1	1
15895	361	pharmacological treatment current treatment	[Pharmacological treatment current treatment]	0.0	4	1	1	1
15896	361	improvement of inflammatory biomarker	[improvement of inflammatory biomarkers]	0.0	4	1	1	1
15897	361	recently for patient as destination therapy	[recently for patients as destination therapy]	0.0	6	1	1	1
15898	361	consecutive patient aged 40 year	[consecutive patients aged 40 years]	0.0	5	1	1	1
15899	361	5.1 million American	[5.1 million Americans]	0.0	3	1	1	1
15900	361	two population	[two populations]	0.0	2	1	1	1
15901	361	treatment in exertional increase	[treatment in exertional increase]	0.0	4	1	1	1
15902	361	long cost-effectiveness analysis	[long-term cost-effectiveness analyses]	0.0	3	1	1	1
15903	361	manage significant bleed in this population	[managing significant bleeding in this population]	0.0	6	1	1	1
15904	361	demographic characteristic use	[demographic characteristics use]	0.0	3	1	1	1
15905	361	MEDLINE database	[MEDLINE databases]	0.0	2	1	1	1
15906	361	RV failure after the insertion	[RV failure after the insertion]	0.0	5	1	1	1
15907	361	human resistin Retn	[human resistin Retn]	0.0	3	1	1	1
15908	361	conscious New Zealand rabbit undergo DNx	[conscious New Zealand rabbits undergoing DNx]	0.0	6	1	1	1
15909	361	all-cause hospitalization within the 1 month	[all-cause hospitalization within the 1 months]	0.0	6	1	1	1
15910	361	improvement of cardiac nt-probnp biomarker	[improvement of cardiac NT-ProBNP biomarkers]	0.0	5	1	1	1
15911	361	four-week training period with training	[four-week training period with trainings]	0.0	5	1	1	1
15912	361	23.7 ng interquartile range	[23.7 ng interquartile range]	0.0	4	1	1	1
15913	361	above comparison significant	[above comparisons significant]	0.0	3	1	1	1
15914	361	kidney disease median glomerular filtration rate	[kidney disease median glomerular filtration rate]	0.0	6	1	1	1
15915	361	end-systolic pressure	[end-systolic pressure]	0.0	2	1	1	1
15916	361	result with a mva of cm2	[resulting with an MVA of cm2]	0.0	6	1	1	1
15917	361	vivo inhibition	[vivo inhibition]	0.0	2	1	1	1
15918	361	17 trial of agent therapy	[17 trials of agent therapy]	0.0	5	1	1	1
15919	361	decoy vegf receptor ad-flk	[decoy VEGF receptor Ad-Flk]	0.0	4	1	1	1
15920	361	guanylate cyclase	[guanylate cyclase]	0.0	2	1	1	1
15921	361	tethering	[tethering]	0.0	1	1	1	1
15922	361	event-free rate by kccq category	[event-free rates by KCCQ category]	0.0	5	1	1	1
15923	361	hazard of cardiovascular event	[hazards of cardiovascular events]	0.0	4	1	1	1
15924	361	one model	[one model]	0.0	2	1	1	1
15925	361	early medical management	[early medical management]	0.0	3	1	1	1
15926	361	small difference among ef bnp	[smallest difference among EF BNP]	0.0	5	1	1	1
15927	361	different metric	[different metric]	0.0	2	1	1	1
15928	361	brain peptide BNP level	[brain peptide BNP levels]	0.0	4	1	1	1
15929	361	fractional area change	[fractional area change]	0.0	3	1	1	1
15930	361	promising alternative	[promising alternative]	0.0	2	1	1	1
15931	361	200 HeartWare patient	[200 HeartWare patients]	0.0	3	1	1	1
15932	361	left diastolic function	[left diastolic function]	0.0	3	2	2	1
15933	361	Arg16	[Arg16]	0.0	1	1	1	1
15934	361	day of hospital discharge	[days of hospital discharge]	0.0	4	1	1	1
15935	361	cost per patient	[cost per patient]	0.0	3	1	1	1
15936	361	Centers for Medicare Service	[Centers for Medicare Services]	0.0	4	1	1	1
15937	361	normalize	[normalizing]	0.0	1	1	1	1
15938	361	medical treatment for HF with vasodilator	[medical treatment for HF with vasodilators]	0.0	6	1	1	1
15939	361	association of impairment with mortality	[association of impairment with mortality]	0.0	5	1	1	1
15940	361	ongoing gdmt treatment group for month	[ongoing GDMT treatment group for months]	0.0	6	1	1	1
15941	361	150 minute	[150 minutes]	0.0	2	1	1	1
15942	361	impact on quality	[impact on quality]	0.0	3	1	1	1
15943	361	ZSF1 group	[ZSF1 groups]	0.0	2	1	1	1
15944	361	circulatory assist	[circulatory assist]	0.0	2	1	1	1
15945	361	undergo lvad implantation from 2000	[undergoing LVAD implantation from 2000]	0.0	5	1	1	1
15946	361	mouse model lack resistin	[mouse model lacking resistin]	0.0	4	1	1	1
15947	361	novel intracellular antiadrenergic strategy	[novel intracellular antiadrenergic strategy]	0.0	4	1	1	1
15948	361	Ehrlich carcinoma	[Ehrlich carcinoma]	0.0	2	1	1	1
15949	361	African American AAs	[African Americans AAs]	0.0	3	1	1	1
15950	361	difference histologically	[difference histologically]	0.0	2	1	1	1
15951	361	system modulation	[system modulation]	0.0	2	1	1	1
15952	361	right contractile reserve in patient	[right contractile reserve in patients]	0.0	5	2	2	1
15953	361	datum examine outcome	[data examining outcomes]	0.0	3	1	1	1
15954	361	moderate evidence from trial	[Moderate evidence from trials]	0.0	4	1	1	1
15955	361	medical hospitalization	[medical hospitalization]	0.0	2	2	2	1
15956	361	basis pressure	[basis pressure]	0.0	2	1	1	1
15957	361	beta-blocker dose after month	[Beta-blocker dose after months]	0.0	4	1	1	1
15958	361	experience distressing cardioverter-defibrillator shock	[experiencing distressing cardioverter-defibrillator shocks]	0.0	4	1	1	1
15959	361	require pump replacement	[requiring pump replacement]	0.0	3	1	1	1
15960	361	development of ms	[development of MS]	0.0	3	1	1	1
15961	361	site-specific monoclonal antibody	[site-specific monoclonal antibodies]	0.0	3	1	1	1
15962	361	patient require lvad	[patients requiring LVAD]	0.0	3	1	1	1
15963	361	non-survivor 64.26 year year	[non-survivors 64.26 years years]	0.0	4	1	1	1
15964	361	ejection fraction pef	[ejection fraction pEF]	0.0	3	1	1	1
15965	361	acute HF trial	[acute HF trials]	0.0	3	1	1	1
15966	361	fatal arrhythmia event	[fatal arrhythmia events]	0.0	3	1	1	1
15967	361	exercise training on endothelial function	[exercise training on endothelial function]	0.0	5	1	1	1
15968	361	role include nuclear factor	[role including nuclear factor]	0.0	4	1	1	1
15969	361	cardioverter defibrillator icd	[cardioverter defibrillators ICDs]	0.0	3	1	1	1
15970	361	use of beta-blocker	[use of beta-blockers]	0.0	3	1	1	1
15971	361	study-a multicenter study of exercise training	[study-a multicenter study of exercise training]	0.0	6	1	1	1
15972	361	most powerful predictor period	[most powerful predictor period]	0.0	4	1	1	1
15973	361	hyperkalemia in American AAs	[hyperkalemia in Americans AAs]	0.0	4	1	1	1
15974	361	acs problem	[ACS problems]	0.0	2	1	1	1
15975	361	fifty-four asymptomatic Fontan patient	[Fifty-four asymptomatic Fontan patients]	0.0	4	1	1	1
15976	361	≥3 co-morbidity	[≥3 co-morbidities]	0.0	2	1	1	1
15977	361	treatment of MI animal	[Treatment of MI animals]	0.0	4	1	1	1
15978	361	have ≥1 predictor	[having ≥1 predictor]	0.0	3	1	1	1
15979	361	framework	[framework]	0.0	1	1	1	1
15980	361	change no production	[changes NO production]	0.0	3	1	1	1
15981	361	difference between two group patient	[difference between two groups patients]	0.0	5	1	1	1
15982	361	increase in function	[increase in function]	0.0	3	1	1	1
15983	361	assessor	[assessors]	0.0	1	1	1	1
15984	361	management of bleed	[management of bleeding]	0.0	3	1	1	1
15985	361	334 patient 224 man mean	[334 patients 224 men mean]	0.0	5	1	1	1
15986	361	further adjustment	[Further adjustment]	0.0	2	1	1	1
15987	361	include factor of T cell nfat	[including factor of T cells NFAT]	0.0	6	1	1	1
15988	361	implantable deactivation preference	[implantable deactivation preferences]	0.0	3	1	1	1
15989	361	diuretic effect of peptide	[diuretic effect of peptides]	0.0	4	1	1	1
15990	361	such as hospitalisation	[such as hospitalisations]	0.0	3	1	1	1
15991	361	272 consecutive patient undergo lvad implantation	[272 consecutive patients undergoing LVAD implantation]	0.0	6	1	1	1
15992	361	ventricular function in volume overload	[ventricular function in volume overload]	0.0	5	1	1	1
15993	361	myofibrillar	[myofibrillar]	0.0	1	1	1	1
15994	361	induction of hretn resistin mrna	[induction of hRetn resistin mRNA]	0.0	5	1	1	1
15995	361	endpoint death	[endpoint death]	0.0	2	1	1	1
15996	361	RV failure in the setting	[RV failure in the setting]	0.0	5	1	1	1
15997	361	range muscle	[range muscle]	0.0	2	1	1	1
15998	361	infarction with complication	[infarction with complications]	0.0	3	1	1	1
15999	361	year year	[years years]	0.0	2	1	1	1
16000	361	reason for the reduction	[reasons for the reduction]	0.0	4	1	1	1
16001	361	old patient with stable hfpef	[older patients with stable HFPEF]	0.0	5	1	1	1
16002	361	left anterior descending	[left anterior descending]	0.0	3	1	1	1
16003	361	response the difference in heart rate	[response the difference in heart rate]	0.0	6	1	1	1
16004	361	measurement of flow velocity e	[measurement of flow velocities E]	0.0	5	1	1	1
16005	361	measure of health status symptom	[measure of health status symptoms]	0.0	5	1	1	1
16006	361	participatory health intervention	[participatory health interventions]	0.0	3	1	1	1
16007	361	resonance t1 time	[resonance T1 time]	0.0	3	1	1	1
16008	361	consecutive patient with recent onset HFrEF	[consecutive patients with recent onset HFrEF]	0.0	6	1	1	1
16009	361	particularly biomarker	[particularly biomarkers]	0.0	2	1	1	1
16010	361	outcome over month	[outcome over months]	0.0	3	1	1	1
16011	361	growth factor-β signal level	[growth factor-β signaling level]	0.0	4	1	1	1
16012	361	writer protein	[writer proteins]	0.0	2	1	1	1
16013	361	variant encode nonfunctional channel	[variants encoding nonfunctional channels]	0.0	4	1	1	1
16014	361	dysfunction of a rad variant	[dysfunction of a Rad variant]	0.0	5	1	1	1
16015	361	child with undiagnosed heart disease	[children with undiagnosed heart disease]	0.0	5	1	1	1
16016	361	Chinese medicine CHM	[Chinese medicine CHM]	0.0	3	1	1	1
16017	361	beneficial effect from exercise training	[beneficial effects from exercise training]	0.0	5	1	1	1
16018	361	moderate-severe right dysfunction	[moderate-severe right dysfunction]	0.0	3	1	1	1
16019	361	difference in heart rate	[difference in heart rate]	0.0	4	1	1	1
16020	361	decline in eGFR	[decline in eGFR]	0.0	3	1	1	1
16021	361	five death occur within day	[five deaths occurring within days]	0.0	5	1	1	1
16022	361	right pump function	[right pump function]	0.0	3	1	1	1
16023	361	all-cause readmission acr	[all-cause readmission ACR]	0.0	3	1	1	1
16024	361	midregional proanp MR-proANP	[midregional proANP MR-proANP]	0.0	3	1	1	1
16025	361	consistency among patient	[consistency among patients]	0.0	3	1	1	1
16026	361	R. cluster analysis	[R. Cluster analysis]	0.0	3	1	1	1
16027	361	protective effect on function	[protective effects on function]	0.0	4	1	1	1
16028	361	surgical correction of aortic valve insufficiency	[Surgical correction of aortic valve insufficiency]	0.0	6	1	1	1
16029	361	Mechanistic insight into prolonged electromechanical delay	[Mechanistic insight into prolonged electromechanical delay]	0.0	6	1	1	1
16030	361	thirty-seven hospital	[thirty-seven hospitals]	0.0	2	1	1	1
16031	361	early mitral annular velocity 3.1	[early mitral annular velocity 3.1]	0.0	5	1	1	1
16032	361	age of year	[age of years]	0.0	3	1	1	1
16033	361	such as diabete mellitus	[such as diabetes mellitus]	0.0	4	1	1	1
16034	361	beta-blocker on activity	[beta-blockers on activity]	0.0	3	1	1	1
16035	361	powerful independent predictor of outcome	[powerful independent predictor of outcome]	0.0	5	1	1	1
16036	361	925 ed visit age year	[925 ED visits age years]	0.0	5	1	1	1
16037	361	trial of agent therapy	[trials of agent therapy]	0.0	4	1	1	1
16038	361	risk for the outcome	[risk for the outcome]	0.0	4	1	1	1
16039	361	Global left ventricular strain	[Global left ventricular strain]	0.0	4	1	1	1
16040	361	contribution of haemodynamic abnormality	[contribution of haemodynamic abnormalities]	0.0	4	1	1	1
16041	361	energy x-ray absorptiometry	[energy X-ray absorptiometry]	0.0	3	1	1	1
16042	361	iiib	[IIIB]	0.0	1	1	1	1
16043	361	level of transition marker	[level of transition markers]	0.0	4	1	1	1
16044	361	similar risk of mortality	[similar risk of mortality]	0.0	4	1	1	1
16045	361	receptor signal in healthy cardiomyocyte	[receptor signaling in healthy cardiomyocytes]	0.0	5	1	1	1
16046	361	porcine model of ischemia stent	[porcine model of ischemia stent]	0.0	5	1	1	1
16047	361	Healthcare Procedure Coding System code	[Healthcare Procedure Coding System codes]	0.0	5	1	1	1
16048	361	disease management program	[disease management programs]	0.0	3	2	2	1
16049	361	uniform nomenclature for right failure	[uniform nomenclature for right failure]	0.0	5	1	1	1
16050	361	longitudinal strain GLS	[longitudinal strain GLS]	0.0	3	1	1	1
16051	361	age man	[age men]	0.0	2	1	1	1
16052	361	race in patient with HF	[race in patients with HF]	0.0	5	1	1	1
16053	361	odd ratio of 2.2	[odds ratio of 2.2]	0.0	4	1	1	1
16054	361	alteration in marker of SkM growth	[alterations in markers of SkM growth]	0.0	6	1	1	1
16055	361	use Cochrane effective Practice	[using Cochrane Effective Practice]	0.0	4	1	1	1
16056	361	muscle mass r=0.67	[muscle mass r=0.67]	0.0	3	1	1	1
16057	361	conscious New Zealand rabbit	[conscious New Zealand rabbits]	0.0	4	1	1	1
16058	361	detailed analysis	[Detailed analysis]	0.0	2	1	1	1
16059	361	resistance training	[resistance training]	0.0	2	1	1	1
16060	361	bundle branch block activation sequence	[bundle branch block activation sequence]	0.0	5	1	1	1
16061	361	10 transplant patient receive PD	[10 transplant patients receiving PD]	0.0	5	1	1	1
16062	361	tachycardia in response indicative	[tachycardia in response indicative]	0.0	4	1	1	1
16063	361	risk hazard ratio 0.91	[risk hazard ratio 0.91]	0.0	4	1	1	1
16064	361	study enrollment	[study enrollment]	0.0	2	1	1	1
16065	361	minute walk test distance	[min walk test distance]	0.0	4	1	1	1
16066	361	index versus 2.8 L 2	[index versus 2.8 L 2]	0.0	5	1	1	1
16067	361	iii heart failure	[III heart failure]	0.0	3	1	1	1
16068	361	Cardiac amyloidosis	[Cardiac amyloidosis]	0.0	2	1	1	1
16069	361	patient gender odd ratio	[patients gender odds ratio]	0.0	4	1	1	1
16070	361	grading	[grading]	0.0	1	1	1	1
16071	361	patient mean age	[patients mean age]	0.0	3	1	1	1
16072	361	Multivariate regression analysis	[Multivariate regression analysis]	0.0	3	1	1	1
16073	361	absolute risk	[absolute risk]	0.0	2	1	1	1
16074	361	protein content	[protein content]	0.0	2	1	1	1
16075	361	charm	[CHARM]	0.0	1	1	1	1
16076	361	patient survive a infarction	[patients surviving an infarction]	0.0	4	1	1	1
16077	361	percutaneous one model	[percutaneous one model]	0.0	3	1	1	1
16078	361	addition indicate possible suboptimal care	[addition indicating possible suboptimal care]	0.0	5	1	1	1
16079	361	ischemic conditioning	[ischemic conditioning]	0.0	2	1	1	1
16080	361	von willebrand	[von Willebrand]	0.0	2	1	1	1
16081	361	relationship between qrs duration of benefit	[relationship between QRS duration of benefit]	0.0	6	1	1	1
16082	361	Fig 1B	[Fig 1B]	0.0	2	1	1	1
16083	361	novel approach for the treatment	[novel approach for the treatment]	0.0	5	1	1	1
16084	361	bottleneck stent model	[bottleneck stent model]	0.0	3	1	1	1
16085	361	turn off Mena overexpression	[turning off Mena overexpression]	0.0	4	1	1	1
16086	361	two group patient	[two groups patients]	0.0	3	1	1	1
16087	361	2-fold risk	[2-fold risk]	0.0	2	1	1	1
16088	361	North America	[North America]	0.0	2	2	2	1
16089	361	Cardiac amyloidosis about a case	[Cardiac amyloidosis about an case]	0.0	5	1	1	1
16090	361	n=44 925 ed visit age	[n=44 925 ED visits age]	0.0	5	1	1	1
16091	361	promote cardiac fill during exercise	[promoting cardiac filling during exercise]	0.0	5	1	1	1
16092	361	effector molecule	[effector molecules]	0.0	2	1	1	1
16093	361	require intervention	[requiring intervention]	0.0	2	1	1	1
16094	361	myxoma	[myxoma]	0.0	1	2	2	1
16095	361	ss 31	[SS 31]	0.0	2	1	1	1
16096	361	even with normal ventricular function	[even with normal ventricular function]	0.0	5	1	1	1
16097	361	resonance t1 mapping	[resonance T1 mapping]	0.0	3	1	1	1
16098	361	aberrant reactivation of gene program	[aberrant reactivation of gene programs]	0.0	5	1	1	1
16099	361	cardiac volume overload	[cardiac volume overload]	0.0	3	1	1	1
16100	361	regional strain contribution	[regional strain contributions]	0.0	3	1	1	1
16101	361	398 patient	[398 patients]	0.0	2	1	1	1
16102	361	patient with cardiomyopathy in Tuscany	[patients with cardiomyopathy in Tuscany]	0.0	5	1	1	1
16103	361	use historical datum	[using historical data]	0.0	3	1	1	1
16104	361	hemodynamic feature similar	[hemodynamic features similar]	0.0	3	1	1	1
16105	361	plane excursion	[plane excursion]	0.0	2	1	1	1
16106	361	b-type peptide	[B-type peptide]	0.0	2	4	4	1
16107	361	Large-scale multicenter trial Paradigm-hf with individual	[Large-scale multicenter trial PARADIGM-HF with individuals]	0.0	6	1	1	1
16108	361	colony-forming unit	[colony-forming units]	0.0	2	1	1	1
16109	361	ventricular RV annular plane excursion tapse	[ventricular RV annular plane excursion TAPSE]	0.0	6	1	1	1
16110	361	proteome change	[proteome changes]	0.0	2	1	1	1
16111	361	pulmonary artery pressure increase by means	[pulmonary artery pressure increase by means]	0.0	6	1	1	1
16112	361	impact on therapy	[impact on therapy]	0.0	3	1	1	1
16113	361	symptom despite maximal medical treatment	[symptoms despite maximal medical treatment]	0.0	5	1	1	1
16114	361	LCX late 2-vessel model	[LCX later 2-vessel model]	0.0	4	1	1	1
16115	361	index L 2	[index L 2]	0.0	3	1	1	1
16116	361	life assessment	[life assessment]	0.0	2	1	1	1
16117	361	oppose action	[opposing actions]	0.0	2	2	2	1
16118	361	HF for HF	[HF for HF]	0.0	3	1	1	1
16119	361	low mg daily equivalent dose	[low mg daily equivalent dose]	0.0	5	1	1	1
16120	361	powerful predictor period	[powerful predictor period]	0.0	3	1	1	1
16121	361	bnp level pg	[BNP levels pg]	0.0	3	1	1	1
16122	361	concordance c	[concordance c]	0.0	2	1	1	1
16123	361	cardiac resonance	[cardiac resonance]	0.0	2	1	1	1
16124	361	1.6 vs. 0.8 reason per patient	[1.6 vs. 0.8 reasons per patient]	0.0	6	1	1	1
16125	361	fifty-four predominantly asymptomatic Fontan patient	[Fifty-four predominantly asymptomatic Fontan patients]	0.0	5	1	1	1
16126	361	systolic pressure relationship a index	[systolic pressure relationship an index]	0.0	5	1	1	1
16127	361	5.0 42.4 gram	[5.0 42.4 g]	0.0	3	1	1	1
16128	361	left function assessment	[left function assessment]	0.0	3	1	1	1
16129	361	transoesophageal guidance under general anaesthesia	[transoesophageal guidance under general anaesthesia]	0.0	5	1	1	1
16130	361	130 patient	[130 patients]	0.0	2	1	1	1
16131	361	heart failure with function	[heart failure with function]	0.0	4	1	1	1
16132	361	three metric	[three metrics]	0.0	2	1	1	1
16133	361	independent prognostic marker	[independent prognostic markers]	0.0	3	1	1	1
16134	361	repolarization instability	[repolarization instability]	0.0	2	1	1	1
16135	361	glomerular filtration rate of millileter	[glomerular filtration rate of mL]	0.0	5	2	2	1
16136	361	Transoesophageal echocardiography	[Transoesophageal echocardiography]	0.0	2	1	1	1
16137	361	beta-blocker on activity in patient	[beta-blockers on activity in patients]	0.0	5	1	1	1
16138	361	peritoneal	[Peritoneal]	0.0	1	1	1	1
16139	361	idiopathic cardiomyopathy include negative angiography	[idiopathic cardiomyopathy including negative angiography]	0.0	5	1	1	1
16140	361	2.08 event	[2.08 events]	0.0	2	1	1	1
16141	361	N-terminal pro-b-type peptide nt-probnp	[N-terminal pro-B-type peptide NT-proBNP]	0.0	4	1	1	1
16142	361	patient class	[Patients class]	0.0	2	1	1	1
16143	361	septum biopsy	[septum biopsies]	0.0	2	1	1	1
16144	361	blood pressure control	[blood pressure control]	0.0	3	1	1	1
16145	361	patient care	[patient care]	0.0	2	1	1	1
16146	361	8-fluo-cAMP binding by type	[8-fluo-cAMP binding by type]	0.0	4	1	1	1
16147	361	left ventricular systolic function	[left ventricular systolic function]	0.0	4	1	1	1
16148	361	condition such as acute myocardial infarction	[conditions such as acute myocardial infarction]	0.0	6	1	1	1
16149	361	hazard ratio across CRF category	[hazard ratios across CRF categories]	0.0	5	1	1	1
16150	361	systolic function in volume overload	[systolic function in volume overload]	0.0	5	1	1	1
16151	361	clinical parameter in af	[clinical parameters in AF]	0.0	4	1	1	1
16152	361	cardiovascular complication stroke	[cardiovascular complications stroke]	0.0	3	1	1	1
16153	361	impact on gross development	[impact on gross development]	0.0	4	1	1	1
16154	361	suburban hospital in Jersey	[suburban hospitals in Jersey]	0.0	4	1	1	1
16155	361	esrd from the Registry on Dialysis	[ESRD from the Registry on Dialysis]	0.0	6	1	1	1
16156	361	hospitalization in congestive heart failure	[hospitalizations in congestive heart failure]	0.0	5	1	1	1
16157	361	detailed transcriptional analysis of tissue	[Detailed transcriptional analysis of tissue]	0.0	5	1	1	1
16158	361	improvement in one	[improvement in one]	0.0	3	1	1	1
16159	361	Psychometric testing	[Psychometric testing]	0.0	2	1	1	1
16160	361	future 30-day	[future 30-day]	0.0	2	1	1	1
16161	361	advanced heart disease	[advanced heart disease]	0.0	3	1	1	1
16162	361	cardiopulmonary exercise variable	[cardiopulmonary exercise variables]	0.0	3	1	1	1
16163	361	hospitalization a case series	[hospitalizations a case series]	0.0	4	1	1	1
16164	361	Impact after discharge	[Impact after discharge]	0.0	3	1	1	1
16165	361	use neonatal rat cardiomyocyte	[Using neonatal rat cardiomyocytes]	0.0	4	1	1	1
16166	361	global systolic strain	[global systolic strain]	0.0	3	1	1	1
16167	361	left systolic strain GLS	[left systolic strain GLS]	0.0	4	1	1	1
16168	361	include hypertension	[including hypertension]	0.0	2	1	1	1
16169	361	model system	[model system]	0.0	2	1	1	1
16170	361	change with treatment in increase	[change with treatment in increase]	0.0	5	1	1	1
16171	361	oscillation originate	[oscillations originating]	0.0	2	1	1	1
16172	361	impact on health-related quality	[impact on health-related quality]	0.0	4	1	1	1
16173	361	lean mass index	[lean mass index]	0.0	3	1	1	1
16174	361	chain	[chain]	0.0	1	1	1	1
16175	361	heart failure with renal dysfunction	[heart failure with renal dysfunction]	0.0	5	1	1	1
16176	361	signalling pathway	[signalling pathways]	0.0	2	1	1	1
16177	361	search of the electronic database	[search of the electronic databases]	0.0	5	1	1	1
16178	361	relationship between ventricular RV function	[relationships between ventricular RV function]	0.0	5	1	1	1
16179	361	appropriate end point	[appropriate end points]	0.0	3	1	1	1
16180	361	amino-terminal peptide	[amino-terminal peptide]	0.0	2	1	1	1
16181	361	surgical method of constriction tac	[surgical method of constriction TAC]	0.0	5	1	1	1
16182	361	necessitate a understanding	[necessitating a understanding]	0.0	3	1	1	1
16183	361	70 versus ≥70 bpm 17.5±5.5 p	[70 versus ≥70 bpm 17.5±5.5 P]	0.0	6	1	1	1
16184	361	15 millileter per m 2	[15 mL per m 2]	0.0	5	1	1	1
16185	361	well-treated cohort of patient	[well-treated cohort of patients]	0.0	4	1	1	1
16186	361	high-density lipoprotein	[High-density lipoprotein]	0.0	2	1	1	1
16187	361	normal ejection fraction	[normal ejection fraction]	0.0	3	1	1	1
16188	361	849 patient	[849 patients]	0.0	2	1	1	1
16189	361	moderate-intensity aerobic exercise	[moderate-intensity aerobic exercise]	0.0	3	1	1	1
16190	361	insulin-signaling component regulate metabolism	[insulin-signaling components regulating metabolism]	0.0	4	1	1	1
16191	361	gene deg between heart failure sample	[genes DEGs between heart failure samples]	0.0	6	1	1	1
16192	361	ejection time complicate pulmonary hypertension	[ejection time complicating pulmonary hypertension]	0.0	5	1	1	1
16193	361	hno donor cxl-1020	[HNO donor CXL-1020]	0.0	3	1	1	1
16194	361	exercise parameter for diagnosis	[exercise parameters for diagnosis]	0.0	4	1	1	1
16195	361	other factor at admission	[Other factors at admission]	0.0	4	1	1	1
16196	361	right ejection fraction p=0.01	[right ejection fraction P=0.01]	0.0	4	1	1	1
16197	361	peptide drug	[peptide drugs]	0.0	2	1	1	1
16198	361	antibody target epitope	[antibodies targeting epitopes]	0.0	3	1	1	1
16199	361	impact of the treatment strategy	[impact of the treatment strategies]	0.0	5	1	1	1
16200	361	pulmonary arterial pressure relationship	[pulmonary arterial pressure relationship]	0.0	4	1	1	1
16201	361	future a cardiology-cardiovascular surgery consensus report	[Future A Cardiology-Cardiovascular Surgery Consensus Report]	0.0	6	1	1	1
16202	361	Hospital Compare	[Hospital Compare]	0.0	2	1	1	1
16203	361	Global left longitudinal systolic strain	[Global left longitudinal systolic strain]	0.0	5	1	1	1
16204	361	Survival after left ventricular assist device	[Survival after left ventricular assist device]	0.0	6	1	1	1
16205	361	matrix accumulation	[matrix accumulation]	0.0	2	1	1	1
16206	361	MI animal with metoprolol	[MI animals with metoprolol]	0.0	4	1	1	1
16207	361	pump dysfunction	[pump dysfunction]	0.0	2	1	1	1
16208	361	proximal LCX late model	[proximal LCX later model]	0.0	4	1	1	1
16209	361	death in the control group	[deaths in the control group]	0.0	5	1	1	1
16210	361	aas race	[AAs race]	0.0	2	1	1	1
16211	361	restoration of plasma membrane level	[restoration of plasma membrane levels]	0.0	5	1	1	1
16212	361	old woman	[older women]	0.0	2	1	1	1
16213	361	protein-C	[protein-C]	0.0	1	1	1	1
16214	361	situation in pediatrics	[situations in pediatrics]	0.0	3	1	1	1
16215	361	complex V activity	[complex V activity]	0.0	3	1	1	1
16216	361	mechanical circulatory support	[mechanical circulatory support]	0.0	3	1	1	1
16217	361	potential as novel target	[potential as novel targets]	0.0	4	1	1	1
16218	361	relative importance	[relative importance]	0.0	2	1	1	1
16219	361	free wall rs	[free wall RS]	0.0	3	1	1	1
16220	361	brain natriuretic peptide level	[brain natriuretic peptide levels]	0.0	4	1	1	1
16221	361	energy substrate metabolism	[energy substrate metabolism]	0.0	3	1	1	1
16222	361	hospitalization in refractory congestive heart failure	[hospitalizations in refractory congestive heart failure]	0.0	6	1	1	1
16223	361	artery systolic pressure pasp increase	[artery systolic pressure PASP increase]	0.0	5	1	1	1
16224	361	multivariate-adjusted odd ratio	[multivariate-adjusted odds ratio]	0.0	3	1	1	1
16225	361	global left ventricular strain	[global left ventricular strain]	0.0	4	1	1	1
16226	361	angiotensin infusion	[angiotensin infusion]	0.0	2	1	1	1
16227	361	change in the ratio	[change in the ratio]	0.0	4	1	1	1
16228	361	treatment for HF with vasodilator	[treatment for HF with vasodilators]	0.0	5	1	1	1
16229	361	extensive characterization	[extensive characterization]	0.0	2	1	1	1
16230	361	use the surgical method of constriction	[using the surgical method of constriction]	0.0	6	1	1	1
16231	361	cardiotoxicity a agent	[cardiotoxicity a agent]	0.0	3	1	1	1
16232	361	type ii regulatory subunit expression	[type II regulatory subunit expression]	0.0	5	1	1	1
16233	361	time after valve plasty	[time after valve plasty]	0.0	4	1	1	1
16234	361	muscle sarcomere	[muscle sarcomere]	0.0	2	1	1	1
16235	361	jugular pressure	[jugular pressure]	0.0	2	1	1	1
16236	361	race training	[race training]	0.0	2	1	1	1
16237	361	several change	[several changes]	0.0	2	1	1	1
16238	361	good information	[better information]	0.0	2	1	1	1
16239	361	65 year	[65 years]	0.0	2	1	1	1
16240	361	area auc	[area AUC]	0.0	2	1	1	1
16241	361	investigate hf-related cachexia	[investigating HF-related cachexia]	0.0	3	1	1	1
16242	361	major component regulate cellular metabolism	[major components regulating cellular metabolism]	0.0	5	1	1	1
16243	361	cad involve the left descend artery	[CAD involving the left descending artery]	0.0	6	1	1	1
16244	361	kidney disease filtration rate	[kidney disease filtration rate]	0.0	4	1	1	1
16245	361	Swedish Inpatient Registry	[Swedish Inpatient Registry]	0.0	3	1	1	1
16246	361	sympathetic activity by (123)i-meta-iodobenzylguanidine ((123)i-mibg	[sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]	0.0	5	1	1	1
16247	361	hospital in a decile	[hospitals in an decile]	0.0	4	1	1	1
16248	361	novel target for heart failure	[novel targets for heart failure]	0.0	5	1	1	1
16249	361	index ed	[index ED]	0.0	2	1	1	1
16250	361	high event rate	[highest event rate]	0.0	3	1	1	1
16251	361	ejection fraction HF in condition	[ejection fraction HF in conditions]	0.0	5	1	1	1
16252	361	significant improvement in rate	[significant improvement in rate]	0.0	4	1	1	1
16253	361	center retrospective study in child	[center retrospective study in children]	0.0	5	1	1	1
16254	361	diuretic response	[diuretic response]	0.0	2	1	1	1
16255	361	open surgery	[open surgery]	0.0	2	1	1	1
16256	361	antiadrenergic therapeutic strategy	[antiadrenergic therapeutic strategy]	0.0	3	1	1	1
16257	361	hazard ratio for peak	[hazard ratio for peak]	0.0	4	1	1	1
16258	361	significant change with exercise effect	[significant change with exercise effect]	0.0	5	1	1	1
16259	361	addition indicate possible care	[addition indicating possible care]	0.0	4	1	1	1
16260	361	obstruction	[obstruction]	0.0	1	1	1	1
16261	361	absence in patient	[absence in patients]	0.0	3	1	1	1
16262	361	sternotomy for aortic valve procedure	[sternotomy for aortic valve procedures]	0.0	5	1	1	1
16263	361	28 hospitalisation	[28 hospitalisations]	0.0	2	1	1	1
16264	361	determination of a cutoff value	[Determination of a cutoff value]	0.0	5	1	1	1
16265	361	thereby decrease risk of HF mortality	[thereby decreasing risk of HF mortality]	0.0	6	1	1	1
16266	361	bet family	[BET family]	0.0	2	1	1	1
16267	361	serious adverse event	[serious adverse events]	0.0	3	1	1	1
16268	361	assembly	[assembly]	0.0	1	1	1	1
16269	361	system major event	[system major events]	0.0	3	1	1	1
16270	361	role of reader	[role of readers]	0.0	3	1	1	1
16271	361	summary in all subdomain	[summary in all subdomains]	0.0	4	1	1	1
16272	361	afterload of patient	[afterload of patients]	0.0	3	1	1	1
16273	361	1.6 reason per patient p	[1.6 reasons per patient P]	0.0	5	1	1	1
16274	361	high frequency	[higher frequency]	0.0	2	1	1	1
16275	361	treadmill exercise testing	[treadmill exercise testing]	0.0	3	1	1	1
16276	361	norepinephrine-induced response	[norepinephrine-induced responses]	0.0	2	1	1	1
16277	361	all-cause mortality after hospitalization for HF	[All-cause mortality after hospitalization for HF]	0.0	6	1	1	1
16278	361	beneficial approach	[beneficial approach]	0.0	2	1	1	1
16279	361	receptor haplotype	[receptor haplotype]	0.0	2	2	2	1
16280	361	e-wave early mitral velocity	[E-wave early mitral velocity]	0.0	4	1	1	1
16281	361	transmitral blood flow velocity	[transmitral blood flow velocity]	0.0	4	1	1	1
16282	361	dopamine on end point reflective	[dopamine on end points reflective]	0.0	5	1	1	1
16283	361	direct observation at the time	[Direct observation at the time]	0.0	5	1	1	1
16284	361	low walking distance peak	[lower walking distance peak]	0.0	4	1	1	1
16285	361	broad discussion about treatment preference	[broader discussions about treatment preferences]	0.0	5	1	1	1
16286	361	can handling in HF	[Ca handling in HF]	0.0	4	1	1	1
16287	361	2.8 L	[2.8 L]	0.0	2	1	1	1
16288	361	moderate-severe dysfunction	[moderate-severe dysfunction]	0.0	2	1	1	1
16289	361	type of lvas HeartMate	[types of LVADs HeartMate]	0.0	4	1	1	1
16290	361	process of repair	[process of repair]	0.0	3	1	1	1
16291	361	level in anthracycline-treated breast cancer patient	[levels in anthracycline-treated breast cancer patients]	0.0	6	1	1	1
16292	361	ventricular ejection fraction HF	[ventricular ejection fraction HF]	0.0	4	1	1	1
16293	361	index E ratio at diastole	[indices E ratio at diastole]	0.0	5	1	1	1
16294	361	≥35 kg	[≥35 kg]	0.0	2	1	1	1
16295	361	patient undergo lvad implantation from 2000	[patients undergoing LVAD implantation from 2000]	0.0	6	1	1	1
16296	361	brief arrest	[brief arrest]	0.0	2	1	1	1
16297	361	risk of hospitalization hazard ratio	[risk of hospitalization hazard ratio]	0.0	5	1	1	1
16298	361	development follow ring annuloplasty	[development following ring annuloplasty]	0.0	4	1	1	1
16299	361	psoriasis patient with mild disease	[Psoriasis patients with mild disease]	0.0	5	1	1	1
16300	361	originate from the pattern generator	[originating from the pattern generator]	0.0	5	1	1	1
16301	361	150 minute of exercise	[150 minutes of exercise]	0.0	4	1	1	1
16302	361	mutant mouse	[mutant mice]	0.0	2	1	1	1
16303	361	advance in treatment for infarction	[Advances in treatment for infarction]	0.0	5	1	1	1
16304	361	month of follow-up datum	[months of follow-up data]	0.0	4	1	1	1
16305	361	hypertrophy of cardiomyocyte	[hypertrophy of cardiomyocytes]	0.0	3	1	1	1
16306	361	logistic analysis	[logistic analysis]	0.0	2	1	1	1
16307	361	measurement at the point of care	[Measurement at the point of care]	0.0	6	1	1	1
16308	361	Grading Assessment methodology	[Grading Assessment methodology]	0.0	3	1	1	1
16309	361	utilize testimony	[Utilizing testimonies]	0.0	2	1	1	1
16310	361	training intervention	[training intervention]	0.0	2	1	1	1
16311	361	therapeutic strategy in HF	[therapeutic strategy in HF]	0.0	4	1	1	1
16312	361	activation PKC-βII	[activation PKC-βII]	0.0	2	1	1	1
16313	361	elevate pressure	[elevated pressure]	0.0	2	1	1	1
16314	361	new-onset ai require surgical intervention	[new-onset AI requiring surgical intervention]	0.0	5	1	1	1
16315	361	extreme N termini	[extreme N termini]	0.0	3	1	1	1
16316	361	factor insight a Trial	[Factors Insights A Trial]	0.0	4	1	1	1
16317	361	cardioverter-defibrillator shock	[cardioverter-defibrillator shocks]	0.0	2	1	1	1
16318	361	heart dilatation after transverse constriction tac	[heart dilatation after transverse constriction TAC]	0.0	6	1	1	1
16319	361	reason for the modest reduction	[reasons for the modest reduction]	0.0	5	1	1	1
16320	361	day of the index	[days of the index]	0.0	4	1	1	1
16321	361	mortality for HF	[mortality for HF]	0.0	3	1	1	1
16322	361	≥1 independent predictor	[≥1 independent predictor]	0.0	3	1	1	1
16323	361	score range	[score range]	0.0	2	1	1	1
16324	361	heterogeneous group	[heterogeneous group]	0.0	2	1	1	1
16325	361	clinical benefit for patient in study	[clinical benefit for patients in studies]	0.0	6	1	1	1
16326	361	filtration rate egfr millileter	[filtration rate eGFR ml]	0.0	4	1	1	1
16327	361	diastolic annular velocity 3.1	[diastolic annular velocity 3.1]	0.0	4	1	1	1
16328	361	n-terminal pro-b-type	[N-terminal pro-B-type]	0.0	2	1	1	1
16329	361	Prognostic value of indeterminable anaerobic threshold	[Prognostic value of indeterminable anaerobic threshold]	0.0	6	1	1	1
16330	361	tool of Patient management intervention	[Tools of Patient Management Interventions]	0.0	5	1	1	1
16331	361	endpoint cardiovascular death	[endpoint cardiovascular death]	0.0	3	1	1	1
16332	361	mitral annulus velocity E	[mitral annulus velocity E]	0.0	4	1	1	1
16333	361	outcome-monitoring phase	[outcome-monitoring phase]	0.0	2	1	1	1
16334	361	hfpef with left ventricular ejection fraction	[HFpEF with left ventricular ejection fraction]	0.0	6	1	1	1
16335	361	transfusion threshold	[transfusion thresholds]	0.0	2	1	1	1
16336	361	change with exercise effect exercise	[change with exercise effect exercise]	0.0	5	1	1	1
16337	361	receptor family member	[receptor family member]	0.0	3	1	1	1
16338	361	o2 consumption rate	[O2 consumption rate]	0.0	3	1	1	1
16339	361	high consistency among patient	[high consistency among patients]	0.0	4	1	1	1
16340	361	10 heart failure patient with tachycardia	[10 heart failure patients with tachycardia]	0.0	6	1	1	1
16341	361	role include factor	[role including factor]	0.0	3	1	1	1
16342	361	tracking	[tracking]	0.0	1	1	1	1
16343	361	readmission ppr	[Readmission PPR]	0.0	2	1	1	1
16344	361	great difference	[greatest difference]	0.0	2	1	1	1
16345	361	age year p=0.016	[age years P=0.016]	0.0	3	1	1	1
16346	361	cardiology-cardiovascular surgery consensus report	[Cardiology-Cardiovascular Surgery Consensus Report]	0.0	4	1	1	1
16347	361	cardiac hypertrophic response protective role	[cardiac hypertrophic response protective role]	0.0	5	1	1	1
16348	361	myocardial infarction in western Australia	[myocardial infarction in Western Australia]	0.0	5	1	1	1
16349	361	time frame	[time frame]	0.0	2	1	1	1
16350	361	phospholipase a2	[phospholipase A2]	0.0	2	1	1	1
16351	361	hypokalemia with spironolactone	[hypokalemia with spironolactone]	0.0	3	1	1	1
16352	361	evidence for usefulness in HF	[evidence for usefulness in HF]	0.0	5	1	1	1
16353	361	nonstandardized N-terminal pro-b-type peptide nt-probnp	[nonstandardized N-terminal pro-B-type peptide NT-proBNP]	0.0	5	1	1	1
16354	361	cardiorespiratory fitness Cooper Center Study	[Cardiorespiratory fitness Cooper Center Study]	0.0	5	1	1	1
16355	361	Lesion CORAL	[Lesions CORAL]	0.0	2	1	1	1
16356	361	part of this study	[part of this study]	0.0	4	1	1	1
16357	361	track VA patient from hfpsi	[tracking VA patients from HFPSI]	0.0	5	1	1	1
16358	361	criterion cardiac transplantation	[criteria cardiac transplantation]	0.0	3	1	1	1
16359	361	new-onset insufficiency	[New-onset insufficiency]	0.0	2	1	1	1
16360	361	readmission rate for patient	[readmission rate for patients]	0.0	4	1	1	1
16361	361	aldosterone receptor	[Aldosterone receptor]	0.0	2	1	1	1
16362	361	Eplerenone in patient hospitalization	[Eplerenone in Patients Hospitalization]	0.0	4	1	1	1
16363	361	medication among outpatient	[medications among outpatients]	0.0	3	1	1	1
16364	361	patient with CHF-NYHA-III	[patients with CHF-NYHA-III]	0.0	3	1	1	1
16365	361	consecutive HF patient ventricular ejection fraction	[consecutive HF patients ventricular ejection fraction]	0.0	6	1	1	1
16366	361	Registry on Dialysis	[Registry on Dialysis]	0.0	3	1	1	1
16367	361	ANG ii infusion	[ANG II infusion]	0.0	3	1	1	1
16368	361	nonsurvivor with a distribution	[nonsurvivors with a distribution]	0.0	4	1	1	1
16369	361	nonfailing canine electromechanic	[nonfailing canine electromechanics]	0.0	3	1	1	1
16370	361	target exercise status	[targeting exercise status]	0.0	3	1	1	1
16371	361	ambulatory HF patient ejection fraction	[ambulatory HF patients ejection fraction]	0.0	5	1	1	1
16372	361	aas 4.32±0.54-4.31±0.49	[AAs 4.32±0.54-4.31±0.49]	0.0	2	1	1	1
16373	361	right area index 10.0 cm(2)	[right area index 10.0 cm(2)]	0.0	5	1	1	1
16374	361	adult rat	[adult rats]	0.0	2	1	1	1
16375	361	stem cardiomyocyte hipsc-ct	[stem cardiomyocytes hiPSC-CMs]	0.0	3	1	1	1
16376	361	heart failure risk	[Heart failure risk]	0.0	3	1	1	1
16377	361	rate of rehospitalization	[rate of rehospitalization]	0.0	3	1	1	1
16378	361	abnormality of gastrointestinal region	[abnormalities of gastrointestinal regions]	0.0	4	1	1	1
16379	361	encode channel	[encoding channels]	0.0	2	1	1	1
16380	361	further analysis	[Further analysis]	0.0	2	1	1	1
16381	361	consist after infarction	[consisting after infarction]	0.0	3	1	1	1
16382	361	day p-value for difference	[days P-value for difference]	0.0	4	1	1	1
16383	361	take all follow-up visit	[Taking all follow-up visits]	0.0	4	1	1	1
16384	361	transmitral e-wave diastolic mitral velocity	[transmitral E-wave diastolic mitral velocity]	0.0	5	1	1	1
16385	361	1.56 percentage point	[1.56 percentage points]	0.0	3	1	1	1
16386	361	still a highly effective agent	[still a highly effective agent]	0.0	5	1	1	1
16387	361	contain heart failure	[containing heart failure]	0.0	3	1	1	1
16388	361	bnp level with the great difference	[BNP levels with the greatest difference]	0.0	6	1	1	1
16389	361	relevance of contractile reserve	[relevance of contractile reserve]	0.0	4	1	1	1
16390	361	impact on patient with bte	[impact on patients with BTES]	0.0	5	1	1	1
16391	361	ambulatory HF patient	[ambulatory HF patients]	0.0	3	1	1	1
16392	361	LV dysfunction alone	[LV dysfunction alone]	0.0	3	1	1	1
16393	361	qol co-primary outcome	[QOL co-primary outcome]	0.0	3	1	1	1
16394	361	body of evidence	[body of evidence]	0.0	3	1	1	1
16395	361	significant 42 percent reduction	[significant 42 percent reduction]	0.0	4	1	1	1
16396	361	limited number	[limited number]	0.0	2	1	1	1
16397	361	membrane oxygenation ecmo on function	[membrane oxygenation ECMO on function]	0.0	5	1	1	1
16398	361	killip	[Killip]	0.0	1	1	1	1
16399	361	symptom despite medical treatment	[symptoms despite medical treatment]	0.0	4	1	1	1
16400	361	change in control group	[changes in control group]	0.0	4	1	1	1
16401	361	renin inhibitor	[renin inhibitors]	0.0	2	1	1	1
16402	361	9 subject with heart	[9 subjects with hearts]	0.0	4	1	1	1
16403	361	CI for HF respectively	[CI for HF respectively]	0.0	4	1	1	1
16404	361	acute system modulation on QTV	[acute system modulation on QTV]	0.0	5	1	1	1
16405	361	embryonic kidney	[embryonic kidney]	0.0	2	1	1	1
16406	361	patient with left ventricular ejection fraction	[patients with left ventricular ejection fraction]	0.0	6	1	1	1
16407	361	effective elastance end-systolic elastance ees	[Effective elastance end-systolic elastance Ees]	0.0	5	1	1	1
16408	361	amelioration of the ingenuity pathway analysis	[amelioration of the ingenuity pathway analysis]	0.0	6	1	1	1
16409	361	one model for chronic ischemia	[one model for chronic ischemia]	0.0	5	1	1	1
16410	361	patient in retrospective study	[patients in retrospective studies]	0.0	4	1	1	1
16411	361	Addition of HABC battery score discrimination	[Addition of HABC Battery scores discrimination]	0.0	6	1	1	1
16412	361	mt group day	[MT group days]	0.0	3	1	1	1
16413	361	cutoff value for survival	[cutoff value for survival]	0.0	4	1	1	1
16414	361	promote cardiac fill	[promoting cardiac filling]	0.0	3	1	1	1
16415	361	low national income	[lower national income]	0.0	3	1	1	1
16416	361	dietary approach	[dietary approaches]	0.0	2	1	1	1
16417	361	t1 of minute	[t1 of minutes]	0.0	3	1	1	1
16418	361	sphingosine-1-phosphate receptor	[sphingosine-1-phosphate receptor]	0.0	2	1	1	1
16419	361	test for HFpEF	[test for HFpEF]	0.0	3	1	1	1
16420	361	high confidence	[High confidence]	0.0	2	1	1	1
16421	361	potentially promising biomarker	[potentially promising biomarker]	0.0	3	1	1	1
16422	361	echocardiography at wk	[Echocardiography at wk]	0.0	3	1	1	1
16423	361	include negative coronary angiography	[including negative coronary angiography]	0.0	4	1	1	1
16424	361	trial of erythropoiesis-stimulating agent therapy	[trials of erythropoiesis-stimulating agent therapy]	0.0	5	1	1	1
16425	361	transform	[transforming]	0.0	1	1	1	1
16426	361	good prognostic information than the other	[better prognostic information than the others]	0.0	6	1	1	1
16427	361	foundation of management	[foundation of management]	0.0	3	1	1	1
16428	361	autonomic system modulation on QTV	[autonomic system modulation on QTV]	0.0	5	1	1	1
16429	361	well-recognised risk factor for health	[well-recognised risk factor for health]	0.0	5	1	1	1
16430	361	onset follow infarction	[onset following infarction]	0.0	3	1	1	1
16431	361	ventricular tachycardia storm	[ventricular tachycardia storm]	0.0	3	1	1	1
16432	361	10 lb	[10 lb]	0.0	2	1	1	1
16433	361	12-lead ecg	[12-lead ECG]	0.0	2	1	1	1
16434	361	left longitudinal strain as a predictor	[left longitudinal strain as a predictor]	0.0	6	1	1	1
16435	361	percutaneous intervention hr	[percutaneous intervention HR]	0.0	3	1	1	1
16436	361	even in a patient	[even in a patient]	0.0	4	2	2	1
16437	361	enormous burden in adult medicine	[enormous burden in adult medicine]	0.0	5	1	1	1
16438	361	survive ventricle	[surviving ventricle]	0.0	2	1	1	1
16439	361	Cardiovascular Outcome in Lesion CORAL	[Cardiovascular Outcomes in Lesions CORAL]	0.0	5	1	1	1
16440	361	right ventricular plane excursion	[right ventricular plane excursion]	0.0	4	1	1	1
16441	361	m 2 age	[m 2 age]	0.0	3	1	1	1
16442	361	common medical condition	[common medical conditions]	0.0	3	1	1	1
16443	361	cause of mortality	[cause of mortality]	0.0	3	2	2	1
16444	361	can 2+)-uptake	[Ca 2+)-uptake]	0.0	2	1	1	1
16445	361	STS HH hr	[STS HH HR]	0.0	3	1	1	1
16446	361	global left ventricular longitudinal strain	[global left ventricular longitudinal strain]	0.0	5	1	1	1
16447	361	trend for common condition	[trends for common conditions]	0.0	4	1	1	1
16448	361	Disease Registry	[Disease Registry]	0.0	2	1	1	1
16449	361	rate of hypokalemia	[rates of hypokalemia]	0.0	3	1	1	1
16450	361	outcome of catheter ablation in patient	[outcomes of catheter ablation in patients]	0.0	6	1	1	1
16451	361	antibody target epitope p	[antibodies targeting epitopes P]	0.0	4	1	1	1
16452	361	practice for a number	[practice for a number]	0.0	4	1	1	1
16453	361	cell ec nitric oxide production	[cell EC nitric oxide production]	0.0	5	1	1	1
16454	361	patient with hr bpm p	[patients with HR bpm P]	0.0	5	1	1	1
16455	361	e-wave early mitral annular velocity ratio	[E-wave early mitral annular velocity ratio]	0.0	6	1	1	1
16456	361	great physical activity	[greater physical activity]	0.0	3	1	1	1
16457	361	die in day p-value for difference	[dying in days P-value for difference]	0.0	6	1	1	1
16458	361	type HeartMate	[types HeartMate]	0.0	2	1	1	1
16459	361	Effect of care management a analysis	[Effects of care management a analysis]	0.0	6	1	1	1
16460	361	analysis of tissue from mouse	[analysis of tissue from mice]	0.0	5	1	1	1
16461	361	vascular growth factor	[vascular growth factor]	0.0	3	1	1	1
16462	361	regulate cellular metabolism	[regulating cellular metabolism]	0.0	3	1	1	1
16463	361	presence with proteolysis between pro2-leu3	[presence with proteolysis between Pro2-Leu3]	0.0	5	1	1	1
16464	361	mortality among woman	[mortality among women]	0.0	3	1	1	1
16465	361	undergo procedure	[undergoing procedures]	0.0	2	1	1	1
16466	361	potential for effect	[potential for effects]	0.0	3	1	1	1
16467	361	clinical study hm	[clinical studies HM]	0.0	3	1	1	1
16468	361	evidence-based therapy in this patient	[evidence-based therapies in these patients]	0.0	5	1	1	1
16469	361	intracellular antiadrenergic strategy	[intracellular antiadrenergic strategy]	0.0	3	1	1	1
16470	361	thirty hfpef patient aged year	[Thirty HFpEF patients aged years]	0.0	5	1	1	1
16471	361	similar risk as patient	[similar risk as patients]	0.0	4	1	1	1
16472	361	improvement in ejection fraction	[improvement in ejection fraction]	0.0	4	1	1	1
16473	361	factorial	[factorial]	0.0	1	1	1	1
16474	361	100 obese participant	[100 obese participants]	0.0	3	1	1	1
16475	361	investigate Outcome study-a multicenter study	[Investigating Outcomes study-a multicenter study]	0.0	5	1	1	1
16476	361	measure of ventricular mechanic	[measure of ventricular mechanics]	0.0	4	1	1	1
16477	361	transplant ineligible patient receive PD	[transplant ineligible patients receiving PD]	0.0	5	1	1	1
16478	361	sitagliptin for saxagliptin	[sitagliptin for saxagliptin]	0.0	3	1	1	1
16479	361	14 study hm ii	[14 studies HM II]	0.0	4	1	1	1
16480	361	microstructure at baseline	[microstructure at baseline]	0.0	3	1	1	1
16481	361	functioning of treatment	[functioning of treatments]	0.0	3	1	1	1
16482	361	rat possible mechanism	[rats possible mechanism]	0.0	3	1	1	1
16483	361	left anterior descending lad	[left anterior descending LAD]	0.0	4	1	1	1
16484	361	myocyte from normal heart	[myocytes from normal hearts]	0.0	4	1	1	1
16485	361	volume overload of regurgitation	[volume overload of regurgitation]	0.0	4	1	1	1
16486	361	especially in the case of survival	[especially in the case of survival]	0.0	6	1	1	1
16487	361	indicator of status 6-mwt	[indicators of status 6-MWT]	0.0	4	1	1	1
16488	361	proBNP NT-proBNP	[proBNP NT-proBNP]	0.0	2	1	1	1
16489	361	mi-induced decrease	[MI-induced decreases]	0.0	2	1	1	1
16490	361	stable medical therapy	[stable medical therapy]	0.0	3	1	1	1
16491	361	1-year survival in patient	[1-year survival in patients]	0.0	4	1	1	1
16492	361	paf level	[PAF levels]	0.0	2	1	1	1
16493	361	partial attenuation of proteomics change	[partial attenuation of proteomics changes]	0.0	5	1	1	1
16494	361	significant improvement in composite response	[significant improvements in composite response]	0.0	5	1	1	1
16495	361	independent predictor of outcome period	[independent predictor of outcome period]	0.0	5	1	1	1
16496	361	such as short-term scaling exponent	[such as short-term scaling exponent]	0.0	5	1	1	1
16497	361	understand of heart failure	[Understanding of heart failure]	0.0	4	1	1	1
16498	361	learning from trial	[Learning from trials]	0.0	3	1	1	1
16499	361	history of angina	[history of angina]	0.0	3	1	1	1
16500	361	ventricular fill pressure	[ventricular filling pressure]	0.0	3	1	1	1
16501	361	optimize cardiac progenitor function for application	[optimizing cardiac progenitor function for application]	0.0	6	1	1	1
16502	361	time domain heart rate variability	[time domain heart rate variability]	0.0	5	1	1	1
16503	361	efficacy of interatrial shunting	[efficacy of interatrial shunting]	0.0	4	1	1	1
16504	361	Trial hf-action	[Trial HF-ACTION]	0.0	2	1	1	1
16505	361	new-onset ai	[new-onset AI]	0.0	2	1	1	1
16506	361	effect of inhibition	[Effect of inhibition]	0.0	3	1	1	1
16507	361	risk factor such as obesity	[risk factors such as obesity]	0.0	5	1	1	1
16508	361	24 hour	[24 hours]	0.0	2	1	1	1
16509	361	multicenter placebo-controlled clinical trial of patient	[Multicenter placebo-controlled clinical trial of patients]	0.0	6	1	1	1
16510	361	setting of embolism	[setting of embolism]	0.0	3	1	1	1
16511	361	size reduction by the ring implantation	[size reduction by the ring implantation]	0.0	6	1	1	1
16512	361	response the difference	[response the difference]	0.0	3	1	1	1
16513	361	BNP value	[BNP values]	0.0	2	1	1	1
16514	361	improvement of cardiac biomarker	[improvement of cardiac biomarkers]	0.0	4	1	1	1
16515	361	median pasp increase	[median PASP increase]	0.0	3	1	1	1
16516	361	radial arterial tonometry	[radial arterial tonometry]	0.0	3	1	1	1
16517	361	ongoing gdmt control group	[ongoing GDMT control group]	0.0	4	1	1	1
16518	361	experience distressing cardioverter-defibrillator shock at end	[experiencing distressing cardioverter-defibrillator shocks at end]	0.0	6	1	1	1
16519	361	right after artery ligation	[right after artery ligation]	0.0	4	1	1	1
16520	361	prolonged delay	[prolonged delay]	0.0	2	1	1	1
16521	361	rat ventricular cardiomyocyte	[rat ventricular cardiomyocytes]	0.0	3	1	1	1
16522	361	β-blocker-induced enhancement of angiogenesis	[β-Blocker-induced enhancement of angiogenesis]	0.0	4	1	1	1
16523	361	ventricular structure	[ventricular structure]	0.0	2	1	1	1
16524	361	participant area	[participants area]	0.0	2	1	1	1
16525	361	rad q66p	[Rad Q66P]	0.0	2	2	2	1
16526	361	heart dilatation after aortic constriction	[heart dilatation after aortic constriction]	0.0	5	1	1	1
16527	361	include risk	[including risk]	0.0	2	1	1	1
16528	361	CHF dysfunction	[CHF dysfunction]	0.0	2	1	1	1
16529	361	York heart association class	[York Heart Association class]	0.0	4	2	2	1
16530	361	additional benefit over parameter	[additional benefit over parameters]	0.0	4	1	1	1
16531	361	effect of acute system modulation	[effect of acute system modulation]	0.0	5	1	1	1
16532	361	function with measure	[function with measures]	0.0	3	1	1	1
16533	361	STS HH interval CrI	[STS HH interval CrI]	0.0	4	1	1	1
16534	361	pulmonary resistance p	[pulmonary resistance P]	0.0	3	1	1	1
16535	361	resection	[resection]	0.0	1	1	1	1
16536	361	access programme	[access programme]	0.0	2	1	1	1
16537	361	New York heart Association Class	[New York Heart Association Class]	0.0	5	1	1	1
16538	361	N-terminal natriuretic peptide	[N-terminal natriuretic peptide]	0.0	3	4	4	1
16539	361	improvement of the valve opening	[improvement of the valve opening]	0.0	5	1	1	1
16540	361	characteristic eg use Cochrane effective Practice	[characteristics eg using Cochrane Effective Practice]	0.0	6	1	1	1
16541	361	four common condition	[four common conditions]	0.0	3	1	1	1
16542	361	chronic obstructive disease copd	[chronic obstructive disease COPD]	0.0	4	1	1	1
16543	361	dysfunction treatment paradigm	[dysfunction treatment paradigm]	0.0	3	1	1	1
16544	361	comment	[Comment]	0.0	1	2	2	1
16545	361	American aged	[Americans aged]	0.0	2	1	1	1
16546	361	dtt]-insensitive cdp choline	[DTT]-insensitive CDP choline]	0.0	3	1	1	1
16547	361	2-year study period	[2-year study period]	0.0	3	1	1	1
16548	361	difference among ef median bnp	[difference among EF median BNP]	0.0	5	1	1	1
16549	361	54 patient aged 62.4 year	[54 patients aged 62.4 years]	0.0	5	1	1	1
16550	361	other disease	[other diseases]	0.0	2	1	1	1
16551	361	bpm 17.5±5.5 versus millileter p	[bpm 17.5±5.5 versus mL P]	0.0	5	1	1	1
16552	361	N-terminal natriuretic peptide assessment	[N-terminal natriuretic peptide assessment]	0.0	4	1	1	1
16553	361	acute infarction in western Australia	[acute infarction in Western Australia]	0.0	5	1	1	1
16554	361	many HF trial	[many HF trials]	0.0	3	1	1	1
16555	361	systolic strain as a major predictor	[systolic strain as a major predictor]	0.0	6	1	1	1
16556	361	β-adrenergic receptor agonist	[β-adrenergic receptor agonist]	0.0	3	1	1	1
16557	361	ventricular plane excursion from the end	[ventricular plane excursion from the end]	0.0	6	1	1	1
16558	361	tonometry study	[tonometry study]	0.0	2	1	1	1
16559	361	outcome over 6 month	[outcome over 6 months]	0.0	4	1	1	1
16560	361	good information than the other	[better information than the others]	0.0	5	1	1	1
16561	361	global left systolic strain GLS	[global left systolic strain GLS]	0.0	5	1	1	1
16562	361	optimization strategy evaluation	[Optimization Strategies Evaluation]	0.0	3	1	1	1
16563	361	association of dietary pattern	[associations of dietary patterns]	0.0	4	1	1	1
16564	361	study of transfusion	[studies of transfusion]	0.0	3	1	1	1
16565	361	target epitope p	[targeting epitopes P]	0.0	3	1	1	1
16566	361	transient potential	[transient potential]	0.0	2	1	1	1
16567	361	LVAS	[LVAS]	0.0	1	1	1	1
16568	361	lb in 1 year	[lb in 1 year]	0.0	4	1	1	1
16569	361	mortality at 4 year	[mortality at 4 years]	0.0	4	1	1	1
16570	361	two third	[two thirds]	0.0	2	1	1	1
16571	361	akt→forkhead box	[Akt→forkhead box]	0.0	2	1	1	1
16572	361	systemic hypertension	[systemic hypertension]	0.0	2	1	1	1
16573	361	renal Lesion	[Renal Lesions]	0.0	2	1	1	1
16574	361	59.6 m vs. m	[59.6 m vs. m]	0.0	4	1	1	1
16575	361	insulin receptor substrate irs1	[insulin receptor substrates IRS1]	0.0	4	1	1	1
16576	361	dysfunction by week	[dysfunction by weeks]	0.0	3	1	1	1
16577	361	Baseline	[Baseline]	0.0	1	1	1	1
16578	361	perhaps the important component	[perhaps the important component]	0.0	4	1	1	1
16579	361	change in prognosis	[changes in prognosis]	0.0	3	1	1	1
16580	361	definition of heart failure	[definition of heart failure]	0.0	4	1	1	1
16581	361	myocardial ischemia open stent	[myocardial ischemia open stent]	0.0	4	1	1	1
16582	361	Turkey	[Turkey]	0.0	1	1	1	1
16583	361	coprimary end	[Coprimary end]	0.0	2	1	1	1
16584	361	relevance in the follow-up	[relevance in the follow-up]	0.0	4	1	1	1
16585	361	odd ratio after adjustment	[odds ratio after adjustment]	0.0	4	1	1	1
16586	361	STE analysis of strain	[STE analysis of strain]	0.0	4	1	1	1
16587	361	inoperable chronic hypertension	[inoperable chronic hypertension]	0.0	3	1	1	1
16588	361	isolated heart rate reduction	[isolated heart rate reduction]	0.0	4	1	1	1
16589	361	underlying heart disease	[underlying heart disease]	0.0	3	1	1	1
16590	361	matrix of biopsy n=9	[matrix of biopsies n=9]	0.0	4	1	1	1
16591	361	qrs morphology	[QRS morphology]	0.0	2	2	2	1
16592	361	early blood flow velocity	[early blood flow velocity]	0.0	4	1	1	1
16593	361	benefit over conventional clinical parameter	[benefit over conventional clinical parameters]	0.0	5	1	1	1
16594	361	limitation in model	[limitations in models]	0.0	3	1	1	1
16595	361	complication of therapy in severe HF	[complications of therapy in severe HF]	0.0	6	1	1	1
16596	361	precipitate factor	[precipitating factor]	0.0	2	1	1	1
16597	361	First-in-class angiotensin receptor	[First-in-class angiotensin receptor]	0.0	3	1	1	1
16598	361	quality of life Minnesota live	[quality of life Minnesota Living]	0.0	5	1	1	1
16599	361	absolute change the percent	[absolute change the percent]	0.0	4	1	1	1
16600	361	important outcome	[important outcomes]	0.0	2	1	1	1
16601	361	severe hypertension of 104 mm hg	[severe hypertension of 104 mm Hg]	0.0	6	1	1	1
16602	361	exhaustion	[exhaustion]	0.0	1	1	1	1
16603	361	ratio at diastole with transmitral flow	[ratio at diastole with transmitral flow]	0.0	6	1	1	1
16604	361	least a level	[least a level]	0.0	3	1	1	1
16605	361	change dose	[changing doses]	0.0	2	1	1	1
16606	361	23.7 ng	[23.7 ng]	0.0	2	1	1	1
16607	361	acute ventricular pressure overload rvpo	[acute ventricular pressure overload RVPO]	0.0	5	1	1	1
16608	361	novel hno donor cxl-1020	[novel HNO donor CXL-1020]	0.0	4	1	1	1
16609	361	grade low-quality evidence	[Grade low-quality evidence]	0.0	3	1	1	1
16610	361	subclass	[subclass]	0.0	1	1	1	1
16611	361	left assist device use	[left assist device use]	0.0	4	1	1	1
16612	361	arterial coupling resistance p	[arterial coupling resistance P]	0.0	4	1	1	1
16613	361	scaffold in heart pathology	[scaffolds in heart pathology]	0.0	4	1	1	1
16614	361	ventricular ejection fraction r=0.28 p=0.01	[ventricular ejection fraction R=0.28 P=0.01]	0.0	5	1	1	1
16615	361	include tool	[including tools]	0.0	2	1	1	1
16616	361	right arterial coupling resistance p	[right arterial coupling resistance P]	0.0	5	1	1	1
16617	361	Permanente	[Permanente]	0.0	1	1	1	1
16618	361	treatment for acute infarction	[treatment for acute infarction]	0.0	4	1	1	1
16619	361	kidney cell	[kidney cells]	0.0	2	1	1	1
16620	361	proximal circumflex artery	[proximal circumflex artery]	0.0	3	1	1	1
16621	361	HF patient without spontaneous VT	[HF patients without spontaneous VT]	0.0	5	1	1	1
16622	361	120 consecutive patient	[120 consecutive patients]	0.0	3	1	1	1
16623	361	cardiomyopathy include coronary angiography	[cardiomyopathy including coronary angiography]	0.0	4	1	1	1
16624	361	energy production	[energy production]	0.0	2	1	1	1
16625	361	clinical burden	[clinical burden]	0.0	2	1	1	1
16626	361	add-on diagnostic feature such as detection	[add-on diagnostic features such as detection]	0.0	6	1	1	1
16627	361	pre-specified analysis	[pre-specified analysis]	0.0	2	1	1	1
16628	361	conduction abnormality	[conduction abnormalities]	0.0	2	1	1	1
16629	361	hospital ranking	[hospital rankings]	0.0	2	1	1	1
16630	361	use Classification of Disease	[using Classification of Diseases]	0.0	4	1	1	1
16631	361	early metabolic change	[early metabolic changes]	0.0	3	1	1	1
16632	361	inpatient medical condition	[inpatient medical conditions]	0.0	3	1	1	1
16633	361	myocardial enhancement imaging	[myocardial enhancement imaging]	0.0	3	1	1	1
16634	361	postnatal myocardium	[postnatal myocardium]	0.0	2	1	1	1
16635	361	number of cell in any	[numbers of cells in any]	0.0	5	1	1	1
16636	361	assessment of patient with heart failure	[assessments of patients with heart failure]	0.0	6	1	1	1
16637	361	hemodynamic assessment	[hemodynamic assessments]	0.0	2	1	1	1
16638	361	optimization control heart rate	[optimization controlling heart rate]	0.0	4	1	1	1
16639	361	feature such as detection	[features such as detection]	0.0	4	1	1	1
16640	361	interaction between the randomization group	[interaction between the randomization group]	0.0	5	1	1	1
16641	361	repair	[repair]	0.0	1	1	1	1
16642	361	renal function WRF in EMPHASIS-HF	[renal function WRF in EMPHASIS-HF]	0.0	5	1	1	1
16643	361	exercise parameter	[exercise parameters]	0.0	2	1	1	1
16644	361	consecutive patient 224 man	[consecutive patients 224 men]	0.0	4	1	1	1
16645	361	hand grip	[hand grip]	0.0	2	1	1	1
16646	361	CHF model	[CHF model]	0.0	2	1	1	1
16647	361	error	[error]	0.0	1	3	3	1
16648	361	result of shortcoming	[result of shortcomings]	0.0	3	1	1	1
16649	361	function WRF	[function WRF]	0.0	2	1	1	1
16650	361	Transoesophageal echocardiography at month	[Transoesophageal echocardiography at month]	0.0	4	1	1	1
16651	361	function in cardiac volume overload	[function in cardiac volume overload]	0.0	5	1	1	1
16652	361	cardiac hypertrophy a predictor of HF	[cardiac hypertrophy a predictor of HF]	0.0	6	1	1	1
16653	361	exercise test investigation at study enrollment	[exercise test investigations at study enrollment]	0.0	6	1	1	1
16654	361	521 patient	[521 patients]	0.0	2	1	1	1
16655	361	involve the left anterior descend artery	[involving the left anterior descending artery]	0.0	6	1	1	1
16656	361	circulate fragment of pro-b-type peptide	[Circulating fragments of pro-B-type peptides]	0.0	5	1	1	1
16657	361	mm hg pasp	[mm Hg PASP]	0.0	3	1	1	1
16658	361	left ventricular end diameter mm difference	[left ventricular end diameter mm difference]	0.0	6	1	1	1
16659	361	month of treatment	[months of treatment]	0.0	3	2	2	1
16660	361	patient with unfavorable outcome	[patients with unfavorable outcome]	0.0	4	1	1	1
16661	361	percent of patient	[percent of patients]	0.0	3	1	1	1
16662	361	emergency setting status	[emergency setting status]	0.0	3	1	1	1
16663	361	brachial pressure 155	[brachial pressure 155]	0.0	3	1	1	1
16664	361	Sudden cardiac death	[Sudden cardiac death]	0.0	3	1	1	1
16665	361	Novel tool	[Novel tools]	0.0	2	1	1	1
16666	361	survive a acute myocardial infarction	[surviving an acute myocardial infarction]	0.0	5	1	1	1
16667	361	stage 3 chronic kidney disease	[Stage 3 chronic kidney disease]	0.0	5	1	1	1
16668	361	ventricular longitudinal strain as a predictor	[ventricular longitudinal strain as a predictor]	0.0	6	1	1	1
16669	361	inoperable thromboembolic pulmonary hypertension	[inoperable thromboembolic pulmonary hypertension]	0.0	4	1	1	1
16670	361	rate in patient	[rate in patients]	0.0	3	1	1	1
16671	361	nanomolar dose	[nanomolar doses]	0.0	2	1	1	1
16672	361	ventricular LV systolic pressure	[ventricular LV systolic pressure]	0.0	4	1	1	1
16673	361	individual association among cardiorespiratory fitness	[individual associations among cardiorespiratory fitness]	0.0	5	1	1	1
16674	361	average length of stay	[average length of stay]	0.0	4	1	1	1
16675	361	health insurance	[health insurance]	0.0	2	1	1	1
16676	361	structure geometry	[structure geometry]	0.0	2	1	1	1
16677	361	somewhat good information	[somewhat better information]	0.0	3	1	1	1
16678	361	precise role in pathophysiology	[precise role in pathophysiology]	0.0	4	1	1	1
16679	361	resolution	[resolution]	0.0	1	1	1	1
16680	361	walking distance	[walking distance]	0.0	2	1	1	1
16681	361	cardiovascular event rate at event	[cardiovascular event rate at events]	0.0	5	1	1	1
16682	361	relationship between qrs duration	[relationship between QRS duration]	0.0	4	1	1	1
16683	361	include stress echocardiography	[including stress echocardiography]	0.0	3	1	1	1
16684	361	fibrillation pvf	[fibrillation PVF]	0.0	2	1	1	1
16685	361	relation between preoperative dysfunction within month	[Relation between preoperative dysfunction within months]	0.0	6	1	1	1
16686	361	determine assessment for patient with ras	[determining assessment for patients with RAS]	0.0	6	1	1	1
16687	361	microarray datum	[microarray data]	0.0	2	1	1	1
16688	361	total expenditure on health	[total expenditure on health]	0.0	4	2	2	1
16689	361	2.0±3.2 millileter increase	[2.0±3.2 mL increase]	0.0	3	1	1	1
16690	361	sixty-one patient	[Sixty-one patients]	0.0	2	2	2	1
16691	361	use of implantable cardioverter defibrillator-CRT	[use of implantable cardioverter defibrillator-CRT]	0.0	5	1	1	1
16692	361	use the Kansas City Cardiomyopathy Questionnaire	[using the Kansas City Cardiomyopathy Questionnaire]	0.0	6	1	1	1
16693	361	almost 7 kg	[almost 7 kg]	0.0	3	1	1	1
16694	361	advancement	[advancement]	0.0	1	1	1	1
16695	361	patient have heart failure	[patients having heart failure]	0.0	4	1	1	1
16696	361	patient with advanced obstructive disease	[patients with advanced obstructive disease]	0.0	5	1	1	1
16697	361	syndrome of right heart failure	[syndrome of right heart failure]	0.0	5	1	1	1
16698	361	such as detection	[such as detection]	0.0	3	1	1	1
16699	361	potential therapeutic implication	[potential therapeutic implications]	0.0	3	1	1	1
16700	361	incidence outcome after myocardial infarction	[incidence outcomes after myocardial infarction]	0.0	5	1	1	1
16701	361	ventricular systolic pressure	[ventricular systolic pressure]	0.0	3	1	1	1
16702	361	hr 70	[HR 70]	0.0	2	1	1	1
16703	361	high level	[higher levels]	0.0	2	1	1	1
16704	361	novel one model for ischemia	[novel one model for ischemia]	0.0	5	1	1	1
16705	361	multicenter defibrillator implantation Cardiac resynchronization therapy	[Multicenter Defibrillator Implantation Cardiac Resynchronization Therapy]	0.0	6	1	1	1
16706	361	bad qol	[worse QOL]	0.0	2	1	1	1
16707	361	surgical method	[surgical method]	0.0	2	1	1	1
16708	361	such as heart failure	[such as heart failure]	0.0	4	1	1	1
16709	361	pressure overload	[pressure overload]	0.0	2	1	1	1
16710	361	change in nyha class	[changes in NYHA class]	0.0	4	1	1	1
16711	361	bpm 17.5±5.5	[bpm 17.5±5.5]	0.0	2	1	1	1
16712	361	heart failure mortality	[heart failure mortality]	0.0	3	1	1	1
16713	361	Cardiac function among patient	[Cardiac Function Among Patients]	0.0	4	1	1	1
16714	361	12 patient	[12 patients]	0.0	2	1	1	1
16715	361	great incidence	[greater incidence]	0.0	2	1	1	1
16716	361	7 kg with improvement	[7 kg with improvement]	0.0	4	1	1	1
16717	361	activity of paf-ah	[activities of PAF-AH]	0.0	3	1	1	1
16718	361	several key gene	[several key genes]	0.0	3	1	1	1
16719	361	case series of transplant patient	[case series of transplant patients]	0.0	5	1	1	1
16720	361	rate of atp	[rate of ATP]	0.0	3	1	1	1
16721	361	result in the patient	[resulting in the patients]	0.0	4	1	1	1
16722	361	regard the circulate form	[regarding the circulating forms]	0.0	4	1	1	1
16723	361	heart failure HF risk stratification model	[heart failure HF risk stratification models]	0.0	6	1	1	1
16724	361	characterization	[characterization]	0.0	1	1	1	1
16725	361	variance in hospital mortality	[variance in hospital mortality]	0.0	4	1	1	1
16726	361	603 consecutive patient	[603 consecutive patients]	0.0	3	1	1	1
16727	361	insight into prolonged electromechanical delay	[insight into prolonged electromechanical delay]	0.0	5	1	1	1
16728	361	measure of mechanic	[measure of mechanics]	0.0	3	1	1	1
16729	361	primary diagnosis of HF	[primary diagnosis of HF]	0.0	4	1	1	1
16730	361	ras blocker hr	[RAS blockers HR]	0.0	3	1	1	1
16731	361	further randomised study	[Further randomised studies]	0.0	3	1	1	1
16732	361	Cancer Registry–Medicare	[Cancer Registry–Medicare]	0.0	2	1	1	1
16733	361	measure of HF with ef	[measure of HF with EF]	0.0	5	1	1	1
16734	361	20 consecutive patient	[20 consecutive patients]	0.0	3	1	1	1
16735	361	such patient	[such patients]	0.0	2	1	1	1
16736	361	Duke activity	[Duke Activity]	0.0	2	1	1	1
16737	361	consist after myocardial infarction	[consisting after myocardial infarction]	0.0	4	1	1	1
16738	361	endothelial-protective effect	[endothelial-protective effects]	0.0	2	1	1	1
16739	361	composite quality measure for inpatient condition	[Composite quality measures for inpatient conditions]	0.0	6	1	1	1
16740	361	secretion	[secretion]	0.0	1	1	1	1
16741	361	modest effect on heart failure	[modest effects on heart failure]	0.0	5	1	1	1
16742	361	ANG infusion	[ANG infusion]	0.0	2	1	1	1
16743	361	reason p	[reasons P]	0.0	2	1	1	1
16744	361	overall effect on rate	[overall effects on rate]	0.0	4	1	1	1
16745	361	Mediterranean Approaches	[Mediterranean Approaches]	0.0	2	1	1	1
16746	361	Δ50%W	[Δ50%W]	0.0	1	1	1	1
16747	361	echocardiogram of the ventricular midpapillary level	[Echocardiograms of the ventricular midpapillary level]	0.0	6	1	1	1
16748	361	human HF tissue sample	[human HF tissue samples]	0.0	4	1	1	1
16749	361	validity replicate resource use	[validity replicating resource use]	0.0	4	1	1	1
16750	361	consensus regard the circulate form	[consensus regarding the circulating forms]	0.0	5	1	1	1
16751	361	start date for the cohort	[start date for the cohort]	0.0	5	1	1	1
16752	361	presence of mild clinical dysfunction	[presence of mild clinical dysfunction]	0.0	5	1	1	1
16753	361	effect on beta-adrenergic receptor β-ar signal	[effects on beta-adrenergic receptor β-AR signaling]	0.0	6	1	1	1
16754	361	medicine CHM	[medicine CHM]	0.0	2	1	1	1
16755	361	2 month	[2 months]	0.0	2	1	1	1
16756	361	unit increase	[unit increase]	0.0	2	1	1	1
16757	361	even in subgroup at high risk	[even in subgroups at high risk]	0.0	6	1	1	1
16758	361	patient with ms	[patients with MS]	0.0	3	1	1	1
16759	361	patient with mr	[patients with MR]	0.0	3	1	1	1
16760	361	effect of ejection fraction	[effect of ejection fraction]	0.0	4	1	1	1
16761	361	reason per patient p	[reasons per patient P]	0.0	4	1	1	1
16762	361	effective therapy in this patient	[effective therapies in these patients]	0.0	5	1	1	1
16763	361	Carvedilol a β-blocker	[Carvedilol a β-blocker]	0.0	3	1	1	1
16764	361	management involve assist device	[management involving assist devices]	0.0	4	1	1	1
16765	361	regression line shift in nonsurvivor	[regression line shift in nonsurvivors]	0.0	5	1	1	1
16766	361	standard practice for a number	[standard practice for a number]	0.0	5	1	1	1
16767	361	CHF visit rate	[CHF visit rates]	0.0	3	1	1	1
16768	361	difference in the percentage control	[difference in the percentage control]	0.0	5	1	1	1
16769	361	provide prognostic information for a outcome	[providing prognostic information for an outcome]	0.0	6	1	1	1
16770	361	hemodynamic phenotype	[Hemodynamic phenotype]	0.0	2	1	1	1
16771	361	m vs. m	[m vs. m]	0.0	3	1	1	1
16772	361	pasp relationship	[PASP relationship]	0.0	2	1	1	1
16773	361	risk 5.5 mmol	[risk 5.5 mmol]	0.0	3	1	1	1
16774	361	sickle	[sickle]	0.0	1	1	1	1
16775	361	3 postoperative month	[3 postoperative months]	0.0	3	1	1	1
16776	361	objective of this trial	[objective of this trial]	0.0	4	1	1	1
16777	361	risk of potassium mmol	[risk of potassium mmol]	0.0	4	1	1	1
16778	361	functional decline c-kit	[functional decline c-Kit]	0.0	3	1	1	1
16779	361	potential for success	[potential for success]	0.0	3	1	1	1
16780	361	75 year of age	[75 years of age]	0.0	4	1	1	1
16781	361	mouse rad q65p	[mouse Rad Q65P]	0.0	3	1	1	1
16782	361	group millileter	[group mL]	0.0	2	1	1	1
16783	361	blood pressure via arterial tonometry	[blood pressure via arterial tonometry]	0.0	5	1	1	1
16784	361	dual x-ray absorptiometry	[dual x-ray absorptiometry]	0.0	3	1	1	1
16785	361	large study sample	[large study sample]	0.0	3	1	1	1
16786	361	hretn human resistin mrna	[hRetn human resistin mRNA]	0.0	4	1	1	1
16787	361	first 7 day	[first 7 days]	0.0	3	1	1	1
16788	361	improve quality of care	[improving quality of care]	0.0	4	1	1	1
16789	361	risk of 30-day death	[risk of 30-day death]	0.0	4	1	1	1
16790	361	402 patient normal geometry	[402 patients normal geometry]	0.0	4	1	1	1
16791	361	LVET at entry	[LVET at entry]	0.0	3	1	1	1
16792	361	prognostic marker	[prognostic markers]	0.0	2	1	1	1
16793	361	left systolic strain as a predictor	[left systolic strain as a predictor]	0.0	6	1	1	1
16794	361	cell differentiation	[cell differentiation]	0.0	2	1	1	1
16795	361	program of exercise	[program of exercise]	0.0	3	1	1	1
16796	361	readmission rate use metric	[readmission rates using metrics]	0.0	4	1	1	1
16797	361	effective elastance Ea	[effective elastance Ea]	0.0	3	1	1	1
16798	361	deleterious β1ar overstimulation	[deleterious β1AR overstimulation]	0.0	3	1	1	1
16799	361	practice-level difference	[practice-level differences]	0.0	2	1	1	1
16800	361	low activity p	[lower activities P]	0.0	3	1	1	1
16801	361	receptor antagonist in heart failure	[receptor antagonists in heart failure]	0.0	5	1	1	1
16802	361	additional benefit over systolic parameter	[additional benefit over systolic parameters]	0.0	5	1	1	1
16803	361	east early treatment	[EAST Early treatment]	0.0	3	1	1	1
16804	361	protective effect of antioxidant	[protective effects of antioxidant]	0.0	4	1	1	1
16805	361	8 patient HDL	[8 patients HDL]	0.0	3	1	1	1
16806	361	yield	[yield]	0.0	1	1	1	1
16807	361	bad qol co-primary outcome	[worse QOL co-primary outcome]	0.0	4	1	1	1
16808	361	ventricular end diameter mm	[ventricular end diameter mm]	0.0	4	1	1	1
16809	361	3 economic evaluation hm	[3 economic evaluations HM]	0.0	4	1	1	1
16810	361	assessment in hypertension patient	[assessment in hypertension patients]	0.0	4	1	1	1
16811	361	study hm	[studies HM]	0.0	2	1	1	1
16812	361	clinically significant bleed	[clinically significant bleeding]	0.0	3	1	1	1
16813	361	preliminary datum	[preliminary data]	0.0	2	1	1	1
16814	361	patient with hr	[patients with HR]	0.0	3	1	1	1
16815	361	dog with tachypacing-induced HF	[dogs with tachypacing-induced HF]	0.0	4	1	1	1
16816	361	crude rate	[Crude rates]	0.0	2	1	1	1
16817	361	absolute detectable change	[absolute detectable change]	0.0	3	1	1	1
16818	361	2-vessel cad involve the proximal artery	[2-vessel CAD involving the proximal artery]	0.0	6	1	1	1
16819	361	Antihyperglycemic drug	[Antihyperglycemic Drugs]	0.0	2	1	1	1
16820	361	new-onset severe ai	[new-onset severe AI]	0.0	3	1	1	1
16821	361	precise role in cardiac pathophysiology	[precise role in cardiac pathophysiology]	0.0	5	1	1	1
16822	361	patient survive a myocardial infarction	[patients surviving an myocardial infarction]	0.0	5	1	1	1
16823	361	pGE2-mediated effect on receptor β-ar signal	[PDE2-mediated effects on receptor β-AR signaling]	0.0	6	1	1	1
16824	361	common type	[common type]	0.0	2	1	1	1
16825	361	wk effect	[wk effects]	0.0	2	1	1	1
16826	361	eight control	[eight controls]	0.0	2	1	1	1
16827	361	major cause of morbidity	[major cause of morbidity]	0.0	4	1	1	1
16828	361	pathological change include cardiac hypertrophy	[pathological changes including cardiac hypertrophy]	0.0	5	1	1	1
16829	361	ventricular-pulmonary coupling resistance p	[ventricular-pulmonary coupling resistance P]	0.0	4	1	1	1
16830	361	experience cardioverter-defibrillator shock	[experiencing cardioverter-defibrillator shocks]	0.0	3	1	1	1
16831	361	therapeutic interruption of system	[therapeutic interruption of systems]	0.0	4	1	1	1
16832	361	future experimental research	[future experimental research]	0.0	3	1	1	1
16833	361	conduct study	[conducting studies]	0.0	2	1	1	1
16834	361	Periodic breathing	[Periodic breathing]	0.0	2	1	1	1
16835	361	General use	[General use]	0.0	2	1	1	1
16836	361	atypical case	[atypical case]	0.0	2	1	1	1
16837	361	include calcium-sensin agent	[including calcium-sensitizing agents]	0.0	3	1	1	1
16838	361	B-type peptide	[B-type peptide]	0.0	2	1	1	1
16839	361	cardiac pathogenesis	[cardiac pathogenesis]	0.0	2	1	1	1
16840	361	replicate resource use	[replicating resource use]	0.0	3	1	1	1
16841	361	Comparison of Outcome heart Failure	[Comparison Of Outcomes Heart Failure]	0.0	5	1	1	1
16842	361	hospitalization within the 1 month	[hospitalization within the 1 months]	0.0	5	1	1	1
16843	361	novel porcine model of ischemia	[novel porcine model of ischemia]	0.0	5	1	1	1
16844	361	perioperative death in the experimental procedure	[perioperative deaths in the experimental procedures]	0.0	6	1	1	1
16845	361	IL 0.5 mg	[IL 0.5 mg]	0.0	3	1	1	1
16846	361	effect on 72-hour urine volume	[effect on 72-hour urine volume]	0.0	5	2	2	1
16847	361	trend with severe dilatation	[trend with severe dilatation]	0.0	4	1	1	1
16848	361	af ablation	[AF ablation]	0.0	2	1	1	1
16849	361	esrd from the Danish Registry	[ESRD from the Danish Registry]	0.0	5	1	1	1
16850	361	minimal exertion	[minimal exertion]	0.0	2	1	1	1
16851	361	potential clinical application	[potential clinical application]	0.0	3	1	1	1
16852	361	embryonic kidney cell overexpress β1ar	[embryonic kidney cells overexpressing β1AR]	0.0	5	1	1	1
16853	361	adverse rate	[adverse rate]	0.0	2	1	1	1
16854	361	effect of ARNI	[effect of ARNI]	0.0	3	1	1	1
16855	361	risk predictor	[risk predictor]	0.0	2	1	1	1
16856	361	atrial mass removal	[atrial mass removal]	0.0	3	1	1	1
16857	361	β-ar stimulation via catecholamine infusion	[β-AR stimulation via catecholamine infusions]	0.0	5	1	1	1
16858	361	20 812 patient	[20 812 patients]	0.0	3	1	1	1
16859	361	patient with ef	[patients with EF]	0.0	3	1	1	1
16860	361	predictor of response	[predictors of response]	0.0	3	1	1	1
16861	361	3000 patient	[3,000 patients]	0.0	2	1	1	1
16862	361	measure of right contractile reserve	[measure of right contractile reserve]	0.0	5	1	1	1
16863	361	CV event AF	[CV events AF]	0.0	3	1	1	1
16864	361	addition of low-dose dopamine	[addition of low-dose dopamine]	0.0	4	1	1	1
16865	361	ventricular tricuspid plane excursion tapse	[ventricular tricuspid plane excursion TAPSE]	0.0	5	1	1	1
16866	361	medical center	[medical center]	0.0	2	1	1	1
16867	361	bpm 17.5±5.5 respectively p	[bpm 17.5±5.5 respectively P]	0.0	4	1	1	1
16868	361	first month after cabg	[first months after CABG]	0.0	4	1	1	1
16869	361	consecutive patient with onset	[consecutive patients with onset]	0.0	4	1	1	1
16870	361	benefit of treatment in adult	[benefits of treatments in adults]	0.0	5	1	1	1
16871	361	LV strain rate	[LV strain rate]	0.0	3	1	1	1
16872	361	insight on the possible contribution	[insight on the possible contribution]	0.0	5	1	1	1
16873	361	atrial natriuretic peptide b-type peptide	[atrial natriuretic peptide B-type peptide]	0.0	5	1	1	1
16874	361	simulation model	[simulation models]	0.0	2	1	1	1
16875	361	adult male rat	[adult male rats]	0.0	3	1	1	1
16876	361	17 day range	[17 days range]	0.0	3	1	1	1
16877	361	potential benefit with few consequence	[potential benefit with few consequences]	0.0	5	1	1	1
16878	361	new-onset aortic insufficiency	[New-onset aortic insufficiency]	0.0	3	1	1	1
16879	361	nervous system activity	[nervous system activity]	0.0	3	1	1	1
16880	361	strain as a predictor	[strain as a predictor]	0.0	4	1	1	1
16881	361	include tool for risk stratification	[including tools for risk stratification]	0.0	5	1	1	1
16882	361	patient with s'lateral of cm	[patients with s'lateral of cm]	0.0	5	1	1	1
16883	361	paf biosynthetic enzyme	[PAF biosynthetic enzymes]	0.0	3	1	1	1
16884	361	left ventricular ejection fraction HF	[left ventricular ejection fraction HF]	0.0	5	1	1	1
16885	361	CF device	[CF devices]	0.0	2	1	1	1
16886	361	trial in HF	[trials in HF]	0.0	3	1	1	1
16887	361	major rate	[major rate]	0.0	2	1	1	1
16888	361	option in heart failure	[option in heart failure]	0.0	4	1	1	1
16889	361	non-survivor year versus 72.83 year	[non-survivors years vs 72.83 years]	0.0	5	1	1	1
16890	361	irs2 gene double-knockout	[IRS2 gene double-knockout]	0.0	3	1	1	1
16891	361	nitroxyl	[nitroxyl]	0.0	1	1	1	1
16892	361	ventricular LV remodeling	[ventricular LV remodeling]	0.0	3	1	1	1
16893	361	economic savings	[economic savings]	0.0	2	1	1	1
16894	361	Left ventricular assist system treat HF	[Left Ventricular Assist System Treating HF]	0.0	6	1	1	1
16895	361	nesiritide 0.005 μg	[nesiritide 0.005 μg]	0.0	3	1	1	1
16896	361	detect normal fill pressure	[detecting normal filling pressures]	0.0	4	1	1	1
16897	361	≥60 millileter per m	[≥60 mL per m]	0.0	4	1	1	1
16898	361	24-hour brachial pressure	[24-hour brachial pressure]	0.0	3	1	1	1
16899	361	11 587 user	[11 587 users]	0.0	3	1	1	1
16900	361	index of contractile function	[index of contractile function]	0.0	4	1	1	1
16901	361	ch LV volume	[CH LV volume]	0.0	3	1	1	1
16902	361	psoriasis ultra-violet treatment	[psoriasis UV treatment]	0.0	3	1	1	1
16903	361	Systolic dysfunction reverse	[Systolic dysfunction REVERSE]	0.0	3	1	1	1
16904	361	trichrome blue analysis	[trichrome blue analysis]	0.0	3	1	1	1
16905	361	mitochondrial-targeted peptide drug	[mitochondrial-targeted peptide drugs]	0.0	3	1	1	1
16906	361	prognosis of a large cohort	[prognosis of a large cohort]	0.0	5	1	1	1
16907	361	estimate capillary wedge pressure in patient	[estimating capillary wedge pressure in patients]	0.0	6	1	1	1
16908	361	area hazard ratio	[area hazard ratio]	0.0	3	1	1	1
16909	361	optimize progenitor function for clinical application	[optimizing progenitor function for clinical application]	0.0	6	1	1	1
16910	361	independent predictor for the development	[Independent predictors for the development]	0.0	5	1	1	1
16911	361	systolic pressure 155 35	[systolic pressure 155 35]	0.0	4	1	1	1
16912	361	108 hfpef with ventricular ejection fraction	[108 HFpEF with ventricular ejection fraction]	0.0	6	1	1	1
16913	361	atrioventricular delay	[atrioventricular delay]	0.0	2	1	1	1
16914	361	breathing with no heart beat	[breathing with no heart beat]	0.0	5	1	1	1
16915	361	hyponatremia in most country	[hyponatremia in most countries]	0.0	4	1	1	1
16916	361	fluctuation in beat-to-beat qt interval	[fluctuations in beat-to-beat QT intervals]	0.0	5	1	1	1
16917	361	resynchronization reverse remodeling	[REsynchronization reVErses Remodeling]	0.0	3	1	1	1
16918	361	Postoperative survival of patient	[Postoperative survival of patients]	0.0	4	1	1	1
16919	361	pause release	[pause release]	0.0	2	1	1	1
16920	361	99 patient	[99 patients]	0.0	2	1	1	1
16921	361	trial of walking in patient	[trial of walking in patients]	0.0	5	1	1	1
16922	361	regression line shift	[regression line shift]	0.0	3	1	1	1
16923	361	reduction in the outcome	[reduction in the outcome]	0.0	4	1	1	1
16924	361	s ST2	[s ST2]	0.0	2	1	1	1
16925	361	significantly large hr reduction	[significantly larger HR reduction]	0.0	4	1	1	1
16926	361	circulate fragment	[Circulating fragments]	0.0	2	1	1	1
16927	361	increase in LV wall thickness	[increase in LV wall thickness]	0.0	5	1	1	1
16928	361	web-system for enhancement	[Web-system for Enhancement]	0.0	3	1	1	1
16929	361	epinephrine	[epinephrine]	0.0	1	1	1	1
16930	361	thirty hfpef patient	[Thirty HFpEF patients]	0.0	3	1	1	1
16931	361	selective beta-blocker on sympathetic activity	[selective beta-blockers on sympathetic activity]	0.0	5	1	1	1
16932	361	tool for Analysis	[Tools for Analysis]	0.0	3	1	1	1
16933	361	less severe ventricular dilatation	[less severe ventricular dilatation]	0.0	4	1	1	1
16934	361	risk of potassium	[risk of potassium]	0.0	3	1	1	1
16935	361	proangiogenic effect of b act	[proangiogenic effects of B act]	0.0	5	1	1	1
16936	361	low-frequency lf ratio	[low-frequency LF ratio]	0.0	3	1	1	1
16937	361	transmitral flow velocity	[transmitral flow velocities]	0.0	3	1	1	1
16938	361	commissioning on completion	[commissioning on completion]	0.0	3	1	1	1
16939	361	first trial	[first trials]	0.0	2	1	1	1
16940	361	percent of hospital remain	[percent of hospitals remaining]	0.0	4	1	1	1
16941	361	variation in use	[variation in use]	0.0	3	1	1	1
16942	361	mean SD testosterone level	[mean SD testosterone levels]	0.0	4	1	1	1
16943	361	treatment of fibrillation	[treatment of fibrillation]	0.0	3	1	1	1
16944	361	minute m	[min m]	0.0	2	1	1	1
16945	361	N-terminal proBNP NT-proBNP	[N-terminal proBNP NT-proBNP]	0.0	3	1	1	1
16946	361	hr CI	[HR CI]	0.0	2	1	1	1
16947	361	goal-directed therapy	[goal-directed therapy]	0.0	2	1	1	1
16948	361	treatment strategy in patient	[treatment strategies in patients]	0.0	4	1	1	1
16949	361	range from medication	[ranging from medication]	0.0	3	1	1	1
16950	361	critical importance	[critical importance]	0.0	2	1	1	1
16951	361	patient with pulmonary disease	[patients with pulmonary disease]	0.0	4	1	1	1
16952	361	30-day rehospitalization of percentage point	[30-day rehospitalization of percentage points]	0.0	5	1	1	1
16953	361	reliability in HF	[reliability in HF]	0.0	3	1	1	1
16954	361	up tug	[Up TUG]	0.0	2	1	1	1
16955	361	Hypertension	[Hypertension]	0.0	1	1	1	1
16956	361	2331 patient with ejection fraction 0.35	[2331 patients with ejection fraction 0.35]	0.0	6	1	1	1
16957	361	baseline follow-up level	[Baseline follow-up levels]	0.0	3	1	1	1
16958	361	patient with rest hr bpm	[patients with resting HR bpm]	0.0	5	1	1	1
16959	361	care surgery in heart transplant recipient	[care surgery in heart transplant recipients]	0.0	6	1	1	1
16960	361	carotid baroreflex	[carotid baroreflex]	0.0	2	1	1	1
16961	361	guidance	[guidance]	0.0	1	1	1	1
16962	361	clinical benefit for patient	[clinical benefit for patients]	0.0	4	1	1	1
16963	361	association with saxagliptin	[associations with saxagliptin]	0.0	3	1	1	1
16964	361	adverse CV event AF	[adverse CV events AF]	0.0	4	1	1	1
16965	361	aortic insufficiency	[aortic insufficiency]	0.0	2	1	1	1
16966	361	Sudden death in athlete	[Sudden death in athletes]	0.0	4	1	1	1
16967	361	grow population	[growing population]	0.0	2	1	1	1
16968	361	bb dose versus mg dose	[BB dose versus mg dose]	0.0	5	1	1	1
16969	361	Diuretic use	[Diuretic use]	0.0	2	1	1	1
16970	361	improvement in diuretic response	[improvement in diuretic response]	0.0	4	1	1	1
16971	361	role of ERK1 scaffold	[role of ERK1 scaffolds]	0.0	4	1	1	1
16972	361	Classification	[Classification]	0.0	1	2	2	1
16973	361	annular plane excursion from the end	[annular plane excursion from the end]	0.0	6	1	1	1
16974	361	receptor s1pr1	[receptor S1PR1]	0.0	2	1	1	1
16975	361	cardiac hypertrophy a robust predictor	[cardiac hypertrophy a robust predictor]	0.0	5	1	1	1
16976	361	comparative effect	[Comparative effects]	0.0	2	1	1	1
16977	361	model a significant predictor	[model a significant predictor]	0.0	4	1	1	1
16978	361	role 2 scaffold	[role 2 scaffolds]	0.0	3	1	1	1
16979	361	randomised-controlled trial	[randomised-controlled trials]	0.0	2	1	1	1
16980	361	sitagliptin versus insulin	[sitagliptin versus insulin]	0.0	3	1	1	1
16981	361	hfpef ventricular LV ejection fraction	[HFPEF ventricular LV ejection fraction]	0.0	5	1	1	1
16982	361	achievement of metabolism respiratory quotient	[achievement of metabolism respiratory quotient]	0.0	5	1	1	1
16983	361	kg versus 2.5 kg	[kg vs 2.5 kg]	0.0	4	1	1	1
16984	361	Global systolic strain as a predictor	[Global systolic strain as a predictor]	0.0	6	1	1	1
16985	361	diagnostic biomarker in patient	[diagnostic biomarkers in patients]	0.0	4	1	1	1
16986	361	idiopathic cohort	[idiopathic cohort]	0.0	2	1	1	1
16987	361	tone result	[tone resulting]	0.0	2	1	1	1
16988	361	mass quantification	[mass quantification]	0.0	2	1	1	1
16989	361	ed visit mean age 76.4 year	[ED visits mean age 76.4 years]	0.0	6	1	1	1
16990	361	randomized trial of walking	[Randomized trial of walking]	0.0	4	1	1	1
16991	361	biomarker in patient	[biomarkers in patients]	0.0	3	1	1	1
16992	361	quality Minnesota live	[quality Minnesota Living]	0.0	3	1	1	1
16993	361	ventricular tachycardia hfvt(+)	[ventricular tachycardia HFVT(+)]	0.0	3	1	1	1
16994	361	analysis of subgroup	[analysis of subgroups]	0.0	3	1	1	1
16995	361	PD initiation kg	[PD initiation kg]	0.0	3	1	1	1
16996	361	symptom cpet in patient with CHF	[symptom CPET in patients with CHF]	0.0	6	1	1	1
16997	361	high phosphorylation	[higher phosphorylation]	0.0	2	1	1	1
16998	361	manage clinically significant gastrointestinal bleed	[managing clinically significant gastrointestinal bleeding]	0.0	5	1	1	1
16999	361	cardiac mena overexpression comparable	[cardiac Mena overexpression comparable]	0.0	4	1	1	1
17000	361	multiacquisition t1-mapping MRI	[Multiacquisition T1-mapping MRI]	0.0	3	1	1	1
17001	361	die in day	[dying in days]	0.0	3	1	1	1
17002	361	decrease risk	[decreasing risk]	0.0	2	1	1	1
17003	361	outcome at year	[outcome at year]	0.0	3	1	1	1
17004	361	7 gram	[7 g]	0.0	2	1	1	1
17005	361	rare with.estimate range from 1	[rare with.estimates ranging from 1]	0.0	5	1	1	1
17006	361	left fill pressure response	[left filling pressure response]	0.0	4	1	1	1
17007	361	Effect of care management	[Effects of care management]	0.0	4	1	1	1
17008	361	Moderate-strength evidence from trial	[Moderate-strength evidence from trials]	0.0	4	1	1	1
17009	361	fit index	[fit indices]	0.0	2	1	1	1
17010	361	soluble s ST2	[soluble s ST2]	0.0	3	1	1	1
17011	361	trastuzumab-related cardiotoxicity	[Trastuzumab-related cardiotoxicity]	0.0	2	1	1	1
17012	361	part of the network	[part of the network]	0.0	4	1	1	1
17013	361	association with DNA	[association with DNA]	0.0	3	1	1	1
17014	361	influence	[influence]	0.0	1	1	1	1
17015	361	treatment of heart disease	[treatment of heart disease]	0.0	4	1	1	1
17016	361	hazard of event	[hazards of events]	0.0	3	1	1	1
17017	361	functional class nyha ii-iii	[functional class NYHA II-III]	0.0	4	1	1	1
17018	361	multihospital study	[multihospital study]	0.0	2	1	1	1
17019	361	permanent breathing pb	[permanent breathing PB]	0.0	3	1	1	1
17020	361	serum resistin	[serum resistin]	0.0	2	1	1	1
17021	361	staff responsible for patient care	[staff responsible for patient care]	0.0	5	1	1	1
17022	361	mandatory follow-up visit	[mandatory follow-up visits]	0.0	3	1	1	1
17023	361	rs10927887 p	[rs10927887 p]	0.0	2	1	1	1
17024	361	concentration of soluble ST2	[Concentrations of soluble ST2]	0.0	4	1	1	1
17025	361	longitudinal performance	[longitudinal performance]	0.0	2	1	1	1
17026	361	three age subject from the population	[three age subjects from the population]	0.0	6	1	1	1
17027	361	diagnostic performance detect normal fill pressure	[diagnostic performance detecting normal filling pressures]	0.0	6	1	1	1
17028	361	plasma NE	[plasma NE]	0.0	2	1	1	1
17029	361	ventricle overload	[ventricle overload]	0.0	2	1	1	1
17030	361	care surgery consultation	[care surgery consultations]	0.0	3	1	1	1
17031	361	extra membrane oxygenation ecmo	[extra membrane oxygenation ECMO]	0.0	4	1	1	1
17032	361	childhood disease	[childhood disease]	0.0	2	1	1	1
17033	361	sheet	[sheet]	0.0	1	1	1	1
17034	361	loss of fat free mass	[loss of fat free mass]	0.0	5	1	1	1
17035	361	Saxagliptin	[Saxagliptin]	0.0	1	1	1	1
17036	361	resistin Retn	[resistin Retn]	0.0	2	1	1	1
17037	361	1.73 m age	[1.73 m age]	0.0	3	1	1	1
17038	361	last dose	[last dose]	0.0	2	1	1	1
17039	361	crude rr	[crude RR]	0.0	2	1	1	1
17040	361	role of nervous system activity	[role of nervous system activity]	0.0	5	1	1	1
17041	361	possible reason for the modest reduction	[Possible reasons for the modest reduction]	0.0	6	1	1	1
17042	361	measure of hr dynamic	[measures of HR dynamics]	0.0	4	1	1	1
17043	361	restore capacity	[restoring capacity]	0.0	2	1	1	1
17044	361	adopt practice	[adopting practices]	0.0	2	1	1	1
17045	361	myocardial loss	[Myocardial loss]	0.0	2	1	1	1
17046	361	mediate a cross talk	[mediating a cross talk]	0.0	4	1	1	1
17047	361	cardiac magnetic resonance postcontrast	[cardiac magnetic resonance postcontrast]	0.0	4	1	1	1
17048	361	patient across 4372 hospital	[patients across 4372 hospitals]	0.0	4	1	1	1
17049	361	interruption	[interruption]	0.0	1	1	1	1
17050	361	pro-b-type natriuretic peptide nt-probnp	[pro-B-type natriuretic peptide NT-proBNP]	0.0	4	1	1	1
17051	361	plane	[plane]	0.0	1	2	2	1
17052	361	reversal of dysfunction by metoprolol	[Reversal of dysfunction by metoprolol]	0.0	5	1	1	1
17053	361	proximal descending	[proximal descending]	0.0	2	1	1	1
17054	361	coupling resistance p	[coupling resistance P]	0.0	3	1	1	1
17055	361	efficacy end point	[efficacy end points]	0.0	3	1	1	1
17056	361	pressure of co2	[pressure of CO2]	0.0	3	1	1	1
17057	361	exercise-induced pulmonary artery pressure pasp increase	[exercise-induced pulmonary artery pressure PASP increase]	0.0	6	1	1	1
17058	361	such as infarction with expansion	[such as infarction with expansion]	0.0	5	1	1	1
17059	361	dysfunction in doxorubicin-induced heart failure	[dysfunction in doxorubicin-induced heart failure]	0.0	5	1	1	1
17060	361	wedge	[wedge]	0.0	1	1	1	1
17061	361	peritoneal dialysis PD	[Peritoneal dialysis PD]	0.0	3	1	1	1
17062	361	3 pharmacologic study include calcium-sensin agent	[3 pharmacologic studies including calcium-sensitizing agents]	0.0	6	1	1	1
17063	361	cell differentiation toward cell	[cell differentiation toward cells]	0.0	4	1	1	1
17064	361	preventive measure	[preventive measures]	0.0	2	1	1	1
17065	361	almost 7 kg with improvement	[almost 7 kg with improvement]	0.0	5	1	1	1
17066	361	usefulness in such patient	[usefulness in such patients]	0.0	4	1	1	1
17067	361	hypothese addition μg	[hypotheses addition μg]	0.0	3	1	1	1
17068	361	common underlying characteristic eg	[common underlying characteristics eg]	0.0	4	1	1	1
17069	361	use of protocol-driven poc testing	[use of protocol-driven POC testing]	0.0	5	1	1	1
17070	361	cause of death in patient	[cause of death in patients]	0.0	5	1	1	1
17071	361	mean of month	[mean of months]	0.0	3	1	1	1
17072	361	interquartile range 18.6	[interquartile range 18.6]	0.0	3	1	1	1
17073	361	statistically significant change effect exercise	[statistically significant change effect exercise]	0.0	5	1	1	1
17074	361	hdl-induced production by EC	[HDL-induced production by EC]	0.0	4	1	1	1
17075	361	ventricular-pulmonary arterial coupling resistance	[ventricular-pulmonary arterial coupling resistance]	0.0	4	1	1	1
17076	361	monitoring rm strategy	[monitoring RM strategies]	0.0	3	1	1	1
17077	361	2900 hm ii	[2900 HM II]	0.0	3	1	1	1
17078	361	incidence of renal disease in outpatient	[Incidence of renal disease in outpatients]	0.0	6	1	1	1
17079	361	2 scaffold in heart pathology	[2 scaffolds in heart pathology]	0.0	5	1	1	1
17080	361	right heart failure with shock	[right heart failure with shock]	0.0	5	1	1	1
17081	361	date death	[date death]	0.0	2	1	1	1
17082	361	effect of treatment	[effects of treatment]	0.0	3	1	1	1
17083	361	echocardiographic guidance under general anaesthesia	[echocardiographic guidance under general anaesthesia]	0.0	5	1	1	1
17084	361	peak vo2 of millileter	[peak VO2 of mL]	0.0	4	1	1	1
17085	361	NYHA Class	[NYHA Class]	0.0	2	1	1	1
17086	361	risk among New user of Saxagliptin	[Risk Among New Users of Saxagliptin]	0.0	6	1	1	1
17087	361	worsen function WRF	[worsening function WRF]	0.0	3	1	1	1
17088	361	such as fractal scaling exponent	[such as fractal scaling exponent]	0.0	5	1	1	1
17089	361	incidence in vad group	[incidence in VAD groups]	0.0	4	1	1	1
17090	361	fill pressure response	[filling pressure response]	0.0	3	1	1	1
17091	361	quality measure for condition	[quality measures for conditions]	0.0	4	1	1	1
17092	361	intact heart in model	[intact hearts in models]	0.0	4	1	1	1
17093	361	western Australian health datum	[Western Australian health data]	0.0	4	1	1	1
17094	361	30 mm hg pasp	[30 mm Hg PASP]	0.0	4	1	1	1
17095	361	patient with hypertension ph	[patients with hypertension PH]	0.0	4	1	1	1
17096	361	etiology of HF in LA	[etiologies of HF in LA]	0.0	5	1	1	1
17097	361	activity by (123)i-meta-iodobenzylguanidine ((123)i-mibg	[activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]	0.0	4	1	1	1
17098	361	thalassaemia major	[thalassaemia major]	0.0	2	1	1	1
17099	361	outcome change score for old adult	[outcome change scores for older adults]	0.0	6	1	1	1
17100	361	multivariate regression analysis	[multivariate regression analysis]	0.0	3	1	1	1
17101	361	advanced obstructive disease	[advanced obstructive disease]	0.0	3	1	1	1
17102	361	transoesophageal echocardiographic guidance	[transoesophageal echocardiographic guidance]	0.0	3	1	1	1
17103	361	consecutive consent HF patient ejection fraction	[consecutive consenting HF patients ejection fraction]	0.0	6	1	1	1
17104	361	central pressure 18	[central pressure 18]	0.0	3	1	1	1
17105	361	gly16	[Gly16]	0.0	1	1	1	1
17106	361	little impact on morphological development	[little impact on morphological development]	0.0	5	1	1	1
17107	361	study selection trial of blood transfusion	[Study Selection trials of blood transfusions]	0.0	6	1	1	1
17108	361	transcriptional analysis of cardiac tissue	[transcriptional analysis of cardiac tissue]	0.0	5	1	1	1
17109	361	heart failure with dialysis	[heart failure with dialysis]	0.0	4	1	1	1
17110	361	cardiac index versus 2.8 L 2	[cardiac index versus 2.8 L 2]	0.0	6	1	1	1
17111	361	increase refill compliance p	[increasing refill compliance P]	0.0	4	1	1	1
17112	361	negative value	[negative value]	0.0	2	1	1	1
17113	361	patient with SD testosterone level	[patients with SD testosterone levels]	0.0	5	1	1	1
17114	361	quality-of-life score –17.4 point	[quality-of-life score –17.4 points]	0.0	4	1	1	1
17115	361	Trial investigate Outcome	[Trial Investigating Outcomes]	0.0	3	2	2	1
17116	361	trial design	[trial design]	0.0	2	1	1	1
17117	361	mechanical cardiac support on function	[mechanical cardiac support on function]	0.0	5	1	1	1
17118	361	use of pro-b-type natriuretic peptide	[use of pro-B-type natriuretic peptide]	0.0	5	1	1	1
17119	361	non-diastolic abnormality	[non-diastolic abnormalities]	0.0	2	1	1	1
17120	361	future of heart failure	[Future of heart failure]	0.0	4	1	1	1
17121	361	ventricular assist system treat Advanced HF	[Ventricular Assist System Treating Advanced HF]	0.0	6	1	1	1
17122	361	treadmill testing vo2max	[treadmill testing VO2max]	0.0	3	1	1	1
17123	361	role in patient	[roles in patients]	0.0	3	1	1	1
17124	361	ten-year	[Ten-year]	0.0	1	1	1	1
17125	361	patient in heart failure	[patients in Heart Failure]	0.0	4	1	1	1
17126	361	5 age group	[5 age groups]	0.0	3	1	1	1
17127	361	simultaneous reduction in increase	[simultaneous reduction in increase]	0.0	4	1	1	1
17128	361	fifty consecutive patient with onset HFrEF	[Fifty consecutive patients with onset HFrEF]	0.0	6	1	1	1
17129	361	length of stay 37	[length of stay 37]	0.0	4	1	1	1
17130	361	fluctuation in qt interval	[fluctuations in QT intervals]	0.0	4	1	1	1
17131	361	mediator	[mediator]	0.0	1	1	1	1
17132	361	fat ratio	[fat ratio]	0.0	2	1	1	1
17133	361	event rate for myocardial infarction	[event rates for myocardial infarction]	0.0	5	1	1	1
17134	361	ventricular strain as a major predictor	[ventricular strain as a major predictor]	0.0	6	1	1	1
17135	361	exercise programme	[exercise programme]	0.0	2	1	1	1
17136	361	outcome of Exercise training hf-action	[Outcomes of Exercise Training HF-ACTION]	0.0	5	1	1	1
17137	361	characterization of one	[characterization of one]	0.0	3	1	1	1
17138	361	extracellular flux analyzer	[extracellular flux analyzer]	0.0	3	1	1	1
17139	361	sized LV	[sized LV]	0.0	2	1	1	1
17140	361	1.02±0.18 mm for reference subject	[1.02±0.18 mm for reference subjects]	0.0	5	1	1	1
17141	361	significant effect on urine volume	[significant effect on urine volume]	0.0	5	2	2	1
17142	361	cardiovascular event rate 2.08 event	[cardiovascular event rate 2.08 events]	0.0	5	1	1	1
17143	361	acute setting	[acute settings]	0.0	2	1	1	1
17144	361	Cox model analysis	[Cox model analysis]	0.0	3	1	1	1
17145	361	die in 30 day	[dying in 30 days]	0.0	4	1	1	1
17146	361	stable severe heart failure	[stable severe heart failure]	0.0	4	1	1	1
17147	361	novel percutaneous one model	[novel percutaneous one model]	0.0	4	1	1	1
17148	361	Particular topic	[Particular topics]	0.0	2	1	1	1
17149	361	β-Adrenergic	[β-Adrenergic]	0.0	1	1	1	1
17150	361	medicare coverage	[Medicare coverage]	0.0	2	1	1	1
17151	361	effect on pb characteristic	[effect on PB characteristics]	0.0	4	1	1	1
17152	361	endpoint of inappropriate therapy	[endpoint of inappropriate therapy]	0.0	4	1	1	1
17153	361	breathing pb	[breathing PB]	0.0	2	1	1	1
17154	361	CI for sitagliptin versus pioglitazone CI	[CI for sitagliptin versus pioglitazone CI]	0.0	6	1	1	1
17155	361	adequate self-management training	[adequate self-management training]	0.0	3	1	1	1
17156	361	change association	[changing association]	0.0	2	1	1	1
17157	361	benefit with adverse consequence	[benefit with adverse consequences]	0.0	4	1	1	1
17158	361	main cause	[main cause]	0.0	2	1	1	1
17159	361	benefit in patient	[benefits in patients]	0.0	3	1	1	1
17160	361	scale dimension	[scale dimensions]	0.0	2	1	1	1
17161	361	primary culprit extend EMD	[primary culprit extending EMD]	0.0	4	1	1	1
17162	361	treatment preference	[treatment preferences]	0.0	2	1	1	1
17163	361	screening patient	[Screening patients]	0.0	2	1	1	1
17164	361	physical activity control	[physical activity controls]	0.0	3	1	1	1
17165	361	jugular venous pressure	[jugular venous pressure]	0.0	3	1	1	1
17166	361	good outcome for patient	[better outcomes for patients]	0.0	4	1	1	1
17167	361	non-diabetic patient with heart failure	[non-diabetic patients with heart failure]	0.0	5	1	1	1
17168	361	acute embolism	[acute embolism]	0.0	2	1	1	1
17169	361	favorable effect on function	[favorable effects on function]	0.0	4	1	1	1
17170	361	stem from ischemic cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[stemming from ischemic cardiomyopathies]	0.0	4	1	1	1
17171	361	mortality hazard ratio all hazard ratio	[mortality hazard ratio all hazard ratios]	0.0	6	1	1	1
17172	361	randomized trial of walking with moderate	[Randomized trial of walking with moderate]	0.0	6	1	1	1
17173	361	10 transplant ineligible patient	[10 transplant ineligible patients]	0.0	4	1	1	1
17174	361	change in chromatin subproteome	[changes in chromatin subproteomes]	0.0	4	1	1	1
17175	361	capacity peak vo2	[capacity peak VO2]	0.0	3	1	1	1
17176	361	arterial elastance ea elastance ees	[arterial elastance Ea elastance Ees]	0.0	5	1	1	1
17177	361	high risk of death	[higher risk of death]	0.0	4	1	1	1
17178	361	cardiomyopathy DCM	[cardiomyopathy DCM]	0.0	2	1	1	1
17179	361	icd-hf patient	[ICD-HF patients]	0.0	2	1	1	1
17180	361	e-wave early mitral annular velocity	[E-wave early mitral annular velocity]	0.0	5	1	1	1
17181	361	thus give rise in HF	[thus giving rise in HF]	0.0	5	1	1	1
17182	361	administration of doxorubicin in rat	[administration of doxorubicin in rats]	0.0	5	1	1	1
17183	361	patient with RAS	[patients with RAS]	0.0	3	1	1	1
17184	361	LV end-diastolic volume LV	[LV end-diastolic volume LV]	0.0	4	1	1	1
17185	361	explant-derived c-kit	[explant-derived c-Kit]	0.0	2	1	1	1
17186	361	worsen function in EMPHASIS-HF	[worsening function in EMPHASIS-HF]	0.0	4	1	1	1
17187	361	ventricular-pulmonary coupling pulmonary resistance	[ventricular-pulmonary coupling pulmonary resistance]	0.0	4	1	1	1
17188	361	hazard model	[hazard models]	0.0	2	1	1	1
17189	361	level in breast cancer patient	[levels in breast cancer patients]	0.0	5	1	1	1
17190	361	least a moderate level	[least a moderate level]	0.0	4	1	1	1
17191	361	Comparison of predictor	[Comparison of predictors]	0.0	3	1	1	1
17192	361	outcome median versus millisecond	[outcome median vs milliseconds]	0.0	4	1	1	1
17193	361	patient with without diabete	[patients with without diabetes]	0.0	4	1	1	1
17194	361	new-onset esrd	[new-onset ESRD]	0.0	2	1	1	1
17195	361	study participant	[study participants]	0.0	2	1	1	1
17196	361	amyloidosis about a atypical case	[amyloidosis about an atypical case]	0.0	5	1	1	1
17197	361	important determinant of survival	[important determinants of survival]	0.0	4	1	1	1
17198	361	hypothermic arrest	[hypothermic arrest]	0.0	2	1	1	1
17199	361	hazard ratio in analysis	[hazard ratio in analyses]	0.0	4	1	1	1
17200	361	Nordic walking in patient	[Nordic walking in patients]	0.0	4	1	1	1
17201	361	two increase	[two increase]	0.0	2	1	1	1
17202	361	telephone support STS programme	[telephone support STS programmes]	0.0	4	1	1	1
17203	361	2,462 event	[2,462 events]	0.0	2	1	1	1
17204	361	gdmt treatment group for 6 month	[GDMT treatment group for 6 months]	0.0	6	1	1	1
17205	361	evidence of left ventricular dyssynchrony	[evidence of left ventricular dyssynchrony]	0.0	5	1	1	1
17206	361	range from 1	[ranging from 1]	0.0	3	1	1	1
17207	361	period of fibrillation	[period of fibrillation]	0.0	3	1	1	1
17208	361	neonatal rat	[neonatal rat]	0.0	2	1	1	1
17209	361	Swedish web-system	[Swedish Web-system]	0.0	2	1	1	1
17210	361	research study	[research studies]	0.0	2	1	1	1
17211	361	medication for patient	[medications for patients]	0.0	3	1	1	1
17212	361	insufficiency ai	[insufficiency AI]	0.0	2	1	1	1
17213	361	number of risk factor	[number of risk factors]	0.0	4	1	1	1
17214	361	ejection fraction on long mortality	[ejection fraction on long-term mortality]	0.0	5	1	1	1
17215	361	management of heart failure in child	[management of heart failure in children]	0.0	6	1	1	1
17216	361	millileter odd ratio	[ml odds ratio]	0.0	3	1	1	1
17217	361	N-terminal proBNP	[N-terminal proBNP]	0.0	2	1	1	1
17218	361	Patient management intervention	[Patient Management Interventions]	0.0	3	1	1	1
17219	361	contract ventricle	[contracting ventricles]	0.0	2	1	1	1
17220	361	QT variability	[QT variability]	0.0	2	1	1	1
17221	361	hypothese addition	[hypotheses addition]	0.0	2	1	1	1
17222	361	interaction on outcome	[interaction on outcomes]	0.0	3	1	1	1
17223	361	center for Medicare readmission cms	[Centers for Medicare readmission CMS]	0.0	5	1	1	1
17224	361	cAMP-dependent protein kinase pka signal downstream	[cAMP-dependent protein kinase PKA signaling downstream]	0.0	6	1	1	1
17225	361	50 mg dose	[50 mg dose]	0.0	3	1	1	1
17226	361	reference value	[reference values]	0.0	2	1	1	1
17227	361	threshold in heart failure	[threshold in heart failure]	0.0	4	1	1	1
17228	361	basal resistin level	[basal resistin levels]	0.0	3	1	1	1
17229	361	chronic hypertension pah	[chronic hypertension PAH]	0.0	3	1	1	1
17230	361	early treatment of fibrillation	[Early treatment of fibrillation]	0.0	4	1	1	1
17231	361	left 3-vessel cad	[left 3-vessel CAD]	0.0	3	1	1	1
17232	361	Cox hazard analysis	[Cox hazards analyses]	0.0	3	2	2	1
17233	361	addition of dopamine μg	[addition of dopamine μg]	0.0	4	1	1	1
17234	361	bnp EF	[BNP EF]	0.0	2	1	1	1
17235	361	continuous flow	[continuous flow]	0.0	2	1	1	1
17236	361	initiative	[initiative]	0.0	1	1	1	1
17237	361	comparative effect of assist device	[Comparative effects of assist device]	0.0	5	1	1	1
17238	361	factor-κB	[factor-κB]	0.0	1	1	1	1
17239	361	centrifugal-flow lvass	[centrifugal-flow LVAS]	0.0	2	1	1	1
17240	361	hemodynamic feature	[hemodynamic features]	0.0	2	1	1	1
17241	361	ed visit mean age year	[ED visits mean age years]	0.0	5	1	1	1
17242	361	power of various measure	[power of various measures]	0.0	4	1	1	1
17243	361	reduce the risk	[reducing the risk]	0.0	3	1	1	1
17244	361	variation in mortality	[variation in mortality]	0.0	3	1	1	1
17245	361	ventricular tricuspid annular plane excursion tapse	[ventricular tricuspid annular plane excursion TAPSE]	0.0	6	1	1	1
17246	361	significant collateral growth	[significant collateral growth]	0.0	3	1	1	1
17247	361	effect of b	[effects of B]	0.0	3	1	1	1
17248	361	significant change effect	[significant change effect]	0.0	3	1	1	1
17249	361	describe a uniform nomenclature for failure	[describing a uniform nomenclature for failure]	0.0	6	1	1	1
17250	361	ventricular dilatation during the year	[ventricular dilatation during the years]	0.0	5	1	1	1
17251	361	seven abdominal problem	[seven abdominal problems]	0.0	3	1	1	1
17252	361	6-wk period	[6-wk periods]	0.0	2	1	1	1
17253	361	include 3 sample	[including 3 samples]	0.0	3	1	1	1
17254	361	available model	[available models]	0.0	2	1	1	1
17255	361	interview with care clinician care	[interviews with care clinicians caring]	0.0	5	1	1	1
17256	361	entry millisecond	[entry milliseconds]	0.0	2	1	1	1
17257	361	interaction between this 2 receptor	[interaction between these 2 receptors]	0.0	5	1	1	1
17258	361	human LV myocyte	[human LV myocytes]	0.0	3	1	1	1
17259	361	good evidence for the treatment	[good evidence for the treatment]	0.0	5	1	1	1
17260	361	pump-exchange technique	[pump-exchange technique]	0.0	2	1	1	1
17261	361	elastance ea elastance	[elastance Ea elastance]	0.0	3	1	1	1
17262	361	trastuzumab-related cardiotoxicity among patient	[Trastuzumab-related cardiotoxicity among patients]	0.0	4	1	1	1
17263	361	outcome in patient with heart failure	[outcomes in patients with heart failure]	0.0	6	1	1	1
17264	361	proteomics analysis	[proteomics analysis]	0.0	2	1	1	1
17265	361	inpatient condition	[inpatient conditions]	0.0	2	1	1	1
17266	361	patient with a cardiac defibrillator	[patients with an cardiac defibrillator]	0.0	5	1	1	1
17267	361	selective beta-blocker on activity	[selective beta-blockers on activity]	0.0	4	1	1	1
17268	361	variation in use of medication insight	[variation in use of medications Insights]	0.0	6	1	1	1
17269	361	Effect	[Effects]	0.0	1	3	3	1
17270	361	mitral leaflet motion	[mitral leaflet motions]	0.0	3	1	1	1
17271	361	transmitral e-wave early mitral velocity	[transmitral E-wave early mitral velocity]	0.0	5	1	1	1
17272	361	per cent with five death	[per cent with five deaths]	0.0	5	1	1	1
17273	361	advantage of the period	[advantage of the period]	0.0	4	1	1	1
17274	361	hospital performance	[hospital performance]	0.0	2	1	1	1
17275	361	trend in the risk	[trends in the risk]	0.0	4	1	1	1
17276	361	median follow-up of day	[median follow-up of days]	0.0	4	1	1	1
17277	361	PD initiation	[PD initiation]	0.0	2	1	1	1
17278	361	perturbation in muscle sarcomere structure	[Perturbations in muscle sarcomere structure]	0.0	5	1	1	1
17279	361	age of the patient	[age of the patients]	0.0	4	1	1	1
17280	361	dysfunction by 3 week	[dysfunction by 3 weeks]	0.0	4	1	1	1
17281	361	symptom domain	[Symptom domains]	0.0	2	1	1	1
17282	361	intermediate odd ratio for cardiovascular event	[intermediate odds ratios for cardiovascular events]	0.0	6	1	1	1
17283	361	adjustment hazard ratio	[adjustment hazard ratio]	0.0	3	1	1	1
17284	361	robust predictor of HF	[robust predictor of HF]	0.0	4	1	1	1
17285	361	response role of s1pr1 gene therapy	[response role of S1PR1 gene therapy]	0.0	6	1	1	1
17286	361	target abnormal exercise status	[targeting abnormal exercise status]	0.0	4	1	1	1
17287	361	preoperative serum albumin level	[preoperative serum albumin levels]	0.0	4	1	1	1
17288	361	outcome versus millisecond 237 millisecond	[outcome vs milliseconds 237 milliseconds]	0.0	5	1	1	1
17289	361	presence of several N form	[presence of several N forms]	0.0	5	1	1	1
17290	361	mortality in woman with HF	[mortality in women with HF]	0.0	5	1	1	1
17291	361	incidence outcome after acute infarction	[incidence outcomes after acute infarction]	0.0	5	1	1	1
17292	361	mg daily dose	[mg daily dose]	0.0	3	1	1	1
17293	361	reversal of detrimental alteration	[reversal of detrimental alterations]	0.0	4	1	1	1
17294	361	study-related adverse event	[study-related adverse events]	0.0	3	1	1	1
17295	361	patient aged 40 year	[patients aged 40 years]	0.0	4	1	1	1
17296	361	extend EMD in the heart	[extending EMD in the heart]	0.0	5	1	1	1
17297	361	lvad implantation hazard ratio	[LVAD implantation hazard ratio]	0.0	4	1	1	1
17298	361	small-molecule inhibitor c-kit	[small-molecule inhibitors c-Kit]	0.0	3	1	1	1
17299	361	treatment of severe-end-stage HF	[treatment of severe-end-stage HF]	0.0	4	1	1	1
17300	361	placebo for 7 day	[placebo for 7 days]	0.0	4	1	1	1
17301	361	home telemonitoring tm with medical support	[home telemonitoring TM with medical support]	0.0	6	1	1	1
17302	361	limit of agreement mean difference	[limits of agreement mean difference]	0.0	5	1	1	1
17303	361	24-hour pressure 155	[24-hour pressure 155]	0.0	3	1	1	1
17304	361	heart failure irrespective	[heart failure irrespective]	0.0	3	1	1	1
17305	361	mortality with HF	[mortality with HF]	0.0	3	1	1	1
17306	361	indicate suboptimal care	[indicating suboptimal care]	0.0	3	1	1	1
17307	361	non-urbanized midwestern state	[non-urbanized Midwestern state]	0.0	3	1	1	1
17308	361	training protocol	[training protocol]	0.0	2	1	1	1
17309	361	versus without ventricular ejection fraction	[versus without ventricular ejection fraction]	0.0	5	1	1	1
17310	361	large series	[largest series]	0.0	2	1	1	1
17311	361	heart fill	[heart filling]	0.0	2	1	1	1
17312	361	p trend=0.08	[P trend=0.08]	0.0	2	1	1	1
17313	361	academic center	[academic center]	0.0	2	1	1	1
17314	361	revascularization with angioplasty	[revascularization with angioplasty]	0.0	3	1	1	1
17315	361	endothelial function in chronic heart failure	[endothelial function in chronic heart failure]	0.0	6	1	1	1
17316	361	novel one model	[novel one model]	0.0	3	1	1	1
17317	361	method of aortic constriction	[method of aortic constriction]	0.0	4	1	1	1
17318	361	402 patient with hfpef geometry	[402 patients with HFpEF geometry]	0.0	5	1	1	1
17319	361	STE analysis of regional strain	[STE analysis of regional strain]	0.0	5	1	1	1
17320	361	degree	[degree]	0.0	1	2	2	1
17321	361	management of HF in infancy	[management of HF in infancy]	0.0	5	1	1	1
17322	361	ventricular assist device with support	[ventricular assist device with support]	0.0	5	1	1	1
17323	361	last dose of doxorubicin	[last dose of doxorubicin]	0.0	4	1	1	1
17324	361	chronic thromboembolic pulmonary hypertension	[chronic thromboembolic pulmonary hypertension]	0.0	4	1	1	1
17325	361	749 black patient	[749 black patients]	0.0	3	1	1	1
17326	361	right ventricular end-diastolic area index cm(2)	[right ventricular end-diastolic area index cm(2)]	0.0	6	1	1	1
17327	361	significant decrease in re-hospitalization	[significant decrease in re-hospitalization]	0.0	4	1	1	1
17328	361	enhance management	[enhancing management]	0.0	2	1	1	1
17329	361	cardiac energy metabolism	[cardiac energy metabolism]	0.0	3	1	1	1
17330	361	predictor of cad	[predictors of CAD]	0.0	3	1	1	1
17331	361	left end diameter mm difference	[left end diameter mm difference]	0.0	5	1	1	1
17332	361	comprise hospitalization among study patient	[comprising hospitalization among study patients]	0.0	5	1	1	1
17333	361	infarction AMI	[infarction AMI]	0.0	2	5	5	1
17334	361	Moderate-strength evidence from 3 trial	[Moderate-strength evidence from 3 trials]	0.0	5	1	1	1
17335	361	week post-aac	[weeks post-AAC]	0.0	2	1	1	1
17336	361	SR can 2+)-uptake	[SR Ca 2+)-uptake]	0.0	3	1	1	1
17337	361	outcome in a cohort	[outcomes in a cohort]	0.0	4	1	1	1
17338	361	cardioversion	[cardioversions]	0.0	1	1	1	1
17339	361	average 3.2	[average 3.2]	0.0	2	1	1	1
17340	361	electromechanical delay the time interval	[electromechanical delay the time interval]	0.0	5	1	1	1
17341	361	effect on process	[effects on processes]	0.0	3	1	1	1
17342	361	valve surgery	[valve surgery]	0.0	2	1	1	1
17343	361	systolic ventricular function	[systolic ventricular function]	0.0	3	1	1	1
17344	361	allocation	[allocation]	0.0	1	1	1	1
17345	361	multicenter clinical trial	[Multicenter clinical trial]	0.0	3	1	1	1
17346	361	nursing-sensitive outcome measure in prospective research	[nursing-sensitive outcome measures in prospective research]	0.0	6	1	1	1
17347	361	acute heart failure in pulmonary hypertension	[Acute heart failure in pulmonary hypertension]	0.0	6	1	1	1
17348	361	role of BNP in patient	[roles of BNP in patients]	0.0	5	1	1	1
17349	361	versus good quintile	[versus best quintile]	0.0	3	1	1	1
17350	361	complication in severe HF	[complications in severe HF]	0.0	4	1	1	1
17351	361	chronotropic response the difference	[chronotropic response the difference]	0.0	4	1	1	1
17352	361	area under the receiver curve auc	[area under the receiver curve AUC]	0.0	6	1	1	1
17353	361	5.0 gram	[5.0 g]	0.0	2	1	1	1
17354	361	heart failure in human	[heart failure in humans]	0.0	4	1	1	1
17355	361	promote fill during exercise	[promoting filling during exercise]	0.0	4	1	1	1
17356	361	guanosine monophosphate	[guanosine monophosphate]	0.0	2	1	1	1
17357	361	participation of apoptosis during the development	[Participation of apoptosis during the development]	0.0	6	1	1	1
17358	361	14 study hm	[14 studies HM]	0.0	3	1	1	1
17359	361	include MEDLINE	[including MEDLINE]	0.0	2	1	1	1
17360	361	reliable mortality predictor	[reliable mortality predictors]	0.0	3	1	1	1
17361	361	af type other than long-standing af	[AF type other than long-standing AF]	0.0	6	1	1	1
17362	361	function in the onset follow infarction	[function in the onset following infarction]	0.0	6	1	1	1
17363	361	major ventricle overload	[Major ventricle overload]	0.0	3	1	1	1
17364	361	global left ventricular systolic strain GLS	[global left ventricular systolic strain GLS]	0.0	6	1	1	1
17365	361	event during the 3 month	[events during the 3 months]	0.0	5	1	1	1
17366	361	low status versus white	[lower status versus whites]	0.0	4	1	1	1
17367	361	measurement of transmitral flow velocity	[measurement of transmitral flow velocities]	0.0	5	1	1	1
17368	361	describe a nomenclature for right failure	[describing a nomenclature for right failure]	0.0	6	1	1	1
17369	361	home telemonitoring with medical support	[home telemonitoring with medical support]	0.0	5	1	1	1
17370	361	main effect	[main effect]	0.0	2	1	1	1
17371	361	morpholino-based knockdown	[Morpholino-based knockdown]	0.0	2	1	1	1
17372	361	effect via stimulation	[effects via stimulation]	0.0	3	1	1	1
17373	361	diastolic dysfunction LV relaxation	[diastolic dysfunction LV relaxation]	0.0	4	1	1	1
17374	361	10-year increase	[10-year increase]	0.0	2	1	1	1
17375	361	clinical systolic parameter in af	[clinical systolic parameters in AF]	0.0	5	1	1	1
17376	361	Thoratec	[Thoratec]	0.0	1	1	1	1
17377	361	end diameter mm	[end diameter mm]	0.0	3	1	1	1
17378	361	significant gap	[significant gaps]	0.0	2	1	1	1
17379	361	lung weight p	[lung weight P]	0.0	3	1	1	1
17380	361	mostly in functional class nyha ii-iii	[mostly in functional class NYHA II-III]	0.0	6	1	1	1
17381	361	body composition body fat distribution	[Body composition body fat distribution]	0.0	5	1	1	1
17382	361	element of successful intervention	[elements of successful interventions]	0.0	4	1	1	1
17383	361	Mena level	[Mena levels]	0.0	2	1	1	1
17384	361	treatment of anemia a systematic review	[Treatment of anemia a systematic review]	0.0	6	1	1	1
17385	361	key role 2 molecular scaffold	[Key role 2 molecular scaffolds]	0.0	5	1	1	1
17386	361	treatment target exercise hemodynamic status	[treatments targeting exercise hemodynamic status]	0.0	5	1	1	1
17387	361	negative value of E	[negative value of E]	0.0	4	1	1	1
17388	361	function in the onset	[function in the onset]	0.0	4	1	1	1
17389	361	high blood pressure	[higher blood pressure]	0.0	3	1	1	1
17390	361	pressure of co2 petco2	[pressure of CO2 PETCO2]	0.0	4	1	1	1
17391	361	mg hr	[mg HR]	0.0	2	1	1	1
17392	361	Assessment GRADE	[Assessment GRADE]	0.0	2	1	1	1
17393	361	bleed in patient with assist device	[bleeding in patients with assist devices]	0.0	6	1	1	1
17394	361	sympathetic activity in patient	[sympathetic activity in patients]	0.0	4	1	1	1
17395	361	underperfusion	[underperfusion]	0.0	1	1	1	1
17396	361	imaging technique	[imaging techniques]	0.0	2	1	1	1
17397	361	practice rate	[Practice rates]	0.0	2	1	1	1
17398	361	patient below the pasp increase	[patients below the PASP increase]	0.0	5	1	1	1
17399	361	follow-up period in patient	[follow-up period in patients]	0.0	4	1	1	1
17400	361	glomerular	[glomerular]	0.0	1	1	1	1
17401	361	prognostic benefit over parameter	[prognostic benefit over parameters]	0.0	4	1	1	1
17402	361	right annular plane systolic excursion	[right annular plane systolic excursion]	0.0	5	1	1	1
17403	361	management of ventricular dysfunction	[management of ventricular dysfunction]	0.0	4	1	1	1
17404	361	pharmacologic study include agent	[pharmacologic studies including agents]	0.0	4	1	1	1
17405	361	multicenter trial of patient	[Multicenter trial of patients]	0.0	4	1	1	1
17406	361	approximately 3000 patient with onset af	[approximately 3,000 patients with onset AF]	0.0	6	1	1	1
17407	361	candidate for cell therapy	[candidates for cell therapy]	0.0	4	1	1	1
17408	361	left systolic function	[left systolic function]	0.0	3	1	1	1
17409	361	heart rate hr reduction with ivabradine	[heart rate HR reduction with ivabradine]	0.0	6	1	1	1
17410	361	have co-morbidity	[having co-morbidities]	0.0	2	1	1	1
17411	361	person	[persons]	0.0	1	1	1	1
17412	361	main effect exercise	[main effect exercise]	0.0	3	1	1	1
17413	361	blot with antibody	[blots with antibodies]	0.0	3	1	1	1
17414	361	function in the onset of HF	[function in the onset of HF]	0.0	6	1	1	1
17415	361	efficacy of therapeutic left-to-right interatrial shunting	[efficacy of therapeutic left-to-right interatrial shunting]	0.0	6	1	1	1
17416	361	Preoperative characteristic	[Preoperative characteristics]	0.0	2	1	1	1
17417	361	nondiabetic patient	[nondiabetic patients]	0.0	2	1	1	1
17418	361	undergo isolated heart transplant	[undergoing isolated heart transplant]	0.0	4	1	1	1
17419	361	significantly low walking distance	[significantly lower walking distance]	0.0	4	1	1	1
17420	361	heart failure 925 ed visit	[heart failure 925 ED visits]	0.0	5	1	1	1
17421	361	presentation Canadian Society guideline	[Presentation Canadian Society guidelines]	0.0	4	1	1	1
17422	361	value of error	[Values of error]	0.0	3	1	1	1
17423	361	index ratio	[indices ratio]	0.0	2	1	1	1
17424	361	LV relaxation	[LV relaxation]	0.0	2	1	1	1
17425	361	day in this double-blind trial	[days in this double-blind trial]	0.0	5	1	1	1
17426	361	early management	[early management]	0.0	2	1	1	1
17427	361	paradigm shift	[paradigm shift]	0.0	2	1	1	1
17428	361	survive a infarction AMI	[surviving an infarction AMI]	0.0	4	1	1	1
17429	361	3 study include agent of endothelin	[3 studies including agents of endothelin]	0.0	6	1	1	1
17430	361	remain in decile	[remaining in deciles]	0.0	3	1	1	1
17431	361	serum potassium mmol	[serum potassium mmol]	0.0	3	1	1	1
17432	361	cardiomyopathy include negative coronary angiography	[cardiomyopathy including negative coronary angiography]	0.0	5	1	1	1
17433	361	cutoff of 8	[cutoff of 8]	0.0	3	1	1	1
17434	361	mitral flow	[mitral flow]	0.0	2	1	1	1
17435	361	mrna level of inflammatory gene	[mRNA levels of inflammatory genes]	0.0	5	1	1	1
17436	361	acute pressure overload	[acute pressure overload]	0.0	3	1	1	1
17437	361	treatment Guideline	[Treatment Guidelines]	0.0	2	1	1	1
17438	361	disease modify drug nbdmard	[disease modifying drug nbDMARD]	0.0	4	1	1	1
17439	361	clinical systolic parameter	[clinical systolic parameters]	0.0	3	1	1	1
17440	361	large limit of agreement difference	[large limits of agreement difference]	0.0	5	1	1	1
17441	361	high-density lipoprotein functional property	[high-density lipoprotein functional properties]	0.0	4	1	1	1
17442	361	surgeon	[surgeons]	0.0	1	1	1	1
17443	361	10 heart failure HF	[10 heart failure HF]	0.0	4	1	1	1
17444	361	ventricular end diameter difference	[ventricular end diameter difference]	0.0	4	1	1	1
17445	361	predict survival at the time	[predicting survival at the time]	0.0	5	1	1	1
17446	361	assessment of body composition skinfold thickness	[assessment of body composition skinfold thickness]	0.0	6	1	1	1
17447	361	adverse CV event in model	[adverse CV events in models]	0.0	5	1	1	1
17448	361	framework determine individualized assessment	[framework determining individualized assessment]	0.0	4	1	1	1
17449	361	gross national income per capita	[gross national income per capita]	0.0	5	1	1	1
17450	361	major event-free rate	[major event-free rate]	0.0	3	1	1	1
17451	361	signal paradigm	[signaling paradigms]	0.0	2	1	1	1
17452	361	paediatric heart failure concern	[paediatric heart failure concern]	0.0	4	1	1	1
17453	361	secretion of arginine vasopressin avp	[secretion of arginine vasopressin AVP]	0.0	5	1	1	1
17454	361	mechanism behind the development	[mechanisms behind the development]	0.0	4	1	1	1
17455	361	tissue doppler imaging	[tissue Doppler imaging]	0.0	3	1	1	1
17456	361	aggressive treatment for heart failure	[aggressive treatment for heart failure]	0.0	5	1	1	1
17457	361	common element	[common elements]	0.0	2	1	1	1
17458	361	decrease in score	[decrease in score]	0.0	3	1	1	1
17459	361	pre-hct chest radiation	[pre-HCT chest radiation]	0.0	3	1	1	1
17460	361	end-stage heart failure CHF	[end-stage heart failure CHF]	0.0	4	1	1	1
17461	361	45 center	[45 centers]	0.0	2	1	1	1
17462	361	US healthcare programme	[US healthcare programmes]	0.0	3	1	1	1
17463	361	grade recommendation moderate-quality evidence	[Grade recommendation moderate-quality evidence]	0.0	4	1	1	1
17464	361	contribution of nursing care	[contribution of nursing care]	0.0	4	1	1	1
17465	361	impact on resource	[impact on resources]	0.0	3	1	1	1
17466	361	hr dynamic	[HR dynamics]	0.0	2	1	1	1
17467	361	involvement in a study	[involvement in a study]	0.0	4	1	1	1
17468	361	type V	[type V]	0.0	2	1	1	1
17469	361	tapse as individual measure	[TAPSE as individual measures]	0.0	4	1	1	1
17470	361	ejection fraction LVEF	[ejection fraction LVEF]	0.0	3	1	1	1
17471	361	relation between CPC	[relations between CPCs]	0.0	3	1	1	1
17472	361	qrs m	[QRS ms]	0.0	2	1	1	1
17473	361	812 patient	[812 patients]	0.0	2	1	1	1
17474	361	improvement at advanced stage	[improvement at advanced stages]	0.0	4	1	1	1
17475	361	LV end-diastolic dimension	[LV end-diastolic dimension]	0.0	3	1	1	1
17476	361	body weight in CC	[body weight in CC]	0.0	4	1	1	1
17477	361	ventricular function assessment	[ventricular function assessment]	0.0	3	1	1	1
17478	361	randomized trial of Nordic walking	[Randomized trial of Nordic walking]	0.0	5	1	1	1
17479	361	National trend for common condition	[National trends for common conditions]	0.0	5	1	1	1
17480	361	policy	[policy]	0.0	1	1	1	1
17481	361	health-related quality HRQoL	[health-related quality HRQoL]	0.0	3	1	1	1
17482	361	indeterminable anaerobic threshold	[indeterminable anaerobic threshold]	0.0	3	1	1	1
17483	361	advanced obstructive pulmonary disease	[advanced obstructive pulmonary disease]	0.0	4	1	1	1
17484	361	nonglycosylated epitope	[nonglycosylated epitopes]	0.0	2	1	1	1
17485	361	e-wave diastolic mitral velocity ratio	[E-wave diastolic mitral velocity ratio]	0.0	5	1	1	1
17486	361	history of hypertension	[history of hypertension]	0.0	3	1	1	1
17487	361	worldwide increase	[worldwide increase]	0.0	2	1	1	1
17488	361	assist device with support	[assist device with support]	0.0	4	1	1	1
17489	361	function among patient	[Function Among Patients]	0.0	3	1	1	1
17490	361	candidate gene	[candidate genes]	0.0	2	1	1	1
17491	361	strain as a major predictor	[strain as a major predictor]	0.0	5	1	1	1
17492	361	treatment of acute heart failure	[treatment of acute heart failure]	0.0	5	1	1	1
17493	361	chronic stable guideline-directed therapy GDMT	[chronic stable guideline-directed therapy GDMT]	0.0	5	1	1	1
17494	361	annular plane systolic excursion tapse	[annular plane systolic excursion TAPSE]	0.0	5	1	1	1
17495	361	patient with chronic obstructive disease	[patients with chronic obstructive disease]	0.0	5	1	1	1
17496	361	significant stenosis	[significant stenosis]	0.0	2	1	1	1
17497	361	left strain as a major predictor	[left strain as a major predictor]	0.0	6	1	1	1
17498	361	patient with advanced pulmonary disease	[patients with advanced pulmonary disease]	0.0	5	1	1	1
17499	361	several trial	[several trials]	0.0	2	1	1	1
17500	361	single most important component	[single most important component]	0.0	4	1	1	1
17501	361	percent of 7-day visit	[percent of 7-day visits]	0.0	4	1	1	1
17502	361	percutaneous one model for ischemia	[percutaneous one model for ischemia]	0.0	5	1	1	1
17503	361	system major adverse event	[system major adverse events]	0.0	4	1	1	1
17504	361	multicenter trial Paradigm-hf with 8000 individual	[multicenter trial PARADIGM-HF with 8000 individuals]	0.0	6	1	1	1
17505	361	effect of antioxidant	[effects of antioxidant]	0.0	3	1	1	1
17506	361	196 af patient	[196 AF patients]	0.0	3	1	1	1
17507	361	well-being	[well-being]	0.0	1	1	1	1
17508	361	number of inpatient admission	[number of inpatient admissions]	0.0	4	1	1	1
17509	361	global ventricular strain	[global ventricular strain]	0.0	3	1	1	1
17510	361	systolic heart failure of etiology	[systolic heart failure of etiology]	0.0	5	1	1	1
17511	361	start with B.	[start with B.]	0.0	3	1	1	1
17512	361	negative cross talk	[negative cross talk]	0.0	3	1	1	1
17513	361	mitochondrial proteome change	[mitochondrial proteome changes]	0.0	3	1	1	1
17514	361	monitoring after hospital discharge in patient	[monitoring after hospital discharge in patients]	0.0	6	1	1	1
17515	361	event during the month	[events during the months]	0.0	4	1	1	1
17516	361	activity (123)i-meta-iodobenzylguanidine	[activity (123)I-meta-iodobenzylguanidine]	0.0	2	1	1	1
17517	361	non-biological disease modify antirheumatic drug	[non-biological disease modifying antirheumatic drug]	0.0	5	1	1	1
17518	361	distinct population of patient	[distinct populations of patients]	0.0	4	1	1	1
17519	361	awareness of cardioverter-defibrillator deactivation discussion	[awareness of cardioverter-defibrillator deactivation discussions]	0.0	5	1	1	1
17520	361	acute care hospital	[acute care hospital]	0.0	3	1	1	1
17521	361	patient need	[patient needs]	0.0	2	1	1	1
17522	361	renal failure	[renal failure]	0.0	2	1	1	1
17523	361	low testosterone status a feasibility study	[low testosterone status a feasibility study]	0.0	6	1	1	1
17524	361	change in subject	[changes in subjects]	0.0	3	1	1	1
17525	361	na current	[Na current]	0.0	2	1	1	1
17526	361	prospective validation cohort	[prospective validation cohort]	0.0	3	1	1	1
17527	361	Large-scale prospective multicenter trial with individual	[Large-scale prospective multicenter trial with individuals]	0.0	6	1	1	1
17528	361	treat Advanced HF	[Treating Advanced HF]	0.0	3	1	1	1
17529	361	effect via activation	[effects via activation]	0.0	3	1	1	1
17530	361	society	[society]	0.0	1	2	2	1
17531	361	glucose transporter	[glucose transporter]	0.0	2	1	1	1
17532	361	plasma b-type natriuretic peptide level	[plasma B-type natriuretic peptide levels]	0.0	5	1	1	1
17533	361	Cardiac cachexia	[Cardiac cachexia]	0.0	2	1	1	1
17534	361	occur within 30 day	[occurring within 30 days]	0.0	4	1	1	1
17535	361	ongoing gdmt treatment group	[ongoing GDMT treatment group]	0.0	4	1	1	1
17536	361	aortic valve repair	[aortic valve repairs]	0.0	3	1	1	1
17537	361	result in HF trial	[results in HF trials]	0.0	4	1	1	1
17538	361	predict high performer	[predicting high performers]	0.0	3	1	1	1
17539	361	1.6 vs. 0.8 reason p	[1.6 vs. 0.8 reasons P]	0.0	5	1	1	1
17540	361	common form of left remodeling	[common forms of left remodeling]	0.0	5	1	1	1
17541	361	echocardiographic assessment of function	[echocardiographic assessment of function]	0.0	4	1	1	1
17542	361	large group	[large group]	0.0	2	1	1	1
17543	361	midwestern state	[Midwestern state]	0.0	2	1	1	1
17544	361	individual association among fitness CRF	[individual associations among fitness CRF]	0.0	5	1	1	1
17545	361	gastrointestinal region	[gastrointestinal regions]	0.0	2	1	1	1
17546	361	tricuspid plane excursion	[tricuspid plane excursion]	0.0	3	1	1	1
17547	361	cost-effectiveness ratio	[cost-effectiveness ratios]	0.0	2	1	1	1
17548	361	action potential duration	[action potential duration]	0.0	3	1	1	1
17549	361	comment in acute heart failure	[Comments in acute heart failure]	0.0	5	1	1	1
17550	361	electromechanical delay EMD	[electromechanical delay EMD]	0.0	3	1	1	1
17551	361	high survival rate	[high survival rates]	0.0	3	1	1	1
17552	361	safety end point	[safety end point]	0.0	3	1	1	1
17553	361	treatment of anemia in patient	[Treatment of anemia in patients]	0.0	5	2	2	1
17554	361	predominantly asymptomatic pediatric Fontan PF patient	[predominantly asymptomatic pediatric Fontan PF patients]	0.0	6	1	1	1
17555	361	twenty-seven adult Fontan patient	[Twenty-seven adult Fontan patients]	0.0	4	1	1	1
17556	361	aortic insufficiency ai	[aortic insufficiency AI]	0.0	3	1	1	1
17557	361	pathological change include hypertrophy	[pathological changes including hypertrophy]	0.0	4	1	1	1
17558	361	benefit with ejection fraction	[Benefits with ejection fraction]	0.0	4	1	1	1
17559	361	ST2 in patient with heart failure	[ST2 in patients with heart failure]	0.0	6	1	1	1
17560	361	involvement of receptor kinase-2	[involvement of receptor kinase-2]	0.0	4	1	1	1
17561	361	c-index	[C-index]	0.0	1	1	1	1
17562	361	Impact of resonance imaging	[Impact of resonance imaging]	0.0	4	1	1	1
17563	361	6-minute walk distance	[6-minute walk distance]	0.0	3	1	1	1
17564	361	give rise	[giving rise]	0.0	2	1	1	1
17565	361	several Medical outcome	[several Medical Outcomes]	0.0	3	1	1	1
17566	361	ventricular fractional area change	[ventricular fractional area change]	0.0	4	1	1	1
17567	361	first diagnosis	[first diagnosis]	0.0	2	1	1	1
17568	361	range 22.8	[range 22.8]	0.0	2	1	1	1
17569	361	chloride channel	[chloride channel]	0.0	2	1	1	1
17570	361	serum albumin level in patient	[serum albumin levels in patients]	0.0	5	1	1	1
17571	361	Inpatient	[Inpatient]	0.0	1	1	1	1
17572	361	potential usefulness of CRT	[potential usefulness of CRT]	0.0	4	1	1	1
17573	361	dynamic resistance training	[dynamic resistance training]	0.0	3	1	1	1
17574	361	gene expression profile	[gene expression profile]	0.0	3	1	1	1
17575	361	right ventricular dysfunction	[right ventricular dysfunction]	0.0	3	1	1	1
17576	361	median bnp EF	[median BNP EF]	0.0	3	1	1	1
17577	361	usual care group	[usual care group]	0.0	3	1	1	1
17578	361	end-point of mortality	[end-point of mortality]	0.0	3	1	1	1
17579	361	grain intake	[grain intake]	0.0	2	1	1	1
17580	361	clinical prognostic dysfunction	[clinical prognostic dysfunction]	0.0	3	1	1	1
17581	361	possibly diminish the ros effect	[possibly diminishing the ROS effects]	0.0	5	1	1	1
17582	361	survival 3.5 gram	[survival 3.5 g]	0.0	3	1	1	1
17583	361	low median activity of lyso-paf-at	[lower median activities of lyso-PAF-AT]	0.0	5	1	1	1
17584	361	receptor β-ar signal in cardiomyocyte	[receptor β-AR signaling in cardiomyocytes]	0.0	5	1	1	1
17585	361	contact HH	[contact HH]	0.0	2	1	1	1
17586	361	psychosocial factor insight	[Psychosocial Factors Insights]	0.0	3	1	1	1
17587	361	interquartile range with copd n=95	[interquartile range with COPD n=95]	0.0	5	1	1	1
17588	361	Canadian Society guideline	[Canadian Society guidelines]	0.0	3	1	1	1
17589	361	good value	[good value]	0.0	2	1	1	1
17590	361	useful technique detect fibrosis	[useful technique detecting fibrosis]	0.0	4	1	1	1
17591	361	overwhelming contribution of cad	[overwhelming contribution of CAD]	0.0	4	1	1	1
17592	361	amyloidosis about a case	[amyloidosis about an case]	0.0	4	1	1	1
17593	361	hospital from January	[hospitals from January]	0.0	3	1	1	1
17594	361	chronic stable guideline-directed medical therapy	[chronic stable guideline-directed medical therapy]	0.0	5	1	1	1
17595	361	english-language trial	[English-language trials]	0.0	2	1	1	1
17596	361	flux analyzer	[flux analyzer]	0.0	2	1	1	1
17597	361	Effect a analysis	[Effects a analysis]	0.0	3	1	1	1
17598	361	af type other	[AF type other]	0.0	3	1	1	1
17599	361	fill formalism	[filling formalism]	0.0	2	1	1	1
17600	361	prospective crossover study	[prospective crossover study]	0.0	3	1	1	1
17601	361	mitral annular velocity 3.1 vs. 1.3	[mitral annular velocity 3.1 vs. 1.3]	0.0	6	1	1	1
17602	361	change on exercise	[changes on exercise]	0.0	3	1	1	1
17603	361	60000 patient	[60,000 patients]	0.0	2	1	1	1
17604	361	IL6 hscrp	[IL6 hsCRP]	0.0	2	1	1	1
17605	361	control without exercise	[control without exercise]	0.0	3	1	1	1
17606	361	vena cava	[vena cava]	0.0	2	1	1	1
17607	361	right arterial coupling pulmonary resistance	[right arterial coupling pulmonary resistance]	0.0	5	1	1	1
17608	361	study with 1887	[studies with 1887]	0.0	3	1	1	1
17609	361	practice-level variation in rate	[practice-level variation in rates]	0.0	4	1	1	1
17610	361	class ii	[class II]	0.0	2	1	1	1
17611	361	impact on chelation choice	[impact on chelation choices]	0.0	4	1	1	1
17612	361	incidence complicate AMI	[incidence complicating AMI]	0.0	3	1	1	1
17613	361	medical staff responsible	[medical staff responsible]	0.0	3	1	1	1
17614	361	favorable change in ventricular function	[favorable changes in ventricular function]	0.0	5	1	1	1
17615	361	remodeling after AMI	[remodeling after AMI]	0.0	3	1	1	1
17616	361	30 day p-value for difference	[30 days P-value for difference]	0.0	5	1	1	1
17617	361	systolic pressure relationship in heart failure	[systolic pressure relationship in heart failure]	0.0	6	1	1	1
17618	361	bte with exercise time	[BTES with exercise time]	0.0	4	1	1	1
17619	361	non-biological disease modify drug nbdmard	[non-biological disease modifying drug nbDMARD]	0.0	5	1	1	1
17620	361	median of mm hg	[median of mm Hg]	0.0	4	1	1	1
17621	361	overall management	[Overall management]	0.0	2	1	1	1
17622	361	major cause	[major cause]	0.0	2	3	3	1
17623	361	impact on gross morphological development	[impact on gross morphological development]	0.0	5	1	1	1
17624	361	significant change	[significant change]	0.0	2	1	1	1
17625	361	small difference bnp EF	[smallest difference BNP EF]	0.0	4	1	1	1
17626	361	current strategy	[current strategies]	0.0	2	1	1	1
17627	361	protein kinase pka signal downstream	[protein kinase PKA signaling downstream]	0.0	5	1	1	1
17628	361	patient with onset HFrEF	[patients with onset HFrEF]	0.0	4	1	1	1
17629	361	university	[university]	0.0	1	1	1	1
17630	361	group 30 millileter per m 2	[group 30 mL per m 2]	0.0	6	1	1	1
17631	361	regular activity control	[Regular activity controls]	0.0	3	1	1	1
17632	361	glucocorticoid	[glucocorticoids]	0.0	1	1	1	1
17633	361	body composition with regard	[Body composition with regard]	0.0	4	1	1	1
17634	361	composite response with CRT	[composite response with CRT]	0.0	4	1	1	1
17635	361	hallmark of heart failure CHF	[hallmark of heart failure CHF]	0.0	5	1	1	1
17636	361	isoelectric focus	[Isoelectric focusing]	0.0	2	1	1	1
17637	361	differential relation in patient	[differential relations in patients]	0.0	4	1	1	1
17638	361	CLCNKA polymorphism rs10927887	[CLCNKA polymorphism rs10927887]	0.0	3	1	1	1
17639	361	experience with a interatrial shunt	[experience with an interatrial shunt]	0.0	5	1	1	1
17640	361	impact on hdl-mediated effect	[impact on HDL-mediated effects]	0.0	4	1	1	1
17641	361	surgical correction of valve insufficiency	[Surgical correction of valve insufficiency]	0.0	5	1	1	1
17642	361	technique detect myocardial fibrosis	[technique detecting myocardial fibrosis]	0.0	4	1	1	1
17643	361	patient survive a infarction AMI	[patients surviving an infarction AMI]	0.0	5	1	1	1
17644	361	absolute increase for infarction	[absolute increase for infarction]	0.0	4	1	1	1
17645	361	testosterone therapy	[Testosterone therapy]	0.0	2	1	1	1
17646	361	monitoring a review	[monitoring a review]	0.0	3	1	1	1
17647	361	first 3 postoperative month	[first 3 postoperative months]	0.0	4	1	1	1
17648	361	substantial proportion	[substantial proportion]	0.0	2	1	1	1
17649	361	gap in impact on quality	[gaps in impact on quality]	0.0	5	1	1	1
17650	361	rotor with blood-flow path	[rotor with blood-flow paths]	0.0	4	1	1	1
17651	361	patient safety initiative	[patient safety initiatives]	0.0	3	1	1	1
17652	361	event in patient with fibrillation	[events in patients with fibrillation]	0.0	5	1	1	1
17653	361	nyha class rank	[NYHA class ranking]	0.0	3	1	1	1
17654	361	chronic stable medical therapy	[chronic stable medical therapy]	0.0	4	1	1	1
17655	361	clinical doppler echocardiography	[clinical Doppler echocardiography]	0.0	3	1	1	1
17656	361	important trigger of infarction	[important trigger of infarction]	0.0	4	1	1	1
17657	361	improvement in functioning of evidence-based treatment	[improvements in functioning of evidence-based treatments]	0.0	6	1	1	1
17658	361	several N form	[several N forms]	0.0	3	1	1	1
17659	361	tool for risk stratification	[tool for risk stratification]	0.0	4	1	1	1
17660	361	lipoprotein functional property	[lipoprotein functional properties]	0.0	3	1	1	1
17661	361	degree early after surgery	[degree early after surgery]	0.0	4	1	1	1
17662	361	phase of the disease	[phase of the disease]	0.0	4	1	1	1
17663	361	resident of Olmsted County	[residents of Olmsted County]	0.0	4	1	1	1
17664	361	cad involve the proximal artery	[CAD involving the proximal artery]	0.0	5	1	1	1
17665	361	arterial coupling resistance	[arterial coupling resistance]	0.0	3	1	1	1
17666	361	optimize progenitor function for application	[optimizing progenitor function for application]	0.0	5	1	1	1
17667	361	Left ventricular assist system	[Left Ventricular Assist System]	0.0	4	1	1	1
17668	361	systole s	[systole s]	0.0	2	1	1	1
17669	361	medical management of HF in infancy	[medical management of HF in infancy]	0.0	6	1	1	1
17670	361	receptor family	[receptor family]	0.0	2	1	1	1
17671	361	assessment with the inclusion	[assessment with the inclusion]	0.0	4	1	1	1
17672	361	thromboembolic hypertension	[thromboembolic hypertension]	0.0	2	1	1	1
17673	361	range 22.8 with advanced copd	[range 22.8 with advanced COPD]	0.0	5	1	1	1
17674	361	biosynthetic enzyme	[biosynthetic enzymes]	0.0	2	1	1	1
17675	361	impact on the incidence of	[impact on the incidence of]	0.0	5	1	1	1
17676	361	antibody target nonglycosylated epitope	[antibodies targeting nonglycosylated epitopes]	0.0	4	1	1	1
17677	361	tunel-positive cell	[TUNEL-positive cells]	0.0	2	1	1	1
17678	361	cardiomyopathy ic	[cardiomyopathy IC]	0.0	2	1	1	1
17679	361	basis of review	[basis of review]	0.0	3	1	1	1
17680	361	long wk effect	[long-term wk effects]	0.0	3	1	1	1
17681	361	procedure 146 vs. 238	[procedures 146 vs. 238]	0.0	4	1	1	1
17682	361	endpoint death for heart failure	[endpoint death for heart failure]	0.0	5	1	1	1
17683	361	principle	[principles]	0.0	1	1	1	1
17684	361	alphalisa®	[AlphaLISA®]	0.0	1	1	1	1
17685	361	nonstandardized pro-b-type natriuretic peptide nt-probnp	[nonstandardized pro-B-type natriuretic peptide NT-proBNP]	0.0	5	1	1	1
17686	361	occurrence within day of the index	[Occurrence within days of the index]	0.0	6	1	1	1
17687	361	York heart Association NYHA Class	[York Heart Association NYHA Class]	0.0	5	1	1	1
17688	361	management for HF	[management for HF]	0.0	3	1	1	1
17689	361	transcriptional analysis of tissue	[transcriptional analysis of tissue]	0.0	4	1	1	1
17690	361	inhibition of endothelial growth factor	[inhibition of endothelial growth factor]	0.0	5	1	1	1
17691	361	peak capacity	[peak capacity]	0.0	2	1	1	1
17692	361	tension	[tension]	0.0	1	1	1	1
17693	361	lvad insertion	[LVAD insertion]	0.0	2	1	1	1
17694	361	phosphodiesterase-2	[phosphodiesterase-2]	0.0	1	1	1	1
17695	361	plasma n-terminal pro-b-type peptide nt-probnp	[plasma N-terminal pro-B-type peptide NT-proBNP]	0.0	5	1	1	1
17696	361	pure hno donor	[pure HNO donor]	0.0	3	1	1	1
17697	361	undergo chemotherapy	[undergoing chemotherapy]	0.0	2	1	1	1
17698	361	survive a infarction	[surviving an infarction]	0.0	3	1	1	1
17699	361	novel therapeutic strategy	[novel therapeutic strategy]	0.0	3	1	1	1
17700	361	malignancy include cancer	[malignancies including cancer]	0.0	3	1	1	1
17701	361	10 heart failure	[10 heart failure]	0.0	3	1	1	1
17702	361	–17.4 point vs. point	[–17.4 points vs. points]	0.0	4	1	1	1
17703	361	One-year event-free rate	[One-year event-free rates]	0.0	3	1	1	1
17704	361	major determinant	[major determinant]	0.0	2	1	1	1
17705	361	change the percent remain	[change the percent remaining]	0.0	4	1	1	1
17706	361	longitudinal strain as a major predictor	[longitudinal strain as a major predictor]	0.0	6	1	1	1
17707	361	difference histologically in the percentage	[difference histologically in the percentage]	0.0	5	1	1	1
17708	361	low median activity	[lower median activities]	0.0	3	1	1	1
17709	361	aortocaval	[aortocaval]	0.0	1	1	1	1
17710	361	156 consent HF patient	[156 consenting HF patients]	0.0	4	1	1	1
17711	361	strain of left ventricle	[strain of left ventricle]	0.0	4	2	2	1
17712	361	prognosis of patient	[prognosis of patients]	0.0	3	1	1	1
17713	361	rate by kccq category	[rates by KCCQ category]	0.0	4	1	1	1
17714	361	progressive loss	[progressive loss]	0.0	2	1	1	1
17715	361	two population of patient	[two populations of patients]	0.0	4	1	1	1
17716	361	other medical staff	[other medical staff]	0.0	3	1	1	1
17717	361	effect of walking	[effects of walking]	0.0	3	1	1	1
17718	361	chest model surrogate	[chest model surrogates]	0.0	3	1	1	1
17719	361	plasma membrane	[plasma membrane]	0.0	2	1	1	1
17720	361	therapy include anticoagulation	[therapy including anticoagulation]	0.0	3	1	1	1
17721	361	exercise variable exercise oscillatory ventilation	[exercise variables exercise oscillatory ventilation]	0.0	5	1	1	1
17722	361	pair	[pairs]	0.0	1	1	1	1
17723	361	noninvasive tool	[noninvasive tools]	0.0	2	1	1	1
17724	361	intervention hr	[intervention HR]	0.0	2	1	1	1
17725	361	odd ratio 1.76	[odds ratio 1.76]	0.0	3	1	1	1
17726	361	percutaneous revascularization	[percutaneous revascularization]	0.0	2	1	1	1
17727	361	risk develop certain malignancy	[risk developing certain malignancies]	0.0	4	1	1	1
17728	361	circulatory derangement	[circulatory derangement]	0.0	2	1	1	1
17729	361	user between 1996	[users between 1996]	0.0	3	1	1	1
17730	361	subject receive methotrexate	[Subjects receiving methotrexate]	0.0	3	1	1	1
17731	361	anaerobic threshold in heart failure	[anaerobic threshold in heart failure]	0.0	5	1	1	1
17732	361	use of agent	[use of agents]	0.0	3	1	1	1
17733	361	important covariate	[important covariates]	0.0	2	1	1	1
17734	361	pGE2-mediated effect on beta-adrenergic receptor signal	[PDE2-mediated effects on beta-adrenergic receptor signaling]	0.0	6	1	1	1
17735	361	ventricular end-diastolic area index cm(2)	[ventricular end-diastolic area index cm(2)]	0.0	5	1	1	1
17736	361	consistent approach	[consistent approach]	0.0	2	1	1	1
17737	361	receive ventricular assist device support	[receiving ventricular assist device support]	0.0	5	1	1	1
17738	361	pro-b-type peptide nt-probnp	[pro-B-type peptide NT-proBNP]	0.0	3	1	1	1
17739	361	suppression	[suppression]	0.0	1	1	1	1
17740	361	Kv4.3 channel rrna	[Kv4.3 channel mRNAs]	0.0	3	1	1	1
17741	361	3 study include agent	[3 studies including agents]	0.0	4	1	1	1
17742	361	study selection trial in adult	[Study Selection trials in adults]	0.0	5	1	1	1
17743	361	1.39 time	[1.39 times]	0.0	2	1	1	1
17744	361	patient with reduction in lvef	[patients with reduction in LVEF]	0.0	5	2	2	1
17745	361	right pacing	[right pacing]	0.0	2	1	1	1
17746	361	crude 28-day case-fatality rate	[crude 28-day case-fatality rate]	0.0	4	1	1	1
17747	361	retn gene	[Retn gene]	0.0	2	1	1	1
17748	361	several change include cardiac hypertrophy	[several changes including cardiac hypertrophy]	0.0	5	1	1	1
17749	361	Seattle heart Failure	[Seattle Heart Failure]	0.0	3	1	1	1
17750	361	ejection time complicate precapillary pulmonary hypertension	[ejection time complicating precapillary pulmonary hypertension]	0.0	6	1	1	1
17751	361	non-diabetic patient	[non-diabetic patients]	0.0	2	1	1	1
17752	361	experimental model	[experimental models]	0.0	2	1	1	1
17753	361	improvement for patient	[improvements for patients]	0.0	3	1	1	1
17754	361	risk as patient with reduction	[risk as patients with reduction]	0.0	5	1	1	1
17755	361	local myocyte depolarization	[local myocyte depolarization]	0.0	3	1	1	1
17756	361	improve survival rate over decade	[Improving survival rates over decades]	0.0	5	1	1	1
17757	361	absolute change mdc	[absolute change MDC]	0.0	3	1	1	1
17758	361	Impact on the response	[Impact on the response]	0.0	4	1	1	1
17759	361	thigh muscle	[thigh muscle]	0.0	2	1	1	1
17760	361	obese zsf1 with diet n=11	[obese ZSF1 with diet n=11]	0.0	5	1	1	1
17761	361	anemia treatment	[anemia treatment]	0.0	2	1	1	1
17762	361	medical therapy GDMT	[medical therapy GDMT]	0.0	3	1	1	1
17763	361	selectively potentiate the response	[selectively potentiating the response]	0.0	4	1	1	1
17764	361	diagnostic role	[diagnostic roles]	0.0	2	1	1	1
17765	361	routine np assessment	[routine NP assessment]	0.0	3	1	1	1
17766	361	advisor	[advisors]	0.0	1	1	1	1
17767	361	Global strain as a predictor	[Global strain as a predictor]	0.0	5	1	1	1
17768	361	right assist device	[right assist devices]	0.0	3	1	1	1
17769	361	right ventricular tricuspid plane excursion tapse	[right ventricular tricuspid plane excursion TAPSE]	0.0	6	1	1	1
17770	361	Nicorandil mg	[Nicorandil mg]	0.0	2	1	1	1
17771	361	few cell	[few cells]	0.0	2	1	1	1
17772	361	hence of importance	[Hence of importance]	0.0	3	1	1	1
17773	361	t1 in swine	[T1 in swine]	0.0	3	1	1	1
17774	361	human retn gene	[human Retn gene]	0.0	3	1	1	1
17775	361	outpatient assessment	[outpatient assessments]	0.0	2	1	1	1
17776	361	canine model	[canine model]	0.0	2	1	1	1
17777	361	ejection fraction EF	[ejection fraction EF]	0.0	3	1	1	1
17778	361	focus of RIα	[focusing of RIα]	0.0	3	1	1	1
17779	361	relationship between broad qrs	[relationship between broader QRS]	0.0	4	1	1	1
17780	361	express human resistin	[expressing human resistin]	0.0	3	1	1	1
17781	361	inappropriate atp hr	[inappropriate ATP HR]	0.0	3	1	1	1
17782	361	mortality rate across the age category	[mortality rates across the age categories]	0.0	6	1	1	1
17783	361	1:1 allocation ratio	[1:1 allocation ratio]	0.0	3	1	1	1
17784	361	q wave	[Q waves]	0.0	2	1	1	1
17785	361	only after 4 week	[only after 4 weeks]	0.0	4	1	1	1
17786	361	systolic left ejection fraction HF	[systolic left ejection fraction HF]	0.0	5	1	1	1
17787	361	adenylyl	[adenylyl]	0.0	1	1	1	1
17788	361	prescribing	[prescribing]	0.0	1	1	1	1
17789	361	care surgery ACS	[care surgery ACS]	0.0	3	1	1	1
17790	361	common underlying characteristic	[common underlying characteristics]	0.0	3	1	1	1
17791	361	stand-alone device	[stand-alone devices]	0.0	2	1	1	1
17792	361	Renin-angiotensin-aldosterone	[Renin-angiotensin-aldosterone]	0.0	1	1	1	1
17793	361	background—heart	[Background—Heart]	0.0	1	1	1	1
17794	361	determination of risk	[Determination of risk]	0.0	3	1	1	1
17795	361	right coupling	[right coupling]	0.0	2	1	1	1
17796	361	burden of heart failure hospitalization	[burden of heart failure hospitalizations]	0.0	5	1	1	1
17797	361	atp demand	[ATP demand]	0.0	2	1	1	1
17798	361	Ivabradine	[Ivabradine]	0.0	1	1	1	1
17799	361	pro-b-type peptide a biomarker approach	[pro-B-type peptide a biomarker approach]	0.0	5	1	1	1
17800	361	vascular resistance hazard ratio	[vascular resistance hazard ratio]	0.0	4	1	1	1
17801	361	right ventricle overload	[right ventricle overload]	0.0	3	1	1	1
17802	361	possible reason	[Possible reasons]	0.0	2	1	1	1
17803	361	esrd from the Registry	[ESRD from the Registry]	0.0	4	1	1	1
17804	361	global attenuation of proteomic alteration	[global attenuation of proteomic alterations]	0.0	5	1	1	1
17805	361	heart Failure questionnaire score range	[Heart Failure Questionnaire score range]	0.0	5	1	1	1
17806	361	8 month	[8 months]	0.0	2	2	2	1
17807	361	risk among user of Saxagliptin	[Risk Among Users of Saxagliptin]	0.0	5	1	1	1
17808	361	flow velocity	[flow velocities]	0.0	2	1	1	1
17809	361	mixed-method study of veteran	[Mixed-methods study of veterans]	0.0	4	1	1	1
17810	361	interview with 62 care clinician	[interviews with 62 care clinicians]	0.0	5	1	1	1
17811	361	show minor improvement	[showing minor improvement]	0.0	3	1	1	1
17812	361	evidence on effect	[evidence on effects]	0.0	3	1	1	1
17813	361	patient HFrEF with ejection fraction	[patients HFrEF with ejection fraction]	0.0	5	1	1	1
17814	361	score predict CRT response	[score predicting CRT response]	0.0	4	1	1	1
17815	361	tachycardia hfvt(+)	[tachycardia HFVT(+)]	0.0	2	1	1	1
17816	361	factor analysis CFA	[factor analysis CFA]	0.0	3	1	1	1
17817	361	therapeutic treatment	[therapeutic treatments]	0.0	2	1	1	1
17818	361	50 mg equivalent dose	[50 mg equivalent dose]	0.0	4	1	1	1
17819	361	e-wave diastolic mitral annular velocity ratio	[E-wave diastolic mitral annular velocity ratio]	0.0	6	1	1	1
17820	361	normal systolic ventricular function	[normal systolic ventricular function]	0.0	4	1	1	1
17821	361	management involve ventricular assist device	[management involving ventricular assist devices]	0.0	5	1	1	1
17822	361	low stimulation	[lower stimulation]	0.0	2	1	1	1
17823	361	value of E	[value of E]	0.0	3	1	1	1
17824	361	public health	[public health]	0.0	2	1	1	1
17825	361	intervention pacing	[interventions pacing]	0.0	2	1	1	1
17826	361	ejection fraction HF	[ejection fraction HF]	0.0	3	1	1	1
17827	361	interquartile range with advanced copd n=95	[interquartile range with advanced COPD n=95]	0.0	6	1	1	1
17828	361	diet in renal disease	[diet in renal disease]	0.0	4	1	1	1
17829	361	symptomatic chronic heart failure patient	[symptomatic chronic heart failure patients]	0.0	5	1	1	1
17830	361	independent predictor of favorable outcome	[independent predictor of favorable outcome]	0.0	5	1	1	1
17831	361	robust predictor	[robust predictor]	0.0	2	1	1	1
17832	361	low gross national income	[lower gross national income]	0.0	4	1	1	1
17833	361	value of error of measurement	[Values of error of measurement]	0.0	5	1	1	1
17834	361	myocyte-specific mena overexpression TTA comparable	[myocyte-specific Mena overexpression TTA comparable]	0.0	5	1	1	1
17835	361	advanced disease copd	[advanced disease COPD]	0.0	3	1	1	1
17836	361	immunodetection	[Immunodetection]	0.0	1	1	1	1
17837	361	vascular endothelial growth factor	[vascular endothelial growth factor]	0.0	4	1	1	1
17838	361	circumflex	[circumflex]	0.0	1	1	1	1
17839	361	powerful predictor of outcome period	[powerful predictor of outcome period]	0.0	5	1	1	1
17840	361	small trial	[small trial]	0.0	2	1	1	1
17841	361	improvement in response	[improvement in response]	0.0	3	1	1	1
17842	361	valve area mva	[valve area MVA]	0.0	3	1	1	1
17843	361	53.2 year	[53.2 years]	0.0	2	1	1	1
17844	361	absorption function in patient	[absorption function in patients]	0.0	4	1	1	1
17845	361	per cent with five death occur	[per cent with five deaths occurring]	0.0	6	1	1	1
17846	361	region with HF risk factor	[region with HF risk factors]	0.0	5	1	1	1
17847	361	lipoprotein-associated phospholipase a2	[lipoprotein-associated phospholipase A2]	0.0	3	1	1	1
17848	361	last decade	[last decade]	0.0	2	1	1	1
17849	361	good performance detect fill pressure	[good performance detecting filling pressures]	0.0	5	1	1	1
17850	361	helix-loop-helix bhlh transcription factor	[helix-loop-helix bHLH transcription factor]	0.0	4	1	1	1
17851	361	institutional experience	[institutional experience]	0.0	2	1	1	1
17852	361	Public reporting	[Public reporting]	0.0	2	1	1	1
17853	361	germline	[germline]	0.0	1	1	1	1
17854	361	peak work	[peak work]	0.0	2	1	1	1
17855	361	ventricular hypertrophy in heart failure	[ventricular hypertrophy in heart failure]	0.0	5	1	1	1
17856	361	efflux	[efflux]	0.0	1	1	1	1
17857	361	measurable overall improvement	[measurable overall improvements]	0.0	3	1	1	1
17858	361	microrna target	[MicroRNAs targets]	0.0	2	1	1	1
17859	361	sodium current	[sodium current]	0.0	2	1	1	1
17860	361	activation of β1ar	[activation of β1ARs]	0.0	3	1	1	1
17861	361	ventricular remodeling in heart failure	[ventricular remodeling in heart failure]	0.0	5	1	1	1
17862	361	moderate level	[moderate level]	0.0	2	1	1	1
17863	361	deleterious effect on physiologic process	[deleterious effects on physiologic processes]	0.0	5	1	1	1
17864	361	cachectic heart failure	[cachectic heart failure]	0.0	3	1	1	1
17865	361	baseline sst2 status	[baseline sST2 status]	0.0	3	1	1	1
17866	361	adoption	[adoption]	0.0	1	1	1	1
17867	361	odd ratio for cardiovascular event	[odds ratios for cardiovascular events]	0.0	5	1	1	1
17868	361	heart failure Assessment	[Heart Failure Assessment]	0.0	3	1	1	1
17869	361	exercise-induced artery systolic pressure increase	[exercise-induced artery systolic pressure increase]	0.0	5	1	1	1
17870	361	108 hfpef	[108 HFpEF]	0.0	2	1	1	1
17871	361	effect with a physician	[effect with a physician]	0.0	4	1	1	1
17872	361	268 inpatient record	[268 inpatient records]	0.0	3	1	1	1
17873	361	modification of diet	[modification of diet]	0.0	3	1	1	1
17874	361	STS HH with support	[STS HH with support]	0.0	4	1	1	1
17875	361	microembolization-induced HF	[microembolization-induced HF]	0.0	2	1	1	1
17876	361	effector	[effector]	0.0	1	1	1	1
17877	361	kg with improvement in response	[kg with improvement in response]	0.0	5	1	1	1
17878	361	intracellular strategy	[intracellular strategy]	0.0	2	1	1	1
17879	361	change effect exercise	[change effect exercise]	0.0	3	1	1	1
17880	361	left diastolic end diameter mm	[left diastolic end diameter mm]	0.0	5	1	1	1
17881	361	palliation	[palliation]	0.0	1	1	1	1
17882	361	749 self-identified patient	[749 self-identified patients]	0.0	3	1	1	1
17883	361	23.7 ng range	[23.7 ng range]	0.0	3	1	1	1
17884	361	impaired right pump function	[impaired right pump function]	0.0	4	1	1	1
17885	361	study evaluate predictor	[studies evaluating predictors]	0.0	3	1	1	1
17886	361	epigenetic reader in biology	[epigenetic readers in biology]	0.0	4	1	1	1
17887	361	atrioventricular delay avd	[atrioventricular delay AVD]	0.0	3	1	1	1
17888	361	hospitalization for acute coronary syndrome	[hospitalization for acute coronary syndromes]	0.0	5	1	1	1
17889	361	gene code	[genes coding]	0.0	2	1	1	1
17890	361	drug-untreated fail heart	[drug-untreated failing hearts]	0.0	3	1	1	1
17891	361	cardiac response protective role	[cardiac response protective role]	0.0	4	1	1	1
17892	361	adjust for 20 clinical variable	[adjusting for 20 clinical variables]	0.0	5	1	1	1
17893	361	time interval	[time interval]	0.0	2	1	1	1
17894	361	longitudinal RV fiber shortening	[longitudinal RV fiber shortening]	0.0	4	1	1	1
17895	361	hypotension	[hypotension]	0.0	1	1	1	1
17896	361	performance in patient with s'lateral	[performance in patients with s'lateral]	0.0	5	1	1	1
17897	361	one trial	[one trial]	0.0	2	1	1	1
17898	361	hospitalization in patient	[hospitalization in patients]	0.0	3	1	1	1
17899	361	quality measure for common condition	[quality measures for common conditions]	0.0	5	1	1	1
17900	361	relationship between right RV function	[relationships between right RV function]	0.0	5	1	1	1
17901	361	surrogate for change	[surrogates for changes]	0.0	3	1	1	1
17902	361	191 mm hg	[191 mm Hg]	0.0	3	1	1	1
17903	361	low mortality with HF	[lower mortality with HF]	0.0	4	1	1	1
17904	361	multiple gene in HF	[multiple genes in HF]	0.0	4	1	1	1
17905	361	age group mortality rate	[age group mortality rates]	0.0	4	1	1	1
17906	361	proteomics analysis of heart failure	[proteomics analysis of heart failure]	0.0	5	1	1	1
17907	361	favorable effect	[favorable effects]	0.0	2	1	1	1
17908	361	group of rat	[groups of rats]	0.0	3	1	1	1
17909	361	severe perturbation in component	[severe perturbations in components]	0.0	4	1	1	1
17910	361	left ventricular base	[left ventricular base]	0.0	3	1	1	1
17911	361	prognostic factor at admission	[prognostic factors at admission]	0.0	4	1	1	1
17912	361	shotgun proteomics approach	[shotgun proteomics approach]	0.0	3	1	1	1
17913	361	common syndrome	[common syndrome]	0.0	2	1	1	1
17914	361	arterial elastance ea	[arterial elastance Ea]	0.0	3	1	1	1
17915	361	binomial regression model	[binomial regression models]	0.0	3	1	1	1
17916	361	amyloidotic pattern	[amyloidotic pattern]	0.0	2	1	1	1
17917	361	central region	[central region]	0.0	2	1	1	1
17918	361	rapid pacing	[rapid pacing]	0.0	2	1	1	1
17919	361	regard the form of nt-probnp	[regarding the forms of NT-proBNP]	0.0	5	1	1	1
17920	361	area index 10.0 cm(2)	[area index 10.0 cm(2)]	0.0	4	1	1	1
17921	361	intermediate outcome	[intermediate outcomes]	0.0	2	1	1	1
17922	361	intermuscular fat ratio	[intermuscular fat ratio]	0.0	3	1	1	1
17923	361	major complication stroke	[major complications stroke]	0.0	3	1	1	1
17924	361	useful technique detect myocardial fibrosis	[useful technique detecting myocardial fibrosis]	0.0	5	1	1	1
17925	361	subject with structurally normal heart	[subjects with structurally normal hearts]	0.0	5	1	1	1
17926	361	cardiac resonance imaging	[cardiac resonance imaging]	0.0	3	1	1	1
17927	361	risk develop malignancy include cancer	[risk developing malignancies including cancer]	0.0	5	1	1	1
17928	361	disease group	[disease groups]	0.0	2	1	1	1
17929	361	achieve a level	[achieving a level]	0.0	3	1	1	1
17930	361	sitagliptin versus sulfonylurea	[sitagliptin versus sulfonylureas]	0.0	3	1	1	1
17931	361	hemodynamic disorder	[hemodynamic disorder]	0.0	2	1	1	1
17932	361	frailty a indicator in heart failure	[Frailty an indicator in heart failure]	0.0	6	1	1	1
17933	361	V activity	[V activity]	0.0	2	1	1	1
17934	361	role in coronary artery disease	[role in coronary artery disease]	0.0	5	1	1	1
17935	361	multiple abnormality	[multiple abnormalities]	0.0	2	1	1	1
17936	361	limited success	[limited success]	0.0	2	1	1	1
17937	361	randomized trial	[Randomized trial]	0.0	2	1	1	1
17938	361	previous revascularization coronary artery bypass surgery	[previous revascularization coronary artery bypass surgery]	0.0	6	1	1	1
17939	361	prior stroke score	[prior stroke score]	0.0	3	1	1	1
17940	361	patient undergo vad	[patients undergoing VAD]	0.0	3	1	1	1
17941	361	cardiovascular CV event in fibrillation	[cardiovascular CV events in fibrillation]	0.0	5	1	1	1
17942	361	sympathetic activity by ((123)i-mibg	[sympathetic activity by ((123)I-MIBG]	0.0	4	1	1	1
17943	361	review of the effect	[review of the effects]	0.0	4	1	1	1
17944	361	ventricular RV tricuspid plane systolic excursion	[ventricular RV tricuspid plane systolic excursion]	0.0	6	1	1	1
17945	361	viable option in heart failure	[viable option in heart failure]	0.0	5	1	1	1
17946	361	New Zealand rabbit undergo renal DNx	[New Zealand rabbits undergoing renal DNx]	0.0	6	1	1	1
17947	361	simple model	[simple model]	0.0	2	1	1	1
17948	361	take advantage	[taking advantage]	0.0	2	1	1	1
17949	361	change in treatment	[changes in treatment]	0.0	3	1	1	1
17950	361	week from infarction	[weeks from infarction]	0.0	3	1	1	1
17951	361	minimal detectable change mdc value	[minimal detectable change MDC values]	0.0	5	1	1	1
17952	361	use the process redesign framework	[using the Process Redesign framework]	0.0	5	1	1	1
17953	361	low income per capita	[lower income per capita]	0.0	4	1	1	1
17954	361	SkM growth	[SkM growth]	0.0	2	1	1	1
17955	361	parallel-group trial the effect	[parallel-group trial the effects]	0.0	4	1	1	1
17956	361	validity replicate resource use from trial	[validity replicating resource use from trials]	0.0	6	1	1	1
17957	361	Monitoring	[Monitoring]	0.0	1	1	1	1
17958	361	left end diameter mm mean difference	[left end diameter mm mean difference]	0.0	6	1	1	1
17959	361	HDL before et	[HDL before ET]	0.0	3	1	1	1
17960	361	ventricular fibrillation	[ventricular fibrillation]	0.0	2	1	1	1
17961	361	five patient IL mg	[five patients IL mg]	0.0	4	1	1	1
17962	361	support patient	[supporting patients]	0.0	2	1	1	1
17963	361	patient with CHF-NYHA-II HDL	[patients with CHF-NYHA-II HDL]	0.0	4	1	1	1
17964	361	treatment variation independent	[treatment variation independent]	0.0	3	1	1	1
17965	361	9868 participant	[9868 participants]	0.0	2	1	1	1
17966	361	pulmonary capillary wedge pressure	[pulmonary capillary wedge pressure]	0.0	4	1	1	1
17967	361	sensitive measure	[sensitive measure]	0.0	2	1	1	1
17968	361	mild disease from the population	[mild disease from the population]	0.0	5	1	1	1
17969	361	Expression	[Expression]	0.0	1	1	1	1
17970	361	patient respectively	[patients respectively]	0.0	2	1	1	1
17971	361	heart failure in a state	[heart failure in a state]	0.0	5	1	1	1
17972	361	testing of the self-care	[testing of the Self-Care]	0.0	4	1	1	1
17973	361	datum analysis	[data analysis]	0.0	2	1	1	1
17974	361	device therapy	[device therapies]	0.0	2	1	1	1
17975	361	Global left ventricular longitudinal strain	[Global left ventricular longitudinal strain]	0.0	5	1	1	1
17976	361	twofold increase in LV pressure	[twofold increase in LV pressure]	0.0	5	1	1	1
17977	361	neprilysin block renin-angiotensin-aldosteron axis	[neprilysin blocks renin-angiotensin-aldosteron axis]	0.0	4	1	1	1
17978	361	pharmacologic study of therapeutics include agent	[pharmacologic studies of therapeutics including agents]	0.0	6	1	1	1
17979	361	nonstandardized N-terminal pro-b-type peptide	[nonstandardized N-terminal pro-B-type peptide]	0.0	4	1	1	1
17980	361	month after cabg	[months after CABG]	0.0	3	1	1	1
17981	361	medical treatment for heart failure	[medical treatment for heart failure]	0.0	5	1	1	1
17982	361	knowledge on diuretic use	[knowledge on diuretic use]	0.0	4	1	1	1
17983	361	good evidence	[good evidence]	0.0	2	1	1	1
17984	361	resistive afterload	[resistive afterload]	0.0	2	1	1	1
17985	361	cardiac inflammatory biomarker	[cardiac inflammatory biomarkers]	0.0	3	1	1	1
17986	361	stable heart failure patient ejection fraction	[stable heart failure patients ejection fraction]	0.0	6	1	1	1
17987	361	prognostic marker hazard ratio for peak	[prognostic markers hazard ratio for peak]	0.0	6	1	1	1
17988	361	acute heart failure in hypertension	[Acute heart failure in hypertension]	0.0	5	1	1	1
17989	361	2-vessel cad involve the artery	[2-vessel CAD involving the artery]	0.0	5	1	1	1
17990	361	hospitalization within the month	[hospitalization within the months]	0.0	4	1	1	1
17991	361	improve survival rate	[Improving survival rates]	0.0	3	1	1	1
17992	361	study medication	[study medication]	0.0	2	1	1	1
17993	361	exercise training ET	[exercise training ET]	0.0	3	1	1	1
17994	361	period of year	[period of years]	0.0	3	1	1	1
17995	361	predict future performer	[predicting future performers]	0.0	3	1	1	1
17996	361	bpm 17.5±5.5 versus 14.4±3.3 millileter p	[bpm 17.5±5.5 versus 14.4±3.3 mL P]	0.0	6	1	1	1
17997	361	follow event rate HF hospitalization	[following event rates HF hospitalization]	0.0	5	1	1	1
17998	361	choice for common application	[choice for common applications]	0.0	4	1	1	1
17999	361	ras inhibition	[RAS inhibition]	0.0	2	1	1	1
18000	361	pressure 155 35	[pressure 155 35]	0.0	3	1	1	1
18001	361	heart failure care	[heart failure care]	0.0	3	1	1	1
18002	361	fifty patient with onset HFrEF	[Fifty patients with onset HFrEF]	0.0	5	1	1	1
18003	361	156 consecutive consent ambulatory HF patient	[156 consecutive consenting ambulatory HF patients]	0.0	6	1	1	1
18004	361	infarction heart failure patient with ejection	[infarction heart failure patients with ejection]	0.0	6	1	1	1
18005	361	non-hf population	[non-HF populations]	0.0	2	1	1	1
18006	361	far elevation	[Further elevation]	0.0	2	1	1	1
18007	361	LV systolic pressure	[LV systolic pressure]	0.0	3	1	1	1
18008	361	valve plasty for mr	[valve plasty for MR]	0.0	4	2	2	1
18009	361	treatment in all patient	[treatment in all patients]	0.0	4	1	1	1
18010	361	l-dko	[L-DKO]	0.0	1	1	1	1
18011	361	promising target	[promising targets]	0.0	2	1	1	1
18012	361	common characteristic	[common characteristics]	0.0	2	1	1	1
18013	361	descriptive study	[descriptive study]	0.0	2	1	1	1
18014	361	class nyha ii-iii	[class NYHA II-III]	0.0	3	1	1	1
18015	361	pressure relationship a index of function	[pressure relationship an index of function]	0.0	6	1	1	1
18016	361	PD initiation kg with improvement	[PD initiation kg with improvement]	0.0	5	1	1	1
18017	361	ischemic problem	[ischemic problems]	0.0	2	1	1	1
18018	361	medical support	[medical support]	0.0	2	2	2	1
18019	361	von willebrand factor concentration	[von Willebrand factor concentrations]	0.0	4	1	1	1
18020	361	defibrillator implantation Cardiac resynchronization therapy	[Defibrillator Implantation Cardiac Resynchronization Therapy]	0.0	5	1	1	1
18021	361	patient man mean year	[patients men mean years]	0.0	4	1	1	1
18022	361	heart failure tissue	[heart failure tissue]	0.0	3	1	1	1
18023	361	event rate 2.08 event	[event rate 2.08 events]	0.0	4	1	1	1
18024	361	cardiac mena overexpression	[cardiac Mena overexpression]	0.0	3	1	1	1
18025	361	hypertrophy antecedent	[hypertrophy antecedent]	0.0	2	1	1	1
18026	361	3 evaluation hm ii	[3 evaluations HM II]	0.0	4	1	1	1
18027	361	receptor blocker therapy	[receptor blocker therapy]	0.0	3	1	1	1
18028	361	all-cause mortality at 4 year	[All-cause mortality at 4 years]	0.0	5	1	1	1
18029	361	growth factor VEGF	[growth factor VEGF]	0.0	3	1	1	1
18030	361	outcome measure related	[outcome measures related]	0.0	3	1	1	1
18031	361	measure of ventricular contractile reserve	[measure of ventricular contractile reserve]	0.0	5	1	1	1
18032	361	Physio Ring Edwards Lifescience	[Physio Ring Edwards Lifesciences]	0.0	4	1	1	1
18033	361	various serum factor	[various serum factors]	0.0	3	1	1	1
18034	361	determine individualized assessment for patient	[determining individualized assessment for patients]	0.0	5	1	1	1
18035	361	kidney 293 cell overexpress β1ar	[kidney 293 cells overexpressing β1AR]	0.0	5	1	1	1
18036	361	use multivariable regression	[using multivariable regression]	0.0	3	1	1	1
18037	361	low muscle mass r=0.67	[Low muscle mass r=0.67]	0.0	4	1	1	1
18038	361	confirmatory test	[Confirmatory tests]	0.0	2	1	1	1
18039	361	improve survival rate over 3 decade	[Improving survival rates over 3 decades]	0.0	6	1	1	1
18040	361	stable coronary artery disease	[stable coronary artery disease]	0.0	4	1	1	1
18041	361	CI 1.27	[CI 1.27]	0.0	2	1	1	1
18042	361	key role of ERK1	[Key role of ERK1]	0.0	4	1	1	1
18043	361	western blot with site-specific antibody	[Western blots with site-specific antibodies]	0.0	5	1	1	1
18044	361	Global proteomics analysis of heart failure	[Global proteomics analysis of heart failure]	0.0	6	1	1	1
18045	361	event evaluation	[events evaluation]	0.0	2	1	1	1
18046	361	development in candidate gene	[development in candidate genes]	0.0	4	1	1	1
18047	361	cardiorespiratory	[Cardiorespiratory]	0.0	1	1	1	1
18048	361	nt-probnp cutoff point	[NT-proBNP cutoff point]	0.0	3	1	1	1
18049	361	role of Mena	[role of Mena]	0.0	3	1	1	1
18050	361	center for Medicare readmission	[Centers for Medicare readmission]	0.0	4	1	1	1
18051	361	heart failure-related hospitalization	[heart failure-related hospitalization]	0.0	3	1	1	1
18052	361	53 patient	[53 patients]	0.0	2	1	1	1
18053	361	Excessive secretion of arginine vasopressin	[Excessive secretion of arginine vasopressin]	0.0	5	1	1	1
18054	361	angiogenesis in the post-myocardial infarction heart	[angiogenesis in the post-myocardial infarction heart]	0.0	6	1	1	1
18055	361	first infarction in Australia	[first infarction in Australia]	0.0	4	1	1	1
18056	361	effect of b on function	[effects of B on function]	0.0	5	1	1	1
18057	361	grade holosystolic murmur	[grade holosystolic murmur]	0.0	3	1	1	1
18058	361	surgical correction after assist device implantation	[Surgical correction after assist device implantation]	0.0	6	1	1	1
18059	361	continuous relationship between qrs duration	[continuous relationship between QRS duration]	0.0	5	1	1	1
18060	361	such response	[such responses]	0.0	2	1	1	1
18061	361	live with heart Failure Questionnaire	[Living with Heart Failure Questionnaire]	0.0	5	1	1	1
18062	361	datum regard the role	[data regarding the role]	0.0	4	1	1	1
18063	361	decrease in LV fractional shortening	[decreases in LV fractional shortening]	0.0	5	1	1	1
18064	361	HF in LA	[HF in LA]	0.0	3	2	2	1
18065	361	time interval between local depolarization	[time interval between local depolarization]	0.0	5	1	1	1
18066	361	use logistic regression analysis	[Using logistic regression analysis]	0.0	4	1	1	1
18067	361	increase bte	[increasing BTES]	0.0	2	1	1	1
18068	361	resuscitation cpr	[resuscitation CPR]	0.0	2	1	1	1
18069	361	typical event	[typical event]	0.0	2	1	1	1
18070	361	cAMP-dependent protein kinase signal downstream	[cAMP-dependent protein kinase signaling downstream]	0.0	5	1	1	1
18071	361	low concentration	[low concentration]	0.0	2	1	1	1
18072	361	minimal change mdc value	[minimal change MDC values]	0.0	4	1	1	1
18073	361	left ventricular biopsy	[left ventricular biopsies]	0.0	3	1	1	1
18074	361	natriuretic peptide level like biomarker	[Natriuretic peptide levels like biomarkers]	0.0	5	1	1	1
18075	361	manipulation via the target	[manipulation via the targeting]	0.0	4	1	1	1
18076	361	control CHF	[controls CHF]	0.0	2	1	1	1
18077	361	diameter	[diameters]	0.0	1	1	1	1
18078	361	high bnp group	[high BNP group]	0.0	3	1	1	1
18079	361	doppler ultrasonography	[Doppler ultrasonography]	0.0	2	1	1	1
18080	361	level pg high bnp group	[levels pg high BNP group]	0.0	5	1	1	1
18081	361	percent of visit	[percent of visits]	0.0	3	1	1	1
18082	361	Prognostic value of indeterminable threshold	[Prognostic value of indeterminable threshold]	0.0	5	1	1	1
18083	361	optimization of diastolic fill time	[optimization of diastolic filling time]	0.0	5	1	1	1
18084	361	ambulatory HF patient left ejection fraction	[ambulatory HF patients left ejection fraction]	0.0	6	1	1	1
18085	361	strength as a predictor	[strength as an predictor]	0.0	4	1	1	1
18086	361	HNO donor	[HNO donor]	0.0	2	1	1	1
18087	361	short-term treatment	[short-term treatment]	0.0	2	1	1	1
18088	361	performance in patient with heart failure	[performance in patients with heart failure]	0.0	6	1	1	1
18089	361	median left ejection fraction	[median left ejection fraction]	0.0	4	1	1	1
18090	361	time of inclusion	[time of inclusion]	0.0	3	1	1	1
18091	361	global left ventricular longitudinal systolic strain	[global left ventricular longitudinal systolic strain]	0.0	6	1	1	1
18092	361	advantage of the fast turnaround time	[advantage of the faster turnaround times]	0.0	6	1	1	1
18093	361	ventricular tissue from control animal	[ventricular tissue from control animals]	0.0	5	1	1	1
18094	361	chelation regimen	[chelation regimens]	0.0	2	1	1	1
18095	361	rehospitalization of 1.56 percentage point	[rehospitalization of 1.56 percentage points]	0.0	5	1	1	1
18096	361	HF tissue sample	[HF tissue samples]	0.0	3	1	1	1
18097	361	(-)-epicatechin-rich cocoa	[(-)-epicatechin-rich cocoa]	0.0	2	1	1	1
18098	361	reduce the endpoint in all subgroup	[reducing the endpoint in all subgroups]	0.0	6	1	1	1
18099	361	recent onset af	[recent onset AF]	0.0	3	1	1	1
18100	361	hazard ratio 0.91	[hazard ratio 0.91]	0.0	3	1	1	1
18101	361	methotrexate	[methotrexate]	0.0	1	1	1	1
18102	361	type of cardiac tumor	[type of cardiac tumors]	0.0	4	1	1	1
18103	361	clinical application of peptide drug	[clinical application of peptide drugs]	0.0	5	1	1	1
18104	361	p38α protein kinase p38	[p38α protein kinase p38]	0.0	4	1	1	1
18105	361	kg with improvement	[kg with improvement]	0.0	3	1	1	1
18106	361	symptom in HFpEF	[symptoms in HFpEF]	0.0	3	1	1	1
18107	361	high relevance in hypertension patient	[high relevance in hypertension patients]	0.0	5	1	1	1
18108	361	na current during human HF	[Na current during human HF]	0.0	5	1	1	1
18109	361	acute care surgery ACS consultation	[acute care surgery ACS consultations]	0.0	5	1	1	1
18110	361	3.5 gram	[3.5 g]	0.0	2	1	1	1
18111	361	heart Association guideline on evaluation	[Heart Association guidelines on evaluation]	0.0	5	1	1	1
18112	361	trial involve center	[trial involving centers]	0.0	3	1	1	1
18113	361	pka subunit	[PKA subunits]	0.0	2	1	1	1
18114	361	post-translational modification	[post-translational modification]	0.0	2	1	1	1
18115	361	such as pressure ulcer in patient	[such as pressure ulcers in patients]	0.0	6	1	1	1
18116	361	heart muscle cell	[heart muscle cells]	0.0	3	1	1	1
18117	361	reprogramming event	[reprogramming events]	0.0	2	1	1	1
18118	361	LV mass versus 5.0 gram p=0.04	[LV mass versus 5.0 g P=0.04]	0.0	6	1	1	1
18119	361	difference between group patient p	[difference between groups patients P]	0.0	5	1	1	1
18120	361	cardiopulmonary exercise testing guide	[cardiopulmonary exercise testing guide]	0.0	4	1	1	1
18121	361	cardiac activity by (123)i-meta-iodobenzylguanidine ((123)i-mibg	[cardiac activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG]	0.0	5	1	1	1
18122	361	N-terminal pro-brain peptide	[N-terminal pro-brain peptide]	0.0	3	3	3	1
18123	361	lvef respectively	[LVEF respectively]	0.0	2	1	1	1
18124	361	pulseless fibrillation	[pulseless fibrillation]	0.0	2	1	1	1
18125	361	pulmonary disease copd	[pulmonary disease COPD]	0.0	3	1	1	1
18126	361	diagnosis of multiple myeloma	[diagnosis of multiple myeloma]	0.0	4	1	1	1
18127	361	use CardioPulmonary Exercise test guide	[using CardioPulmonary Exercise Testing guide]	0.0	5	1	1	1
18128	361	target exercise hemodynamic status	[targeting exercise hemodynamic status]	0.0	4	1	1	1
18129	361	acute care surgery consultation	[acute care surgery consultations]	0.0	4	1	1	1
18130	361	achievement	[achievement]	0.0	1	1	1	1
18131	361	independent role	[independent role]	0.0	2	1	1	1
18132	361	random-effect	[random-effects]	0.0	1	1	1	1
18133	361	atrial myxoma	[atrial myxoma]	0.0	2	2	2	1
18134	361	per cent	[per cent]	0.0	2	1	1	1
18135	361	hypothermic circulatory arrest	[hypothermic circulatory arrest]	0.0	3	1	1	1
18136	361	24 per cent	[24 per cent]	0.0	3	1	1	1
18137	361	national medicare datum	[national Medicare data]	0.0	3	1	1	1
18138	361	significant decline in event rate	[significant decline in event rates]	0.0	5	1	1	1
18139	361	cardiorespiratory fitness CRF	[cardiorespiratory fitness CRF]	0.0	3	1	1	1
18140	361	aerobic training period with training	[aerobic training period with trainings]	0.0	5	1	1	1
18141	361	primary endpoint cardiovascular death	[primary endpoint cardiovascular death]	0.0	4	1	1	1
18142	361	distinctive component	[distinctive components]	0.0	2	1	1	1
18143	361	week of pacing	[weeks of pacing]	0.0	3	1	1	1
18144	361	proanp MR-proANP	[proANP MR-proANP]	0.0	2	1	1	1
18145	361	absence of coronary artery disease	[absence of coronary artery disease]	0.0	5	1	1	1
18146	361	circumferential shortening	[circumferential shortening]	0.0	2	1	1	1
18147	361	area of E ratio	[area of E ratios]	0.0	4	1	1	1
18148	361	difference bnp	[difference BNP]	0.0	2	1	1	1
18149	361	mortality in 90-day survivor	[mortality in 90-day survivors]	0.0	4	1	1	1
18150	361	safe effective off-pump sternal sparing approach	[Safe effective off-pump sternal sparing approach]	0.0	6	1	1	1
18151	361	ischemic mr	[ischemic MR]	0.0	2	1	1	1
18152	361	nondiabete risk factor age man	[nondiabetes risk factors age men]	0.0	5	1	1	1
18153	361	day range day	[days range days]	0.0	3	1	1	1
18154	361	potential for deleterious effect	[potential for deleterious effects]	0.0	4	1	1	1
18155	361	previous revascularization artery bypass surgery	[previous revascularization artery bypass surgery]	0.0	5	1	1	1
18156	361	two-vessel disease model	[two-vessel disease model]	0.0	3	1	1	1
18157	361	arterial compliance	[arterial compliance]	0.0	2	1	1	1
18158	361	frailty a prognostic indicator	[Frailty an prognostic indicator]	0.0	4	1	1	1
18159	361	renal failure CRF	[renal failure CRF]	0.0	3	1	1	1
18160	361	global strain GLS	[global strain GLS]	0.0	3	1	1	1
18161	361	subunit	[subunit]	0.0	1	1	1	1
18162	361	undergo cardiac resynchronization therapy	[undergoing cardiac resynchronization therapy]	0.0	4	1	1	1
18163	361	outflow	[outflow]	0.0	1	1	1	1
18164	361	systolic parameter in af	[systolic parameters in AF]	0.0	4	1	1	1
18165	361	usually the result	[usually the result]	0.0	3	1	1	1
18166	361	298 sitagliptin user	[298 sitagliptin users]	0.0	3	1	1	1
18167	361	Healthcare	[Healthcare]	0.0	1	1	1	1
18168	361	participant dopamine	[participants dopamine]	0.0	2	1	1	1
18169	361	mortality in 28-day survivor	[mortality in 28-day survivors]	0.0	4	1	1	1
18170	361	improvement after device implantation	[improvement after device implantation]	0.0	4	1	1	1
18171	361	rate of change	[rates of changes]	0.0	3	1	1	1
18172	361	axis	[axis]	0.0	1	1	1	1
18173	361	inhibitor JQ1	[inhibitor JQ1]	0.0	2	1	1	1
18174	361	right annular plane excursion	[right annular plane excursion]	0.0	4	1	1	1
18175	361	ventricular systolic strain GLS	[ventricular systolic strain GLS]	0.0	4	1	1	1
18176	361	derangement with hemodynamic feature similar	[derangement with hemodynamic features similar]	0.0	5	1	1	1
18177	361	strong recommendation	[strong recommendation]	0.0	2	1	1	1
18178	361	consecutive HF patient left ejection fraction	[consecutive HF patients left ejection fraction]	0.0	6	1	1	1
18179	361	channel α-subunit	[channel α-subunit]	0.0	2	1	1	1
18180	361	ejection fraction a Trial	[Ejection Fraction A Trial]	0.0	4	1	1	1
18181	361	5.0 mmol	[5.0 mmol]	0.0	2	2	2	1
18182	361	12- recovery period	[12-s recovery period]	0.0	3	1	1	1
18183	361	New York heart Association functional class	[New York Heart Association functional class]	0.0	6	1	1	1
18184	361	bpm with beta-blocker therapy	[bpm with beta-blocker therapy]	0.0	4	1	1	1
18185	361	descending lad	[descending LAD]	0.0	2	1	1	1
18186	361	estimation	[estimation]	0.0	1	1	1	1
18187	361	mouse HF model of HHD	[mouse HF model of HHD]	0.0	5	1	1	1
18188	361	chronic medical therapy	[chronic medical therapy]	0.0	3	1	1	1
18189	361	modifiable risk factor	[modifiable risk factors]	0.0	3	1	1	1
18190	361	rest hr bpm	[resting HR bpm]	0.0	3	1	1	1
18191	361	range from .85	[ranging from .85]	0.0	3	1	1	1
18192	361	specific effector molecule	[specific effector molecules]	0.0	3	1	1	1
18193	361	search of the database	[search of the databases]	0.0	4	1	1	1
18194	361	inotropic effect in vivo	[inotropic effects in vivo]	0.0	4	1	1	1
18195	361	baseline egfr group p	[Baseline eGFR group P]	0.0	4	1	1	1
18196	361	muscle sarcomere structure	[muscle sarcomere structure]	0.0	3	1	1	1
18197	361	describe trend in HF	[describing trends in HF]	0.0	4	1	1	1
18198	361	broad panel	[broad panel]	0.0	2	1	1	1
18199	361	english-language trial of blood transfusion	[English-language trials of blood transfusions]	0.0	5	1	1	1
18200	361	regard the need for antiplatelet agent	[regarding the need for antiplatelet agents]	0.0	6	1	1	1
18201	361	use of evidence-based medication	[use of evidence-based medications]	0.0	4	1	1	1
18202	361	discrimination change in c-index	[discrimination change in C-index]	0.0	4	1	1	1
18203	361	3 pharmacologic study include agent	[3 pharmacologic studies including agents]	0.0	5	1	1	1
18204	361	low status	[lower status]	0.0	2	1	1	1
18205	361	change in the development	[changes in the development]	0.0	4	1	1	1
18206	361	percent remain in extreme decile	[percent remaining in extreme deciles]	0.0	5	1	1	1
18207	361	growth factor-β tgf-β signal	[growth factor-β TGF-β signaling]	0.0	4	1	1	1
18208	361	benefit with consequence	[benefit with consequences]	0.0	3	1	1	1
18209	361	annulus velocity Sa	[annulus velocity Sa]	0.0	3	1	1	1
18210	361	TAPSE relationship as a index	[TAPSE relationship as a index]	0.0	5	1	1	1
18211	361	transcriptional pause release	[transcriptional pause release]	0.0	3	1	1	1
18212	361	change in diastolic function	[changes in diastolic function]	0.0	4	1	1	1
18213	361	change in chronic heart failure	[change in chronic heart failure]	0.0	5	1	1	1
18214	361	plane systolic excursion from the end	[plane systolic excursion from the end]	0.0	6	1	1	1
18215	361	conventional systolic parameter	[conventional systolic parameters]	0.0	3	1	1	1
18216	361	diagnosis of prognostic dysfunction lead	[diagnosis of prognostic dysfunction leading]	0.0	5	1	1	1
18217	361	dog with coronary HF	[dogs with coronary HF]	0.0	4	1	1	1
18218	361	right ventricular ejection fraction	[right ventricular ejection fraction]	0.0	4	1	1	1
18219	361	heart failure in practice	[heart failure in practice]	0.0	4	1	1	1
18220	361	plasma b-type peptide bnp level	[plasma B-type peptide BNP levels]	0.0	5	1	1	1
18221	361	μmol L	[μmol L]	0.0	2	1	1	1
18222	361	transmitral e-wave mitral annular velocity	[transmitral E-wave mitral annular velocity]	0.0	5	1	1	1
18223	361	use simple procedure	[using simple procedures]	0.0	3	1	1	1
18224	361	mass index	[mass index]	0.0	2	1	1	1
18225	361	metabolic evaluation	[metabolic evaluations]	0.0	2	1	1	1
18226	361	undergo lvad implantation	[undergoing LVAD implantation]	0.0	3	1	1	1
18227	361	icu admission	[ICU admission]	0.0	2	1	1	1
18228	361	review protocol	[review protocol]	0.0	2	1	1	1
18229	361	patient with recent onset	[patients with recent onset]	0.0	4	1	1	1
18230	361	reflect decrease period	[reflecting decreases period]	0.0	3	1	1	1
18231	361	phenylephrine-mediated hypertrophy	[phenylephrine-mediated hypertrophy]	0.0	2	1	1	1
18232	361	require revision by surgery	[requiring revision by surgery]	0.0	4	1	1	1
18233	361	gene expression programme	[gene expression programme]	0.0	3	1	1	1
18234	361	increase volume index	[increasing volume index]	0.0	3	1	1	1
18235	361	length 37	[length 37]	0.0	2	1	1	1
18236	361	angiotensin-receptor neprilysin inhibitor	[angiotensin-receptor neprilysin inhibitors]	0.0	3	1	1	1
18237	361	low mg equivalent dose	[low mg equivalent dose]	0.0	4	1	1	1
18238	361	serum level of brain natriuretic peptide	[serum levels of brain natriuretic peptide]	0.0	6	1	1	1
18239	361	(Fpassive)-sarcomere length	[(Fpassive)-sarcomere length]	0.0	2	1	1	1
18240	361	even in subgroup at risk	[even in subgroups at risk]	0.0	5	1	1	1
18241	361	biomarker approach	[biomarker approach]	0.0	2	1	1	1
18242	361	transmitral flow	[transmitral flow]	0.0	2	1	1	1
18243	361	hrqol change	[HRQoL changes]	0.0	2	1	1	1
18244	361	multisystem disease with comorbidity	[multisystem disease with comorbidities]	0.0	4	1	1	1
18245	361	advanced obstructive pulmonary disease copd	[advanced obstructive pulmonary disease COPD]	0.0	5	1	1	1
18246	361	ventricular-pulmonary arterial coupling	[ventricular-pulmonary arterial coupling]	0.0	3	1	1	1
18247	361	mechanism of cardioprotection	[mechanism of cardioprotection]	0.0	3	1	1	1
18248	361	study with long follow-up	[studies with long-term follow-up]	0.0	4	1	1	1
18249	361	combination restrict the leaflet opening	[combination restricting the leaflet opening]	0.0	5	2	2	1
18250	361	open chest model surrogate	[open chest model surrogates]	0.0	4	1	1	1
18251	361	First-in-class angiotensin	[First-in-class angiotensin]	0.0	2	1	1	1
18252	361	effect of ventricular ejection fraction	[effect of ventricular ejection fraction]	0.0	5	1	1	1
18253	361	extra corporeal membrane oxygenation	[extra corporeal membrane oxygenation]	0.0	4	1	1	1
18254	361	variation in use of medication	[variation in use of medications]	0.0	5	1	1	1
18255	361	mild heart failure HF	[mild heart failure HF]	0.0	4	1	1	1
18256	361	heart Failure MLHF questionnaire	[Heart Failure MLHF Questionnaire]	0.0	4	1	1	1
18257	361	ejection fraction lvef	[ejection fraction LVEF]	0.0	3	1	1	1
18258	361	with icc value range	[with ICC values ranging]	0.0	4	1	1	1
18259	361	normal geometry no LV hypertrophy	[normal geometry no LV hypertrophy]	0.0	5	1	1	1
18260	361	necessitate a good understanding	[necessitating a better understanding]	0.0	4	1	1	1
18261	361	high event rate event	[highest event rate events]	0.0	4	1	1	1
18262	361	topic of debate	[topics of debate]	0.0	3	1	1	1
18263	361	behavior	[behavior]	0.0	1	1	1	1
18264	361	threshold at	[threshold AT]	0.0	2	1	1	1
18265	361	effectiveness of Chinese medicine CHM	[effectiveness of Chinese medicine CHM]	0.0	5	1	1	1
18266	361	acute heart failure filtration rate	[acute heart failure filtration rate]	0.0	5	1	1	1
18267	361	neurotransmission	[neurotransmission]	0.0	1	1	1	1
18268	361	hypertrophy a robust predictor of HF	[hypertrophy a robust predictor of HF]	0.0	6	1	1	1
18269	361	artery disease hr	[artery disease HR]	0.0	3	1	1	1
18270	361	interval between local depolarization	[interval between local depolarization]	0.0	4	1	1	1
18271	361	Hospital anxiety	[Hospital Anxiety]	0.0	2	1	1	1
18272	361	brain peptide level pg bnp group	[brain peptide levels pg BNP group]	0.0	6	1	1	1
18273	361	normal ventricular function	[normal ventricular function]	0.0	3	1	1	1
18274	361	association of hypoalbuminemia	[association of hypoalbuminemia]	0.0	3	1	1	1
18275	361	gene between heart failure sample	[genes between heart failure samples]	0.0	5	1	1	1
18276	361	exercise training response	[exercise training response]	0.0	3	1	1	1
18277	361	≥60 millileter per m 2	[≥60 mL per m 2]	0.0	5	1	1	1
18278	361	adverse event rate for infarction	[adverse event rates for infarction]	0.0	5	1	1	1
18279	361	create uncertainty	[creating uncertainty]	0.0	2	1	1	1
18280	361	biventricular pacing	[biventricular pacing]	0.0	2	1	1	1
18281	361	treatment for infarction AMI	[treatment for infarction AMI]	0.0	4	1	1	1
18282	361	framework determine assessment for patient	[framework determining assessment for patients]	0.0	5	1	1	1
18283	361	arginine	[arginine]	0.0	1	1	1	1
18284	361	right ventricular area index 10.0 cm(2)	[right ventricular area index 10.0 cm(2)]	0.0	6	1	1	1
18285	361	fitness	[fitness]	0.0	1	1	1	1
18286	361	such as heart failure HF	[such as heart failure HF]	0.0	5	1	1	1
18287	361	multiple abnormality in cardiovascular function	[multiple abnormalities in cardiovascular function]	0.0	5	1	1	1
18288	361	symptom Hospital anxiety	[symptoms Hospital Anxiety]	0.0	3	1	1	1
18289	361	high serum level of peptide bnp	[higher serum levels of peptide BNP]	0.0	6	1	1	1
18290	361	detectable change mdc value	[detectable change MDC values]	0.0	4	1	1	1
18291	361	heart fill pressure	[heart filling pressures]	0.0	3	1	1	1
18292	361	Health ABC physical performance Battery	[Health ABC Physical Performance Battery]	0.0	5	1	1	1
18293	361	first infarction	[first infarction]	0.0	2	1	1	1
18294	361	diastolic index ratio at diastole	[diastolic indices ratio at diastole]	0.0	5	1	1	1
18295	361	patient with idiopathic cardiomyopathy	[patients with idiopathic cardiomyopathy]	0.0	4	1	1	1
18296	361	left base during baseline	[left base during baseline]	0.0	4	1	1	1
18297	361	conditioning	[conditioning]	0.0	1	1	1	1
18298	361	result in the suppression	[resulting in the suppression]	0.0	4	1	1	1
18299	361	several pathological change	[several pathological changes]	0.0	3	1	1	1
18300	361	prognostic diastolic dysfunction	[prognostic diastolic dysfunction]	0.0	3	1	1	1
18301	361	African American	[African Americans]	0.0	2	1	1	1
18302	361	single referral centre	[Single referral centre]	0.0	3	1	1	1
18303	361	absolute change mdc value	[absolute change MDC values]	0.0	4	1	1	1
18304	361	composite outcome of death	[composite outcome of death]	0.0	4	1	1	1
18305	361	breakdown	[breakdown]	0.0	1	1	1	1
18306	361	exercise hemodynamic status	[exercise hemodynamic status]	0.0	3	1	1	1
18307	361	reactivation of gene program	[reactivation of gene programs]	0.0	4	1	1	1
18308	361	Functional stimulation fes	[Functional stimulation FES]	0.0	3	1	1	1
18309	361	identify death	[identifying death]	0.0	2	1	1	1
18310	361	benefit of treatment for anemia	[benefits of treatments for anemia]	0.0	5	1	1	1
18311	361	stretch	[stretch]	0.0	1	1	1	1
18312	361	effect of left ejection fraction	[effect of left ejection fraction]	0.0	5	1	1	1
18313	361	mean score	[mean score]	0.0	2	2	2	1
18314	361	significant trend	[significant trends]	0.0	2	1	1	1
18315	361	hypertension ph	[hypertension PH]	0.0	2	1	1	1
18316	361	right atrial area	[right atrial area]	0.0	3	1	1	1
18317	361	emergency Department	[Emergency Department]	0.0	2	1	1	1
18318	361	use the method of constriction	[using the method of constriction]	0.0	5	1	1	1
18319	361	Danish Registry	[Danish Registry]	0.0	2	1	1	1
18320	361	N2Bus segment	[N2Bus segment]	0.0	2	1	1	1
18321	361	structurally normal heart	[structurally normal hearts]	0.0	3	1	1	1
18322	361	HeartWare patient	[HeartWare patients]	0.0	2	1	1	1
18323	361	positive inotropic effect	[positive inotropic effects]	0.0	3	1	1	1
18324	361	extracorporeal membrane oxygenation ecmo on function	[extracorporeal membrane oxygenation ECMO on function]	0.0	6	1	1	1
18325	361	Cox modeling	[Cox modeling]	0.0	2	1	1	1
18326	361	objective criteriabased institution	[Objective criteriabased institution]	0.0	3	1	1	1
18327	361	shock therapy hr	[shock therapy HR]	0.0	3	1	1	1
18328	361	benefit with few consequence	[benefit with few consequences]	0.0	4	1	1	1
18329	361	diastolic dysfunction impaired LV relaxation	[diastolic dysfunction impaired LV relaxation]	0.0	5	1	1	1
18330	361	partial pressure of end-tidal co2	[partial pressure of end-tidal CO2]	0.0	5	1	1	1
18331	361	project cost	[projecting costs]	0.0	2	1	1	1
18332	361	change in pressure development	[changes in pressure development]	0.0	4	1	1	1
18333	361	HeartMate lvas	[HeartMate LVADs]	0.0	2	1	1	1
18334	361	address difference	[Addressing differences]	0.0	2	1	1	1
18335	361	Hospital compare	[Hospital Compare]	0.0	2	1	1	1
18336	361	training period	[training period]	0.0	2	1	1	1
18337	361	however a important disease	[however an important disease]	0.0	4	1	1	1
18338	361	2.1 millileter 2	[2.1 mL 2]	0.0	3	1	1	1
18339	361	degree of ms	[degree of MS]	0.0	3	1	1	1
18340	361	Grading Assessment GRADE methodology	[Grading Assessment GRADE methodology]	0.0	4	1	1	1
18341	361	main 3-vessel cad	[main 3-vessel CAD]	0.0	3	1	1	1
18342	361	anthracycline-treated breast cancer patient	[anthracycline-treated breast cancer patients]	0.0	4	1	1	1
18343	361	valid measure	[valid measure]	0.0	2	2	2	1
18344	361	exercise testing guide	[exercise testing guide]	0.0	3	1	1	1
18345	361	practitioner	[practitioners]	0.0	1	1	1	1
18346	361	benefit over parameter in af	[benefit over parameters in AF]	0.0	5	1	1	1
18347	361	extracorporeal membrane oxygenation ecmo	[extracorporeal membrane oxygenation ECMO]	0.0	4	1	1	1
18348	361	control non-cachectic CHF	[controls non-cachectic CHF]	0.0	3	1	1	1
18349	361	significant decrease	[significant decrease]	0.0	2	3	3	1
18350	361	cardiac-resynchronization therapy with a qrs complex	[Cardiac-resynchronization therapy with a QRS complex]	0.0	6	1	1	1
18351	361	large limit of agreement	[large limits of agreement]	0.0	4	1	1	1
18352	361	electromechanical delay the time	[electromechanical delay the time]	0.0	4	1	1	1
18353	361	increase for myocardial infarction	[increase for myocardial infarction]	0.0	4	1	1	1
18354	361	low-dose dopamine on end point	[low-dose dopamine on end points]	0.0	5	1	1	1
18355	361	ventricular annular plane systolic excursion tapse	[ventricular annular plane systolic excursion TAPSE]	0.0	6	1	1	1
18356	361	obese participant mean	[obese participants mean]	0.0	3	1	1	1
18357	361	Toronto	[Toronto]	0.0	1	1	1	1
18358	361	assay n-terminal pro-b-type peptide	[assay N-terminal pro-B-type peptide]	0.0	4	1	1	1
18359	361	hr reduction 17±22 versus bpm	[HR reduction 17±22 versus bpm]	0.0	5	1	1	1
18360	361	pacing on heart twist	[pacing on heart twist]	0.0	4	1	1	1
18361	361	stress marker	[stress markers]	0.0	2	1	1	1
18362	361	Classification of Disease	[Classification of Diseases]	0.0	3	2	2	1
18363	361	mandatory monitoring	[mandatory monitoring]	0.0	2	1	1	1
18364	361	relative risk of heart failure	[relative risk of heart failure]	0.0	5	1	1	1
18365	361	pro-adrenomedullin	[pro-adrenomedullin]	0.0	1	1	1	1
18366	361	risk of death visit	[risk of death visit]	0.0	4	1	1	1
18367	361	left area	[left area]	0.0	2	1	1	1
18368	361	basis of left ventricle	[basis of left ventricle]	0.0	4	1	1	1
18369	361	American College	[American College]	0.0	2	4	4	1
18370	361	York heart Association class hr	[York Heart Association class HR]	0.0	5	1	1	1
18371	361	morbidity especially in elderly people	[morbidity especially in elderly people]	0.0	5	1	1	1
18372	361	support for the concept appropriate	[support for the concept appropriate]	0.0	5	1	1	1
18373	361	extracellular matrix of left biopsy	[Extracellular matrix of left biopsies]	0.0	5	1	1	1
18374	361	left ventricular strain as a predictor	[left ventricular strain as a predictor]	0.0	6	1	1	1
18375	361	right ventricular pump function	[right ventricular pump function]	0.0	4	1	1	1
18376	361	decline explant-derived c-kit	[decline explant-derived c-Kit]	0.0	3	1	1	1
18377	361	additive for peak vo2 effect	[additive for peak VO2 effect]	0.0	5	1	1	1
18378	361	great impact on patient	[greater impact on patients]	0.0	4	1	1	1
18379	361	prior infarction-both n	[prior infarction-both n]	0.0	3	1	1	1
18380	361	target for the prevention	[targets for the prevention]	0.0	4	1	1	1
18381	361	exercise variable exercise ventilation	[exercise variables exercise ventilation]	0.0	4	1	1	1
18382	361	hospital nationwide from January through September	[hospitals nationwide from January through September]	0.0	6	1	1	1
18383	361	hfpef with ejection fraction	[HFpEF with ejection fraction]	0.0	4	1	1	1
18384	361	plane systolic excursion tapse	[plane systolic excursion TAPSE]	0.0	4	1	1	1
18385	361	patient with breast cancer	[patients with breast cancer]	0.0	4	1	1	1
18386	361	pulseless ventricular fibrillation	[pulseless ventricular fibrillation]	0.0	3	1	1	1
18387	361	diagnosis of diastolic dysfunction	[diagnosis of diastolic dysfunction]	0.0	4	1	1	1
18388	361	home telemonitoring tm	[home telemonitoring TM]	0.0	3	1	1	1
18389	361	ventricular RV plane excursion tapse	[ventricular RV plane excursion TAPSE]	0.0	5	1	1	1
18390	361	type V na	[type V Na]	0.0	3	1	1	1
18391	361	dipeptidyl peptidase-4 dpp-4	[dipeptidyl peptidase-4 DPP-4]	0.0	3	1	1	1
18392	361	proanp	[proANP]	0.0	1	1	1	1
18393	361	deleterious effect in CHF inhibition	[deleterious effects in CHF Inhibition]	0.0	5	1	1	1
18394	361	potential as target	[potential as targets]	0.0	3	1	1	1
18395	361	safety of receptor antagonist	[safety of receptor antagonists]	0.0	4	1	1	1
18396	361	moderate-severe ventricular dysfunction	[moderate-severe ventricular dysfunction]	0.0	3	1	1	1
18397	361	particularly in patient with dysfunction	[particularly in patients with dysfunction]	0.0	5	1	1	1
18398	361	coronary intervention hr	[coronary intervention HR]	0.0	3	1	1	1
18399	361	scn5a mrna splicing	[SCN5A mRNA splicing]	0.0	3	1	1	1
18400	361	positive rate	[positive rates]	0.0	2	1	1	1
18401	361	minute 59.6 m vs. m	[min 59.6 m vs. m]	0.0	5	1	1	1
18402	361	hospital readmission reduction	[hospital readmission reduction]	0.0	3	1	1	1
18403	361	standard cardiac rehabilitation care on capacity	[standard cardiac rehabilitation care on capacity]	0.0	6	1	1	1
18404	361	cause of ras	[cause of RAS]	0.0	3	1	1	1
18405	361	important factor in heart failure	[important factor in heart failure]	0.0	5	1	1	1
18406	361	more datum	[more data]	0.0	2	1	1	1
18407	361	four-week aerobic training period	[four-week aerobic training period]	0.0	4	1	1	1
18408	361	diastolic mitral velocity 3.1	[diastolic mitral velocity 3.1]	0.0	4	1	1	1
18409	361	murine resistin	[murine resistin]	0.0	2	1	1	1
18410	361	predictor of hospitalization	[predictors of hospitalization]	0.0	3	1	1	1
18411	361	abnormal can handling	[abnormal Ca handling]	0.0	3	1	1	1
18412	361	mandate	[mandate]	0.0	1	1	1	1
18413	361	2.1 17.6 millileter 2	[2.1 17.6 mL 2]	0.0	4	1	1	1
18414	361	wave doppler echocardiography	[wave Doppler echocardiography]	0.0	3	1	1	1
18415	361	throughput of patient	[throughput of patients]	0.0	3	1	1	1
18416	361	low gross income per capita	[lower gross income per capita]	0.0	5	1	1	1
18417	361	peptide assessment	[peptide assessment]	0.0	2	1	1	1
18418	361	advanced pulmonary disease copd	[advanced pulmonary disease COPD]	0.0	4	1	1	1
18419	361	measurement of peptide NPs	[measurement of peptides NPs]	0.0	4	1	1	1
18420	361	potential dysfunction	[potential dysfunction]	0.0	2	1	1	1
18421	361	carotid baroreflex activation therapy	[carotid baroreflex activation therapy]	0.0	4	1	1	1
18422	361	die in 30 day p-value	[dying in 30 days P-value]	0.0	5	1	1	1
18423	361	bhlh transcription	[bHLH transcription]	0.0	2	1	1	1
18424	361	enzyme in patient	[enzymes in patients]	0.0	3	1	1	1
18425	361	climate within the NHS	[climate within the NHS]	0.0	4	1	1	1
18426	361	collagen density of the survive ventricle	[collagen density of the surviving ventricle]	0.0	6	1	1	1
18427	361	septum thickness	[septum thickness]	0.0	2	1	1	1
18428	361	randomised study	[randomised studies]	0.0	2	1	1	1
18429	361	six thousand five hundred thirty-seven hospital	[Six thousand five hundred thirty-seven hospitals]	0.0	6	1	1	1
18430	361	120 patient	[120 patients]	0.0	2	1	1	1
18431	361	LV stiffness	[LV stiffness]	0.0	2	1	1	1
18432	361	result in a high sv	[resulting in a higher SV]	0.0	5	1	1	1
18433	361	e-wave mitral annular velocity	[E-wave mitral annular velocity]	0.0	4	1	1	1
18434	361	evaluation of patient	[evaluation of patients]	0.0	3	1	1	1
18435	361	walk test 6-mwt	[walk test 6-MWT]	0.0	3	1	1	1
18436	361	all-cause hospitalisation	[all-cause hospitalisations]	0.0	2	1	1	1
18437	361	function in b-treated	[function in B-treated]	0.0	3	1	1	1
18438	361	paediatric transplant in child	[paediatric transplants in children]	0.0	4	1	1	1
18439	361	effective elastance ea elastance ees	[Effective elastance Ea elastance Ees]	0.0	5	1	1	1
18440	361	refill compliance for etidronate p	[refill compliance for etidronate P]	0.0	5	1	1	1
18441	361	use a HF registry	[Using a HF registry]	0.0	4	1	1	1
18442	361	safe off-pump sparing approach	[Safe off-pump sparing approach]	0.0	4	1	1	1
18443	361	hand grip strength kg from baseline	[hand grip strength kg from baseline]	0.0	6	1	1	1
18444	361	type of benign tumor	[type of benign tumors]	0.0	4	1	1	1
18445	361	University Health Network	[University Health Network]	0.0	3	1	1	1
18446	361	inappropriate cardioverter-defibrillator therapy defibrillator implantation	[inappropriate cardioverter-defibrillator therapy Defibrillator Implantation]	0.0	5	1	1	1
18447	361	80 year	[80 years]	0.0	2	1	1	1
18448	361	evidence for the treatment of HF	[evidence for the treatment of HF]	0.0	6	1	1	1
18449	361	30 mm hg	[30 mm Hg]	0.0	3	1	1	1
18450	361	thrombotic obstruction of the artery	[thrombotic obstruction of the artery]	0.0	5	1	1	1
18451	361	new-onset esrd from the Danish Registry	[new-onset ESRD from the Danish Registry]	0.0	6	1	1	1
18452	361	muscle strip	[muscle strips]	0.0	2	1	1	1
18453	361	prognostic factor in heart failure	[prognostic factor in heart failure]	0.0	5	1	1	1
18454	361	HDL particle	[HDL particles]	0.0	2	1	1	1
18455	361	fourteen database include MEDLINE	[Fourteen databases including MEDLINE]	0.0	4	1	1	1
18456	361	complexity	[complexities]	0.0	1	1	1	1
18457	361	population-based cohort study	[Population-based cohort study]	0.0	3	1	1	1
18458	361	prognostic role	[prognostic role]	0.0	2	1	1	1
18459	361	component regulate metabolism	[components regulating metabolism]	0.0	3	1	1	1
18460	361	tool for assessment	[tool for assessment]	0.0	3	1	1	1
18461	361	remote ischemic conditioning	[Remote ischemic conditioning]	0.0	3	1	1	1
18462	361	pulmonary hypertension pah	[pulmonary hypertension PAH]	0.0	3	1	1	1
18463	361	extracellular matrix of ventricular biopsy	[Extracellular matrix of ventricular biopsies]	0.0	5	1	1	1
18464	361	year versus 53.2 year	[years versus 53.2 years]	0.0	4	1	1	1
18465	361	concept also appropriate	[concept also appropriate]	0.0	3	1	1	1
18466	361	pre-hct germline DNA	[pre-HCT germline DNA]	0.0	3	1	1	1
18467	361	HeartMate exchange	[HeartMate exchange]	0.0	2	1	1	1
18468	361	change include hypertrophy	[changes including hypertrophy]	0.0	3	1	1	1
18469	361	self-identified black patient	[self-identified black patients]	0.0	3	1	1	1
18470	361	trials-Enriching	[trials-Enriching]	0.0	1	1	1	1
18471	361	effect on physiologic process	[effects on physiologic processes]	0.0	4	1	1	1
18472	361	require RV support after lvad insertion	[requiring RV support after LVAD insertion]	0.0	6	1	1	1
18473	361	vascular resistance SVR index	[vascular resistance SVR index]	0.0	4	1	1	1
18474	361	Outcome in Patient	[Outcomes In Patients]	0.0	3	1	1	1
18475	361	association with outcome	[association with outcomes]	0.0	3	1	1	1
18476	361	ethically complex situation	[ethically complex situations]	0.0	3	1	1	1
18477	361	Left ventricular ejection time complicate hypertension	[Left ventricular ejection time complicating hypertension]	0.0	6	1	1	1
18478	361	xanthine	[Xanthine]	0.0	1	2	2	1
18479	361	compare b-treated with drug-untreated heart	[comparing B-treated with drug-untreated hearts]	0.0	5	1	1	1
18480	361	outcome from any cause	[outcome from any cause]	0.0	4	1	1	1
18481	361	setting other	[settings other]	0.0	2	1	1	1
18482	361	impact on the effectiveness	[impact on the effectiveness]	0.0	4	1	1	1
18483	361	dietary recommendation for patient	[dietary recommendations for patients]	0.0	4	1	1	1
18484	361	14 clinical study 2900 hm	[14 clinical studies 2900 HM]	0.0	5	1	1	1
18485	361	223 patient mean age	[223 patients mean age]	0.0	4	1	1	1
18486	361	effect of type of lvas	[effects of types of LVADs]	0.0	5	1	1	1
18487	361	specialty hospital	[specialty hospital]	0.0	2	1	1	1
18488	361	proximal left anterior descending	[proximal left anterior descending]	0.0	4	1	1	1
18489	361	multicenter double-blind trial of patient	[Multicenter double-blind trial of patients]	0.0	5	1	1	1
18490	361	new target for HHD	[new targets for HHD]	0.0	4	1	1	1
18491	361	LCX late model	[LCX later model]	0.0	3	1	1	1
18492	361	regard treatment of adult	[regarding treatment of adults]	0.0	4	1	1	1
18493	361	hyperkalemia in African American	[hyperkalemia in African Americans]	0.0	4	1	1	1
18494	361	saxagliptin for saxagliptin versus insulin	[saxagliptin for saxagliptin versus insulin]	0.0	5	1	1	1
18495	361	zsf1 with high-fat diet	[ZSF1 with high-fat diet]	0.0	4	1	1	1
18496	361	symptom of heart failure at rest	[symptoms of heart failure at rest]	0.0	6	1	1	1
18497	361	proteolysis	[proteolysis]	0.0	1	1	1	1
18498	361	complicate precapillary pulmonary hypertension	[complicating precapillary pulmonary hypertension]	0.0	4	1	1	1
18499	361	ANG infusion at	[ANG infusion AT]	0.0	3	1	1	1
18500	361	ventricular assist device support	[ventricular assist device support]	0.0	4	1	1	1
18501	361	one model for ischemia	[one model for ischemia]	0.0	4	1	1	1
18502	361	prognostic factor in patient	[prognostic factor in patients]	0.0	4	1	1	1
18503	361	even volume	[even volumes]	0.0	2	1	1	1
18504	361	condition such as infarction with expansion	[conditions such as infarction with expansion]	0.0	6	1	1	1
18505	361	addition of dopamine	[addition of dopamine]	0.0	3	1	1	1
18506	361	myofibrillar can	[myofibrillar Ca]	0.0	2	1	1	1
18507	361	25th-75th	[25th-75th]	0.0	1	1	1	1
18508	361	pluripotent stem cardiomyocyte	[pluripotent stem cardiomyocytes]	0.0	3	1	1	1
18509	361	spectrometry	[spectrometry]	0.0	1	1	1	1
18510	361	mrna splicing of the type V	[mRNA splicing of the type V]	0.0	6	1	1	1
18511	361	17.0 millileter	[17.0 ml]	0.0	2	1	1	1
18512	361	prospective research	[prospective research]	0.0	2	1	1	1
18513	361	expenditure on health	[expenditure on health]	0.0	3	2	2	1
18514	361	heart failure datum	[Heart failure data]	0.0	3	1	1	1
18515	361	LVEF on mortality	[LVEF on mortality]	0.0	3	1	1	1
18516	361	reversal of cardiac dysfunction	[Reversal of cardiac dysfunction]	0.0	4	1	1	1
18517	361	hospital change	[hospital change]	0.0	2	1	1	1
18518	361	management of dysfunction	[management of dysfunction]	0.0	3	1	1	1
18519	361	credible interval	[credible interval]	0.0	2	1	1	1
18520	361	myocyte depolarization	[myocyte depolarization]	0.0	2	1	1	1
18521	361	childhood malignant disease	[childhood malignant disease]	0.0	3	1	1	1
18522	361	emergency room practice	[emergency room practice]	0.0	3	1	1	1
18523	361	mitochondrial oxidation	[mitochondrial oxidation]	0.0	2	1	1	1
18524	361	72-hour urine volume decongestion end point	[72-hour urine volume decongestion end point]	0.0	6	1	1	1
18525	361	bpm 17.5±5.5 p	[bpm 17.5±5.5 P]	0.0	3	1	1	1
18526	361	York heart	[York Heart]	0.0	2	1	1	1
18527	361	arterial disease	[arterial disease]	0.0	2	1	1	1
18528	361	change in status	[change in status]	0.0	3	1	1	1
18529	361	effective arterial elastance elastance	[Effective arterial elastance elastance]	0.0	4	1	1	1
18530	361	Practice Guideline recommendation	[Practice Guideline recommendations]	0.0	3	1	1	1
18531	361	even mild diastolic dysfunction	[even mild diastolic dysfunction]	0.0	4	1	1	1
18532	361	median stay	[median stay]	0.0	2	1	1	1
18533	361	cardiac index score	[cardiac index score]	0.0	3	1	1	1
18534	361	effect of caloric restriction	[Effect of Caloric Restriction]	0.0	4	1	1	1
18535	361	complication of therapy	[complications of therapy]	0.0	3	1	1	1
18536	361	wall rs	[wall RS]	0.0	2	1	1	1
18537	361	brief insight into the potential	[brief insight into the potential]	0.0	5	1	1	1
18538	361	hypertrophy a robust predictor	[hypertrophy a robust predictor]	0.0	4	1	1	1
18539	361	modulation of repolarization instability in patient	[modulation of repolarization instability in patients]	0.0	6	1	1	1
18540	361	CHF rate	[CHF rates]	0.0	2	1	1	1
18541	361	protective role	[protective role]	0.0	2	1	1	1
18542	361	arterial coupling pulmonary resistance p	[arterial coupling pulmonary resistance P]	0.0	5	1	1	1
18543	361	CRF after trial	[CRF after trials]	0.0	3	1	1	1
18544	361	sympathetic control	[sympathetic control]	0.0	2	1	1	1
18545	361	reticular can 2+)-uptake	[reticular Ca 2+)-uptake]	0.0	3	1	1	1
18546	361	finding from heart failure	[findings from Heart Failure]	0.0	4	1	1	1
18547	361	pdrelated complication	[PDrelated complications]	0.0	2	1	1	1
18548	361	25mg kg ip	[25mg kg ip]	0.0	3	1	1	1
18549	361	include death	[including death]	0.0	2	1	1	1
18550	361	metoprolol treatment	[metoprolol treatment]	0.0	2	1	1	1
18551	361	exercise test a quality	[exercise test a quality]	0.0	4	1	1	1
18552	361	L-type can	[L-type Ca]	0.0	2	1	1	1
18553	361	role 2 molecular scaffold	[role 2 molecular scaffolds]	0.0	4	1	1	1
18554	361	17.6 millileter 2	[17.6 mL 2]	0.0	3	1	1	1
18555	361	eight-week-old c57bl	[Eight-week-old C57BL]	0.0	2	1	1	1
18556	361	assess ventricular fill pressure	[assessing ventricular filling pressure]	0.0	4	1	1	1
18557	361	series of acs problem	[series of ACS problems]	0.0	4	1	1	1
18558	361	transmitral e-wave early mitral velocity ratio	[transmitral E-wave early mitral velocity ratio]	0.0	6	1	1	1
18559	361	usefulness of cardiac resynchronization therapy	[Usefulness of cardiac resynchronization therapy]	0.0	5	1	1	1
18560	361	uniform nomenclature for failure	[uniform nomenclature for failure]	0.0	4	1	1	1
18561	361	Peripheral artery disease	[Peripheral artery disease]	0.0	3	1	1	1
18562	361	enhance neoangiogenesis	[enhancing neoangiogenesis]	0.0	2	1	1	1
18563	361	224 man year	[224 men years]	0.0	3	1	1	1
18564	361	care delivery	[care delivery]	0.0	2	1	1	1
18565	361	pre-specified analysis of subgroup	[pre-specified analysis of subgroups]	0.0	4	1	1	1
18566	361	interaction with LVEF	[interaction with LVEF]	0.0	3	1	1	1
18567	361	common contextual reason	[common contextual reasons]	0.0	3	1	1	1
18568	361	postoperative month after cabg	[postoperative months after CABG]	0.0	4	1	1	1
18569	361	risk among trial	[risk among trials]	0.0	3	1	1	1
18570	361	valve procedure bioprosthetic valve replacement	[valve procedures bioprosthetic valve replacement]	0.0	5	1	1	1
18571	361	involve the proximal descend artery	[involving the proximal descending artery]	0.0	5	1	1	1
18572	361	several outcome	[several Outcomes]	0.0	2	1	1	1
18573	361	median activity	[median activities]	0.0	2	1	1	1
18574	361	loss of fat mass	[loss of fat mass]	0.0	4	1	1	1
18575	361	potential predictor biomarker	[potential predictors biomarkers]	0.0	3	1	1	1
18576	361	serum albumin level	[serum albumin levels]	0.0	3	1	1	1
18577	361	variable contribute	[variables contributing]	0.0	2	1	1	1
18578	361	heart failure therapy in patient	[heart failure therapy in patients]	0.0	5	1	1	1
18579	361	precipitate factor for clinical deterioration	[precipitating factor for clinical deterioration]	0.0	5	1	1	1
18580	361	lean body	[lean body]	0.0	2	1	1	1
18581	361	practice for a number of patient	[practice for a number of patients]	0.0	6	1	1	1
18582	361	coronary HF	[coronary HF]	0.0	2	1	1	1
18583	361	autonomic system activity	[autonomic system activity]	0.0	3	1	1	1
18584	361	risk of Ie	[risk of IE]	0.0	3	1	1	1
18585	361	3 evaluation use simulation model	[3 evaluations using simulation models]	0.0	5	1	1	1
18586	361	great reduction of activity	[greater reduction of activity]	0.0	4	1	1	1
18587	361	east treatment of atrial fibrillation	[EAST treatment of Atrial fibrillation]	0.0	5	1	1	1
18588	361	heart failure in rat	[heart failure in rats]	0.0	4	1	1	1
18589	361	common characteristic eg use Cochrane Practice	[common characteristics eg using Cochrane Practice]	0.0	6	1	1	1
18590	361	nomenclature for heart circulatory failure	[nomenclature for heart circulatory failure]	0.0	5	1	1	1
18591	361	ventricular area index cm(2)	[ventricular area index cm(2)]	0.0	4	1	1	1
18592	361	Global proteomics analysis	[Global proteomics analysis]	0.0	3	1	1	1
18593	361	925 ed visit mean age year	[925 ED visits mean age years]	0.0	6	1	1	1
18594	361	minimal detectable change value	[minimal detectable change values]	0.0	4	1	1	1
18595	361	Robot-assisted gait therapy	[Robot-assisted gait therapy]	0.0	3	1	1	1
18596	361	3 month after cabg	[3 months after CABG]	0.0	4	1	1	1
18597	361	key role of ERK1 2 scaffold	[Key role of ERK1 2 scaffolds]	0.0	6	1	1	1
18598	361	usefulness in patient	[usefulness in patients]	0.0	3	1	1	1
18599	361	multicenter trial optimization strategy evaluation rose	[Multicenter trial Optimization Strategies Evaluation ROSE]	0.0	6	1	1	1
18600	361	validation cohort	[validation cohort]	0.0	2	1	1	1
18601	361	female odd ratio	[females Odds Ratio]	0.0	3	1	1	1
18602	361	downregulation of na	[downregulation of Na]	0.0	3	1	1	1
18603	361	apparent concentration circulate nt-probnp	[apparent concentration circulating NT-proBNP]	0.0	4	1	1	1
18604	361	patient with right myxoma	[patient with right myxoma]	0.0	4	1	1	1
18605	361	use a aldosterone antagonist	[using an aldosterone antagonist]	0.0	4	1	1	1
18606	361	temporary ventricular support	[temporary ventricular support]	0.0	3	1	1	1
18607	361	understand of chronic heart failure	[Understanding of chronic heart failure]	0.0	5	1	1	1
18608	361	reticular SR can 2+)-uptake	[reticular SR Ca 2+)-uptake]	0.0	4	1	1	1
18609	361	pharmacological treatment of heart failure treatment	[Pharmacological treatment of heart failure treatment]	0.0	6	1	1	1
18610	361	advanced chronic disease	[advanced chronic disease]	0.0	3	1	1	1
18611	361	Effect of pacing	[Effects of pacing]	0.0	3	1	1	1
18612	361	global attenuation of proteome change	[global attenuation of proteome changes]	0.0	5	1	1	1
18613	361	Left ventricular assist device	[Left ventricular assist devices]	0.0	4	1	1	1
18614	361	reduction of activity	[reduction of activity]	0.0	3	1	1	1
18615	361	express resistin Retn	[expressing resistin Retn]	0.0	3	1	1	1
18616	361	2-fold activity	[2-fold activity]	0.0	2	1	1	1
18617	361	comprise hospitalization for acute coronary syndrome	[comprising hospitalization for acute coronary syndromes]	0.0	6	1	1	1
18618	361	relevance in the clinical follow-up	[relevance in the clinical follow-up]	0.0	5	1	1	1
18619	361	resonance imaging include t1 mapping	[resonance imaging including T1 mapping]	0.0	5	1	1	1
18620	361	inotrope	[inotropes]	0.0	1	1	1	1
18621	361	readmission metric all-cause readmission	[readmission metrics all-cause readmission]	0.0	4	1	1	1
18622	361	n=36	[n=36]	0.0	1	1	1	1
18623	361	assist device use	[assist device use]	0.0	3	1	1	1
18624	361	relation between CPC in patient	[relations between CPCs in patients]	0.0	5	1	1	1
18625	361	4 wk per ounce	[4 wk per os]	0.0	4	1	1	1
18626	361	hretn resistin mrna	[hRetn resistin mRNA]	0.0	3	1	1	1
18627	361	intubation for heart failure	[intubations for heart failure]	0.0	4	1	1	1
18628	361	workload during stress	[workload during stress]	0.0	3	1	1	1
18629	361	effect of follow-up	[effect of follow-up]	0.0	3	1	1	1
18630	361	proteomic alteration	[proteomic alterations]	0.0	2	1	1	1
18631	361	remote conditioning	[Remote conditioning]	0.0	2	1	1	1
18632	361	arterial pressure relationship	[arterial pressure relationship]	0.0	3	1	1	1
18633	361	mg equivalent dose	[mg equivalent dose]	0.0	3	1	1	1
18634	361	age category	[age categories]	0.0	2	1	1	1
18635	361	concrete datum	[concrete data]	0.0	2	1	1	1
18636	361	resistance index	[resistance index]	0.0	2	1	1	1
18637	361	few admission for individual	[fewer admissions for individuals]	0.0	4	1	1	1
18638	361	left ventricular diastolic end diameter mm	[left ventricular diastolic end diameter mm]	0.0	6	1	1	1
18639	361	dysfunction treatment	[dysfunction treatment]	0.0	2	1	1	1
18640	361	significant percent relative reduction	[significant percent relative reduction]	0.0	4	1	1	1
18641	361	strain GLS	[strain GLS]	0.0	2	1	1	1
18642	361	involve center	[involving centers]	0.0	2	1	1	1
18643	361	behavioural-change intervention	[behavioural-change interventions]	0.0	2	1	1	1
18644	361	exercise status	[exercise status]	0.0	2	1	1	1
18645	361	right plane excursion	[right plane excursion]	0.0	3	1	1	1
18646	361	skeletal muscle mass r=0.67	[skeletal muscle mass r=0.67]	0.0	4	1	1	1
18647	361	Addition discrimination change	[Addition discrimination change]	0.0	3	1	1	1
18648	361	nad(p) h-oxidase subunit	[NAD(P) H-oxidase subunit]	0.0	3	1	1	1
18649	361	time-varying	[time-varying]	0.0	1	1	1	1
18650	361	transform growth factor-β signal	[transforming growth factor-β signaling]	0.0	4	1	1	1
18651	361	implication of choice for common application	[Implications of choice for common applications]	0.0	6	1	1	1
18652	361	involve assist device	[involving assist devices]	0.0	3	1	1	1
18653	361	importance of follow-up	[importance of follow-up]	0.0	3	1	1	1
18654	361	systematic search of the database	[systematic search of the databases]	0.0	5	1	1	1
18655	361	hypertrophy in tta animal	[hypertrophy in TTA animals]	0.0	4	1	1	1
18656	361	pulmonary hypertension patient	[pulmonary hypertension patients]	0.0	3	2	2	1
18657	361	datum regard the role of stenting	[data regarding the role of stenting]	0.0	6	1	1	1
18658	361	edge-to-edge	[edge-to-edge]	0.0	1	1	1	1
18659	361	hypertrophic response protective role	[hypertrophic response protective role]	0.0	4	1	1	1
18660	361	sitagliptin user	[sitagliptin users]	0.0	2	1	1	1
18661	361	endothelial growth factor blockade	[endothelial growth factor blockade]	0.0	4	1	1	1
18662	361	sonographic abnormality of region	[sonographic abnormalities of regions]	0.0	4	1	1	1
18663	361	endothelial cell ec oxide production	[endothelial cell EC oxide production]	0.0	5	1	1	1
18664	361	systolic pressure 155	[systolic pressure 155]	0.0	3	1	1	1
18665	361	cardiac cell	[cardiac cells]	0.0	2	1	1	1
18666	361	fragment of pro-b-type peptide	[fragments of pro-B-type peptides]	0.0	4	1	1	1
18667	361	oxygen uptake	[oxygen uptake]	0.0	2	1	1	1
18668	361	important prognostic factor	[important prognostic factor]	0.0	3	1	1	1
18669	361	guideline-directed medical therapy	[guideline-directed medical therapy]	0.0	3	1	1	1
18670	361	ventricular pressure overload	[ventricular pressure overload]	0.0	3	1	1	1
18671	361	great benefit from cardioverter defibrillator-CRT	[greater benefit from cardioverter defibrillator-CRT]	0.0	5	1	1	1
18672	361	left ventricular function in volume overload	[left ventricular function in volume overload]	0.0	6	1	1	1
18673	361	investigate Outcome study	[Investigating Outcomes study]	0.0	3	1	1	1
18674	361	vary combination	[varying combinations]	0.0	2	1	1	1
18675	361	ventricular diastolic end diameter mm	[ventricular diastolic end diameter mm]	0.0	5	1	1	1
18676	361	survival rate of patient	[survival rates of patients]	0.0	4	1	1	1
18677	361	hemoglobin threshold of gram	[hemoglobin threshold of g]	0.0	4	1	1	1
18678	361	modestly low mortality in woman	[modestly lower mortality in women]	0.0	5	1	1	1
18679	361	incidence of renal disease	[Incidence of renal disease]	0.0	4	1	1	1
18680	361	medical history	[medical history]	0.0	2	1	1	1
18681	361	patient with advanced chronic disease	[patients with advanced chronic disease]	0.0	5	1	1	1
18682	361	analysis of subgroup with egfr	[analysis of subgroups with eGFR]	0.0	5	1	1	1
18683	361	index of ventricular function	[index of ventricular function]	0.0	4	1	1	1
18684	361	p decrease	[P decrease]	0.0	2	1	1	1
18685	361	psoriasis patient with disease	[Psoriasis patients with disease]	0.0	4	1	1	1
18686	361	observation at the time	[observation at the time]	0.0	4	1	1	1
18687	361	annular plane systolic excursion	[annular plane systolic excursion]	0.0	4	1	1	1
18688	361	n=72	[n=72]	0.0	1	1	1	1
18689	361	mild disease	[mild disease]	0.0	2	1	1	1
18690	361	n=68	[n=68]	0.0	1	1	1	1
18691	361	respective pathway in patient	[respective pathways in patients]	0.0	4	1	1	1
18692	361	presence of clinical dysfunction	[presence of clinical dysfunction]	0.0	4	1	1	1
18693	361	reason prescribe angiotensin	[reasons prescribing angiotensin]	0.0	3	1	1	1
18694	361	tta mouse	[TTA mice]	0.0	2	1	1	1
18695	361	institute circulatory support	[instituting circulatory support]	0.0	3	1	1	1
18696	361	outcome-monitoring phase mean month	[outcome-monitoring phase mean months]	0.0	4	1	1	1
18697	361	early mitral velocity 3.1	[early mitral velocity 3.1]	0.0	4	1	1	1
18698	361	24-hour pressure	[24-hour pressure]	0.0	2	1	1	1
18699	361	reason prescribe medication with heart failure	[Reasons prescribing medications with heart failure]	0.0	6	1	1	1
18700	361	referent age group	[referent age group]	0.0	3	1	1	1
18701	361	treatment for cardiomyopathy	[treatment for cardiomyopathy]	0.0	3	1	1	1
18702	361	Italy	[Italy]	0.0	1	1	1	1
18703	361	difference between patient	[differences between patients]	0.0	3	1	1	1
18704	361	include good tool regard the need	[including better tools regarding the need]	0.0	6	1	1	1
18705	361	origin	[origin]	0.0	1	1	1	1
18706	361	size reduction for mr	[size reduction for MR]	0.0	4	1	1	1
18707	361	variation in the use	[Variation in the use]	0.0	4	1	1	1
18708	361	first time	[first time]	0.0	2	1	1	1
18709	361	role of resistin	[role of resistin]	0.0	3	1	1	1
18710	361	deterioration of HFPEF	[deterioration of HFPEF]	0.0	3	1	1	1
18711	361	available datum	[available data]	0.0	2	1	1	1
18712	361	nonadherence in young	[nonadherence in youngest]	0.0	3	1	1	1
18713	361	regional strain cs	[regional strain CS]	0.0	3	1	1	1
18714	361	heart failure AHF study	[heart failure AHF studies]	0.0	4	1	1	1
18715	361	physician continuity on readmission	[physician continuity on readmission]	0.0	4	1	1	1
18716	361	e-wave early mitral velocity ratio	[E-wave early mitral velocity ratio]	0.0	5	1	1	1
18717	361	major determinant of quality qol	[major determinant of quality QOL]	0.0	5	1	1	1
18718	361	model of dyssynchronous nonfailing canine electromechanic	[models of dyssynchronous nonfailing canine electromechanics]	0.0	6	1	1	1
18719	361	include st-segment-elevation MIs	[including ST-segment-elevation MIs]	0.0	3	1	1	1
18720	361	stable guideline-directed medical therapy	[stable guideline-directed medical therapy]	0.0	4	1	1	1
18721	361	type of tumor	[type of tumors]	0.0	3	1	1	1
18722	361	normal albumin concentration	[normal albumin concentration]	0.0	3	1	1	1
18723	361	other index	[other indices]	0.0	2	1	1	1
18724	361	little influence on the burden	[little influence on the burden]	0.0	5	1	1	1
18725	361	literature January	[literature January]	0.0	2	1	1	1
18726	361	cost-effectiveness limit	[cost-effectiveness limits]	0.0	2	1	1	1
18727	361	Study on treatment	[Studies on treatment]	0.0	3	1	1	1
18728	361	refill compliance p for trend	[refill compliance P for trend]	0.0	5	1	1	1
18729	361	irs1 irs2 gene double-knockout h-dko mouse	[IRS1 IRS2 gene double-knockout H-DKO mice]	0.0	6	1	1	1
18730	361	contemporary trend	[Contemporary trends]	0.0	2	1	1	1
18731	361	right patient	[right patients]	0.0	2	1	1	1
18732	361	degree of MS	[degree of MS]	0.0	3	1	1	1
18733	361	Impact of carvedilol on cardioverter-defibrillator therapy	[Impact of carvedilol on cardioverter-defibrillator therapy]	0.0	6	1	1	1
18734	361	early management of HF	[early management of HF]	0.0	4	1	1	1
18735	361	pulmonary pressure relationship in heart failure	[pulmonary pressure relationship in heart failure]	0.0	6	1	1	1
18736	361	range year	[range years]	0.0	2	1	1	1
18737	361	contemporary option	[Contemporary options]	0.0	2	1	1	1
18738	361	ventricular ejection fraction p	[ventricular ejection fraction P]	0.0	4	1	1	1
18739	361	acute heart failure with dysfunction	[acute heart failure with dysfunction]	0.0	5	1	1	1
18740	361	Gly16	[Gly16]	0.0	1	1	1	1
18741	361	enormous clinical burden in medicine	[enormous clinical burden in medicine]	0.0	5	1	1	1
18742	361	maximal treatment	[maximal treatment]	0.0	2	1	1	1
18743	361	risk factor in fit	[risk factors in fit]	0.0	4	1	1	1
18744	361	conservation	[conservation]	0.0	1	1	1	1
18745	361	pyridostigmine administration	[pyridostigmine administration]	0.0	2	1	1	1
18746	361	predictor of cardiovascular event	[predictor of cardiovascular events]	0.0	4	1	1	1
18747	361	ecg in old athlete	[ECG in older athletes]	0.0	4	1	1	1
18748	361	AMI between 1996	[AMI between 1996]	0.0	3	1	1	1
18749	361	patient presentation	[patient presentation]	0.0	2	1	1	1
18750	361	awareness of implantable cardioverter-defibrillator deactivation discussion	[awareness of implantable cardioverter-defibrillator deactivation discussions]	0.0	6	1	1	1
18751	361	HeartMate assist system	[HeartMate assist system]	0.0	3	1	1	1
18752	361	advanced heart failure therapy	[advanced heart failure therapy]	0.0	4	1	1	1
18753	361	4 week of pacing	[4 weeks of pacing]	0.0	4	1	1	1
18754	361	e-wave early diastolic mitral velocity	[E-wave early diastolic mitral velocity]	0.0	5	1	1	1
18755	361	index score	[index score]	0.0	2	1	1	1
18756	361	addition 2 μg	[addition 2 μg]	0.0	3	1	1	1
18757	361	quartile of E email	[quartile of E e]	0.0	4	1	1	1
18758	361	catheter ablation of fibrillation	[catheter ablation of fibrillation]	0.0	4	1	1	1
18759	361	conditioning for patient	[conditioning for patients]	0.0	3	1	1	1
18760	361	predictor of heart failure-related hospitalization	[predictors of heart failure-related hospitalization]	0.0	5	1	1	1
18761	361	use hr variability	[using HR variability]	0.0	3	1	1	1
18762	361	calcineurin	[calcineurin]	0.0	1	1	1	1
18763	361	level pg bnp group	[levels pg BNP group]	0.0	4	1	1	1
18764	361	single component	[single component]	0.0	2	1	1	1
18765	361	cardiomyopathy cohort	[cardiomyopathy cohort]	0.0	2	1	1	1
18766	361	include negative angiography	[including negative angiography]	0.0	3	1	1	1
18767	361	assess the link	[Assessing the link]	0.0	3	1	1	1
18768	361	mortality at the bad versus quintile	[mortality at the worst versus quintile]	0.0	6	1	1	1
18769	361	6-minute walking distance	[6-minute walking distance]	0.0	3	1	1	1
18770	361	antiplatelet medication	[antiplatelet medication]	0.0	2	1	1	1
18771	361	hfpef LV ejection fraction	[HFPEF LV ejection fraction]	0.0	4	1	1	1
18772	361	Bradycardia indicative of tone	[Bradycardia indicative of tone]	0.0	4	1	1	1
18773	361	mechanism of action	[mechanism of action]	0.0	3	1	1	1
18774	361	cutoff value for admission nt-probnp	[cutoff value for admission NT-proBNP]	0.0	5	1	1	1
18775	361	experienced electrocardiographer	[experienced electrocardiographers]	0.0	2	1	1	1
18776	361	change in the development of hypertrophy	[changes in the development of hypertrophy]	0.0	6	1	1	1
18777	361	cognitive impairment with mortality	[cognitive impairment with mortality]	0.0	4	1	1	1
18778	361	gait therapy with the Lokomat® System	[gait therapy with the Lokomat® System]	0.0	6	1	1	1
18779	361	restriction of leaflet motion	[restriction of leaflet motion]	0.0	4	1	1	1
18780	361	complete occlusion	[Complete occlusion]	0.0	2	1	1	1
18781	361	adult without inotrope	[adults without inotropes]	0.0	3	1	1	1
18782	361	indicator of functional status	[indicators of functional status]	0.0	4	1	1	1
18783	361	topic in heart failure concern	[topics in heart failure concern]	0.0	5	1	1	1
18784	361	Cancer	[Cancer]	0.0	1	1	1	1
18785	361	measurable improvement for patient	[measurable improvements for patients]	0.0	4	1	1	1
18786	361	size reduction for degenerative mr	[size reduction for degenerative MR]	0.0	5	1	1	1
18787	361	indicate suboptimal care of patient	[indicating suboptimal care of patients]	0.0	5	1	1	1
18788	361	cumulative administration	[cumulative administration]	0.0	2	1	1	1
18789	361	positive rate of change	[positive rates of changes]	0.0	4	1	1	1
18790	361	objective criteriabased institution of PD	[Objective criteriabased institution of PD]	0.0	5	1	1	1
18791	361	eGFR group p	[eGFR group P]	0.0	3	1	1	1
18792	361	bb dose versus low mg dose	[BB dose versus low mg dose]	0.0	6	1	1	1
18793	361	Grading of recommendation	[Grading of Recommendations]	0.0	3	1	1	1
18794	361	acute right heart failure in hypertension	[Acute right heart failure in hypertension]	0.0	6	1	1	1
18795	361	differential response in activity (123)i-meta-iodobenzylguanidine	[differential response in activity (123)I-meta-iodobenzylguanidine]	0.0	5	1	1	1
18796	361	Advanced HF	[Advanced HF]	0.0	2	1	1	1
18797	361	dosage prior HF hospitalisation	[dosage prior HF hospitalisations]	0.0	4	1	1	1
18798	361	pressure-volume conductance	[pressure-volume conductance]	0.0	2	1	1	1
18799	361	survival from the time through year	[survival from the time through years]	0.0	6	1	1	1
18800	361	left diastolic end diameter mean difference	[left diastolic end diameter mean difference]	0.0	6	1	1	1
18801	361	hretn	[hRetn]	0.0	1	1	1	1
18802	361	flow reserve	[flow reserve]	0.0	2	1	1	1
18803	361	apoptotic signal pathway	[apoptotic signaling pathway]	0.0	3	1	1	1
18804	361	vivo RV	[vivo RV]	0.0	2	1	1	1
18805	361	small difference median bnp in woman	[smallest difference median BNP in women]	0.0	6	1	1	1
18806	361	five death	[five deaths]	0.0	2	1	1	1
18807	361	event rate HF hospitalization	[event rates HF hospitalization]	0.0	4	1	1	1
18808	361	College of Cardiology ACC	[College of Cardiology ACC]	0.0	4	1	1	1
18809	361	left longitudinal strain GLS	[left longitudinal strain GLS]	0.0	4	1	1	1
18810	361	3-vessel cad	[3-vessel CAD]	0.0	2	1	1	1
18811	361	β2-receptor haplotype status	[β2-receptor haplotype status]	0.0	3	1	1	1
18812	361	predictive value of E	[predictive value of E]	0.0	4	1	1	1
18813	361	centre in Canada	[centre in Canada]	0.0	3	1	1	1
18814	361	change mdc	[change MDC]	0.0	2	1	1	1
18815	361	aerobic	[aerobic]	0.0	1	1	1	1
18816	361	Briggs	[Briggs]	0.0	1	1	1	1
18817	361	evaluation of the indication	[evaluation of the indications]	0.0	4	1	1	1
18818	361	group ii millileter	[group II mL]	0.0	3	1	1	1
18819	361	post-myocardial infarction heart failure patient	[post-myocardial infarction heart failure patients]	0.0	5	1	1	1
18820	361	support use a HeartMate lvad	[support using a HeartMate LVAD]	0.0	5	1	1	1
18821	361	paf enzyme	[PAF enzymes]	0.0	2	1	1	1
18822	361	360 patient with heart failure	[360 patients with heart failure]	0.0	5	1	1	1
18823	361	twenty-seven symptomatic adult Fontan patient	[Twenty-seven symptomatic adult Fontan patients]	0.0	5	1	1	1
18824	361	continuity of care	[continuity of care]	0.0	3	1	1	1
18825	361	contemporary use of device	[Contemporary use of devices]	0.0	4	1	1	1
18826	361	importance for DD	[importance for DD]	0.0	3	1	1	1
18827	361	plateau phase	[plateau phase]	0.0	2	1	1	1
18828	361	toxicity on blood pressure	[toxicity on blood pressure]	0.0	4	1	1	1
18829	361	show improvement	[showing improvement]	0.0	2	1	1	1
18830	361	class cpg recommendation in HF	[class CPG recommendations in HF]	0.0	5	1	1	1
18831	361	af patient	[AF patients]	0.0	2	1	1	1
18832	361	brief circulatory arrest	[brief circulatory arrest]	0.0	3	1	1	1
18833	361	replicate resource use from 3 trial	[replicating resource use from 3 trials]	0.0	6	1	1	1
18834	361	validation in study	[validation in studies]	0.0	3	1	1	1
18835	361	final bb dose high	[final BB dose high]	0.0	4	1	1	1
18836	361	reduction in Ea	[reduction in Ea]	0.0	3	1	1	1
18837	361	beta-adrenergic receptor	[beta-adrenergic receptor]	0.0	2	1	1	1
18838	361	cerebrovascular event	[cerebrovascular events]	0.0	2	1	1	1
18839	361	postmarketing	[postmarketing]	0.0	1	1	1	1
18840	361	mild diastolic dysfunction	[mild diastolic dysfunction]	0.0	3	1	1	1
18841	361	odd die in 30 day	[odds dying in 30 days]	0.0	5	1	1	1
18842	361	prescribe angiotensin	[prescribing angiotensin]	0.0	2	1	1	1
18843	361	relationship with CV event in fibrillation	[relationship with CV events in fibrillation]	0.0	6	1	1	1
18844	361	sarcoplasmic reticular SR can	[sarcoplasmic reticular SR Ca]	0.0	4	1	1	1
18845	361	right plane systolic excursion tapse	[right plane systolic excursion TAPSE]	0.0	5	1	1	1
18846	361	precapillary pulmonary hypertension	[precapillary pulmonary hypertension]	0.0	3	1	1	1
18847	361	randomized outcome assessment trial	[randomized outcome assessment trial]	0.0	4	1	1	1
18848	361	new-user cohort study	[new-user cohort study]	0.0	3	1	1	1
18849	361	change in treatment in subject	[changes in treatment in subjects]	0.0	5	1	1	1
18850	361	risk of outcome in other patient	[risk of outcomes in other patients]	0.0	6	1	1	1
18851	361	akt→forkhead	[Akt→forkhead]	0.0	1	1	1	1
18852	361	effect of left ventricular ejection fraction	[effect of left ventricular ejection fraction]	0.0	6	1	1	1
18853	361	poc system	[POC systems]	0.0	2	1	1	1
18854	361	uncertainty about the safety	[uncertainty about the safety]	0.0	4	1	1	1
18855	361	ventricular base	[ventricular base]	0.0	2	1	1	1
18856	361	first 3 month	[first 3 months]	0.0	3	1	1	1
18857	361	key regulator	[key regulator]	0.0	2	1	1	1
18858	361	duration of biventricular support	[duration of biventricular support]	0.0	4	1	1	1
18859	361	effective arterial elastance end-systolic elastance ees	[Effective arterial elastance end-systolic elastance Ees]	0.0	6	1	1	1
18860	361	right ventricular reserve in patient	[right ventricular reserve in patients]	0.0	5	2	2	1
18861	361	structure of record	[structure of records]	0.0	3	1	1	1
18862	361	therapeutic interatrial shunting	[therapeutic interatrial shunting]	0.0	3	1	1	1
18863	361	non-cachectic CHF	[non-cachectic CHF]	0.0	2	1	1	1
18864	361	non-survivor year year	[non-survivors years years]	0.0	3	1	1	1
18865	361	hypothese addition of dopamine	[hypotheses addition of dopamine]	0.0	4	1	1	1
18866	361	correlate of increase in exercise capacity	[correlates of increase in exercise capacity]	0.0	6	1	1	1
18867	361	dysfunction LV relaxation	[dysfunction LV relaxation]	0.0	3	1	1	1
18868	361	simple prediction rule	[simple prediction rule]	0.0	3	1	1	1
18869	361	CV event in model	[CV events in models]	0.0	4	1	1	1
18870	361	2-vessel cad involve the descend artery	[2-vessel CAD involving the descending artery]	0.0	6	1	1	1
18871	361	insight in dyssynchronous heart failure	[insight in dyssynchronous heart failure]	0.0	5	1	1	1
18872	361	circulatory derangement with feature	[circulatory derangement with features]	0.0	4	1	1	1
18873	361	45 death in the CRT group	[45 deaths in the CRT group]	0.0	6	1	1	1
18874	361	basis of ventricle pressure	[basis of ventricle pressure]	0.0	4	1	1	1
18875	361	clinical study approximately 2900 hm ii	[clinical studies approximately 2900 HM II]	0.0	6	1	1	1
18876	361	right tricuspid annular plane excursion	[right tricuspid annular plane excursion]	0.0	5	1	1	1
18877	361	assess fill pressure	[assessing filling pressure]	0.0	3	1	1	1
18878	361	na current during HF	[Na current during HF]	0.0	4	1	1	1
18879	361	dyssynchronous heart failure a study	[dyssynchronous heart failure a study]	0.0	5	1	1	1
18880	361	undiagnosed heart disease of HF	[undiagnosed heart disease of HF]	0.0	5	1	1	1
18881	361	severe congestive heart failure	[severe congestive heart failure]	0.0	4	1	1	1
18882	361	onset HFrEF	[onset HFrEF]	0.0	2	1	1	1
18883	361	19 patient with heart failure	[19 patients with heart failure]	0.0	5	1	1	1
18884	361	treatment group effect	[Treatment group effects]	0.0	3	1	1	1
18885	361	Fontan adult	[Fontan adults]	0.0	2	1	1	1
18886	361	echocardiographic assessment	[echocardiographic assessment]	0.0	2	1	1	1
18887	361	patient with this condition	[patients with this condition]	0.0	4	1	1	1
18888	361	54 patient with heart failure	[54 patients with heart failure]	0.0	5	1	1	1
18889	361	eccentric hypertrophy	[eccentric hypertrophy]	0.0	2	1	1	1
18890	361	sympathetic tone result in imbalance	[sympathetic tone resulting in imbalance]	0.0	5	1	1	1
18891	361	4.6 mm hg	[4.6 mm Hg]	0.0	3	1	1	1
18892	361	patient IL mg	[patients IL mg]	0.0	3	1	1	1
18893	361	2 valve repair	[2 valve repairs]	0.0	3	1	1	1
18894	361	assist device with temporary support	[assist device with temporary support]	0.0	5	1	1	1
18895	361	patient in nyha functional class	[patients in NYHA functional class]	0.0	5	1	1	1
18896	361	cardiac sodium	[cardiac sodium]	0.0	2	1	1	1
18897	361	75 year with diabete	[75 years with diabetes]	0.0	4	1	1	1
18898	361	role in artery disease	[role in artery disease]	0.0	4	1	1	1
18899	361	predictor for the development of Ie	[predictors for the development of IE]	0.0	6	1	1	1
18900	361	trial of blood transfusion in adult	[trials of blood transfusions in adults]	0.0	6	1	1	1
18901	361	patient with disease copd	[patients with disease COPD]	0.0	4	1	1	1
18902	361	systemic vascular resistance SVR index	[systemic vascular resistance SVR index]	0.0	5	1	1	1
18903	361	effectiveness of medicine CHM	[effectiveness of medicine CHM]	0.0	4	1	1	1
18904	361	age of 62 year	[age of 62 years]	0.0	4	1	1	1
18905	361	prognostic role in HF	[prognostic role in HF]	0.0	4	1	1	1
18906	361	reliable diagnostic biomarker	[reliable diagnostic biomarkers]	0.0	3	1	1	1
18907	361	HF of unclear etiology	[HF of unclear etiology]	0.0	4	2	2	1
18908	361	health outcome in patient	[health outcomes in patients]	0.0	4	1	1	1
18909	361	York heart Association Class	[York Heart Association Class]	0.0	4	1	1	1
18910	361	receptor 1	[receptor 1]	0.0	2	1	1	1
18911	361	Cardiac magnetic resonance t1 time	[Cardiac magnetic resonance T1 time]	0.0	5	1	1	1
18912	361	ventricular LV dilatation	[ventricular LV dilatation]	0.0	3	1	1	1
18913	361	brain peptide	[brain peptide]	0.0	2	1	1	1
18914	361	blood pressure hr	[blood pressure HR]	0.0	3	1	1	1
18915	361	right tricuspid plane excursion tapse	[right tricuspid plane excursion TAPSE]	0.0	5	1	1	1
18916	361	three readmission metric	[three readmission metrics]	0.0	3	1	1	1
18917	361	cardiac index versus 2.8 0.7 L	[cardiac index versus 2.8 0.7 L]	0.0	6	1	1	1
18918	361	334 consecutive patient man mean	[334 consecutive patients men mean]	0.0	5	1	1	1
18919	361	stable pure hno donor	[stable pure HNO donor]	0.0	4	1	1	1
18920	361	readmission metric all-cause readmission acr	[readmission metrics all-cause readmission ACR]	0.0	5	1	1	1
18921	361	significant improvement in composite response p=0.02	[significant improvements in composite response P=0.02]	0.0	6	1	1	1
18922	361	Anecdotal evidence	[Anecdotal evidence]	0.0	2	1	1	1
18923	361	normal heart HNorm	[normal hearts HNorm]	0.0	3	1	1	1
18924	361	protection from norepinephrine-induced response	[protection from norepinephrine-induced responses]	0.0	4	1	1	1
18925	361	Case	[Case]	0.0	1	1	1	1
18926	361	uptake of class cpg recommendation	[uptake of class CPG recommendations]	0.0	5	1	1	1
18927	361	therapy of heart disease	[therapy of heart disease]	0.0	4	1	1	1
18928	361	severe hypertension of mm hg	[severe hypertension of mm Hg]	0.0	5	1	1	1
18929	361	development of ms follow ring annuloplasty	[development of MS following ring annuloplasty]	0.0	6	1	1	1
18930	361	grade strong recommendation	[Grade strong recommendation]	0.0	3	1	1	1
18931	361	20 cm	[20 cm]	0.0	2	1	1	1
18932	361	hall walk distance	[hall walk distance]	0.0	3	1	1	1
18933	361	power index	[power index]	0.0	2	1	1	1
18934	361	heart Failure MLHF	[Heart Failure MLHF]	0.0	3	1	1	1
18935	361	hypertension sh	[hypertension SH]	0.0	2	1	1	1
18936	361	still a effective anti-neoplastic agent	[still a effective anti-neoplastic agent]	0.0	5	1	1	1
18937	361	other exercise variable exercise ventilation	[other exercise variables exercise ventilation]	0.0	5	1	1	1
18938	361	additional prognostic benefit over parameter	[additional prognostic benefit over parameters]	0.0	5	1	1	1
18939	361	public health problem worldwide	[public health problem worldwide]	0.0	4	1	1	1
18940	361	decrement	[decrement]	0.0	1	1	1	1
18941	361	high drs decile	[highest DRS deciles]	0.0	3	1	1	1
18942	361	Neprilysin	[Neprilysin]	0.0	1	1	1	1
18943	361	matrix of left biopsy n=9	[matrix of left biopsies n=9]	0.0	5	1	1	1
18944	361	similar tissue from control animal	[similar tissue from control animals]	0.0	5	1	1	1
18945	361	date	[date]	0.0	1	2	2	1
18946	361	sitagliptin for sitagliptin versus insulin	[sitagliptin for sitagliptin versus insulin]	0.0	5	1	1	1
18947	361	many study in practice setting	[Many studies in practice settings]	0.0	5	1	1	1
18948	361	burden in medicine	[burden in medicine]	0.0	3	1	1	1
18949	361	metoprolol hazard ratio	[metoprolol hazard ratio]	0.0	3	1	1	1
18950	361	qrs duration of msec	[QRS duration of msec]	0.0	4	2	2	1
18951	361	progressive development	[progressive development]	0.0	2	1	1	1
18952	361	absorption function	[absorption function]	0.0	2	1	1	1
18953	361	differential relation between CPC in patient	[differential relations between CPCs in patients]	0.0	6	1	1	1
18954	361	endothelial cell oxide production	[endothelial cell oxide production]	0.0	4	1	1	1
18955	361	outcome measure in prospective research	[outcome measures in prospective research]	0.0	5	1	1	1
18956	361	positron emission	[positron emission]	0.0	2	1	1	1
18957	361	predictor of post-transplant mortality	[predictor of post-transplant mortality]	0.0	4	1	1	1
18958	361	nyha functional class iv	[NYHA functional class IV]	0.0	4	1	1	1
18959	361	killip class	[Killip class]	0.0	2	1	1	1
18960	361	more than 8000 individual	[more than 8000 individuals]	0.0	4	1	1	1
18961	361	effect in patient	[effect in patients]	0.0	3	1	1	1
18962	361	possible biomarker	[possible biomarker]	0.0	2	1	1	1
18963	361	10.7 nmol ng	[10.7 nmol ng]	0.0	3	1	1	1
18964	361	CI for sitagliptin versus pioglitazone	[CI for sitagliptin versus pioglitazone]	0.0	5	1	1	1
18965	361	fifty patient with onset	[Fifty patients with onset]	0.0	4	1	1	1
18966	361	include nuclear factor	[including nuclear factor]	0.0	3	1	1	1
18967	361	promote fill in subject	[promoting filling in subjects]	0.0	4	1	1	1
18968	361	6-mwt of foot	[6-MWT of feet]	0.0	3	1	1	1
18969	361	heartmate	[HeartMate]	0.0	1	1	1	1
18970	361	patient with first myocardial infarction	[patients with first myocardial infarction]	0.0	5	1	1	1
18971	361	such as acute infarction with expansion	[such as acute infarction with expansion]	0.0	6	1	1	1
18972	361	repression	[repression]	0.0	1	1	1	1
18973	361	multicenter defibrillator implantation resynchronization therapy	[Multicenter Defibrillator Implantation Resynchronization Therapy]	0.0	5	1	1	1
18974	361	finding from heart failure a Trial	[findings from Heart Failure a Trial]	0.0	6	1	1	1
18975	361	sitagliptin for sitagliptin versus sulfonylurea	[sitagliptin for sitagliptin versus sulfonylureas]	0.0	5	1	1	1
18976	361	penalty	[penalties]	0.0	1	1	1	1
18977	361	data describe trend in HF	[Data describing trends in HF]	0.0	5	1	1	1
18978	361	effect on Ie risk	[effect on IE risk]	0.0	4	1	1	1
18979	361	1:1 propensity	[1:1 propensity]	0.0	2	1	1	1
18980	361	three age subject	[three age subjects]	0.0	3	1	1	1
18981	361	Impact of carvedilol	[Impact of carvedilol]	0.0	3	1	1	1
18982	361	Hypertension diet score with mortality	[Hypertension diet scores with mortality]	0.0	5	1	1	1
18983	361	great risk of cardiac event	[greater risk of cardiac events]	0.0	5	1	1	1
18984	361	appendicular lean mass index	[appendicular lean mass index]	0.0	4	1	1	1
18985	361	percent reduction	[percent reduction]	0.0	2	1	1	1
18986	361	artery systolic pressure increase by means	[artery systolic pressure increase by means]	0.0	6	1	1	1
18987	361	multiple non-diastolic abnormality in function	[multiple non-diastolic abnormalities in function]	0.0	5	1	1	1
18988	361	key role	[Key role]	0.0	2	1	1	1
18989	361	2 type of continuous-flow lvas	[2 types of continuous-flow LVADs]	0.0	5	1	1	1
18990	361	form of peripheral disease	[form of peripheral disease]	0.0	4	1	1	1
18991	361	traditional enhancement imaging	[traditional enhancement imaging]	0.0	3	1	1	1
18992	361	50 mg daily equivalent dose	[50 mg daily equivalent dose]	0.0	5	1	1	1
18993	361	delay the time	[delay the time]	0.0	3	1	1	1
18994	361	rupture	[ruptures]	0.0	1	1	1	1
18995	361	vo2max maximum oxygen consumption	[VO2max maximum oxygen consumption]	0.0	4	1	1	1
18996	361	peptide NPs	[peptides NPs]	0.0	2	1	1	1
18997	361	refractory end-stage heart failure CHF	[refractory end-stage heart failure CHF]	0.0	5	1	1	1
18998	361	elastance ea end-systolic elastance ees	[elastance Ea end-systolic elastance Ees]	0.0	5	1	1	1
18999	361	modulation of repolarization instability	[modulation of repolarization instability]	0.0	4	1	1	1
19000	361	activate adaptive cardiac remodelling	[activating adaptive cardiac remodelling]	0.0	4	1	1	1
19001	361	PDE2 in HF	[PDE2 in HF]	0.0	3	1	1	1
19002	361	influence on the overall financial burden	[influence on the overall financial burden]	0.0	6	1	1	1
19003	361	average length	[average length]	0.0	2	1	1	1
19004	361	effective arterial elastance end-systolic elastance	[Effective arterial elastance end-systolic elastance]	0.0	5	1	1	1
19005	361	combination with factor	[combination with factors]	0.0	3	1	1	1
19006	361	N-terminal proBNP midregional proanp MR-proANP	[N-terminal proBNP midregional proANP MR-proANP]	0.0	5	1	1	1
19007	361	hypertension pah	[hypertension PAH]	0.0	2	1	1	1
19008	361	index 0.7 L 2	[index 0.7 L 2]	0.0	4	1	1	1
19009	361	rate of inappropriate atp	[rate of inappropriate ATP]	0.0	4	1	1	1
19010	361	long 4-year survival	[long-term 4-year survival]	0.0	3	1	1	1
19011	361	comanagement	[comanagement]	0.0	1	1	1	1
19012	361	renal denervation DNx	[Renal denervation DNx]	0.0	3	1	1	1
19013	361	readmission rate follow hospital stay	[readmission rate following hospital stay]	0.0	5	1	1	1
19014	361	62 care clinician	[62 care clinicians]	0.0	3	1	1	1
19015	361	saxagliptin versus insulin	[saxagliptin versus insulin]	0.0	3	1	1	1
19016	361	eraser	[erasers]	0.0	1	1	1	1
19017	361	trend with ventricular dilatation	[trend with ventricular dilatation]	0.0	4	1	1	1
19018	361	patient with onset HFrEF day	[patients with onset HFrEF days]	0.0	5	1	1	1
19019	361	consultation for problem	[consultation for problems]	0.0	3	1	1	1
19020	361	study-a multicenter study	[study-a multicenter study]	0.0	3	1	1	1
19021	361	3000 patient with recent onset af	[3,000 patients with recent onset AF]	0.0	6	1	1	1
19022	361	myeloma	[myeloma]	0.0	1	1	1	1
19023	361	dilatation during the year	[dilatation during the years]	0.0	4	1	1	1
19024	361	ventricular RV failure after the insertion	[ventricular RV failure after the insertion]	0.0	6	1	1	1
19025	361	bnp level pg bnp group	[BNP levels pg BNP group]	0.0	5	1	1	1
19026	361	resistance hazard ratio	[resistance hazard ratio]	0.0	3	1	1	1
19027	361	clinical circumstance	[clinical circumstances]	0.0	2	1	1	1
19028	361	early annular velocity 3.1 vs. 1.3	[early annular velocity 3.1 vs. 1.3]	0.0	6	1	1	1
19029	361	decline in event rate	[decline in event rates]	0.0	4	1	1	1
19030	361	determine assessment for patient	[determining assessment for patients]	0.0	4	1	1	1
19031	361	final multivariate model	[final multivariate models]	0.0	3	1	1	1
19032	361	reason for the reduction in mva	[reasons for the reduction in MVA]	0.0	6	1	1	1
19033	361	acceptable internal validity replicate resource use	[acceptable internal validity replicating resource use]	0.0	6	1	1	1
19034	361	group iv 15 millileter per m	[group IV 15 mL per m]	0.0	6	1	1	1
19035	361	York heart Association NYHA class	[York Heart Association NYHA class]	0.0	5	2	2	1
19036	361	vasodilatory	[vasodilatory]	0.0	1	1	1	1
19037	361	assessment within day of hospital discharge	[assessments within days of hospital discharge]	0.0	6	1	1	1
19038	361	pressure of end-tidal co2 petco2	[pressure of end-tidal CO2 PETCO2]	0.0	5	1	1	1
19039	361	number in any	[numbers in any]	0.0	3	1	1	1
19040	361	patient with outcome median	[patients with outcome median]	0.0	4	1	1	1
19041	361	atrial peptide b-type peptide	[atrial peptide B-type peptide]	0.0	4	1	1	1
19042	361	midregional proanp	[midregional proANP]	0.0	2	1	1	1
19043	361	frailty a important prognostic indicator	[Frailty an important prognostic indicator]	0.0	5	1	1	1
19044	361	Cooper	[Cooper]	0.0	1	1	1	1
19045	361	millisecond 237 millisecond	[milliseconds 237 milliseconds]	0.0	3	1	1	1
19046	361	heart failure in pulmonary hypertension	[heart failure in pulmonary hypertension]	0.0	5	1	1	1
19047	361	diagnosis of myeloma	[diagnosis of myeloma]	0.0	3	1	1	1
19048	361	14 clinical study hm ii	[14 clinical studies HM II]	0.0	5	1	1	1
19049	361	common form of peripheral disease	[common form of peripheral disease]	0.0	5	1	1	1
19050	361	multicenter double-blind clinical trial	[Multicenter double-blind clinical trial]	0.0	4	1	1	1
19051	361	2 hypothese	[2 hypotheses]	0.0	2	1	1	1
19052	361	average hospital rate	[Average hospital rates]	0.0	3	1	1	1
19053	361	pro-brain-type natriuretic peptide assessment	[pro-brain-type natriuretic peptide assessment]	0.0	4	1	1	1
19054	361	patient with obstructive disease copd	[patients with obstructive disease COPD]	0.0	5	1	1	1
19055	361	low resistance SVR index	[low resistance SVR index]	0.0	4	1	1	1
19056	361	Wilcoxon matched-pair	[Wilcoxon matched-pairs]	0.0	2	1	1	1
19057	361	good well-being	[better well-being]	0.0	2	1	1	1
19058	361	myocarditis versus cardiomyopathy	[myocarditis versus cardiomyopathy]	0.0	3	1	1	1
19059	361	patient with York heart Association NYHA	[Patients with York Heart Association NYHA]	0.0	6	1	1	1
19060	361	dacron	[Dacron]	0.0	1	1	1	1
19061	361	incubation with HDL	[Incubation with HDL]	0.0	3	1	1	1
19062	361	≥60 millileter	[≥60 mL]	0.0	2	1	1	1
19063	361	ten-year experience	[Ten-year experience]	0.0	2	1	1	1
19064	361	use Spearman correlation	[using Spearman correlations]	0.0	3	1	1	1
19065	361	simultaneous reduction	[simultaneous reduction]	0.0	2	1	1	1
19066	361	examine outcome with this strategy	[examining outcomes with this strategy]	0.0	5	1	1	1
19067	361	regurgitation mr	[regurgitation MR]	0.0	2	1	1	1
19068	361	include inotrope	[including inotropes]	0.0	2	1	1	1
19069	361	circumstance	[circumstances]	0.0	1	1	1	1
19070	361	standard rehabilitation care	[standard rehabilitation care]	0.0	3	1	1	1
19071	361	important disease	[important disease]	0.0	2	1	1	1
19072	361	safe means	[safe means]	0.0	2	1	1	1
19073	361	heart failure trial	[heart failure trials]	0.0	3	1	1	1
19074	361	extra membrane oxygenation	[extra membrane oxygenation]	0.0	3	1	1	1
19075	361	diastolic mitral velocity 3.1 vs. 1.3	[diastolic mitral velocity 3.1 vs. 1.3]	0.0	6	1	1	1
19076	361	platelet-activating factor paf	[platelet-activating factor PAF]	0.0	3	1	1	1
19077	361	effect on heart rate	[effect on heart rate]	0.0	4	1	1	1
19078	361	association between preoperative dysfunction	[association between preoperative dysfunction]	0.0	4	1	1	1
19079	361	retrospective cohort study	[retrospective cohort study]	0.0	3	1	1	1
19080	361	suggest postcontrast t1 as biomarker	[suggesting postcontrast T1 as biomarker]	0.0	5	1	1	1
19081	361	cell therapy	[cell therapy]	0.0	2	1	1	1
19082	361	important role for microrna rirnas	[important role for microRNAs miRNAs]	0.0	5	1	1	1
19083	361	partial improvement of cardiac performance	[partial improvement of cardiac performance]	0.0	5	1	1	1
19084	361	comprise hospitalization for syndrome	[comprising hospitalization for syndromes]	0.0	4	1	1	1
19085	361	recognition of disease	[recognition of disease]	0.0	3	1	1	1
19086	361	9868 participant without HF area	[9868 participants without HF area]	0.0	5	1	1	1
19087	361	60000 patient across 4372 hospital	[60,000 patients across 4372 hospitals]	0.0	5	1	1	1
19088	361	animal model of myocardial ischemia	[animal model of myocardial ischemia]	0.0	5	1	1	1
19089	361	left ventricular LV pressure	[left ventricular LV pressure]	0.0	4	1	1	1
19090	361	HF patient left ejection fraction	[HF patients left ejection fraction]	0.0	5	1	1	1
19091	361	patient enrollment	[patient enrollment]	0.0	2	1	1	1
19092	361	safety measure	[safety measures]	0.0	2	1	1	1
19093	361	atpase activity	[ATPase activity]	0.0	2	1	1	1
19094	361	more recently for transplant-ineligible patient	[more recently for transplant-ineligible patients]	0.0	5	1	1	1
19095	361	addition μg	[addition μg]	0.0	2	1	1	1
19096	361	mouse heart failure model	[mouse heart failure model]	0.0	4	1	1	1
19097	361	chronic kidney disease median filtration rate	[chronic kidney disease median filtration rate]	0.0	6	1	1	1
19098	361	4.9 year for patient	[4.9 years for patients]	0.0	4	1	1	1
19099	361	pressure 155	[pressure 155]	0.0	2	1	1	1
19100	361	symptomatic advanced heart failure patient	[symptomatic advanced heart failure patients]	0.0	5	1	1	1
19101	361	vivo phosphorylation site	[vivo phosphorylation sites]	0.0	3	1	1	1
19102	361	LV end volume index	[LV end volume index]	0.0	4	1	1	1
19103	361	benefit with ejection fraction pef	[Benefits with ejection fraction pEF]	0.0	5	1	1	1
19104	361	Candesartan	[Candesartan]	0.0	1	1	1	1
19105	361	cad involve the descend artery	[CAD involving the descending artery]	0.0	5	1	1	1
19106	361	small difference among ef median bnp	[smallest difference among EF median BNP]	0.0	6	1	1	1
19107	361	diastolic index E	[diastolic indices E]	0.0	3	1	1	1
19108	361	overview of trial design	[overview of trial design]	0.0	4	1	1	1
19109	361	aldosterone antagonism	[Aldosterone antagonism]	0.0	2	1	1	1
19110	361	Wilcoxon	[Wilcoxon]	0.0	1	1	1	1
19111	361	pulmonary systolic pressure relationship	[pulmonary systolic pressure relationship]	0.0	4	1	1	1
19112	361	group ii 30 millileter per m	[group II 30 mL per m]	0.0	6	1	1	1
19113	361	disease complex	[disease complex]	0.0	2	1	1	1
19114	361	expression during hypertrophy	[expression during hypertrophy]	0.0	3	1	1	1
19115	361	confirmation	[confirmation]	0.0	1	1	1	1
19116	361	high-risk group	[high-risk group]	0.0	2	1	1	1
19117	361	e-wave mitral velocity	[E-wave mitral velocity]	0.0	3	1	1	1
19118	361	atp production	[ATP production]	0.0	2	1	1	1
19119	361	low resistance index	[low resistance index]	0.0	3	1	1	1
19120	361	patient with syndrome	[patients with syndromes]	0.0	3	1	1	1
19121	361	relevance carry two increase	[relevance carrying two increase]	0.0	4	1	1	1
19122	361	allocation ratio	[allocation ratio]	0.0	2	1	1	1
19123	361	single-centre parallel-group trial	[single-centre parallel-group trial]	0.0	3	1	1	1
19124	361	assist device support	[assist device support]	0.0	3	1	1	1
19125	361	6-month risk	[6-month risk]	0.0	2	2	2	1
19126	361	use the method of aortic constriction	[using the method of aortic constriction]	0.0	6	1	1	1
19127	361	difference between patient with ef	[differences between patients with EF]	0.0	5	1	1	1
19128	361	development of event ies	[development of events IEs]	0.0	4	1	1	1
19129	361	restoration of lipoprotein property	[restoration of lipoprotein properties]	0.0	4	1	1	1
19130	361	meet inclusion	[meeting inclusion]	0.0	2	1	1	1
19131	361	early change	[early changes]	0.0	2	1	1	1
19132	361	adjust for variable	[adjusting for variables]	0.0	3	1	1	1
19133	361	acute right pressure overload	[acute right pressure overload]	0.0	4	1	1	1
19134	361	e-wave diastolic mitral annular velocity	[E-wave diastolic mitral annular velocity]	0.0	5	1	1	1
19135	361	Effect of mechanical support on function	[Effects of mechanical support on function]	0.0	6	1	1	1
19136	361	differential relation	[differential relations]	0.0	2	1	1	1
19137	361	practice-level prescription rate	[practice-level prescription rates]	0.0	3	1	1	1
19138	361	right ventricular pacing	[right ventricular pacing]	0.0	3	1	1	1
19139	361	especially in the case	[especially in the case]	0.0	4	1	1	1
19140	361	chemical instability	[chemical instability]	0.0	2	1	1	1
19141	361	heart failure Model	[Heart Failure Model]	0.0	3	1	1	1
19142	361	patient as destination therapy	[patients as destination therapy]	0.0	4	1	1	1
19143	361	concrete datum regard the role	[concrete data regarding the role]	0.0	5	1	1	1
19144	361	left ventricular longitudinal strain GLS	[left ventricular longitudinal strain GLS]	0.0	5	1	1	1
19145	361	Concomitant treatment	[Concomitant treatment]	0.0	2	1	1	1
19146	361	contribution of nursing	[contribution of nursing]	0.0	3	1	1	1
19147	361	(egfr)-group I millileter per 1.73 m	[(eGFR)-group I mL per 1.73 m]	0.0	6	1	1	1
19148	361	dysfunction reverse	[dysfunction REVERSE]	0.0	2	1	1	1
19149	361	interaction between this receptor	[interaction between these receptors]	0.0	4	1	1	1
19150	361	daily practice	[daily practice]	0.0	2	1	1	1
19151	361	risk factor for cardiovascular disease	[risk factor for cardiovascular disease]	0.0	5	1	1	1
19152	361	hazard ratio for increase	[hazard ratio for increase]	0.0	4	1	1	1
19153	361	other exercise variable exercise oscillatory ventilation	[other exercise variables exercise oscillatory ventilation]	0.0	6	1	1	1
19154	361	adjustment for all confounder	[adjustment for all confounders]	0.0	4	1	1	1
19155	361	high consistency among patient with hfpef	[high consistency among patients with HFpEF]	0.0	6	1	1	1
19156	361	third of patient	[thirds of patients]	0.0	3	1	1	1
19157	361	MADIT-CRT trial	[MADIT-CRT trial]	0.0	2	1	1	1
19158	361	910 patient with plasma sample	[910 patients with plasma samples]	0.0	5	1	1	1
19159	361	cardiac function in the onset	[cardiac function in the onset]	0.0	5	1	1	1
19160	361	manner	[manner]	0.0	1	1	1	1
19161	361	poc testing	[POC testing]	0.0	2	1	1	1
19162	361	diverse cohort	[diverse cohort]	0.0	2	1	1	1
19163	361	abcc2	[ABCC2]	0.0	1	1	1	1
19164	361	odd July	[odds July]	0.0	2	1	1	1
19165	361	overall icu mortality stay	[Overall ICU mortality stay]	0.0	4	1	1	1
19166	361	change with vary regional strain contribution	[changes with varying regional strain contributions]	0.0	6	1	1	1
19167	361	effect of intervention	[effect of interventions]	0.0	3	1	1	1
19168	361	accumulation	[accumulation]	0.0	1	1	1	1
19169	361	α-myosin chain	[α-myosin chain]	0.0	2	1	1	1
19170	361	nitric oxide no	[nitric oxide NO]	0.0	3	1	1	1
19171	361	cardiac tissue from mouse	[cardiac tissue from mice]	0.0	4	1	1	1
19172	361	glycolysis rate	[glycolysis rates]	0.0	2	1	1	1
19173	361	previous revascularization hazard ratio	[previous revascularization hazard ratio]	0.0	4	1	1	1
19174	361	all-cause medical hospitalization	[all-cause medical hospitalization]	0.0	3	2	2	1
19175	361	cardiac pathophysiology	[cardiac pathophysiology]	0.0	2	1	1	1
19176	361	tm intervention	[TM interventions]	0.0	2	1	1	1
19177	361	ventricular diastolic end diameter mean difference	[ventricular diastolic end diameter mean difference]	0.0	6	1	1	1
19178	361	volume overload vo	[volume overload VO]	0.0	3	1	1	1
19179	361	ST2 level a Trial investigate Outcome	[ST2 levels A Trial Investigating Outcomes]	0.0	6	1	1	1
19180	361	β1-adrenergic receptor	[β1-adrenergic receptor]	0.0	2	1	1	1
19181	361	mistarget	[mistargeting]	0.0	1	1	1	1
19182	361	nonsignificant trend toward a association	[nonsignificant trend toward an association]	0.0	5	1	1	1
19183	361	ventricular LV pressure	[ventricular LV pressure]	0.0	3	1	1	1
19184	361	possible measure of reserve	[possible measure of reserve]	0.0	4	1	1	1
19185	361	new-onset insufficiency ai	[New-onset insufficiency AI]	0.0	3	1	1	1
19186	361	elastance end-systolic elastance	[elastance end-systolic elastance]	0.0	3	1	1	1
19187	361	METs vs. METs	[METs vs. METs]	0.0	3	1	1	1
19188	361	e wave ratio	[E wave ratio]	0.0	3	1	1	1
19189	361	overall effect	[overall effects]	0.0	2	1	1	1
19190	361	department	[Department]	0.0	1	1	1	1
19191	361	even accounting	[even accounting]	0.0	2	1	1	1
19192	361	transmitral e-wave diastolic mitral annular velocity	[transmitral E-wave diastolic mitral annular velocity]	0.0	6	1	1	1
19193	361	patient male gender	[patients male gender]	0.0	3	1	1	1
19194	361	β2-receptor	[β2-receptor]	0.0	1	1	1	1
19195	361	powerful predictor of favorable outcome	[powerful predictor of favorable outcome]	0.0	5	1	1	1
19196	361	patient treatment with a contribution	[patients treatment with a contribution]	0.0	5	1	1	1
19197	361	use regression	[using regression]	0.0	2	1	1	1
19198	361	limit of agreement	[limits of agreement]	0.0	3	1	1	1
19199	361	quotient	[quotient]	0.0	1	1	1	1
19200	361	use of cardioverter defibrillator-CRT	[use of cardioverter defibrillator-CRT]	0.0	4	1	1	1
19201	361	affair HF clinic VA cohort	[Affairs HF clinic VA cohort]	0.0	5	1	1	1
19202	361	monoclonal antibody	[monoclonal antibodies]	0.0	2	1	1	1
19203	361	bet family bromodomain protein	[BET family bromodomain proteins]	0.0	4	1	1	1
19204	361	composite outcome	[composite outcome]	0.0	2	1	1	1
19205	361	peritoneal dialysis for management	[Peritoneal dialysis for management]	0.0	4	1	1	1
19206	361	tension (Fpassive)-sarcomere length relation	[tension (Fpassive)-sarcomere length relations]	0.0	4	1	1	1
19207	361	mi-induced decrease in septum thickness	[MI-induced decreases in septum thickness]	0.0	5	1	1	1
19208	361	University Health Network Toronto	[University Health Network Toronto]	0.0	4	1	1	1
19209	361	vo2max oxygen consumption	[VO2max oxygen consumption]	0.0	3	1	1	1
19210	361	system adverse event	[system adverse events]	0.0	3	1	1	1
19211	361	other subgroup analysis include quality	[other subgroup analyses including quality]	0.0	5	1	1	1
19212	361	only after week	[only after weeks]	0.0	3	1	1	1
19213	361	high amount	[higher amount]	0.0	2	1	1	1
19214	361	evidence of dysfunction	[evidence of dysfunction]	0.0	3	1	1	1
19215	361	absorption	[absorption]	0.0	1	1	1	1
19216	361	patient categorization	[patient categorization]	0.0	2	1	1	1
19217	361	loss of fat mass FFM	[loss of fat mass FFM]	0.0	5	1	1	1
19218	361	guideline-recommended drug	[guideline-recommended drugs]	0.0	2	1	1	1
19219	361	many reason	[many reasons]	0.0	2	1	1	1
19220	361	steady decline	[steady decline]	0.0	2	1	1	1
19221	361	dilatation improvement	[dilatation improvement]	0.0	2	1	1	1
19222	361	effect on rate	[effects on rate]	0.0	3	1	1	1
19223	361	bb dose high	[BB dose high]	0.0	3	1	1	1
19224	361	great activity	[greater activity]	0.0	2	1	1	1
19225	361	four group Wistar-Kyoto	[Four groups Wistar-Kyoto]	0.0	3	1	1	1
19226	361	demonstration	[demonstration]	0.0	1	1	1	1
19227	361	chronic thromboembolic hypertension	[chronic thromboembolic hypertension]	0.0	3	1	1	1
19228	361	improvement in outcome rating	[improvement in outcome ratings]	0.0	4	1	1	1
19229	361	kidney disease	[kidney disease]	0.0	2	1	1	1
19230	361	ratio ees	[ratio Ees]	0.0	2	1	1	1
19231	361	effect in CHF inhibition	[effects in CHF Inhibition]	0.0	4	1	1	1
19232	361	disease such as exercise programme	[disease such as exercise programmes]	0.0	5	1	1	1
19233	361	impaired ventricular pump function	[impaired ventricular pump function]	0.0	4	1	1	1
19234	361	Kaiser Permanente California	[Kaiser Permanente California]	0.0	3	1	1	1
19235	361	other exercise variable exercise ventilation eov	[other exercise variables exercise ventilation EOV]	0.0	6	1	1	1
19236	361	tachyarrhythmias	[tachyarrhythmias]	0.0	1	1	1	1
19237	361	distinct derangement with feature similar	[distinct derangement with features similar]	0.0	5	1	1	1
19238	361	ankle-brachial	[ankle-brachial]	0.0	1	1	1	1
19239	361	human tissue	[human tissue]	0.0	2	1	1	1
19240	361	gradient	[gradient]	0.0	1	1	1	1
19241	361	east treatment of fibrillation	[EAST treatment of fibrillation]	0.0	4	1	1	1
19242	361	guanosine monophosphate cgmp	[guanosine monophosphate cGMP]	0.0	3	1	1	1
19243	361	right ventricular pressure overload	[right ventricular pressure overload]	0.0	4	1	1	1
19244	361	exercise protocol	[exercise protocol]	0.0	2	1	1	1
19245	361	effective elastance ea end-systolic elastance	[Effective elastance Ea end-systolic elastance]	0.0	5	1	1	1
19246	361	standing	[standing]	0.0	1	1	1	1
19247	361	similar incidence mt	[similar incidence MT]	0.0	3	1	1	1
19248	361	knowledge on use	[knowledge on use]	0.0	3	1	1	1
19249	361	14.0 millileter	[14.0 ml]	0.0	2	1	1	1
19250	361	recent onset HFrEF	[recent onset HFrEF]	0.0	3	1	1	1
19251	361	mortality among postmenopausal woman	[mortality among postmenopausal women]	0.0	4	1	1	1
19252	361	standard therapy	[standard therapy]	0.0	2	1	1	1
19253	361	only partial attenuation	[only partial attenuation]	0.0	3	1	1	1
19254	361	attenuation of proteomics change	[attenuation of proteomics changes]	0.0	4	1	1	1
19255	361	future hospital mortality	[future hospital mortality]	0.0	3	1	1	1
19256	361	effective agent	[effective agent]	0.0	2	1	1	1
19257	361	performance detect normal fill pressure	[performance detecting normal filling pressures]	0.0	5	1	1	1
19258	361	relevant health service provision	[relevant health service provision]	0.0	4	1	1	1
19259	361	2.5 kg	[2.5 kg]	0.0	2	1	1	1
19260	361	individual aged 55	[individuals aged 55]	0.0	3	1	1	1
19261	361	right ventricular ejection fraction p=0.01	[right ventricular ejection fraction P=0.01]	0.0	5	1	1	1
19262	361	effect of exercise training ET	[effects of exercise training ET]	0.0	5	1	1	1
19263	361	global ventricular strain GLS	[global ventricular strain GLS]	0.0	4	1	1	1
19264	361	np measurement	[NP measurement]	0.0	2	1	1	1
19265	361	20 variable	[20 variables]	0.0	2	1	1	1
19266	361	right ventricular RV plane excursion	[right ventricular RV plane excursion]	0.0	5	1	1	1
19267	361	analysis match	[analysis matching]	0.0	2	1	1	1
19268	361	group validity	[groups validity]	0.0	2	1	1	1
19269	361	effect on quality	[effect on quality]	0.0	3	1	1	1
19270	361	various process	[various processes]	0.0	2	1	1	1
19271	361	risk for heart failure among user	[Risk for Heart Failure Among Users]	0.0	6	1	1	1
19272	361	patient require RV support	[Patients requiring RV support]	0.0	4	1	1	1
19273	361	incidence outcome of heart failure	[incidence outcomes of heart failure]	0.0	5	1	1	1
19274	361	effect of CHF	[effect of CHF]	0.0	3	1	1	1
19275	361	3058 patient	[3058 patients]	0.0	2	1	1	1
19276	361	revascularization coronary artery bypass surgery	[revascularization coronary artery bypass surgery]	0.0	5	1	1	1
19277	361	ultra-violet treatment	[UV treatment]	0.0	2	1	1	1
19278	361	user of a TNF antagonist	[users of a TNF antagonist]	0.0	5	1	1	1
19279	361	indicate possible suboptimal care	[indicating possible suboptimal care]	0.0	4	1	1	1
19280	361	hemodynamic phenotype of the Fontan	[Hemodynamic phenotype of the Fontan]	0.0	5	1	1	1
19281	361	transmitral e-wave mitral velocity	[transmitral E-wave mitral velocity]	0.0	4	1	1	1
19282	361	transform growth factor-β tgf-β signal	[transforming growth factor-β TGF-β signaling]	0.0	5	1	1	1
19283	361	economic consideration	[economic considerations]	0.0	2	1	1	1
19284	361	intermediate odd ratio for event	[intermediate odds ratios for events]	0.0	5	1	1	1
19285	361	overview	[overview]	0.0	1	3	3	1
19286	361	death in the experimental procedure	[deaths in the experimental procedures]	0.0	5	1	1	1
19287	361	rotation	[rotation]	0.0	1	2	2	1
19288	361	index 2.2	[index 2.2]	0.0	2	1	1	1
19289	361	Society guideline definition	[Society guidelines definition]	0.0	3	1	1	1
19290	361	effective elastance	[effective elastance]	0.0	2	1	1	1
19291	361	potential efficacy of left-to-right interatrial shunting	[potential efficacy of left-to-right interatrial shunting]	0.0	6	1	1	1
19292	361	cardiac death in athlete	[cardiac death in athletes]	0.0	4	1	1	1
19293	361	therapeutic potential	[therapeutic potential]	0.0	2	1	1	1
19294	361	outcome change score	[outcome change scores]	0.0	3	1	1	1
19295	361	tapse RV fiber shortening	[TAPSE RV fiber shortening]	0.0	4	1	1	1
19296	361	peak early mitral flow velocity	[peak early mitral flow velocity]	0.0	5	3	3	1
19297	361	2-vessel cad involve the left artery	[2-vessel CAD involving the left artery]	0.0	6	1	1	1
19298	361	risk stratification with heart failure	[risk stratification with heart failure]	0.0	5	1	1	1
19299	361	previous revascularization	[previous revascularization]	0.0	2	1	1	1
19300	361	high activity	[higher activities]	0.0	2	1	1	1
19301	361	ventricular RV tricuspid annular plane excursion	[ventricular RV tricuspid annular plane excursion]	0.0	6	1	1	1
19302	361	early diastolic mitral velocity 3.1	[early diastolic mitral velocity 3.1]	0.0	5	1	1	1
19303	361	6-minute walking distance peak	[6-minute walking distance peak]	0.0	4	1	1	1
19304	361	absolute change between performance	[absolute change between performance]	0.0	4	1	1	1
19305	361	acute heart failure in patient	[acute heart failure in patients]	0.0	5	1	1	1
19306	361	involve the proximal anterior descend artery	[involving the proximal anterior descending artery]	0.0	6	1	1	1
19307	361	70 bpm 17.5±5.5 p	[70 bpm 17.5±5.5 P]	0.0	4	1	1	1
19308	361	603 patient age	[603 patients age]	0.0	3	1	1	1
19309	361	beneficial clinical outcome	[beneficial clinical outcomes]	0.0	3	1	1	1
19310	361	natriuretic peptide assessment	[natriuretic peptide assessment]	0.0	3	1	1	1
19311	361	healthy pilot study	[healthy pilot study]	0.0	3	1	1	1
19312	361	sympathetic activity (123)i-meta-iodobenzylguanidine	[sympathetic activity (123)I-meta-iodobenzylguanidine]	0.0	3	1	1	1
19313	361	control adenovirus	[control adenovirus]	0.0	2	1	1	1
19314	361	systolic annulus velocity	[systolic annulus velocity]	0.0	3	1	1	1
19315	361	change in mlhf score effect	[change in MLHF score effect]	0.0	5	1	1	1
19316	361	respective molecular pathway	[respective molecular pathways]	0.0	3	1	1	1
19317	361	provide information for a clinical outcome	[providing information for an clinical outcome]	0.0	6	1	1	1
19318	361	occur rad variant	[occurring Rad variant]	0.0	3	1	1	1
19319	361	oral dosage	[oral dosage]	0.0	2	1	1	1
19320	361	patient with stable cad	[patients with stable CAD]	0.0	4	1	1	1
19321	361	mitral annulus velocity Sa	[mitral annulus velocity Sa]	0.0	4	1	1	1
19322	361	moderate evidence from 17 trial	[Moderate evidence from 17 trials]	0.0	5	1	1	1
19323	361	heart failure study	[heart failure studies]	0.0	3	1	1	1
19324	361	left area hazard ratio	[left area hazard ratio]	0.0	4	1	1	1
19325	361	diagnosis of clinical dysfunction lead	[diagnosis of clinical dysfunction leading]	0.0	5	1	1	1
19326	361	left ejection fraction lvef	[left ejection fraction LVEF]	0.0	4	1	1	1
19327	361	sdqt-to-sdrr	[SDQT-to-SDRR]	0.0	1	1	1	1
19328	361	filtration rate 30 millileter	[filtration rate 30 ml]	0.0	4	1	1	1
19329	361	community HF cohort	[community HF cohort]	0.0	3	1	1	1
19330	361	optimal cutoff level	[optimal cutoff level]	0.0	3	1	1	1
19331	361	content-driven telehealth system	[content-driven telehealth system]	0.0	3	1	1	1
19332	361	good performance in patient with s'lateral	[good performance in patients with s'lateral]	0.0	6	1	1	1
19333	361	heart association class iii	[Heart Association class III]	0.0	4	1	1	1
19334	361	sitagliptin CI	[sitagliptin CI]	0.0	2	1	1	1
19335	361	41-year-old man	[41-year-old man]	0.0	2	1	1	1
19336	361	successful approach improve the prognosis	[Successful approaches improving the prognosis]	0.0	5	1	1	1
19337	361	further large-scale study	[Further large-scale studies]	0.0	3	1	1	1
19338	361	index of right contractile function	[index of right contractile function]	0.0	5	1	1	1
19339	361	socioeconomic status	[socioeconomic status]	0.0	2	1	1	1
19340	361	feasibility of a program	[feasibility of a program]	0.0	4	1	1	1
19341	361	oedema	[oedema]	0.0	1	1	1	1
19342	361	mena overexpression TTA comparable	[Mena overexpression TTA comparable]	0.0	4	1	1	1
19343	361	variation in use insight	[variation in use Insights]	0.0	4	1	1	1
19344	361	paf of metabolic enzyme	[PAF of metabolic enzymes]	0.0	4	1	1	1
19345	361	Clinical characteristic of young adult	[Clinical characteristics of young adults]	0.0	5	1	1	1
19346	361	quality-of-life score point	[quality-of-life score points]	0.0	3	1	1	1
19347	361	approach extrapolate outcome	[approach extrapolating outcomes]	0.0	3	1	1	1
19348	361	pressure curve	[pressure curve]	0.0	2	1	1	1
19349	361	effective practice	[effective practice]	0.0	2	1	1	1
19350	361	Multivariable regression model	[Multivariable regression models]	0.0	3	1	1	1
19351	361	SkM muscle	[SkM muscle]	0.0	2	1	1	1
19352	361	pressure gradient	[pressure gradient]	0.0	2	3	3	1
19353	361	ischemia stent	[ischemia stent]	0.0	2	1	1	1
19354	361	alendronate- patient	[alendronate- patients]	0.0	2	1	1	1
19355	361	cardiac resonance postcontrast t1 time	[cardiac resonance postcontrast T1 time]	0.0	5	1	1	1
19356	361	doxorubicin-induced heart failure	[doxorubicin-induced heart failure]	0.0	3	2	2	1
19357	361	management of patient stem from cardiomyopathythyothyordiomyotiomyotiomyotdiooocio	[Management of patients stemming from cardiomyopathies]	0.0	6	1	1	1
19358	361	fragment of pro-b-type natriuretic peptide	[fragments of pro-B-type natriuretic peptides]	0.0	5	1	1	1
19359	361	open without any clear lesion	[opening without any clear lesion]	0.0	5	1	1	1
19360	361	749 patient	[749 patients]	0.0	2	1	1	1
19361	361	decision about treatment	[decisions about treatment]	0.0	3	1	1	1
19362	361	12 stroke	[12 stroke]	0.0	2	1	1	1
19363	361	panel of assessment	[panel of assessments]	0.0	3	1	1	1
19364	361	vasopressin type 2	[vasopressin type 2]	0.0	3	1	1	1
19365	361	patient with mild reduction	[patients with mild reduction]	0.0	4	2	2	1
19366	361	important indicator in heart failure	[important indicator in heart failure]	0.0	5	1	1	1
19367	361	future mortality	[future mortality]	0.0	2	1	1	1
19368	361	disease with important comorbidity	[disease with important comorbidities]	0.0	4	1	1	1
19369	361	overall management of patient	[Overall management of patients]	0.0	4	1	1	1
19370	361	ischemia open stent	[ischemia open stent]	0.0	3	1	1	1
19371	361	adverse event profile	[adverse event profile]	0.0	3	1	1	1
19372	361	additional benefit over clinical parameter	[additional benefit over clinical parameters]	0.0	5	1	1	1
19373	361	≥3.5 gram	[≥3.5 g]	0.0	2	1	1	1
19374	361	role of clinical doppler echocardiography	[role of clinical Doppler echocardiography]	0.0	5	1	1	1
19375	361	transplant recipient	[transplant recipients]	0.0	2	1	1	1
19376	361	target individual with heart failure	[targeting individuals with heart failure]	0.0	5	1	1	1
19377	361	functional characterization of one	[functional characterization of one]	0.0	4	1	1	1
19378	361	induction of a gene program	[induction of a gene program]	0.0	5	1	1	1
19379	361	surgical intervention	[surgical intervention]	0.0	2	1	1	1
19380	361	event rate event	[event rate events]	0.0	3	1	1	1
19381	361	TAPSE vs. pasp	[TAPSE vs. PASP]	0.0	3	1	1	1
19382	361	ventricular assist device lvad implantation	[ventricular assist device LVAD implantation]	0.0	5	1	1	1
19383	361	recreational athlete	[recreational athletes]	0.0	2	1	1	1
19384	361	quality-of-life score –17.4 point vs. point	[quality-of-life score –17.4 points vs. points]	0.0	6	1	1	1
19385	361	right-sided catheterization	[right-sided catheterization]	0.0	2	1	1	1
19386	361	guidance under anaesthesia	[guidance under anaesthesia]	0.0	3	1	1	1
19387	361	L-DKO	[L-DKO]	0.0	1	1	1	1
19388	361	hdl-mediated protective effect	[HDL-mediated protective effects]	0.0	3	1	1	1
19389	361	coupling vascular resistance	[coupling vascular resistance]	0.0	3	1	1	1
19390	361	receptor antagonist valsartan	[receptor antagonist valsartan]	0.0	3	1	1	1
19391	361	body mass index of ethnicity	[body mass index of ethnicity]	0.0	5	1	1	1
19392	361	symptom despite treatment	[symptoms despite treatment]	0.0	3	1	1	1
19393	361	angiotensin-receptor	[angiotensin-receptor]	0.0	1	1	1	1
19394	361	therapy in heart failure patient	[therapy in heart failure patients]	0.0	5	1	1	1
19395	361	chromatin remodeling event	[chromatin remodeling events]	0.0	3	1	1	1
19396	361	morbidity in childhood	[morbidity in childhood]	0.0	3	1	1	1
19397	361	hospitalization worsen heart failure	[hospitalization worsening heart failure]	0.0	4	1	1	1
19398	361	improvement in effective rate risk	[improvement in effective rate risk]	0.0	5	1	1	1
19399	361	Cardiovascular Outcome	[Cardiovascular Outcomes]	0.0	2	1	1	1
19400	361	diverse community-based cohort	[diverse community-based cohort]	0.0	3	1	1	1
19401	361	stable artery disease	[stable artery disease]	0.0	3	1	1	1
19402	361	good quintile of performance	[best quintile of performance]	0.0	4	1	1	1
19403	361	45 death in the control group	[45 deaths in the control group]	0.0	6	1	1	1
19404	361	use acid	[using acid]	0.0	2	1	1	1
19405	361	redo sternotomy for aortic valve procedure	[redo sternotomy for aortic valve procedures]	0.0	6	1	1	1
19406	361	224 man	[224 men]	0.0	2	1	1	1
19407	361	beta-blocker on sympathetic activity	[beta-blockers on sympathetic activity]	0.0	4	1	1	1
19408	361	patient with rest hr 70	[patients with resting HR 70]	0.0	5	1	1	1
19409	361	ventricular LV myocyte	[ventricular LV myocytes]	0.0	3	1	1	1
19410	361	herbal medicine CHM	[herbal medicine CHM]	0.0	3	1	1	1
19411	361	PB in patient	[PB in patients]	0.0	3	1	1	1
19412	361	trial in adult with anemia	[trials in adults with anemia]	0.0	5	1	1	1
19413	361	receptor β1ar	[receptor β1AR]	0.0	2	1	1	1
19414	361	multicenter trial with individual	[multicenter trial with individuals]	0.0	4	1	1	1
19415	361	approximately 2900 hm	[approximately 2900 HM]	0.0	3	1	1	1
19416	361	adult aged year	[adults aged years]	0.0	3	1	1	1
19417	361	novel therapeutic strategy in HF	[novel therapeutic strategy in HF]	0.0	5	1	1	1
19418	361	mm hg Fig	[mm Hg Fig]	0.0	3	1	1	1
19419	361	Edwards Lifescience	[Edwards Lifesciences]	0.0	2	1	1	1
19420	361	support on function	[support on function]	0.0	3	1	1	1
19421	361	perfusion in b-treated rat	[perfusion in B-treated rats]	0.0	4	1	1	1
19422	361	antecedent weight loss	[antecedent weight loss]	0.0	3	1	1	1
19423	361	patient in region	[patients in regions]	0.0	3	1	1	1
19424	361	transmitral e-wave diastolic mitral velocity ratio	[transmitral E-wave diastolic mitral velocity ratio]	0.0	6	1	1	1
19425	361	patient spironolactone	[patients spironolactone]	0.0	2	1	1	1
19426	361	selective heart rate reduction	[Selective heart rate reduction]	0.0	4	1	1	1
19427	361	terminal phase	[terminal phase]	0.0	2	1	1	1
19428	361	testosterone status a double-blind feasibility study	[testosterone status a double-blind feasibility study]	0.0	6	1	1	1
19429	361	serum cystatin c	[serum cystatin C]	0.0	3	1	1	1
19430	361	follow-up of month	[follow-up of months]	0.0	3	1	1	1
19431	361	total deg	[total DEGs]	0.0	2	1	1	1
19432	361	systemic resistance SVR index	[systemic resistance SVR index]	0.0	4	1	1	1
19433	361	HF with ventricular ejection fraction	[HF with ventricular ejection fraction]	0.0	5	1	1	1
19434	361	testosterone status a feasibility study	[testosterone status a feasibility study]	0.0	5	1	1	1
19435	361	compare b-treated with heart	[comparing B-treated with hearts]	0.0	4	1	1	1
19436	361	improvement of performance at stage	[improvement of performance at stages]	0.0	5	1	1	1
19437	361	identify cad	[Identifying CAD]	0.0	2	1	1	1
19438	361	SD testosterone level of nmol	[SD testosterone levels of nmol]	0.0	5	1	1	1
19439	361	right pressure overload rvpo	[right pressure overload RVPO]	0.0	4	1	1	1
19440	361	heart dilatation after constriction	[heart dilatation after constriction]	0.0	4	1	1	1
19441	361	velocity 3.1 vs. 1.3	[velocity 3.1 vs. 1.3]	0.0	4	1	1	1
19442	361	consent HF patient ventricular ejection fraction	[consenting HF patients ventricular ejection fraction]	0.0	6	1	1	1
19443	361	exercise test investigation	[exercise test investigations]	0.0	3	1	1	1
19444	361	independent hypothese	[independent hypotheses]	0.0	2	1	1	1
19445	361	Hand2 mouse	[Hand2 mice]	0.0	2	1	1	1
19446	361	improvement of cardiac inflammatory biomarker	[improvement of cardiac inflammatory biomarkers]	0.0	5	1	1	1
19447	361	association among cardiorespiratory fitness	[associations among cardiorespiratory fitness]	0.0	4	1	1	1
19448	361	effective arterial elastance ea end-systolic elastance	[Effective arterial elastance Ea end-systolic elastance]	0.0	6	1	1	1
19449	361	proximal left descending	[proximal left descending]	0.0	3	1	1	1
19450	361	relevance of ventricular reserve in patient	[relevance of ventricular reserve in patients]	0.0	6	1	1	1
19451	361	Postoperative survival of patient with hypoalbuminemia	[Postoperative survival of patients with hypoalbuminemia]	0.0	6	1	1	1
19452	361	receive cardioverter defibrillator-CRT	[receiving cardioverter defibrillator-CRT]	0.0	3	1	1	1
19453	361	consecutive patient with hfpef	[consecutive patients with HFPEF]	0.0	4	1	1	1
19454	361	peak oxygen uptake with reduction	[peak oxygen uptake with reduction]	0.0	5	1	1	1
19455	361	good function	[better function]	0.0	2	1	1	1
19456	361	channel mrna splice variant	[channel mRNA splice variants]	0.0	4	1	1	1
19457	361	development of novel approach	[development of novel approaches]	0.0	4	1	1	1
19458	361	Lesion	[Lesions]	0.0	1	1	1	1
19459	361	HF hospitalization hr 1.58 CI	[HF hospitalization HR 1.58 CI]	0.0	5	1	1	1
19460	361	current predictor	[current predictors]	0.0	2	1	1	1
19461	361	cost-effective population-specific health intervention	[cost-effective population-specific health interventions]	0.0	4	1	1	1
19462	361	predictor after admission	[predictor after admission]	0.0	3	1	1	1
19463	361	site-specific antibody	[site-specific antibodies]	0.0	2	1	1	1
19464	361	Ie risk	[IE risk]	0.0	2	1	1	1
19465	361	b-type natriuretic peptide level	[B-type natriuretic peptide levels]	0.0	4	1	1	1
19466	361	four US healthcare programme	[four US healthcare programmes]	0.0	4	1	1	1
19467	361	factor-β	[factor-β]	0.0	1	1	1	1
19468	361	multicenter double-blind trial optimization strategy evaluation	[Multicenter double-blind trial Optimization Strategies Evaluation]	0.0	6	1	1	1
19469	361	pluripotent stem	[pluripotent stem]	0.0	2	1	1	1
19470	361	receptor potential	[receptor potential]	0.0	2	1	1	1
19471	361	body mass index strata	[body mass index strata]	0.0	4	1	1	1
19472	361	refractory congestive heart failure CHF	[refractory congestive heart failure CHF]	0.0	5	1	1	1
19473	361	effect of nonselective	[effects of nonselective]	0.0	3	1	1	1
19474	361	several marker indicative	[several markers indicative]	0.0	3	1	1	1
19475	361	cardiac gene expression programme	[cardiac gene expression programme]	0.0	4	1	1	1
19476	361	lvef hazard ratio	[LVEF hazard ratio]	0.0	3	1	1	1
19477	361	8 patient	[8 patients]	0.0	2	1	1	1
19478	361	subject with normal heart HNorm	[subjects with normal hearts HNorm]	0.0	5	1	1	1
19479	361	indicate possible care of patient	[indicating possible care of patients]	0.0	5	1	1	1
19480	361	especially in subject	[especially in subjects]	0.0	3	1	1	1
19481	361	affair HF clinic outcome	[Affairs HF clinic outcomes]	0.0	4	1	1	1
19482	361	veteran aged 50 year	[veterans aged 50 years]	0.0	4	1	1	1
19483	361	insulin-signaling component regulate cellular metabolism	[insulin-signaling components regulating cellular metabolism]	0.0	5	1	1	1
19484	361	ivabradine exercise capacity	[ivabradine exercise capacity]	0.0	3	1	1	1
19485	361	differential response in activity	[differential response in activity]	0.0	4	1	1	1
19486	361	nontreatment	[nontreatment]	0.0	1	1	1	1
19487	361	resynchronization therapy in dialysis-dependent patient	[resynchronization therapy in dialysis-dependent patients]	0.0	5	1	1	1
19488	361	HF mortality risk	[HF mortality risk]	0.0	3	1	1	1
19489	361	0 day	[0 days]	0.0	2	1	1	1
19490	361	case of a man	[case of a man]	0.0	4	1	1	1
19491	361	practice-level variation in use insight	[Practice-level variation in use Insights]	0.0	5	1	1	1
19492	361	distribution in HFrEF	[distribution in HFrEF]	0.0	3	1	1	1
19493	361	402 patient geometry	[402 patients geometry]	0.0	3	1	1	1
19494	361	patient with hfpef normal geometry	[patients with HFpEF normal geometry]	0.0	5	1	1	1
19495	361	treatment interaction	[treatment interaction]	0.0	2	1	1	1
19496	361	presumably decrease risk	[presumably decreasing risk]	0.0	3	1	1	1
19497	361	maximal elastance	[maximal elastance]	0.0	2	1	1	1
19498	361	include cancer	[including cancer]	0.0	2	1	1	1
19499	361	diagnostic feature such as early detection	[diagnostic features such as early detection]	0.0	6	1	1	1
19500	361	evidence for potential usefulness in HF	[evidence for potential usefulness in HF]	0.0	6	1	1	1
19501	361	accurate risk stratification of patient appropriate	[accurate risk stratification of patient appropriate]	0.0	6	1	1	1
19502	361	incidence mt	[incidence MT]	0.0	2	1	1	1
19503	361	hierarchical regression model	[hierarchical regression models]	0.0	3	1	1	1
19504	361	potential of a strategy	[potential of a strategy]	0.0	4	1	1	1
19505	361	aortic valve insufficiency	[aortic valve insufficiency]	0.0	3	1	1	1
19506	361	characteristic the charm programme	[characteristics The CHARM programme]	0.0	4	1	1	1
19507	361	approach improve the prognosis of patient	[approaches improving the prognosis of patients]	0.0	6	1	1	1
19508	361	HF unit	[HF units]	0.0	2	1	1	1
19509	361	gene control	[gene control]	0.0	2	1	1	1
19510	361	tricuspid plane systolic excursion tapse	[tricuspid plane systolic excursion TAPSE]	0.0	5	1	1	1
19511	361	lipid-lowering therapy	[lipid-lowering therapy]	0.0	2	1	1	1
19512	361	DEGs	[DEGs]	0.0	1	1	1	1
19513	361	Clinical characteristic the charm programme	[Clinical characteristics The CHARM programme]	0.0	5	1	1	1
19514	361	current economic climate	[current economic climate]	0.0	3	1	1	1
19515	361	patient in fibrillation	[patients in fibrillation]	0.0	3	1	1	1
19516	361	ventricular midpapillary level	[ventricular midpapillary level]	0.0	3	1	1	1
19517	361	PKC-βII	[PKC-βII]	0.0	1	1	1	1
19518	361	young patient with co-morbidity burden	[younger patients with co-morbidity burden]	0.0	5	1	1	1
19519	361	outpatient assessment within day	[outpatient assessments within days]	0.0	4	1	1	1
19520	361	prognostic diastolic dysfunction lead	[prognostic diastolic dysfunction leading]	0.0	4	1	1	1
19521	361	transplant-ineligible patient	[transplant-ineligible patients]	0.0	2	1	1	1
19522	361	patient with hfpef α=0.96	[patients with HFpEF α=0.96]	0.0	4	1	1	1
19523	361	cardiac sympathetic activity by ((123)i-mibg	[cardiac sympathetic activity by ((123)I-MIBG]	0.0	5	1	1	1
19524	361	pioglitazone for saxagliptin	[pioglitazone for saxagliptin]	0.0	3	1	1	1
19525	361	reduce the composite endpoint	[reducing the composite endpoint]	0.0	4	1	1	1
19526	361	atheromatous disease	[atheromatous disease]	0.0	2	1	1	1
19527	361	left ejection fraction mean difference	[left ejection fraction mean difference]	0.0	5	1	1	1
19528	361	benefit of spironolactone	[benefits of spironolactone]	0.0	3	1	1	1
19529	361	high hazard	[highest hazard]	0.0	2	1	1	1
19530	361	form of remodeling in heart failure	[forms of remodeling in heart failure]	0.0	6	1	1	1
19531	361	clinical trials-Enriching patient identification	[clinical trials-Enriching patient identification]	0.0	4	1	1	1
19532	361	few procedure 146 vs. 238	[fewer procedures 146 vs. 238]	0.0	5	1	1	1
19533	361	charm programme	[CHARM programme]	0.0	2	1	1	1
19534	361	mean of year	[mean of years]	0.0	3	1	1	1
19535	361	ventricular power index	[ventricular power index]	0.0	3	1	1	1
19536	361	comprise hospitalization for coronary syndrome	[comprising hospitalization for coronary syndromes]	0.0	5	1	1	1
19537	361	measurable improvement	[measurable improvements]	0.0	2	1	1	1
19538	361	bisoprolol reduce mortality	[bisoprolol reducing mortality]	0.0	3	1	1	1
19539	361	spectrometric analysis	[spectrometric analysis]	0.0	2	1	1	1
19540	361	suburban hospital in New Jersey	[suburban hospitals in New Jersey]	0.0	5	1	1	1
19541	361	criteriabased institution for the treatment	[criteriabased institution for the treatment]	0.0	5	1	1	1
19542	361	urban center	[urban center]	0.0	2	1	1	1
19543	361	Physio	[Physio]	0.0	1	1	1	1
19544	361	dilatation diameter	[dilatation diameter]	0.0	2	1	1	1
19545	361	organic lesion	[organic lesion]	0.0	2	2	2	1
19546	361	outcome use a aldosterone antagonist	[outcomes using an aldosterone antagonist]	0.0	5	1	1	1
19547	361	treatment with a contribution	[treatment with a contribution]	0.0	4	1	1	1
19548	361	decline c-kit	[decline c-Kit]	0.0	2	1	1	1
19549	361	gdmt for 6 month	[GDMT for 6 months]	0.0	4	1	1	1
19550	361	median bnp	[median BNP]	0.0	2	1	1	1
19551	361	ST2 in ambulatory patient	[ST2 in ambulatory patients]	0.0	4	1	1	1
19552	361	cross-talk	[Cross-talk]	0.0	1	1	1	1
19553	361	investigate Outcome of Exercise Training	[Investigating Outcomes of Exercise Training]	0.0	5	2	2	1
19554	361	all-cause mortality all hazard ratio	[all-cause mortality all hazard ratios]	0.0	5	1	1	1
19555	361	373 patient	[373 patients]	0.0	2	1	1	1
19556	361	disease accounting	[disease accounting]	0.0	2	1	1	1
19557	361	microrna rirnas	[microRNAs miRNAs]	0.0	2	1	1	1
19558	361	infarction heart	[infarction heart]	0.0	2	1	1	1
19559	361	hum-retn mouse	[Hum-Retn mice]	0.0	2	1	1	1
19560	361	percutaneous revascularization with angioplasty	[percutaneous revascularization with angioplasty]	0.0	4	1	1	1
19561	361	receive implantable cardioverter defibrillator-CRT	[receiving implantable cardioverter defibrillator-CRT]	0.0	4	1	1	1
19562	361	sarcoplasmic can 2+)-uptake	[sarcoplasmic Ca 2+)-uptake]	0.0	3	1	1	1
19563	361	perception of implantable cardioverter-defibrillator deactivation discussion	[perceptions of implantable cardioverter-defibrillator deactivation discussions]	0.0	6	1	1	1
19564	361	diagnosis of clinical dysfunction	[diagnosis of clinical dysfunction]	0.0	4	1	1	1
19565	361	HF-REF	[HF-REF]	0.0	1	1	1	1
19566	361	adipose	[adipose]	0.0	1	2	2	1
19567	361	therapeutic target for HHD	[therapeutic targets for HHD]	0.0	4	1	1	1
19568	361	hypothese addition of low-dose dopamine	[hypotheses addition of low-dose dopamine]	0.0	5	1	1	1
19569	361	technique detect early myocardial fibrosis	[technique detecting early myocardial fibrosis]	0.0	5	1	1	1
19570	361	worsen function WRF in EMPHASIS-HF	[worsening function WRF in EMPHASIS-HF]	0.0	5	1	1	1
19571	361	initial diagnosis	[initial diagnosis]	0.0	2	1	1	1
19572	361	mean of 0.25	[mean of 0.25]	0.0	3	1	1	1
19573	361	provide information for a unfavourable outcome	[providing information for an unfavourable outcome]	0.0	6	1	1	1
19574	361	activate pde2	[activating PDE2]	0.0	2	1	1	1
19575	361	prescribe medication	[prescribing medications]	0.0	2	1	1	1
19576	361	long-acting insulin product	[long-acting insulin products]	0.0	3	1	1	1
19577	361	arterial elastance end-systolic elastance	[arterial elastance end-systolic elastance]	0.0	4	1	1	1
19578	361	writer	[writer]	0.0	1	1	1	1
19579	361	change in rs synchrony	[changes in RS synchrony]	0.0	4	1	1	1
19580	361	7 kg with improvement in response	[7 kg with improvement in response]	0.0	6	1	1	1
19581	361	HF patient hfvt(-)	[HF patients HFVT(-)]	0.0	3	1	1	1
19582	361	individual with chronic disease	[individuals with chronic disease]	0.0	4	1	1	1
19583	361	effectiveness for systolic heart failure	[Effectiveness for systolic heart failure]	0.0	5	1	1	1
19584	361	advanced chronic obstructive disease copd	[advanced chronic obstructive disease COPD]	0.0	5	1	1	1
19585	361	β-ar drive	[β-AR drive]	0.0	2	1	1	1
19586	361	study sample with 60000 patient	[study sample with 60,000 patients]	0.0	5	1	1	1
19587	361	practice rate with angiotensin-converting enzyme inhibitor	[Practice rates with angiotensin-converting enzyme inhibitors]	0.0	6	1	1	1
19588	361	care surgery consultation within year	[care surgery consultations within year]	0.0	5	1	1	1
19589	361	heart with level	[hearts with levels]	0.0	3	1	1	1
19590	361	transcatheter	[transcatheter]	0.0	1	1	1	1
19591	361	Fontan SAF	[Fontan SAF]	0.0	2	1	1	1
19592	361	outcome of care	[outcomes of care]	0.0	3	1	1	1
19593	361	use the flux analyzer	[using the flux analyzer]	0.0	4	1	1	1
19594	361	nearly one million people	[nearly one million people]	0.0	4	1	1	1
19595	361	interquartile range with copd	[interquartile range with COPD]	0.0	4	1	1	1
19596	361	poc measurement	[POC measurement]	0.0	2	1	1	1
19597	361	normal function	[normal function]	0.0	2	1	1	1
19598	361	millileter 2	[mL 2]	0.0	2	1	1	1
19599	361	patient receive assist device support	[patients receiving assist device support]	0.0	5	1	1	1
19600	361	2.8 L 2	[2.8 L 2]	0.0	3	1	1	1
19601	361	Comparable performance	[Comparable performance]	0.0	2	1	1	1
19602	361	exist measure explain variation	[existing measures explaining variation]	0.0	4	1	1	1
19603	361	70 bpm 17.5±5.5	[70 bpm 17.5±5.5]	0.0	3	1	1	1
19604	361	regard effective treatment	[regarding effective treatment]	0.0	3	1	1	1
19605	361	risk-adjusted mortality at the bad	[risk-adjusted mortality at the worst]	0.0	5	1	1	1
19606	361	proBNP	[proBNP]	0.0	1	1	1	1
19607	361	patient with function	[patients with function]	0.0	3	1	1	1
19608	361	circulate fragment of pro-b-type natriuretic peptide	[Circulating fragments of pro-B-type natriuretic peptides]	0.0	6	1	1	1
19609	361	improvement in composite response p=0.02	[improvements in composite response P=0.02]	0.0	5	1	1	1
19610	361	cardiac procedure 146 vs. 238	[cardiac procedures 146 vs. 238]	0.0	5	1	1	1
19611	361	heart Association guideline	[Heart Association guidelines]	0.0	3	1	1	1
19612	361	patient with moderate	[patients with moderate]	0.0	3	1	1	1
19613	361	recently for transplant-ineligible patient	[recently for transplant-ineligible patients]	0.0	4	1	1	1
19614	361	change in co.	[changes in CO.]	0.0	3	1	1	1
19615	361	clinical diastolic dysfunction lead	[clinical diastolic dysfunction leading]	0.0	4	1	1	1
19616	361	beta-adrenergic receptor β-ar signal	[beta-adrenergic receptor β-AR signaling]	0.0	4	1	1	1
19617	361	metabolic enzyme over a follow-up period	[metabolic enzymes over a follow-up period]	0.0	6	1	1	1
19618	361	presence of mild dysfunction	[presence of mild dysfunction]	0.0	4	1	1	1
19619	361	utilize testimony with participate nurse	[Utilizing testimonies with participating nurses]	0.0	5	1	1	1
19620	361	CI for sitagliptin CI	[CI for sitagliptin CI]	0.0	4	1	1	1
19621	361	patient with LV ejection fraction LVEF	[patients with LV ejection fraction LVEF]	0.0	6	1	1	1
19622	361	diagnostic feature	[diagnostic features]	0.0	2	1	1	1
19623	361	2331 patient with left ejection fraction	[2331 patients with left ejection fraction]	0.0	6	1	1	1
19624	361	defense mechanism during cardiac stress	[defense mechanism during cardiac stress]	0.0	5	1	1	1
19625	361	outcome use a antagonist	[outcomes using an antagonist]	0.0	4	1	1	1
19626	361	patient with a ejection fraction	[patients with a ejection fraction]	0.0	5	1	1	1
19627	361	Cardiovascular Outcome in atherosclerotic Lesion	[Cardiovascular Outcomes in Atherosclerotic Lesions]	0.0	5	1	1	1
19628	361	volume overload of mitral regurgitation	[volume overload of mitral regurgitation]	0.0	5	1	1	1
19629	361	cardiac index 0.7 L 2	[cardiac index 0.7 L 2]	0.0	5	1	1	1
19630	361	ischemic cardiomyopathy ic	[ischemic cardiomyopathy IC]	0.0	3	1	1	1
19631	361	fish	[fish]	0.0	1	1	1	1
19632	361	Comparable performance in patient	[Comparable performance in patients]	0.0	4	1	1	1
19633	361	congenital lesion	[congenital lesions]	0.0	2	1	1	1
19634	361	target the patient	[targeting the patients]	0.0	3	1	1	1
19635	361	emphasis-hf study	[EMPHASIS-HF study]	0.0	2	1	1	1
19636	361	heart Association class	[Heart Association class]	0.0	3	1	1	1
19637	361	more severe LV dysfunction	[more severe LV dysfunction]	0.0	4	1	1	1
19638	361	form of ventricular LV remodeling	[forms of ventricular LV remodeling]	0.0	5	1	1	1
19639	361	proximal descending lad	[proximal descending LAD]	0.0	3	1	1	1
19640	361	volume group	[volume groups]	0.0	2	1	1	1
19641	361	area index	[area index]	0.0	2	1	1	1
19642	361	evidence for potential usefulness	[evidence for potential usefulness]	0.0	4	1	1	1
19643	361	selective β-blocker metoprolol	[selective β-blocker metoprolol]	0.0	3	1	1	1
19644	361	emphasis-hf	[EMPHASIS-HF]	0.0	1	1	1	1
19645	361	determination of option	[determination of options]	0.0	3	1	1	1
19646	361	cardiac hypertrophic response role	[cardiac hypertrophic response role]	0.0	4	1	1	1
19647	361	mostly in class nyha ii-iii	[mostly in class NYHA II-III]	0.0	5	1	1	1
19648	361	include quality	[including quality]	0.0	2	1	1	1
19649	361	therapeutic interruption	[therapeutic interruption]	0.0	2	1	1	1
19650	361	single test for HFpEF	[single test for HFpEF]	0.0	4	1	1	1
19651	361	adult with systolic heart failure	[adults with systolic heart failure]	0.0	5	1	1	1
19652	361	prospective outcome assessment trial	[prospective outcome assessment trial]	0.0	4	1	1	1
19653	361	Jersey	[Jersey]	0.0	1	1	1	1
19654	361	Left ejection time complicate hypertension	[Left ejection time complicating hypertension]	0.0	5	1	1	1
19655	361	metoprolol succinate	[metoprolol succinate]	0.0	2	1	1	1
19656	361	date of participant contact	[date of participant contact]	0.0	4	1	1	1
19657	361	10 week	[10 weeks]	0.0	2	1	1	1
19658	361	have independent predictor	[having independent predictor]	0.0	3	1	1	1
19659	361	heart Failure questionnaire	[Heart Failure Questionnaire]	0.0	3	1	1	1
19660	361	Hypertension diet score	[Hypertension diet scores]	0.0	3	1	1	1
19661	361	systematic monitoring	[systematic monitoring]	0.0	2	1	1	1
19662	361	Specific signalling pathway activate adaptive remodelling	[Specific signalling pathways activating adaptive remodelling]	0.0	6	1	1	1
19663	361	ef r=-0.55	[EF r=-0.55]	0.0	2	1	1	1
19664	361	prognostic relevance of ventricular reserve	[prognostic relevance of ventricular reserve]	0.0	5	1	1	1
19665	361	one million people	[one million people]	0.0	3	1	1	1
19666	361	cardioverter-defibrillator deactivation at implant	[cardioverter-defibrillator deactivation at implant]	0.0	4	1	1	1
19667	361	status of np measurement	[status of NP measurement]	0.0	4	1	1	1
19668	361	mm hg fig 1a	[mm Hg Fig 1A]	0.0	4	1	1	1
19669	361	regulate metabolism	[regulating metabolism]	0.0	2	1	1	1
19670	361	hypothese addition 2 μg	[hypotheses addition 2 μg]	0.0	4	1	1	1
19671	361	present with a diagnosis	[presenting with a diagnosis]	0.0	4	1	1	1
19672	361	novel intracellular antiadrenergic therapeutic strategy	[novel intracellular antiadrenergic therapeutic strategy]	0.0	5	1	1	1
19673	361	epidemiology	[Epidemiology]	0.0	1	2	2	1
19674	361	incidence of liver texture change	[incidence of liver texture changes]	0.0	5	1	1	1
19675	361	heart HNorm	[hearts HNorm]	0.0	2	1	1	1
19676	361	2538 patient with a follow-up	[2,538 patients with a follow-up]	0.0	5	1	1	1
19677	361	Low-dose dopamine in acute heart failure	[Low-dose dopamine in acute heart failure]	0.0	6	1	1	1
19678	361	home telemonitoring tm include monitoring device	[home telemonitoring TM including monitoring devices]	0.0	6	1	1	1
19679	361	use in HF	[use in HF]	0.0	3	1	1	1
19680	361	STS HH credible interval CrI	[STS HH credible interval CrI]	0.0	5	1	1	1
19681	361	include RELAX-AHF	[including RELAX-AHF]	0.0	2	1	1	1
19682	361	cardiac sympathetic tone	[cardiac sympathetic tone]	0.0	3	1	1	1
19683	361	ventricular RV annular plane systolic excursion	[ventricular RV annular plane systolic excursion]	0.0	6	1	1	1
19684	361	dilation	[dilation]	0.0	1	1	1	1
19685	361	carry two increase	[carrying two increase]	0.0	3	1	1	1
19686	361	heart Foundation	[Heart Foundation]	0.0	2	1	1	1
19687	361	24-hour brachial systolic pressure	[24-hour brachial systolic pressure]	0.0	4	1	1	1
19688	361	panel of experienced electrocardiographer	[panel of experienced electrocardiographers]	0.0	4	1	1	1
19689	361	significant improvement in effective rate risk	[significant improvement in effective rate risk]	0.0	6	1	1	1
19690	361	caspase-3 activity	[caspase-3 activity]	0.0	2	1	1	1
19691	361	stable heart failure patient	[stable heart failure patients]	0.0	4	1	1	1
19692	361	noninvasive surrogate for change during rvpo	[noninvasive surrogates for changes During RVPO]	0.0	6	1	1	1
19693	361	diagnosis of heart failure role	[Diagnosis of heart failure role]	0.0	5	1	1	1
19694	361	benefit in HF	[Benefits in HF]	0.0	3	1	1	1
19695	361	mean follow-up	[mean follow-up]	0.0	2	3	3	1
19696	361	antitumor activity	[antitumor activity]	0.0	2	1	1	1
19697	361	sphingosine-1-phosphate receptor 1	[sphingosine-1-phosphate receptor 1]	0.0	3	1	1	1
19698	361	matrix of left biopsy	[matrix of left biopsies]	0.0	4	1	1	1
19699	361	first acute infarction	[first acute infarction]	0.0	3	1	1	1
19700	361	effect of nervous system modulation	[effect of nervous system modulation]	0.0	5	1	1	1
19701	361	RV function evaluation	[RV function evaluation]	0.0	3	1	1	1
19702	361	multicenter clinical trial optimization strategy evaluation	[Multicenter clinical trial Optimization Strategies Evaluation]	0.0	6	1	1	1
19703	361	ratio diastolic mitral annulus velocity	[ratio diastolic mitral annulus velocity]	0.0	5	1	1	1
19704	361	left assist device with support	[left assist device with support]	0.0	5	1	1	1
19705	361	80 year of age	[80 years of age]	0.0	4	1	1	1
19706	361	left LV dilatation	[left LV dilatation]	0.0	3	1	1	1
19707	361	year with diabete	[years with diabetes]	0.0	3	1	1	1
19708	361	primary symptom of hfpef	[primary symptom of HFPEF]	0.0	4	1	1	1
19709	361	extracellular matrix of left ventricular biopsy	[Extracellular matrix of left ventricular biopsies]	0.0	6	1	1	1
19710	361	right coupling vascular resistance	[right coupling vascular resistance]	0.0	4	1	1	1
19711	361	19 patient	[19 patients]	0.0	2	1	1	1
19712	361	type of lvas	[types of LVADs]	0.0	3	1	1	1
19713	361	median of day	[median of days]	0.0	3	1	1	1
19714	361	mild regurgitation	[mild regurgitation]	0.0	2	1	1	1
19715	361	only a amount	[only a amount]	0.0	3	1	1	1
19716	361	weak recommendation	[weak recommendation]	0.0	2	1	1	1
19717	361	promote pause release during stress	[promoting pause release during stress]	0.0	5	1	1	1
19718	361	role of doppler echocardiography	[role of Doppler echocardiography]	0.0	4	1	1	1
19719	361	major mechanism of HFPEF	[major mechanism of HFPEF]	0.0	4	1	1	1
19720	361	kidney infection without complication	[kidney infection without complications]	0.0	4	1	1	1
19721	361	severe systolic HF	[severe systolic HF]	0.0	3	1	1	1
19722	361	survivor of childhood disease	[survivors of childhood disease]	0.0	4	1	1	1
19723	361	ivabradine mg	[ivabradine mg]	0.0	2	1	1	1
19724	361	tricuspid annular plane systolic excursion tapse	[tricuspid annular plane systolic excursion TAPSE]	0.0	6	1	1	1
19725	361	catheterisation with transoesophageal echocardiographic guidance	[catheterisation with transoesophageal echocardiographic guidance]	0.0	5	1	1	1
19726	361	therapy hr	[therapy HR]	0.0	2	1	1	1
19727	361	value of indeterminable threshold	[value of indeterminable threshold]	0.0	4	1	1	1
19728	361	result in a high sv p	[resulting in a higher SV p]	0.0	6	1	1	1
19729	361	p value=0.033	[P value=0.033]	0.0	2	1	1	1
19730	361	observation period	[observation period]	0.0	2	1	1	1
19731	361	total of individual aged 55	[total of individuals aged 55]	0.0	5	1	1	1
19732	361	chamber	[chamber]	0.0	1	1	1	1
19733	361	role of ERK1	[role of ERK1]	0.0	3	1	1	1
19734	361	human-to-human contact	[human-to-human contact]	0.0	2	1	1	1
19735	361	result in the support score	[resulting in the support score]	0.0	5	1	1	1
19736	361	predictor of mortality a systematic review	[Predictors of mortality a systematic review]	0.0	6	1	1	1
19737	361	degree early	[degree early]	0.0	2	1	1	1
19738	361	12-week program of exercise	[12-week program of exercise]	0.0	4	1	1	1
19739	361	acute myocardial infarction with complication	[acute myocardial infarction with complications]	0.0	5	1	1	1
19740	361	N-terminal fragment	[N-terminal fragment]	0.0	2	1	1	1
19741	361	four condition	[four conditions]	0.0	2	1	1	1
19742	361	capacity for CF lvad patient	[capacity for CF LVAD patients]	0.0	5	1	1	1
19743	361	Left ventricular ejection time	[Left ventricular ejection time]	0.0	4	1	1	1
19744	361	arthritis	[arthritis]	0.0	1	1	1	1
19745	361	Coding System	[Coding System]	0.0	2	1	1	1
19746	361	cumulative urine volume decongestion end point	[cumulative urine volume decongestion end point]	0.0	6	1	1	1
19747	361	endothelial cell oxide no production	[endothelial cell oxide NO production]	0.0	5	1	1	1
19748	361	hospitalization in severe refractory heart failure	[hospitalizations in severe refractory heart failure]	0.0	6	1	1	1
19749	361	tract	[tract]	0.0	1	1	1	1
19750	361	new user of a nbdmard	[new users of a nbDMARD]	0.0	5	1	1	1
19751	361	paf-acetylhydrolase	[PAF-acetylhydrolase]	0.0	1	1	1	1
19752	361	patient with chronic organ failure	[patients with chronic organ failure]	0.0	5	1	1	1
19753	361	MADIT-CRT study	[MADIT-CRT study]	0.0	2	1	1	1
19754	361	proximal LCX model	[proximal LCX model]	0.0	3	1	1	1
19755	361	high morbidity especially in people	[high morbidity especially in people]	0.0	5	1	1	1
19756	361	basic relevance in the follow-up	[basic relevance in the follow-up]	0.0	5	1	1	1
19757	361	consecutive patient with onset HFrEF	[consecutive patients with onset HFrEF]	0.0	5	1	1	1
19758	361	HF patient without VT hfvt(-)	[HF patients without VT HFVT(-)]	0.0	5	1	1	1
19759	361	presence of clinical diastolic dysfunction	[presence of clinical diastolic dysfunction]	0.0	5	1	1	1
19760	361	endothelial cell	[endothelial cell]	0.0	2	1	1	1
19761	361	therapy mt	[therapy MT]	0.0	2	1	1	1
19762	361	fig 1a	[Fig 1A]	0.0	2	1	1	1
19763	361	224 man mean	[224 men mean]	0.0	3	1	1	1
19764	361	frailty hr	[frailty HR]	0.0	2	1	1	1
19765	361	risk predictor for cardiac death	[risk predictor for cardiac death]	0.0	5	1	1	1
19766	361	STS HH interval	[STS HH interval]	0.0	3	1	1	1
19767	361	statistically significant change	[statistically significant change]	0.0	3	1	1	1
19768	361	shortness	[Shortness]	0.0	1	1	1	1
19769	361	woman with a history of hypertension	[women with a history of hypertension]	0.0	6	1	1	1
19770	361	small subgroup	[small subgroup]	0.0	2	1	1	1
19771	361	survival from the time	[survival from the time]	0.0	4	1	1	1
19772	361	adjust for 20 variable	[adjusting for 20 variables]	0.0	4	1	1	1
19773	361	patient 224 man 65±12 year	[patients 224 men 65±12 years]	0.0	5	1	1	1
19774	361	open outcome assessment trial	[open outcome assessment trial]	0.0	4	1	1	1
19775	361	large increase	[largest increases]	0.0	2	1	1	1
19776	361	include t1 mapping	[including T1 mapping]	0.0	3	1	1	1
19777	361	littermate	[littermate]	0.0	1	1	1	1
19778	361	bundle branch block odd ratio	[bundle branch block odds ratio]	0.0	5	1	1	1
19779	361	STE analysis of circumferential strain	[STE analysis of circumferential strain]	0.0	5	1	1	1
19780	361	implication of metric choice	[Implications of metric choice]	0.0	4	1	1	1
19781	361	National trend in patient safety	[National trends in patient safety]	0.0	5	1	1	1
19782	361	VA cohort	[VA cohort]	0.0	2	1	1	1
19783	361	patient experience implantable cardioverter-defibrillator shock	[patients experiencing implantable cardioverter-defibrillator shocks]	0.0	5	1	1	1
19784	361	hf-induced remodeling aspect	[HF-induced remodeling aspects]	0.0	3	1	1	1
19785	361	center retrospective study	[center retrospective study]	0.0	3	1	1	1
19786	361	matrix of biopsy	[matrix of biopsies]	0.0	3	1	1	1
19787	361	N-terminal proBNP NT-proBNP midregional proanp	[N-terminal proBNP NT-proBNP midregional proANP]	0.0	5	1	1	1
19788	361	only a amount of recent datum	[only a amount of recent data]	0.0	6	1	1	1
19789	361	action of Rad	[actions of Rad]	0.0	3	1	1	1
19790	361	cardiac na current	[cardiac Na current]	0.0	3	1	1	1
19791	361	periodic breathing	[periodic breathing]	0.0	2	1	1	1
19792	361	anthracycline exposure	[anthracycline exposure]	0.0	2	1	1	1
19793	361	exercise variable exercise oscillatory ventilation eov	[exercise variables exercise oscillatory ventilation EOV]	0.0	6	1	1	1
19794	361	heart failure patient ventricular ejection fraction	[heart failure patients ventricular ejection fraction]	0.0	6	1	1	1
19795	361	functional decline	[functional decline]	0.0	2	1	1	1
19796	361	interaction on outcome p	[interaction on outcomes P]	0.0	4	1	1	1
19797	361	heart in experimental model	[hearts in experimental models]	0.0	4	1	1	1
19798	361	medical management of heart failure	[medical management of heart failure]	0.0	5	1	1	1
19799	361	191 104 mm hg	[191 104 mm Hg]	0.0	4	1	1	1
19800	361	serum potassium level	[serum potassium level]	0.0	3	1	1	1
19801	361	time feasible	[time feasible]	0.0	2	1	1	1
19802	361	uncertainty	[uncertainty]	0.0	1	1	1	1
19803	361	ST2 level with capacity a Trial	[ST2 levels with capacity A Trial]	0.0	6	1	1	1
19804	361	hospital quality improvement	[hospital quality improvement]	0.0	3	1	1	1
19805	361	optimal treatment for heart failure	[optimal treatment for heart failure]	0.0	5	1	1	1
19806	361	cardiac index versus 2.8 L	[cardiac index versus 2.8 L]	0.0	5	1	1	1
19807	361	annular velocity 3.1 vs. 1.3	[annular velocity 3.1 vs. 1.3]	0.0	5	1	1	1
19808	361	difference median bnp in woman	[difference median BNP in women]	0.0	5	1	1	1
19809	361	HF resource	[HF resources]	0.0	2	1	1	1
19810	361	cardiac mrna level	[cardiac mRNA levels]	0.0	3	1	1	1
19811	361	other database	[other databases]	0.0	2	1	1	1
19812	361	dramatic induction of hretn mrna	[dramatic induction of hRetn mRNA]	0.0	5	1	1	1
19813	361	non-survivor year	[non-survivors years]	0.0	2	1	1	1
19814	361	velocity time	[velocity time]	0.0	2	1	1	1
19815	361	two increase in risk	[two increase in risk]	0.0	4	1	1	1
19816	361	9 subject with structurally normal heart	[9 subjects with structurally normal hearts]	0.0	6	1	1	1
19817	361	significant improvement in outcome rating	[significant improvement in outcome ratings]	0.0	5	1	1	1
19818	361	nonterminal epitope	[nonterminal epitopes]	0.0	2	1	1	1
19819	361	outcome versus 257 millisecond millisecond	[outcome vs 257 milliseconds milliseconds]	0.0	5	1	1	1
19820	361	development via direct effect	[development via direct effects]	0.0	4	1	1	1
19821	361	conflict result	[conflicting results]	0.0	2	1	1	1
19822	361	burden in adult medicine	[burden in adult medicine]	0.0	4	1	1	1
19823	361	significant cardioprotection	[significant cardioprotection]	0.0	2	1	1	1
19824	361	pioglitazone for saxagliptin for saxagliptin	[pioglitazone for saxagliptin for saxagliptin]	0.0	5	1	1	1
19825	361	low stimulation of phosphorylation	[lower stimulation of phosphorylation]	0.0	4	1	1	1
19826	361	most event	[Most events]	0.0	2	1	1	1
19827	361	attenuation by peptide	[attenuation by peptides]	0.0	3	1	1	1
19828	361	role molecular scaffold	[role molecular scaffolds]	0.0	3	1	1	1
19829	361	regard risk factor	[regarding risk factors]	0.0	3	1	1	1
19830	361	current predictor of mortality	[current predictors of mortality]	0.0	4	1	1	1
19831	361	tool in the diagnosis	[tool in the diagnosis]	0.0	4	1	1	1
19832	361	still a highly effective anti-neoplastic agent	[still a highly effective anti-neoplastic agent]	0.0	6	1	1	1
19833	361	ventricle the Fontan circulation	[ventricle the Fontan circulation]	0.0	4	1	1	1
19834	361	resistin in heart failure in mouse	[resistin in heart failure in mice]	0.0	6	1	1	1
19835	361	crucial role	[crucial role]	0.0	2	1	1	1
19836	361	patient male gender odd ratio	[patients male gender odds ratio]	0.0	5	1	1	1
19837	361	regulator of actin dynamic	[regulator of actin dynamics]	0.0	4	1	1	1
19838	361	consecutive patient man mean year	[consecutive patients men mean years]	0.0	5	1	1	1
19839	361	9 subject with normal heart	[9 subjects with normal hearts]	0.0	5	1	1	1
19840	361	SS31	[SS31]	0.0	1	1	1	1
19841	361	improvement between baseline exercise capacity METs	[improvement between baseline exercise capacity METs]	0.0	6	1	1	1
19842	361	undergo β-adrenergic receptor stimulation	[undergoing β-adrenergic receptor stimulation]	0.0	4	1	1	1
19843	361	stage i-iii	[stage I-III]	0.0	2	1	1	1
19844	361	stage kidney disease CKD	[Stage kidney disease CKD]	0.0	4	1	1	1
19845	361	oxidative metabolism	[oxidative metabolism]	0.0	2	1	1	1
19846	361	valve plasty for degenerative mr	[valve plasty for degenerative MR]	0.0	5	2	2	1
19847	361	effective arterial elastance elastance ees	[Effective arterial elastance elastance Ees]	0.0	5	1	1	1
19848	361	area 26 cm	[area 26 cm]	0.0	3	1	1	1
19849	361	neonatal rat ventricular cardiomyocyte	[neonatal rat ventricular cardiomyocytes]	0.0	4	1	1	1
19850	361	factor insight from heart failure	[Factors Insights From Heart Failure]	0.0	5	1	1	1
19851	361	hfpef left LV ejection fraction	[HFPEF left LV ejection fraction]	0.0	5	1	1	1
19852	361	pulmonary pressure relationship	[pulmonary pressure relationship]	0.0	3	1	1	1
19853	361	can 2 handling in dyssynchronous HF	[Ca 2 handling in dyssynchronous HF]	0.0	6	1	1	1
19854	361	individual component	[individual component]	0.0	2	1	1	1
19855	361	common cause of cardiovascular hospitalization	[common cause of cardiovascular hospitalization]	0.0	5	1	1	1
19856	361	even on therapy	[Even on therapy]	0.0	3	1	1	1
19857	361	range 22.8 with copd	[range 22.8 with COPD]	0.0	4	1	1	1
19858	361	variation insight	[variation Insights]	0.0	2	1	1	1
19859	361	odd of future 30-day	[odds of future 30-day]	0.0	4	1	1	1
19860	361	Diagnostic role in stable artery disease	[Diagnostic role in stable artery disease]	0.0	6	1	1	1
19861	361	nonpace dnx	[nonpace DNx]	0.0	2	1	1	1
19862	361	nursing-sensitive outcome measure in research	[nursing-sensitive outcome measures in research]	0.0	5	1	1	1
19863	361	often contextual factor	[often contextual factors]	0.0	3	1	1	1
19864	361	Statewide Health	[Statewide Health]	0.0	2	1	1	1
19865	361	mitral annulus velocity during systole	[mitral annulus velocities during systole]	0.0	5	1	1	1
19866	361	systolic strain as a predictor	[systolic strain as a predictor]	0.0	5	1	1	1
19867	361	include hypertrophy	[including hypertrophy]	0.0	2	1	1	1
19868	361	exercise-induced pulmonary artery pressure increase	[exercise-induced pulmonary artery pressure increase]	0.0	5	1	1	1
19869	361	impact of qrs morphology	[impact of QRS morphology]	0.0	4	1	1	1
19870	361	cost related	[costs related]	0.0	2	1	1	1
19871	361	efficacy of therapeutic interatrial shunting	[efficacy of therapeutic interatrial shunting]	0.0	5	1	1	1
19872	361	early change in the development	[early changes in the development]	0.0	5	1	1	1
19873	361	cardiomyopathic restriction	[cardiomyopathic restriction]	0.0	2	1	1	1
19874	361	80 mm	[80 mm]	0.0	2	1	1	1
19875	361	effectiveness of spironolactone for heart failure	[Effectiveness of spironolactone for heart failure]	0.0	6	1	1	1
19876	361	agent in patient with anemia	[agents in patients with anemia]	0.0	5	1	1	1
19877	361	potentiate the adaptive response	[potentiating the adaptive response]	0.0	4	1	1	1
19878	361	cause a physiology	[causing a physiology]	0.0	3	1	1	1
19879	361	association between renal dysfunction	[association between renal dysfunction]	0.0	4	1	1	1
19880	361	important trigger of acute infarction	[important trigger of acute infarction]	0.0	5	1	1	1
19881	361	patient with HFPEF	[patients with HFPEF]	0.0	3	1	1	1
19882	361	Genetic susceptibility in survivor	[Genetic susceptibility in survivors]	0.0	4	1	1	1
19883	361	pre-defined inclusion criterion	[pre-defined inclusion criteria]	0.0	3	1	1	1
19884	361	standard rehabilitation care on capacity	[standard rehabilitation care on capacity]	0.0	5	1	1	1
19885	361	100 participant mean	[100 participants mean]	0.0	3	1	1	1
19886	361	hand grip strength kg	[hand grip strength kg]	0.0	4	1	1	1
19887	361	cabg	[CABG]	0.0	1	1	1	1
19888	361	novel antiadrenergic strategy	[novel antiadrenergic strategy]	0.0	3	1	1	1
19889	361	high readmission rate	[higher readmission rates]	0.0	3	1	1	1
19890	361	af type	[AF type]	0.0	2	1	1	1
19891	361	encode nonfunctional channel	[encoding nonfunctional channels]	0.0	3	1	1	1
19892	361	N-terminal proBNP proanp	[N-terminal proBNP proANP]	0.0	3	1	1	1
19893	361	hno donor	[HNO donor]	0.0	2	1	1	1
19894	361	concentric remodeling	[concentric remodeling]	0.0	2	1	1	1
19895	361	time of second HF	[time of second HF]	0.0	4	1	1	1
19896	361	Sudden death	[Sudden death]	0.0	2	1	1	1
19897	361	NCDR	[NCDR]	0.0	1	1	1	1
19898	361	Medicare 30-day readmission cms	[Medicare 30-day readmission CMS]	0.0	4	1	1	1
19899	361	bmi-matched volunteer	[BMI-matched volunteers]	0.0	2	1	1	1
19900	361	half of patient	[Half of patients]	0.0	3	1	1	1
19901	361	onset of HF	[onset of HF]	0.0	3	1	1	1
19902	361	idiopathic-dilated cardiomyopathy	[idiopathic-dilated cardiomyopathy]	0.0	2	1	1	1
19903	361	vivo assessment of function	[vivo assessment of function]	0.0	4	1	1	1
19904	361	approach for the treatment	[approach for the treatment]	0.0	4	1	1	1
19905	361	2 g-protein-coupled receptor	[2 G-protein-coupled receptors]	0.0	3	1	1	1
19906	361	patient IL	[patients IL]	0.0	2	1	1	1
19907	361	occur within day of acs consultation	[occurring within days of ACS consultation]	0.0	6	1	1	1
19908	361	156 consent HF patient ejection fraction	[156 consenting HF patients ejection fraction]	0.0	6	1	1	1
19909	361	multivariate Cox hazard regression modeling	[multivariate Cox hazards regression modeling]	0.0	5	1	1	1
19910	361	use in practice	[use in practice]	0.0	3	1	1	1
19911	361	patient with HFrEF	[patients with HFrEF]	0.0	3	2	2	1
19912	361	N-terminal proBNP NT-proBNP proanp	[N-terminal proBNP NT-proBNP proANP]	0.0	4	1	1	1
19913	361	left ventricular end diameter mm	[left ventricular end diameter mm]	0.0	5	1	1	1
19914	361	0 day after MI	[0 days after MI]	0.0	4	1	1	1
19915	361	Health Insurance	[Health Insurance]	0.0	2	1	1	1
19916	361	dose of β-blocker	[doses of β-blocker]	0.0	3	1	1	1
19917	361	fulfil World Health Organization criterion	[fulfilling World Health Organization criteria]	0.0	5	1	1	1
19918	361	reversal	[reversal]	0.0	1	2	2	1
19919	361	detect early fibrosis	[detecting early fibrosis]	0.0	3	1	1	1
19920	361	pharmacological treatment treatment	[Pharmacological treatment treatment]	0.0	3	1	1	1
19921	361	incident HF in participant aged year	[incident HF in participants aged years]	0.0	6	1	1	1
19922	361	role determine the remodelling	[role determining the remodelling]	0.0	4	1	1	1
19923	361	mitochondrial metabolism	[mitochondrial metabolism]	0.0	2	1	1	1
19924	361	dopamine in acute heart failure	[dopamine in acute heart failure]	0.0	5	1	1	1
19925	361	patient with arterial hypertension	[patients with arterial hypertension]	0.0	4	1	1	1
19926	361	mitral valve plasty for regurgitation	[mitral valve plasty for regurgitation]	0.0	5	1	1	1
19927	361	hfpef patient aged 69 year	[HFpEF patients aged 69 years]	0.0	5	1	1	1
19928	361	bnp measurement	[BNP measurements]	0.0	2	1	1	1
19929	361	saxagliptin user	[saxagliptin users]	0.0	2	1	1	1
19930	361	population-specific health intervention	[population-specific health interventions]	0.0	3	1	1	1
19931	361	Society guideline definition of HFPEF	[Society guidelines definition of HFPEF]	0.0	5	1	1	1
19932	361	short-form quality	[Short-Form quality]	0.0	2	1	1	1
19933	361	current climate	[current climate]	0.0	2	1	1	1
19934	361	ischemic heart failure	[ischemic heart failure]	0.0	3	1	1	1
19935	361	β-blocker therapy for treatment	[β-blockers therapy for treatment]	0.0	4	1	1	1
19936	361	global attenuation of tac-induced alteration	[global attenuation of TAC-induced alterations]	0.0	5	1	1	1
19937	361	outcome measure in future research	[outcome measures in future research]	0.0	5	1	1	1
19938	361	3000 patient with onset af	[3,000 patients with onset AF]	0.0	5	1	1	1
19939	361	affair HF clinic 106 outcome	[Affairs HF clinic 106 outcomes]	0.0	5	1	1	1
19940	361	CV event in fibrillation AF	[CV events in fibrillation AF]	0.0	5	1	1	1
19941	361	long management	[long-term management]	0.0	2	1	1	1
19942	361	validation study	[Validation studies]	0.0	2	1	1	1
19943	361	paucity of datum	[paucity of data]	0.0	3	1	1	1
19944	361	hazard ratio 0.521	[hazard ratio 0.521]	0.0	3	1	1	1
19945	361	data describe trend after MI	[Data describing trends after MI]	0.0	5	1	1	1
19946	361	42 percent relative reduction	[42 percent relative reduction]	0.0	4	1	1	1
19947	361	target specific effector molecule	[targeting specific effector molecules]	0.0	4	1	1	1
19948	361	systolic dysfunction by week	[systolic dysfunction by weeks]	0.0	4	1	1	1
19949	361	Society guideline	[Society guidelines]	0.0	2	1	1	1
19950	361	promote transcriptional pause release during stress	[promoting transcriptional pause release during stress]	0.0	6	1	1	1
19951	361	HF guideline	[HF guidelines]	0.0	2	1	1	1
19952	361	38 control CHF	[38 controls CHF]	0.0	3	1	1	1
19953	361	open chest model	[open chest model]	0.0	3	1	1	1
19954	361	patient a Trial hf-action	[patients A Trial HF-ACTION]	0.0	4	1	1	1
19955	361	effect from exercise training	[effects from exercise training]	0.0	4	1	1	1
19956	361	predict 4-year survival	[predicting 4-year survival]	0.0	3	1	1	1
19957	361	severe frailty	[severe frailty]	0.0	2	1	1	1
19958	361	receive PD solely	[receiving PD solely]	0.0	3	1	1	1
19959	361	study of therapeutics include agent	[studies of therapeutics including agents]	0.0	5	1	1	1
19960	361	sarcomere	[sarcomere]	0.0	1	1	1	1
19961	361	example antagonize β-ar drive	[example antagonizing β-AR drive]	0.0	4	1	1	1
19962	361	valve cause a physiology	[valve causing a physiology]	0.0	4	1	1	1
19963	361	action on adenylyl cyclase	[actions on adenylyl cyclase]	0.0	4	1	1	1
19964	361	HF hospitalization hr CI 1.27	[HF hospitalization HR CI 1.27]	0.0	5	1	1	1
19965	361	scenario of total expenditure	[scenario of total expenditure]	0.0	4	1	1	1
19966	361	receive methotrexate	[receiving methotrexate]	0.0	2	1	1	1
19967	361	shortness of breath	[Shortness of Breath]	0.0	3	1	1	1
19968	361	low co-morbidity burden	[low co-morbidity burden]	0.0	3	1	1	1
19969	361	result in the ivabradine-treated patient	[resulting in the ivabradine-treated patients]	0.0	5	1	1	1
19970	361	same time period	[same time period]	0.0	3	1	1	1
19971	361	one hundred patient	[One hundred patients]	0.0	3	1	1	1
19972	361	office-based emergency room practice	[office-based emergency room practice]	0.0	4	1	1	1
19973	361	association with diet score	[association with diet scores]	0.0	4	1	1	1
19974	361	inpatient	[inpatient]	0.0	1	1	1	1
19975	361	ans	[ANS]	0.0	1	1	1	1
19976	361	current knowledge of abnormality	[current knowledge of abnormalities]	0.0	4	1	1	1
19977	361	phospholipase a2 lp-pla2	[phospholipase A2 Lp-PLA2]	0.0	3	1	1	1
19978	361	HeartMate assist system LVAS	[HeartMate assist system LVAS]	0.0	4	1	1	1
19979	361	comment in heart failure	[Comments in heart failure]	0.0	4	1	1	1
19980	361	multicenter placebo-controlled trial of 360 patient	[Multicenter placebo-controlled trial of 360 patients]	0.0	6	1	1	1
19981	361	adverse impact	[adverse impact]	0.0	2	1	1	1
19982	361	Medicare readmission cms	[Medicare readmission CMS]	0.0	3	1	1	1
19983	361	measure of left mechanic	[measure of left mechanics]	0.0	4	1	1	1
19984	361	disease model	[disease model]	0.0	2	1	1	1
19985	361	51 year	[51 years]	0.0	2	1	1	1
19986	361	blood-flow path	[blood-flow paths]	0.0	2	1	1	1
19987	361	Clinical characteristic	[Clinical characteristics]	0.0	2	1	1	1
19988	361	development of therapeutic strategy	[development of therapeutic strategies]	0.0	4	1	1	1
19989	361	low blood pressure	[lower blood pressure]	0.0	3	1	1	1
19990	361	dapc protein level	[DAPC protein levels]	0.0	3	1	1	1
19991	361	permanent breathing	[permanent breathing]	0.0	2	1	1	1
19992	361	approach improve the prognosis	[approaches improving the prognosis]	0.0	4	1	1	1
19993	361	practical recommendation	[practical Recommendations]	0.0	2	1	1	1
19994	361	primary culprit	[primary culprit]	0.0	2	1	1	1
19995	361	prognostic information for a outcome	[prognostic information for an outcome]	0.0	5	1	1	1
19996	361	resort	[resort]	0.0	1	1	1	1
19997	361	SkM muscle structure	[SkM muscle structure]	0.0	3	1	1	1
19998	361	importance of diastolic dysfunction	[importance of diastolic dysfunction]	0.0	4	1	1	1
19999	361	treatment current treatment	[treatment current treatment]	0.0	3	1	1	1
20000	361	frailty for heart failure the health	[Frailty for heart failure the health]	0.0	6	1	1	1
20001	361	survival through 4 year	[survival through 4 years]	0.0	4	1	1	1
20002	361	Left ejection time	[Left ejection time]	0.0	3	1	1	1
20003	361	Practice Guideline	[Practice Guideline]	0.0	2	1	1	1
20004	361	early clinical outcome	[early clinical outcomes]	0.0	3	1	1	1
20005	361	exercise capacity in obese old patient	[exercise capacity in obese older patients]	0.0	6	1	1	1
20006	361	value of threshold	[value of threshold]	0.0	3	1	1	1
20007	361	advanced stage	[advanced stages]	0.0	2	1	1	1
20008	361	datum among group	[data among groups]	0.0	3	1	1	1
20009	361	young age group	[youngest age group]	0.0	3	1	1	1
20010	361	Cardiac resonance t1 time	[Cardiac resonance T1 time]	0.0	4	1	1	1
20011	361	mortality among this subgroup	[mortality among these subgroups]	0.0	4	1	1	1
20012	361	novel porcine model	[novel porcine model]	0.0	3	1	1	1
20013	361	HeartMate 3 assist system LVAS	[HeartMate 3 assist system LVAS]	0.0	5	1	1	1
20014	361	follow-up time	[follow-up times]	0.0	2	1	1	1
20015	361	echocardiographic guidance under anaesthesia	[echocardiographic guidance under anaesthesia]	0.0	4	1	1	1
20016	361	psoriasis systemic ultra-violet treatment	[psoriasis systemic UV treatment]	0.0	4	1	1	1
20017	361	10 HF patient hfvt(-)	[10 HF patients HFVT(-)]	0.0	4	1	1	1
20018	361	after revascularization	[After revascularization]	0.0	2	1	1	1
20019	361	minute walking	[minutes walking]	0.0	2	1	1	1
20020	361	reduction of cardiac na	[reduction of cardiac Na]	0.0	4	1	1	1
20021	361	epithelial transition marker	[epithelial transition markers]	0.0	3	1	1	1
20022	361	asymptomatic pediatric Fontan patient	[asymptomatic pediatric Fontan patients]	0.0	4	1	1	1
20023	361	trend in event rate between 2005	[trends in event rates between 2005]	0.0	6	1	1	1
20024	361	N form	[N forms]	0.0	2	1	1	1
20025	361	more datum regard the role	[more data regarding the role]	0.0	5	1	1	1
20026	361	78 saxagliptin user	[78 saxagliptin users]	0.0	3	1	1	1
20027	361	early metabolic change in the development	[early metabolic changes in the development]	0.0	6	1	1	1
20028	361	adenosine monophosphate camp	[adenosine monophosphate cAMP]	0.0	3	1	1	1
20029	361	calf	[calf]	0.0	1	1	1	1
20030	361	confirmatory factor analysis	[confirmatory factor analysis]	0.0	3	1	1	1
20031	361	possible mechanism	[possible mechanism]	0.0	2	1	1	1
20032	361	hvad device	[HVAD devices]	0.0	2	1	1	1
20033	361	activate cardiac remodelling	[activating cardiac remodelling]	0.0	3	1	1	1
20034	361	beta blockade	[beta blockade]	0.0	2	1	1	1
20035	361	patient characteristic	[patient characteristics]	0.0	2	1	1	1
20036	361	stable severe HF	[stable severe HF]	0.0	3	1	1	1
20037	361	7-day visit	[7-day visits]	0.0	2	1	1	1
20038	361	neutral result in HF trial	[neutral results in HF trials]	0.0	5	1	1	1
20039	361	global proteomics change in constriction	[global proteomics changes in constriction]	0.0	5	1	1	1
20040	361	underlying characteristic use Cochrane Practice	[underlying characteristics using Cochrane Practice]	0.0	5	1	1	1
20041	361	mri-based model of nonfailing canine electromechanic	[MRI-based models of nonfailing canine electromechanics]	0.0	6	1	1	1
20042	361	delay VVD	[delay VVD]	0.0	2	1	1	1
20043	361	regulation in mouse heart	[regulation in mouse hearts]	0.0	4	1	1	1
20044	361	blood cell transfusion strategy	[blood cell transfusion strategy]	0.0	4	1	1	1
20045	361	consecutive patient with pad	[consecutive patients with PAD]	0.0	4	1	1	1
20046	361	statistic	[statistics]	0.0	1	1	1	1
20047	361	Nitroxyl	[Nitroxyl]	0.0	1	1	1	1
20048	361	Advanced HF a Multicenter Study	[Advanced HF A Multicenter Study]	0.0	5	1	1	1
20049	361	detect fill pressure	[detecting filling pressures]	0.0	3	1	1	1
20050	361	normal reference mean	[normal reference mean]	0.0	3	1	1	1
20051	361	8-fluo-cAMP binding	[8-fluo-cAMP binding]	0.0	2	1	1	1
20052	361	comparison statistically significant	[comparisons statistically significant]	0.0	3	1	1	1
20053	361	volunteer	[volunteers]	0.0	1	1	1	1
20054	361	B-type	[B-type]	0.0	1	1	1	1
20055	361	ventricular RV plane excursion	[ventricular RV plane excursion]	0.0	4	1	1	1
20056	361	Health Planning	[Health Planning]	0.0	2	1	1	1
20057	361	unadjusted prescription rate	[unadjusted prescription rates]	0.0	3	1	1	1
20058	361	risk predictor for sudden death	[risk predictor for sudden death]	0.0	5	1	1	1
20059	361	potential efficacy of interatrial shunting	[potential efficacy of interatrial shunting]	0.0	5	1	1	1
20060	361	such as time-domain measure	[such as time-domain measures]	0.0	4	1	1	1
20061	361	compare b-treated	[comparing B-treated]	0.0	2	1	1	1
20062	361	reduction of outflow	[reduction of outflow]	0.0	3	1	1	1
20063	361	common consensus	[common consensus]	0.0	2	1	1	1
20064	361	n=44 925 ed visit	[n=44 925 ED visits]	0.0	4	1	1	1
20065	361	prognostic power of measure	[prognostic power of measures]	0.0	4	1	1	1
20066	361	information for a clinical outcome	[information for an clinical outcome]	0.0	5	1	1	1
20067	361	p 0.01	[P 0.01]	0.0	2	1	1	1
20068	361	fail Fontan circulation	[failing Fontan circulation]	0.0	3	1	1	1
20069	361	cardiomyopathy in Tuscany	[cardiomyopathy in Tuscany]	0.0	3	1	1	1
20070	361	modern heart failure study	[modern heart failure studies]	0.0	4	1	1	1
20071	361	common cause	[common cause]	0.0	2	3	3	1
20072	361	basal contractility	[basal contractility]	0.0	2	1	1	1
20073	361	center in the State	[centers in the States]	0.0	4	1	1	1
20074	361	pre-participation screen of athlete	[pre-participation screening of athletes]	0.0	4	1	1	1
20075	361	problem of current cardiology	[problem of current cardiology]	0.0	4	1	1	1
20076	361	clinical trial registry	[clinical trial registries]	0.0	3	1	1	1
20077	361	significant lesion	[significant lesions]	0.0	2	1	1	1
20078	361	evidence for the treatment	[evidence for the treatment]	0.0	4	1	1	1
20079	361	ventricular end-diastolic pressure	[ventricular end-diastolic pressure]	0.0	3	1	1	1
20080	361	even low volume	[even lower volumes]	0.0	3	1	1	1
20081	361	key role of ERK1 scaffold	[Key role of ERK1 scaffolds]	0.0	5	1	1	1
20082	361	Rankin	[Rankin]	0.0	1	1	1	1
20083	361	simple ecg parameter	[simple ECG parameters]	0.0	3	1	1	1
20084	361	cell nitric oxide production	[cell nitric oxide production]	0.0	4	1	1	1
20085	361	receive drug for heart failure	[receiving drugs for heart failure]	0.0	5	1	1	1
20086	361	only after week of pacing	[only after weeks of pacing]	0.0	5	1	1	1
20087	361	myocardial fibrosis	[myocardial fibrosis]	0.0	2	1	1	1
20088	361	right pressure overload	[right pressure overload]	0.0	3	1	1	1
20089	361	other drug	[Other Drugs]	0.0	2	1	1	1
20090	361	Effect of pacing on heart twist	[Effects of pacing on heart twist]	0.0	6	1	1	1
20091	361	final model	[final models]	0.0	2	1	1	1
20092	361	other medical staff responsible	[other medical staff responsible]	0.0	4	1	1	1
20093	361	patient as control without exercise	[patients as control without exercise]	0.0	5	1	1	1
20094	361	restore functional capacity	[restoring functional capacity]	0.0	3	1	1	1
20095	361	obese zsf1 with diet	[obese ZSF1 with diet]	0.0	4	1	1	1
20096	361	left ventricular dyssynchrony	[left ventricular dyssynchrony]	0.0	3	1	1	1
20097	361	contemporary heart failure	[Contemporary heart failure]	0.0	3	1	1	1
20098	361	only the ZSF1 group	[Only the ZSF1 groups]	0.0	4	1	1	1
20099	361	Specific signalling pathway	[Specific signalling pathways]	0.0	3	1	1	1
20100	361	diuretic effect	[diuretic effect]	0.0	2	1	1	1
20101	361	left biopsy n=9	[left biopsies n=9]	0.0	3	1	1	1
20102	361	e-wave mitral velocity ratio	[E-wave mitral velocity ratio]	0.0	4	1	1	1
20103	361	practitioner in emergency room practice	[practitioners in emergency room practice]	0.0	5	1	1	1
20104	361	maintain sinus rhythm	[maintaining sinus rhythm]	0.0	3	1	1	1
20105	361	possible reason for the reduction	[Possible reasons for the reduction]	0.0	5	1	1	1
20106	361	system major neurological event	[system major neurological events]	0.0	4	1	1	1
20107	361	investigation of apoptosis	[Investigation of apoptosis]	0.0	3	1	1	1
20108	361	increase in exercise capacity	[increase in exercise capacity]	0.0	4	1	1	1
20109	361	Wistar-Kyoto	[Wistar-Kyoto]	0.0	1	1	1	1
20110	361	relationship between tapse	[relationship between TAPSE]	0.0	3	1	1	1
20111	361	function WRF in EMPHASIS-HF	[function WRF in EMPHASIS-HF]	0.0	4	1	1	1
20112	361	contribution of cad	[contribution of CAD]	0.0	3	1	1	1
20113	361	extracellular matrix accumulation	[extracellular matrix accumulation]	0.0	3	1	1	1
20114	361	nmol ng	[nmol ng]	0.0	2	1	1	1
20115	361	infarction AMI with complication	[infarction AMI with complications]	0.0	4	1	1	1
20116	361	hypertension of 104 mm hg	[hypertension of 104 mm Hg]	0.0	5	1	1	1
20117	361	independent marker hazard ratio for peak	[independent markers hazard ratio for peak]	0.0	6	1	1	1
20118	361	16 patient HDL before et	[16 patients HDL before ET]	0.0	5	1	1	1
20119	361	effect of autonomic system modulation	[effect of autonomic system modulation]	0.0	5	1	1	1
20120	361	factor on physician adherence	[factors on physician adherence]	0.0	4	1	1	1
20121	361	therapy cardiogenic shock	[therapy cardiogenic shock]	0.0	3	1	1	1
20122	361	kidney 293 cell	[kidney 293 cells]	0.0	3	1	1	1
20123	361	4 sample	[4 samples]	0.0	2	1	1	1
20124	361	study end point oxygen uptake	[study end point oxygen uptake]	0.0	5	1	1	1
20125	361	key enzyme lyso-paf acetyltransferase	[key enzymes lyso-PAF acetyltransferase]	0.0	4	1	1	1
20126	361	detailed transcriptional analysis of cardiac tissue	[Detailed transcriptional analysis of cardiac tissue]	0.0	6	1	1	1
20127	361	intracellular antiadrenergic therapeutic strategy	[intracellular antiadrenergic therapeutic strategy]	0.0	4	1	1	1
20128	361	optimize progenitor function	[optimizing progenitor function]	0.0	3	1	1	1
20129	361	left ejection fraction LVEF	[left ejection fraction LVEF]	0.0	4	1	1	1
20130	361	mitral annular velocity 3.1	[mitral annular velocity 3.1]	0.0	4	1	1	1
20131	361	patient with rest hr	[patients with resting HR]	0.0	4	1	1	1
20132	361	signed-rank	[signed-rank]	0.0	1	1	1	1
20133	361	hospital discharge in patient	[hospital discharge in patients]	0.0	4	1	1	1
20134	361	Left ejection time in heart failure	[Left ejection time in heart failure]	0.0	6	1	1	1
20135	361	outcome in patient with HFrEF	[outcome in patients with HFrEF]	0.0	5	1	1	1
20136	361	other medication	[other medications]	0.0	2	1	1	1
20137	361	Global left strain	[Global left strain]	0.0	3	1	1	1
20138	361	outcome assessment trial	[outcome assessment trial]	0.0	3	1	1	1
20139	361	event rate for acute infarction	[event rates for acute infarction]	0.0	5	1	1	1
20140	361	department of cardiology	[Department of cardiology]	0.0	3	1	1	1
20141	361	asymptomatic pediatric Fontan PF patient	[asymptomatic pediatric Fontan PF patients]	0.0	5	1	1	1
20142	361	package	[packages]	0.0	1	1	1	1
20143	361	8 wk	[8 wk]	0.0	2	1	1	1
20144	361	24-hour systolic pressure	[24-hour systolic pressure]	0.0	3	1	1	1
20145	361	refill compliance for etidronate	[refill compliance for etidronate]	0.0	4	1	1	1
20146	361	right ventricular end-diastolic area index	[right ventricular end-diastolic area index]	0.0	5	1	1	1
20147	361	new-onset ai require intervention	[new-onset AI requiring intervention]	0.0	4	1	1	1
20148	361	odd die in day	[odds dying in days]	0.0	4	1	1	1
20149	361	predictor of mortality in heart failure	[predictors of mortality in heart failure]	0.0	6	1	1	1
20150	361	transfer	[transfer]	0.0	1	2	2	1
20151	361	provide care	[providing care]	0.0	2	1	1	1
20152	361	administration of doxorubicin	[administration of doxorubicin]	0.0	3	1	1	1
20153	361	grade strong recommendation evidence	[Grade strong recommendation evidence]	0.0	4	1	1	1
20154	361	elastance ea end-systolic elastance	[elastance Ea end-systolic elastance]	0.0	4	1	1	1
20155	361	microrna new target in disease management	[MicroRNAs new targets in disease management]	0.0	6	1	1	1
20156	361	abnormality of the heart	[abnormalities of the heart]	0.0	4	1	1	1
20157	361	cost savings	[cost savings]	0.0	2	1	1	1
20158	361	perturbation in component of the dapc	[perturbations in components of the DAPC]	0.0	6	1	1	1
20159	361	copd n=95	[COPD n=95]	0.0	2	1	1	1
20160	361	little influence on the financial burden	[little influence on the financial burden]	0.0	6	1	1	1
20161	361	2 independent hypothese addition	[2 independent hypotheses addition]	0.0	4	1	1	1
20162	361	nt-probnp cutoff point predict survival	[NT-proBNP cutoff point predicting survival]	0.0	5	1	1	1
20163	361	correction after ventricular assist device implantation	[correction after ventricular assist device implantation]	0.0	6	1	1	1
20164	361	creatine kinase	[creatine kinase]	0.0	2	1	1	1
20165	361	new understanding	[new understanding]	0.0	2	1	1	1
20166	361	variation in future mortality	[variation in future mortality]	0.0	4	1	1	1
20167	361	noninvasive surrogate	[noninvasive surrogates]	0.0	2	1	1	1
20168	361	skeletal muscle sarcomere structure	[skeletal muscle sarcomere structure]	0.0	4	1	1	1
20169	361	telehealth system	[telehealth system]	0.0	2	1	1	1
20170	361	sandwich	[sandwich]	0.0	1	1	1	1
20171	361	adult mouse myocyte	[adult mouse myocytes]	0.0	3	1	1	1
20172	361	few admission	[fewer admissions]	0.0	2	1	1	1
20173	361	statitistical significance	[statitistical significance]	0.0	2	1	1	1
20174	361	therapy in this patient	[therapies in these patients]	0.0	4	1	1	1
20175	361	denervation DNx	[denervation DNx]	0.0	2	1	1	1
20176	361	arginine vasopressin	[arginine vasopressin]	0.0	2	1	1	1
20177	361	administration in rat	[administration in rats]	0.0	3	1	1	1
20178	361	significant improvement between baseline exercise capacity	[significant improvement between baseline exercise capacity]	0.0	6	1	1	1
20179	361	carry increase	[carrying increase]	0.0	2	1	1	1
20180	361	end-stage HF	[end-stage HF]	0.0	2	1	1	1
20181	361	Mini-Sentinel	[Mini-Sentinel]	0.0	1	1	1	1
20182	361	reveal a fundamental mechanism of dysfunction	[revealing a fundamental mechanism of dysfunction]	0.0	6	1	1	1
20183	361	association among fitness CRF	[associations among fitness CRF]	0.0	4	1	1	1
20184	361	low vascular resistance index	[low vascular resistance index]	0.0	4	1	1	1
20185	361	specifically on cardiomyopathy	[specifically on cardiomyopathy]	0.0	3	1	1	1
20186	361	camp hydrolytic activity	[cAMP hydrolytic activity]	0.0	3	1	1	1
20187	361	global left longitudinal strain GLS	[global left longitudinal strain GLS]	0.0	5	1	1	1
20188	361	abnormal cardiac t2	[Abnormal cardiac T2]	0.0	3	1	1	1
20189	361	infarct	[infarct]	0.0	1	1	1	1
20190	361	enhancement imaging	[enhancement imaging]	0.0	2	1	1	1
20191	361	clinical sign	[clinical signs]	0.0	2	1	1	1
20192	361	multicenter trial with 8000 individual	[multicenter trial with 8000 individuals]	0.0	5	1	1	1
20193	361	adverse cardiovascular CV event	[adverse cardiovascular CV events]	0.0	4	1	1	1
20194	361	event p=0.001	[events P=0.001]	0.0	2	1	1	1
20195	361	improve outcome in patient	[Improving outcomes in patients]	0.0	4	1	1	1
20196	361	quality measure for inpatient medical condition	[quality measures for inpatient medical conditions]	0.0	6	1	1	1
20197	361	AAs	[AAs]	0.0	1	1	1	1
20198	361	trend with less severe dilatation	[trend with less severe dilatation]	0.0	5	1	1	1
20199	361	key regulator of actin dynamic	[key regulator of actin dynamics]	0.0	5	1	1	1
20200	361	20812 patient with myocardial infarction	[20,812 patients with myocardial infarction]	0.0	5	1	1	1
20201	361	cardiology-cardiovascular surgery	[Cardiology-Cardiovascular Surgery]	0.0	2	1	1	1
20202	361	patient 48	[patients 48]	0.0	2	1	1	1
20203	361	individual association	[individual associations]	0.0	2	1	1	1
20204	361	ACC	[ACC]	0.0	1	1	1	1
20205	361	involve adult	[involving adults]	0.0	2	1	1	1
20206	361	phosphorylation at eNOS-Thr	[phosphorylation at eNOS-Thr]	0.0	3	1	1	1
20207	361	right ventricular support	[right ventricular support]	0.0	3	1	1	1
20208	361	2.1 17.6 millileter p=0.01	[2.1 17.6 mL P=0.01]	0.0	4	1	1	1
20209	361	decrease in septum systolic thickness	[decreases in septum systolic thickness]	0.0	5	1	1	1
20210	361	ejection time in acute heart failure	[ejection time in acute heart failure]	0.0	6	1	1	1
20211	361	protocol-driven poc testing	[protocol-driven POC testing]	0.0	3	1	1	1
20212	361	renal optimization	[Renal Optimization]	0.0	2	1	1	1
20213	361	type of beta-blocker	[types of beta-blockers]	0.0	3	1	1	1
20214	361	prior disease	[prior disease]	0.0	2	1	1	1
20215	361	cardiac t2	[cardiac T2]	0.0	2	1	1	1
20216	361	correlation of index	[correlation of indices]	0.0	3	1	1	1
20217	361	reduction in increase	[reduction in increase]	0.0	3	1	1	1
20218	361	American College ACC	[American College ACC]	0.0	3	1	1	1
20219	361	oral dosage prior HF hospitalisation	[oral dosage prior HF hospitalisations]	0.0	5	1	1	1
20220	361	Main etiology of HF	[Main etiologies of HF]	0.0	4	1	1	1
20221	361	more hypertension	[more hypertension]	0.0	2	1	1	1
20222	361	similar ventricular tissue	[similar ventricular tissue]	0.0	3	1	1	1
20223	361	pilot trial	[pilot trial]	0.0	2	1	1	1
20224	361	Age-dependent effect of left ejection fraction	[Age-dependent effect of left ejection fraction]	0.0	6	1	1	1
20225	361	prognostic indicator in heart failure	[prognostic indicator in heart failure]	0.0	5	1	1	1
20226	361	excitation-contraction ec	[excitation-contraction EC]	0.0	2	1	1	1
20227	361	3 economic evaluation	[3 economic evaluations]	0.0	3	1	1	1
20228	361	ED visit	[ED visits]	0.0	2	1	1	1
20229	361	nonstandardized pro-b-type peptide	[nonstandardized pro-B-type peptide]	0.0	3	1	1	1
20230	361	American College ACP	[American College ACP]	0.0	3	1	1	1
20231	361	rate potassium	[rates potassium]	0.0	2	1	1	1
20232	361	stable guideline-directed therapy	[stable guideline-directed therapy]	0.0	3	1	1	1
20233	361	multicenter placebo-controlled trial optimization strategy evaluation	[Multicenter placebo-controlled trial Optimization Strategies Evaluation]	0.0	6	1	1	1
20234	361	isolated heart rate hr reduction	[isolated heart rate HR reduction]	0.0	5	1	1	1
20235	361	156 ambulatory HF patient	[156 ambulatory HF patients]	0.0	4	1	1	1
20236	361	ventricular-arterial coupling in hfpef	[ventricular-arterial coupling in HFPEF]	0.0	4	1	1	1
20237	361	retrospective study	[retrospective studies]	0.0	2	1	1	1
20238	361	pure HNO donor	[pure HNO donor]	0.0	3	1	1	1
20239	361	retrospective chart review	[retrospective chart review]	0.0	3	1	1	1
20240	361	regulatory	[regulatory]	0.0	1	1	1	1
20241	361	spironolactone in practice	[spironolactone in practice]	0.0	3	1	1	1
20242	361	hand grip strength kg versus kg	[hand grip strength kg vs kg]	0.0	6	1	1	1
20243	361	human kidney 293 cell	[human kidney 293 cells]	0.0	4	1	1	1
20244	361	arterial pressure relationship in heart failure	[arterial pressure relationship in heart failure]	0.0	6	1	1	1
20245	361	acute ischemic right heart failure	[acute ischemic right heart failure]	0.0	5	1	1	1
20246	361	63 predictor on ICD patient	[63 predictors on ICD patients]	0.0	5	1	1	1
20247	361	measure of quality	[measures of quality]	0.0	3	1	1	1
20248	361	non-biological disease modify drug	[non-biological disease modifying drug]	0.0	4	1	1	1
20249	361	early measurement	[early measurement]	0.0	2	1	1	1
20250	361	surgery patient	[surgery patients]	0.0	2	1	1	1
20251	361	proximal anterior descending lad	[proximal anterior descending LAD]	0.0	4	1	1	1
20252	361	consecutive 74 patient	[consecutive 74 patients]	0.0	3	1	1	1
20253	361	study of exercise training	[study of exercise training]	0.0	4	1	1	1
20254	361	characteristic use Cochrane Practice	[characteristics using Cochrane Practice]	0.0	4	1	1	1
20255	361	Disease Registry Innovation	[Disease Registry Innovation]	0.0	3	1	1	1
20256	361	inducible ischemia	[inducible ischemia]	0.0	2	1	1	1
20257	361	derangement albeit with limited ability	[derangement albeit with limited ability]	0.0	5	1	1	1
20258	361	study with 1887 patient	[studies with 1887 patients]	0.0	4	1	1	1
20259	361	cardiovascular function with measure	[cardiovascular function with measures]	0.0	4	1	1	1
20260	361	frailty the health	[Frailty the health]	0.0	3	1	1	1
20261	361	amount of malondialdehyde	[amount of malondialdehyde]	0.0	3	1	1	1
20262	361	pg low bnp group	[pg low BNP group]	0.0	4	1	1	1
20263	361	emergency Department ED presentation	[Emergency Department ED presentation]	0.0	4	1	1	1
20264	361	presence with proteolysis	[presence with proteolysis]	0.0	3	1	1	1
20265	361	potentially beneficial new approach	[potentially beneficial new approach]	0.0	4	1	1	1
20266	361	benefit in HF with ejection fraction	[Benefits in HF with ejection fraction]	0.0	6	1	1	1
20267	361	Lokomat® System	[Lokomat® System]	0.0	2	1	1	1
20268	361	mitochondrial	[mitochondrial]	0.0	1	1	1	1
20269	361	relation between dysfunction within month	[Relation between dysfunction within months]	0.0	5	1	1	1
20270	361	Impact of physician continuity on readmission	[Impact of physician continuity on readmission]	0.0	6	1	1	1
20271	361	post-hct	[post-HCT]	0.0	1	1	1	1
20272	361	longitudinal outcome-monitoring phase mean	[longitudinal outcome-monitoring phase mean]	0.0	4	1	1	1
20273	361	cardiac defibrillator	[cardiac defibrillator]	0.0	2	1	1	1
20274	361	significant improvement in rate relative risk	[significant improvement in rate relative risk]	0.0	6	1	1	1
20275	361	change in chromatin structure	[changes in chromatin structure]	0.0	4	1	1	1
20276	361	primary care clinician care	[primary care clinicians caring]	0.0	4	1	1	1
20277	361	factor for deterioration of HFPEF	[factor for deterioration of HFPEF]	0.0	5	1	1	1
20278	361	reason prescribe medication	[Reasons prescribing medications]	0.0	3	1	1	1
20279	361	few cardiac procedure 146	[fewer cardiac procedures 146]	0.0	4	1	1	1
20280	361	LV fractional shortening	[LV fractional shortening]	0.0	3	1	1	1
20281	361	5 patient	[5 patients]	0.0	2	1	1	1
20282	361	'D HF	['D HF]	0.0	2	1	1	1
20283	361	benefit across all study participant	[benefits across all study participants]	0.0	5	1	1	1
20284	361	ventricular HF tissue sample	[ventricular HF tissue samples]	0.0	4	1	1	1
20285	361	fill time	[filling time]	0.0	2	1	1	1
20286	361	prior myocardial n	[prior myocardial n]	0.0	3	1	1	1
20287	361	current Cardiovascular Outcome in Lesion	[current Cardiovascular Outcomes in Lesions]	0.0	5	1	1	1
20288	361	early diastolic mitral annulus velocity	[early diastolic mitral annulus velocity]	0.0	5	1	1	1
20289	361	total cost	[total cost]	0.0	2	1	1	1
20290	361	promote cardiac fill especially in subject	[promoting cardiac filling especially in subjects]	0.0	6	1	1	1
20291	361	sitagliptin for sitagliptin for sitagliptin	[sitagliptin for sitagliptin for sitagliptin]	0.0	5	1	1	1
20292	361	mixed-method study of veteran aged year	[Mixed-methods study of veterans aged years]	0.0	6	1	1	1
20293	361	patient with outcome versus millisecond	[patients with outcome vs milliseconds]	0.0	5	1	1	1
20294	361	carotid body	[carotid bodies]	0.0	2	1	1	1
20295	361	prognostic composite HF index p	[prognostic composite HF index P]	0.0	5	1	1	1
20296	361	difference between number	[difference between numbers]	0.0	3	1	1	1
20297	361	proximal descend artery	[proximal descending artery]	0.0	3	1	1	1
20298	361	precipitate factor for deterioration	[precipitating factor for deterioration]	0.0	4	1	1	1
20299	361	ejection fraction HF-REF	[ejection fraction HF-REF]	0.0	3	1	1	1
20300	361	β-adrenoceptor blockade with esmolol	[β-adrenoceptor blockade with esmolol]	0.0	4	1	1	1
20301	361	few death	[few deaths]	0.0	2	1	1	1
20302	361	outcome rating	[outcome ratings]	0.0	2	2	2	1
20303	361	evaluation at baseline	[evaluations at baseline]	0.0	3	1	1	1
20304	361	regard treatment of old adult	[regarding treatment of older adults]	0.0	5	1	1	1
20305	361	Medical outcome study short-form quality	[Medical Outcomes Study Short-Form quality]	0.0	5	1	1	1
20306	361	biomarker study	[biomarker studies]	0.0	2	1	1	1
20307	361	TAPSE vs. pasp relationship	[TAPSE vs. PASP relationship]	0.0	4	1	1	1
20308	361	outpatient model	[outpatient models]	0.0	2	1	1	1
20309	361	heart dilatation	[heart dilatation]	0.0	2	1	1	1
20310	361	quality-of-life score point vs. 2.1 point	[quality-of-life score points vs. 2.1 points]	0.0	6	1	1	1
20311	361	base during baseline	[base during baseline]	0.0	3	1	1	1
20312	361	aim of this prospective study	[aim of this prospective study]	0.0	5	1	1	1
20313	361	appropriate follow-up	[appropriate follow-up]	0.0	2	1	1	1
20314	361	atp production rate	[ATP production rates]	0.0	3	1	1	1
20315	361	encourage decline	[encouraging declines]	0.0	2	1	1	1
20316	361	402 patient with hfpef normal geometry	[402 patients with HFpEF normal geometry]	0.0	6	1	1	1
20317	361	epigenetic change	[epigenetic changes]	0.0	2	1	1	1
20318	361	impact on health-related quality HRQoL	[impact on health-related quality HRQoL]	0.0	5	1	1	1
20319	361	analysis use medicare datum	[analysis using medicare data]	0.0	4	1	1	1
20320	361	TAPSE	[TAPSE]	0.0	1	2	2	1
20321	361	end-diastolic area index 10.0 cm(2)	[end-diastolic area index 10.0 cm(2)]	0.0	5	1	1	1
20322	361	use simple experimental procedure	[using simple experimental procedures]	0.0	4	1	1	1
20323	361	reduction in hospital length	[reduction in hospital length]	0.0	4	1	1	1
20324	361	ANG	[ANG]	0.0	1	2	2	1
20325	361	forty-six patient	[forty-six patients]	0.0	2	1	1	1
20326	361	use of the system	[use of the systems]	0.0	4	1	1	1
20327	361	hospitalization rate	[hospitalization rates]	0.0	2	1	1	1
20328	361	even in subgroup	[even in subgroups]	0.0	3	1	1	1
20329	361	considerable number	[considerable number]	0.0	2	1	1	1
20330	361	unfavorable outcome median versus millisecond	[unfavorable outcome median vs milliseconds]	0.0	5	1	1	1
20331	361	hemoglobin hgb	[hemoglobin Hgb]	0.0	2	1	1	1
20332	361	2 ecg parameter	[2 ECG parameters]	0.0	3	1	1	1
20333	361	powerful independent predictor	[powerful independent predictor]	0.0	3	1	1	1
20334	361	mass analysis	[mass analysis]	0.0	2	1	1	1
20335	361	Minnesota quality of life	[Minnesota quality of life]	0.0	4	1	1	1
20336	361	pressure gradient of mm hg	[pressure gradient of mm Hg]	0.0	5	3	3	1
20337	361	prognostic relevance of right contractile reserve	[prognostic relevance of right contractile reserve]	0.0	6	1	1	1
20338	361	reduction in lvef respectively	[reductions in LVEF respectively]	0.0	4	1	1	1
20339	361	histone deacetylase	[histone deacetylases]	0.0	2	1	1	1
20340	361	patient with co-morbidity burden	[patients with co-morbidity burden]	0.0	4	1	1	1
20341	361	difference between patient with HF	[differences between patients with HF]	0.0	5	1	1	1
20342	361	common problem with mortality	[common problem with mortality]	0.0	4	1	1	1
20343	361	desensitization	[desensitization]	0.0	1	1	1	1
20344	361	procedure 146	[procedures 146]	0.0	2	1	1	1
20345	361	ninety-three HF patient hfref	[ninety-three HF patients HFrEF]	0.0	4	1	1	1
20346	361	percent body mass	[percent body mass]	0.0	3	1	1	1
20347	361	0.28 millileter	[0.28 mL]	0.0	2	1	1	1
20348	361	value of np assessment	[value of NP assessment]	0.0	4	1	1	1
20349	361	growth factor-β signal	[growth factor-β signaling]	0.0	3	1	1	1
20350	361	cell oxide production	[cell oxide production]	0.0	3	1	1	1
20351	361	predictor of favorable outcome	[predictor of favorable outcome]	0.0	4	1	1	1
20352	361	potentially beneficial approach	[potentially beneficial approach]	0.0	3	1	1	1
20353	361	similar tissue	[similar tissue]	0.0	2	1	1	1
20354	361	improvement in functioning of treatment	[improvements in functioning of treatments]	0.0	5	1	1	1
20355	361	risk in patient with ic	[risk in patients with IC]	0.0	5	1	1	1
20356	361	low mg dose	[low mg dose]	0.0	3	1	1	1
20357	361	three month	[three months]	0.0	2	1	1	1
20358	361	such as scaling exponent	[such as scaling exponent]	0.0	4	1	1	1
20359	361	hdl-induced production	[HDL-induced production]	0.0	2	1	1	1
20360	361	composite end-point of mortality	[composite end-point of mortality]	0.0	4	1	1	1
20361	361	cytotoxic effect	[cytotoxic effect]	0.0	2	1	1	1
20362	361	prognostic dysfunction	[prognostic dysfunction]	0.0	2	1	1	1
20363	361	powerful predictor of outcome	[powerful predictor of outcome]	0.0	4	1	1	1
20364	361	risk of therapy	[risk of therapy]	0.0	3	2	2	1
20365	361	paf-cpt in parallel	[PAF-CPT in parallel]	0.0	3	1	1	1
20366	361	use in patient	[use in patients]	0.0	3	1	1	1
20367	361	alternative for heart failure therapy	[alternative for heart failure therapy]	0.0	5	1	1	1
20368	361	data describe trend	[Data describing trends]	0.0	3	1	1	1
20369	361	change in platelet-activating factor	[changes in platelet-activating factor]	0.0	4	1	1	1
20370	361	224 man mean year	[224 men mean years]	0.0	4	1	1	1
20371	361	vascular resistance index	[vascular resistance index]	0.0	3	1	1	1
20372	361	require lvad	[requiring LVAD]	0.0	2	1	1	1
20373	361	myocardial matrix accumulation	[myocardial matrix accumulation]	0.0	3	1	1	1
20374	361	adenosine monophosphate	[adenosine monophosphate]	0.0	2	1	1	1
20375	361	risk stratification appropriate	[risk stratification appropriate]	0.0	3	1	1	1
20376	361	aggressive treatment with vasodilator	[aggressive treatment with vasodilators]	0.0	4	1	1	1
20377	361	atrial area hazard ratio	[atrial area hazard ratio]	0.0	4	1	1	1
20378	361	right area index cm(2)	[right area index cm(2)]	0.0	4	1	1	1
20379	361	relevance of ventricular contractile reserve	[relevance of ventricular contractile reserve]	0.0	5	1	1	1
20380	361	right ventricular-pulmonary coupling	[right ventricular-pulmonary coupling]	0.0	3	1	1	1
20381	361	brain peptide BNP	[brain peptide BNP]	0.0	3	1	1	1
20382	361	endothelial function in heart failure	[endothelial function in heart failure]	0.0	5	1	1	1
20383	361	recent trial in HF	[recent trials in HF]	0.0	4	1	1	1
20384	361	power analysis	[Power analysis]	0.0	2	1	1	1
20385	361	body composition skinfold thickness	[body composition skinfold thickness]	0.0	4	1	1	1
20386	361	response in cardiac sympathetic activity	[response in cardiac sympathetic activity]	0.0	5	1	1	1
20387	361	feasibility study	[feasibility study]	0.0	2	1	1	1
20388	361	tone result in imbalance	[tone resulting in imbalance]	0.0	4	1	1	1
20389	361	hr 70 bpm p	[HR 70 bpm P]	0.0	4	1	1	1
20390	361	cardiac insulin-resistance by 2 week	[cardiac insulin-resistance by 2 weeks]	0.0	5	1	1	1
20391	361	outcome 0.92 event	[outcomes 0.92 events]	0.0	3	1	1	1
20392	361	anastomosis	[anastomosis]	0.0	1	1	1	1
20393	361	≥1 predictor	[≥1 predictor]	0.0	2	1	1	1
20394	361	significant 42 percent relative reduction	[significant 42 percent relative reduction]	0.0	5	1	1	1
20395	361	human kidney cell	[human kidney cells]	0.0	3	1	1	1
20396	361	large hr reduction	[larger HR reduction]	0.0	3	1	1	1
20397	361	hospital day for participant	[hospital days for participants]	0.0	4	1	1	1
20398	361	reviewer	[reviewers]	0.0	1	2	2	1
20399	361	ng range 18.6	[ng range 18.6]	0.0	3	1	1	1
20400	361	option in refractory heart failure	[option in refractory heart failure]	0.0	5	1	1	1
20401	361	gradient of HF risk	[gradient of HF risk]	0.0	4	1	1	1
20402	361	30-day survival rate	[30-day survival rates]	0.0	3	1	1	1
20403	361	cyclic adenosine monophosphate	[cyclic adenosine monophosphate]	0.0	3	1	1	1
20404	361	0.7 L 2	[0.7 L 2]	0.0	3	1	1	1
20405	361	muscle abnormality in adult	[muscle abnormalities in adults]	0.0	4	1	1	1
20406	361	include mortality	[including mortality]	0.0	2	1	1	1
20407	361	level of social support	[levels of social support]	0.0	4	1	1	1
20408	361	achieve at least a level	[achieving at least a level]	0.0	5	1	1	1
20409	361	hemoglobin threshold	[hemoglobin threshold]	0.0	2	1	1	1
20410	361	addition indicate care	[addition indicating care]	0.0	3	1	1	1
20411	361	overlapping part	[overlapping part]	0.0	2	1	1	1
20412	361	mm hg low pasp	[mm Hg low PASP]	0.0	4	1	1	1
20413	361	factor in heart failure HF	[factor in heart failure HF]	0.0	5	1	1	1
20414	361	behavioural-change intervention in disease	[behavioural-change interventions in disease]	0.0	4	1	1	1
20415	361	scientific literature	[scientific literature]	0.0	2	1	1	1
20416	361	median bnp in woman EF	[median BNP in women EF]	0.0	5	1	1	1
20417	361	measure heart failure care	[Measuring heart failure care]	0.0	4	1	1	1
20418	361	patient with copd	[patients with COPD]	0.0	3	1	1	1
20419	361	1.35 kg	[1.35 kg]	0.0	2	1	1	1
20420	361	cd34	[CD34]	0.0	1	1	1	1
20421	361	approach for the acute treatment	[approach for the acute treatment]	0.0	5	1	1	1
20422	361	characteristic the charm programme Candesartan	[characteristics The CHARM programme Candesartan]	0.0	5	1	1	1
20423	361	consecutive patient age	[consecutive patients age]	0.0	3	1	1	1
20424	361	patient with type diabete	[patients with type diabetes]	0.0	4	1	1	1
20425	361	pre-participation screen	[pre-participation screening]	0.0	2	1	1	1
20426	361	low cost	[lower costs]	0.0	2	1	1	1
20427	361	agent therapy	[agent therapy]	0.0	2	1	1	1
20428	361	epidemiology of heart failure	[Epidemiology of heart failure]	0.0	4	1	1	1
20429	361	natriuretic peptide NPs	[natriuretic peptides NPs]	0.0	3	1	1	1
20430	361	interquartile range 22.8	[interquartile range 22.8]	0.0	3	1	1	1
20431	361	relation with commissioning	[relation with commissioning]	0.0	3	1	1	1
20432	361	start after week	[start After weeks]	0.0	3	1	1	1
20433	361	absence of fibrillation	[absence of fibrillation]	0.0	3	1	1	1
20434	361	class cpg recommendation	[class CPG recommendations]	0.0	3	1	1	1
20435	361	favour in the pathogenesis	[favour in the pathogenesis]	0.0	4	1	1	1
20436	361	low-strength evidence	[Low-strength evidence]	0.0	2	1	1	1
20437	361	patient HF	[patients HF]	0.0	2	1	1	1
20438	361	association of impairment	[association of impairment]	0.0	3	1	1	1
20439	361	for heart	[for hearts]	0.0	2	1	1	1
20440	361	decrease in rate	[decrease in rates]	0.0	3	1	1	1
20441	361	cad involve the left artery	[CAD involving the left artery]	0.0	5	1	1	1
20442	361	use rat ventricular cardiomyocyte	[Using rat ventricular cardiomyocytes]	0.0	4	1	1	1
20443	361	analysis of subgroup at risk	[analysis of subgroups at risk]	0.0	5	1	1	1
20444	361	occurrence of HF within day	[Occurrence of HF within days]	0.0	5	1	1	1
20445	361	other aspect	[other aspects]	0.0	2	1	1	1
20446	361	functioning	[functioning]	0.0	1	1	1	1
20447	361	organ failure	[organ failure]	0.0	2	1	1	1
20448	361	vivo experiment	[vivo experiments]	0.0	2	1	1	1
20449	361	depolarization	[depolarization]	0.0	1	1	1	1
20450	361	impact on gene program	[impact on gene programs]	0.0	4	1	1	1
20451	361	form of left remodeling	[forms of left remodeling]	0.0	4	1	1	1
20452	361	cost-effective participatory health intervention	[cost-effective participatory health interventions]	0.0	4	1	1	1
20453	361	dose of mg	[dose of mg]	0.0	3	1	1	1
20454	361	subgroup at risk develop hyperkalemia	[subgroups at risk developing hyperkalemia]	0.0	5	1	1	1
20455	361	average age of year	[average age of years]	0.0	4	1	1	1
20456	361	odd ratio 1.76 after adjustment	[odds ratio 1.76 after adjustment]	0.0	5	1	1	1
20457	361	history with artery	[history with arteries]	0.0	3	1	1	1
20458	361	left ventricular LV myocyte	[left ventricular LV myocytes]	0.0	4	1	1	1
20459	361	key role scaffold in heart pathology	[Key role scaffolds in heart pathology]	0.0	6	1	1	1
20460	361	effect on receptor signal	[effects on receptor signaling]	0.0	4	1	1	1
20461	361	onset HFrEF 30 day	[onset HFrEF 30 days]	0.0	4	1	1	1
20462	361	describe a nomenclature with a view	[describing a nomenclature with a view]	0.0	6	1	1	1
20463	361	arrest in human	[arrest in humans]	0.0	3	1	1	1
20464	361	LV pressure in 20 week	[LV pressure in 20 weeks]	0.0	5	1	1	1
20465	361	fifty-four Fontan PF patient	[Fifty-four Fontan PF patients]	0.0	4	1	1	1
20466	361	age subject from the general population	[age subjects from the general population]	0.0	6	1	1	1
20467	361	brachial systolic pressure 155 35	[brachial systolic pressure 155 35]	0.0	5	1	1	1
20468	361	pilot program	[pilot program]	0.0	2	1	1	1
20469	361	only a limited amount	[only a limited amount]	0.0	4	1	1	1
20470	361	effect of nonselective versus beta-blocker	[effects of nonselective versus beta-blockers]	0.0	5	1	1	1
20471	361	other staff responsible for patient care	[other staff responsible for patient care]	0.0	6	1	1	1
20472	361	consistency among patient with hfpef	[consistency among patients with HFpEF]	0.0	5	1	1	1
20473	361	independent prognostic marker hazard ratio	[independent prognostic markers hazard ratio]	0.0	5	1	1	1
20474	361	change in readmission rate	[change in readmission rate]	0.0	4	1	1	1
20475	361	population in rural South Dakota	[population in rural South Dakota]	0.0	5	1	1	1
20476	361	circulatory derangement with hemodynamic feature	[circulatory derangement with hemodynamic features]	0.0	5	1	1	1
20477	361	aortic valve procedure valve replacement	[aortic valve procedures valve replacement]	0.0	5	1	1	1
20478	361	suggest t1	[suggesting T1]	0.0	2	1	1	1
20479	361	bb dose high versus mg dose	[BB dose high versus mg dose]	0.0	6	1	1	1
20480	361	target for HHD	[targets for HHD]	0.0	3	1	1	1
20481	361	effect of LVEF on mortality	[effect of LVEF on mortality]	0.0	5	1	1	1
20482	361	single-payer perspective	[single-payer perspective]	0.0	2	1	1	1
20483	361	effective elastance elastance ees	[Effective elastance elastance Ees]	0.0	4	1	1	1
20484	361	method of transverse constriction tac	[method of transverse constriction TAC]	0.0	5	1	1	1
20485	361	antagonize β-ar drive	[antagonizing β-AR drive]	0.0	3	1	1	1
20486	361	chronic therapy	[chronic therapy]	0.0	2	1	1	1
20487	361	l-type process	[L-type processes]	0.0	2	1	1	1
20488	361	group millileter per 1.73 m	[group mL per 1.73 m]	0.0	5	1	1	1
20489	361	increase population	[increasing population]	0.0	2	1	1	1
20490	361	age-specific CRF category	[age-specific CRF categories]	0.0	3	1	1	1
20491	361	even on optimal therapy	[Even on optimal therapy]	0.0	4	1	1	1
20492	361	use three metric for disease group	[using three metrics for disease groups]	0.0	6	1	1	1
20493	361	rat mechanism	[rats mechanism]	0.0	2	1	1	1
20494	361	nmol 309 ng	[nmol 309 ng]	0.0	3	1	1	1
20495	361	Fontan circulation exhibit	[Fontan circulation exhibit]	0.0	3	1	1	1
20496	361	reprogramming	[reprogramming]	0.0	1	1	1	1
20497	361	fetal gene	[fetal gene]	0.0	2	1	1	1
20498	361	0.53 event	[0.53 events]	0.0	2	1	1	1
20499	361	follow-up medication	[follow-up medication]	0.0	2	1	1	1
20500	361	predictor period	[predictor period]	0.0	2	1	1	1
20501	361	argument	[arguments]	0.0	1	1	1	1
20502	361	start of the treatment	[start of the treatment]	0.0	4	1	1	1
20503	361	impairment with 6-month mortality	[impairment with 6-month mortality]	0.0	4	1	1	1
20504	361	healthy volunteer	[healthy volunteers]	0.0	2	1	1	1
20505	361	practice rate of treatment	[Practice rates of treatment]	0.0	4	1	1	1
20506	361	induction of hretn mrna	[induction of hRetn mRNA]	0.0	4	1	1	1
20507	361	chronic guideline-directed therapy	[chronic guideline-directed therapy]	0.0	3	1	1	1
20508	361	woman with HF	[women with HF]	0.0	3	1	1	1
20509	361	role of timing	[role of timing]	0.0	3	1	1	1
20510	361	age-by-LVEF	[age-by-LVEF]	0.0	1	1	1	1
20511	361	male rat	[male rats]	0.0	2	1	1	1
20512	361	change include cardiac hypertrophy	[changes including cardiac hypertrophy]	0.0	4	1	1	1
20513	361	30 day p-value 0.001	[30 days P-value 0.001]	0.0	4	1	1	1
20514	361	thorough history	[thorough history]	0.0	2	1	1	1
20515	361	nursing-sensitive outcome measure in experimental research	[nursing-sensitive outcome measures in experimental research]	0.0	6	1	1	1
20516	361	ventricular ejection fraction difference	[ventricular ejection fraction difference]	0.0	4	1	1	1
20517	361	right ventricular annular plane excursion tapse	[right ventricular annular plane excursion TAPSE]	0.0	6	1	1	1
20518	361	millileter in peak vo2 p	[mL in peak VO2 P]	0.0	5	1	1	1
20519	361	prospective multicenter trial Paradigm-hf	[prospective multicenter trial PARADIGM-HF]	0.0	4	1	1	1
20520	361	acute heart failure study	[acute heart failure studies]	0.0	4	1	1	1
20521	361	cardiac procedure 146	[cardiac procedures 146]	0.0	3	1	1	1
20522	361	use of N-terminal pro-b-type peptide	[use of N-terminal pro-B-type peptide]	0.0	5	1	1	1
20523	361	improvement in rate	[improvement in rate]	0.0	3	1	1	1
20524	361	Age-dependent effect of ventricular ejection fraction	[Age-dependent effect of ventricular ejection fraction]	0.0	6	1	1	1
20525	361	patient with onset HFrEF 30 day	[patients with onset HFrEF 30 days]	0.0	6	1	1	1
20526	361	inpatient record	[inpatient records]	0.0	2	1	1	1
20527	361	rr interval	[RR intervals]	0.0	2	1	1	1
20528	361	hallmark feature	[hallmark feature]	0.0	2	1	1	1
20529	361	such as detection of fluid overload	[such as detection of fluid overload]	0.0	6	1	1	1
20530	361	only a amount of datum	[only a amount of data]	0.0	5	1	1	1
20531	361	hyponatremia in country	[hyponatremia in countries]	0.0	3	1	1	1
20532	361	limited valve opening	[limited valve opening]	0.0	3	1	1	1
20533	361	addition of low-dose dopamine μg	[addition of low-dose dopamine μg]	0.0	5	1	1	1
20534	361	effective anti-neoplastic agent	[effective anti-neoplastic agent]	0.0	3	1	1	1
20535	361	patient with a ventricular ejection fraction	[patients with a ventricular ejection fraction]	0.0	6	1	1	1
20536	361	risk-standardized mortality	[risk-standardized mortality]	0.0	2	1	1	1
20537	361	CPET guide	[CPET guiding]	0.0	2	1	1	1
20538	361	crucial role include nuclear factor	[crucial role including nuclear factor]	0.0	5	1	1	1
20539	361	human kidney cell overexpress β1ar	[human kidney cells overexpressing β1AR]	0.0	5	1	1	1
20540	361	nitroxyl HNO	[nitroxyl HNO]	0.0	2	1	1	1
20541	361	fast grow subclass	[fastest growing subclass]	0.0	3	1	1	1
20542	361	pediatric cardiac support	[pediatric cardiac support]	0.0	3	1	1	1
20543	361	validate nursing-sensitive outcome measure	[Validating nursing-sensitive outcome measures]	0.0	4	1	1	1
